﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tan, JSL
   Mitchell, P
   Smith, W
   Wang, JJ
AF Tan, Jennifer S. L.
   Mitchell, Paul
   Smith, Wayne
   Wang, Jie Jin
TI Cardiovascular risk factors and the long-term incidence of age-related
   macular degeneration - The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID DENSITY-LIPOPROTEIN CHOLESTEROL; DIETARY-FAT; POOLED FINDINGS;
   MACULOPATHY; ATHEROSCLEROSIS; PATHOGENESIS; SMOKING; DISEASE;
   PREVALENCE; PLASMA
AB Purpose: To assess the relationship between cardiovascular disease and cardiovascular risk factors, other than smoking, and risk of long-term incident age-related macular degeneration (AMD).
   Design: Population-based cohort study.
   Participants: There were 3654 baseline (1992-1994) participants aged >= 49 years included in the Blue Mountains region, west of Sydney, Australia. Of these, 2335 (75% of survivors) were reexamined after 5 years (1997-1999) and 1952 (76% of survivors) after 10 years (2002-2004).
   Methods: Stereoscopic color fundus photographs were graded using the Wisconsin Age-related Maculopathy Grading System. History, physical examination, and fasting blood samples provided data on possible risk factors. Age-related macular degeneration incidence was calculated using the Kaplan-Meier survival approach. Discrete linear logistic models were used to assess risk of incident AMD. Relative risks (RR) and 95% confidence intervals (CI) are presented after adjusting for age, gender, smoking, and other risk factors. Main Outcome Measure: Incident early and late AMD.
   Results: Increasing high-density lipoprotein (HDL) cholesterol was inversely related to incident late AMD (RR per standard deviation [SD] increase, 0.74; 95% CI, 0.56-0.99). Elevated total/HDL cholesterol ratio predicted late AMD (RR per SD increase, 1.35; 95% CI, 1.07-1.70) and geographic atrophy (GA; RR per SD, 1.63; 95% CI, 1.18-2.25). Diabetes predicted incident GA (RR, 3.89; 95% CI, 1.36-11.08), but not neovascularAMD. History of stroke (RR 2.01; 95% CI, 1.12-3.58), or any cardiovascular disease (stroke, myocardial infarction, or angina; RR, 1.57; 95% CI, 1.13-2.16) predicted incident early AMD and incident indistinct soft or reticular drusen (RR, 2.38; 95% CI, 1.33-4.27 for stroke; RR, 1.80; 95% CI, 1.28-2.52 for any cardiovascular disease). Neither pulse pressure, systolic or diastolic blood pressure, or presence of hypertension at baseline were associated with incident AMD.
   Conclusions: Our findings provide some evidence of links between cardiovascular risk factors and AMD. Further prospective evaluation of these relationships is warranted, as these findings could have therapeutic implications.
C1 Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium INst, Westmead, NSW 2145, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Danesh J, 2005, JAMA-J AM MED ASSOC, V294, P1799, DOI 10.1001/jama.294.14.1799
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duncan JL, 2005, BRIT J OPHTHALMOL, V89, P1549, DOI 10.1136/bjo.2005.077370
   DURRINGTON PN, 1990, SCAND J CLIN LAB INV, V50, P86, DOI 10.3109/00365519009091092
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fazio Sergio, 2003, Mol Interv, V3, P436, DOI 10.1124/mi.3.8.436
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   LINN S, 1993, AM J PUBLIC HEALTH, V83, P811, DOI 10.2105/AJPH.83.6.811
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WALLACH J, 2000, INTERPRETATION DIAGN, P35
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 46
TC 168
Z9 174
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1143
EP 1150
DI 10.1016/j.ophtha.2006.09.033
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600018
PM 17275090
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Kozak, IR
   Mojana, F
   Cheng, LY
   Morrison, VL
   Wang, HY
   Kim, JS
   Dustin, L
   Azen, S
   Freeman, WR
AF Chhablani, Jay
   Kozak, Igor R.
   Mojana, Francesca
   Cheng, Lingyun
   Morrison, Victoria L.
   Wang, Haiyan
   Kim, Jae Suk
   Dustin, Laurie
   Azen, Stanley
   Freeman, William R.
TI FUNDUS AUTOFLUORESCENCE NOT PREDICTIVE OF TREATMENT RESPONSE TO
   INTRAVITREAL BEVACIZUMAB IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE autofluorescence; choroidal neovascularization; AMD; Avastin
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE;
   CHOROIDAL-NEOVASCULARIZATION; RPE-AUTOFLUORESCENCE; IN-VIVO; LIPOFUSCIN
AB Purpose: Foveal autofluorescence (AF) has been suggested to be a potential predictor of treatment outcome in choroidal neovascularization (CNV) secondary to age-related macular degeneration and could be a useful marker to help prognosticate for patients and for clinical trials. This retrospective study aims to determine if pretreatment foveal AF can predict treatment response to intravitreal bevacizumab monotherapy in CNV secondary to age-related macular degeneration.
   Methods: Ninety-five eyes (85 patients) with naive CNV secondary to age-related macular degeneration, treated with intravitreal bevacizumab monotherapy were included in this study. Lesion size, CNV type on fluorescein angiography, pretreatment best-corrected visual acuity, and foveal AF pattern (intact/nonintact) were used as predictors. Multivariate linear regression and logistic regression were performed using best-corrected visual acuity change and anatomical response at 6 months as the dependent variables separately.
   Results: Pretreatment foveal AF (intact or nonintact) did not predict visual outcome (P = 0.17) nor did lesion size (P = 0.2) or CNV type (P = 0.61). Foveal AF did correlate with the visual acuity but it did not predict any treatment response. Pretreatment best-corrected visual acuity was the only predictive factor for the visual outcome (P = 0.043).
   Conclusion: Pretreatment AF is not a predictor for the treatment response to intravitreal bevacizumab monotherapy in eyes with CNV secondary to age-related macular degeneration.
C1 [Chhablani, Jay; Kozak, Igor R.; Mojana, Francesca; Cheng, Lingyun; Morrison, Victoria L.; Wang, Haiyan; Kim, Jae Suk; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Dustin, Laurie; Azen, Stanley] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 University of California System; University of California San Diego;
   Doheny Eye Institute; University of Southern California
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, 9415 Campus Point Dr,Room 217B, La Jolla, CA 92093 USA.
EM freeman@eyecenter.ucsd.edu
RI Chhablani, Jay/F-6241-2012; Kozak, Igor/AAC-4645-2019
OI Chhablani, Jay/0000-0003-1772-3558
FU National Institutes of Health [EYO 7366]; Jacobs Retina Center; NATIONAL
   EYE INSTITUTE [P30EY022589, R01EY007366] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health grant EYO 7366 ( to W.R.F.)
   and unrestricted funding from Jacobs Retina Center.
CR Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   Cohen J., 1989, STAT POWER ANAL BEHA, V2nd
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spital G, 1998, KLIN MONATSBL AUGENH, V213, P23, DOI 10.1055/s-2008-1034939
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   von Ruckmann A, 1998, OPHTHALMOLOGE, V95, P699, DOI 10.1007/s003470050338
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 21
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1465
EP 1470
DI 10.1097/IAE.0b013e3182475aea
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300005
PM 22466489
DA 2022-11-30
ER

PT J
AU Mehta, H
AF Mehta, Hemal
TI Management of Cataract in Patients with Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE cataract surgery; age-related macular degeneration; clinical trials;
   real-world evidence
ID QUALITY-OF-LIFE; POSTERIOR CAPSULE RUPTURE; ENDOTHELIAL GROWTH-FACTOR;
   INTRAOCULAR-LENS; VISUAL-ACUITY; INTRAVITREAL BEVACIZUMAB; SURGERY;
   RISK; EYES; IMPLANTATION
AB Cataract and age-related macular degeneration (AMD) are two of the most common eye diseases of aging. This review addresses the pre-operative, intra-operative, and post-operative considerations in managing cataract in patients with age-related macular degeneration. Surgery for visually significant cataracts in patients with AMD can substantially improve the quality of life and reduce the risk of falls. Pre-operative optical coherence tomography is now recommended where possible to identify pre-existing macula disease. Careful counselling of patients is required before cataract surgery, especially with respect to the expected visual outcome, intraocular lens choice and potential risks of surgery. Real-world data has suggested 6 months of intravitreal anti-VEGF therapy for neovascular AMD before cataract surgery is compatible with optimum long-term visual outcomes. Patients receiving intravitreal therapy for neovascular AMD should be advised of the slightly higher risk of intraoperative complications and the surgeon should be prepared to manage these during the operation. During cataract surgery, unnecessary light exposure should be avoided to reduce phototoxicity. Careful planning of intravitreal therapy for neovascular AMD just before cataract surgery allows the eye greater recovery time in the post-operative period before further planned intravitreal therapy.
C1 [Mehta, Hemal] Univ Sydney, Save Sight Registries, Sydney, NSW 2000, Australia.
   [Mehta, Hemal] Strathfield Retina Clin, Sydney, NSW 2135, Australia.
   [Mehta, Hemal] Royal Free London NHS Fdn Trust, Ophthalmol Dept, London NW3 2QG, England.
C3 University of Sydney; University of London; University College London;
   Royal Free London NHS Foundation Trust
RP Mehta, H (通讯作者)，Univ Sydney, Save Sight Registries, Sydney, NSW 2000, Australia.; Mehta, H (通讯作者)，Strathfield Retina Clin, Sydney, NSW 2135, Australia.; Mehta, H (通讯作者)，Royal Free London NHS Fdn Trust, Ophthalmol Dept, London NW3 2QG, England.
EM HM@cantab.net
CR AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   Alio JL, 2017, SURV OPHTHALMOL, V62, P611, DOI 10.1016/j.survophthal.2017.03.005
   Amoaku WM, 2020, EYE, V34, P1, DOI 10.1038/s41433-020-0961-6
   Banta James T, 2012, Int Ophthalmol Clin, V52, P73, DOI 10.1097/IIO.0b013e31824b3ed3
   Bellucci R, 2005, J CATARACT REFR SURG, V31, P712, DOI 10.1016/j.jcrs.2004.08.049
   Bhandari S, 2020, CLIN EXP OPHTHALMOL, V48, P462, DOI 10.1111/ceo.13707
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Buchan JC, 2020, EYE, V34, P1866, DOI 10.1038/s41433-019-0761-z
   Cajochen C, 2005, J CLIN ENDOCR METAB, V90, P1311, DOI 10.1210/jc.2004-0957
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Castelli GP, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03572-y
   Chen AX, 2021, CAN J OPHTHALMOL, V56, P348, DOI 10.1016/j.jcjo.2021.01.018
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Downie LE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011977.pub2
   Enz TJ, 2018, J CATARACT REFR SURG, V44, P23, DOI 10.1016/j.jcrs.2017.09.030
   Feng YR, 2018, CLIN INTERV AGING, V13, P1457, DOI 10.2147/CIA.S164419
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Goldhardt R, 2020, CURR OPHTHALMOL REP, V8, P129, DOI 10.1007/s40135-020-00243-z
   Grixti Andre, 2014, ISRN Ophthalmol, V2014, P417603, DOI 10.1155/2014/417603
   Grzybowski A, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5851
   Grzybowski A, 2017, GRAEF ARCH CLIN EXP, V255, P1687, DOI 10.1007/s00417-017-3740-8
   Hahn P, 2016, EYE, V30, P1101, DOI 10.1038/eye.2016.109
   Hahn P, 2016, OPHTHALMOLOGY, V123, P309, DOI 10.1016/j.ophtha.2015.06.040
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   HOPEROSS MW, 1993, EYE, V7, P29, DOI 10.1038/eye.1993.7
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kernt M, 2012, CLIN EXP OPHTHALMOL, V40, pE87, DOI 10.1111/j.1442-9071.2011.02620.x
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Lee AY, 2016, OPHTHALMOLOGY, V123, P1252, DOI 10.1016/j.ophtha.2016.02.014
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Leung EH, 2020, OPHTHALMOLOGY, V127, P859, DOI 10.1016/j.ophtha.2020.01.049
   Liu Y., 2021, COMPUT METHOD BIOMEC, V46, P333, DOI [10.1080/02713683.2020.1798467, DOI 10.1080/10255842.2020.1719403]
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   MARSHALL J, 1989, HEALTH PHYS, V56, P617, DOI 10.1097/00004032-198905000-00003
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Morris D, 2007, CLIN INTERV AGING, V2, P105, DOI 10.2147/ciia.2007.2.1.105
   Nagar AM, 2020, J CATARACT REFR SURG, V46, P204, DOI 10.1016/j.jcrs.2019.09.004
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Ozulken K, 2021, CURR EYE RES, V46, P811, DOI 10.1080/02713683.2020.1833347
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Potgieter FJ, 2014, J CATARACT REFR SURG, V40, P1085, DOI 10.1016/j.jcrs.2013.10.049
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Reinhard T, 2021, GRAEF ARCH CLIN EXP, V259, P431, DOI 10.1007/s00417-020-04868-5
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Shalchi Z, 2017, AM J OPHTHALMOL, V177, P77, DOI 10.1016/j.ajo.2017.02.006
   Shentu XC, 2008, CLIN EXP OPHTHALMOL, V36, P620, DOI 10.1111/j.1442-9071.2008.01856.x
   Sparrow JM, 2012, EYE, V26, P821, DOI 10.1038/eye.2012.51
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sul S, 2019, TURK OFTALMOL DERG, V49, P15, DOI 10.4274/tjo.galenos.2018.76429
   Swampillai AJ, 2020, EYE, V34, P1142, DOI 10.1038/s41433-019-0744-0
   Taipale C, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-2020-965
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   Trikha S, 2016, EYE, V30, P1331, DOI 10.1038/eye.2016.108
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub4
   Weill Y, 2021, J CATARACT REFR SURG, V47, P78, DOI 10.1097/j.jcrs.0000000000000389
   Westborg I, 2021, ACTA OPHTHALMOL, V99, pE124, DOI 10.1111/aos.14519
   Wolffe M, 2016, EYE, V30, P186, DOI 10.1038/eye.2015.247
NR 59
TC 1
Z9 1
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2021
VL 10
IS 12
AR 2538
DI 10.3390/jcm10122538
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SZ4TB
UT WOS:000666558300001
PM 34201114
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wada, I
   Shiose, S
   Ishikawa, K
   Kano, K
   Notomi, S
   Mori, K
   Akiyama, M
   Nakao, S
   Sonoda, KH
AF Wada, Iori
   Shiose, Satomi
   Ishikawa, Keijiro
   Kano, Kumiko
   Notomi, Shoji
   Mori, Kenichiro
   Akiyama, Masato
   Nakao, Shintaro
   Sonoda, Koh-Hei
TI One-year efficacy of "rescue photodynamic therapy" for patients with
   typical age-related macular degeneration, polypoidal choroidal
   vasculopathy, and pachychoroid neovasculopathy refractory to
   anti-vascular endothelial growth factor therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Rescue photodynamic therapy; Age-related macular degeneration;
   Recurrence; Anti-VEGF refractory; One-year result
ID RANIBIZUMAB; VERTEPORFIN; OUTCOMES; COMBINATION; BEVACIZUMAB;
   AFLIBERCEPT; INJECTION; SAFETY
AB Purpose This study aimed to evaluate the one-year outcomes of photodynamic therapy (PDT) as a rescue treatment for age-related macular degeneration (AMD) refractory to anti-vascular endothelial growth factor (VEGF) therapy. Methods Patients with AMD refractory to anti-VEGF therapy, treated with "rescue-PDT" were retrospectively investigated. The time of PDT was defined as the baseline value. Baseline characteristics including sex, age, best-corrected visual acuity (BCVA), central macular thickness (CMT), and foveal choroidal thickness (FCT) were examined. The changes in BCVA, CMT, and recurrence were also assessed at the 1-year follow-up. The logMAR VA change of 0.3 or more was defined as "improved" or "declined." Results Twenty-three consecutive eyes (typical AMD: 10 eyes, polypoidal choroidal vasculopathy: 10 eyes, and pachychoroid neovasculopathy: 3 eyes), which underwent "rescue-PDT," were analyzed in this study. The BCVA was improved in three patients and maintained in 20 patients at 12 months after PDT (mean BCVA change: 0.11 +/- 0.19). The CMT improved in 19 patients (82.6%), and the mean CMT changed from 318.5 +/- 93.7 mu m to 225.9 +/- 51.6 mu m (p < 0.01) 12 months after PDT. "Retreatment" of anti-VEGF drug injections was considered if the retinal fluid or retinal hemorrhage recurred after PDT. The baseline FCT of the "retreatment group (15 eyes)" was significantly lower than that of the "no retreatment group (8 eyes)" (206.3 +/- 50.7 mu m vs 293.9 +/- 85.7 mu m: p = 0.033). Conclusions PDT could be an effective treatment option for anti-VEGF refractory AMD to maintain visual acuity and control retinal fluid for up to 12 months.
C1 [Wada, Iori; Shiose, Satomi; Ishikawa, Keijiro; Kano, Kumiko; Notomi, Shoji; Mori, Kenichiro; Akiyama, Masato; Nakao, Shintaro; Sonoda, Koh-Hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Shiose, S (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM asshyharyu@gmail.com
RI Akiyama, Masato/AHC-2589-2022
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Komuku Y, 2020, JPN J OPHTHALMOL, V64, P265, DOI 10.1007/s10384-020-00734-3
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Park UC, 2021, ACTA OPHTHALMOL, V99, pE899, DOI 10.1111/aos.14719
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2022
VL 260
IS 6
BP 2029
EP 2036
DI 10.1007/s00417-022-05553-5
EA JAN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0X7EL
UT WOS:000744778700004
PM 35038016
DA 2022-11-30
ER

PT J
AU Saito, M
   Kano, M
   Itagaki, K
   Sekiryu, T
AF Saito, Masaaki
   Kano, Mariko
   Itagaki, Kanako
   Sekiryu, Tetsuju
TI Efficacy of intravitreal aflibercept in Japanese patients with exudative
   age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Geographic atrophy; Vascular endothelial growth factor
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY;
   NATURAL-HISTORY; RANIBIZUMAB; VERTEPORFIN; DETACHMENT
AB To clarify the efficacy of aflibercept for treating exudative age-related macular degeneration (AMD).
   We prospectively studied 47 eyes with AMD. Forty-seven patients (mean age 72.2 years) received three consecutive monthly intravitreal aflibercept injections followed by an injection every 2 months until 12 months. The primary outcome was the 12-month visual results compared with baseline; the secondary outcomes were the prevalence of geography atrophy (GA), a dry macula at month 12, and anatomic changes on optical coherence tomography.
   The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) in 27 eyes with typical AMD and 20 eyes with polypoidal choroidal vasculopathy (PCV) significantly (p < 0.0001, p < 0.05, respectively) improved from 0.60 to 0.32 at baseline to 0.29 and 0.21 at month 12. At month 12, 22 (81.5 %) eyes with typical AMD and 17 (85 %) eyes with PCV had dry macula. The subfoveal choroidal thicknesses in typical AMD and PCV decreased significantly (p < 0.0001 for both comparisons) from 241 +/- 118 and 294 +/- 76 mu at baseline to 198 +/- 104 and 244 +/- 84 mu at month 12. Progressing or new GA was seen in three eyes with typical AMD and one eye with PCV; the mean change in the BCVA was significantly (p = 0.0026) worse at month 12. No other complications developed.
   Intravitreal aflibercept significantly improved VA and anatomic changes in typical AMD and PCV over 12 months. Development of GA might be a risk for declining VA.
C1 [Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 1-1-1 Hondo, Akita 0108543, Japan.
C3 Fukushima Medical University; Akita University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.; Saito, M (通讯作者)，Akita Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 1-1-1 Hondo, Akita 0108543, Japan.
EM masaaki@med.akita-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Sekiryu, Tetsuju/0000-0001-8042-2729
FU Bayer; HOYA; Novartis; Santen; Senju
FX M. Saito, Lecture fees (Bayer, HOYA, Novartis, Santen, Senju); M. Kano,
   None; K. Itagaki, None; T. Sekiryu, Grant (Bayer, Novartis).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 16
Z9 16
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2017
VL 61
IS 1
BP 74
EP 83
DI 10.1007/s10384-016-0478-5
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH7BZ
UT WOS:000391929100007
PM 27660164
DA 2022-11-30
ER

PT J
AU Sato, T
   Suzuki, M
   Ooto, S
   Spaide, RF
AF Sato, Taku
   Suzuki, Mihoko
   Ooto, Sotaro
   Spaide, Richard F.
TI MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   anti-vascular endothelial growth factor; fundus autofluorescence;
   optical coherence tomography; microperimetry; ETDRS; contrast
   sensitivity; reading speed test
ID CONTRAST SENSITIVITY; INTRAVITREAL RANIBIZUMAB; MICROPERIMETRIC CHANGES;
   EPITHELIAL-CELLS; VISUAL-ACUITY; GROWTH-FACTOR; OUTER RETINA; THERAPY;
   AUTOFLUORESCENCE; VERTEPORFIN
AB Purpose:To investigate the interactions among multimodal imaging findings and multimodal vision testing in neovascular age-related macular degeneration.Methods:Patients enrolled in a prospective study of neovascular age-related macular degeneration with at least 3 previous intravitreal anti-vascular endothelial growth factor injections. Each patient underwent multimodal fundus imaging including spectral domain optical coherence tomography and fundus autofluorescence, and multimodal vision testing, including visual acuity, contrast sensitivity, reading speed, and microperimetry.Results:There were 73 eyes of 49 consecutive patients enrolled. Generalized estimating equations' modelling showed that the significant independent predictors of visual acuity were the area of confluent hypoautofluorescence and involvement of the foveal center with either granular or confluent hypoautofluorescence (P < 0.001). Contrast sensitivity was negatively correlated with the area of confluent hypoautofluorescence (P < 0.001), involvement of the foveal center with granular hypoautofluorescence (P = 0.017), and subfoveal choroidal thickness (P = 0.042). The only significant predictor of reading speed was the size of confluent hypoautofluorescence (P < 0.001). The size of the defect in the ellipsoid zone (P < 0.001) and the presence of intraretinal fluid (P = 0.045) were correlated with microperimetry score.Conclusion:Confluent absence of autofluorescence was a highly significant predictor of vision testing and serves as an easy parameter to obtain in patients with neovascular age-related macular degeneration.
C1 [Sato, Taku; Suzuki, Mihoko; Ooto, Sotaro; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Sato, Taku; Suzuki, Mihoko; Ooto, Sotaro; Spaide, Richard F.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU LuEsther T. Mertz Retinal Research Foundation; United States from Alcon
   Japan Ltd.; Topcon Inc.
FX Suppported by the LuEsther T. Mertz Retinal Research Foundation.; T.
   Sato, S. Ooto, and M. Suzuki were funded by grants for fellowship study
   in the United States from Alcon Japan Ltd. R. F. Spaide receives
   consultant and royalty payments from Topcon Inc. None of the other
   authors have any conflicting interests to disclose.
CR Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Amore FM, 2013, OPHTHAL PHYSL OPT, V33, P611, DOI 10.1111/opo.12048
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Eldaly MA, 2009, RETINA-J RET VIT DIS, V29, P325, DOI 10.1097/IAE.0b013e31819a6154
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GINSBURG AP, 1982, AM J OPTOM PHYS OPT, V59, P105
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 42
TC 21
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1292
EP 1302
DI 10.1097/IAE.0000000000000505
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600002
PM 25830697
DA 2022-11-30
ER

PT J
AU Kamao, H
   Goto, K
   Matsuno, K
   Mizukawa, K
   Miki, A
   Kiryu, J
AF Kamao, Hiroyuki
   Goto, Katsutoshi
   Matsuno, Kento
   Mizukawa, Kenichi
   Miki, Atsushi
   Kiryu, Junichi
TI Clinical Characteristics of Neovascular Age-Related Macular Degeneration
   without Typical Drusen
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PACHYCHOROID NEOVASCULOPATHY;
   MACULOPATHY; RISK; EYES; DEPOSITS; SMOKING
AB Purpose. To evaluate the clinical characteristics of neovascular age-related macular degeneration (nAMD) patients without typical drusen. Methods. We retrospectively studied 165 eyes in 165 patients with treatment-naive nAMD, including typical AMD and polypoidal choroidal vasculopathy (PCV). According to the fellow eye condition, the patients were divided into nAMD with and without typical drusen groups. Eyes with soft drusen or subretinal drusenoid deposits were classified into the nAMD with the typical drusen group. Smoking status and diagnoses of hypertension and diabetes were identified from hospital records and patient recall. We assessed best-corrected visual acuity (BCVA), central retinal thickness (CRT) at the fovea, subfoveal choroidal thickness (SFCT), and the number of injections received. Results. The nAMD without typical drusen group was significantly younger (77.9 +/- 7.6 vs. 71.8 +/- 8.3, P<0.001) and had thicker SFCT at baseline (207.9 +/- 99.5 vs. 260.1 +/- 113.2 mu m, P=0.007) and a higher proportion of PCV (30.6 vs. 63.1%, P<0.001). The proportion of ever-smokers was significantly higher in the nAMD without typical drusen group (54.8 vs. 70.9%, P=0.036). There were no statistically significant differences in the proportion of patients with hypertension or diabetes; BCVA, CRT, or SFCT changes; or the number of injections between the nAMD with and without typical drusen groups. Conclusion. The clinical features of patients in the nAMD without typical drusen group were almost identical to those of pachychoroid-driven choroidal neovascularization (CNV) patients. The nAMD without typical drusen group had a significantly higher proportion of ever-smokers than the nAMD with typical drusen group. Smoking could be a risk factor for the development of pachychoroid-driven CNV.
C1 [Kamao, Hiroyuki; Goto, Katsutoshi; Matsuno, Kento; Miki, Atsushi; Kiryu, Junichi] Kawasaki Med Sch, Dept Ophthalmol, 577 Matsushima Kurashiki, Okayama 7010114, Japan.
   [Mizukawa, Kenichi] Shirai Eye Hosp, 1339 Takasecho Kamitakase, Mitoya, Kagawa 7670001, Japan.
C3 Kawasaki Medical School
RP Kamao, H (通讯作者)，Kawasaki Med Sch, Dept Ophthalmol, 577 Matsushima Kurashiki, Okayama 7010114, Japan.
EM hironeri@med.kawasaki-m.ac.jp
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   BURNS DM, 1991, CLIN CHEST MED, V12, P631
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamao H, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7189241
   Kamao H, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2353428
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 55
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD APR 27
PY 2021
VL 2021
AR 6683532
DI 10.1155/2021/6683532
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SF2IL
UT WOS:000652584600001
PM 33996151
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nishiguchi, KM
   Yasuma, TR
   Tomida, D
   Nakamura, M
   Ishikawa, K
   Kikuchi, M
   Ohmi, Y
   Niwa, T
   Hamajima, N
   Furukawa, K
   Terasaki, H
AF Nishiguchi, Koji M.
   Yasuma, Tetsuhiro R.
   Tomida, Daisuke
   Nakamura, Makoto
   Ishikawa, Kohei
   Kikuchi, Masato
   Ohmi, Yuhsuke
   Niwa, Toshimitsu
   Hamajima, Nobuyuki
   Furukawa, Koichi
   Terasaki, Hiroko
TI C9-R95X Polymorphism in Patients with Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MEMBRANE ATTACK COMPLEX; REACTIVE
   PROTEIN-LEVELS; FACTOR-H POLYMORPHISM; PHOTODYNAMIC THERAPY; 9TH
   COMPONENT; C9; GENE; DEFICIENCY; RISK
AB PURPOSE. A non-sense mutation at codon 95 in the gene encoding complement factor C9 (C9-R95X) is found most frequently among Japanese. The authors investigated the association between C9-R95X and Japanese patients with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   METHODS. The presence of the C9-R95X polymorphism was assessed by direct sequencing in Japanese patients with either PCV (n = 105) or neovascular AMD (n = 198) and 396 control subjects. Multivariate regression analyses were conducted. Photocoagulation was applied in the eyes of mice with a heterozygous defect in the C3 gene and control wild-type mice. Photocoagulation was also applied to wild-type mice before either anti-C9 antibody or isotype IgG was injected into the eyes. The eyes were collected later for measurement of vascular endothelial growth factor (VEGF) and histological evaluation of choroidal neovascularization (CNV).
   RESULTS. The frequency of those with one or two C9-R95X variants was lower in neovascular AMD (2.02%) than in PCV (5.71%) and controls (6.05%). The presence of C9-R95X conferred a 4.7-fold reduction (95% confidence interval, 1.2-18.1; P = 0.021) in the risk for neovascular AMD after adjusting for the major AMD risk factors. A heterozygous defect in the C3 gene was associated with the reduced growth of laser-induced CNV, as was intraocular injection of anti-C9 antibody. This reduced CNV growth was accompanied by a decreased level of secreted VEGF in the intraocular fluid.
   CONCLUSIONS. These findings support the notion that the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development. (Invest Ophthalmol Vis Sci. 2012; 53: 508-512) DOI:10.1167/iovs.11-8425
C1 [Nishiguchi, Koji M.] Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Ohmi, Yuhsuke; Furukawa, Koichi] Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4668550, Japan.
   [Niwa, Toshimitsu] Nagoya Univ, Sch Med, Dept Adv Med Uremia, Nagoya, Aichi 4668550, Japan.
   [Niwa, Toshimitsu] Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan.
   [Hamajima, Nobuyuki] Nagoya Univ, Sch Med, Dept Prevent Med, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University; Nagoya University; Nagoya University; Nagoya
   University; Nagoya University
RP Nishiguchi, KM (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM kojinish@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Hamajima, Nobuyuki/I-7237-2014; OHMI,
   Yuhsuke/I-7302-2014
OI Nakamura, Makoto/0000-0002-6464-4302
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [B21791676, B20390448]; Ministry of Health, Labor, and Welfare of Japan,
   Tokyo, Japan; Grants-in-Aid for Scientific Research [23659171] Funding
   Source: KAKEN
FX Supported in part by Grants-in-Aid for Scientific Research B21791676
   (KMN) and B20390448 (HT) from the Ministry of Education, Culture,
   Sports, Science, and Technology of Japan and by a Grant-in Aid from the
   Ministry of Health, Labor, and Welfare of Japan, Tokyo, Japan (HT).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARRIMAN GR, 1981, J IMMUNOL, V127, P2386
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Horiuchi T, 1998, J IMMUNOL, V160, P1509
   Khajoee V, 2003, HUM GENET, V112, P244, DOI 10.1007/s00439-002-0870-8
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kira R, 1999, J HUM GENET, V44, P109, DOI 10.1007/s100380050119
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lin J, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.029066
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MERI S, 1990, IMMUNOLOGY, V71, P1
   NAGATA M, 1989, J PEDIATR-US, V114, P260, DOI 10.1016/S0022-3476(89)80793-0
   Nishiguchi KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013493
   PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Tsujimura Ryusuke, 2009, Leg Med (Tokyo), V11 Suppl 1, pS482, DOI 10.1016/j.legalmed.2009.01.043
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YONEMURA Y, 1990, BRIT J HAEMATOL, V74, P108, DOI 10.1111/j.1365-2141.1990.tb02546.x
NR 37
TC 37
Z9 42
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2012
VL 53
IS 1
BP 508
EP 512
DI 10.1167/iovs.11-8425
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924LY
UT WOS:000302694500073
PM 22190594
DA 2022-11-30
ER

PT J
AU Tenbrock, L
   Wolf, J
   Boneva, S
   Schlecht, A
   Agostini, H
   Wieghofer, P
   Schlunck, G
   Lange, C
AF Tenbrock, Louis
   Wolf, Julian
   Boneva, Stefaniya
   Schlecht, Anja
   Agostini, Hansjuergen
   Wieghofer, Peter
   Schlunck, Guenther
   Lange, Clemens
TI Subretinal fibrosis in neovascular age-related macular degeneration:
   current concepts, therapeutic avenues, and future perspectives
SO CELL AND TISSUE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Degenerative disease; Human retina;
   Subretinal fibrosis; scar formation; choroidal neovascularization;
   macular neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULARIZATION; FIBROTIC SCAR; FIBROBLASTS FORM; NATURAL-HISTORY;
   INHIBITION; MEMBRANES; MODEL; DEDIFFERENTIATION
AB Age-related macular degeneration (AMD) is a progressive, degenerative disease of the human retina which in its most aggressive form is associated with the formation of macular neovascularization (MNV) and subretinal fibrosis leading to irreversible blindness. MNVs contain blood vessels as well as infiltrating immune cells, myofibroblasts, and excessive amounts of extracellular matrix proteins such as collagens, fibronectin, and laminin which disrupts retinal function and triggers neurodegeneration. In the mammalian retina, damaged neurons cannot be replaced by tissue regeneration, and subretinal MNV and fibrosis persist and thus fuel degeneration and visual loss. This review provides an overview of subretinal fibrosis in neovascular AMD, by summarizing its clinical manifestations, exploring the current understanding of the underlying cellular and molecular mechanisms and discussing potential therapeutic approaches to inhibit subretinal fibrosis in the future.
C1 [Tenbrock, Louis; Wolf, Julian; Boneva, Stefaniya; Schlecht, Anja; Agostini, Hansjuergen; Schlunck, Guenther; Lange, Clemens] Univ Freiburg, Fac Med, Med Ctr, Ctr Eye, Freiburg, Germany.
   [Wieghofer, Peter] Univ Leipzig, Inst Anat, Leipzig, Germany.
C3 University of Freiburg; Leipzig University
RP Lange, C (通讯作者)，Univ Freiburg, Fac Med, Med Ctr, Ctr Eye, Freiburg, Germany.
EM clemens.lange@uniklinik-freiburg.de
RI Wieghofer, Peter/AAV-9572-2020
OI Wolf, Julian/0000-0002-3470-9697; Boneva, Stefaniya/0000-0002-9811-2160
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bo QY, 2020, J OCUL PHARMACOL TH, V36, P618, DOI 10.1089/jop.2019.0112
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Caballero S, 2011, INVEST OPHTH VIS SCI, V52, P2490, DOI 10.1167/iovs.10-6351
   Casalino G, 2020, EXPERT REV OPHTHALMO, V15, P83, DOI 10.1080/17469899.2020.1745062
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Cui W, 2014, INT J OPHTHALMOL-CHI, V7, P194, DOI 10.3980/j.issn.2222-3959.2014.02.02
   D'Ambrosi N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01394
   Daftarian N, 2019, EXP EYE RES, V184, P286, DOI 10.1016/j.exer.2019.04.027
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0
   Dorrier CE, 2021, NAT NEUROSCI, V24, P234, DOI 10.1038/s41593-020-00770-9
   Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675
   Ellison JA, 1998, STROKE, V29, P1698, DOI 10.1161/01.STR.29.8.1698
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Fernandez-Klett F, 2014, BRAIN PATHOL, V24, P404, DOI 10.1111/bpa.12162
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Guidry C, 1996, INVEST OPHTH VIS SCI, V37, P740
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hinz B, 2016, EXP EYE RES, V142, P56, DOI 10.1016/j.exer.2015.07.009
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Hwang B, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0071-8
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2168, DOI 10.1097/IAE.0000000000001845
   Kim KL, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011908, 10.1097/md.0000000000011908]
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072242
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   Meng XM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.402
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mitchell TS, 2008, ANGIOGENESIS, V11, P141, DOI 10.1007/s10456-007-9085-x
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Pardali E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102157
   Peng XN, 2018, EXP EYE RES, V176, P88, DOI 10.1016/j.exer.2018.06.030
   Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Ramazani Y, 2018, MATRIX BIOL, V68-69, P44, DOI 10.1016/j.matbio.2018.03.007
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Sato Kota, 2018, Immunol Med, V41, P23, DOI 10.1080/09114300.2018.1451609
   Schlecht A, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.618598
   Schlecht A, 2020, AM J PATHOL, V190, P1632, DOI 10.1016/j.ajpath.2020.04.004
   Schrimpf C, 2011, CURR OPIN NEPHROL HY, V20, P297, DOI 10.1097/MNH.0b013e328344c3d4
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shimizu H, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.21
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Tanaka M, 2021, AM J PATHOL, V191, P652, DOI 10.1016/j.ajpath.2020.12.012
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Van Bergen T, 2015, INVEST OPHTH VIS SCI, V56, P5280, DOI 10.1167/iovs.14-15513
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Wehner D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00143-0
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Wilson MS, 2007, J CLIN INVEST, V117, P2941, DOI 10.1172/JCI31546
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191279
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yoshida S, 2019, ADV EXP MED BIOL, V1132, P113, DOI 10.1007/978-981-13-6657-4_12
   Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 106
TC 11
Z9 11
U1 7
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD MAR
PY 2022
VL 387
IS 3
SI SI
BP 361
EP 375
DI 10.1007/s00441-021-03514-8
EA SEP 2021
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0F1VS
UT WOS:000692299500001
PM 34477966
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Perez-Ortiz, AC
   Luna-Angulo, A
   Zenteno, JC
   Rendon, A
   Cortes-Ballinas, LG
   Jimenez-Collado, D
   Antonio-Aguirre, B
   Peralta-Ildefonso, MJ
   Ramirez, I
   Jacob-Kuttothara, S
   Estrada-Mena, FJ
AF Christopher Perez-Ortiz, Andric
   Luna-Angulo, Alexandra
   Carlos Zenteno, Juan
   Rendon, Alvaro
   Guadalupe Cortes-Ballinas, Liliana
   Jimenez-Collado, David
   Antonio-Aguirre, Bani
   Janneth Peralta-Ildefonso, Martha
   Ramirez, Israel
   Jacob-Kuttothara, Stefany
   Javier Estrada-Mena, Francisco
TI Significant Association Between Variant in SGCD and Age-Related Macular
   Degeneration
SO GENES
LA English
DT Article
DE SGCD; delta-sarcoglycan; candidate-gene approach; AMD
ID VISION IMPAIRMENT; GLOBAL PREVALENCE; SARCOGLYCAN; COMPLEX;
   METAANALYSIS; DYSTROPHIN; DISEASE; RISK
AB CFH and HTRA1 genes are traditional markers of increased risk of age-related macular degeneration (AMD) across populations. Recent findings suggest that additional genes-for instance, in the dystrophin-associated protein complex-might be promising markers for AMD. Here, we performed a case-control study to assess the effect of SGCD single nucleotide polymorphisms (SNPs), a member of this protein family, on AMD diagnosis and phenotype. We performed a case-control study of an under-studied population from Hispanics in Mexico City, with 134 cases with 134 unpaired controls. Cases were 60 years or older (Clinical Age-Related Maculopathy Staging (CARMS) grade 4-5, as assessed by experienced ophthalmologists following the American Association of Ophthalmology (AAO) guidelines), without other retinal disease or history of vitreous-retinal surgery. Controls were outpatients aged 60 years or older, with no drusen or retinal pigment epithelium (RPE) changes on a fundus exam and a negative family history of AMD. We examined SNPs in the SGCD gene (rs931798, rs140617, rs140616, and rs970476) by sequencing and real-time PCR. Genotyping quality checks and univariate analyses were performed with PLINK v1.90b3.42. Furthermore, logistic regression models were done in SAS v.9.4 and haplotype configurations in R v.3.3.1. After adjusting for clinical covariates, the G/A genotype of the SGCD gene (rs931798) significantly increases the odds of being diagnosed with AMD in 81% of cases (1.81; 95% CI 1.06-3.14; p = 0.031), especially the geographic atrophy phenotype (1.82; 95% CI 1.03-3.21; p = 0.038) compared to the G/G homozygous genotype. Moreover, the GATT haplotype in this gene (rs931798, rs140617, rs140616, and rs970476) is associated with lower odds of AMD (adjusted odds ratio (OR) 0.13; 95% CI 0.02-0.91; p = 0.041). SGCD is a promising gene for AMD research. Further corroboration in other populations is warranted, especially among other Hispanic ethnicities.
C1 [Christopher Perez-Ortiz, Andric; Luna-Angulo, Alexandra; Guadalupe Cortes-Ballinas, Liliana; Jimenez-Collado, David; Antonio-Aguirre, Bani; Janneth Peralta-Ildefonso, Martha; Ramirez, Israel; Jacob-Kuttothara, Stefany; Javier Estrada-Mena, Francisco] Univ Panamer, Escuela Med, Lab Biol Mol, Donatello 59 Insurgentes Mixcoac Benito Juarez, Ciudad De Mexico 03920, Mexico.
   [Christopher Perez-Ortiz, Andric] Yale Univ, Sch Publ Hlth, LEPH, New Haven, CT 06510 USA.
   [Luna-Angulo, Alexandra] Inst Nacl Rehabil, Dept Neurociencias, Calzada Mexico Xochimilco 289, Ciudad De Mexico 14389, Mexico.
   [Carlos Zenteno, Juan] Univ Nacl Autonoma Mexico, Fac Med, Inst Ophthalmol Conde Valenciana Fdn, Genet Dept,Res Unit,Dept Biochem, Ciudad De Mexico 06080, Mexico.
   [Rendon, Alvaro] Sorbonne Univ, Inst Vis, F-75012 Paris, France.
   [Guadalupe Cortes-Ballinas, Liliana; Janneth Peralta-Ildefonso, Martha] Univ Nacl Autonoma Mexico, Fac Quim, Ciudad Univ, Ciudad De Mexico 04510, Coyoacan, Mexico.
C3 Yale University; Universidad Nacional Autonoma de Mexico; UDICE-French
   Research Universities; Sorbonne Universite; Universidad Nacional
   Autonoma de Mexico
RP Estrada-Mena, FJ (通讯作者)，Univ Panamer, Escuela Med, Lab Biol Mol, Donatello 59 Insurgentes Mixcoac Benito Juarez, Ciudad De Mexico 03920, Mexico.
EM andric@aya.yale.edu; lunangulo@gmail.com;
   jczenteno@institutodeoftalmologia.org; alvaro.rendon@inserm.fr;
   lilixar@gmail.com; djimcoll@gmail.com; bani.aantonio@gmail.com;
   martha.janneth2830@gmail.com; israel.ramirez04@gmail.com;
   skuttothara@gmail.com; festrada@up.edu.mx
RI Perez-Ortiz, Andric C/AAA-3292-2019; luna, alexandra/AAA-5836-2021;
   Antonio-Aguirre, Bani/AAS-2450-2020; Jimenez-Collado,
   David/AAI-1796-2020; Estrada-Mena, Francisco/AAI-2437-2020
OI Perez-Ortiz, Andric C/0000-0003-0731-2464; Antonio-Aguirre,
   Bani/0000-0003-2393-1097; Estrada-Mena, Francisco/0000-0002-0833-3630;
   Jimenez-Collado, David/0000-0002-6092-9984
FU Universidad Panamericana [UP-CI-2017-CS-MX-01]
FX This research was funded by Universidad Panamericana grant number
   UP-CI-2017-CS-MX-01 through the grant "Fomento a la Investigacion UP
   2017".
CR American Academy of OphthalmologyRetina/Vitreous Panel, 2015, AG REL MAC DEG, P12
   Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Perez-Ortiz AC, 2016, INVEST OPHTH VIS SCI, V57
   Claudepierre T, 2000, J CELL SCI, V113, P3409
   Costa MF, 2007, AM J HUM GENET, V80, P1064, DOI 10.1086/518127
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Development Core R & Team R, 2011, R LANG ENV STAT COMP, DOI [10.1007/978-3-540-74686-7, DOI 10.1007/978-3-540-74686-7]
   Fort P, 2005, NEUROSCI RES, V53, P25, DOI 10.1016/j.neures.2005.05.007
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashimoto R, 2006, BIOCHEM BIOPH RES CO, V348, P212, DOI 10.1016/j.bbrc.2006.07.045
   Hernández-Narváez María Guadalupe, 2015, Rev Cubana Oftalmol, V28, P190
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin Wan-Yu, 2010, BMC Res Notes, V3, P26, DOI 10.1186/1756-0500-3-26
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ryu E, 2010, MOL VIS, V16, P2811
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   SAS Institute, 2014, SAS SOFTW 9 4, P1
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 30
TC 3
Z9 3
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD OCT
PY 2018
VL 9
IS 10
AR 467
DI 10.3390/genes9100467
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GY5XI
UT WOS:000448656700005
PM 30257524
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, YH
   Lee, B
   Kang, E
   Oh, J
AF Kim, Young Ho
   Lee, Boram
   Kang, Edward
   Oh, Jaeryung
TI Clustering of eyes with age-related macular degeneration or pachychoroid
   spectrum diseases based on choroidal thickness profile
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Choroidal changes have been suggested to be involved in the pathophysiology of both age-related macular degeneration (AMD) and pachychoroid spectrum diseases (PSD). To find out the choroidal characteristics of each disease groups, various groups of AMD and PSD were classified into several clusters according to choroidal profiles based on subfoveal choroidal thickness (CT), peripapillary CT, the ratio of subfoveal CT to peripapillary CT and age. We retrospectively analyzed 661 eyes, including 190 normal controls and 471 with AMD or PSDs. In the AMD groups, eyes with soft drusen or reticular pseudodrusen were belonged to the same cluster as those with classic exudative AMD (all p<0.001). However, eyes with pachydrusen were not clustered with eyes from other AMD groups; instead, they were classified in the same cluster as eyes from the PSD group (all p<0.001). In the PSD group, eyes with pachychoroid neovasculopathy were grouped in the same cluster of those with polypoidal choroidal vasculopathy (p<0.001). The cluster analysis based on the CT profiles, including subfoveal CT, peripapillary CT, and their ratio, revealed a clustering pattern of eyes with AMD and PSDs. These findings support the suggestion that pachydrusen has the common pathogenesis as PSD.
C1 [Kim, Young Ho; Lee, Boram; Kang, Edward; Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, 73 Goryeodae Ro, Seoul 02841, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 73 Goryeodae Ro, Seoul 02841, South Korea.
EM ojr4991@korea.ac.kr
RI Kim, Young Ho/ABH-7801-2020; Kang, Edward/V-4367-2019; Oh,
   Jaeryung/ABD-3090-2021
OI Kim, Young Ho/0000-0002-5281-1185; Kang, Edward/0000-0001-7482-8757; Oh,
   Jaeryung/0000-0002-1036-6562
FU Korea Medical Device Development Fund - Korea government (the Ministry
   of Science and ICT); Korea Medical Device Development Fund - Korea
   government (Ministry of Trade, Industry and Energy); Korea Medical
   Device Development Fund - Korea government (Ministry of Health Welfare);
   Korea Medical Device Development Fund - Korea government (Ministry of
   Food and Drug Safety) [9991007076, KMDF-RnD 202011B20-02]
FX This work was supported by the Korea Medical Device Development Fund
   grant funded by the Korea government (the Ministry of Science and ICT,
   the Ministry of Trade, Industry and Energy, the Ministry of Health &
   Welfare, the Ministry of Food and Drug Safety) (NTIS Number: 9991007076,
   KMDF-RnD 202011B20-02).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77566-1
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chang IB, 2017, RETINA-J RET VIT DIS, V37, P896, DOI 10.1097/IAE.0000000000001262
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gupta MP, 2016, CLIN OPHTHALMOL, V10, P1275, DOI 10.2147/OPTH.S105080
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Ho J, 2011, OPHTHALMOLOGY, V118, P2001, DOI 10.1016/j.ophtha.2011.02.049
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jordan-Yu JM, 2021, RETINA-J RET VIT DIS, V41, P1084, DOI 10.1097/IAE.0000000000002966
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YH, 2021, GRAEF ARCH CLIN EXP, V259, P1711, DOI 10.1007/s00417-020-05051-6
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee Kyou Ho, 2017, Korean J Ophthalmol, V31, P431, DOI 10.3341/kjo.2016.0101
   Lee MW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229134
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu S., 2020, CURR EYE RES, P1
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nam KT, 2020, RETINA-J RET VIT DIS, V40, P2270, DOI 10.1097/IAE.0000000000002758
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   Ozcimen M, 2016, CUTAN OCUL TOXICOL, V35, P26, DOI 10.3109/15569527.2015.1004079
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 63
TC 6
Z9 6
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 2
PY 2021
VL 11
IS 1
AR 4999
DI 10.1038/s41598-021-84650-7
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QR7RG
UT WOS:000625411400032
PM 33654225
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gattoussi, S
   Cougnard-Gregoire, A
   Korobelnik, JF
   Rougier, MB
   Delyfer, MN
   Schweitzer, C
   Le Goff, M
   Merle, BMJ
   Dartigues, JF
   Delcourt, C
AF Gattoussi, Sarra
   Cougnard-Gregoire, Audrey
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Delyfer, Marie-Noelle
   Schweitzer, Cedric
   Le Goff, Melanie
   Merle, Benedicte M. J.
   Dartigues, Jean-Francois
   Delcourt, Cecile
TI CHOROIDAL THICKNESS, VASCULAR FACTORS, AND AGE-RELATED MACULAR
   DEGENERATION The ALIENOR Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroid; macular degeneration; risk factors; diabetes; smoking
ID OPTICAL COHERENCE TOMOGRAPHY; OCULAR PERFUSION-PRESSURE; COMPLEMENT
   FACTOR-H; RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY; HEALTHY-SUBJECTS;
   BLOOD-FLOW; ASSOCIATION; SMOKING; MACULOPATHY
AB Purpose: To study the associations of subfoveal choroidal thickness with vascular risk factors and age-related macular degeneration.
   Methods: Two hundred sixty-one participants of the Alienor study had gradable enhanced-depth imaging optical coherence tomography scans of the macula and available data on vascular and genetic risk factors (assessed through face-to-face interview and fasting blood samples) and age-related macular degeneration status (assessed from retinal photographs and optical coherence tomography). Subfoveal choroidal thickness was measured manually on one horizontal scan passing through the fovea.
   Results: In a multivariate mixed linear model, subfoveal choroidal thickness was independently associated with age greater than 80 years (-21.77 mu m, P = 0.02), axial length (-21.77 mu m, P < 0.0001), heavy smoking (>= 20 pack-years: 224.89 mm, P = 0.05), fasting blood glucose higher than 7 mmol/L (-53.17 mu m, P = 0.02), and lipid-lowering treatment (+18.23, P = 0.047). After multivariate adjustment for age, sex, axial length, and vascular and genetic risk factors, subfoveal choroidal thickness was thinner in eyes with central hyperpigmentation (-45.39 mu m, P = 0.006), central hypopigmentation (-44.99 mu m, P = 0.001), and central pigmentary abnormalities (-44.50 mu m, P = 0.001), but not in eyes with late agerelated macular degeneration (-18.05 mu m, P = 0.33) or soft drusen.
   Conclusion: These findings indicate a relationship between vascular risk factors and choroidal thinning and suggest an early involvement of the choroid in the pathogenesis of age-related macular degeneration.
C1 [Gattoussi, Sarra; Cougnard-Gregoire, Audrey; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle; Schweitzer, Cedric; Le Goff, Melanie; Merle, Benedicte M. J.; Dartigues, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Team LEHA,UMR 1219, Bordeaux, France.
   [Gattoussi, Sarra; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle; Schweitzer, Cedric] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Delcourt, C (通讯作者)，Bordeaux Populat Hlth Res Ctr, INSERM, U1219, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@u-bordeaux.fr
RI SCHWEITZER, CEDRIC/AAY-2787-2020; COUGNARD-GREGOIRE, Audrey/T-4443-2019;
   Delcourt, Cecile/I-2627-2013; Merle, Benedicte MJ/AAQ-5021-2021
OI COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Schweitzer, Cedric/0000-0002-2162-9479; LE GOFF,
   Melanie/0000-0003-2848-6287; Gattoussi, Sarra/0000-0002-8905-7112
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P7775, DOI 10.1167/iovs.14-14915
   Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Geyer O, 1999, ACTA OPHTHALMOL SCAN, V77, P522, DOI 10.1034/j.1600-0420.1999.770507.x
   Gok M, 2015, INDIAN J OPHTHALMOL, V63, P239, DOI 10.4103/0301-4738.156928
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kavroulaki D, 2010, ACTA OPHTHALMOL, V88, P850, DOI 10.1111/j.1755-3768.2009.01607.x
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Li XQ, 2014, INVEST OPHTH VIS SCI, V55, P550, DOI 10.1167/iovs.13-13476
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Unsal E, 2014, CLIN OPHTHALMOL, V8, P637, DOI 10.2147/OPTH.S59395
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong IY, 2013, RETINA-J RET VIT DIS, V33, P423, DOI 10.1097/IAE.0b013e3182753b5a
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 58
TC 20
Z9 20
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2019
VL 39
IS 1
BP 34
EP 43
DI 10.1097/IAE.0000000000002237
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4QS
UT WOS:000480736000014
PM 29975345
DA 2022-11-30
ER

PT J
AU Cheung, LK
   Eaton, A
AF Cheung, Lily K.
   Eaton, Angie
TI Age-Related Macular Degeneration
SO PHARMACOTHERAPY
LA English
DT Article
DE macular degeneration; visual acuity; choroidal neovascularization;
   geographic atrophy; antioxidant vitamins; vascular endothelial growth
   factor inhibitor; drusen
ID ENDOTHELIAL GROWTH-FACTOR; SINGLE INTRAVITREAL INJECTION; OPEN-LABEL
   EXTENSION; CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR PHARMACOKINETICS;
   IRIS NEOVASCULARIZATION; BEVACIZUMAB AVASTIN; GEOGRAPHIC ATROPHY;
   CIGARETTE-SMOKING; PEGAPTANIB SODIUM
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, and the prevalence of the disease increases exponentially with every decade after age 50years. It is a multifactorial disease involving a complex interplay of genetic, environmental, metabolic, and functional factors. Besides smoking, hypertension, obesity, and certain dietary habits, a growing body of evidence indicates that inflammation and the immune system may play a key role in the development of the disease. AMD may progress from the early form to the intermediate form and then to the advanced form, where two subtypes exist: the nonneovascular (dry) type and the neovascular (wet) type. AMD, supplementation with high-dose antioxidants (vitamin C, vitamin E, and -carotene) and zinc is recommended for those with the intermediate form of AMD in one or both eyes or with advanced AMD or vision loss due to AMD in one eye. As for the neovascular type of the advanced AMD, the current standard of therapy is intravitreal injections of vascular endothelial growth factor inhibitors. In addition, lifestyle and dietary modifications including improved physical activity, reduced daily sodium intake, and reduced intake of solid fats, added sugars, cholesterol, and refined grain foods are recommended. AMD can be cured or effectively prevented. Clearly, more research is needed to fully understand the pathophysiology as well as to develop prevention and treatment strategies for this devastating disease.
C1 [Cheung, Lily K.; Eaton, Angie] Texas So Univ, Dept Pharm Practice, Coll Pharm & Hlth Sci, Houston, TX 77004 USA.
C3 Texas Southern University
RP Cheung, LK (通讯作者)，2450 Holcombe Blvd Suite 2-25G, Houston, TX 77021 USA.
EM cheunglk@tsu.edu
RI Liew, Gerald/AAB-6870-2022; Gopinath, Bamini/K-4286-2019; Nivison-Smith,
   Lisa/H-3297-2019
OI Gopinath, Bamini/0000-0003-3573-359X; 
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   American Academy of Ophthalmology, 2008, AGE REL MACULAR DEG
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2006, AGE RELATED MACULAR
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   BARKER CF, 1977, ADV IMMUNOL, V25, P1
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Center for Nutrition Policy and Promotion, DIET GUID AM
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   *EYETECH INC, 2008, MAC PEG SOD INJ PACK
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Feucht N, 2008, CLIN OPHTHALMOL, V2, P253
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Genentech Inc, 2006, LUC RAN INJ PACK INS
   Genentech Inc, 2011, AV BEV PACK INS
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragouda ES, 2004, PHOTODYNAMIC THERAPY
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Koevary, 2000, Clin Eye Vis Care, V12, P97, DOI 10.1016/S0953-4431(00)00041-2
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pascolini D, 2002, OPHTHAL EPIDEMIOL, V2004, P67
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Regeneron, 2 YEAR RES PHAS 3 ST
   Regeneron, REG ANN FDA APPR EYL
   Regeneron Pharmaceuticals Inc, 2011, EYL TM AFL INJ INTR
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Streilein J W, 1999, Chem Immunol, V73, P11
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   The AREDS2 Research Group, 2012, OPHTHALMOLOGY, V119, P2282
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   U.S. Food and Drug Administration, DRUGS FDA
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
NR 128
TC 76
Z9 87
U1 1
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD AUG
PY 2013
VL 33
IS 8
BP 838
EP 855
DI 10.1002/phar.1264
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 242ZO
UT WOS:000326285900007
PM 23580402
DA 2022-11-30
ER

PT J
AU Weiss, JN
AF Weiss, Jeffrey N.
TI Hyperbaric oxygen therapy and age-related macular degeneration
SO UNDERSEA & HYPERBARIC MEDICINE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; PRESSURES; VARIANT; GROWTH; RISK
AB Age-related macular degeneration (AMD) is a significant cause of visual loss in the United States and Western Europe. As the population ages, the prevalence rate of advanced AMD is expected to double by 2030. A one-hour session of hyperbaric oxygen therapy (HBO(2)) was used to treated a group of 14 patients with advanced AMD. Eight patients were treated at 1.75 ATA, and six patients were treated at 1.5 ATA for one hour. Significant improvements in visual acuity and/or visual field, with improvements in the activities of daily living were observed.
C1 Retina Associates S Florida, Margate, FL USA.
RP Weiss, JN (通讯作者)，Retina Associates S Florida, Margate, FL USA.
EM JWEISSMD@aol.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jain KK., 2004, TXB HYPERBARIC MED, P16
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan D., 2007, International Journal of Biology and Biotechnology, V4, P43
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MURPHYLAVOIE H, 2009, HYPERBARIC OXYGEN TH
   NICHOLS CW, 1969, NEW ENGL J MED, V281, P25, DOI 10.1056/NEJM196907032810106
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 17
TC 8
Z9 8
U1 0
U2 8
PU UNDERSEA & HYPERBARIC MEDICAL SOC INC
PI DUNKIRK
PA 10020 SOUTHER MARYLAND BLVD, PO BOX 1020, DUNKIRK, MD 20754-1020 USA
SN 1066-2936
J9 UNDERSEA HYPERBAR M
JI Undersea Hyperb. Med.
PD MAR-APR
PY 2010
VL 37
IS 2
BP 101
EP 105
PG 5
WC Marine & Freshwater Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Marine & Freshwater Biology; Research & Experimental Medicine
GA 589FW
UT WOS:000277133300005
PM 20462142
DA 2022-11-30
ER

PT J
AU Rakoczy, PE
   Yu, MJT
   Nusinowitz, S
   Chang, B
   Heckenlively, JR
AF Rakoczy, P. Elizabeth
   Yu, Meaghan J. T.
   Nusinowitz, Steven
   Chang, Bo
   Heckenlively, John R.
TI Mouse models of age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization (CNV);
   retina; retinal degeneration; animal models; transgenic
ID ENDOTHELIAL GROWTH-FACTOR; BASAL LAMINAR DEPOSIT; FACTOR-H POLYMORPHISM;
   RETINAL DEGENERATION; CHOROIDAL NEOVASCULARIZATION; TRANSGENIC MICE;
   SUBRETINAL NEOVASCULARIZATION; MESSENGER-RNA; SLOW RDS; INCREASED
   EXPRESSION
AB Recent advances in genetic technologies have greatly accelerated our ability to find disease-related genes and to generate animal models. The availability of ocular tissues with known genetic diseases are greatly contributing to our understanding of retinal disease processes including age-related macular degeneration (AMD), and panretinal and cone degenerations. While the macula is a highly specialised area of the retina not present in many mammals, the use of animal models such as mouse strains will give basic physiology and visual processing genetics relevant to human AMD. This review aims to provide a framework for better understanding some of the existing animal models and the knowledge that has been derived from their evaluations. (c) 2005 Elsevier Ltd. All rights reserved.
C1 QEII Med Ctr, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Dept Mol Ophthalmol, Nedlands, WA 6009, Australia.
   Univ Western Australia, Ctr Ophthalmol & Visual Sci, Nedlands, WA 6009, Australia.
   Lions Eye Inst Ltd, Dept Mol Biol, Nedlands, WA 6009, Australia.
   Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Jackson Lab, Bar Harbor, ME 04609 USA.
   Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
C3 Lions Eye Institute; University of Western Australia; University of
   Western Australia; Lions Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA; Jackson
   Laboratory; University of Michigan System; University of Michigan
RP Rakoczy, PE (通讯作者)，QEII Med Ctr, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Dept Mol Ophthalmol, AA Block,2 Verdun St, Nedlands, WA 6009, Australia.
EM rakoczy@cyllene.uwa.edu.au; meaghan@cyllene.uwa.edu.au;
   nusinowitz@jsei.ucla.edu; bchang@jax.org; jrheck@umich.edu
OI Chang, Bo/0000-0001-8259-7290
FU NEI NIH HHS [R01 EY7758-16] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY007758] Funding Source: NIH RePORTER
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   BATEMAN JB, 1992, GENOMICS, V12, P601, DOI 10.1016/0888-7543(92)90454-Z
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bravo-Nuevo A, 2003, ADV EXP MED BIOL, V533, P241
   CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   CHANG B, 1998, INVEST OPHTHALMOL S, V39
   CHANG B, RETINAL DEGENERATION
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   LAMOREUX ML, 1992, J HERED, V83, P435, DOI 10.1093/oxfordjournals.jhered.a111247
   LERNER AB, 1986, MOUSE NEWS LETT, V74, P125
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   MA JS, 1995, GENOMICS, V28, P212, DOI 10.1006/geno.1995.1133
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Matsui H, 2001, INVEST OPHTH VIS SCI, V42, P2935
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Reich S, 2003, MOL VIS, V9, P210
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Smith RS, 2000, P NATL ACAD SCI USA, V97, P2191, DOI 10.1073/pnas.040531597
   Smith S. B., 1995, Mouse Genome, V93, P871
   SMITH SB, 1994, EXP EYE RES, V58, P77, DOI 10.1006/exer.1994.1196
   SMITH SB, 1995, EXP EYE RES, V60, P333, DOI 10.1016/S0014-4835(05)80115-0
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tang M., 1992, Mouse Genome, V90, P441
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P
   TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0
   VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wilson AS, 2003, INVEST OPHTH VIS SCI, V44, P1426, DOI 10.1167/iovs.02-0622
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
NR 72
TC 69
Z9 74
U1 1
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2006
VL 82
IS 5
BP 741
EP 752
DI 10.1016/j.exer.2005.10.012
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041FU
UT WOS:000237440300002
PM 16325179
DA 2022-11-30
ER

PT J
AU Ziada, J
   Hagenau, F
   Compera, D
   Wolf, A
   Scheler, R
   Schaumberger, MM
   Priglinger, SG
   Schumann, RG
AF Ziada, Jean
   Hagenau, Felix
   Compera, Denise
   Wolf, Armin
   Scheler, Renate
   Schaumberger, Markus M.
   Priglinger, Siegfried G.
   Schumann, Ricarda G.
TI VITRECTOMY FOR INTERMEDIATE AGE-RELATED MACULAR DEGENERATION ASSOCIATED
   WITH TANGENTIAL VITREOMACULAR TRACTION A CLINICOPATHOLOGIC CORRELATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intermediate age-related macular degeneration; premacular membrane;
   vitrectomy; vitreomacular traction
ID GROWTH-FACTOR THERAPY; EPIRETINAL MEMBRANES; LIMITING MEMBRANE;
   INFLAMMATION; DRUSEN; VITREOSCHISIS
AB Purpose: To describe the morphologic characteristics of the vitreomacular interface in intermediate age-related macular degeneration associated with tangential traction due to premacular membrane formation and to correlate with optical coherence tomography (OCT) findings and clinical data.
   Methods: Premacular membrane specimens were removed sequentially with the internal limiting membrane from 27 eyes of 26 patients with intermediate age-related macular degeneration during standard vitrectomy. Specimens were processed for immunocytochemical staining of epiretinal cells and extracellular matrix components. Ultrastructural analysis was performed using transmission electron microscopy. Spectral domain optical coherence tomography images and patient charts were evaluated in retrospect.
   Results: Immunocytochemistry revealed hyalocytes and myofibroblasts as predominant cell types. Ultrastructural analysis demonstrated evidence of vitreoschisis in all eyes. Myofibroblasts with contractile properties were observed to span between folds of the internal limiting membrane and vitreous cortex collagen. Retinal pigment epithelial cells or inflammatory cells were not detected. Mean visual acuity (Snellen) showed significant improvement from 20/72 +/- 20/36 to 20/41 +/- 20/32 (P < 0.001) after a mean follow-up period of 19 months (median, 17 months). During this period, none of the eyes required anti-vascular endothelial growth factor therapy.
   Conclusion: Fibrocellular premacular proliferation in intermediate age-related macular degeneration predominantly consists of vitreous collagen, hyalocytes, and myofibroblasts with contractile properties. Vitreoschisis and vitreous-derived cells appear to play an important role in traction formation of this subgroup of eyes. In patients with intermediate age-related macular degeneration and contractile premacular membrane, release of traction by vitrectomy with internal limiting membrane peeling results in significantly functional and anatomical improvement.
C1 [Ziada, Jean; Hagenau, Felix; Compera, Denise; Wolf, Armin; Scheler, Renate; Schaumberger, Markus M.; Priglinger, Siegfried G.; Schumann, Ricarda G.] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Mathildenstr 6, D-80336 Munich, Germany.
C3 University of Munich
RP Schumann, RG (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Mathildenstr 6, D-80336 Munich, Germany.
EM ricarda.schumann@med.uni-muenchen.de
RI Hagenau, Felix/AAE-7516-2020
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dithmar S, 2013, EYE, V27, P779, DOI 10.1038/eye.2013.35
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gupta P, 2011, BRIT J OPHTHALMOL, V95, P376, DOI 10.1136/bjo.2009.175109
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Inoue Y, 2009, RETINA-J RET VIT DIS, V29, P477, DOI 10.1097/IAE.0b013e31819a6004
   Joussen AM, 2014, KLIN MONATSBL AUGENH, V231, P874, DOI 10.1055/s-0034-1382853
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Schlanitz FG, 2016, BR J OPHTHALMOL, V0, P1
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Schumann RG, 2014, GRAEF ARCH CLIN EXP, V252, P1887, DOI 10.1007/s00417-014-2841-x
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2015, RETINA-J RET VIT DIS, V35, P1715, DOI 10.1097/IAE.0000000000000718
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J., 2014, VITREOUS EALTH DIS
   Sheybani A, 2012, J OPHTHALMIC INFLAMM, V2, P243, DOI 10.1007/s12348-012-0074-x
   Snead DRJ, 2008, EYE, V22, P1310, DOI 10.1038/eye.2008.36
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Zhao F, 2013, RETINA-J RET VIT DIS, V33, P77, DOI 10.1097/IAE.0b013e3182602087
NR 28
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2018
VL 38
IS 3
BP 531
EP 540
DI 10.1097/IAE.0000000000001573
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2AB
UT WOS:000440619200015
PM 28257377
DA 2022-11-30
ER

PT J
AU Yan, M
   He, BF
   Liu, K
   Xu, HF
   Luo, DL
   Wu, ZG
   Xu, K
   Huang, J
   Song, YP
AF Yan, Ming
   He, Bifang
   Liu, Kun
   Xu, Haifeng
   Luo, Delun
   Wu, Zhigang
   Xu, Kai
   Huang, Jian
   Song, Yanping
TI Pharmacogenetics of genes associated with outcome of conbercept
   treatment for age-related macular degeneration in a Chinese population
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE SNP; neovascular AMD; conbercept; SNP genotyping; genetic biomarker
ID GROWTH-FACTOR TREATMENT; ANTI-VEGF TREATMENT; INTRAVITREAL RANIBIZUMAB;
   NEOVASCULAR AMD; RISK-FACTORS; BEVACIZUMAB; POLYMORPHISM; VARIANTS;
   HTRA1; LOCI
AB To ascertain whether single-nucleotide polymorphisms (SNP) of complement factor H (CFH), interleukin 8 (IL8), vascular endothelial growth factor A (VEGFA), age-related maculopathy susceptibility 2 (LOC387715/ARMS2), high-temperature requirement A-1 (HTRA1), and complement component C3 (C3) genes impact the outcomes of neovascular age-related macular degeneration (AMD) by conbercept in Chinese patients, we enrolled 184 neovascular AMD patients from the AURORA and PHOENIX trials, and participants were administrated conbercept. For each patient, baseline best corrected visual acuity (BCVA) letter score was recorded, and the BCVA score at each subsequent visit, age, sex, and the number of injections were also recorded. Seven candidate SNPs were selected. The SNP genotyping was performed by TaqMan SNP genotyping assays. Single-locus analysis and haplotype analysis were used to determine the influence of each SNP on treatment outcome at 6 and 12 months. We found that, both in single-locus analysis and haplotype analysis, rs10490924 and rs11200638 were significantly associated with patient response to conbercept treatment for neovascular AMD in the Chinese population. These findings suggest that SNPs rs10490924 and rs11200638 could be used as genetic biomarkers for estimation of visual outcomes in response to conbercept treatment for neovascular AMD. As a result, a subgroup of Chinese patients that benefit from this modality of treatment can be identified.
C1 [Yan, Ming; Song, Yanping] Southern Med Univ, Wuhan Sch Clin Med, Dept Ophthalmol, Wuhan Gen Hosp Guangzhou Mil Reg, Wuhan, Hubei, Peoples R China.
   [He, Bifang; Huang, Jian] UESTC, Ctr Informat Biol, 2006 Xiyuan Ave, Chengdu 611731, Sichuan, Peoples R China.
   [He, Bifang; Huang, Jian] UESTC, Sch Life Sci & Technol, Chengdu, Sichuan, Peoples R China.
   [Liu, Kun; Wu, Zhigang] Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Xu, Haifeng] Qingdao Eye Hosp, Dept Med Retina, Qingdao, Shandong, Peoples R China.
   [Luo, Delun; Wu, Zhigang; Xu, Kai] Chengdu Nuoen Biotechnol LTD, Res Ctr, Chengdu, Peoples R China.
   [Luo, Delun; Wu, Zhigang; Xu, Kai] Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, Chengdu, Sichuan, Peoples R China.
C3 Southern Medical University - China; University of Electronic Science &
   Technology of China; University of Electronic Science & Technology of
   China; Chengdu University of Traditional Chinese Medicine
RP Huang, J (通讯作者)，UESTC, Ctr Informat Biol, 2006 Xiyuan Ave, Chengdu 611731, Sichuan, Peoples R China.; Song, YP (通讯作者)，Southern Med Univ, Wuhan Clin Med Coll, Wuhan 430070, Hubei, Peoples R China.
EM hj@uestc.edu.cn; songyan-ping@medmail.com.cn
RI wu, zhi/GXH-3041-2022; Huang, Jian/G-8437-2011
OI Huang, Jian/0000-0003-3282-8892
FU National Natural Science Foundation of China [61571095]; Fundamental
   Research Funds for the Central Universities of China [ZYGX-2015Z006];
   Chengdu Nuoen Biotechnologies, LTD, Chengdu, China
FX The study was supported by the National Natural Science Foundation of
   China [61571095]; the Fundamental Research Funds for the Central
   Universities of China [grant no. ZYGX-2015Z006]. The study was also
   sponsored by Chengdu Nuoen Biotechnologies, LTD, Chengdu, China. The
   sponsor participated in the design and conduct of the study, data
   collection, management, analysis, and interpretation, as well as
   preparation of the manuscript.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park UC, 2014, MOL VIS, V20, P1680
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang Y, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.10
NR 40
TC 0
Z9 0
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 3
BP 2524
EP +
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GB4BZ
UT WOS:000429006600132
DA 2022-11-30
ER

PT J
AU Mataix, J
   Desco, MC
   Palacios, E
   Garcia-Pous, M
   Navea, A
AF Mataix, Jorge
   Carmen Desco, M.
   Palacios, Elena
   Garcia-Pous, Maria
   Navea, Amparo
TI Photodynamic Therapy for Age-Related Macular Degeneration Treatment:
   Epidemiological and Clinical Analysis of a Long-Term Study
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; TAP;
   FLUORESCEIN; IMPACT
AB BACKGROUND AND OBJECTIVE: The aim of this article was to analyze the long-term results of patients with exudative age-related macular degeneration treated with photodynamic therapy (PDT).
   PATIENTS AND METHODS: This prospective nonrandomized clinical trial Included 262 patients with exudative age-related macular degeneration who Were treated with PDT in accordance with the Protocol of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study. The follow-up lasted 48 months.
   RESULTS: There was a significant loss of visual acuity 3 months after the first PDT treatment, a slow, progressive decrease of vision until month 12, and then visual acuity remained stable from months 24 to 48. The choroidal neovascularization size increased noticeably during the first 12 months, particularly the first 3 months after PDT. The higher the classic component of choroidal neovascularization, the better it responded to PDT The evolution of juxtafoveal choroidal neovascularization was worse than iliac of subfoveal choroidal neovascularization after PDT because it grew quickly toward the fovea and visual acuity loss was greater.
   CONCLUSION: PDT is a safe, long-term treatment for exudative age-related macular degeneration, but it is nor definitive because this treatment cannot stop the initial growth of the choroidal neovascularization lesion.
C1 [Mataix, Jorge; Carmen Desco, M.; Palacios, Elena; Garcia-Pous, Maria; Navea, Amparo] Fdn Oftalmol Mediterraneo, Valencia, Spain.
RP Mataix, J (通讯作者)，Bifurcac Pio Baroja Gen Aviles S-N, Valencia 46015, Spain.
EM jormabo@ono.com
RI Desco, Manuel/AAD-7137-2019; Desco, Manuel/D-2822-2009; ESTEBAN, MARIA
   CARMEN DESCO/J-2281-2016; Navea, Amparo/D-4577-2009
OI Desco, Manuel/0000-0003-0989-3231; ESTEBAN, MARIA CARMEN
   DESCO/0000-0002-9239-7847; Navea, Amparo/0000-0002-9856-5370; Mataix
   Boronat, Jorge/0000-0002-7018-3506
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atmaca LS, 1996, OPHTHALMOLOGICA, V210, P148, DOI 10.1159/000310695
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Essex RW, 2003, CLIN EXP OPHTHALMOL, V31, P476, DOI 10.1046/j.1442-9071.2003.00714.x
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P651, DOI 10.1111/j.1600-0420.2004.00382.x
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 23
TC 8
Z9 8
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2009
VL 40
IS 3
BP 277
EP 284
DI 10.3928/15428877-20090430-09
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 446RY
UT WOS:000266140000009
PM 19485292
DA 2022-11-30
ER

PT J
AU Guidry, C
   Medeiros, NE
   Curcio, CA
AF Guidry, C
   Medeiros, NE
   Curcio, CA
TI Phenotypic variation of retinal pigment epithelium in age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBRETINAL NEOVASCULAR MEMBRANES; PORCINE MULLER CELLS; 5-YEAR
   INCIDENCE; GROWTH-FACTOR; MACULOPATHY; DRUSEN; ABNORMALITIES;
   PREVALENCE; TRANSDIFFERENTIATION; PROGNOSIS
AB PURPOSE. To determine whether retinal pigment epithelium (RPE) in eyes with age-related macular degeneration (ARMD) express vimentin and a smooth muscle actin (alphaSMA), two cytoskeletal proteins associated with phenotypic variation in culture.
   METHODS. Six eyes with late ARMD and three age-matched control eyes were preserved in buffered 4% paraformaldehyde and cryosectioned at 10 mum. Stages of RPE morphology and pigmentation were assessed by the Alabama Age-Related Macular Degeneration Grading System. Vitmentin, alphaSMA, and glial fibrillary acidic protein (GFAp) expression was detected by indirect immunofluorescence, These results were compared with regional variations in disease severity,
   RESULTS. RPE changes in ARMD included acquired expression of vimentin, but alphaSMA-positive cells were rare. GFAP expression increased in Muller cells in the neural retina in association with RPE changes and photoreceptor degeneration.
   CONCLUSIONS. The initial stages of RPE changes in eyes with ARMD mimic those reported for Cultured RPE cells. The absence of alphaSMA-positive cells in regions of RPE atrophy, suggests that RPE arc lost rather than persist in a dedifferentiated state.
C1 Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Retina Specialists N Alabama, Huntsville, AL USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Rm H020,700 S 18th St, Birmingham, AL 35294 USA.
EM curcio@uab.edu
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chou YH, 2000, J CELL BIOL, V150, pF101, DOI 10.1083/jcb.150.3.F101
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Eckes B, 1998, J CELL SCI, V111, P1897
   ERICKSON PA, 1987, EXP EYE RES, V44, P37, DOI 10.1016/S0014-4835(87)80023-4
   FUCHS U, 1991, INVEST OPHTH VIS SCI, V32, P3178
   Gilles C, 1999, J CELL SCI, V112, P4615
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   GUERIN CJ, 1990, INVEST OPHTH VIS SCI, V31, P1474
   Guidry C, 1996, INVEST OPHTH VIS SCI, V37, P740
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   HUMPHREY MF, 1993, J COMP NEUROL, V334, P545, DOI 10.1002/cne.903340404
   Kivela T, 1998, PROG RETIN EYE RES, V17, P385, DOI 10.1016/S1350-9462(98)00001-9
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mamballikalathil I, 2000, INVEST OPHTH VIS SCI, V41, P529
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARTHY V, 1995, DNA CELL BIOL, V14, P313, DOI 10.1089/dna.1995.14.313
   SCHNITZER J, 1988, DEV BRAIN RES, V44, P59, DOI 10.1016/0165-3806(88)90118-6
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zhao SL, 1997, INT REV CYTOL, V171, P225
NR 47
TC 88
Z9 89
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2002
VL 43
IS 1
BP 267
EP 273
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 509DV
UT WOS:000173130400038
PM 11773041
DA 2022-11-30
ER

PT J
AU Lee, B
   Ahn, J
   Yun, C
   Kim, SW
   Oh, J
AF Lee, Boram
   Ahn, Jaemoon
   Yun, Cheolmin
   Kim, Seong-woo
   Oh, Jaeryung
TI Variation of Retinal and Choroidal Vasculatures in Patients With
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography
   angiography; choriocapillaris; retinal vasculature; choroidal
   vasculature
ID OXYGEN DISTRIBUTION; BLOOD-FLOW; MACULOPATHY; EYES; DISEASE;
   BINARIZATION; ANGIOGRAPHY; CONSUMPTION; THICKNESS; LAYERS
AB PURPOSE. To investigate variations in chorioretinal vasculatures in fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD).
   METHODS. We included fellow eyes of consecutive patients with unilateral nAMD from swept source optical coherence tomography (SS-OCT) angiography database. Vascular and nonvascular indices were determined based on SS-OCT and SS-OCT angiography images. Variation of the vascular or nonvascular index was compared between fellow eyes with and without early AMD.
   RESULTS. In 146 fellow eyes, 88 (60.3%) had early AMD and 58 (39.7%) had a normal fundus. Vascular density (VD) values of the superficial and deep retinal capillary plexus and choriocapillaris were smaller in eyes with early AMD than in those without (P < 0.001, P = 0.001, P = 0.006, respectively). Flow void area in choriocapillaris was greater in eyes with early AMD than those without (P = 0.015). In 88 fellow eyes with early AMD, vascular indices of the retina were correlated with those of choroid while nonvascular indices were not. Fellow eyes of patients with classic exudative AMD had greater foveal avascular zone area and smaller VD values of the deep retinal capillary plexus than those with polypoidal choroidal vasculopathy (P < 0.001, P = 0.004).
   CONCLUSIONS. In addition to vascular insufficiency in the choroid or choriocapillaris, retinal vascular alteration was apparent in eyes with early AMD. It may suggest that retinal vessels were involved in the pathogenesis of AMD even while changes in nonvascular components of the retina were not yet apparent.
C1 [Lee, Boram; Ahn, Jaemoon; Yun, Cheolmin; Kim, Seong-woo; Oh, Jaeryung] Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Dept Ophthalmol, Coll Med, 73 Inchon Ro, Seoul 02841, South Korea.
EM ojr4991@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Korea University [K1620061]
FX Supported by a grant from Korea University (K1620061).
CR Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Ahn J, 2018, GRAEF ARCH CLIN EXP, V256, P11, DOI 10.1007/s00417-017-3814-7
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Aqrawal R, 2016, PLOS ONE, V11
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Birol G, 2007, AM J PHYSIOL-HEART C, V293, pH1696, DOI 10.1152/ajpheart.00221.2007
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Coscas F, 2016, INVEST OPHTH VIS SCI, V57, pOCT211, DOI 10.1167/iovs.15-18793
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Linsenmeier R. A., 2012, OCULAR BLOOD FLOW, P65
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   REICHENBACH A, 1995, PROG RETIN EYE RES, V14, P1, DOI 10.1016/1350-9462(93)E0001-K
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Wei YT, 2017, INVEST OPHTH VIS SCI, V58, P3804, DOI 10.1167/iovs.17-21460
   Yun C, 2017, GRAEF ARCH CLIN EXP, V255, P1923, DOI 10.1007/s00417-017-3742-6
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 45
TC 28
Z9 28
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2018
VL 59
IS 12
BP 5246
EP 5255
DI 10.1167/iovs.17-23600
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ4YH
UT WOS:000449417000024
PM 30383196
OA gold
DA 2022-11-30
ER

PT J
AU Deng, YH
   Shuai, P
   Wang, HX
   Zhang, SS
   Li, J
   Du, MY
   Huang, PR
   Qu, C
   Huang, LL
AF Deng, Yanhui
   Shuai, Ping
   Wang, Haixin
   Zhang, Shanshan
   Li, Jie
   Du, Mingyan
   Huang, Peirong
   Qu, Chao
   Huang, Lulin
TI Untargeted metabolomics for uncovering plasma biological markers of wet
   age-related macular degeneration
SO AGING-US
LA English
DT Article
DE wAMD; CNV; PCV; plasma; metabonomics
ID FACTOR-H POLYMORPHISM; RISK-FACTORS; LIPID MEDIATORS; METABOLISM;
   MECHANISMS; CYCLAMATE; VARIANT; CANCER; CYCLOHEXYLAMINE; VASCULOPATHY
AB Wet age-related macular degeneration (wAMD) causes central vision loss and represents a major health problem in elderly people. Here we have used untargeted metabolomics using UHPLC-MS to profile plasma from 127 patients with wAMD (67 choroidal neovascularization (CNV) and 60 polypoidal choroidal vasculopathy (PCV)) and 50 controls. A total of 545 biochemicals were detected. Among them, 17 metabolites presented difference between patients with wAMD and controls. Most of them were oxidized lipids (N=6, 35.29%). Comparing to controls, 28 and 18 differential metabolites were identified in patients with CNV and PCV, respectively. Two metabolites, hyodeoxycholic acid and L-tryptophanamide, were differently distributed between PCV and CNV. We first investigated the genetic association with metabolites in wet AMD (CFH rs800292 and HTRA1 rs10490924). We identified six differential metabolites between the GG and AA genotypes of CFH rs800292, five differential metabolites between the GG and AA genotypes of HTRA1 rs10490924, and four differential metabolites between the GG and GA genotypes of rs10490924. We selected four metabolites (cyclamic acid, hyodeoxycholic acid, L-tryptophanamide and O-phosphorylethanolamine) for in vitro experiments. Among them, cyclamic acid reduced the activity, inhibited the proliferation, increased the apoptosis and necrosis in human retinal pigment epithelial cells (HRPECs). L-tryptophanamide affected the proliferation, apoptosis and necrosis in HRPECs, and promoted the tube formation and migration in primary human retinal endothelial cells (HRECs). Hyodeoxycholic acid and O-phosphorylethanolamine inhibited the tube formation and migration in HRECs. The results suggested that differential metabolites have certain effects on wAMD pathogenesis-related HRPECs and HRECs.
C1 [Deng, Yanhui; Wang, Haixin; Zhang, Shanshan; Du, Mingyan; Huang, Lulin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Key Lab Human Dis Gene Study Sichuan Prov, Chengdu, Sichuan, Peoples R China.
   [Deng, Yanhui; Wang, Haixin; Zhang, Shanshan; Du, Mingyan; Huang, Lulin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Ctr Lab Med, Chengdu, Sichuan, Peoples R China.
   [Deng, Yanhui; Du, Mingyan; Huang, Lulin] Sichuan Acad Med Sci, Chinese Acad Med Sci 2019RU026, Res Unit Blindness Prevent, Chengdu, Sichuan, Peoples R China.
   [Shuai, Ping] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Hlth Management Ctr & Phys Examinat Ctr, Chengdu, Sichuan, Peoples R China.
   [Li, Jie; Qu, Chao] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Huang, Peirong] Shanghai Gen Hosp, Shanghai, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Sichuan Provincial People's
   Hospital; Sichuan Provincial People's Hospital; University of Electronic
   Science & Technology of China; Sichuan Provincial People's Hospital;
   University of Electronic Science & Technology of China
RP Huang, LL (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Key Lab Human Dis Gene Study Sichuan Prov, Chengdu, Sichuan, Peoples R China.; Huang, LL (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Ctr Lab Med, Chengdu, Sichuan, Peoples R China.; Huang, LL (通讯作者)，Sichuan Acad Med Sci, Chinese Acad Med Sci 2019RU026, Res Unit Blindness Prevent, Chengdu, Sichuan, Peoples R China.
EM huangluling@yeah.net
FU National Natural Science Foundation of China [81970839, 81670895,
   81300802]; Department of Science and Technology of Sichuan Province,
   China [2017JZ0039]
FX This work was supported by the National Natural Science Foundation of
   China (81970839 (L.H.), 81670895 (L.H.), and 81300802 (L.H.)); the
   Department of Science and Technology of Sichuan Province, China
   (2021YFS0033 (L.H.), 2017JQ0024 (L.H.), 2016HH0072 (L.H.) and 2013JY0195
   (L.H.); the Department of Science and Technology of Sichuan Province,
   China (2017JZ0039 (P.S.).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Asiago VM, 2010, CANCER RES, V70, P8309, DOI 10.1158/0008-5472.CAN-10-1319
   BOPP BA, 1986, CRC CR REV TOXICOL, V16, P213, DOI 10.3109/10408448609037465
   Brantley MA, 2012, OXID STRESS APPL BAS, P367, DOI 10.1007/978-1-61779-606-7_18
   Brereton RG, 2014, J CHEMOMETR, V28, P213, DOI 10.1002/cem.2609
   BUSS NE, 1992, TOXICOL APPL PHARM, V115, P199, DOI 10.1016/0041-008X(92)90324-L
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Caudle WM, 2010, EXPERT REV NEUROTHER, V10, P925, DOI 10.1586/ERN.10.54
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chen YH, 2009, ANALYST, V134, P2003, DOI 10.1039/b907243h
   Chen ZH, 2019, BIOCHEM BIOPH RES CO, V508, P507, DOI 10.1016/j.bbrc.2018.11.172
   Chi YY, 2014, STAT MED, V33, P812, DOI 10.1002/sim.5986
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DRASAR BS, 1972, BIOCHEM J, V129, P881, DOI 10.1042/bj1290881
   Dunn WB, 2007, METABOLOMICS, V3, P413, DOI 10.1007/s11306-007-0063-5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farooqui AA, 2012, J ALZHEIMERS DIS, V30, pS163, DOI 10.3233/JAD-2011-111085
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fischer T, 2015, ORVOSI HETILAP, V156, P358, DOI 10.1556/OH.2015.30017
   Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaarniranta K, 2019, ACTA BIOCHIM POL, V66, P147, DOI 10.18388/abp.2018_2810
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Midelfart A, 2009, ACTA OPHTHALMOL, V87, P697, DOI 10.1111/j.1755-3768.2009.01516.x
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morimoto S, 1996, Int J Urol, V3, P212, DOI 10.1111/j.1442-2042.1996.tb00519.x
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Oakman C, 2011, ANN ONCOL, V22, P1295, DOI 10.1093/annonc/mdq606
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1
   Renwick AG, 2004, TOXICOL APPL PHARM, V196, P367, DOI 10.1016/j.taap.2004.01.013
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Soltow QA, 2013, METABOLOMICS, V9, pS132, DOI 10.1007/s11306-011-0332-1
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Sun Y, 2014, INT J MOL MED, V34, P1013, DOI 10.3892/ijmm.2014.1861
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Urpi-Sarda M, 2019, DIABETES METAB, V45, P167, DOI 10.1016/j.diabet.2018.02.006
   Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307
   Willeford KT, 2012, OPTOMETRY VISION SCI, V89, P1662, DOI 10.1097/OPX.0b013e31826c5df2
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Young Stephen P, 2009, J Ocul Biol Dis Infor, V2, P235
NR 64
TC 7
Z9 7
U1 5
U2 20
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY 31
PY 2021
VL 13
IS 10
BP 13968
EP 14000
PG 33
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA SL1ZG
UT WOS:000656718900011
PM 33946050
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ambati, J
   Fowler, BJ
AF Ambati, Jayakrishna
   Fowler, Benjamin J.
TI Mechanisms of Age-Related Macular Degeneration
SO NEURON
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULAR MEMBRANES; FACTOR-H POLYMORPHISM; EMBRYONIC STEM-CELLS;
   ASSESSING SUSCEPTIBILITY; COMPLEMENT ACTIVATION; GEOGRAPHIC ATROPHY;
   BRUCHS MEMBRANE; GENE-EXPRESSION
AB Age-related macular degeneration (AMD), a progressive condition that is untreatable in up to 90% of patients, is a leading cause of blindness in the elderly worldwide. The two forms of AMD, wet and dry, are classified based on the presence or absence of blood vessels that have disruptively invaded the retina, respectively. A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are no approved treatments for dry AMD. In this review, we provide insight into the critical effector pathways mediating each form of the disease. A recurring theme that spans most aspects of AMD pathogenesis is defective immune modulation in the classically immune-privileged ocular haven. Interestingly, the latest advances in AMD research also highlight common molecular disease pathways with other neurodegenerative disorders. Finally, the therapeutic potential of intervening at known mechanistic steps of AMD pathogenesis is discussed.
C1 [Ambati, Jayakrishna; Fowler, Benjamin J.] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Ambati, Jayakrishna; Fowler, Benjamin J.] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
C3 University of Kentucky; University of Kentucky
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
FU National Eye Institute (NEI)/National Institutes of Health (NIH)
   [R01EY018350, R01EY018836, R01EY020672, R01EY022238, R21EY019778,
   RC1EY020442]; Doris Duke Distinguished Clinical Scientist Award;
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research; Dr. E. Vernon Smith and Eloise C. Smith Macular Degeneration
   Endowed Chair; NIH [T32HL091812, UL1RR033173]; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [TL1TR000115, UL1TR001998, UL1TR000117]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES
   [TL1RR033172, UL1RR033173] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY015422, RC1EY020442, R21EY019778, R01EY022238,
   R01EY018350, R01EY020672, R01EY018836] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091812] Funding Source:
   NIH RePORTER
FX We thank D.H. Fowler, A.M. Rao, G.S. Rao, and K. Ambati for discussions,
   and T. Dolan and M. Hazzard for figure assistance. J.A. was supported by
   National Eye Institute (NEI)/National Institutes of Health (NIH) grants
   R01EY018350, R01EY018836, R01EY020672, R01EY022238, R21EY019778,
   RC1EY020442, Doris Duke Distinguished Clinical Scientist Award,
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, Dr. E. Vernon Smith and Eloise C. Smith Macular Degeneration
   Endowed Chair, and B.J.F. was supported by by NIH T32HL091812 and
   UL1RR033173. J.A. is named as an inventor on patent applications about
   age-related macular degeneration filed by the University of Kentucky and
   is a founder of iVeena Pharmaceuticals, which is commercializing these
   technologies.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Belancio VP, 2008, GENOME RES, V18, P343, DOI 10.1101/gr.5558208
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blalock EM, 2011, J CHEM NEUROANAT, V42, P118, DOI 10.1016/j.jchemneu.2011.06.007
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Boothby LA, 2005, ANN PHARMACOTHER, V39, P2073, DOI 10.1345/aph.1E495
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Christensen M, 2009, NEUROSCI LETT, V466, P55, DOI 10.1016/j.neulet.2009.04.043
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Ferrara N, 2010, CURR OPIN HEMATOL, V17, P219, DOI 10.1097/MOH.0b013e3283386660
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Glenn J.V., 2011, A VONGRAEFES ARCH KL, V32, P1407
   Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hasler J, 2006, NUCLEIC ACIDS RES, V34, P2374, DOI 10.1093/nar/gkl246
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Majumder S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025416
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Paynter NP, 2010, JAMA-J AM MED ASSOC, V303, P631, DOI 10.1001/jama.2010.119
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sen CK, 2009, J VASC RES, V46, P527, DOI 10.1159/000226221
   Shen L, 2010, J ALZHEIMERS DIS, V19, P1141, DOI 10.3233/JAD-2010-1307
   Sheridan CM, 2009, EYE, V23, P1910, DOI 10.1038/eye.2008.420
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Szumiel I, 2011, FREE RADICAL RES, V45, P253, DOI 10.3109/10715762.2010.525233
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tong JP, 2006, MOL VIS, V12, P1490
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Underwood BR, 2010, HUM MOL GENET, V19, P3413, DOI 10.1093/hmg/ddq253
   Walshe TE, 2009, ARTERIOSCL THROM VAS, V29, P1185, DOI 10.1161/ATVBAHA.109.186742
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Wiesen JL, 2009, MOL IMMUNOL, V46, P1222, DOI 10.1016/j.molimm.2008.11.012
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Woolcock KJ, 2011, NAT STRUCT MOL BIOL, V18, P94, DOI 10.1038/nsmb.1935
   Yakovchuk P, 2009, P NATL ACAD SCI USA, V106, P5569, DOI 10.1073/pnas.0810738106
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2008, AM J OPHTHALMOL, V146, P151, DOI 10.1016/j.ajo.2008.05.027
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 152
TC 581
Z9 619
U1 21
U2 163
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD JUL 12
PY 2012
VL 75
IS 1
BP 26
EP 39
DI 10.1016/j.neuron.2012.06.018
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 975VM
UT WOS:000306539600006
PM 22794258
OA Green Accepted, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Laude, A
   Yeo, I
   Tan, SP
   Fan, Q
   Mathur, R
   Lee, SY
   Chan, CM
   Tan, G
   Lim, TH
   Cheng, CY
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Laude, Augustinus
   Yeo, Ian
   Tan, Shu-Pei
   Fan, Qiao
   Mathur, Ranjana
   Lee, Shu Yen
   Chan, Choi Mun
   Tan, Gavin
   Lim, Tock Han
   Cheng, Ching-Yu
   Wong, Tien Yin
TI Systemic, Ocular and Genetic Risk Factors for Age-related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy in Singaporeans
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LONG-TERM INCIDENCE; CATARACT-SURGERY; BEAVER DAM;
   CARDIOVASCULAR-DISEASE; NATIONAL-HEALTH; EYE DISEASES; 10-YEAR
   INCIDENCE; 5-YEAR INCIDENCE; POOLED FINDINGS; PREVALENCE
AB To examine the association of systemic, ocular and genetic risk factors in neovascular age-related macular degeneration (nAMD) in a large cohort of Asian patients, and to further compare risk factors between those with typical AMD and polypoidal choroidal vasculoapthy (PCV) subtypes. We recruited 456 cases and 1,824 controls matched for age, gender and ethnicity. Data on systemic and ocular risk factors were collected on questionnaires. In a subgroup of subjects, we included genetic data on four AMD-associated single nucleotide polymorphisms (SNPs). Risk factors for nAMD and subtypes were analyzed. Systemic risk factors for nAMD included older age, male gender, higher BMI and higher HDL-cholesterol. Ocular risk factors included pseudophakic and shorter axial length. Risk factors common to both typical AMD and PCV subtypes included age, BMI and HDL-cholesterol. Shorter axial length was only associated with PCV, while male gender and pseudophakia were only associated with typical AMD. In the subgroup with genotype data, ARMS2 rs10490924 and CFH rs800292 were associated with nAMD. None of the risk factors were significantly different between PCV and typical AMD. Systemic, ocular and genetic risk factors were largely similar for typical AMD and PCV subtypes in this Asian population based in Singapore.
C1 [Cheung, Chui Ming Gemmy; Yeo, Ian; Mathur, Ranjana; Lee, Shu Yen; Chan, Choi Mun; Tan, Gavin; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Laude, Augustinus; Tan, Shu-Pei; Fan, Qiao; Cheng, Ching-Yu; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Dept Ophthalmol, Natl Healthcare Grp, Inst Eye, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore; Tan
   Tock Seng Hospital
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.; Cheung, CMG (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/1003/2009]; BMRC
   [10/1/35/19/671]
FX This study was supported by National Medical Research Council grant
   NMRC/NIG/1003/2009 and BMRC Grant No. 10/1/35/19/671.
CR Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Paulus YM, 2016, JAMA OPHTHALMOL, V134, P627, DOI 10.1001/jamaophthalmol.2016.0564
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Singapore Department of Statistics, POP BRIEF 2015
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 57
TC 20
Z9 20
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 25
PY 2017
VL 7
AR 41386
DI 10.1038/srep41386
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EI6GA
UT WOS:000392592000001
PM 28120909
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kuehlewein, L
   Dansingani, KK
   De Carlo, TE
   Bonini, MA
   Iafe, NA
   Lenis, TL
   Freund, KB
   Waheed, NK
   Duker, JS
   Sadda, SR
   Sarraf, D
AF Kuehlewein, Laura
   Dansingani, Kunal K.
   De Carlo, Talisa E.
   Bonini Filho, Marco A.
   Iafe, Nicholas A.
   Lenis, Tamara L.
   Freund, K. Bailey
   Waheed, Nadia K.
   Duker, Jay S.
   Sadda, Srinivas R.
   Sarraf, David
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TYPE 3 NEOVASCULARIZATION
   SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; angiography; optical coherence
   tomography angiography
ID RETINAL ANGIOMATOUS PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; OCT
   ANGIOGRAPHY; CLINICOPATHOLOGICAL CORRELATION; MOTION CORRECTION;
   CLASSIFICATION; SPECTRUM; THERAPY
AB Purpose: To characterize the vascular structure of Type 3 neovascularization secondary to age-related macular degeneration using optical coherence tomography angiography.
   Methods: Optical coherence tomography angiography cube scans (3 mm x 3 mm) were acquired in 29 eyes of 24 patients with Type 3 lesions secondary to age-related macular degeneration using the RTVue XR Avanti with AngioVue, Split-spectrum amplitude-decorrelation, and motion correction technology. Automated layer segmentation boundaries were adjusted to best visualize the neovascular complex on en face projection images.
   Results: A distinct neovascular complex could be identified in 10 (34%) eyes, all of which were active on optical coherence tomography imaging. In all 10 eyes, the neovascular complex appeared as a small tuft of bright, high-flow tiny vessels with curvilinear morphology located in the outer retinal layers with a feeder vessel communicating with the inner retinal circulation (i.e., deep retinal capillary plexus). The mean (SD) size of the neovascular complex measured 0.07 ( 0.07) mm(2).
   Conclusion: With optical coherence tomography angiography, it is possible to identify small intraretinal neovascular complexes communicating with the deep retinal capillary plexus in eyes with Type 3 neovascularization secondary to age-related macular degeneration. Qualitative and quantitative analyses of Type 3 neovascular complexes can be performed using optical coherence tomography angiography.
C1 [Kuehlewein, Laura; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Kuehlewein, Laura; Iafe, Nicholas A.; Lenis, Tamara L.; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Dansingani, Kunal K.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dansingani, Kunal K.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [De Carlo, Talisa E.; Bonini Filho, Marco A.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA.
   [De Carlo, Talisa E.; Bonini Filho, Marco A.; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA.
   [De Carlo, Talisa E.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [De Carlo, Talisa E.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Bonini Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil.
   [Iafe, Nicholas A.; Lenis, Tamara L.; Sarraf, David] Stein Eye Inst, Los Angeles, CA USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Vitreous Retina Macula
   Consultants of New York; Manhattan Eye Ear & Throat Hospital; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; Tufts University; Tufts Medical Center; Tufts
   University; Massachusetts Institute of Technology (MIT); Massachusetts
   Institute of Technology (MIT); Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES); New York University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI BONINI FILHO, MARCO/GLR-8943-2022; Freund, K. Bailey/V-7488-2018;
   Dansingani, Kunal/D-1025-2015
OI BONINI FILHO, MARCO/0000-0003-0796-8025; Freund, K.
   Bailey/0000-0002-7888-9773; Dansingani, Kunal/0000-0002-7430-8601
FU Macular Foundation, Inc, New York, NY; Carl Zeiss Meditech;
   Massachusetts Lions Clubs; Optovue; Allergan; Carl Zeiss Meditec;
   Genentech; Optos; Regeneron
FX K. Bailey Freund is supported by the Macular Foundation, Inc, New York,
   NY. He is a consultant to Optovue, Genentech, Optos, ThromboGenics, Ohr
   Pharmaceutical, and Heidelberg Engineering (honorarium for each). N. K.
   Waheed was a consultant for Iconic therapeutics, served the speaker's
   bureau for Thrombogenics, and receives research support from Carl Zeiss
   Meditech. J. S. Duker is supported by the Massachusetts Lions Clubs. He
   is a consultant for and receives research support from Optovue and Carl
   Zeiss Meditech. S. R. Sadda is a coinventor of Doheny intellectual
   property related to optical coherence tomography that has been licensed
   by Topcon Medical Systems and is a member of the scientific advisory
   board for Heidelberg Engineering. He receives research support from and
   serves as a consultant for Allergan, Carl Zeiss Meditec, Genentech, and
   Optos. He also serves as a consultant for Alcon, Novartis, and Roche. D.
   Sarraf has research grants from Regeneron and Genentech, has served on
   an advisory board for Genentech, and has been loaned the Optovue machine
   with Split-spectrum amplitude-decorrelation capability from Optovue Inc.
   for research purposes. The other authors have no financial/conflicting
   interests to disclose.
CR Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 22
TC 99
Z9 102
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2229
EP 2235
DI 10.1097/IAE.0000000000000835
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100009
PM 26502007
DA 2022-11-30
ER

PT J
AU Ye, HH
   Zhang, Q
   Liu, XH
   Cai, X
   Yu, WJ
   Yu, SY
   Wang, TY
   Lu, WY
   Li, X
   Jin, HY
   Hu, YQ
   Kang, XL
   Zhao, PQ
AF Ye, Hehua
   Zhang, Qi
   Liu, Xiaohong
   Cai, Xuan
   Yu, Wenjing
   Yu, Siyi
   Wang, Tianyu
   Lu, Wuyi
   Li, Xiang
   Jin, Haiying
   Hu, Yiqian
   Kang, Xiaoli
   Zhao, Peiquan
TI Prevalence of Age-Related Macular Degeneration in an Elderly Urban
   Chinese Population in China: The Jiangning Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; prevalence; epidemiology
ID RISK-FACTORS; BEIJING-EYE; JAPANESE POPULATION; VISUAL IMPAIRMENT;
   ADULT-POPULATION; UNITED-STATES; MACULOPATHY; RIGIDITY; HISAYAMA;
   INDIANS
AB PURPOSE. To describe the prevalence of AMD in an elderly urban Chinese population in China.
   METHODS. A population-based, cross-sectional study was conducted using a cluster random sample of residents aged 50 years or older living in the Jiangning Road Subdistrict, Jing'an District, Shanghai, China. All participants underwent a standardized interview and comprehensive eye examinations, including digital retinal photography and spectral-domain optical coherence tomography (OCT) examinations of both eyes between November 2012 and February 2013. Trained graders assessed the presence and severity of AMD lesions based on a modified version of the Wisconsin Age-Related Maculopathy Grading System.
   RESULTS. Of the 2044 subjects who participated (82.5% response rate), 2005 had fundus photographs and OCT results of sufficient quality for grading of AMD signs. Early and late AMD were present in 206 (10.3%) and 23 (1.1%) participants, respectively. After age standardization, the prevalence of early AMD in Chinese persons aged 50 years or older was 9.5% (95% confidence interval [CI], 8.2-10.8) and that of late AMD was 1.0% (95% CI, 0.51.5).
   CONCLUSIONS. The prevalence of early and late AMD in this urban Chinese sample was higher than that reported in the Beijing and Handan studies. Age-related macular degeneration is highly prevalent among the elderly urban Chinese population in mainland China.
C1 [Ye, Hehua; Zhang, Qi; Liu, Xiaohong; Cai, Xuan; Yu, Wenjing; Yu, Siyi; Wang, Tianyu; Lu, Wuyi; Li, Xiang; Jin, Haiying; Hu, Yiqian; Kang, Xiaoli; Zhao, Peiquan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai 200092, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhao, PQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM zhaopeiquan@126.com
OI Cai, Xuan/0000-0003-4012-2726
FU National Natural Science Foundation Project of China (Beijing, China)
   [81200682, 81271045, 81100655]; Shanghai Outstanding Young Scientist
   Foundation from the Shanghai Municipal Health Bureau (Shanghai, China)
   [XBR2011060]
FX This study was supported by the National Natural Science Foundation
   Project of China (81200682, 81271045, 81100655; Beijing, China), the
   Shanghai Outstanding Young Scientist Foundation from the Shanghai
   Municipal Health Bureau (XBR2011060, Shanghai, China).
CR Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090897
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 37
TC 32
Z9 38
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2014
VL 55
IS 10
BP 6374
EP 6380
DI 10.1167/iovs.14-14899
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DY
UT WOS:000343147100034
PM 25190650
DA 2022-11-30
ER

PT J
AU Nunes, RP
   Hirai, FE
   Rodrigues, EB
   Farah, ME
AF Nunes, Renata Portella
   Hirai, Flavio Eduardo
   Rodrigues, Eduardo Buchelle
   Farah, Michel Eid
TI Cost-effectiveness of Anti-VEGF treatments for age-related macular
   degeneration: a Brazilian perspective
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Age-related macular degeneration; Cost-benefit analysis; Retina;
   Bevacizumab; Ranibizumab
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   VERTEPORFIN; THERAPY; AVASTIN; TRIAL
AB Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Rani-bizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.
C1 [Nunes, Renata Portella; Hirai, Flavio Eduardo; Rodrigues, Eduardo Buchelle; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Nunes, Renata Portella] Inst Olhos Florianopolis, Rua Presidente Coutinho 579,Cj 501, BR-88015231 Florianopolis, SC, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Nunes, RP (通讯作者)，Inst Olhos Florianopolis, Rua Presidente Coutinho 579,Cj 501, BR-88015231 Florianopolis, SC, Brazil.
EM reportellanunes@gmail.com
RI Hirai, Flavio E/G-3583-2012; Farah, Michel Eid/F-3285-2012
OI Hirai, Flavio E/0000-0002-5757-4254; Farah, Michel
   Eid/0000-0001-5951-0193
FU CNPq [558868/2009-6]; FAPESP [2010/15451-0]
FX This study was supported by CNPq (558868/2009-6) e FAPESP
   (2010/15451-0).
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brasil. Ministerio da Saude, BANC PREC SAUD
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ministe&PRIME;rio da Sau&PRIME;de Brasil, 2009, DIR MET EST AV EC TE
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Nunes RP, 2019, ARQ BRAS OFTALMOL, V82, P225, DOI 10.5935/0004-2749.20190043
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Elias FTS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139556
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 0
Z9 0
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JAN-FEB
PY 2020
VL 83
IS 1
BP 48
EP 54
DI 10.5935/0004-2749.20200020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KS0US
UT WOS:000518027800010
PM 32130306
OA gold
DA 2022-11-30
ER

PT J
AU Sahu, Y
   Chaudhary, N
   Joshi, M
   Gandhi, A
AF Sahu, Yamini
   Chaudhary, Niharika
   Joshi, Mukesh
   Gandhi, Aastha
TI Idiopathic polypoidal choroidal vasculopathy: a review of literature
   with clinical update on current management practices
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Polypoidal choroidal vasculopathy; Polyps; Indocyanine green
   angiography; Photodynamic therapy; Optical coherence tomography; Anti
   VEGF agents
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; PIGMENT
   EPITHELIAL DETACHMENTS; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB;
   CLINICOPATHOLOGICAL CORRELATION; INDOCYANINE GREEN; RANIBIZUMAB;
   EFFICACY; FEATURES
AB Purpose Polypoidal choroidal vasculopathy is a major cause of visual disability in a vast majority of Asian population due to exudative maculopathy. Although it is a distinctive disease entity with characteristic pathophysiology, genetics, immunology and clinical features, but it is still misdiagnosed as neovascular age related macular degeneration as both the diseases are a part of pachychoroid spectrum and have some similar features. Also, there are varied options for the management of this disease, but there are no clear recommendations. So, a detailed review of the literature has been done along with special attention to the recent therapeutic advances to help the readers get a better understanding of the disease and its current management practices. Method Detailed review of literature regarding polypoidal choroidal vasculopathy was done. The disease pathophysiology, genetics, risk factors, diagnostic modalities along with current treatment guidelines were extensively studied and compiled. Result A comprehensive clinical update on polypoidal choroidal vasculopathy was compiled with special emphasis on the recent diagnostic modalities and treatment guidelines. Conclusion Polypoidal choroidal vasculopathy is a distinct clinical entity which can be diagnosed based on indocyanine green angiography and optical coherence tomography. Treatment includes various options like photodynamic therapy, anti VEGF agents and thermal laser ablation. A review of literature has been done and recent diagnostic modalities with management practices have been compiled for the better understanding of the disease.
C1 [Sahu, Yamini; Chaudhary, Niharika; Gandhi, Aastha] Vardhaman Mahavir Med Coll, Dept Ophthalmol, Room 430 Eye OPD,4th Floor OPD Bldg,Ansari Nagar, New Delhi 110029, India.
   [Sahu, Yamini; Chaudhary, Niharika; Gandhi, Aastha] Safdarjang Hosp, Room 430 Eye OPD,4th Floor OPD Bldg,Ansari Nagar, New Delhi 110029, India.
   [Joshi, Mukesh] HIMSR & HAH Centenary Hopsital, Dept Ophthalmol, Nears GK-2, New Delhi, India.
C3 Vardhman Mahavir Medical College & Safdarjung Hospital; Vardhman Mahavir
   Medical College & Safdarjung Hospital; Jamia Hamdard University
RP Chaudhary, N (通讯作者)，Vardhaman Mahavir Med Coll, Dept Ophthalmol, Room 430 Eye OPD,4th Floor OPD Bldg,Ansari Nagar, New Delhi 110029, India.; Chaudhary, N (通讯作者)，Safdarjang Hosp, Room 430 Eye OPD,4th Floor OPD Bldg,Ansari Nagar, New Delhi 110029, India.
EM niharikachaudhary7@gmail.com
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Asano-Shimizu K, 2020, INT OPHTHALMOL, V40, P1335, DOI 10.1007/s10792-020-01299-3
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Calvo-Gonzalez C, 2019, INT OPHTHALMOL, V39, P2441, DOI 10.1007/s10792-019-01082-z
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kleiner RC, 1984, OPHTHALMOLOGY S9, V94, P110
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kubisz P, 2010, ACTA DIABETOL, V47, P119, DOI 10.1007/s00592-009-0127-2
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Li HT, 2004, RETINA-J RET VIT DIS, V24, P629, DOI 10.1097/00006982-200408000-00026
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Mahdy RA, 2010, EYE, V24, P1576, DOI 10.1038/eye.2010.86
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Tan CS, 2017, INT OPHTHALMOL, V37, P779, DOI 10.1007/s10792-016-0351-z
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tao Y, 2012, CHINESE J OCULAR FUN, V28, P4
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zeng RP, 2013, MOL VIS, V19, P729
   Zuo CG, 2019, INT OPHTHALMOL, V39, P987, DOI 10.1007/s10792-018-0900-8
NR 87
TC 3
Z9 3
U1 1
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2021
VL 41
IS 2
BP 753
EP 765
DI 10.1007/s10792-020-01620-0
EA OCT 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG9RC
UT WOS:000580440600003
PM 33079309
DA 2022-11-30
ER

PT J
AU Lee, K
   Kwon, JW
   Jahng, WJ
   Park, YH
   Jee, D
AF Lee, Kook
   Kwon, Jin-Woo
   Jahng, Wan Jin
   Park, Young-Hoon
   Jee, Donghyun
TI Age- and sex-based evaluation of the association between refractive
   error and age-related macular degeneration in the Korean population
SO PLOS ONE
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; NUTRITION EXAMINATION SURVEY;
   NATIONAL-HEALTH; RISK-FACTORS; VITREOMACULAR ADHESION; SUNLIGHT
   EXPOSURE; PREVALENCE; MACULOPATHY; MYOPIA; CHORIOCAPILLARIS
AB Purpose
   The aim of this study was to investigate the association between refractive error and prevalence of age-related macular degeneration (AMD) in Korean adults, based on the sex and age group.
   Methods
   This was a nationwide population-based cross-sectional study that included 17,676 subjects aged over 40 years who participated in the 2008-2012 Korean National Health and Nutrition Examination Survey. Digital fundus images (45 degrees) were obtained for both eyes under physiologic mydriasis and were graded using the international classification and grading system for age-related macular degeneration. The spherical equivalents of refractive errors were calculated in diopters using auto-refraction data.
   Results
   After adjustment for potential confounders, myopia was associated with lower risk of any age-related macular degeneration [odds ratio (OR), 0.74; 95% Confidence Interval (CI), 0.61-0.91]. In particular, myopia was significantly associated with lower odds of age-related macular degeneration in female participants (any AMD: OR, 0.71; 95% CI, 0.54-0.93; early AMD: OR, 0.70; 95% CI, 0.53-0.93) and in participants younger than 50 years (any AMD: OR, 0.46; 95% CI, 0.24-0.90; early AMD: OR, 0.47; 95% CI, 0.24-0.93). There was no significant association between myopia and age-related macular degeneration in male participants and in participants older than 50 years.
   Conclusions
   In the Korean adult population, myopia was associated with significantly lower odds of any type of early age-related macular degeneration, particularly in females and in younger age groups.
C1 [Lee, Kook; Park, Young-Hoon] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
   [Kwon, Jin-Woo; Jee, Donghyun] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
   [Jahng, Wan Jin] Amer Univ Nigeria, Dept Petr Chem, Yola, Nigeria.
   [Park, Young-Hoon] Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea; American University of Nigeria; Catholic University
   of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
EM donghyunjee@catholic.ac.kr
RI Jahng, Wan Jin/C-1236-2018
OI Jahng, Wan Jin/0000-0001-8241-7739; Kwon, Jin-woo/0000-0003-2093-4284
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2016R1A6A1A03010528]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF), funded by the
   Ministry of Education [2016R1A6A1A03010528]. The funder had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Centofanti M, 2000, BRIT J OPHTHALMOL, V84, P786, DOI 10.1136/bjo.84.7.786
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Hirata A, 1998, GRAEF ARCH CLIN EXP, V236, P132, DOI 10.1007/s004170050053
   Hwang HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134338
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Inhoffen W, 2012, OPHTHALMOLOGE, V109, P749, DOI 10.1007/s00347-011-2498-3
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kavroulaki D, 2010, ACTA OPHTHALMOL, V88, P850, DOI 10.1111/j.1755-3768.2009.01607.x
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080361
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lin SC, 2016, ASIA-PAC J OPHTHALMO, V5, P115, DOI 10.1097/APO.0000000000000169
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Morgan IG, 2013, OPHTHAL PHYSL OPT, V33, P329, DOI 10.1111/opo.12040
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Park HA, 2013, KOREAN J FAM MED, V34, P79, DOI 10.4082/kjfm.2013.34.2.79
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Shimada N, 2004, GRAEF ARCH CLIN EXP, V242, P284, DOI 10.1007/s00417-003-0836-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tokoro T, 1988, Acta Ophthalmol Suppl, V185, P107
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Weber-Krause B, 1997, OPHTHALMOLOGE, V94, P619, DOI 10.1007/s003470050170
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   West Emily S., 2005, International Ophthalmology Clinics, V45, P41
   Wood A, 2019, AM J OPHTHALMOL, V206, P87, DOI 10.1016/j.ajo.2019.03.018
NR 53
TC 1
Z9 1
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2020
VL 15
IS 1
AR e0228468
DI 10.1371/journal.pone.0228468
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LP9AX
UT WOS:000534609400071
PM 31995613
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schmidl, D
   Garhofer, G
   Schmetterer, L
AF Schmidl, Doreen
   Garhoefer, Gerhard
   Schmetterer, Leopold
TI Nutritional supplements in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; Age-Related Eye Disease Study; lutein;
   reactive oxygen intermediates; supplementation; vitamins; zeaxanthin;
   zinc
ID PIGMENT OPTICAL-DENSITY; VITAMIN-E SUPPLEMENTATION; GINKGO-BILOBA
   EXTRACT; ALPHA-LIPOIC ACID; POLYUNSATURATED FATTY-ACIDS;
   ENDOTOXIN-INDUCED MODEL; RETINAL LIGHT DAMAGE; OCULAR BLOOD-FLOW;
   OXIDATIVE STRESS; ZINC-DEFICIENCY
AB Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. While with new therapies that are directed towards vascular endothelial growth factor (VEGF), a potentially efficient treatment option for the wet form of the disease has been introduced, a therapeutic regimen for dry AMD is still lacking. There is evidence from several studies that oral intake of supplements is beneficial in preventing progression of the disease. Several formulations of micronutrients are currently available. The present review focuses on the role of supplements in the treatment and prevention of AMD and sums up the current knowledge about the most frequently used micronutrients. In addition, regulatory issues are discussed, and future directions for the role of supplementation in AMD are highlighted.
C1 [Schmidl, Doreen; Garhoefer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Garhofer, G (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM gerhard.garhoefer@meduniwien.ac.at
OI Schmidl, Doreen/0000-0001-5664-7768; Schmetterer,
   Leopold/0000-0002-7189-1707
CR Aksenova MV, 2005, CURR NEUROVASC RES, V2, P73, DOI 10.2174/1567202052773463
   ALVAREZ RA, 1987, AM J CLIN NUTR, V46, P481, DOI 10.1093/ajcn/46.3.481
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Balaiya S, 2013, MOL VIS, V19, P2385
   Bandyopadhyay D, 2004, CURR MED CHEM, V11, P369, DOI 10.2174/0929867043456016
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Becker K, 2014, PHYTOMEDICINE, V21, P164, DOI 10.1016/j.phymed.2013.08.008
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Booth SL, 2004, AM J CLIN NUTR, V80, P143
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chidlow G, 2002, NEUROPHARMACOLOGY, V43, P1015, DOI 10.1016/S0028-3908(02)00129-6
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chopra RK, 1999, INT J VITAM NUTR RES, V69, P92, DOI 10.1024/0300-9831.69.2.92
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chung HS, 1999, J OCUL PHARMACOL TH, V15, P233, DOI 10.1089/jop.1999.15.233
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9
   CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173
   Dam H, 1970, Bibl Nutr Dieta, V15, P114
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferrieres J, 2004, HEART, V90, P107, DOI 10.1136/heart.90.1.107
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fies P, 2002, Wien Med Wochenschr, V152, P423, DOI 10.1046/j.1563-258X.2002.02066.x
   Forte R, 2013, J OCUL PHARMACOL TH, V29, P733, DOI 10.1089/jop.2013.0010
   FOSMIRE GJ, 1990, AM J CLIN NUTR, V51, P225, DOI 10.1093/ajcn/51.2.225
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gaynes BI, 2003, ARCH OPHTHALMOL-CHIC, V121, P416, DOI 10.1001/archopht.121.3.416
   Gordon WC, 2013, CURR EYE RES, V38, P995, DOI 10.3109/02713683.2013.827211
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807
   Haritoglou C, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329470
   Hathcock JN, 2005, AM J CLIN NUTR, V81, P736, DOI 10.1093/ajcn/81.4.736
   Ho E, 2011, ADV NUTR, V2, P497, DOI 10.3945/an.111.001032
   HUBER AM, 1975, J NUTR, V105, P1486, DOI 10.1093/jn/105.11.1486
   Jarrard DF, 2005, ARCH OPHTHALMOL-CHIC, V123, P102, DOI 10.1001/archopht.123.1.102
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   Karlsen A, 2007, J NUTR, V137, P1951
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1978, INVEST OPHTH VIS SCI, V17, P1049
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P29
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J
   Kolodjaschna J, 2008, EXP EYE RES, V87, P131, DOI 10.1016/j.exer.2008.05.006
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Kristal AR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt456
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Kurihara T, 2008, DIABETES, V57, P2191, DOI 10.2337/db07-1281
   Lachapelle MY, 2011, GENETICA, V139, P199, DOI 10.1007/s10709-010-9537-x
   Leach JK, 2001, CANCER RES, V61, P3894
   LEBUISSON DA, 1986, PRESSE MED, V15, P1556
   Leitzmann MF, 2003, J NATL CANCER I, V95, P1004, DOI 10.1093/jnci/95.13.1004
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Lin J, 2006, DIABETOLOGIA, V49, P1089, DOI 10.1007/s00125-006-0174-y
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Mackey DA, 2014, CURR OPIN OPHTHALMOL, V25, P386, DOI 10.1097/ICU.0000000000000090
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   McGinnis JM, 2007, AM J CLIN NUTR, V85, p257S
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Miceli MV, 1999, INVEST OPHTH VIS SCI, V40, P1238
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller SL, 2012, NEUROENDOCRINOLOGY, V96, P13, DOI 10.1159/000336378
   Monsen ER, 2000, J AM DIET ASSOC, V100, P637, DOI 10.1016/S0002-8223(00)00189-9
   Morris KC, 2011, J CEREBR BLOOD F MET, V31, P1003, DOI 10.1038/jcbfm.2010.229
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NIELSEN JC, 1988, INVEST OPHTH VIS SCI, V29, P22
   Norkus EP, 2010, J AM COLL NUTR, V29, P575, DOI 10.1080/07315724.2010.10719896
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   ORGANISCIAK DT, 1990, INVEST OPHTH VIS SCI, V31, P1195
   Paasche G, 2000, OPHTHALMIC RES, V32, P229, DOI 10.1159/000055618
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Pemp B, 2010, INVEST OPHTH VIS SCI, V51, P2, DOI 10.1167/iovs.09-3888
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pleiner J, 2002, CIRCULATION, V106, P1460, DOI 10.1161/01.CIR.0000030184.70207.FF
   Prasad AS, 2014, J TRACE ELEM MED BIO, V28, P364, DOI 10.1016/j.jtemb.2014.07.019
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Rahman MM, 2006, FREE RADICAL RES, V40, P993, DOI 10.1080/10715760600815322
   Rees K, 2013, TLS-TIMES LIT SUPPL, P12
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Roberts R, 2006, INVEST OPHTH VIS SCI, V47, P4077, DOI 10.1167/iovs.06-0464
   Rosado JL, 2003, J NUTR, V133, p2985S, DOI 10.1093/jn/133.9.2985S
   RUNGE P, 1986, BRIT J OPHTHALMOL, V70, P166, DOI 10.1136/bjo.70.3.166
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   Shindler KS, 2010, J NEURO-OPHTHALMOL, V30, P328, DOI 10.1097/WNO.0b013e3181f7f833
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SOBREVILLA LA, 1964, AM J MED, V37, P821, DOI 10.1016/0002-9343(64)90030-0
   SOLOMONS NW, 1981, AM J CLIN NUTR, V34, P475, DOI 10.1093/ajcn/34.4.475
   STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Sun YD, 2012, ANN NUTR METAB, V60, P293, DOI 10.1159/000338444
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P396, DOI 10.1167/iovs.06-0872
   Tanvetyanon T, 2008, CANCER-AM CANCER SOC, V113, P150, DOI 10.1002/cncr.23527
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Thomas LDK, 2013, JAMA INTERN MED, V173, P386, DOI 10.1001/jamainternmed.2013.2296
   Told R, 2014, INVEST OPHTH VIS SCI, V55, P2220, DOI 10.1167/iovs.13-13784
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WIEGAND RD, 1986, INVEST OPHTH VIS SCI, V27, P727
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wimpissinger B, 2007, ACTA OPHTHALMOL SCAN, V85, P445, DOI 10.1111/j.1600-0420.2007.00887.x
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8
   Zealley B, 2013, GERONTOLOGY, V59, P183, DOI 10.1159/000342197
NR 174
TC 28
Z9 29
U1 2
U2 55
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2015
VL 93
IS 2
BP 105
EP 121
DI 10.1111/aos.12650
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB8SC
UT WOS:000349900200027
PM 25586104
OA Bronze
DA 2022-11-30
ER

PT J
AU Kopplin, LJ
   Igo, RP
   Wang, Y
   Sivakumaran, TA
   Hagstrom, SA
   Peachey, NS
   Francis, PJ
   Klein, ML
   SanGiovanni, JP
   Chew, EY
   Pauer, GJT
   Sturgill, GM
   Joshi, T
   Tian, L
   Xi, Q
   Henning, AK
   Lee, KE
   Klein, R
   Klein, BEK
   Iyengar, SK
AF Kopplin, L. J.
   Igo, R. P., Jr.
   Wang, Y.
   Sivakumaran, T. A.
   Hagstrom, S. A.
   Peachey, N. S.
   Francis, P. J.
   Klein, M. L.
   SanGiovanni, J. P.
   Chew, E. Y.
   Pauer, G. J. T.
   Sturgill, G. M.
   Joshi, T.
   Tian, L.
   Xi, Q.
   Henning, A. K.
   Lee, K. E.
   Klein, R.
   Klein, B. E. K.
   Iyengar, S. K.
TI Genome-wide association identifies SKIV2L and MYRIP as protective
   factors for age-related macular degeneration
SO GENES AND IMMUNITY
LA English
DT Article
DE macular degeneration; association testing; melanosome trafficking
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; BLUE MOUNTAINS EYE;
   BEAVER DAM EYE; MYOSIN-VIIA; FACTOR-B; COMPONENT 2; CHINESE POPULATION;
   10-YEAR INCIDENCE; 5-YEAR INCIDENCE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in the developed world. We conducted a genome-wide association study in a series of families enriched for AMD and completed a meta-analysis of this new data with results from reanalysis of an existing study of a late-stage case-control cohort. We tested the top findings for replication in 1896 cases and 1866 controls and identified two novel genetic protective factors for AMD. In addition to the complement factor H (CFH) (P = 2.3 x 10(-64)) and age-related maculopathy susceptibility 2 (ARMS2) (P = 1.2 x 10(-60)) loci, we observed a protective effect at rs429608, an intronic SNP in SKIV2L (P=5.3 x 10(-15)), a gene near the complement component 2 (C2)/complement factor B (BF) locus, that indicates the protective effect may be mediated by variants other than the C2/BF variants previously studied. Haplotype analysis at this locus identified three protective haplotypes defined by the rs429608 protective allele. We also identified a new potentially protective effect at rs2679798 in MYRIP (P=2.9 x 10(-4)), a gene involved in retinal pigment epithelium melanosome trafficking. Interestingly, MYRIP was initially identified in the family-based scan and was confirmed in the case-control set. From these efforts, we report the identification of two novel protective factors for AMD and confirm the previously known associations at CFH, ARMS2 and C3. Genes and Immunity (2010) 11, 609-621; doi: 10.1038/gene.2010.39; published online 23 September 2010
C1 [Igo, R. P., Jr.; Wang, Y.; Sivakumaran, T. A.; Joshi, T.; Tian, L.; Xi, Q.; Iyengar, S. K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Kopplin, L. J.; Iyengar, S. K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Hagstrom, S. A.; Peachey, N. S.; Pauer, G. J. T.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Hagstrom, S. A.; Peachey, N. S.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Peachey, N. S.; Sturgill, G. M.] Vet Affairs Med Ctr, Res Serv, Cleveland, OH USA.
   [Francis, P. J.; Klein, M. L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [SanGiovanni, J. P.; Chew, E. Y.] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
   [Henning, A. K.] EMMES Corp, Rockville, MD USA.
   [Lee, K. E.; Klein, R.; Klein, B. E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Case Western Reserve University; Case Western Reserve University;
   Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Case Western Reserve University; Louis Stokes
   Cleveland Veterans Affairs Medical Center; Oregon Health & Science
   University; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation; University of Wisconsin System;
   University of Wisconsin Madison
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg,Room 1315,2103 Cornell Rd, Cleveland, OH 44106 USA.
EM ski@case.edu
RI Igo, Rob/P-3438-2019; SanGiovanni, John Paul/AAU-3895-2020;
   /S-1190-2019; Peachey, Neal/G-5533-2010
OI Igo, Rob/0000-0002-0024-1993; /0000-0001-7488-250X; Peachey,
   Neal/0000-0002-4419-7226
FU National Eye Institute [EY015810, U10EY06594, EY015286, EY13438,
   EY10605, T32 EY07157, T32 GM07250]; National Institute of General
   Medical Sciences [GM28356]; Research to Prevent Blindness; Foundation
   Fighting Blindness, Columbia, MD; Macular Degeneration Center; Goodall
   Macular Degeneration Fund; Casey Eye Institute; Research to Prevent
   Blindness, New York, NY; Department of Ophthalmology, Case Western
   Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner
   College of Medicine of CWRU; Gene Expression and Genotyping Facility of
   the Comprehensive Cancer Center at CWRU; University Hospitals of
   Cleveland [P30CA43703]; Genotyping Core Facility at CWRU; National
   Center for Research Resources [RR03655]; National Center for Research
   Resources (NCRR), a component of the National Institutes of Health [UL1
   RR024989]; NIH roadmap for Medical Research; NATIONAL CANCER INSTITUTE
   [P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [P41RR003655, UL1RR024989] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R03EY013438, R01EY015286, R01EY015810,
   R01EY010605, T32EY007157, U10EY006594] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028356,
   R37GM028356, T32GM007250] Funding Source: NIH RePORTER
FX This study was supported by the NIH grants EY015810, U10EY06594,
   EY015286, EY13438 and EY10605 from the National Eye Institute, training
   grant T32 EY07157 to the Visual Sciences Training Program and T32
   GM07250 to the Case Medical Scientist Training Program; US Public Health
   Service research grants GM28356, from the National Institute of General
   Medical Sciences; and by Senior Scientific Investigator Awards from
   Research to Prevent Blindness (Dr R Klein and Dr B Klein), The
   Foundation Fighting Blindness, Columbia, MD (Dr PJ Francis); the Macular
   Degeneration Center Research Fund and the Goodall Macular Degeneration
   Fund, Casey Eye Institute (Dr ML Klein), Research to Prevent Blindness,
   New York, NY (unrestricted grants to Casey Eye Institute and a Career
   Development Award to Dr PJ Francis) and unrestricted awards from
   Research to Prevent Blindness (Department of Ophthalmology, Case Western
   Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner
   College of Medicine of CWRU), a VA Merit Review and a Center Grant from
   Foundation Fighting Blindness. This study was also supported by the Gene
   Expression and Genotyping Facility of the Comprehensive Cancer Center at
   CWRU and University Hospitals of Cleveland (P30CA43703) and the
   Genotyping Core Facility at CWRU. The results of this paper were
   obtained by using the software package S.A.G.E., which is supported by a
   US Public Health Service Resource Grant (RR03655) from the National
   Center for Research Resources. This publication was made possible by the
   CWRU/Cleveland Clinic CTSA Grant Number UL1 RR024989 from the National
   Center for Research Resources (NCRR), a component of the National
   Institutes of Health and NIH roadmap for Medical Research. Its contents
   are solely the responsibility of the authors and do not necessarily
   represent the official view of NCRR or NIH.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001
   Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bernstein KA, 2006, MOL CELL BIOL, V26, P1195, DOI 10.1128/MCB.26.4.1195-1208.2006
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cupples LA, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S1
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090
   ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171
   Fei H, 2008, TRAFFIC, V9, P1425, DOI 10.1111/j.1600-0854.2008.00771.x
   Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Guo Y, 2008, J OPT SOC AM A, V25, P304, DOI 10.1364/JOSAA.25.000304
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klomp AE, 2007, CELL MOTIL CYTOSKEL, V64, P474, DOI 10.1002/cm.20198
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kuroda TS, 2005, METHOD ENZYMOL, V403, P431, DOI 10.1016/S0076-6879(05)03038-7
   LEE SG, 1995, GENOMICS, V25, P660, DOI 10.1016/0888-7543(95)80008-A
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2006, AM J HUM GENET S, VS79, P2290
   Lopes VS, 2007, TRAFFIC, V8, P486, DOI 10.1111/j.1600-0854.2007.00548.x
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Newell-Litwa K, 2007, J CELL SCI, V120, P531, DOI 10.1242/jcs.03365
   Newton-Cheh C, 2009, NAT GENET, V41, P666, DOI 10.1038/ng.361
   ORLIN A, 2009, INVEST OPHTHALMOL VI, V50
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   PURCELL S, 2008, PLINK
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ramalho JS, 2009, PIGM CELL MELANOMA R, V22, P461, DOI 10.1111/j.1755-148X.2009.00567.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Schaid DJ, 2004, GENET EPIDEMIOL, V27, P348, DOI 10.1002/gepi.20037
   Schmid M, 2008, TRENDS BIOCHEM SCI, V33, P501, DOI 10.1016/j.tibs.2008.07.003
   Schonthaler HB, 2005, DEV BIOL, V284, P421, DOI 10.1016/j.ydbio.2005.06.001
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Warburton S, 2007, MOL VIS, V13, P318
   Weil D, 1996, P NATL ACAD SCI USA, V93, P3232, DOI 10.1073/pnas.93.8.3232
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yang ZY, 2001, FRONT BIOSCI-LANDMRK, V6, pD927, DOI 10.2741/Yang
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015
   2007, SAGE STAT ANAL GENET
NR 85
TC 51
Z9 53
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD DEC
PY 2010
VL 11
IS 8
BP 609
EP 621
DI 10.1038/gene.2010.39
PG 13
WC Genetics & Heredity; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Immunology
GA 688TP
UT WOS:000284877100002
PM 20861866
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ting, TD
   Oh, M
   Cox, TA
   Meyer, CH
   Toth, CA
AF Ting, TD
   Oh, M
   Cox, TA
   Meyer, CH
   Toth, CA
TI Decreased visual acuity associated with cystoid macular edema in
   neovascular age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; VEIN
   OCCLUSION; MACULOPATHY; PREVALENCE
AB Objective: To determine the prevalence and visual significance of cystoid macular edema (CME) in eyes with subfoveal neovascular age-related macular degeneration using optical coherence tomography (OCT).
   Materials and Methods: The medical records of 61 consecutive patients initially seen with nondisciform subfoveal neovascular age-related macular degeneration were retrospectively reviewed. All patients underwent fluorescein angiography and OCT imaging. Eyes with intraretinal hyporeflective spaces in the macula in the OCT images were considered to have CME.
   Results: Twenty-eight (46%) of 61 eves demonstrated CME on the OCT images. The presence of CME and increased foveal thickness correlated with decreased visual acuity, but not with the duration of symptoms. Twenty-six (93%) of 28 eyes with CME contained classic choroidal neovascularization, whereas 16 (48%) of 33 eyes without CME contained classic choroidal neovascularization.
   Conclusions: Cystoid macular edema is a common finding in patients with choroidal neovascularization associated with age-related macular degeneration. The presence of CME and foveal thickening is associated with worse visual acuity in these patients. Cystoid macular edema is more common with choroidal neovascularization containing classic component. The OCT is a useful test to detect the presence of CME in these patients since CME may be difficult to identify on fluorescein angiogram.
C1 Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Ting, TD (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
RI toth, cynthia a/F-5614-2011; Meyer, Carsten/A-3981-2017; Toth,
   Cynthia/L-5534-2019
OI Meyer, Carsten/0000-0002-0530-5298; Toth, Cynthia/0000-0002-2324-0854
FU NATIONAL EYE INSTITUTE [R24EY013015] Funding Source: NIH RePORTER; NEI
   NIH HHS [5R24 EY-13015-02] Funding Source: Medline
CR Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Berger JW, 1999, AUGMENTED REALITY, P19
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1991, ARCH OPHTHALMOL-CHIC, V109, P211, DOI 10.1001/archopht.1991.01080020057043
   Christoffersen N, 1998, AM J OPHTHALMOL, V126, P454, DOI 10.1016/S0002-9394(98)00107-X
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P40
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Hirakawa H, 1999, AM J OPHTHALMOL, V128, P185, DOI 10.1016/S0002-9394(99)00100-2
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KIRBER WM, 1980, ARCH OPHTHALMOL-CHIC, V98, P725, DOI 10.1001/archopht.1980.01020030719015
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Marshall J, 1984, DOC OPHTHALMOL P SER, P21
   Massin P, 2000, AM J OPHTHALMOL, V130, P732, DOI 10.1016/S0002-9394(00)00574-2
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Sekiryu T, 2000, OPHTHALMIC SURG LAS, V31, P198
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   SOUBRANE G, 1988, J FR OPHTALMOL, V11, P711
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 26
TC 74
Z9 79
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2002
VL 120
IS 6
BP 731
EP 737
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 561MV
UT WOS:000176145500004
PM 12049577
DA 2022-11-30
ER

PT J
AU Rubner, R
   Li, KV
   Canto-Soler, MV
AF Rubner, Rhianna
   Li, Karig, V
   Canto-Soler, M. Valeria
TI Progress of clinical therapies for dry age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE dry age-related macular degeneration; age-related macular degeneration;
   drug therapy
ID GEOGRAPHIC ATROPHY SECONDARY; RETINAL PROSTHESES; CELLS
AB ? Dry age-related macular degeneration (AMD) is a progressive blinding disease that currently affects millions of people worldwide with no successful treatment available. Significant research efforts are currently underway to develop therapies aimed at slowing the progression of this disease or, more notably, reversing it. Here the therapies which have reached clinical trial for treatment of dry AMD were reviewed. A thorough search of PubMed, Embase, therapeutics for this debilitating condition.
C1 [Rubner, Rhianna; Li, Karig, V; Canto-Soler, M. Valeria] Univ Colorado, Sch Med, Sue Anschutz Rodgers Eye Ctr, Dept Ophthalmol,CellSight Ocular Stem Cell & Rege, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Canto-Soler, MV (通讯作者)，Univ Colorado, Sch Med, Sue Anschutz Rodgers Eye Ctr, Dept Ophthalmol, Aurora, CO 80045 USA.
EM valeria.canto-soler@cuanschutz.edu
FU Gates Family Fund; Doni Solich Family Chair in Ocular Stem Cell
   Research; CellSight Fund; Research to Prevent Blindness
FX Supported by the Gates Family Fund, the Doni Solich Family Chair in
   Ocular Stem Cell Research, the CellSight Fund, and an Unrestricted
   Research Award from Research to Prevent Blindness to the Department of
   Ophthalmology at the University of Colorado.
CR Alikhan A, 2010, AM J CLIN DERMATOL, V11, P79, DOI 10.2165/11530200-000000000-00000
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freeman WR., RETINAL PHYS BRIMONI
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Lin TC, 2015, J CHIN MED ASSOC, V78, P501, DOI 10.1016/j.jcma.2015.05.010
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mettu P, 2019, RETINAL PHYS, V16, P40
   Mills JO, 2017, EYE, V31, P1383, DOI 10.1038/eye.2017.65
   Munk MR, 2018, INVEST OPHTH VIS SCI, V59
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Ramlogan-Steel CA, 2019, CLIN EXP OPHTHALMOL, V47, P521, DOI 10.1111/ceo.13416
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roche Pharmaceuticals, 2019, GR39821 PAT LAY SUMM
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sena DF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006539.pub4
   Singh RP., 2018, MAC SOC ANN M FEB 21
   Sivapathasuntharam C, 2017, NEUROBIOL AGING, V52, P66, DOI 10.1016/j.neurobiolaging.2017.01.001
   Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259
   US Census Bureau Population Division, 2000, NAT POP PROJ SUMM TA
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Weiland JD, 2011, OPHTHALMOLOGY, V118, P2227, DOI 10.1016/j.ophtha.2011.08.042
   Weiss Jeffrey N, 2020, Medicines (Basel), V7, DOI 10.3390/medicines7040016
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
NR 41
TC 0
Z9 0
U1 8
U2 13
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2022
VL 15
IS 1
BP 157
EP 166
DI 10.18240/ijo.2022.01.23
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YD8SS
UT WOS:000740705900023
PM 35047371
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gemenetzi, M
   Lotery, AJ
AF Gemenetzi, M.
   Lotery, A. J.
TI Epigenetics in age-related macular degeneration: new discoveries and
   future perspectives
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Age-related macular degeneration; Retina epigenetics
ID PIGMENT EPITHELIAL-CELLS; AMYLOID-BETA; DNA METHYLATION; NLRP3
   INFLAMMASOME; GENE-EXPRESSION; TRANSPOSABLE ELEMENTS; HISTONE
   ACETYLATION; IN-VITRO; ACTIVATION; RETINA
AB The study of epigenetics has explained some of the 'missing heritability' of age-related macular degeneration (AMD). The epigenome also provides a substantial contribution to the organisation of the functional retina. There is emerging evidence of specific epigenetic mechanisms associated with AMD. This 'AMD epigenome' may offer the chance to develop novel AMD treatments.
C1 [Gemenetzi, M.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
   [Gemenetzi, M.] UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
   [Lotery, A. J.] Univ Southampton, Southampton Univ Hosp, Clin & Expt Sci, Fac Med, South Lab & Path Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Univ Hosp, Clin & Expt Sci, Fac Med, South Lab & Path Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
CR Balaiya S, 2012, MOL VIS, V18, P114
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Breitling LP, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0186-5
   Buysschaert I, 2008, J CELL MOL MED, V12, P2533, DOI 10.1111/j.1582-4934.2008.00515.x
   Callinan P, 2006, GENOME DYN, V1, P104, DOI 10.1159/000092503
   Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chuong EB, 2017, NAT REV GENET, V18, P71, DOI 10.1038/nrg.2016.139
   Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   DELPRIORE LV, 1993, EUR J IMPLANT REF SU, V5, P128, DOI DOI 10.1016/S0955-3681(13)80263-8
   Dilks DD, 2014, OPTOMETRY VISION SCI, V91, pE199, DOI 10.1097/OPX.0000000000000325
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Economopoulou M, 2009, NAT MED, V15, P553, DOI 10.1038/nm.1947
   Fadloun A, 2013, NAT STRUCT MOL BIOL, V20, P332, DOI 10.1038/nsmb.2495
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Goke J, 2015, CELL STEM CELL, V16, P135, DOI 10.1016/j.stem.2015.01.005
   Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hageman GS, 1999, MOL VIS, V5
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Hellebrekers DMEI, 2006, MOL CANCER THER, V5, P467, DOI 10.1158/1535-7163.MCT-05-0417
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   HO MW, 1979, J THEOR BIOL, V78, P573, DOI 10.1016/0022-5193(79)90191-7
   Hogg Ruth E, 2007, Ophthalmology, V114, P1028, DOI 10.1016/j.ophtha.2006.11.013
   Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Huang PR, 2017, INVEST OPHTH VIS SCI, V58, P1726, DOI 10.1167/iovs.16-20043
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   IJIMA R, 2014, INVEST OPHTH VIS SCI, V55
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jacques PE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003504
   Johnson R, 2014, RNA, V20, P959, DOI 10.1261/rna.044560.114
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Keilhauer CN, 2011, OPHTHALMIC GENET, V32, P237, DOI 10.3109/13816810.2011.592177
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kim J, 2015, J NEUROSCI, V35, P14717, DOI 10.1523/JNEUROSCI.2053-15.2015
   Kim S, 2014, MOL CELL, V56, P564, DOI 10.1016/j.molcel.2014.10.003
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klemm SL, 2019, NAT REV GENET, V20, P207, DOI 10.1038/s41576-018-0089-8
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   KUWABARA T, 1981, OPHTHALMOLOGY, V88, P331
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Levine ME, 2015, AGING-US, V7, P690, DOI 10.18632/aging.100809
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   Marioni RE, 2015, INT J EPIDEMIOL, V44, P1388, DOI 10.1093/ije/dyu277
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032
   Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1
   NANNEY DL, 1958, P NATL ACAD SCI USA, V44, P712, DOI 10.1073/pnas.44.7.712
   Noble D, 2015, J EXP BIOL, V218, P816, DOI 10.1242/jeb.120071
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Popp NA, 2016, ENVIRON MOL MUTAGEN, V57, P58, DOI 10.1002/em.21982
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Rhein M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00182
   Rivera CM, 2013, CELL, V155, P39, DOI 10.1016/j.cell.2013.09.011
   Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Shapiro JA, 2017, CRIT REV BIOCHEM MOL, V52, P1, DOI 10.1080/10409238.2016.1226748
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Simonti CN, 2017, MOL BIOL EVOL, V34, P2856, DOI 10.1093/molbev/msx219
   Skalsky RL, 2007, J VIROL, V81, P12836, DOI 10.1128/JVI.01804-07
   STEVENSON AJ, 2018, TRAJECTORIES INFLAMM, P1
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tezel TH, 2006, INVEST OPHTH VIS SCI, V47, P5075, DOI 10.1167/iovs.05-1557
   Thompson PJ, 2016, MOL CELL, V62, P766, DOI 10.1016/j.molcel.2016.03.029
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   Valinluck V, 2004, NUCLEIC ACIDS RES, V32, P4100, DOI 10.1093/nar/gkh739
   Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032
   WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang JY, 2016, TRENDS GENET, V32, P284, DOI 10.1016/j.tig.2016.02.005
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Watroba M, 2016, ADV MED SCI-POLAND, V61, P52, DOI 10.1016/j.advms.2015.09.003
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wen XF, 2018, PROG RETIN EYE RES, V64, P84, DOI 10.1016/j.preteyeres.2018.01.001
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zentner GE, 2014, NAT REV GENET, V15, P814, DOI 10.1038/nrg3798
   Zhang H, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/250812
   Zhang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11829-y
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 125
TC 12
Z9 13
U1 1
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 807
EP 818
DI 10.1007/s00018-019-03421-w
EA JAN 2020
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000505379200004
PM 31897542
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Foran, S
   Smith, W
   Mitchell, P
AF Wang, JJ
   Foran, S
   Smith, W
   Mitchell, P
TI Risk of age-related macular degeneration in eyes with macular drusen or
   hyperpigmentation
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; 5-YEAR INCIDENCE; VISUAL IMPAIRMENT;
   GRADING SYSTEM; FELLOW EYES; MACULOPATHY; PREVALENCE; PROGRESSION;
   POPULATION
AB Objective: To quantify the 5-year risk of age-related macular degeneration (AMD) in eyes with different macular drusen characteristics (ie, size, type, location, and total area) or hyperpigmentation in a population-based cohort.
   Methods: The Blue Mountains Eye Study examined 3654 residents during 1992-1994; 2335 (75.1% of survivors) were reexamined during 1997-1999. Retinal photographs were graded using the Wisconsin Age-Related Maculopathy Grading System. Incident AMD lesions were defined by development of neovascular AMD or geographic atrophy in eyes without these lesions at baseline (eyes at risk). Age-adjusted relative risks (RRs) were determined. Generalized estimating equation models were used to estimate odds ratios, adjusting for the correlation between eyes and other AMD risk factors.
   Main Outcome Measure: Incidence of AMD.
   Results: Of the 4634 eyes at risk, 52 (1.1%) developed neovascular or atrophic AMD lesions over 5 years. In right eyes, presence vs absence of the following macular signs predicted AMD: drusen that were 125 mum or larger (13.9 vs 0.6%; age-adjusted RR, 5.7; 95% confidence interval [Cl], 3.6-9.0), indistinct soft or reticular drusen (23.2% vs 0.4%, RR, 9.9; 95% CI, 6.4-15.4), total drusen area of half the disc area or more (31.4% vs 0.6%; RR, 13.5; 95% CI, 8.0-22.8), and hyperpigmentation (14.4% vs 0.5%; RR, 8.0; 95% Cl, 5.4-11.9). After adjusting for age, sex, and smoking status, eyes with these signs at baseline had a high likelihood of developing AMD. Eyes with Age-Related Eye Disease Study categories 3 and 4 were 5 times more likely to develop AMD compared with eyes in categories I and 2.
   Conclusion: This study quantifies the 5-year risk of AMD in eyes with macular drusen and hyperpigmentation.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   Univ Sydney, Save Sight & Westmead Millenium Inst, Westmead, NSW 2145, Australia.
   Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.
C3 University of Sydney; University of Sydney; Australian National
   University
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Maguire MG, 1997, OPHTHALMOLOGY, V104, P5, DOI 10.1016/S0161-6420(97)30369-8
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 25
TC 138
Z9 146
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2003
VL 121
IS 5
BP 658
EP 663
DI 10.1001/archopht.121.5.658
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676XU
UT WOS:000182778500008
PM 12742843
OA Bronze
DA 2022-11-30
ER

PT J
AU Istrate, M
   Hasbei-Popa, M
   Iliescu, DA
   Ghita, AC
   Vlaicu, B
   Ghita, MA
AF Istrate, Marina
   Hasbei-Popa, Mihai
   Iliescu, Daniela Adriana
   Ghita, Ana Cristina
   Vlaicu, Brigitha
   Ghita, Mihai Aurelian
TI Dual Sensory Impairment: The Correlation between Age Related Macular
   Degeneration and Sensorineural Hearing Loss
SO MEDICINA-LITHUANIA
LA English
DT Article
DE age-related macular degeneration; melanin; retinal pigment epithelium;
   cochlea; sensorineural hearing loss
ID OCULAR MELANIN; MELANOCYTES; PHYSIOLOGY
AB The pathogeneses of age-related macular degeneration (AMD) and age-related hearing impairment are not yet fully understood. If AMD and age-related hearing impairment are correlated, the cause of both may be a result of a common vulnerability. The aim of this study was to assess the interrelation between age-related macular degeneration and age-related hearing loss. Material and methods: In our case-control analysis, the hearing conditions of 40 subjects with AMD were compared with 40 age-matched healthy controls. In all patients, retinal changes were certified by clinical examinations, optical coherence tomography (OCT), and fluorescein angiography (FA). All subjects were inspected with pure tone audiometry (PTA), impedance audiometry, and speech audiometry. Results: A significant correlation (p < 0.001) was identified between age-related macular degeneration and age-related hearing impairment. The predominant hearing impairment in this case was sensorineural (SNHL). Of the patients diagnosed with AMD, SNHL was found in 88.89% of those with exudative macular degeneration and in 67.74% of those with atrophic macular degeneration. In contrast, we found that a significant proportion of the control group had normal hearing. Conclusion: One possible explanation for the association between retinal and cochlear impairment may be due to a melanin disorder.
C1 [Istrate, Marina] Victor Babes Univ Med & Pharm, Dept Doctoral Sch, Timisoara 300041, Romania.
   [Istrate, Marina] Infosan Ophthalmol Clin, Dept Ophthalmol, Bucharest 010538, Romania.
   [Hasbei-Popa, Mihai] Iuliu Hatieganu Univ Med & Pharm, Dept Med, Cluj Napoca 400000, Romania.
   [Iliescu, Daniela Adriana; Ghita, Mihai Aurelian] Carol Davila Univ Med & Pharm, Dept Physiol, Bucharest 050474, Romania.
   [Iliescu, Daniela Adriana; Ghita, Ana Cristina; Ghita, Mihai Aurelian] Ocularcare Eye Clin, Dept Ophtalmol, Bucharest 012244, Romania.
   [Vlaicu, Brigitha] Victor Babes Univ Med & Pharm, Dept Hyg, Timisoara 300041, Romania.
C3 Victor Babes University of Medicine & Pharmacy, Timisoara; Iuliu
   Hatieganu University of Medicine & Pharmacy; Carol Davila University of
   Medicine & Pharmacy; Victor Babes University of Medicine & Pharmacy,
   Timisoara
RP Istrate, M (通讯作者)，Victor Babes Univ Med & Pharm, Dept Doctoral Sch, Timisoara 300041, Romania.; Istrate, M (通讯作者)，Infosan Ophthalmol Clin, Dept Ophthalmol, Bucharest 010538, Romania.
EM istratemarina@yahoo.com
CR Bozkurt MK, 2011, J LARYNGOL OTOL, V125, P231, DOI 10.1017/S0022215110002604
   Chalam K.V., 2011, FUNDAMENTALS PRINCIP, P303
   Ghasemi Hassan, 2016, J Ophthalmic Vis Res, V11, P54, DOI 10.4103/2008-322X.180699
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Kansky J.J., 2011, CLIN OPHTHALMOLOGY A, V8th, P598
   Maranduca MA, 2019, ONCOL LETT, V17, P4183, DOI 10.3892/ol.2019.10071
   MASUDA M, 1994, ANAT RECORD, V240, P481, DOI 10.1002/ar.1092400406
   Rzepka Z, 2016, POSTEP HIG MED DOSW, V70, P695, DOI 10.5604/17322693.1208033
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Solano F, 2014, NEW J SCI, V2014, P1, DOI DOI 10.1155/2014/498276
   Tachibana M, 2001, J INVEST DERM SYMP P, V6, P95, DOI 10.1046/j.0022-202x.2001.00017.x
   ZUMGOTTESBERGE AMM, 1988, PIGM CELL RES, V1, P238
NR 12
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD FEB
PY 2022
VL 58
IS 2
AR 291
DI 10.3390/medicina58020291
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZU2LN
UT WOS:000769676400001
PM 35208614
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Velez-Montoya, R
   Oliver, SCN
   Olson, JL
   Fine, SL
   Mandava, N
   Quiroz-Mercado, H
AF Velez-Montoya, Raul
   Oliver, Scott C. N.
   Olson, Jeffrey L.
   Fine, Stuart L.
   Mandava, Naresh
   Quiroz-Mercado, Hugo
TI CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION Today's
   and Future Treatments
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; ranibizumab; bevacizumab; aflibercept;
   antipericyte therapy; combined therapy; geographic atrophy; choroidal
   neovascular membrane
ID ENDOTHELIAL GROWTH-FACTOR; X-RAY-IRRADIATION; INTRAVITREAL BEVACIZUMAB
   AVASTIN; CHOROIDAL NEOVASCULARIZATION SECONDARY; VERTEPORFIN
   PHOTODYNAMIC THERAPY; EXTERNAL-BEAM RADIATION; AMD 6-MONTH SAFETY;
   TRIAMCINOLONE ACETONIDE; RANIBIZUMAB LUCENTIS; STERILE ENDOPHTHALMITIS
AB Purpose: To address the most dynamic and current issues concerning today's treatment options and promising research efforts regarding treatment for age-related macular degeneration. This review is aimed to serve as a practical reference for more in-depth reviews on the subject.
   Methods: An online review of the database PubMed and Ovid were performed, searching for the key words age-related macular degeneration, AMD, VEGF, treatment, PDT, steroids, bevacizumab, ranibizumab, VEGF-trap, radiation, combined therapy, as well as their compound phrases. The search was limited to articles published since 1985. All returned articles were carefully screened, and their references were manually reviewed for additional relevant data. The web page www.clinicaltrials.gov was also accessed in search of relevant research trials.
   Results: A total of 363 articles were reviewed, including 64 additional articles extracted from the references. At the end, only 160 references were included in this review.
   Conclusion: Treatment for age-related macular degeneration is a very dynamic research field. While current treatments are mainly aimed at blocking vascular endothelial growth factor, future treatments seek to prevent vision loss because of scarring. Promising efforts have been made to address the dry form of the disease, which has lacked effective treatment.
C1 [Velez-Montoya, Raul; Oliver, Scott C. N.; Olson, Jeffrey L.; Fine, Stuart L.; Mandava, Naresh] Univ Colorado, Sch Med, Rocky Mt Lions Eye Inst, Dept Ophthalmol,Hlth & Sci Ctr, Aurora, CO USA.
   [Quiroz-Mercado, Hugo] Univ Colorado, Sch Med, Dept Ophthalmol, Denver Hlth Med Ctr, Denver, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Denver Health Medical Center; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   Denver
RP Velez-Montoya, R (通讯作者)，1675 Aurora Court, Aurora, CO 80045 USA.
EM raul.velez-montoya@ucdenver.edu
OI Oliver, Scott/0000-0002-3654-6502
FU Genetech; Ophthotech; Thrombogenics; National Eye Institute, National
   Institutes of Health
FX S.C.N. Oliver, J.L. Olson, and N. Mandava received research support from
   Genetech, Ophthotech, and Thrombogenics. S. L. Fine received research
   support from the National Eye Institute, National Institutes of Health.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Aras C, 2009, GRAEF ARCH CLIN EXP, V247, P619, DOI 10.1007/s00417-008-1025-y
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barakat MR, 2011, ARCH OPHTHALMOL-CHIC, V129, P628, DOI 10.1001/archophthalmol.2011.99
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buhrmann RHW, FORECASTING VISION L
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Cheng JW, 2011, NEW ENGL J MED, V364, P582, DOI 10.1056/NEJMc1013316
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dugel P, 2009, RETINA TODAY, V4, P38
   Dutcher JP, 2004, CLIN CANCER RES, V10, p6382S, DOI 10.1158/1078-0432.CCR-050008
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Evans JR, 2010, COCHRANE DB SYST REV, V12
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   Foster WJ, 2010, BRIT J OPHTHALMOL, V94, P1118, DOI 10.1136/bjo.2009.170282
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gordon-Angelozzi M, 2009, OPHTHALMOLOGY, V116, P2264, DOI 10.1016/j.ophtha.2009.07.027
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Holloway T B, 1928, Trans Am Ophthalmol Soc, V26, P206
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hosseini H, 2012, CORNEA, V31, P322, DOI 10.1097/ICO.0b013e31822480f9
   Jackson TL, 2012, EYE, V26, P557, DOI 10.1038/eye.2011.351
   Jain RK, 2003, J CLIN INVEST, V112, P1134, DOI 10.1172/JCI200320087
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Kim Hyun Woong, 2011, Korean J Ophthalmol, V25, P231, DOI 10.3341/kjo.2011.25.4.231
   Kimoto K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/852183
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MacDonald IM, 2007, CAN J OPHTHALMOL, V42, P399, DOI 10.3129/i07-039
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mata NL, 2010, CURR OPIN OPHTHALMOL, V21, P190, DOI 10.1097/ICU.0b013e32833866c8
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oraya Therapeutics Inc, 2012, OR THER ACH SUCC INT
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   Pollack A, 2011, NY TIMES
   QLT Inc, 2009, QLT ANN 12 MONTH RES
   QLT Inc, 2010, FIN RES VIS PHAS 3B
   Quiroz-Mercado H, 2008, GAC MED MEX, V144, P245
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2004, NOVART FDN SYMP, p[255, 63]
   Radu RA, 2004, NOVART FDN SYMP, V255, P63
   Radu Roxana A, 2004, Novartis Found Symp, V255, P51
   Ratner M, 2012, NAT BIOTECHNOL, V30, P4
   Regeneron Pharmaceuticals Inc and Bayer HealthCare, 2011, 2 YEAR RES PHAS 3 ST
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Seth RK, 2009, RETINA-J RET VIT DIS, V29, P956, DOI 10.1097/IAE.0b013e3181a91dfd
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V18
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Sun XD, 2011, NEW ENGL J MED, V365, P378, DOI 10.1056/NEJMc1106415
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Valmaggia Christophe, 2001, Documenta Ophthalmologica, V103, P201, DOI 10.1023/A:1013047722865
   Velez-Montoya R, 2010, CLIN OPHTHALMOL, V4, P947, DOI 10.2147/OPTH.S11650
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weisshardt P, 2012, HISTOCHEM CELL BIOL, V137, P391, DOI 10.1007/s00418-011-0898-8
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wu L, 2009, JPN J OPHTHALMOL, V53, P125, DOI 10.1007/s10384-008-0622-y
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
   Yenerel NM, 2008, J OCUL PHARMACOL TH, V24, P362, DOI 10.1089/jop.2007.0126
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang CR, 2011, GRAEF ARCH CLIN EXP, V249, P1493, DOI 10.1007/s00417-011-1709-6
NR 140
TC 44
Z9 45
U1 0
U2 36
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1487
EP 1502
DI 10.1097/IAE.0b013e318271f265
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200002
PM 23222393
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Li, M
   Zhang, XZ
   Chen, H
   Su, Y
   Wu, KF
   Wen, F
AF Zuo, Chengguo
   Li, Meng
   Zhang, Xiongze
   Chen, Hui
   Su, Yu
   Wu, Kunfang
   Wen, Feng
TI ENOS polymorphisms in neovascular age-related macular degeneration and
   polypoidal choroidal vasculopathy in a Chinese Han population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Endothelial nitric oxide synthase; polymorphism; polypoidal choroidal
   vasculopathy
ID NITRIC-OXIDE; GENE POLYMORPHISMS; ASSOCIATION; RETINOPATHY; LESIONS
AB Purpose: To investigate whether common genetic variants in the endothelial nitric oxide synthase gene (eNOS) are associated with neovascular age-related macular degeneration (nAMD) and polypoidal choroidalvasculopathy (PCV) in a Chinese Han population.Methods: DNA samples were obtained from 157 nAMD patients, 250 PCV patients and 204 healthy control subjects. Tag single nucleotide polymorphisms (SNPs) across the extended eNOS region were selected using data derived from the HapMap project. Genotyping of each tag SNP was performed by Multiplex SNaPshot system and direct DNA sequencing techniques. Genotypes and allele frequencies were evaluated with PLINK software for each group.Results: Seven SNPs for eNOS, rs1799983, rs1800783, rs3918186, rs3800787, rs3918188, rs7830, and rs3918227, were chosen as tag SNPs. Among these tag SNPs, rs1800783, rs3918186, rs3918188, and rs3918227 were not associated with nAMD or PCV. Rs1799983, rs3800787, and rs7830 was significantly associated with nAMD (p = 0.0192, 0.0170, and 0.0164, respectively), but not associated with PCV (p = 0.4852, 0.4568, and 0.4014, respectively). The discovered associations were no longer significant after Bonferroni correction.Conclusions: We found no sufficient evidence to support the role of any common eNOS variants in the susceptibility to nAMD or PCV in a Chinese Han population.
C1 [Zuo, Chengguo; Li, Meng; Zhang, Xiongze; Chen, Hui; Su, Yu; Wu, Kunfang; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
RI meng, li/GVT-2063-2022
FU Natural Science Foundation of China [81400426, 81470647]; Fundamental
   Research Funds for the Central Universities (Young Teacher Training
   Project of Sun Yat-sen University) [15ykpy31]; Fundamental Research
   Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the Natural Science Foundation of China
   (grant number: 81400426 & 81470647), the Fundamental Research Funds for
   the Central Universities (the Young Teacher Training Project of Sun
   Yat-sen University, grant number: 15ykpy31), and the Fundamental
   Research Funds of State Key Laboratory of Ophthalmology.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Awadalla MS, 2013, INVEST OPHTH VIS SCI, V54, P2108, DOI 10.1167/iovs.12-11391
   Awata T, 2004, DIABETES CARE, V27, P2184, DOI 10.2337/diacare.27.9.2184
   Ayub H, 2010, MOL VIS, V16, P18
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bazzaz JT, 2010, OPHTHALMIC GENET, V31, P103, DOI 10.3109/13816810.2010.482553
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   da Silva TM, 2012, GENE, V502, P142, DOI 10.1016/j.gene.2012.04.047
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Haas P, 2011, ACTA OPHTHALMOL, V89, P335, DOI 10.1111/j.1755-3768.2009.01697.x
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kaur C, 2009, INVEST OPHTH VIS SCI, V50, P5364, DOI 10.1167/iovs.09-3552
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Laspas P, 2014, EXP EYE RES, V127, P1, DOI 10.1016/j.exer.2014.06.018
   Liao QO, 2011, MOL VIS, V17, P153
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Pan L, 2012, INT J MOL SCI, V13, P2717, DOI 10.3390/ijms13032717
   Piatti PM, 2013, ACTA DIABETOL, V50, P373, DOI 10.1007/s00592-012-0426-x
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   QUYYUMI AA, 1995, CIRCULATION, V92, P320, DOI 10.1161/01.CIR.92.3.320
   SANDERS KM, 1992, AM J PHYSIOL, V262, pG379, DOI 10.1152/ajpgi.1992.262.3.G379
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Shi HH, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/164104
   Suganthalakshmi B, 2006, MOL VIS, V12, P336
   Synowiec E, 2013, FRONT BIOSCI-LANDMRK, V18, P80, DOI 10.2741/4088
   Uthra S, 2007, OPHTHALMIC GENET, V28, P77, DOI 10.1080/13816810701209669
   Xu HM, 2010, INT J MOL SCI, V11, P3323, DOI 10.3390/ijms11093323
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 40
TC 1
Z9 1
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2016
VL 37
IS 4
BP 394
EP 399
DI 10.3109/13816810.2015.1107598
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA EC0HQ
UT WOS:000387780700007
PM 26914548
DA 2022-11-30
ER

PT J
AU Emilsson, V
   Gudmundsson, EF
   Jonmundsson, T
   Jonsson, BG
   Twarog, M
   Gudmundsdottir, V
   Li, ZG
   Finkel, N
   Poor, S
   Liu, X
   Esterberg, R
   Zhang, YY
   Jose, S
   Huang, CL
   Liao, SM
   Loureiro, J
   Zhang, Q
   Grosskreutz, CL
   Nguyen, AA
   Huang, Q
   Leehy, B
   Pitts, R
   Aspelund, T
   Lamb, JR
   Jonasson, F
   Launer, LJ
   Cotch, MF
   Jennings, LL
   Gudnason, V
   Walshe, TE
AF Emilsson, Valur
   Gudmundsson, Elias F.
   Jonmundsson, Thorarinn
   Jonsson, Brynjolfur G.
   Twarog, Michael
   Gudmundsdottir, Valborg
   Li, Zhiguang
   Finkel, Nancy
   Poor, Stephen
   Liu, Xin
   Esterberg, Robert
   Zhang, Yiyun
   Jose, Sandra
   Huang, Chia-Ling
   Liao, Sha-Mei
   Loureiro, Joseph
   Zhang, Qin
   Grosskreutz, Cynthia L.
   Nguyen, Andrew A.
   Huang, Qian
   Leehy, Barrett
   Pitts, Rebecca
   Aspelund, Thor
   Lamb, John R.
   Jonasson, Fridbert
   Launer, Lenore J.
   Cotch, Mary Frances
   Jennings, Lori L.
   Gudnason, Vilmundur
   Walshe, Tony E.
TI A proteogenomic signature of age-related macular degeneration in blood
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL-DNA HAPLOGROUPS; GENOME-WIDE
   ASSOCIATION; FACTOR-H POLYMORPHISM; MENDELIAN RANDOMIZATION; MOLECULAR
   NETWORKS; COMPLEMENT; RISK; SERUM; PROGRESSION
AB Age-related macular degeneration (AMD) is one of the most common causes of visual impairment in the elderly, with a complex and still poorly understood etiology. Whole-genome association studies have discovered 34 genomic regions associated with AMD. However, the genes and cognate proteins that mediate the risk, are largely unknown. In the current study, we integrate levels of 4782 human serum proteins with all genetic risk loci for AMD in a large population-based study of the elderly, revealing many proteins and pathways linked to the disease. Serum proteins are also found to reflect AMD severity independent of genetics and predict progression from early to advanced AMD after five years in this population. A two-sample Mendelian randomization study identifies several proteins that are causally related to the disease and are directionally consistent with the observational estimates. In this work, we present a robust and unique framework for elucidating the pathobiology of AMD.
   Age related macular degeneration is a common cause of visual impairment in the elderly, but the etiology is not fully understood. Here, the authors use genetic data, serum proteomics, and AMD phenotypic data from a large Icelandic cohort to discover proteins altered in, causally related to AMD or signifying progression of advanced AMD.
C1 [Emilsson, Valur; Gudmundsson, Elias F.; Jonmundsson, Thorarinn; Jonsson, Brynjolfur G.; Gudmundsdottir, Valborg; Aspelund, Thor; Gudnason, Vilmundur] Iceland Heart Assoc, Holtasmari 1, IS-201 Kopavogur, Iceland.
   [Emilsson, Valur; Gudmundsdottir, Valborg; Jonasson, Fridbert; Gudnason, Vilmundur] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
   [Twarog, Michael; Finkel, Nancy; Poor, Stephen; Liu, Xin; Esterberg, Robert; Zhang, Yiyun; Jose, Sandra; Huang, Chia-Ling; Liao, Sha-Mei; Loureiro, Joseph; Zhang, Qin; Grosskreutz, Cynthia L.; Nguyen, Andrew A.; Huang, Qian; Leehy, Barrett; Pitts, Rebecca; Jennings, Lori L.; Walshe, Tony E.] Novartis Inst Biomed Res, 22 Windsor St, Cambridge, MA 02139 USA.
   [Li, Zhiguang; Launer, Lenore J.] Natl Inst Aging, Lab Epidemiol & Populat Sci, Bethesda, MD USA.
   [Lamb, John R.] Novartis Inst Biomed Res, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
   [Jonasson, Fridbert] Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Cotch, Mary Frances] NEI, NIH, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
C3 Icelandic Heart Association; University of Iceland; Novartis; National
   Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA);
   Novartis; Landspitali National University Hospital; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Emilsson, V (通讯作者)，Iceland Heart Assoc, Holtasmari 1, IS-201 Kopavogur, Iceland.; Emilsson, V (通讯作者)，Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.; Walshe, TE (通讯作者)，Novartis Inst Biomed Res, 22 Windsor St, Cambridge, MA 02139 USA.
EM valur@hjarta.is; tony.walshe@agios.com
RI ; Gudnason, Vilmundur/K-6885-2015
OI Poor, Stephen/0000-0003-4374-1178; Gudnason,
   Vilmundur/0000-0001-5696-0084; Gudmundsson, Elias
   Freyr/0000-0002-7661-4872; Jonmundsson, THorarinn/0000-0001-9158-0087;
   Gudmundsdottir, Valborg/0000-0002-7459-1603; Emilsson,
   Valur/0000-0001-9982-0524
FU National Institute on Aging (NIA) [N01-AG-12100, HHSN271201200022C]; NIH
   Intramural Research Program [ZIAEY000401]; NIA [1R01AG065596]; Althingi
   (the Icelandic Parliament); Icelandic Research Fund (IRF) [195761-051,
   184845-053, 206692-051]; University of Iceland Research Fund
FX The authors acknowledge the contribution of the Icelandic Heart
   Association (IHA) staff to the AGES-RS, as well as the involvement of
   all study participants. We thank the IAMDGC consortium for supplying us
   with their GWAS summary statistics data. National Institute on Aging
   (NIA) contracts N01-AG-12100 and HHSN271201200022C for V.G. financed the
   AGES study; retinal image collection and AMD readings were funded by the
   NIH Intramural Research Program (ZIAEY000401). V.G. received a funding
   from the NIA (1R01AG065596), and IHA received a support from Althingi
   (the Icelandic Parliament). The Icelandic Research Fund (IRF) funded
   V.E. and Va.G. with grants 195761-051, 184845-053, and 206692-051, while
   Va.G. received a postdoctoral research grant from the University of
   Iceland Research Fund
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Alic L, 2020, P NATL ACAD SCI USA, V117, P9942, DOI 10.1073/pnas.1913970117
   Babu E, 2011, INVEST OPHTH VIS SCI, V52, P5749, DOI 10.1167/iovs.10-6825
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757
   Choi S, 2008, BBA-GEN SUBJECTS, V1780, P1062, DOI 10.1016/j.bbagen.2008.05.010
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Dionne KL, 2019, J BIOL CHEM, V294, P1944, DOI 10.1074/jbc.RA118.004928
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Emilsson V, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28081-6
   Emilsson V, 2019, NAT MED, V25, P1815, DOI 10.1038/s41591-019-0677-y
   Emilsson V, 2018, SCIENCE, V361, P769, DOI 10.1126/science.aaq1327
   Enroth S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23860-y
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geyer PE, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910427
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Go YM, 2020, FASEB J, V34, P12502, DOI 10.1096/fj.202000612R
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   Gospe SM, 2019, J BIOL CHEM, V294, P12432, DOI 10.1074/jbc.RA119.007945
   Gudjonsson A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-021-27850-z
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Hathout Y, 2015, P NATL ACAD SCI USA, V112, P7153, DOI 10.1073/pnas.1507719112
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hoffmann TJ, 2018, NAT GENET, V50, P401, DOI 10.1038/s41588-018-0064-5
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Irmscher S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10766-0
   Jaffe G. J., 2020, OPHTHALMOL RETINA, V5
   Jain IH, 2016, SCIENCE, V352, P54, DOI 10.1126/science.aad9642
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Kuhn M., 2018, APPL PREDICTIVE MODE
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lamb J. R., 2020, TRENDS MOL MED, V27, P2030
   Lehallier B, 2019, NAT MED, V25, P1843, DOI 10.1038/s41591-019-0673-2
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Liu L, 2017, CELL METAB, V26, P719, DOI 10.1016/j.cmet.2017.08.024
   Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Martin PM, 2007, INVEST OPHTH VIS SCI, V48, P3356, DOI 10.1167/iovs.06-0888
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Raffield LM, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.201900278
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnick RB, 2018, J IMMUNOL, V200, P2280, DOI 10.4049/jimmunol.1701641
   Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454
   Schwenk JM, 2017, J PROTEOME RES, V16, P4299, DOI 10.1021/acs.jproteome.7b00467
   Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Swiercz R, 2007, J BIOL CHEM, V282, P16917, DOI 10.1074/jbc.M609778200
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tuck MK, 2009, J PROTEOME RES, V8, P113, DOI 10.1021/pr800545q
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wallace C, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009440
   Williams SA, 2019, NAT MED, V25, P1851, DOI 10.1038/s41591-019-0665-2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang B, 2013, CELL, V153, P707, DOI 10.1016/j.cell.2013.03.030
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 82
TC 0
Z9 0
U1 4
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 13
PY 2022
VL 13
IS 1
AR 3401
DI 10.1038/s41467-022-31085-x
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 2C2TT
UT WOS:000810727500026
PM 35697682
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Cheung, GCM
AF Teo, Kelvin Y. C.
   Cheung, Gemmy C. M.
TI New Concepts in Polypoidal Choroidal Vasculopathy Imaging: A Focus on
   Optical Coherence Tomography and Optical Coherence Tomography
   Angiography
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE choroidal neovascularization; macular degeneration; optical coherence
   tomography; polyps
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR
   DEGENERATION; GENETIC RISK; RANIBIZUMAB; ARTIFACTS; FEATURES; DIAGNOSIS;
   EFFICACY; SAFETY
AB Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular age-related macular degeneration. It is characterized by polypoidal dilatations at the terminus of branching vascular network located beneath the retinal pigment epithelium. These polypoidal lesions are best visualized on indocyanine green angiography. With recent advances in ocular imaging, optical coherence tomography (OCT) and OCT angiography (OCTA) have been increasingly used to aid in the diagnosis and monitoring of treatment responses in PCV. This review provides a summary of the current status of various imaging modalities in PCV, with special focus on OCT and OCTA.
C1 [Teo, Kelvin Y. C.; Cheung, Gemmy C. M.] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Cheung, Gemmy C. M.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Cheung, Gemmy C. M.] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore
RP Cheung, GCM (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
OI Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Teo,
   Kelvin/0000-0002-7458-7081
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Cheung CH, 2018, NEW J PHYS, V20, DOI 10.1088/1367-2630/aaf11d
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Ferrara D, 2016, CLIN EXP OPHTHALMOL, V44, P367, DOI 10.1111/ceo.12781
   Fukuchi T, 2001, JPN J OPHTHALMOL, V45, P252, DOI 10.1016/S0021-5155(00)00381-6
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2017, INVEST OPHTH VIS SCI, V58
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shiraki K, 2001, JPN J OPHTHALMOL, V45, P368, DOI 10.1016/S0021-5155(01)00362-8
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan ACS, 2018, EYE, V32, P262, DOI 10.1038/eye.2017.181
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   WOON WH, 1992, BRIT J OPHTHALMOL, V76, P470, DOI 10.1136/bjo.76.8.470
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
NR 62
TC 7
Z9 7
U1 0
U2 2
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2019
VL 8
IS 2
BP 165
EP 171
DI 10.22608/APO.201909
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JT1SV
UT WOS:000500778600009
PM 30916497
OA gold
DA 2022-11-30
ER

PT J
AU Querques, G
   Capuano, V
   Frascio, P
   Bandello, F
   Souied, EH
AF Querques, Giuseppe
   Capuano, Vittorio
   Frascio, Pietro
   Bandello, Francesco
   Souied, Eric H.
TI Emerging Therapeutic Options in Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Steroids; Zimura; Fovista; POT-4;
   Abicipar pegol; Pazopanib; Anti-VEGF drugs; Anti-PDGF drugs;
   Encapsulated cell technology
ID FOCUS
AB Intravitreal injection of anti-VEGF drugs currently represents the standard of treatment for exudative age-related macular degeneration. Several therapeutic options including steroids, inhibitors of complement factors, anti-platelet-derived growth factor agents, new anti-VEGF drugs, designed ankyrin repeat proteins, sustained drug delivery devices as an alternative to intravitreal injections and encapsulated cell technology are the objects of several studies and trials worldwide in association with anti-VEGF therapy or not. Expectations are that such efforts will help overcome limitations of current therapy with anti-VEGF, extending the duration of effects and hopefully contributing to the regression of neovascular lesions. (C) 2015 S. Karger AG, Basel
C1 [Querques, Giuseppe; Capuano, Vittorio; Frascio, Pietro; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, Creteil, France.
   [Querques, Giuseppe; Bandello, Francesco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, IRCCS, Dept Ophthalmol, Milan, Italy.
   [Frascio, Pietro] Univ Genoa, Dept Ophthalmol, Genoa, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Genoa
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Serv Ophthalmol, 40 Ave Verdun, FR-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682; Querques,
   Giuseppe/0000-0002-3292-9581
CR Augustin AJ, 2009, RETINA, V29, P573
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Kaushal S., 2009, INVESTIG OPHTHALMOL, V50, P5010
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Loewenstein A, 2010, SAFETY EFFICACY OZUR
   Mollnes Tom E., 2002, Trends in Immunology, V23, P61, DOI 10.1016/S1471-4906(01)02129-9
   NACHOD G R, 1951, J Am Med Womens Assoc, V6, P453
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Weber M, 2014, J FR OPHTALMOL, V37, P566, DOI 10.1016/j.jfo.2014.06.001
NR 16
TC 8
Z9 8
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 53
IS 4
BP 194
EP 199
DI 10.1159/000379754
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH0PG
UT WOS:000353723500003
PM 25871486
OA Bronze
DA 2022-11-30
ER

PT J
AU Meng, QY
   Huang, LZ
   Sun, YY
   Bai, YJ
   Wang, B
   Yu, WZ
   Zhao, MW
   Li, XX
AF Meng, Qingyu
   Huang, Lvzhen
   Sun, Yaoyao
   Bai, Yujing
   Wang, Bin
   Yu, Wenzhen
   Zhao, Mingwei
   Li, Xiaoxin
TI Effect of High-Density Lipoprotein Metabolic Pathway Gene Variations and
   Risk Factors on Neovascular Age-Related Macular Degeneration and
   Polypoidal Choroidal Vasculopathy in China
SO PLOS ONE
LA English
DT Article
ID ESTER TRANSFER PROTEIN; CARDIOVASCULAR-DISEASE; SUSCEPTIBILITY GENES;
   ASSOCIATION; VARIANTS; POPULATION; PREVALENCE; LOCI; MACULOPATHY;
   POLYMORPHISMS
AB Purpose
   To investigate the effect of genetic variants in the high-density lipoprotein (HDL) metabolic pathway and risk factors on neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in China.
   Methods
   A total of 742 Chinese subjects, including 221 controls, 230 cases with nAMD, and 291 cases with PCV, were included in the present study. Five single nucleotide polymorphisms (SNPs) from three genes in the HDL metabolic pathway (HDLMP) including cholesteryl ester transfer protein (CETP), hepatic lipase (LIPC) and lipoprotein lipase (LPL) were genotyped in all study subjects with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Risk factors including gender, hypertension, hyperlipidemia, diabetes mellitus, and coronary artery disease were identified. Chi-square tests or Fisher's exact tests were applied to discover associations between SNPs and risk factors for PCV and nAMD. Gene-gene interactions and gene-environment interactions were evaluated by the multifactor-dimensionality reduction (MDR) method.
   Results
   CETP rs3764261 were significantly associated with an increased risk for PCV (odds ratio (OR) = 1.444, P = 0.0247). LIPC rs1532085 conferred an increased risk for PCV (OR = 1.393, P = 0.0094). We found no association between PCV and LPL rs12678919, LIPC rs10468017 or CETP rs173539. No association was found between five SNPs with nAMD. Regarding risk factors, females were found to have significantly decreased risks for both PCV and nAMD (P = 0.006 and 0.001, respectively). Coronary artery disease (CAD) was a risk factor in PCV patients but played a protective role in nAMD patients. Hyperlipidemia was associated with PCV but not with nAMD. Neither hypertension nor diabetes mellitus was associated with PCV or nAMD. The MDR analysis revealed that a three-locus model with rs12678919, rs1532085, and gender was the best model for nAMD, while a five-locus model consisting of rs10468017, rs3764261, rs1532085, gender, and hyperlipidemia was best for PCV.
   Conclusion
   Our large-sample study suggested that CETP rs3764261 conferred an increased risk for PCV. We also first found the association between rs1532085 and PCV. The result of present study also showed that gender and CAD are associated with PCV and nAMD. Significant association was found between hyperlipidemia and PCV but not nAMD.
C1 [Meng, Qingyu; Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Meng, Qingyu; Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Meng, Qingyu; Huang, Lvzhen; Sun, Yaoyao; Bai, Yujing; Wang, Bin; Yu, Wenzhen; Zhao, Mingwei; Li, Xiaoxin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
C3 Peking University
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM zhaomingwei@medmail.com.cn; drlixiaoxin@163.com
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81100666, 81170854];
   Research Fund for Science and Technology Program of Beijing
   [Z121100005312006]
FX This study was supported by the National Basic Research Program of China
   (973 Program; #2011CB510200), National Natural Science Foundation of
   China Grant (81100666, 81170854), and the Research Fund for Science and
   Technology Program of Beijing (No. Z121100005312006). The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Aulchenko YS, 2009, NAT GENET, V41, P47, DOI 10.1038/ng.269
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Folkersen L, 2010, CIRC-CARDIOVASC GENE, V3, P365, DOI 10.1161/CIRCGENETICS.110.948935
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Joachim N, 2015, OPHTHALMOLOGY
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Ma L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092469
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nishino Y, 2014, PREV MED, V67, P41, DOI 10.1016/j.ypmed.2014.06.029
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Radovica I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064191
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Socias ME, 2015, WOMENS HLTH ISSUES
   Suhy A, 2015, PHARMACOGENET GENOM, V25, P394, DOI 10.1097/FPC.0000000000000151
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tinetti ME, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4984
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103594
   Wang JW, 2014, AM J HYPERTENS, V27, P1355, DOI 10.1093/ajh/hpu053
   Wang SB, 2014, BR J OPHTHALMOL
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Xu HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108103
   Yang SS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118500
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zheng W, 2014, J LIPID RES
NR 60
TC 11
Z9 14
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2015
VL 10
IS 12
AR e0143924
DI 10.1371/journal.pone.0143924
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CX7OL
UT WOS:000365891600076
PM 26624898
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Vrabec, R
   Vatavuk, Z
   Bencic, G
   Cima, I
   Zrinscak, O
   Mandic, Z
AF Vrabec, Romano
   Vatavuk, Zoran
   Bencic, Goran
   Cima, Ivan
   Zrinscak, Ognjen
   Mandic, Zdravko
TI Choroidal neovascularization in age-related macular degeneration treated
   with photodynamic therapy and intravitreal triamcinolone acetonide
SO ACTA CLINICA CROATICA
LA English
DT Article
DE macular degeneration, complications; macular degeneration, therapy;
   choroidal neovascularization, etiology; choroidal neovascularization,
   drug therapy; photochemotherapy
ID RANDOMIZED CLINICAL-TRIALS; REPORT NO. 1; VERTEPORFIN THERAPY; BRUCHS
   MEMBRANE; PHOTOCOAGULATION; ANGIOGENESIS; MACROPHAGES; LEUKOCYTES;
   BREAKDOWN; LESIONS
AB The aim of the study was to show the effect of combined photodynamic therapy and intravitreal injection of triamcinolone acetonide, in the treatment of choroidal neovascularization due 10 age-related macular degeneration. This retrospective, nonrandomized study included 20 patients with predominantly classic choroidal neovascularization due to age-related macular degeneration with no prior treatment. At baseline, all patients underwent ophthalmologic examination. Fluorescein angiography and optical coherent tomography were performed and analyzed. Triamcinolone acetonide, 4 mg, was intravitreally applied at 24-48 hours after standard photodynamic therapy. Follow up was scheduled at 3, 6 and 9 months. After 9 months, visual acuity improved in four, remained unchanged in 14 and decreased in two patients. In all patients, complete closure of choroidal neovascularization occurred after 9 months. At that time, a decrease in the central foveal thickness was also recorded in all patients. Combined photodynamic therapy and intravitreal injection of triamcinolone acetonide is a safe method in the treatment of choroidal neovascularization due to age-related macular degeneration, and leads to complete closure of choroidal neovascularization. To prove these promising results, a carefully designed, randomized, controlled study in a larger group Of patients is needed.
C1 [Vrabec, Romano; Vatavuk, Zoran; Bencic, Goran; Cima, Ivan; Zrinscak, Ognjen; Mandic, Zdravko] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Univ Dept Ophthalmol, HR-10000 Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine
RP Vrabec, R (通讯作者)，Univ Zagreb, Sestre Milosrdnice Univ Hosp, Univ Dept Ophthalmol, Vinogradska C 29, HR-10000 Zagreb, Croatia.
EM romanovrabec@yahoo.com
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, EUR J OPHTHALMOL, V16, P824, DOI 10.1177/112067210601600607
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ebrahem Q, 2006, INVEST OPHTH VIS SCI, V47, P4935, DOI 10.1167/iovs.05-1651
   Fackler TK, 2006, ANN ACAD MED SINGAP, V35, P701
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2006, OPHTHALMIC RES, V38, P324, DOI 10.1159/000096226
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Rudolf M, 2004, KLIN MONATSBL AUGENH, V221, P1026, DOI 10.1055/s-2004-813851
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
NR 25
TC 1
Z9 1
U1 1
U2 3
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD JUN
PY 2007
VL 46
IS 2
BP 161
EP 165
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 318UX
UT WOS:000257119400004
DA 2022-11-30
ER

PT J
AU Kang, KT
   Kim, YC
AF Kang, Kyung Tae
   Kim, Yu Cheol
TI Dietary Patterns and Age-Related Macular Degeneration in Korea: The
   Korea National Health and Nutrition Examination Survey 2010-2011
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RISK-FACTORS; VISUAL IMPAIRMENT; BETA-CAROTENE; EYE DISEASE; PREVALENCE;
   ZEAXANTHIN; LUTEIN; MACULOPATHY; ASSOCIATION; ANTIOXIDANTS
AB This study was performed to reveal dietary patterns and age-related macular degeneration risk association in general Korean population. A retrospective cross-sectional database analysis using the data collected from January 2010 to December 2011 at a Korea nationwide survey was conducted. The present analysis was performed from December 2016 to November 2017. Detailed grading with fundus photographs was performed by observers blinded to the patient characteristics. The current study focused on subjects forty year and older who had fundus photographs that is assessable from at least one eye (7,899 participants). Participants were excluded if they reported extreme energy intake (142 participants) or if they were likely to have changed dietary behavior (1,171 participants), or with missing data (n = 764). After exclusion, 5,843 participants data were analyzed in the current study. As the result, 6.8% of the participants exhibited early stages of age-related macular degeneration and 0.6% exhibited late stages. Furthermore, relatively more frequent fish consumption was associated reduced odds of early age-related macular degeneration when comparing the third quartile with the first quartile groups, however, relatively more frequent legume consumption was associated with reduced odds of late age-related macular degeneration when comparing the third quartile with the first quartile groups. In conclusion, the current study insists that the diet pattern rich in fish and legume might have protective effect against age-related macular degeneration in Korean population.
C1 [Kang, Kyung Tae; Kim, Yu Cheol] Keimyung Univ, Dept Ophthalmol, Dongsan Med Ctr, Sch Med, Daegu, South Korea.
C3 Keimyung University
RP Kim, YC (通讯作者)，Keimyung Univ, Dept Ophthalmol, Dongsan Med Ctr, Sch Med, Daegu, South Korea.
EM eyedr@dsmc.or.kr
OI Kang, Kyung Tae/0000-0001-9276-9607
FU National Research Foundation of Korea (NRF) - Korean government (MSIP)
   [2014R1A5A2010008]
FX This work was supported by the National Research Foundation of Korea
   (NRF) Grant funded by the Korean government (MSIP)(No.
   2014R1A5A2010008). The sponsor had no role in the desgin or conduct of
   this research.
CR Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Britton G, 2009, CAROTENOIDS SER, V5, P45, DOI 10.1007/978-3-7643-7501-0_3
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Magalhaes B, 2012, EUR J CANCER PREV, V21, P15, DOI 10.1097/CEJ.0b013e3283472241
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Maruyama K, 2013, NUTR METAB CARDIOVAS, V23, P519, DOI 10.1016/j.numecd.2011.10.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Neves D., 2015, ANTIAGEING NUTR EVID
   Newby PK, 2004, NUTR REV, V62, P177, DOI [10.1111/j.1753-4887.2004.tb00040.x, 10.1301/rn.2004.may.177-203]
   Nidhi B, 2013, INDIAN J OPHTHALMOL, V61, P722, DOI 10.4103/0301-4738.120218
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rim TH, 2019, BRIT J OPHTHALMOL, V103, P19, DOI 10.1136/bjophthalmol-2018-312693
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 59
TC 4
Z9 4
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 3
PY 2019
VL 9
AR 8200
DI 10.1038/s41598-019-44632-2
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IA9YE
UT WOS:000469912700041
PM 31160668
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hibert, ML
   Chen, YI
   Ohringer, N
   Feuer, WJ
   Waheed, NK
   Heier, JS
   Calhoun, MW
   Rosenfeld, PJ
   Polimeni, JR
AF Hibert, M. L.
   Chen, Y., I
   Ohringer, N.
   Feuer, W. J.
   Waheed, N. K.
   Heier, J. S.
   Calhoun, M. W.
   Rosenfeld, P. J.
   Polimeni, J. R.
TI Altered Blood Flow in the Ophthalmic and Internal Carotid Arteries in
   Patients with Age-Related Macular Degeneration Measured Using
   Noncontrast MR Angiography at 7T
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID MAGNETIC-RESONANCE ANGIOGRAPHY; PHASE-CONTRAST; EYE
AB BACKGROUND AND PURPOSE: Age-related macular degeneration is associated with reduced perfusion of the eye; however, the role of altered blood flow in the upstream ophthalmic or internal carotid arteries is unclear. We used ultra-high-field MR imaging to investigate whether the diameter of and blood flow in the ophthalmic artery and/or the ICA are altered in age-related macular degeneration and whether any blood flow changes are associated with disease progression. MATERIALS AND METHODS: Twenty-four patients with age-related macular degeneration and 13 similarly-aged healthy controls participated. TOF and high-resolution dynamic 2D phase-contrast MRA (0.26???0.26???2mm(3), 100-ms effective sampling rate) was acquired at 7T. Vessel diameters were calculated from cross-sectional areas in phase-contrast acquisitions. Blood flow time-series were measured across the cardiac cycle. RESULTS: The ophthalmic artery vessel diameter was found to be significantly smaller in patients with age-related macular degeneration than in controls. Volumetric flow through the ophthalmic artery was significantly lower in patients with late age-related macular degeneration, with a significant trend of decreasing volumetric ophthalmic artery flow rates with increasing disease severity. The resistance index was significantly greater in patients with age-related macular degeneration than in controls in the ophthalmic artery. Flow velocity through the ophthalmic artery and ICA was significantly higher in patients with age-related macular degeneration. Ophthalmic artery blood flow as a percentage of ipsilateral ICA blood flow was nearly double in controls than in patients with age-related macular degeneration. CONCLUSIONS: These findings support the hypothesis that vascular changes upstream to the eye are associated with the severity of age-related macular degeneration. Additional investigation into the potential causality of this relationship and whether treatments that improve ocular circulation slow disease progression is warranted.
C1 [Hibert, M. L.; Chen, Y., I; Ohringer, N.; Polimeni, J. R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA.
   [Chen, Y., I; Polimeni, J. R.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.
   [Feuer, W. J.; Rosenfeld, P. J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Waheed, N. K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Heier, J. S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Calhoun, M. W.] OcuDyne Inc, Roseville, MN USA.
   [Polimeni, J. R.] MIT, Harvard MIT, Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Bascom Palmer Eye Institute; University of
   Miami; Tufts Medical Center; Ophthalmic Consultants of Boston; Harvard
   University; Massachusetts Institute of Technology (MIT)
RP Polimeni, JR (通讯作者)，Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA.
EM jonp@nmr.mgh.harvard.edu
RI ; Polimeni, Jonathan/P-1395-2014
OI Ohringer, Ned/0000-0002-3964-6816; Heier, Jeffrey/0000-0003-4625-3145;
   Polimeni, Jonathan/0000-0002-1348-1179; Calhoun,
   Michael/0000-0003-2709-4484; Waheed, Nadia K./0000-0002-8229-7519;
   Rosenfeld, Philip/0000-0002-4068-6671; Feuer,
   William/0000-0002-9442-3076; Hibert, Matthew/0000-0002-2030-0903
FU National Institutes of Health (National Institute of Biomedical Imaging
   and Bioengineering) [P41-EB015896, R01-EB019437]; BRAIN Initiative
   (National Institute of Mental Health) [R01-MH111419]; Massachusetts
   General Hospital/Harvard-Massachusetts Institute of Technology Division
   of Health Sciences; Technology Athinoula A. Martinos Center for
   Biomedical Imaging; National Institutes of Health Shared Instrumentation
   Grants [S10-RR023401, S10-RR019307, S10RR023043, S10-RR019371,
   S10-RR020948]; OcuDyne Inc.
FX This work was supported, in part, by the National Institutes of Health
   (National Institute of Biomedical Imaging and Bioengineering grants
   P41-EB015896 and R01-EB019437), the BRAIN Initiative (National Institute
   of Mental Health grant R01-MH111419), and the Massachusetts General
   Hospital/Harvard-Massachusetts Institute of Technology Division of
   Health Sciences and Technology Athinoula A. Martinos Center for
   Biomedical Imaging and was made possible by the resources provided by
   National Institutes of Health Shared Instrumentation Grants
   S10-RR023401, S10-RR019307, S10RR023043, S10-RR019371, and S10-RR020948.
   It was also supported by OcuDyne Inc.
CR Ambarki K, 2013, INVEST OPHTH VIS SCI, V54, P2738, DOI 10.1167/iovs.13-11737
   [Anonymous], NTR
   Bernstein M. A., 2004, HDB MRI PULSE SEQUEN
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   Kang CK, 2016, MAGN RESON MED, V75, P1640, DOI 10.1002/mrm.25600
   Keil B., 2010, P INT SOC MAGN RESON, P1493
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   PELC NJ, 1994, MAGN RESON QUART, V10, P125
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Stamm AC, 2013, MAGN RESON IMAGING, V31, P545, DOI 10.1016/j.mri.2012.10.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
   Yu G, 2016, P INT SOC MAG RESON, V24, P1416
NR 18
TC 2
Z9 2
U1 2
U2 4
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD SEP
PY 2021
VL 42
IS 9
BP 1653
EP 1660
DI 10.3174/ajnr.A7187
EA JUL 2021
PG 8
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA UL6LT
UT WOS:000670402700001
PM 34210664
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Switzer, DW
   Mendonca, LS
   Saito, M
   Zweifel, SA
   Spaide, RF
AF Switzer, David W., Jr.
   Mendonca, Luis S.
   Saito, Masaaki
   Zweifel, Sandrine A.
   Spaide, Richard F.
TI SEGREGATION OF OPHTHALMOSCOPIC CHARACTERISTICS ACCORDING TO CHOROIDAL
   THICKNESS IN PATIENTS WITH EARLY AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related choroidal atrophy; age-related macular degeneration;
   choroid; choroidal thickness; enhanced depth imaging optical coherence
   tomography; reticular drusen; reticular pseudodrusen; subretinal
   drusenoid deposits
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; RETICULAR
   PSEUDODRUSEN; HIGH-SPEED; PREVALENCE; MACULOPATHY; RETINA; POPULATION;
   RESOLUTION; EYES
AB Purpose: To investigate the association of fundus features with choroidal thickness in eyes with early age-related macular degeneration.
   Methods: Consecutive patients with age-related macular degeneration were evaluated. Major exclusionary criteria included late age-related macular degeneration (central geographic atrophy or choroidal neovascularization), macular laser therapy, myopia greater than -6 diopters, past vitreoretinal surgery, or central serous chorioretinopathy. Charts and multimodal imaging were reviewed for refraction, cataract, hypertension, diabetes, open-angle glaucoma, beta-zone peripapillary atrophy, fundus tessellation, pigmentary changes, drusen, subretinal drusenoid deposits (also known as reticular pseudodrusen). Data measured from enhanced-depth imaging spectral-domain optical coherence tomography included subfoveal choroidal thickness, central foveal thickness, outer nuclear layer thickness, inner segment to retinal pigment epithelium aggregate thickness, presence of subretinal drusenoid deposit, and outer retinal hyperreflective layers (including the band corresponding to overlap between retinal pigment epithelium apical processes and outer segments). Correlations were calculated among the measured variables, fundus features, open-angle glaucoma, and visual acuity.
   Results: In 90 eyes of 70 early age-related macular degeneration patients with mean visual acuity 20/31 (logarithm of the minimum angle of resolution 0.193), subfoveal choroidal thickness showed a significant inverse correlation with age (P = 0.004) and increasing myopic spherical equivalent refractive error (P = 0.023). Subfoveal choroidal thickness was thinner in eyes with fundus tessellation (P < 0.001), subretinal drusenoid deposit (P = 0.023), an absence of conventional drusen (P < 0.001), the presence of beta-zone peripapillary atrophy (P < 0.001), and in eyes with a diagnosis of open-angle glaucoma (P = 0.003) or an absent band on optical coherence tomography corresponding to overlap between outer segment and retinal pigment epithelium apical processes (P = 0.022).
   Conclusion: Major ocular manifestations in early age-related macular degeneration and open-angle glaucoma are associated with the choroid-the main blood supply in the eye. Theories concerning the pathogenesis of these two diseases should incorporate interactions involving the choroid. RETINA 32:1265-1271, 2012
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Zweifel, Sandrine/AAX-5045-2020; Saito, Masaaki/ABI-2783-2020; Spaide,
   Richard/ABD-7368-2020
OI Saito, Masaaki/0000-0003-1494-6350; 
FU Topcon royalties; Macula Foundation
FX R. F Spaide was supported by Topcon royalties. This study is supported
   in part by the Macula Foundation.
CR AREDS Study Group, AREDS SUMM GRAD PROT
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   JONAS JB, 1992, ARCH OPHTHALMOL-CHIC, V110, P214, DOI 10.1001/archopht.1992.01080140070030
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas Jost B, 2005, Curr Opin Ophthalmol, V16, P84, DOI 10.1097/01.icu.0000156135.20570.30
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 88
Z9 90
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1265
EP 1271
DI 10.1097/IAE.0b013e31824453ac
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100006
PM 22222760
DA 2022-11-30
ER

PT J
AU Kulkarni, AD
   Kuppermann, BD
AF Kulkarni, AD
   Kuppermann, BD
TI Wet age-related macular degeneration
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE choroidal neovascularization; Bruch's membrane; retinal pigment
   epithelium; laser photocoagulation; photodynamic therapy
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; ENDOTHELIAL GROWTH-FACTOR;
   SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-E; GENETIC PREDISPOSITION;
   BASEMENT-MEMBRANE; 5-YEAR INCIDENCE; CLINICAL-TRIAL
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in industrialized nations for those age 65 and above. The majority of patients with severe visual loss suffer from the wet form of AMD wherein there is choroidal neovascularization (CNV) and associated manifestations such as retinal pigment epithelial detachment, subretinal hemorrhages, and fibrovascular disciform scarring. The main focus on understanding the pathogenesis of CNV has been on the hypothesis that the diffuse thickening of Bruch's membrane predisposes it to develop cracks and in-growth of new vessels from choriocapillaries with associated low-grade inflammatory response. Currently, three types of treatments (laser photocoagulation, photodynamic therapy, and anti-Vascular Endothelial Growth Factor (VEGF) therapy) have been demonstrated to limit or delay loss of vision in patients. Only a minority of cases show stabilization of vision and a small proportion of cases show significant improvement in vision. This highlights the need for more and better pharmacologic or other interventions, with the goal of lowering recurrence rates and preventing the development of CNV in order to achieve better functional outcomes. (c) 2005 Elsevier B.V.. All rights reserved.
C1 Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Kuppermann, BD (通讯作者)，Univ Calif Irvine, Dept Ophthalmol, 118 Med Surge 1, Irvine, CA 92697 USA.
EM bdkupper@uci.edu
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Flower RW, 2002, AM J OPHTHALMOL, V134, P228, DOI 10.1016/S0002-9394(02)01579-9
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GARRETT SK, 1999, OPHTHALMOL EPIDEMIOL, V60, P195
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P428
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1993, AM J OPHTHALMOL, V116, P414, DOI 10.1016/S0002-9394(14)71398-4
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mandava N, 1997, OPHTHALMIC SURG LAS, V28, P844
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Moisseiev J, 1990, INVEST OPHTHALMOL  S, V31, P462
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   OFFLER KU, 1986, GRAEFE ARCH CLIN EXP, V224, P493
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   SORENSON JA, 1985, OPHTHALMOLOGY, V92, P1059
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 2000, ARCH OPHTHALMOL-CHIC, V118, P1428
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 89
TC 50
Z9 53
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 13
PY 2005
VL 57
IS 14
BP 1994
EP 2009
DI 10.1016/j.addr.2005.09.003
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 996QD
UT WOS:000234188300002
PM 16309781
DA 2022-11-30
ER

PT J
AU Yang, K
   Wang, FH
   Liang, YB
   Wong, TY
   Wang, JJ
   Zhan, SY
   Wang, NL
AF Yang, Ke
   Wang, Feng-Hua
   Liang, Yuan-Bo
   Wong, Tien-Yin
   Wang, Jie-Jin
   Zhan, Si-Yan
   Wang, Ning-Li
TI ASSOCIATIONS BETWEEN CARDIOVASCULAR RISK FACTORS AND EARLY AGE-RELATED
   MACULAR DEGENERATION IN A RURAL CHINESE ADULT POPULATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; cardiovascular disease; hypertension;
   risk factors; rural Chinese
ID CHRONIC KIDNEY-DISEASE; APOLIPOPROTEIN-E GENE; ATHEROSCLEROSIS RISK;
   5-YEAR INCIDENCE; MACULOPATHY; PREVALENCE; CLASSIFICATION; GUIDELINES;
   MEMBRANE; SMOKING
AB Background: There have been a limited number of population-based studies investigating the associations between cardiovascular disease risk factors and early age-related macular degeneration (AMD).
   Methods: A total of 7,557 eligible people aged 30 or older were recruited from 2006 to 2007. Cardiovascular risk factors and serum lipids including total cholesterol, total triglycerides, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and fasting plasma glucose, and urines were assessed. Digital photographs of the optic disk and macula fields (Early Treatment of Diabetic Retinopathy Study) were taken and graded after the modified Wisconsin Age-related Maculopathy Grading System. Logistic regression models were constructed to assess odds ratios and 95% confidence intervals. Cases of late AMD were excluded.
   Results: Of 6,577 subjects included in the analysis, there were 200 (3.04%) cases with early AMD. Multivariate analysis showed that higher age, untreated hypertension, coronary heart disease, and smoking were associated with an increased risk of early AMD. After adjusting for other variables in the final model, no variable was significantly associated with hyperpigmentation while smoking was significantly associated with an increased risk of hypopigmentation; higher age and any cardiovascular disease were associated with an increased risk of large drusen, and higher age, smoking, untreated hypertension, and coronary heart disease were associated with an increased risk of soft drusen.
   Conclusion: Our findings support the associations between smoking, coronary heart disease, and early AMD.
C1 [Yang, Ke; Zhan, Si-Yan] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.
   [Wang, Feng-Hua] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Liang, Yuan-Bo; Wang, Ning-Li] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Wong, Tien-Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
   [Wang, Jie-Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Wang, Jie-Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie-Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Peking University; Capital Medical University; Chinese University of
   Hong Kong; National University of Singapore; Singapore National Eye
   Center; University of Sydney; University of Sydney; Westmead Institute
   for Medical Research; Centre for Eye Research Australia; University of
   Melbourne
RP Zhan, SY (通讯作者)，Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM siyan-zhan@bjmu.edu.cn
RI Wang, Jie Jin/P-1499-2014; Wong, Tien Yin/AAC-9724-2020; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   liang, Yuanbo/0000-0001-9685-7356
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Amer Diabet Assoc, 2000, DIABETES CARE, V23, pS32
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jiang LP, 2010, NEPHRON CLIN PRACT, V114, pC295, DOI 10.1159/000276582
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Keane WF, 1999, AM J KIDNEY DIS, V33, P1004, DOI 10.1016/S0272-6386(99)70442-7
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Liang YB, 2009, OPHTHAL EPIDEMIOL, V16, P115, DOI 10.1080/09286580902738159
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNEAD MP, 1992, SURV OPHTHALMOL, V36, P439, DOI 10.1016/S0039-6257(05)80025-6
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Sun E, 2011, MOL VIS, V17, P997
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhao Y, 2012, GRAEF ARCH CLIN EXP, V250, P1755, DOI 10.1007/s00417-012-2109-2
   Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83
NR 53
TC 10
Z9 12
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2014
VL 34
IS 8
BP 1539
EP 1553
DI 10.1097/IAE.0000000000000118
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM7ZE
UT WOS:000340086600013
PM 24978429
DA 2022-11-30
ER

PT J
AU Dantzig, PI
AF Dantzig, PI
TI Age-related macular degeneration and cutaneous signs of mercury toxicity
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE age-related macular degeneration; Grovers disease; mercury; signs of
   mercury toxicity
ID GROVERS-DISEASE
AB Objective. The objective of this study is to determine the relationship between age-related macular disease, and cutaneous signs of mercury toxicity. Methods. Fourteen patients with macular degeneration, 14 patients with Grover's disease, 14 control patients over the age of 52 with no signs of Grover's disease, and nine control patients over age 57 with measurable blood mercury levels but no evidence of macular degeneration were randomly selected. All patients had physical exam, skin biopsies where applicable, and blood mercury levels checked. Results. Of the 14 patients with macular degeneration, 11 patients had Grover's disease, two had spongiotic papules as reported by Dantzig, and 13 had measurable blood mercury levels. Of the 14 patients with Grover's disease, all 14 patients had measurable blood mercury levels and three of the patients were treated with diet and chelation with excellent response. Conclusions. Grover's disease may represent a cutaneous marker for age-related macular degeneration, and low levels of mercury may represent an etiology for both age-related macular degeneration and Grover's disease. If these findings are corroborated and proven to be true, then both diseases could potentially be drastically reduced or eradicated through strict environment controls.
C1 Columbia Univ, Dept Dermatol, Sch Med, New York, NY 10022 USA.
C3 Columbia University
RP Dantzig, PI (通讯作者)，Columbia Univ, Dept Dermatol, Sch Med, 30 E 60th St Suite 705, New York, NY 10022 USA.
EM pidmd@aol.com
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Chan S, 1998, CLIN LAB MED, V18, P615
   Dantzig PI, 2003, J AM ACAD DERMATOL, V49, P1109, DOI 10.1016/S0190-9622(03)02485-X
   Davis MDP, 1999, MAYO CLIN PROC, V74, P229, DOI 10.4065/74.3.229
   *FDA CONS ADV, 2001, IMP MESS PREGN WOM W
   French LE, 1999, DERMATOLOGY, V198, P410
   GILCHREST B, 1993, AGING SKIN DERMATOLO, P150
   Hashimoto K, 1995, J CUTAN PATHOL, V22, P488, DOI 10.1111/j.1600-0560.1995.tb01145.x
   Koh AHC, 2002, ANN ACAD MED SINGAP, V31, P399
   MCNEIL NI, 1984, LANCET, V1, P269
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   SHANKER BJ, 1998, ENVIRON RES, V77, P149
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 14
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2005
VL 24
IS 1
BP 3
EP 9
DI 10.1081/CUS-200046177
PG 7
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 949CQ
UT WOS:000230762900001
DA 2022-11-30
ER

PT J
AU Higgins, BE
   Taylor, DJ
   Bi, W
   Binns, AM
   Crabb, DP
AF Higgins, Bethany E.
   Taylor, Deanna J.
   Bi, Wei
   Binns, Alison M.
   Crabb, David P.
TI Novel computer-based assessments of everyday visual function in people
   with age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID CRASH INVOLVEMENT; FIELD DEFECTS; EYE-MOVEMENTS; OLDER DRIVERS;
   RISK-FACTORS; SEARCH; CLASSIFICATION; PERFORMANCE; POPULATION;
   IMPAIRMENT
AB Purpose
   To test the hypothesis that the performance in novel computer-based tasks of everyday visual function worsens with disease severity in people with non-neovascular age-related macular degeneration.
   Methods
   Participants with and without non-neovascular age-related macular degeneration (>= 60 years, minimum logMAR binocular visual acuity 0.7) performed a series of standard visual function tests and two novel computer-based tasks. In a visual search task, participants had to locate an image of a single real-world object within an array of 49 distractor images. Next, in a series of simulated dynamic driving scenes, participants were asked to identify one or two approaching real-world road signs and then select these road signs from four options. Outcome measures were median response times and total correct responses.
   Results
   Forty-nine participants had no macular disease (n = 11), early/intermediate age-related macular degeneration (n = 16) or geographic atrophy (n = 22). Groups were age-similar with median (interquartile range) logMAR visual acuity of 0.00 (-0.08,0.12), 0.13 (-0.08,0.70) and 0.32 (0.12,0.70) respectively. Median (interquartile range) visual search response times were 1.9 (1.0,2.4), 1.8 (1.1,3.7) and 2.4 (1.2,6.0) seconds respectively. Median (interquartile range) road sign response times (single road signs) were 1.2 (0.4,1.7), 1.5 (0.9,2.8) and 1.8 (1.0,5.5) seconds respectively. Median (interquartile range) road sign response times (double road signs) were 1.7 (0.7,2.4), 2.3 (1.2,3.1) and 2.5 (1.7,6) seconds respectively. Participants with geographic atrophy recorded slower response times in all tasks and over 50% performed outside the normative limit for task performance. There were no significant differences between groups in total correct responses across all tasks.
   Conclusions
   In a novel computer-based assessment, people with increasing severity of age-related macular degeneration take longer to perform visual search of everyday objects and take longer to identify road signs than those with no age-related macular degeneration. These novel assessments could be useful as patient-relevant, secondary outcomes for clinical trials.
C1 [Higgins, Bethany E.; Taylor, Deanna J.; Bi, Wei; Binns, Alison M.; Crabb, David P.] Univ London, Sch Hlth Sci, Optometry & Visual Sci, London, England.
C3 University of London
RP Crabb, DP (通讯作者)，Univ London, Sch Hlth Sci, Optometry & Visual Sci, London, England.
EM David.Crabb.1@city.ac.uk
OI Higgins, Bethany/0000-0002-4530-6156; Crabb, David/0000-0001-8754-3902
FU Roche Products Ltd, UK
FX This study was funded as part of an unrestricted investigator-initiated
   research grant from Roche Products Ltd, UK, (https://www.roche.co.uk/)
   awarded to DPC. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], DRIV EYES RUL
   Aspinall PA, 2014, BRIT J OPHTHALMOL, V98, P1393, DOI 10.1136/bjophthalmol-2014-305032
   Brady TF, 2008, P NATL ACAD SCI USA, V105, P14325, DOI 10.1073/pnas.0803390105
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coeckelbergh TRM, 2002, VISION RES, V42, P669, DOI 10.1016/S0042-6989(01)00297-8
   Denniss J, 2017, INVEST OPHTH VIS SCI, V58, P2652, DOI 10.1167/iovs.16-21086
   Driving Standards Agency-Great Britain, 2007, OFF HIGHW COD
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P323, DOI 10.1111/j.1475-1313.1990.tb00877.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   FORD A, 1959, J OPT SOC AM, V49, P287, DOI 10.1364/JOSA.49.000287
   Freeze J, 2018, PROCEEDINGS OF THE 51ST ANNUAL HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS), P913
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   Geringswald F, 2013, J VISION, V13, DOI 10.1167/13.3.28
   Haegerstrom-Portnoy G, 2000, OPTOMETRY VISION SCI, V77, P653, DOI 10.1097/00006324-200012000-00012
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Jacko J. A., 2002, Universal Access in the Information Society, V1, P197, DOI 10.1007/s102090100015
   Jones PR, 2020, OPHTHAL PHYSL OPT, V40, P35, DOI 10.1111/opo.12658
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Lovie-Kitchin JE, 1986, OPTOMETRY VISION SCI, DOI [10.1097/00006324-198605000-00008, DOI 10.1097/00006324-198605000-00008]
   MacKeben M, 2011, INVEST OPHTH VIS SCI, V52, P7603, DOI 10.1167/iovs.10-6728
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   McGwin G, 1998, ACCIDENT ANAL PREV, V30, P781, DOI 10.1016/S0001-4575(98)00031-1
   McGwin G, 2013, BRIT J OPHTHALMOL, V97, P1173, DOI 10.1136/bjophthalmol-2013-303601
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   MURPHY KS, 1988, OPHTHAL PHYSL OPT, V8, P345, DOI 10.1111/j.1475-1313.1988.tb01065.x
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Patnaik JL, 2019, OPHTHALMOL RETINA, V3, P336, DOI 10.1016/j.oret.2018.11.004
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Schoonjans F, 2011, EPIDEMIOLOGY, V22, P750, DOI 10.1097/EDE.0b013e318225c1de
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   Taylor DJ, 2018, GRAEF ARCH CLIN EXP, V256, P815, DOI 10.1007/s00417-017-3879-3
   Taylor DJ, 2017, INVEST OPHTH VIS SCI, V58, P1887, DOI 10.1167/iovs.16-21122
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Team RC. R, 2013, R CORE TEAM R LANGUA, DOI DOI 10.1890/0012-9658(2002)083[3097:CFHIWS]2.0.CO;2
   Thibaut M, 2016, J FR OPHTALMOL, V39, P82, DOI 10.1016/j.jfo.2015.08.010
   Thibaut M, 2018, CLIN EXP OPTOM, V101, P372, DOI 10.1111/cxo.12644
   Van der Stigchel S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00579
   Wiecek E, 2012, INVEST OPHTH VIS SCI, V53, P6600, DOI 10.1167/iovs.12-10012
   Wood JM, 2018, INVEST OPHTH VIS SCI, V59, P273, DOI 10.1167/iovs.17-22751
NR 45
TC 3
Z9 3
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2020
VL 15
IS 12
AR e0243578
DI 10.1371/journal.pone.0243578
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PD8LW
UT WOS:000597930500048
PM 33284855
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Saito, M
   Iida, T
   Saito, K
   Kano, M
   Itagaki, K
   Maruko, I
   Sekiryu, T
AF Saito, Masaaki
   Iida, Tomohiro
   Saito, Kuniharu
   Kano, Mariko
   Itagaki, Kanako
   Maruko, Ichiro
   Sekiryu, Tetsuju
TI Long-term characteristics of exudative age-related macular degeneration
   in Japanese patients
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; RANIBIZUMAB;
   VERTEPORFIN; NEOVASCULARIZATION; OUTCOMES; BEVACIZUMAB; MECHANISM;
   TRIALS
AB Purpose
   The present study aimed to evaluate the clinical characteristics of exudative age-related macular degeneration (AMD) in Japanese patients over a 10-year period and to compare the past our report.
   Methods
   We retrospectively reviewed 1,600 treatment-naive patients (1,777 eyes) with exudative AMD. The 10 years were divided into 2-year phases I to V.
   Results
   Of the 1,600 patients, 720 (45.0%), 733 (45.8%), 98 (6.1%), and 49 (3.1%) were diagnosed with typical AMD, polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation, and combined subtypes, respectively. The prevalence of PCV decreased from 54.7% in phase I to 46.0% at phase V. Of the 1,777 eyes, the mean baseline logarithm of the minimum angle of resolution best-corrected visual acuities (BCVAs) in phases I, II, III, IV, and V were 0.70, 0.66, 0.55, 0.50, and 0.48, respectively. Phases III, IV, and V had significantly (P = 0.0012, P<0.0001, P<0.0001, respectively) better baseline VAs compared with phase I. The mean lesion sizes in phases I, II, III, IV, and V were 8.6, 6.7, 5.3, 5.7, and 5.7 Macular Photocoagulation Study disc areas, respectively. The sizes were significantly (P<0.0001 for all comparisons) smaller in phases III, IV, and V compared with phase I.
   Conclusions
   Although the prevalence of PCV decreased from 54.7% in phase I to 46.0% at phase V, PCV has nevertheless been highly prevalent in Japanese patients with AMD compared with Caucasian patients. The annual better baseline VAs and smaller lesion sizes over time might be related to development of treatment and better concerns about AMD.
C1 [Saito, Masaaki; Iida, Tomohiro; Saito, Kuniharu; Kano, Mariko; Itagaki, Kanako; Maruko, Ichiro; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.
   [Saito, Masaaki] Hirosaki Univ, Dept Ophthalmol, Grad Sch Med, Hirosaki, Aomori, Japan.
   [Iida, Tomohiro; Kano, Mariko; Maruko, Ichiro] Tokyo Womens Med Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
C3 Fukushima Medical University; Hirosaki University; Tokyo Women's Medical
   University
RP Saito, M (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.; Saito, M (通讯作者)，Hirosaki Univ, Dept Ophthalmol, Grad Sch Med, Hirosaki, Aomori, Japan.
EM masaaki@hirosaki-u.ac.jp
OI Sekiryu, Tetsuju/0000-0001-8042-2729; Saito, Masaaki/0000-0003-1494-6350
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243458
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Saito M, 2010, AM J OPHTHALMOL, V149, P472, DOI 10.1016/j.ajo.2009.09.016
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2021
VL 16
IS 12
AR e0261320
DI 10.1371/journal.pone.0261320
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YY2HZ
UT WOS:000754615500035
PM 34905560
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Amato, A
   Barresi, C
   Aragona, E
   Saladino, A
   Pina, A
   Calcagno, F
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Amato, Alessia
   Barresi, Costanza
   Aragona, Emanuela
   Saladino, Andrea
   Pina, Adelaide
   Calcagno, Francesca
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Choroidal Modifications Preceding the Onset of Macular
   Neovascularization in Age-Related Macular Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE AMD; Choriocapillaris; Choroid; MNV; OCT; OCTA
ID HYPERREFLECTIVE FOCI; GEOGRAPHIC ATROPHY; THICKNESS
AB Introduction Macular neovascularization (MNV) is a common complication of age-related macular degeneration (AMD). Although several biomarkers may help to estimate the risk of MNV onset, neovascular complication is difficult to predict. Previous studies showed that the quantitative assessment of choroidal and choriocapillaris changes is useful for the assessment of atrophy expansion. On the other hand, scant data are available regarding the role of this kind of assessment in the setting of MNV. The aim of the study is to analyze choroidal and choriocapillaris changes occurring before the onset of MNV in patients affected by AMD using quantitative optical coherence tomography (OCT) and OCT angiography (OCTA). Methods The study was designed as a retrospective case series. Patients affected by AMD, categorized in eyes complicated by MNV and eyes not developing MNV, were retrospectively analyzed for 1 year of follow-up. Choroidal thickness (CT), Sattler layer thickness (SLT) and Haller layer thickness (HLT) were measured on OCT scans. Vessel density (VD) and choriocapillaris (CC) porosity were quantified on OCTA reconstructions. The main outcome measure was the relationship between choroidal and CC parameters, and MNV onset. Results We included 50 eyes of 50 AMD patients (28 male; mean age 74 +/- 5 years). Over the 1-year follow-up, 15/50 eyes developed MNV (9 type 1; 3 type 2; 3 mixed type 1-2). Mean best-corrected visual acuity (BCVA) was 0.15 +/- 0.15 logMAR at baseline, remaining stable in eyes not developing MNV (0.15 +/- 0.12 logMAR; p > 0.05), and worsening to 0.38 +/- 0.20 logMAR in eyes developing MNV (p < 0.01). VD values were similar between eyes developing MNV and eyes not complicated by MNV at baseline, with significant worsening detected only in MNV eyes. CC porosity was significantly higher in MNV eyes already before the onset of MNV. Furthermore, SLT was significantly lower in eyes developing MNV. The onset of MNV was preceded by a significant increase in intraretinal hyperreflective foci, whereas choroidal hyperreflective foci showed no evident changes. Conclusions The degeneration of CC and the SLT thinning represent early an biomarker of MNV onset in AMD.
C1 [Arrigo, Alessandro; Amato, Alessia; Barresi, Costanza; Aragona, Emanuela; Saladino, Andrea; Pina, Adelaide; Calcagno, Francesca; Bandello, Francesco; Parodi, Maurizio Battaglia] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI Arrigo, Alessandro/0000-0003-4715-8414
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Parodi MB, 2022, BRIT J OPHTHALMOL, V106, P564, DOI 10.1136/bjophthalmol-2020-317635
   Parodi MB, 2018, INVEST OPHTH VIS SCI, V59, P3314, DOI 10.1167/iovs.18-24291
   Romano F, 2019, EYE, V33, P1916, DOI 10.1038/s41433-019-0483-2
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD FEB
PY 2022
VL 11
IS 1
BP 377
EP 386
DI 10.1007/s40123-021-00443-1
EA DEC 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YJ5MU
UT WOS:000731496700001
PM 34923601
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Invernizzi, A
   Parrulli, S
   Monteduro, D
   Cereda, MG
   Nguyen, V
   Staurenghi, G
   Cheung, CMG
   Gillies, M
   Teo, KYC
AF Invernizzi, Alessandro
   Parrulli, Salvatore
   Monteduro, Davide
   Cereda, Matteo G.
   Nguyen, Vuong
   Staurenghi, Giovanni
   Cheung, Chui Ming Gemmy
   Gillies, Mark
   Teo, Kelvin Yi Chong
TI Outer Retinal Layer Thickening Predicts the Onset of Exudative
   Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PROGRESSION; DISEASE;
   DRUSEN; EYES; OCT
AB PURPOSE: To assess changes in outer retinal layer (ORL) thickness before the development of exudative macular neovascularization (MNV) in eyes with age-related macular degeneration.
   DESIGN: Retrospective observational case series.
   METHODS: Eyes with age-related macular degeneration that eventually developed exudative MNV followed with sequential optical coherence tomography for >= 2 years before the exudation occurred were enrolled. The ORL thickness was automatically calculated by the optical coherence tomography software for each sector of the early treatment diabetic retinopathy study map at each follow-up visit. The ORL thickness change from baseline to the day when the exudative MNV developed was compared between sectors that eventually developed exudative MNV and those that did not.
   RESULTS: Forty-seven eyes (47 patients) were included. At baseline (24 +/- 3 months before exudative MNV), mean (standard deviation) ORL thickness of sec-tors that eventually developed exudative MNV was similar to that of sectors that did not (85.2 [8.2] mu m vs 86.8 [5.7] mu m, P = .08). ORL thickness significantly in-creased in sectors that developed exudative MNV compared with those that did not (+5.8 [10.4] mu m vs -2.8 [3.6] mu m, P < .01). The regression model based on these data predicted an increase in ORL thickness from baseline of +4.2% 55 days and +11.1% 30 days before exudative MNV was detected. The ORL thickness of areas that did not develop exudative MNV did not change.
   CONCLUSION: Thickening of the ORL begins in the area where exudative MNV will develop long before the exudation, accelerating significantly in the last 2 months. The occurrence of exudative MNV could be predicted by 2 months using this simple analysis. ((C) 2021 Elsevier Inc. All rights reserved.)
C1 [Invernizzi, Alessandro; Parrulli, Salvatore; Monteduro, Davide; Cereda, Matteo G.; Nguyen, Vuong; Staurenghi, Giovanni; Cheung, Chui Ming Gemmy; Gillies, Mark; Teo, Kelvin Yi Chong] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Invernizzi, Alessandro; Parrulli, Salvatore; Monteduro, Davide; Cereda, Matteo G.; Nguyen, Vuong; Staurenghi, Giovanni; Cheung, Chui Ming Gemmy; Gillies, Mark; Teo, Kelvin Yi Chong] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Invernizzi, Alessandro; Parrulli, Salvatore; Monteduro, Davide; Cereda, Matteo G.; Nguyen, Vuong; Staurenghi, Giovanni; Cheung, Chui Ming Gemmy; Gillies, Mark; Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Invernizzi, Alessandro; Parrulli, Salvatore; Monteduro, Davide; Cereda, Matteo G.; Nguyen, Vuong; Staurenghi, Giovanni; Cheung, Chui Ming Gemmy; Gillies, Mark; Teo, Kelvin Yi Chong] Singapore Eye Res Inst, Singapore, Singapore.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney;
   Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center
RP Invernizzi, A (通讯作者)，Univ Milan, L Sacco Hosp, Dept Biomed & Clin Sci, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Heinemann M, 2019, OPHTHAL EPIDEMIOL, V26, P238, DOI 10.1080/09286586.2019.1597898
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Invernizzi A, 2018, OPHTHALMOL RETINA, V2, P808, DOI 10.1016/j.oret.2017.12.012
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nittala MG, EYE LOND, DOI [10.1038/s41433-020- 01293-0. 2020.11.19, DOI 10.1038/S41433-020-01293-0.2020.11.19]
   Querques G, EUR J OPHTHALMOL, DOI [10.1177/1120672120986370. 2021.01.14, DOI 10.1177/1120672120986370.2021.01.14]
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Sim PY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017771
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P126, DOI 10.1016/j.oret.2020.07.005
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
NR 29
TC 5
Z9 5
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2021
VL 231
BP 19
EP 27
DI 10.1016/j.ajo.2021.05.015
EA AUG 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WG0VE
UT WOS:000706716500003
PM 34058152
DA 2022-11-30
ER

PT J
AU Vujosevic, S
   Toma, C
   Sarao, V
   Veritti, D
   Brambilla, M
   Muraca, A
   De Cilla, S
   Villani, E
   Nucci, P
   Lanzetta, P
AF Vujosevic, Stela
   Toma, Caterina
   Sarao, Valentina
   Veritti, Daniele
   Brambilla, Marco
   Muraca, Andrea
   De Cilla, Stefano
   Villani, Edoardo
   Nucci, Paolo
   Lanzetta, Paolo
TI Color Fundus Autofluorescence to Determine Activity of Macular
   Neovascularization in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE color fundus autofluorescence; age-related macular degeneration; macular
   neovascularization; disease activity; fluorophores
ID GLYCATION END-PRODUCTS; SPECTRAL-DOMAIN-OCT; CHOROIDAL
   NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; RPE; DETACHMENTS;
   LIPOFUSCIN
AB Purpose: To evaluate with color fundus autofluorescence (FAF) different lesion components of macular neovascularization (MNV) secondary to age-related macular degeneration (AMD) and to assess its activity. Methods: In total, 137 eyes (102 patients) with MNV underwent a complete eye examination, including color fundus photography, optical coherence tomography (OCT), OCT angiography, and confocal color FAF, with an excitation wavelength at 450 nm. Each image was imported into a custom-image analysis software for quantitative estimation of emission wavelength and green and red emission fluorescence (GEFC/REFC) intensity, considering both single components of neovascular AMD and different MNV types (type 1 and type 2 MNV, active and inactive MNV). Results: Subretinal fluid (SRF) had significantly higher values of GEFC (P = 0.008 and P = 0.0004) and REFC intensity (P = 0.005 and P = 0.0003) versus fibrosis and atrophy. The emission wavelength from SRF was lower compared to atrophy (P = 0.024) but not to fibrosis (P = 0.46). No significant differences were detected between type 1 and 2 MNV. Considering active versus inactive MNVs, a difference was detected for all evaluated parameters (P < 0.001). Mean FAF wavelength of both MNV with SRF and intraretinal fluid (IRF) was lower versus inactive MNV (P < 0.001 and P = 0.005). MNV with SRF (P < 0.001) had higher values of GEFC and REFC versus inactive MNV (P < 0.001). MNV with IRF had higher values of GEFC versus inactive MNV (P = 0.05). Conclusions: Quantitative color FAF can differentiate active versus inactive MNV, whereas no differences were found between type 1 and type 2 MNV. If these data can be further confirmed, color FAF may be useful for automatic detection of active MNV in AMD and as a guide for treatment. Translational Relevance: Automatic quantitative evaluation of green and red emission components of FAF in AMD can help determine the activity of MNV and guide the treatment.
C1 [Vujosevic, Stela; Villani, Edoardo] Eye Clin IRCCS MultiMed, Via San Vittore 12, I-20123 Milan, Italy.
   [Vujosevic, Stela; Toma, Caterina; Muraca, Andrea; De Cilla, Stefano] Univ Hosp Maggiore Carita, Eye Clin, Novara, Italy.
   [Sarao, Valentina; Veritti, Daniele; Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Udine, Italy.
   [Sarao, Valentina; Lanzetta, Paolo] Ist Europeo Microchirurg Oculare IEMO, Udine, Italy.
   [Brambilla, Marco] Univ Hosp Maggiore Carita, Dept Med Phys, Novara, Italy.
   [De Cilla, Stefano] Univ East Piedmont A Avogadro, Dept Hlth Sci, Novara, Italy.
   [Villani, Edoardo; Nucci, Paolo] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
C3 Azienda Ospedaliera Maggiore della Carita di Novara; University of
   Udine; Azienda Ospedaliera Maggiore della Carita di Novara; University
   of Eastern Piedmont Amedeo Avogadro; University of Milan
RP Vujosevic, S (通讯作者)，Eye Clin IRCCS MultiMed, Via San Vittore 12, I-20123 Milan, Italy.
EM stela.vujosevic@gmail.com
OI Vujosevic, Stela/0000-0001-6773-9967
CR Borrelli E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082388
   Borrelli E, 2019, BRIT J OPHTHALMOL, V103, P610, DOI 10.1136/bjophthalmol-2018-311849
   Borrelli E, 2018, BRIT J OPHTHALMOL, V102, P827, DOI 10.1136/bjophthalmol-2017-310881
   Chaudhuri J, 2018, CELL METAB, V28, P337, DOI 10.1016/j.cmet.2018.08.014
   Croce AC, 2014, EUR J HISTOCHEM, V58, P320, DOI 10.4081/ejh.2014.2461
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Forrester JV, 2015, FUNDUS AUTOFLUORESCE, V2nd
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Gabai A, 2015, INDIAN J OPHTHALMOL, V63, P406, DOI 10.4103/0301-4738.159868
   Hammer M, 2008, GRAEF ARCH CLIN EXP, V246, P979, DOI 10.1007/s00417-008-0789-4
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Khurana RN, 2020, OPHTHALMOL RETINA, V4, P1054, DOI 10.1016/j.oret.2020.04.016
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Makino H, 1996, NEPHROL DIAL TRANSPL, V11, P76
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Munch G, 1997, BRAIN RES REV, V23, P134, DOI 10.1016/S0165-0173(96)00016-1
   Parekh PK, 2018, OPHTHALMOL RETINA, V2, P659, DOI 10.1016/j.oret.2018.01.002
   Ravera V, 2019, RETINA-J RET VIT DIS, V39, P281, DOI 10.1097/IAE.0000000000001960
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spital G, 1998, KLIN MONATSBL AUGENH, V213, P23, DOI 10.1055/s-2008-1034939
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Vujosevic S, 2020, J CLIN MED, V10, pE48
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
NR 38
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.33
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2SX
UT WOS:000635394600003
PM 34003918
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ngai, LY
   Stocks, N
   Sparrow, JM
   Patel, R
   Rumley, A
   Lowe, G
   Smith, GD
   Ben-Shlomo, Y
AF Ngai, L-Y
   Stocks, N.
   Sparrow, J. M.
   Patel, R.
   Rumley, A.
   Lowe, G.
   Smith, G. Davey
   Ben-Shlomo, Y.
TI The prevalence and analysis of risk factors for age-related macular
   degeneration: 18-year follow-up data from the Speedwell eye study,
   United Kingdom
SO EYE
LA English
DT Article
DE maculopathy; macular degeneration; prevalence; risk factors; cohort
   study; United Kingdom
ID C-REACTIVE PROTEIN; VISUAL IMPAIRMENT; CARDIOVASCULAR-DISEASE;
   CIGARETTE-SMOKING; SOCIOECONOMIC-STATUS; 10-YEAR INCIDENCE; 5-YEAR
   INCIDENCE; PARTIAL SIGHT; DIETARY-FAT; MACULOPATHY
AB Aims/Purpose To determine the prevalence of age-related maculopathy (ARM) and age-related macular degeneration (AMD) in men aged 65-83 years living in the Speedwell region of Bristol, United Kingdom and identify modifiable risk factors.
   Methods A total of 2348 men recruited to the Speedwell prospective cohort study in 1979 were followed up in 1997 with an eye questionnaire and had retinal photographs that were assessed using the International Classification System for ARM.
   Results In all, 934 men (66.8% response rate) attended with a mean of 17.9 years (15.3-20.6 years) follow-up. Early ARM (grades 2-3) was found in 9.2% (95% confidence interval (CI) 7.4%, 11.4%) and late age-related maculopathy (grade 4, AMD) in 0.5% (95% CI 0.2%, 1.2%). The risk of ARM (grades 2-4) was increased with raised C-reactive protein and consumption of lard and solid fats, whereas triglyceride levels were associated with a lower risk. The latter were confirmed in multivariable analyses and in addition, haemodynamic measures also predicted risk (eg mean arterial pressure odds ratio (OR) per z-score 1.37, 95% CI 1.04, 1.79).
   Conclusions In a representative cohort of men aged 65-83 from Bristol, United Kingdom, many had macular changes that put them at higher risk of developing AMD. Various modifiable exposures were associated with an increased risk ARM/AMD. Opportunities for screening and undertaking secondary prevention interventions need to be explored to prevent progression of the disease and blindness. Eye (2011) 25, 784-793; doi:10.1038/eye.2011.56; published online 25 March 2011
C1 [Stocks, N.] Univ Adelaide, Discipline Gen Practice, Adelaide, SA 5005, Australia.
   [Ngai, L-Y; Patel, R.; Smith, G. Davey; Ben-Shlomo, Y.] Univ Bristol, Dept Social Med, Bristol, Avon, England.
   [Sparrow, J. M.] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   [Rumley, A.; Lowe, G.] Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
C3 University of Adelaide; University of Bristol; Bristol Eye Hospital;
   University of Glasgow
RP Stocks, N (通讯作者)，Univ Adelaide, Discipline Gen Practice, Adelaide, SA 5005, Australia.
EM nigel.stocks@adelaide.edu.au
RI Davey Smith, George/A-7407-2013; Ben-Shlomo, Yoav/ABD-2004-2021; Stocks,
   Nigel P/I-1083-2012
OI Davey Smith, George/0000-0002-1407-8314; Ben-Shlomo,
   Yoav/0000-0001-6648-3007; s, hema/0000-0002-3440-9475; Stocks,
   Nigel/0000-0002-9018-0361; Venkatasubramanian,
   Siddharth/0000-0002-5860-0768
FU Research into Ageing; National Eye Research Centre
FX We would like to thank Research into Ageing and the National Eye
   Research Centre for funding this research and the Bristol Eye Hospital
   for providing suitable facilities for performing the eye examinations.
   We would like to acknowledge the assistance given by Hans Vingerling and
   Paulus de Jong in the preparation of data for analysis.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DAS BN, 1994, J ROY SOC MED, V87, P219
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954
   ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gray PJ, 1996, J ROY SOC MED, V89, P23, DOI 10.1177/014107689608900107
   GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88
   Hawkins BS, 1999, MOL VIS, V5
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MUELLER CW, 1981, CHILD DEV, V52, P13, DOI 10.2307/1129211
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Stocks N, 2002, EYE, V16, P275, DOI 10.1038/sj.eye.6700106
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P95, DOI 10.1136/bjo.73.2.95
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103
   2003, INVEST OPHTHALMOL VI, V44, P3771
NR 82
TC 17
Z9 18
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2011
VL 25
IS 6
BP 784
EP 793
DI 10.1038/eye.2011.56
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 775BA
UT WOS:000291430100017
PM 21436849
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kent, DL
AF Kent, David L.
TI Age-related macular degeneration: Beyond anti-angiogenesis
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULAR MEMBRANES; ENDOTHELIAL
   GROWTH-FACTOR; FACTOR-H POLYMORPHISM; INDUCIBLE FACTOR-I;
   CLINICOPATHOLOGICAL CORRELATION; NATURAL-HISTORY; INFLAMMATION; DISEASE;
   GENE
AB Recently, anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration have been developed. These agents, originally developed for their anti-angiogenic mechanism of action, probably also work through an anti-permeability effect in preventing or reducing the amount of leakage from submacular neovascular tissue. Other treatment modalities include laser photocoagulation, photodynamic therapy with verteporfin, and submacular surgery. In reality, these latter treatments can be similarly categorized as anti-angiogenic because their sole aim is destroying or removing choroidal neovascularization (CNV). At the cellular level, CNV resembles stereotypical tissue repair that consists of several matricellular components in addition to neovascularization. In the retina, the clinical term CNV is a misnomer since the term may more appropriately be referred to as aberrant submacular repair. Furthermore, CNV raises a therapeutic conundrum: To complete or correct any reparative process in the body, angiogenesis becomes an essential component. Anti-angiogenic therapy, in all its guises, arrests repair and causes the hypoxic environment to persist, thus fueling pro-angiogenesis and further development of CNV as a component of aberrant repair. However, we realize that anti-vascular endothelial growth factor therapy preserves vision in patients with age-related macular degeneration, albeit temporarily and therefore, repeated treatment is needed. More importantly, however, anti-angiogenic therapy demonstrates that we can at the very least tolerate neovascular tissue beneath the macula and preserve vision in contrast to our historical approach of total vascular destruction. In this clinical scenario, it may be possible to look beyond anti-angiogenesis if our goal is facilitating submacular repair without destroying the neurosensory retina. Thus, in this situation of neovascular tolerance, it may be timely to consider treatments that facilitate vascular maturation, rather than its arrest or destruction. This would neutralize hypoxia, thus removing the stimulus that drives neovascularization and in turn the need for repeated lifelong intravitreal therapy. A pro-angiogenic approach would eliminate neovascular leakage and ultimately complete repair and preserve the neurosensory retina.
C1 [Kent, David L.] Vis Clin, Kilkenny, Ireland.
   [Kent, David L.] Univ Liverpool, Fac Hlth & Life Sci, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England.
C3 University of Liverpool
RP Kent, DL (通讯作者)，Vis Clin, Circular Rd, Kilkenny, Ireland.
EM dkent@liverpool.ac.uk
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P376
   [Anonymous], 1976, AM J OPHTHALMOL, V81, P383
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Augoustides JGT, 2009, J CARDIOTHOR VASC AN, V23, P259, DOI 10.1053/j.jvca.2008.12.022
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Acosta JB, 2008, INT WOUND J, V5, P530, DOI 10.1111/j.1742-481X.2008.00457.x
   Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x
   Bitto A, 2008, CLIN SCI, V114, P707, DOI 10.1042/CS20070250
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Cianfarani F, 2006, AM J PATHOL, V169, P1167, DOI 10.2353/ajpath.2006.051314
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   DASTGHEIB K, 1993, RETINA-J RET VIT DIS, V13, P345, DOI 10.1097/00006982-199313040-00013
   Demidova-Rice TN, 2012, ADV SKIN WOUND CARE, V25, P304, DOI 10.1097/01.ASW.0000416006.55218.d0
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eriksson A, 2003, CIRCULATION, V107, P1532, DOI 10.1161/01.CIR.0000055324.34758.32
   FINE SL, 1980, ARCH OPHTHALMOL-CHIC, V98, P832
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Green G E, 1968, Surg Forum, V19, P159
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   HUNINK MGM, 1995, JAMA-J AM MED ASSOC, V274, P165, DOI 10.1001/jama.274.2.165
   Hunt TK, 1990, J TRAUMA
   Kakisis JD, 2012, EUR J VASC ENDOVASC, V44, P238, DOI 10.1016/j.ejvs.2012.04.015
   Kan P, 2012, CURR PROB CARDIOLOGY, V37, P127, DOI 10.1016/j.cpcardiol.2011.11.001
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Kent D, 2003, MOL VIS, V9, P747
   KIRSNER RS, 1993, DERMATOL CLIN, V11, P629, DOI 10.1016/S0733-8635(18)30216-X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   MACLEAN AL, 1960, AM J OPHTHALMOL, V50, P3, DOI 10.1016/0002-9394(60)90833-3
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAIMAN TH, 1960, NATURE, V187, P493, DOI 10.1038/187493a0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MEYERSCHWICKERATH GRE, 1989, AUST NZ J OPHTHALMOL, V17, P427, DOI 10.1111/j.1442-9071.1989.tb00566.x
   MORGAN CM, 1989, OPHTHALMOLOGY, V96, P96
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Ndubuizu OI, 2010, BRAIN RES, V1366, P101, DOI 10.1016/j.brainres.2010.09.064
   Nicolaides AN, 2005, ANGIOLOGY, V56, pS11, DOI 10.1177/00033197050560i103
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   OKUNAKA T, 1992, LASER SURG MED, V12, P98, DOI 10.1002/lsm.1900120115
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PIERCE GF, 1992, AM J PATHOL, V140, P1375
   Pradhan L, 2011, J SURG RES, V167, P336, DOI 10.1016/j.jss.2009.09.012
   Pradhan L, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000945
   Raffetto JD, 2009, THROMB RES, V123, pS66, DOI 10.1016/S0049-3848(09)70147-1
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SASAYAMA S, 1992, CIRCULATION, V85, P1197, DOI 10.1161/01.CIR.85.3.1197
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Shyu KG, 2003, LIFE SCI, V73, P563, DOI 10.1016/S0024-3205(03)00318-7
   Sibbald RG, 2008, DIABETES-METAB RES, V24, pS25, DOI 10.1002/dmrr.847
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Smith PDC, 2001, ANGIOLOGY, V52, pS35
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
   WOOD CM, 1990, BRIT J OPHTHALMOL, V74, P93, DOI 10.1136/bjo.74.2.93
   WYSZYNSKI RE, 1988, RETINA-J RET VIT DIS, V8, P237, DOI 10.1097/00006982-198808040-00003
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamamoto Y, 2009, AM J PHYSIOL-HEART C, V297, pH1329, DOI 10.1152/ajpheart.00321.2009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 104
TC 26
Z9 27
U1 2
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 6
PY 2014
VL 20
BP 46
EP 55
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AB5JM
UT WOS:000331824700005
PM 24426775
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Kano, M
   Yamamoto, A
   Saito, M
   Maruko, I
   Sekiryu, T
   Okada, AA
   Iida, T
AF Koizumi, Hideki
   Kano, Mariko
   Yamamoto, Akiko
   Saito, Masaaki
   Maruko, Ichiro
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
TI Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VEGF TRAP-EYE; DIURNAL-VARIATION;
   HEALTHY-SUBJECTS; RANIBIZUMAB; VASCULOPATHY; VERTEPORFIN
AB Purpose: To investigate changes in subfoveal choroidal thickness after intravitreal aflibercept injections (IAIs) for neovascular age-related macular degeneration (AMD) at 12 months.
   Design: Retrospective, consecutive, interventional case series.
   Participants: One hundred forty-four patients with treatment-naive neovascular AMD examined at 3 university hospitals.
   Methods: After a loading phase of 3 monthly 2.0-mg IAIs, the patients were injected bimonthly with additional rescue injections performed for worsening. Subfoveal choroidal thickness in IAI-treated eyes was evaluated using enhanced depth imaging optical coherence tomography (OCT) or swept-source OCT.
   Main Outcome Measures: Changes in subfoveal choroidal thickness over a 12-month period.
   Results: Of the 144 treated eyes, 58 (40.3%) had typical neovascular AMD and 86 (59.7%) had polypoidal choroidal vasculopathy (PCV). The mean subfoveal choroidal thickness of treated eyes decreased from 268.1 +/- 101.3 mm at baseline to 233.0 +/- 99.7 mm at 3 months and remained unchanged at 232.4 +/- 99.6 mm at 12 months (percentage decrease, 13.3% at 12 months compared with baseline; P < 0.0001), although there was some fluctuation in between treatments. This decrease in subfoveal choroidal thickness was associated significantly with gain in visual acuity for PCV eyes (P = 0.0087; R = 0.28), but not for eyes with typical neovascular AMD (P = 0.17; R = 0.18). Eyes without persistent or recurrent retinal fluid after the loading phase showed greater decrease in subfoveal choroidal thickness compared with those with persistent or recurrent retinal fluid, in both typical neovascular AMD (P = 0.042) and PCV (P = 0.038) eyes.
   Conclusions: Subfoveal choroidal thickness decreased over 12 months with IAI therapy in eyes with neovascular AMD. Changes in subfoveal choroidal thickness after IAIs seem to be related to visual and anatomic outcomes. (C) 2016 by the American Academy of Ophthalmology.
C1 [Koizumi, Hideki; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Kano, Mariko; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Tokyo Women's Medical University; Fukushima Medical University; Kyorin
   University
RP Koizumi, H (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM koizumi.hideki@twmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Maruko, Ichiro/AFP-1311-2022
OI Saito, Masaaki/0000-0003-1494-6350; Maruko, Ichiro/0000-0001-5647-6372;
   Koizumi, Hideki/0000-0002-9610-4386; Sekiryu,
   Tetsuju/0000-0001-8042-2729
FU Ministry of Education, Culture, Sports, Science and Technology, Tokyo,
   Japan [25670739]
FX Supported by the Ministry of Education, Culture, Sports, Science and
   Technology, Tokyo, Japan (grant no.: 25670739 [H.K.]).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee SW, 2014, RETINA-J RET VIT DIS, V34, P385, DOI 10.1097/IAE.0b013e3182993f29
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Ogasawara Masashi, 2012, Nippon Ganka Gakkai Zasshi, V116, P643
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seidel G, 2015, AM J OPHTHALMOL, V159, P365, DOI 10.1016/j.ajo.2014.11.002
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 34
TC 84
Z9 84
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2016
VL 123
IS 3
BP 617
EP 624
DI 10.1016/j.ophtha.2015.10.039
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE4UQ
UT WOS:000370626300038
PM 26686967
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Chong, NV
AF Sivaprasad, S.
   Chong, N. V.
TI The complement system and age-related macular degeneration
SO EYE
LA English
DT Review
DE complement; complement factor H; CFH; age-related macular deneration;
   angiogenesis; oxidation stress
ID FACTOR-H POLYMORPHISM; OXIDATIVE STRESS; DRUSEN; ACTIVATION;
   MACULOPATHY; PATHOGENESIS; INFLAMMATION; PREVALENCE; PROTEINS; DISEASE
AB Purpose Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. There are increasing evidences to suggest the complement system may play a significant role on the pathogenesis of AMD. In this review, we summarise the current research in this area.
   Methods Review of literature.
   Results The complement system is a complex system with several activation pathways. Complement factor H (CFH) polymorphisms has been associated with increase risk of AMD. CFH is an inhibitor protein; the polymorphisms might cause uncontrolled activation by initiation events.
   Conclusion Further studies on the molecular basis of the complement-mediated pathogenesis of AMD may offer novel therapy to AMD.
C1 Kings Coll London, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 University of London; King's College London
RP Chong, NV (通讯作者)，Kings Coll London, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Sivaprasad, S./D-6876-2015; Chong, Ngaihang
   V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659; 
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kostner KM, 2004, EUR J CLIN INVEST, V34, P800, DOI 10.1111/j.1365-2362.2004.01431.x
   Laufer J, 2001, MOL IMMUNOL, V38, P221, DOI 10.1016/S0161-5890(01)00044-X
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MULLINS RF, 2004, OPHTHALMOL VIS SCI, V45
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   RAISLER BJ, 2005, OPHTHALMOL VIS SCI, V46
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 36
TC 46
Z9 59
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2006
VL 20
IS 8
BP 867
EP 872
DI 10.1038/sj.eye.6702176
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 071TO
UT WOS:000239625700001
PM 16410816
OA Bronze
DA 2022-11-30
ER

PT J
AU Yang, ZL
   Stratton, C
   Francis, PJ
   Kleinman, ME
   Tan, PL
   Gibbs, D
   Tong, ZZ
   Chen, HY
   Constantine, R
   Yang, X
   Chen, YH
   Zeng, JX
   Davey, L
   Ma, XN
   Hau, VS
   Wang, C
   Harmon, J
   Buehler, J
   Pearson, E
   Patel, S
   Kaminoh, Y
   Watkins, S
   Luo, L
   Zabriskie, NA
   Bernstein, PS
   Cho, WG
   Schwager, A
   Hinton, DR
   Klein, ML
   Hamon, SC
   Simmons, E
   Yu, BF
   Campochiaro, B
   Sunness, JS
   Campochiaro, P
   Jorde, L
   Parmigiani, G
   Zack, DJ
   Katsanis, N
   Ambati, J
   Zhang, K
AF Yang, Zhenglin
   Stratton, Charity
   Francis, Peter J.
   Kleinman, Mark E.
   Tan, Perciliz L.
   Gibbs, Daniel
   Tong, Zongzhong
   Chen, Haoyu
   Constantine, Ryan
   Yang, Xian
   Chen, Yuhong
   Zeng, Jiexi
   Davey, Lisa
   Ma, Xiang
   Hau, Vincent S.
   Wang, Chi
   Harmon, Jennifer
   Buehler, Jeanette
   Pearson, Erik
   Patel, Shrena
   Kaminoh, Yuuki
   Watkins, Scott
   Luo, Ling
   Zabriskie, Norman A.
   Bernstein, Paul S.
   Cho, Wongil
   Schwager, Andrea
   Hinton, David R.
   Klein, Michael L.
   Hamon, Sara C.
   Simmons, Emily
   Yu, Beifeng
   Campochiaro, Betsy
   Sunness, Janet S.
   Campochiaro, Peter
   Jorde, Lynn
   Parmigiani, Giovanni
   Zack, Donald J.
   Katsanis, Nicholas
   Ambati, Jayakrishna
   Zhang, Kang
TI Toll-like receptor 3 and geographic atrophy in age-related macular
   degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; DOUBLE-STRANDED-RNA; UTAH MORMONS;
   GENETIC-STRUCTURE; BLOOD-GROUPS; RISK; VARIANT; SUSCEPTIBILITY;
   HAPLOTYPE; DNA
AB BACKGROUND Age- related macular degeneration is the most common cause of irreversible visual impairment in the developed world. Advanced age- related macular degeneration consists of geographic atrophy and choroidal neovascularization. The specific genetic variants that predispose patients to geographic atrophy are largely unknown.
   METHODS We tested for an association between the functional toll- like receptor 3 gene ( TLR3) variant rs3775291 ( involving the substitution of phenylalanine for leucine at amino acid 412) and age- related macular degeneration in Americans of European descent. We also tested for the effect of TLR3 Leu and Phe variants on the viability of human retinal pigment epithelial cells in vitro and on apoptosis of retinal pigment epithelial cells from wild- type mice and Tlr3- knockout ( Tlr3(-/-)) mice.
   RESULTS The Phe variant ( encoded by the T allele at rs3775291) was associated with protection against geographic atrophy ( P = 0.005). This association was replicated in two independent case - control series of geographic atrophy ( P = 5.43 x 10(-4) and P = 0.002). No association was found between TLR3 variants and choroidal neovascularization. A prototypic TLR3 ligand induced apoptosis in a greater fraction of human retinal pigment epithelial cells with the Leu - Leu genotype than those with the Leu - Phe genotype and in a greater fraction of wild- type mice than Tlr3(-/-) mice.
   CONCLUSIONS The TLR3 412Phe variant confers protection against geographic atrophy, probably by suppressing the death of retinal pigment epithelial cells. Since double- stranded RNA ( dsRNA) can activate TLR3- mediated apoptosis, our results suggest a role of viral dsRNA in the development of geographic atrophy and point to the potential toxic effects of short- interfering- RNA therapies in the eye.
C1 [Yang, Zhenglin; Chen, Haoyu; Yang, Xian; Chen, Yuhong; Zeng, Jiexi; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92037 USA.
   [Tan, Perciliz L.; Davey, Lisa; Wang, Chi; Campochiaro, Betsy; Sunness, Janet S.; Campochiaro, Peter; Parmigiani, Giovanni; Zack, Donald J.; Katsanis, Nicholas] Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21205 USA.
   [Yang, Zhenglin] Sichuan Acad Med Sci, Chengdu, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.
   [Yang, Zhenglin; Stratton, Charity; Gibbs, Daniel; Tong, Zongzhong; Chen, Haoyu; Constantine, Ryan; Yang, Xian; Chen, Yuhong; Zeng, Jiexi; Ma, Xiang; Hau, Vincent S.; Harmon, Jennifer; Buehler, Jeanette; Pearson, Erik; Patel, Shrena; Kaminoh, Yuuki; Watkins, Scott; Luo, Ling; Zabriskie, Norman A.; Bernstein, Paul S.; Schwager, Andrea; Yu, Beifeng; Jorde, Lynn; Zhang, Kang] Univ Utah, Sch Med, Salt Lake City, UT USA.
   [Francis, Peter J.; Klein, Michael L.; Simmons, Emily] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Kleinman, Mark E.; Cho, Wongil; Ambati, Jayakrishna] Univ Kentucky, Lexington, KY USA.
   [Sunness, Janet S.] Greater Baltimore Med Ctr, Baltimore, MD USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Hamon, Sara C.] Rockefeller Univ, New York, NY 10021 USA.
   [Zhang, Kang] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.
C3 University of California System; University of California San Diego;
   Johns Hopkins University; Sichuan Provincial People's Hospital; Sichuan
   Provincial People's Hospital; Utah System of Higher Education;
   University of Utah; Oregon Health & Science University; University of
   Kentucky; Greater Baltimore Medical Center; University of Southern
   California; Rockefeller University; Peking University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92037 USA.
EM nkatsan1@jhmi.edu; kangzhang@ucsd.edu
RI Chu, Kai On/E-2325-2016; Chen, Haoyu/A-7432-2013; Mitchell,
   Paul/P-1498-2014; Ma, Xiang/E-4173-2013; Katsanis, Nicholas/E-1837-2012;
   Zhang, Kang/Y-2740-2019
OI Chen, Haoyu/0000-0003-0676-4610; Ma, Xiang/0000-0001-9427-8385; Zhang,
   Kang/0000-0002-4549-1697; Zack, Don/0000-0002-7966-1973; Sunness,
   Janet/0000-0001-8823-0780; Blum, Emily/0000-0002-3110-9944; Katsanis,
   Nicholas/0000-0002-2480-0171
FU National Institutes of Health; Veterans Affairs Merit Award; Foundation
   Fighting Blindness; Macula Vision Research Foundation; Ruth and Milton
   Steinbach Fund; Research to Prevent Blindness; Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research; American Health
   Assistance Foundation; Dr. E. Vernon & Eloise C. Smith Endowment Fund;
   Arnold and Mabel Beckman Foundation; Alcon; GlaxoSmithKline; Alimera;
   Genentech; CoMentis; Quark Pharmaceuticals; Allergan; Acucela; Oxigene;
   NATIONAL EYE INSTITUTE [R01EY014428, R01EY014448] Funding Source: NIH
   RePORTER
FX Supported by grants from the National Institutes of Health (to Drs.
   Klein, Campochiaro, Zack, Katsanis, Ambati, and Zhang); a Veterans
   Affairs Merit Award (to Dr. Zhang); grants from the Foundation Fighting
   Blindness (to Drs. Francis, Campochiaro, Zack, Katsanis, and Zhang), the
   Macula Vision Research Foundation (to Drs. Katsanis, Ambati, and Zhang),
   the Ruth and Milton Steinbach Fund (to Drs. Campochiaro, Zack, and
   Zhang), and Research to Prevent Blindness ( to Drs. Francis,
   Campochiaro, Zack, Ambati, and Zhang); a Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research ( to Drs. Ambati and
   Zhang); grants from the American Health Assistance Foundation ( to Drs.
   Z. Yang, Ambati, and Zhang), the Dr. E. Vernon & Eloise C. Smith
   Endowment Fund ( to Dr. Ambati), and the Arnold and Mabel Beckman
   Foundation ( to Dr. Hinton); and generous gifts from the Guerrieri
   Family Foundation and from Robert and Clarice Smith ( to Dr. Zack).; Dr.
   Campochiaro reports receiving grant support from Alcon, GlaxoSmithKline,
   Alimera, Genentech, and CoMentis. Dr. Zack reports receiving consulting
   fees from Alcon, Fovea, and Novartis, receiving lecture fees from Alcon,
   owning equity in Merck and Pfizer, and receiving grant support from
   Alcon and Fovea. Dr. Ambati reports receiving consulting fees from Quark
   Pharmaceuticals and Allergan and being listed on a patent on TLR3 that
   has been applied for by the University of Kentucky. Dr. Zhang reports
   having an equity interest in Navigen, receiving grant support and
   lecture fees from Genentech, and receiving consulting fees from Acucela
   and Oxigene. No other potential conflict of interest relevant to this
   article was reported.; We thank the participants and their families; the
   staff of the Ambati, Katsanis, and Zhang laboratories; Jonathan
   Stoddard, Bradley Katz, Robert Kwan, Gregory Brinton, John Carver, John
   Brand, Lisa Schneider, Adam Jorgenson, Neil Bressler, Mary Gail Engle,
   and Christine Spee for assistance in obtaining blood samples and
   technical assistance; and Dr. Guy Zimmerman for critical reading of a
   draft of the manuscript.
CR ABRAMSON HJ, 2001, COMPUTER PROGRAMS EP
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782
   Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337
   MCLELLAN T, 1984, AM J HUM GENET, V36, P836
   OBRIEN E, 1994, HUM BIOL, V66, P743
   OBrien E, 1996, AM J HUM BIOL, V8, P609, DOI 10.1002/(SICI)1520-6300(1996)8:5<609::AID-AJHB6>3.0.CO;2-Q
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002
   Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   1999, 1 AREDS, V20, P573
NR 42
TC 170
Z9 186
U1 1
U2 22
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 2
PY 2008
VL 359
IS 14
BP 1456
EP U57
DI 10.1056/NEJMoa0802437
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 354ID
UT WOS:000259631700006
PM 18753640
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Siemsen, DW
   Brown, WL
AF Siemsen, Dennis W.
   Brown, William L.
TI Vision Rehabilitation of Persons with Age Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; low vision; vision rehabilitation
ID QUALITY-OF-LIFE; INTERVENTION TRIAL LOVIT; VISUAL FUNCTION; READING
   PERFORMANCE; PERIPHERAL-VISION; PSYCHOPHYSICS; MACULOPATHY; VETERANS;
   IMPACT; OUTCOMES
AB As the population of the United States ages, there is an increase in the number of persons with age related macular degeneration (ARMD). Even as new prevention and treatment techniques are developed, the vision loss associated with ARMD may lead to loss of independence and quality of life. Low vision is a rehabilitative process designed to improve visual function and restore independence. This paper is a review of the current research related to low vision in the areas of magnification, contrast and illumination, reading, training, driving and outcomes assessment.
C1 [Siemsen, Dennis W.; Brown, William L.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55095 USA.
C3 Mayo Clinic
RP Siemsen, DW (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55095 USA.
EM siemsen.dennis@mayo.edu
RI Brown, William/GXN-2777-2022
CR *AM OPT ASS, 2004, DEF LOW VIS
   Beckmann PJ, 1996, VISION RES, V36, P3723, DOI 10.1016/0042-6989(96)00084-3
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Cheong AMY, 2009, OPTOMETRY VISION SCI, V86, P1078, DOI 10.1097/OPX.0b013e3181b4c4d9
   Chung STL, 2004, VISION RES, V44, P695, DOI 10.1016/j.visres.2003.09.028
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Cross JM, 2009, BRIT J OPHTHALMOL, V93, P400, DOI 10.1136/bjo.2008.144584
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Eperjesi F, 2007, OPHTHAL PHYSL OPT, V27, P93, DOI 10.1111/j.1475-1313.2006.00431.x
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Hinds A, 2003, BRIT J OPHTHALMOL, V87, P1391, DOI 10.1136/bjo.87.11.1391
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kuyk T, 2008, QUAL LIFE RES, V17, P497, DOI 10.1007/s11136-008-9336-3
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   Massof RW, 2007, INVEST OPHTH VIS SCI, V48, P4955, DOI 10.1167/iovs.06-0566
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   McGwin G, 2008, ARCH OPHTHALMOL-CHIC, V126, P1544, DOI 10.1001/archopht.126.11.1544
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   OWSLEY C, 1994, OPTOMETRY VISION SCI, V71, P727, DOI 10.1097/00006324-199412000-00002
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Ryan B, 2008, OPTOMETRY VISION SCI, V85, P112, DOI 10.1097/OPX.0b013e31816225dc
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2007, CLIN TRIALS, V4, P650, DOI 10.1177/1740774507085274
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
NR 39
TC 3
Z9 5
U1 0
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 65
EP 68
DI 10.3109/08820538.2010.527426
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200001
PM 21609218
DA 2022-11-30
ER

PT J
AU Holz, FG
   Iida, T
   Maruko, I
   Sadda, SR
AF Holz, Frank G.
   Iida, Tomohiro
   Maruko, Ichiro
   Sadda, Srinivas R.
TI A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION Patient Selection, Evaluation, and
   Treatment
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE brolucizumab; intraocular inflammation; retinal vasculitis; retinal
   vascular occlusion; occlusive retinal vasculitis; adverse events;
   neovascular age-related macular degeneration
ID INTRAVITREAL INJECTION; ENDOPHTHALMITIS; RANIBIZUMAB
AB Purpose: Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion typically in the presence of other signs of intraocular inflammation (IOI). The purpose of this report is to provide guidance on the use of brolucizumab for neovascular age-related macular degeneration to a global audience. Methods: A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration. Results: Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment. Conclusion: Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Iida, Tomohiro; Maruko, Ichiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of Bonn; Tokyo Women's Medical University; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukbonn.de
FU Novartis Pharma AG
FX Medical writing support was provided by Ann Todd (IMPRINT Science, New
   York, NY) and was funded by Novartis Pharma AG. This manuscript was
   developed in accordance with Good Publication Practice (GPP3)
   guidelines. The authors had full control of the content and made the
   final decision on all aspects of this publication.
CR Angerer MPM, 2021, OPHTHALMOLOGE, V118, P1048, DOI 10.1007/s00347-020-01253-9
   [Anonymous], BEOVU BROLUCIZUMAB G
   [Anonymous], 2022, SUMM BEOV PROD CHAR
   Antaki F, 2022, CAN J OPHTHALMOL, V57, pE40, DOI 10.1016/j.jcjo.2021.04.004
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Beovu, 2022, PRESCRIBING INFORM
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Hikichi T, 2021, JPN J OPHTHALMOL, V65, P208, DOI 10.1007/s10384-021-00819-7
   Holz FG, 2021, OPHTHALMOLOGE, V118, P248, DOI 10.1007/s00347-021-01321-8
   Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Kaupke N, 2021, OPHTHALMOLOGE, V118, P1276, DOI 10.1007/s00347-021-01343-2
   Kessler LJ, 2022, OPHTHALMOLOGE, V119, P93, DOI 10.1007/s00347-021-01330-7
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Kondapalli SSA, 2020, JAMA OPHTHALMOL, V138, P1103, DOI 10.1001/jamaophthalmol.2020.2810
   Leclaire MD, 2022, OPHTHALMOLOGE, V119, P296, DOI 10.1007/s00347-021-01341-4
   MacCumber MW, 2020, RETINA TODAY
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Narayanan R, 2021, INDIAN J OPHTHALMOL, V69, P469, DOI 10.4103/ijo.IJO_3436_20
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Riedel AM, 2022, OPHTHALMOLOGE, V119, P75, DOI 10.1007/s00347-021-01323-6
   Sharma A, 2021, EYE, V35, P1548, DOI 10.1038/s41433-020-01324-w
   Sharma A, 2021, EYE, V35, P1292, DOI 10.1038/s41433-020-01227-w
   Singer M, 2022, OPHTHALMOL RETINA, V6, P97, DOI 10.1016/j.oret.2021.05.003
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
NR 39
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2022
VL 42
IS 9
BP 1629
EP 1637
DI 10.1097/IAE.0000000000003556
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W9IM
UT WOS:000842662100003
PM 35994582
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU De Bats, F
   Mathis, T
   Mauget-Faysse, M
   Joubert, F
   Denis, P
   Kodjikian, L
AF De Bats, Flore
   Mathis, Thibaud
   Mauget-Faysse, Martine
   Joubert, Fabien
   Denis, Philippe
   Kodjikian, Laurent
TI PREVALENCE OF RETICULAR PSEUDODRUSEN IN AGE-RELATED MACULAR DEGENERATION
   USING MULTIMODAL IMAGING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; infrared
   imaging; multicolor imaging; reticular pseudodrusen; spectral domain
   optical coherence tomography
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   GEOGRAPHIC-ATROPHY; GRADING SYSTEM; RISK-FACTOR; EYES; MACULOPATHY;
   DISEASE; SENSITIVITY; ASSOCIATION
AB Purpose:To determine the rate of reticular pseudodrusen (RPD) in age-related macular degeneration using multimodal imaging, including color fundus photography, the blue channel image of fundus photography, infrared reflectance, fundus autofluorescence, multicolor imaging, and spectral domain optical coherence tomography, as well as to compare the sensitivities and specificities of these modalities for detecting RPD.Methods:This prospective study included 243 eyes from 125 consecutive patients with age-related macular degeneration. They underwent fundus examination including color fundus photography, blue channel, infrared reflectance, fundus autofluorescence, multicolor imaging, and spectral domain optical coherence tomography in both eyes. To be considered as having RPD, eyes had to have reticular patterns on spectral domain optical coherence tomography in a large studied cube of 30 degrees x 25 degrees or on infrared reflectance with at least one other examination.Results:The mean age of the 125 patients was 81.1 years (8.1). Eighty-six patients (68.8%) were diagnosed with RPD. Spectral domain optical coherence tomography, infrared reflectance, and multicolor imaging had the highest sensitivity (99.3, 84.6, and 87.1%, respectively) and specificity (100%). The color fundus photography, blue channel, and fundus autofluorescence had lower sensitivity to detect RPD.Conclusion:Reticular pseudodrusen is frequently associated with soft drusen in patients with age-related macular degeneration. As RPD may be rarely located only in the perifoveal area, spectral domain optical coherence tomography with a larger cube (30 x 25 degrees) than that usually used (20 x 20 degrees) had the highest sensitivity and specificity to detect RPD and is recommended to optimize the rate of detection.
C1 [De Bats, Flore; Mathis, Thibaud; Denis, Philippe; Kodjikian, Laurent] Univ Med Lyon 1, Croix Rousse Univ Hosp, Dept Ophthalmol, UMR CNRS Mateis 5510,Hosp Civils Lyon, F-69317 Lyon, France.
   [De Bats, Flore] Clin Val dOuest, Pole Vis, Ecully, France.
   [Mauget-Faysse, Martine] Rothschild Ophthalmol Fdn, Prof Sahel Dept, Paris, France.
   [Joubert, Fabien] Univ Med Lyon 1, Le Vinatier Hosp, Dept Med Informat & Epidemiol, Bron, France.
C3 CHU Lyon; Institut National des Sciences Appliquees de Lyon - INSA Lyon
RP Kodjikian, L (通讯作者)，Hosp Civils Lyon, Croix Rousse Univ Hosp, Dept Ophthalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM kodjikian.laurent@wanadoo.fr
RI Mathis, Thibaud/R-3696-2016; Mathis, Thibaud/AAK-5745-2021
OI Mathis, Thibaud/0000-0002-1418-1872; 
CR Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 32
TC 32
Z9 33
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2016
VL 36
IS 1
BP 46
EP 52
DI 10.1097/IAE.0000000000000648
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2BN
UT WOS:000367600400006
PM 26090899
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UH
   Kamppeter, BA
   Harder, B
AF Jonas, J. B.
   Spandau, U. H.
   Kamppeter, B. A.
   Harder, B.
TI Follow-up after intravitreal triamcinolone acetonide for exudative
   age-related macular degeneration
SO EYE
LA English
DT Article
DE intravitreal triamcinolone acetonide; intravitreal steroids; age-related
   macular degeneration; intraocular neovascularization; macular disease
ID PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; SUBRETINAL
   NEOVASCULARIZATION; CRYSTALLINE CORTISONE; ADJUNCTIVE TREATMENT;
   INJECTION; ENDOPHTHALMITIS; VERTEPORFIN; PROLIFERATION; INHIBITION
AB Purpose To report on the follow-up of patients who received an intravitreal triamcinolone acetonide injection (IVTA) as treatment of exudative age-related macular degeneration.
   Methods The clinical interventional case-series study included 205 patients (222 eyes) with progressive exudative age-related macular degeneration with subfoveal neovascularization who consecutively received an IVTA of about 20mg as only therapeutic procedure and for whom follow-up was at least 3 months. Mean follow- up was 10.4 +/- 7.1 months (range, 3-35.7 months).
   Results Visual acuity improved significantly (P < 0.001) from baseline (0.90 +/- 0.45 logarithm of the minimum angle of resolution (LogMar)) to a mean minimum of 0.79 +/- 0.42 LogMar during follow-up. In 86 (38.7%) eyes and in 55 (24.8%) eyes, best visual acuity increased by at least two and three Snellen lines, respectively. Comparing the measurements at specific postinjection examination dates showed that visual acuity measurements taken at 1, 2, and 3 months after injection were not significantly different from the baseline value. Measurements taken at 6, 9, and 12 months after the injection were significantly (P < 0.001) lower than the measurements at baseline. Mean loss at 6 months was 1.4 +/- 3.8 Snellen lines, at 9 months, 2.5 +/- 4.6 lines, and at 12 months after the injection, 2.6 +/- 4.0 lines. Intraocular pressure increased significantly (P < 0.001) during the first 6 months, and returned to baseline at 9 months after injection.
   Conclusions Single injection high-dosage IVTA did not show an apparent benefit at 12 months after injection in patients with neovascular age-related macular degeneration.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   AREVALO JF, 2005, GRAEFES ARCH CLIN EX
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   AUGUSTIN AJ, 2005, IN PRESS OPHTHALMOLO
   AUGUSTIN AJ, 2005, AM J OPHTHALMOL
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P745, DOI 10.1136/bjo.2004.052563
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 47
TC 11
Z9 11
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2007
VL 21
IS 3
BP 387
EP 394
DI 10.1038/sj.eye.6702222
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141US
UT WOS:000244604900015
PM 16410809
OA Bronze
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Bojanowski, CM
   Chan, CC
AF Tuo, JS
   Bojanowski, CM
   Chan, CC
TI Genetic factors of age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; SORSBY FUNDUS DYSTROPHY; STARGARDT-DISEASE
   GENE; APOLIPOPROTEIN-E GENE; PERIPHERIN-RDS GENE; TISSUE INHIBITOR;
   ALLELIC VARIATION; BEST-DISEASE; MALATTIA LEVENTINESE; BRUCHS MEMBRANE
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the United States and developed countries. Although the etiology and pathogenesis of AMD remain unknown, a complex interaction of genetic and environmental factors is thought to exist. The incidence and progression of all of the features of AMD are known to increase significantly with age. The tendency for familial aggregation and the findings of gene variation association studies implicate a significant genetic component in the development of AMD. This review summarizes in detail the AMD-related genes identified by studies on genetically engineered and spontaneously gene-mutated (naturally mutated) animals, AMD chromosomal loci identified by linkage studies, AMD-related genes identified through studies of monogenic degenerative retinal diseases, and AMD-related gene variation identified by association studies. Published by Elsevier Ltd.
C1 NEI, Immunol Lab, Immunopathol Sect, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chan, CC (通讯作者)，NEI, Immunol Lab, Immunopathol Sect, NIH, Bldg 10,Rm 10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
FU NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000418] Funding Source: NIH
   RePORTER; Intramural NIH HHS [Z01 EY000418-04] Funding Source: Medline
CR Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   APFELSTEDTSYLLA E, 1995, BRIT J OPHTHALMOL, V79, P28, DOI 10.1136/bjo.79.1.28
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   CarreroValenzuela RD, 1996, ARCH OPHTHALMOL-CHIC, V114, P737, DOI 10.1001/archopht.1996.01100130729016
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   CHANG B, 1994, INVEST OPHTH VIS SCI, V35, P1071
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   CHANG B, 1993, GENOMICS, V16, P45, DOI 10.1006/geno.1993.1138
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DEMANT P, 1979, TISSUE ANTIGENS, V13, P53, DOI 10.1111/j.1399-0039.1979.tb01136.x
   Dentchev T, 2003, MOL VIS, V9, P184
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Downes SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1373, DOI 10.1001/archopht.117.10.1373
   Ekstrom U, 1998, OPHTHALMIC GENET, V19, P149, DOI 10.1076/opge.19.3.149.2186
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fujii GY, 2003, AM J OPHTHALMOL, V135, P109, DOI 10.1016/S0002-9394(02)01854-8
   Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Gregory-Evans K, 2000, BRIT J OPHTHALMOL, V84, P679, DOI 10.1136/bjo.84.7.679
   Gulcher J, 2001, CANCER J, V7, P61
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Guymer Robyn, 2001, Clin Exp Optom, V84, P182
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212
   Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HECKENLIVELY JR, 1989, DOC OPHTHALMOL, V71, P229
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Keen TJ, 1996, HUM MUTAT, V8, P297
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khani SC, 2003, INVEST OPHTH VIS SCI, V44, P3570, DOI 10.1167/iovs.02-1287
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kniazeva M, 2000, AM J OPHTHALMOL, V130, P197, DOI 10.1016/S0002-9394(00)00585-7
   Kohl S, 1998, ACTA ANAT, V162, P75
   KORNZWEIG AL, 1965, AM J OPHTHALMOL, V60, P835, DOI 10.1016/0002-9394(65)92002-7
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Kramer Franziska, 2003, Hum Mutat, V22, P418, DOI 10.1002/humu.9189
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   Li Y, 2001, J MED GENET, V38, P478, DOI 10.1136/jmg.38.7.478
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   LITHVERHOEVEN JJ, 2003, MOL VIS, V9, P138
   LITHVERHOEVEN JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P1452
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lutty G, 1999, MOL VIS, V5
   MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27
   McBee Wendy L, 2003, Curr Opin Ophthalmol, V14, P159, DOI 10.1097/00055735-200306000-00009
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa M, 1995, RETINA-J RET VIT DIS, V15, P518, DOI 10.1097/00006982-199515060-00011
   NICHOLS BE, 1993, HUM MOL GENET, V2, P1347, DOI 10.1093/hmg/2.8.1347-a
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   Payne AM, 1998, AM J HUM GENET, V62, P192, DOI 10.1086/301679
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Piguet B, 1996, OPHTHALMIC GENET, V17, P175, DOI 10.3109/13816819609057891
   Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200
   POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Rice DS, 1997, INVEST OPHTH VIS SCI, V38, P2112
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rohrer B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/iovs.02-0567
   Sato M, 2000, JPN J OPHTHALMOL, V44, P115, DOI 10.1016/S0021-5155(99)00198-7
   Sauer CG, 2001, BRIT J OPHTHALMOL, V85, P969, DOI 10.1136/bjo.85.8.969
   SCHICK JH, 2003, AM J OPHTHALMOL, V136, P970
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   SIDMAN RL, 1965, J HERED, V56, P23, DOI 10.1093/oxfordjournals.jhered.a107364
   Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith RS, 2000, P NATL ACAD SCI USA, V97, P2191, DOI 10.1073/pnas.040531597
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4
   TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G
   Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200
   TUO J, 2004, KEYST S HUM GEN SEQ
   Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com
   Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200
   Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7
   VANNIE R, 1978, TISSUE ANTIGENS, V12, P106, DOI 10.1111/j.1399-0039.1978.tb01305.x
   Vogel BE, 2001, DEVELOPMENT, V128, P883
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WEBER BHF, 1994, AM J HUM GENET, V55, P1182
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134
   White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N
   Yanagihashi S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1458, DOI 10.1001/archopht.121.10.1458
   Yoshida A, 2000, JPN J OPHTHALMOL, V44, P290, DOI 10.1016/S0021-5155(99)00227-0
   Zhang C, 2001, J POROUS MEDIA, V4, P89
   Zhang K, 1999, GENOMICS, V60, P234, DOI 10.1006/geno.1999.5896
NR 174
TC 71
Z9 75
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2004
VL 23
IS 2
BP 229
EP 249
DI 10.1016/j.preteyeres.2004.02.001
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 819AU
UT WOS:000221286400004
PM 15094132
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Liisborg, C
   Sondergaard, HB
   Sellebjerg, F
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Liisborg, Charlotte
   Sondergaard, Helle Bach
   Sellebjerg, Finn
   Sorensen, Torben Lykke
TI The transcriptome of peripheral blood mononuclear cells in patients with
   clinical subtypes of late age-related macular degeneration
SO IMMUNITY & AGEING
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Geographic atrophy; Polypoidal choroidal vasculopathy; Subretinal
   fibrosis; Peripheral blood mononuclear cells; Transcriptome
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CIRCULATING MONOCYTES; T-CELLS;
   PHYSICAL-ACTIVITY; EXPRESSION; RECEPTOR; INFLAMMATION; PREVALENCE;
   CONTRIBUTES; ACTIVATION
AB Background Peripheral blood mononuclear cells (PBMCs) are implicated in the pathogenesis of age-related macular degeneration (AMD). We here mapped the global gene transcriptome of PBMCs from patients with different clinical subtypes of late AMD. Results We sampled fresh venous blood from patients with geographic atrophy (GA) secondary to AMD without choroidal neovascularizations (n = 19), patients with neovascular AMD without GA (n = 38), patients with polypoidal choroidal vasculopathy (PCV) (n = 19), and aged control individuals with healthy retinae (n = 20). We isolated PBMCs, extracted RNA, and used microarray to investigate gene expression. Volcano plots identified statistically significant differentially expressed genes (P < 0.05) at a high magnitude (>= 30% higher/lower) for GA (62 genes), neovascular AMD (41 genes), and PCV (41 genes). These clinical subtypes differed substantially across gene expression and the following pathways identified in enrichment analyses. In a subgroup analysis, we investigated presence vs. absence of subretinal fibrosis and found 826 differentially expressed genes (>= 30% higher/lower, P < 0.05) with relation to mRNA splicing, endothelial migration, and interleukin-1 signaling. Conclusions We here map the global gene transcriptome of PBMCs related to clinical subtypes of late AMD and find evidence of subtype-specific immunological involvement. Our findings provide a transcriptomic insight into the systemic immunity associated with AMD.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Liisborg, Charlotte; Sellebjerg, Finn; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Molbech, Christopher Rue; Liisborg, Charlotte; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Sondergaard, Helle Bach; Sellebjerg, Finn] Rigshosp, Danish Multiple Sclerosis Ctr, Copenhagen Univ Hosp, Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet; University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Liisborg,
   Charlotte/0000-0002-6353-6027; Sellebjerg, Finn/0000-0002-1333-9623;
   Sondergaard, Helle Bach/0000-0001-9435-0658
FU Danish Eye Research Foundation; Fight for Sight Denmark; Velux
   Foundation; University of Copenhagen; Bayer AG
FX This study was funded by the Danish Eye Research Foundation, Fight for
   Sight Denmark, the Velux Foundation, the University of Copenhagen, and
   Bayer AG. The sponsors had no role in the design, execution,
   interpretation, or writing of the study.
CR Alasil Tarek, 2017, Int J Retina Vitreous, V3, P9, DOI 10.1186/s40942-017-0060-4
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dudley AC, 2005, BIOCHEM J, V390, P427, DOI 10.1042/BJ20050351
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Halim L, 2017, CELL REP, V20, P757, DOI 10.1016/j.celrep.2017.06.079
   Hampton T, 2010, JAMA-J AM MED ASSOC, V304, P1541, DOI 10.1001/jama.2010.1411
   Hernangomez M, 2012, GLIA, V60, P1437, DOI 10.1002/glia.22366
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568
   Kos FJ, 2002, IMMUNOL CELL BIOL, V80, P364, DOI 10.1046/j.1440-1711.2002.01098.x
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Michel JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00530
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Ozaki S, 2000, INVEST OPHTH VIS SCI, V41, P568
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sedeh FB, 2017, DAN MED J, V64
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Subhi Y, 2019, INVEST OPHTH VIS SCI, V60, P2583, DOI 10.1167/iovs.19-26882
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, DAN MED J, V63
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
NR 68
TC 8
Z9 8
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PD AUG 15
PY 2019
VL 16
IS 1
AR 20
DI 10.1186/s12979-019-0160-0
PG 16
WC Geriatrics & Gerontology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Immunology
GA IR9AB
UT WOS:000481734400001
PM 31428180
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rozzini, L
   Riva, M
   Ghilardi, N
   Facchinetti, P
   Forbice, E
   Semeraro, F
   Padovani, A
AF Rozzini, Luca
   Riva, Maddalena
   Ghilardi, Nausica
   Facchinetti, Paola
   Forbice, Eliana
   Semeraro, Francesco
   Padovani, Alessandro
TI Cognitive Dysfunction and Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
LA English
DT Article
DE cognitive impairment; dementia; neuro-ophtalmology; vision; drusen
ID ALZHEIMERS ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL
   INSTITUTE; DISEASE; DEMENTIA; DRUSEN; IMPAIRMENT; RISK; ATHEROSCLEROSIS;
   RECOMMENDATIONS
AB Several previous studies showed that age-related macular degeneration (AMD) and Alzheimer's disease (AD) share common risk factors and histopathology changes, and there is epidemiological evidence linking AMD to cognitive impairment. We tested this theory in 51 patients with late-stage AMD and 24 controls by analyzing their neuropsychological profiles. In this study, data showed that patients affected by late-stage AMD have a worse global cognitive function than those of the controls and, in particular, show worse performances in memory tasks. Moreover, patients affected by the dry form of AMD are significantly impaired in executive functions in addition to memory. Data support the hypothesis of a possible association between AMD and cognitive impairment. In particular, patients affected by the dry form of AMD may be at greater risk of developing subsequent dementia.
C1 [Rozzini, Luca; Riva, Maddalena; Facchinetti, Paola; Padovani, Alessandro] Univ Brescia, Dept Neurol, I-25100 Brescia, Italy.
   [Ghilardi, Nausica; Forbice, Eliana; Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, I-25100 Brescia, Italy.
C3 University of Brescia; University of Brescia
RP Rozzini, L (通讯作者)，Univ Brescia, Dept Neurol, Piazzale Spedali Civili, I-25100 Brescia, Italy.
EM lrozzini@iol.it
RI Padovani, Alessandro/ABI-7312-2020; Semeraro, Francesco fs/K-8667-2016
OI Padovani, Alessandro/0000-0002-0119-3639; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Armstrong RA, 1998, DEMENT GERIATR COGN, V9, P227, DOI 10.1159/000017051
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bertone A, 2005, INT C SER, V1282, P26, DOI DOI 10.1016/J.ICS.2005.05.151
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hutchinson J., 1874, R LOND OPHTHALMIC HO, V8, P231
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P278
   NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477
   Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7
   REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271
   Rozzini L, 2007, INT J GERIATR PSYCH, V22, P1217, DOI 10.1002/gps.1816
   Rozzini L, 2006, INT J GERIATR PSYCH, V21, P550, DOI 10.1002/gps.1523
   Sheikh JI, 1986, CLIN GERONTOL, V5, P65
   SPSS, 2006, SPSS 15 0 WIND
   SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 40
TC 17
Z9 17
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1533-3175
EI 1938-2731
J9 AM J ALZHEIMERS DIS
JI Am. J. Alzheimers Dis. Other Dement.
PD MAY
PY 2014
VL 29
IS 3
BP 256
EP 262
DI 10.1177/1533317513517032
PG 7
WC Geriatrics & Gerontology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AI0HL
UT WOS:000336527000010
PM 24370621
DA 2022-11-30
ER

PT J
AU Flores, R
   Carneiro, A
   Vieira, M
   Tenreiro, S
   Seabra, MC
AF Flores, Rita
   Carneiro, Angela
   Vieira, Miguel
   Tenreiro, Sandra
   Seabra, Miguel C.
TI Age-Related Macular Degeneration: Pathophysiology, Management, and
   Future Perspectives
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Biomarkers; Macular
   neovascularization; Geographic atrophy
ID GEOGRAPHIC ATROPHY SECONDARY; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; RISK-FACTORS; FUNCTIONAL-CHARACTERIZATION;
   NATURAL-HISTORY; SEVERITY SCALE; ABICIPAR-PEGOL; CLINICAL-TRIAL;
   VISUAL-ACUITY
AB Among older adults, age-related macular degeneration (AMD) is a prevalent disabling condition that begins as subtle visual disturbances and can progress to permanent loss of central vision. In its late neovascular form, AMD is treatable with inhibitors of vascular endothelial growth factor, the key driver of exudative disease. In the atrophic form, treatment remains elusive. This review addresses the natural history of AMD - through early, intermediate, and advanced disease stages - and concentrates on diagnosis and risk stratification, deficiencies of current treatments, and the promising findings of emerging therapies.
C1 [Flores, Rita; Vieira, Miguel] Ctr Hosp Lisboa Cent EPE, Dept Ophthalmol, Lisbon, Portugal.
   [Flores, Rita; Tenreiro, Sandra; Seabra, Miguel C.] Univ Nova Lisboa, NOVA Med Sch, NMS, iNOVA4Hlth,CEDOC, Lisbon, Portugal.
   [Carneiro, Angela] Ctr Hosp Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
   [Seabra, Miguel C.] UCL Inst Ophthalmol, London, England.
C3 Centro Hospitalar de Lisboa Ocidental, EPE; Universidade Nova de Lisboa;
   University of London; University College London
RP Flores, R (通讯作者)，Ctr Hosp Lisboa Cent EPE, Dept Ophthalmol, Lisbon, Portugal.; Flores, R (通讯作者)，Univ Nova Lisboa, NOVA Med Sch, NMS, iNOVA4Hlth,CEDOC, Lisbon, Portugal.
EM ritamariaflores@gmail.com
OI Rio Pedro Flores, Rita Maria/0000-0002-7523-2418
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Allergan plc, 2019, ALL MOL PARTN ANN TO
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chen HY, 2012, MOL VIS, V18, P816
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Choi EJ, 2020, MOLECULES, V25, DOI 10.3390/molecules25030663
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chung SH, 2020, MOL THER-METH CLIN D, V17, P409, DOI 10.1016/j.omtm.2020.01.006
   ClinicalTrials, 2019, NCT02087085
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dugel PU., 2018, RETIN PHYS, V15
   Eichenbaum D., 2020, EFFICACY SAFETY ABIC
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Flores R., 2021, RETINA-J RET VIT DIS, V41, P555
   Freeman WR., 2019, RETIN PHYS, V16, P43
   Freeman WR., 2019, RETIN PHYS, V16, P51
   Freeman WR., 2019, RETIN PHYS, V16, P42
   Friberg TR, 2011, OPHTHAL SURG LAS IM, V42, P369, DOI 10.3928/15428877-20110812-01
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gattoussi S, 2019, ACTA OPHTHALMOL, V97, P364, DOI 10.1111/aos.13883
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Ladas ID, 2012, OPHTHALMOLOGICA, V228, P93, DOI 10.1159/000337347
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lander ES, 2016, CELL, V164, P18, DOI 10.1016/j.cell.2015.12.041
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Ly A, 2018, CLIN EXP OPTOM, V101, P172, DOI 10.1111/cxo.12624
   Matuskova V, 2020, ACTA OPHTHALMOL, V98, pE691, DOI 10.1111/aos.14357
   Miller JW, 2020, OPHTHALMOLOGY, V127, pS133, DOI 10.1016/j.ophtha.2019.11.025
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Moshfeghi DM, 2020, BRIT J OPHTHALMOL, V104, P1223, DOI 10.1136/bjophthalmol-2019-315021
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Or C, 2018, ASIA-PAC J OPHTHALMO, V7, P46, DOI 10.22608/APO.201812
   Pai SS, 2011, BIOCONJUGATE CHEM, V22, P2317, DOI 10.1021/bc2003583
   Parravano M, 2019, ADV THER, V36, P2493, DOI 10.1007/s12325-019-01016-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosa R, 2021, EUR J OPHTHALMOL, V31, P505, DOI 10.1177/1120672120914530
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seal J, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Smithwick Elizabeth, 2017, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V16, P33, DOI 10.2174/1871523016666170502115816
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Usha C., 2017, INVEST OPHTHALMOL VI, V58, P2979
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Veronese FM, 2009, MILESTONES DRUG THER, P11, DOI 10.1007/978-3-7643-8679-5_2
   Waksmunski AR, 2019, INVEST OPHTH VIS SCI, V60, P4041, DOI 10.1167/iovs.19-27827
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 105
TC 7
Z9 7
U1 2
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2021
VL 244
IS 6
BP 495
EP 511
DI 10.1159/000517520
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1U6VT
UT WOS:000805548500004
PM 34130290
OA Bronze
DA 2022-11-30
ER

PT J
AU Lam, WC
   Choudhry, N
   Wong, D
AF Lam, Wai-Ching
   Choudhry, Netan
   Wong, David
TI Polypoidal choroidal vasculopathy in Canada
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
ID VERTEPORFIN PHOTODYNAMIC THERAPY; EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL
   GROWTH-FACTOR; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   INTRAVITREAL BEVACIZUMAB; RISK-FACTORS; RANIBIZUMAB; EFFICACY; DIAGNOSIS
AB Polypoidal choroidal vasculopathy (PCV) is an exudative age-related macular degeneration (AMD) subtype found more frequently among Asians than Caucasians. If untreated, it may lead to severe vision loss. PCV appears to be frequently underdiagnosed in Canada, although misdiagnosis of PCV as AMD carries the risk of inadequate treatment and unsatisfactory clinical outcomes. Diagnosis can be made on the basis of multimodal imaging, including optical coherence tomography (OCT) and OCT angiography combined with colour fundus photography, or by other imaging techniques; the gold-standard indocyanine green angiography (ICGA) is not widely used in Canada. Treatment involves anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, or aflibercept), alone or in combination with photodynamic therapy (PDT). Recent clinical trials have shown that ranibizumab in combination with PDT is superior to ranibizumab monotherapy (EVEREST II), and aflibercept monotherapy is as effective in patients meeting PDT rescue criteria as aflibercept combined with rescue PDT (PLANET). It appears that most Canadian PCV patients are treated with anti-VEGF monotherapy, with or without PDT.
C1 [Lam, Wai-Ching] Univ Hong Kong, Dept Ophthalmol, Room 301,Block B,Cyberport 4,100 Cyberport Rd, Hong Kong, Peoples R China.
   [Lam, Wai-Ching; Wong, David] Univ Toronto, Dept Ophthalmol & Vis Sci, Unity Hlth Toronto, St Michaels Hosp, Toronto, ON, Canada.
   [Choudhry, Netan] Vitreous Retina Macula Specialists Toronto, Toronto, ON, Canada.
C3 University of Hong Kong; University of Toronto; University Toronto
   Affiliates; Saint Michaels Hospital Toronto
RP Lam, WC (通讯作者)，Univ Hong Kong, Dept Ophthalmol, Room 301,Block B,Cyberport 4,100 Cyberport Rd, Hong Kong, Peoples R China.
EM waichlam@hku.hk
OI Wong, David/0000-0003-1376-845X
FU Bayer Canada
FX Supported by: This work was supported by Bayer Canada.
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Chen YFN, 2017, CAN J OPHTHALMOL, V52, P475, DOI 10.1016/j.jcjo.2017.02.014
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A., 2017, 11 AS PAC VITR RET S
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37523-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Marques JP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015785
   Marques JP, 2019, 2019 RET WORLD C MAR
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Ogura Y., 2017, 11 AS PAC VITR RET S
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oztas Z, 2016, TURK OFTALMOL DERG, V46, P165, DOI 10.4274/tjo.54280
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2017, JAMA OPHTHALMOL, V135, P1316, DOI 10.1001/jamaophthalmol.2017.4453
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Zhang J, 2018, OSLI RETINA, V49, pE249, DOI 10.3928/23258160-20181203-15
NR 70
TC 2
Z9 3
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2020
VL 55
IS 3
BP 199
EP 211
DI 10.1016/j.jcjo.2019.10.011
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LY3QW
UT WOS:000540442800017
PM 31879067
OA hybrid
DA 2022-11-30
ER

PT J
AU Jeng, KW
   Wilgucki, J
   Halperin, S
   Feuer, WJ
   Fine, HF
   Roth, D
   Prenner, JL
AF Jeng, Karen W.
   Wilgucki, John
   Halperin, Scott
   Feuer, William J.
   Fine, Howard F.
   Roth, Daniel
   Prenner, Jonathan L.
TI RETINA SPECIALISTS TREATING AGE-RELATED MACULAR DEGENERATION RECOMMEND
   DIFFERENT APPROACHES FOR PATIENTS THAN THEY WOULD CHOOSE FOR THEMSELVES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; anti-VEGF therapy; bevacizumab; cognitive biases; exudative
   age-related macular degeneration; physician treatment preferences;
   ranibizumab; treatment choices for exudative AMD
ID BEVACIZUMAB; RANIBIZUMAB; LESIONS; IMPACT; CATT
AB Purpose: To evaluate the presence of cognitive biases among retina physicians when recommending treatment options for exudative age-related macular degeneration.
   Methods: Two random samples of retina specialists were surveyed regarding their treatment and dosing regimen choices among three anti-vascular endothelial growth factor biologics (aflibercept, bevacizumab, and ranibizumab). One group was asked to provide recommendations for a standardized hypothetical patient with exudative age-related macular degeneration, whereas the other group was asked to provide recommendations as if they themselves were the standardized hypothetical patient with exudative age-related macular degeneration.
   Results: Two hundred and twenty-six respondents (28.3%) completed the survey and were divided equally between the survey groups. For patients, most physicians recommended bevacizumab (52.2%), but when choosing for themselves, physicians were divided equally among all 3 biologics (P = 0.011). The results were influenced by geographical location of the physician but not by the gender or length of practice. Furthermore, physicians differed in dosing regimen selection with the majority (73%) choosing treat and extend for patients, whereas only 63% selected this regimen for themselves (P = 0.004).
   Conclusion: When considering cases of exudative age-related macular degeneration, physicians would recommend different treatments for themselves than they would for a patient.
C1 [Jeng, Karen W.; Wilgucki, John; Fine, Howard F.; Roth, Daniel; Prenner, Jonathan L.] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA.
   [Feuer, William J.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Fine, Howard F.; Roth, Daniel; Prenner, Jonathan L.] NJ Retina, New Brunswick, NJ 08901 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Bascom Palmer Eye Institute
RP Prenner, JL (通讯作者)，NJ Retina, 10 Plum St,Suite 600, New Brunswick, NJ 08901 USA.
EM jonathanprenner@gmail.com
CR Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   DeNavas-Walt C., 2013, CURRENT POPULATION R
   Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration, 1993, ARCH OPHTHALMOL, V111, P1200
   Levinson DR, 2011, REV MEDICARE B
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   SIMINOFF LA, 1989, MED DECIS MAKING, V9, P262, DOI 10.1177/0272989X8900900406
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Ubel PA, 2003, SOC SCI MED, V56, P1727, DOI 10.1016/S0277-9536(02)00167-3
   Ubel PA, 2011, ARCH INTERN MED, V171, P630, DOI 10.1001/archinternmed.2011.91
   Wheatley H, 2012, AM SOC RET SPEC M AU
NR 16
TC 16
Z9 16
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1796
EP 1801
DI 10.1097/IAE.0000000000000182
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400015
PM 24859475
DA 2022-11-30
ER

PT J
AU Ma, L
   Li, Z
   Liu, K
   Rong, SS
   Brelen, ME
   Young, AL
   Kumaramanickavel, G
   Pang, CP
   Chen, HY
   Chen, LJ
AF Ma, Li
   Li, Zhen
   Liu, Ke
   Rong, Shi Song
   Brelen, Marten E.
   Young, Alvin L.
   Kumaramanickavel, Govindasamy
   Pang, Chi Pui
   Chen, Haoyu
   Chen, Li Jia
TI Association of Genetic Variants with Polypoidal Choroidal Vasculopathy A
   Systematic Review and Updated Meta-analysis
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; GENOME-WIDE ASSOCIATION; ESTER TRANSFER PROTEIN;
   SUSCEPTIBILITY 2 GENE; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB;
   FACTOR B; LOC387715/HTRA1 VARIANTS; HEREDITARY CONTRIBUTION; RETICULAR
   PSEUDODRUSEN
AB Topic: A systematic review and meta-analysis of the genetic association with polypoidal choroidal vasculopathy (PCV) and the genetic difference between PCV and neovascular age-related macular degeneration (nAMD).
   Clinical Relevance: To identify genetic biomarkers that are potentially useful for genetic diagnosis of PCV and for differentiating PCV from nAMD.
   Methods: We performed a literature search in EMBASE, PubMed, Web of Science, and the Chinese Biomedical Database for PCV genetic studies published before February 6, 2015. We then conducted a meta-analysis of all polymorphisms that had sufficient genotype/allele data reported in >= 2 studies and estimated the summary odds ratio (OR) and 95% confidence intervals (CIs) for PCV. We also compared the association profiles between PCV and nAMD, and performed a sensitivity analysis.
   Results: A total of 66 studies were included in the meta-analysis, involving 56 polymorphisms in 19 genes/loci. In total, 31 polymorphisms in 10 genes/loci (age-related maculopathy susceptibility 2 [ARMS2], high-temperature requirement factor A1 [HTRA1], complement factor H [CFH], complement component 2 [C2], CFB, RDBP, SKIV2L, CETP, 8p21, and 4q12) were significantly associated with PCV. Another 25 polymorphisms in 13 genes (ARMS2, HTRA1, C2, CFB, ELN, LIPC, LPL, ABCA1, VEGF-A, TLR3, LOXL1, SERPING1, and PEDF) had no significant association. Twelve polymorphisms at the ARMS2-HTRA1 locus showed significant differences between PCV and nAMD. The sensitivity analysis validated the significance of our analysis.
   Conclusions: This study revealed 31 polymorphisms in 10 genes/loci that contribute to PCV susceptibility. Among them, ARMS2-HTRA1 also showed allelic diversity between PCV and nAMD. Our results confirm the gene variants that could affect the phenotypic expressions of PCV and nAMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Ma, Li; Liu, Ke; Rong, Shi Song; Brelen, Marten E.; Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Li, Zhen; Pang, Chi Pui; Chen, Haoyu; Chen, Li Jia] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Li, Zhen; Pang, Chi Pui; Chen, Haoyu; Chen, Li Jia] Chinese Univ Hong Kong, Shantou, Peoples R China.
   [Brelen, Marten E.; Young, Alvin L.; Pang, Chi Pui; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Ke] Shenzhen Eye Hosp, Shenzhen, Peoples R China.
   [Kumaramanickavel, Govindasamy] Narayana Nethralaya, Bangalore, Karnataka, India.
C3 Chinese University of Hong Kong; Shantou University; Chinese University
   of Hong Kong; Prince of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Brelen, Marten E./D-1133-2016; Chen, Haoyu/A-7432-2013; Chu, Kai
   On/E-2325-2016; Chen, Li Jia/I-5078-2014; KUMARAMANICKAVEL,
   GOVINDASAMY/AAN-9203-2021; Rong, Shi Song/L-9735-2019
OI Chen, Haoyu/0000-0003-0676-4610; Chen, Li Jia/0000-0003-3500-5840;
   KUMARAMANICKAVEL, GOVINDASAMY/0000-0001-8516-8301; Rong, Shi
   Song/0000-0001-8352-6363
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bessho H, 2012, MOL VIS, V18, P121
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chang W, 2013, MOL VIS, V19, P702
   Chantaren P, 2012, CLIN OPHTHALMOL, V6, P465, DOI 10.2147/OPTH.S30529
   Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
   Chen HY, 2012, MOL VIS, V18, P816
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chin YC, 2014, LUPUS, V23, P319, DOI 10.1177/0961203313519160
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Cornes Belinda K., 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P5218
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Guo J, 2013, MOL VIS, V19, P2050
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang LZ, 2014, OPHTHALMIC RES, V52, P102, DOI 10.1159/000362763
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Ji YY, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-140
   Jiang JJ, 2012, GENET MOL RES, V11, P4256, DOI 10.4238/2012.December.17.1
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, MOL VIS, V15, P1819
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nakata Isao, 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P5225
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Parihar A, 2008, LIFE SCI, V82, P1077, DOI 10.1016/j.lfs.2008.03.019
   Park DH, 2014, RETINA-J RET VIT DIS, V34, P1167, DOI 10.1097/IAE.0000000000000047
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Yoichi, 2013, Nippon Ganka Gakkai Zasshi, V117, P886
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Su Y, 2013, OPHTHALMIC GENET, V36, P1
   Sun YY, 2013, INVEST OPHTH VIS SCI, V54, P8199, DOI 10.1167/iovs.13-12867
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Wells GA, 2000, EBM REV 3 S SYSTEMAT
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yang F, 2014, OPHTHALMOLOGICA, V232, P37, DOI 10.1159/000358241
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yang ZY, 1998, GENOMICS, V53, P338, DOI 10.1006/geno.1998.5499
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zeng RP, 2014, OPHTHALMIC GENET, V35, P235, DOI 10.3109/13816810.2014.952832
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   Zuo CG, 2012, MOL VIS, V18, P1787
NR 130
TC 50
Z9 52
U1 2
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2015
VL 122
IS 9
BP 1854
EP 1865
DI 10.1016/j.ophtha.2015.05.012
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8BU
UT WOS:000360116900027
PM 26081444
DA 2022-11-30
ER

PT J
AU McBain, VA
   Townend, J
   Lois, N
AF McBain, Vikki A.
   Townend, John
   Lois, Noemi
TI Fundus autofluorescence in exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM;
   CHOROIDAL-NEOVASCULARIZATION; IN-VIVO; NATURAL COURSE; LIPOFUSCIN;
   FLUORESCENCE; LIGHT; RISK
AB Aim: To evaluate the distribution of fundus autofluorescence in patients with age-related macular degeneration and choroidal neovascularisation (CNV).
   Methods: Colour fundus photographs, fundus fluorescein angiograms (FFA) and fundus autofluorescence images were obtained from a group of 40 patients (43 eyes) with age-related macular degeneration and purely classic or occult CNV. Only patients with newly diagnosed CNV and in whom autofluorescence images were obtained within 2 weeks from FFA were included. The distribution of autofluorescence was qualitatively evaluated, and the findings compared with those from colour fundus photographs and FFA.
   Results: 29 (67%) eyes had classic CNV and 14 (33%) had occult CNV. In 26 (90%) eyes with classic CNV, a low autofluorescence signal was detected at the site of the CNV; in 7 (50%) eyes with occult CNV, multiple foci of low autofluorescence signal were detected. Outside the area affected by the lesion, homogeneous autofluorescence was observed in most of the cases (n=33, 77%). Similarly, homogeneous autofluorescence was commonly observed in fellow eyes (62%). A pattern of focal increased autofluorescence was rarely seen in eyes with CNV (n=4, 9%) or in fellow eyes (n=4, 15%). In 11 of 43 (25%) eyes, areas of increased autofluorescence, other than a pattern of focal increased autofluorescence, were detected. In four patients, autofluorescence images had been obtained before the development of CNV; in none was any increased autofluorescence detected before the formation of CNV.
   Conclusions: Distinct patterns of autofluorescence were observed in eyes with pure classic and occult CNV. Increased autofluorescence was rarely seen in eyes with CNV and in fellow eyes, suggesting that increased autofluorescence, and thus, retinal pigment epithelium lipofuscin, may not play an essential part in the formation of CNV.
C1 Grampian Univ Hosp NHS Trust, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland.
   Univ Aberdeen, Dept Publ Hlth, Med Stat Grp, Aberdeen, Scotland.
C3 University of Aberdeen; University of Aberdeen
RP Lois, N (通讯作者)，Grampian Univ Hosp NHS Trust, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland.
EM noemilois@aol.com
CR Altman D, 2000, STAT CONFIDENCE
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey K, 1993, RETINAL DEGENERATION, P3
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Lois N, 2004, COMP OPHTHALMOL UPDA, V5, P143
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 35
TC 36
Z9 40
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2007
VL 91
IS 4
BP 491
EP 496
DI 10.1136/bjo.2006.095109
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 147XH
UT WOS:000245037700023
PM 16956913
OA Green Published
DA 2022-11-30
ER

PT J
AU Saksens, NTM
   Fleckenstein, M
   Schmitz-Valckenberg, S
   Holz, FG
   den Hollander, AI
   Keunen, JEE
   Boon, CJF
   Hoyng, CB
AF Saksens, Nicole T. M.
   Fleckenstein, Monika
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   den Hollander, Anneke I.
   Keunen, Jan E. E.
   Boon, Camiel J. F.
   Hoyng, Care B.
TI Macular dystrophies mimicking age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; AMD; Macular dystrophy; Differential
   diagnosis; Retina; Clinical characteristics
ID SORSBY FUNDUS DYSTROPHY; CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL
   COHERENCE TOMOGRAPHY; ONSET RETINAL DEGENERATION; FOVEOMACULAR
   VITELLIFORM DYSTROPHY; AREOLAR CHOROIDAL DYSTROPHY; COMPLEMENT FACTOR-H;
   INDOCYANINE GREEN ANGIOGRAPHY; TERM-FOLLOW-UP; DOMINANTLY INHERITED
   DRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly population in the Western world. AMD is a clinically heterogeneous disease presenting with drusen, pigmentary changes, geographic atrophy and/or choroidal neovascularization. Due to its heterogeneous presentation, it can be challenging to distinguish AMD from several macular diseases that can mimic the features of AMD. This clinical overlap may potentially lead to misdiagnosis. In this review, we discuss the characteristics of AMD and the macular dystrophies that can mimic AMD. The appropriate use of clinical and genetic analysis can aid the clinician to establish the correct diagnosis, and to provide the patient with the appropriate prognostic information. An overview is presented of overlapping and distinguishing clinical features. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Saksens, Nicole T. M.; den Hollander, Anneke I.; Keunen, Jan E. E.; Boon, Camiel J. F.; Hoyng, Care B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Boon, Camiel J. F.] Univ Oxford, John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Boon, Camiel J. F.] Univ Oxford, John Radcliffe Hosp, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
C3 Radboud University Nijmegen; University of Bonn; University of Oxford;
   University of Oxford; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC
RP Hoyng, CB (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Nicole.Saksens@radboudumc.nl; Monika.FIeckenstein@ukb.uni-bonn.de;
   Steffen.Schmitz-Valckenberg@ukb.uni-bonn.de; frank.holz@ukb.uni-bonn.de;
   Anneke.denHollander@radboudumc.nl; Jan.Keunen@radboudumc.nl;
   Camiel.Boon@radboudumc.nl; Carel.Hoyng@radboudumc.nl
RI Keunen, J.E.E./H-8061-2014; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014; Boon, CJF/P-7534-2014
OI Fleckenstein, Monika/0000-0001-8321-8037; Boon, CJF/0000-0002-6737-7932
FU Niels Stensen Fellowship
FX Camiel J.F. Boon was supported by a Niels Stensen Fellowship Award.
CR Agarwal A, 2005, ARCH OPHTHALMOL-CHIC, V123, P923, DOI 10.1001/archopht.123.7.923
   Agarwal A, 2012, GASS ATLAS MACULAR D
   Alchi B, 2010, PEDIATR NEPHROL, V25, P1409, DOI 10.1007/s00467-009-1322-7
   Alkuraya H., 2010, RET PHYS
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R., 2007, RETINAL DEGENERATION, P105
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], ARCH OPHTHALMOL, V109, P1242
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659
   Armstrong JD, 1998, OPHTHALMOLOGY, V105, P448, DOI 10.1016/S0161-6420(98)93026-3
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   ASHTON N, 1953, BRIT J OPHTHALMOL, V37, P140, DOI 10.1136/bjo.37.3.140
   Assink JJM, 2000, BRIT J OPHTHALMOL, V84, P682, DOI 10.1136/bjo.84.7.682
   Audo I, 2007, INVEST OPHTH VIS SCI, V48, P4250, DOI 10.1167/iovs.05-1604
   Balaskas K, 2013, EYE, V27, P101, DOI 10.1038/eye.2012.221
   Barbazetto IA, 2008, INVEST OPHTH VIS SCI, V49, P3806, DOI 10.1167/iovs.07-1357
   Batten FE, 1909, BRAIN, V32, P187, DOI 10.1093/brain/32.2.187
   Baumuller S, 2010, OPHTHALMOLOGY, V117, P2162, DOI 10.1016/j.ophtha.2010.02.014
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Berger SP, 2007, SEMIN IMMUNOPATHOL, V29, P375, DOI 10.1007/s00281-007-0090-3
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1100, DOI 10.1001/archopht.125.8.1100
   Boon CJF, 2013, OPHTHALMOLOGY, V120, P809, DOI 10.1016/j.ophtha.2012.09.057
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   Boon CJF, 2009, RETINA-J RET VIT DIS, V29, P835, DOI 10.1097/IAE.0b013e31819d4fda
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Borooah S, 2009, BRIT J OPHTHALMOL, V93, P284, DOI 10.1136/bjo.2008.150151
   Boulton M.E., 2013, AGE RELATED MACULAR, P45
   BRECHER R, 1990, EYE, V4, P210, DOI 10.1038/eye.1990.28
   BROOK, 1992, CELL, V69, P385
   Buitendijk G.H., 2013, OPHTHALMOLOGY
   BURIAN HM, 1967, AM J OPHTHALMOL, V63, P22, DOI 10.1016/0002-9394(67)90577-6
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chassaing N, 2005, J MED GENET, V42, P881, DOI 10.1136/jmg.2004.030171
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Chen Hongling, 2006, Yan Ke Xue Bao, V22, P149
   Cherepanoff S., 2002, BR J OPHTHALMOL, V96, P1404
   Chinnery PF, 1999, J MED GENET, V36, P425
   Chung MM, 2001, RETINA-J RET VIT DIS, V21, P575, DOI 10.1097/00006982-200112000-00003
   CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8
   CLEMETT R, 1991, AUST NZ J OPHTHALMOL, V19, P221, DOI 10.1111/j.1442-9071.1991.tb00665.x
   Collins E.T., 1913, OPHTHALMOCOPE, V11, P2
   CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723
   CONNOR PJ, 1961, AM J MED, V30, P537, DOI 10.1016/0002-9343(61)90078-X
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   de Laat P., 2013, OPHTHALMOLOGY
   de Laat P, 2013, JIMD REP, V8, P47, DOI 10.1007/8904_2012_159
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Deutman A.F., 1971, VITELLIFORM DYSTROPH
   DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001
   DEUTMAN AF, 1970, BRIT J OPHTHALMOL, V54, P373, DOI 10.1136/bjo.54.6.373
   DEUTMAN AF, 1970, ARCH OPHTHALMOL-CHIC, V83, P558
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Dreyer R, 1978, Trans Pa Acad Ophthalmol Otolaryngol, V31, P158
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   DUSEK J, 1982, KLIN MONATSBL AUGENH, V181, P79, DOI 10.1055/s-2008-1055171
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FERRY AP, 1972, ARCH OPHTHALMOL-CHIC, V88, P39
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   FISHMAN GA, 2001, OPHTHALMOLOGY MONOGR
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Framme C, 2006, OPHTHAL SURG LAS IM, V37, P406, DOI 10.3928/15428877-20060901-08
   FRANCOIS J, 1974, OPHTHALMOLOGICA, V169, P255, DOI 10.1159/000307127
   Francois J., 1980, DOC OPHTHALMOL P SER, V23, P19
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P729, DOI 10.1097/00006982-200310000-00029
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   Gerber DM, 2002, KLIN MONATSBL AUGENH, V219, P206, DOI 10.1055/s-2002-30647
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   Gillies MC, 2009, OPHTHALMOLOGY, V116, P2422, DOI 10.1016/j.ophtha.2009.05.010
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomes-Pereira M, 2011, TRENDS MOL MED, V17, P506, DOI 10.1016/j.molmed.2011.05.004
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gronblad E, 1958, ACTA OPHTHALMOL, V36, P472
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Gundogan FC, 2010, EUR J OPHTHALMOL, V20, P919, DOI 10.1177/112067211002000517
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2002, EYE, V16, P7, DOI 10.1038/sj.eye.6700018
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Hannan SR, 2013, BRIT J OPHTHALMOL, V97, P605, DOI 10.1136/bjophthalmol-2011-301257
   Harper PS, 2001, MYOTONIC DYSTROPHY
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   Hoyng CB, 1996, GRAEF ARCH CLIN EXP, V234, P87, DOI 10.1007/BF00695246
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Inhoffen W, 2012, KLIN MONATSBL AUGENH, V229, P889, DOI 10.1055/s-0032-1315077
   Isashiki Y, 1999, JPN J OPHTHALMOL, V43, P472, DOI 10.1016/S0021-5155(99)00117-3
   Issa PC, 2008, INVEST OPHTH VIS SCI, V49, P1172, DOI 10.1167/iovs.07-0636
   Issa PC, 2007, INVEST OPHTH VIS SCI, V48, P3788, DOI 10.1167/iovs.06-1272
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jaouni T, 2012, ARCH OPHTHALMOL-CHIC, V130, P987, DOI 10.1001/archophthalmol.2012.1483
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kellner U, 2009, OPHTHALMOLOGE, V106, P99, DOI 10.1007/s00347-008-1863-3
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Khurana RN, 2009, OPHTHALMOLOGY, V116, P1976, DOI 10.1016/j.ophtha.2009.03.028
   Kiernan DF, 2011, OPHTHALMOLOGY, V118, P1435, DOI 10.1016/j.ophtha.2010.10.041
   KIM RY, 1995, ARCH OPHTHALMOL-CHIC, V113, P451, DOI 10.1001/archopht.1995.01100040067029
   Kim RY, 1997, AM J OPHTHALMOL, V123, P619, DOI 10.1016/S0002-9394(14)71074-8
   Kim Ungsoo Samuel, 2009, Korean J Ophthalmol, V23, P121, DOI 10.3341/kjo.2009.23.2.121
   KIMIZUKA Y, 1993, RETINA-J RET VIT DIS, V13, P129, DOI 10.1097/00006982-199313020-00007
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   KLIEN BA, 1947, AM J OPHTHALMOL, V30, P955
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   KRILL AE, 1973, DOC OPHTHALMOL, V35, P1
   KRILL AE, 1973, AM J OPHTHALMOL, V76, P875, DOI 10.1016/0002-9394(73)90076-7
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Ladewig M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1557, DOI 10.1001/archopht.121.11.1557
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P346, DOI 10.1007/s004170050089
   Lam LA, 2013, RETINA, VII, P1267
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Langwinska-Wosko E, 2010, DOC OPHTHALMOL, V120, P215, DOI 10.1007/s10633-010-9214-5
   LEFLER WH, 1971, AM J OPHTHALMOL, V71, P224, DOI 10.1016/0002-9394(71)90394-1
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Leu J, 2007, GRAEF ARCH CLIN EXP, V245, P1723, DOI 10.1007/s00417-007-0604-7
   LEYS A, 1991, PEDIATR NEPHROL, V5, P189, DOI 10.1007/BF01095950
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Lip PL, 1999, EYE, V13, P16, DOI 10.1038/eye.1999.4
   Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125
   Lueck JD, 2007, AM J PHYSIOL-CELL PH, V292, pC1291, DOI 10.1152/ajpcell.00336.2006
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   MANSOUR AM, 1993, OPHTHALMOLOGICA, V207, P57, DOI 10.1159/000310407
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Michaelides M, 2005, OPHTHALMOLOGY, V112, P1592, DOI 10.1016/j.ophtha.2005.04.004
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P2178, DOI 10.1167/iovs.02-1094
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   Michaelides M, 2006, INVEST OPHTH VIS SCI, V47, P3085, DOI 10.1167/iovs.05-1600
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa M, 1995, RETINA-J RET VIT DIS, V15, P518, DOI 10.1097/00006982-199515060-00011
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   Oosterhuis JA, 1996, GRAEF ARCH CLIN EXP, V234, P337, DOI 10.1007/BF00220710
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Parmalee NL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024268
   PATRINELY JR, 1985, OPHTHALMOLOGY, V92, P1712
   Pawlak D, 2006, J FR OPHTALMOL, V29, P188, DOI 10.1016/S0181-5512(06)73770-6
   Pece A, 1997, ACTA OPHTHALMOL SCAN, V75, P261
   Peters AL, 2006, RETINA-J RET VIT DIS, V26, P1082, DOI 10.1097/01.iae.0000254886.25401.9e
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Piguet B, 1996, OPHTHALMIC GENET, V17, P175, DOI 10.3109/13816819609057891
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Powner M.B., 2013, OPHTHALMOLOGY
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   QUARANTA M, 1995, AM J OPHTHALMOL, V119, P136, DOI 10.1016/S0002-9394(14)73865-6
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Querques G, 2008, AM J OPHTHALMOL, V146, P501, DOI 10.1016/j.ajo.2008.05.029
   Querques G, 2013, GRAEF ARCH CLIN EXP, V251, P705, DOI 10.1007/s00417-012-2106-5
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014
   Ranum LPW, 2004, AM J HUM GENET, V74, P793, DOI 10.1086/383590
   Rath PP, 2008, BRIT J OPHTHALMOL, V92, P623, DOI 10.1136/bjo.2007.131177
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Reichel MB, 1998, BRIT J OPHTHALMOL, V82, P1162, DOI 10.1136/bjo.82.10.1162
   Renner AB, 2004, RETINA-J RET VIT DIS, V24, P929, DOI 10.1097/00006982-200412000-00014
   Renner AB, 2009, AM J OPHTHALMOL, V147, P518, DOI 10.1016/j.ajo.2008.09.007
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ringpfeil E, 2001, EXP DERMATOL, V10, P221, DOI 10.1034/j.1600-0625.2001.100401.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Rosenberg T, 2010, MOL VIS, V16, P2659
   ROWE SE, 1990, OPHTHALMOLOGY, V97, P1632
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saihan Z, 2009, MOL VIS, V15, P1218
   Sallo FB, 2011, OPHTHALMOLOGY, V118, P2461, DOI 10.1016/j.ophtha.2011.05.022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Sawa M, 2006, OPHTHALMOLOGY, V113, P814, DOI 10.1016/j.ophtha.2006.01.037
   Schara Ulrike, 2006, Semin Pediatr Neurol, V13, P71
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmitz-Valckenberg S, 2009, RETINA-J RET VIT DIS, V29, P1314, DOI 10.1097/IAE.0b013e3181a4d2f1
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schoenberger SD, 2013, RETINA-J RET VIT DIS, V33, P429, DOI 10.1097/IAE.0b013e318263d3b4
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schworm HD, 1998, OPHTHALMOLOGE, V95, P13, DOI 10.1007/s003470050229
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shiraki Kunihiko, 2001, International Ophthalmology, V24, P243, DOI 10.1023/A:1025433431654
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Sicot G, 2011, HUM MOL GENET, V20, pR116, DOI 10.1093/hmg/ddr343
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   SJOGREN H, 1950, Acta Ophthalmol (Copenh), V28, P279
   Slezak H, 1969, Albrecht Von Graefes Arch Klin Exp Ophthalmol, V178, P176
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Small K W, 1998, Trans Am Ophthalmol Soc, V96, P925
   Small K W, 2001, Trans Am Ophthalmol Soc, V99, P233
   Small K.W., 2001, T AM OPHTHAL SOC, V99, P237
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   SMALL KW, 1991, BRIT J OPHTHALMOL, V75, P401, DOI 10.1136/bjo.75.7.401
   SMALL KW, 1989, OPHTHALMOLOGY, V96, P1747
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Sohn E.H., 2013, RETINA
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   Souied EH, 2006, BRIT J OPHTHALMOL, V90, P296, DOI 10.1136/bjo.2005.081802
   Souied EH, 2006, AM J OPHTHALMOL, V141, P404, DOI 10.1016/j.ajo.2005.09.001
   Souied EH, 2005, AM J OPHTHALMOL, V140, P312
   Soumplis V, 2013, ACTA OPHTHALMOL, V91, pE191, DOI 10.1111/aos.12010
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301
   Steinert H., 1909, DTSCH Z NERVENHEILKU, V37, P58, DOI [10.1007/BF01671719, DOI 10.1007/BF01671719]
   Stohr H, 2012, ADV EXP MED BIOL, V723, P261, DOI 10.1007/978-1-4614-0631-0_34
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Suzuki M., 2013, GRAEFES ARCH CLIN EX
   Szental JA, 2009, CLIN EXP OPHTHALMOL, V37, P325, DOI 10.1111/j.1442-9071.2009.02025.x
   Szlyk JP, 2005, RETINA-J RET VIT DIS, V25, P489, DOI 10.1097/00006982-200506000-00015
   Takeuchi T, 2010, INVEST OPHTH VIS SCI, V51, P1643, DOI 10.1167/iovs.09-4497
   Theelen T, 2008, EXP EYE RES, V86, P296, DOI 10.1016/j.exer.2007.10.022
   TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G
   TUPPURAINEN K, 1994, DOC OPHTHALMOL, V87, P233, DOI 10.1007/BF01203853
   ULBIG MRW, 1993, AM J OPHTHALMOL, V116, P410, DOI 10.1016/S0002-9394(14)71397-2
   Vaclavik V, 2012, RETINA-J RET VIT DIS, V32, P1942, DOI 10.1097/IAE.0b013e31824b32e4
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vincent A, 2012, RETINA-J RET VIT DIS, V32, P1643, DOI 10.1097/IAE.0b013e318240a574
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P81, DOI 10.1055/s-2008-1034951
   Voo I, 2001, AM J OPHTHALMOL, V132, P933, DOI 10.1016/S0002-9394(01)01184-9
   Wabbels B, 2006, GRAEF ARCH CLIN EXP, V244, P1453, DOI 10.1007/s00417-006-0286-6
   Wabbels B, 2006, GRAEF ARCH CLIN EXP, V244, P36, DOI 10.1007/s00417-005-0043-2
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Wang MSM, 2002, AM J OPHTHALMOL, V133, P787, DOI 10.1016/S0002-9394(02)01438-1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weenink AC, 2001, OPHTHALMOLOGICA, V215, P183, DOI 10.1159/000050855
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wickham L, 2009, INVEST OPHTH VIS SCI, V50, P3553, DOI 10.1167/iovs.08-2715
   Williams DG, 1997, PEDIATR NEPHROL, V11, P96, DOI 10.1007/s004670050241
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yang ZL, 2008, VISION RES, V48, P470, DOI 10.1016/j.visres.2007.09.015
   Yang Zhenglin, 2004, Ophthalmic Genet, V25, P133, DOI 10.1080/13816810490514388
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang K, 2002, ARCH OPHTHALMOL-CHIC, V120, P485
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu MD, 2013, RETINA-J RET VIT DIS, V33, P1547, DOI 10.1097/IAE.0b013e318285cb9c
   Zhuk S, 2006, MOL VIS, V12, P811
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 331
TC 46
Z9 48
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2014
VL 39
BP 23
EP 57
DI 10.1016/j.preteyeres.2013.11.001
PG 35
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC0OI
UT WOS:000332194200002
PM 24291520
DA 2022-11-30
ER

PT J
AU Yonekawa, Y
   Miller, JW
   Kim, IK
AF Yonekawa, Yoshihiro
   Miller, Joan W.
   Kim, Ivana K.
TI Age-Related Macular Degeneration: Advances in Management and Diagnosis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; fundus
   autofluorescence; fluorescein angiography; optical coherence tomography;
   retina; vascular endothelial growth factor; visual impairment
ID VERTEPORFIN PLUS RANIBIZUMAB; ENDOTHELIAL GROWTH-FACTOR; 3RD
   NATIONAL-HEALTH; GEOGRAPHIC ATROPHY; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; 5-YEAR INCIDENCE;
   CIGARETTE-SMOKING; ZINC INTAKE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment in older populations in industrialized nations. AMD is a late-onset deterioration of photoreceptors and retinal pigment epithelium in the central retina caused by various environmental and genetic factors. Great strides in our understanding of AMD pathogenesis have been made in the past several decades, which have translated into revolutionary therapeutic agents in recent years. In this review, we describe the clinical and pathologic features of AMD and present an overview of current diagnosis and treatment strategies.
C1 [Yonekawa, Yoshihiro; Miller, Joan W.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Kim, IK (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
EM Yoshihiro_Yonekawa@meei.harvard.edu; joan_miller@meei.harvard.edu;
   Ivana_Kim@meei.harvard.edu
OI Kim, Ivana/0000-0003-0310-6129; Miller, Joan/0000-0003-2046-3996
CR Allergan, ALL MOL PARTN ENT EX
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   [Anonymous], SQUAL
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Clinicaltrials.Gov, PHAS 1 DOS ESC SAF S
   Dugel P. U., 2013, P 36 ANN M MAC SOC D
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kaiser P. K., 2013, INVESTIG OPHTHALMOL, V54
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lpath Inc. Overview, 2014, OVERVIEW
   Guerrero-Naranjo JL, 2013, INVEST OPHTH VIS SCI, V54
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1995, ARCH OPHTHALMOL-CHIC, V113, P190
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Regillo C. D., 2013, P 2013 ANN M AM AC O
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tsai JC, 2013, CAN J OPHTHALMOL, V48, P141, DOI 10.1016/j.jcjo.2013.02.003
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   World Health Organization, PREV BLINDN VIS IMP
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 96
TC 87
Z9 89
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2015
VL 4
IS 2
BP 343
EP 359
DI 10.3390/jcm4020343
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9IY
UT WOS:000363131700008
PM 26239130
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Knudtson, MD
   Meuer, SM
   Swift, M
   Gangnon, RE
AF Klein, Ronald
   Klein, Barbara E. K.
   Knudtson, Michael D.
   Meuer, Stacy M.
   Swift, Maria
   Gangnon, Ronald E.
TI Fifteen-year cumulative incidence of age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; RETINAL-PIGMENT EPITHELIUM; BLUE MOUNTAINS EYE;
   VISUAL-ACUITY; FOLLOW-UP; CHOROIDAL NEOVASCULARIZATION; 5-YEAR
   INCIDENCE; 2ND EYE; NATURAL COURSE; UNITED-STATES
AB Purpose: To describe the 15-year cumulative incidence of signs of early and late age-related macular degeneration (AMD).
   Design: Population-based cohort study.
   Participants: We included 3917 persons, 43 to 86 years of age at the time of a baseline examination in 1988 through 1990 and with information collected in follow-up in 1993 through 1995, and/or 1998 through 2000, and/or 2003 through 2005.
   Methods: Grading of stereoscopic fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Cumulative incidence of drusen type and size, pigmentary abnormalities, geographic atrophy, and exudative AMD accounting for competing risk of death.
   Results: The 15-year cumulative incidence was 14.3% for early AMD (the presence of either soft indistinct drusen or the presence of pigmentary abnormalities together with any type of drusen) and 3.1% for late AMD (presence of exudative AMD or geographic atrophy). There was an increased incidence of AMD lesions with age (P < 0.05). Individuals >= 75 years of age at baseline had significantly (P < 0.01) higher 15-year incidences of the following characteristics than people 43 to 54 years of age: larger drusen (125 mu m in diameter, 24.1% vs 10.6%), soft indistinct drusen (18.7% vs 6.5%), retinal pigmentary abnormalities (20.2% vs 3.7%), exudative macular degeneration (4.4% vs 0.4%), and pure geographic atrophy (3.2% vs 0%). Controlling for age, compared with those with small numbers of only small hard drusen (1-2), those with large numbers of only hard drusen (>= 8) had an increased 15-year age-adjusted incidence of both soft indistinct drusen (16.3% vs 4.7%) and pigmentary abnormalities (10.6% vs 2.7%). Eyes with soft indistinct drusen or pigmentary abnormalities at baseline were more likely to develop late AMD at follow-up than eyes without these lesions (17.8% vs 1.2% and 12.9% vs 1.7%, respectively).
   Conclusions: We document the long-term incidence of signs of AMD and a continuum from small hard drusen to late AMD in older persons in the population. The 15-year cumulative incidence of late AMD in people >= 75 years of age (8%) indicates a public health problem of significant proportions because the United States population this age is expected to increase by 54% between 2005 and 2025.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   Univ Wisconsin, Dept Populat & Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Gangnon, Ronald/0000-0003-2587-6714
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FLEISS JL, 1973, STATISTICAL METHODS, P144
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HOSMER DW, 1989, WILEY SERIES PROBABI, P238
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, NTIS PUBL, P185
   Klein R, 1991, NTIS PUBL, P182
   KLEIN R, 1991, NTIS PUBL
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   ROY M, 1990, Eye (London), V4, P813
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 60
TC 476
Z9 492
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2007
VL 114
IS 2
BP 253
EP 262
DI 10.1016/j.ophtha.2006.10.040
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131CC
UT WOS:000243844600010
PM 17270675
DA 2022-11-30
ER

PT J
AU Kato, Y
   Oguchi, Y
   Omori, T
   Shintake, H
   Tomita, R
   Kasai, A
   Ogasawara, M
   Sugano, Y
   Itagaki, K
   Ojima, A
   Machida, T
   Sekine, H
   Sekiryu, T
AF Kato, Yutaka
   Oguchi, Yasuharu
   Omori, Tomoko
   Shintake, Hiroaki
   Tomita, Ryutaro
   Kasai, Akihito
   Ogasawara, Masashi
   Sugano, Yukinori
   Itagaki, Kanako
   Ojima, Akira
   Machida, Takeshi
   Sekine, Hideharu
   Sekiryu, Tetsuju
TI Complement Activation Products and Cytokines in Pachychoroid
   Neovasculopathy and Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE pachychoroid neovasculopathy; neovascular age-related macular
   degeneration; aqueous humor; complement; cytokine
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H POLYMORPHISM; AQUEOUS-HUMOR;
   ASSOCIATION; MONOCYTES
AB PURPOSE. To investigate the characteristics of complement activation products and angiogenic cytokines in the aqueous humor in eyes with pachychoroid neovasculopathy (PNV) and neovascular age-related macular degeneration (nAMD).
   METHODS. This was a prospective, comparative, observational study. All patients with choroidal neovascularization were classified as PNV without polyps, PNV with polyps (polypoidal choroidal vasculopathy [PCV]), or drusen-associated nAMD according to the presence or absence of pachychoroid features and soft drusen. This study included a total of 105 eyes. Aqueous humor samples were collected from 25 eyes with PNV without polyps, 23 eyes with PCV, and 24 eyes with drusen-associated nAMD before intravitreal anti-vascular endothelial growth factor (VEGF) injection and cataract surgery in 33 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, C5a, VEGF, and macrophage chemoattractant protein 1 (MCP-1) using a bead-based immunoassay.
   RESULTS. C3a and MCP-1 levels were significantly higher in PCV (P = 0.032 and P = 0.039, respectively) and drusen-associated nAMD (P = 0.01 for both comparisons) than in controls, and no difference was seen in C3a and MCP-1 levels between PNV and controls (P = 0.747 and P = 0.294, respectively). VEGF levels were significantly higher in PNV (P = 0.016), PCV (P = 0.009), and drusen-associated nAMD (P = 0.043) than in controls. In PNV, the VEGF levels elevated without elevated C3a and MCP-1.
   CONCLUSIONS. PNV, PCV, and drusen-associated nAMD had significantly distinct profiles of complement activation products and cytokines in the aqueous humor.
C1 [Kato, Yutaka; Oguchi, Yasuharu; Shintake, Hiroaki; Tomita, Ryutaro; Kasai, Akihito; Ogasawara, Masashi; Sugano, Yukinori; Itagaki, Kanako; Ojima, Akira; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima 9601247, Japan.
   [Omori, Tomoko; Machida, Takeshi; Sekine, Hideharu] Fukushima Med Univ, Dept Immunol, Fukushima, Japan.
C3 Fukushima Medical University; Fukushima Medical University
RP Sekiryu, T (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Fukushima 9601247, Japan.
EM sekiryu@fmu.ac.jp
FU Japan Society for the Promotion of Science (KAKENHI) [JP17K11427]
FX Supported by a Grant-in-Aid for Scientific Research from the Japan
   Society for the Promotion of Science (KAKENHI JP17K11427).
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Biro A, 2006, MOL DIAGN THER, V10, P303, DOI 10.1007/BF03256205
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hu J., 2016, PLOS ONE, V11, P1
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Knott RM, 1999, DIABETOLOGIA, V42, P870, DOI 10.1007/s001250051240
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   MEAD A, 1992, STATISTICIAN, V41, P27, DOI 10.2307/2348634
   Miao H, 2012, MOL VIS, V18, P574
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oguchi Y, 2020, EXP EYE RES, V195, DOI 10.1016/j.exer.2020.108025
   Omori T, 2020, OPHTHALMIC RES, V63, P252, DOI 10.1159/000503258
   Ozturk BT, 2009, MOL VIS, V15, P1906
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sato T, 2019, SCI REP, V9, P1, DOI [10.1038/s41598-018-37186-2, DOI 10.1038/S41598-018-37186-2]
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sorensen JO, 2020, ACTA OPHTHALMOL, V98, P384, DOI 10.1111/aos.14295
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Terao N, 2018, INVEST OPHTH VIS SCI, V59, P5924, DOI 10.1167/iovs.18-25517
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
NR 45
TC 7
Z9 7
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2020
VL 61
IS 13
AR 39
DI 10.1167/iovs.61.13.39
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA0NK
UT WOS:000595313500033
PM 33252634
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Knudtson, MD
   Cotch, MF
   Wong, TY
   Liu, K
   Burke, GL
   Saad, MF
   Jacobs, DR
   Sharrett, AR
AF Klein, Ronald
   Klein, Barbara E. K.
   Knudtson, Michael D.
   Cotch, Mary Frances
   Wong, Tien Yin
   Liu, Kiang
   Burke, Gregory L.
   Saad, Mohammed F.
   Jacobs, David R., Jr.
   Sharrett, A. Richey
TI Subclinical atherosclerotic cardiovascular disease and early age-related
   macular degeneration in a multiracial cohort - The multiethnic study of
   atherosclerosis
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; POOLED FINDINGS; BLOOD-PRESSURE; OXIDIZED LDL; STATIN USE;
   MACULOPATHY; ASSOCIATION; CHOLESTEROL; PREVALENCE; PLASMA
AB Objective: To investigate the relationship of subclinical atherosclerotic cardiovascular disease (CVD) and its risk factors with age-related macular degeneration (AMD) in the Multiethnic Study of Atherosclerosis.
   Methods: This study included 6176 white, black, Hispanic, and Chinese participants aged 44 to 84 years from 6 communities in the United States. Measurements of subclinical CVD were performed according to standardized protocols. Fundus images were graded using the Wisconsin Age-Related Maculopathy Grading System.
   Results: In analyses controlled for age, sex, race/ethnicity, and study location, early AMD was associated with a higher serum high-density lipoprotein cholesterol level (odds ratio per 15 mg/dL, 1.16; 95% confidence interval, 1.01-1.36) and the presence of echolucent carotid artery plaque (odds ratio for present vs no plaque, 0.37; 95% confidence interval, 0.18-0.74) in the whole cohort. Interactions of race/ethnicity and early AMD were found for carotid intima-media thickness, increasing severity of maximum carotid artery stenosis, serum triglyceride level, subclinical CVD severity, and Agatston calcium score.
   Conclusion: Few associations were found between subclinical CVD and CVD risk factors with early AMD. The findings of associations of early AMD with some signs of subclinical atherosclerotic CVD are different among the 4 racial/ethnic groups, which suggests that care must be taken in generalizing from one racial/ethnic group to another.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   NEI, NIH, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   Univ Melbourne, Ctr Eye Res, Melbourne, Vic, Australia.
   Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
   Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA.
   SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA.
   Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Melbourne; Northwestern University; Wake Forest
   University; State University of New York (SUNY) System; SUNY Community
   College; State University of New York (SUNY) Stony Brook; University of
   Minnesota System; University of Minnesota Twin Cities; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,450 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cotch, Mary
   Frances/0000-0002-2046-4350; Jacobs, David/0000-0002-7232-0543
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095163,
   N01HC095162, N01HC095160, N01HC095161, N01HC095159, N01HC095169,
   N01HC095165, N01HC095166, N01HC095164] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [Z01EY000403] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069979]
   Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA EY000403-11, ZIA
   EY000403-14, ZIA EY000403-15, ZIA EY000403-13, ZIA EY000403-10, Z01
   EY000403-07, ZIA EY000403-08, Z01 EY000403-06, Z99 EY999999, ZIA
   EY000403-09, ZIA EY000403-12] Funding Source: Medline; NCRR NIH HHS
   [M01-RR00645] Funding Source: Medline; NHLBI NIH HHS [HL69979-03,
   N01-HC-95162, N01-HC-95169, N01-HC-95160, N01-HC-95164, N01-HC-95159,
   N01-HC-95163, N01-HC-95165, N01-HC-95166, N01-HC-95161] Funding Source:
   Medline
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Carr JJ, 2000, AM J ROENTGENOL, V174, P915, DOI 10.2214/ajr.174.4.1740915
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CUSHMAN M, 1995, CLIN CHEM, V41, P264
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gronholdt MLM, 2002, J VASC SURG, V35, P137, DOI 10.1067/mva.2002.119042
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487
   Holvoet P, 1996, THROMB HAEMOSTASIS, V76, P663
   Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Honda O, 2004, J AM COLL CARDIOL, V43, P1177, DOI 10.1016/j.jacc.2003.09.063
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, MACULAR DEGENERATION, P79
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006
   LAGE SG, 1994, AM J CARDIOL, V74, P691, DOI 10.1016/0002-9149(94)90311-5
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   POLAK JF, 1993, RADIOLOGY, V188, P363, DOI 10.1148/radiology.188.2.8327679
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANLEEUWEN R, 2003, BRIT MED J, V326, P256
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 48
TC 41
Z9 43
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2007
VL 125
IS 4
BP 534
EP 543
DI 10.1001/archopht.125.4.534
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 155AC
UT WOS:000245548900011
PM 17420374
OA Bronze
DA 2022-11-30
ER

PT J
AU Woo, JH
   Sanjay, S
   Eong, KGA
AF Woo, Jyh Haur
   Sanjay, Srinivasan
   Eong, Kah-Guan Au
TI The epidemiology of age-related macular degeneration in the Indian
   subcontinent
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; blindness; epidemiology; Indian
   subcontinent; prevalence; risk factors
ID PAKISTAN NATIONAL BLINDNESS; VISUAL IMPAIRMENT SURVEY; CATARACT-SURGERY;
   RURAL-POPULATION; EYE SURVEY; GRADING SYSTEM; ANDHRA-PRADESH; OLDER
   ADULTS; RISK-FACTORS; SOUTH-INDIA
AB The Indian subcontinent is one of the most populous regions in the world. Given the projected rapid population growth and ageing of the population, age-related macular degeneration (AMD) is likely to emerge as a major public health threat in the near future. However, existing literature on AMD in the region is scarce.
   This paper reviews the epidemiology and risk factors of AMD in the Indian subcontinent.
   Data on AMD in India show prevalences ranging from 1.8% to 4.7%. Blindness prevalence studies in Pakistan, Bangladesh and Nepal have also reported rates of 2.1% to 8.7% for all blindness attributable to AMD. Age-related macular degeneration is therefore a significant cause of visual morbidity in these countries. To date, no reliable epidemiological data on AMD or blindness have been published for Sri Lanka, Afghanistan, Maldives or Bhutan.
   The prevalence of AMD in the region is likely to follow a trend similar to that seen in the developed world in the coming years. Eye care policies should therefore make provisions for this chronic age-related eye disease. In addition, there is an urgent need for more data on the epidemiology of AMD in the Indian subcontinent.
C1 [Woo, Jyh Haur; Sanjay, Srinivasan; Eong, Kah-Guan Au] Alexandra Hosp, Dept Ophthalmol & Visual Sci, Singapore 159964, Singapore.
   [Sanjay, Srinivasan; Eong, Kah-Guan Au] Jurong Med Ctr, Eye Clin, Singapore, Singapore.
   [Eong, Kah-Guan Au] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Eong, Kah-Guan Au] Natl Healthcare Grp, Inst Eye, Singapore, Singapore.
C3 National University of Singapore
RP Woo, JH (通讯作者)，Alexandra Hosp, Dept Ophthalmol & Visual Sci, 378 Alexandra Rd, Singapore 159964, Singapore.
EM jyhhaur01@hotmail.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Angra SK, 1997, INDIAN J MED RES, V106, P312
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   BRILLIANT LB, 1985, B WORLD HEALTH ORGAN, V63, P375
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dineen B, 2007, BRIT J OPHTHALMOL, V91, P1005, DOI 10.1136/bjo.2006.108035
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Eong KGA, 2006, ANN ACAD MED SINGAP, V35, P133
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   *GOV IND, 1993, PRES STAT NAT PROGR
   *GOV IND, 2007, NAT PROGR CONTR BLIN
   *GOV PEOPL REP BAN, 2005, NAT EYE CAR PLAN IMP
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Handa S, 2006, ANN ACAD MED SINGAP, V35, P379
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   *INT MON FUND, 2007, REG EC OUTL AS PAC
   Jadoon MZ, 2006, INVEST OPHTH VIS SCI, V47, P4749, DOI 10.1167/iovs.06-0374
   Jain I S, 1984, Indian J Ophthalmol, V32, P343
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Memon M. Saleh, 1992, JPMA (Journal of the Pakistan Medical Association), V42, P196
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOHAN M, 1992, SURVEY BLINDNESS IND, P80
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P600, DOI 10.1136/bjo.82.6.600
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sapkota YD, 2006, BRIT J OPHTHALMOL, V90, P411, DOI 10.1136/bjo.2005.082503
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Thomas R, 2005, SURV OPHTHALMOL, V50, P85, DOI 10.1016/j.survophthal.2004.10.008
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Venkata G, 2005, BRIT J OPHTHALMOL, V89, P257, DOI 10.1136/bjo.2004.056937
   Vijaya L, 2006, BRIT J OPHTHALMOL, V90, P407, DOI 10.1136/bjo.2005.081406
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Virgili G, 2007, ACTA OPHTHALMOL SCAN, V85, P6, DOI 10.1111/j.1600-0420.2006.00711.x
   WHO, 2004, MAGN CAUS VIS IMP
   *WHO, 1999, VIS 2020 RIGHTS SIGH
   World Health Organization, 2007, WORLD HLTH STAT 2007
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
NR 54
TC 29
Z9 29
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2009
VL 87
IS 3
BP 262
EP 269
DI 10.1111/j.1755-3768.2008.01376.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 434BY
UT WOS:000265251400005
PM 19016663
OA Bronze
DA 2022-11-30
ER

PT J
AU Kuroda, Y
   Yamashiro, K
   Tsujikawa, A
   Ooto, S
   Tamura, H
   Oishi, A
   Nakanishi, H
   Miyake, M
   Yoshikawa, M
   Yoshimura, N
AF Kuroda, Yoshimasa
   Yamashiro, Kenji
   Tsujikawa, Akitaka
   Ooto, Sotaro
   Tamura, Hiroshi
   Oishi, Akio
   Nakanishi, Hideo
   Miyake, Masahiro
   Yoshikawa, Munemitsu
   Yoshimura, Nagahisa
TI Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular
   Degeneration After Ranibizumab Treatment
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR TREATMENT; GEOGRAPHIC ATROPHY; INTRAVITREAL RANIBIZUMAB;
   TREATMENTS TRIALS; ANGIOMATOUS PROLIFERATION; CHOROIDAL THICKNESS;
   DOSING REGIMEN; PROGRESSION; OUTCOMES; RISK
AB PURPOSE: To investigate the risk factors for development and progression of retinal pigment epithelial (RPE) atrophy during ranibizumab treatment for neovascular age-related macular degeneration (AMD) in Japanese patients.
   DESIGN: Retrospective interventional case series.
   METHODS: This study included 195 eyes with treatment-naive subfoveal neovascular AMD. All patients were treated with an as-needed regimen after 3 monthly ranibizumab treatments. Color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence were evaluated for RPE atrophy diagnosis. Baseline characteristics and ARMS2 A69S and CFH I62V polymorphisms were analyzed for their association with development and progression of RPE atrophy.
   RESULTS: Ten of 195 eyes (5.1%) had RPE atrophy at baseline; 3 had typical AMD and 7 had polypoidal choroidal vasculopathy (PCV). Among 185 eyes without preexisting RPE atrophy at baseline, 7 (3.8%) developed RPE atrophy at 12 months and 10 (5.4%) during the mean follow-up of 26.7 months. The incidence of newly developed RPE atrophy was lower in PCV than in typical AMD (P = .036), while the progression of the RPE atrophy area was faster in typical AMD than in PCV (0.57 +/- 0.35 and 0.31 +/- 0.13 mm/year, respectively; P = .018). The ARMS2 A69S and CFH 162V polymorphisms were significantly associated with the baseline RPE atrophy (P = .014 and P = .009, respectively).
   CONCLUSIONS: The RPE atrophy developed in 5.4% of eyes with neovascular AMD during the 26.7 months of ranibizumab treatment. When compared with white individuals, RPE atrophy developed less frequently in Japanese patients, but the progression rate was similar. The subtype of AMD thus affects the development of RPE atrophy. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Kuroda, Yoshimasa; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Oishi, Akio; Nakanishi, Hideo; Miyake, Masahiro; Yoshikawa, Munemitsu; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020; TAMURA,
   Hiroshi/H-1855-2011
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0001-5506-0412; Yamashiro, Kenji/0000-0001-9354-8558;
   Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [24592624]
FX THIS RESEARCH WAS SUPPORTED IN PART BY A GRANT-IN-AID FOR SCIENTIFIC
   RESEARCH (24592624) FROM the Japan Society for the Promotion of Science
   (JSPS), Tokyo, Japan.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Teper SJ, 2010, MOL VIS, V16, P2598
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 45
TC 36
Z9 38
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2016
VL 161
BP 94
EP 103
DI 10.1016/j.ajo.2015.09.032
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2NG
UT WOS:000367632300013
PM 26432927
DA 2022-11-30
ER

PT J
AU Macnamara, A
   Schinazi, VR
   Chen, CL
   Coussens, S
   Loetscher, T
AF Macnamara, Anne
   Schinazi, Victor R.
   Chen, Celia
   Coussens, Scott
   Loetscher, Tobias
TI The effect of age-related macular degeneration on cognitive test
   performance
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VISUAL IMPAIRMENT; OLDER-ADULTS; ALZHEIMERS; PREVALENCE; CANTAB
AB The reliable assessment of cognitive functioning is critical to the study of brain-behaviour relationships. Yet conditions that are synchronous which ageing, including visual decline, are easily overlooked when interpreting cognitive test scores. The purpose of this study was to demonstrate the negative consequences of visual impairments on cognitive tests performance. Moderate to severe levels of age-related macular degeneration were simulated, with a set of goggles, in a sample of twenty-four normally sighted participants while they completed two cognitive tasks: a vision-dependent reaction time task and a vision-independent verbal fluency test. Performance on the reaction time task significantly decreased (p<0.001) in the simulated age-related macular degeneration condition, by as much as 25 percentile ranks. In contrast, performance on the verbal fluency test were not statistically different between the simulated and normal vision conditions (p=0.78). The findings highlight the importance of considering visual functioning when assessing cognitive function. When vision is not accounted for, low test scores may inaccurately indicate poor cognition. Such false attributions may have significant ramification for diagnosis and research on cognitive functioning.
C1 [Macnamara, Anne; Coussens, Scott; Loetscher, Tobias] Univ South Australia, Cognit Ageing & Impairment Neurosci Lab, Justice & Soc, Adelaide, SA, Australia.
   [Schinazi, Victor R.] Bond Univ, Fac Soc & Design, Dept Psychol, Gold Coast, Qld, Australia.
   [Schinazi, Victor R.] Campus Res Excellence & Technol Enterprise CREATE, Singapore ETH Ctr, Future Hlth Technol, Singapore, Singapore.
   [Chen, Celia] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA, Australia.
C3 University of South Australia; Bond University; Flinders Medical Centre;
   Flinders University South Australia
RP Macnamara, A (通讯作者)，Univ South Australia, Cognit Ageing & Impairment Neurosci Lab, Justice & Soc, Adelaide, SA, Australia.
EM anne.macnamara@mymail.unisa.edu.au
OI Loetscher, Tobias/0000-0003-1967-2926
FU Australian Government Research Training Program Scholarship - National
   Health and Medical Research Council (NHMRC) Dementia Research Leadership
   Fellowship [GNT1136269]
FX A.M. was supported by the Australian Government Research Training
   Program Scholarship and T.L. was funded by a National Health and Medical
   Research Council (NHMRC) Dementia Research Leadership Fellowship
   (GNT1136269).
CR American Psychological Association, 2002, ETHICAL PRINCIPLES P, V57, P1060, DOI 10.1037/0003-066x.57.12.1060
   Bertone A, 2007, J CLIN EXP NEUROPSYC, V29, P467, DOI 10.1080/13803390600770793
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   CANTAB [Cognitive assessment software, 2021, CAMBR COGN
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Court H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0181-7
   de Haan GA, 2020, CLIN NEUROPSYCHOL, V34, P140, DOI 10.1080/13854046.2019.1596315
   Egerhazi A, 2007, PROG NEURO-PSYCHOPH, V31, P746, DOI 10.1016/j.pnpbp.2007.01.011
   Evans BJW, 2004, OPHTHAL PHYSL OPT, V24, P161, DOI 10.1111/j.1475-1313.2004.00197.x
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Fork in the Road Vision Rehabilitation Services, 2019, LOW VIS SIM
   Giedraitiene N, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00572
   Howard R, 2021, INT J GERIATR PSYCH, V36, P799, DOI 10.1002/gps.5538
   Jefferis JM, 2012, AGE AGEING, V41, P565, DOI 10.1093/ageing/afs042
   Kanzler CM, 2016, IEEE ENG MED BIO, P4979, DOI 10.1109/EMBC.2016.7591845
   Killen A, 2013, AGE AGEING, V42, P98, DOI 10.1093/ageing/afs157
   Lakens D, 2018, ADV METH PRACT PSYCH, V1, P259, DOI 10.1177/2515245918770963
   Lakens D, 2017, SOC PSYCHOL PERS SCI, V8, P355, DOI 10.1177/1948550617697177
   Lenhard A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222279
   Macnamara A., 2021, NAT AGING, V1, P975, DOI [10.1038/s43587-021-00135-2, DOI 10.1038/S43587-021-00135-2]
   Macnamara A, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.663062
   Maki Y, 2021, J PRIM HEALTH CARE, V13, P112, DOI 10.1071/HC20115
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Patterson J., 2011, ENCY CLIN NEUROPSYCH, P1024
   Samanta A, 2020, J TELEMED TELECARE, DOI 10.1177/1357633X20970398
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   The jamovi project, 2020, JAM VERS 1 2 COMP SO
   Troyer AK, 1998, J INT NEUROPSYCH SOC, V4, P137, DOI 10.1017/S1355617798001374
   Vaughan RM, 2018, J AM GERIATR SOC, V66, P755, DOI 10.1111/jgs.15294
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood J, 2010, OPTOMETRY VISION SCI, V87, P1037, DOI 10.1097/OPX.0b013e3181fe64d7
NR 35
TC 1
Z9 1
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 8
PY 2022
VL 12
IS 1
AR 4033
DI 10.1038/s41598-022-07924-8
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 2Z3IA
UT WOS:000826474600131
PM 35260721
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Xu, LN
   Blonska, AM
   Pumariega, NM
   Bearelly, S
   Sohrab, MA
   Hageman, GS
   Smith, RT
AF Xu, Luna
   Blonska, Anna M.
   Pumariega, Nicole M.
   Bearelly, Srilaxmi
   Sohrab, Mahsa A.
   Hageman, Gregory S.
   Smith, R. Theodore
TI RETICULAR MACULAR DISEASE IS ASSOCIATED WITH MULTILOBULAR GEOGRAPHIC
   ATROPHY IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; reticular macular
   disease; scanning laser ophthalmoscopy; autofluorescence imaging;
   progression
ID FUNDUS AUTOFLUORESCENCE; INTERACTIVE SEGMENTATION; HIGH-RISK;
   PSEUDODRUSEN; PROGRESSION; EPIDEMIOLOGY; REGISTRATION; MACULOPATHY;
   PREVALENCE; EYE
AB Purpose: To investigate the incidence of reticular macular disease (RMD), a subpheno-type of age-related macular degeneration, in multilobular geographic atrophy (GA) and its relation to GA progression.
   Methods: One hundred and fifty-seven eyes of 99 subjects with age-related macular degeneration, primary GA, and good quality autofluorescence, and/or infrared images were classified into unilobular GA (1 lesion) or multilobular GA (>= 2 distinct and/or coalescent lesions). Thirty-four subjects (50 eyes) had serial imaging. The authors determined the spatiotemporal relationships of RMD to GA and GA progression rates in five macular fields.
   Results: 91.7% eyes (144 of 157) had multilobular GA, 95.8% of which exhibited RMD. In subjects with serial imaging, the mean GA growth rate significantly differed between the unilobular and multilobular groups (0.40 vs. 1.30 mm(2)/year, P < 0.001). Of the macular fields in these eyes, 77.1% of fields with RMD at baseline showed subsequent GA progression, while 53.4% of fields without RMD showed progression (P < 0.001). Percentage of fields with RMD significantly correlated with GA progression rate (P = 0.01).
   Conclusion: Autofluorescence and infrared imaging demonstrates that RMD is nearly always present with multilobular GA in age-related macular degeneration. Furthermore, GA lobules frequently develop in areas of RMD, suggesting progression of a single underlying disease process.
C1 [Xu, Luna; Blonska, Anna M.; Pumariega, Nicole M.; Bearelly, Srilaxmi; Sohrab, Mahsa A.] Columbia Univ, Dept Ophthalmol, ES Harkness Eye Inst, New York, NY 10027 USA.
   [Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Smith, R. Theodore] NYU, Langone Med Ctr, Dept Ophthalmol, New York, NY 10016 USA.
C3 Columbia University; Utah System of Higher Education; University of
   Utah; New York University; NYU Langone Medical Center
RP Smith, RT (通讯作者)，NYU, Langone Med Ctr, Dept Ophthalmol, 462 First Ave, New York, NY 10016 USA.
EM roland.smith@nyumc.org
OI smith, theodore/0000-0002-1693-943X
FU New York Community Trust (New York, NY); National Eye Institute
   (Bethesda, MD) [R01 EY015520, R24 EY017404]; Research to Prevent
   Blindness (New York, NY); Kaplen Foundation; Doris Duke Clinical
   Research Fellowship Program; NATIONAL EYE INSTITUTE [P30EY014800,
   R24EY017404, R01EY015520] Funding Source: NIH RePORTER
FX Supported by grants from The New York Community Trust (New York, NY) (R.
   T. S.); National Eye Institute (Bethesda, MD) grants R01 EY015520 (R. T.
   S.) and R24 EY017404 (G. S. H.); unrestricted grants to the E. S.
   Harkness Eye Institute and the University of Utah's Department of
   Ophthalmology and Visual Sciences from Research to Prevent Blindness
   (New York, NY); the Kaplen Foundation (S. B.); and the Doris Duke
   Clinical Research Fellowship Program (L.X.).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen J, 2008, IEEE ENG MED BIO, P2242, DOI 10.1109/IEMBS.2008.4649642
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee N, 2009, IFMBE PROC, V25, P227, DOI 10.1007/978-3-642-03891-4_61
   Lee N, 2008, CONF REC ASILOMAR C, P655, DOI 10.1109/ACSSC.2008.5074488
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 72
Z9 72
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1850
EP 1862
DI 10.1097/IAE.0b013e31828991b2
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500013
PM 23632954
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pechan, P
   Wadsworth, S
   Scaria, A
AF Pechan, Peter
   Wadsworth, Samuel
   Scaria, Abraham
TI Gene Therapies for Neovascular Age-Related Macular Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CHOROIDAL
   NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; NONHUMAN PRIMATE; SOLUBLE VEGF;
   VASCULAR-PERMEABILITY; NEUROTROPHIC ACTIVITY; MONOCLONAL-ANTIBODY
AB Pathological neovascularization is a key component of the neovascular form (also known as thewet form) of age-related macular degeneration (AMD) and proliferative diabetic retinopathy. Several preclinical studies have shown that antiangiogenesis strategies are effective for treating neovascular AMD in animal models. Vascular endothelial growth factor (VEGF) is one of the main inducers of ocular neovascularization, and several clinical trials have shown the benefits of neutralizing VEGF in patients with neovascular AMD or diabetic macular edema. In this review, we summarize several preclinical and early-stage clinical trials with intraocular gene therapies, which have the potential to reduce or eliminate the repeated intravitreal injections that are currently required for the treatment of neovascular AMD.
C1 [Pechan, Peter; Wadsworth, Samuel; Scaria, Abraham] Sanofi Genzyme R&D Ctr, Gene Therapy, Framingham, MA 01701 USA.
C3 Sanofi-Aventis; Genzyme Corporation
RP Scaria, A (通讯作者)，Sanofi Genzyme R&D Ctr, Gene Therapy, Framingham, MA 01701 USA.
EM abraham.scaria@genzyme.com
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Boyer DS, 2009, INVEST OPHTH VIS SCI, V50, P1260
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   El Sanharawi M, 2013, GENE THER, V20, P1093, DOI 10.1038/gt.2013.36
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Julien S, 2008, MOL VIS, V14, P1358
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lamartina S, 2007, J GENE MED, V9, P862, DOI 10.1002/jgm.1083
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Presta LG, 1997, CANCER RES, V57, P4593
   Rakoczy PE, 2003, DIABETES, V52, P857, DOI 10.2337/diabetes.52.3.857
   RASMUSSEN HS, 2003, PRECLINICA, V1, P77
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yu MJT, 1999, AUST NZ J OPHTHALMOL, V27, P250, DOI 10.1046/j.1440-1606.1999.00182.x
NR 67
TC 4
Z9 5
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JUL
PY 2015
VL 5
IS 7
AR a017335
DI 10.1101/cshperspect.a017335
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CQ1WU
UT WOS:000360391700002
PM 25524721
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Klettner, A
   Roider, J
AF Klettner, A.
   Roider, J.
TI Treating Age-Related Macular Degeneration - Interaction of
   VEGF-Antagonists with their Target
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE VEGF; ranibizumab; lucentis; AMD; pegaptanib; VEGF-trap
ID ENDOTHELIAL GROWTH-FACTOR; HEPARIN-BINDING DOMAIN; 165-AMINO ACID FORM;
   CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ANTI-VEGF; OCULAR
   NEOVASCULARIZATION; VASCULAR-PERMEABILITY; MONOCLONAL-ANTIBODY;
   SIGNAL-TRANSDUCTION
AB The neutralization of VEGF is the current treatment of choice for age-related macular degeneration. Current approaches include anti-VEGF-antibodies and -Fab Fragments, aptamers, soluble receptors (Traps) and siRNA. The molecular properties of VEGF and its antagonists are reviewed and the pathways of action of these substances are discussed.
C1 [Klettner, A.; Roider, J.] UK SH, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，UK SH, Dept Ophthalmol, Campus Kiel,Hegewischstr 2, D-24105 Kiel, Germany.
EM aklettner@ophthalmol.uni-kiel.de
RI Roider, Johann/E-4513-2010; Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
CR [Anonymous], 2005, SCCP085104
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bates DO, 2002, CANCER RES, V62, P4123
   BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7
   Bozza M, 2006, BIOCHEMISTRY-US, V45, P7639, DOI 10.1021/bi0521442
   Brandner B, 2006, BIOCHEM BIOPH RES CO, V340, P836, DOI 10.1016/j.bbrc.2005.12.079
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322
   DE VC, 1992, SCIENCE, V255, P989
   Dejneka NS, 2008, MOL VIS, V14, P997
   Deudero JJP, 2008, J BIOL CHEM, V283, P11435, DOI 10.1074/jbc.M703875200
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Gaspar NJ, 2002, ARCH BIOCHEM BIOPHYS, V404, P126, DOI 10.1016/S0003-9861(02)00239-4
   Gatto Barbara, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P287, DOI 10.2174/187152006777698178
   Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519
   Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Hamma-Kourbali Y, 2001, J BIOL CHEM, V276, P39748, DOI 10.1074/jbc.M101117200
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200
   Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4
   Kasap Murat, 2005, Turkish Journal of Biology, V29, P217
   Kasap M, 2008, J THEOR BIOL, V253, P446, DOI 10.1016/j.jtbi.2008.03.018
   Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7
   Kramer I, 2007, J CLIN PHARM THER, V32, P1, DOI 10.1111/j.1365-2710.2007.00800.x
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lee JH, 2008, FEBS LETT, V582, P1835, DOI 10.1016/j.febslet.2008.05.003
   Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200
   Moreira IS, 2007, ANTI-CANCER AGENT ME, V7, P223
   Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pan Q, 2007, J BIOL CHEM, V282, P24049, DOI 10.1074/jbc.M703554200
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639
   Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390
   Presta LG, 1997, CANCER RES, V57, P4593
   Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h
   Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7
   Reich S, 2003, MOL VIS, V9, P210
   Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200
   Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681
   von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
NR 83
TC 23
Z9 24
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PY 2009
VL 9
IS 9
BP 1127
EP 1135
DI 10.2174/138955709788922665
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 517MV
UT WOS:000271619400010
PM 19689408
DA 2022-11-30
ER

PT J
AU Fenwick, EK
   Man, REK
   Cheung, CMG
   Sabanayagam, C
   Cheng, CY
   Neelam, K
   Chua, J
   Gan, ATL
   Mitchell, P
   Wong, TY
   Lamoureux, EL
AF Fenwick, Eva K.
   Man, Ryan E. K.
   Cheung, Chui Ming Gemmy
   Sabanayagam, Charumathi
   Cheng, Ching-Yu
   Neelam, Kumari
   Chua, Jacqueline
   Gan, Alfred T. L.
   Mitchell, Paul
   Wong, Tien Y.
   Lamoureux, Ecosse L.
TI Ethnic Differences in the Association Between Age-Related Macular
   Degeneration and Vision-Specific Functioning
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; URBAN ASIAN POPULATION; DIABETES-MELLITUS; RASCH
   ANALYSIS; SINGAPORE; PREVALENCE; EYE; QUESTIONNAIRE; MACULOPATHY;
   AUSTRALIA
AB IMPORTANCE Understanding the link between ethnicity and health is critical to making appropriate public policy decisions. Few population-level data are available about this connection, however, including the influence of ethnicity on the association between age-related macular degeneration (AMD) and vision-specific functioning (VSF).
   OBJECTIVE To identify the influence of ethnicity on VSF among Chinese, Malay, and Indian patients with AMD.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, population-based study relied on patients and their data from 3 population-based studies in 3 ethnic groups: Chinese, Malay and Indian. Of 10 033 Chinese, Malay, and Indian adults who participated in the study, 9962 (99.3%) who had gradable fundus images and Visual Function Index (VF-11) data available were included in the analyses for the present study. Uniocular presenting distance visual acuity was measured using the logMAR chart. Separate multiple linear regression models examined the association between AMD and VSF in the 3 ethnic groups, adjusting for age, sex, presenting visual acuity in the better-seeing eye, educational level, income, smoking status, hypertension, diabetes, cardiovascular disease, total cholesterol level, and other eye conditions. Data were collected between January 20, 2004, and December 19, 2011; data analysis was conducted between November 12, 2015, and December 28, 2016.
   EXPOSURES Age-related macular degeneration according to fundus photographs graded using a modified Wisconsin Age-Related Maculopathy Grading System.
   MAIN OUTCOMES AND MEASURES Rasch analysis was used to convert VF-11 questionnaire scores to estimated interval measures of VSF.
   RESULTS Of the 9962 participants, the mean (SD) age was 58.8 (10.4) years; 4909 (49.3%) were male; 590 (5.9%) had early AMD (241 Chinese, 161 Malays, and 188 Indians) and 60 (0.6%) had late AMD (25 Chinese, 21 Malays, and 14 Indians). In the adjusted models, compared with no AMD, early AMD was associated with a small reduction in VSF (2.9%; beta = -0.12; 95% CI, -0.23 to -0.00; P = .046) in the Chinese group but not in the Indian and Malay groups. Moreover, Chinese participants with late AMD had a clinically significant 19.1% loss of VSF (beta = -0.78; 95% CI, -1.13 to -0.43, P < .001). In the Malay group, those with late AMD had a 13.5% drop in VSF (beta = -0.49; 95% CI, -1.01 to 0.04; P = .07) compared with their counterparts without AMD. Similarly, late AMD was not associated with VSF in the Indian group.
   CONCLUSIONS AND RELEVANCE Early and late AMD negatively affected VSF in Chinese but not in Indian and Malay participants. This finding suggests that there is an independent ethnic influence in the association of the disease with VSF in multiethnic Asian populations, thus warranting ethnicity-based strategies to delay the onset or progression of AMD.
C1 [Fenwick, Eva K.; Man, Ryan E. K.; Cheung, Chui Ming Gemmy; Sabanayagam, Charumathi; Cheng, Ching-Yu; Neelam, Kumari; Chua, Jacqueline; Gan, Alfred T. L.; Wong, Tien Y.; Lamoureux, Ecosse L.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Fenwick, Eva K.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Fenwick, Eva K.; Cheung, Chui Ming Gemmy; Sabanayagam, Charumathi; Cheng, Ching-Yu; Neelam, Kumari; Chua, Jacqueline; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Inst, Sydney, NSW, Australia.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; University of
   Sydney; University of Sydney; Westmead Institute for Medical Research
RP Lamoureux, EL (通讯作者)，Singapore Eye Res Inst, 20 Coll Rd,Level 6, Singapore 169856, Singapore.
EM ecosselamoureux@seri.com.sg
RI Sabanayagam, Charumathi/C-1294-2011; Lamoureux, Ecosse/Z-5482-2019;
   Mitchell, Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020; Cheng,
   Ching-Yu/Y-2229-2019
OI Sabanayagam, Charumathi/0000-0002-4042-4719; Wong, Tien
   Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X; Cheung,
   Chui Ming Gemmy/0000-0003-3358-3516; Chua,
   Jacqueline/0000-0002-6474-5293; Man, Ryan/0000-0001-5028-605X
FU National Medical Research Council [0796/2003, IRG07nov013, IRG09nov014,
   STaR/0003/2008, CG/SERI/2010]; Biomedical Research Council
   [08/1/35/19/550, 09/1/35/19/616, CSA/033/2012]; Australian National
   Health and Medical Research Council's Early Career Fellowship [1072987]
FX This study is funded by grants 0796/2003, IRG07nov013, IRG09nov014,
   STaR/0003/2008, and CG/SERI/2010 from the National Medical Research
   Council and by grants 08/1/35/19/550 and 09/1/35/19/616 from the
   Biomedical Research Council. Dr Cheng is supported by grant CSA/033/2012
   from the National Medical Research Council. Dr Fenwick is funded by the
   Australian National Health and Medical Research Council's Early Career
   Fellowship (1072987). The Centre for Eye Research Australia receives
   operational infrastructure support from the Victorian government.
CR ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Ashing-Giwa K, 1999, CANCER, V85, P418, DOI 10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO;2-9
   Bishop GD, 1998, PSYCHOL HEALTH, V13, P121, DOI 10.1080/08870449808406136
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Caldwell EM, 1998, AM J PUBLIC HEALTH, V88, P1225, DOI 10.2105/AJPH.88.8.1225
   Canada AL, 2013, J BEHAV MED, V36, P441, DOI 10.1007/s10865-012-9439-8
   Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS POP A
   Fenwick EK, BR J OPHTHALMOL
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Globe D, 2003, INVEST OPHTH VIS SCI, V44, P1470, DOI 10.1167/iovs.02-0292
   Khadka J, 2014, INVEST OPHTH VIS SCI, V55, P4413, DOI 10.1167/iovs.14-14017
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P2607, DOI 10.1167/iovs.08-2359
   Lim A S, 2000, Psychol Health, V14, P965, DOI 10.1080/08870440008407361
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linacre, 2014, USERS GUIDE WINSTEPS
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Misra R, 2009, J DIABETES COMPLICAT, V23, P54, DOI 10.1016/j.jdiacomp.2007.11.003
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   SCHULMAN KA, 1995, HEALTH SERV RES, V30, P179
   Thumboo J, 2003, SOC SCI MED, V56, P1761, DOI 10.1016/S0277-9536(02)00171-5
   Wee HL, 2006, J DIABETES COMPLICAT, V20, P170, DOI 10.1016/j.jdiacomp.2005.06.010
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   Wong TY, 2001, ARCH OPHTHALMOL-CHIC, V119, P727, DOI 10.1001/archopht.119.5.727
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P990, DOI 10.1136/bjo.84.9.990
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Xie F, 2006, OSTEOARTHR CARTILAGE, V14, P224, DOI 10.1016/j.joca.2005.09.009
NR 35
TC 7
Z9 7
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2017
VL 135
IS 5
BP 469
EP 476
DI 10.1001/jamaophthalmol.2017.0266
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EU5ZN
UT WOS:000401113400016
PM 28358956
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Arifoglu, HB
   Hashas, ASK
   Atas, M
   Sarli, B
   Ozkose, A
   Demircan, S
AF Arifoglu, Hasan Basri
   Hashas, Arzu Seyhan Karatepe
   Atas, Mustafa
   Sarli, Bahadir
   Ozkose, Ayse
   Demircan, Suleyman
TI Systemic endothelial function in cases with wet-type age-related macular
   degeneration
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE AMD; FMD; Endothelial function
ID BLOOD-FLOW; DYSFUNCTION; PATHOGENESIS; AMD
AB Choroidal endothelial dysfunction plays key role in wet-type age-related macular degeneration (AMD). Peripheral vascular endothelial function is not known in wet AMD.
   We aimed to analyze peripheral vascular endothelial function in cases with wet-type age-related macular degeneration by measuring flow-mediated dilatation (FMD).
   The study included 20 cases with wet AMD (Group 1, mean age 65.9 +/- 7.2 years) and 24 healthy individuals (Group 2, mean age 62.0 +/- 11.9 years). In all cases, a cardiologist assessed the responses of endothelial function by measuring the FMD following brachial artery occlusion.
   Mean FMD, an indicator of endothelial function was found to be 6.4 +/- 2.7 % in Group 1 and 15.6 +/- 7.3 % in Group 2 (p < 0.001). There was no significant difference between patient and control groups regarding age, sex, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, ESR and CRP.
   Reduced FMD is present in patients with wet AMD, suggesting that impaired peripheral endothelial function may be involved in its pathogenesis.
C1 [Arifoglu, Hasan Basri; Hashas, Arzu Seyhan Karatepe; Atas, Mustafa; Ozkose, Ayse; Demircan, Suleyman] SB Kayseri Res & Educ Hosp, Dept Ophthalmol, Sanayi Mah Ataturk Blvd Hastane St 78, TR-38010 Kayseri, Turkey.
   [Sarli, Bahadir] SB Kayseri Res & Educ Hosp, Dept Cardiol, Sanayi Mah Ataturk Blvd Hastane St 78, TR-38010 Kayseri, Turkey.
C3 Kayseri Training & Research Hospital; Kayseri Training & Research
   Hospital
RP Arifoglu, HB (通讯作者)，SB Kayseri Res & Educ Hosp, Dept Ophthalmol, Sanayi Mah Ataturk Blvd Hastane St 78, TR-38010 Kayseri, Turkey.
EM habasa@yahoo.com
RI Atas, Mustafa/K-2319-2013
OI Atas, Mustafa/0000-0003-0545-184X
CR Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859
   Economou MA, 2008, ACTA OPHTHALMOL, V86, P930, DOI [10.1111/j.1755-3768.2008.01188.x, 10.1111/j.1755-3768.2008.01182.x, 10.1111/j.1755-3768.2008.01185.x, 10.1111/j.1755-3768.2008.01184.x]
   Fischer T., 2012, J NEUROSCI BEHAV HLT, V4, P42
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Polak K, 2001, INVEST OPHTH VIS SCI, V42, P2949
   Ras RT, 2013, INT J CARDIOL, V168, P344, DOI 10.1016/j.ijcard.2012.09.047
   Sakai T, 2011, OPHTHALMOLOGY, V118, P1217, DOI 10.1016/j.ophtha.2011.01.033
   SORENSEN KE, 1995, BRIT HEART J, V74, P247
   Su WW, 2006, INVEST OPHTH VIS SCI, V47, P3390, DOI 10.1167/iovs.06-0024
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
NR 17
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2016
VL 28
IS 5
BP 853
EP 856
DI 10.1007/s40520-015-0377-5
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DV4FP
UT WOS:000382881100006
PM 26003670
DA 2022-11-30
ER

PT J
AU Pece, A
   Borrelli, E
   Sacconi, R
   Maione, G
   Bandello, F
   Querques, G
AF Pece, Alfredo
   Borrelli, Enrico
   Sacconi, Riccardo
   Maione, Giulio
   Bandello, Francesco
   Querques, Giuseppe
TI Choroidal cleft simulating choroidal caverns in neovascular age-related
   macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; choroidal neovascular
   membranes; uvea; anatomy; biochemistry; physiology; techniques of
   retinal examination
AB The authors report a case of a female patient affected by neovascular age-related macular degeneration (AMD). In particular, multiple sub-retinal hyperreflective infiltrates were found on optical coherence tomography. Optical coherence tomography examination of her right eye displayed the presence of sub-retinal pigment epithelium hyporeflective spaces located beneath a hyperreflective fibrotic neovascularization. This case highlights the importance of differentiating choroidal clefts from choroidal caverns.
C1 [Pece, Alfredo; Maione, Giulio] Melegnano Hosp, Eye Clin, Vizzolo Predabissi, Italy.
   [Borrelli, Enrico; Sacconi, Riccardo; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Borrelli, Enrico/AAR-3693-2020; bandello, francesco/AAH-2405-2019
OI Borrelli, Enrico/0000-0003-2815-5031; bandello,
   francesco/0000-0003-3238-9682; Sacconi, Riccardo/0000-0003-2891-2012;
   Querques, Giuseppe/0000-0002-3292-9581
CR Carnevali A, 2018, OSLI RETINA, V49, P284, DOI 10.3928/23258160-20180329-14
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
NR 4
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2019
VL 29
IS 5
BP 471
EP 473
AR 1120672119855540
DI 10.1177/1120672119855540
EA JUL 2019
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IW9ET
UT WOS:000479587300001
PM 31353948
DA 2022-11-30
ER

PT J
AU Nussenblatt, RB
   Liu, BY
   Li, ZQ
AF Nussenblatt, Robert B.
   Liu, Baoying
   Li, Zhuqing
TI Age-related macular degeneration: An immunologically driven disease
SO CURRENT OPINION IN INVESTIGATIONAL DRUGS
LA English
DT Review
DE Age-related macular degeneration; AMD; immune response; intraocular
   inflammatory disease
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; CHOROIDAL NEOVASCULARIZATION;
   MACROPHAGE ACTIVATION; IMMUNE-RESPONSE; BRUCHS MEMBRANE; DRUSEN;
   POLYMORPHISM; MACULOPATHY; MONOCYTE
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly individuals worldwide. Genome-wide association studies have provided evidence that the immune system is involved in the pathogenesis of AMD. This review discusses historical and more recent studies that have led to the recognition that AMD is an intraocular inflammatory disease, and that is possibly driven by an immune response. A particular focus of this review is recent studies on the contribution of the complement system and macrophages to the pathogenesis of AMD. A working hypothesis is also presented that may reconcile the current understanding of the pathogenesis of AMD and some apparently contradictory findings in the literature.
C1 [Nussenblatt, Robert B.; Liu, Baoying; Li, Zhuqing] NEI, NIH, Immunol Lab, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Nussenblatt, RB (通讯作者)，NEI, NIH, Immunol Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM DrBob@nei.nih.gov
FU NATIONAL EYE INSTITUTE [Z01EY000439, ZIAEY000439] Funding Source: NIH
   RePORTER
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   CASPI RR, 1987, SCIENCE, V237, P1029, DOI 10.1126/science.2956685
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cummings KL, 2007, VIRAL IMMUNOL, V20, P505, DOI 10.1089/vim.2007.0061
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Gordon S, 2007, J CLIN INVEST, V117, P89, DOI 10.1172/JCI30992
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   IGIC R, 1985, EXP EYE RES, V41, P117, DOI 10.1016/0014-4835(85)90100-9
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jara LJ, 2006, AUTOIMMUN REV, V5, P195, DOI 10.1016/j.autrev.2005.06.005
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopf M, 2002, NAT MED, V8, P373, DOI 10.1038/nm0402-373
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lalli PN, 2008, BLOOD, V112, P1759, DOI 10.1182/blood-2008-04-151068
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076
   Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nataf S, 1999, J IMMUNOL, V162, P4018
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2007, ACTA OPHTHALMOL SCAN, V85, P230, DOI 10.1111/j.1600-0420.2006.00858.x
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001
   Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950
   Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wenderfer SE, 2005, J AM SOC NEPHROL, V16, P3572, DOI 10.1681/ASN.2005040373
   Werfel T, 2000, J IMMUNOL, V165, P6599, DOI 10.4049/jimmunol.165.11.6599
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 91
TC 46
Z9 48
U1 0
U2 3
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1472-4472
EI 2040-3429
J9 CURR OPIN INVEST DR
JI Curr. Opin. Investig. Drugs
PD MAY
PY 2009
VL 10
IS 5
BP 434
EP 442
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 441PY
UT WOS:000265782500005
PM 19431076
DA 2022-11-30
ER

PT J
AU Wu, JL
   Sun, XD
AF Wu, Jiali
   Sun, Xiaodong
TI Complement system and age-related macular degeneration: drugs and
   challenges
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE age-related macular degeneration; inflammation; complement system;
   immunotherapy
ID RARE GENETIC-VARIANTS; GEOGRAPHIC ATROPHY; DRUSEN FORMATION; INHIBITION;
   ACTIVATION; PATHWAY; COMPSTATIN; DEPOSITS; THERAPIES; FRAGMENT
AB Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of complement pathways involved in AMD and their therapies correspondingly. Finally, we discuss the development of the therapeutics existed now. Also, we enclose a list of drugs undergoing clinical trials.
C1 [Wu, Jiali; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
OI Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China (Key Program) [81730026,
   81425006]; Frontier Project of Shanghai Hospital Development Center
   [SHDC12016105]; Science and Technology Commission of Shanghai
   Municipality [17411953000, 16140900800, 0303N17001]
FX This study was supported by the National Natural Science Foundation of
   China (Key Program) (81730026, 81425006), Frontier Project of Shanghai
   Hospital Development Center (SHDC12016105), Science and Technology
   Commission of Shanghai Municipality (17411953000, 16140900800,
   0303N17001).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2016, PIPELINE DRY AMD FEA
   [Anonymous], 2016, ANTICOMPLEMENT C5 MO
   Bansal R, 2009, WO, Patent No. [2009/ 029669A1, 2009029669]
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brockmann C, 2015, GRAEF ARCH CLIN EXP, V253, P1695, DOI 10.1007/s00417-015-3041-z
   Campagne MVL, 2010, INVEST OPHTH VIS SCI, V51
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chen JY, 2018, MOL IMMUNOL, V102, P58, DOI 10.1016/j.molimm.2018.05.018
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Collier RJ, 2012, INVEST OPHTH VIS SCI, V53, P5362
   Crowley MA, 2018, INVEST OPHTH VIS SCI, V59, P940, DOI 10.1167/iovs.17-22605
   Dalton Michelle, 2018, WHAT APL 2 MEANS GEO
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Dobo J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01851
   Dobo J, 2016, IMMUNOL REV, V274, P98, DOI 10.1111/imr.12460
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   de Jorge EG, 2018, SEMIN IMMUNOPATHOL, V40, P3, DOI 10.1007/s00281-017-0643-z
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Grossman TR, 2017, MOL VIS, V23, P561
   Gupta-Bansal R, 2000, MOL IMMUNOL, V37, P191, DOI 10.1016/S0161-5890(00)00047-X
   Hageman GS, 1999, MOL VIS, V5
   Holz F. G., 2013, EUR M 28 SEPT
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joseph RR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16791-7
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lenier Steve, 2018, APL 2 SLOWS GROWTH G
   Lesher AM, 2013, MOL IMMUNOL, V56, P191, DOI 10.1016/j.molimm.2013.06.002
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Moisseiev E, 2017, DEV OPHTHALMOL, V58, P87, DOI 10.1159/000455276
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Ophthotech, 2017, OPHTH PROV UPD ZIM C
   Osthoff M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134107
   Pauly D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096371
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Roche, 2017, ROCH PROV UPD 1 LAMP
   Roguska M, 2014, INVEST OPHTH VIS SCI, V55
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   VOLANAKIS JE, 1985, NEW ENGL J MED, V312, P395, DOI 10.1056/NEJM198502143120702
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wallis R, 2010, IMMUNOBIOLOGY, V215, P1, DOI 10.1016/j.imbio.2009.08.006
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Wolf-Schnurrbusch UEK, 2009, RETINA-J RET VIT DIS, V29, P966, DOI 10.1097/IAE.0b013e3181a2f40f
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 83
TC 50
Z9 52
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2019
VL 13
BP 2413
EP 2425
DI 10.2147/DDDT.S206355
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IK8CK
UT WOS:000476820800002
PM 31409975
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sizmaz, S
   Esen, E
   Isik-Ericek, P
   Demircan, N
AF Sizmaz, Selcuk
   Esen, Ebru
   Isik-Ericek, Puren
   Demircan, Nihal
TI Comparison of intravitreal injections of Ranibizumab and Aflibercept in
   neovascular age related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE Aflibercept; central macular thickness; neovascular age-related macular
   degeneration; ranibizumab; subfoveal choroidal thickness
AB Background: The aim of this study is to analyse the real-world outcome of vascular endothelial growth factor blocking agents in neovascular age-related macular degeneration.
   Methods: This is a retrospective comparative study of treatment-naive patients who received intravitreal aflibercept or ranibizumab administration for neovascular age-related macular degeneration for at least 12 months on an as needed regimen following a loading phase of three-monthly injections. Full eye examination and optical coherence tomography scans were provided at all visits. The drugs were compared on the basis of visual acuity, central macular thickness, and subfoveal choroidal thickness. The baseline optical coherence tomography features were analysed seeking a correlation with the outcome.
   Results: One hundred and forty-one eyes were enrolled. The mean age was 71.7 +/- 8.5 years. Sixty-eight (48.2%) patients received aflibercept and 73 (51.8%) received ranibizumab injections. The mean number of injections was 6.5 +/- 2.5. The mean number of injections were also similar between groups (6.4 +/- 2.5 vs. 6.5 +/- 2.6, respectively, p = 0.783). At one year, both drugs caused significant increase in visual acuity and decrease in central macular thickness and subfoveal choroidal thickness.
   Conclusion: In a real-world setting, aflibercept and ranibizumab yielded similar results at one year in the management of neovascular age-related macular degeneration.
C1 [Sizmaz, Selcuk; Esen, Ebru; Isik-Ericek, Puren; Demircan, Nihal] Cukurova Univ, Sch Med, Dept Ophthalmol, Adana, Turkey.
C3 Cukurova University
RP Sizmaz, S (通讯作者)，Cukurova Univ, Sch Med, Dept Ophthalmol, CUTF Goz Hastaliklari AD, TR-01250 Adana, Turkey.
EM ssizmaz@cu.edu.tr
OI Esen, Ebru/0000-0001-7448-451X
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bouteleux V, 2019, GRAEF ARCH CLIN EXP, V257, P699, DOI 10.1007/s00417-018-04216-8
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, RETINA-J RET VIT DIS, V38, P1134, DOI 10.1097/IAE.0000000000001681
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Ozkaya A, 2018, TURK OFTALMOL DERG, V48, P232, DOI 10.4274/tjo.31697
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 31
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN 2
PY 2022
VL 105
IS 1
BP 55
EP 60
DI 10.1080/08164622.2021.1896334
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YC4LM
UT WOS:000629080000001
PM 33719869
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Sugiyama, A
   Yoneyama, S
   Matsubara, M
   Fukuda, Y
   Kashiwagi, K
AF Kikushima, Wataru
   Sakurada, Yoichi
   Sugiyama, Atsushi
   Yoneyama, Seigo
   Matsubara, Mio
   Fukuda, Yoshiko
   Kashiwagi, Kenji
TI Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related
   Macular Degeneration with Good Baseline Visual Acuity
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE aflibercept monotherapy; polypoidal choroidal vasculopathy; neovascular
   age-related macular degeneration; good baseline visual acuity
AB We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA >= 0.6 secondary to exudative AMD. Three monthly injections were administrated, and thereafter additional injection was performed if needed over 5 years. In total, 13 eyes with neovascular AMD (nAMD) and 27 eyes with polypoidal choroidal vasculopathy (PCV) were enrolled. In both groups, the mean BCVA significantly improved at the 12-month visit (p < 0.05). However, the significant improvement in BCVA disappeared at the 24-month visit, and the final mean BCVA was equivalent to that at baseline (p = 0.17 in the nAMD group and p = 0.15 in the PCV group). The median number of injections required after the loading dose was 15.0 during the 5-year follow-up (nAMD:15.0 vs. PCV:15). During the study period, 37 (92.5%) eyes required retreatment(s). Cox regression analysis demonstrated that the protective allele of ARMS2 A69S was associated with a retreatment-free period from the initial injection (p = 0.041, repeated forward selection method). As-needed aflibercept monotherapy is a preferable treatment option for exudative AMD with good initial visual acuity regardless of nAMD or PCV during the 5-year study period.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Sugiyama, Atsushi; Yoneyama, Seigo; Matsubara, Mio; Fukuda, Yoshiko; Kashiwagi, Kenji] Univ Yamanashi, Dept Ophthalmol, Chuo Ku, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Chuo Ku, Yamanashi 4093898, Japan.
EM wkikushima@yamanashi.ac.jp; sakurada@yamanashi.ac.jp;
   asugiyama@yamanashi.ac.jp; syoneyama@yamanashi.ac.jp;
   miom@yamanashi.ac.jp; ysugiyama@yamanashi.ac.jp; kenjik@yamanashi.ac.jp
OI Kashiwagi, Kenji/0000-0001-8506-8503; Sakurada,
   Yoichi/0000-0002-2894-0454
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Javidi S, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/3207614
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khanani AM, 2019, CLIN OPHTHALMOL, V13, P347, DOI 10.2147/OPTH.S191170
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Minami S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18255-4
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shijo T, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090257
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
NR 19
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2021
VL 10
IS 5
AR 1098
DI 10.3390/jcm10051098
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QV9MP
UT WOS:000628286600001
PM 33807964
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Skondra, D
   Papakostas, T
   Vavvas, DG
AF Skondra, Dimitra
   Papakostas, Thanos
   Vavvas, Demetrios G.
TI Enhanced Depth Imaging Optical Coherence Tomography in Age-related
   Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE AMD; Choroidal thickness; Imaging
ID SUBFOVEAL CHOROIDAL THICKNESS; RETICULAR PSEUDODRUSEN;
   MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; IN-VIVO; FREQUENCY; THERAPY
AB Imaging of the choroidal layer has been limited with the conventional commercial SD-OCTs. Enhanced depth imaging optical coherence tomography (EDI-OCT) is a modification of the standard spectral-domain OCT (SD-OCT) technique that enables better non-invasive imaging of the choroid. This review contains an introduction of EDI imaging technique and principles and summarizes the findings of EDI-OCT imaging in age-related macular degeneration.
C1 [Skondra, Dimitra; Papakostas, Thanos; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Vavvas, DG (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu
OI Vavvas, Demetrios/0000-0002-8622-6478
CR An L, 2007, OPT LETT, V32, P3423, DOI 10.1364/OL.32.003423
   Chhablani J, 2012, INVEST OPHTH VIS SCI, V53, P2274, DOI 10.1167/iovs.12-9435
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   Panozzo Giacomo, 2003, Semin Ophthalmol, V18, P74, DOI 10.1076/soph.18.2.74.15854
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Vakoc BJ, 2006, OPT LETT, V31, P362, DOI 10.1364/OL.31.000362
   Wang RK, 2007, PHYS MED BIOL, V52, P5897, DOI 10.1088/0031-9155/52/19/011
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 7
Z9 7
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2012
VL 27
IS 5-6
BP 209
EP 212
DI 10.3109/08820538.2012.708807
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041SD
UT WOS:000311420600019
PM 23163278
DA 2022-11-30
ER

PT J
AU Gobel, AP
   Fleckenstein, M
   Schmitz-Valckenberg, S
   Brinkmann, CK
   Holz, FG
AF Goebel, Arno P.
   Fleckenstein, Monika
   Schmitz-Valckenberg, Steffen
   Brinkmann, Christian K.
   Holz, Frank G.
TI Imaging Geographic Atrophy in Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Geographic atrophy; Fundus
   autofluorescence; Scanning laser ophthalmoscopy
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE PATTERNS; IN-VIVO;
   DISEASE PROGRESSION; JUNCTIONAL ZONE; HIGH-RESOLUTION; HUMAN RPE;
   LIPOFUSCIN; MACULOPATHY; OCT
AB Advances in retinal imaging technology have largely contributed to the understanding of the natural history, prognostic markers and disease mechanisms of geographic atrophy (GA) due to age-related macular degeneration. There is still no therapy available to halt or slow the disease process. In order to evaluate potential therapeutic effects in interventional trials, there is a need for precise quantification of the GA progression rate. Fundus autofluorescence imaging allows for accurate identification and segmentation of atrophic areas and currently represents the gold standard for evaluating progressive GA enlargement. By means of high-resolution spectral-domain optical coherence tomography, distinct microstructural alterations related to GA can be visualized. Copyright (C) 2011 S. Karger AG, Basel
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, DE-53127 Bonn, Germany.
   Univ Bonn, GRADE Reading Ctr, DE-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU A.P. Gobel, Heidelberg Engineering; Heidelberg Engineering, Optos Ltd.;
   S. Schmitz-Valckenberg, Heidelberg Engineering, Optos Ltd, Topcon UK;
   Heidelberg Engineering
FX A.P. Gobel, Heidelberg Engineering, F; M. Fleckenstein, Heidelberg
   Engineering, Optos Ltd., F; Heidelberg Engineering, R; S.
   Schmitz-Valckenberg, Heidelberg Engineering, Optos Ltd, Topcon UK, F;
   Heidelberg Engineering, R; C.K. Brinkmann, Heidelberg Engineering, F;
   F.G. Holz, Heidelberg Engineering, Optos Ltd., F; Heidelberg
   Engineering, Zeiss MediTec AG, C; Heidelberg Engineering, R (F =
   Financial Support; R = Recipient; C = Consultant).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Pircher M, 2004, OPT EXPRESS, V12, P3236, DOI 10.1364/OPEX.12.003236
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sayegh RG, 2011, OPHTHALMOLOGY
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2011, INVEST OPHTHALMOL VI
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schneider U, 1997, ACTA OPHTHALMOL SCAN, V75, P653
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 2010, METHODS MOL BIOL, V652, P315, DOI 10.1007/978-1-60327-325-1_18
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
NR 63
TC 42
Z9 44
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 226
IS 4
BP 182
EP 190
DI 10.1159/000330420
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 841JQ
UT WOS:000296509000002
PM 21865677
OA Bronze
DA 2022-11-30
ER

PT J
AU Simpson, ARH
   Petrarca, R
   Jackson, TL
AF Simpson, Andrew R. H.
   Petrarca, Robert
   Jackson, Timothy L.
TI Vitreomacular Adhesion and Neovascular Age-Related Macular Degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; vitreomacular adhesion; vitreomactilar
   traction; vitreous
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; POSTERIOR
   VITREOUS DETACHMENT; RETINAL-PIGMENT EPITHELIUM; VITREORETINAL
   INTERFACE; CHOROIDAL NEOVASCULARIZATION; PHARMACOLOGICAL VITREOLYSIS;
   PLASMINOGEN-ACTIVATOR; DIABETIC-RETINOPATHY; ASSISTED VITRECTOMY
AB We explore the hypothesis that vitreomacular adhesion (VMA) and vitreomacular traction (VMT) play a role in the pathogenesis and clinical course of neovascular ("wet") age-related macular degeneration (AMD). Several biological theories are offered to explain this possible association, including direct tractional force, altered vitreous oxygenation, altered diffusion coefficients of intravitreal molecules, and alterations in the pharmacokinetics of intravitreal drugs. Release of VMT may improve the clinical course of neovascular AMD, and a few case series suggest that vitrectomy can lead to both a functional and anatomic improvement. A large, randomized, controlled clinical trial is underway, investigating pharmacologic release of VMA in eyes with neovascular AMD. (Surv Ophthalmol 57:498-509, 2012. (c) 2012 Elsevier Inc. All rights reserved.)
C1 [Jackson, Timothy L.] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
   Kings Coll London, London WC2R 2LS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Petrarca, Robert/0000-0001-8693-3423; Jackson,
   Timothy/0000-0001-7618-1555
FU Novartis; Oraya; NeoVista; Thrombogenics
FX Dr Jackson has served as consultant or advisor to Thrombogenics, and has
   received research funding from Novartis, Oraya, NeoVista, and
   Thrombogenics.
CR Abdelkader E, 2008, SURV OPHTHALMOL, V53, P368, DOI 10.1016/j.survophthal.2008.04.006
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ansari H, 2002, AM J OPHTHALMOL, V134, P447, DOI 10.1016/S0002-9394(02)01572-6
   Ansari RR, 2004, J BIOMED OPT, V9, P22, DOI 10.1117/1.1626663
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Azzolini C, 2001, AM J OPHTHALMOL, V132, P348, DOI 10.1016/S0002-9394(01)01005-4
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Baumal C R, 1999, Curr Opin Ophthalmol, V10, P182, DOI 10.1097/00055735-199906000-00006
   Blair N P, 2000, Trans Am Ophthalmol Soc, V98, P305
   BLANKENSHIP GW, 1985, OPHTHALMOLOGY, V92, P503
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Casuso LA, 2001, OPHTHALMOLOGY, V108, P1150, DOI 10.1016/S0161-6420(01)00581-4
   CHAN CK, 1995, OPHTHALMOLOGY, V102, P757, DOI 10.1016/S0161-6420(95)30958-X
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P4605, DOI 10.1167/iovs.10-6387
   Charbonnel J, 2004, GRAEF ARCH CLIN EXP, V242, P223, DOI 10.1007/s00417-003-0824-4
   Chuo JY, 2006, AM J OPHTHALMOL, V142, P931, DOI 10.1016/j.ajo.2006.08.002
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   de Smet MD, 2009, INVEST OPHTH VIS SCI, V50, P814, DOI 10.1167/iovs.08-2185
   DEJUAN E, 1986, ARCH OPHTHALMOL-CHIC, V104, P1063
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebato K, 2000, OPHTHALMIC SURG LAS, V31, P245
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2001, RETINA-J RET VIT DIS, V21, P389, DOI 10.1097/00006982-200108000-00021
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Gandorfer A, 2002, EYE, V16, P95, DOI 10.1038/sj.eye.6700064
   Gandorfer A, 2002, AM J OPHTHALMOL, V133, P156, DOI 10.1016/S0002-9394(01)01252-1
   Gandorfer A, 2001, BRIT J OPHTHALMOL, V85, P6, DOI 10.1136/bjo.85.1.6
   GASS JDM, 1988, ARCH OPHTHALMOL-CHIC, V106, P629, DOI 10.1001/archopht.1988.01060130683026
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   Gupta B., 2011, International Ophthalmology, V31, P23, DOI 10.1007/s10792-010-9364-1
   Gupta D, 2009, RETINA-J RET VIT DIS, V29, P430, DOI 10.1097/IAE.0b013e3181a0bd01
   HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1
   HIKICHI T, 1995, RETINA-J RET VIT DIS, V15, P29, DOI 10.1097/00006982-199515010-00006
   Hikichi T, 1999, RETINA-J RET VIT DIS, V19, P55, DOI 10.1097/00006982-199901000-00009
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hvarfner C, 2006, ACTA OPHTHALMOL SCAN, V84, P812, DOI 10.1111/j.1600-0420.2006.00749.x
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Imai M, 2003, AM J OPHTHALMOL, V136, P187, DOI 10.1016/S0002-9394(02)02255-9
   Ishida M, 2004, RETINA-J RET VIT DIS, V24, P625, DOI 10.1097/00006982-200408000-00024
   Jaffe N S, 1967, Trans Am Acad Ophthalmol Otolaryngol, V71, P642
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Johnson MW, 2005, AM J OPHTHALMOL, V140, P184, DOI 10.1016/j.ajo.2005.01.033
   Johnson MW, 2001, ARCH OPHTHALMOL-CHIC, V119, P215
   Jorge R, 2006, AM J OPHTHALMOL, V142, P869, DOI 10.1016/j.ajo.2006.05.062
   Jumper JM, 2000, RETINA-J RET VIT DIS, V20, P232, DOI 10.1097/00006982-200005000-00001
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2001, AM J OPHTHALMOL, V131, P44, DOI 10.1016/S0002-9394(00)00872-2
   Kasuga Y, 2000, AM J OPHTHALMOL, V130, P675, DOI 10.1016/S0002-9394(00)00587-0
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Kumagai K, 2007, RETINA-J RET VIT DIS, V27, P49, DOI 10.1097/01.iae.0000221996.77421.69
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laidlaw DAH, 2008, EYE, V22, P1337, DOI 10.1038/eye.2008.84
   Lapchak PA, 2002, STROKE, V33, P2279, DOI 10.1161/01.STR.0000028267.09604.7B
   LEE B, 1992, BIORHEOLOGY, V29, P521
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   LEWIS H, 1992, OPHTHALMOLOGY, V99, P753
   LIOTTA LA, 1981, CANCER RES, V41, P4629
   Liu YL, 2011, ACTA OPHTHALMOL, V89, pE291, DOI 10.1111/j.1755-3768.2009.01814.x
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maeda N, 1996, GRAEF ARCH CLIN EXP, V234, pS66, DOI 10.1007/BF02343050
   Margherio AR, 1998, OPHTHALMOLOGY, V105, P1617, DOI 10.1016/S0161-6420(98)99027-3
   Marmor M, 2001, RETINA
   MCDONALD HR, 1994, OPHTHALMOLOGY, V101, P1397
   MINCHENKO A, 1994, LAB INVEST, V71, P374
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Murakami T, 2007, RETINA-J RET VIT DIS, V27, P1031, DOI 10.1097/IAE.0b013e318074bc39
   NASRALLAH FP, 1988, OPHTHALMOLOGY, V95, P1335
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Ophir A, 2010, EUR J OPHTHALMOL, V20, P733, DOI 10.1177/112067211002000414
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   REESE AB, 1967, AM J OPHTHALMOL, V64, P544
   Rheaume MA, 2010, SEMIN OPHTHALMOL, V25, P295, DOI 10.3109/08820538.2010.518865
   RICE TA, 1983, AM J OPHTHALMOL, V95, P1
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   RUSSELL SR, 1991, INVEST OPHTH VIS SCI, V32, P1986
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Sakuma T, 2006, EUR J OPHTHALMOL, V16, P138, DOI 10.1177/112067210601600122
   Sakuma T, 2005, INVEST OPHTH VIS SCI, V46, P3295, DOI 10.1167/iovs.04-1517
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schneider EW, 2011, CLIN OPHTHALMOL, V5, P1151, DOI 10.2147/OPTH.S14840
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   Sebag J, 2007, T AM OPHTHAL SOC, V105, P129
   Sebag Jerry, 2007, Trans Am Ophthalmol Soc, V105, P121
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHI GY, 1988, J BIOL CHEM, V263, P17071
   Shui YB, 2009, ARCH OPHTHALMOL-CHIC, V127, P475, DOI 10.1001/archophthalmol.2008.621
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Sivaprasad S, 2008, RETINA-J RET VIT DIS, V28, P1435, DOI 10.1097/IAE.0b013e31817f2dae
   SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811
   SMIDDY WE, 1988, ARCH OPHTHALMOL-CHIC, V106, P624
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stalmans P, 2010, RETINA-J RET VIT DIS, V30, P1122, DOI 10.1097/IAE.0b013e3181e0970a
   Stefansson E, 1981, Trans Am Ophthalmol Soc, V79, P307
   STEFANSSON E, 1982, RETINA-J RET VIT DIS, V2, P159, DOI 10.1097/00006982-198200230-00006
   STEFANSSON E, 1990, INVEST OPHTH VIS SCI, V31, P284
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P718, DOI 10.1111/j.1600-0420.2006.00778.x
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Suzuki Y, 2004, STROKE, V35, P2402, DOI 10.1161/01.STR.0000140628.00927.1a
   Takahashi H, 1999, AM J OPHTHALMOL, V128, P519, DOI 10.1016/S0002-9394(99)00173-7
   Takahashi MK, 1997, OPHTHALMIC SURG LAS, V28, P294
   Tanner V, 2001, BRIT J OPHTHALMOL, V85, P1092, DOI 10.1136/bjo.85.9.1092
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   Thomas D, 2003, EYE, V17, P541, DOI 10.1038/sj.eye.6700438
   Ting F. S. M., 2005, Hong Kong Medical Journal, V11, P496
   Trese MT, 2000, OPHTHALMOLOGY, V107, P1607, DOI 10.1016/S0161-6420(00)00210-4
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   VANNEWKIRK MR, 1994, AM J OPHTHALMOL, V117, P13
   VERSTRAETEN TC, 1993, ARCH OPHTHALMOL-CHIC, V111, P849, DOI 10.1001/archopht.1993.01090060139038
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Williams JG, 2001, OPHTHALMOLOGY, V108, P1902, DOI 10.1016/S0161-6420(01)00720-5
   Williamson TH, 2009, GRAEF ARCH CLIN EXP, V247, P1019, DOI 10.1007/s00417-009-1072-z
   WILSON CA, 1994, ARCH OPHTHALMOL-CHIC, V112, P839, DOI 10.1001/archopht.1994.01090180139048
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 139
TC 55
Z9 57
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV-DEC
PY 2012
VL 57
IS 6
BP 498
EP 509
DI 10.1016/j.survophthal.2012.01.011
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 027XI
UT WOS:000310387000002
PM 23068973
DA 2022-11-30
ER

PT J
AU Hsu, MH
   Hsu, CA
   Lai, SC
   Yen, JC
AF Hsu, Min-Huei
   Hsu, Chia-An
   Lai, Shih-Chung
   Yen, Ju-Chuan
TI Gout as a Risk Factor for Age-Related Macular Degeneration in Taiwanese
   Adults-A Population-Based Study in Taiwan
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; gout; Taiwan National Health Insurance
   Research Database
ID INFLAMMASOME; ASSOCIATION; ACTIVATION; RECEPTORS
AB The relationship between gout and age-related macular degeneration (AMD) was suggested in previous literature but has yet to be accepted fully among physicians. This study aimed to explore the effect of gout on the development of age-related macular degeneration in Taiwan. A retrospective cohort study was conducted using Taiwan's National Health Insurance Database that includes a 2-million-persons dataset. The crude hazard ratio, Kaplan-Meier plot, and separate cox proportional hazard ratio were utilized to demonstrate the effect of gout on the development of age-related macular degeneration. The crude hazard ratio for gout patients developing AMD was 1.55 and the adjusted hazard ratio 1.20. In conclusion, gout is a risk factor for developing AMD, and achieving good disease management is therefore essential for preventing AMD from occurring.
C1 [Hsu, Min-Huei] Taipei Med Univ, Grad Inst Data Sci, Coll Management, Taipei 11042, Taiwan.
   [Hsu, Min-Huei] Taipei Med Univ, Shuang Ho Hosp, Dept Neurosurg, Taipei 23561, Taiwan.
   [Hsu, Chia-An] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 11217, Taiwan.
   [Lai, Shih-Chung] Taipei Med Univ, Shuang Ho Hosp, Dept Ophthalmol, Taipei 23561, Taiwan.
   [Yen, Ju-Chuan] Taipei Med Univ, Grad Inst Biomed Informat, Coll Med Sci & Technol, Taipei 11042, Taiwan.
   [Yen, Ju-Chuan] Taipei City Hosp, Ren Ai Branch, Dept Ophthalmol, Taipei 10341, Taiwan.
   [Yen, Ju-Chuan] Taipei City Hosp, Dept Educ & Res, Taipei 10341, Taiwan.
   [Yen, Ju-Chuan] Univ Taipei, Taipei 10048, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Veterans General Hospital; Taipei Medical University;
   Shuang Ho Hospital; Taipei Medical University; Taipei City Hospital;
   Taipei City Hospital; University of Taipei
RP Yen, JC (通讯作者)，Taipei Med Univ, Grad Inst Biomed Informat, Coll Med Sci & Technol, Taipei 11042, Taiwan.; Yen, JC (通讯作者)，Taipei City Hosp, Ren Ai Branch, Dept Ophthalmol, Taipei 10341, Taiwan.; Yen, JC (通讯作者)，Taipei City Hosp, Dept Educ & Res, Taipei 10341, Taiwan.; Yen, JC (通讯作者)，Univ Taipei, Taipei 10048, Taiwan.
EM m701061@gmail.com
OI Hsu, Chia-an/0000-0003-4221-7307
FU Taipei Medical University [NTUT-TMU-98-14]
FX We thank Taipei Medical University (NTUT-TMU-98-14) for their grant
   support.
CR Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Chen YH, 2011, ANN RHEUM DIS, V70, P1655, DOI 10.1136/ard.2010.145821
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Jiang Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0669-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Kuang TM, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-05638-5
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Pagidipati NJ, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009328
   Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238
   Shinozaki T, 2017, EMERG THEMES EPIDEMI, V14, DOI 10.1186/s12982-017-0060-8
   Shiozawa A, 2017, J RHEUMATOL, V44, P388, DOI 10.3899/jrheum.160452
   Singh JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199562
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Yeh CC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050790
   Yen JC, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14010107
NR 18
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2022
VL 19
IS 16
AR 10142
DI 10.3390/ijerph191610142
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 4B2YX
UT WOS:000845650800001
PM 36011777
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mao, JB
   Chen, N
   Zhang, S
   Fang, YY
   Zheng, ZC
   Wu, S
   Ye, X
   Chen, YJ
   Chen, YQ
   Shen, LJ
AF Mao, Jianbo
   Chen, Nuo
   Zhang, Shian
   Fang, Yuyan
   Zheng, Zicheng
   Wu, Sulan
   Ye, Xin
   Chen, Yijing
   Chen, Yiqi
   Shen, Lijun
TI Association between inflammatory cytokines in the aqueous humor and
   hyperreflective foci on optical coherence tomography in patients with
   neovascular age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE aqueous humor; cytokine; hyperreflective foci; neovascular age-related
   macular degeneration; polypoidal choroidal vasculopathy; spectral-domain
   optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR
AB PurposeTo investigate the associations between cytokine levels in the aqueous humor (AH) and hyperreflective foci (HF) on spectral-domain optical coherence tomography (SD-OCT) in neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). MethodsThe prospective study included 63 eyes with nAMD, 44 with PCV, and 43 with cataracts (Controls). AH samples were obtained before anti-vascular endothelial growth factor (VEGF) therapy or cataract surgery. Cytokines interleukin 6 (IL-6), IL-8, IL-10, interferon-inducible protein 10 (IP-10), monocyte chemotactic protein 1 (MCP-1), and VEGF were measured by multiplex bead assay. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and the number of HF were evaluated at baseline and 1 month after anti-VEGF treatment. ResultsNo significances difference in IL-6 and IL-8 levels were noted among the three groups (P = 0.370 and P = 0.067). VEGF, IP-10, and IL-10 levels were significantly higher in nAMD and PCV groups than in Controls (all P < 0.05). In nAMD, HF was positively correlated with VEGF (r(s) = 0.300, P = 0.025) and in eyes with HF group, VEGF and IL-10 were significantly higher than those without HF (P = 0.008 and P = 0.022). In PCV, no correlation was observed between HF and cytokines (all P > 0.05). After anti-VEGF treatment, patients with HF in nAMD and PCV were predisposed to worse visual outcomes (P = 0.022 and P = 0.015) and a significantly greater reduction in CMT (P = 0.001 and P = 0.057). And nAMD patients with HF were more sensitive to anti-VEGF treatment than those without HF (P = 0.029). ConclusionsIn the nAMD group, HF was positively correlated with VEGF. Patients in nAMD with HF had elevated levels of VEGF and IL-10 and responded favorably to anti-VEGF. HF might serve as an inflammatory biomarker and a predictive factor for therapeutic efficacy in patients with nAMD.
C1 [Mao, Jianbo; Zhang, Shian; Chen, Yiqi; Shen, Lijun] Zhejiang Prov Peoples Hosp, Ctr Rehabil Med, Dept Ophthalmol, Hangzhou, Peoples R China.
   [Mao, Jianbo; Chen, Nuo; Fang, Yuyan; Wu, Sulan; Ye, Xin; Chen, Yijing; Chen, Yiqi; Shen, Lijun] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
   [Zheng, Zicheng] Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China.
C3 Zhejiang Provincial People's Hospital; Wenzhou Medical University;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS
RP Shen, LJ (通讯作者)，Zhejiang Prov Peoples Hosp, Ctr Rehabil Med, Dept Ophthalmol, Hangzhou, Peoples R China.; Shen, LJ (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
EM slj@mail.eye.ac.cn
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Basurto L, 2019, EXP GERONTOL, V124, DOI 10.1016/j.exger.2019.05.013
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Borrelli E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091271
   Boulday G, 2006, J IMMUNOL, V176, P3098, DOI 10.4049/jimmunol.176.5.3098
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Hsia Y, 2020, GRAEF ARCH CLIN EXP, V258, P273, DOI 10.1007/s00417-019-04546-1
   Joo JH, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02152-6
   Kim JH, 2020, GRAEF ARCH CLIN EXP, V258, P1677, DOI 10.1007/s00417-020-04710-y
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Mao JB, 2022, ACTA OPHTHALMOL, V100, pE891, DOI 10.1111/aos.15008
   Minaker SA, 2021, ACTA OPHTHALMOL, V99, P134, DOI 10.1111/aos.14537
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Noma H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010058
   Parodi MB, 2018, INVEST OPHTH VIS SCI, V59, P3314, DOI 10.1167/iovs.18-24291
   Pilotto Elisabetta, 2022, PLoS One, V17, pe0272318, DOI 10.1371/journal.pone.0272318
   Romero-Vazquez S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070763
   Schreur V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206482
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Sitnilska V, 2021, GRAEF ARCH CLIN EXP, V259, P623, DOI 10.1007/s00417-020-04910-6
   Song S, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107641
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Udaondo P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111841
   Wu J, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6648191
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
NR 36
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 23
PY 2022
VL 9
AR 973025
DI 10.3389/fmed.2022.973025
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 5N3KI
UT WOS:000871690000001
PM 36213652
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Toto, L
   Mastropasqua, L
   Depollo, M
   Ravalico, G
AF Parodi, MB
   Toto, L
   Mastropasqua, L
   Depollo, M
   Ravalico, G
TI Prismatic correction in patients affected by age-related macular
   degeneration
SO CLINICAL REHABILITATION
LA English
DT Article
ID LOW-VISION AIDS; PREFERRED RETINAL LOCI; CENTRAL SCOTOMA; MACULOPATHY;
   PREVALENCE; FIXATION
AB Objective: To evaluate by means of a controlled clinical trial the effectiveness and the tolerance of prismatic correction in improving visual function in patients affected by advanced bilateral age-related macular degeneration.
   Setting: Department of Ophthalmology, Eye Clinic, University of Trieste.
   Subjects and interventions: Each patient underwent an ophthalmologic examination, complete with distance visual acuity measurement using the Standard Early Treatment Diabetic Retinopathy Study chart. Patients were then randomly assigned to the treatment or control group. The treatment group received spectacles lenses with a prismatic correction of low power (5-7 prismatic dioptres) in the better eye.
   Main measures: Visual acuity was measured at baseline and 1, 90, 180 and 360 days after prescription in both groups.
   Results: The treatment group consisted of 14 patients, while the control group was of 14 patients. The prismatic correction was well tolerated in 85.7% of cases. Visual acuity in the treatment group improved mostly at three-month follow-up, with a slight further improvement at the six- and 12-month follow-ups, showing a statistically significant difference in comparison with the control group. No visual acuity improvement was registered in the control group.
   Conclusion: Monolateral prismatic correction may be considered a viable means to improve visual function in patients affected by bilateral age-related macular degeneration at an advanced stage.
C1 Univ Trieste, Eye Clin, I-34127 Trieste, Italy.
   Univ Chieti, Sect Ophthalmol, Dept Med & Aging Sci, Chieti, Italy.
C3 University of Trieste; G d'Annunzio University of Chieti-Pescara
RP Parodi, MB (通讯作者)，Univ Trieste, Osped Maggiore, Eye Clin, I-34129 Trieste, Italy.
EM maubp@yahoo.it
RI Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Bertrand T, 1997, J FR OPHTALMOL, V20, P271
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Frennesson C, 1995, DOC OPHTHALMOL, V91, P9, DOI 10.1007/BF01204619
   Gok H, 2003, CLIN REHABIL, V17, P137, DOI 10.1191/0269215503cr605oa
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LONG WF, 1984, OPHTHALMOLOGY, V9, pA45
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Rinnert T, 1999, KLIN MONATSBL AUGENH, V215, P305, DOI 10.1055/s-2008-1034719
   ROMAYANANDA N, 1982, OPHTHALMOLOGY, V89, P937
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHUCHARD RA, 1995, AM J OCCUP THER, V49, P870, DOI 10.5014/ajot.49.9.870
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Verezen CA, 1996, OPTOMETRY VISION SCI, V73, P413, DOI 10.1097/00006324-199606000-00009
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 23
TC 11
Z9 11
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
EI 1477-0873
J9 CLIN REHABIL
JI Clin. Rehabil.
PD NOV
PY 2004
VL 18
IS 7
BP 828
EP 832
DI 10.1191/0269215504cr801oa
PG 5
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rehabilitation
GA 871VM
UT WOS:000225164700014
PM 15573840
DA 2022-11-30
ER

PT J
AU Yuan, A
   Kaiser, PK
AF Yuan, Alex
   Kaiser, Peter K.
TI Emerging Therapies for the Treatment of Neovascular Age Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE macular degeneration; vascular endothelial growth factor; angiogenesis
ID EPITHELIUM-DERIVED FACTOR; CHOROIDAL NEOVASCULARIZATION; INTEGRIN
   ALPHA-5-BETA-1; ALPHA(5)BETA(1) INTEGRIN; COMBRETASTATIN A-4; DEFICIENT
   MICE; UNITED-STATES; GROWTH-FACTOR; PDGF-B; ANGIOGENESIS
AB Numerous drugs that show promise in the treatment of neovascular age related macular degeneration are currently being evaluated in early clinical trials. Some of these drugs target the vascular endothelial growth factor pathway while others act on different targets along the angiogenesis cascade. The mechanism of action of these novel therapeutics and the results of early clinical trials will be discussed along with a review of angiogenesis.
C1 [Yuan, Alex; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkai-ser@aol.com
OI Yuan, Alex/0000-0003-0191-8035; Kaiser, Peter/0000-0001-5126-045X
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dark GG, 1997, CANCER RES, V57, P1829
   FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6
   GEORGE EL, 1993, DEVELOPMENT, V119, P1079
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kiselyov A, 2007, EXPERT OPIN INV DRUG, V16, P83, DOI 10.1517/13543784.16.1.83
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   WILLIAMS PB, 2010, ARVO
   Wilson SH, 2003, INVEST OPHTH VIS SCI, V44, P1704, DOI 10.1167/iovs.02-0773
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   YANG JT, 1993, DEVELOPMENT, V119, P1093
   Zahn G, 2010, INVEST OPHTH VIS SCI, V51, P1028, DOI 10.1167/iovs.09-3575
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 37
TC 13
Z9 13
U1 1
U2 5
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 149
EP 155
DI 10.3109/08820538.2011.570846
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200011
PM 21609228
DA 2022-11-30
ER

PT J
AU Moshfeghi, DM
   Blumenkranz, MS
AF Moshfeghi, Darius M.
   Blumenkranz, Mark S.
TI Role of genetic factors and inflammation in age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; candidate gene; complement factor H;
   LOC387715; Y402H; 1q32; 6p21; 10q26
ID COMPLEMENT FACTOR-H; CHLAMYDIA-PNEUMONIAE INFECTION; C-REACTIVE PROTEIN;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; APOLIPOPROTEIN-E; Y402H
   VARIANT; GEOGRAPHIC ATROPHY; STRONG ASSOCIATION; CIGARETTE-SMOKING; ABCR
   GENE
AB Complement factor H (CFH) has been implicated in the predisposition to advanced forms of age-related macular degeneration (AMD). The purpose of this review is to highlight recent discoveries implicating single nucleotide polymorphisms on 1q32, 6p21, and 11q26 in the risk for development of AMD. In addition, the central role of CFH in the complement cascade and its role in the inflammatory hypothesis for AMD are reviewed.
C1 Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 Stanford University
RP Moshfeghi, DM (通讯作者)，1225 Crane St,Suite 202, Menlo Pk, CA 94025 USA.
EM dariusm@stanford.edu
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOTOH N, 2006, HUM GENET       0519
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   JANSEN JH, 1995, VET REC, V137, P240, DOI 10.1136/vr.137.10.240
   Jansen JH, 1998, KIDNEY INT, V53, P331, DOI 10.1046/j.1523-1755.1998.00765.x
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Okamoto H, 2006, MOL VIS, V12, P156
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Watanabe S, 2001, CLIN TRANSPLANT, V15, P45, DOI 10.1034/j.1399-0012.2001.0150s5045.x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang K, 1999, GENOMICS, V60, P234, DOI 10.1006/geno.1999.5896
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 78
TC 45
Z9 48
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2007
VL 27
IS 3
BP 269
EP 275
DI 10.1097/IAE.0b013e31802e3e9b
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AT
UT WOS:000246985100001
PM 17460581
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kang, SW
   Kim, JR
   Kim, SJ
AF Kim, J. H.
   Kang, S. W.
   Kim, J. R.
   Kim, S. J.
TI Variability of subfoveal choroidal thickness measurements in patients
   with age-related macular degeneration and central serous
   chorioretinopathy
SO EYE
LA English
DT Article
DE intraobserver variability; interobserver variability; choroid;
   age-related macular degeneration; central serous chorioretinopathy
AB Purpose To evaluate the variability in subfoveal choroidal thickness measurements in patients with age-related macular degeneration (AMD) and central serous chorioretinopathy using enhanced depth imaging optical coherence tomography (EDI-OCT).
   Methods One hundred and sixty eyes of 160 patients who were diagnosed with early AMD (N = 40), exudative AMD (N = 40), polypoidal choroidal vasculopathy (PCV, N = 40), or central serous chorioretinopathy (CSC, N = 40) were included in this retrospective observational study. In addition, we included 40 normal eyes of 40 subjects. Subfoveal choroidal thickness was measured manually by two masked observers based on EDI-OCT images. The correlation of choroidal thickness with the absolute value of the difference in the choroidal thickness measurement was estimated for all 200 eyes. Intraobserver and interobserver coefficients of repeatability (CRs) were calculated.
   Results There was a significant positive correlation between subfoveal choroidal thickness and both intraobserver (P<0.001) and interobserver (P<0.001) difference in choroidal thickness measurements. The mean intraobserver CRs in nonexudative AMD, exudative AMD, PCV, CSC, and normal eyes were similar to 15-21, 23-29, 24-35, 32-38, and 19-25 mu m, respectively. The mean interobserver CRs were similar to 24-28, 30-36, 39-45, 46-57, and 26-35 mu m, respectively.
   Conclusions Relatively great measurement variability should be considered when investigating eyes with pathologic conditions related to a thick choroid, including PCV or CSC.
C1 [Kim, J. H.] Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Kims Eye Hosp,Dept Ophthalmol, Seoul, South Korea.
   [Kang, S. W.; Kim, J. R.; Kim, S. J.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
C3 Konyang University; Konyang University Hospital; Sungkyunkwan University
   (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
RI Kim, Jaeryung/AAB-6693-2022
OI Kim, Jaeryung/0000-0002-8003-5849
CR Bland JM, 1996, BRIT MED J, V313, P744
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bland JM, 2004, WHAT IS STANDARD ERR
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 14
TC 27
Z9 29
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2013
VL 27
IS 7
BP 809
EP 815
DI 10.1038/eye.2013.78
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 181WN
UT WOS:000321700800006
PM 23598679
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
AF Vojnikovic, Bozidar
TI Age-related macular degeneration is not macular process only -
   Peripheral retina is attacked too
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE macular degeneration; solar radiation; perimetric analysis
ID ULTRAVIOLET-RADIATION; LENS
AB On a small island of Rab, geographical latitude 44 degrees 40'N, with the highest solar radiation among Adriatic islands, 1371 patients were examined in 2003-2005 period, with the aim of estimating the frequency of the patients number with Age-related Macular Degeneration (AMD), and further if the peripheral retina is damaged similarly as the macular region. In the first group of agriculturists and fishermen (n=1300) we estimated the AMD, initial and middle stage of AMD, in 18% of population, but in urban population only by 2 patients. Perimetric analysis with computerized Kowa perimeter, estimated that the peripheral retina is affected similarly as the macular region. Author concludes that for this reason, the usual term of >> Age-related Macular Degeneration << should necessarily be named with the suffix >> Peripheral <<, or >> Age-related Retinopathy <<.
C1 Eye Polyclin Dr B Vojnikovic, Rijeka 51000, Croatia.
C3 University of Rijeka
RP Vojnikovic, B (通讯作者)，Eye Polyclin Dr B Vojnikovic, Autuna Barca 3B, Rijeka 51000, Croatia.
EM decv@decv.com
CR Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   FAJDIC CM, 2002, INT J CANCER, V101, P175
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HAM WT, 1983, INVEST OPHTHALMOL  S, V24, P70
   Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028
   HENDERSON ST, 1997, DAYLIGHT ITS SPECTRU
   JAMPOL LM, 1985, ARCH OPHTHALMOL-CHIC, V103, P28
   KANC RP, 1998, INT J CLIMAT, V18, P457
   KEATES RH, 1982, OPHTHALMIC SURG LAS, V13, P374
   KOHEN E, 1991, PHOTOBIOLOGY
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Lerman S., 1980, RADIANT ENERGY EYE, P73
   MARMOR M, 1982, AGING HUMAN VISUAL F
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   MYRON Y, 1989, OCULAR PATHOLOGY
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   PENZAR B, 2001, DR FELETAR KOPRIVNIC
   SLINEY DH, 1983, J OCCUP ENVIRON MED, V25, P203, DOI 10.1097/00043764-198303000-00013
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   VALENZEO DP, 1991, NATO ASI SERIES, V216
   VOJNIKOVIC B, 2005, EINSTEINOV ZAKON ELE
   ZIGMAN S, 1983, DOC OPHTHALMOL, V55, P375, DOI 10.1007/BF00161292
NR 22
TC 3
Z9 4
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 3
EP 5
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800002
PM 17469740
DA 2022-11-30
ER

PT J
AU Madheswaran, G
   Nasim, P
   Ganeshrao, SB
   Raman, R
   Ve, RS
AF Madheswaran, Gopinath
   Nasim, Pinaz
   Ballae Ganeshrao, Shonraj
   Raman, Rajiv
   Ve, Ramesh S.
TI Role of microperimetry in evaluating disease progression in age-related
   macular degeneration: a scoping review
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Mesopic microperimetry;
   Microperimeter; Fundus controlled perimetry; Scotopic microperimetry;
   Scoping review
ID FUNDUS-CONTROLLED PERIMETRY; RETINAL THICKNESS; DRUSEN; EYES
AB Purpose Recent research has found variable evidence on the role of mesopic and dark-adapted scotopic microperimetry assessment in age-related macular degeneration. This scoping review summarises how mesopic and scotopic microperimetry can be used to assess disease progression in age-related macular degeneration and identifies gaps in the literature. Methods A population, concept, and context approach was used to develop the search strategy. Ovid MEDLINE, EMBASE, Cochrane Library, PubMed, CINAHL Plus, Web of Science, and SCOPUS databases were used to conduct the literature search. The key search terms used in the databases were age-related macular degeneration and microperimetry. Results Twelve studies were eligible and included in the review. All the studies (n = 12) were conducted in European countries [Germany (9), Italy (2), and the United Kingdom (1)]. The mesopic and scotopic sensitivities were measured using the Nidek scotopic microperimeter (MP1-S) (n = 6), scotopic Macular Integrity Assessment device (S-MAIA) (n = 5), and both MP1-s and S MAIA (n = 1). 83.3% (n = 10) studied (cross-sectional design) on mesopic, scotopic microperimetry and found reduced rod (scotopic) photoreceptors sensitivities compared to cone (mesopic) photoreceptors sensitivities in patients with small and reticular pseudodrusen despite having good visual acuity. Only 16.7% (n = 2) of studies followed participants with reticular drusen/large drusen for three years (longitudinal design) and found reduced scotopic over mesopic sensitivity at baseline and localized mesopic with profound scotopic sensitivity loss during follow-ups. Conclusion Scotopic sensitivity is a better functional indicator than mesopic sensitivity to understand early and intermediate age-related macular degeneration progression. The evidence from longitudinal studies is debatable due to the limited stimuli range of existing microperimeters, smaller sample size, and lost follow-ups.
C1 [Madheswaran, Gopinath; Nasim, Pinaz; Ballae Ganeshrao, Shonraj; Ve, Ramesh S.] Manipal Acad Higher Educ, Manipal Coll Hlth Profess, Dept Optometry, Manipal, Karnataka, India.
   [Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
C3 Manipal Academy of Higher Education (MAHE)
RP Ve, RS (通讯作者)，Manipal Acad Higher Educ, Manipal Coll Hlth Profess, Dept Optometry, Manipal, Karnataka, India.
EM ramesh.sve@manipal.edu
RI Madheswaran, Gopinath/Q-2318-2017
OI Madheswaran, Gopinath/0000-0003-4670-329X; S Ve,
   Ramesh/0000-0002-7592-9151; Ballae Ganeshrao,
   Shonraj/0000-0002-4323-6035
FU Manipal Academy of Higher Education, Manipal
FX Open access funding provided by Manipal Academy of Higher Education,
   Manipal. No funding was received to conduct the study.
CR Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]
   Bowl W, 2013, INVEST OPHTH VIS SCI, V54, P4666, DOI 10.1167/iovs.12-11241
   Cassels, 2017, QUALITY OF LIFE CLIN
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Grewal MK, 2021, VISUAL FUNCTION AGIN
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Molina-Martin A, 2018, SEMIN OPHTHALMOL, V33, P620, DOI 10.1080/08820538.2017.1375125
   Montesano Giovanni, 2020, Transl Vis Sci Technol, V9, P43, DOI 10.1167/tvst.9.13.43
   Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-017-0468-4
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   NEBBIOSO M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/671529
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peters MDJ, 2021, JBI EVID IMPLEMENT, V19, P3, DOI 10.1097/XEB.0000000000000277
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SVe, 2021, OSF REGISTRIES SCOTO
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2022
VL 42
IS 6
BP 1975
EP 1986
DI 10.1007/s10792-021-02170-9
EA JAN 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1S4GR
UT WOS:000740160900002
PM 34994874
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Amato, A
   Mularoni, C
   Saladino, A
   Aragona, E
   Pina, A
   Calcagno, F
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Amato, Alessia
   Mularoni, Cecilia
   Saladino, Andrea
   Aragona, Emanuela
   Pina, Adelaide
   Calcagno, Francesca
   Bandello, Francesco
   Battaglia Parodi, Maurizio
TI Optical Coherence Tomography Angiography Parameters Correlated to the
   Growth of Macular Neovascularization in Age-Related Macular Degeneration
SO FRONTIERS IN PHYSICS
LA English
DT Article
DE macular neovascularization; age-related macula degeneration; OCTA; MNV
   growth; reflectivity
AB Background: To investigate optical coherence tomography angiography (OCTA) quantitative parameters associated with macular neovascularization (MNV) size modifications in age-related macular degeneration.Methods: Study design was prospective, with 1-year of follow-up. All the included MNV eyes were treated by anti-VEGF intravitreal injections. Quantitative OCTA parameters, including MNV vessel tortuosity (VT) and MNV reflectivity, were calculated. Post-hoc analyses assessed the correlation between quantitative OCTA metrics and MNV size modifications.Results: A total of 28 MNV eyes of 28 patients were included. Baseline LogMAR BCVA was 0.36 +/- 0.21 LogMAR, improved to 0.28 +/- 0.22 Log-MAR after 1-year (p < 0.01), with a mean number of 8 +/- 3 anti-VEGF injections. Eyes characterized by high MNV VT values group showed worse outcome and higher increases of MNV size. A mean MNV reflectivity value of 101 was associated with a high probability of changes in MNV size. MNV growth was also influenced by the type of MNV, with type 2 and mixed type lesions showing increases in MNV size, unlike type 1 MNV. These factors showed a cumulative effect in determining MNV size modifications. In most of the cases, we observed MNV size increases. Conversely, MNV lesions characterized by low MNV VT values may experience size reductions over the follow-up (34% of cases). The number of intravitreal injections had no significant influence on MNV size changes.Conclusions: Quantitative OCTA allowed to discriminate highly perfused MNV lesions, providing a basis to predict MNV size modifications and the direction of MNV expansion.
C1 [Arrigo, Alessandro; Amato, Alessia; Mularoni, Cecilia; Saladino, Andrea; Aragona, Emanuela; Pina, Adelaide; Calcagno, Francesca; Bandello, Francesco; Battaglia Parodi, Maurizio] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
EM alessandro.arrigo@hotmail.com
CR Arrigo A., 2020, RETINA-J RET VIT DIS, V41, P1463, DOI [10.1097/iae.0000000000003065, DOI 10.1097/IAE.0000000000003065]
   Arrigo A, 2022, OPHTHALMOL THER, V11, P377, DOI 10.1007/s40123-021-00443-1
   Arrigo A, 2021, FRONT PHYS-LAUSANNE, V9, DOI 10.3389/fphy.2021.694035
   Arrigo A, 2021, EYE, V35, P3266, DOI 10.1038/s41433-021-01396-2
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Arrigo A, 2018, AM J OPHTHALMOL, V195, P233, DOI 10.1016/j.ajo.2018.08.001
   Calzetti G, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.9
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Nelis P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26475-5
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 13
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-424X
J9 FRONT PHYS-LAUSANNE
JI Front. Physics
PD MAY 27
PY 2022
VL 10
AR 758658
DI 10.3389/fphy.2022.758658
PG 7
WC Physics, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics
GA 2D1PK
UT WOS:000811327600001
OA gold
DA 2022-11-30
ER

PT J
AU Andonegui, J
   Aliseda, D
   Serrano, L
   Eguzkiza, A
   Arruti, N
   Arias, L
   Alcaine, A
AF Andonegui, Jose
   Aliseda, Daniel
   Serrano, Luis
   Eguzkiza, Aitor
   Arruti, Natalia
   Arias, Luis
   Alcaine, Araceli
TI EVALUATION OF A TELEMEDICINE MODEL TO FOLLOW UP PATIENTS WITH EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; follow-up; telemedicine
ID DIABETIC-RETINOPATHY; FUNDUS PHOTOGRAPHY; UNITED-STATES; RANIBIZUMAB;
   TRIAL; PREVALENCE; CARE
AB Purpose:To evaluate a telemedicine model to follow up patients with exudative age-related macular degeneration and compare the time spent using this model with the time spent conducting office examinations.Methods:Results of office and telemedicine evaluations were compared to determine whether patients with exudative age-related macular degeneration previously treated with intravitreal injections needed additional treatment. The office examinations included visual acuity measurement, fundus examination, and optical coherence tomography. The telemedicine evaluation included evaluation of retinography images, optical coherence tomography images, and visual acuity data obtained in the office. We also measured the time spent on telemedicine evaluations and compared it with the time spent on office examinations.Results:Twenty-one patients were included. A comparison of office and remote diagnostic decisions showed the same results in 181 cases. Among the 20 remaining patients and considering office diagnostic decisions as the gold standard, 17 (8%) patients had false-positive diagnoses and 3 (1%) had false-negative diagnoses. The sensitivity and specificity of the telemedicine evaluations were 96% and 85%, respectively. The average time spent on remote evaluations was 1 minute 21 seconds compared with 10 minutes spent on office examination (P < 0.001).Conclusion:The telemedicine model can be a useful alternative for following up patients with age-related macular degeneration.
C1 [Andonegui, Jose; Aliseda, Daniel; Arruti, Natalia; Alcaine, Araceli] Complejo Hosp Navarra, Dept Ophthalmol, Pamplona 31008, Spain.
   [Serrano, Luis; Eguzkiza, Aitor] Univ Publ Navarra, Dept Elect & Elect Engn, Pamplona, Spain.
   [Arias, Luis] Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona, Spain.
C3 Servicio Navarro de Salud - Osasunbidea; Universidad Publica de Navarra;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona
RP Andonegui, J (通讯作者)，Complejo Hosp Navarra, Dept Ophthalmol, Pamplona 31008, Spain.
EM jandonen@cfnavarra.es
RI Aliseda, Daniel/AAB-5107-2021; Serrano, Luis/E-4063-2016
OI Serrano, Luis/0000-0002-7072-4464
FU "Instituto de Salud Carlos III", National Health Care System, Spain [PI
   11/02797]
FX Supported in part by a grant of the "Instituto de Salud Carlos III" (PI
   11/02797), National Health Care System, Spain.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chiang MF, 2011, OPHTHALMOLOGY, V118, P1681, DOI 10.1016/j.ophtha.2011.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Stellingwerf C, 2001, DIABETES CARE, V24, P2086, DOI 10.2337/diacare.24.12.2086
NR 17
TC 13
Z9 14
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 279
EP 284
DI 10.1097/IAE.0000000000000729
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500007
PM 26383707
DA 2022-11-30
ER

PT J
AU Shen, JH
   He, JF
   Wang, F
AF Shen, Junhui
   He, Jianfeng
   Wang, Fang
TI Association Lipids with Age-related Macular Degeneration
SO DISCOVERY MEDICINE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHAIN FATTY-ACIDS; LOW-DENSITY LIPOPROTEINS;
   RISK-FACTORS; DIETARY-FAT; LONG-CHAIN; BRUCHS MEMBRANE;
   CARDIOVASCULAR-DISEASE; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS
AB In the past decades, much investigation has been done on the role of lipids in the development and progression of age-related macular degeneration (AMD). The lipids involved in those research studies had included PUFAs, phospholipids, sphingolipids, cholesterol, lipid protein, etc. There are a large number of clinical research studies on the association of PUFAs with the development and progression of AMD. The relationship between cholesterol level and AMD has been explored for decades and much data and analysis results have been obtained. As for phospholipids, sphingolipids, and lipid proteins, progress towards understanding their role in AMD has been achieved mainly at the laboratory level. The goal of this paper is to review the most recent published findings according to different lipid types and discuss the roles various lipids might play in AMD pathogenesis and their implications in future preventive measures and treatments.
C1 [Shen, Junhui; He, Jianfeng; Wang, Fang] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200072, Peoples R China.
C3 Tongji University
RP Wang, F (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200072, Peoples R China.
EM dreyemilwang_122@163.com
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Auslender N, 2007, INVEST OPHTH VIS SCI, V48, P5431, DOI 10.1167/iovs.07-0736
   Bennett LD, 2014, INVEST OPHTH VIS SCI, V55, P3150, DOI 10.1167/iovs.14-13995
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cezario SM, 2015, ARQ BRAS OFTALMOL, V78, P85, DOI 10.5935/0004-2749.20150023
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2001, BR J OPHTHALMOL, V95, P1638
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Fang IM, 2014, MOL NUTR FOOD RES, V58, P2053, DOI 10.1002/mnfr.201400196
   Fourgeux C, 2014, BIOCHEM BIOPH RES CO, V446, P775, DOI 10.1016/j.bbrc.2014.01.118
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   GARGINI M, 2009, ARVO ANN M
   German OL, 2006, INVEST OPHTH VIS SCI, V47, P1658, DOI 10.1167/iovs.05-1310
   GHIDONI R, 2009, ARVO ANN M
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Handa JT, 2015, T AM OPHTHALMOL SOC, V113, pT51
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu YJ, 2014, DISCOV MED, V18, P7
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Javadzadeh A, 2007, SAUDI MED J, V28, P221
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li C, 2014, BBA-MOL BASIS DIS, V1842, P1121, DOI 10.1016/j.bbadis.2014.04.009
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McMahon A, 2007, MOL VIS, V13, P258
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Miranda GE, 2011, INVEST OPHTH VIS SCI, V52, P6580, DOI 10.1167/iovs.10-7065
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pollreisz A, 2013, EXP EYE RES, V116, P177, DOI 10.1016/j.exer.2013.08.021
   Qiao YB, 2012, INVEST OPHTH VIS SCI, V53, P8200, DOI 10.1167/iovs.12-10965
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Ramchani-Ben Othman K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128395
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   ROTSTEIN N, 2009, ARVO ANN M
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Simon MV, 2016, J NEUROCHEM, V136, P931, DOI 10.1111/jnc.13487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107
   Suh M, 2000, PEDIATR RES, V48, P524, DOI 10.1203/00006450-200010000-00017
   Suh M, 2009, INVEST OPHTH VIS SCI, V50, P4394, DOI 10.1167/iovs.08-2565
   Suzuki M, 2007, MOL VIS, V13, P772
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Tuson M, 2004, AM J HUM GENET, V74, P128, DOI 10.1086/381055
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V424, P704, DOI 10.1016/j.bbrc.2012.07.014
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Xiao QH, 2009, J PHYSIOL-LONDON, V587, P4379, DOI 10.1113/jphysiol.2009.176800
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yating Q, 2014, CURR EYE RES, V40, P1
   Yin LL, 2011, CURR EYE RES, V36, P379, DOI 10.3109/02713683.2010.537427
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 139
TC 9
Z9 10
U1 0
U2 9
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD SEP
PY 2016
VL 22
IS 120
BP 129
EP 145
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EE3YE
UT WOS:000389537500005
PM 27755968
DA 2022-11-30
ER

PT J
AU Li, M
   Wen, F
   Zuo, CG
   Zhang, XZ
   Chen, H
   Huang, SZ
   Luo, GW
AF Li, Meng
   Wen, Feng
   Zuo, Chengguo
   Zhang, Xiongze
   Chen, Hui
   Huang, Shizhou
   Luo, Guangwei
TI SERPING1 polymorphisms in polypoidal choroidal vasculopathy
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPONENT 2 C2; FACTOR-B BF; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; GENE POLYMORPHISMS; COMMON
   VARIATION; ASSOCIATION; VARIANT; RISK
AB Purpose: To investigate whether common genetic variants in the complement component 1 inhibitor gene (serpin peptidase inhibitor, clade G, member 1, SERPING1) are associated with polypoidal choroidal vasculopathy (PCV) in a Chinese Han population.
   Methods: DNA samples were obtained from 118 PCV patients and 115 healthy subjects. Data derived from the HapMap project were used to select tag single nucleotide polymorphisms (SNPs) across the extended SERPING1 region. A previously reported age-related macular degeneration-related risk factor (rs2511989) was forcibly included. Genotyping of each tag SNP was performed by PCR restriction fragment length polymorphism and direct DNA sequencing techniques.
   Results: Four SNPs for SERPING1, rs2509897, rs1005510, rs11603020, and rs2511989, were chosen as tag SNPs. None of these tag SNPs were associated with PCV, according to the single-SNP association test (p= 0.41-0.83). Evaluation of common haplotypes across SERPING1 did not reveal any association with PCV (p= 0.49-0.82).
   Conclusions: We found no evidence to support the role of any common SERPING1 variants, including the rs2511989 variant, in the susceptibility to PCV in a Chinese Han population.
C1 [Li, Meng; Wen, Feng; Zuo, Chengguo; Zhang, Xiongze; Chen, Hui; Huang, Shizhou; Luo, Guangwei] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Basic Research Program of China [2007CB512206]
FX The authors thank all the patients and family members for their
   participation. This study was supported by the National Basic Research
   Program of China (grant number 2007CB512206). The authors have no
   financial or conflicting interests to disclose.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chen LJ, 2006, MOL VIS, V12, P1536
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen AR, 2005, J NEUROIMMUNOL, V166, P197, DOI 10.1016/j.jneuroim.2005.06.002
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Morgan B P, 2000, Methods Mol Biol, V150, P1
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Park KH, 2009, MOL VIS, V15, P200
   Pearce CL, 2008, HUM MOL GENET, V17, P2456, DOI 10.1093/hmg/ddn145
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang QJ, 1996, JPN J OPHTHALMOL, V40, P79
NR 45
TC 17
Z9 19
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 16
PY 2010
VL 16
IS 29-30
BP 231
EP 239
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 570ZJ
UT WOS:000275717100001
PM 20161815
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Bressler, N
   Doan, QV
   Dolan, C
   Ferreira, A
   Osborne, A
   Rochtchina, E
   Danese, M
   Colman, S
   Wong, TY
AF Mitchell, Paul
   Bressler, Neil
   Doan, Quan V.
   Dolan, Chantal
   Ferreira, Alberto
   Osborne, Aaron
   Rochtchina, Elena
   Danese, Mark
   Colman, Shoshana
   Wong, Tien Y.
TI Estimated Cases of Blindness and Visual Impairment from Neovascular
   Age-Related Macular Degeneration Avoided in Australia by Ranibizumab
   Treatment
SO PLOS ONE
LA English
DT Article
ID BLUE MOUNTAINS EYE; OLDER-ADULTS; RESOURCE UTILIZATION; INJURIOUS FALLS;
   LEGAL BLINDNESS; PUBLIC-HEALTH; BURDEN; MACULOPATHY; LIMITATIONS;
   POPULATION
AB Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the number of individuals in Australia who would have been likely to avoid legal blindness or visual impairment due to neovascular age-related macular degeneration over a 2-year period as a result of intravitreal ranibizumab injections. The modelling approach used existing data for the incidence of neovascular age-related macular degeneration in Australia and outcomes from ranibizumab trials. Blindness and visual impairment were defined as visual acuity in the better-seeing eye of worse than 6/60 or 6/12, respectively. In 2010, 14 634 individuals in Australia were estimated to develop neovascular age-related macular degeneration who would be eligible for ranibizumab therapy. Without treatment, 2246 individuals would become legally blind over 2 years. Monthly 0.5 mg intravitreal ranibizumab would reduce incident blindness by 72% (95% simulation interval, 70-74%). Ranibizumab given as needed would reduce incident blindness by 68% (64-71%). Without treatment, 4846 individuals would become visually impaired over 2 years; this proportion would be reduced by 37% (34-39%) with monthly intravitreal ranibizumab, and by 28% (23-33%) with ranibizumab given as needed. These data suggest that intravitreal injections of ranibizumab, given either monthly or as needed, can substantially lower the number of cases of blindness and visual impairment over 2 years after the diagnosis of neovascular age-related macular degeneration.
C1 [Mitchell, Paul; Rochtchina, Elena] Univ Sydney, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   [Mitchell, Paul; Rochtchina, Elena] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Bressler, Neil] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Doan, Quan V.; Danese, Mark] Outcomes Insights Inc, Westlake Village, CA USA.
   [Dolan, Chantal] CMD Consulting Inc, Sandy, UT USA.
   [Ferreira, Alberto; Osborne, Aaron] Novartis, Basel, Switzerland.
   [Colman, Shoshana] Genentech Inc, San Francisco, CA 94080 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Parkville, Vic 3052, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Johns Hopkins University; Johns Hopkins Medicine;
   Roche Holding; Genentech; National University of Singapore; Singapore
   National Eye Center; Centre for Eye Research Australia; University of
   Melbourne
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Westmead, NSW 2145, Australia.
EM paul.mitchell@sydney.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014
OI Wong, Tien Yin/0000-0002-8448-1264; 
FU Novartis AG; Genentech, Inc.
FX This study was funded by Novartis AG and Genentech, Inc. Novartis AG and
   Genentech, Inc. participated in the design and conduct of the study, in
   the distribution of the raw data to Outcomes Insights, in the analysis
   and interpretation of the data and in the preparation of the manuscript.
   Novartis AG and Genentech, Inc. reviewed the manuscript before
   submission. Third-party medical writing assistance, but not editorial
   content sufficient to meet International Committee of Medical Journal
   Editors (ICMJE) authorship criteria, was funded by Novartis AG.
CR Abedi F, 2014, RETINA
   Australian Bureau of Statistics, 2010, 33020 AUSTR BUR STAT
   Australian Bureau of Statistics, 2010, 32010 AUSTR BUR STAT
   Australian Institute of Health and Welfare, 2005, BULLETIN, V27
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Macular Degeneration Foundation, 2011, EYES FUT
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
NR 30
TC 41
Z9 40
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 30
PY 2014
VL 9
IS 6
AR e101072
DI 10.1371/journal.pone.0101072
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK5ZO
UT WOS:000338506400072
PM 24979237
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Axer-Siegel, R
   Bor, E
   Bourla, DH
   Weinberger, D
   Mimouni, K
AF Axer-Siegel, Ruth
   Bor, Elite
   Bourla, Dan H.
   Weinberger, Dov
   Mimouni, Karin
TI INTRAVITREAL BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION WITH GOOD VISUAL ACUITY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; avastin; central macular thickness;
   intravitreal bevacizumab; optical coherent tomography; visual acuity
ID CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; AVASTIN; INJECTION; REGIMEN;
   EYES; AMD; CYTOKINES; THERAPY; ANCHOR
AB Purpose: To investigate the effect of intravitreal bevacizumab on the visual and anatomic outcome of patients with exudative age-related macular degeneration presenting with good visual acuity (VA).
   Methods: A file review was performed for all consecutive patients with newly diagnosed exudative age-related macular degeneration and initial VA of >= 20/40 treated in 2005 to 2010 and followed for at least 6 months. Treatment consisted of 3 loading doses of intravitreal bevacizumab every 6 weeks and was repeated when fluid or hemorrhage was present.
   Results: The cohort included 130 patients (150 eyes). Mean follow-up was 20.2 +/- 13.2 months, and mean number of injections was 11.3 +/- 6.2. At the last examination, VA was stable or improved in 106 eyes (70.7%); 11 eyes (7.3%) lost >= 3 lines. Mean logarithm of the minimum angle of resolution VA measured 0.22 +/- 0.1 (0-0.3) at presentation and 0.22 +/- 0.2 (0-1.3) at the last visit. Corresponding values for central macular thickness were 267 +/- 75 mu m (137-562) and 226 +/- 75 mu m (75-568) (P = 0.14). The most frequent complication (18 eyes, 12%) was corneal epithelial defects.
   Conclusion: Prompt intravitreal bevacizumab treatment for newly diagnosed exudative age-related macular degeneration in patients with good initial best-corrected visual acuity is associated with sustained or improved vision and a good safety profile. Attempts should be made to expedite the access of these patients to treatment, regardless of initial VA. RETINA 32:1811-1820, 2012
C1 [Axer-Siegel, Ruth; Bor, Elite; Bourla, Dan H.; Weinberger, Dov; Mimouni, Karin] Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   [Axer-Siegel, Ruth; Bor, Elite; Weinberger, Dov; Mimouni, Karin] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Axer-Siegel, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus,39 Jabotinski St, IL-49100 Petah Tiqwa, Israel.
EM seegs@netvision.co.il
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chopovska Y, 2011, OPHTHALMOLOGICA, V225, P27, DOI 10.1159/000316693
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Day S, 2010, AM J OPHTHALMOL, V54, P565
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P467, DOI 10.1089/jop.2011.0038
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Wolf- Schnurrbusch UE, 2011, INVEST OPHTH VIS SCI, V95, P1552
NR 42
TC 7
Z9 7
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1811
EP 1820
DI 10.1097/IAE.0b013e31825db771
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800016
PM 22825407
DA 2022-11-30
ER

PT J
AU Skrbek, M
AF Skrbek, Matej
TI Binocular Refraction in Patients with Age-Related Macular Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE binocular vision; macular degeneration; vision disparity; visual acuity
AB We've been finding possible association of central vision damage with binocular vision disorders in our clients suffering from age-related macular degeneration (ARMD), but whose visual acuity still allowed us to examine their binocular vision. Our findings show that there is a significant number of patients with heterophoria in horizontal, as well as vertical direction. The clients rate the vision with prismatic correction as more comfortable, clearer and long-term tolerable. Getting used to prismatic correction was spontaneous and non-problematic. Based on these results we expect to find possibly the most effective rehabilitation of vision in patients suffering from ARMD.
C1 [Skrbek, Matej] Masaryk Univ, Dept Optometry & Orthopt, Sch Med, Brno, Czech Republic.
C3 Masaryk University Brno
RP Skrbek, M (通讯作者)，Dept Optometry & Orthopt, 1 Maje 78, Jablonec Nad Nisou 46604, Czech Republic.
EM matejskrbek@seznam.cz
CR Quillen DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1725
   RUTRLE M., 2000, BINOKULARNI KOREKCE
   Tarita-Nistor L, 2006, CAN J OPHTHALMOL, V41, P327, DOI 10.1139/I06-029
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 5
TC 1
Z9 1
U1 0
U2 6
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2013
VL 37
SU 1
BP 153
EP 156
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 137SD
UT WOS:000318456800029
PM 23837236
DA 2022-11-30
ER

PT J
AU Ding, XY
   Patel, M
   Chan, CC
AF Ding, Xiaoyan
   Patel, Mrinali
   Chan, Chi-Chao
TI Molecular pathology of age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Inflammation; Single nucleotide
   polymorphism; Genetics Retinal pigment epithelium; Retinal
   photoreceptors; Drusen; Vascular endothelial growth factor; Bruch's
   membrane; Molecular pathology
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-E GENE;
   CHOROIDAL NEOVASCULAR MEMBRANES; HTRA1 PROMOTER POLYMORPHISM;
   MITOCHONDRIAL-DNA DAMAGE; GROWTH-FACTOR-BETA; DIETARY-FAT; ANGIOMATOUS
   PROLIFERATION; STARGARDT-DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the world. Although the etiology and pathogenesis of AMD remain largely unclear, a complex interaction of genetic and environmental factors is thought to exist. AMD pathology is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium, and Bruch's membrane, as well as, in some cases, alterations in choroidal capillaries. Recent research on the genetic and molecular underpinnings of AMD brings to light several basic molecular pathways and pathophysiological processes that might mediate AMD risk, progression, and/or response to therapy. This review summarizes, in detail, the molecular pathological findings in both humans and animal models, including genetic variations in CFH, CX3CR1, and ARMS2/HtrA1, as well as the role of numerous molecules implicated in inflammation, apoptosis, cholesterol trafficking, angiogenesis, and oxidative stress. Published by Elsevier Ltd.
C1 [Ding, Xiaoyan; Patel, Mrinali; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, Bethesda, MD 20892 USA.
   [Ding, Xiaoyan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Patel, Mrinali] Howard Hughes Med Inst, Chevy Chase, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Sun Yat Sen University; Howard Hughes Medical Institute
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
FU NEI Intramural Research Program; NATIONAL EYE INSTITUTE [ZIAEY000222,
   ZICEY000461, ZIAEY000418] Funding Source: NIH RePORTER
FX We would like to thank Dr. Robert B. Nussenblatt for his critical
   review. The support for this study was provided by the NEI Intramural
   Research Program.
CR Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   BOJANOWSKI CM, 2005, T AM OPHTHAL SOC, V103, P44
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   BRANTLEY MA, 2008, EYE             0222
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 1998, BIOCHEM BIOPH RES CO, V253, P728, DOI 10.1006/bbrc.1998.9849
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky K, 2004, ARCH OPHTHALMOL-CHIC, V122, P650, DOI 10.1001/archopht.122.4.650
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DEJONG PT, 2007, OPHTHALMOL VIS SCI, V48, pE2119
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   ENNIS S, 2008, LANCET          1006
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FAGERNESS JA, 2008, EUR J HUM GENET 0806
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1996, OPHTHALMIC PATHOLOGY, V2, P676
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Hutchison J, 1875, R LOND OPHTHALMOL HO, V8, P231
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kaiser J, 2008, SCIENCE, V321, P1146, DOI 10.1126/science.321.5893.1146b
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Khabar KSA, 2005, J INTERF CYTOK RES, V25, P1, DOI 10.1089/jir.2005.25.1
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Kovacs Katalin A, 2007, Ideggyogy Sz, V60, P169
   Krasnianski A, 2008, J MOL NEUROSCI, V34, P45, DOI 10.1007/s12031-007-9001-2
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lehner T, 2008, IMMUNOLOGY, V123, P40, DOI 10.1111/j.1365-2567.2007.02780.x
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Misch EA, 2008, CLIN SCI, V114, P347, DOI 10.1042/CS20070214
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rime M, 2004, MOL CANCER THER, V3, P955
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   SHEN D, 2008, BR J OPHTHALMOL 1107
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith C, 2005, NATURE, V435, P991, DOI 10.1038/435991a
   SMITH SR, 2007, INVEST OPHTHALMOL VI
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tsoumakidou M, 2008, AM J RESP CRIT CARE, V177, P1180, DOI 10.1164/rccm.200711-1727PP
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tzourio C, 2008, NEUROLOGY, V70, P1322, DOI 10.1212/01.wnl.0000308819.43401.87
   Wahl SM, 2007, CURR OPIN IMMUNOL, V19, P55, DOI 10.1016/j.coi.2006.11.008
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Wylegala Edward, 2007, Klin Oczna, V109, P97
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 208
TC 426
Z9 446
U1 3
U2 138
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2009
VL 28
IS 1
BP 1
EP 18
DI 10.1016/j.preteyeres.2008.10.001
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RF
UT WOS:000264306200001
PM 19026761
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Krishnan, T
   Ravindran, RD
   Murthy, GVS
   Vashist, P
   Fitzpatrick, KE
   Thulasiraj, RD
   John, N
   Maraini, G
   Camparini, M
   Chakravarthy, U
   Fletcher, AE
AF Krishnan, Tiruvengada
   Ravindran, Ravilla D.
   Murthy, Gudlavalleti V. S.
   Vashist, Praveen
   Fitzpatrick, Kathryn E.
   Thulasiraj, R. Duraisami
   John, Neena
   Maraini, Giovanni
   Camparini, Monica
   Chakravarthy, Usha
   Fletcher, Astrid E.
TI Prevalence of Early and Late Age-Related Macular Degeneration in India:
   The INDEYE Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; RISK-FACTORS; JAPANESE POPULATION;
   RURAL-POPULATION; NATIONAL-HEALTH; UNITED-STATES; MACULOPATHY; EYE;
   ROTTERDAM
AB PURPOSE. To estimate the prevalence of early and late age-related macular degeneration (AMD) in India.
   METHODS. Of 7518 people aged 60 years and older identified from randomly sampled villages in North and South India, 5853 (78%) attended an eye examination including fundus photography. Fundus images were graded according to the Wisconsin Age-Related Maculopathy Grading System.
   RESULTS. Fundus images were ungradable in 1587 people, mainly because of cataract. People 80 years of age and older were less likely to attend the eye examination and more likely to have ungradable images. For ages 60 to 79 years, the percent prevalence (95% confidence interval [CI]) were late AMD 1.2 (0.8-1.5); and early AMD: grade 1 (soft distinct drusen or pigmentary irregularities), 39.3 (37.2-41.5); grade 2 (soft distinct drusen with pigmentary irregularities or soft indistinct or reticular drusen), 6.7 (5.8-7.6); and grade 3 (soft indistinct or reticular drusen with pigmentary irregularities), 0.2 (0.1-0.4). For ages 80 and older, the respective percent prevalence was: late AMD, 2.5 (0.4-4.7); and early AMD: grade 1, 43.1(35.7-50.6); grade 2, 8.1 (4.3-12.0); and grade 3, 0.5 (0-1.5).
   CONCLUSIONS. The prevalence of early AMD (grades 1 and 2) is similar to that observed in Western populations, but grade 3 appears to be lower. The prevalence of late AMD is comparable to that in Western populations in the age group 60 to 79 years. It is likely that the prevalence in the 80 and older age group is underestimated. (Invest Ophthalmol Vis Sci. 2010; 51: 701-707) DOI: 10.1167/iovs.09-4114
C1 [Fitzpatrick, Kathryn E.; Fletcher, Astrid E.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Krishnan, Tiruvengada; Ravindran, Ravilla D.] Aravind Eye Hosp Pondicherry, Pondicherry, India.
   [Murthy, Gudlavalleti V. S.; Vashist, Praveen; John, Neena] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
   [Thulasiraj, R. Duraisami] Lions Aravind Inst Community Ophthalmol, Madurai, Tamil Nadu, India.
   [Maraini, Giovanni; Camparini, Monica] Univ Parma, Sez Oftalmol, Dipartimento Sci Otorinoodontooftalmol & Cerv Fac, I-43100 Parma, Italy.
   [Chakravarthy, Usha] Queens Univ Belfast, Belfast, Antrim, North Ireland.
C3 University of London; London School of Hygiene & Tropical Medicine; All
   India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; University of Parma; Queens
   University Belfast
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
FU Wellcome Trust UK [073300]
FX Supported by Wellcome Trust UK Grant 073300.
CR [Anonymous], 2004, LANCET, V363, P157
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, pe1
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 26
TC 44
Z9 44
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2010
VL 51
IS 2
BP 701
EP 707
DI 10.1167/iovs.09-4114
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 545AS
UT WOS:000273704700011
PM 19696177
OA Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Pepple, K
   Mruthyunjaya, P
AF Pepple, Kathryn
   Mruthyunjaya, Prithvi
TI Retinal Pigment Epithelial Detachments in Age-Related Macular
   Degeneration: Classification and Therapeutic Options
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE retinal pigment epithelial tear; serous; hemorrhagic; fibrovascular;
   drusenoid
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   INDOCYANINE GREEN ANGIOGRAPHY; INTRAVITREAL BEVACIZUMAB INJECTION;
   TISSUE-PLASMINOGEN ACTIVATOR; GUIDED PHOTODYNAMIC THERAPY; FUNDUS
   AUTOFLUORESCENCE; PROPHYLACTIC TREATMENT; SEROUS DETACHMENTS; VISUAL
   FUNCTION
AB Retinal pigment epithelial detachment (PED) is an important predictor of vision loss in patients with age-related macular degeneration (AMD). Here we review the historical PEDs subtypes, include recent insights into PED pathogenesis provided by modern imaging modalities, and summarize the current options for treatment.
C1 [Pepple, Kathryn; Mruthyunjaya, Prithvi] Duke Eye Ctr, Durham, NC 27710 USA.
C3 Duke University
RP Mruthyunjaya, P (通讯作者)，Duke Eye Ctr, Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM Mruth001@mc.duke.edu
RI Pepple, Kathryn/J-6229-2016; Pepple, Kathryn/E-8275-2018
OI mruthyunjaya, prithvi/0000-0003-1087-9736; Pepple,
   Kathryn/0000-0002-2844-811X
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chalam KV, 2011, INDIAN J OPHTHALMOL, V59, P47, DOI 10.4103/0301-4738.73712
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cho M, 2010, BRIT J OPHTHALMOL, V94, P597, DOI 10.1136/bjo.2008.149724
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Costa RA, 2003, GRAEF ARCH CLIN EXP, V241, P245, DOI 10.1007/s00417-003-0627-7
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gomez-Ulla F, 2001, ACTA OPHTHALMOL SCAN, V79, P39, DOI 10.1034/j.1600-0420.2001.079001039.x
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HO PC, 1984, ANN OPHTHALMOL, V16, P213
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   KOREEN L, 2010, RETINAL PHYS     OCT
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Krishnan R, 2010, CAN J OPHTHALMOL, V45, P83, DOI 10.3129/i09-187
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Lee Na Young, 2008, Korean J Ophthalmol, V22, P194, DOI 10.3341/kjo.2008.22.3.194
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sallet G, 1996, GRAEF ARCH CLIN EXP, V234, P25, DOI 10.1007/BF00186515
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   STEEL DH, 2010, BR J OPHTHALMOL  SEP
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   1991, ARCH OPHTHALMOLOGY, V109, P1220
   1982, BRIT J OPHTHALMOLOGY, V66, P1
NR 90
TC 30
Z9 38
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 198
EP 208
DI 10.3109/08820538.2011.570850
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200016
PM 21609233
DA 2022-11-30
ER

PT J
AU Rastoin, O
   Pages, G
   Dufies, M
AF Rastoin, Olivia
   Pages, Gilles
   Dufies, Maeva
TI Experimental Models in Neovascular Age Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE neovascular age related macular degeneration (vAMD); wet AMD; in vitro
   model of AMD; mice and zebrafish model of AMD
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; BRUCHS
   MEMBRANE; STEM-CELLS; HIGH-RISK; IN-VITRO; GENE; MICE; ACCUMULATION;
   PHENOTYPE
AB Neovascular age-related macular degeneration (vAMD), characterized by the neo-vascularization of the retro-foveolar choroid, leads to blindness within few years. This disease depends on angiogenesis mediated by the vascular endothelial growth factor A (VEGF) and to inflammation. The only available treatments consist of monthly intravitreal injections of antibodies directed against VEGF or VEGF/VEGFB/PlGF decoy receptors. Despite their relative efficacy, these drugs only delay progression to blindness and 30% of the patients are insensitive to these treatments. Hence, new therapeutic strategies are urgently needed. Experimental models of vAMD are essential to screen different innovative therapeutics. The currently used in vitro and in vivo models in ophthalmic translational research and their relevance are discussed in this review.
C1 [Rastoin, Olivia; Pages, Gilles] UCA, Ctr Antoine Lacassagne, Inst Res Canc & Aging Nice, CNRS,INSERM,UMR 7284,U1081, F-06000 Nice, France.
   [Pages, Gilles; Dufies, Maeva] Ctr Sci Monaco, Biomed Dept, MC-98000 Monaco, Monaco.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); CHU Nice; Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne
RP Dufies, M (通讯作者)，Ctr Sci Monaco, Biomed Dept, MC-98000 Monaco, Monaco.
EM olivia.rastoin@unice.fr; gilles.pages@unice.fr; maeva.dufies@gmail.com
OI Dufies, Maeva/0000-0003-1732-0388
FU Centre Scientifique de Monaco Research Program - Government of the
   Principality of Monaco
FX This study was conducted as part of the Centre Scientifique de Monaco
   Research Program, funded by the Government of the Principality of
   Monaco.
CR Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ali Z, 2019, ARTERIOSCL THROM VAS, V39, P1402, DOI 10.1161/ATVBAHA.118.312190
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Biehlmaier O, 2003, INVEST OPHTH VIS SCI, V44, P1287, DOI 10.1167/iovs.02-0363
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   De Cilla Stefano, 2020, Cell Physiol Biochem, V54, P161, DOI 10.33594/000000212
   Djigo AD, 2019, ACTA BIOMATER, V84, P305, DOI 10.1016/j.actbio.2018.11.033
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Gerri C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15492
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Hanovice NJ, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007939
   Huang H, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108061
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033
   Jeong HS, 2019, J CELL PHYSIOL, V234, P3837, DOI 10.1002/jcp.27156
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Leclaire MD, 2019, GRAEF ARCH CLIN EXP, V257, P931, DOI 10.1007/s00417-019-04253-x
   Lennikov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01903
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Link BA, 2015, ANNU REV VIS SCI, V1, P125, DOI 10.1146/annurev-vision-082114-035717
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Murphy AR, 2020, ACTA BIOMATER, V104, P1, DOI 10.1016/j.actbio.2020.01.013
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Saidi EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135211
   Samuel W, 2017, MOL VIS, V23, P60
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Rooijen E, 2010, DIS MODEL MECH, V3, P343, DOI 10.1242/dmm.004036
   Vascotto SG, 1997, BIOCHEM CELL BIOL, V75, P479, DOI 10.1139/bcb-75-5-479
   VEMUGANTI G, 2005, INDIAN J OPHTHALMOL, V53, P109, DOI DOI 10.4103/0301-4738.16174
   Viringipurampeer IA, 2014, CELL DEATH DIFFER, V21, P665, DOI 10.1038/cdd.2013.191
   Wei X, 2018, EXP EYE RES, V168, P2, DOI 10.1016/j.exer.2017.12.009
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 63
TC 11
Z9 11
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 13
AR 4627
DI 10.3390/ijms21134627
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MM5MY
UT WOS:000550201800001
PM 32610682
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Roberts, PK
   Schranz, M
   Motschi, A
   Desissaire, S
   Hacker, V
   Pircher, M
   Sacu, S
   Buehl, W
   Hitzenberger, CK
   Schmidt-Erfurth, UM
AF Roberts, Philipp K.
   Schranz, Markus
   Motschi, Alice
   Desissaire, Sylvia
   Hacker, Valentin
   Pircher, Michael
   Sacu, Stefan
   Buehl, Wolf
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula M.
TI Baseline predictors for subretinal fibrosis in neovascular age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; ANGIOGRAPHY
   FEATURES; IDENTIFICATION; QUANTIFICATION; OUTCOMES; EYES
AB To find baseline predictors for subretinal fibrosis (SF) in neovascular age-related macular degeneration (nAMD). Forty-five eyes of 45 participants with treatment-naive nAMD were consecutively enrolled and treated according to a standardized treat-and-extend protocol. Spectral-domain optical coherence tomography (OCT), color fundus photography and fluorescein angiography as well as novel imaging modalities polarization-sensitive OCT and OCT angiography (OCTA) were performed to detect SF after 1 year and find baseline predictors for SF development. Baseline OCTA scans were evaluated for quantitative features such as lesion area, vessel area, vessel junctions, vessel length, vessel endpoints and mean lacunarity. Additionally, the type of macular neovascularization, the presence of subretinal fluid, intraretinal fluid (IRF), subretinal hyperreflective material (SHRM), retinal hemorrhage as well as best-corrected visual acuity (BCVA) were evaluated. After 12 months 8 eyes (18%) developed SF. Eyes with SF had worse baseline BCVA (p=.001) and a higher prevalence of IRF (p=.014) and SHRM at baseline (p=.017). There was no significant difference in any of the evaluated quantitative OCTA parameters (p>.05) between eyes with and without SF. There were no quantitative baseline microvascular predictors for SF in our study. Low baseline BCVA, the presence of IRF and SHRM, however, are easily identifiable baseline parameters indicating increased risk.
C1 [Roberts, Philipp K.; Schranz, Markus; Hacker, Valentin; Sacu, Stefan; Buehl, Wolf; Schmidt-Erfurth, Ursula M.] Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Motschi, Alice; Desissaire, Sylvia; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
FU FWF (Austrian Science Fund) [KLI 749-B]
FX This work was supported by the FWF (Austrian Science Fund; Grant number
   KLI 749-B).
CR Babalola O, 2014, ARCH DERMATOL RES, V306, P1, DOI 10.1007/s00403-013-1417-7
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Boer JF, 2017, BIOMED OPT EXPRESS, V8, P1838, DOI 10.1364/BOE.8.001838
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Grafe MGO, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.13
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Motschi AR, 2021, BIOMED OPT EXPRESS, V12, P4380, DOI 10.1364/BOE.426650
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Pierce MC, 2004, J INVEST DERMATOL, V123, P458, DOI 10.1111/j.0022-202X.2004.23404.x
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Sugano Y, 2018, CLIN OPHTHALMOL, V12, P2267, DOI 10.2147/OPTH.S179634
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Takeuchi J, 2018, OPHTHALMOLOGICA, V240, P90, DOI 10.1159/000487611
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 36
TC 1
Z9 1
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 7
PY 2022
VL 12
IS 1
AR 88
DI 10.1038/s41598-021-03716-8
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YD5VU
UT WOS:000740510500047
PM 34996934
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Davidson, KC
   Guymer, RH
   Pera, MF
   Pebay, A
AF Davidson, Kathryn C.
   Guymer, Robyn H.
   Pera, Martin F.
   Pebay, Alice
TI Human Pluripotent Stem Cell Strategies for Age-Related Macular
   Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE age-related macular degeneration; induced pluripotent stem cells;
   embryonic stem cells; cell transplantation; disease modeling; drug
   screening
ID RETINAL-PIGMENT EPITHELIUM; VESICLE-LIKE STRUCTURES; VISUAL FUNCTION;
   BRUCHS MEMBRANE; ROYAL-COLLEGE; RPE; TRANSPLANTATION; DIFFERENTIATION;
   LINES; RESTORATION
AB Age-related macular degeneration (AMD) is a leading cause of severe vision loss in the Western world and is increasing exponentially as the population ages. Despite enormous worldwide efforts, the earliest pathogenic pathways involved in AMD are still not fully understood. It is essential to develop research tools for effective modeling of AMD pathogenesis and for subsequent drug discovery and cell or molecular therapies. This review will focus on the current progress in human pluripotent stem cells for understanding and treating AMD.
C1 [Davidson, Kathryn C.; Guymer, Robyn H.; Pebay, Alice] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Davidson, Kathryn C.; Guymer, Robyn H.; Pebay, Alice] Univ Melbourne, Dept Ophthalmol, East Melbourne, Australia.
   [Pera, Martin F.] Univ Melbourne, Dept Anat & Neurosci, Florey Inst Neurosci & Mental Hlth, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne; Florey Institute of Neuroscience & Mental Health;
   University of Melbourne
RP Pebay, A (通讯作者)，Ctr Eye Res Australia, Level 1 RVEEH,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM apebay@unimelb.edu.au
RI PERA, MARTIN/A-9812-2012
OI PERA, MARTIN/0000-0001-6239-0428; Guymer, Robyn/0000-0002-9441-4356;
   Pebay, Alice/0000-0002-7408-9453
FU National Health and Medical Research Council (NHMRC) of Australia
   Fellowship; NHMRC Career Development Award Fellowship; NHMRC Project
   Grant [1059369]; National Stem Cell Foundation of Australia Research
   Support grant; Ophthalmic Research Institute of Australia/RANZCO Eye
   Foundation Grant; Stem Cells Australia, a Special Research Initiative in
   Stem Cell Science - Australian Research Council; NHMRC Centre for
   Clinical Research Excellence Award [529923]
FX This work was supported by a National Health and Medical Research
   Council (NHMRC) of Australia Fellowship (RHG), an NHMRC Career
   Development Award Fellowship (AP), an NHMRC Project Grant (#1059369), a
   National Stem Cell Foundation of Australia Research Support grant, an
   Ophthalmic Research Institute of Australia/RANZCO Eye Foundation Grant,
   and Stem Cells Australia, a Special Research Initiative in Stem Cell
   Science funded by the Australian Research Council. The Centre for Eye
   Research Australia receives operational infrastructure support from the
   Victorian government and is supported by an NHMRC Centre for Clinical
   Research Excellence Award (#529923).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Bellin M, 2012, NAT REV MOL CELL BIO, V13, P713, DOI 10.1038/nrm3448
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Boland MJ, 2009, NATURE, V461, P91, DOI 10.1038/nature08310
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chin MH, 2010, CELL STEM CELL, V7, P263, DOI 10.1016/j.stem.2010.06.019
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hambright D, 2012, MOL VIS, V18, P920
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang L, 2009, CELL STEM CELL, V5, P135, DOI 10.1016/j.stem.2009.07.001
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lustremant C, 2013, CELL REPROGRAM, V15, P233, DOI 10.1089/cell.2012.0076
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Onnela N, 2012, MED BIOL ENG COMPUT, V50, P107, DOI 10.1007/s11517-011-0850-z
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Qin S, 2008, J INFLAMM RES, V1, P49
   Rajamohan D, 2013, BIOESSAYS, V35, P281, DOI 10.1002/bies.201200053
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Svendsen CN, 2013, HUM MOL GENET, V22, pR32, DOI 10.1093/hmg/ddt379
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Yagi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041572
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267
NR 63
TC 5
Z9 7
U1 2
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 887
EP 893
DI 10.1097/OPX.0000000000000282
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500012
PM 24859130
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Lai, TYY
   Chen, SJ
   Chong, V
   Lee, WK
   Htoon, H
   Ng, WY
   Ogura, Y
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Lai, Timothy Y. Y.
   Chen, Shih-Jen
   Chong, Victor
   Lee, Won Ki
   Htoon, Hla
   Ng, Wei Yan
   Ogura, Yuichiro
   Wong, Tien Yin
TI UNDERSTANDING INDOCYANINE GREEN ANGIOGRAPHY IN POLYPOIDAL CHOROIDAL
   VASCULOPATHY The Group Experience With Digital Fundus Photography and
   Confocal Scanning Laser Ophthalmoscopy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-vascular endothelial growth factor; treatment; photodynamic
   therapy; retreatment
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN;
   DIAGNOSIS; FEATURES; LESION
AB Purpose: To evaluate the angiographic features in using fundus camera-based versus confocal scanning laser ophthalmoscope (cSLO)-based indocyanine green angiography in differentiating polypoidal choroidal vasculopathy (PCV) from typical age-related macular degeneration.
   Methods: Sixty-five eyes of 44 patients with exudative maculopathy due to PCV or typical age-related macular degeneration were prospectively imaged with indocyanine green angiography using fundus camera and cSLO. Images were graded independently by retinal specialists. The main outcome measure was agreement between cSLO and fundus camera for the diagnosis of PCV. The rate of detection and area under the receiver operating characteristic curve of 7 preselected individual features were also compared.
   Results: The diagnosis of PCV was made with the cSLO system in 36 eyes (55.4%) and typical age-related macular degeneration in 29 eyes (44.6%), whereas the fundus camera diagnosed PCV in 39 eyes (60.0%) and typical age-related macular degeneration in 26 eyes (40.0%). There was moderate agreement between the two indocyanine green angiography systems (Kappa = 0.53). Using cSLO as the gold standard, fundus camera has a sensitivity and specificity of 83.3% and 69.0%, respectively. Typical nodular appearance was the most commonly detected feature (median, 88.9% for cSLO, 80.6% for fundus camera, P = 0.63) and had the highest area under the curve for the diagnosis of PCV in both systems (median, 80.2% for cSLO, 73.2% for fundus camera, P = 0.13). Confocal scanning laser ophthalmoscope was more sensitive in detecting branching vascular network and late hyperfluorescent plaque.
   Conclusion: Both systems detected >80% of PCV based on typical nodular appearance of polyps. However, the cSLO is superior in detecting additional features, particularly branching vascular network.
C1 [Cheung, Chui Ming Gemmy; Ng, Wei Yan; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Htoon, Hla; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Duke NUS Grad Med Sch, Eye Acad Clin Program, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Chong, Victor] Oxford Eye Hosp, Oxford, England.
   [Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Chinese University of Hong Kong;
   National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; Catholic University of Korea; Seoul St. Mary's Hospital;
   Nagoya City University
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Lai, Timothy Y Y/AAC-2120-2020; Wong, Tien Yin/AAC-9724-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; Wong, Tien
   Yin/0000-0002-8448-1264; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Singapore Eye Research Institute Health Research Endowment fund
   [R893/02/2012]
FX Supported by Singapore Eye Research Institute Health Research Endowment
   fund R893/02/2012.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 32
TC 27
Z9 27
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2014
VL 34
IS 12
BP 2397
EP 2406
DI 10.1097/IAE.0000000000000255
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU9KK
UT WOS:000345911300015
PM 25072645
DA 2022-11-30
ER

PT J
AU Warwick, A
   Lotery, A
AF Warwick, A.
   Lotery, A.
TI Genetics and genetic testing for age-related macular degeneration
SO EYE
LA English
DT Review
ID COMPLEMENT FACTOR-H; MEMBRANE ATTACK COMPLEX; GROWTH-FACTOR THERAPY;
   ANTI-VEGF TREATMENT; HIGH-RISK; COMMON VARIANTS; RARE VARIANTS;
   CHOROIDAL NEOVASCULARIZATION; TREATMENT RESPONSE; AREDS SUPPLEMENTS
AB Considerable advances have been made in our understanding of age-related macular degeneration (AMD) genetics over the past decade. The genetic associations discovered to date are estimated to account for approximately half of AMD heritability, and functional studies of these variants have revealed new insights into disease pathogenesis, leading to the development of potential novel therapies. There is furthermore growing interest in genetic testing for predicting an individual's risk of AMD and offering personalised preventive or therapeutic treatments. We review the progress made so far in AMD genetics and discuss the possible applications for genetic testing.
C1 [Warwick, A.] Moorfields Eye Hosp, London, England.
   [Lotery, A.] Univ Southampton, Fac Med, Clin Neurosci Res Grp Clin & Expt Sci, Southampton, Hants, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Southampton
RP Lotery, A (通讯作者)，Univ Southampton, Fac Med, Clin Neurosci Res Grp Clin & Expt Sci, Southampton, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305; Warwick,
   Alasdair/0000-0002-0800-2890
FU National Institute for Health Research [NF-SI-0515-10020] Funding
   Source: researchfish
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apellis, AP PHARM ANN APL 2 M
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Bomback AS, 2012, CLIN J AM SOC NEPHRO, V7, P748, DOI 10.2215/CJN.12901211
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky K.G., 2017, J VITR DIS, V1, P75, DOI [10.1177/2474126416680671, DOI 10.1177/2474126416680671]
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2014, OPHTHALMOLOGY, V121, P1663, DOI 10.1016/j.ophtha.2014.02.025
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   roche, ROCH PROV UPD 1 LAMP
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Stanton CM, 2012, ADV EXP MED BIOL, V723, P365, DOI 10.1007/978-1-4614-0631-0_47
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Stone EM, RECOMMENDATIONS AM A
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 103
TC 30
Z9 30
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2018
VL 32
IS 5
BP 849
EP 857
DI 10.1038/eye.2017.245
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF3FR
UT WOS:000431831500002
PM 29125146
OA Green Published, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Dandekar, SS
   Jenkins, SA
   Peto, T
   Scholl, HPN
   Sehmi, KS
   Fitzke, FW
   Bird, AC
   Webster, AR
AF Dandekar, SS
   Jenkins, SA
   Peto, T
   Scholl, HPN
   Sehmi, KS
   Fitzke, FW
   Bird, AC
   Webster, AR
TI Autofluorescence imaging of choroidal neovascularization due to
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; FUNDUS
   AUTOFLUORESCENCE; BRUCHS MEMBRANE; LIPOFUSCIN; MACULOPATHY; EXPRESSION;
   OPHTHALMOSCOPE; PATTERNS; LESIONS
AB Objective: To describe the autofluorescence (AF) characteristics of choroidal neovascularization (CNV) in patients with age-related macular degeneration.
   Methods: Autofluorescence images of 65 consecutive eyes with CNV at various stages of evolution were analyzed. Twenty images were of recent-onset CNV (group 1), 8 were of eyes 1 to 6 months after CNV diagnosis (group 2), and 37 were late-stage CNV (group 3). Antofluorescence images from groups 1 and 2 were compared with fundus fluorescein angiographic images.
   Results: Group 1 showed areas of hyperfluorescence on fundus fluorescein angiography corresponding to areas of normal AF in 16 of 20 cases, with adjacent areas of increased AF in 13 cases. The main areas of abnormal AF were larger than the main areas of abnormal fluorescence on fundus fluorescein angiography in 18 of the 20 cases. Groups 2 and 3 showed areas of decreased AF corresponding to areas of previous leakage on fundus fluorescein angiography (in group 2) or atrophy.
   Conclusions: Preserved AF in group 1 indicates viable retinal pigment epithelium initially, which has implications for visual prognosis. Decreased AF in groups 2 and 3 indicates loss of retinal pigment epithelium and photoreceptors. Autofluorescence imaging may increase our understanding of CNV in age-related macular degeneration.
C1 Moorfields Eye Hosp, London N6 5HL, England.
   Inst Ophthalmol, London, England.
   Univ Eye Hosp, Dept Pathophysiol Vis & Neuroophthalmol, Tubingen, Germany.
   Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; University of Bonn
RP Dandekar, SS (通讯作者)，Moorfields Eye Hosp, 10 Cromwell Ave,Highgate, London N6 5HL, England.
EM sam@hitbits.co.uk
RI Peto, Tunde/G-8812-2018; Fitzke, Fred/C-3535-2008
OI Peto, Tunde/0000-0001-6265-0381; 
CR BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BYNOE LA, 1994, OPHTHALMOLOGY, V101, P1112
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   YAMAGISHI K, 1988, Nippon Ganka Gakkai Zasshi, V92, P1629
NR 26
TC 41
Z9 45
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2005
VL 123
IS 11
BP 1507
EP 1513
DI 10.1001/archopht.123.11.1507
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981BM
UT WOS:000233062100003
PM 16286612
OA Bronze
DA 2022-11-30
ER

PT J
AU Grzybowski, A
   Wasinska-Borowiec, W
   Alio, JL
   Amat-Peral, P
   Tabernero, J
AF Grzybowski, Andrzej
   Wasinska-Borowiec, Weronika
   Alio, Jorge L.
   Amat-Peral, Pedro
   Tabernero, Juan
TI Intraocular lenses in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Implantable miniature telescope; IOL-VIP system; Lipshitz macular
   implant; Fresnel prism intraocular lens; iolAMD; Scharioth macula lens
ID IMPLANTABLE MINIATURE TELESCOPE; SAFETY OUTCOMES; VISUAL-ACUITY;
   MAGNIFICATION; EFFICACY; DISEASE; SYSTEM
AB The aim of this work is to review the lenses, assessing their advantages and disadvantages. We describe a total of seven types of intraocular lenses (IOLs) recommended for age-related macular degeneration (AMD).
   We used the PubMed web platform to search for implantable devices in various stages of AMD. We searched for both prospective and retrospective studies and also case reports.
   Clinical results in AMD patients have been described for a total of seven types of IOLs recommended for AMD: an implantable miniature telescope (IMT), IOL-VIP System, Lipshitz macular implant (LMI), sulcus-implanted Lipshitz macular implant, LMI-SI, Fresnel Prism Intraocular Lens, iolAMD and Scharioth Macula Lens.
   We conclude that to objectively ascertain the effectiveness and safety of these lenses, further independent clinical studies with longer follow-up data are necessary prior to the general use of these optical devices.
C1 [Grzybowski, Andrzej] Univ Warmia & Mazury, Chair Ophthalmol, Olsztyn, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Ul Szwajcarska 3, PL-61285 Poznan, Poland.
   [Wasinska-Borowiec, Weronika] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Alio, Jorge L.; Amat-Peral, Pedro] Vissum Corp, Alicante, Spain.
   [Alio, Jorge L.; Amat-Peral, Pedro] Univ Miguel Hernandez, Div Ophthalmol, Alicante, Spain.
   [Tabernero, Juan] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England.
C3 University of Warmia & Mazury; University of Warmia & Mazury; VISSUM;
   Universidad Miguel Hernandez de Elche; Anglia Ruskin University
RP Grzybowski, A (通讯作者)，Univ Warmia & Mazury, Chair Ophthalmol, Olsztyn, Poland.; Grzybowski, A (通讯作者)，Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.; Grzybowski, A (通讯作者)，Ul Szwajcarska 3, PL-61285 Poznan, Poland.
EM ae.grzybowski@gmail.com
RI Tabernero, Juan/D-1120-2014; Tabernero, Juan/AAO-9855-2020; Grzybowski,
   A/E-4486-2010
OI Tabernero, Juan/0000-0002-5149-8350; Grzybowski, A/0000-0002-3724-2391
FU Foundation for Ophthalmology Development, "Ophthalmology 21", Poznan,
   Poland
FX The study was supported by the Foundation for Ophthalmology Development,
   "Ophthalmology 21", Poznan, Poland. The sponsor had no role in the
   design or conduct of this research.
CR Agarwal A, 2011, OCULAR SURG NEWS U S
   Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Altpeter EK, 2015, OPHTHALMOLOGE, V112, P923, DOI 10.1007/s00347-015-0062-2
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   [Anonymous], 2015, AGE RELATED MACULAR
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Boyd K, 2016, WHAT IS AGE RELATED
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   D'averse G, 2015, CATARACT REFRACT SUR, P84
   Fortin MJ, 2015, J OPHTHALMIC PHOTOGR, V37, P70
   Hengerer FH, 2015, CATARACT REFRACT SUR, V2, P40
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Joondeph Brian C, 2014, Retin Cases Brief Rep, V8, P342, DOI 10.1097/ICB.0000000000000065
   Kaskaloglu M, 2001, J CATARACT REFR SURG, V27, P1751, DOI 10.1016/S0886-3350(01)00976-2
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Pappas A, 2015, RETINA TODAY, V10, P44
   Potgieter FJ, 2014, J CATARACT REFR SURG, V40, P1085, DOI 10.1016/j.jcrs.2013.10.049
   Primo SA, 2010, OPTOMETRY, V81, P86, DOI 10.1016/j.optm.2009.08.014
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Roach L, 2015, EYENET, P17
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Schlimgen M, 2015, RETINA TODAY, V10, P51
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Singer MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1065, DOI 10.1001/archophthalmol.2010.156
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Zick J, 2015, RETINA TODAY, V10, P80
NR 31
TC 14
Z9 16
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2017
VL 255
IS 9
BP 1687
EP 1696
DI 10.1007/s00417-017-3740-8
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD5RN
UT WOS:000407587600001
PM 28741158
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Rimayanti, U
   Kiuchi, Y
   Yamane, K
   Latief, MA
   Mochizuki, H
   Hirata, J
   Akita, T
   Tanaka, J
AF Rimayanti, Ulfah
   Kiuchi, Yoshiaki
   Yamane, Ken
   Latief, Miftahul Akhyar
   Mochizuki, Hideki
   Hirata, Junko
   Akita, Tomoyuki
   Tanaka, Junko
TI Inner retinal layer comparisons of eyes with exudative age-related
   macular degeneration and eyes with age-related macular degeneration and
   glaucoma
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Glaucoma; Ganglion cell complex;
   Retinal nerve fiber layer
ID OPTICAL COHERENCE TOMOGRAPHY; NERVE-FIBER LAYER; PHOTODYNAMIC THERAPY;
   THICKNESS; RANIBIZUMAB; AREA; OCT
AB Background The incidence of glaucoma increases with age, as does age-related macular degeneration (AMD), with the reported incidence of glaucoma among AMD subjects being 5.4 %. Optical coherence tomography (OCT) can detect glaucomatous changes in the inner retina with high sensitivity. The purpose of this study was to compare ganglion cell complex (GCC) parameters and the thickness of the peripapillary retinal nerve fiber layer (RNFL) in normal eyes to that observed in eyes with age-related macular degeneration (AMD) and eyes with both AMD and glaucoma.
   Methods The GCC components [GCC thickness, focal loss volume (FLV), and global loss volume (GLV)] and peripapillary RNFL thickness were measured using RTVue spectral-domain OCT (SD-OCT). The GCC and RNFL parameters of normal eyes, AMD eyes treated with different types of therapy, and AMD eyes with and without glaucoma were evaluated using nonparametric tests. Univariate and multivariate analyses were used to determine whether the GCC and RNFL parameters could be used to differentiate AMD eyes with glaucoma from those without glaucoma.
   Results Seventy-one normal eyes, 120 eyes with AMD, and 23 eyes with AMD and glaucoma were studied. The values of all GCC components were significantly different in the normal eyes from those observed in the eyes with AMD, except for the RNFL thicknesses. The GCC and RNFL parameters were not significantly different between the eyes receiving different types of therapy among the AMD groups. The RNFL thickness was significantly correlated with glaucoma diagnosis in AMD eyes.
   Conclusions These findings indicate that there is damage to the inner retinal layers in eyes with AMD. The RNFL thickness can be a useful parameter for differentiating eyes with AMD from eyes with both AMD and glaucoma.
C1 [Rimayanti, Ulfah; Kiuchi, Yoshiaki; Yamane, Ken; Latief, Miftahul Akhyar; Mochizuki, Hideki; Hirata, Junko] Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Minami Ku, Hiroshima 7348551, Japan.
   [Akita, Tomoyuki; Tanaka, Junko] Hiroshima Univ, Grad Sch Biomed Sci, Dept Epidemiol Infect Dis Control & Prevent, Hiroshima 7348551, Japan.
C3 Hiroshima University; Hiroshima University
RP Rimayanti, U (通讯作者)，Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM inersia_uteri@yahoo.com
RI Tanaka, Junko/G-6166-2019
OI Tanaka, Junko/0000-0002-5669-4051
CR Arintawati P, 2013, J GLAUCOMA, V22, P713, DOI 10.1097/IJG.0b013e318259b2e1
   Blair MP, 2010, OPHTHAL SURG LAS IM, V41, P175, DOI 10.3928/15428877-20100303-04
   Chen HY, 2005, J FORMOS MED ASSOC, V104, P927
   Dupont WD, 2002, STAT MODELLING BIOME, P320
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Harwerth RS, 2007, INVEST OPHTH VIS SCI, V48, P763, DOI 10.1167/iovs.06-0688
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hill T, 2006, STAT METHODS APPL CO, P25
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kim NR, 2010, INVEST OPHTH VIS SCI, V51, P4646, DOI 10.1167/iovs.09-5053
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KRUEGER DE, 1980, SURV OPHTHALMOL, V24, P614, DOI 10.1016/0039-6257(80)90122-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Medeiros FA, 2006, INVEST OPHTH VIS SCI, V47, P2520, DOI 10.1167/iovs.05-1441
   Menke MN, 2011, ACTA OPHTHALMOL, V89, P346, DOI 10.1111/j.1755-3768.2009.01692.x
   Nakatani Y, 2011, J GLAUCOMA, V20, P252, DOI 10.1097/IJG.0b013e3181e079ed
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Pepe MS, 2006, BIOMETRICS, V62, P221, DOI 10.1111/j.1541-0420.2005.00420.x
   Reeves BC, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16060
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Seong M, 2010, INVEST OPHTH VIS SCI, V51, P1446, DOI 10.1167/iovs.09-4258
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
NR 30
TC 17
Z9 20
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2014
VL 252
IS 4
BP 563
EP 570
DI 10.1007/s00417-013-2496-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8HN
UT WOS:000335659500003
PM 24146272
DA 2022-11-30
ER

PT J
AU Klein, ML
   Wilson, DJ
AF Klein, Michael L.
   Wilson, David J.
TI Clinicopathologic Correlation of Choroidal and Retinal Neovascular
   Lesions in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANGIOMATOUS PROLIFERATION; DRUSEN; MEMBRANES; TRIAL
AB PURPOSE: To describe histopathologic findings in donor eyes of 3 individuals with neovascular age-related macular degeneration and to correlate with results of clinical and fluorescein angiographic studies performed before death.
   DESIGN: Retrospective, observational case series.
   METHODS: Three eyes of 3 individuals with neovascular age-related macular degeneration were obtained after death and were prepared for histopathologic examination at a tertiary care referral center. Serial sections through the macula and optic nerve were evaluated with light microscopy. Findings were correlated with results of clinical evaluation, including findings of fluorescein angiography performed from 1 week to 5 months before death.
   RESULTS: In Case 1, histopathologic examination revealed a thin choroidal neovascular membrane beneath a relatively intact retinal pigment epithelium (type 1 neovascularization). This correlated with an occult choroidal neovascular membrane on fluorescein angiography characterized by a stippled appearance with minimal late leakage, representing possibly the earliest clinically detectable neovascular membrane for which histopathologic correlation is available. In Case 2, histopathologic examination demonstrated subfoveal choroidal neovascularization with distinctly separate subretinal pigment epithelial (type 1) and subretinal (type 2) components, correlating to fluorescein angiographic appearance of a mixed neovascular membrane with corresponding occult and classic features. The histopathologic findings in Case 3 revealed a plexus of blood vessels in the outer retina surrounded by an abundant eosinophiolic extracellular matrix and associated with a pigment epithelial detachment. There was no communication with the choroid. This correlated with clinical findings of retinal angiomatous proliferation.
   CONCLUSIONS: These 3 in situ clinicopathologic correlative studies add new knowledge of the broad clinical spectrum of neovascular age-related macular degeneration. (Am J Ophthalmol 2011;151:161-169. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Klein, Michael L.; Wilson, David J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   [Klein, Michael L.; Wilson, David J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Leonard Christensen Eye Pathol Lab, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Oregon Health & Science University
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu
FU Research to Prevent Blindness, Inc, New York, New York; Casey Eye
   Institute, Portland, Oregon
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY AN UNRESTRICTED GRANT TO
   THE CASEY EYE INSTITUTE FROM Research to Prevent Blindness, Inc, New
   York, New York, and by the Macular Degeneration Center Research Fund at
   the Casey Eye Institute, Portland, Oregon. The authors indicate no
   financial conflict of interest. Involved in Design and conduct of the
   study (M.L.K., D.J.W.); Collection, management, analysis, and
   interpretation of the data (M.L.K., D.J.W.); and Preparation, review, or
   approval of the manuscript (M.L.K., D.J.W.). The Oregon Health & Science
   University Institutional Review Board determined that human subjects
   approval was not necessary for this study, because it does not meet the
   definition of human subjects per 45 CFR 46.102(e). The Institutional
   Review Board determined that the research does meet the requirements of
   the Health Insurance Portability and Accountability Act Privacy Rule.
   The study was in compliance with the tenets of the Declaration of
   Helsinki and all federal and state laws. The authors thank Susan Nolte,
   who administered the Retina Eye Donor Program and was responsible for
   obtaining these donor eyes; the Oregon Lions Eye Bank, which collected
   the postmortem specimens; and Genevieve J. Long, who edited the
   manuscript for publication.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   HARTNETT ME, 1992, ORACLES ARCH CLIN EX, V230, P11
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lauer AK, 2000, RETINA-J RET VIT DIS, V20, P492, DOI 10.1097/00006982-200009000-00010
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 25
TC 31
Z9 33
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2011
VL 151
IS 1
BP 161
EP 169
DI 10.1016/j.ajo.2010.07.020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 704UN
UT WOS:000286081200025
PM 20970772
DA 2022-11-30
ER

PT J
AU Brady, CJ
   Garg, S
AF Brady, Christopher J.
   Garg, Seema
TI Telemedicine for Age-Related Macular Degeneration
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE telemedicine; teleophthalmology; ophthalmology
ID DIABETIC-RETINOPATHY; IMAGES; SYSTEM
AB Background: As the leading cause of vision loss in the United States, age-related macular degeneration (AMD) would seem to be amenable to interventions that increase access to screening and management services for patients. AMD poses several unique challenges for telemedicine, however. The disease lacks clinical consensus on the effectiveness and cost-effectiveness of screening the general population, and more complex imaging modalities may be required than for what has traditionally been used for diabetic retinopathy telehealth systems.
   Methods: The current literature was reviewed to find clinical trials and expert consensus documents on the state-of-the-art of telemedicine for AMD.
   Results: A range of feasibility studies have reported success with telemedicine strategies for AMD. Several investigators have reported experience with AMD screening and remote-monitoring systems as well as artificial intelligence applications.
   Conclusions: There are currently no large-scale telemedicine programs for either screening or managing AMD, but new approaches to screening and managing the condition may allow for expansion of high-quality convenient care for an increasing patient population.
C1 [Brady, Christopher J.] Univ Vermont, Larner Coll Med, Dept Surg, Div Ophthalmol, Burlington, VT 05401 USA.
   [Garg, Seema] Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC 27515 USA.
C3 University of Vermont; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina School of Medicine
RP Brady, CJ (通讯作者)，Univ Vermont, Med Ctr, Lamer Coll Med, Div Ophthalmol,Dept Surg, 111 Colchester Ave,ACC WP5, Burlington, VT 05401 USA.
EM cbrady3@uym.edu
FU National Institute of General Medical Sciences of the National
   Institutes of Health [P20GM103644]
FX C.J.B. was supported by the National Institute of General Medical
   Sciences of the National Institutes of Health under Award Number
   P20GM103644. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Andonegui J, 2016, RETINA-J RET VIT DIS, V36, P279, DOI 10.1097/IAE.0000000000000729
   Azzolini C, 2013, J TELEMED TELECARE, V19, P437, DOI 10.1177/1357633X13501760
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Duchin KS, 2015, OPTOMETRY VISION SCI, V92, P714, DOI 10.1097/OPX.0000000000000598
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Maa AY, 2017, TELEMED E-HEALTH, V23, P42, DOI 10.1089/tmj.2016.0039
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
NR 21
TC 7
Z9 8
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD APR 1
PY 2020
VL 26
IS 4
BP 565
EP 568
DI 10.1089/tmj.2020.0011
EA MAR 2020
PG 4
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA LF2SB
UT WOS:000525014600001
PM 32209019
OA Green Published
DA 2022-11-30
ER

PT J
AU Kishan, AU
   Modjtahedi, BS
   Martins, EN
   Modjtahedi, SP
   Morse, LS
AF Kishan, Amar U.
   Modjtahedi, Bobeck S.
   Martins, Elisabeth N.
   Modjtahedi, Sara P.
   Morse, Lawrence S.
TI Lipids an Age-related Macular Degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; cholesterol; eicosapentaenoic acid;
   diet; docosahexaenoic acid; human; lipids; metabolism; omega-3; statin
ID POLYUNSATURATED FATTY-ACIDS; COMPLEMENT FACTOR-H; PIGMENT
   EPITHELIAL-CELLS; CHOLESTEROL-LOWERING MEDICATIONS; RECEPTOR CLASS-B;
   DIETARY-FAT; RISK-FACTORS; DOCOSAHEXAENOIC ACID; CARDIOVASCULAR-DISEASE;
   5-YEAR INCIDENCE
AB Given the considerable public health burden imposed by age-related macular degeneration (AMD), much effort has been directed towards elucidating principles of pathogenesis in order to identify risk factors and develop preventive measures and treatments. Together with epidemiological evidence linking cardiovascular risk factors with AMD risk and basic science work examining the role of lipid metabolism in AMD, numerous human studies have assayed a potential relationship between dietary lipids and the development of AMD. We examine the evidence for a role for lipid metabolism in AMD, highlighting key basic biochemical principles, work in animal models, and relevant human studies. The topics of lipoprotein modulation and omega-3 fatty acid intake receive special attention from both a basic science and clinical study standpoint. The evidence suggests that consumption of omega-3 fatty acids, perhaps in concert with antioxidants, may constitute a rational preventative strategy against AMD development, though, absent an appropriately developed double-blind, randomized control trial, insufficient data exist to recommend implementation in the clinical setting at this time. (Surv Ophthalmol 56:195-213, 2011. (C) 2011 Elsevier Inc. All rights reserved.)
C1 [Modjtahedi, Bobeck S.; Martins, Elisabeth N.; Modjtahedi, Sara P.; Morse, Lawrence S.] UC Davis Eye Ctr, Sacramento, CA 95817 USA.
   [Kishan, Amar U.] Harvard Univ, Sch Med, Boston, MA USA.
   [Martins, Elisabeth N.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Harvard University; Harvard Medical School; Universidade Federal de Sao
   Paulo (UNIFESP)
RP Modjtahedi, BS (通讯作者)，UC Davis Eye Ctr, 4890 Y St,Suite 240, Sacramento, CA 95817 USA.
EM Bobeck.Modjtahedi@ucdmc.ucdavis.edu
OI Morse, Lawrence/0000-0002-1758-2348
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Akanuma S, 2009, BIOL PHARM BULL, V32, P1131, DOI 10.1248/bpb.32.1131
   ANDERSON RE, 1972, ARCH BIOCHEM BIOPHYS, V151, P270, DOI 10.1016/0003-9861(72)90497-3
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Bazan NG, 2009, PROSTAG LEUKOTR ESS, V81, P205, DOI 10.1016/j.plefa.2009.05.024
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FLIESLER SJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P138, DOI 10.1016/0005-2760(82)90020-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   FUKUZUMI K, 1986, J ENVIRON PATHOL TOX, V6, P25
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gounopoulos P, 2007, Minerva Cardioangiol, V55, P821
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   He K, 2009, PROG CARDIOVASC DIS, V52, P95, DOI 10.1016/j.pcad.2009.06.003
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Innis SM, 2009, J PEDIATR GASTR NUTR, V48, pS16, DOI 10.1097/MPG.0b013e31819773cf
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kotani S, 2006, NEUROSCI RES, V56, P159, DOI 10.1016/j.neures.2006.06.010
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lavie CJ, 2009, J AM COLL CARDIOL, V54, P585, DOI 10.1016/j.jacc.2009.02.084
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li F, 2009, MOL VIS, V15, P1185
   Ludman A, 2009, PHARMACOL THERAPEUT, V122, P30, DOI 10.1016/j.pharmthera.2009.01.002
   MacDonald IM, 2004, BRIT J OPHTHALMOL, V88, P305, DOI 10.1136/bjo.2003.024299
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Montecucco F, 2009, SEMIN IMMUNOPATHOL, V31, P127, DOI 10.1007/s00281-009-0150-y
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Parker G, 2006, AM J PSYCHIAT, V163, P969, DOI 10.1176/appi.ajp.163.6.969
   Pawlosky RJ, 1997, AM J CLIN NUTR, V65, P465, DOI 10.1093/ajcn/65.2.465
   Politi L, 2001, LIPIDS, V36, P927, DOI 10.1007/s11745-001-0803-8
   Politi LE, 2001, INVEST OPHTH VIS SCI, V42, P3008
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Riediger ND, 2009, J AM DIET ASSOC, V109, P668, DOI 10.1016/j.jada.2008.12.022
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Russo GL, 2009, BIOCHEM PHARMACOL, V77, P937, DOI 10.1016/j.bcp.2008.10.020
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Suh M, 2000, PEDIATR RES, V48, P524, DOI 10.1203/00006450-200010000-00017
   Suh M, 2009, INVEST OPHTH VIS SCI, V50, P4394, DOI 10.1167/iovs.08-2565
   Tachikawa M, 2007, MOL VIS, V13, P2041
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   *TEDC CS G, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Watts GF, 2001, CURR CONTR TRIALS C, V2, P118, DOI 10.1186/CVM-2-3-118
   Webers CAB, 2008, DRUG AGING, V25, P729, DOI 10.2165/00002512-200825090-00002
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 147
TC 54
Z9 54
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2011
VL 56
IS 3
BP 195
EP 213
DI 10.1016/j.survophthal.2010.08.008
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 758SU
UT WOS:000290187600003
PM 21439604
DA 2022-11-30
ER

PT J
AU Adamis, AP
AF Adamis, Anthony P.
TI THE RATIONALE FOR DRUG COMBINATIONS IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; angiogenesis; inflammation; fibrosis;
   neuroprotection
ID CHOROIDAL NEOVASCULARIZATION
AB The strategies for improving control of age-related macular degeneration with combination therapies are evolving. The focus on more effective blockade of choroidal neovascularization has shifted to include control of additional processes implicated in disease progression, such as neural death, inflammation, or fibrosis. Although there is likely to be a strong interrelationship between choroidal neovascularization and inflammation that contributes to advanced stages of disease progression, including fibrosis, combining treatment strategies may enlarge the opportunity to prevent both early and late vision loss. RETINA 29:S42-S44, 2009
C1 [Adamis, Anthony P.] Jerini Ophthalm, New York, NY 10020 USA.
   [Adamis, Anthony P.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
C3 Shire Pharmaceuticals Limited; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital
RP Adamis, AP (通讯作者)，Jerini Ophthalm, New York, NY 10020 USA.
EM tadamis@jophth.com
CR Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
NR 4
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S42
EP S44
DI 10.1097/IAE.0b013e3181ad2500
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700016
PM 19553800
DA 2022-11-30
ER

PT J
AU Nita, M
   Grzybowski, A
AF Nita, Malgorzata
   Grzybowski, Andrzej
TI INTERPLAY BETWEEN REACTIVE OXYGEN SPECIES AND AUTOPHAGY IN THE COURSE OF
   AGE-RELATED MACULAR DEGENERATION
SO EXCLI JOURNAL
LA English
DT Review
DE Reactive oxygen species; oxidative stress; autophagy; age-related
   macular degeneration; retina disease; ophthalmology
ID RETINAL-PIGMENT EPITHELIUM; GLYCATION END-PRODUCTS; CHOROIDAL
   BLOOD-FLOW; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; BRUCHS
   MEMBRANE; DNA-DAMAGE; CELL-DEATH; AGGREGATED PROTEINS; NLRP3
   INFLAMMASOME
AB Pathological biomolecules such as lipofuscin, methylglyoxal-modified proteins (the major precursors of advanced glycationend products), misfolding protein deposits and dysfunctional mitochondria are source of oxidafive stress and act as strong autophagic stimulators in age-related macular degeneration. Disturbed autophagy accelerates progression of the disease, since it leads to retinal cells' death and activates inflammation by the interplay with the NLRP3 inflammasome complex. Vascular dysfunction and hypoxia, as well as circulating autoantibodies against autophagy regulators (anti-S100A9, anti-ANXA5, and anti-HSPA8, A9 and B4) compromise an autophagy-mediated mechanism as well. Metformin, the autophagic stimulator, may act as a senostatic drug to inhibit the senescent phenotype in the age-related macular degeneration. PGC-1 alpha, Sirt1 and AMPK represent new therapeutic targets for interventions in this disease.
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed Katowice, Katowice, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Med Fac, Dept Ophthalmol, Olsztyn, Poland.
   [Grzybowski, Andrzej] Inst Res Ophthalmol, Gorczyczewskiego 2-3, PL-61553 Poznan, Poland.
C3 University of Warmia & Mazury
RP Grzybowski, A (通讯作者)，Inst Res Ophthalmol, Gorczyczewskiego 2-3, PL-61553 Poznan, Poland.
EM m.nita@wp.pl; ae.grzybowski@gmail.com
OI Grzybowski, Andrzej/0000-0002-3724-2391
CR Ahmad T, 2015, FASEB J, V29, P2912, DOI 10.1096/fj.14-268276
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Ban T, 2010, HUM MOL GENET, V19, P2113, DOI 10.1093/hmg/ddq088
   Bauernfeind F, 2011, CELL MOL LIFE SCI, V68, P765, DOI 10.1007/s00018-010-0567-4
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bonet-Ponce L, 2016, MOL NEUROBIOL, V53, P6194, DOI 10.1007/s12035-015-9509-3
   Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bueno M, 2015, J CLIN INVEST, V125, P521, DOI 10.1172/JCI74942
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YC, 2015, TOXICOL IN VITRO, V29, P1358, DOI 10.1016/j.tiv.2015.05.014
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Chilelli NC, 2013, NUTR METAB CARDIOVAS, V23, P913, DOI 10.1016/j.numecd.2013.04.004
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Field MG, 2012, OPHTHAL SURG LAS IM, V43, P358, DOI 10.3928/15428877-20120712-02
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Geeraert C, 2010, J BIOL CHEM, V285, P24184, DOI 10.1074/jbc.M109.091553
   Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129
   Ghislat G, 2012, J CELL SCI, V125, P92, DOI 10.1242/jcs.086728
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gredilla R, 2011, J AGING RES, V2011
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   Harja E, 2008, J CLIN INVEST, V118, P183, DOI 10.1172/JCI32703
   Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Kaarniranta K, 2018, ADV DRUG DELIVER REV, V126, P177, DOI 10.1016/j.addr.2018.04.016
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim JI, 2001, ANN NY ACAD SCI, V928, P182, DOI 10.1111/j.1749-6632.2001.tb05648.x
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Labbe K, 2008, CELL DEATH DIFFER, V15, P1339, DOI 10.1038/cdd.2008.91
   lannaccone A., 2015, PLOS ONE, V10
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu J-G, 2016, SCI REP, P6, DOI DOI 10.1038/SREP20639
   Lue LF, 2005, CNS NEUROL DISORD-DR, V4, P249, DOI 10.2174/1568007054038210
   Maciel-Baron LA, 2016, AGE, V38, DOI 10.1007/s11357-016-9886-1
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Mena NP, 2015, MITOCHONDRION, V21, P92, DOI 10.1016/j.mito.2015.02.001
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200
   Onyango IG, 2008, NEUROCHEM RES, V33, P589, DOI 10.1007/s11064-007-9482-y
   Palikaras K, 2017, PHARMACOL THERAPEUT, V178, P157, DOI 10.1016/j.pharmthera.2017.04.005
   Pallanck LJ, 2010, J CELL BIOL, V191, P1225, DOI 10.1083/jcb.201011068
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pezze PD, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003728
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rubinsztein DC, 2012, CURR BIOL, V22, pR29, DOI 10.1016/j.cub.2011.11.034
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Song YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010122
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tabner BJ, 2005, BIOCHEM SOC T, V33, P1082, DOI 10.1042/BST0331082
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Toussaint Olivier, 2002, TheScientificWorldJOURNAL, V2, P230
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang A.L, 2009, PLOS ONE, V4, pe5304, DOI DOI 10.1371/JOURNAL.PONE.0004160
   Wang XY, 2016, NEUROBIOL AGING, V47, P168, DOI 10.1016/j.neurobiolaging.2016.07.025
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Yamagishi S, 2007, HORM METAB RES, V39, P845, DOI 10.1055/s-2007-991176
   Yamamoto A, 2011, NEUROBIOL DIS, V43, P17, DOI 10.1016/j.nbd.2010.08.015
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 131
TC 6
Z9 6
U1 2
U2 8
PU EXCLI JOURNAL MANAGING OFFICE
PI DORTMUND
PA LEIBNIZ RESEARCH CENTRE WORKING ENVIRONMENT & HUMAN FACTORS EXCLI
   JOURNAL, ARDEYSTR 67, DORTMUND, D-44139, GERMANY
SN 1611-2156
J9 EXCLI J
JI EXCLI J.
PY 2020
VL 19
BP 1353
EP 1371
DI 10.17179/excli2020-2915
PG 19
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA NW7HN
UT WOS:000575190400001
PM 33192217
DA 2022-11-30
ER

PT J
AU Hayashi, H
   Yamashiro, K
   Tsujikawa, A
   Ota, M
   Otani, A
   Yoshimura, N
AF Hayashi, Hisako
   Yamashiro, Kenji
   Tsujikawa, Akitaka
   Ota, Masafumi
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Association between Foveal Photoreceptor Integrity and Visual Outcome in
   Neovascular Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL
   SEROUS CHORIORETINOPATHY; RETINAL VEIN OCCLUSION; OCCULT OUTER
   RETINOPATHY; PHOTODYNAMIC THERAPY; ULTRAHIGH-RESOLUTION;
   RETINITIS-PIGMENTOSA; VERTEPORFIN; SEGMENT
AB PURPOSE: To evaluate the correlation between visual outcome and foveal photoreceptor integrity after successful treatment of eyes with neovascular age,related macular degeneration (AMD).
   DESIGN: Retrospective chart review.
   METHODS: We retrospectively studied the medical records of 51 eyes of 51 patients with neovascular AMD who were treated successfully with photodynamic therapy (PDT). All eyes were followed-up for more than 24 months after the initial treatment. Using spectral-domain optical coherence tomography, the status of the inner segment and outer segment (IS/OS) photoreceptor junction was assessed as a hallmark of the integrity of the foveal photoreceptor layer.
   RESULTS: At the final visit, no eyes showed an exudative change. A complete or discontinuous IS/OS line was detected beneath the fovea in 8 (15.7%) and 25 (29.4%) eyes, respectively, whereas 28 (54.9%) had no IS/OS line. Eyes with a continuous or discontinuous IS/OS line beneath the fovea had better final visual acuity (VA) than did eyes without an IS/OS line (P < .001, respectively). Of the 51 eyes, 36 showed polypoidal choroidal vasculopathy (PCV), whereas 15 were diagnosed as having typical AMD without PCV. Visual outcome was significantly better in eyes with PCV (P = .026). Most eyes (13/15; 86.7%) with typical AMD had no IS/OS line at the final visit, whereas only 13 (36.1%) of the 36 eyes with PCV had no IS/OS line beneath the fovea.
   CONCLUSIONS: Integrity of the photoreceptor layer beneath the fovea is associated with the final VA in neovascular AMD after successful PDT. (Am J Ophthalmol 2009;148:83-89. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Yamashiro, Kenji] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390442,
   19592015]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX THIS STUDY WAS SUPPORTED IN PART BY GRANTS-IN-AID FOR SCIENTIFIC
   RESEARCH NOS. 19390442 AND 19592015 FROM THE Japan Society for the
   Promotion of Science, Tokyo, Japan, and the Japan National Society for
   the Prevention of Blindness, Tokyo, Japan. The authors indicate no
   financial conflict of interest. Involved in conception and design of
   study (H.H., K.Y., A.T., N.Y.); analysis and interpretation of data
   (H.H., K.Y., A.T., M.O., A.O.); writing of the article (H.H., K.Y.,
   A.T.); critical revision of the article (K.Y., A.T., M.O., A.O., N.Y.);
   final approval of the article (H.H., K.Y., AT., M.O., A.O., N.Y.); and
   data collection (H.H., K.Y., M.O.). The current study was approved by
   the Institutional Review Board at Kyoto University Graduate School of
   Medicine. All investigations in the current study adhered to the tenets
   of the Declaration of Helsinki.
CR Aizawa S, 2009, EYE, V23, P304, DOI 10.1038/sj.eye.6703076
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewi NA, 2008, JPN J OPHTHALMOL, V52, P277, DOI 10.1007/s10384-008-0551-9
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Ghajarnia Mehdi, 2007, Semin Ophthalmol, V22, P127, DOI 10.1080/08820530701421635
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gupta V, 2008, AM J OPHTHALMOL, V145, P1018, DOI 10.1016/j.ajo.2008.01.021
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hangai Masanori, 2007, Nippon Ganka Gakkai Zasshi, V111, P509
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Li D, 2007, ARCH OPHTHALMOL-CHIC, V125, P1194, DOI 10.1001/archopht.125.9.1194
   Maruko I, 2009, AM J OPHTHALMOL, V147, P489, DOI 10.1016/j.ajo.2008.09.030
   Matsumoto H, 2008, AM J OPHTHALMOL, V145, P162, DOI 10.1016/j.ajo.2007.08.024
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Murakami T, 2007, AM J OPHTHALMOL, V143, P171, DOI 10.1016/j.ajo.2006.08.030
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Oishi A, 2009, EYE, V23, P299, DOI 10.1038/sj.eye.6703077
   Ojima Y, 2008, AM J OPHTHALMOL, V146, P77, DOI 10.1016/j.ajo.2008.02.016
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Sayanagi K, 2008, AM J OPHTHALMOL, V145, P902, DOI 10.1016/j.ajo.2008.01.011
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P111, DOI 10.1016/j.ajo.2008.02.027
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
NR 45
TC 89
Z9 97
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 83
EP 89
DI 10.1016/j.ajo.2009.01.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700014
PM 19327745
DA 2022-11-30
ER

PT J
AU Hussnain, SA
   Dolz-Marco, R
   Dunaief, JL
   Curcio, CA
   Freund, KB
AF Hussnain, S. Amal
   Dolz-Marco, Rosa
   Dunaief, Joshua L.
   Curcio, Christine A.
   Freund, K. Bailey
TI SPECKLED HYPOAUTOFLUORESCENCE AS A SIGN OF RESOLVED SUBRETINAL
   HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE subretinal hemorrhage; autofluorescence; neovascular AMD; iron toxicity;
   blood; RPE and outer retinal atrophy; geographic atrophy
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; SUBMACULAR
   HEMORRHAGE; IRON ACCUMULATION; EYES; ATROPHY; LIPOFUSCIN; SECONDARY;
   MODEL
AB Purpose: To describe patterns of hypoautofluorescence in eyes with neovascular age-related macular degeneration occurring after subretinal hemorrhage.
   Methods: This was a retrospective descriptive analysis of neovascular age-related macular degeneration eyes presenting with subretinal hemorrhage over the last 5 years that underwent serial multimodal imaging. A review of color fundus photographs, fundus autofluorescence, near-infrared reflectance, and optical coherence tomography was performed at baseline and all available follow-up visits to document the course and evolution of subretinal hemorrhage in these eyes.
   Results: Eleven eyes of 10 patients (9 female, 1 male; mean age: 84.1 years, range: 72-99 years) with a mean follow-up of 19.8 months (range: 3-68 months) were included. Color fundus photographs showed subretinal hemorrhage that resolved over a mean of 5.5 months. During and after hemorrhage resolution, all eyes showed hypoautofluorescence, which appeared distinct from that due to retinal pigment epithelium loss. Discrete multifocal punctate hyperpigmented lesions were observed in 90% of eyes and were markedly hypoautofluorescent, producing a speckled pattern on fundus autofluorescence.
   Conclusion: Areas of hypoautofluorescence in the absence of retinal pigment epithelium atrophy, often with a speckled pattern, delineate areas of prior subretinal hemorrhage long after its resolution in patients with neovascular age-related macular degeneration. Potential mechanisms for the development of this pattern are proposed.
C1 [Hussnain, S. Amal; Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Hussnain, S. Amal; Dolz-Marco, Rosa; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Hussnain, S. Amal; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Hussnain, S. Amal; Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
   [Curcio, Christine A.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Columbia University; New York University; University of
   Pennsylvania; Pennsylvania Medicine; University of Alabama System;
   University of Alabama Birmingham
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, NY; Macula Foundation Inc, New York, NY; NIH
   [R01 EY015240, R01 R01EY027948, R01EY015520]; NATIONAL EYE INSTITUTE
   [R01EY015240] Funding Source: NIH RePORTER
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Hospital, New York, NY, the Macula Foundation Inc,
   New York, NY, NIH R01 EY015240 (J.L.D.), NIH R01 R01EY027948 (CAC),
   R01EY015520 (CAC) and institutional support to the Department of
   Ophthalmology at UAB from EyeSight Foundation of Alabama and Research to
   Prevent Blindness. The funding organizations had no role in the design
   or execution of this research.
CR Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Adler L, 2015, PHOTOCH PHOTOBIO SCI, V14, P1983, DOI 10.1039/c5pp00156k
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Freund KB, 2013, JAMA OPHTHALMOL, V131, P1645, DOI 10.1001/jamaophthalmol.2013.5030
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Hwang JU, 2012, RETINA-J RET VIT DIS, V32, P652, DOI 10.1097/IAE.0b013e318233abb4
   Kim JH, 2018, GRAEF ARCH CLIN EXP, V256, P469, DOI 10.1007/s00417-017-3877-5
   Lavinsky D, 2011, ACTA OPHTHALMOL, V89, pE89, DOI 10.1111/j.1755-3768.2009.01716.x
   Guerra RLL, 2014, ARQ BRAS OFTALMOL, V77, P139, DOI 10.5935/0004-2749.20140036
   Margolis Ron, 2010, Retin Cases Brief Rep, V4, P1, DOI 10.1097/ICB.0b013e3181b5ef3b
   Moriyama M, 2011, RETINA-J RET VIT DIS, V31, P74, DOI 10.1097/IAE.0b013e3181e91148
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   Sawa M, 2008, GRAEF ARCH CLIN EXP, V246, P1087, DOI 10.1007/s00417-008-0835-2
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Wolkow N, 2014, EXP EYE RES, V128, P92, DOI 10.1016/j.exer.2014.09.010
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 33
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1925
EP 1935
DI 10.1097/IAE.0000000000002367
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300012
PM 30355956
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lestak, J
   Tintera, J
   Karel, I
   Svata, Z
   Rozsival, P
AF Lestak, Jan
   Tintera, Jaroslav
   Karel, Ivan
   Svata, Zuzana
   Rozsival, Pavel
TI Functional Magnetic Resonance Imaging in Patients with the Wet Form of
   Age-Related Macular Degeneration
SO NEURO-OPHTHALMOLOGY
LA English
DT Article
DE Brain fMRI; ganglion cells; wet AMD
ID PRIMARY VISUAL-CORTEX; RETINOTOPIC ORGANIZATION; CORTICAL FUNCTION;
   GREY-MATTER; BEVACIZUMAB; GLAUCOMA; CELLS
AB The study is designed to determine the relationship between the progress of the wet form of age-related macular degeneration and the activity of the visual cortex examined using functional magnetic resonance imaging. Ten patients with the wet form of age-related macular degeneration (9 female and 1 male) with a mean age of 74.7 years (58-85 years) at various stages of bilateral involvement of the disease were included. Patients did not suffer from any other ocular nor neurological disease. All the patients underwent functional magnetic resonance imaging examinations with stimulation of both eyes using a black-and-white checkerboard of size 25.8 x 16.2 degrees. The group was compared with a group of healthy subjects with an average age of 54.1 years (45-65 years). For statistical evaluation, the Mann-Whitney U test was used. Comparing the extent of visual cortex activations we found a statistically significant difference between both the groups (p = 0.0247). However, the dependence of functional magnetic resonance imaging activity on visual acuity was not statistically significant (p = 0.223). We conclude that in patients with the wet form of age-related macular degeneration, lower functional magnetic resonance imaging activity of the visual cortex was found compared with the control group of healthy subjects. Dependence of functional magnetic resonance imaging activity on visual acuity was not statistically significant.
C1 [Lestak, Jan; Tintera, Jaroslav; Karel, Ivan; Svata, Zuzana] JL Clin, Prague, Czech Republic.
   [Lestak, Jan] Czech Tech Univ, Fac Biomed Engn, CR-16635 Prague, Czech Republic.
   [Lestak, Jan; Rozsival, Pavel] Charles Univ Prague, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic.
C3 Czech Technical University Prague; Charles University Prague
RP Lestak, J (通讯作者)，JL Clin, V Hurkach 1296-10, Prague, Czech Republic.
EM lestak@seznam.cz
RI Rozsival, Pavel/N-9978-2017
OI Rozsival, Pavel/0000-0001-6628-7954
CR Avci B, 2009, INVEST OPHTH VIS SCI, V50, P3438, DOI 10.1167/iovs.08-2871
   Baseler HA, 2011, OPTOMETRY VISION SCI, V88, P1255, DOI 10.1097/OPX.0b013e3182282f13
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Brar VS, 2010, MOL VIS, V16, P1848
   Duncan RO, 2007, INVEST OPHTH VIS SCI, V48, P733, DOI 10.1167/iovs.06-0773
   Duncan RO, 2007, PROG RETIN EYE RES, V26, P38, DOI 10.1016/j.preteyeres.2006.10.001
   Grosso A, 2007, AM J OPHTHALMOL, V143, P157, DOI 10.1016/j.ajo.2006.07.040
   Hendry SHC, 1998, TRENDS NEUROSCI, V21, P344, DOI 10.1016/S0166-2236(98)01245-4
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   LESTAK J, 2011, J CLIN EXP OPHTHALMO, P4, DOI DOI 10.4172/2155-9570.S4-002
   MASSEY SC, 1990, J NEUROPHYSIOL, V63, P16, DOI 10.1152/jn.1990.63.1.16
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Nguyen T, 2004, J FR OPHTALMOL, V27, p3S65
   NGUYEN TH, 2004, J FR OPHTALMOL, V7, P72
   PYCOCK CJ, 1985, SURV OPHTHALMOL, V29, P355, DOI 10.1016/0039-6257(85)90111-0
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   von dem Hagen EAH, 2005, EUR J NEUROSCI, V22, P2475, DOI 10.1111/j.1460-9568.2005.04433.x
NR 17
TC 9
Z9 9
U1 0
U2 4
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0165-8107
EI 1744-506X
J9 NEURO-OPHTHALMOLOGY
JI Neuro-Ophthalmol.
PD OCT
PY 2013
VL 37
IS 5
BP 192
EP 197
DI 10.3109/01658107.2013.819581
PG 6
WC Clinical Neurology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 224MX
UT WOS:000324892200002
PM 28167987
OA Green Published
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Mohla, A
   Lee, SY
   Mathur, R
   Chan, CM
   Yeo, I
   Wong, TY
   Cheung, CMG
AF Yanagi, Yasuo
   Mohla, Aditi
   Lee, Shu Yen
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Incidence of Fellow Eye Involvement in Patients With Unilateral
   Exudative Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COHERENCE TOMOGRAPHY ANGIOGRAPHY;
   INDOCYANINE-GREEN VIDEOANGIOGRAPHY; SPECTRAL-DOMAIN; NEOVASCULARIZATION;
   PREVALENCE; DRUSEN
AB IMPORTANCE Since the advent of optical coherence tomography angiography (OCT-A), nonexudative neovascularization has been described in the fellow eyes of unilateral exudative age-related macular degeneration (AMD). However, there is limited literature describing the natural course and optimal management of these lesions.
   OBJECTIVE To determine the incidence of fellow eye involvement in patients presenting with unilateral typical AMD or polypoidal choroidal vasculopathy and to evaluate the patterns of OCT-A changes within 6 months before the onset of exudative changes, especially focusing on nonexudative neovascularization.
   DESIGN, SETTING. AND PARTICIPANTS Data for this study were taken from a prospective, observational cohort study involving Asian patients with exudative AMD in the Asian AMD Phenotyping Study between October 2015 and March 2016. Analyses began in June 2017. Only patients who had gradable OCT-A and indocyanine green angiography (ICGA) scans of the fellow eye at baseline and follow-up at least 6 months apart were included for the analysis. The contralateral eye was evaluated for presence of nonexudative neovascularization based on multimodal imaging, which included ICGA, spectral domain optical coherence tomography, and OCT-A.
   MAIN OUTCOMES AND MEASURES The difference between the incidence of those with nonexudative choroidal neovascularization and those without as analyzed using log-rank test and qualitative analysis of OCT-A images.
   RESULTS We included 95 fellow eyes of 95 patients who presented with unilateral exudative AMD with a mean (SD) age of 68.6 (8.6) years. Nonexudative neovascularization was present in 18 eyes (19%) (8 [22.9%) and 10 [19.0%) fellow eyes with typical AMD and polypoidal choroidal vasculopathy, respectively; 8 [44.4%) on OCT-A; 5 [27.8%) on ICGA; and 5 [27.8%] on both OCT-A and ICGA). Development of exudative changes was noted in 6 fellow eyes (6.3%), Four eyes developed exudation from previously noted nonexudative neovascularization, and 2 eyes arose exudative changes from de novo. The probability of developing exudation within 6 months was significantly higher in eyes with baseline nonexudative neovascularization (0.087; 95% CI, 0.0033-0.210) compared with eyes without (0.010; 95% CI, 0.0026-0.041) (P=.008). In all eyes whose OCT-A images were available immediately before the onset of exudative changes, there was an increase in the size of network vessels compared with baseline.
   CONCLUSIONS AND RELEVANCE The presence of nonexudative neovascularization may predispose to the development of exudative changes.
C1 [Yanagi, Yasuo; Mohla, Aditi; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Yanagi, Yasuo; Lee, Shu Yen; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Yanagi, Yasuo/AAA-5441-2022; Wong, Tien Yin/AAC-9724-2020; Yanagi,
   Yasuo/AAF-2670-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Yanagi, Yasuo/0000-0002-0362-7285;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/100312009]; Biomedical
   Research Council [10/11351191671]
FX This study was supported by the National Medical Research Council (grant
   NMRC/NIG/100312009) and Biomedical Research Council (grant
   10/11351191671)
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   BOTTONI FG, 1994, GRAEF ARCH CLIN EXP, V232, P458, DOI 10.1007/BF00195354
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Lim FPM, 2016, BRIT J OPHTHALMOL, V100, P918, DOI 10.1136/bjophthalmol-2015-307055
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   Teo KYC, RETINA
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 32
TC 21
Z9 21
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2018
VL 136
IS 8
BP 905
EP 911
DI 10.1001/jamaophthalmol.2018.2154
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP8TE
UT WOS:000441186300015
PM 29879284
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Shah, VP
   Shah, SA
   Mrejen, S
   Freund, KB
AF Shah, Vinnie P.
   Shah, Sabah A.
   Mrejen, Sarah
   Freund, K. Bailey
TI SUBRETINAL HYPERREFLECTIVE EXUDATION ASSOCIATED WITH NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION
AB Purpose: To describe the multimodal imaging findings of subretinal hyperreflective exudation (SHE) observed in association with choroidal neovascularization and to distinguish SHE from other forms of subretinal hyperreflective material (SHM) seen in patients with age-related macular degeneration and other macular disorders.
   Methods: A retrospective study on 46 eyes of 42 patients with SHE associated with Types 1, 2, and 3 choroidal neovascularization secondary to neovascular age-related macular degeneration. Patients were examined using multimodal imaging, including color photography, near-infrared reflectance imaging, spectral domain optical coherence tomography, fluorescein angiography, fundus autofluorescence imaging, and indocyanine green angiography. Clinical and imaging characteristics were evaluated at baseline, after the initiation of intravitreal antivascular endothelial growth factor therapy, and during the resolution of SHE.
   Results: Forty-five of the 46 eyes were treatment naive. The mean +/- SD age at the first detection of SHE was 77.2 +/- 10.1 years. The mean +/- SD follow-up was 2.1 +/- 0.6 years. Fluorescein angiography was performed in 42 eyes and demonstrated leakage and/or staining of underlying or adjacent choroidal neovascularization but not of the SHE itself in all eyes. On fluorescein angiography, SHE was transparent in 29 eyes and blocking in 7 eyes. In 32 eyes, SHE showed isoautofluorescence on fundus autofluorescence imaging, and in 8 eyes, SHE showed varying degrees of hyperautofluorescence. Indocyanine green angiography was performed in eight eyes and demonstrated hyperfluorescence of SHE in seven eyes. In eight eyes, SHE was the only evidence of neovascular activity. All eyes having follow-up (42 eyes) showed resolution of the subretinal material with partial or full reconstitution of the ellipsoid zone after a median of 2 injections range (1-16 injections). Subretinal hyperreflective exudation persisted for a median of 9 weeks (range, 4-60 weeks) after the initiation of treatment. The mean visual acuity before treatment was 0.619 (20/83), and it improved to 0.380 (20/48) (P = 0.03) after the resolution of SHE.
   Conclusion: Subretinal hyperreflective exudation differs from other types of SHM based on the findings from multimodal imaging. This novel type of SHM likely represents a sign of active neovascular age-related macular degeneration distinct from subretinal fluid, hemorrhage, neovascular tissue, lipid, pigment hyperplasia, subretinal fibrosis, and the SHM observed with acquired vitelliform lesions. Intravitreal antivascular endothelial growth factor agents can be used to successfully resolve SHE, often resulting in better visual outcomes in eyes manifesting this form of exudation.
C1 [Shah, Vinnie P.; Mrejen, Sarah; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Shah, Vinnie P.; Shah, Sabah A.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.
FX Supported in part by the Macula Foundation, Inc. The funding
   organization had no role in the design or conduct of this research.
CR Bourhis A, 2010, GRAEF ARCH CLIN EXP, V248, P161, DOI 10.1007/s00417-009-1175-6
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Ho I-Van, 2008, Retin Cases Brief Rep, V2, P1, DOI 10.1097/ICB.0b013e318074bc8c
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kandula Sushma, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS81, DOI 10.3928/15428877-20101031-09
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Leibowitz HM, 1980, SURV OPHTHALMOL, V24, pS428
   PINO RM, 1985, AM J ANAT, V172, P279, DOI 10.1002/aja.1001720403
   Williams WJ, 1983, HEMATOLOGY, P1222
NR 12
TC 53
Z9 54
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2014
VL 34
IS 7
BP 1281
EP 1288
DI 10.1097/IAE.0000000000000166
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK9UG
UT WOS:000338772600004
PM 24695062
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Rubin, GS
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Rubin, Gary S.
   Tufail, Adnan
TI Intersession Repeatability of Contrast Sensitivity Scores in Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY; RELIABILITY; DISABILITY; IMPAIRMENT; VALIDITY; MOBILITY;
   THERAPY
AB PURPOSE. To describe the intersession repeatability of contrast sensitivity (CS) measurement using Pelli-Robson charts in patients with age-related macular degeneration.
   METHODS. Repeatability was calculated from three measurements of CS over a 12-week period using a standardized protocol in 107 nontreated eyes of 107 patients with age-related macular degeneration who were enrolled in an ongoing clinical trial.
   RESULTS. Data from 91 patients were included in the analysis, with a 95% coefficient of repeatability of 7 letters (0.35 log CS), ranging from 6 letters for 32 eyes with drusen only to 8 letters for patients with late AMD (macular scars or geographic atrophy). Three (3%) of these stable patients had an apparent six or more letter reduction in contrast sensitivity at the week 1 visit compared with baseline.
   CONCLUSIONS. There is a high intersession test-retest variability of Pelli-Robson CS scores in patients with AMD, with implications for AMD clinical trial design. Although a change criterion of six or more letters may be an adequate end point in clinical trials for patients with early AMD, a larger change criterion may be necessary for clinical trials of patients with late AMD. (Invest Ophthalmol Vis Sci. 2009; 50: 2621-2625) DOI:10.1167/iovs.08-2407
C1 [Patel, Praveen J.; Chen, Fred K.; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Rubin, Gary S.] UCL, Inst Ophthalmol, London, England.
   [Rubin, Gary S.] Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
CR ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bland JM, 1996, BRIT MED J, V313, P744
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dougherty BE, 2005, OPTOMETRY VISION SCI, V82, P970, DOI 10.1097/01.opx.0000187844.27025.ea
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   ELLIOTT DB, 1993, INVEST OPHTH VIS SCI, V34, P108
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Haymes SA, 2004, OPTOMETRY VISION SCI, V81, P308, DOI 10.1097/01.opx.0000134904.21274.db
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lovie-Kitchin JE, 2000, OPTOMETRY VISION SCI, V77, P412, DOI 10.1097/00006324-200008000-00008
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Richter-Mueksch S, 2006, GRAEF ARCH CLIN EXP, V244, P154, DOI 10.1007/s00417-005-0063-y
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
NR 22
TC 15
Z9 16
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2621
EP 2625
DI 10.1167/iovs.08-2407
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450ME
UT WOS:000266403800012
PM 19218618
DA 2022-11-30
ER

PT J
AU Honda, S
   Matsumiya, W
   Negi, A
AF Honda, Shigeru
   Matsumiya, Wataru
   Negi, Akira
TI Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic
   Predisposition
SO OPHTHALMOLOGICA
LA English
DT Review
DE Polypoidal choroidal vasculopathy; Choroidal neovascularization;
   Clinical features; Genetic predisposition
ID COMPLEMENT-FACTOR-H; AGE-RELATED MACULOPATHY; EXUDATIVE HEMORRHAGIC
   CHORIORETINOPATHY; RETINAL-PIGMENT EPITHELIUM; FACTOR HY402H
   POLYMORPHISM; ANTI-VEGF TREATMENT; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; INTRAVITREAL RANIBIZUMAB; JAPANESE POPULATION
AB Polypoidal choroidal vasculopathy (PCV) is currently recognized as a phenotype of age-related macular degeneration (AMD). PCV is believed to be a type of choroidal neovascularization, although some cases of PCV show a distinct vascular abnormality of the choroidal vessels. PCV often shows several unique clinical manifestations which are apparently different from typical neovascular AMD (tAMD). In addition, the natural course and response to treatment are often different between tAMD and PCV. Moreover, recent genetic studies suggested a possible difference in the genetic susceptibility to disease between tAMD and PCV, as well as the existence of heterogeneity among PCV cases. In viewing the accumulation of knowledge about PCV, we have summarized the recent literature regarding PCV in this review article to improve the understanding of this clinical entity including possible susceptibility genes. We will also discuss the optimal treatment strategies for PCV in accordance with the results of recent clinical and genetic studies. (C) 2013 S. Karger AG, Basel
C1 [Honda, Shigeru; Matsumiya, Wataru; Negi, Akira] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Al-Rashaed S, 2008, MIDDLE EAST AFR J OP, V15, P90, DOI 10.4103/0974-9233.52000
   Bessho H, 2011, J CLIN EXP OPHTHALMO, V2, P122
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang W, 2013, MOL VIS, V19, P702
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen H, 2012, PLOS ONE, V7
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chowers I, 2008, MOL VIS, V14, P1829
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Honda S, 2012, MOL VIS, V18, P2796
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jiang JJ, 2012, GENET MOL RES, V11, P4256, DOI 10.4238/2012.December.17.1
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantel I, 2012, AM J OPHTHALMOL, V153, P910, DOI 10.1016/j.ajo.2011.10.017
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Miki A, 2013, JPN J OPHTHALMOL, V57, P301, DOI 10.1007/s10384-013-0237-9
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nagase Satoko, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe5, DOI 10.3928/15428877-20120130-02
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Okamoto H, 2006, MOL VIS, V12, P156
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsuchihashi T, 2013, CLIN OPHTHALMOL, V7, P615, DOI 10.2147/OPTH.S43566
   Tsujikawa A, 2013, JPN J CLIN OPHTHAL, V67, P1058
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tsujikawa A, 2008, CLIN EXP OPHTHALMOL, V36, P817, DOI 10.1111/j.1442-9071.2009.01907.x
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Yuan DQ, 2013, MOL VIS, V19, P374
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 157
TC 52
Z9 54
U1 0
U2 16
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 2
BP 59
EP 74
DI 10.1159/000355488
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296AE
UT WOS:000330156700001
PM 24280967
OA Bronze
DA 2022-11-30
ER

PT J
AU Krasnik, V
   Stefanickova, J
   Popov, I
   Valaskova, J
   Saxena, S
   Kruzliak, P
AF Krasnik, Vladimir
   Stefanickova, Jana
   Popov, Ivajlo
   Valaskova, Jela
   Saxena, Sandeep
   Kruzliak, Peter
TI Prevalence of Age-Related Macular Degeneration in Slovakia and
   Associated Risk Factors: A Mobile Clinic-Based Cross-Sectional
   Epidemiological Survey
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; epidemiology; mobile clinic;
   prevalence; risk factors
ID SKIN SUN SENSITIVITY; BLUE MOUNTAINS EYE; BEAVER DAM EYE; VISUAL
   IMPAIRMENT; POOLED FINDINGS; 3 CONTINENTS; IRIS COLOR; MACULOPATHY;
   DISEASE; SMOKING
AB Purpose: Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly population. Although there are prevalence studies for AMD in Europe, data are scarce for the Slovakian population. Methods: This was a prospective, multicenter, non-interventional, mobile clinic-based cross-sectional study that assessed age-specific prevalence of AMD in the Slovakian population and risk factors associated with AMD. The type of AMD was graded based on the international age-related maculopathy grading system; optical coherence tomography (OCT) was used for the differential diagnosis. Overall, 3,278 patients were screened; the fundus photographs, OCT scans, and self-reports were collected at the mobile clinic in a single visit. Results: The prevalence of AMD in the study population was 8.99% (wet AMD 1.01%; dry AMD 7.85%), whereas the extrapolated estimate in the entire Slovakian population was 3.3% (wet AMD 0.3%; dry AMD 3.0%). Age, smoking, and hypertension were risk factors associated with AMD; however, contrary to reports in the literature, no gender-specific association was observed. Conclusion: Based on the results of this study, mobile clinics may be an effective way to extend health care access to a larger population. Early diagnosis of AMD will assist in early treatment and effective disease management of the population at risk.
C1 [Krasnik, Vladimir; Stefanickova, Jana; Popov, Ivajlo; Valaskova, Jela] Comenius Univ, Univ Hosp Ruzinov, Dept Ophthalmol, Bratislava, Slovakia.
   [Saxena, Sandeep] King Georges Med Univ, Dept Ophthalmol, Retina Serv, Lucknow, Uttar Pradesh, India.
   [Kruzliak, Peter] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Chem Drugs, Brno, Czech Republic.
C3 Comenius University Bratislava; King George's Medical University;
   University of Veterinary Sciences Brno
RP Stefanickova, J (通讯作者)，Comenius Univ, Dept Ophthalmol, Ruzinovska 6, Bratislava 82606, Slovakia.; Stefanickova, J (通讯作者)，Univ Hosp, Ruzinovska 6, Bratislava 82606, Slovakia.
EM jstefanicka@gmail.com
FU Novartis Slovakia, SRO
FX This study was supported by Novartis Slovakia, SRO. The authors thank
   all ophthalmologists across the Slovak republic who made this study
   happen and performed screening in the field.
CR Ahmad O.B., AGE STANDARDIZATION
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Doci J, 1988, Cesk Oftalmol, V44, P241
   Doi H, 2014, JAMA OPHTHALMOL, V132, P874, DOI 10.1001/jamaophthalmol.2014.849
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Hill C, 2012, AM J PUBLIC HEALTH, V102, P406, DOI 10.2105/AJPH.2011.300472
   Hill CF, 2014, AM J MANAG CARE, V20, P261
   Hiratsuka Y, 2001, J STUD ALCOHOL, V62, P397, DOI 10.15288/jsa.2001.62.397
   Horii T, 2010, AM J OPHTHALMOL, V150, P840, DOI 10.1016/j.ajo.2010.06.015
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Khan M., 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/608390
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Scholl HPN, 2007, MOL VIS, V13, P196
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 33
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 4
BP 506
EP 511
DI 10.1080/08820538.2017.1316861
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH6JW
UT WOS:000433551400012
PM 28524715
DA 2022-11-30
ER

PT J
AU Grizzard, WS
   Arnett, D
   Haag, SL
AF Grizzard, WS
   Arnett, D
   Haag, SL
TI Twin study of age-related macular degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; twin study; genetics; polygenic
   etiology; zygosity
ID GENETICS; MACULOPATHY; RISK
AB PURPOSE To evaluate the genetic contribution in age-related macular degeneration (ARMD) by a disease-ascertained twin study.
   METHODS Concordance rates for ARMD in 25 twins were obtained by using four masked graders to confirm the diagnosis of ARMD and place subjects in one of three categories; concordant, intermediate, or discordant. Demographic features and known risk factors for ARMD were compared between monozygotic and dizygotic twin pairs.
   RESULTS Of the 25 twin pairs, 15 were monzygotic and 10 were dizygotic. All 15 monozygotic twins were concordant or intermediate for ARMD. Of the dizygotic twin pairs, only one was concordant and five were discordant. In the demographic and risk factor analysis no unusual contributing or confounding variables were detected.
   CONCLUSIONS The association between zygosity and concordance for ARMD suggests a major importance for genetics in the etiology of ARMD. Our data further support a multi-factorial, primarily polygenic etiology for the condition.
C1 Retina Assoc Florida PA, Tampa, FL 33609 USA.
   Univ S Florida, Coll Publ Hlth, Tampa, FL USA.
   Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA.
C3 State University System of Florida; University of South Florida;
   University of Minnesota System; University of Minnesota Twin Cities
RP Grizzard, WS (通讯作者)，Retina Assoc Florida PA, 602 S MacDill Ave, Tampa, FL 33609 USA.
EM retinasg@tampabay.rr.com
CR CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Deutman A.F., 1971, HEREDITARY DYSTROPHI
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Evans K, 1996, BRIT J OPHTHALMOL, V80, P763, DOI 10.1136/bjo.80.8.763
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FLAM F, 1993, SCIENCE, V259, P1824, DOI 10.1126/science.259.5103.1824
   FRANCOIS J, 1977, OPHTHALMOLOGICA, V175, P67, DOI 10.1159/000308637
   Garibaldi DC, 1999, INT OPHTHALMOL CLIN, V39, P117, DOI 10.1097/00004397-199903940-00009
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 1999, MOL VIS, V5, pU31
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kaprio J, 1978, Prog Clin Biol Res, V24 Pt B, P179
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MURPHY EA, 1992, AM J MED GENET, V42, P842, DOI 10.1002/ajmg.1320420620
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5
   SMALL KW, 1992, ARCH OPHTHALMOL-CHIC, V110, P515, DOI 10.1001/archopht.1992.01080160093040
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   WAARDENBURG PJ, 1958, ACTA 18 CONC OPHTH B, V1, P446
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 29
TC 20
Z9 21
U1 2
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2003
VL 10
IS 5
BP 315
EP 322
DI 10.1076/opep.10.5.315.17317
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 745TW
UT WOS:000186705400003
PM 14566632
DA 2022-11-30
ER

PT J
AU Cook, HL
   Patel, PJ
   Tufail, A
AF Cook, H. L.
   Patel, P. J.
   Tufail, A.
TI Age-related macular degeneration: diagnosis and management
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
DE age-related macular degeneration; treatment; diagnosis; prophylaxis
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; RETINAL-PIGMENT EPITHELIUM;
   PHOTODYNAMIC THERAPY; OPHTHALMIC FINDINGS; TRANSLOCATION; VERTEPORFIN;
   RISK; RANIBIZUMAB
AB Background: Age-related macular degeneration (AMD) is a leading cause of blind registration in Western Europe and the third leading cause of blindness worldwide.
   Methods: The management of AMD is discussed with a review of current and new treatments.
   Results: Although there is no treatment for advanced dry AMD (geographic atrophy), there have been considerable advances in the management of neovascular AMD (nAMD). Established therapies for nAMD include laser photocoagulation and photodynamic therapy (PDT), but these have largely been superseded by agents which block the action of vascular endothelial growth factor (anti-VEGF agents). Current preventative strategies involve cessation of smoking and use of specific nutritional supplements to reduce the risk of developing nAMD.
   Conclusions: There have been exciting advances in the treatment of nAMD and increased understanding of the genetics and pathogenic mechanisms involved will hopefully lead to the development of new therapies in the future.
C1 [Cook, H. L.; Patel, P. J.; Tufail, A.] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
OI Tufail, Adnan/0000-0001-6131-7640
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BROWN DM, 2007, PIER STUDY DATA
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Okamoto H, 2006, MOL VIS, V12, P156
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Souied EH, 2005, MOL VIS, V11, P1135
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
NR 54
TC 71
Z9 75
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-1420
EI 1471-8391
J9 BRIT MED BULL
JI Br. Med. Bull.
PD MAR
PY 2008
VL 85
BP 127
EP 149
DI 10.1093/bmb/ldn012
PG 23
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 274NX
UT WOS:000254009100010
PM 18334518
OA Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU von der Emde, L
   Pfau, M
   Holz, FG
   Fleckenstein, M
   Kortuem, K
   Keane, PA
   Rubin, DL
   Schmitz-Valckenberg, S
AF von der Emde, Leon
   Pfau, Maximilian
   Holz, Frank G.
   Fleckenstein, Monika
   Kortuem, Karsten
   Keane, Pearse A.
   Rubin, Daniel L.
   Schmitz-Valckenberg, Steffen
TI AI-based structure-function correlation in age-related macular
   degeneration
SO EYE
LA English
DT Review
ID MICROPERIMETRY; DETERMINANTS; ASSOCIATION; PERFORMANCE; SECONDARY;
   VISION; DRUSEN
AB Sensitive and robust outcome measures of retinal function are pivotal for clinical trials in age-related macular degeneration (AMD). A recent development is the implementation of artificial intelligence (AI) to infer results of psychophysical examinations based on findings derived from multimodal imaging. We conducted a review of the current literature referenced in PubMed and Web of Science among others with the keywords 'artificial intelligence' and 'machine learning' in combination with 'perimetry', 'best-corrected visual acuity (BCVA)', 'retinal function' and 'age-related macular degeneration'. So far AI-based structure-function correlations have been applied to infer conventional visual field, fundus-controlled perimetry, and electroretinography data, as well as BCVA, and patient-reported outcome measures (PROM). In neovascular AMD, inference of BCVA (hereafter termed inferred BCVA) can estimate BCVA results with a root mean squared error of similar to 7-11 letters, which is comparable to the accuracy of actual visual acuity assessment. Further, AI-based structure-function correlation can successfully infer fundus-controlled perimetry (FCP) results both for mesopic as well as dark-adapted (DA) cyan and red testing (hereafter termed inferred sensitivity). Accuracy of inferred sensitivity can be augmented by adding short FCP examinations and reach mean absolute errors (MAE) of -3-5 dB for mesopic, DA cyan and DA red testing. Inferred BCVA, and inferred retinal sensitivity, based on multimodal imaging, may be considered as a quasi-functional surrogate endpoint for future interventional clinical trials in the future.
C1 [von der Emde, Leon; Pfau, Maximilian; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Pfau, Maximilian; Rubin, Daniel L.] Stanford Univ, Dept Biomed Data Sci Radiol & Med, Stanford, CA 94305 USA.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   [Kortuem, Karsten] Univ Ulm, Augenklin, Ulm, Germany.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of Bonn; Stanford University; Utah System of Higher
   Education; University of Utah; Ulm University; University of Hamburg;
   University Medical Center Hamburg-Eppendorf; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM steffen.valckenberg@utah.edu
OI Pfau, Maximilian/0000-0001-9761-9640; Keane, Pearse/0000-0002-9239-745X
FU German Research Foundation (DFG) [PF950/1-1]; PRO RETINA research
   stipend; Research to Prevent Blindness, New York, NY; Projekt DEAL
FX This work was supported by the German Research Foundation (DFG, grant
   PF950/1-1 to MP), PRO RETINA research stipend to LvdE and in part by an
   Unrestricted Grant from Research to Prevent Blindness, New York, NY, to
   the Department of Ophthalmology and Visual Sciences, University of Utah.
   Open Access funding enabled and organized by Projekt DEAL.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Aslam TM, 2018, AM J OPHTHALMOL, V185, P94, DOI 10.1016/j.ajo.2017.10.015
   Ayhan MS, 2020, MED IMAGE ANAL, V64, DOI 10.1016/j.media.2020.101724
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Christopher M, 2020, OPHTHALMOLOGY, V127, P346, DOI 10.1016/j.ophtha.2019.09.036
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DRASDO N, 1988, OPHTHAL PHYSL OPT, V8, P3
   Gerendas BS, 2017, VISION RES, V139, P204, DOI 10.1016/j.visres.2017.03.008
   Hess K, 2020, JAMA OPHTHALMOL, V138, P1272, DOI 10.1001/jamaophthalmol.2020.4335
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151
   Keane PA, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0048-y
   Kihara Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8029
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2019, OPHTHALMOL RETINA, V3, P201, DOI 10.1016/j.oret.2018.11.005
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Maloca PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220063
   McGuinness MB, 2020, OPHTHALMOL RETINA, V4, P881, DOI 10.1016/j.oret.2020.03.015
   Midena E, 2015, INT OPHTHALMOL, V35, P623, DOI 10.1007/s10792-012-9566-9
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Muller PL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082428
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Pfau M, 2020, OPHTHALMOLOGE, V117, P973, DOI 10.1007/s00347-020-01209-z
   Pfau M, 2020, AM J OPHTHALMOL, V217, P162, DOI 10.1016/j.ajo.2020.04.003
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pondorfer SG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.55
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Silva FR, 2013, ARQ BRAS OFTALMOL, V76, P170, DOI 10.1590/S0004-27492013000300008
   Sivaprasad S, 2018, AM J OPHTHALMOL, V190, P1, DOI 10.1016/j.ajo.2018.03.006
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sumaroka A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00800
   Sumaroka A, 2019, INVEST OPHTH VIS SCI, V60, P2551, DOI 10.1167/iovs.19-27156
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   VandenBosch ME, 1997, EYE, V11, P411, DOI 10.1038/eye.1997.87
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
NR 47
TC 3
Z9 3
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2021
VL 35
IS 8
BP 2110
EP 2118
DI 10.1038/s41433-021-01503-3
EA MAR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TS0VQ
UT WOS:000632801200001
PM 33767409
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Rojas-Fernandez, CH
   Tyber, K
AF Rojas-Fernandez, Carlos H.
   Tyber, Kevin
TI Benefits, Potential Harms, and Optimal Use of Nutritional
   Supplementation for Preventing Progression of Age-Related Macular
   Degeneration
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Review
DE Nutrition; Aging; Opthalmology; Pharmacogenetics and Pharmacogenomics;
   Drug Safety
ID CLINICALLY SIGNIFICANT ASSOCIATION; AREDS SUPPLEMENTS; ARMS2 GENOTYPES;
   EYE DISEASE; ZINC; CFH; ANTIOXIDANTS; QUALITY; NUMBER; GRADE
AB Objective: To briefly review age-related macular degeneration (AMD), the main findings from the Age Related Eye Disease Study (AREDS) report number 8 on the use of nutritional supplements for AMD, and to focus on data suggesting that supplement use should be guided using genetic testing of AMD risk genes. Data Sources: A literature search (January 2001 through October 26, 2016) was conducted using MEDLINE and the following MeSH terms: Antioxidants/therapeutic use, Genotype, Macular Degeneration/drug therapy, Macular degeneration/genetics, Dietary Supplements, Proteins/genetics, and Zinc Compounds/therapeutic use. Bibliographies of publications identified were also reviewed. Study Selection and Data Extraction: English-language studies assessing AREDS supplement response in patients with AMD in relation to complement factor H gene (CFH) and age-related maculopathy susceptibility 2 gene (ARMS2) risk alleles were evaluated. Data Synthesis: Three of the 4 studies demonstrated a treatment interaction between ARMS2 and CFH genotypes and a differential response to supplements. The fourth study documented an interaction for the CFH genotype only. Reported response interactions included attenuated response, no response, and good response, whereas a subset showed increased progression of AMD. Conversely, one study reported no interactions between CFH and ARMS2 risk alleles and response to supplements. Conclusions: The weight of the evidence supports using genetic testing to guide selection of ocular vitamin use. This approach will avoid using supplements that could speed the progression of AMD in vulnerable patients, avoid using supplements that will have little to no effect in others, and result in appropriately using supplements in those that are likely to derive meaningful benefits.
C1 [Rojas-Fernandez, Carlos H.] CRF Consulting, Waterloo, ON, Canada.
   [Rojas-Fernandez, Carlos H.] McMaster Univ, Hamilton, ON, Canada.
C3 McMaster University
RP Rojas-Fernandez, CH (通讯作者)，CRF Consulting, Waterloo, ON, Canada.
EM consultcrf@gmail.com
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambati J, 2002, ARCH OPHTHALMOL-CHIC, V120, P997
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2008, N ENGL J MED, V359, P1735
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE62, DOI 10.1016/j.ophtha.2015.03.028
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE59, DOI 10.1016/j.ophtha.2015.02.039
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE46, DOI 10.1016/j.ophtha.2014.12.042
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   Cherry J.D., 1982, PEDIATRICS, V69, P810, DOI 10.1542/peds.69.6.810
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x
   Dacks PA, 2014, JAMA NEUROL, V71, P137, DOI 10.1001/jamaneurol.2013.5376
   Ellingson C, 2016, INVEST OPHTH VIS SCI, V57, P17
   Gaynes BI, 2003, ARCH OPHTHALMOL-CHIC, V121, P416, DOI 10.1001/archopht.121.3.416
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seigel D, 2003, STAT MED, V22, P3419, DOI 10.1002/sim.1641
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   SPERDUTO RD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1403, DOI 10.1001/archopht.1990.01070120051026
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
NR 36
TC 7
Z9 7
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD MAR
PY 2017
VL 51
IS 3
BP 264
EP 270
DI 10.1177/1060028016680643
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EL1VZ
UT WOS:000394410800011
PM 27866147
DA 2022-11-30
ER

PT J
AU van de Graaf, ES
   Despriet, DDG
   Klaver, CCW
   Simonsz, HJ
AF van de Graaf, Elizabeth S.
   Despriet, Dominiek D. G.
   Klaver, Caroline C. W.
   Simonsz, Huibert J.
TI Patient-reported utilities in bilateral visual impairment from amblyopia
   and age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Patient-reported utilities; Bilateral visual impairment; Amblyopia;
   Age-related macular degeneration; Elderly
ID QUALITY-OF-LIFE; COMORBIDITIES
AB Background: Utility of visual impairment caused by amblyopia is important for the cost-effectiveness of screening for amblyopia (lazy eye, prevalence 3-3.5 %). We previously measured decrease of utility in 35-year-old persons with unilateral persistent amblyopia. The current observational case-control study aimed to measure loss of utility in patients with amblyopia with recent decrease of vision in their better eye. As these patients are rare, the sample was supplemented by patients with bilateral age-related macular degeneration with similar decrease of vision.
   Methods: From our out-patient department, two groups of patients with recent deterioration to bilateral visual acuity less than Snellen 0.5 (bilateral visual impairment, BVI) were recruited, with either persistent amblyopia and age-related macular degeneration (AMB + AMD), or with bilateral age-related macular degeneration (BAMD). To measure utility, the time trade-off method and the standard gamble method were applied through interviews. Correlations were sought between utility values and visual acuity, age and Visual Function Questionnaire-25 scores.
   Results: Seventeen AMB + AMD patients (mean age 72.9 years), and 63 BAMD patients (mean age 79.6 years) were included in the study. Among AMB + AMD, 80 % were willing to trade lifetime in exchange for cure. The overall mean time trade-off utility was 0.925. Among BAMD, 75 % were willing to trade, utility was 0.917. Among AMB + AMD, 38 % accepted risk of death in exchange for cure, overall mean standard gamble utility was 0.999. Among BAMD, 49 % accepted risk of death, utility was 0.998. Utility was not related to visual acuity but it was to age (p = 0.02).
   Conclusion: Elderly patients with BVI, caused by persistent amblyopia and age-related macular degeneration (AMD) or by bilateral AMD, had an approximately 8 % loss of TTO utility. Notably, the 8 % loss in elderly with BVI differs little from the 3.7 % loss we found previously in 35-year-old persons with unilateral amblyopia with good vision in the other eye. The moderate impact of BVI in senescence could be explained by adaptation, comorbidity, avoidance of risk and a changed percept of cure.
C1 [van de Graaf, Elizabeth S.; Klaver, Caroline C. W.; Simonsz, Huibert J.] Univ Med Ctr Rotterdam, Dept Ophthalmol, Erasmus MC, POB 2040NL, NL-3000 CA Rotterdam, Netherlands.
   [Despriet, Dominiek D. G.] Admiraal de Ruyter Hosp, Dept Ophthalmol, POB 3200NL, NL-4380 DD Vlissingen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Simonsz, HJ (通讯作者)，Univ Med Ctr Rotterdam, Dept Ophthalmol, Erasmus MC, POB 2040NL, NL-3000 CA Rotterdam, Netherlands.
EM Simonsz@compuserve.com
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258
FU Prof. Dr. Henkes Foundation; Foundation Nederlands Oogheelkundig
   Onderzoek
FX ESvdG was supported by grants from the Prof. Dr. Henkes Foundation and
   the Foundation Nederlands Oogheelkundig Onderzoek.
CR Achterberg WP., 2011, MULTIDISCIPLINAIRE R
   Brouwer WBF, 2005, SOC SCI MED, V61, P1083, DOI 10.1016/j.socscimed.2005.01.008
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2002, BRIT J OPHTHALMOL, V86, P8, DOI 10.1136/bjo.86.1.8
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Carlton J, 2008, HEALTH TECHNOL ASSES, V12, P1
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Groenewoud JH, 2010, INVEST OPHTH VIS SCI, V51, P3476, DOI 10.1167/iovs.08-3352
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Real FJ, 2008, BRIT J OPHTHALMOL, V92, P770, DOI 10.1136/bjo.2007.127407
   Schilling OK, 2011, PSYCHOL AGING, V26, P203, DOI 10.1037/a0021127
   Snowdon SK, 1997, HEALTH TECHNOL ASSES, V1, P1
   van de Graaf E S, 2004, Strabismus, V12, P181
   van de Graaf ES, 2010, GRAEFES ARCH CLIN EX, V248, P1263
   van Leeuwen R, 2007, BRIT J OPHTHALMOL, V91, P1450, DOI 10.1136/bjo.2006.113670
NR 17
TC 4
Z9 4
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 17
PY 2016
VL 16
AR 56
DI 10.1186/s12886-016-0234-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN0ES
UT WOS:000376737800001
PM 27184381
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Bornfeld, N
AF Joussen, Antonia M.
   Bornfeld, Norbert
TI The Treatment of Wet Age-Related Macular Degeneration
SO DEUTSCHES ARZTEBLATT INTERNATIONAL
LA English
DT Review
DE macular degeneration; age-related macular degeneration; off-label
   treatment; treatment; monoclonal antibodies
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ENDOTHELIAL GROWTH-FACTOR;
   RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; PEGAPTANIB SODIUM; PROFESSIONAL-ASSOCIATION; AUTOLOGOUS
   TRANSLOCATION; TRIPLE THERAPY; RANIBIZUMAB
AB Background: Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the area of the retina that has the highest visual acuity. It can progress to geographic atrophy or choroidal neovascularization.
   Method: Selective literature review.
   Results: The authors discuss the results of therapeutic trials and the treatment recommendations of the ophthalmological societies. Mechanism-targeted treatments and improved modes of administration offer the potential for improved therapy.
   Conclusions: With the advent of the antivascular endothelial growth factor (anti-VEGF) therapy, the prognosis of choroidal neovascularization has changed dramatically. Visual acuity can actually be improved, but, in most cases, the improvement can only be sustained with repeated intravitreal injections. Dtsch Arztebl Int 2009; 106(18): 312-7 DOI: 10.3238/arztebl.2009.0312
C1 [Joussen, Antonia M.] Univ Dusseldorf, Augenklin, D-40225 Dusseldorf, Germany.
   [Bornfeld, Norbert] Univ Essen Gesamthsch, Augenklin, Abt Hinterer Augenabschnitt, Essen, Germany.
C3 Heinrich Heine University Dusseldorf; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; University of Duisburg Essen;
   University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Augenklin, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM JoussenA@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo-Gonzalez C, 2008, BRIT J OPHTHALMOL, V92, P74, DOI 10.1136/bjo.2007.128942
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   CHAKRAVARTHY U, 2006, OPHTHALMOLOGY
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EVANS JR, 2008, COCHRANE DA IN PRESS, V1
   FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KIM I, 2000, INVEST OPHTH VIS SCI, V41, P368
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   KLAIS CM, 2006, RETINA, V26, P780
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Pauleikhoff D, 2005, KLIN MONATSBL AUGENH, V222, P381, DOI 10.1055/s-2005-858225
   Position of the Retinological Society, 2007, KLIN MONATSBL AUGENH, V224, P559
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Silva RLE, 2006, EXP EYE RES, V83, P1260, DOI 10.1016/j.exer.2006.07.003
   Silva RLE, 2005, INVEST OPHTH VIS SCI, V46, P3323, DOI 10.1167/iovs.04-1210
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   SPIRO T, 2007, DTSCH ARZTEBL, V104, pA2033
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   COMP AGE RELATED MAC
NR 69
TC 18
Z9 22
U1 0
U2 2
PU DEUTSCHER AERZTE-VERLAG GMBH
PI COLOGNE
PA DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY
SN 1866-0452
J9 DTSCH ARZTEBL INT
JI Dtsch. Arztebl. Int.
PD MAY 1
PY 2009
VL 106
IS 18
BP 312
EP +
DI 10.3238/arztebl.2009.0312
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 476UD
UT WOS:000268470600002
PM 19547647
OA Green Published
DA 2022-11-30
ER

PT J
AU Yim, J
   Chopra, R
   Spitz, T
   Winkens, J
   Obika, A
   Kelly, C
   Askham, H
   Lukic, M
   Huemer, J
   Fasler, K
   Moraes, G
   Meyer, C
   Wilson, M
   Dixon, J
   Hughes, C
   Rees, G
   Khaw, PT
   Karthikesalingam, A
   King, D
   Hassabis, D
   Suleyman, M
   Back, T
   Ledsam, JR
   Keane, PA
   De Fauw, J
AF Yim, Jason
   Chopra, Reena
   Spitz, Terry
   Winkens, Jim
   Obika, Annette
   Kelly, Christopher
   Askham, Harry
   Lukic, Marko
   Huemer, Josef
   Fasler, Katrin
   Moraes, Gabriella
   Meyer, Clemens
   Wilson, Marc
   Dixon, Jonathan
   Hughes, Cian
   Rees, Geraint
   Khaw, Peng T.
   Karthikesalingam, Alan
   King, Dominic
   Hassabis, Demis
   Suleyman, Mustafa
   Back, Trevor
   Ledsam, Joseph R.
   Keane, Pearse A.
   De Fauw, Jeffrey
TI Predicting conversion to wet age-related macular degeneration using deep
   learning
SO NATURE MEDICINE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; DRUSEN VOLUME; CHOROIDAL NEOVASCULARIZATION;
   RETICULAR PSEUDODRUSEN; VISUAL OUTCOMES; PROGRESSION; PREVALENCE; DELAY;
   MANAGEMENT; DELIVERY
AB In individuals diagnosed with age-related macular degeneration in one eye, a deep learning model can predict progression to the 'wet', sight-threatening form of the disease in the second eye within a 6-month time frame.
   Progression to exudative 'wet' age-related macular degeneration (exAMD) is a major cause of visual deterioration. In patients diagnosed with exAMD in one eye, we introduce an artificial intelligence (AI) system to predict progression to exAMD in the second eye. By combining models based on three-dimensional (3D) optical coherence tomography images and corresponding automatic tissue maps, our system predicts conversion to exAMD within a clinically actionable 6-month time window, achieving a per-volumetric-scan sensitivity of 80% at 55% specificity, and 34% sensitivity at 90% specificity. This level of performance corresponds to true positives in 78% and 41% of individual eyes, and false positives in 56% and 17% of individual eyes at the high sensitivity and high specificity points, respectively. Moreover, we show that automatic tissue segmentation can identify anatomical changes before conversion and high-risk subgroups. This AI system overcomes substantial interobserver variability in expert predictions, performing better than five out of six experts, and demonstrates the potential of using AI to predict disease progression.
C1 [Yim, Jason; Chopra, Reena; Obika, Annette; Meyer, Clemens; Hassabis, Demis; Suleyman, Mustafa; Back, Trevor; Ledsam, Joseph R.; De Fauw, Jeffrey] DeepMind, London, England.
   [Chopra, Reena; Lukic, Marko; Huemer, Josef; Fasler, Katrin; Moraes, Gabriella; Khaw, Peng T.; Keane, Pearse A.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Chopra, Reena; Lukic, Marko; Huemer, Josef; Fasler, Katrin; Moraes, Gabriella; Khaw, Peng T.; Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
   [Spitz, Terry; Winkens, Jim; Kelly, Christopher; Askham, Harry; Wilson, Marc; Dixon, Jonathan; Hughes, Cian; Karthikesalingam, Alan; King, Dominic] Google Hlth, London, England.
   [Rees, Geraint] UCL, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Ledsam, JR; De Fauw, J (通讯作者)，DeepMind, London, England.; Keane, PA (通讯作者)，Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.; Keane, PA (通讯作者)，UCL Inst Ophthalmol, London, England.
EM jledsam@google.com; pearse.keane1@nhs.net; defauw@google.com
RI Rees, Geraint/C-1493-2008
OI Rees, Geraint/0000-0002-9623-7007; Kelly,
   Christopher/0000-0002-1246-844X; Lukic, Marko/0000-0002-7636-8368; Khaw,
   Sir Peng Tee/0000-0002-8087-2268; Keane, Pearse/0000-0002-9239-745X;
   Spitz, Terry/0000-0002-9791-3767
FU NIHR [NIHR-CS-2014-14-023]; College of Optometrists, United Kingdom; MRC
   [MC_PC_19005] Funding Source: UKRI; UKRI [MR/T019050/1] Funding Source:
   UKRI
FX We thank the patients under the care of Moorfields Eye Hospital. We
   would also like to thank B. Romera-Paredes, O. Ronneberger, N. Tomasev,
   S. Blackwell, J. Schrouff, M. Chesus, C. Cooper, V. Cornelius, A.
   Khawaja, R. Ahamed, T. Corkett, R. Ogbe, Y. Ibitoye, M. Bawn, J. Besley,
   C. Meaden, C. Chorley, S. Rowley, A. Ahmad, K. Clancy, C. Semturs, A.
   Varadarajan, B. Babenko, I. Traynis, Y. Liu, L. Peng, N. Hammel, K.
   Blumer, K. Kavukcuoglu, S. Bouton, G. Corrado, E. Manna, A. C. Bird, W.
   Tucker, Y. Obadeyi, Z. Jessa, D. Sim, M. Natkunarajah and A. Jindal.
   P.A.K. is supported by an NIHR Clinician Scientist Award (no.
   NIHR-CS-2014-14-023). The views expressed are those of the author(s) and
   not necessarily those of the NHS, the NIHR or the Department of Health.
   R.C. receives studentship support from the College of Optometrists,
   United Kingdom.
CR Abadi M, 2015, TENSORFLOW LARGE SCA
   Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2015, ARXIV150302531
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x
   Babenko B, 2019, PREDICTING PROGRESSI
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Banerjee I, 2019, ARXIV PREPRINT ARXIV
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buchlovsky P., 2019, TF REPLICATOR DISTRI
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cicek Ozgun, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P424, DOI 10.1007/978-3-319-46723-8_49
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   De Fauw Jeffrey, 2016, F1000Res, V5, P1573
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Fasler K, 2019, 2 BIORXIV, DOI DOI 10.1101/615252
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kingma J., 2014, ARXIV
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   NIHR Oxford Biomedical Research Centre, 2019, WORLDS 1 GEN THER OP
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds M, OPEN SOURCING SONNET
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Tomasev N, 2019, NATURE, V572, P116, DOI 10.1038/s41586-019-1390-1
   Tonekaboni S., 2019, ARXIV190505134, parXiv:1905.05134
   UK Information Commissioner's Office, 2015, AN MAN DAT PROT RISK
   Vander JF, 2006, YEARB OPHTHALMOL, V2006, P119
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wang K, 2015, IEEE ICC, P7007, DOI 10.1109/ICC.2015.7249443
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie S., 2018, P EUROPEAN C COMPUTE, P305
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 64
TC 84
Z9 86
U1 1
U2 32
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2020
VL 26
IS 6
BP 892
EP +
DI 10.1038/s41591-020-0867-7
EA MAY 2020
PG 25
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA LZ3ZG
UT WOS:000534540300001
PM 32424211
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Pitlick, JM
   Vecera, KF
   Barnes, KN
   Reski, JW
   Forinash, AB
AF Pitlick, Jamie M.
   Vecera, Kayla F.
   Barnes, Kylie N.
   Reski, John W.
   Forinash, Alicia B.
TI Bevacizumab for the Treatment of Neovascular Age-Related Macular
   Degeneration
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE Avastin; bevacizumab; neovascular macular degeneration; vascular
   endothelial growth factor
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL TEARS; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; CLINICAL-TRIALS; INJECTION; AVASTIN; RANIBIZUMAB;
   THERAPY
AB OBJECTIVE: To review data regarding the efficacy and safety of bevacizumab for the treatment of neovascular age-related macular degeneration (nARMD).
   DATA SOURCES: Literature was searched using MEDLINE (1976-September 2011) and EMBASE (1973-September 2011). Search terms included bevacizumab, Avastin, neovascular macular degeneration, age-related macular degeneration, vascular endothelial growth factor, intravitreal, and safety. Reference citations were reviewed for relevant information.
   STUDY SELECTION AND DATA EXTRACTION: All randomized clinical trials published in English with data assessing the safety and efficacy of bevacizumab for nARMD were evaluated.
   DATA SYNTHESIS: The only Food and Drug Administration approved treatments for nARMD are photodynamic therapy (PDT) with verteporfin, intravitreal pegaptanib, and ranibizumab. However, bevacizumab has gained attention as a potential agent in treating nARMD and is now widely used in practice. PDT with verteporfin and pegaptanib has shown only stabilization of visual acuity (VA). When the efficacy of bevacizumab was compared to these therapies, bevacizumab clinically and statistically improved VA outcomes. When compared to ranibizumab, which has also been shown to improve VA, bevacizumab showed no significant difference in VA outcomes and was associated with a decrease in average annual cost of $22,805.
   CONCLUSIONS: Bevacizumab administered intravitreally is appropriate for prevention of vision loss and recovery of VA in patients with nARMD. Although further analysis of long-term effects of bevacizumab on VA and safety is needed, it is potentially a more cost-effective option than ranibizumab for the treatment of nARMD.
C1 [Pitlick, Jamie M.] St Louis Coll Pharm, Dept Pharm Practice, St Louis, MO 63110 USA.
   [Reski, John W.] NW Eye Care Professionals, Portland, OR USA.
RP Pitlick, JM (通讯作者)，St Louis Coll Pharm, Dept Pharm Practice, St Louis, MO 63110 USA.
EM jpitlick@stlcop.edu
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   American Academy of Ophthalmology Retina/Vitreous Panel, 2008, AG REL MAC DEG
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bezerra HG, 2009, JACC-CARDIOVASC INTE, V2, P1035, DOI 10.1016/j.jcin.2009.06.019
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown DP, 2008, OPT COMMUN, V281, P5287, DOI 10.1016/j.optcom.2008.07.033
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Cavalcante LL, 2010, CLIN OPHTHALMOL, V4, P519
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cleary C A, 2011, Ir Med J, V104, P146
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inman ZD, 2011, RETINA-J RET VIT DIS, V31, P669, DOI 10.1097/IAE.0b013e3181ef463d
   Inoue M, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329863
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Sheybani A, 2009, RETINA-J RET VIT DIS, V29, P1404, DOI 10.1097/IAE.0b013e3181b32d13
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
NR 54
TC 6
Z9 6
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD FEB
PY 2012
VL 46
IS 2
BP 290
EP 296
DI 10.1345/aph.1Q471
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 900XA
UT WOS:000300923800016
PM 22274144
DA 2022-11-30
ER

PT J
AU De Sutter, C
   Schauwvlieghe, PP
   Ruys, J
   Cosemans, I
   Depla, J
   Van Laere, S
   Veckeneer, M
AF De Sutter, Charlotte
   Schauwvlieghe, Pieter-Paul
   Ruys, Joke
   Cosemans, Ine
   Depla, Jozef
   Van Laere, Sven
   Veckeneer, Marc
TI Occurrence of Macular Neovascularization after Retinal Pigment
   Epithelium-Choroid Translocation Surgery to Treat Complicated
   Age-Related Macular Degeneration: Incidence, Management, and Outcome
SO OPHTHALMOLOGICA
LA English
DT Article
DE Retinal pigment epithelium and choroid graft translocation; Macular
   neovascularization; Age-related macular degeneration; Retina;
   Vitreoretinal surgery
ID TYPE-3 NEOVASCULARIZATION; GRAFT
AB Introduction: This study investigates the incidence, clinical characteristics, and treatment response of macular neovascularization (MNV) occurring after retinal pigment epithelium (RPE) and choroid graft translocation surgery (RPE-choroid TS). Methods: Retrospective analysis of 36 eyes of 36 consecutive patients who underwent RPE-choroid TS. Longer term follow-up of graft survival focusing on the occurrence of MNV was performed using multimodal imaging. Results: Indications for RPE-choroid TS included complications of neovascular age-related macular degeneration in 34 patients and drusenoid pigment epithelial detachment in 2 patients. With a mean follow-up of 30 months, 8 patients out of 36 developed signs of MNV. Of these 8 patients, 4 presented with a drop in visual acuity (VA) due to centrally located type 3 MNV. Early diagnosis and treatment prevented significant functional consequences. Four patients developed type 2 MNV at the border of the graft, which did not tend to affect the VA. Conclusion: We report a high incidence of MNV after RPE-choroid TS. Early diagnosis and treatment may preserve function in these patients. The type of MNV and location can be used to guide the management. (C) 2021 S. Karger AG, Basel
C1 [De Sutter, Charlotte] Free Univ Brussels, Univ Hosp Brussels, Dept Ophthalmol, Brussels, Belgium.
   [Schauwvlieghe, Pieter-Paul; Ruys, Joke; Cosemans, Ine; Depla, Jozef; Veckeneer, Marc] ZNA Middelheim, Dept Ophthalmol, Antwerp, Belgium.
   [Van Laere, Sven] Free Univ Brussels, Interfac Ctr Data Proc & Stat, Brussels, Belgium.
C3 Universite Libre de Bruxelles; Vrije Universiteit Brussel; University
   Hospital Brussels; ZNA Middelheim Hospital; Universite Libre de
   Bruxelles; Vrije Universiteit Brussel
RP De Sutter, C (通讯作者)，Free Univ Brussels, Univ Hosp Brussels, Dept Ophthalmol, Brussels, Belgium.
EM desutterchar@gmail.com
OI Veckeneer, Marc/0000-0003-2240-9053
CR Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53307-x
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Parolini B, 2020, RETINA-J RET VIT DIS, V40, P507, DOI 10.1097/IAE.0000000000002429
   Pertile G, 2018, INVEST OPHTH VIS SCI, V59, P93, DOI 10.1167/iovs.18-24229
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sillen Hedwig, 2020, GMS Ophthalmol Cases, V10, pDoc24, DOI 10.3205/oc000151
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   van Romunde SHM, 2019, RETINA-J RET VIT DIS, V39, P288, DOI 10.1097/IAE.0000000000001945
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Veckeneer M, 2017, EYE, V31, P1274, DOI 10.1038/eye.2017.137
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 23
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2022
VL 245
IS 1
BP 69
EP 79
DI 10.1159/000519519
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2P4NS
UT WOS:000819720600010
PM 34530427
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Lee, KE
   Gangnon, RE
   Klein, BEK
AF Klein, Ronald
   Knudtson, Michael D.
   Lee, Kristine E.
   Gangnon, Ronald E.
   Klein, Barbara E. K.
TI Age-period-cohort effect on the incidence of age-related macular
   degeneration - The Beaver Dam Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; UNITED-STATES; BIRTH COHORT; MACULOPATHY; PREVALENCE;
   POPULATION; PROGRESSION; ADULTS
AB Objective: To examine relationships of age, period, and birth cohort with the 5-year incidence of age-related macular degeneration (AMD).
   Design: Population-based cohort study with 4 examination visits 5 years apart from 1988 through 1990, 1993 through 1995, 1998 through 2000, and 2003 through 2005.
   Participants: Two thousand nine hundred sixty-eight persons (6603 participant visits) and 3588 persons (8184 participant visits) 43 to 86 years of age at baseline contributing to the incidence of early and late AMD, respectively.
   Methods: Grading of stereoscopic fundus photographs using the Wisconsin Age-Related Maculopathy Grading System. Main Outcome Measures: Five-year incidence of early AMD.
   Results: While controlling for age, there was a lower 5-year incidence of early AMD in later rather than in earlier birth cohorts (odds ratio per increasing category, 0.70; 95% confidence interval, 0.62-0.78; P<0.001). This remained while controlling for smoking, blood pressure, and other related factors. There was no evidence for a period or birth cohort effect with late AMD.
   Conclusions: Lower incidence of early AMD in more recent birth cohorts is likely the result of unmeasured risk factors for early AMD. Further study of possible unmeasured risk factors that may have caused this cohort effect may help to identify new modifiable risk factors for AMD. Diminishing incidence of early AMD in later birth cohorts would be expected to result in lower long-term estimates of future incidence of AMD than do current estimates that do not take this effect into account.
C1 [Klein, Ronald; Knudtson, Michael D.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Gangnon, Ronald/0000-0003-2587-6714; Klein, Ronald/0000-0002-4428-6237
FU National Institutes of Health, Bethesda, Maryland [EY06594]; Research to
   Prevent Blindness, Inc., New York, New York; National Eye Institute;
   NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant no. EY06594 [RK, BEKK]), and in part by Senior Scientific
   Investigator Awards from Research to Prevent Blindness, Inc., New York,
   New York (RK, BEKK). The National Eye Institute provided funding for the
   entire study, including collection and analyses of data; Research to
   Prevent Blindness provided further additional support for data analyses.
CR Akaike H., 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding JZ, 2007, AM J CLIN NUTR, V85, P405
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1991, BEAVER DAM EYE STUDY, P74
   KLEIN R, 1991, WISCONSIN AGE RELATE, P8
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2, P61
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Moore AA, 2005, AM J PUBLIC HEALTH, V95, P458, DOI 10.2105/AJPH.2003.019471
   Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49
NR 22
TC 38
Z9 39
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2008
VL 115
IS 9
BP 1460
EP 1467
DI 10.1016/j.ophtha.2008.01.026
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 346LZ
UT WOS:000259071300004
PM 18762073
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Inoue, M
   Arakawa, A
   Yamane, S
   Kadonosono, K
AF Inoue, Maiko
   Arakawa, Akira
   Yamane, Shin
   Kadonosono, Kazuaki
TI Imaging of sub-retinal pigment epithelial linear structures in patients
   with age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Bruch membrane; Optical coherence
   tomography; Pigment epithelial detachment; Retinal angiomatous
   proliferation; Retinal pigment epithelium
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY;
   DEPOSITS; MACULOPATHY; DRUSEN
AB Purpose: To evaluate hyperreflective linear structures (HLS), as assessed using spectral-domain optical coherence tomography (SD-OCT), identified under the retinal pigment epithelium (RPE) in patients with age-related macular degeneration (AMD).
   Methods: This retrospective observational case study was conducted on 427 eyes of 408 consecutive patients who were scheduled to undergo anti-vascular endothelial growth factor (anti-VEGF) therapy for AMD. Patients with HLS under the RPE were investigated based on the SD-OCT findings at baseline or during the follow-up period. The associations between HLS and the lesion subtypes, localization in SD-OCT, clinical findings, and structural change after anti-VEGF treatment were also investigated.
   Results: HLS were identified in 18 eyes of 16 patients. From the eyes with HLS, 12 eyes (66.7%) were diagnosed with retinal angiomatous proliferation (RAP), 4 eyes (22.2%) were diagnosed with occult choroidal neovascularization, and the remaining 2 eyes (11.1%) were diagnosed with polypoidal choroidal vasculopathy, HLS were multifocal and exhibited multilocalization under the RPE in all the eyes. Although it was difficult to identify these structures in the clinical findings at baseline, crystalline deposits correlated with the linear bands were observed during the follow-up period in 16 eyes (88.9%). After the anti-VEGF treatments, the HLS remained between the Bruch membrane and RPE or combined with the fibrovascular component.
   Conclusions: HLS are rare SD-OCT findings found in patients with AMD, found in only 4.2% of the patients examined in this study. HLS were found especially in RAP lesions.
C1 [Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 232, Japan.
C3 Yokohama City University
RP Inoue, M (通讯作者)，4-57 Urafune Cho Minami Ku, Yokohama, Kanagawa 2320024, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Lima LH, 2010, RETINA-J RET VIT DIS, V30, P542, DOI 10.1097/IAE.0b013e3181c713e4
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 18
TC 1
Z9 1
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2014
VL 24
IS 5
BP 744
EP 750
DI 10.5301/ejo.5000433
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0OH
UT WOS:000343270700016
PM 24474382
DA 2022-11-30
ER

PT J
AU Corvi, F
   Cozzi, M
   Invernizzi, A
   Pace, L
   Sadda, SR
   Staurenghi, G
AF Corvi, Federico
   Cozzi, Mariano
   Invernizzi, Alessandro
   Pace, Lucia
   Sadda, Srinivas R.
   Staurenghi, Giovanni
TI Optical coherence tomography angiography for detection of macular
   neovascularization associated with atrophy in age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Fluorescein angiography; Geographic atrophy; Indocyanine green
   angiography; Macular atrophy; Macular neovascularization; Optical
   coherence tomography; Optical coherence tomography angiography
ID CHOROIDAL NEOVASCULARIZATION; EYES
AB Purpose To evaluate the ability of optical coherence tomography angiography (OCTA) to detect macular neovascularization (MNV) in eyes with atrophy compared with fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). Methods In this prospective study, eyes with MNV and atrophy (termed macular atrophy or MA) secondary to age-related macular degeneration (AMD), and AMD eyes with geographic atrophy (GA) without MNV underwent multimodal imaging with FA, ICGA, structural OCT, and OCTA. The presence of MNV was determined using all imaging modalities by senior retina specialists and was considered the gold standard reference. Each individual imaging modality was then evaluated independently by two expert readers for the presence of MNV in a masked fashion. Morphologic characteristics of the MNV were evaluated on the custom OCTA slab. Results Twenty-one patients with MA+MNV and 21 with GA only were enrolled. Manual segmentation on OCTA allowed detection of the MNV in 95.2% of eyes with MA+MNV and in 4.7% of eyes with GA, showing high specificity (95.2%) and sensitivity (95.2%). FA, ICGA, and OCT detected MNV in 57.1%, 52.3%, and 66.7% of eyes with MA+MNV and in 14.2%, 9.5%, and 42.8% with GA. Sensitivity and specificity were 85.7% and 57.1% for FA, 90.5% and 52.4% for ICGA, and 66.7% and 57.1% for OCT. Conclusions OCTA appears to be superior to other imaging modalities for identification of MNV in eyes with macular atrophy. OCTA should be considered as part of the multimodal imaging evaluation of eyes with atrophy, particularly in the context of clinical trials.
C1 [Corvi, Federico; Cozzi, Mariano; Invernizzi, Alessandro; Pace, Lucia; Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
   [Corvi, Federico; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Corvi, Federico; Sadda, Srinivas R.] Univ Calif Los Angeles, Davide Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Invernizzi, Alessandro] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
C3 University of Milan; Luigi Sacco Hospital; Doheny Eye Institute;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Sydney
RP Corvi, F (通讯作者)，Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.; Corvi, F (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.; Corvi, F (通讯作者)，Univ Calif Los Angeles, Davide Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM federico.corvi@yahoo.it
RI Corvi, Federico/AAD-7691-2021
OI Corvi, Federico/0000-0002-2661-5500; Cozzi, Mariano/0000-0001-7777-2461
CR American Academy of Ophthalmology, 2015, AG REL MAC DEG PREF
   Bagchi A, 2019, EYE, V33, P1111, DOI 10.1038/s41433-019-0378-2
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Nesper PL, 2018, RETINA-J RET VIT DIS, V38, P1289, DOI 10.1097/IAE.0000000000001863
   Novais EA, 2016, OSLI RETINA, V47, P201, DOI 10.3928/23258160-20160229-01
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 27
TC 9
Z9 10
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2021
VL 259
IS 2
BP 291
EP 299
DI 10.1007/s00417-020-04821-6
EA JUL 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA9UY
UT WOS:000545206700001
PM 32620993
OA Green Published
DA 2022-11-30
ER

PT J
AU Gehlbach, P
   Li, T
   Hatef, E
AF Gehlbach, P.
   Li, T.
   Hatef, E.
TI Statins for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID REDUCTASE INHIBITORS STATINS; 5-YEAR INCIDENCE; MACULOPATHY;
   PROGRESSION; RISK; PREVALENCE; COHORT
AB Background
   Age-related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age-related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries (Congdon 2003). Recent epidemiologic, genetic and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.
   Objectives
   To examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and/or progression of AMD.
   Search strategy
   We searched CENTRAL in The Cochrane Library, MEDLINE, EMBASE and LILACS on 30 April 2009 and the WHO International Clinical Trials Registry Platform on 11 May 2009. We searched reference lists and the Science Citation Index. There were no language or date restrictions in the search for trials.
   Selection criteria
   We included randomized controlled trials (RCTs) that compared statins with other treatments, no treatment, or placebo in participants who were either susceptible to or diagnosed as having early stages of AMD.
   Data collection and analysis
   Two authors independently evaluated the search results against the selection criteria. Two Italian speaking colleagues extracted data. One author entered data. We did not perform a meta-analysis because only one completed RCT was identified.
   Main results
   Two studies met the selection criteria. One trial reported insufficient details to assess the risk of bias; the other trial is ongoing.
   Of the completed trial, the analyses of 30 participants did not show a statistically significant difference between the simvastatin and the placebo arm in visual acuity at three months of treatment (decimal visual acuity 0.21 +/- 0.56 in simvastatin and 0.19 +/- 0.40 in placebo arm) or 45 days after the completion of treatment (decimal visual acuity 0.20 +/- 0.50 in simvastatin and 0.19 +/- 0.48 in placebo arm). The lens and retina status were unchanged during and after the treatment period for both groups.
   Of the ongoing trial, the preliminary analyses of 42 participants who completed 12 months follow-up did not show a statistically significant difference between the simvastatin and the placebo arm in visual acuity, drusen score or visual function (effect estimates and confidence intervals were not available). We contacted the investigators and will update the review as data become available.
   Authors' conclusions
   Evidence from currently available RCTs was insufficient to conclude that statins have any role in preventing or delaying the onset or progression of AMD.
C1 [Gehlbach, P.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21231 USA.
   [Li, T.] Johns Hopkins Bloomberg Sch Publ Hlth, Cochrane Eyes & Vis Grp, US Project, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Gehlbach, P (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.
EM pgelbach@jhmi.edu
FU NEI NIH HHS [N01EY21003] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [N01EY021003] Funding Source: NIH RePORTER
CR *AM ACC OPHTH RET, 2006, AG REL MAC DEG LIM R
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P249
   DELLAVALLE V, 2000, ANN OTTALMOLOGIA CLI, V125, P89
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Geltzer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub2
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guymer RH, 2005, INVEST OPHTH VIS SCI, V46
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sagara N, 2007, EXP EYE RES, V84, P1074, DOI 10.1016/j.exer.2007.02.005
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   VIRGILI G, 2007, COCHRANE DB SYST REV
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 41
TC 12
Z9 12
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 3
AR CD006927
DI 10.1002/14651858.CD006927.pub2
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 471EE
UT WOS:000268037500018
PM 19588411
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Afshari, FT
   Kwok, JC
   Andrews, MR
   Blits, B
   Martin, KR
   Faissner, A
   Ffrench-Constant, C
   Fawcett, JW
AF Afshari, Fardad T.
   Kwok, Jessica C.
   Andrews, Melissa R.
   Blits, Bas
   Martin, Keith R.
   Faissner, Andreas
   Ffrench-Constant, Charles
   Fawcett, James W.
TI Integrin activation or alpha9 expression allows retinal pigmented
   epithelial cell adhesion on Bruch's membrane in wet age-related macular
   degeneration
SO BRAIN
LA English
DT Article
DE Integrins; retinal pigment epithelium; Bruch's membrane; Tenascin-C;
   age-related macular; degeneration
ID CHOROIDAL NEOVASCULAR MEMBRANES; TENASCIN-C EXPRESSION; NEURITE
   OUTGROWTH; EXTRACELLULAR-MATRIX; LIGAND-BINDING; III REPEAT; ADULT-RAT;
   HUMAN RPE; IN-VITRO; TRANSPLANTATION
AB Retinal pigment epithelial cell malfunction is a causative feature of age-related macular degeneration, and transplantation of new retinal pigment epithelial cells is an attractive strategy to prevent further progression and visual loss. However, transplants have shown limited efficacy, mainly because transplanted cells fail to adhere and migrate onto pathological Bruch's membrane. Adhesion to Bruch's membrane is integrin-mediated. Ageing of Bruch's membrane leads to a decline in integrin ligands and, added to this, wet age-related macular degeneration leads to upregulation of anti-adhesive molecules such as tenascin-C. We have therefore investigated whether manipulation of integrin function in retinal pigment epithelial cells can restore their adhesion and migration on wet age-related macular degeneration-damaged Bruch's membrane. Using spontaneously immortalized human retinal pigment epithelial cells (adult retinal pigment epithelium-19), we show that adhesion and migration on the Bruch's membrane components is integrin-dependent and enhanced by integrin-activating agents manganese and TS2/16. These allowed cells to adhere and migrate on low concentrations of ligand, as would be found in aged Bruch's membrane. We next developed a method for stripping cells from Bruch's membrane so that adhesion and migration assays can be performed on its surface. Integrin activation had a moderate effect on enhancing retinal pigmented epithelial cell adhesion and migration on normal human and rat Bruch's membrane. However, on Bruch's membrane prepared from human wet age-related macular degeneration-affected eyes, adhesion was lower and integrin activation had a much greater effect. A candidate molecule for preventing retinal pigmented epithelial interaction with age-related macular degeneration-affected Bruch's membrane is tenascin-C which we confirm is present at high levels in wet age-related macular degeneration membrane. We show that tenascin-C is anti-adhesive for retinal pigmented epithelial cells, but after integrin activation, they can adhere and migrate on it using alphaVbeta3 integrin. Alternatively, we find that transduction of retinal pigmented epithelial cells with alpha9 integrin, a tenascin-C-binding integrin, led to a large increase in alpha9beta1-mediated adhesion and migration on tenascin-C. Both expression of alpha9 integrin and integrin activation greatly enhanced the ability of retinal pigment epithelial cells to adhere to tenascin-rich wet age-related macular degeneration-affected Bruch's membranes. Our results suggest that manipulation of retinal pigment epithelial cell integrins through integrin activating strategies, or expression of new integrins such as alpha9, could be effective in improving the efficacy of retinal pigment epithelial cell transplantation in wet age-related macular degeneration-affected eyes.
C1 [Afshari, Fardad T.; Kwok, Jessica C.; Andrews, Melissa R.; Martin, Keith R.; Fawcett, James W.] Univ Cambridge, Cambridge Ctr Brain Repair, Dept Clin Neurosci, Cambridge CB2 0PY, England.
   [Blits, Bas] Inst Royal Acad Arts & Sci, Netherlands Inst Neurosci, Lab Neuroregenerat, NL-1105 BA Amsterdam, Netherlands.
   [Faissner, Andreas] Ruhr Univ Bochum, Fac Biol, Dept Cell Morphol & Mol Neurobiol, D-44780 Bochum, Germany.
   [Ffrench-Constant, Charles] Univ Edinburgh, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland.
C3 University of Cambridge; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); Ruhr University
   Bochum; University of Edinburgh
RP Fawcett, JW (通讯作者)，Univ Cambridge, Cambridge Ctr Brain Repair, Dept Clin Neurosci, Forvie Site,Robinson Way, Cambridge CB2 0PY, England.
EM jf108@cam.ac.uk
RI Kwok, Jessica/A-6740-2013; Faissner, Andreas/A-5314-2008
OI Faissner, Andreas/0000-0002-2211-8259; Andrews,
   Melissa/0000-0001-5960-5619; Kwok, Jessica/0000-0002-9798-9083; Fawcett,
   James/0000-0002-7990-4568
FU Medical Research Council; Henry Smith Charity; John and Lucille van
   Geest foundation; European Union; Medical Research Council [G0800784B,
   G0701518, G0800784, G0700711B, G9900991B, G0300723B, G0300723] Funding
   Source: researchfish; MRC [G0800784, G0701518, G0300723] Funding Source:
   UKRI
FX Medical Research Council; Henry Smith Charity; John and Lucille van
   Geest foundation; European Union Framework 6 network of excellence
   NeuroNE.
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Andrews MR, 2009, J NEUROSCI, V29, P5546, DOI 10.1523/JNEUROSCI.0759-09.2009
   Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229
   BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Cai H, 2006, MOL VIS, V12, P1
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   Crowe DL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-18
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   FANG IM, 2008, EXP EYE RES
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   FOKSEANG J, 1995, DEV BIOL, V171, P1, DOI 10.1006/dbio.1995.1255
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hoffmann Stephan, 2005, BMC Ophthalmol, V5, P16, DOI 10.1186/1471-2415-5-16
   Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008
   Huang WT, 2001, CANCER RES, V61, P8586
   Humphries MJ, 2004, BIOCHEM SOC T, V32, P407, DOI 10.1042/BST0320407
   Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9
   Ivins JK, 2000, J NEUROSCI, V20, P6551, DOI 10.1523/JNEUROSCI.20-17-06551.2000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kiernan BW, 1996, MOL CELL NEUROSCI, V7, P322, DOI 10.1006/mcne.1996.0024
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   LIN WH, 1993, J NEUROSCI RES, V34, P546, DOI 10.1002/jnr.490340507
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MCKEON RJ, 1991, J NEUROSCI, V11, P3398
   Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008
   Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865
   MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270
   Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   Nieswandt B, 2007, J EXP MED, V204, P3113, DOI 10.1084/jem.20071827
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101
   Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37
   Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0
   SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687
   Sun K, 2007, MOL VIS, V13, P2310
   Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652
   Taga T, 2002, INT J CANCER, V98, P690, DOI 10.1002/ijc.10265
   Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tsuchida J, 1997, FEBS LETT, V416, P212, DOI 10.1016/S0014-5793(97)01206-4
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang H, 2006, J REHABIL RES DEV, V43, P713, DOI 10.1682/JRRD.2005.06.0114
   WEHRLEHALLER B, 1993, J CELL SCI, V106, P597
   Wennerberg K, 1998, J CELL SCI, V111, P1117
   Wilby MJ, 1999, MOL CELL NEUROSCI, V14, P66, DOI 10.1006/mcne.1999.0766
   YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691
   Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423
   Zagzag D, 1996, CANCER RES, V56, P182
   Zagzag D, 2002, HISTOL HISTOPATHOL, V17, P301, DOI 10.14670/HH-17.301
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zhang Y, 1997, J NEUROSCI RES, V49, P433
NR 71
TC 20
Z9 22
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2010
VL 133
BP 448
EP 464
DI 10.1093/brain/awp319
PN 2
PG 17
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 558VY
UT WOS:000274777700012
PM 20159768
OA Bronze
DA 2022-11-30
ER

PT J
AU Chieh, JJ
   Fekrat, S
AF Chieh, Janet J.
   Fekrat, Sharon
TI Large subretinal hemorrhage after intravitreal bevacizumab (Avastin (R))
   for age-related macular degeneration
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION
AB We report the development of a large subretinal hemorrhage 4 weeks after intravitreal bevacizumab in an 84-year-old male with 20/70 visual acuity caused by occult choroidal neovascularization from neovascular age-related macular degeneration in one eye that was treated with 1.25 mg of intravitreal bevacizumab.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   Duke Univ, Ctr Med, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, POB 3802,Erwin Rd, Durham, NC 27710 USA.
EM fekra001@rnc.duke.edu
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 5
TC 11
Z9 11
U1 0
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD SPR
PY 2007
VL 39
IS 1
BP 51
EP 52
DI 10.1007/BF02697326
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 188SI
UT WOS:000247939200009
PM 17914205
DA 2022-11-30
ER

PT J
AU Chen, L
   Messinger, JD
   Sloan, KR
   Swain, TA
   Sugiura, Y
   Yannuzzi, LA
   Curcio, CA
   Freund, KB
AF Chen, Ling
   Messinger, Jeffrey D.
   Sloan, Kenneth R.
   Swain, Thomas A.
   Sugiura, Yoshimi
   Yannuzzi, Lawrence A.
   Curcio, Christine A.
   Freund, K. Bailey
TI Nonexudative Macular Neovascularization Supporting Outer Retina in
   Age-Related Macular Degeneration A Clinicopathologic Correlation
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE-GREEN VIDEOANGIOGRAPHY; EARLY
   CHOROIDAL NEOVASCULARIZATION; SUBMACULAR SURGERY TRIALS; ENDOTHELIAL
   GROWTH-FACTOR; PIGMENT EPITHELIUM; BRUCHS MEMBRANE; GEOGRAPHIC ATROPHY;
   TYPE-1 NEOVASCULARIZATION; SUBCLINICAL NEOVASCULARIZATION
AB Purpose: Type 1 macular neovascularization (MNV) secondary to age-related macular degeneration (AMD) may sustain hypoxic and micronutrient-insufficient outer retinal cells compensatorily. We explored this hypothesis via histologic analysis of an eye with a shallow irregular retinal pigment epithelial elevation (SIRE) on OCT and good vision.
   Design: Case study and clinicopathologic correlation.
   Participant: A white woman with untreated nonexudative neovascular AMD and 20/30 visual acuity (left eye) and neovascular AMD (right eye), with 9 years' multimodal imaging before dying at 90 years of age.
   Methods: The left eye was preserved 6.25 hours after death and prepared for submicrometer epoxy resin sections and transmission electron microscopy aligned to clinical OCT B-scans. Inside and outside the MNV area, layer thicknesses, phenotypes, and vascular density of native choriocapillaris and neovessels were measured. Lengths of choriocapillaries and intervening gaps in the index eye and in early AMD eyes and healthy eyes with similar age (n = 19 each) from the Project MACULA (Maculopathy Unveiled by Laminar Analysis) online histopathologic resource (http://projectmacula.cis.uab.edu/) were measured with custom software (Caps and Gaps).
   Main Outcome Measures: Descriptive features, vascular density, histologic and OCT layer thicknesses, and distribution of choriocapillaries and intervening gaps.
   Results: The SIRE correlated to a type 1 MNV that expanded slowly without evidence of exudation and with numerous choroidal vessels traversing Bruch's membrane defects, some visible on OCT. Tissue layers in and adjacent to the MNV area showed continuous RPE and characteristic AMD deposits. Capillary-like neovessels with fenestrations and caveolae resembling native choriocapillaris lined the retinal pigment epithelium (RPE) with a vascular density comparable with surrounding non-MNV areas. Relative to early AMD and healthy aged eyes, the index eye showed similar capillary lengths but larger gaps between vessels, indicating dropout. Outer nuclear layer thickness was preserved and showed less photoreceptor degeneration over areas of relative choriocapillaris health, including the type 1 MNV.
   Conclusions: Eyes with nonexudative type 1 MNV in AMD may progress to exudation, yet this stable MNV complex supported outer retinal structure for 9 years. Distinguishing features were numerous connecting vessels, high density of neovessels, continuous RPE, and slow growth. Maintaining beneficial type 1 MNV may be a therapeutic strategy. (C) 2020 by the American Academy of Ophthalmology
C1 [Chen, Ling; Messinger, Jeffrey D.; Sloan, Kenneth R.; Swain, Thomas A.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Chen, Ling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Sugiura, Yoshimi; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Sugiura, Yoshimi] Univ Tsukuba, Fac Med, Dept Ophthalmol, Tsukuba, Ibaraki, Japan.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Harkness Eye Inst, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Vitreous Retina Macula Consultants of New York;
   University of Tsukuba; Manhattan Eye Ear & Throat Hospital; New York
   University; Columbia University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, EyeSight Fdn Alabama Vis Res Labs, Sch Med, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI ; Freund, K. Bailey/V-7488-2018
OI Sugiura, Yoshimi/0000-0003-2970-2658; Chen, Ling/0000-0002-5552-4667;
   Freund, K. Bailey/0000-0002-7888-9773; Curcio,
   Christine/0000-0001-9769-1538; Sloan, Kenneth/0000-0002-8747-4449
FU Macula Foundation, Inc., New York, NY; National Eye Institute, National
   Institutes of Health, Bethesda, Maryland; Hoffman LaRoche; Research to
   Prevent Blindness, Inc., New York, New York; EyeSight Foundation of
   Alabama; Heidelberg Engineering
FX Supported by The Macula Foundation, Inc., New York, NY (C.A.C); the
   National Eye Institute, National Institutes of Health, Bethesda,
   Maryland (T.A.S.); Hoffman LaRoche; Heidelberg Engineering; Research to
   Prevent Blindness, Inc., New York, New York (unrestricted funds to the
   Department of Ophthalmology); the Sarks Fund (C.A.C.); and the EyeSight
   Foundation of Alabama (unrestricted funds to the Department of
   Ophthalmology).
CR [Anonymous], 1980, T OPHTHAL SOC UK
   [Anonymous], 2015, RETINA J RET VIT DIS
   [Anonymous], 2015, J CLIN MED, DOI DOI 10.3390/JCM4071380
   [Anonymous], 2019, BRIT J OPHTHALMOL, DOI DOI 10.1136/BJOPHTHALMOL-2018-313004
   [Anonymous], 2016, JAMA OPHTHALMOL, DOI DOI 10.1001/JAMAOPHTHALMOL.2016.3519
   [Anonymous], 2018, RETINA J RET VIT DIS, DOI DOI 10.1097/IAE.0000000000002198
   [Anonymous], 2018, RETINA J RET VIT DIS, DOI DOI 10.1097/IAE.0000000000002182
   [Anonymous], 2018, INVEST OPHTH VIS SCI, DOI DOI 10.1167/IOVS.17-22953
   [Anonymous], 2005, ARCH OPHTHALMOL CHIC
   [Anonymous], 2016, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2016.03.045
   [Anonymous], 2018, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2017.08.019
   [Anonymous], 2018, OPHTHALMOL RETINA
   [Anonymous], 2018, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2018.08.014
   [Anonymous], 1992, OPHTHALMOLOGY
   [Anonymous], 2019, ACTA OPHTHALMOL, DOI DOI 10.1111/AOS.14088
   [Anonymous], 2018, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2018.06.020
   [Anonymous], 2014, AM J PATHOL, DOI DOI 10.1016/J.AJPATH.2014.07.017
   [Anonymous], 1998, OPHTHALMOLOGY
   [Anonymous], 2011, INVEST OPHTH VIS SCI, DOI DOI 10.1167/IOVS.10-6476
   [Anonymous], 2015, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2015.08.028
   [Anonymous], 2016, RETINA J RET VIT S1
   [Anonymous], 2015, INVEST OPHTH VIS SCI, DOI DOI 10.1167/IOVS.15-16432
   [Anonymous], 2019, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2019.04.037
   [Anonymous], 2006, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2005.07.076
   [Anonymous], 1990, OPHTHALMOLOGY
   [Anonymous], 2020, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2019.11.007
   [Anonymous], 1994, OPHTHALMOLOGY
   [Anonymous], 2012, J CLIN INVEST, DOI DOI 10.1172/JCI65157
   [Anonymous], 2019, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2019.06.017
   [Anonymous], 2019, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2019.07.003
   [Anonymous], 1996, OPHTHALMOLOGY
   [Anonymous], 1994, OPHTHALMOLOGY
   [Anonymous], 2001, INVEST OPHTH VIS SCI
   [Anonymous], 2019, EXP EYE RES, DOI DOI 10.1016/J.EXER.2019.02.018
   [Anonymous], 2007, RETINA J RET VIT DIS
   [Anonymous], 2016, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2016.05.005
   [Anonymous], 2019, AM J PATHOL, DOI DOI 10.1016/J.AJPATH.2019.04.005
   [Anonymous], 1997, EYE 4
   [Anonymous], 2016, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2016.01.044
   [Anonymous], 2018, RETINA J RET VIT DIS, DOI DOI 10.1097/IAE.0000000000001766
   [Anonymous], 2013, JAMA OPHTHALMOL
   [Anonymous], 2015, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2015.08.001
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Chen Katherine G, 2021, Retin Cases Brief Rep, V15, P207, DOI 10.1097/ICB.0000000000000826
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Dhrami-Gavazi E, 2015, INT J RETINA VITREOU, V1, P15
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hou KK, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.50
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Li M, 2019, OPHTHALMOL RETINA, V3, P99
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Or C, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0187-6
   Pettenkofer M, 2019, OPHTHALMIC SURG LASE, V50, P302
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1978, CHANGES REGION CHORI
   Shi Y, 2019, OPHTHALMOL RETINA, V3, P211
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zouache MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35754
NR 76
TC 37
Z9 37
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2020
VL 127
IS 7
BP 931
EP 947
DI 10.1016/j.ophtha.2020.01.040
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ND9OC
UT WOS:000562228700020
PM 32247535
OA Bronze
DA 2022-11-30
ER

PT J
AU Gualino, V
   Tadayoni, R
   Cohen, SY
   Erginay, A
   Fajnkuchen, F
   Haouchine, B
   Krivosic, V
   Quentel, G
   Vicaut, E
   Gaudric, A
AF Gualino, Vincent
   Tadayoni, Ramin
   Cohen, Salomon Yves
   Erginay, Ali
   Fajnkuchen, Franck
   Haouchine, Belkacem
   Krivosic, Valerie
   Quentel, Gabriel
   Vicaut, Eric
   Gaudric, Alain
TI OPTICAL COHERENCE TOMOGRAPHY, FLUORESCEIN ANGIOGRAPHY, AND DIAGNOSIS OF
   CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; color fundus photograph; choroidal
   neovascularization; optical coherence tomography; fluorescein
   angiography; sensitivity; specificity
ID SPECTRAL-DOMAIN; TIME-DOMAIN; MANAGEMENT; LEAKAGE
AB Purpose: To determine the sensitivity and specificity of different retinal imaging combinations for the diagnosis of choroidal neovascularization (CNV) in age-related macular degeneration.
   Methods: Patients aged 50 years or older referred for suspicious recent-onset CNV related to age-related macular degeneration were prospectively included for 6 months. Data recorded included color fundus photographs (CFPs), spectral domain optical coherence tomography (SD-OCT), and fluorescein angiography (FA) images. Five retina specialists randomly interpreted SD-OCT combined with CFP, and then FA combined with CFP. The reference diagnosis of CNV was based on the agreement of two readers in the interpretation of the SD-OCT + FA + CFP combination.
   Results: One hundred and forty-eight patients (148 eyes) were included. For the diagnosis of CNV, the sensitivity of both SD-OCT + CFP and FA + CFP was of 90.9%. Type 2 CNV was diagnosed in 98% to 100% of cases with SD-OCT + CFP or FA + CFP, whereas Type 1 CNV was diagnosed in 82.9% of cases with SD-OCT + CFP and 81.6% with FA + CFP.
   Conclusion: When used as a first diagnostic test, SD-OCT combined with CFP had sensitivity and specificity similar to those of FA combined with CFP, for the diagnosis of CNV in age-related macular degeneration. This shows the increasingly important role of SD-OCT as a first-line test in the diagnosis of CNV.
C1 [Gualino, Vincent; Tadayoni, Ramin; Erginay, Ali; Haouchine, Belkacem; Krivosic, Valerie; Gaudric, Alain] Univ Paris Diderot, Sorbonne Paris Cite, Hop Lariboisiere, AP HP,Ophthalmol Dept, Paris, France.
   [Cohen, Salomon Yves; Fajnkuchen, Franck; Quentel, Gabriel] Ctr Imagerie & Laser, Paris, France.
   [Vicaut, Eric] Univ Paris Diderot, Sorbonne Paris Cite, Hop Lariboisiere, AP HP,Clin Res Unit, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French
   Research Universities; Universite Paris Cite
RP Tadayoni, R (通讯作者)，Lariboisiere Hosp, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM ramin.tadayoni@aphp.fr
OI Gualino, Vincent/0000-0002-3941-1304; Gaudric, Alain/0000-0002-2486-4722
FU Departement de la Recherche Clinique et du Developpement (DRCD), AP-HP,
   Paris, France
FX Departement de la Recherche Clinique et du Developpement (DRCD), AP-HP,
   Paris, France
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
NR 29
TC 13
Z9 13
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2019
VL 39
IS 9
BP 1664
EP 1671
DI 10.1097/IAE.0000000000002220
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EB
UT WOS:000507473000006
PM 30045134
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Battu, P
   Sharma, K
   Rain, M
   Singh, R
   Anand, A
AF Battu, Priya
   Sharma, Kaushal
   Rain, Manjari
   Singh, Ramandeep
   Anand, Akshay
TI Serum Levels of ARMS2, COL8A1, RAD51B, and VEGF and their Correlations
   in Age-related Macular Degeneration
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Age-related macular degeneration; ARMS2; RAD51B; VEGF; ELISA
ID BRCA1; ASSOCIATION; EXPRESSION; THERAPY; GENES
AB Background: Many factors including genetic and environmental are responsible for the incidence of Age-related Macular Degeneration (AMD). However, its pathogenesis has not been clearly elucidated yet. Objective: This study aimed to estimate the Age-Related Maculopathy Susceptibility 2 (ARMS2), Collagen type VIII Alpha 1 chain (COL8A1), Rad 51 paralog(RAD51B), and Vascular Endothelial Growth Factor (VEGF) protein levels in serum of AMD and control participants and to further investigate their correlation to understand AMD pathogenesis. Methods: For this case-control study, 31 healthy control and 57 AMD patients were recruited from Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. A blood sample was taken and serum was isolated from it. ELISA (enzyme-linked immunosorbent assay) was used for the estimation of proteins in the serum of patients. Results: ARMS2 and COL8A1 levels were significantly elevated in the AMD group than in the control group. The highest levels of ARMS2, COL8A1, and VEGF proteins were recorded for the wet AMD sub-group. The study results endorsed significant positive correlation between these following molecules; ARMS2 and COL8A1 (r = 0.933, p < 0.0001), ARMS2 and RAD51B (r = 0.704, p < 0.0001), ARMS2 and VEGF (r = 0.925, p < 0.0001), COL8A1 and RAD51B (r = 0.736, p < 0.0001), COL8A1 and VEGF (r = 0.879, p < 0.0001), and RAD51B and VEGF (r = 0.691, p < 0.0001). Conclusion: The ARMS2 and COL8A1 levels were significantly higher and RAD51B was significantly lower in the AMD group than controls. Also, a significant statistical correlation was detected between these molecules, indicating that their interaction may be involved in the pathogenesis of AMD.
C1 [Battu, Priya; Sharma, Kaushal; Rain, Manjari; Anand, Akshay] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
   [Singh, Ramandeep] Post Grad Inst Med Educ & Res, Adv Eye Ctr, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.
EM akshay1anand@rediffmail.com
FU Department of Biotechnology, New Delhi, India
   [BT/PR17550/MED/30/1755/2016]
FX The study was funded by the Department of Biotechnology, New Delhi,
   India (grant no. BT/PR17550/MED/30/1755/2016) .
CR Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Ferrara N., 2019, EXPERT REV ANTICANC, V18, P251
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Hopfer U, 2005, FASEB J, V19, P1232, DOI 10.1096/fj.04-3019com
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Jin Y., 2018, INT EYE SCI, V18, P2244
   Kang HJ, 2006, J BIOL CHEM, V281, P13047, DOI 10.1074/jbc.M513033200
   Kaplan AR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav4508
   Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Ma ZH, 2012, EXP THER MED, V4, P621, DOI 10.3892/etm.2012.652
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Pires E, 2017, DNA REPAIR, V59, P76, DOI 10.1016/j.dnarep.2017.09.008
   Pugazhendhi A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031170
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Sharma K, 2021, GENOMICS, V113, P514, DOI 10.1016/j.ygeno.2020.09.044
   Shin HT, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01830-9
   Singh KK, 2013, J THORAC CARDIOV SUR, V146, P949, DOI 10.1016/j.jtcvs.2012.12.064
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Zhao WX, 2017, NATURE, V550, P360, DOI 10.1038/nature24060
NR 30
TC 5
Z9 5
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PY 2021
VL 18
IS 2
BP 181
EP 188
DI 10.2174/1567202618666210531130711
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA WQ3GO
UT WOS:000713707700003
PM 34060991
DA 2022-11-30
ER

PT J
AU Itagaki, K
   Sekiryu, T
   Kasai, A
   Sugano, Y
   Ogasawara, M
   Saito, M
AF Itagaki, Kanako
   Sekiryu, Tetsuju
   Kasai, Akihito
   Sugano, Yukinori
   Ogasawara, Masashi
   Saito, Masaaki
TI Three-year outcome of aflibercept treatment for Japanese patients with
   neovascular age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Treat-and-extend
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTEND REGIMEN; FOLLOW-UP;
   THERAPY; RECURRENCE; ANCHOR; MARINA
AB BackgroundTo evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD).MethodsForty-nine treatment-naive nAMD patients (50 eyes) were enrolled in this prospective study. The eyes received IAI at two-month intervals in the first year. The treatment regimen was changed to IAI based on a treat-and-extend approach in the second and third years.ResultsTwenty-nine eyes of 28 patients were successfully followed up over 36months. The nAMD subtypes included 15 eyes with typical AMD and 14 eyes with polypoidal choroidal vasculopathy. The number of IAIs performed over the 3 years was 17.23.1 (mean +/- standard deviation). The mean logMAR, which was 0.42 at baseline, improved to 0.19 (P=0.001) at 12months, and 0.26 (P=0.049) at 36months. The central retinal thickness (CRT) was 329 +/- 120 mu m at baseline, 151 +/- 38 mu m (P<0.001) at 12months, and 143 +/- 61 mu m (P<0.001) at 36months. The mean subfoveal choroidal thickness (SFCT) was 288 +/- 97 mu m at baseline, 243 +/- 82 mu m (P<0.001) at 12months, and 208 +/- 63 mu m (P<0.01) at 36months. The changes in logMAR, CRT, and SFCT over the study period did not differ between typical AMD and PCV.Conclusion Long-term aflibercept injection can achieve visual improvement and reduce the thickness of the retina and choroid in nAMD. Morphological improvement of these tissues may not be sufficient to sustain earlier visual improvement over the long-term.
C1 [Itagaki, Kanako; Sekiryu, Tetsuju; Kasai, Akihito; Sugano, Yukinori; Ogasawara, Masashi] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Fukushima, Japan.
   [Saito, Masaaki] Hirosaki Univ, Dept Ophthalmol, Hirosaki, Aomori, Japan.
C3 Fukushima Medical University; Hirosaki University
RP Sekiryu, T (通讯作者)，Fukushima Med Univ, Dept Ophthalmol, Fukushima, Fukushima, Japan.
EM sekiryu@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Sekiryu, Tetsuju/0000-0001-8042-2729
FU Bayer Yakuhin, Osaka
FX This study was supported by Bayer Yakuhin, Osaka. The support covers
   materials and equipment required for the study. The funder had no role
   in study design, data collection and analysis, decision to publish,
   interpretation of data and preparation of the manuscript.
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barakat A, 2018, J FR OPHTALMOL, V41, P603, DOI 10.1016/j.jfo.2018.01.005
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Massougnes S, 2018, RETINA-J RET VIT DIS, V38, P717, DOI 10.1097/IAE.0000000000001613
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
NR 29
TC 7
Z9 7
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 10
PY 2020
VL 20
IS 1
AR 276
DI 10.1186/s12886-020-01542-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MP2FW
UT WOS:000552026100001
PM 32650757
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gomi, F
   Sawa, M
   Tsujikawa, M
   Nishida, K
AF Gomi, Fumi
   Sawa, Miki
   Tsujikawa, Motokazu
   Nishida, Kohji
TI TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL
   RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adjunctive treatment; age-related macular degeneration; inflammation;
   injection frequency; neovascularization; nonsteroidal antiinflammatory
   drug; ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; JAPANESE
   PATIENTS; COMBINATION THERAPY; CONTROLLED-TRIAL; DOSING REGIMEN;
   EFFICACY; PATHOGENESIS; INSTILLATION; VERTEPORFIN
AB Purpose: Intravitreal injection of ranibizumab is highly effective for wet age-related macular degeneration. Its limitation is that most patients require repeated intravitreal injections to achieve and maintain the visual gain. We assessed the effectiveness of adjunctive topical bromfenac, a nonsteroidal antiinflammatory drug, with ranibizumab.
   Methods: Patients with wet age-related macular degeneration with lesions smaller than 2 disk diameters were randomized 2:3 to adjunctive topical bromfenac (n = 16) or sham (n = 22) and a 0.5-mg ranibizumab injection in a double-masked fashion. Subjects were examined monthly, and ranibizumab was injected as needed from baseline. The primary endpoint was the comparison of the number of ranibizumab injections over 6 months. The visual and anatomic responses also were compared.
   Results: The mean number of ranibizumab injections over 6 months was 2.2 in the bromfenac group and 3.2 in the sham, a difference that reached significance (P = 0.0274). The changes in visual acuity did not differ significantly (P = 0.3141) although the central retinal thickness was tended to decrease more in bromfenac group (P = 0.0604). Multivariate analysis showed that topical bromfenac is significantly associated with fewer ranibizumab injections.
   Conclusion: Topical bromfenac might reduce the frequency of ranibizumab over 6 months in eyes with relatively small age-related macular degeneration lesions. RETINA 32:1804-1810, 2012
C1 [Gomi, Fumi; Sawa, Miki; Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Grad Sch Med, Dept Ophthalmol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817; Nishida, Kohji/0000-0001-9069-3610
FU Japan Society for the Promotion of Science, Tokyo, Japan [22591942]
FX Supported in part by the Japan Society for the Promotion of Science,
   Tokyo, Japan (Grant-in-Aid for Scientific Research, no. 22591942).
CR Asai T, 2006, CORNEA, V25, P224, DOI 10.1097/01.ico.0000177835.93130.d4
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Baklayan GA, 2008, J OCUL PHARMACOL TH, V24, P392, DOI 10.1089/jop.2007.0082
   Bekendam PD, 2007, CORNEA, V26, P1002, DOI 10.1097/ICO.0b013e3180cfe626
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grant CA, 2008, INVEST OPHTHALMOL  S, V49, P563, DOI [10.1167/iovs.07-0624, DOI 10.1167/IOVS.07-0624]
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P222, DOI 10.1001/archopht.1995.01100020106040
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Warren KA, 2010, RETINA-J RET VIT DIS, V30, P260, DOI 10.1097/IAE.0b013e3181b8628e
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 31
TC 28
Z9 29
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1804
EP 1810
DI 10.1097/IAE.0b013e31825be87f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800015
PM 22718152
DA 2022-11-30
ER

PT J
AU Ansary, MF
   Crincoli, E
   Semoun, O
   Uzzan, J
   Amoroso, F
   Jung, C
   Miere, A
   Souied, E
AF Ansary, Meryem Filali
   Crincoli, Emanuele
   Semoun, Oudy
   Uzzan, Joel
   Amoroso, Francesca
   Jung, Camille
   Miere, Alexandra
   Souied, Eric
TI Undetectable Macular Neovascularization on OCT Angiography in Age
   Related Macular Degeneration: Comparison between Different Devices
SO MEDICINA-LITHUANIA
LA English
DT Article
DE optical coherence tomography (OCT); OCT-angiography (OCTA); macular
   neovascularization; spectral-domain OCTA; swept-source OCTA
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; TYPE-1
AB Background and Objectives: The aim of this study was to report the characteristics of macular neovascularization (MNV) with undetectable flow on optical coherence tomography angiography (OCTA) in neovascular age related macular degeneration (nAMD), and compare them with the characteristics of detectable MNV. Materials and Methods: Patients with a diagnosis of nAMD who underwent dye imaging and OCTA in the same day were included and divided into two groups: undetectable and detectable flow on OCTA. Three OCTA devices were used, two with spectral-domain technology (AngioVue, RTVue 100xAvanti, Optovue, Freemont, CA, USA and Heidelberg OCT2 Beta Angiography Module, Heidelberg Engineering, Germany) and one swept-source OCTA (PlexElite 9000; Carl Zeiss Meditec, Inc., Dublin, CA, USA). We studied the demographics, neovascularization characteristics, and OCTA device and acquisition characteristics for both groups. Results: A global comparison between Group 1 and Group 2 was made, followed by an analysis of variables associated with (un)detectability for each OCTA device. A total of 108 eyes were included: 90 in the detectable group (Group 1) and 18 in the undetectable group (Group 2), corresponding to a global sensitivity of OCTA for the detection of MNV of 83.49%. There was a statistically significant difference between the two groups regarding MNV type (p = 0.02) and PED height (p = 0.017). For the three devices, detection sensitivity with automatic segmentation was significantly lower than with manual segmentation. For Heidelberg, PED Height and scan quality explained 68.3% of the undetectability. For AngioVue, PED Height and absence of hemorrhage explained 67.9% of undetectability. Conclusions: In this study, we found a global sensitivity of 83.49% for the three OCTA devices combined, with a range from 55.5% to 96.26% depending on the segmentation and OCTA device. This means that undetectable/undetected MNV can represent up to 45% of the examinations, eventually misdiagnosing choroidal neovascularization for 1 out every 2 patients.
C1 [Ansary, Meryem Filali; Crincoli, Emanuele; Semoun, Oudy; Uzzan, Joel; Amoroso, Francesca; Miere, Alexandra; Souied, Eric] Univ Paris Est, Creteil Univ, Dept Ophthalmol, Hop Intercommunal Creteil,Eye Clin, 40 Ave Verdun, F-94010 Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Ctr Clin Res, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Miere, A (通讯作者)，Univ Paris Est, Creteil Univ, Dept Ophthalmol, Hop Intercommunal Creteil,Eye Clin, 40 Ave Verdun, F-94010 Creteil, France.
EM alexandra.miere@chicreteil.fr
OI Crincoli, Emanuele/0000-0001-9996-9871; JUNG,
   Camille/0000-0001-8486-8939
CR Arrigo A, 2021, FRONT PHYS-LAUSANNE, V9, DOI 10.3389/fphy.2021.694035
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Colantuono D, 2021, EUR J OPHTHALMOL, V31, P2474, DOI 10.1177/1120672120968758
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Coscas Florence M, 2008, Retin Cases Brief Rep, V2, P94, DOI 10.1097/ICB.0b013e31804576a9
   Coscas G, 2016, DEV OPHTHALMOL, V56, P1, DOI 10.1159/000442768
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Ellis P P, 1980, Trans Am Ophthalmol Soc, V78, P190
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lira Rodrigo Pessoa Cavalcanti, 2007, Arq. Bras. Oftalmol., V70, P615, DOI 10.1590/S0004-27492007000400011
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Mrejen S, 2019, RETINA-J RET VIT DIS, V39, P1973, DOI 10.1097/IAE.0000000000002244
   Nikolopoulou E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6724818
   Ohayon A, 2019, OSLI RETINA, V50, pE242, DOI 10.3928/23258160-20190905-16
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Soomro T, 2018, EYE, V32, P662, DOI 10.1038/eye.2018.2
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Wang FP, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0113-2
   Yeo JH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091272
NR 28
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD SEP
PY 2022
VL 58
IS 9
AR 1246
DI 10.3390/medicina58091246
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4S9CJ
UT WOS:000857729200001
PM 36143923
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Tomita, K
   Tsujikawa, A
   Nakata, I
   Akagi-Kurashige, Y
   Miyake, M
   Ooto, S
   Tamura, H
   Yoshimura, N
AF Yamashiro, Kenji
   Tomita, Kaoruko
   Tsujikawa, Akitaka
   Nakata, Isao
   Akagi-Kurashige, Yumiko
   Miyake, Masahiro
   Ooto, Sotaro
   Tamura, Hiroshi
   Yoshimura, Nagahisa
TI Factors Associated With the Response of Age-Related Macular Degeneration
   to Intravitreal Ranibizumab Treatment
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT FACTOR-H; PHOTODYNAMIC
   THERAPY; SUBGROUP ANALYSIS; JAPANESE PATIENTS; BEVACIZUMAB; INJECTION;
   EFFICACY; NEOVASCULARIZATION; GENOTYPE
AB PURPOSE: To investigate factors affecting patient response to intravitreal ranibizumab treatment for age-related macular degeneration (AMD).
   DESIGN: Retrospective chart review.
   METHODS: We reviewed medical records of 105 consecutive eyes with AMD treated with intravitreal ranibizumab injections and followed for more than 1 year after treatment. Response to ranibizumab treatment was compared between typical neovascular AMD and polypoidal choroidal vasculopathy (PCV). Furthermore, we investigated associations of age, lesion size, and single nucleotide polymorphisms (SNPs) in CFH and ARMS2 genes with treatment response.
   RESULTS: Forty-nine eyes were diagnosed with typical neovascular AMD and 56 eyes with PCV. Serous retinal detachment and retinal edema resolved similarly in both typical neovascular AMD and PCV after treatment. However, visual acuity (VA) significantly improved in eyes with PCV, whereas VA was maintained in typical neovascular AMD. At the third and twelfth months after injection, VA was better in PCV than in typical neovascular AMD (P = .027 and P = .044, respectively), although there were no differences in baseline VA between the 2 groups. Age and size of greatest linear dimension were significantly associated with visual prognosis in typical neovascular AMD but not in PCV. There was no clear association between 3 SNPs and responsiveness to ranibizumab treatment.
   CONCLUSIONS: Although exudative changes were equivalent following ranibizumab treatment in both typical neovascular AMD and PCV, there was a significant increase in VA in PCV compared to typical neovascular AMD. Age and greatest linear dimension correlated with visual prognosis only in typical neovascular AMD and not in PCV. (Am J Ophthalmol 2012;154:125-136. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Yamashiro, Kenji] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Miyake, Masahiro/V-1261-2019
OI TAMURA, Hiroshi/0000-0002-7740-2732; Miyake,
   Masahiro/0000-0001-7410-3764; Yamashiro, Kenji/0000-0001-9354-8558;
   Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [21249084,
   22791653]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest. Publication of this article was
   supported in part by grants-in-aid for scientific research (Nos.
   21249084 and 22791653) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and the Japan National Society for the Prevention
   of Blindness, Tokyo, Japan. The authors declare no
   relationships/conditions/circumstances that represent a potential
   conflict of interest for the present study and outside the present
   study. Involved in conception and design of the study (K.Y., A.T.,
   N.Y.); analysis and interpretation (K.Y., K.T., A.T., I.N., Y.A., M.M.);
   writing of the article (K.Y., K.T.); critical revision of the article
   (A.T., S.O., H.T., N.Y.); final approval of the article (K.Y., K.T.,
   A.T., I.N., Y.A., M.M., S.O., H.T., N.Y.); and data collection (K.Y.,
   K.T., A.T., I.N., Y.A., M.M.). This study was approved by the
   Institutional Review Board at Kyoto University Graduate School of
   Medicine. According to their guidelines, it is not mandatory to obtain
   informed consent from patients for a retrospective study in which only
   the medical records are reviewed. All investigations in the current
   study adhered to the tenets of the Declaration of Helsinki.
CR Bessho H, 2011, MOL VIS, V17, P977
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 42
TC 76
Z9 87
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2012
VL 154
IS 1
BP 125
EP 136
DI 10.1016/j.ajo.2012.01.010
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 966XX
UT WOS:000305871800018
PM 22465368
DA 2022-11-30
ER

PT J
AU Klein, BEK
   Howard, KP
   Gangnon, RE
   Dreyer, JO
   Lee, KE
   Klein, R
AF Klein, Barbara E. K.
   Howard, Kerri P.
   Gangnon, Ronald E.
   Dreyer, Jennifer O.
   Lee, Kristine E.
   Klein, Ronald
TI Long-term Use of Aspirin and Age-Related Macular Degeneration
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID BEAVER-DAM EYE; LOW-DOSE ASPIRIN; VISUAL-ACUITY; INTRAOCULAR HEMORRHAGE;
   MACULOPATHY; POPULATION; ANTICOAGULANTS; PROGRESSION; PHYSICIANS; PERIOD
AB Context Aspirin is widely used for relief of pain and for cardioprotective effects. Its use is of concern to ophthalmologists when ocular surgery is being considered and also in the presence of age-related macular degeneration (AMD).
   Objective To examine the association of regular aspirin use with incidence of AMD.
   Design, Setting, and Participants The Beaver Dam Eye Study, a longitudinal population-based study of age-related eye diseases conducted in Wisconsin. Examinations were performed every 5 years over a 20-year period (1988-1990 through 20082010). Study participants (N=4926) were aged 43 to 86 years at the baseline examination. At subsequent examinations, participants were asked if they had regularly used aspirin at least twice a week for more than 3 months.
   Main Outcome Measure Incidence of early AMD, late AMD, and 2 subtypes of late AMD (neovascular AMD and pure geographic atrophy), assessed in retinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.
   Results The median duration of follow-up was 14.8 years. There were 512 incident cases of early AMD (of 6243 person-visits at risk) and 117 incident cases of late AMD (of 8621 person-visits at risk) over the course of the study. Regular aspirin use 10 years prior to retinal examination was associated with late AMD (hazard ratio [HR], 1.63 [95% CI, 1.01-2.63]; P=.05), with estimated incidence of 1.76% (95% CI, 1.17%-2.64%) in regular users and 1.03% (95% CI, 0.70%-1.51%) in nonusers. For subtypes of late AMD, regular aspirin use 10 years prior to retinal examination was significantly associated with neovascular AMD (HR, 2.20 [95% CI, 1.20-4.15]; P=.01) but not pure geographic atrophy (HR, 0.66 [95% CI, 0.25-1.95]; P=.45). Aspirin use 5 years (HR, 0.86 [95% CI, 0.71-1.05]; P=.13) or 10 years (HR, 0.86 [95% CI, 0.65-1.13]; P=.28) prior to retinal examination was not associated with incident early AMD.
   Conclusions Among an adult cohort, aspirin use 5 years prior to observed incidence was not associated with incident early or late AMD. However, regular aspirin use 10 years prior was associated with a small but statistically significant increase in the risk of incident late and neovascular AMD. JAMA. 2012;308(23):2469-2478 www.jama.com
C1 [Klein, Barbara E. K.; Howard, Kerri P.; Dreyer, Jennifer O.; Lee, Kristine E.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, BEK (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinb@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237; Gangnon, Ronald/0000-0003-2587-6714
FU National Institutes of Health (NIH) [EY06594]; National Eye Institute;
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [U10EY006594]
   Funding Source: NIH RePORTER
FX This study was supported by National Institutes of Health (NIH) grant
   EY06594 (Drs B. E. K. Klein, R. Klein). The National Eye Institute
   provided funding for the entire study, including for collection and
   analyses of data. Additional support was provided by Senior Scientific
   Investigator Awards from Research to Prevent Blindness (Drs B. E. K.
   Klein, R. Klein).
CR Battinelli EM, 2011, BLOOD, V118, P1359, DOI 10.1182/blood-2011-02-334524
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Goertz O, 2011, BURNS, V37, P656, DOI 10.1016/j.burns.2011.01.004
   Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   RIDKER PM, 1991, AM HEART J, V122, P1588, DOI 10.1016/0002-8703(91)90275-M
   Sahakyan K, 2011, DIABETOLOGIA, V54, P1335, DOI 10.1007/s00125-011-2096-6
   Scheck A, DAILY ASPIRIN USE AS
   Singer JD, 2003, APPL LONGITUDINAL DA, P407
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   US FOOD and Drug Administration (FDA), ASP QUEST ANSW
NR 22
TC 47
Z9 50
U1 0
U2 23
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 19
PY 2012
VL 308
IS 23
BP 2469
EP 2478
DI 10.1001/jama.2012.65406
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 055TU
UT WOS:000312441400023
PM 23288416
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Kang, EC
   Koh, HJ
AF Kang, Eui Chun
   Koh, Hyoung Jun
TI Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; POSTERIOR VITREOUS DETACHMENT; PARS-PLANA
   VITRECTOMY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL OCRIPLASMIN;
   POTENTIAL MECHANISMS; DIABETIC-RETINOPATHY; CYCLIC STRETCH; RANIBIZUMAB;
   TRACTION
AB Herein, we review the association between vitreomacular adhesion (VMA) and neovascular age-related macular degeneration (AMD). Meta-analyses have shown that eyes with neovascular AMD are twice as likely to have VMA as normal eyes. VMA in neovascular AMD may induce inflammation, macular traction, decrease in oxygenation, sequestering of vascular endothelial growth factor (VEGF), and other cytokines or may directly stimulate VEGF production. VMA may also interfere with the treatment effects of anti-VEGF therapy, which is the standard treatment for neovascular AMD, and releasing VMA can improve the treatment response to anti-VEGF treatment in neovascular AMD. We also reviewed currently available methods of relieving VMA.
C1 [Kang, Eui Chun; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Blair NP, 2004, RETINA-J RET VIT DIS, V24, P120, DOI 10.1097/00006982-200402000-00017
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424
   Gross-Jendroska M, 1998, AUST NZ J OPHTHALMOL, V26, P311, DOI 10.1111/j.1442-9071.1998.tb01335.x
   Haller JA, 2015, OPHTHALMOLOGY, V122, P117, DOI 10.1016/j.ophtha.2014.07.045
   Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Kaiser PK, 2001, AM J OPHTHALMOL, V131, P44, DOI 10.1016/S0002-9394(00)00872-2
   Kerimoglu H, 2011, ACTA OPHTHALMOL, V89, P138, DOI 10.1111/j.1755-3768.2009.01656.x
   Kim YM, 2011, RETINA-J RET VIT DIS, V31, P2123, DOI 10.1097/IAE.0B013E31822F5720
   Kinoshita H, 2014, INVEST OPHTH VIS SCI, V55, P4320, DOI 10.1167/iovs.13-13839
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Liu YL, 2011, ACTA OPHTHALMOL, V89, pE291, DOI 10.1111/j.1755-3768.2009.01814.x
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McHugh D, 2011, CLIN OPHTHALMOL, V5, P1543, DOI 10.2147/OPTH.S25348
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Novack RL, 2015, OPHTHALMOLOGY, V122, P796, DOI 10.1016/j.ophtha.2014.10.006
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   REESE AB, 1967, AM J OPHTHALMOL, V64, P544
   Rodrigues IA, 2013, AM J OPHTHALMOL, V155, P270, DOI 10.1016/j.ajo.2012.08.018
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schneider EW, 2011, CLIN OPHTHALMOL, V5, P1151, DOI 10.2147/OPTH.S14840
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Sebag J, 2009, BRIT J OPHTHALMOL, V93, P989, DOI 10.1136/bjo.2009.157313
   Seymenoglu G, 2012, CLIN OPHTHALMOL, V6, P1239, DOI 10.2147/OPTH.S34311
   Shah Sanket U, 2012, Acta Ophthalmol, V90, pe569, DOI 10.1111/j.1755-3768.2011.02372.x
   Simpson ARH, 2013, INVEST OPHTH VIS SCI, V54, P2028, DOI 10.1167/iovs.12-11258
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Sin M, 2014, ACTA OPHTHALMOL, V92, P328, DOI 10.1111/aos.12238
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Syed YY, 2013, DRUGS, V73, P1617, DOI 10.1007/s40265-013-0124-1
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   WILSON CA, 1994, ARCH OPHTHALMOL-CHIC, V112, P839, DOI 10.1001/archopht.1994.01090180139048
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Yu DY, 2014, PROG RETIN EYE RES, V40, P53, DOI 10.1016/j.preteyeres.2014.02.001
NR 67
TC 7
Z9 10
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 865083
DI 10.1155/2015/865083
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR3DW
UT WOS:000361211800001
PM 26425354
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic
   Macular Edema
SO MEDICAL LETTER ON DRUGS AND THERAPEUTICS
LA English
DT Article
AB Faricimab-svoa (Vabysmo - Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
CR [Anonymous], 2020, MED LETT DRUGS THER, V62, P23
   [Anonymous], 2019, MED LETT DRUGS THER, V61, P187
   [Anonymous], 2015, MED LETT DRUGS THER, V57, P41
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Wykoff CC, 2022, LANCET, V399, P741, DOI 10.1016/S0140-6736(22)00018-6
NR 5
TC 1
Z9 1
U1 3
U2 3
PU MED LETTER INC
PI NEW ROCHELLE
PA 145 HUGUENOT ST, SUITE 312, NEW ROCHELLE, NY 10801-7537 USA
SN 0025-732X
EI 1523-2859
J9 MED LETT DRUGS THER
JI Med. Lett. Drugs Ther.
PD MAR 21
PY 2022
VL 64
IS 1646
BP 45
EP 46
PG 2
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZO7SY
UT WOS:000765929000003
PM 35294428
DA 2022-11-30
ER

PT J
AU Ichiyama, Y
   Sawada, T
   Sawada, O
   Ito, Y
   Kakinoki, M
   Obata, S
   Saishin, Y
   Ohji, M
AF Ichiyama, Yusuke
   Sawada, Tomoko
   Sawada, Osamu
   Ito, Yuka
   Kakinoki, Masashi
   Obata, Shumpei
   Saishin, Yoshitsugu
   Ohji, Masahito
TI THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL
   AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor;
   aqueous humor; clinical activity
AB Purpose: The aim of the current study was to investigate the correlation between the pretreatment aqueous level of vascular endothelial growth factor (VEGF) and clinical activity in neovascular age-related macular degeneration. Methods: Patients with neovascular age-related macular degeneration treated by intravitreal ranibizumab injections and followed for 12 months were included in the current study. The treatment regimen consisted of three consecutive monthly intravitreal ranibizumab injections (loading treatment) followed by a pro re nata (PRN) treatment regimen. The aqueous VEGF levels were measured by enzyme-linked immunosorbent assay using aqueous humor samples obtained just before the first intravitreal ranibizumab injections. Results: Sixty-four eyes of 64 patients were included in the current study. The mean number of intravitreal ranibizumab injections during 12 months was 4.6 +/- 1.4, and 17 eyes had no recurrence after loading treatment. The mean aqueous VEGF level was significantly higher in eyes with recurrence after loading treatment than in eyes without recurrence (107.6 vs. 83.8 pg/mL, respectively; P = 0.04) and significantly higher in eyes with recurrence within 3 months after loading treatment than in other eyes (114.9 vs. 86.7 pg/mL, respectively; P < 0.01). Conclusion: Pretreatment aqueous VEGF level was significantly correlated with the likelihood of recurrence in neovascular age-related macular degeneration. The measurement of pretreatment aqueous VEGF level may be useful to determine the best treatment options for patients with neovascular age-related macular degeneration.
C1 [Ichiyama, Yusuke; Sawada, Tomoko; Sawada, Osamu; Ito, Yuka; Kakinoki, Masashi; Obata, Shumpei; Saishin, Yoshitsugu; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowacho, Otsu, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Ichiyama, Y (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowacho, Otsu, Shiga 5202192, Japan.
EM ichiyama@belle.shiga-med.ac.jp
RI Ichiyama, Yusuke/AAN-5983-2021
FU Shiga University of Medical Science
FX Supported in part by a grant from the Shiga University of Medical
   Science.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Baek J, 2018, RETINA-J RET VIT DIS, V38, P1993, DOI 10.1097/IAE.0000000000001817
   Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fujikawa M, 2013, CLIN OPHTHALMOL, V7, P1497, DOI 10.2147/OPTH.S46817
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Isildak H, 2018, CASE REP OPHTHALMOL, V2018, DOI 10.1155/2018/8561895
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koh A., 2019, RETINA-J RET VIT DIS
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Paine SK, 2017, MOL VIS, V23, P356
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2011, JPN J OPHTHALMOL, V55, P401, DOI 10.1007/s10384-011-0027-1
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 32
TC 0
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 111
EP 117
DI 10.1097/IAE.0000000000002790
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100016
PM 32134804
DA 2022-11-30
ER

PT J
AU Ethen, CM
   Hussong, SA
   Reilly, C
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Ethen, Cheryl M.
   Hussong, Stacy A.
   Reilly, Cavan
   Feng, Xiao
   Olsen, Timothy W.
   Ferrington, Deborah A.
TI Transformation of the proteasome with age-related macular degeneration
SO FEBS LETTERS
LA English
DT Article
DE 20S proteasome; chymotrypsin-like activity; immunoproteasome;
   age-related macular degeneration
ID FACTOR-H POLYMORPHISM; SELECTIVE DEGRADATION; ANTIGEN PRESENTATION;
   PEPTIDE PRODUCTION; 20S PROTEASOMES; PATHOGENESIS; PROTEINS;
   IMMUNOPROTEASOME; IMPAIRMENT; PREVALENCE
AB The proteasome mediates pathways associated with oxidative stress and inflammation, two pathogenic events correlated with age-related macular degeneration (AMD). In human donor eyes corresponding to four stages of AMD, we found the proteasomal chymotrypsin-like activity increased in neurosensory retina with disease progression. Increased activity correlated with a dramatic increase in the inducible subunits of the immunoproteasome, which was not due to an increase in CD45 positive immune cells in the retina. The novel observation of proteasome transformation may reflect retinal response to local inflammation or oxidative stress with AMD. (c) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NATIONAL EYE INSTITUTE [T32EY007133, R03EY014176, R01EY013623] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025392] Funding
   Source: NIH RePORTER; NEI NIH HHS [T32 EY007133, EY014176, R01 EY013623,
   T32 EY017133, R03 EY014176, EY013623] Funding Source: Medline; NIA NIH
   HHS [R01 AG025392, AG025392] Funding Source: Medline
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Di Napoli Mario, 2003, Curr Opin Investig Drugs, V4, P1333
   Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P130, DOI 10.1089/ars.2006.8.130
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   ETHEN CM, 2006, OPHTHALMOL VIS SCI, V47, P280
   Ferrington DA, 2004, FEBS LETT, V578, P217, DOI 10.1016/j.febslet.2004.11.003
   Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200
   GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808
   Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976
   Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HUSOM AD, 2000, ARCH BIOCHEM BIOPHYS, V421, P67
   Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloetzel PM, 1999, BIOL CHEM, V380, P293, DOI 10.1515/BC.1999.040
   Kotamraju S, 2006, FREE RADICAL BIO MED, V40, P1034, DOI 10.1016/j.freeradbiomed.2005.10.052
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Rechsteiner M, 2005, TRENDS CELL BIOL, V15, P27, DOI 10.1016/j.tcb.2004.11.003
   Rivett AJ, 2004, CURR PROTEIN PEPT SC, V5, P153, DOI 10.2174/1389203043379774
   Teoh CY, 2004, ARCH BIOCHEM BIOPHYS, V423, P88, DOI 10.1016/j.abb.2003.12.001
   ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520
NR 31
TC 63
Z9 66
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD MAR 6
PY 2007
VL 581
IS 5
BP 885
EP 890
DI 10.1016/j.febslet.2007.01.061
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 146NL
UT WOS:000244941100016
PM 17289037
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shechtman, D
   Tyler, JA
AF Shechtman, D
   Tyler, JA
TI Idiopathic polypoidal choroidal vasculopathy (IPCV) presenting with
   simultaneous choroidal neovascular membrane (CNM)
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE idiopathic polypoidal choroidal vasculopathy (IPCV); posterior uveal
   bleeding syndrome (PUBS); serosanguineous retinal pigment epithelial
   (RPE) detachment; subretinal hemorrhages; choroidal neovascularization
   membrane (CNM)
ID PIGMENT EPITHELIAL DETACHMENTS; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL HEMORRHAGE; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; CLINICAL SPECTRUM; BLACK-WOMEN;
   RETINOPATHY; FEATURES
AB Idiopathic polypoidal choroidal vasculopathy (IPCV), a rare retinal condition initially described in 1982, is characterized by retinal pigment epithelial (RPE) detachments associated with choroidal polypoidals. Although it is recognized as a unique entity, many consider it a peculiar representation of choroidal neovascular membrane (CNM), commonly associated with age-related macular degeneration (ARMD). We report a case of IPCV with simultaneous presentation of CNM. Dilated examination and fluorescein angiography (FA) revealed RPE detachments associated with choroidal polypoidals. FA also revealed a lacy hyperfluorescent vascular lesion. Ocular manifestations, differential diagnoses, and treatment options are discussed, with emphasis on similarities and differences between IPCV and CNM. It is imperative to consider IPCV in the differential diagnosis of RPE detachments, including those associated with CNM. Careful funduscopic evaluation, FA, and/or indocyanine green videoangiography analysis helps confirm the diagnosis.
C1 Nova SE Univ, Coll Optometry, Ft Lauderdale, FL 33328 USA.
C3 Nova Southeastern University
RP Shechtman, D (通讯作者)，Nova SE Univ, Coll Optometry, 3200 S Univ Dr, Ft Lauderdale, FL 33328 USA.
EM dianashe@nova.edu
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P250
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith RE, 2000, AM J OPHTHALMOL, V129, P544, DOI 10.1016/S0002-9394(99)00436-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 2
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUL
PY 2004
VL 81
IS 7
BP 491
EP 498
DI 10.1097/00006324-200407000-00009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 840GG
UT WOS:000222844700004
PM 15252347
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Mullins, RF
AF Skeie, J. M.
   Mullins, R. F.
TI Macrophages in neovascular age-related macular degeneration: friends or
   foes?
SO EYE
LA English
DT Review
DE macular degeneration; macrophage; choroid; angiogenesis; inflammation;
   animal model
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; C-REACTIVE PROTEIN; CHOROIDAL NEOVASCULARIZATION; BRUCHS
   MEMBRANE; RISK-FACTORS; VISUAL IMPAIRMENT; ANIMAL-MODEL; DRUSEN
AB The events that lead to choroidal neovascularization in eyes with age-related macular degeneration are poorly understood. One possibility that has been explored in a number of studies is that macrophages can promote neovascular changes. In this paper, we summarize the evidence for inflammation in general and macrophages in particular in pathologic neovascularization, and discuss how the diverse functions of these cells may promote or inhibit macular disease. We also discuss some of the conflicting findings regarding the role of macrophages in experimental choroidal neovascularization in mouse models, and suggest areas for future research.
C1 [Skeie, J. M.; Mullins, R. F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Family Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   [Skeie, J. M.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Family Ctr Macular Degenerat, 375 Newton Rd,4135E MERF, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mohammed, Imran/J-8271-2012; Mullins, Robert F/I-6717-2013
OI Mohammed, Imran/0000-0002-8412-0768; Mullins, Robert/0000-0002-5006-0891
FU National Eye Institute [EY-017451]; Macula Vision Research Foundation;
   NATIONAL EYE INSTITUTE [F32EY022280, R01EY017451] Funding Source: NIH
   RePORTER
FX This study was supported in part by National Eye Institute grant
   EY-017451 and the Macula Vision Research Foundation. We thank Drs John E
   Mullins, Michael G Anderson, John H Fingert, Markus H Kuehn, and Stephen
   R Russell for helpful discussions.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   BIEWENGA J, 1995, CELL TISSUE RES, V280, P189, DOI 10.1007/BF00304524
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELKHOURY J, 1994, J BIOL CHEM, V269, P10197
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAGEMAN GS, 2007, ANTIGEN PRESENTING C, P209
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lightman S, 2006, PLOS MED, V3, P1218, DOI 10.1371/journal.pmed.0030364
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   Mocellin S, 2004, CYTOKINE GROWTH F R, V15, P61, DOI 10.1016/j.cytogfr.2003.11.001
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200
   PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI17712
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P29, DOI 10.1007/BF00413394
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   Tao M, 2001, LEUKEMIA LYMPHOMA, V41, P161, DOI 10.3109/10428190109057966
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vora M, 1996, J EXP MED, V184, P821, DOI 10.1084/jem.184.3.821
   Wangoo A, 1997, INT J EXP PATHOL, V78, P33, DOI 10.1046/j.1365-2613.1997.d01-241.x
   Zhou JH, 2005, MOL VIS, V11, P414
   Zittermann SI, 2006, J LEUKOCYTE BIOL, V80, P247, DOI 10.1189/jlb.1205718
NR 85
TC 56
Z9 56
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2009
VL 23
IS 4
BP 747
EP 755
DI 10.1038/eye.2008.206
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 433QK
UT WOS:000265220700001
PM 18600240
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Han, J
   Choi, S
   Park, JI
   Hwang, JS
   Han, JM
   Lee, HJ
   Ko, J
   Yoon, J
   Hwang, DDJ
AF Han, Jinyoung
   Choi, Seong
   Park, Ji In
   Hwang, Joon Seo
   Han, Jeong Mo
   Lee, Hak Jun
   Ko, Junseo
   Yoon, Jeewoo
   Hwang, Daniel Duck-Jin
TI Classifying neovascular age-related macular degeneration with a deep
   convolutional neural network based on optical coherence tomography
   images
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   TYPE-3 NEOVASCULARIZATION; PREVALENCE
AB Neovascular age-related macular degeneration (nAMD) is among the main causes of visual impairment worldwide. We built a deep learning model to distinguish the subtypes of nAMD using spectral domain optical coherence tomography (SD-OCT) images. Data from SD-OCT images of nAMD (polypoidal choroidal vasculopathy, retinal angiomatous proliferation, and typical nAMD) and normal healthy patients were analyzed using a convolutional neural network (CNN). The model was trained and validated based on 4749 SD-OCT images from 347 patients and 50 healthy controls. To adopt an accurate and robust image classification architecture, we evaluated three well-known CNN structures (VGG-16, VGG-19, and ResNet) and two customized classification layers (fully connected layer with dropout vs. global average pooling). Following the test set performance, the model with the highest classification accuracy was used. Transfer learning and data augmentation were applied to improve the robustness and accuracy of the model. Our proposed model showed an accuracy of 87.4% on the test data (920 images), scoring higher than ten ophthalmologists, for the same data. Additionally, the part that our model judged to be important in classification was confirmed through Grad-CAM images, and consequently, it has a similar judgment criteria to that of ophthalmologists. Thus, we believe that our model can be used as an auxiliary tool in clinical practice.
C1 [Han, Jinyoung; Choi, Seong; Ko, Junseo; Yoon, Jeewoo] Sungkyunkwan Univ, Dept Appl Artificial Intelligence, Seoul, South Korea.
   [Han, Jinyoung; Choi, Seong; Ko, Junseo; Yoon, Jeewoo] RAON DATA, Seoul, South Korea.
   [Park, Ji In] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Med, Sch Med, Chunchon, Gangwon Do, South Korea.
   [Hwang, Joon Seo] Seoul Plus Eye Clin, Seoul, South Korea.
   [Han, Jeong Mo] Kong Eye Ctr, Seoul, South Korea.
   [Lee, Hak Jun; Hwang, Daniel Duck-Jin] Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.
   [Hwang, Daniel Duck-Jin] Lux Mind, Incheon, South Korea.
   [Hwang, Daniel Duck-Jin] Catholic Kwandong Univ, Coll Med, Dept Ophthalmol, Incheon, South Korea.
C3 Sungkyunkwan University (SKKU); Kangwon National University; Kangwon
   National University Hospital; Catholic Kwandong University
RP Hwang, DDJ (通讯作者)，Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.; Hwang, DDJ (通讯作者)，Lux Mind, Incheon, South Korea.; Hwang, DDJ (通讯作者)，Catholic Kwandong Univ, Coll Med, Dept Ophthalmol, Incheon, South Korea.
EM daniel.dj.hwang@gmail.com
OI Hwang, Daniel Duck-Jin/0000-0003-1808-3169
FU National Research Foundation of Korea [NRF-2020K2A9A2A11103842]; MSIT
   (Ministry of Science and ICT), Korea, under the ICAN (ICT Challenge and
   Advanced Network of HRD) program [IITP-2021-2020-0-01816]
FX The authors thank Zee Yoon Byun, MD, Sung Yeon Jun, MD, Jung Hwa Lee,
   MD, Jayoung Ahn, MD, and Kyu Hwan Jang, MD for the thoughtful advice and
   data analysis. This research was supported by the framework of
   international cooperation program managed by the National Research
   Foundation of Korea (NRF-2020K2A9A2A11103842) and the MSIT (Ministry of
   Science and ICT), Korea, under the ICAN (ICT Challenge and Advanced
   Network of HRD) program (IITP-2021-2020-0-01816) supervised by the IITP
   (Institute of Information & Communications Technology Planning &
   Evaluation). The funding organizations had no role in the design or
   conduct of this research.
CR Baer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46235-3
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Chou YB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86526-2
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hwang DDJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88543-7
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   Kim JH, 2016, RETINA-J RET VIT DIS, V36, P1506, DOI 10.1097/IAE.0000000000000932
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Moraru AD, 2020, EXP THER MED, V20, P3469, DOI 10.3892/etm.2020.9118
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Shin HC, 2016, IEEE T MED IMAGING, V35, P1285, DOI 10.1109/TMI.2016.2528162
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wang J, 2018, ENVIRON TECHNOL, V39, P3055, DOI 10.1080/09593330.2017.1371797
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yang HK, 2020, AM J OPHTHALMOL, V216, P140, DOI 10.1016/j.ajo.2020.03.035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 36
TC 2
Z9 2
U1 2
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 9
PY 2022
VL 12
IS 1
AR 2232
DI 10.1038/s41598-022-05903-7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZC3XN
UT WOS:000757457000055
PM 35140257
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Amoroso, F
   Souied, EH
   Cohen, SY
   Pedinielli, A
   Astroz, P
   Garavito, RB
   Capuano, V
   Querques, G
   Miere, A
AF Amoroso, Francesca
   Souied, Eric H.
   Cohen, Salomon Yves
   Pedinielli, Alexandre
   Astroz, Polina
   Blanco Garavito, Rocio
   Capuano, Vittorio
   Querques, Giuseppe
   Miere, Alexandra
TI OCTA-guided navigated laser therapy for advanced macula
   neovascularization secondary to age related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; RETINA; retina; medical therapies;
   retinal pathology; research; techniques of retinal examination
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SWEPT-SOURCE OCT;
   SPECTRAL-DOMAIN; FEEDER VESSELS; PHOTOCOAGULATION; RANIBIZUMAB;
   ANGIOGRAPHY; MEMBRANES; LESIONS
AB Introduction: To evaluate the effects of the Navilas system guided by optical coherence tomography angiography for advanced macular neovascularization (MNV) secondary to age-related macular degeneration (AMD). Methods: Prospective case-series including nine eyes presenting with advanced MNV with persistence of exudative signs, no longer responding to anti-VEGF therapy, best-corrected visual acuity at least of 1.3 logMar. All patients were treated with Navilas guided by overlaid optical coherence tomography angiography (OCTA) images at the site of branching large neovascular trunks. Results: Occlusion of large neovascular trunks successfully occurred in all nine included patients. OCTA analysis revealed, at 1 month follow up, MNV total area decreasing from 6.2 +/- 3.1 to 2.6 +/- 3.4 mm(2). At 6 months follow up, mean MNV area was 3.3 +/- 3.4 mm(2) (p = 0.008). Conclusion: This preliminary study showed that Navilas treatment guided by OCTA may represent an attractive therapeutic option in advanced neovascular lesions secondary to AMD.
C1 [Amoroso, Francesca; Souied, Eric H.; Cohen, Salomon Yves; Pedinielli, Alexandre; Astroz, Polina; Blanco Garavito, Rocio; Capuano, Vittorio; Querques, Giuseppe; Miere, Alexandra] Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Amoroso, Francesca; Souied, Eric H.; Cohen, Salomon Yves; Pedinielli, Alexandre; Astroz, Polina; Blanco Garavito, Rocio; Capuano, Vittorio; Querques, Giuseppe; Miere, Alexandra] Paris Est Univ, Creteil, France.
   [Cohen, Salomon Yves] Ophthalm Ctr Imaging & Laser, Paris, France.
   [Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Souied, EH (通讯作者)，Ctr Hosp Intercommunal, Dept Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM esouied@hotmail.com
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581
CR Alshahrani Saeed T, 2015, Retin Cases Brief Rep, V9, P117, DOI 10.1097/ICB.0000000000000107
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borrelli E., BRIT J OPHTHALMOL, DOI [10.1136/bjophthalmol-2018-13685, DOI 10.1136/BJOPHTHALMOL-2018-13685]
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calucci, 2003, GRAEFES ARCH CLIN EX, V241, P245
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Coscas F, 2003, J FR OPHTALMOL, V26, P602
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flower RW, 2002, AM J OPHTHALMOL, V134, P228, DOI 10.1016/S0002-9394(02)01579-9
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kernt M, 2012, CLIN OPHTHALMOL, V6, P289, DOI 10.2147/OPTH.S27859
   Kernt M, 2011, ACTA OPHTHALMOL, V89, pe662, DOI 10.1111/j.1755-3768.2010.02017.x
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kozak I, 2011, OPHTHALMOLOGY, V118, P1119, DOI 10.1016/j.ophtha.2010.10.007
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113981
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Neubauer AS, 2013, CLIN OPHTHALMOL, V7, P121, DOI 10.2147/OPTH.S38559
   ORTH DH, 1994, RETINA-J RET VIT DIS, V14, P153, DOI 10.1097/00006982-199414020-00008
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TORNAMBE PE, 1992, RETINA-J RET VIT DIS, V12, P305, DOI 10.1097/00006982-199212040-00003
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 3182
EP 3189
AR 1120672120983191
DI 10.1177/1120672120983191
EA DEC 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA5GJ
UT WOS:000679149900001
PM 33353405
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Mastropasqua, R
   Senatore, A
   Palmieri, M
   Toto, L
   Sadda, SR
   Mastropasqua, L
AF Borrelli, Enrico
   Mastropasqua, Rodolfo
   Senatore, Alfonso
   Palmieri, Michele
   Toto, Lisa
   Sadda, SriniVas R.
   Mastropasqua, Leonardo
TI Impact of Choriocapillaris Flow on Multifocal Electroretinography in
   Intermediate Age-Related Macular Degeneration Eyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   electroretinogram
ID OPTICAL COHERENCE TOMOGRAPHY; OCT ANGIOGRAPHY; VISUAL-ACUITY; RETICULAR
   PSEUDODRUSEN; GEOGRAPHIC ATROPHY; ULTRAHIGH-SPEED; NEOVASCULARIZATION;
   MICROPERIMETRY; MACULOPATHY; PROGRESSION
AB PURPOSE. To investigate the relationship between perfusion of the choriocapillaris (CC) and macular function in eyes with intermediate age-related macular degeneration.
   METHODS. In this prospective, observational, cross-sectional study, macular optical coherence tomography angiography images and multifocal electroretinograms were obtained in 20 eyes with intermediate age-related macular degeneration from 20 patients. The main outcome measures were (1) the percent nonperfused choriocapillaris area (PNPCA), which represents a measure of the total area of CC vascular dropout, and (2) the average size of the CC signal voids, which represent contiguous regions of CC dropout. Furthermore, amplitude and implicit time of multifocal electroretinograms N1 and P1 waves in the two central rings (R1 and R2) were included in the analysis.
   RESULTS. Of the 20 patients enrolled, only 17 eyes from 17 patients (13 women) were included in this analysis. Three patients were excluded because of poor scan quality. Mean +/- SD age was 75.1 +/- 7.9 years (range, 62-89 years). The best corrected visual acuity was 0.17 +/- 0.13 logarithm of the minimum angle of resolution. In univariate analysis, both the PNPCA and average signal void size were found to have a significant direct relationship with N1 implicit time in the R2 ring (P = 0.006 and P = 0.035, respectively). Neither PNPCA nor the average signal void size was associated with P1 or N1 implicit times in R1.
   CONCLUSIONS. In intermediate age-related macular degeneration eyes, PNPCA and average signal void size are related to N1 multifocal electroretinogram implicit times, which suggests an association between CC perfusion and photoreceptor function.
C1 [Borrelli, Enrico; Senatore, Alfonso; Palmieri, Michele; Toto, Lisa; Mastropasqua, Leonardo] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Via Vestini 31, I-66100 Chieti, Italy.
   [Mastropasqua, Rodolfo] Whipps Cross Univ Hosp, Eye Treatment Ctr, London, England.
   [Mastropasqua, Rodolfo] Univ Marche, Ophthalmol Clin, Ancona, Italy.
   [Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 G d'Annunzio University of Chieti-Pescara; University of London; Queen
   Mary University London; Marche Polytechnic University; Doheny Eye
   Institute; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA
RP Borrelli, E (通讯作者)，Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Via Vestini 31, I-66100 Chieti, Italy.
EM borrelli.enrico@yahoo.com
RI Palmieri, Michele/T-5931-2019; Borrelli, Enrico/AAR-3693-2020;
   Mastropasqua, Rodolfo/AAC-6453-2022; Senatore, Alfonso/T-3105-2019;
   Toto, Lisa/K-3473-2018
OI Palmieri, Michele/0000-0002-8263-7077; Borrelli,
   Enrico/0000-0003-2815-5031; Senatore, Alfonso/0000-0002-8190-8269; Toto,
   Lisa/0000-0001-5311-5184
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Bearse MA, 2006, PROG RETIN EYE RES, V25, P425, DOI 10.1016/j.preteyeres.2006.07.001
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Borrelli E, 2019, RETINA-J RET VIT DIS, V39, P1216, DOI 10.1097/IAE.0000000000002123
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   CELESIA GG, 1987, ELECTROEN CLIN NEURO, V68, P161, DOI 10.1016/0168-5597(87)90023-2
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gundogan FC, 2007, CLIN EXP OPHTHALMOL, V35, P32, DOI 10.1111/j.1442-9071.2006.01384.x
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Hood DC, 2013, PROG RETIN EYE RES, V32, P1, DOI 10.1016/j.preteyeres.2012.08.003
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tepelus TC, 2017, OSLI RETINA, V48, P312, DOI 10.3928/23258160-20170329-05
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, INVEST OPHTH VIS SCI, V57, P6360, DOI 10.1167/iovs.16-20544
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 46
TC 30
Z9 30
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
DI 10.1167/iovs.18-23943
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH0FB
UT WOS:000433076600001
PM 29860309
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Segal, O
   Barayev, E
   Nemet, AY
   Geffen, N
   Vainer, I
   Mimouni, M
AF Segal, Ori
   Barayev, Edward
   Nemet, Arie Y.
   Geffen, Noa
   Vainer, Igor
   Mimouni, Michael
TI PROGNOSTIC VALUE OF HYPERREFLECTIVE FOCI IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION TREATED WITH BEVACIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE hyperreflective; dots; foci; OCT; AMD; neovascular; bevacizumab;
   quantity; location
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; INTRAVITREAL
   BEVACIZUMAB; VISUAL FUNCTION; EDEMA; THERAPY
AB Purpose: To study the prognostic value of optical coherence tomography hyperreflective foci (HF) in neovascular age-related macular degeneration.
   Methods: Charts of naive neovascular age-related macular degeneration eyes treated with intravitreal bevacizumab between January 2011 and January 2014 were reviewed, and optical coherence tomography was collected at baseline, 3 months, and 12 months. The presence, location (inner vs. outer retinal layers), and number (few = [0-10], moderate [11-20], many [> 20]) of HF were graded.
   Results: Overall, charts of 111 eyes were reviewed and 76 eyes of 73 patients fulfilled inclusion criteria. Baseline best-corrected visual acuity was lower in eyes with HF > 20 (P = 0.001), inner layer HF (P = 0.009), increased central retinal thickness (P < 0.001), and intraretinal fluid (P < 0.001). Baseline HF. 20 (P = 0.002), inner layer HF (P = 0.01), increased central retinal thickness (P < 0.001), and intraretinal fluid (P = 0.001) had worst best-corrected visual acuity at 12 months. Eyes with intraretinal fluid, HF > 20, and HF adjacent to intraretinal fluid demonstrated a greater reduction in central retinal thickness; only baseline HF > 20 remained significant in multivariate analysis (P < 0.001). Eyes with a reduction in HF (P = 0.02) and resolution of inner layer HF (P = 0.01) had a greater central retinal thickness reduction.
   Conclusion: Quantity and location of HF are of prognostic value in intravitreal bevacizumab-treated naive neovascular age-related macular degeneration. Increased awareness of specialists interpreting optical coherence tomography scans toward the number and location of HF is prudent.
C1 [Segal, Ori; Barayev, Edward; Nemet, Arie Y.; Geffen, Noa] Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
   [Segal, Ori; Barayev, Edward; Nemet, Arie Y.; Geffen, Noa] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Vainer, Igor; Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Rambam Health Care Campus
RP Segal, O (通讯作者)，Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
EM orisegal@gmail.com
RI Mimouni, Michael/S-2916-2018
OI Mimouni, Michael/0000-0002-4661-0993; Segal, Ori/0000-0001-5701-9544
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Coscas G, 2008, TOMOGRAPHIE COHERENC
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Kang JW, 2014, GRAEF ARCH CLIN EXP, V252, P1413, DOI 10.1007/s00417-014-2595-5
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Pemp B, 2014, RETINA-J RET VIT DIS, V34, P2407, DOI 10.1097/IAE.0000000000000250
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
NR 22
TC 21
Z9 21
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2175
EP 2182
DI 10.1097/IAE.0000000000001033
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800025
PM 27078799
DA 2022-11-30
ER

PT J
AU Gerstenblith, AT
   Baskin, DE
   Shah, CP
   Wolfe, JD
   Fineman, MS
   Kaiser, RS
   Ho, AC
AF Gerstenblith, Adam T.
   Baskin, Darrell E.
   Shah, Chirag P.
   Wolfe, Jeremy D.
   Fineman, Mitchell S.
   Kaiser, Richard S.
   Ho, Allen C.
TI Electroretinographic Effects of Omega-3 Fatty Acid Supplementation on
   Dry Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIETARY DOCOSAHEXAENOIC ACID; BLOOD-CELL MEMBRANES; FATTY-ACIDS;
   EICOSAPENTAENOIC ACID; FISH CONSUMPTION; OMEGA-3 INDEX; RISK-FACTOR;
   HEART; ASSOCIATION; PROGRESSION
AB Objectives: To evaluate the effects of high-dose oral omega-3 fatty acid supplementation on electroretinography and omega-3 index in patients with dry age-related macular degeneration.
   Design: Single institution, prospective, nonrandomized, noncomparative interventional case series comprising 34 eyes of 17 patients older than 50 years of age with early to intermediate age-related macular degeneration. Patients received oral supplementation with 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months. The main outcome measures included Early Treatment Diabetic Retinopathy Study best-corrected visual acuity, change in N1 and P1 peak amplitudes on multifocal electroretinographic testing, and change in serum omega-3 index.
   Results: Mean baseline Early Treatment Diabetic Retinopathy Study best-corrected visual acuity letter score was 77 letters (Snellen equivalent of 20/32). There were no statistically significant changes in visual acuity (P=.12) or retinal function by multifocal electroretinographic testing. Serum omega-3 index increased by an average of 7.6% during the course of the study (P < .001). Study limitations included the relatively short duration of the study and small number of participants.
   Conclusions: Short-term supplementation with high doses of omega-3 fatty acids does not result in any measurable changes in visual acuity or retinal function by multifocal electroretinographic testing. Dietary supplementation with 4 g of omega-3 fatty acids results in a significant increase in serum omega-3 index in patients with dry age-related macular degeneration and may provide a useful clinical measure for future studies.
C1 [Gerstenblith, Adam T.; Fineman, Mitchell S.; Kaiser, Richard S.; Ho, Allen C.] Mid Atlantic Retina, Wills Eye Inst Retina Serv, Philadelphia, PA 19107 USA.
   [Baskin, Darrell E.] Lackland AFB, San Antonio Mil Hlth Syst, Vitreoretinal Serv, San Antonio, TX USA.
   [Shah, Chirag P.] Ophthalm Consultants Boston, Boston, MA USA.
   [Wolfe, Jeremy D.] Oakland Univ William Beaumont SOM, Associated Retinal Consultants, Royal Oak, MI USA.
C3 Ophthalmic Consultants of Boston; Oakland University
RP Ho, AC (通讯作者)，Mid Atlantic Retina, Wills Eye Inst Retina Serv, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
EM acho@att.net
OI Wolfe, Jeremy/0000-0003-2781-7152; Ho, Allen/0000-0003-3921-608X
FU Physician Recommended Nutriceuticals; Eye Research Institute; Wills Eye
   Institute at Thomas Jefferson University Hospital
FX This study was funded by Physician Recommended Nutriceuticals, the Eye
   Research Institute, and the Wills Eye Institute at Thomas Jefferson
   University Hospital.
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Berson EL, 2012, ARCH OPHTHALMOL-CHIC, V130, P707, DOI 10.1001/archophthalmol.2011.2580
   Block RC, 2008, ATHEROSCLEROSIS, V197, P821, DOI 10.1016/j.atherosclerosis.2007.07.042
   Block RC, 2008, AM HEART J, V156, P1117, DOI 10.1016/j.ahj.2008.07.014
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P91
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cohen BE, 2008, J NUTR, V138, P1135, DOI 10.1093/jn/138.6.1135
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dornstauder B, 2012, INVEST OPHTH VIS SCI, V53, P2256, DOI 10.1167/iovs.11-8569
   Farzaneh-Far R, 2010, JAMA-J AM MED ASSOC, V303, P250, DOI 10.1001/jama.2009.2008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Harris WS, 2007, AM J CLIN NUTR, V86, P1621
   Harris WS, 2009, CURR ATHEROSCLER REP, V11, P411, DOI 10.1007/s11883-009-0062-2
   Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030
   Harris WS, 2004, CIRCULATION, V110, P1645, DOI 10.1161/01.CIR.0000142292.10048.B2
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Regillo CD, 2003, RETINA OPTIC NERVE I, P213
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363
   Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4
   STINSON AM, 1991, J LIPID RES, V32, P2009
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
NR 33
TC 5
Z9 6
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2013
VL 131
IS 3
BP 365
EP 369
DI 10.1001/jamaophthalmol.2013.642
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 113SD
UT WOS:000316687600014
PM 23494041
OA Bronze
DA 2022-11-30
ER

PT J
AU Prasad, PS
   Schwartz, SD
   Hubschman, JP
AF Prasad, Pradeep S.
   Schwartz, Steven D.
   Hubschman, Jean-Pierre
TI Age-related macular degeneration: Current and novel therapies
SO MATURITAS
LA English
DT Review
DE Macular degeneration; Exudative; Nonexudative; Treatment; Vitamin;
   Antioxidant; Neuroprotection; VEGF
ID RETINAL-PIGMENT EPITHELIUM; RANIBIZUMAB; MACULOPATHY; PREVALENCE; RISK
AB Age-related macular degeneration (AMD) is a leading cause of vision loss in people over the age of 60 with a prevalence that continues to rise, particularly in industrialized nations. Although treatments for AMD were once limited, with disappointing clinical results, new treatments have emerged for both the nonexudative and exudative forms of the disease, which have improved prognostic outcomes. These treatments include nutritional supplementation, antioxidant prophylaxis, and intravitreal injection of medications that inhibit aberrant vascular proliferation. This review serves as a summary of the current and experimental therapies for both exudative and nonexudative AMD. Although a number of challenges and clinical questions remain, the future of treating AMD appears promising particularly as we gain further insights into the genetic and biochemical pathways of the disease. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Hubschman, Jean-Pierre] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Prasad, Pradeep S.; Schwartz, Steven D.; Hubschman, Jean-Pierre] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Hubschman, JP (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM hubschman@jsei.ucla.edu
OI Hubschman, Jean-Pierre/0000-0002-8631-3467
FU Price Foundation Retina Research Fund
FX This research was supported by the Price Foundation Retina Research Fund
   (PP and J-PH). The sources of our financial support played no role in
   the preparation of this article.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Borrillo JL, 2001, CURR OPIN OPHTHALMOL, V12, P207, DOI 10.1097/00055735-200106000-00011
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chaum E, 2002, SURV OPHTHALMOL, V47, P449, DOI 10.1016/S0039-6257(02)00336-3
   Decensi A, 2009, J CLIN ONCOL, V27, P3749, DOI 10.1200/JCO.2008.19.3797
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SLAKTER JS, 2007, COMMUNICATION
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thylefors B, 1998, Community Eye Health, V11, P1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   2001, ARCH OPHTHALMOL, V119, P1416
NR 32
TC 32
Z9 34
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD MAY
PY 2010
VL 66
IS 1
BP 46
EP 50
DI 10.1016/j.maturitas.2010.02.006
PG 5
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA 599ZN
UT WOS:000277953200009
PM 20219298
DA 2022-11-30
ER

PT J
AU Casaroli-Marano, RP
   Bernal-Morales, C
   Chamorro-Lopez, L
   Dotti-Boada, M
   Figueroa-Vercellino, JP
   Alforja, S
AF Casaroli-Marano, Ricardo P.
   Bernal-Morales, Carolina
   Chamorro-Lopez, Lillian
   Dotti-Boada, Marina
   Figueroa-Vercellino, Juan P.
   Alforja, Socorro
TI Fixed Regimen Treatment in Unselected Naive Patients Cohort with
   Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; AFLIBERCEPT; OUTCOMES; BEVACIZUMAB; THERAPY
AB The current treatment of neovascular age-related macular degeneration (nAMD) generates an excessive care pressure in the public health system. The search for a satisfactory treatment regimen, whose anatomical and functional stability may be achieved, is a challenge and a goal to be reached. We analyzed the outcomes in a patient cohort under fixed regimen treatment with intravitreal aflibercept (IVA). A retrospective study, with at least 1-year follow-up, in consecutive treated unselected naive patients was carried out. Standard protocol was performed and evaluated at baseline, month 4 (after loading dose, LD), and month 12 (after fixed bimonthly regimen). One hundred six patients (123 eyes) aged 80.3 +/- 7.7 years were included, receiving 6.8 +/- 0.7 IVA. Visual acuity gain after LD was 5.5 +/- 12.0 letters (p<0.0001). At month 12, 23 eyes (18.7%) gained >= 15 letters and 58 (47.1%) had best-corrected visual acuity >= 20/40 (70 letters). The improvement in visual acuity was lower in patients with polypoidal choroidal vasculopathy (+4.9 +/- 18.1 letters; p = 0.2544) and somewhat higher in patients with retinal angiomatous proliferation (+5.4 +/- 12.3 letters; p=0.0373). Dry macula was present in only 9.8% of cohort at baseline vs. 69.7% at month 12 (p<0.0001). Atrophy was the most observed complication and related to the elderly patients. The average of follow-up visits was 3 +/- 0.5. Functional and anatomical improvement were observed with IVA in a fixed bimonthly regimen treatment after LD, with results maintained up to one year with a good compliance. The fixed bimonthly regimen optimized patient management and logistic issues.
C1 [Casaroli-Marano, Ricardo P.; Bernal-Morales, Carolina; Chamorro-Lopez, Lillian; Dotti-Boada, Marina; Figueroa-Vercellino, Juan P.; Alforja, Socorro] Hosp Clin Barcelona, Serv Ophthalmol, Barcelona, Spain.
   [Casaroli-Marano, Ricardo P.] Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; University of
   Barcelona
RP Casaroli-Marano, RP (通讯作者)，Hosp Clin Barcelona, Serv Ophthalmol, Barcelona, Spain.; Casaroli-Marano, RP (通讯作者)，Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain.
EM rcasaroli@ub.edu
RI Bernal-Morales, Carolina/ABI-8449-2020; Casaroli-Marano, Ricardo
   Pedro/D-4535-2014
OI Bernal-Morales, Carolina/0000-0001-5469-3963; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Chamorro Lopez, Lillian/0000-0003-0767-5011
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tewarie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034823
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Udaondo P, 2016, OPHTHALMOLOGICA, V236, P29, DOI 10.1159/000445724
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 27
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD NOV 21
PY 2020
VL 2020
AR 8848336
DI 10.1155/2020/8848336
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA7SY
UT WOS:000595831600001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cackett, P
   Wong, D
   Yeo, I
AF Cackett, Peter
   Wong, Doric
   Yeo, Ian
TI A CLASSIFICATION SYSTEM FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; Chinese; indocyanine green
   angiography; multiple; cluster; string; extrafoveal; juxtafoveal;
   subfoveal; peripapillary
ID MACULAR DEGENERATION
AB Purpose: To describe the demographic features and clinical characteristics of polypoidal choroidal vasculopathy (PCV) in Chinese patients and define a new classification system.
   Methods: Retrospective review of 138 eyes of 123 patients presenting to the Singapore National Eye Center with PCV. Patients underwent ophthalmologic examination including digital color fundus photography and stereoscopic indocyanine green angiography. Classification based on indocyanine green angiography findings.
   Results: Mean age of patient 68.3 years and 62.4% were men. PCV was unilateral in 87.8% cases and age-related maculopathy was present in the unaffected fellow eye in 22.8%. Average largest size of polyp was 207 mu m. PCV lesions were found in multiple discrete areas in 34.8%. Formation of lesion was cluster in 66.7%, single in 27.5%, and string in 5.8%. PCV lesions were found in the extrafoveal area in 63.0%, subfoveal in 29.7%, juxtafoveal in 15.9%, and peripapillary in 8.0%.
   Conclusions: Demographics of PCV, unilaterality and frequency of age-related maculopathy in fellow eye similar to other reports in Asians. We describe a classification system for PCV comprising polyp size, location, formation, and number of discrete polyp areas, which can be used for prospective interventional clinical studies and may aid in future prognosis and management of this condition.
C1 [Cackett, Peter; Wong, Doric; Yeo, Ian] Singapore Natl Eye Ctr, Vitreoretinal Dept, Singapore 168751, Singapore.
   [Cackett, Peter] Singapore Eye Res Inst, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center
RP Yeo, I (通讯作者)，Singapore Natl Eye Ctr, Vitreoretinal Dept, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ian.yeo.y.s@snec.com.sg
OI Wong, Damon/0000-0003-4601-9121
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   LEE MW, 2008, EYE             0829
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 19
TC 58
Z9 68
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 187
EP 191
DI 10.1097/IAE.0b013e318188c839
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407BR
UT WOS:000263339100008
PM 18827731
DA 2022-11-30
ER

PT J
AU Yoshida, I
   Sakamoto, M
   Sakai, A
   Maeno, T
AF Yoshida, Izumi
   Sakamoto, Masashi
   Sakai, Asao
   Maeno, Takatoshi
TI Effect of the Duration of Intraretinal or Subretinal Fluid on the
   Response to Treatment in Undertreated Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; THERAPY; OUTCOMES
AB We investigated the association between the duration of intraretinal fluid (IRF) or subretinal fluid (SRF) and the response to antivascular endothelial growth factor injection in patients with undertreated age-related macular degeneration (ARMD). The Ethics Committee of Toho University Sakura Medical Center approved this study (no. S18030). Eighty eyes of ARMD patients with VA <= 20/100 were retrospectively assessed. Each injection's efficacy was classified, and the fluid accumulation prior to each injection was evaluated. The effect changes following to accumulated IRF, SRF, the longest persistent IRF period (>= 10 months), and their determining factors were evaluated. Throughout observation, acquired refractoriness was rarely associated with increased accumulation of IRF or SRF. The injection span had a tendency to be short, and the polypoidal choroidal vasculopathy and occult choroidal neovasculopathy (CNV) proportions had a tendency to be higher among patients with diminished effects than among those with maintained effects. VA differed significantly with continuous IRF duration, but not with accumulated fluid. The diminishing effect of injections during long-standing IRF was rarely associated with undertreatment. The mechanism underlying acquired refractoriness remains unknown; the effect change demonstrated various patterns, including diminished and improved responses. The longest continuous IRF duration was associated with VA decline. Shortening the duration of continuous IRF may be necessary.
C1 [Yoshida, Izumi; Sakamoto, Masashi; Sakai, Asao; Maeno, Takatoshi] Toho Univ, Sakura Med Ctr, Sakura, Chiba, Japan.
C3 Toho University
RP Yoshida, I (通讯作者)，Toho Univ, Sakura Med Ctr, Sakura, Chiba, Japan.
EM izumi.yoshida@med.toho-u.ac.jp; masashi.sakamoto@med.toho-u.ac.jp;
   asakai333@yahoo.co.jp; tmaeno@sakura.med.toho-u.ac.jp
OI Yoshida, Izumi/0000-0001-8921-052X
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Ahlers C., 2008, OPHTHALMOLOGY, V115, P39, DOI [10.1016/j.ophtha.2008.05.0172-s2.0-48149084442, DOI 10.1016/J.OPHTHA.2008.05.0172-S2.0-48149084442]
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Inoue M., 2009, AM J OPHTHALMOLOGY, V148, P70, DOI [10.1016/j.ajo.2009.02.0122-s2.0-67349233537, DOI 10.1016/J.AJO.2009.02.0122-S2.0-67349233537]
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Mak MYK, 2015, CLIN OPHTHALMOLOGY, V12, P1877
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   NICE, 2008, TECHN APPR PEG RAN T
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shin J. Y., 2013, J OPHTHALMOLOGY, V27, P425, DOI [10.3341/kjo.2013.27.6.4252-s2.0-84927171369, DOI 10.3341/KJO.2013.27.6.4252-S2.0-84927171369]
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Toth L., RETINA, V35, P1957
NR 24
TC 4
Z9 4
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 26
PY 2020
VL 2020
AR 5308597
DI 10.1155/2020/5308597
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NC6ON
UT WOS:000561336900002
PM 32774905
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Mulero, J
   Manresa, N
   Zafrilla, P
   Losada, M
AF Mulero, J.
   Manresa, N.
   Zafrilla, P.
   Losada, M.
TI Markers of cardiovascular risk in elderly patients with age-related
   macular degeneration
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Cardiovascular risk; age-related macular degeneration; lipidic profile;
   C-Reactive protein; homocysteine
ID PATHOGENESIS; ASSOCIATION
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment and blindness among persons aged 60 years and older and many theories exist and feature mechanisms of oxidative stress, atherosclerotic-like changes, genetic predisposition, and inflammation in development of AMD. The aim of this study was to evaluate the association between markers of inflammation and cardiovascular risk with age-related macular degeneration.
   METHODS: Case-control study that includes 163 patients with wet AMD (age group of 55-82 years with the mean age of 71 years and 170 age-matched healthy controls in the age group of 55-78 years with the mean age of 71 years. The following parameters were determined: lipidic profile (Total Cholesterol, Triglycerides, HDL-c, LDL-c), CRP (C-Reactive Protein), homocysteine and fibrinogen.
   RESULTS: We found significant differences between AMD patients and control group in baseline values of homocysteine, CRP and fibrinogen, although we do not observed differences in levels of lipidic profile.
   CONCLUSION: Our data support the role of chronic inflammation in the development of AMD, however, further studies are needed to determine which common disease mechanisms of chronic inflammation and atherosclerosis contribute to the pathogenesis of AMD.
C1 [Mulero, J.; Zafrilla, P.] Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
   [Manresa, N.; Losada, M.] Univ Hosp Jose Ma Morales Meseguer, Murcia, Spain.
C3 Universidad Catolica de Murcia
RP Mulero, J (通讯作者)，Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
EM jmulero@pdi.ucam.edu
RI Zafrilla, Pilar/H-8132-2012
CR Alexander J., 2001, RETINA, V2, P1687
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bautista LE, 2002, J CLIN EPIDEMIOL, V55, P882, DOI 10.1016/S0895-4356(02)00434-1
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Mangoni AA, 2002, AM J MED, V112, P556, DOI 10.1016/S0002-9343(02)01021-5
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McConnell V, 2005, Ulster Med J, V74, P82
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak J.Z., 2005, MAG OKUL, V2
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ockene IS, 2001, CLIN CHEM, V47, P444
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05
   ROSSI E, 1988, THROMB RES, V52, P453, DOI 10.1016/0049-3848(88)90029-1
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Tracy RP, 2003, INT J CLIN PRACT, P10
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vaya A, 2013, CLIN HEMORHEOL MICRO, V54, P287, DOI [10.3233/CH-131734, 10.3233/CH-31734]
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 14
Z9 14
U1 0
U2 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2014
VL 58
IS 3
BP 447
EP 453
DI 10.3233/CH-141807
PG 7
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA AW4TF
UT WOS:000346272600007
PM 24418867
DA 2022-11-30
ER

PT J
AU Dewan, A
   Bracken, MB
   Hoh, J
AF DeWan, Andrew
   Bracken, Michael B.
   Hoh, Josephine
TI Two genetic pathways for age-related macular degeneration
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Review
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; RISK; POLYMORPHISM; ACTIVATION;
   VARIANT; SUSCEPTIBILITY; ASSOCIATION; JAPANESE; DISEASE
AB The discovery of strong associations of the His402 variant of complement factor H (CFH) and the change in the promoter region of HtrA serine peptidase 1 (HTRA1) with age-related macular degeneration (AMD) have altered our conception of the pathophysiology of this disease. The complement system has been placed at the center of a flurry of research interest, and a similar growth in attention to the serine proteases is not far behind. The specific role of these variants in causing AMD is unknown, but they will undoubtedly lead to a deeper understanding of the biological mechanisms and will point to new avenues for pharmacologic management. Furthermore, these variants will enable clinicians and investigators to identify people at high risk for this condition, thereby establishing the preconditions for preventing the disease.
C1 Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
C3 Yale University
RP Hoh, J (通讯作者)，Yale Univ, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
OI DeWan, Andrew/0000-0002-7679-8704
CR Ajees AA, 2006, NATURE, V444, P221, DOI 10.1038/nature05258
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   MULLEREBERHARD HJ, 1960, J EXP MED, V111, P201, DOI 10.1084/jem.111.2.201
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   REGUEIRO JR, 1988, TISSUE ANTIGENS, V31, P14, DOI 10.1111/j.1399-0039.1988.tb02060.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schlaf G, 2004, EUR J IMMUNOL, V34, P3257, DOI 10.1002/eji.200324806
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
   2006, SCIENCE, V314, P1850
NR 46
TC 30
Z9 30
U1 0
U2 5
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD JUN
PY 2007
VL 17
IS 3
BP 228
EP 233
DI 10.1016/j.gde.2007.04.004
PG 6
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 183FA
UT WOS:000247556900009
PM 17467263
DA 2022-11-30
ER

PT J
AU Wickremasinghe, SS
   Guymer, RH
   Wong, TY
   Kawasaki, R
   Wong, WL
   Qureshi, S
AF Wickremasinghe, Sanjeewa S.
   Guymer, Robyn H.
   Wong, Tien Y.
   Kawasaki, Ryo
   Wong, Wanling
   Qureshi, Salmaan
TI Retinal venular calibre dilatation after intravitreal ranibizumab
   treatment for neovascular age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization;
   vasculature; venule
ID ENDOTHELIAL GROWTH-FACTOR; CARDIOVASCULAR RISK-FACTORS; CHOROIDAL
   BLOOD-FLOW; VASCULAR CALIBER; VEGF; BEVACIZUMAB; EXPRESSION;
   INFLAMMATION; CAPILLARIES; INJECTIONS
AB Background: To describe the changes in retinal vascular calibre in response to intravitreal ranibizumab injections in patients with neovascular age-related macular degeneration.
   Design: Prospective interventional case series.
   Participants: Treatment naive patients with neovascular age-related macular degeneration were recruited over a 1-year period.
   Methods: Each patient received three monthly intravitreal injections according to a 'loading dose'. Retinal arteriolar and venular calibre was measured from digital fundus photographs and summarized as central retinal artery equivalent and central retinal vein equivalent at baseline and 3 months.
   Main Outcome Measure: Central retinal artery equivalent and central retinal vein equivalent changes from baseline to 3 months.
   Results: Seventy-four eyes of 71 patients had good quality images for grading vessel calibre at baseline and at 3 months in treated (study) eyes and 51 eyes of 51 patients had good quality images in fellow (control) eyes. Over 3 months, in study eyes treated with ranibizumab, there was a significant increase in central retinal vein equivalent over baseline (+6.20 mu m, P = 0.005), but no significant change in central retinal artery equivalent (+0.86 mu m, P = 0.55). In control eyes, there was no change in central retinal vein equivalent (-0.82 mu m, P = 0.70) or central retinal artery equivalent (0.34 mu m, P = 0.75).
   Conclusion: Intravitreal ranibizumab has a significant vasodilational effect on retinal venular calibre in eyes treated for neovascular age-related macular degeneration. The reason for this change is unclear, but may relate to changes in blood flow or inflammatory changes within the retina.
C1 [Wickremasinghe, Sanjeewa S.; Guymer, Robyn H.; Wong, Tien Y.; Kawasaki, Ryo; Qureshi, Salmaan] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Wong, Tien Y.; Wong, Wanling] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; Singapore
   National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Kawasaki, Ryo/H-9716-2019; Kawasaki, Ryo/B-7266-2009; Wong, Tien
   Yin/AAC-9724-2020
OI Kawasaki, Ryo/0000-0002-7492-6303; Wong, Tien Yin/0000-0002-8448-1264;
   Guymer, Robyn/0000-0002-9441-4356
FU Novartis; Pfizer; National Health and Medical Research Council (NHMRC)
   [52993]
FX Drs Guymer and Wong are on advisory boards of Novartis and Pfizer and
   have received research funding, speaking fees, travel and accommodation
   from either/both companies. Drs Wickremasinghe's and Kawasaki's
   scholarships are supported by Novartis.; This study was partially funded
   by a National Health and Medical Research Council (NHMRC) grant, 52993.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1991, Ophthalmology, V98, P786
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Canavese M, 2010, J DERMATOL SCI, V58, P171, DOI 10.1016/j.jdermsci.2010.03.023
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x
   Edirisinghe I, 2008, FASEB J, V22, P2297, DOI 10.1096/fj.07-099481
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mendrinos E, 2009, INVEST OPHTHALMOL VI
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sun C, 2008, INVEST OPHTH VIS SCI, V49, P1784, DOI 10.1167/iovs.07-1450
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wirostko B, 2008, PROG RETIN EYE RES, V27, P608, DOI 10.1016/j.preteyeres.2008.09.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoo SA, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/129873
NR 36
TC 8
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD FEB
PY 2012
VL 40
IS 1
BP 59
EP 66
DI 10.1111/j.1442-9071.2011.02613.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 888JW
UT WOS:000300000800029
PM 21668787
DA 2022-11-30
ER

PT J
AU Epstein, D
   Amren, U
AF Epstein, David
   Amren, Urban
TI NEAR VISION OUTCOME IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
   TREATED WITH AFLIBERCEPT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; age-related macular degeneration; choroidal
   neovascularization; ETDRS; near vision
ID RANIBIZUMAB TREATMENT; VISUAL-FIELD; INFORMATION; EYE
AB Purpose:The aim of this study was to investigate the outcome in near vision and the best-corrected visual acuity in patients with wet, age-related macular degeneration treated with aflibercept in a fixed bimonthly regimen in an ordinary clinical setting.Methods:The study was a retrospective, nonrandomized consecutive case series including 85 patients with wet, age-related macular degeneration followed for 18 months. During the first year all the patients received aflibercept injections in a fixed regimen at the following time points: Month 0, 1, 2, 4, 6, 8, 10, and 12. From Month 12 to Month 18, patients were treated with a treat and extend algorithm.Results:The median near visual acuity improved from 12 points (95% confidence interval [CI] 10.5-13.4) at baseline to 5 points both at Month 12 (95% CI 3.8-6.2) and at Month 18 (95% CI 3.6-6.4) (P < 0.0001). At the 18-month visit, 58% (42/73) of the patients had a near visual acuity of at least 5 points compared with 7% (6/85) (P < 0.0001) at baseline. Best-corrected visual acuity improved from 60.9 letters (Snellen 20/63) (95% CI 58.4-63.4) at baseline to 68.1 letters (20/40) (95% CI 65.3-70.9) (P < 0.001) at Month 12 and 69.6 letters (20/40) (95% CI 66.7-72.5) (P < 0.001) at Month 18.Conclusion:Significant improvements were found in near vision and best-corrected visual acuity. The improvement in near vision was comparably greater than the change in best-corrected visual acuity. Monitoring near vision can contribute additional information when managing the patient with wet, age-related macular degeneration.
C1 [Epstein, David; Amren, Urban] Karolinska Inst, St Erik Eye Hosp, Polhemsgatan 50, S-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Epstein, D (通讯作者)，Karolinska Inst, St Erik Eye Hosp, Polhemsgatan 50, S-11282 Stockholm, Sweden.
EM david.epstein@sankterik.se
RI Epstein, David/AAK-4413-2021
CR [Anonymous], 2009, DUANES OPHTHALMOLOGY, V5
   BLANCHARD HE, 1989, PERCEPT PSYCHOPHYS, V46, P85, DOI 10.3758/BF03208078
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Gambon R, 2014, KLIN MONATSBL AUGENH, V231, P423, DOI 10.1055/s-0034-1368292
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Legge GE, 2011, J VIS, P11
   Martin D.F., 2011, NEW ENGL J MED, V364, P1897, DOI DOI 10.1056/NEJM0A1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MORRIS RK, 1990, J EXP PSYCHOL HUMAN, V16, P268, DOI 10.1037/0096-1523.16.2.268
   RAYNER K, 1980, PERCEPT PSYCHOPHYS, V27, P537, DOI 10.3758/BF03198682
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 14
TC 9
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2016
VL 36
IS 9
BP 1773
EP 1777
DI 10.1097/IAE.0000000000000978
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9KZ
UT WOS:000383979500025
PM 26866528
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Iacono, P
   La Spina, C
   Iuliano, L
   Lo Giudice, G
   Introini, U
   Bandello, F
AF Parodi, Maurizio B.
   Iacono, Pierluigi
   La Spina, Carlo
   Iuliano, Lorenzo
   Lo Giudice, Giuseppe
   Introini, Ugo
   Bandello, Francesco
TI INTRAVITREAL RANIBIZUMAB FOR NAIVE EXTRAFOVEAL CHOROIDAL
   NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID PHOTODYNAMIC THERAPY; BEVACIZUMAB; TRIAMCINOLONE
AB Purpose: To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending on detection of any type of fluid on optical coherence tomography and/or the presence of leakage on fluorescein angiography. Primary outcome measures were mean changes in best-corrected visual acuity and the proportion of eyes gaining at least 15 letters (3 Early Treatment Diabetic Retinopathy Study [ETDRS] lines) at the end of the follow-up. Secondary outcome measures were central macular thickness variations and changes in choroidal neovascularization size.
   Results: Mean best-corrected visual acuity presented a significant improvement during the follow-up period, being 0.3 +/- 0.2 logMAR at baseline and 0.2 +/- 0.2 logMAR at the 12-month examination (P < 0.001). An improvement of at least 3 EDTRS lines was achieved by 6 eyes (33.3%), whereas 6 patients (33.3%) gained 1 to 2 lines. The mean central macular thickness at baseline was 314 +/- 87 mu m, changing to 268 +/- 65 mu m at the 12-month examination (P = 0.003). The mean lesion size was 1.4 +/- 1.4 mm(2) and remained stable throughout the follow-up, being 1.8 +/- 2.9 mm(2) at 12 months (P = 0.64).
   Conclusion: Intravitreal ranibizumab administered after a pro re nata regimen with monthly evaluation is a beneficial approach for the management of extrafoveal choroidal neovascularization secondary to age-related macular degeneration over 12 months of follow-up. Further studies are warranted to confirm our preliminary results.
C1 [Parodi, Maurizio B.; La Spina, Carlo; Iuliano, Lorenzo; Introini, Ugo; Bandello, Francesco] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Iacono, Pierluigi] IRCCS, GB Bietti Fdn Study & Res Ophthalmol, I-00198 Rome, Italy.
   [Lo Giudice, Giuseppe] St Antonio Hosp, San Paolo Ophthalm Ctr, Padua, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS
   - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia;
   ULSS 6 Euganea; Ospedale Sant'antonio Padova
RP Iacono, P (通讯作者)，IRCCS, GB Bietti Fdn Study & Res Ophthalmol, Via Livenza 3, I-00198 Rome, Italy.
EM pierluigi.iacono@libero.it
RI Iuliano, Lorenzo/X-1333-2019; Parodi, Maurizio Battaglia/K-7876-2016;
   Iuliano, Lorenzo/L-5889-2019; Iacono, Pierluigi/AAD-3158-2020; LO
   GIUDICE, GIUSEPPE/GQB-0418-2022; bandello, francesco/AAH-2405-2019
OI Iuliano, Lorenzo/0000-0001-6664-1327; Iuliano,
   Lorenzo/0000-0001-6664-1327; bandello, francesco/0000-0003-3238-9682;
   Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Beaumont PE, 2006, ARCH OPHTHALMOL-CHIC, V124, P807, DOI 10.1001/archopht.124.6.807
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Etter J, 2006, ANN OPHTHALMOL, V38, P239, DOI 10.1007/s12009-006-0012-3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mikuni Eri, 2003, Nippon Ganka Gakkai Zasshi, V107, P695
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Parodi MB, 2013, RETINA-J RET VIT DIS, V33, P593, DOI 10.1097/IAE.0b013e31826b6731
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Tranos P, 2006, CLIN EXP OPHTHALMOL, V34, P226, DOI 10.1111/j.1442-9071.2006.01198.x
   Voelker M, 2005, GRAEF ARCH CLIN EXP, V243, P1241, DOI 10.1007/s00417-005-0021-8
NR 15
TC 2
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2014
VL 34
IS 11
BP 2167
EP 2170
DI 10.1097/IAE.0000000000000223
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0DK
UT WOS:000344607100008
PM 24999724
DA 2022-11-30
ER

PT J
AU Thach, AB
   Sipperley, JO
   Dugel, PU
   Sneed, SR
   Park, DW
   Cornelius, J
AF Thach, AB
   Sipperley, JO
   Dugel, PU
   Sneed, SR
   Park, DW
   Cornelius, J
TI Large-spot size transpupillary thermotherapy for the treatment of occult
   choroidal neovascularization associated with age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MELANOMAS
AB Objective: To describe the outcome of patients with occult choroidal neovascularization in age-related macular degeneration treated with transpupillary thermotherapy.
   Design: Prospective, nonrandomized, nonmasked case series.
   Methods: All patients with age-related macular degeneration with a predominantly occult choroidal neovascular membrane and an initial visual acuity of 20/400 or better were offered treatment using transpupillary thermotherapy. The treatment consisted of using a diode laser, a spot size of about 3000 to 6000 pm delivered over 60 seconds, and a power of 600 to 1000 mW.
   Main Outcome Measures: A stable, improved, or worsened visual acuity and the need for additional treatment.
   Results: Sixty-nine patients were treated. All patients have been followed up for at least 6 months. At the 6-, 9-, and 12-month follow-up visits, 71% of patients. have stable or improved visual acuity and 29% have lost 2 or more lines of visual acuity on the Snellen letter chart.
   Conclusion: Large-spot size transpupillary thermotherapy is effective in stabilizing the visual acuity in those patients who have occult choroidal neovascularization due to age-related macular degeneration.
C1 Retinal Consultants Arizona, Phoenix, AZ 85064 USA.
RP Thach, AB (通讯作者)，Retinal Consultants Arizona, POB 32530, Phoenix, AZ 85064 USA.
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friberg T R, 2001, Semin Ophthalmol, V16, P70, DOI 10.1076/soph.16.2.70.4207
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Park C H, 2001, Semin Ophthalmol, V16, P66, DOI 10.1076/soph.16.2.66.4208
   PULIAFITO CA, 1987, ARCH OPHTHALMOL-CHIC, V105, P424
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   VOGL A, 1992, LASERS LIGHT OPHTHAL, V5, P9
   WELCH AJ, 1980, IEEE T BIO-MED ENG, V27, P164, DOI 10.1109/TBME.1980.326619
   [No title captured]
NR 26
TC 22
Z9 26
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2003
VL 121
IS 6
BP 817
EP 820
DI 10.1001/archopht.121.6.817
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 687ZY
UT WOS:000183408600008
PM 12796252
OA Bronze
DA 2022-11-30
ER

PT J
AU McKibbin, MA
   Suter, CA
   Willis, TA
AF McKibbin, Martin A.
   Suter, Carlo A.
   Willis, Thomas A.
TI THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT
   THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vitreomacular attachment; posterior vitreous detachment; aflibercept;
   age-related macular degeneration
ID POSTERIOR VITREOUS DETACHMENT; ENDOTHELIAL GROWTH-FACTOR; SUBGROUP
   ANALYSIS; RANIBIZUMAB; RISK; EYE
AB Purpose:To evaluate the influence of vitreomacular attachment on outcomes after intravitreal aflibercept for neovascular age-related macular degeneration.Methods:In a prospective case series, eyes with neovascular age-related macular degeneration were treated with intravitreal aflibercept, given as 3 consecutive monthly injections, followed by further injection every 2 months. Spectral domain optical coherence tomography images were reviewed at each visit to determine the attachment of the posterior hyaloid. Best-corrected visual acuity and retinal thickness were also recorded. Outcomes at Months 2 and 6 were compared between the eyes with persistent vitreomacular attachment (Stage 1) and those with posterior vitreous detachment (Stages 2 or 3 PVD) at baseline.Results:At baseline, 30 eyes had Stage 1 PVD and 63 eyes had either Stage 2 or 3 PVD. Although there was a trend for both greater visual acuity gains and reductions in retinal thickness for the eyes with Stages 2 or 3 PVD, this failed to reach significance. Baseline visual acuity and age were negatively associated with visual acuity change, and baseline retinal thickness alone was associated with retinal thickness change.Conclusion:Visual acuity, retinal thickness, and age at the baseline examination, but not PVD status, are associated with functional and anatomical outcomes after intravitreal aflibercept for neovascular age-related macular degeneration.
C1 [McKibbin, Martin A.] St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
   [Suter, Carlo A.] City Hosp, Birmingham Midlands Eye Ctr, Birmingham, W Midlands, England.
   [Willis, Thomas A.] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England.
C3 Saint James's University Hospital; University of Birmingham; University
   of Leeds
RP McKibbin, MA (通讯作者)，St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
EM martin.mckibbin@nhs.net
RI Willis, Thomas A/M-7433-2017; Willis, Thomas/V-3140-2019
OI Willis, Thomas A/0000-0002-0252-9923; Willis, Thomas/0000-0002-0252-9923
FU Alcon; Novartis Pharmaceuticals; Bayer Healthcare
FX M. A. McKibbin has received research support from Alcon, personal fees
   and nonfinancial support from Novartis Pharmaceuticals and Bayer
   Healthcare, outside the submitted work.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Gawecki Maciej, 2010, Klin Oczna, V112, P210
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 20
TC 9
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1951
EP 1956
DI 10.1097/IAE.0000000000000587
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000004
PM 25932561
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Neelam, K
   Hogg, RE
   Stevenson, MR
   Johnston, E
   Anderson, R
   Beatty, S
   Chakravarthy, U
AF Neelam, Kumari
   Hogg, Ruth E.
   Stevenson, Michael R.
   Johnston, Elinor
   Anderson, Roger
   Beatty, Stephen
   Chakravarthy, Usha
TI Carotenoids and Co-Antioxidants in Age-Related Maculopathy: Design and
   Methods
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-Related maculopathy; antioxidant supplementation; interferometric
   acuity; macular pigment; oxidative damage; randomized clinical trial
ID QUALITY-OF-LIFE; MACULAR PIGMENT; LUTEIN SUPPLEMENTATION; VISUAL
   IMPAIRMENT; ALPHA-TOCOPHEROL; RAMAN DETECTION; DEGENERATION; PREVALENCE;
   SERUM; ADJUSTMENT
AB Age-related macular degeneration (AMD), is the leading cause of blind registration in the Western World among individuals 65 years or older. Early AMD, a clinical state without overt functional loss, is said to be present clinically when yellowish deposits known as drusen and/or alterations of fundus pigmentation are seen in the macular retina. Although the etiopathogenesis of AMD remains uncertain, there is a growing body of evidence in support of the view that cumulative oxidative damage plays a causal role. Appropriate dietary antioxidant supplementation is likely to be beneficial in maintaining visual function in patients with AMD, and preventing or delaying the progression of early AMD to late AMD. The Carotenoids in Age-Related Maculopathy (CARMA) Study is a randomized and double-masked clinical trial of antioxidant supplementation versus placebo in 433 participants with either early AMD features of sufficient severity in at least one eye or any level of AMD in one eye with late AMD (neovascular AMD or central geographic atrophy) in the fellow eye. The aim of the CARMA Study is to investigate whether lutein and zeaxanthin, in combination with co-antioxidants (vitamin C, E, and zinc), has a beneficial effect on visual function and/or prevention of progression from early to late stages of disease. The primary outcome is improved or preserved distance visual acuity at 12 months. Secondary outcomes include improved or preserved interferometric acuity, contrast sensitivity, shape discrimination ability, and change in AMD severity as monitored by fundus photography. This article outlines the CARMA Study design and methodology, including its rationale.
C1 [Hogg, Ruth E.; Stevenson, Michael R.; Johnston, Elinor; Beatty, Stephen; Chakravarthy, Usha] Queens Univ, Belfast BT12 6BA, Antrim, North Ireland.
   [Neelam, Kumari; Anderson, Roger] Waterford Inst Technol, Waterford, Ireland.
   [Neelam, Kumari; Anderson, Roger] Waterford Reg Hosp, Waterford, Ireland.
   [Anderson, Roger] Univ Ulster, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Chakravarthy, Usha] Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; South East Technological University (SETU);
   Ulster University
RP Chakravarthy, U (通讯作者)，Queens Univ, Belfast BT12 6BA, Antrim, North Ireland.
EM U.Chakravarthy@queens-belfast.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Bausch and Lomb, Berlin
FX This study was supported by a grant from Bausch and Lomb, Berlin.
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   BARLETT HE, 2007, EUR J CLIN NUTR, V31
   BARTLETT H, 2004, OPTOM PRACTISE, V5, P15
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   CHEW E, 2006, AGE RELATED EY UNPUB
   CHONG EWT, 2007, BMJ
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dagnelie G, 2000, Optometry, V71, P147
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GORALCZCYK R, 2002, ASS RES VISION OPHTH, V43, P2546
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   GRIGNOLO FM, 1988, ANN OPHTHALMOL, V20, P335
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jenkins MY, 2000, NUTR CANCER, V37, P207, DOI 10.1207/S15327914NC372_14
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leibowitz HM, 1980, SURV OPHTHALMOL S, V24
   MASSACESI KR, 2001, ASS RES VIS OPHTHALM, V42, P234
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Olmedilla B, 2002, CLIN SCI, V102, P447, DOI 10.1042/CS20010159
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROSNER B, 1982, BIOMETRICS, V38, P105, DOI 10.2307/2530293
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   *TREATM AG REL MAC, 2002, ARCH OPHTHALMOL-CHIC, V119, P198
   *TREATM AG REL MAC, 2001, ARCH OPHTHALMOL-CHIC, V117, P1329
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
NR 57
TC 25
Z9 29
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2008
VL 15
IS 6
BP 389
EP 401
AR PII 906500594
DI 10.1080/09286580802154275
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 380ZQ
UT WOS:000261505000006
PM 19065432
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Hogg, RE
   McKay, GJ
   Hughes, AE
   Muldrew, KA
   Chakravarthy, U
AF Hogg, Ruth E.
   McKay, Gareth J.
   Hughes, Anne E.
   Muldrew, Katherine A.
   Chakravarthy, Usha
TI GENOTYPE-PHENOTYPE ASSOCIATIONS IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; ARMS2; CFH; HTRA1; genotype-phenotype
   correlation; lesion characteristics; fluorescein angiography
ID COMPLEMENT FACTOR-H; OCCULT CHOROIDAL NEOVASCULARIZATION; RISK-FACTORS;
   CIGARETTE-SMOKING; POOLED FINDINGS; COMPONENT 2; CFH Y402H;
   POLYMORPHISM; DRUSEN; HTRA1
AB Purpose: To examine associations between recognized genetic susceptibility loci and angiographic subphenotypes of the neovascular variant of age-related macular degeneration (nvAMD).
   Methods: Participants (247 nvAMD, 52 early age-related macular degeneration [AMD], and 103 controls) were genotyped (complement factor H and ARMS2/HTRA1). nvAMD participants were assigned to one of two subcategories: mainly classic or mainly occult (based on the proportions of classic and occult choroidal neovascularization). nvAMD and early AMD were reassigned to two groups based on the extent and severity of drusen (retinal pigment epithelium dysfunction or not). Univariate and multivariate analysis were used to examine for associations between participant characteristics and genetic loci after adjusting for age, smoking status, and history of cardiovascular disease.
   Results: Univariate analysis confirmed the known significant associations between AMD stage and age, hypertension, and a history of cardiovascular disease. Those with retinal pigment epithelium dysfunction (F = 5.46; P = 0.02) or a positive smoking history (F = 3.89; P = 0.05) were more likely to have been classified as having mainly an occult rather than a mainly classic lesion. Multivariate analysis showed that significant associations were noted with the number of ARMS2/HTRA1 risk alleles (P < 0.001), smoking (ever vs. never) (P = 0.03), and cardiovascular disease (P = 0.01). With early AMD as the reference category, the mainly classic group exhibited significant associations with the number of ARMS2/HTRA1 risk alleles present (P < 0.001) and cardiovascular disease (P = 0.02). When mainly classic was compared with mainly occult, the latter was associated with the ARMS2/HTRA1 locus (P = 0.02).
   Conclusion: ARMS2/HTRA1 risk genotype may play a role in determining neovascular subphenoptye, whereas genetics/demographics, smoking, and systemic health factors contribute to the development of advanced AMD in the presence of early AMD. RETINA 32:1950-1958, 2012
C1 [Hogg, Ruth E.; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [McKay, Gareth J.; Hughes, Anne E.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Muldrew, Katherine A.] Queens Univ Belfast, Cent Angiog Resource Facil, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Vis & Vasc Sci, Inst Clin Sci, Royal Victoria Hosp, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; McKay, Gareth/AAZ-2601-2020
OI Hogg, Ruth E./0000-0001-9413-2669; McKay, Gareth/0000-0001-8197-6280;
   Chakravarthy, Usha/0000-0002-2606-3734
FU EU's 7th Framework EVIGENORET
FX Supported in part by EU's 7th Framework EVIGENORET.
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chowers I, 2008, MOL VIS, V14, P1829
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Egleton RD, 2009, PHARMACOL THERAPEUT, V121, P205, DOI 10.1016/j.pharmthera.2008.10.007
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   REID DD, 1976, LANCET, V2, P979
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Takeuchi A, 2009, INVEST OPHTH VIS SCI, V50, P3410, DOI 10.1167/iovs.08-2299
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vassallo R, 2008, MOL IMMUNOL, V45, P3321, DOI 10.1016/j.molimm.2008.04.014
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 48
TC 6
Z9 6
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1950
EP 1958
DI 10.1097/IAE.0b013e31824dadf1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800031
PM 22487577
DA 2022-11-30
ER

PT J
AU Fassbender, JM
   Sherman, MP
   Barr, CC
   Schaal, S
AF Fassbender, Janelle M.
   Sherman, Mark P.
   Barr, Charles C.
   Schaal, Shlomit
TI TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED
   MACULAR DEGENERATION: Comparison of 3 Treatment Modalities
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE submacular hemorrhage; age-related macular degeneration; tissue
   plasminogen activator; vitrectomy; pneumatic displacement
ID EXPERIMENTAL SUBRETINAL HEMORRHAGE; THICK SUBMACULAR HEMORRHAGE;
   ENDOTHELIAL GROWTH-FACTOR; PNEUMATIC DISPLACEMENT; INTRAVITREAL
   INJECTION; NATURAL-HISTORY; GAS; MANAGEMENT; REMOVAL; SECONDARY
AB Purpose:To analyze and compare the effects of three common treatment modalities for a thick subfoveal hemorrhage due to exudative age-related macular degeneration on final visual acuity and the size of the final subretinal scar.Design:Retrospective case series.Setting:Single-site, tertiary referral center.Patients:Thirty-nine patients with exudative age-related macular degeneration and acute SMH greater than 250 m.Intervention:Patients received vitrectomy with a subretinal tissue plasminogen activator (tPA) injection, pneumatic displacement (PD) with intravitreal tPA, or PD without tPA within 2 weeks of presentation.Main Outcome Measure:Functional outcome was determined by Snellen visual acuity. Anatomical outcome was determined as the final disciform scar size.Results:Treatment groups did not differ in age, sex, initial visual acuity, the initial area of the thick subfoveal hemorrhage, follow-up duration, lens status, duration of exudative age-related macular degeneration, previous intravitreal bevacizumab injections, or time from last given injection to the acute thick subfoveal hemorrhage. Final visual acuity improved significantly in both the vitrectomy and subretinal tPA injection group (P < 0.001), and the intravitreal tPA injection group (P = 0.002) but not with PD alone. Patients treated with subretinal tPA achieved 40% 54% reduction in final scar area, in contrast to 27% +/- 35% decrease in patients treated with intravitreal tPA (P = 0.001).Conclusion:Treatment with tPA improves the functional and anatomical outcomes in patients with thick subfoveal hemorrhage due to subfoveal choroidal neovascular membrane secondary to exudative age-related macular degeneration and was superior to PD without tPA. Vitrectomy with subretinal tPA injection reduced the final disciform scar compared with PD with or without intravitreal tPA.
C1 [Fassbender, Janelle M.; Sherman, Mark P.; Barr, Charles C.; Schaal, Shlomit] Univ Louisville, Dept Ophthalmol & Visual Sci, 301E Muhammad Ali Blvd, Louisville, KY 40202 USA.
C3 University of Louisville
RP Schaal, S (通讯作者)，Univ Louisville, Dept Ophthalmol & Visual Sci, 301E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM s.schaal@louisville.edu
FU Research to Prevent Blindness, Inc, New York City, NY
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc, New York City, NY.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1997, ADV THER, V14, P275
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klettner A, 2015, BR J OPHTHALMOL
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Lumi X, 2013, COLLEGIUM ANTROPOL, V37, P223
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Schaal S, 2015, AM J OPHTHALMOL, V159, P404, DOI 10.1016/j.ajo.2014.10.024
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Shroff GR, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000756
   Sobolewska B, 2014, J OCUL PHARMACOL TH, V30, P567, DOI 10.1089/jop.2013.0135
   Stanescu-Segall D, 2015, SURV OPHTHALMOL
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Steinhorst UH, 1997, OPHTHALMOLOGICA, V211, P399, DOI 10.1159/000310841
   Terasaki H, 1997, AM J OPHTHALMOL, V123, P207, DOI 10.1016/S0002-9394(14)71037-2
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
NR 46
TC 16
Z9 17
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1860
EP 1865
DI 10.1097/IAE.0000000000001030
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ6US
UT WOS:000385998600019
PM 26945238
DA 2022-11-30
ER

PT J
AU Casten, RJ
   Rovner, BW
AF Casten, Robin J.
   Rovner, Barry W.
TI Update on depression and age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; depression; late-onset vision loss
ID QUALITY-OF-LIFE; SELF-MANAGEMENT; VISION; SYMPTOMS; RANIBIZUMAB;
   PREVALENCE; ANXIETY; PEOPLE; ADULTS
AB Purpose of review
   This review updates the literature on depression in age-related macular degeneration (AMD). Treatment for AMD has been revolutionized since the 2004 review of depression and AMD. New data describing the prevalence of depression in AMD, as well as novel interventions for managing depression in AMD, are discussed.
   Recent findings
   Depression continues to be prevalent in AMD and new information is available on the pathways by which impaired vision leads to depression. Strategies for the treatment of depression in patients with impaired vision have evolved.
   Summary
   AMD is still a major risk factor for depression and people with activity restriction due to vision loss are at greatest risk. An integrated approach to depression management in older adults with impaired vision may be the best course of action.
C1 [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University
RP Casten, RJ (通讯作者)，Thomas Jefferson Univ, Jefferson Hosp Neurosci, 900 Walnut St,2nd Floor, Philadelphia, PA 19107 USA.
EM Robin.Casten@jefferson.edu
FU National Eye Institute [U01 5U01EY018819]; NATIONAL EYE INSTITUTE
   [U01EY018819] Funding Source: NIH RePORTER
FX This work was supported by grant U01 5U01EY018819 from the National Eye
   Institute.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2008, AGE REL MAC DEG
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bookwala J, 2011, GERONTOLOGIST, V51, P798, DOI 10.1093/geront/gnr051
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cole MG, 2005, PSYCHIAT CLIN N AM, V28, P785, DOI 10.1016/j.psc.2005.09.010
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   Girdler SJ, 2010, BRIT J OPHTHALMOL, V94, P223, DOI 10.1136/bjo.2008.147538
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Horowitz A, 2005, AGING MENT HEALTH, V9, P563, DOI 10.1080/13607860500193500
   Huang CQ, 2010, AGEING RES REV, V9, P131, DOI 10.1016/j.arr.2009.05.005
   Jones GC, 2009, REHABIL PSYCHOL, V54, P164, DOI 10.1037/a0015910
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Nyman S, 2009, AGE AGEING, V38, pii65
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Rees G, 2011, AUSTRALAS J AGEING, V30, P130, DOI 10.1111/j.1741-6612.2010.00467.x
   Rees G, 2010, OPTOMETRY VISION SCI, V87, P494, DOI 10.1097/OPX.0b013e3181df5286
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2005, AM J GERIAT PSYCHIAT, V13, P255
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Steffens DC, 2009, INT PSYCHOGERIATR, V21, P879, DOI 10.1017/S1041610209990044
   Tournier M, 2008, ACTA OPHTHALMOL, V86, P196, DOI 10.1111/j.1600-0420.2007.01024.x
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   Zhang X, ARCH OPHTHA IN PRESS
NR 36
TC 55
Z9 56
U1 1
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2013
VL 24
IS 3
BP 239
EP 243
DI 10.1097/ICU.0b013e32835f8e55
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 123ML
UT WOS:000317394000009
PM 23429599
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Feigl, B
AF Feigl, Beatrix
TI Age-related maculopathy - Linking aetiology and pathophysiological
   changes to the ischaemia hypothesis
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related maculopathy; Ischaemia; Hypoxia; Basal laminar deposits;
   Basal linear deposits; Complement factor H; Electroretinography; VEGF;
   Ranibizumab; Bevacizumab
ID COMPLEMENT FACTOR-H; MEDIATED MULTIFOCAL ELECTRORETINOGRAM; CHOROIDAL
   BLOOD-FLOW; EPITHELIUM-DERIVED FACTOR; CHLAMYDIA-PNEUMONIAE INFECTION;
   SENILE MACULAR DEGENERATION; CENTRAL VISUAL-FIELD; LONG-TERM INCIDENCE;
   GROWTH-FACTOR VEGF; DARK-ADAPTATION
AB Age-related maculopathy, (ARM) has remained a challenging topic with respect to its aetiology, pathomechanisms, early detection and treatment since the late 19th century when it was first described as its own entity. ARM was previously considered an inflammatory disease, a degenerative disease, a tumor and as the result of choroidal hemodynamic disturbances and ischaemia. The latter processes have been repeatedly suggested to have a key role in its development and progression. In vivo experiments under hypoxic conditions could be models for the ischaemic deficits in ARM. Recent research has also linked ARM with gene polymorphisms. It is however unclear what triggers a person's gene susceptibility. In this manuscript, a linking hypothesis between aetiological factors including ischaemia and genetics and the development of early clinicopathological changes in ARM is proposed. New clinical psychophysical and electrophysiological tests are introduced that can detect ARM at an early stage. Models of early ARM based upon hemodynamic, photoreceptor and post-receptoral deficits are described and the mechanisms by which ischaemia may be involved as a final common pathway are considered. In neovascular age-related macular degeneration (neovascular AMD), ischaemia is thought to promote release of vascular endothelial growth factor (VEGF) which induces chorioretinal neovascularisation. VEGF is critical in the maintenance of the healthy choriocapillaris. In the final section of the manuscript the documentation of the effect of new anti-VEGF treatments on retinal function in neovascular AMD is critically viewed. (c) 2008 Elsevier Ltd. All rights reserved.
C1 Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Adler R, 1999, MOL VIS, V5
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AIBA TS, 1967, J PHYSIOL-LONDON, V189, P43, DOI 10.1113/jphysiol.1967.sp008154
   ALDER VA, 1990, GRAEF ARCH CLIN EXP, V228, P151
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   ARDEN GB, 1966, BRIT J OPHTHALMOL, V50, P740, DOI 10.1136/bjo.50.12.740
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   BAIRD PN, 2008, HUM MOL GENET
   Balslev E, 1999, APMIS, V107, P997, DOI 10.1111/j.1699-0463.1999.tb01502.x
   BARNETT NL, 1995, EXP EYE RES, V61, P83, DOI 10.1016/S0014-4835(95)80061-1
   BASHSHUR ZF, 2007, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2007.1009.1031
   Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P296, DOI 10.1167/iovs.03-0424
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BIERSDORF WR, 1969, AM J OPHTHALMOL, V68, P296, DOI 10.1016/0002-9394(69)94073-2
   BIRD AC, 1992, OPHTHALMIC PAED GEN, V13, P57, DOI 10.3109/13816819209087605
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BOWEN RW, 1980, NATURE, V285, P440, DOI 10.1038/285440a0
   BRANTLEY MA, 2008, EYE, DOI DOI 10.1038/EYE.2008.1028
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRINCHMANNHANSEN O, 1989, AVIAT SPACE ENVIR MD, V60, P1183
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bui BV, 2003, EXP EYE RES, V77, P125, DOI 10.1016/S0014-4835(03)00132-5
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Cao D, 2008, VISUAL NEUROSCI, V25, P399, DOI 10.1017/S0952523808080425
   Cao DC, 2008, VISION RES, V48, P2586, DOI 10.1016/j.visres.2008.05.001
   Casson RJ, 2004, ARCH OPHTHALMOL-CHIC, V122, P361, DOI 10.1001/archopht.122.3.361
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG A, 1992, OPTOMETRY VISION SCI, V70, P89
   Chong EWT, 2006, CLIN EXP OPHTHALMOL, V34, P464, DOI 10.1111/j.1442-9071.2006.01250.x
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Coats G, 1908, R LOND OPHTHALMOL HO, V17, P440
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Connolly DM, 2008, INVEST OPHTH VIS SCI, V49, P820, DOI 10.1167/iovs.07-1004
   Connolly DM, 2006, VISION RES, V46, P1784, DOI 10.1016/j.visres.2005.10.027
   CRAWFORD Y, 2008, CELL TISSUE RES, DOI DOI 10.1007/S00441-00008-00675-00448
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELANEY VW, 1986, ANN OPHTHALMOL, V14, P21
   Derwent JK, 2000, INVEST OPHTH VIS SCI, V41, P3634
   DEUTMAN AF, 1970, PERSPECTIVES OPHTHAL, pCH2
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Din JN, 2004, BMJ-BRIT MED J, V328, P30, DOI 10.1136/bmj.328.7430.30
   DONNER KO, 1959, J PHYSIOL-LONDON, V149, P288, DOI 10.1113/jphysiol.1959.sp006340
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DUKEELDER S, 1966, SYSTEM OPHTHALMOLOGY, V9, P610
   EASTWOOD M, 1997, PRINCIPLES HUMAN NUT
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER AE, 2002, J OPT SOC AM A, V19, P215
   EMERSON MV, 2007, RETINA, V24, P439
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTEVEZ O, 1982, VISION RES, V22, P681, DOI 10.1016/0042-6989(82)90104-3
   EVANS J, 2000, FROG RETIN EYE RES, V20, P227
   FALLON TJ, 1985, OPHTHALMOLOGY, V92, P701
   Falsini B, 2002, INVEST OPHTH VIS SCI, V43, P2309
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2006, VISUAL NEUROSCI, V23, P863, DOI 10.1017/S0952523806230190
   Feigl B, 2005, DOC OPHTHALMOL, V111, P135, DOI 10.1007/s10633-005-5319-7
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FEIGL B, 2004, 2004 ANN M ASS RES V
   FEIGL B, 2007, CLIN EXP OPHTHALM S1, V35, pA85
   Feigl B, 2008, J NEUROSCI METH, V167, P207, DOI 10.1016/j.jneumeth.2007.08.006
   Feigl B, 2008, INVEST OPHTH VIS SCI, V49, P807, DOI 10.1167/iovs.07-0994
   Feigl B, 2007, CLIN NEUROPHYSIOL, V118, P887, DOI 10.1016/j.clinph.2006.12.012
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRARA N, 1999, MICROBIOL IMMUNOL, V237, P1
   Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FUCHS E, 1893, AV GRAEFES ARCH OPHT, V39, P229
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   GASS JDM, 1997, AGE RELATED MACULAR, P70
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   GAUDRIC A, 1982, AM J OPHTHALMOL, V94, P489, DOI 10.1016/0002-9394(82)90242-2
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Granit R, 1933, J PHYSIOL-LONDON, V77, P207, DOI 10.1113/jphysiol.1933.sp002964
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grozdanic SD, 2003, INVEST OPHTH VIS SCI, V44, P2597, DOI 10.1167/iovs.02-0600
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hare William A., 2002, Documenta Ophthalmologica, V105, P189, DOI 10.1023/A:1020553020264
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   HARTRIDGE G, 1896, T OPHTHAL SOC UK, V16, P90
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   HOLM E, 1917, KLIN MONATSBL AUGENH, V59, P319
   Holopigian K, 2004, INVEST OPHTH VIS SCI, V45, P275, DOI 10.1167/iovs.03-0627
   Holopigian K, 2001, INVEST OPHTH VIS SCI, V42, P779
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   Hood DC, 1999, VISION RES, V39, P2285, DOI 10.1016/S0042-6989(98)00296-X
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 1999, VISUAL NEUROSCI, V16, P411, DOI 10.1017/S0952523899163028
   HOOD DC, 2007, STANDARD CLIN MULTIF
   Horiguchi M, 1998, INVEST OPHTH VIS SCI, V39, P2171
   Howell WH, 1997, AM J CLIN NUTR, V65, P1747, DOI 10.1093/ajcn/65.6.1747
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Hutchinson J., 1874, R LOND OPHTHALMIC HO, V8, P231
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman L, 1992, AGE RELATED MACULAR, P1
   IKEDA H, 1992, EXP EYE RES, V55, P435, DOI 10.1016/0014-4835(92)90116-A
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   JAGER RD, 2008, NEW ENGL J MED, V24, P2607
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   JONES R, 1986, CLIN VISION SCI, V1, P153
   Junius P, 1926, SCHEIBENFOERMIGE ENT
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiserman I, 2002, AM J OPHTHALMOL, V133, P581, DOI 10.1016/S0002-9394(01)01371-X
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Karakucuk S, 2004, AVIAT SPACE ENVIR MD, V75, P364
   Kergoat H, 2006, INVEST OPHTH VIS SCI, V47, P5423, DOI 10.1167/iovs.06-0602
   KEYS A, 1970, CIRCULATION, V41, P1162
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   KILLINGSWORTH MC, 1995, GRAEFES ARCH CLIN EX, V233, P1995
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   KLAVER CCW, 1995, ARCH OPHTHALMOL-CHIC, V113, P1281, DOI 10.1001/archopht.1995.01100100069031
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V131, P167
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klemp K, 2007, INVEST OPHTH VIS SCI, V48, P3405, DOI 10.1167/iovs.06-0471
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kopsa H, 1978, Proc Eur Dial Transplant Assoc, V15, P372
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Kremers J, 2003, PROG RETIN EYE RES, V22, P579, DOI 10.1016/S1350-9462(03)00049-1
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL, V25, P333
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   LINSENMEIER RA, 1983, INVEST OPHTH VIS SCI, V24, P37
   LINSENMEIER RA, 1990, GRAEF ARCH CLIN EXP, V228, P143, DOI 10.1007/BF02764309
   LINSENMEIER RA, 1987, CLIN VISION SCI, V2, P111
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Lipski A, 2007, RETINA-J RET VIT DIS, V27, P864, DOI 10.1097/IAE.0b013e318154b9b9
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   MASSAY S, 1990, PROGR RETINAL RES, P339
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McFarland RA, 1939, AM J PHYSIOL, V127, P37, DOI 10.1152/ajplegacy.1939.127.1.37
   MELROSE MA, 1987, ANN OPHTHALMOL, V19, P396
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MICHEL J, 1878, A VONGRAEFES ARCH OP, V24
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   MIYAKE Y, 1981, JPN J OPHTHALMOL, V25, P438
   MIYAKE Y, 1993, ARCH OPHTHALMOL-CHIC, V111, P1605, DOI 10.1001/archopht.1993.01090120027008
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027
   MOLLON JD, 1980, NATURE, V283, P623, DOI 10.1038/283623a0
   Montalvo V, 2007, CURR EYE RES, V32, P917, DOI 10.1080/02713680701656343
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Moser C, 2007, CLIN COLORECTAL CANC, V6, P564, DOI 10.3816/CCC.2007.n.023
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   NAARENDORP F, 1991, VISION RES, V31, P1, DOI 10.1016/0042-6989(91)90068-G
   Napper GA, 1999, VISUAL NEUROSCI, V16, P1169, DOI 10.1017/S0952523899166161
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   NIEMEYER G, 1982, INVEST OPHTH VIS SCI, V23, P678
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   OBERMAN AE, 1975, WESTERN J MED, V123, P184
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Osborne NN, 1996, NEUROCHEM INT, V29, P263, DOI 10.1016/0197-0186(96)00005-8
   Osborne NN, 1996, INVEST OPHTH VIS SCI, V37, P274
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Pagenstecher H. a. G., 1875, ATLAS PATHOLOGISCHEN
   PALMOWSKI A, 2001, VIS SCI APPL OSA, P32
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pavlidis M, 2005, OPHTHALMOLOGICA, V219, P404, DOI 10.1159/000088387
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pokorny J, 2004, VISUAL NEUROSCI, V21, P263, DOI 10.1017/S0952523804213207
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rangaswamy NV, 2003, INVEST OPHTH VIS SCI, V44, P3233, DOI 10.1167/iovs.03-0009
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RICH B, 2006, RETINA, V26, P495
   Riedemann NC, 2003, AM J PATHOL, V162, P363, DOI 10.1016/S0002-9440(10)63830-8
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   Riva CE, 2005, PROG RETIN EYE RES, V24, P183, DOI 10.1016/j.preteyeres.2004.07.002
   ROBBINS S, 2004, ROBBINS COTRAN PATHO
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Rodrigues EB, 2007, ACTA OPHTHALMOL SCAN, V85, P915, DOI 10.1111/j.1600-0420.2007.00968.x
   ROMANO C, 1993, INVEST OPHTH VIS SCI, V34, P72
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Roy C S, 1890, J Physiol, V11, P85
   RUECKMANN AV, 1997, INVEST OPHTH VIS SCI, V38, P478
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   RYAN SJ, 2006, RETINA, P991
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SANDBERG MA, 1977, ARCH OPHTHALMOL-CHIC, V95, P1881
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SCHAFER H, 1986, J IMMUNOL, V137, P1945
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SEIPLE WH, 1986, AM J OPTOM PHYS OPT, V63, P1
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shapiro AG, 1996, J OPT SOC AM A, V13, P2319, DOI 10.1364/JOSAA.13.002319
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SILCOCK AQ, 1898, T OPHTHAL SOC UK, V19, P69
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith V C, 1976, Mod Probl Ophthalmol, V17, P248
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   SPARROW JR, 2001, INVEST OPHTH VIS SCI, V41, P1981
   Stahl GL, 2003, AM J PATHOL, V162, P449, DOI 10.1016/S0002-9440(10)63839-4
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   STILES WS, 1959, P NATL ACAD SCI USA, V45, P100, DOI 10.1073/pnas.45.1.100
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thurman JM, 2005, KIDNEY INT, V67, P524, DOI 10.1111/j.1523-1755.2005.67109.x
   Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517
   Tinjust D, 2002, AVIAT SPACE ENVIR MD, V73, P1189
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vardi N, 2000, J NEUROSCI, V20, P7657
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGRYS AJ, 1987, DOC OPHTHALMOL, V66, P171, DOI 10.1007/BF00140454
   VOGT A, 1934, KLIN MONATSBL AUGENH, V92, P743
   Wachtmeister L, 1998, PROG RETIN EYE RES, V17, P485, DOI 10.1016/S1350-9462(98)00006-8
   WALD G, 1964, SCIENCE, V145, P1007, DOI 10.1126/science.145.3636.1007
   Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wellard J, 2005, VISUAL NEUROSCI, V22, P501, DOI 10.1017/S0952523805224112
   WISE GN, 1971, RETINAL CIRCULATION, P34
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0
   YAMAMOTO S, 1995, VISION RES, V35, P1641, DOI 10.1016/0042-6989(94)00271-M
   YANG Z, 2008, N ENGL J MED
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YARR MT, 1898, T OPHTHAL SOC UK, V19, P68
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu DY, 2002, COMP BIOCHEM PHYS A, V132, P47, DOI 10.1016/S1095-6433(01)00528-1
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zele AJ, 2006, GRAEF ARCH CLIN EXP, V244, P425, DOI 10.1007/s00417-005-0121-5
   Zele AJ, 2008, VISION RES, V48, P2593, DOI 10.1016/j.visres.2008.04.003
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 358
TC 102
Z9 106
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2009
VL 28
IS 1
BP 63
EP 86
DI 10.1016/j.preteyeres.2008.11.004
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RF
UT WOS:000264306200004
PM 19070679
DA 2022-11-30
ER

PT J
AU Wallace, JM
   Chung, STL
   Tjan, BS
AF Wallace, Julian M.
   Chung, Susana T. L.
   Tjan, Bosco S.
TI Object crowding in age-related macular degeneration
SO JOURNAL OF VISION
LA English
DT Article
DE crowding; form vision; peripheral vision; central vision loss
ID CONTRAST SENSITIVITY; CONTOUR ENHANCEMENT; READING SPEED; VISUAL-ACUITY;
   RECOGNITION; VISION; CHARACTERS; RESOLUTION; SHAPE
AB Crowding, the phenomenon of impeded object identification due to clutter, is believed to be a key limiting factor of form vision in the peripheral visual field. The present study provides a characterization of object crowding in age-related macular degeneration (AMD) measured at the participants' respective preferred retinal loci with binocular viewing. Crowding was also measured in young and age-matched controls at the same retinal locations, using a fixation-contingent display paradigm to allow unlimited stimulus duration. With objects, the critical spacing of crowding for AMD participants was not substantially different from controls. However, baseline contrast energy thresholds in the noncrowded condition were four times that of the controls. Crowding further exacerbated deficits in contrast sensitivity to three times the normal crowdinginduced contrast energy threshold elevation. These findings indicate that contrast-sensitivity deficit is a major limiting factor of object recognition for individuals with AMD, in addition to crowding. Focusing on this more tractable deficit of AMD may lead to more effective remediation and technological assistance.
C1 [Wallace, Julian M.; Tjan, Bosco S.] Univ Southern Calif, Dept Psychol, Los Angeles, CA USA.
   [Chung, Susana T. L.] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
   [Tjan, Bosco S.] Univ Southern Calif, Neurosci Grad Program, Los Angeles, CA USA.
C3 University of Southern California; University of California System;
   University of California Berkeley; University of Southern California
RP Chung, STL (通讯作者)，Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
EM s.chung@berkeley.edu
OI Chung, Susana/0000-0003-2729-1808
FU NIH/NEI [R01-EY017707, R01-EY012810]; NATIONAL EYE INSTITUTE
   [R01EY017707, R01EY012810] Funding Source: NIH RePORTER
FX We dedicate this paper to our dear friend and colleague, Bosco Tjan, who
   passed away due to a tragic incident on December 2, 2016, after this
   paper had been sent to production. This work was supported by NIH/NEI
   Grants R01-EY017707 and R01-EY012810.
CR ANDRIESSEN JJ, 1976, VISION RES, V16, P71, DOI 10.1016/0042-6989(76)90078-X
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   BOUMA H, 1973, VISION RES, V13, P767, DOI 10.1016/0042-6989(73)90041-2
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Choudhury A., 2010, P IEEE COMPUTER SOC, P33
   Chung STL, 2001, VISION RES, V41, P1833, DOI 10.1016/S0042-6989(01)00071-2
   Chung STL, 2008, OPTOMETRY VISION SCI, V85, P827, DOI 10.1097/OPX.0b013e31818527ea
   Chung STL, 2016, INVEST OPHTH VIS SCI, V57, P198, DOI 10.1167/iovs.15-18084
   Chung STL, 2014, VISION RES, V101, P167, DOI 10.1016/j.visres.2014.06.015
   Chung STL, 2013, J NEUROSCI, V33, P18080, DOI 10.1523/JNEUROSCI.2764-13.2013
   Coates DR, 2013, OPTOMETRY VISION SCI, V90, P628, DOI 10.1097/OPX.0b013e31829908a4
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Farzin F, 2009, J VISION, V9, DOI 10.1167/9.6.18
   FLOM MERTON C., 1963, SCIENCE, V142, P979, DOI 10.1126/science.142.3594.979
   He S, 1996, NATURE, V383, P334, DOI 10.1038/383334a0
   Ikeda H, 2013, J VISION, V13, DOI 10.1167/13.4.20
   Kwon M, 2012, OPTOMETRY VISION SCI, V89, P1374, DOI 10.1097/OPX.0b013e3182678e52
   LEGGE GE, 1984, VISION RES, V24, P385, DOI 10.1016/0042-6989(84)90064-6
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Levi DM, 2002, J VISION, V2, P167, DOI 10.1167/2.2.3
   Li XR, 2003, J NEUROSCI METH, V130, P9, DOI 10.1016/S0165-0270(03)00174-2
   Louie EG, 2007, J VISION, V7, DOI 10.1167/7.2.24
   MARMOR MF, 1986, BRIT J OPHTHALMOL, V70, P553, DOI 10.1136/bjo.70.7.553
   Martelli M, 2005, J VISION, V5, P58, DOI 10.1167/5.1.6
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   Nandy A. S., 2009, J VISION, V9, P1001, DOI [10.1167/9.8.1001, DOI 10.1167/9.8.1001]
   Nandy AS, 2012, NAT NEUROSCI, V15, P463, DOI 10.1038/nn.3021
   Nandy AS, 2007, J VISION, V7, DOI 10.1167/7.2.5
   PARDHAN S, 1991, EYE, V5, P31, DOI 10.1038/eye.1991.6
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Pelli DG, 2008, NAT NEUROSCI, V11, P1129, DOI 10.1038/nn.2187
   Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12
   Petrov Y, 2007, J VISION, V7, DOI 10.1167/7.2.8
   Satgunam P, 2012, OPTOMETRY VISION SCI, V89, pE1364, DOI 10.1097/OPX.0b013e318266f92f
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tarita-Nistor L, 2012, OPTOMETRY VISION SCI, V89, P277, DOI 10.1097/OPX.0b013e318244e8b1
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   TJAN BS, 1995, VISION RES, V35, P3053, DOI 10.1016/0042-6989(95)00070-G
   TOET A, 1992, VISION RES, V32, P1349, DOI 10.1016/0042-6989(92)90227-A
   Wallace JM, 2013, VISION RES, V84, P50, DOI 10.1016/j.visres.2013.03.010
   Wallace JM, 2011, J VISION, V11, DOI 10.1167/11.6.19
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   Whitney D, 2011, TRENDS COGN SCI, V15, P160, DOI 10.1016/j.tics.2011.02.005
   WOLKSTEIN M, 1980, OPHTHALMOLOGY, V87, P1140
NR 47
TC 11
Z9 11
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PD JAN
PY 2017
VL 17
IS 1
AR 33
DI 10.1167/17.1.33
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ1DB
UT WOS:000392949400032
PM 28129416
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Klein, BEK
   Wong, TY
   Cotch, MF
   Barr, G
AF Klein, Ronald
   Knudtson, Michael D.
   Klein, Barbara E. K.
   Wong, Tien Y.
   Cotch, Mary Frances
   Barr, Graham
TI Emphysema, Airflow Limitation, and Early Age-Related Macular
   Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ATHEROSCLEROSIS MESA; COMPUTED-TOMOGRAPHY; CARDIAC CT; LUNG;
   SEGMENTATION; ASSOCIATION; MACULOPATHY
AB Objective: To describe the associations of lung function and emphysema, measured with spirometry and computed tomography (CT), with early age-related macular degeneration (AMD) in a sample of white, black, Hispanic, and Chinese subjects.
   Methods: Three thousand three hundred ninety-nine persons aged 45 to 84 years residing in 6 US communities participated in a period cross-sectional study. Age-related macular degeneration was measured from digital retinal photographs at the second Multi-Ethnic Study of Atherosclerosis (MESA) examination. Forced expiratory volume in 1 second (FEV1) and FEV1 to forced vital capacity (FVC) ratio were measured at the third or fourth MESA examination. Percent emphysema was measured from cardiac CT scans at baseline. Apical and basilar lung segments were defined as the cephalad or caudal regions of the lung on the cardiac CT scan. Logistic regression models were used to examine the association of lung function and structure with AMD, controlling for age, sex, and other factors.
   Results: The prevalence of early AMD was 3.7%. Early AMD was not associated with FEV1 (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.58-1.15; P=.25), FEV1: FVC ratio (OR, 0.92; 95% CI, 0.76-1.12; P=.43), percent emphysema (OR, 1.13; 95% CI, 0.91-1.40; P=.26), and apical-basilar difference in percent emphysema (OR, 1.14; 95% CI, 0.95-1.37; P=.17). Associations were stronger in smokers. Apical-basilar difference in percent emphysema was significantly associated with early AMD among those whoever smoked (OR, 1.28; 95% CI, 1.02-1.60; P=.03). Associations were not modified by race/ethnicity.
   Conclusions: Lung function and emphysema on CT scan were not cross-sectionally associated with AMD; this might be explained by the relatively low smoking exposure in this cohort.
C1 [Klein, Ronald; Knudtson, Michael D.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Barr, Graham] Columbia Univ, Div Gen Med, Dept Med, Med Ctr, New York, NY USA.
   [Barr, Graham] Columbia Univ, Dept Epidemiol, Med Ctr, New York, NY USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Centre
   for Eye Research Australia; University of Melbourne; National University
   of Singapore; Singapore National Eye Center; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Columbia
   University; Columbia University
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,450 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237;
   Cotch, Mary Frances/0000-0002-2046-4350
FU National Heart, Lung and Blood Institute [N01-HC-95159, N01-HC-95165,
   N01-HC-95169]; National Eye Institute [Z01000403]; National Institutes
   of Health [HL69979-03, HL077612]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONS [N01HC095161, N01HC095162, N01HC095169, N01HC095164,
   N01HC095163, N01HC095160, N01HC095165, N01HC095159] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000403] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL095169,
   R01HL077612, R01HL069979, R21HL095165, R44HL095169] Funding Source: NIH
   RePORTER
FX This research was supported by contracts N01-HC-95159 through
   N01-HC-95165 and N01-HC-95169 from the National Heart, Lung and Blood
   Institute; National Institutes of Health Intramural Research program
   award Z01000403 from the National Eye Institute (Dr Cotch); and grants
   HL69979-03 (Drs R. Klein and Wong) and HL077612 (Dr Barr) from the
   National Institutes of Health.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439
   COXSON HO, 1995, J APPL PHYSIOL, V79, P1525, DOI 10.1152/jappl.1995.79.5.1525
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Guo J, 2002, 2002 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING, PROCEEDINGS, P871, DOI 10.1109/ISBI.2002.1029398
   Hankermeyer C R, 1999, Rev Environ Contam Toxicol, V159, P1
   Hankinson JL, 2010, CHEST, V137, P138, DOI 10.1378/chest.09-0919
   Hoffman EA, 2009, ACAD RADIOL, V16, P689, DOI 10.1016/j.acra.2008.12.024
   Hu SY, 2001, IEEE T MED IMAGING, V20, P490, DOI 10.1109/42.929615
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   *MESA COORD CTR, 2007, MULT STUD ATH FIELD
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Reddy SB, 2005, INT C RAD SOC N AM N
   Hoffman Eric A, 2006, Proc Am Thorac Soc, V3, P519, DOI 10.1513/pats.200603-086MS
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tschirren J, 2005, IEEE T MED IMAGING, V24, P1540, DOI 10.1109/TMI.2005.857653
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Zhang L, 2006, IEEE T MED IMAGING, V25, P1, DOI 10.1109/TMI.2005.859209
NR 27
TC 4
Z9 4
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2010
VL 128
IS 4
BP 472
EP 477
DI 10.1001/archophthalmol.2010.25
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 581YC
UT WOS:000276560800013
PM 20385944
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Berman, K
   Brodaty, H
AF Berman, K.
   Brodaty, H.
TI Psychosocial effects of age-related macular degeneration
SO INTERNATIONAL PSYCHOGERIATRICS
LA English
DT Review
DE blind; blindness; depression; aging; functional impairment
ID CHARLES-BONNET-SYNDROME; COMPLEX VISUAL HALLUCINATIONS; QUALITY-OF-LIFE;
   DEPRESSIVE SYMPTOMS; PHYSICAL-DISABILITY; SELF-MANAGEMENT; OLDER-PEOPLE;
   IMPAIRMENT; VISION; BLINDNESS
AB Background: Age-related macular degeneration (AMD) affects approximately 10% of persons aged 65-74 years and 30% of those aged 75 and older and is the major cause of blindness in old age. AMD is progressive and irreversible.
   Aim: To review the psychosocial effects of AMD.
   Method: OVID data bases (MEDLINE, psycINFO and CINAHL) from 1966 to 2004 were reviewed.
   Results: AMD is associated with functional impairment, high rates of depression, anxiety and emotional distress and increased mortality. Risk factors for depression are not well-defined, except for the degree of functional impairment and impending or actual loss of vision in the second eye. Behavioral and self-management programs may be effective in managing depression associated with AMD, but few studies have been performed, and none using drugs or multimodal therapy.
   Conclusion: AMD will become even more prevalent as the population ages. Identification of risk factors for psychological consequences and of effective interventions remain to be recognized.
C1 Prince Wales Hosp, Eurora Ctr, Dept Old Age Psychiat, Randwick, NSW 2031, Australia.
   Univ New S Wales, Sch Psychiat, Randwick, NSW, Australia.
C3 University of New South Wales Sydney
RP Brodaty, H (通讯作者)，Prince Wales Hosp, Eurora Ctr, Dept Old Age Psychiat, Randwick, NSW 2031, Australia.
EM h.brodaty@unsw.edu.au
RI Brodaty, Henry/E-2753-2010
OI Brodaty, Henry/0000-0001-9487-6617
CR Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   ASH DDG, 1978, CAN J OPHTHALMOL, V13, P15
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Campbell V A, 1999, MMWR CDC Surveill Summ, V48, P131
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Cox DJ, 1998, DIABETES EDUCATOR, V24, P481, DOI 10.1177/014572179802400406
   DargentMolina P, 1996, INT J EPIDEMIOL, V25, P621, DOI 10.1093/ije/25.3.621
   De Leo D, 1999, PSYCHOSOMATICS, V40, P339, DOI 10.1016/S0033-3182(99)71229-6
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P664
   Eperjesi Frank, 2004, Clin Exp Optom, V87, P149
   Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009
   Fitzgerald RG, 1998, BRIT MED J, V316, P1160, DOI 10.1136/bmj.316.7138.1160
   FITZGERALD RG, 1970, ARCH GEN PSYCHIAT, V22, P370
   FITZGERALD RG, 1973, EYE EAR NOSE THROAT, V52, P127
   Freiman TM, 2004, J NEUROSURG, V101, P846, DOI 10.3171/jns.2004.101.5.0846
   GILLMAN AE, 1986, J VISUAL IMPAIR BLIN, V80, P588
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hunt DWC, 2003, IDRUGS, V6, P464
   Ip SPS, 2000, INT J GERIATR PSYCH, V15, P1120, DOI 10.1002/1099-1166(200012)15:12<1120::AID-GPS256>3.0.CO;2-X
   Jacob A, 2004, BMJ-BRIT MED J, V328, P1552, DOI 10.1136/bmj.328.7455.1552
   JORM AF, 1995, AGE AGEING, V24, P389, DOI 10.1093/ageing/24.5.389
   Keller BK, 1999, J AM GERIATR SOC, V47, P1319, DOI 10.1111/j.1532-5415.1999.tb07432.x
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Kleinschmidt JJ, 1996, GERONTOLOGIST, V36, P534
   KORNREICH C, 2000, J CLIN PSYCHOPHARMAC, V20
   Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Lenze EJ, 2001, AM J GERIAT PSYCHIAT, V9, P113, DOI 10.1176/appi.ajgp.9.2.113
   Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   OXMAN TE, 1992, AM J EPIDEMIOL, V135, P356, DOI 10.1093/oxfordjournals.aje.a116297
   Park W, 1999, INT OPHTHALMOL CLIN, V39, P143, DOI 10.1097/00004397-199903940-00010
   PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22
   Paulig M, 2001, J NEUROL NEUROSUR PS, V70, P813, DOI 10.1136/jnnp.70.6.813
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   Reuben DB, 1999, J AM GERIATR SOC, V47, P930, DOI 10.1111/j.1532-5415.1999.tb01286.x
   RIFFENBURGH RS, 1967, GERIATRICS, V22, P127
   ROBINSON RG, 1984, STROKE, V15, P510, DOI 10.1161/01.STR.15.3.510
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, GERIATRICS, V57, P45
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scott Katie, 2000, J DES HIST, V31, P1
   Teunisse RJ, 1998, J NERV MENT DIS, V186, P190, DOI 10.1097/00005053-199803000-00009
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1999, COMPR PSYCHIAT, V40, P315, DOI 10.1016/S0010-440X(99)90133-5
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
   Wallhagen MI, 2001, J AM GERIATR SOC, V49, P1086, DOI 10.1046/j.1532-5415.2001.49213.x
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   WHITE NJ, 1980, BRIT J PSYCHIAT, V136, P284, DOI 10.1192/bjp.136.3.284
   WULSIN LR, 1991, PSYCHOSOM MED, V53, P109, DOI 10.1097/00006842-199101000-00010
   Yates WR, 1999, MED PSYCHIATRY, V13, P41
   Zeiss AM, 1996, PSYCHOL AGING, V11, P572, DOI 10.1037/0882-7974.11.4.572
NR 71
TC 51
Z9 51
U1 1
U2 15
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1041-6102
EI 1741-203X
J9 INT PSYCHOGERIATR
JI Int. Psychogeriatr.
PD SEP
PY 2006
VL 18
IS 3
BP 415
EP 428
DI 10.1017/S1041610205002905
PG 14
WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry;
   Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Geriatrics & Gerontology; Psychiatry
GA 086LH
UT WOS:000240674300005
PM 16466594
DA 2022-11-30
ER

PT J
AU Arden, GB
   Wolf, JE
AF Arden, GB
   Wolf, JE
TI Colour vision testing as an aid to diagnosis and management of age
   related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CONTRAST SENSITIVITY; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS APPEARANCE; EARLY-STAGE; FELLOW EYE;
   ELECTROOCULOGRAM; RESPONSES; PERIMETRY; SYSTEM
AB Aim: To provide a simple test that detects the onset of age related maculopathy ( ARM), and can be used to monitor its severity.
   Methods: Colour contrast sensitivity was measured using computer graphics techniques. Colour thresholds were measured along tritan and protan colour confusion axes in the presence of dynamic luminance noise. Thresholds were determined separately for two sizes of optotypes (6.5degrees and 1.5degrees). Natural pupils were used. Normal values for the test have been established.
   Results: In all patients with unilateral age related macular degeneration, the smaller optotype was invisible in that eye and in almost all, the larger optotype could not be seen. In the symptomless fellow eyes (with ARM) the larger optotype thresholds were raised. The degree of loss was larger for tritan. For the smaller optotype, protan thresholds were elevated in the majority of patients. Tritan losses were greater and disproportionate to the loss seen with the larger optotype. Every person including those with minimal fundal changes had tritan test results for 1.5 degree optotypes >2 SD above the normal mean. Tritan thresholds varied with the severity of the ARM.
   Conclusions: The test is sensitive, simple and quick to administer, and easy for patients. Therefore, it should be useful in detecting and monitoring elderly people with age related changes in their fundi before irreversible loss of vision has occurred.
C1 City Univ London, Dept Optometry & Visual Sci, Appl Vis Res Ctr, London EC1V 0HB, England.
C3 City University London
RP Arden, GB (通讯作者)，City Univ London, Dept Optometry & Visual Sci, Appl Vis Res Ctr, London EC1V 0HB, England.
EM g.arden@city.ac.uk
OI Arden, Geoffrey/0000-0001-7334-2026
CR Adams CW, 1999, OPTOMETRY VISION SCI, V76, P582, DOI 10.1097/00006324-199908000-00027
   ARDEN G, 1988, DOC OPHTHALMOL, V69, P167, DOI 10.1007/BF00153698
   ARDEN GB, 1988, CLIN VISION SCI, V2, P303
   ARDEN GB, 1991, OPHTHALMOLOGY, V98, P567
   Arden GB, 2000, INVEST OPHTH VIS SCI, V41, P2722
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arden GB, 1995, EYE, V9, P686, DOI 10.1038/eye.1995.180
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P79
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON JC, 1996, EUR J OPHTHALMOL, V3, P307
   GUNDUZ K, 1988, ARCH OPHTHALMOL-CHIC, V106, P929
   GUNDUZ K, 1989, BRIT J OPHTHALMOL, V73, P241, DOI 10.1136/bjo.73.4.241
   GUPTA LY, 1994, DOC OPHTHALMOL, V88, P49, DOI 10.1007/BF01203701
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   HOLTZ FG, 1985, GER J OPHTHALMOL, V4, P336
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   JOHNSON CA, 1988, J OPT SOC AM A, V5, P2131, DOI 10.1364/JOSAA.5.002131
   Knoblauch K, 2001, VISION RES, V41, P23, DOI 10.1016/S0042-6989(00)00205-4
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   La Heij E C, 2001, Ned Tijdschr Geneeskd, V145, P1390
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   LIM JI, 1994, AM J OPHTHALMOL, V117, P1
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   MEDINA E, 1997, INVEST OPHTH VIS SCI, V38, P469
   NGUYENTRI D, 2004, IN PRESS INVEST OPHT
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   OWSLEY C, 2000, INVEST OPHTH VIS SCI, V41, P367
   Remky A, 2001, J OPT SOC AM A, V18, P1425, DOI 10.1364/JOSAA.18.001425
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   ROVER J, 1987, DOC OPHTHALMOL, V65, P385, DOI 10.1007/BF00149945
   Shirao Y, 1997, JPN J OPHTHALMOL, V41, P174, DOI 10.1016/S0021-5155(97)00026-9
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Starr CE, 1998, POSTGRAD MED, V103, P153, DOI 10.3810/pgm.1998.05.480
   SUNNESS JS, 1986, AM J OPTOM PHYS OPT, V63, P7
   ULBIG MRW, 1994, AM J OPHTHALMOL, V117, P583, DOI 10.1016/S0002-9394(14)70063-7
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WYSZECKI G, 1982, COLOR SCI CONCEPTS M, P306
   YU VT, 1991, INVEST OPHTHALMOL, V32, P2779
NR 53
TC 40
Z9 42
U1 0
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2004
VL 88
IS 9
BP 1180
EP 1185
DI 10.1136/bjo.2003.033480
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 846YN
UT WOS:000223355700018
PM 15317712
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Ehrlich, R
   Harris, A
   Kheradiya, NS
   Winston, DM
   Ciulla, TA
   Wirostko, B
AF Ehrlich, Rita
   Harris, Alon
   Kheradiya, Nisha S.
   Winston, Diana M.
   Ciulla, Thomas A.
   Wirostko, Barbara
TI Age-related macular degeneration and the aging eye
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE age-related macular degeneration; aging; blood flow; eye; retina;
   macula; vision
ID OCULAR BLOOD-FLOW; RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE;
   RETROBULBAR CIRCULATION; CARDIOVASCULAR-DISEASE; MORPHOMETRIC-ANALYSIS;
   CHOROIDAL NEOVASCULARIZATION; MACULOPATHY; PREVALENCE; PATHOGENESIS
AB Age-related macular degeneration (AMD) is an ocular disease that causes damage to the retinal macula, mostly in the elderly. Normal aging processes can lead to structural and blood flow changes that can predispose patients to AMD, although advanced age does not inevitably cause AMD. In this review, we describe changes that occur in the macular structure, such as the retinal pigment epithelium and Bruch's membrane, with advancing age and in AMD. The role of genetics in AMD and age-related changes in ocular blood flow that may play a role in the pathogenesis of AMD are also discussed. Understanding the pathophysiology of AMD development can help guide future research to further comprehend this disease and to develop better treatments to prevent its irreversible central vision loss in the elderly.
C1 [Ehrlich, Rita; Harris, Alon; Kheradiya, Nisha S.; Winston, Diana M.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Wirostko, Barbara] SUNY Stony Brook, Med Ctr Res Way, Dept Ophthalmol, Stony Brook, NY 11794 USA.
   [Ciulla, Thomas A.] Methodist Hosp, Retina Serv, Midwest Eye Inst, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; State
   University of New York (SUNY) System; SUNY Community College; State
   University of New York (SUNY) Stony Brook; Indiana University System
RP Harris, A (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, 702 Rotary Circle, Indianapolis, IN 46202 USA.
EM alharris@indiana.edu
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
FU Research to Prevent Blindness, New York, NY
FX Funded in part by an unrestricted grant from Research to Prevent
   Blindness, New York, NY. The authors would like to thank Lynne McCranor
   for her assistance with this manuscript.
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Boehm AG, 2005, INVEST OPHTH VIS SCI, V46, P1291, DOI 10.1167/iovs.04-0987
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   Embleton SJ, 2002, EYE, V16, P156
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fitzgerald MEC, 2005, EXP EYE RES, V81, P478, DOI 10.1016/j.exer.2005.03.008
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Groh MJM, 1996, OPHTHALMOLOGY, V103, P529
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1076, DOI 10.1001/archopht.118.8.1076
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hogg RE, 2007, OPHTHALMOLOGY, V115, P1046
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2003, OPHTHALMOLOGY, V110, P273
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lam AKC, 2003, OPTOMETRY VISION SCI, V80, P305, DOI 10.1097/00006324-200304000-00008
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lutty G, 1999, MOL VIS, V5
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   National Eye Institute, 2007, STAT DAT PREV BLINDN
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ravalico G, 1996, INVEST OPHTH VIS SCI, V37, P2645
   RIZZO JF, 1991, INVEST OPHTH VIS SCI, V32, P3263
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Salter JM, 1998, J APPL PHYSIOL, V85, P1024, DOI 10.1152/jappl.1998.85.3.1024
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Suzuki M, 2007, MOL VIS, V13, P772
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 89
TC 67
Z9 73
U1 1
U2 13
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2008
VL 3
IS 3
BP 473
EP 482
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WX
UT WOS:000208238800007
PM 18982917
DA 2022-11-30
ER

PT J
AU Rodrigues, EB
AF Rodrigues, Eduardo B.
TI Inflammation in dry age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration, inflammation; vascular endothelial
   growth factor
ID CLASS-II EXPRESSION; C-REACTIVE PROTEIN; BRUCHS MEMBRANE;
   APOLIPOPROTEIN-E; RETINAL NEOVASCULARIZATION; COMPLEMENT ACTIVATION;
   DRUSEN; PATHOGENESIS; POLYMORPHISM; MACULOPATHY
AB Purpose: To summarize the current information regarding the role of immune and inflammatory response in the pathogenesis of dry age-related macular degeneration (ARMD). Methods: A Pubmed search was conducted of the period January 1999 to 2005. Relevant information in the literature on the role of inflammation in early dry ARMD was reviewed. Results: Some important evidence for inflammation in early ARMD consists in the isolation of immunoglobulins, complement proteins, cytokines and activated microglia, in retinal pigment epithelium (RPE) cells and drusen. Pivotal mechanisms in early ARMD include the accumulation of debris and proteins along the RPE surface, followed by immune-complex deposition and complement activation. In contrast, the role of other plasma enzymes such as kallikrein-kinin-bradykinin, the Hageman factor, peptides and coagulation proteins in drusen formation and ARMD has yet to be determined. Conclusion: A clear role for inflammatory mediators and cells has been established in recent years. Future studies should elucidate further mechanisms in ARMD development. Copyright (c) 2007 S. Karger AG, Basel.
C1 Hosp Reg Sao Jose, Inst Olhos Florianopolis, Ctr Oftalm, Retina Dept,Ophthalmol Serv, Florianopolis, SC, Brazil.
RP Rodrigues, EB (通讯作者)，Luiz Frederico Wagner 86 Canasvieiras, BR-88054540 Florianopolis, SC, Brazil.
EM edubrodriguess@yahoo.com.br
OI Buchele Rodrigues, Eduardo/0000-0002-4224-0921
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bazan N G, 1989, Prog Clin Biol Res, V312, P15
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Casini G, 2004, NEUROSCIENCE, V124, P147, DOI 10.1016/j.neuroscience.2003.10.049
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   de Smet MD, 2001, PROG RETIN EYE RES, V20, P761, DOI 10.1016/S1350-9462(01)00011-8
   Dentchev T, 2003, MOL VIS, V9, P184
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HANSSEN R, 1930, Z AUGENHEILKD, V72, P360
   Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200
   Hegner C., 1916, KLIN MONATSBL AUGENH, V57, P27
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KULKARNI PS, 1991, J OCUL PHARMACOL, V7, P135, DOI 10.1089/jop.1991.7.135
   LIEW SCK, 1994, J NEUROPATH EXP NEUR, V53, P150, DOI 10.1097/00005072-199403000-00006
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087
   Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003
   McCusker SM, 2001, LANCET, V357, P436, DOI 10.1016/S0140-6736(00)04008-3
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naveh N, 2000, CURR EYE RES, V21, P554, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT554
   Pagenstecher H. a. G., 1875, ATLAS PATHOLOGISCHEN
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P4195
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   WONG WW, 1990, J INVEST DERMATOL, V94, pS64, DOI 10.1111/1523-1747.ep12875150
   Yasojima K, 2001, ARTERIOSCL THROM VAS, V21, P1214, DOI 10.1161/hq0701.092160
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhang C, 2005, MOL VIS, V11, P887
   Zhou JH, 2005, MOL VIS, V11, P414
NR 70
TC 53
Z9 58
U1 0
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 3
BP 143
EP 152
DI 10.1159/000099293
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162BS
UT WOS:000246062100001
PM 17440275
DA 2022-11-30
ER

PT J
AU Flood, VM
   Mitchell, P
AF Flood, Victoria M.
   Mitchell, Paul
TI Dietary fatty acids and age-related macular degeneration
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
ID 5-YEAR INCIDENCE; FISH INTAKE; MACULOPATHY; RISK; DISEASE; PROGRESSION;
   HEALTH
AB Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness among older people. It is important to identify modifiable risk factors which could prevent or slow the progression of this chronic disease. Dietary fatty acid intakes have been investigated in epidemiological studies as it is plausible that individual lipids have properties which modulate cellular damage in the eye. This paper reviews epidemiological studies investigating links between fatty acids and AMD, Mixed evidence has related the sub-types of saturated and monounsaturated fatty acids to AMD, but nearly all epidemiological studies have demonstrated some level of AMD protection from omega-3 polyunsaturated fatty acids (particularly long-chain fatty acids) and fish, with a tendency for a corresponding dampening effect with increased dietary omega-6 polyunsaturated fatty acids.
C1 [Flood, Victoria M.; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Westmead Hosp, Ctr Vis Res,Westmead Millennium Inst, Sydney, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Westmead Hosp, Ctr Vis Res,Westmead Millennium Inst, Sydney, NSW 2145, Australia.
RI Mitchell, Paul/P-1498-2014; Flood, Victoria M/A-8732-2016; Flood,
   Victoria/H-2279-2011
OI Flood, Victoria M/0000-0001-5310-7221; 
CR *AG REL EYE DIS ST, 2006, AG REL EYE DIS STUD
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 15
TC 0
Z9 0
U1 0
U2 2
PU TEKNOSCIENZE PUBL
PI MILAN
PA VIA AURELIO SAFFI 23, 20123 MILAN, ITALY
SN 1722-6996
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD MAR-APR
PY 2008
VL 19
IS 2
BP 42
EP 43
PG 2
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 309DD
UT WOS:000256440000008
DA 2022-11-30
ER

PT J
AU Nunes, RP
   Hirai, FE
   Barroso, LF
   Badaro, E
   Novais, E
   Rodrigues, EB
   Maia, M
   Magalhaes, O
   Farah, ME
AF Nunes, Renata Portella
   Hirai, Flavio Eduardo
   Barroso, Leticia Fernandes
   Badaro, Emmerson
   Novais, Eduardo
   Rodrigues, Eduardo Buchele
   Maia, Mauricio
   Magalhaes, Octaviano, Jr.
   Farah, Michel Eid
TI Effectiveness of monthly and fortnightly anti-VEGF treatments for
   age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Retina; Bevacizumab; Ranibizumab; Clinical trial
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN;
   RANIBIZUMAB; TRIAL
AB Purpose: To study the efficacy and safety of treatments with ranibizumab and bevacizumab for exudative age-related macular degeneration. Methods: A parallel randomized clinical trial was conducted to compare the efficacy and safety of three regimens (bevacizumab every month, bevacizumab every 2 weeks, and ranibizumab every month), followed by as-needed retreatments, for 1 year, in previously untreated individuals with age-related macular degeneration. The primary outcome was change in visual acuity and in central macular thickness after 1 year of follow-up. Subjects were assigned randomly to one of the three groups in a 1:1:1 ratio, and investigators and examiners were blinded to the randomization results. Results: We included 15 patients in each group. After 1 year of follow-up, we found statistically significant improvements in visual acuity and central macular thickness reduction in all groups. However, we found no statistically significant differences between the three groups. Conclusions: The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.
C1 [Nunes, Renata Portella; Hirai, Flavio Eduardo; Barroso, Leticia Fernandes; Badaro, Emmerson; Novais, Eduardo; Rodrigues, Eduardo Buchele; Maia, Mauricio; Magalhaes, Octaviano, Jr.; Farah, Michel Eid] Univ Fed Sao Paulo, Escola Paulista Med, Dept Ophthalmol & Visual Sci, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Nunes, RP (通讯作者)，Inst Olhos Florianopolis, Rua Presidente Coutinho 579-501, BR-88015231 Florianopolis, SC, Brazil.
EM reportellanunes@gmail.com
RI Farah, Michel Eid E/F-3285-2012; Hirai, Flavio E/G-3583-2012; Barrroso,
   LetÃcia/AAB-7107-2021; Maia, Mauricio/I-5892-2015
OI Farah, Michel Eid E/0000-0001-5951-0193; Hirai, Flavio
   E/0000-0002-5757-4254; Maia, Mauricio/0000-0002-7034-8091
FU CNPq [558868/2009-6]; FAPESP [2010/15451-0]; CAPES [BEX1059/12-2]
FX This study was supported by CNPq (558868/2009-6), FAPESP (2010/15451-0),
   and CAPES (BEX1059/12-2).
CR [Anonymous], 2012, OPHTHALMOLOGY, V119, P1508
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V365, P2237
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2014, JAMA-J AM MED ASSOC, V311, P1491
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P363
   Martin DF, 2012, J COMP EFFECT RES, V1, P485
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P726
   Martin DF, 2011, NEW ENGL J MED, V364, P1966
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1409
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Valmaggia C, 2009, KLIN MONATSBL AUGENH, V226, P294, DOI 10.1055/s-0028-1109298
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2010, EYE LOND, V24, P1708, DOI DOI 10.1038/EYE.2010.147
   2013, OPHTHALMOLOGY, V120, P1719
   2011, EYE LOND, V25, P820, DOI DOI 10.1038/EYE.2011.16
   2011, CLIN EXP OPHTHALMOL, V39, P718, DOI DOI 10.1111/J.1442-9071.2011.02703.X
   2005, OPHTHALMIC SURG LASE, V36, P331
   2013, LANCET, V382, P1258, DOI DOI 10.1016/S0140-6736(13)61501-9
NR 38
TC 4
Z9 4
U1 1
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2019
VL 82
IS 3
BP 225
EP 232
DI 10.5935/0004-2749.20190043
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY4UO
UT WOS:000468123600011
PM 30810619
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Soubrane, G
   Haddad, WM
   Coscas, G
AF Soubrane, G
   Haddad, WM
   Coscas, G
TI Age-related macular degeneration
SO PRESSE MEDICALE
LA English
DT Article
ID GEOGRAPHIC ATROPHY; RISK-FACTORS; MEMBRANE CHANGE; VISUAL-LOSS;
   MACULOPATHY; SMOKING; PREVALENCE; EVOLUTION; HEREDITY; SUNLIGHT
AB Epidemiological and pathogenic data Age-related macular degeneration (ARMD) is the first cause of blindness in industrialized countries in patients over the age of 55. Its prevalence increases with age, affecting up to 25% of the population aged over 75. The pathogenesis of this disease is not well known. Not only aging, but also other varying degrees of genetic and environmental factors are implied.
   Clinical aspects Precursors (first clinical signs of ARMD) can be observed on examination of the fundus: drusen (localized deposits of lipids and lipoproteins) and alterations in retinal pigment epithelium (RPE) (hypo- or hyperpigmentation). Two forms of complications are observed: atrophic (or "dry") and exsudative (or "wet"). The atrophic form is defined by the presence of degeneration in the central RPE, choriocapillaris and photoreceptors, resulting from the enlargement and/or coalescence of small areas of peri-foveolar atrophy (or "geographic" atrophy). The exsudative form, responsible for the majority of cases of blindness due to ARMD, is characterized by the appearance of choroidal new vessels, identifiable on fluorescein angiography and responsible for serous retinal detachment, edema and hemorrhage, leading to the destruction of the macular photoreceptors.
   From a therapeutic point of view Treatment of the atrophic form is currently only palliative (visual aids and re-habilitation of low vision), Treatments of the exsudative form having demonstrated their efficacy are laser photocoagulation and dynamic phototherapy with verteporfine, providing relative stabilization of visual acuity in around 23 of the eyes. Other treatments are under evaluation: anti-angiogenic treatments, surgical techniques (ablation of the new vessels, foveal translocation), new laser treatments (transpupillary thermotherapy, selective photocoagulation of the feeder vessels). Photoreceptor and pigment epithelium transplantations or implantation of microphotodiodes represent other long-term alternatives.
C1 Univ Paris 12, Univ Creteil, Clin Ophtalmol, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Soubrane, G (通讯作者)，Univ Paris 12, Univ Creteil, Clin Ophtalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM gisele.soubrane@chicreteil.fr
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   COSCAS G, 1991, DEGENERESCENCES MACU, P153
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FRIEDMAN E, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P652
   GANLEY J, 1983, DHHS PUBLICATION, V83
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN H, 1972, DHEW PUBLICATION NIH, P73
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Rozet JM, 1999, MOL GENET METAB, V68, P310, DOI 10.1006/mgme.1999.2925
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SORSBY A, 1966, INCIDENCE CAUSES BLI, P114
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 57
TC 5
Z9 9
U1 0
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD AUG 24
PY 2002
VL 31
IS 27
BP 1282
EP 1287
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 589HM
UT WOS:000177752800012
PM 12238278
DA 2022-11-30
ER

PT J
AU Kikushima, W
   Sakurada, Y
   Yoneyama, S
   Sugiyama, A
   Tanabe, N
   Kume, A
   Mabuchi, F
   Iijima, H
AF Kikushima, Wataru
   Sakurada, Yoichi
   Yoneyama, Seigo
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Kume, Atsuki
   Mabuchi, Fumihiko
   Iijima, Hiroyuki
TI Incidence and risk factors of retreatment after three-monthly
   aflibercept therapy for exudative age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GROWTH-FACTOR TREATMENT; TREAT-AND-EXTEND; VASCULAR
   HYPERPERMEABILITY; INTRAVITREAL AFLIBERCEPT; CHOROIDAL THICKNESS; LESION
   SIZE; RANIBIZUMAB; ASSOCIATION; POLYMORPHISMS
AB Though anti-vascular endothelial growth factor therapy has become the standard treatment for exudative age-related macular degeneration (AMD), retreatment after the initial loading injection is inevitable in most eyes with residual or recurrent exudative changes. In the present study, we studied 140 treatment naive eyes with typical neovascular AMD (n = 71) or polypoidal choroidal vasculopathy (PCV) (n = 69) and investigated the incidence and risk factors of retreatment after 3-monthly intravitreal aflibercept injection for exudative AMD during the 12-month period. At 12 months, best-corrected visual acuity (BCVA) improved significantly from 0.45 +/- 0.39 to 0.26 +/- 0.33 (P = 4.1 x 10(-11)). Multiple regression analysis revealed that better baseline BCVA (P = 3.6 x 10(-14)) and thicker subfoveal choroidal thickness (P = 0.039) were associated with better BCVA at 12-months. Retreatment was required in 94 out of 140 (67.1%) eyes. Multivariate logistic regression analysis revealed that older age (P = 7.2 x 10(-3)) and T-allele of ARMS2 A69S (rs10490924) variants (P = 1.9 x 10(-3)) were associated with retreatment. Cox-regression analysis revealed that older age (P = 1.0 x 10(-2)) and T-allele of the ARMS2 gene (P = 6.0 x 10(-3)) were associated with retreatment-free period. The number of retreatment episodes was significantly different among the ARMS2 genotypes (P = 8.1 x 10(-4)). These findings might be helpful for physicians when considering the optimal treatment regimen for exudative AMD.
C1 [Kikushima, Wataru; Sakurada, Yoichi; Yoneyama, Seigo; Sugiyama, Atsushi; Tanabe, Naohiko; Kume, Atsuki; Mabuchi, Fumihiko; Iijima, Hiroyuki] Yamanashi Univ, Dept Ophthalmol, Chuo Ku, Kofu, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Yamanashi Univ, Dept Ophthalmol, Chuo Ku, Kofu, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
FU Japan Society for the Promotion of Science KAKENHI Grant [23791972]
FX This work was supported by Japan Society for the Promotion of Science
   KAKENHI Grant Number 23791972 (Y.S.).
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 30
TC 18
Z9 18
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 7
PY 2017
VL 7
AR 44020
DI 10.1038/srep44020
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN3MU
UT WOS:000395913400002
PM 28266609
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Akuffo, KO
   Nolan, JM
   Howard, AN
   Moran, R
   Stack, J
   Klein, R
   Klein, BE
   Meuer, SM
   Sabour-Pickett, S
   Thurnham, DI
   Beatty, S
AF Akuffo, K. O.
   Nolan, J. M.
   Howard, A. N.
   Moran, R.
   Stack, J.
   Klein, R.
   Klein, B. E.
   Meuer, S. M.
   Sabour-Pickett, S.
   Thurnham, D. I.
   Beatty, S.
TI Sustained supplementation and monitored response with differing
   carotenoid formulations in early age-related macular degeneration
SO EYE
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; CONTRAST SENSITIVITY; MESO-ZEAXANTHIN; GRADING
   SYSTEM; CLINICAL-TRIAL; EYE DISEASE; LUTEIN; IDENTIFICATION;
   MACULOPATHY; RETINAS
AB Purpose To compare the impact of sustained supplementation using different macular carotenoid formulations on macular pigment (MP) and visual function in early age-related macular degeneration (AMD).
   Patients and methods Sixty-seven subjects with early AMD were randomly assigned to: Group 1 (20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein), Group 2 (10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2mg per day Z; Macushield; Macuhealth), Group 3 (17 mg per day MZ, 3mg per day L, 2mg per day Z). MP was measured using customised heterochromatic flicker photometry and visual function was assessed by measuring contrast sensitivity (CS) and best-corrected visual acuity (BCVA). AMD was graded using the Wisconsin Age-Related Maculopathy Grading System (AREDS 11-step severity scale).
   Results At 3 years, a significant increase in MP from baseline was observed in all groups at each eccentricity (P<0.05), except at 1.75 degrees in Group 1 (P=0.160). Between 24 and 36 months, significant increases in MP at each eccentricity were seen in Group 3 (P<0.05 for all), and at 0.50 degrees in Group 2 (P<0.05), whereas no significant increases were seen in Group 1 (P>0.05 for all). At 36 months, compared with baseline, the following significant improvements (P<0.05) in CS were observed: Group 2-1.2, 6, and 9.6 cycles per degree (c.p.d.); Group 115.15 c.p.d.; and Group 3-6, 9.6, and 15.15 c.p.d. No significant changes in BCVA, or progression to advanced AMD, were observed.
   Conclusion In early AMD, MP can be augmented with a variety of supplements, although the inclusion of MZ may confer benefits in terms of panprofile augmentation and in terms of CS enhancement.
C1 [Akuffo, K. O.; Nolan, J. M.; Moran, R.; Stack, J.; Sabour-Pickett, S.; Beatty, S.] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Howard, A. N.] Howard Fdn, Cambridge, England.
   [Klein, R.; Klein, B. E.; Meuer, S. M.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Thurnham, D. I.] Univ Ulster, Northern Ireland Ctr Food & Hlth NICHE, Coleraine BT52 1SA, Londonderry, North Ireland.
C3 South East Technological University (SETU); University of Wisconsin
   System; University of Wisconsin Madison; Ulster University
RP Akuffo, KO (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Vis Res Ctr, West Campus, Carriganore, Waterford, Ireland.
EM kakuffo@wit.ie
RI Akuffo, Kwadwo Owusu/J-2036-2019; Nolan, John/N-4921-2014
OI Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Nolan,
   John/0000-0002-5503-7084; Thurnham, David/0000-0001-9289-1370; Moran,
   Rachel/0000-0003-0501-5431
FU Howard Foundation, Cambridge, UK; European Research Council (ERC)
   [281096]
FX This study was funded by a grant from the Howard Foundation, Cambridge,
   UK. KOA and JMN (the principal investigator) are currently funded by the
   European Research Council (ERC), grant reference number: 281096. We
   would like to thank Industrial Organica and Macuvision Europe for
   providing the study supplements.
CR Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beatty S, 2013, OPHTHALMOLOGY, V120, P645, DOI 10.1016/j.ophtha.2012.09.013
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Charalampidou S, 2011, ARCH OPHTHALMOL-CHIC, V129, P1155, DOI 10.1001/archophthalmol.2011.111
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Sparrow J M, 1997, Ophthalmic Epidemiol, V4, P49
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 30
TC 50
Z9 51
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2015
VL 29
IS 7
BP 902
EP 912
DI 10.1038/eye.2015.64
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5LC
UT WOS:000357728300010
PM 25976647
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Degenring, RF
   Kreissig, I
   Friedemann, T
   Akkoyun, I
AF Jonas, JB
   Degenring, RF
   Kreissig, I
   Friedemann, T
   Akkoyun, I
TI Exudative age-related macular degeneration treated by intravitreal
   triamcinolone acetonide. A prospective comparative nonrandomized study
SO EYE
LA English
DT Article
DE exudative age-related macular degeneration; intravitreal triamcinolone
   acetonide; intraocular pressure; steroid response; macular disease;
   maculopathy
ID CRYSTALLINE CORTISONE; CHOROIDAL NEOVASCULARIZATION; ADJUNCTIVE
   TREATMENT; INJECTION; EDEMA; MACULOPATHY; INHIBITION; PREVALENCE;
   RECURRENCE; EXPRESSION
AB Purpose To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration.
   Methods The prospective comparative nonrandomized clinical interventional study included 187 consecutive patients with progressive exudative age-related macular degeneration, divided into a study group of 115 patients receiving an intravitreal injection of 25 mg triamcinolone acetonide, and a control group of 72 patients without treatment. The mean follow-up was 6.0 +/- 4.2 months.
   Results Visual acuity increased significantly ( P = 0.03) in the study group, and decreased significantly ( P = 0.01) in the control group, at 1 month and 3 months after start of the study. Between the study group and control group, the differences in change of visual acuity were significant ( P = 0.001). In the study group, the number of patients with an increase in visual acuity of 2 or more Snellen lines was significantly ( P = 0.001) larger than in the control group. Correspondingly, the number of patients with a decrease of 2 or more Snellen lines was significantly ( P = 0.007) smaller in the study group. In all, 43 (37.4%) patients of the study group experienced an increase in best visual acuity by 2 or more Snellen lines.
   Conclusions Visual acuity increased in patients with exudative age-related macular degeneration at 1 month and 3 months after an intravitreal injection of 25 mg triamcinolone acetonide.
C1 Heidelberg Univ, Dept Ophthalmol, Fac Clin Med Mannheim, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@ma.augen.uni-heidelberg.de
RI AKKOYUN, IMREN VARDARLI/AAK-7713-2021
OI AKKOYUN, IMREN VARDARLI/0000-0002-2860-7424
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Degenring RF, 2003, ACTA OPHTHALMOL SCAN, V81, P399, DOI 10.1034/j.1600-0420.2003.00084.x
   Degenring RF, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P729, DOI 10.1001/archopht.121.5.729
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P468, DOI 10.1177/112067210301300508
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P575, DOI 10.1177/112067210301300611
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2002, J CATARACT REFR SURG, V28, P2040, DOI 10.1016/S0886-3350(02)01295-6
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, GRAEF ARCH CLIN EXP, V239, P464, DOI 10.1007/s004170100293
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 49
TC 62
Z9 64
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2005
VL 19
IS 2
BP 163
EP 170
DI 10.1038/sj.eye.6701438
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 893LE
UT WOS:000226719700008
PM 15218517
OA Bronze
DA 2022-11-30
ER

PT J
AU Ting, AYC
   Lee, TKM
   MacDonald, IM
AF Ting, Andrew Y. C.
   Lee, Thomas K. M.
   MacDonald, Ian M.
TI Genetics of age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; disease association; genetics; review;
   single-nucleotide polymorphism
ID COMPLEMENT-FACTOR-H; BEAVER DAM EYE; APOLIPOPROTEIN-E POLYMORPHISMS;
   HTRA1 PROMOTER POLYMORPHISM; HUMAN BRUCHS MEMBRANE; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; MANGANESE SUPEROXIDE-DISMUTASE; RETINAL-PIGMENT
   EPITHELIUM; SORSBYS FUNDUS DYSTROPHY; STARGARDT DISEASE GENE
AB Purpose of review
   Age-related macular degeneration (AMD) was until recently viewed as a part of the normal aging process; however, we are increasingly aware that genetic factors play a much greater role than previously suspected. This review will provide an up-to-date snapshot of the genetics of AMD to help guide our thoughts about its causes and the risk for family members.
   Recent findings
   Epidemiological research and basic bench research have identified pathways of oxidative stress, lipid metabolism and inflammation as playing causative roles in the pathogenesis of AMD. Emerging research is focusing on the biology of the retinal pigment epithelium as secreting pro and anti-inflammatory mediators in the eye. Antivascular endothelial growth factor therapy has dramatically improved the prognosis for neovascular or wet AMD patients. Nutritional supplementation with antioxidants and omega-3 fatty acids has provided treatment options for patients with atrophic or dry AMD. We should expect that some of the response to therapy might be genetically determined.
   Summary
   First-degree relatives of patients with AMD tend to have a higher risk of AMD. Recognizing an inherent genetic risk of AMD in these patients will improve their management and potentially help prevent blindness.
C1 [Ting, Andrew Y. C.; Lee, Thomas K. M.; MacDonald, Ian M.] Univ Alberta, Dept Ophthalmol, Edmonton, AB T5H 3V9, Canada.
C3 University of Alberta
RP MacDonald, IM (通讯作者)，Univ Alberta, Dept Ophthalmol, 2319,10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada.
EM macdonal@ualberta.ca
OI MacDonald, Ian/0000-0001-7472-8385
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner SG, 2005, T AM OPHTHAL SOC, V103, P135
   Elner Susan G, 2005, Trans Am Ophthalmol Soc, V103, P126
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Gliemann J, 1998, BIOL CHEM, V379, P951
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jarvik GP, 1997, ANN EPIDEMIOL, V7, P357, DOI 10.1016/S1047-2797(97)00028-8
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim IK, 2008, MOL VIS, V14, P1487
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   LOEFFLER KU, 1992, ARCH OPHTHALMOL-CHIC, V110, P15
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P1399, DOI 10.1136/bjo.85.12.1399
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rondanelli M, 1997, AGING-CLIN EXP RES, V9, P221, DOI 10.1007/BF03340153
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weger M, 2007, MOL VIS, V13, P1274
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   2000, J NUTR S, V130, pS1516
NR 176
TC 43
Z9 47
U1 0
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD SEP
PY 2009
VL 20
IS 5
BP 369
EP 376
DI 10.1097/ICU.0b013e32832f8016
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 487PB
UT WOS:000269285800006
PM 19587596
DA 2022-11-30
ER

PT J
AU Brown, CN
   Green, BD
   Thompson, RB
   den Hollander, AI
   Lengyel, I
   Acar, IE
   Ajana, S
   Arango-Gonzalez, B
   Armento, A
   Badura, F
   Bartz-Schmidt, KU
   Bhatia, V
   Bhattacharya, SS
   Biarnes, M
   Borrell, A
   Calado, SM
   Colijn, JM
   Cougnard-Gregoire, A
   Dammeier, S
   de Breuk, A
   De la Cerda, B
   Delcourt, C
   den Hollander, AI
   Diaz-Corrales, FJ
   Diether, S
   Emri, E
   Endermann, T
   Ferraro, LL
   Garcia, M
   Heesterbeek, TJ
   Honisch, S
   Hoyng, CB
   Kilger, E
   Klaver, CCW
   Kortvely, E
   Langen, H
   Lastrucci, C
   Lengyel, I
   Luthert, P
   Meester-Smoor, M
   Merle, BMJ
   Mones, J
   Nogoceke, E
   Peto, T
   Pool, FM
   Rodriguez-Bocanegra, E
   Serrano, L
   Sousa, J
   Thee, EF
   Ueffing, M
   Verzijden, T
   Zumbansen, M
AF Brown, Connor N.
   Green, Brian D.
   Thompson, Richard B.
   den Hollander, Anneke I.
   Lengyel, Imre
   Acar, Ilhan E.
   Ajana, Soufiane
   Arango-Gonzalez, Blanca
   Armento, Angela
   Badura, Franz
   Bartz-Schmidt, Karl U.
   Bhatia, Vaibhav
   Bhattacharya, Shomi S.
   Biarnes, Marc
   Borrell, Anna
   Calado, Sofia M.
   Colijn, Johanna M.
   Cougnard-Gregoire, Audrey
   Dammeier, Sascha
   de Breuk, Anita
   De la Cerda, Berta
   Delcourt, Cecile
   den Hollander, Anneke I.
   Diaz-Corrales, Francisco J.
   Diether, Sigrid
   Emri, Eszter
   Endermann, Tanja
   Ferraro, Lucia L.
   Garcia, Miriam
   Heesterbeek, Thomas J.
   Honisch, Sabina
   Hoyng, Carel B.
   Kilger, Ellen
   Klaver, Caroline C. W.
   Kortvely, Elod
   Langen, Hanno
   Lastrucci, Claire
   Lengyel, Imre
   Luthert, Phil
   Meester-Smoor, Magda
   Merle, Benedicte M. J.
   Mones, Jordi
   Nogoceke, Everson
   Peto, Tunde
   Pool, Frances M.
   Rodriguez-Bocanegra, Eduardo
   Serrano, Luis
   Sousa, Jose
   Thee, Eric F.
   Ueffing, Marius
   Verzijden, Timo
   Zumbansen, Markus
CA EYE-RISK Consortium
TI Metabolomics and Age-Related Macular Degeneration
SO METABOLITES
LA English
DT Review
DE age-related macular degeneration; metabolomics; metabolism; biomarkers;
   drusen; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   TIME-RESOLVED AUTOFLUORESCENCE; N-RETINYLIDENE ETHANOLAMINE; HUMOR
   COMPARATIVE PROFILES; HUMAN TRABECULAR MESHWORK; OXIDATIVE STRESS;
   BRUCHS MEMBRANE; AQUEOUS-HUMOR; BLOOD-FLOW
AB Age-related macular degeneration (AMD) leads to irreversible visual loss, therefore, early intervention is desirable, but due to its multifactorial nature, diagnosis of early disease might be challenging. Identification of early markers for disease development and progression is key for disease diagnosis. Suitable biomarkers can potentially provide opportunities for clinical intervention at a stage of the disease when irreversible changes are yet to take place. One of the most metabolically active tissues in the human body is the retina, making the use of hypothesis-free techniques, like metabolomics, to measure molecular changes in AMD appealing. Indeed, there is increasing evidence that metabolic dysfunction has an important role in the development and progression of AMD. Therefore, metabolomics appears to be an appropriate platform to investigate disease-associated biomarkers. In this review, we explored what is known about metabolic changes in the retina, in conjunction with the emerging literature in AMD metabolomics research. Methods for metabolic biomarker identification in the eye have also been discussed, including the use of tears, vitreous, and aqueous humor, as well as imaging methods, like fluorescence lifetime imaging, that could be translated into a clinical diagnostic tool with molecular level resolution.
C1 [Brown, Connor N.; Lengyel, Imre] Queens Univ Belfast, WWIEM, Belfast BT9 7BL, Antrim, North Ireland.
   [Green, Brian D.] Queens Univ Belfast, IGFS, Belfast BT9 6AG, Antrim, North Ireland.
   [Thompson, Richard B.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, NL-6525 EX Nijmegen, Netherlands.
C3 Queens University Belfast; Queens University Belfast; University System
   of Maryland; University of Maryland Baltimore; Radboud University
   Nijmegen
RP Lengyel, I (通讯作者)，Queens Univ Belfast, WWIEM, Belfast BT9 7BL, Antrim, North Ireland.
EM cbrown88@qub.ac.uk; b.green@qub.ac.uk; rthompson@som.umaryland.edu;
   a.denhollander@antrg.umcn.nl; i.lengyel@qub.ac.uk
RI Emri, Eszter/ABE-9363-2020; De la cerda, Berta/L-7039-2014;
   Arango-Gonzalez, Blanca/AAR-7427-2021; Merle, Benedicte MJ/F-1247-2015;
   Lengyel, Imre/B-5217-2009; Acar, İlhan Erkin/B-7758-2018; Ajana,
   Soufiane/AAH-5181-2021; Merle, Benedicte MJ/AAQ-5021-2021;
   COUGNARD-GREGOIRE, Audrey/T-4443-2019; Delcourt, Cecile/I-2627-2013;
   Thee, Eric Ferdinand/ABB-9370-2020; Calado, Sofia M./K-2202-2016
OI De la cerda, Berta/0000-0001-5603-6473; Arango-Gonzalez,
   Blanca/0000-0002-9045-182X; Merle, Benedicte MJ/0000-0003-1332-0954;
   Lengyel, Imre/0000-0001-7467-2174; Acar, İlhan
   Erkin/0000-0002-2078-9905; Merle, Benedicte MJ/0000-0003-1332-0954;
   COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Delcourt,
   Cecile/0000-0002-2099-0481; Calado, Sofia M./0000-0001-5509-4145
FU Department for Education PhD studentship; Eye-Risk project - European
   Union's Horizon 2020 research and innovation programme [634479]
FX This review article was supported by a Department for Education PhD
   studentship to C.N.B. and the Eye-Risk project funded by the European
   Union's Horizon 2020 research and innovation programme [634479].
CR Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   ADLER AJ, 1992, OPHTHALMIC RES, V24, P243, DOI 10.1159/000267174
   Adler L, 2015, PHOTOCH PHOTOBIO SCI, V14, P1983, DOI 10.1039/c5pp00156k
   Agudo-Barriuso M, 2013, INVEST OPHTH VIS SCI, V54, P4249, DOI 10.1167/iovs.12-11451
   Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   Aljohani AJ, 2014, INVEST OPHTH VIS SCI, V55, P3413, DOI 10.1167/iovs.13-13570
   ALM A, 1970, ACTA PHYSIOL SCAND, V80, P19, DOI 10.1111/j.1748-1716.1970.tb04765.x
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   ANDERSON B, 1964, ARCH OPHTHALMOL-CHIC, V72, P792
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Aribindi K, 2013, CURR EYE RES, V38, P1017, DOI 10.3109/02713683.2013.803123
   Baca JT, 2007, OCUL SURF, V5, P280, DOI 10.1016/S1542-0124(12)70094-0
   Baca JT, 2007, CLIN CHEM, V53, P1370, DOI 10.1373/clinchem.2006.078543
   Bai S, 2013, EXP EYE RES, V108, P76, DOI 10.1016/j.exer.2012.12.007
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Balashova EE, 2018, J PERS MED, V8, DOI 10.3390/jpm8030028
   Barba I, 2010, INVEST OPHTH VIS SCI, V51, P4416, DOI 10.1167/iovs.10-5348
   Barbas-Bernardos C, 2016, J PHARMACEUT BIOMED, V127, P18, DOI 10.1016/j.jpba.2016.03.032
   Becker W, 2012, J MICROSC-OXFORD, V247, P119, DOI 10.1111/j.1365-2818.2012.03618.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biarnes M, 2018, EXPERT REV PRECIS ME, V3, P249, DOI 10.1080/23808993.2018.1502037
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Blacker TS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4936
   BLEAU G, 1974, BIOCHIM BIOPHYS ACTA, V352, P1, DOI 10.1016/0005-2736(74)90174-6
   Boccard J, 2010, J SEP SCI, V33, P290, DOI 10.1002/jssc.200900609
   Borchman D, 2007, CHEM PHYS LIPIDS, V147, P87, DOI 10.1016/j.chemphyslip.2007.04.001
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Brewer GJ, 2010, CHEM RES TOXICOL, V23, P319, DOI 10.1021/tx900338d
   Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802
   Butovich IA, 2008, INVEST OPHTH VIS SCI, V49, P3779, DOI 10.1167/iovs.08-1889
   Butovich IA, 2013, EXP EYE RES, V117, P4, DOI 10.1016/j.exer.2013.05.010
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CHANCE B, 1976, CIRC RES, V38, P31
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chen GB, 2017, ANAL CHEM, V89, P4897, DOI 10.1021/acs.analchem.6b05006
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen LY, 2018, ANAL CHIM ACTA, V1037, P28, DOI 10.1016/j.aca.2018.01.060
   Chen LY, 2011, J PROTEOME RES, V10, P4876, DOI 10.1021/pr2004874
   Chen MQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109214
   CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Cui L, 2018, MASS SPECTROM REV, V37, P772, DOI 10.1002/mas.21562
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dame ZT, 2015, METABOLOMICS, V11, P1864, DOI 10.1007/s11306-015-0840-5
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DAUM KM, 1982, INVEST OPHTH VIS SCI, V22, P509
   Dean AW, 2012, INVEST OPHTH VIS SCI, V53, P1773, DOI 10.1167/iovs.11-9419
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dowling JE, 2012, RETINA APPROACHABLE, V2nd
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Du JH, 2016, J BIOL CHEM, V291, P4698, DOI 10.1074/jbc.M115.698985
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, EXP EYE RES, V153, P178, DOI 10.1016/j.exer.2016.10.018
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Edwards G, 2014, BIOCHIMIE, V105, P99, DOI 10.1016/j.biochi.2014.06.019
   Edwards G, 2014, BIOCHIMIE, V101, P232, DOI 10.1016/j.biochi.2014.01.020
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Figueira J, 2016, MOL BIOSYST, V12, P2562, DOI 10.1039/c6mb00233a
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1964, INVEST OPHTH VISUAL, V3, P539
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gonzalez A.N., 2016, 262 BARD COLL
   Goodacre R, 2004, TRENDS BIOTECHNOL, V22, P245, DOI 10.1016/j.tibtech.2004.03.007
   Gray N, 2015, J PROTEOME RES, V14, P2714, DOI 10.1021/acs.jproteome.5b00203
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hagan S, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0065-3
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines NR, 2018, J PROTEOME RES, V17, P2421, DOI 10.1021/acs.jproteome.8b00169
   HESS HH, 1975, EXP EYE RES, V21, P471, DOI 10.1016/0014-4835(75)90128-1
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu J, 2001, MOL VIS, V7, P14
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ji YH, 2017, EXP EYE RES, V159, P147, DOI 10.1016/j.exer.2017.03.004
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson SR, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00022
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy BG, 2010, MOL VIS, V16, P665
   KENNEDY CJ, 1994, EXP CELL RES, V210, P209, DOI 10.1006/excr.1994.1031
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Kowalczuk L, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.3
   Krebs HA, 1927, BIOCHEM Z, V189, P57
   Kristal BS, 1998, ANAL BIOCHEM, V263, P18, DOI 10.1006/abio.1998.2831
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, P63, DOI DOI 10.1007/978-0-387-46312-4_3
   Lakowicz J. R, 2006, PRINCIPLES FLUORESCE, P741
   LAKOWICZ JR, 1992, P NATL ACAD SCI USA, V89, P1271, DOI 10.1073/pnas.89.4.1271
   Lam SM, 2014, J LIPID RES, V55, P289, DOI 10.1194/jlr.M044826
   Lam SM, 2013, J CHROMATOGR A, V1308, P166, DOI 10.1016/j.chroma.2013.08.016
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Li M, 2014, MOL BIOSYST, V10, P1055, DOI 10.1039/c3mb70386j
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Lindon JC, 2003, ANAL CHEM, V75, p384A, DOI 10.1021/ac031386+
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Linton JD, 2010, P NATL ACAD SCI USA, V107, P8599, DOI 10.1073/pnas.1002471107
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   MACGREGOR LC, 1986, J BIOL CHEM, V261, P4046
   Mains J, 2012, INVEST OPHTH VIS SCI, V53, P4778, DOI 10.1167/iovs.12-9998
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Maminishkis Arvydas, 2010, J Vis Exp, DOI 10.3791/2032
   Marcu L, 2012, ANN BIOMED ENG, V40, P304, DOI 10.1007/s10439-011-0495-y
   Marko C.K., 2018, RETIN PHYS, V15, P22
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mayordomo-Febrer A, 2015, EXP EYE RES, V131, P84, DOI 10.1016/j.exer.2014.11.012
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Metelo AM, 2015, ONCOTARGET, V6, P23036, DOI 10.18632/oncotarget.4564
   Metelo AM, 2015, J CLIN INVEST, V125, P1987, DOI 10.1172/JCI73665
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MISHIMA S., 1966, INVEST OPHTHALMOL, V5, P264
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Miura Y, 2013, INVEST OPHTH VIS SCI, V54, P3366, DOI 10.1167/iovs.13-11808
   Molday LL, 2007, J BIOL CHEM, V282, P32792, DOI 10.1074/jbc.M706321200
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nicholson JK, 2003, NAT REV DRUG DISCOV, V2, P668, DOI 10.1038/nrd1157
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Overmyer KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117232
   Paris LP, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-015-0877-5
   Park KS, 2018, CELL MOL LIFE SCI, V75, P1559, DOI 10.1007/s00018-018-2744-9
   Park M, 2017, ACS NANO, V11, P438, DOI 10.1021/acsnano.6b06196
   Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708
   PAU H, 1993, GRAEF ARCH CLIN EXP, V231, P656, DOI 10.1007/BF00921961
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Peng B, 2013, BIOSENS BIOELECTRON, V49, P204, DOI 10.1016/j.bios.2013.05.014
   Pieczenik SR, 2007, EXP MOL PATHOL, V83, P84, DOI 10.1016/j.yexmp.2006.09.008
   Pieragostino D, 2015, PROTEOM CLIN APPL, V9, P169, DOI 10.1002/prca.201400084
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pushpoth S, 2013, INVEST OPHTH VIS SCI, V54
   Pushpoth S, 2015, INVEST OPHTH VIS SCI, V56
   Rajapakse D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6926485
   Rantamaki AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019553
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   RICHARDSKORTUM R, 2003, HDB BIOMEDICAL FLUOR, P237
   Rieckmann JC, 2017, NAT IMMUNOL, V18, P583, DOI 10.1038/ni.3693
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Romano A, 1988, Metab Pediatr Syst Ophthalmol (1985), V11, P78
   ROTH S, 1994, INVEST OPHTH VIS SCI, V35, P3209
   Rotstein NP, 2010, J LIPID RES, V51, P1247, DOI 10.1194/jlr.R003442
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Rustam YH, 2018, ANAL CHEM, V90, P374, DOI 10.1021/acs.analchem.7b04836
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sauer L, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.091415
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Saville JT, 2010, INVEST OPHTH VIS SCI, V51, P2843, DOI 10.1167/iovs.09-4609
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schoumacher M., 2016, 30IEM JOUN FRANC BEL
   Schoumacher M., 2018, EUROMAR EUROPEAN MAG
   Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D., 2011, 808780871G SPIE INT, V8087
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Shaban H, 2001, ARCH BIOCHEM BIOPHYS, V394, P111, DOI 10.1006/abbi.2001.2535
   Sharick JT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23691-x
   Shen JH, 2016, DISCOV MED, V22, P129
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Snytnikova OA, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-016-1144-0
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stone J, 2008, BRAIN RES, V1189, P58, DOI 10.1016/j.brainres.2007.10.083
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Szmacinski H., 2018, PROC SPIE, V10484
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Tan SZ, 2016, EXP EYE RES, V149, P8, DOI 10.1016/j.exer.2016.05.019
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   TATE DJ, 1995, CURR EYE RES, V14, P897, DOI 10.3109/02713689508995129
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tolleson WH, 2005, J ENVIRON SCI HEAL C, V23, P105, DOI 10.1080/10590500500234970
   Tsuruoka M, 2013, ELECTROPHORESIS, V34, P2865, DOI 10.1002/elps.201300019
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Urayama PK, 2003, HDB BIOMEDICAL FLUOR, P211
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang JH, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0376
   Wang L, 1997, INVEST OPHTH VIS SCI, V38, P48
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wimmers S, 2007, INVEST OPHTH VIS SCI, V48, P5767, DOI 10.1167/iovs.07-0412
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JPM, 2003, NEUROCHEM RES, V28, P1525, DOI 10.1023/A:1025622425501
   Wurtz P, 2017, AM J EPIDEMIOL, V186, P1084, DOI 10.1093/aje/kwx016
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yan QY, 2011, ANAL CHEM, V83, P8341, DOI 10.1021/ac201700c
   Yonamine I, 2011, J CELL BIOL, V192, P557, DOI 10.1083/jcb.201004098
   Young SP, 2009, MOL VIS, V15, P1210
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yu MX, 2015, INVEST OPHTH VIS SCI, V56, P5706, DOI 10.1167/iovs.14-16338
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zabka TS, 2015, TOXICOL SCI, V144, P163, DOI 10.1093/toxsci/kfu268
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou L, 2006, ANN ACAD MED SINGAP, V35, P400
   Zhou L, 2012, J PROTEOMICS, V75, P3877, DOI 10.1016/j.jprot.2012.04.053
NR 258
TC 24
Z9 24
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD JAN
PY 2019
VL 9
IS 1
AR 4
DI 10.3390/metabo9010004
PG 36
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HK2LO
UT WOS:000457743200002
PM 30591665
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Busquets, MA
   Sabbagh, O
AF Busquets, Miguel A.
   Sabbagh, Osama
TI Current status of home monitoring technology for age-related macular
   degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; ForeseeHome monitoring device; notal home
   optical coherence tomography device; notal optical coherence tomography
   analyzer; preferential hyperacuity perimetry
ID RANIBIZUMAB; OUTCOMES; BEVACIZUMAB
AB Purpose of review Evidence suggests that patients present with exudative age-related macular degeneration (AMD) in a delayed fashion. Increased lesion size associated with this delay directly impacts visual acuity. Upon treatment initiation, patients are monitored largely with optical coherence tomography (OCT) technology to determine the need for treatment. Home-monitoring systems using preferential hyperacuity perimetry (PHP) and OCT may optimize management. Recent findings Comparison of Age-related Macular Degeneration Treatment Trials study and American Academy of Ophthalmology's Intelligent Research in Sight registry data suggest smaller lesion size and better visual acuity upon choroidal neovascularization (CNV) capture are associated with better final visual acuity with therapy. The HOME study and recent PHP-based ForeseeHome data indicate that this modality leads to earlier detection of CNV. Results of a real-world data analysis demonstrate 82% retention of >= 20/40 vision with median visual acuity of 20/40 at time of CNV detection using PHP home-monitoring. Home OCT data suggests excellent patient useability, with >90% of patients obtaining analyzable images. The Notal OCT Analyzer demonstrates superiority over human interpreters regarding the ability to detect intraretinal and subretinal fluid (82% vs. 47% sensitivity). PHP may improve treatment outcomes for exudative AMD by allowing for earlier detection of lesions. Home OCT platforms could allow for more convenient monitoring of patients undergoing treatment for exudative AMD and better enable true PRN models.
C1 [Busquets, Miguel A.; Sabbagh, Osama] Univ Kentucky, Retina Associates Kentucky, Lexington, KY USA.
   [Sabbagh, Osama] Univ Kentucky, Dept Ophthalmol, Lexington, KY USA.
C3 University of Kentucky; University of Kentucky
RP Busquets, MA (通讯作者)，Retina Associates Kentucky, Lexington, KY 40509 USA.
EM mbusquets@retinaky.com
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   [Anonymous], Analysis of the long-term visual outcomes of ForeseeHome remote telemonitoring-the ALOFT study protocol FSH-C2020.00
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Ho A., 2020, ASRS ANN M 2020
   Ho A, 2018, RETINA TODAY, P48
   Ho AC., 2018, ASCRS RET APR 15 WAS
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Lally D, 2020, INVEST OPHTH VIS SCI, V61
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Loewenstein A., 2020, AM AC OPHTH ANN M 20
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller J, 2006, INVEST OPHTHALMOL, V47, P3539
   Pollack JS., 2020, RETINA TIMES, V38, P29
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Suner IJ., 2012, INVEST OPHTHALMOL VI, V53, P3677
   Trivizki O, 2020, AM J OPHTHALMOL, V219, P222, DOI 10.1016/j.ajo.2020.06.028
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 23
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2021
VL 32
IS 3
BP 240
EP 246
DI 10.1097/ICU.0000000000000756
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS7CW
UT WOS:000661913000010
PM 33710010
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Li, X
   Cheng, CY
   Zheng, YF
   Mitchell, P
   Wang, JJ
   Jonas, JB
   Nangia, V
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Li, Xiang
   Cheng, Ching-Yu
   Zheng, Yingfeng
   Mitchell, Paul
   Wang, Jie Jin
   Jonas, Jost B.
   Nangia, Vinay
   Wong, Tien Yin
TI Prevalence and Risk Factors for Age-Related Macular Degeneration in
   Indians: A Comparative Study in Singapore and India
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PRADESH EYE DISEASE; BLUE MOUNTAINS EYE; MALAY EYE; ADULT-POPULATION;
   REFRACTIVE ERROR; ATHEROSCLEROSIS RISK; JAPANESE POPULATION;
   RURAL-POPULATION; POOLED FINDINGS; SOUTHERN INDIA
AB PURPOSE: To compare the prevalence and risk factors for age-related macular degeneration (AMD) in 2 Indian populations, 1 living in urban Singapore and 1 in rural central India.
   DESIGN: Population-based, cross-sectional studies of Indians aged 40+ years.
   METHODS: Our analysis included 3337 Singapore-residing participants and 3422 India-residing participants. All participants underwent comprehensive systemic and ocular examinations and retinal photography. AMD was graded from retinal photographs according to the Wisconsin Age-Related Maculopathy Grading System. Systemic and ocular risk factors were assessed for association with AMD.
   RESULTS: Singapore-residing participants were older (mean age 57.8 years vs 53.8 years) and, after adjusting for age and sex, were more likely to have previous cataract surgery, higher body mass index, hypertension, diabetes, previous myocardial infarction, higher cholesterol, and lower creatinine levels, but less likely to be current smokers, than India-residing participants. The age-standardized prevalence of early and late AMD was 4.45% and 0.34%, respectively, in Singapore and 5.80% and 0.16%, respectively, in India. Shorter axial length was associated with early AMD in both Singapore and India, whereas previous cataract surgery, higher body mass index, hypertension, and lower cholesterol were associated with early AMD in Singapore but not in India.
   CONCLUSION: The prevalence of AMD was similar among Indian adults living in urban Singapore and rural India, despite differences in cardiovascular risk factor profile and demographics. (Am J Ophthalmol 2013;155:764-773. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Li, Xiang; Cheng, Ching-Yu; Zheng, Yingfeng; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Jonas, Jost B.; Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; University of Sydney; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne; Suraj Eye Institute; Ruprecht Karls University Heidelberg;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/K-7017-2013; Zheng,
   Yingfeng/CAE-9225-2022; Wang, Jie Jin/P-1499-2014; Cheng,
   Ching-Yu/Y-2229-2019; Mitchell, Paul/P-1498-2014; Zheng,
   Yingfeng/AAE-2983-2022; wang, jie/GRS-0942-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Zheng, Yingfeng/0000-0002-0914-7864; Wang, Jie Jin/0000-0001-9491-4898;
   Cheng, Ching-Yu/0000-0003-0655-885X; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Biomedical Research Council (BMRC) [08/1/35/19/550]; National Medical
   Research Council (NMRC), Singapore [STaR/0003/2008]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The authors indicate no financial
   disclosures. Publication of this article was supported by Biomedical
   Research Council (BMRC) Grant 08/1/35/19/550 and National Medical
   Research Council (NMRC) Grant STaR/0003/2008, Singapore. Contributions
   of authors: design and conduct of the study (G.C., J.J., V.N., T.Y.W.);
   analysis and interpretation of the data (G.C., X.L., J.J.); writing the
   article (G.C.); data collection (C.Y.C., Y.F.Z.); provision of materials
   (C.Y.C., Y.F.Z., J.J., V.N., T.Y.W.); statistical expertise (X.L.);
   literature search (G.C.); critical revision and final approval of the
   article (G.C., X.L., C.Y.C., Y.F.Z., P.M., J.J.W., J.J., V.N., T.Y.W.).
CR Agresi A, 2007, INTRO CATEGORICAL DA
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung CMG, 2011, AM J OPHTHALMOL, V152, P108, DOI 10.1016/j.ajo.2011.01.012
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Jonas JB, 2010, EPIDEMIOLOGY, V21, P754, DOI 10.1097/EDE.0b013e3181e66201
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Nangia V, 2010, OPHTHALMOLOGY, V117, P1360, DOI 10.1016/j.ophtha.2009.11.040
   Nangia V, 2010, OPHTHALMOLOGY, V117, P705, DOI 10.1016/j.ophtha.2009.09.003
   National Census India, CENS DAT 2001
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pan CW, 2011, INVEST OPHTH VIS SCI, V52, P6636, DOI 10.1167/iovs.10-7148
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Singapore Department of Statistics, CENS POP 2010 ADV CE
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   United Nations Population Division, WORLD POP PROSP 2008
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 47
TC 35
Z9 35
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2013
VL 155
IS 4
BP 764
EP 773
DI 10.1016/j.ajo.2012.10.013
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 118JS
UT WOS:000317022400021
PM 23246273
DA 2022-11-30
ER

PT J
AU Yang, B
   Li, G
   Liu, JX
   Li, XY
   Zhang, SX
   Sun, FY
   Liu, WH
AF Yang, Bo
   Li, Ge
   Liu, Jiaxin
   Li, Xiangyu
   Zhang, Shixin
   Sun, Fengying
   Liu, Wenhua
TI Nanotechnology for Age-Related Macular Degeneration
SO PHARMACEUTICS
LA English
DT Review
DE age-related macular degeneration (AMD); nano-drug delivery system;
   cyclodextrin; CRISPR; Cas9; adeno-associated virus (AAV); hyaluronic
   acid; non-viral vector
ID OCULAR DRUG-DELIVERY; PIGMENT EPITHELIAL-CELLS; IN-VIVO; LIPID
   NANOPARTICLES; OXIDATIVE STRESS; PLGA NANOPARTICLES; GLUCOSE-METABOLISM;
   CONTROLLED-RELEASE; POSTERIOR SEGMENT; SUSTAINED-RELEASE
AB Age-related macular degeneration (AMD) is a degenerative eye disease that is the leading cause of irreversible vision loss in people 50 years and older. Today, the most common treatment for AMD involves repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs. However, the existing expensive therapies not only cannot cure this disease, they also produce a variety of side effects. For example, the number of injections increases the cumulative risk of endophthalmitis and other complications. Today, a single intravitreal injection of gene therapy products can greatly reduce the burden of treatment and improve visual effects. In addition, the latest innovations in nanotherapy provide the best drug delivery alternative for the treatment of AMD. In this review, we discuss the development of nano-drug delivery systems and gene therapy strategies for AMD in recent years. In addition, we discuss some novel targeting strategies and the potential application of these delivery methods in the treatment of AMD. Finally, we also propose that the combination of CRISPR/Cas9 technology with a new non-viral delivery system may be promising as a therapeutic strategy for the treatment of AMD.
C1 [Yang, Bo; Liu, Wenhua] Second Hosp Jilin Univ, Dept Anesthesiol, Changchun 130012, Peoples R China.
   [Yang, Bo; Li, Ge; Liu, Jiaxin; Li, Xiangyu; Zhang, Shixin; Sun, Fengying] Jilin Univ, Sch Life Sci, Changchun 130012, Peoples R China.
C3 Jilin University; Jilin University
RP Liu, WH (通讯作者)，Second Hosp Jilin Univ, Dept Anesthesiol, Changchun 130012, Peoples R China.
EM yangb20@mails.jlu.edu.cn; lige18@mails.jlu.edu.cn;
   liujiaxin@hrbmu.edu.cn; lixiangyu19@mails.jlu.edu.cn;
   shixin20@mails.jlu.edu.cn; sunfengying@jlu.edu.cn; liuwenh@jlu.edu.cn
RI Li, Xiangyu/GXG-4002-2022
OI Sun, Fengying/0000-0001-6199-9311; Zhang, Shixin/0000-0001-6286-7409;
   Liu, Wenhua/0000-0001-5807-4342
FU Bevacizumab Sustained Release Microspheres [3R118T751413]
FX FundingThis research was funded by Bevacizumab Sustained Release
   Microspheres, grant number 3R118T751413.
CR Al-Kassas RS, 2009, DRUG DELIV, V16, P145, DOI 10.1080/10717540802689008
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2020, J RADIOPHARM MOL PRO, V6, P34
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Ayata N, 2020, BRAZ J PHARM SCI, V56, DOI 10.1590/s2175-97902020000118171
   Balazs DA, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/326497
   Behroozi F, 2018, INT J PHARMACEUT, V548, P62, DOI 10.1016/j.ijpharm.2018.05.056
   Benati D, 2020, J MED GENET, V57, P437, DOI 10.1136/jmedgenet-2019-106473
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Bolla PK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090798
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bruning U, 2018, CELL METAB, V28, P866, DOI 10.1016/j.cmet.2018.07.019
   Chaw SY, 2021, J CONTROL RELEASE, V329, P162, DOI 10.1016/j.jconrel.2020.11.053
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Chung SH, 2020, MOL THER-METH CLIN D, V17, P409, DOI 10.1016/j.omtm.2020.01.006
   Cohen EB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232072
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Dammak A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091376
   De Bock K, 2013, CELL METAB, V18, P634, DOI 10.1016/j.cmet.2013.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Draoui N, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170219
   Dreismann AK, 2021, GENE THER, V28, P265, DOI 10.1038/s41434-021-00239-9
   Du MB, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3805967
   Du W, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020147
   Duan L, 2021, CHEMBIOCHEM, V22, P3360, DOI 10.1002/cbic.202100359
   El-Darzi N, 2021, BRIT J PHARMACOL, V178, P3220, DOI 10.1111/bph.15209
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Elsaid N, 2014, EXP EYE RES, V121, P121, DOI 10.1016/j.exer.2014.02.001
   Finn JD, 2018, CELL REP, V22, P2227, DOI 10.1016/j.celrep.2018.02.014
   Fuentes CM, 2018, CURR OPIN BIOMED ENG, V7, P33, DOI 10.1016/j.cobme.2018.08.003
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Gebler C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw183
   Gote V, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111072
   Gupta A, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108482
   Hagigit T, 2012, J CONTROL RELEASE, V160, P225, DOI 10.1016/j.jconrel.2011.11.022
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hoshikawa A, 2017, J DRUG DELIV SCI TEC, V38, P45, DOI 10.1016/j.jddst.2017.01.004
   Huang H, 2017, EMBO J, V36, P2334, DOI 10.15252/embj.201695518
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joseph RR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16791-7
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kam JH, 2015, EXP EYE RES, V135, P59, DOI 10.1016/j.exer.2015.03.023
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Karumanchi DK, 2018, J DRUG DELIV SCI TEC, V47, P275, DOI 10.1016/j.jddst.2018.07.003
   Kaur Indu Pal, 2004, Current Drug Delivery, V1, P351, DOI 10.2174/1567201043334623
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Lai SS, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0498-7
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lamichhane TN, 2015, MOL PHARMACEUT, V12, P3650, DOI 10.1021/acs.molpharmaceut.5b00364
   Laradji AM, 2021, ACS OMEGA, V6, P6172, DOI 10.1021/acsomega.0c05535
   Leaderer D, 2015, EXP EYE RES, V140, P171, DOI 10.1016/j.exer.2015.09.005
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Lim C, 2016, J DRUG DELIV SCI TEC, V36, P168, DOI 10.1016/j.jddst.2016.10.009
   Ling SK, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00656-y
   Lino CA, 2018, DRUG DELIV, V25, P1234, DOI 10.1080/10717544.2018.1474964
   Liu C, 2017, J CONTROL RELEASE, V266, P17, DOI 10.1016/j.jconrel.2017.09.012
   Liu JX, 2019, INT J NANOMED, V14, P8819, DOI 10.2147/IJN.S217038
   Loftsson T, 2007, INT J PHARMACEUT, V329, P1, DOI 10.1016/j.ijpharm.2006.10.044
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Ma FY, 2015, EUR J PHARM BIOPHARM, V89, P271, DOI 10.1016/j.ejpb.2014.12.010
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Matsunaga T, 2002, CIRCULATION, V105, P2185, DOI 10.1161/01.CIR.0000015856.84385.E9
   Maulvi FA, 2021, INT J PHARMACEUT, V608, DOI 10.1016/j.ijpharm.2021.121105
   McAndrews KM, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000875
   Meeus M, 2013, EXPERT OPIN THER TAR, V17, P1081, DOI 10.1517/14728222.2013.818657
   Men K, 2017, SCI CHINA LIFE SCI, V60, P447, DOI 10.1007/s11427-017-9032-4
   Merienne N, 2017, CELL REP, V20, P2980, DOI 10.1016/j.celrep.2017.08.075
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Mundada AS, 2009, CRIT REV THER DRUG, V26, P85, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i1.30
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nordling-David MM, 2013, ISR J CHEM, V53, P737, DOI 10.1002/ijch.201300055
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Patel N, 2016, DRUG DELIV, V23, P3712, DOI 10.1080/10717544.2016.1223225
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rohlenova K, 2020, CELL METAB, V31, P862, DOI 10.1016/j.cmet.2020.03.009
   Sabit H, 2021, GENES ENVIRON, V43, DOI 10.1186/s41021-021-00188-0
   Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362
   Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257
   Sim C, 2014, INVEST OPHTH VIS SCI, V55
   Singh Kavita H., 2010, Current Drug Delivery, V7, P244
   Singh M, 2020, J CONTROL RELEASE, V328, P895, DOI 10.1016/j.jconrel.2020.10.025
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sung D, 2019, BIOCONJUGATE CHEM, V30, P667, DOI 10.1021/acs.bioconjchem.8b00856
   Takashima Y, 2012, YAKUGAKU ZASSHI, V132, P1365, DOI 10.1248/yakushi.12-00234-3
   Tsutsui H, 2006, INTERNAL MED, V45, P809, DOI 10.2169/internalmedicine.45.1765
   Vaishya RD, 2014, AAPS PHARMSCITECH, V15, P1238, DOI 10.1208/s12249-014-0100-4
   Vaishya RD, 2014, WIRES NANOMED NANOBI, V6, P422, DOI 10.1002/wnan.1272
   Vakulskas CA, 2018, NAT MED, V24, P1216, DOI 10.1038/s41591-018-0137-0
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Vivanco-Rojas O, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107977
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   Wang YH, 2015, J FUNCT BIOMATER, V6, P379, DOI 10.3390/jfb6020379
   Wang ZH, 2020, GRAEF ARCH CLIN EXP, V258, P2407, DOI 10.1007/s00417-020-04797-3
   Wu WY, 2017, INVEST OPHTH VIS SCI, V58, P6082, DOI 10.1167/iovs.17-21902
   Xin G, 2020, ACS APPL MATER INTER, V12, P57710, DOI 10.1021/acsami.0c17296
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yang WL, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00030
   Yao WJ, 2010, BIOL PHARM BULL, V33, P1371, DOI 10.1248/bpb.33.1371
   Yavuz B, 2016, J PHARM PHARMACOL, V68, P1010, DOI 10.1111/jphp.12587
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
NR 125
TC 2
Z9 3
U1 17
U2 35
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD DEC
PY 2021
VL 13
IS 12
AR 2035
DI 10.3390/pharmaceutics13122035
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XX8XT
UT WOS:000736571900001
PM 34959316
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU O'Dwyer, PJ
AF O'Dwyer, Peter J.
TI STRATEGIES FOR INHIBITING AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vascular endothelial growth factor; renal cell carcinoma; age-related
   macular degeneration
ID METASTATIC COLORECTAL-CANCER; PLUS IRINOTECAN; BEVACIZUMAB; CETUXIMAB
AB Vascular endothelial growth factor (VEGF), a potent mediator of new blood vessel growth, encompasses multiple receptors and ligands. Expression of both the receptors and the ligands differs across tissues and cell types. The initial inhibitors of VEGF were targeted at one of its several receptors, but subsequent inhibitors of intracellular components of VEGF and downstream enzymatic signaling have also been associated with potent antiangiogenic effects. In cancer, single-agent inhibitors of VEGF have been associated with modest clinical benefits against many types of malignancy. Although greater cancer control is typically achieved when VEGF pathway inhibitors are combined with conventional cytotoxic agents, it is possible that blocking multiple signaling pathways or multiple steps along a single pathway will yield greater therapeutic effects. Encouraging preliminary results with antiangiogenic combinations may be relevant to both cancer and other pathogenic states, such as age-related macular degeneration, where antiangiogenic agents are active. RETINA 29:S21-S23, 2009
C1 Univ Penn, Abramson Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP O'Dwyer, PJ (通讯作者)，Univ Penn, Abramson Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19104 USA.
EM peter.odwyer@uphs.upenn.edu
CR Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
NR 4
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S21
EP S23
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700008
DA 2022-11-30
ER

PT J
AU Brown, DM
   Kaiser, PK
   Michels, M
   Soubrane, G
   Heier, JS
   Kim, RY
   Sy, JP
   Schneider, S
AF Brown, David M.
   Kaiser, Peter K.
   Michels, Mark
   Soubrane, Gisele
   Heier, Jeffrey S.
   Kim, Robert Y.
   Sy, Judy P.
   Schneider, Susan
CA ANCHOR Study Grp
TI Ranibizumab versus verteporfin for neovascular age-related macular
   degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PREVALENCE
AB Background: We compared ranibizumab - a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A - with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration.
   Methods: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.
   Results: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P < 0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P < 0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P < 0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%).
   Conclusions: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594.)
C1 Methodist Hosp, Vitreoretinal Consultants, Houston, TX 77030 USA.
   Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Retina Care Specialists, Palm Beach Gardens, FL USA.
   Univ Paris 12, Clin Ophtalmol, Creteil, France.
   Ophthalm Consultants Boston, Boston, MA USA.
   Genentech Inc, San Francisco, CA 94080 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston;
   Cleveland Clinic Foundation; Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); Ophthalmic Consultants of Boston; Roche Holding; Genentech
RP Brown, DM (通讯作者)，Methodist Hosp, Vitreoretinal Consultants, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
RI Zhang, Kang/Y-2740-2019; Wolf, Sebastian/B-8782-2008
OI Zhang, Kang/0000-0002-4549-1697; Kaiser, Peter/0000-0001-5126-045X;
   Wolf, Sebastian/0000-0002-7467-7028
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 2004, AV
   [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, IN PRESS ARCH OPHTHA
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325
   *NOV PHARM, 2005, VIS
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 22
TC 2632
Z9 2782
U1 3
U2 148
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 5
PY 2006
VL 355
IS 14
BP 1432
EP 1444
DI 10.1056/NEJMoa062655
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 090UA
UT WOS:000240976200005
PM 17021319
DA 2022-11-30
ER

PT J
AU Edwards, AO
   Ritter, R
   Abel, KJ
   Manning, A
   Panhuysen, C
   Farrer, LA
AF Edwards, AO
   Ritter, R
   Abel, KJ
   Manning, A
   Panhuysen, C
   Farrer, LA
TI Complement factor H polymorphism and age-related macular degeneration
SO SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; GENOMEWIDE-SCAN; SUSCEPTIBILITY LOCI; EXTENDED
   FAMILIES; ASSOCIATION; MACULOPATHY; ACTIVATION; DISEASE; LINKAGE;
   GLOMERULONEPHRITIS
AB Age-related macular degeneration (AMD) is a common, late-onset, and complex trait with multiple risk factors. Concentrating on a region harboring a locus for AMD on 1q25-31, the ARMD1 locus, we tested single-nucleotide polymorphisms for association with AMD in two independent case-control populations. Significant association (P = 4.95 x 10(-10)) was identified within the regulation of complement activation locus and was centered over a tyrosine-402 --> histidine-402 protein polymorphism in the gene encoding complement factor H. Possession of at least one histidine at amino acid position 402 increased the risk of AMD 2.7-fold and may account for 50% of the attributable risk of AMD.
C1 Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA.
   Sequenom Inc, San Diego, CA 92121 USA.
   Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
   Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Dept Med, Genet Program, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; Sequenom; Boston University; Boston University; Boston
   University; Boston University; Boston University
RP Edwards, AO (通讯作者)，Inst Retina Res, 3215 Princess Lane, Dallas, TX 75229 USA.
EM albert-edwards@swbell.net
RI Manning, Alisa Knodle/ABC-7711-2021; Mohammed, Imran/J-8271-2012;
   Farrer, Lindsay/AAS-1035-2020
OI Mohammed, Imran/0000-0002-8412-0768; Farrer, Lindsay/0000-0001-5533-4225
FU NATIONAL EYE INSTITUTE [R01EY014467] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Acosta J, 2004, CURR PHARM DESIGN, V10, P203, DOI 10.2174/1381612043453441
   Backes JM, 2004, ANN PHARMACOTHER, V38, P110, DOI 10.1345/aph.1D203
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Greenfield JR, 2004, CIRCULATION, V109, P3022, DOI 10.1161/01.CIR.0000130640.77501.79
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wener MH, 2000, J RHEUMATOL, V27, P2351
   Zhao HY, 2003, PHARMACOGENOMICS, V4, P171, DOI 10.1517/phgs.4.2.171.22636
NR 28
TC 1886
Z9 2039
U1 2
U2 67
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 15
PY 2005
VL 308
IS 5720
BP 421
EP 424
DI 10.1126/science.1110189
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 917TL
UT WOS:000228492000056
PM 15761121
DA 2022-11-30
ER

PT J
AU Ferris, FL
   Wilkinson, CP
   Bird, A
   Chakravarthy, U
   Chew, E
   Csaky, K
   Sadda, SR
AF Ferris, Frederick L., III
   Wilkinson, C. P.
   Bird, Alan
   Chakravarthy, Usha
   Chew, Emily
   Csaky, Karl
   Sadda, SriniVas R.
CA Beckman Initiative Macular Res
TI Clinical Classification of Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RAND-LIKE METHODOLOGY; GLAUCOMA MANAGEMENT; PANEL ASSESSMENT;
   MACULOPATHY; PROGRESSION; RISK; OPHTHALMOLOGY; CONSENSUS
AB Objective: To develop a clinical classification system for age-related macular degeneration (AMD).
   Design: Evidence-based investigation, using a modified Delphi process.
   Participants: Twenty-six AMD experts, 1 neuro-ophthalmologist, 2 committee chairmen, and 1 methodologist.
   Methods: Each committee member completed an online assessment of statements summarizing current AMD classification criteria, indicating agreement or disagreement with each statement on a 9-step scale. The group met, reviewed the survey results, discussed the important components of a clinical classification system, and defined new data analyses needed to refine a classification system. After the meeting, additional data analyses from large studies were provided to the committee to provide risk estimates related to the presence of various AMD lesions.
   Main Outcome Measures: Delphi review of the 9-item set of statements resulting from the meeting.
   Results: Consensus was achieved in generating a basic clinical classification system based on fundus lesions assessed within 2 disc diameters of the fovea in persons older than 55 years. The committee agreed that a single term, age-related macular degeneration, should be used for the disease. Persons with no visible drusen or pigmentary abnormalities should be considered to have no signs of AMD. Persons with small drusen (<63 mu m), also termed drupelets, should be considered to have normal aging changes with no clinically relevant increased risk of late AMD developing. Persons with medium drusen (>= 63-<125 mu m), but without pigmentary abnormalities thought to be related to AMD, should be considered to have early AMD. Persons with large drusen or with pigmentary abnormalities associated with at least medium drusen should be considered to have intermediate AMD. Persons with lesions associated with neovascular AMD or geographic atrophy should be considered to have late AMD. Five-year risks of progressing to late AMD are estimated to increase approximately 100 fold, ranging from a 0.5% 5-year risk for normal aging changes to a 50% risk for the highest intermediate AMD risk group.
   Conclusions: The proposed basic clinical classification scale seems to be of value in predicting the risk of late AMD. Incorporating consistent nomenclature into the practice patterns of all eye care providers may improve communication and patient care.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:844-851 (C) 2013 by the American Academy of Ophthalmology.
C1 [Ferris, Frederick L., III; Chew, Emily] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wilkinson, C. P.] Greater Baltimore Med Ctr, Baltimore, MD USA.
   [Bird, Alan] NHS Fdn Trust, Moorfields Eye Hosp, London, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Csaky, Karl] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Sadda, SriniVas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Greater Baltimore Medical Center; Oxford University Hospitals NHS
   Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; Queens University Belfast;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Doheny Eye Institute
RP Ferris, FL (通讯作者)，NEI, NIH, 10 Ctr Dr,Bldg 10 CRC,Room 3-2531, Bethesda, MD 20892 USA.
EM RickFerris@nei.nih.gov
RI Datta, Sayantan/D-1369-2010; Mitchell, Paul/P-1498-2014
OI Chakravarthy, Usha/0000-0002-2606-3734; Ferris,
   Frederick/0000-0002-4933-0639
FU Arnold and Mabel Beckman Initiative for Macular Research, Irvine,
   California
FX Supported by the Arnold and Mabel Beckman Initiative for Macular
   Research, Irvine, California.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Danis RP, 2010, RETINA-J RET VIT DIS, V30, P1627, DOI 10.1097/IAE.0b013e3181dde5f5
   Davis MD, 2008, INVEST OPHTH VIS SCI, V49, P1745, DOI 10.1167/iovs.07-1257
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duke-Elder S, 1961, SYSTEM OPHTHALMOLOGY, V2, P294
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fitch K., 2001, RANDUCLA APPROPRIATE
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gangaputra S, 2012, RETINA-J RET VIT DIS, V32, P600, DOI 10.1097/IAE.0b013e318221592f
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   Lee PP, 2010, J GLAUCOMA, V19, P281, DOI 10.1097/IJG.0b013e3181b4ca8d
   Lujan BJ, 2008, OPHTHAL SURG LAS IM, V39, pS15, DOI 10.3928/15428877-20080715-01
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh K, 2008, AM J OPHTHALMOL, V145, P575, DOI 10.1016/j.ajo.2007.10.009
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wilson MR, 2008, AM J OPHTHALMOL, V145, P570, DOI 10.1016/j.ajo.2007.10.019
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 22
TC 815
Z9 831
U1 3
U2 105
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2013
VL 120
IS 4
BP 844
EP 851
DI 10.1016/j.ophtha.2012.10.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 122UL
UT WOS:000317343500030
PM 23332590
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Yan, J
   Peng, XF
   Cai, YL
   Cong, WD
AF Yan, Jian
   Peng, Xifeng
   Cai, Yulian
   Cong, Wendong
TI Development of facile drug delivery platform of ranibizumab fabricated
   PLGA-PEGylated magnetic nanoparticles for age-related macular
   degeneration therapy
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Magnetic nanoparticles; PEG-PLGA; Age-related macular degeneration;
   Ranibizumab; Drug delivery
ID IRON-OXIDE NANOPARTICLES; GOLD NANOPARTICLES; ACID; BEVACIZUMAB; TRIAL
AB The present anti-angiogenic therapies for neovascular age-related macular degeneration require effective drug delivery systems for transfer drug molecules. Ranibizumab is an active humanized monoclonal antibody that counteracts active forms of vascular endothelial growth factor A in the neovascular age-related macular degeneration therapy. The development of ranibizumab-related therapies, we have designed the effective drug career with engineered magnetic nanoparticles (Fe3O4) as a facile platform of ranibizumab delivery for the treatment of neovascular age-related macular degeneration. Ranibizumab conjugated iron oxide (Fe3O4)/PEGylated poly lactide-co-glycolide (PEG-PLGA) was successfully designed and the synthesized materials are analyzed different analytical techniques. The microscopic techniques (Scanning Electron Microscopy (SEM) & Transmission Electron Microscopy (TEM)) are clearly displayed that spherical nanoparticles into the PEG-PLGA matrix and presence of elements and chemical interactions confirmed by the results of energy dispersive X-ray analysis (EDX) and Fourier trans-form infrared (FTIR) spectroscopic methods. The in vitro anti-angiogenic evaluation of Fe3O4/PEG-PLGA polymer nanomaterial efficiently inhibits the tube formation in the Matrigel-based assay method by using human umbilical vein endothelial cells. Ranibizumab treated Fe3O4/PEG-PLGA polymer nanomaterials not disturbed cell proliferation and the results could not display the any significant differences in human endothelial cells. The present investigated results describe that Fe3O4/PEG-PLGA polymer nanomaterials can be highly favorable and novel formulation for the treatment of neovascular age-related macular degeneration.
C1 [Yan, Jian; Peng, Xifeng; Cai, Yulian] Longgang Dist Cent Hosp Shenzhen, Dept Ophthalmol, 6082 Longgang Rd, Shenzhen 518117, Guangdong, Peoples R China.
   [Cong, Wendong] Longgang Dist Cent Hosp Shenzhen, Dept Neurol, 6082 Longgang Rd, Shenzhen 518117, Guangdong, Peoples R China.
RP Cong, WD (通讯作者)，Longgang Dist Cent Hosp Shenzhen, Dept Neurol, 6082 Longgang Rd, Shenzhen 518117, Guangdong, Peoples R China.
EM wcong123@yahoo.com
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051-010-9911-8
   [Anonymous], 2014, EUR J PHARM BIOPHARM, V87, P30, DOI 10.1016/j.ejpb.2014.02.007
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dorniani D, 2012, INT J NANOMED, V7, P5745, DOI 10.2147/IJN.S35746
   Fakhimikabir H, 2018, J PHOTOCH PHOTOBIO B, V182, P71, DOI 10.1016/j.jphotobiol.2018.03.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Irshad R, 2017, J PHOTOCH PHOTOBIO B, V170, P241, DOI 10.1016/j.jphotobiol.2017.04.020
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Knezevic NZ, 2013, NANOSCALE, V5, P1544, DOI 10.1039/c2nr33417h
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lee J, 2016, J PHOTOCH PHOTOBIO B, V160, P210, DOI 10.1016/j.jphotobiol.2016.03.058
   Liu Y, 2016, BIOMATERIALS, V80, P33, DOI 10.1016/j.biomaterials.2015.11.060
   Nosrati H, 2018, BIOORG CHEM, V76, P501, DOI 10.1016/j.bioorg.2017.12.033
   Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007
   Patra JK, 2017, J PHOTOCH PHOTOBIO B, V173, P291, DOI 10.1016/j.jphotobiol.2017.05.045
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tian ZF, 2018, MICROPOR MESOPOR MAT, V256, P1, DOI 10.1016/j.micromeso.2017.07.053
   Veiseh O, 2010, ADV DRUG DELIVER REV, V62, P284, DOI 10.1016/j.addr.2009.11.002
   Wei K, 2014, INT J PHARMACEUT, V464, P225, DOI 10.1016/j.ijpharm.2013.12.047
   Zhang KR, 2014, J CONTROL RELEASE, V183, P77, DOI 10.1016/j.jconrel.2014.03.026
   Zhang XH, 2017, MOL THER, V25, P1606, DOI 10.1016/j.ymthe.2017.01.014
NR 27
TC 17
Z9 17
U1 4
U2 30
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD JUN
PY 2018
VL 183
BP 133
EP 136
DI 10.1016/j.jphotobiol.2018.04.033
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GJ1SV
UT WOS:000435049000016
PM 29704861
DA 2022-11-30
ER

PT J
AU Rechtman, E
   Harris, A
   Siesky, B
   Kagemann, L
   Danis, RP
   Sines, D
   Ciulla, TA
AF Rechtman, Ehud
   Harris, Alon
   Siesky, Brent
   Kagemann, Larry
   Danis, Ronald P.
   Sines, Dan
   Ciulla, Thomas A.
TI The relationship between retrobulbar and choroidal hemodynamics in
   non-neovascular age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OCULAR BLOOD-FLOW; OPTIC-NERVE HEAD; PERFUSION; CIRCULATION;
   MACULOPATHY; EYES
AB BACKGROUND AND OBJECTIVE: To evaluate the relationship between retrobulbar and choroidal hemodynamics in non-neovascular age-related macular degeneration.
   PATIENTS AND METHODS: Thirteen patients with age-related macular degeneration were assessed by both color Doppler imaging and scanning laser ophthalmoscope indocyanine green (ICG) angiography. Color Doppler imaging was used to measure peak systolic and end diastolic velocity (from which the resistance index, a measure of the resistance to flow downstream, was calculated) in the retrobulbar vessels. Scanning laser ophthalmoscope ICG angiograms were analyzed by area dilution analysis for quantitative choroidal fluorescence intensity assessment. Color Doppler imaging parameters were correlated with scanning laser ophthalmoscope ICG area dilution analysis parameters.
   RESULTS: A good correlation was found between the posterior ciliary arteries resistance index and scanning laser ophthalmoscope ICG area dilution analysis fluorescence duration.
   CONCLUSIONS: Scanning laser ophthalmoscope ICG area dilution analysis "duration" may serve as an alternative to color Doppler imaging in assessing the resistance to blood flow in the posterior ciliary arteries.
C1 Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
   Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46204 USA.
   Univ Pittsburgh, UPMC Eye Ctr, Eye & Ear Inst, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI 53706 USA.
   Midwest Eye Inst, Indianapolis, IN USA.
C3 Chaim Sheba Medical Center; Indiana University System; Indiana
   University-Purdue University Indianapolis; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Wisconsin System;
   University of Wisconsin Madison
RP Rechtman, E (通讯作者)，Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
RI Kagemann, Larry/B-6255-2013; Ciulla, Thomas/AAA-1299-2020
OI Kagemann, Larry/0000-0001-8961-0187; Ciulla, Thomas/0000-0001-5557-6777
CR Arsene S, 2002, BRIT J OPHTHALMOL, V86, P1243, DOI 10.1136/bjo.86.11.1243
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris Alon, 2005, Ophthalmol Clin North Am, V18, P345, DOI 10.1016/j.ohc.2005.04.001
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   WILLIAMSON TH, 1993, EYE, V7, P74, DOI 10.1038/eye.1993.16
   Zeitz O, 2002, ULTRASOUND MED BIOL, V28, P1023, DOI 10.1016/S0301-5629(02)00555-0
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 19
TC 6
Z9 6
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2007
VL 38
IS 3
BP 219
EP 225
DI 10.3928/15428877-20070501-06
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 168RO
UT WOS:000246541900006
PM 17552388
DA 2022-11-30
ER

PT J
AU Xu, H
   Piao, ZY
   Ma, XY
   Huang, Z
   Zhou, P
   Yu, WZ
   Xu, Q
   Zhao, MW
AF Xu, Hui
   Piao, Zhenyu
   Ma, Xiaoyun
   Huang, Lvzhen
   Zhou, Peng
   Yu, Wenzhen
   Xu, Qiong
   Zhao, Mingwei
TI A functional polymorphism in the promoter of alpha A-crystallin
   increases the risk of nAMD
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE alpha A-crystallin; single-nucleotide polymorphism; neovascular
   age-related macular disease; polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHENOTYPE; CATARACT; PROTEINS; GENE;
   CFH
AB Objective: To analyze the association between the promoter of alpha A-crystallin (CRYAA) variants with neovascular age related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in a northern Chinese population. Methods: We performed a case-control study in a group of Chinese patients with nAMD (n = 345) or PCV (n = 371) and contrasted the results against an independent control group comprising 514 mild cataract patients without any evidence of age related maculopathy. An association analysis of allele frequencies was performed for 6 single-nucleotide polymorphisms (SNPs) at the CRYAA locus (rs3761381, rs3761382, rs79545821, rs13053109, rs7278468, and rs117396767). Differences in the observed genotypic distributions between the cases and controls were tested using chi-square tests, and logistic regression models were used to calculate the odds ratio (OR) and 95% confidence interval (CI) of nAMD or PCV. Results: The CRYAA rs7278468 variant was significantly associated with neovascular age related macular degeneration (OR = 1.253, 95% CI 1.018-1.542, P = 0.033). No association was detected between the other five SNPs and nAMD (P > 0.05). No association was detected between these six SNPs and PCV (P > 0.05). Conclusions: Our data suggest CRYAA rs7278468 increases the risk of nAMD. The data might provide crucial information for future clinical studies on the mechanisms of nAMD and may require larger studies to accurately dissect.
C1 [Xu, Hui; Piao, Zhenyu; Huang, Lvzhen; Yu, Wenzhen; Xu, Qiong; Zhao, Mingwei] Peking Univ, Hlth Sci Ctr, Peoples Hosp,Coll Optometry,Dept Ophthalmol, Eye Dis & Optometry Inst,Beijing Key Lab Diag & T, Beijing, Peoples R China.
   [Xu, Hui; Piao, Zhenyu; Huang, Lvzhen; Yu, Wenzhen; Xu, Qiong; Zhao, Mingwei] Peking Univ, Hlth Sci Ctr, Peoples Hosp,Coll Optometry,Clin Ctr Optometry, Eye Dis & Optometry Inst,Beijing Key Lab Diag & T, Beijing, Peoples R China.
   [Ma, Xiaoyun] Shanghai Guanghua Integrat Med Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhou, Peng] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.
   [Zhou, Peng] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Peking University; Peking University; Fudan University; Fudan University
RP Huang, Z; Zhao, MW (通讯作者)，Peking Univ, Hlth Sci Ctr, Peoples Hosp,Coll Optometry,Dept Ophthalmol, Eye Dis & Optometry Inst,Beijing Key Lab Diag & T, Beijing, Peoples R China.; Huang, Z; Zhao, MW (通讯作者)，Peking Univ, Hlth Sci Ctr, Peoples Hosp,Coll Optometry,Clin Ctr Optometry, Eye Dis & Optometry Inst,Beijing Key Lab Diag & T, Beijing, Peoples R China.
EM drlvzhen123@163.com; rmykzmw@163.com
FU National Natural Science Foundation of China (NSFC) [81470651, 81470649,
   81670870]; Beijing Nova Program [Z161100-004916058]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC, nos. 81470651, 81470649, and 81670870) and the Beijing Nova
   Program (Z161100-004916058). The funders had no role in the study
   design, data collection and analysis, the decision to publish, or the
   preparation of the manuscript.
CR Beby F, 2007, ARCH OPHTHALMOL-CHIC, V125, P213, DOI 10.1001/archopht.125.2.213
   Bhagyalaxmi SG, 2009, BBA-MOL BASIS DIS, V1792, P974, DOI 10.1016/j.bbadis.2009.06.011
   Biswas A, 2008, BIOCHEM J, V409, P771, DOI 10.1042/BJ20071006
   Chen P, 2012, CURR MOL MED, V12, P1164, DOI 10.2174/156652412803306747
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23206
   Ma XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37747
   Meehan S, 2007, J MOL BIOL, V372, P470, DOI 10.1016/j.jmb.2007.06.060
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Rao NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033582
   Schaeffeler E, 2008, CLIN CHEM, V54, P1637, DOI 10.1373/clinchem.2008.103457
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Xu Q, 2015, INVEST OPHTH VIS SCI, V56, P816, DOI 10.1167/iovs.14-14734
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Zhou P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043173
NR 26
TC 2
Z9 2
U1 1
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2019
VL 12
IS 5
BP 1782
EP 1787
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA IB0LU
UT WOS:000469950800031
PM 31933998
DA 2022-11-30
ER

PT J
AU Rouvas, AA
   Ladas, ID
   Georgalas, I
   Vergados, I
   Papakonstantinou, D
   Kotsolis, AI
AF Rouvas, Alexandros A.
   Ladas, Ioannis D.
   Georgalas, Ilias
   Vergados, Ioannis
   Papakonstantinou, Dimitrios
   Kotsolis, Athanasios I.
TI RANIBIZUMAB FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL TEAR
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; ranibizumab; retinal pigment
   epithelial tear
ID INTRAVITREAL BEVACIZUMAB
AB Purpose: To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial tear.
   Methods: In this retrospective case series, patients with active exudative age-related macular degeneration associated with retinal pigment epithelial tear were treated by repeated injections of intravitreal ranibizumab. The outcome measures were best-corrected visual acuity and the signs of lesion activity, as evaluated by optical coherence tomography, fluorescein angiography, and indocyanine green angiography.
   Results: Twenty-one eyes of 20 patients were followed-up for a median of 12 months (range, 6-28 months). The median number of injections was 7 (range, 3-15). The best-corrected visual acuity improved in 6 eyes (28.57%), remained stable in 12 (57.14%), and decreased in 3 (14.28%). At the end of the follow-up time, 19 eyes (90.47%) had an inactive neovascular lesion in angiography, while 18 eyes (85.71%) had no signs of intraretinal or subretinal fluid.
   Conclusion: Intravitreal ranibizumab was effective in improving or stabilizing vision and resulting in a quiescent lesion in the majority of patients with exudative age-related macular degeneration associated with retinal pigment epithelial tear. The functional results were apparently better in eyes without foveal involvement by the retinal pigment epithelial tear. RETINA 31:1083-1088, 2011
C1 [Rouvas, Alexandros A.; Vergados, Ioannis] Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece.
   [Ladas, Ioannis D.; Georgalas, Ilias; Papakonstantinou, Dimitrios; Kotsolis, Athanasios I.] Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens
RP Rouvas, AA (通讯作者)，Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece.
EM rallex@hol.gr
RI Papaconstantinou, Dimitrios S/H-2386-2018; Georgalas,
   Ilias/AAD-5946-2019
OI Papaconstantinou, Dimitrios S/0000-0001-9501-2490; Georgalas,
   Ilias/0000-0002-6171-5865
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   LADAS ID, 2009, RETINA, V29, P305
   Ladas ID, 2007, OPHTHALMOLOGICA, V221, P313, DOI 10.1159/000104761
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P218
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
NR 16
TC 6
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2011
VL 31
IS 6
BP 1083
EP 1088
DI 10.1097/IAE.0b013e318207d1a3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769JT
UT WOS:000291009400010
PM 21427630
DA 2022-11-30
ER

PT J
AU Shin, YI
   Sung, JY
   Sagong, M
   Lee, YH
   Jo, YJ
   Kim, JY
AF Shin, Yong-Il
   Sung, Jae-Yun
   Sagong, Min
   Lee, Young-Hoon
   Jo, Young-Joon
   Kim, Jung-Yeul
TI Risk factors for breakthrough vitreous hemorrhage after intravitreal
   anti-VEGF injection in age-related macular degeneration with submacular
   hemorrhage
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; TISSUE-PLASMINOGEN ACTIVATOR;
   INTRAOCULAR HEMORRHAGE; SUBRETINAL HEMORRHAGE; PHOTODYNAMIC THERAPY;
   PNEUMATIC DISPLACEMENT; RANIBIZUMAB; MANAGEMENT; SECONDARY;
   ANTICOAGULANTS
AB To investigate the risk factors for breakthrough vitreous hemorrhage (VH) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in age-related macular degeneration (AMD) accompanied by submacular hemorrhage (SMH). We retrospectively reviewed the medical records of patients diagnosed with AMD combined with SMH, and enrolled 31 patients. We formed an age-and sex-matched control group of patients with submacular hemorrhage who did not develop breakthrough VH after intravitreal injection during 6 month follow-up. The mean patient age was 70.8 +/- 10.3 years in the breakthrough VH group. Of the 31 patients, 8 were diagnosed with choroidal neovascularization (CNV), 22 with polypoidal choroidal vasculopathy (PCV), and 1 with retinal angiomatous proliferation (RAP). PCV was associated with a significantly higher incidence of VH (odds ratio, 35.01; p = 0.001). The size of the SMH was 22.7 +/- 12.4 disc areas (DAs) in the breakthrough VH group and 5.4 +/- 6.9 DAs in the control group, and was thus significantly related to the development of VH (p < 0.001). The risk of VH was significantly higher in those taking anticoagulants (p = 0.014). There was no significant difference between the types of anti-VEGF agents. When taking anticoagulant medications, a SMH of large diameter, and PCV subtype were risk factors for breakthrough VH after anti-VEGF injection.
C1 [Shin, Yong-Il; Sung, Jae-Yun; Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
   [Sagong, Min] Yeungnam Univ, Dept Ophthalmol, Coll Med, Daegu, South Korea.
   [Lee, Young-Hoon] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Chungnam National University; Yeungnam University; Konyang University;
   Konyang University Hospital
RP Kim, JY (通讯作者)，Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   FEMAN SS, 1972, J AMER MED ASSOC, V220, P1354, DOI 10.1001/jama.220.10.1354
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Humayun M, 1998, AM J OPHTHALMOL, V126, P358, DOI 10.1016/S0002-9394(98)00090-7
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Johnson M W, 2000, Curr Opin Ophthalmol, V11, P201, DOI 10.1097/00055735-200006000-00009
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Malik Farhan F, 2014, Int Ophthalmol Clin, V54, P51, DOI 10.1097/IIO.0000000000000018
   Moon SW, 2013, J OCUL PHARMACOL TH, V29, P556, DOI 10.1089/jop.2012.0148
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SANDERS D, 1975, A GRAEF ARCH KLIN EX, V197, P255, DOI 10.1007/BF00410870
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 38
TC 9
Z9 10
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 12
PY 2018
VL 8
AR 10560
DI 10.1038/s41598-018-28938-1
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GM7ET
UT WOS:000438343600070
PM 30002432
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Halpern, MT
   Schmier, JK
   Covert, D
   Venkataraman, K
AF Halpern, MT
   Schmier, JK
   Covert, D
   Venkataraman, K
TI Resource utilization and costs of age-related macular degeneration
SO HEALTH CARE FINANCING REVIEW
LA English
DT Article
ID MEDICARE POPULATION; VISUAL IMPAIRMENT; EYE DISEASE; CARE; SERVICES;
   DRUSEN; AREDS
AB Data were analyzed from the 1999-2001 Medicare Beneficiary Encrypted Files for patients with age-related macular degeneration (AMD), an ophthalmic condition characterized by central vision loss. Classifying AMD subtype by International Classification of Diseases, Ninth Revision, Clinical Modifications (ICD-9-CM) (Centers for Disease Control and Prevention, 2003) code, resource utilization rates increased with disease progression. Individuals with more severe disease (wet only or wet and dry AMD) had greater costs than did those with less severe disease (drusen only or dry only). Costs among patients with wet disease increased yearly at rates exceeding inflation, possibly due in part to increased rates of treatment with photodynamic therapy among these individuals and the aging of the population.
C1 Exponent Inc, Alexandria, VA 22314 USA.
C3 Exponent
RP Halpern, MT (通讯作者)，Exponent Inc, 1800 Diagonal Rd,Suite 300, Alexandria, VA 22314 USA.
EM mhalpern@exponent.com
RI Schmier, Jordana/I-2994-2019
OI Schmier, Jordana/0000-0002-4662-8800
CR *AM AC OPHTH, GUID AG REL MAC DEG
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   CDC (Cent. Dis. Control Prev.), 2004, MMWR-MORBID MORTAL W, V53, P1069
   Centers for Disease Control and Prevention, INT CLASS DIS 9 REV
   Centers for Medicare and Medicaid Services, HEALTHC COMM PROC CO
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Ellwein LB, 1996, OPHTHALMOLOGY, V103, P1732, DOI 10.1016/S0161-6420(96)30433-8
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRENKEL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P1609
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   *MAC DEG PARTN, TYP AMD
   Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   *SAS I INC, 2002, SAS VERS 8 1
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 18
TC 16
Z9 16
U1 0
U2 2
PU CENTERS FOR MEDICARE & MEDICAID SERVICES
PI BALTIMORE
PA 7500 SECURITY BOULEVARD, BALTIMORE, MD 21244-1850 USA
SN 0195-8631
J9 HEALTH CARE FINANC R
JI Health Care Finan. Rev.
PD SPR
PY 2006
VL 27
IS 3
BP 37
EP 47
PG 11
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 044XZ
UT WOS:000237708300004
PM 17290647
DA 2022-11-30
ER

PT J
AU Song, SJ
   Youm, DJ
   Chang, Y
   Yu, HG
AF Song, Su Jeong
   Youm, Dong Ju
   Chang, Yoosoo
   Yu, Hyeong Gon
TI Age-Related Macular Degeneration in a Screened South Korean Population:
   Prevalence, Risk Factors, and Subtypes
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; South Koreans; prevalence; risk
   factors; subtype
ID BLUE-MOUNTAINS EYE; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   HEALTH-INSURANCE-CORPORATION; LONG-TERM INCIDENCE; NATIONAL-HEALTH;
   JAPANESE POPULATION; RURAL-POPULATION; CHINESE PATIENTS; CANCER RISK;
   DIETARY-FAT
AB Purpose: To identify the prevalence, risk factors, and subtypes of age-related macular degeneration (AMD) in a screened South Korean population. Methods: A total of 10,890 participants (aged 50-92) who underwent a health check-up at Kangbuk Samsung Hospital from January to December 2006 were included. Fundus photographs and systemic risk factors were assessed. Subtype frequencies of neovascular AMD were recorded according to angiograms. AMD was defined in accord with the international classification and grading system. Logistic regression analyses were performed to identify risk factors for AMD. Results: The mean age of the 10,890 participants was 57.2 +/- 6.3 years (50-92 years), and 56.2% were men. The age-gender-adjusted prevalence of early AMD was 5.07%. Multiple logistic regression analysis showed that age (OR per 10-year increment, 2.22) and high blood pressure (adjusted OR: 1.35) were independent risk factors for early AMD. The age-gender-adjusted prevalence of late AMD was 0.34%. Only age was significantly associated with late AMD. Of 9 exudative AMD patients who received fluorescein angiography or indocyanine green angiography, 6 eyes (66.7%) showed choroidal neovascularization, 2 eyes (22.2%) had polypoidal choroidal vasculopathy (PCV), and 1 eye (11.1%) had retinal angiomatous proliferation. Conclusion: In this study, the prevalence of early AMD was similar to other studies though the prevalence of late AMD was low. High blood pressure as well as age was a risk factor of early AMD. South Koreans may have a higher prevalence of PCV than white populations. These findings provide preliminary information for further investigation of AMD in South Koreans.
C1 [Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Song, Su Jeong; Youm, Dong Ju] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Kangbuk Samsung Hosp, Seoul, South Korea.
   [Chang, Yoosoo] Kangbuk Samsung Hosp, Hlth Screening Ctr, Kangbuck, South Korea.
C3 Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Yu, HG (通讯作者)，Seoul Natl Univ Hosp, Dept Ophthalmol, 101 Daehang Ro, Seoul 110744, South Korea.
EM hgonyu@snu.ac.kr
OI Chang, Yoosoo/0000-0002-6945-9050; Yu, Hyeong Gon/0000-0002-1795-202X
FU South Korea Healthcare Technology RD Project [A080588]; Ministry of
   Health & Welfare, Republic of South Korea; Samsung Biomedical Research
   Institute Fund [C-A9-310-1]
FX This study was supported by a grant from the South Korea Healthcare
   Technology R&D Project (A080588), Ministry of Health & Welfare, Republic
   of South Korea and Samsung Biomedical Research Institute Fund
   (C-A9-310-1).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lee SI, 2008, J GASTROEN HEPATOL, V23, P138, DOI 10.1111/j.1440-1746.2007.05181.x
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park SM, 2007, J CLIN ONCOL, V25, P4835, DOI 10.1200/JCO.2006.10.3416
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sung NY, 2007, BRIT J CANCER, V97, P700, DOI 10.1038/sj.bjc.6603893
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   WONG TY, 2008, OPHTHALMOLOGY   0625
   2002, EPIDEMIOL B, V23, P9
NR 33
TC 48
Z9 48
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2009
VL 16
IS 5
BP 304
EP 310
DI 10.3109/09286580902999413
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 517YG
UT WOS:000271654400006
PM 19874110
DA 2022-11-30
ER

PT J
AU Vavvas, DG
   Small, KW
   Awh, CC
   Zanke, BW
   Tibshirani, RJ
   Kustra, R
AF Vavvas, Demetrios G.
   Small, Kent W.
   Awh, Carl C.
   Zanke, Brent W.
   Tibshirani, Robert J.
   Kustra, Rafal
TI CFH and ARMS2 genetic risk determines progression to neovascular
   age-related macular degeneration after antioxidant and zinc
   supplementation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ophthalmology; macular degeneration; bootstrap validation; genetic
   effect modification; statistical interaction
ID COMPLEMENT FACTOR-H; EYE DISEASE; AREDS SUPPLEMENTS; BETA-CAROTENE;
   ASSOCIATION; BOOTSTRAP; MODELS; GENOTYPES; POLYMORPHISM
AB We evaluated the influence of an antioxidant and zinc nutritional supplement [the Age-Related Eye Disease Study (AREDS) formulation] on delaying or preventing progression to neovascular AMD (NV) in persons with age-related macular degeneration (AMD). AREDS subjects (n = 802) with category 3 or 4 AMD at baseline who had been treated with placebo or the AREDS formulation were evaluated for differences in the risk of progression to NV as a function of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotype groups. We used published genetic grouping: a two-SNP haplotype risk-calling algorithm to assess CFH, and either the single SNP rs10490924 or 372_815del443ins54 to mark ARMS2 risk. Progression risk was determined using the Cox proportional hazard model. Genetics-treatment interaction on NV risk was assessed using a multiiterative bootstrap validation analysis. We identified strong interaction of genetics with AREDS formulation treatment on the development of NV. Individuals with high CFH and no ARMS2 risk alleles and taking the AREDS formulation had increased progression to NV compared with placebo. Those with low CFH risk and high ARMS2 risk had decreased progression risk. Analysis of CFH and ARMS2 genotype groups from a validation dataset reinforces this conclusion. Bootstrapping analysis confirms the presence of a genetics-treatment interaction and suggests that individual treatment response to the AREDS formulation is largely determined by genetics. The AREDS formulation modifies the risk of progression to NV based on individual genetics. Its use should be based on patient-specific genotype.
C1 [Vavvas, Demetrios G.] Harvard Med Sch, Massachusetts Eye & Ear Inst, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA.
   [Small, Kent W.] Macula & Retina Inst, Los Angeles, CA 90048 USA.
   [Awh, Carl C.] Tennessee Retina, Nashville, TN 37203 USA.
   [Zanke, Brent W.] Arctic Med Labs, Dept Med Affairs, Grand Rapids, MI 49504 USA.
   [Tibshirani, Robert J.] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Tibshirani, Robert J.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
   [Kustra, Rafal] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 3M7, Canada.
C3 Harvard University; Harvard Medical School; Stanford University;
   Stanford University; University of Toronto
RP Tibshirani, RJ (通讯作者)，Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.; Tibshirani, RJ (通讯作者)，Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
EM tibs@stanford.edu
OI Vavvas, Demetrios/0000-0002-8622-6478
CR Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Brunelli A, 2006, J THORAC CARDIOV SUR, V131, P1243, DOI 10.1016/j.jtcvs.2006.02.002
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390
   Gerds TA, 2013, STAT MED, V32, P2173, DOI 10.1002/sim.5681
   Henderson AR, 2005, CLIN CHIM ACTA, V359, P1, DOI 10.1016/j.cccn.2005.04.002
   Henning A, 2009, AREDS DBGAP DATA TAB
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kulesa A, 2015, NAT METHODS, V12, P477, DOI 10.1038/nmeth.3414
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Perkins SJ, 2010, BIOCHEM SOC T, V38, P894, DOI 10.1042/BST0380894
   Rodriguez E, 2015, J BIOL CHEM, V290, P2334, DOI 10.1074/jbc.M114.605691
   Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Tibshirani R.J., 1993, MONOGRAPHS STAT APPL, V57, P1
   Wittes J, 2015, OPHTHALMOLOGY, V122, P3, DOI 10.1016/j.ophtha.2014.10.023
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 37
TC 34
Z9 34
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 23
PY 2018
VL 115
IS 4
BP E696
EP E704
DI 10.1073/pnas.1718059115
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FT4BW
UT WOS:000423097800019
PM 29311295
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Burton, AE
   Shaw, RL
   Gibson, JM
AF Burton, Amy E.
   Shaw, Rachel L.
   Gibson, Jonathan M.
TI Living together with age-related macular degeneration: An interpretative
   phenomenological analysis of sense-making within a dyadic relationship
SO JOURNAL OF HEALTH PSYCHOLOGY
LA English
DT Article
DE interpretative phenomenological analysis; older person; phenomenology;
   qualitative methods; well-being
ID QUALITY-OF-LIFE; HEALTH; VISION; IMPACT
AB In this article, we present an idiographic analysis of a couple's experience of living and coming to terms with age-related macular degeneration. Interpretative phenomenological analysis was used to explore three joint interviews, conducted over an 18-month period, with a married couple (aged 82 and 77 years) both living with age-related macular degeneration. Three themes are discussed: the disruption of vision impairment, managing mutual deterioration and resilience through togetherness. We discuss the existential challenges of vision impairment and consider the applicability of Galvin and Todres' typology of well-being as a means of understanding well-being in older adults.
C1 [Burton, Amy E.] Staffordshire Univ, Stoke On Trent ST4 2DF, Staffs, England.
   [Shaw, Rachel L.; Gibson, Jonathan M.] Aston Univ, Birmingham B4 7ET, W Midlands, England.
C3 Staffordshire University; Aston University
RP Burton, AE (通讯作者)，Staffordshire Univ, Ctr Sci, Fac Hlth Sci, Leek Rd, Stoke On Trent ST4 2DF, Staffs, England.
EM amy.burton@staffs.ac.uk
RI Burton, Amy/AAZ-5499-2020; Burton, Amy/GNP-1659-2022; ,
   Rachel/L-9107-2019
OI Burton, Amy/0000-0002-3698-0712; , Rachel/0000-0002-0438-7666; Gibson,
   Jonathan M/0000-0002-9281-5244
FU Aston Research Centre for Healthy Ageing (ARCHA), Aston University
FX This work was supported by a studentship provided by Aston Research
   Centre for Healthy Ageing (ARCHA), Aston University.
CR ALLAN G, 1980, J MARRIAGE FAM, V42, P205, DOI 10.2307/351948
   Arksey Hilary, 1996, SOCIAL RES UPDATE, V15, P1
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Benyamini Y, 2009, BRIT J HEALTH PSYCH, V14, P1, DOI 10.1348/135910708X279288
   Bookwala J, 2011, J GERONTOL B-PSYCHOL, V66, P605, DOI 10.1093/geronb/gbr091
   Bookwala J, 2009, J SOC PERS RELAT, V26, P411, DOI 10.1177/0265407509339995
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Burton AE, 2013, THESIS ASTON U BIRMI
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Charmaz K, 1991, GOOD DAYS BAD DAYS S
   Cornwell EY, 2009, J HEALTH SOC BEHAV, V50, P31, DOI 10.1177/002214650905000103
   Ells C., 2001, SOC THEORY PRACT, V27, P599
   Fine M, 2005, AGEING SOC, V25, P601, DOI 10.1017/S0144686X05003600
   Flyvbjerg B, 2006, QUAL INQ, V12, P219, DOI 10.1177/1077800405284363
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galvin KT, 2011, INT J QUAL STUD HEAL, V6, DOI 10.3402/qhw.v6i4.10362
   Harre R, 1984, PERSONAL BEING THEOR
   Heidegger Martin, 1962, BEING TIME
   Koren C, 2011, GERONTOLOGIST, V51, P687, DOI 10.1093/geront/gnr018
   Lincoln Y., 1985, NEW DIRECTIONS EVALU, V9, P438, DOI DOI 10.1002/EV.1427
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Parsons T, 1951, SOCIAL SYSTEM
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Shepperd D, 2010, FEM PSYCHOL, V20, P205, DOI 10.1177/0959353509349604
   Smith J., 2009, QUAL RES PSYCHOL, DOI DOI 10.1080/14780880903340091
   Spinelli E., 1989, INTERPRETED WORLD IN
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Strawbridge WJ, 2007, J GERONTOL B-PSYCHOL, V62, pS315, DOI 10.1093/geronb/62.5.S315
   Todres L, 2010, INT J QUAL STUD HEAL, V5, DOI 10.3402/qhw.v5i3.5444
   Toombs Kay, 1993, MEANING ILLNESS PHEN
   Yardley L, 2000, PSYCHOL HEALTH, V15, P215, DOI 10.1080/08870440008400302
NR 33
TC 15
Z9 15
U1 1
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1359-1053
EI 1461-7277
J9 J HEALTH PSYCHOL
JI J. Health Psychol.
PD OCT
PY 2015
VL 20
IS 10
BP 1285
EP 1295
DI 10.1177/1359105313511134
PG 11
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA CR0LW
UT WOS:000361011200004
PM 24296740
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gehlbach, P
   Li, TJ
   Hatef, E
AF Gehlbach, Peter
   Li, Tianjing
   Hatef, Elham
TI Statins for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use];
   Macular Degeneration [prevention & control]; Randomized Controlled
   Trials as Topic; Simvastatin [therapeutic use]; Humans
ID REDUCTASE INHIBITORS STATINS; 5-YEAR INCIDENCE; RISK-FACTORS;
   MACULOPATHY; PROGRESSION; PREVALENCE; COHORT
AB Background
   Age-related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age-related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries (Congdon 2003). Recent epidemiologic, genetic and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.
   Objectives
   To examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and/or progression of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 9), MEDLINE (January 1950 to September 2011), EMBASE (January 1980 to September 2011), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to September 2011), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 16 September 2011.
   Selection criteria
   We included randomized controlled trials (RCTs) that compared statins with other treatments, no treatment, or placebo in participants who were either susceptible to or diagnosed as having early stages of AMD.
   Data collection and analysis
   Two authors independently evaluated the search results against the selection criteria. Two Italian speaking colleagues extracted data. One author entered data. We did not perform a meta-analysis because only one completed RCT was identified.
   Main results
   Two studies met the selection criteria. One trial reported insufficient details to assess the risk of bias; the other trial is ongoing.
   Of the completed trial, the analyses of 30 participants did not show a statistically significant difference between the simvastatin and the placebo arm in visual acuity at three months of treatment (decimal visual acuity 0.21 +/- 0.56 in simvastatin and 0.19 +/- 0.40 in placebo arm) or 45 days after the completion of treatment (decimal visual acuity 0.20 +/- 0.50 in simvastatin and 0.19 +/- 0.48 in placebo arm). The lens and retina status were unchanged during and after the treatment period for both groups.
   Of the ongoing trial, the preliminary analyses of 42 participants who completed 12 months follow-up did not show a statistically significant difference between the simvastatin and the placebo arm in visual acuity, drusen score or visual function (effect estimates and confidence intervals were not available). We contacted the investigators and will update the review as data become available.
   Authors' conclusions
   Evidence from currently available RCTs was insufficient to conclude that statins have any role in preventing or delaying the onset or progression of AMD.
C1 [Gehlbach, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21231 USA.
   [Li, Tianjing] Johns Hopkins Bloomberg Sch Publ Hlth, Cochrane Eyes & Vis Grp, US Project, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Gehlbach, P (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.
EM pgelbach@jhmi.edu
FU Johns Hopkins Bloomberg School of Public Health, USA; National Eye
   Institute, National Institutes of Health, USA [N-01-EY-2-1003, 1 U01
   EY020522-01]; NATIONAL EYE INSTITUTE [N01EY021003, U01EY020522] Funding
   Source: NIH RePORTER
FX Internal sources; Johns Hopkins Bloomberg School of Public Health, USA.;
   External sources; Contract N-01-EY-2-1003, National Eye Institute,
   National Institutes of Health, USA.; Grant 1 U01 EY020522-01, National
   Eye Institute, National Institutes of Health, USA.
CR American Academy of Ophthalmology, PREF PRACT PATT GUID
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Decks JJ, 2011, COCHRANE HDB SYSTEMA
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P89
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P249
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Geltzer A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub2
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guymer RH, 2005, INVEST OPHTH VIS SCI, V46
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sagara N, 2007, EXP EYE RES, V84, P1074, DOI 10.1016/j.exer.2007.02.005
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   [The Nordic Cochrane Centre The Cochrane Collaboration], 2011, REV MAN REVMAN 5 1
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 46
TC 8
Z9 9
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 3
AR CD006927
DI 10.1002/14651858.CD006927.pub3
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 908QQ
UT WOS:000301505600062
PM 22419318
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tan, W
   Zou, JL
   Yoshida, S
   Jiang, B
   Zhou, YD
AF Tan, Wei
   Zou, Jingling
   Yoshida, Shigeo
   Jiang, Bing
   Zhou, Yedi
TI The Role of Inflammation in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Review
DE inflammation; cytokine; leukocyte; age-related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; C-REACTIVE PROTEIN; ANTI-VEGF THERAPY;
   CHOROIDAL NEOVASCULARIZATION; AQUEOUS-HUMOR; DENDRITIC CELLS; T-CELLS;
   MESENCHYMAL TRANSITION; CIRCULATING MONOCYTES; BRUCHS MEMBRANE
AB Age-related macular degeneration (AMD) is a blinding eye disease which incidence gradually increases with age. Inflammation participates in AMD pathogenesis, including choroidal neovascularization and geographic atrophy. It is also a kind of self-protective regulation from injury for the eyes. In this review, we described inflammation in AMD pathogenesis, summarized the roles played by inflammation-related cytokines, including pro-inflammatory and anti-inflammatory cytokines, as well as leukocytes (macrophages, dendritic cells, neutrophils, T lymphocytes and B lymphocytes) in the innate or adaptive immunity in AMD. Possible clinical applications such as potential diagnostic biomarkers and anti-inflammatory therapies were also discussed. This review overviews the inflammation as a target of novel effective therapies in treating AMD.
C1 [Tan, Wei; Zou, Jingling; Jiang, Bing; Zhou, Yedi] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
   [Tan, Wei; Zou, Jingling; Jiang, Bing; Zhou, Yedi] Hunan Clin Res Ctr Ophthalm Dis, Changsha 410011, Hunan, Peoples R China.
   [Yoshida, Shigeo] Kurume Univ, Dept Ophthalmol, Sch Med, Kurume, Fukuoka 8300011, Japan.
C3 Central South University; Kurume University
RP Zhou, YD (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
EM zhouyedi@csu.edu.cn
OI Tan, Wei/0000-0002-3854-7576; Zhou, Yedi/0000-0002-8948-1108
FU National Natural Science Foundation of China [81800855, 81770930];
   Natural Science Foundation of Hunan Province [2018JJ3765]; Changsha
   Science and Technology Project [kq1907075]; Department of Science and
   Technology, Hunan [2015TP2007]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81800855 and 81770930), Natural Science Foundation of Hunan
   Province (No. 2018JJ3765), Changsha Science and Technology Project (No.
   kq1907075) and Department of Science and Technology, Hunan (No.
   2015TP2007).
CR Afarid M, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_363_18
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambreen F, 2015, MOL VIS, V21, P985
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Bai YJ, 2014, MOL VIS, V20, P1258
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024
   Boshtam M, 2017, INFLAMMATION, V40, P340, DOI 10.1007/s10753-016-0477-1
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Catarino S, 2012, ACTA OPHTHALMOL, V90, pE255, DOI 10.1111/j.1755-3768.2011.02350.x
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen JJ, 2016, APMIS, V124, P406, DOI 10.1111/apm.12511
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15029
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chung SH, 2020, MOL THER-METH CLIN D, V17, P409, DOI 10.1016/j.omtm.2020.01.006
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Du ZJ, 2016, GRAEF ARCH CLIN EXP, V254, P2469, DOI 10.1007/s00417-016-3508-6
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Forrester JV, 2005, BRIT J OPHTHALMOL, V89, P369, DOI 10.1136/bjo.2004.054197
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Han XK, 2020, EUR J EPIDEMIOL, V35, P139, DOI 10.1007/s10654-019-00598-z
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880
   Heuss ND, 2012, J IMMUNOL, V188, P1191, DOI 10.4049/jimmunol.1101621
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Holmgaard Andreas, 2019, Methods Mol Biol, V1961, P307, DOI 10.1007/978-1-4939-9170-9_19
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jiang K, 2013, J CLIN EXP OPHTHA S2
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jing RH, 2019, DEV GROWTH DIFFER, V61, P410, DOI 10.1111/dgd.12630
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Keino H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1679197
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kivinen Niko, 2017, Duodecim, V133, P641
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441-017-2753-2
   Kumari A, 2018, BIOMED PHARMACOTHER, V103, P662, DOI 10.1016/j.biopha.2018.04.046
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   LeBlanc ME, 2019, EXP EYE RES, V181, P120, DOI 10.1016/j.exer.2019.01.009
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018
   Lin W, 2019, IMMUNOL LETT, V209, P4, DOI 10.1016/j.imlet.2019.03.016
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu BY, 2010, MOL VIS, V16, P184
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luk HY, 2016, EUR J APPL PHYSIOL, V116, P2007, DOI 10.1007/s00421-016-3452-5
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Qin TY, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5392432
   Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sato Kota, 2018, Immunol Med, V41, P23, DOI 10.1080/09114300.2018.1451609
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Schwarzer P, 2020, AM J PATHOL, V190, P412, DOI 10.1016/j.ajpath.2019.10.011
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shen EM, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43027
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Wang HB, 2016, MOL VIS, V22, P116
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Wu QW, 2019, MOL IMMUNOL, V114, P243, DOI 10.1016/j.molimm.2019.07.028
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Wu WY, 2017, INVEST OPHTH VIS SCI, V58, P6082, DOI 10.1167/iovs.17-21902
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Xu NN, 2019, INVEST OPHTH VIS SCI, V60, P4596, DOI 10.1167/iovs.19-27493
   Yang IH, 2015, INVEST OPHTH VIS SCI, V56, P761, DOI 10.1167/iovs.14-15299
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131429
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
   Zhou YD, 2017, MOL MED REP, V15, P3949, DOI 10.3892/mmr.2017.6491
NR 168
TC 42
Z9 43
U1 2
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 15
BP 2989
EP 3001
DI 10.7150/ijbs.49890
PG 13
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA NY8MZ
UT WOS:000576638400017
PM 33061811
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rim, TH
   Lee, CS
   Lee, SC
   Kim, DW
   Kim, SS
AF Rim, Tyler Hyungtaek
   Lee, Christopher Seungkyu
   Lee, Sung Chul
   Kim, Do Wook
   Kim, Sung Soo
TI INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION AND THE RISK OF STROKE A National Sample Cohort Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; NHIS-NSC 2002 to 2013; ranibizumab;
   stroke
ID GROWTH-FACTOR INHIBITORS; VERTEPORFIN PHOTODYNAMIC THERAPY;
   CEREBROVASCULAR ACCIDENTS; CARDIOVASCULAR-DISEASE;
   MYOCARDIAL-INFARCTION; MORTALITY; EVENTS; RATES
AB Purpose: To evaluate the risk of stroke after ranibizumab treatment for neovascular age-related macular degeneration.
   Methods: National registry data for 1,025,340 random subjects in the year 2002 were used. The ranibizumab group comprised patients diagnosed with neovascular age-related macular degeneration and treated with ranibizumab between 2009 and 2013 (n = 467). The two types of comparison groups were defined as comorbidity-matched controls (n = 2,330) comprised of randomly selected patients (5 per age-related macular degeneration patient), who were matched to the ranibizumab group according to sociodemographic factors, hypertension, atrial fibrillation, and the Charlson comorbidities index, and sociodemographic-matched controls (n = 2,331) matched according to sociodemographic factors only. Each sampled patient was tracked until 2013. The Cox proportional hazard regression was used.
   Results: Stroke occurred in 6.6% of the ranibizumab group versus 7.0% of the comorbiditymatched controls and 6.7% of the sociodemographic-matched controls; these differences were not statistically significant. The overall incidence of stroke was similar for the ranibizumab group versus the comorbidity-matched controls and sociodemographic-matched controls, based on the multivariable Cox regression (hazard ratio = 0.88; 95% confidence interval, 0.60-1.30; hazard ratio = 0.95, 95% confidence interval, 0.64-1.41, respectively).
   Conclusion: Ranibizumab treatment for neovascular age-related macular degeneration did not increase the overall risk of stroke, compared with comorbidity-matched controls or sociodemographic-matched controls.
C1 [Rim, Tyler Hyungtaek] Yonsei Univ, Coll Med, Natl Hlth Insurance Serv Ilsan Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Christopher Seungkyu; Lee, Sung Chul; Kim, Do Wook; Kim, Sung Soo] Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, 50 Yonsei Ro, Seoul 120752, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Coll Med, Yonsei Healthcare Big Data Based Knowledge Integr, Seoul, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Coll Med, Inst Convergence Sci, Seoul, South Korea.
C3 National Health Insurance Service; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kim, SS (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, 50 Yonsei Ro, Seoul 120752, South Korea.
EM semekim@yuhs.ac
OI Rim, Tyler Hyungtaek/0000-0001-6465-2620; Lee,
   Christopher/0000-0001-5054-9470; , Sung Chul/0000-0001-9438-2385; Kim,
   Sung Soo/0000-0002-0574-7993; Kim, Sung Soo/0000-0003-3049-9554
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Lee J., 2016, INT J EPIDEMIOL
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Moorthy S, 2009, OPHTHALMOLOGY, V116, P1834, DOI 10.1016/j.ophtha.2009.04.008
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 24
TC 17
Z9 17
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2166
EP 2174
DI 10.1097/IAE.0000000000001084
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800024
PM 27341664
DA 2022-11-30
ER

PT J
AU Gragoudas, ES
   Adamis, AP
   Cunningham, ET
   Feinsod, M
   Guyer, DR
AF Gragoudas, ES
   Adamis, AP
   Cunningham, ET
   Feinsod, M
   Guyer, DR
CA VEGF Inhibition Study Ocular Neova
TI Pegaptanib for neovascular age-related macular degeneration
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; NONHUMAN PRIMATE; IRIS NEOVASCULARIZATION;
   INHIBITION; RNA
AB BACKGROUND:
   Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.
   METHODS:
   We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria. Intravitreous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks. The primary end point was the proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks.
   RESULTS:
   In the combined analysis of the primary end point (for a total of 1186 patients), efficacy was demonstrated, without a dose-response relationship, for all three doses of pegaptanib (P<0.001 for the comparison of 0.3 mg with sham injection; P<0.001 for the comparison of 1.0 mg with sham injection; and P=0.03 for the comparison of 3.0 mg with sham injection). In the group given pegaptanib at 0.3 mg, 70 percent of patients lost fewer than 15 letters of visual acuity, as compared with 55 percent among the controls (P<0.001). The risk of severe loss of visual acuity (loss of 30 letters or more) was reduced from 22 percent in the sham-injection group to 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001). More patients receiving pegaptanib (0.3 mg), as compared with sham injection, maintained their visual acuity or gained acuity (33 percent vs. 23 percent; P=0.003). As early as six weeks after beginning therapy with the study drug, and at all subsequent points, the mean visual acuity among patients receiving 0.3 mg of pegaptanib was better than in those receiving sham injections (P<0.002). Among the adverse events that occurred, endophthalmitis (in 1.3 percent of patients), traumatic injury to the lens (in 0.7 percent), and retinal detachment (in 0.6 percent) were the most serious and required vigilance. These events were associated with a severe loss of visual acuity in 0.1 percent of patients.
   CONCLUSIONS:
   Pegaptanib appears to be an effective therapy for neovascular age-related macular degeneration. Its long-term safety is not known.
C1 Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA.
   Eyetech Pharmaceut, New York, NY USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary
RP Gragoudas, ES (通讯作者)，Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM evangelos_gragoudas@meei.harvard.edu
RI Larsen, Michael/E-9620-2010; Schlingemann, Reinier/E-6287-2013
OI Larsen, Michael/0000-0002-5172-5891; 
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gass J.D., 1967, AM J OPHTHALMOL, V63, pS1
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
NR 24
TC 1804
Z9 1939
U1 1
U2 118
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 30
PY 2004
VL 351
IS 27
BP 2805
EP 2816
DI 10.1056/NEJMoa042760
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 883IH
UT WOS:000226004300005
PM 15625332
OA Green Published
DA 2022-11-30
ER

PT J
AU Elguezabal-Rodelo, RG
   Ochoa-Precoma, R
   Porchia, LM
   Perez-Fuentes, R
   Gonzalez-Mejia, ME
AF Elguezabal-Rodelo, Rebeca G.
   Ochoa-Precoma, Renata
   Porchia, Leonardo M.
   Perez-Fuentes, Ricardo
   Elba Gonzalez-Mejia, M.
TI Association between the L55M and Q192R polymorphisms of the
   paraoxonase-1 gene and age-related macular degeneration: a meta-analysis
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Ethnic groups; Macular degeneration; Polymorphism, genetic;
   Paraoxonase-1; Aryldialkylphosphatase
ID ASIAN POPULATIONS; RISK-FACTORS; PON1; SUSCEPTIBILITY; ADULTS; LEVEL;
   BLOOD; INUIT
AB Purpose: Paraoxonase-1 activity is associated with age-related macular degeneration. Two polymorphisms (L55M and Q192R) were shown to increase paraoxonase-1 activity and have been implicated in the development of age-related macular degeneration. The results of studies that have examined these polymorphisms are conflicting, showing no effect, as well as increased or decreased risk. Therefore, this meta-analysis was conducted to determine the effect of these polymorphisms on age-related macular degeneration. Methods: PubMed, EBSCO, LILACS, and Scopus databases, as well as and the retrieved bibliographies of publications were searched for case-control studies that examined for paraoxonase-1 polymorphisms and age-related macular degeneration. Data were analyzed using the Comprehensive Meta-Analysis Version 2.2 and the NCSS Statistical Version 2020 software. Genotype distributions were extracted and, depending on the level of heterogeneity, fixed effects or random effects models were used to calculate pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) for the heterozygous, homozygous, dominant, recessive, and allelic genetic models. Results: Overall, for the L55M polymorphism, none of the genetic models demonstrated a significant association. However, for non-Asian populations, a significant association was determined for the heterozygous and dominant genetic models (ORrange=1.24-1.27, p<0.05). For the Asian population, the heterozygous, dominant, and allelic genetic models demonstrated a benefit/protective factor (ORrange=0.29-0.35, p<0.05). For the Q192R polymorphism, none of the genetic models demonstrated a significant association. However, when the cohort was grouped by ethnicity, a significant association was determined in the Asian population for the recessive and allelic genetic models (ORrange=1.63-2.08, p<0.05). However, for the non-Asian population, there was no association observed. Also, there was no identifiable risk when the cohort was stratified into exudative and non-exudative cases. Conclusions: The paraoxonase-1L55M polymorphism increases the risk of developing age-related macular degeneration in non-Asian populations, whereas in Asian populations, the polymorphism exerts a protective effect. However, for the paraoxonase-1 Q192R polymorphism, only the Asian population demonstrated a risk of developing age-related macular degeneration.
C1 [Elguezabal-Rodelo, Rebeca G.; Ochoa-Precoma, Renata; Perez-Fuentes, Ricardo; Elba Gonzalez-Mejia, M.] Benemerita Univ Autonoma Puebla, Fac Med, Puebla, Mexico.
   [Porchia, Leonardo M.; Perez-Fuentes, Ricardo] Inst Mexicano Seguro Social, Ctr Invest Biomed Oriente, Lab Invest Fisiopatol Enfermedades Cron, Puebla, Mexico.
C3 Benemerita Universidad Autonoma de Puebla; Instituto Mexicano del Seguro
   Social
RP Gonzalez-Mejia, ME (通讯作者)，Benemerita Univ Autonoma Puebla, Fac Med, Puebla, Mexico.
EM elba.gonzalezmejia@gmail.com
OI Ochoa-Precoma, Renata/0000-0002-2259-4562
FU Vicerrectoria de Investigacion of Benemerita Universidad Autonoma de
   Puebla [10051909-VIEP2018, 100170644-VIEP2019]
FX This study was supported by Vicerrectoria de Investigacion of Benemerita
   Universidad Autonoma de Puebla (10051909-VIEP2018 to MEGM and
   100170644-VIEP2019 to RPF).
CR Ali SM, 2008, IND HEALTH, V46, P309, DOI 10.2486/indhealth.46.309
   AnandBabu K, 2016, EXP EYE RES, V152, P100, DOI 10.1016/j.exer.2016.09.009
   Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617
   Awata H, 2017, ENVIRON HEALTH PERSP, V125, P306, DOI 10.1289/EHP27
   Ayotte P, 2011, ENVIRON HEALTH PERSP, V119, P1077, DOI 10.1289/ehp.1003296
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Costa LG, 2013, TOXICOLOGY, V307, P115, DOI 10.1016/j.tox.2012.07.011
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Ginsberg G, 2014, J TOXICOL ENV HEAL A, V77, P1004, DOI 10.1080/15287394.2014.919837
   Hogg RE, 2019, OPHTHALMOLOGY, V126, P391, DOI 10.1016/j.ophtha.2018.09.032
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Laird BD, 2015, CHEMOSPHERE, V120, P479, DOI 10.1016/j.chemosphere.2014.08.073
   Leviev I, 1997, ARTERIOSCL THROM VAS, V17, P2935, DOI 10.1161/01.ATV.17.11.2935
   Liu YY, 2018, ENVIRON RES, V160, P212, DOI 10.1016/j.envres.2017.09.031
   Luo JQ, 2018, J CELL MOL MED, V22, P1720, DOI 10.1111/jcmm.13453
   Otocka-Kmiecik A, 2009, POSTEP HIG MED DOSW, V63, P668
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Permpongpaiboon T, 2011, HUM EXP TOXICOL, V30, P1196, DOI 10.1177/0960327110388536
   Saadat M., 2018, ROM J DIABETES NUTR, V25, P171, DOI DOI 10.2478/RJDNMD-2018-0020
   Sogut E, 2013, RETINA-J RET VIT DIS, V33, P1836, DOI 10.1097/IAE.0b013e318287da59
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomatir AG, 2015, ANTICANCER RES, V35, P4807
   Tomi A, 2014, J Med Life, V7 Spec No. 4, P4
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 30
TC 0
Z9 0
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2021
VL 84
IS 3
BP 249
EP 257
DI 10.5935/0004-2749.20210033
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL8II
UT WOS:000657156800010
PM 33567022
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Moisseiev, E
   Loewenstein, A
AF Moisseiev, Elad
   Loewenstein, Anat
TI Novel Long-acting Pharmacotherapy for Exudative Age Related Macular
   Degeneration
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Age related macular degeneration; long term; long acting; intravitreal
   therapy; anti-VEGF agents; pharmacotherapy
ID ENDOTHELIAL GROWTH-FACTOR; SINGLE INTRAVITREAL INJECTION; INTRAOCULAR
   PHARMACOKINETICS; RETINAL PROSTHESES; RANIBIZUMAB; AFLIBERCEPT;
   PREVALENCE; MACULOPATHY; BEVACIZUMAB; DELIVERY
AB Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.
C1 [Moisseiev, Elad] Meir Med Ctr, Dept Ophthalmol, 59 Tchernichovsky St, IL-4428164 Kefar Sava, Israel.
   [Moisseiev, Elad; Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Loewenstein, Anat] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Moisseiev, E (通讯作者)，Meir Med Ctr, Dept Ophthalmol, 59 Tchernichovsky St, IL-4428164 Kefar Sava, Israel.
EM elad_moi@netvision.net.il
RI Yiu, Glenn/AAF-2858-2020
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Bravo-Osuna I, 2018, ADV DRUG DELIVER REV, V126, P127, DOI 10.1016/j.addr.2018.01.007
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Chakravarthy U, 2017, OPHTHALMOL RETI 0523
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Gavini E, 2018, CURR DRUG DELIV, V15, P930, DOI 10.2174/1567201815666180226121020
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kelly SJ, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030092
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lin TC, 2015, J CHIN MED ASSOC, V78, P501, DOI 10.1016/j.jcma.2015.05.010
   Maghami Mohammad Hossein, 2014, J Ophthalmic Vis Res, V9, P494, DOI 10.4103/2008-322X.150830
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pearce W, 2015, CURR OPIN OPHTHALMOL, V26, P233, DOI 10.1097/ICU.0000000000000143
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Weiland JD, 2011, OPHTHALMOLOGY, V118, P2227, DOI 10.1016/j.ophtha.2011.08.042
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 43
TC 2
Z9 2
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2018
VL 24
IS 41
BP 4860
EP 4863
DI 10.2174/1381612825666190123165216
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HP5XU
UT WOS:000461757700005
PM 30674249
DA 2022-11-30
ER

PT J
AU Joachim, N
   Colijn, JM
   Kifley, A
   Lee, KE
   Buitendijk, GHS
   Klein, BEK
   Myers, CE
   Meuer, SM
   Tan, AG
   Holliday, EG
   Attia, J
   Liew, G
   Iyengar, SK
   de Jong, PTVM
   Hofman, A
   Vingerling, JR
   Mitchell, P
   Klaver, CCW
   Klein, R
   Wang, JJ
AF Joachim, Nichole
   Colijn, Johanna Maria
   Kifley, Annette
   Lee, Kristine E.
   Buitendijk, Gabrielle H. S.
   Klein, Barbara E. K.
   Myers, Chelsea E.
   Meuer, Stacy M.
   Tan, Ava G.
   Holliday, Elizabeth G.
   Attia, John
   Liew, Gerald
   Iyengar, Sudha K.
   de Jong, Paulus T. V. M.
   Hofman, Albert
   Vingerling, Johannes R.
   Mitchell, Paul
   Klaver, Caroline C. W.
   Klein, Ronald
   Wang, Jie Jin
TI Five-year progression of unilateral age-related macular degeneration to
   bilateral involvement: the Three Continent AMD Consortium report
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; 10-YEAR INCIDENCE; MACULOPATHY;
   RISK; ROTTERDAM; PREVALENCE; SMOKING
AB Purpose To assess the 5-year progression from unilateral to bilateral age-related macular degeneration (AMD) and associated risk factors.
   Design Pooled data analyses of three prospective population-based cohorts, the Blue Mountains Eye Study, Beaver Dam Eye Study and Rotterdam Study.
   Methods Retinal photography and interview with comprehensive questionnaires were conducted at each visit of three studies. AMD was assessed following the modified Wisconsin AMD grading protocol. Progression to bilateral any (early and late) or late AMD was assessed among participants with unilateral involvement only. Factors associated with the progression were assessed using logistic regression models while simultaneously adjusting for other significant risk factors.
   Results In any 5-year duration, 19-28% of unilateral any AMD cases became bilateral and 27-68% of unilateral late AMD became bilateral. Factors associated with the progression to bilateral involvement of any AMD were age (per year increase, adjusted OR 1.07), carrying risk alleles of the complement factor H and age-related maculopathy susceptibility 2 genes (compared with none, OR 1.76 for 1 risk allele and OR 3.34 for 2+ risk alleles), smoking (compared with non-smokers, OR 1.64 for past and OR 1.67 for current smokers), and the presence of large drusen area or retinal pigmentary abnormalities in the first eye.
   Conclusion One in four to one in five unilateral any AMD cases, and up to one in two unilateral late AMD cases, progressed to bilateral in 5 years. Known AMD risk factors, including smoking, are significantly associated with the progression to bilateral involvement.
C1 [Joachim, Nichole; Kifley, Annette; Tan, Ava G.; Liew, Gerald; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
   [Colijn, Johanna Maria; Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna Maria; Buitendijk, Gabrielle H. S.; Hofman, Albert; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Lee, Kristine E.; Klein, Barbara E. K.; Myers, Chelsea E.; Meuer, Stacy M.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Holliday, Elizabeth G.; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia.
   [Holliday, Elizabeth G.; Attia, John] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia.
   [Attia, John] John Hunter Hosp, Dept Med, Newcastle, NSW, Australia.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci KNAW, Netherlands Inst Neurosci, Dept Ophthalmol AMC, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] LUMC, Leiden, Netherlands.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
   [Klaver, Caroline C. W.] Radboudumc, Dept Ophthalmol, Nijmegen, Netherlands.
C3 University of Sydney; Westmead Institute for Medical Research; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; University of Wisconsin System; University of Wisconsin Madison;
   University of Newcastle; University of Newcastle; John Hunter Hospital;
   Hunter Medical Research Institute; University of Newcastle; Case Western
   Reserve University; Royal Netherlands Academy of Arts & Sciences;
   Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University
   Nijmegen
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI /S-1190-2019; wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Liew,
   Gerald/AAB-6870-2022; Attia, John R/F-5376-2013; Klaver, Caroline
   C.W./A-2013-2016; Wang, Jie Jin/P-1499-2014
OI /0000-0001-7488-250X; Attia, John R/0000-0001-9800-1308; Wang, Jie
   Jin/0000-0001-9491-4898; Klaver, Caroline/0000-0002-2355-5258; Tan, Ava
   Grace/0000-0003-3344-0339
FU National Health and Medical Research Council (Canberra, Australia)
   [512423, 590204]; National Health and Medical Research Council (NHMRC),
   Canberra, Australia (NHMRC) [974159, 211069, 457349, 302068]; National
   Health and Medical Research Council (NHMRC), Canberra, Australia (Centre
   for Clinical Research Excellence in Translational Clinical Research in
   Eye Diseases, CCRE in TCR-Eye) [529923]; NHMRC, Canberra, Australia
   (NHMRC) [512423, 475604, 529912]; Wellcome Trust, UK as part of Wellcome
   Trust Case Control Consortium 2 [085475/B/08/Z, 085475/08/Z]; National
   Institutes of Health (NIH) [EY006594]; NIH Research Vision Core grant
   [EY016665]; Research to Prevent Blindness, New York, NY; Erasmus Medical
   Center, Rotterdam; Erasmus University, Rotterdam; Netherlands
   Organization for the Health Research and Development (ZonMw); Research
   Institute for Diseases in the Elderly (RIDE); Ministry of Education,
   Culture and Science; Ministry for Health, Welfare and Sports; European
   Commission (DG XII); Municipality of Rotterdam; Rotterdamse Stichting
   Blindenbelangen, Rotterdam; Macula Fonds, Utrecht; Henkes Stichting,
   Rotterdam; Stichting Oogfonds Nederland, Utrecht; Landelijke Stichting
   voor Blinden en Slechtzienden, Utrecht; NHMRC (Canberra, Australia)
   Senior Research Fellowship [358702, 632909]; NHMRC Australia; NIH;
   NATIONAL EYE INSTITUTE [P30EY016665, U10EY006594] Funding Source: NIH
   RePORTER
FX This work was supported by the National Health and Medical Research
   Council (Canberra, Australia) (Project Grant IDs 512423 and 590204 to
   JJW). The Blue Mountains Eye Study (BMES) was supported by the National
   Health and Medical Research Council (NHMRC), Canberra, Australia (NHMRC
   project grant IDs 974159, 211069, 457349, 302068, and Centre for
   Clinical Research Excellence in Translational Clinical Research in Eye
   Diseases, CCRE in TCR-Eye, grant ID 529923). The BMES GWAS and
   genotyping costs was supported by the NHMRC, Canberra, Australia (NHMRC
   project grant IDs 512423, 475604 and 529912), and the Wellcome Trust, UK
   as part of Wellcome Trust Case Control Consortium 2 (A Viswanathan, P
   McGuffin, P Mitchell, F Topouzis, P Foster, grant IDs 085475/B/08/Z and
   085475/08/Z). The Beaver Dam Eye Study was supported by National
   Institutes of Health (NIH) grant EY006594 (BEK Klein and R Klein), an
   NIH Research Vision Core grant EY016665, and, in part, by an
   unrestricted grant from Research to Prevent Blindness, New York, NY. The
   Rotterdam Study (RS) was supported by Erasmus Medical Center and Erasmus
   University, Rotterdam, Netherlands Organization for the Health Research
   and Development (ZonMw), the Research Institute for Diseases in the
   Elderly (RIDE), the Ministry of Education, Culture and Science, the
   Ministry for Health, Welfare and Sports, the European Commission (DG
   XII), and the Municipality of Rotterdam. In addition, the RS was
   supported by Rotterdamse Stichting Blindenbelangen, Rotterdam; Macula
   Fonds, Utrecht; Henkes Stichting, Rotterdam; Stichting Oogfonds
   Nederland, Utrecht; and Landelijke Stichting voor Blinden en
   Slechtzienden, Utrecht. JJW is funded by a NHMRC (Canberra, Australia)
   Senior Research Fellowship (Grant ID 358702, 2005-2009 and ID 632909,
   2010-2015). NHMRC Australia, the NIH and other funding bodies mentioned
   above had no role in the design or conduct of this research.
CR Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
NR 27
TC 25
Z9 25
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2017
VL 101
IS 9
BP 1185
EP 1192
DI 10.1136/bjophthalmol-2016-309729
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE5BJ
UT WOS:000408226700007
PM 28108569
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Valberg, A
   Fosse, P
AF Valberg, A
   Fosse, P
TI Binocular contrast inhibition in subjects with age-related macular
   degeneration
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID LOW VISION; SENSITIVITY; PERFORMANCE; SUMMATION; PSYCHOPHYSICS;
   MACULOPATHY; EYE
AB In subjects with normal vision, binocular contrast sensitivity is generally higher than monocular sensitivity, indicating summation of contrast in the two eyes. We have compared monocular and binocular contrast sensitivity and acuity for a group of 13 subjects with age-related macular degeneration (AMD). Relative to a normal control group, many of the AMD subjects showed reduced binocular contrast summation, and binocular inhibition was found for eight subjects for a narrow or an extended frequency band. A better monocular than binocular function may have practical implications for reading and orientation in AMD. (C) 2002 Optical Society of America.
C1 Norwegian Univ Sci & Technol, Dept Phys, Biophys Sect, N-7491 Trondheim, Norway.
   Tambartun Natl Resource Ctr Visually Impaired, N-7224 Melhus, Norway.
C3 Norwegian University of Science & Technology (NTNU)
RP Valberg, A (通讯作者)，Norwegian Univ Sci & Technol, Dept Biophys, N-7491 Trondheim, Norway.
CR Applegate RA, 1998, J REFRACT SURG, V14, P397, DOI 10.3928/1081-597X-19980701-05
   BROWN B, 1981, AM J OPTOM PHYS OPT, V58, P218
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   CAMPBELL FW, 1965, NATURE, V208, P191, DOI 10.1038/208191a0
   CORNELISSEN FW, 1995, VISION RES, V35, P161, DOI 10.1016/0042-6989(94)00183-M
   CORNELISSEN FW, 1994, LOW VISION RES DEV R
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Fechner G.T., 1966, INTRO FECHNER
   Fosse P, 2001, OPTOMETRY VISION SCI, V78, P162, DOI 10.1097/00006324-200103000-00009
   FOSSE P, UNPUB CONTRAST SENSI
   GILCHRIST J, 1985, VISION RES, V25, P609, DOI 10.1016/0042-6989(85)90167-1
   GILCHRIST J, 1987, OPHTHAL PHYSL OPT, V7, P373
   GJERDE T, 1997, THESIS NORWEGIAN U S
   HYVARINEN L, 1989, CHIBRET INT J OPHTHA, V6, P1
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   LEGGE GE, 1984, VISION RES, V24, P385, DOI 10.1016/0042-6989(84)90064-6
   LEGGE GE, 1984, VISION RES, V24, P373, DOI 10.1016/0042-6989(84)90063-4
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   PARDHAN S, 1991, CLIN VISION SCI, V6, P355
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   VALBERG A, 1994, OPTIKEREN, V4, P3
   Van der Schaft T.L., 1993, THESIS ERASMUS U ROT
   VANMEETEREN A, 1972, VISION RES, V12, P825, DOI 10.1016/0042-6989(72)90008-9
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 29
TC 36
Z9 37
U1 1
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0740-3232
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD JAN
PY 2002
VL 19
IS 1
BP 223
EP 228
DI 10.1364/JOSAA.19.000223
PG 6
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 505TA
UT WOS:000172930600031
PM 11778728
DA 2022-11-30
ER

PT J
AU Holz, FG
   Schmitz-Valckenberg, S
   Fleckenstein, M
AF Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
TI Recent developments in the treatment of age-related macular degeneration
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY;
   CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; RISK; VEGF; BLINDNESS;
   THERAPY; VARIANT
AB Age-related macular degeneration (AMD) is a common cause of visual loss in the elderly, with increasing prevalence due to increasing life expectancy. While the introduction of anti-VEGF therapy has improved outcomes, there are still major unmet needs and gaps in the understanding of underlying biological processes. These include early, intermediate, and atrophic disease stages. Recent studies have assessed therapeutic approaches addressing various disease-associated pathways, including complement inhibitors. Drug-delivery aspects are also relevant, as many agents have to be administered repeatedly. Herein, relevant pathogenetic factors and underlying mechanisms as well as recent and potential therapeutic approaches are reviewed.
C1 [Holz, Frank G.; Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU Federal Ministry of Education and Research (BMBF), Germany [FKZ
   13N10349]; German Research Foundation (DFG) [Ho1926/1-3, FL658/4-1];
   Research Commission of the Medical Faculty at Bonn University (BONFOR)
   [O-137-0012]
FX The authors gratefully acknowledge support and funding from the Federal
   Ministry of Education and Research (BMBF), Germany (grant FKZ 13N10349),
   the German Research Foundation (DFG) (grants Ho1926/1-3 and FL658/4-1),
   and the Research Commission of the Medical Faculty at Bonn University
   (BONFOR) (grant O-137-0012).
CR Barakat M, 2013, AGE RELATED MACULAR
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulton M.E., 2013, AGE RELATED MACULAR, P45
   Boyer D, 2013, INVEST OPHTH VIS SCI, V54
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fritsche L, 2013, AGE RELATED MACULAR, P33
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grisanti S, 2013, AGE RELATED MACULAR, P225
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz F., 2013, 13 EUR C SEPT 27 HAM
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lutty G, 2013, INVEST OPHTH VIS SCI, V54
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mitchell P, 2013, AGE RELATED MACULAR
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sivaprasad S, 2013, INVEST OPHTH VIS SCI, V54
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thumann G., 2013, RETINA, P401
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   Wolf S., 2011, INVEST OPHTH VIS SCI, V52, P1655
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2013, OPHTHALMOLOGY
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 85
TC 128
Z9 143
U1 0
U2 38
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2014
VL 124
IS 4
BP 1430
EP 1438
DI 10.1172/JCI71029
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AE1IQ
UT WOS:000333723400004
PM 24691477
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Elsner, AE
   Weber, A
   Cheney, MC
   VanNasdale, DA
   Miura, M
AF Elsner, Ann E.
   Weber, Anke
   Cheney, Michael C.
   VanNasdale, Dean A.
   Miura, Masahiro
TI Imaging polarimetry in patients with neovascular age-related macular
   degeneration
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID SUBRETINAL STRUCTURES; IMPROVED CONTRAST; BIREFRINGENCE; TOMOGRAPHY
AB Imaging polarimetry was used to examine different components of neovascular membranes in age-related macular degeneration. Retinal images were acquired with a scanning laser polarimeter. An innovative pseudo-color scale, based on cardinal directions of color, displayed two types of image information: relative phases and magnitudes of birefringence. Membranes had relative phase changes that did not correspond to anatomical structures in reflectance images. Further, membrane borders in depolarized light images had significantly higher contrasts than those in reflectance images. The retinal birefringence in neovascular membranes indicates optical activity consistent with molecular changes rather than merely geometrical changes. (C) 2007 Optical Society of America.
C1 Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
   Rhein Westfal TH Aachen, Univ Hosp, D-52074 Aachen, Germany.
   Atlantis Components Inc, Cambridge, MA 02141 USA.
   Tokyo Med Univ, Shinjuku Ku, Tokyo 1600023, Japan.
C3 Indiana University System; Indiana University Bloomington; RWTH Aachen
   University; RWTH Aachen University Hospital; Tokyo Medical University
RP Elsner, AE (通讯作者)，Indiana Univ, Sch Optometry, 800 E Atwater Ave, Bloomington, IN 47405 USA.
EM aeelsner@indiana.edu
FU NATIONAL EYE INSTITUTE [R29EY007624, R01EY007624] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY007624, R01 EY007624] Funding Source: Medline;
   PHS HHS [E002346] Funding Source: Medline
CR Bairaktaris G, 1998, CORNEA, V17, P396, DOI 10.1097/00003226-199807000-00010
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   Elsner AE, 2000, OPT EXPRESS, V7, P95, DOI 10.1364/OE.7.000095
   Elsner AE, 2004, STUD HEALTH TECHNOL, V98, P89
   Elsner AE, 2003, ST HEAL T, V94, P59
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   ELSNER AE, 1986, J OPT SOC AM A, V3, P916, DOI 10.1364/JOSAA.3.000916
   Grossniklaus HE, 2006, OPHTHALMOLOGY, V113, P267, DOI 10.1016/j.ophthzi.2005.10.031
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Hansen T, 2006, J VISION, V6, P239, DOI 10.1167/6.3.5
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hunter DG, 1999, J OPT SOC AM A, V16, P2103, DOI 10.1364/JOSAA.16.002103
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2002, RETINA-J RET VIT DIS, V22, P300, DOI 10.1097/00006982-200206000-00008
   Miura M, 2001, OPT EXPRESS, V9, P436, DOI 10.1364/OE.9.000436
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
   WEBER A, 2006, EYE
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 23
TC 49
Z9 49
U1 0
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD MAY
PY 2007
VL 24
IS 5
BP 1468
EP 1480
DI 10.1364/JOSAA.24.001468
PG 13
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 160II
UT WOS:000245933700026
PM 17429494
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, HJ
   Ahn, SJ
   Woo, SJ
   Hong, HK
   Suh, EJ
   Ahn, J
   Park, JH
   Ryoo, NK
   Lee, JE
   Kim, KW
   Park, KH
   Lee, C
AF Kim, Hye-Jung
   Ahn, Seong Joon
   Woo, Se Joon
   Hong, Hye Kyoung
   Suh, Eui Jin
   Ahn, Jeeyun
   Park, Ji Hyun
   Ryoo, Na-Kyung
   Lee, Ji Eun
   Kim, Ki Woong
   Park, Kyu Hyung
   Lee, Cheolju
TI Proteomics-based identification and validation of novel plasma
   biomarkers phospholipid transfer protein and mannan-binding lectin
   serine protease-1 in age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HIGH-DENSITY-LIPOPROTEINS; PATHWAY ACTIVATION; MASP-1; EXPRESSION;
   HEALTH; IMPACT; PLTP
AB Age-related macular degeneration (AMD) is a major cause of severe, progressive visual loss among the elderly. There are currently no established serological markers for the diagnosis of AMD. In this study, we carried out a large-scale quantitative proteomics analysis to identify plasma proteins that could serve as potential AMD biomarkers. We found that the plasma levels of phospholipid transfer protein (PLTP) and mannan-binding lectin serine protease (MASP)-1 were increased in AMD patients relative to controls. The receiver operating characteristic curve based on data from an independent set of AMD patients and healthy controls had an area under the curve of 0.936 for PLTP and 0.716 for MASP-1, revealing excellent discrimination between the two groups. A proteogenomic combination model that incorporated PLTP and MASP-1 along with two known risk genotypes of age-related maculopathy susceptibility 2 and complement factor H genes further enhanced discriminatory power. Additionally, PLTP and MASP-1 mRNA and protein expression levels were upregulated in retinal pigment epithelial cells upon exposure to oxidative stress in vitro. These results indicate that PLTP and MASP-1 can serve as plasma biomarkers for the early diagnosis and treatment of AMD, which is critical for preventing AMD-related blindness.
C1 [Kim, Hye-Jung; Suh, Eui Jin; Lee, Ji Eun; Lee, Cheolju] Korea Inst Sci & Technol, Ctr Theragnosis, Seoul, South Korea.
   [Ahn, Seong Joon; Woo, Se Joon; Hong, Hye Kyoung; Ahn, Jeeyun; Park, Ji Hyun; Ryoo, Na-Kyung; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
   [Ahn, Seong Joon] Hanyang Univ, Hanyang Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Jeeyun] Seoul Metropolitan Govt Seoul Natl Univ, Boramae Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Songnam, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul, South Korea.
C3 Korea Institute of Science & Technology (KIST); Seoul National
   University (SNU); Hanyang University; Hanyang University Hospital; Seoul
   National University (SNU); Seoul National University Hospital; Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Lee, C (通讯作者)，Korea Inst Sci & Technol, Ctr Theragnosis, Seoul, South Korea.; Woo, SJ; Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
EM sejoon1@snu.ac.kr; jiani4@snu.ac.kr; clee270@kist.re.kr
OI Ahn, Jeeyun/0000-0001-9017-1652
FU Korea Health Technology RD Project; Ministry of Health Welfare, Korea
   [A111161]; Reverse Aging R&D Program from Korean Ministry of Science,
   ICT and Future Planning, Seoul, Korea [2016M3A9D8928724]; Convergence
   Commercialization Project of National Research Council of Science and
   Technology, Seoul, Korea [CCP-13-02-KIST]
FX Support for statistical analyses was provided by the Medical Research
   Collaborating Center at Seoul National University Bundang Hospital. This
   work was supported by the Korea Health Technology R&D Project and grants
   from the Ministry of Health & Welfare, Korea (A111161), the Reverse
   Aging R&D Program from Korean Ministry of Science, ICT and Future
   Planning, Seoul, Korea (2016M3A9D8928724), and the Convergence
   Commercialization Project of National Research Council of Science and
   Technology, Seoul, Korea (CCP-13-02-KIST).
CR Albers JJ, 2004, CURR OPIN LIPIDOL, V15, P255, DOI 10.1097/00041433-200406000-00004
   ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P
   Barlage S, 2001, J LIPID RES, V42, P281
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cheung MC, 2010, BIOCHEMISTRY-US, V49, P7314, DOI 10.1021/bi100359f
   Cheung MC, 2006, BBA-MOL BASIS DIS, V1762, P131, DOI 10.1016/j.bbadis.2005.09.002
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Degn SE, 2012, J IMMUNOL, V189, P3957, DOI 10.4049/jimmunol.1201736
   Desrumaux CM, 2003, J LIPID RES, V44, P1453, DOI 10.1194/jlr.M200281-JLR200
   Doecke JD, 2012, ARCH NEUROL-CHICAGO, V69, P1318, DOI 10.1001/archneurol.2012.1282
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200
   Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916
   Heja D, 2012, P NATL ACAD SCI USA, V109, P10498, DOI 10.1073/pnas.1202588109
   Heja D, 2012, J BIOL CHEM, V287, P20290, DOI 10.1074/jbc.M112.354332
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Levels JHM, 2007, BBA-MOL CELL BIOL L, V1771, P1429, DOI 10.1016/j.bbalip.2007.10.001
   Megyeri M, 2013, J BIOL CHEM, V288, P8922, DOI 10.1074/jbc.M112.446500
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pussinen PJ, 2001, BBA-MOL CELL BIOL L, V1533, P153, DOI 10.1016/S1388-1981(01)00153-6
   Rai AJ, 2005, PROTEOMICS, V5, P3262, DOI 10.1002/pmic.200401245
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   TALL AR, 1985, J LIPID RES, V26, P842
   Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005
   TOLLEFSON JH, 1988, J LIPID RES, V29, P1593
   van Tol A, 2000, INT J TISSUE REACT, V22, P79
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
NR 37
TC 12
Z9 13
U1 0
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 8
PY 2016
VL 6
AR 32548
DI 10.1038/srep32548
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DV0VC
UT WOS:000382637700001
PM 27605007
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sawada, O
   Miyake, T
   Kakinoki, M
   Sawada, T
   Kawamura, H
   Ohji, M
AF Sawada, Osamu
   Miyake, Taichiro
   Kakinoki, Masashi
   Sawada, Tomoko
   Kawamura, Hajime
   Ohji, Masahito
TI AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION
   OF PEGAPTANIB OR RANIBIZUMAB IN PATIENTS WITH AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF drug; aqueous humor;
   pegaptanib; ranibizumab; vascular endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; RETINAL NEOVASCULARIZATION;
   BEVACIZUMAB; INHIBITION; MEMBRANES; ANTIBODY; THERAPY
AB Purpose: The purpose of this study was to evaluate vascular endothelial growth factor (VEGF) concentrations in the aqueous humor of eyes after intravitreal injections of pegaptanib or ranibizumab in patients with age-related macular degeneration.
   Methods: Aqueous humor samples were obtained from 16 eyes with choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal injections of pegaptanib (0.3 mg; 5 eyes) and ranibizumab (0.5 mg; 11 eyes). The VEGF concentration was measured using an enzyme-linked immunosorbent assay using a primary antibody against VEGF(121) and VEGF(165).
   Results: The VEGF concentrations in the aqueous humor of eyes with age-related macular degeneration ranged from 35.3 pg/mL to 142.4 pg/mL (mean +/- standard deviation, 90.9 pg/mL +/- 40.0 pg/mL) before the injection of pegaptanib and increased significantly, ranging from 298.2 pg/mL to 571.3 pg/mL (mean +/- standard deviation, 452.0 pg/mL +/- 106.4 pg/mL) 6 weeks after the injection (P = 0.005). The VEGF concentrations ranged from 47.2 pg/mL to 307.4 pg/mL (mean +/- standard deviation, 125.9 pg/mL +/- 77.2 pg/mL) before injection of ranibizumab and decreased to, 31 pg/mL, the lower limit of detection, 4 weeks after injection.
   Conclusion: The VEGF concentrations in the aqueous humor of eyes with age-related macular degeneration decreased after injections of ranibizumab and increased after injections of pegaptanib. RETINA 30:1034-1038, 2010
C1 [Sawada, Osamu; Miyake, Taichiro; Kakinoki, Masashi; Sawada, Tomoko; Kawamura, Hajime; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Sawada, O (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Shiga 5202192, Japan.
EM osawada@belle.shiga-med.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [21592255]; Ministry of Health, Labor, and Welfare
FX Supported, in part, by the Ministry of Education, Culture, Sports,
   Science and Technology of Japan grant (21592255) and a grant from the
   Ministry of Health, Labor, and Welfare.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Catena R, 2007, INT J CANCER, V120, P2096, DOI 10.1002/ijc.22461
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saed GM, 2002, AM J REPROD IMMUNOL, V48, P387, DOI 10.1034/j.1600-0897.2002.01090.x
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
NR 21
TC 17
Z9 17
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 1034
EP 1038
DI 10.1097/IAE.0b013e3181ce74c8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622CE
UT WOS:000279635600006
PM 20616682
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Shusterman, EM
   Arnoldussen, M
   Chell, E
   Wang, K
   Moshfeghi, DM
AF Jackson, Timothy L.
   Shusterman, E. Mark
   Arnoldussen, Mark
   Chell, Erik
   Wang, Kun
   Moshfeghi, Darius M.
CA INTREPID Study Grp
TI STEREOTACTIC RADIOTHERAPY FOR WET AGE-RELATED MACULAR DEGENERATION
   (INTREPID) Influence of Baseline Characteristics on Clinical Response
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; wet age-related macular
   degeneration; radiation; stereotactic radiotherapy; ranibizumab;
   anti-vascular endothelial growth factor; INTREPID study
ID X-RAY-IRRADIATION; OPTICAL-COHERENCE-TOMOGRAPHY; NEEDED RANIBIZUMAB
   THERAPY; EPIMACULAR BRACHYTHERAPY; EPIRETINAL BRACHYTHERAPY;
   RADIATION-1ST STRATEGY; SEGMENTATION ERROR; OUTCOMES; SAFETY; MERITAGE
AB Purpose: To determine which patients respond best to stereotactic radiotherapy (SRT) for neovascular age-related macular degeneration.
   Methods: Participants (n = 230) receiving intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration enrolled in a randomized, double-masked sham-controlled trial comparing 16 Gray, 24 Gray, or Sham SRT. In a post hoc analysis, participants were grouped according to their baseline characteristics, to determine if these influenced SRT efficacy.
   Results: At 52 weeks, SRT was most effective for lesions <= 4 mm in greatest linear dimension and with a macular volume greater than the median value of 7.4 mm(3). For 26% of the participants with both these characteristics, SRT resulted in 55% fewer ranibizumab injections (2.08 vs. 4.60; P = 0.0002), a mean visual acuity change that was 5.33 letters superior to sham (+2.18 vs. -3.15 letters; P = 0.0284), and a 71.1-mu m greater reduction in mean central subfield thickness (-122.6 vs. -51.5 mm; P = 0.027). Other features associated with a positive response to SRT included pigment epithelial detachment and the absence of fibrosis.
   Conclusion: Stereotactic radiotherapy is most effective for neovascular age-related macular degeneration lesions that are actively leaking at the time of treatment, and no larger than the 4-mm treatment zone.
C1 [Jackson, Timothy L.] Kings Coll London, Sch Med, Dept Ophthalmol, London WC2R 2LS, England.
   [Shusterman, E. Mark; Arnoldussen, Mark; Chell, Erik] Oraya Therapeut Inc, Newark, CA USA.
   [Wang, Kun] Int Inst Drug Dev, Louvain, Belgium.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Horngren Family Vitreoretinal Ctr, Byers Eye Inst,Dept Ophthalmol, Palo Alto, CA 94304 USA.
C3 University of London; King's College London; International Drug
   Development Institute; Stanford University
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Kings Coll London, Dept Ophthalmol, London SE 59RS, England.
EM t.jackson1@nhs.net
RI Kousal, Bohdan/B-9489-2017; Kousal, Bohdan/ABE-2741-2021; Aslam,
   Tariq/A-8532-2016; Studnicka, Jan/K-2875-2017
OI Kousal, Bohdan/0000-0003-2824-2266; Kousal, Bohdan/0000-0003-2824-2266;
   Jackson, Timothy/0000-0001-7618-1555; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; Aslam, Tariq/0000-0002-9739-7280;
   Studnicka, Jan/0000-0002-9911-4379
FU Oraya Therapeutics; Oraya
FX Supported by Oraya Therapeutics for the INTREPID study.; M. Arnoldussen,
   and E. Chell are employees of Oraya. K. Wang's employer received funding
   from Oraya to support the statistical analysis. D. M. Moshfeghi and E.
   M. Shusterman are consultants to Oraya. T. L. Jackson's employer
   received contract research funding from Oraya and he received a single
   advisory board payment.
CR CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2000, AGE RELATED MACULAR, V9
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Krebs I, 2012, BRIT J OPHTHALMOL, V96, P271, DOI 10.1136/bjo.2010.194662
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Morales-Canton V, 2013, AM J OPHTHALMOL, V155, P1000, DOI 10.1016/j.ajo.2013.01.015
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Petrarca R, 2013, RETINA-J RET VIT DIS, V33, P1232, DOI 10.1097/IAE.0b013e3182794b22
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
NR 25
TC 15
Z9 16
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2015
VL 35
IS 2
BP 194
EP 204
DI 10.1097/IAE.0000000000000283
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA2UU
UT WOS:000348764200006
PM 25102198
DA 2022-11-30
ER

PT J
AU Gamulescu, MA
   Helbig, H
AF Gamulescu, Maria-Andreea
   Helbig, Horst
TI A new era in the treatment of age-related macular degeneration: from
   Factor X to antiangiogenesis
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE age-related macular degeneration; anecortave acetate; antiproliferation;
   bevacizumab; choroidal neovascularisation; integrins; pegaptanib;
   photodynamic therapy; ranibizumab; RTK inhibitors; small interfering
   RNA; squalamine lactate; triamcinolone acetonide; vascular endothelial
   growth factor; VEGF-Trap
ID ENDOTHELIAL-GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   EPITHELIUM-DERIVED FACTOR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   ISCHEMIA-INDUCED RETINOPATHY; PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN;
   OCULAR NEOVASCULARIZATION; DIABETIC-RETINOPATHY; CELLS SECRETE
AB Age-related macular degeneration has become the most common cause of visual loss leading to legal blindness in the industrialised world. This progressive disorder of the posterior pole of the eye involves the retinal pigment epithelium, its basal membrane (Bruch's membrane), as well as the choriocapillaris and retina. Multiple factors are thought to be involved, including oxidative damage, retinal pigment epithelium cell lysosomal dysfunction, immunological responses to extracellular matrix proteins and an imbalance between pro- and antiangiogenic cytokines. While little therapeutic options are available for the atrophic form of the disease, several treatment modalities have been developed for the exudative form of age-related macular degeneration. The first therapeutic interventions consisted in laser photocoagulation of choroidal neovascular membranes in the 1970s. In the late 1990s, photodynamic therapy with the photosensitiser verteporfin was the first step towards a more specific therapy, allowing treatment of subfoveal choroidal neovascular membranes without causing retinal damage. However, visual acuity tended to slowly deteriorate despite therapy in most patients. With the new antiangiogenic drugs available today and more in the pipeline to come, the probability to maintain or gain visual acuity has dramatically increased. This review gives an overview of the recent therapeutic advances in age-related macular degeneration with emphasis on antiangiogenic drugs, and will discuss available and future therapeutic concepts.
C1 Univ Regensburg, Klin & Poliklin Augenheilkunde, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Gamulescu, MA (通讯作者)，Univ Regensburg, Klin & Poliklin Augenheilkunde, Franz-Josef-Str Allee 11, D-93053 Regensburg, Germany.
EM gamulescu@eye-regensburg.de
CR ACUITY PHARM INC, 2007, Patent No. 6981971
   Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   ALCHEMIA LTD, 2006, Patent No. 2006081616
   ALCON INC, 2004, Patent No. 2004012742
   ALLERGAN INC, 2005, Patent No. 2005110436
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X
   ASHTON N, 1957, AM J OPHTHALMOL, V44, P7, DOI 10.1016/0002-9394(57)90426-9
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bauer SM, 2005, J VASC SURG, V41, P699, DOI 10.1016/j.jvs.2005.01.015
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Casey R, 1997, AM J OPHTHALMOL, V124, P521, DOI 10.1016/S0002-9394(14)70868-2
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHUGAI PHARM CO LTD, 2007, Patent No. 2007018137
   Ciulla, 1999, Expert Opin Investig Drugs, V8, P2173, DOI 10.1517/13543784.8.12.2173
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   CUILLA TA, 2003, RETINA, V23, P808
   DAWSON DW, 1999, CURR TOP MICROBIOL I, V237, P97
   Eble JA, 2001, OSTEOARTHR CARTILAGE, V9, pS131, DOI 10.1053/joca.2001.0455
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4
   EYEGENE INC, 2005, Patent No. 2005094872
   EYETECH PHARM INC, 2005, Patent No. 2005110489
   EYETECH PHARM INC, 2005, Patent No. 2005020972
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Frank R N, 1974, Ophthalmic Surg, V5, P56
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   GENAERA CORP, 2005, Patent No. 6933383
   GENENTECH INC, 2007, Patent No. 2007011873
   GENENTECH INC, 1997, Patent No. 6054297
   GENENTECH INC, 2005, Patent No. 2005000900
   GENENTECH INC, 2000, Patent No. 7060269
   GENENTECH INC, 2006, Patent No. 2006047325
   GENVEC INC, 2005, Patent No. 2005089811
   GILEAD SCI INC, 1998, Patent No. 6051698
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   HANKS SK, 1991, METHOD ENZYMOL, V200, P38
   HAVENER WH, 1959, ARCH OPHTHALMOL-CHIC, V61, P390
   HEFFERNAN JT, 1978, INVEST OPHTH VIS SCI, V17, P565
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   INTRADIGM CORP, 2005, Patent No. 2005076998
   INTRADIGM CORP, 2005, Patent No. 2005076999
   ISIS PHARM INC, 2006, Patent No. 2006026485
   JERENI AG, 2005, Patent No. 2005090329
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KINNEY WA, 2005, Patent No. 20050026917
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Mabjeesh NJ, 2007, HISTOL HISTOPATHOL, V22, P559, DOI 10.14670/HH-22.559
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   MERCK PHARM, 2005, Patent No. 2005028448
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   MYERS BIGEL SIBLEY, 2005, Patent No. 20050106216
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   NOVARTIS AG, 2002, Patent No. 6833367
   NOVARTIS AG, 2006, Patent No. 2006050946
   NOVARTIS AG, 2006, Patent No. 2006000420
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   OSI PHARM, 2006, Patent No. 2006053342
   Pechan P, 2006, Patent No. [WO2006031689, 2006031689]
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   REGENERON PHARM, 2006, Patent No. 2006086544
   Reich S, 2003, MOL VIS, V9, P210
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SANTARIS PHARM SA, 2006, Patent No. 2006050734
   SCHERING AG, 2006, Patent No. 2006066957
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SCRIPPS RES I, 2005, Patent No. 2005117954
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SIRNA THERAPEUTICS I, 2006, Patent No. 6995259
   SIRNA THERAPEUTICS I, 2004, Patent No. 6818447
   Slakter Jason S, 2006, Ophthalmol Clin North Am, V19, P373
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   SW RES I, 2007, Patent No. 20070053990
   SW RES I, 2007, Patent No. 20070053989
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   U NEW S WALES, 2006, Patent No. 2006024092
   U PENNSYLVANIA, 2005, Patent No. 2005062957
   U SYDNEY, 1998, Patent No. 5770589
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   WILLEMSSENS P., 1960, PRACTICA OTO RHINO LARYNGOL, V22, P439
   WISE G N, 1956, Trans Am Ophthalmol Soc, V54, P729
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Zweng H C, 1968, Trans Am Acad Ophthalmol Otolaryngol, V72, P377
NR 130
TC 2
Z9 2
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD NOV
PY 2007
VL 17
IS 11
BP 1351
EP 1363
DI 10.1517/13543776.17.11.1351
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 237FU
UT WOS:000251360400004
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, HS
   Yoo, SG
   Han, JI
   Lew, YJ
   Cho, SW
   Lee, TG
   Kim, JW
AF Cho, Han Joo
   Kim, Hyoung Seok
   Yoo, Seul Gi
   Han, Jung Il
   Lew, Young Ju
   Cho, Sung Won
   Lee, Tae Gon
   Kim, Jong Woo
TI RETINAL PIGMENT EPITHELIAL TEAR AFTER INTRAVITREAL RANIBIZUMAB TREATMENT
   FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; polypoidal choroidal vasculopathy; retinal angiomatous
   proliferation; retinal pigment epithelial tear
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; PHOTODYNAMIC
   THERAPY; DETACHMENT; INJECTION; PREDICTORS; SECONDARY
AB Purpose:To evaluate the risk factors for retinal pigment epithelium (RPE) tears after intravitreal ranibizumab injections in neovascular age-related macular degeneration (nAMD) and to determine the efficacy of continued ranibizumab treatment after RPE tears.Methods:A total of 407 treatment-naive eyes (377 patients) with nAMD were retrospectively included. All patients were treated with an initial series of 3 monthly loading injections, followed by further injections as required. Baseline characteristics and pigment epithelial detachment (PED) lesion features were evaluated as potential risk factors for RPE tear. The visual and anatomical outcomes after treatment during 12 months were also evaluated.Results:By 12 months, RPE tears developed in 32 eyes (7.9%). Pigment epithelial detachment height was associated with a higher risk of RPE tear (odds ratio [OR], 1.318; 95% confidence interval [CI], 1.217-2.031, P = 0.018). Fibrovascular PED compared with serous PED had a higher risk of developing tears (OR, 9.129; 95% CI, 6.228-32.124, P = 0.039), and typical nAMD (OR, 4.166; 95% CI, 2.030-14.913, P = 0.031) and retinal angiomatous proliferation (OR, 3.778; 95% CI, 2.185-9.277, P = 0.040) had a higher risk of developing tears compared with polypoidal choroidal vasculopathy. Mean best-corrected visual acuity (BCVA) of RPE tear patients showed no significant improvement after treatment at 12 months; however, patients with RPE tears without foveal involvement (19 eyes) showed significant BCVA improvement at 12 months (P = 0.034).Conclusion:PED type and nAMD subtype are associated with the development of RPE tears after intravitreal ranibizumab injections. Continued ranibizumab therapy after RPE tear development can maintain visual acuity when the fovea is not involved.
C1 [Cho, Han Joo; Kim, Hyoung Seok; Yoo, Seul Gi; Han, Jung Il; Lew, Young Ju; Cho, Sung Won; Lee, Tae Gon; Kim, Jong Woo] Konyang Univ Coll Med, Myung Gok Eye Res Inst, Kims Eye Hosp, Dept Ophthalmol, 156,4ga,Yeoungdeungpo Dong, Seoul, South Korea.
C3 Konyang University
RP Cho, HJ (通讯作者)，Konyang Univ Coll Med, Myung Gok Eye Res Inst, Kims Eye Hosp, Dept Ophthalmol, 156,4ga,Yeoungdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Barkmeier AJ, 2011, SEMIN OPHTHALMOL, V26, P94, DOI 10.3109/08820538.2011.571055
   Bloch SB, 2011, ACTA OPHTHALMOL, V89, pe665, DOI 10.1111/j.1755-3768.2010.02023.x
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Fujii A, 2014, CLIN OPHTHALMOL, V8, P1199, DOI 10.2147/OPTH.S65810
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Moreira CA, 2013, RETINA-J RET VIT DIS, V33, P277, DOI 10.1097/IAE.0b013e318263d139
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 30
TC 13
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1851
EP 1859
DI 10.1097/IAE.0000000000001009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ6US
UT WOS:000385998600018
PM 27074658
DA 2022-11-30
ER

PT J
AU Ko, A
   Cao, SJ
   Pakzad-Vaezi, K
   Brasher, PM
   Merkur, AB
   Albiani, DA
   Kirker, AW
   Cui, J
   Matsubara, J
   Forooghian, F
AF Ko, Ashley
   Cao, Sijia
   Pakzad-Vaezi, Kaivon
   Brasher, Penelope M.
   Merkur, Andrew B.
   Albiani, David A.
   Kirker, Andrew W.
   Cui, Jing
   Matsubara, Joanne
   Forooghian, Farzin
TI OPTICAL COHERENCE TOMOGRAPHY-BASED CORRELATION BETWEEN CHOROIDAL
   THICKNESS AND DRUSEN LOAD IN DRY AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adult choroid/anatomy and histology; choroid/blood supply; disease
   progression; humans; macular degeneration/pathology; retinal
   photoreceptors/pathology; retinal drusen/etiology; retinal
   drusen/pathology; tomography; optical coherence
ID CENTRAL SEROUS CHORIORETINOPATHY; BRUCHS MEMBRANE; SD-OCT; EYES;
   CHORIOCAPILLARIS; PHOTORECEPTORS; EVOLUTION; DISEASE
AB Purpose: Spectral domain optical coherence tomography can be used to measure both choroidal thickness and drusen load. The authors conducted an exploratory study using spectral domain optical coherence tomography to determine if a correlation between choroidal thickness and drusen load exists in patients with dry age-related macular degeneration.
   Methods: Forty-four patients with dry age-related macular degeneration were recruited. The drusen area and volume were determined using the automated software algorithm of the spectral domain optical coherence tomography device, and choroidal thickness was measured using enhanced depth imaging. Correlations were determined using multivariable and univariable analyses.
   Results: The authors found an inverse correlation between choroidal thickness and drusen load (r = -0.35, P = 0.04). Drusen load was also correlated with visual acuity (r = 0.32, P = 0.04). A correlation between choroidal thickness and visual acuity was suggested (r = -0.22, P = 0.21).
   Conclusion: Spectral domain optical coherence tomography can be used to assess the correlation between drusen load and choroidal thickness, both of which show a relationship with visual acuity. The measurement of these outcomes may serve as important outcome parameters in routine clinical care and in clinical trials for patients with dry age-related macular degeneration. RETINA 33: 1005-1010, 2013
C1 [Ko, Ashley; Cao, Sijia; Pakzad-Vaezi, Kaivon; Brasher, Penelope M.; Merkur, Andrew B.; Albiani, David A.; Kirker, Andrew W.; Cui, Jing; Matsubara, Joanne; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
   [Brasher, Penelope M.] Univ British Columbia, Dept Stat, Vancouver, BC V6T 1W5, Canada.
C3 University of British Columbia; University of British Columbia
RP Forooghian, F (通讯作者)，St Pauls Hosp, Dept Ophthalmol, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
FU Canadian National Institute for the Blind (CNIB); Canadian Institute of
   Health Research [CIHR MOP 97806]
FX This research was funded by a This research was funded by a New
   Researcher Grant from the Canadian National Institute for the Blind
   (CNIB) and Canadian Institute of Health Research (CIHR MOP 97806).
CR Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   D'Souza YB, 2009, MOL VIS, V15, P906
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Fujiwara A, 2012, JPN J OPHTHALMOL, V56, P230, DOI 10.1007/s10384-012-0128-5
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shin JW, 2012, OPHTHALMOLOGY, V119, P1017, DOI 10.1016/j.ophtha.2011.10.029
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Toth CA, 2012, AREDS 2 ANCILLARY SP
   Yehoshua Z, 2012, P ANN M ASS RES VIS
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 40
TC 23
Z9 24
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 1005
EP 1010
DI 10.1097/IAE.0b013e31827d266e
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100017
PM 23474546
OA Green Accepted
DA 2022-11-30
ER

PT J
AU den Hollander, AI
   de Jong, EK
AF den Hollander, Anneke I.
   de Jong, Eiko K.
TI Highly Penetrant Alleles in Age-Related Macular Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; STARGARDT-DISEASE GENE; RARE VARIANTS; HIGH-RISK;
   MISSING HERITABILITY; COMMON VARIANTS; LOW-FREQUENCY; MUTATION; ABCR;
   SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is a complex disease caused by a combination of genetic and environmental factors. Genome-wide association studies have identified several common genetic variants associated with AMD, which together account for 15%-65% of the heritability of AMD. Multiple hypotheses to clarify the unexplained portion of genetic variance have been proposed, such as gene-gene interactions, gene-environment interactions, structural variations, epigenetics, and rare variants. Several studies support a role for rare variants with large effect sizes in the pathogenesis of AMD. In this work, we review the methods that can be used to detect rare variants in common diseases, as well as the recent progress that has been made in the identification of rare variants in AMD. In addition, the relevance of these rare variants for diagnosis, prognosis, and treatment of AMD is highlighted.
C1 [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Hollander, Anneke den/N-4911-2014; de Jong, Eiko/P-3407-2015
OI de Jong, Eiko/0000-0001-6520-0407
FU Macula Vision Research Foundation; Netherlands Organisation for
   Scientific Research [016.096.309]
FX This work was supported by research grants from the Macula Vision
   Research Foundation and the Netherlands Organisation for Scientific
   Research (016.096.309).
CR Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Annas GJ, 2014, NEW ENGL J MED, V370, P985, DOI 10.1056/NEJMp1316367
   Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Burke TR, 2012, INVEST OPHTH VIS SCI, V53, P4458, DOI 10.1167/iovs.11-9166
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dryja TP, 1998, SCIENCE, V279
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldstein DB, 2013, NAT REV GENET, V14, P460, DOI 10.1038/nrg3455
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Huyghe JR, 2013, NAT GENET, V45, P197, DOI 10.1038/ng.2507
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kalf RRJ, 2014, GENET MED, V16, P85, DOI 10.1038/gim.2013.80
   Kiezun A, 2012, NAT GENET, V44, P623, DOI 10.1038/ng.2303
   Klaver CC, 1998, SCIENCE, V279
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Liu DJ, 2012, AM J HUM GENET, V91, P585, DOI 10.1016/j.ajhg.2012.08.008
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Mayeux R, 2005, J CLIN INVEST, V115, P1404, DOI 10.1172/JCI25421
   McKay GJ, 2004, MOL VIS, V10, P682
   Miller E., 2012, THESIS WASHINGTON U
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764
   Park Alice, 2013, Time, V182, P18
   Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 79
TC 8
Z9 8
U1 0
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD MAR
PY 2015
VL 5
IS 3
AR a017202
DI 10.1101/cshperspect.a017202
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CD6YV
UT WOS:000351237900001
PM 25377141
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Klein, R
   Meuer, SM
   Moss, SE
   Klein, BEK
   Neider, MW
   Reinke, J
AF Klein, R
   Meuer, SM
   Moss, SE
   Klein, BEK
   Neider, MW
   Reinke, J
TI Detection of age-related macular degeneration using a nonmydriatic
   digital camera and a standard film fundus camera
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULOPATHY; ATHEROSCLEROSIS; PREVALENCE; HEALTH
AB Objective: To compare gradings of lesions associated with age-related macular degeneration (AMD) from digital and stereoscopic film images.
   Design: Instrument validation study.
   Participants: Sixty-two subjects (124 eyes) with varying degrees of AMD, including no AMD.
   Methods: images of the optic disc and macula were taken using a 45degrees digital camera (6.3 megapixels) through dark-adapted pupils and pharmacologically dilated pupils. In addition, 30degrees stereoscopic retinal film images were taken through pharmacologically dilated pupils of the same eyes. All images were graded for drusen size, type, and area; pigmentary abnormalities; geographic atrophy; and neovascular lesions using the modified Wisconsin Age-Related Maculopathy Grading System. Exact agreement and unweighted kappa scores were calculated for paired gradings resulting from digital and film images.
   Main Outcome Measure: Agreement between gradings obtained from stereoscopic slide transparencies and digital nonstereoscopic images.
   Results: Exact agreement between gradings of digital and stereoscopic film images taken through pharmacologically dilated pupils was 91% (kappa=0.85) for the categories of none, early AMD, and late AMD. Exact agreement for gradings of digital images taken through dark-adapted pupils compared with gradings of film images was 80% (kappa=0.69). Exact agreement for gradings of digital images captured through dark-adapted and pharmacologically dilated pupils was 86% (kappa=0.78). In addition, kappa scores for agreement between different approaches for individual lesions were moderate to almost perfect.
   Conclusions: Gradings resulting from high-resolution digital images, especially when the pupil is pharmacologically dilated, are comparable with those resulting from film-based images. We conclude that digital imaging of the retina is useful for epidemiological studies of AMD.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
FU NEI NIH HHS [EY 06594] Funding Source: Medline; NHLBI NIH HHS [HL 69979]
   Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL069979] Funding Source: NIH RePORTER
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Diabetic Retinopathy Study Coordinating Center, 1972, DIAB RET STUD MAN OP
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUD
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   *SAS I INC, 1999, SAT STAT US GUID VER, V2, P1247
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   2004, MULTIETHNIC STUDY AT
NR 18
TC 69
Z9 69
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2004
VL 122
IS 11
BP 1642
EP 1646
DI 10.1001/archopht.122.11.1642
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 868SC
UT WOS:000224932300004
PM 15534124
DA 2022-11-30
ER

PT J
AU Muth, DR
   Toro, MD
   Bajka, A
   Jonak, K
   Rieder, R
   Kohler, MM
   Gunzinger, JM
   Souied, EH
   Engelbert, M
   Freund, KB
   Zweifel, SA
AF Muth, Daniel Rudolf
   Toro, Mario Damiano
   Bajka, Anahita
   Jonak, Kamil
   Rieder, Roman
   Kohler, Myrtha Magdalena
   Gunzinger, Jeanne Martine
   Souied, Eric H.
   Engelbert, Michael
   Freund, K. Bailey
   Zweifel, Sandrine Anne
TI Correlation between Macular Neovascularization (MNV) Type and Druse Type
   in Neovascular Age-Related Macular Degeneration (AMD) Based on the CONAN
   Classification
SO BIOMEDICINES
LA English
DT Article
DE subretinal drusenoid deposits; SDDs; reticular pseudodrusen; spectral
   domain optical coherence tomography; OCT; MNV; macular
   neovascularization; CNV; age-related macular degeneration; AMD
ID RETICULAR PSEUDODRUSEN; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; FELLOW EYES; 2ND EYES; PREVALENCE; SYMMETRY; SUBTYPES
AB BackgroundTo investigate associations and predictive factors between macular neovascularization (MNV) lesion variants and drusen types in patients with treatment-naive neovascular age-related macular degeneration (AMD). Methods: Multimodal imaging was retrospectively reviewed for druse type (soft drusen, subretinal drusenoid deposits (SDDs) or mixed) and MNV type (MNV 1, MNV 2, MNV 1/2 or MNV 3). The Consensus on Neovascular AMD Nomenclature (CONAN) classification was used for characterizing MNV at baseline. Results: One eye of each eligible patient was included (n = 191). Patients with predominant SDDs had an increased adjusted odds ratio (aOR) for MNV 2 (23.4453, p = 0.0025) and any type of MNV 3 (8.7374, p < 0.0001). Patients with MNV 1/2 had an aOR for predominant SDDs (0.3284, p = 0.0084). Patients with MNV1 showed an aOR for SDDs (0.0357, p < 0.0001). Eyes with SDDs only without other drusen types showed an aOR for MNV 2 (9.2945, p < 0.0001). Conclusions: SDDs represent a common phenotypic characteristic in AMD eyes with treatment-naive MNV. The aOR for eyes with predominant SDDs to develop MNV 2 and MNV 3 was much higher, possibly due to their location in the subretinal space. The predominant druse type may help to predict which type of MNV will develop during the course of AMD.
C1 [Muth, Daniel Rudolf; Toro, Mario Damiano; Bajka, Anahita; Rieder, Roman; Kohler, Myrtha Magdalena; Gunzinger, Jeanne Martine; Zweifel, Sandrine Anne] Univ Zurich UZH, Univ Hosp Zurich USZ, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Muth, Daniel Rudolf] Univ Zurich UZH, CH-8006 Zurich, Switzerland.
   [Toro, Mario Damiano] Med Univ Lublin, Dept Gen & Pediat Ophthalmol, PL-20093 Lublin, Poland.
   [Toro, Mario Damiano] Univ Naples Federico II, Publ Hlth Dept, Eye Clin, I-80138 Naples, Italy.
   [Jonak, Kamil] Lublin Univ Technol, Dept Biomed Engn, PL-20618 Lublin, Poland.
   [Jonak, Kamil] Med Univ Lublin, Dept Psychiat Psychotherapy & Early Intervent, PL-20093 Lublin, Poland.
   [Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Engelbert, Michael; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Engelbert, Michael; Freund, K. Bailey] NYU Grossman Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Medical University of Lublin; University of Naples Federico II; Lublin
   University of Technology; Medical University of Lublin; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Vitreous Retina
   Macula Consultants of New York
RP Muth, DR; Zweifel, SA (通讯作者)，Univ Zurich UZH, Univ Hosp Zurich USZ, Dept Ophthalmol, CH-8091 Zurich, Switzerland.; Muth, DR (通讯作者)，Univ Zurich UZH, CH-8006 Zurich, Switzerland.
EM dr-muth@t-online.de; sandrine.zweifel@usz.ch
RI ; Jonak, Kamil/C-6258-2017
OI /0000-0003-3670-976X; Jonak, Kamil/0000-0002-9975-1458
CR Agron E, 2022, OPHTHALMOLOGY, V129, P1107, DOI 10.1016/j.ophtha.2022.05.021
   Ahmed D, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01651-2
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2022
VL 10
IS 10
AR 2370
DI 10.3390/biomedicines10102370
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 5O2BN
UT WOS:000872285200001
PM 36289632
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, XX
   Zhu, Q
   Egger, A
   Chang, L
   Wolf, S
   Song, YP
   Zhang, JJ
   Dong, FT
   Xu, X
   Weisberger, A
AF Li, Xiaoxin
   Zhu, Qi
   Egger, Anna
   Chang, Liu
   Wolf, Sebastian
   Song, Yanping
   Zhang, Junjun
   Dong, Fangtian
   Xu, Xun
   Weisberger, Annemarie
TI Two different treatment regimens of ranibizumab 0.5 mg for neovascular
   age-related macular degeneration with or without polypoidal choroidal
   vasculopathy in Chinese patients: results from the Phase IV, randomized,
   DRAGON study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; monthly regimen; polypoidal
   choroidal vasculopathy; pro re nata regimen; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT; EFFICACY; SAFETY;
   PREVALENCE; COMBINATION; POPULATION; SECONDARY
AB Purpose To evaluate the efficacy and safety of monthly and pro re nata (PRN, guided by visual acuity stabilization and disease activity criteria) ranibizumab regimens in Chinese patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
   Methods This double-masked study randomized nAMD patients (1:1) to ranibizumab monthly from baseline to Month (M) 11 to a PRN regimen from M12 to M23 (monthly group, n = 167) versus ranibizumab three monthly doses followed by a PRN regimen up to M23 (PRN group, n = 166). Subgroups were assessed based on the presence/absence of PCV (indicated by indocyanine green angiography).
   Results Of 334 randomized patients, 41.7% had PCV at baseline. Mean average best-corrected visual acuity (BCVA) change from M3 to M4 through M12 was 3.3 letters with monthly and 1.7 letters with PRN (mean difference: 1.6; 95% CI: -2.95, -0.20, primary end-point). Mean change in BCVA from baseline (monthly/PRN, 53.8/53.7) to M12 and M24 was 12.3 and 11.3 letters in monthly and 9.6 and 9.3 letters in PRN group. Corresponding values for patients with PCV/without PCV were 12.7/12.1 letters (M12) and 12.3/10.6 letters (M24) in monthly and 9.4/9.4 letters (M12) and 9.7/8.7 letters (M24) in PRN groups. The mean number of injections was 11.4 (monthly) and 8.2 (PRN) from Day 1 to M11 and 4.8 (monthly) and 5.0 (PRN) from M12 to M23. No new safety findings were reported.
   Conclusions The study results support the use of either ranibizumab monthly or PRN regimens in Chinese patients with nAMD, regardless of presence of PCV.
C1 [Li, Xiaoxin] Peking Univ, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Zhu, Qi; Chang, Liu] China Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China.
   [Egger, Anna] Novartis Pharma AG, Basel, Switzerland.
   [Wolf, Sebastian] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Song, Yanping] Guangzhou Mil Command, Wuhan Gen Hosp, Wuhan, Peoples R China.
   [Zhang, Junjun] Sichuan Univ, West China Hosp, Chengdu, Peoples R China.
   [Dong, Fangtian] Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Xu, Xun] Shanghai First Peoples Hosp, Shanghai, Peoples R China.
   [Weisberger, Annemarie] Novartis Pharmaceut, E Hanover, NJ USA.
C3 Peking University; Novartis; Novartis; University of Bern; University
   Hospital of Bern; Sichuan University; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
   Hospital; Novartis
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM dr_lixiaoxin@163.com
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Novartis Pharma AG
FX LThe authors thank Swati Bhandari (Novartis Healthcare Pvt. Ltd., India)
   for medical writing support and editorial assistance during the
   development of the manuscript. Data from this study were presented at
   the European Society of Retina Specialists Congress, 8-11 September
   2016, Copenhagen, Denmark, American Academy of Ophthalmology, McCormick
   Place, Chicago, United States, 15-18 October 2016; Asia-Pacific
   Vitreo-retina Society, Bangkok, Thailand, 8-10 December 2016; and 32nd
   Asia-Pacific Academy of Ophthalmology congress, Singapore, 1-5 March
   2017. The study was funded by Novartis Pharma AG.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matthe E, 2011, OPHTHALMOLOGE, V108, P237, DOI 10.1007/s00347-010-2282-9
   Ogura Y, 2019, 19 EURETINA C SEPT 5
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
NR 39
TC 0
Z9 1
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2021
VL 99
IS 3
BP E336
EP E345
DI 10.1111/aos.14588
EA DEC 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RW8PX
UT WOS:000603417400001
PM 33377611
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Fletcher, EL
   Jobling, AI
   Greferath, U
   Mills, SA
   Waugh, M
   Ho, T
   de Iongh, RU
   Phipps, JA
   Vessey, KA
AF Fletcher, Erica L.
   Jobling, Andrew I.
   Greferath, Ursula
   Mills, Samuel A.
   Waugh, Michelle
   Ho, Tracy
   de Iongh, Robb U.
   Phipps, Joanna A.
   Vessey, Kirstan A.
TI Studying Age-Related Macular Degeneration Using Animal Models
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE retina; drusen; animal model; age-related macular degeneration
ID SUB-RETINAL NEOVASCULARIZATION; FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE;
   CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIUM; NATURAL-HISTORY;
   RHESUS-MONKEYS; DEFICIENT MICE; KNOCKOUT MICE; MOUSE MODEL
AB Over the recent years, there have been tremendous advances in our understanding of the genetic and environmental factors associated with the development of age-related macular degeneration (AMD). Examination of retinal changes in various animals has aided our understanding of the pathogenesis of the disease. Notably, mouse strains, carrying genetic anomalies similar to those affecting humans, have provided a foundation for understanding how various genetic risk factors affect retinal integrity. However, to date, no single mouse strain that develops all the features of AMD in a progressive age-related manner has been identified. In addition, a mutation present in some background strains has clouded the interpretation of retinal phenotypes in many mouse strains. The aim of this perspective was to describe how animals can be used to understand the significance of each sign of AMD, as well as key genetic risk factors.
C1 [Fletcher, Erica L.; Jobling, Andrew I.; Greferath, Ursula; Mills, Samuel A.; Waugh, Michelle; Ho, Tracy; de Iongh, Robb U.; Phipps, Joanna A.; Vessey, Kirstan A.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3010, Australia.
C3 University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Grattan St, Parkville, Vic 3010, Australia.
EM elf@unimelb.edu.au
RI Fletcher, Erica/E-6364-2012; De Iongh, Robb U/H-9646-2019; Jobling,
   Andrew/C-8221-2015
OI Fletcher, Erica/0000-0001-9412-9523; De Iongh, Robb
   U/0000-0001-7013-1610; Greferath, Ursula/0000-0003-1028-648X; Ho,
   Tracy/0000-0002-9277-7823; Jobling, Andrew/0000-0002-7827-3135; Vessey,
   Kirstan/0000-0003-1031-1964
FU National Health and Medical Research Council of Australia [1021918];
   Retina Australia
FX This work was supported by the National Health and Medical Research
   Council of Australia (grant no. 1021918) and Retina Australia.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Aleman TS, 2011, INVEST OPHTH VIS SCI, V52, P6898, DOI 10.1167/iovs.11-7701
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bujakowska K, 2012, HUM MUTAT, V33, P306, DOI 10.1002/humu.21653
   Capshew CR, 2012, NUCLEIC ACIDS RES, V40, P8637, DOI 10.1093/nar/gks590
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MISHIMA H, 1981, A GRAEF ARCH KLIN EX, V216, P209, DOI 10.1007/BF00408162
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pinto LH, 2007, VISUAL NEUROSCI, V24, P111, DOI 10.1017/S0952523807070149
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P29, DOI 10.1007/BF00413394
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 62
TC 58
Z9 61
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 878
EP 886
DI 10.1097/OPX.0000000000000322
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500011
PM 24978866
OA Green Published
DA 2022-11-30
ER

PT J
AU Chen, M
   Lechner, J
   Zhao, J
   Toth, L
   Hogg, R
   Silvestri, G
   Kissenpfennig, A
   Chakravarthy, U
   Xu, H
AF Chen, M.
   Lechner, J.
   Zhao, J.
   Toth, L.
   Hogg, R.
   Silvestri, G.
   Kissenpfennig, A.
   Chakravarthy, U.
   Xu, H.
TI STAT3 Activation in Circulating Monocytes Contributes to Neovascular
   Age-Related Macular Degeneration
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Macrophage; monocyte; angiogenesis; retina; age-related macular
   degeneration; cytokine
ID VEGF EXPRESSION; TIE2-EXPRESSING MONOCYTES; BLOOD MONOCYTES;
   CD14(++)CD16(+) MONOCYTES; MACROPHAGE POLARIZATION; TUMOR ANGIOGENESIS;
   PERIPHERAL-BLOOD; FRACTALKINE; CELLS; SUBPOPULATIONS
AB Infiltrating macrophages are critically involved in pathogenic angiogenesis such as neovascular age-related macular degeneration (nAMD). Macrophages originate from circulating monocytes and three subtypes of monocyte exist in humans: classical (CD14(+)CD16(-)), non-classical (CD14(-)CD16(+)) and intermediate (CD14(+)CD16(+)) monocytes. The aim of this study was to investigate the role of circulating monocyte in neovascular age-related macular degeneration (nAMD). Flow cytometry analysis showed that the intermediate monocytes from nAMD patients expressed higher levels of CX3CR1 and HLA-DR compared to those from controls. Monocytes from nAMD patients expressed higher levels of phosphorylated Signal Transducer and Activator of Transcription 3 (pSTAT3), and produced higher amount of VEGF. In the mouse model of choroidal neovascularization (CNV), pSTAT3 expression was increased in the retina and RPE/choroid, and 49.24% of infiltrating macrophages express pSTAT3. Genetic deletion of the Suppressor of Cytokine Signalling 3 (SOCS3) in myeloid cells in the LysM-Cre(+/-): SOCS3(fl/fl) mice resulted in spontaneous STAT3 activation and accelerated CNV formation. Inhibition of STAT3 activation using a small peptide LLL12 suppressed laser-induced CNV. Our results suggest that monocytes, in particular the intermediate subset of monocytes are activated in nAMD patients. STAT3 activation in circulating monocytes may contribute to the development of choroidal neovascularisation in AMD.
C1 [Chen, M.; Lechner, J.; Zhao, J.; Toth, L.; Hogg, R.; Silvestri, G.; Chakravarthy, U.; Xu, H.] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Kissenpfennig, A.] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Chen, M (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM m.chen@qub.ac.uk; heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008; Hogg, Ruth E./ABC-9602-2020; Lechner,
   Judith/GQH-8616-2022
OI Xu, Heping/0000-0003-4000-931X; Hogg, Ruth E./0000-0001-9413-2669;
   Chakravarthy, Usha/0000-0002-2606-3734; Kissenpfennig,
   Adrien/0000-0002-9633-3111
FU Dunhill Medical Trust [R188/0211]; Fight for Sight [1361 / 1362]; Guide
   Dogs for the Blind Association UK [2008-5a]; Medical Research Council
   [G1001795] Funding Source: researchfish; The Dunhill Medical Trust
   [R188/0211] Funding Source: researchfish; Fight for Sight [1361/62]
   Funding Source: researchfish; MRC [G1001795] Funding Source: UKRI
FX This work was supported by the Dunhill Medical Trust (R188/0211), Fight
   for Sight (1361 / 1362) and Guide Dogs for the Blind Association UK
   (2008-5a). The authors thank the patients who participated in this
   study. We also thank the research nurses Rebecca Denham and Georgina
   Sterrett for their help in patient recruitment.
CR Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104
   Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588
   Anbazhagan K, 2014, INT REV IMMUNOL, V33, P470, DOI 10.3109/08830185.2014.902453
   Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089548
   Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   De Palma M, 2007, TRENDS IMMUNOL, V28, P519, DOI 10.1016/j.it.2007.09.004
   Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03
   Dirkx AEM, 2006, J LEUKOCYTE BIOL, V80, P1183, DOI 10.1189/jlb.0905495
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   Frankenberger M, 1996, BLOOD, V87, P373
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Heimbeck I, 2010, CYTOM PART A, V77A, P823, DOI 10.1002/cyto.a.20942
   Heine GH, 2012, NAT REV NEPHROL, V8, P362, DOI 10.1038/nrneph.2012.41
   Ilhan N, 2014, OCULAR IMMUNOLOGY IN, P1, DOI 10.3109/09273948.2014.970283
   Jaipersad AS, 2014, J AM COLL CARDIOL, V63, P1, DOI 10.1016/j.jacc.2013.09.019
   Jiang Kailun, 2012, J Clin Exp Ophthalmol, V3, P208
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Lu W, 2006, EUR J GYNAECOL ONCOL, V27, P363
   Lu WB, 2015, INT HEART J, V56, P22, DOI 10.1536/ihj.14-174
   Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088
   Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260
   O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117
   Okazaki H, 2011, BIOCHEM BIOPH RES CO, V412, P441, DOI 10.1016/j.bbrc.2011.07.111
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527
   Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168
   Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109
   Rathinavelu A, 2012, J CELL MOL MED, V16, P1750, DOI 10.1111/j.1582-4934.2011.01472.x
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rogacev KS, 2011, EUR HEART J, V32, P84, DOI 10.1093/eurheartj/ehq371
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schauer D, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0050-3
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Stansfield BK, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-014-0040-3
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Szekanecz Z, 2010, JOINT BONE SPINE, V77, P13, DOI 10.1016/j.jbspin.2009.05.011
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Umehara H, 2001, IMMUNOL CELL BIOL, V79, P298, DOI 10.1046/j.1440-1711.2001.01004.x
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   Wang MJ, 2007, J MOL CELL CARDIOL, V42, P1009, DOI 10.1016/j.yjmcc.2007.04.010
   White GE, 2014, ARTERIOSCL THROM VAS, V34, P2554, DOI 10.1161/ATVBAHA.114.304717
   Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Zawada AM, 2012, IMMUNOBIOLOGY, V217, P1273, DOI 10.1016/j.imbio.2012.07.001
   Zawada AM, 2011, BLOOD, V118, pE50, DOI 10.1182/blood-2011-01-326827
   Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257
   Zhao JW, 2014, INVEST OPHTH VIS SCI, V55, P7572, DOI 10.1167/iovs.14-15495
   Zhao M, 2011, LUNG CANCER, V73, P366, DOI 10.1016/j.lungcan.2011.01.002
   ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167-5699(96)10029-3
NR 76
TC 41
Z9 41
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2016
VL 16
IS 4
BP 412
EP 423
DI 10.2174/1566524016666160324130031
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DK6BX
UT WOS:000375007100007
PM 27009107
OA Green Submitted, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Shu, CW
   Bee, YS
   Chen, JL
   Tsen, CL
   Tsai, WL
   Sheu, SJ
AF Shu, Chih-Wen
   Bee, Youn-Shen
   Chen, Jiunn-Liang
   Tsen, Chui-Lien
   Tsai, Wei-Lun
   Sheu, Shwu-Jiuan
TI Detection of Autophagy-Related Gene Expression by Conjunctival
   Impression Cytology in Age-Related Macular Degeneration
SO DIAGNOSTICS
LA English
DT Article
DE age-related macular degeneration; autophagy; GABARAPL1; impression
   cytology; oxidative damage
AB Purpose: To investigate the association of autophagy-related gene expression with age-related macular degeneration (AMD). Methods: Patients with AMD were recruited for analysis by conjunctival impression cytology. mRNA was assessed by real-time polymerase chain reaction (RT-PCR) to evaluate whether the expression of 26 autophagy-related genes (ATGs) was correlated with AMD. Further studies on cell viability and autophagic flux in response to oxidative stress by H2O2 were performed in human retinal pigment epithelial (RPE) cell lines based on the results of impression cytology. Results: Both the neovascular AMD (nAMD) and polypoidal choroidal vasculopathy (PCV) groups had significantly higher mRNA levels of gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1) and microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) than the control group, but there was no significant difference between these two groups. Age difference existed only in the AMD group. GABARAPL1 and MAP1LC3B mRNA expression increased significantly after acute oxidative stress in adult retinal pigment epithelial (ARPE-19) cells. Cell viability significantly increased and decreased in the cells harboring GABARAPL1 expression vector and silenced with siRNA against GABARAPL1, respectively, during short-term oxidative stress, whereas viability increased in the GABARAPL1-silenced cells after long-term oxidative stress. Silencing GABARAPL1 itself caused a reduction in autophagic flux under both short and long-term oxidative stress. Conclusion: Our study showed the possibility of assessing autophagy-related gene expression by conjunctival impression cytology. GABARAPL1 was significantly higher in AMD. Although an in vitro study showed an initial protective effect of autophagy, a cell viability study revealed the possibility of a harmful effect after long-term oxidative injury. The underlying mechanism or critical factors require further investigation.
C1 [Shu, Chih-Wen] Natl Sun Yat Sen Univ, Inst Biopharmaceut Sci, Kaohsiung 80424, Taiwan.
   [Shu, Chih-Wen] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Shu, Chih-Wen] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 80708, Taiwan.
   [Bee, Youn-Shen; Chen, Jiunn-Liang; Tsen, Chui-Lien] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung 81362, Taiwan.
   [Tsai, Wei-Lun] Kaohsiung Vet Gen Hosp, Dept Internal Med, Kaohsiung 81362, Taiwan.
   [Tsai, Wei-Lun] Natl Yang Ming Univ, Sch Med, Taipei 11221, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 80708, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Med Univ, Sch Med, Kaohsiung 80708, Taiwan.
C3 National Sun Yat Sen University; National Sun Yat Sen University;
   Kaohsiung Medical University; Kaohsiung Veterans General Hospital;
   Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; Kaohsiung Medical University
RP Shu, CW (通讯作者)，Natl Sun Yat Sen Univ, Inst Biopharmaceut Sci, Kaohsiung 80424, Taiwan.; Shu, CW (通讯作者)，Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.; Shu, CW (通讯作者)，Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 80708, Taiwan.; Sheu, SJ (通讯作者)，Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 80708, Taiwan.; Sheu, SJ (通讯作者)，Kaohsiung Med Univ, Sch Med, Kaohsiung 80708, Taiwan.
EM cwshu@g-mail.nsysu.edu.tw; ysbee@vghks.gov.tw; jlchen@vghks.gov.tw;
   cltsen@vghks.gov.tw; tsaiwl@yahoo.com.tw; sjivansheu@gmail.com
FU Kaohsiung Veterans General Hospital [VGHKS106-109 AND KSC107-007]
FX This study was funded by the Kaohsiung Veterans General Hospital
   (VGHKS106-109 AND KSC107-007).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ang WJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221481
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Buyuktepe TC, 2020, OPHTHALMOLOGICA, V243, P391, DOI 10.1159/000507089
   Chang HW, 2019, TOXINS, V11, DOI 10.3390/toxins11060313
   Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506
   Hagan S, 2017, BIOMARK MED, V11, P1135, DOI 10.2217/bmm-2017-0124
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P531, DOI 10.1111/aos.13772
   Lin CJ, 2021, KAOHSIUNG J MED SCI, V37, P166, DOI 10.1002/kjm2.12361
   Lin T, 2017, CLIN OPHTHALMOL, V11, P773, DOI 10.2147/OPTH.S124889
   Liu PF, 2022, SEMIN CANCER BIOL, V83, P269, DOI 10.1016/j.semcancer.2020.10.009
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Russo R, 2015, PROG BRAIN RES, V220, P87, DOI 10.1016/bs.pbr.2015.04.009
   Sheng R, 2015, ACTA PHARMACOL SIN, V36, P411, DOI 10.1038/aps.2014.151
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Terluk MR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5174957
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao JY, 2018, AUTOPHAGY, V14, P1226, DOI 10.1080/15548627.2018.1463121
NR 26
TC 3
Z9 3
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD FEB
PY 2021
VL 11
IS 2
AR 296
DI 10.3390/diagnostics11020296
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QN5CO
UT WOS:000622477500001
PM 33673354
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lazzeri, S
   Figus, M
   Sartini, MS
   Scarinci, F
   Casini, G
   Guidi, G
   Cupo, G
   Cacciamani, A
   Fasanella, V
   Agnifili, L
   Piaggi, P
   Varano, M
   Ripandelli, G
   Nardi, M
   Parravano, M
AF Lazzeri, Stefano
   Figus, Michele
   Sartini, Maria Sole
   Scarinci, Fabio
   Casini, Giamberto
   Guidi, Gianluca
   Cupo, Gaetano
   Cacciamani, Andrea
   Fasanella, Vincenzo
   Agnifili, Luca
   Piaggi, Paolo
   Varano, Monica
   Ripandelli, Guido
   Nardi, Marco
   Parravano, Mariacristina
TI Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Fundus-related microperimetry;
   Intravitreal ranibizumab; Predominantly hemorrhagic choroidal
   neovascularization Intravitreal injections
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBMACULAR HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; SUBRETINAL HEMORRHAGE; NATURAL-HISTORY; VISUAL-ACUITY;
   BEVACIZUMAB; MANAGEMENT; SECONDARY; LESIONS
AB Purpose: To evaluate the effects of intravitreal ranibizumab monotherapy on predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Materials and Methods: Twenty-two consecutive eyes with hemorrhagic neovascularization were treated with 3 monthly intravitreal ranibizumab injections. Additional injections were administered according to retreatment criteria during 12 months of follow- up. Results: A mean of 6.64 +/- 1.36 injections was administered. Overall, the mean visual acuity increased from 10.90 +/- 6.02 to 12.81 +/- 8.34 ETDRS letters (p > 0.05) at 12 months. The 'early treatment group' gained a mean of 2.83 +/- 2.24 ETDRS letters (p < 0.05), while the 'late treatment group' gained a mean of 0.30 +/- 1.25 ETDRS letters (p > 0.05) with significant differences between the groups (p < 0.05). A progressive resolution of macular bleeding was registered in 20 patients (mean time: 5.3 +/- 1.6 months). Conclusions: Ranibizumab injections can be considered a beneficial approach for the management of predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Furthermore, the time interval between hemorrhage and the first injection seems to be an important predicting factor of final visual acuity. (C) 2015 S. Karger AG, Basel
C1 [Lazzeri, Stefano; Scarinci, Fabio; Cupo, Gaetano; Cacciamani, Andrea; Varano, Monica; Ripandelli, Guido; Parravano, Mariacristina] IRCCS Rome, Fdn GB Bietti, Rome, Italy.
   [Lazzeri, Stefano; Figus, Michele; Sartini, Maria Sole; Casini, Giamberto; Guidi, Gianluca; Nardi, Marco] Univ Pisa, Ophthalm Unit, Surg Med & Mol Pathol & Crit Area, IT-56100 Pisa, Italy.
   [Piaggi, Paolo] Univ Pisa, Dept Endocrinol & Metab, IT-56100 Pisa, Italy.
   [Piaggi, Paolo] Univ Pisa, Dept Energy & Syst Engn, IT-56100 Pisa, Italy.
   [Fasanella, Vincenzo; Agnifili, Luca] Univ G dAnnunzio, Dept Med & Ageing Sci, Ophthalm Clin, Chieti, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; University of Pisa; University of Pisa; University of
   Pisa; G d'Annunzio University of Chieti-Pescara
RP Lazzeri, S (通讯作者)，Univ Pisa, Ophthalm Unit, Surg Med & Mol Pathol & Crit Area, Via Paradisa,2 Edificio 30, IT-56100 Pisa, Italy.
EM stefano_lazzeri@hotmail.it
RI Figus, Michele/AAD-6850-2020; Cacciamani, Andrea/AAB-2154-2021; Varano,
   Monica/K-8573-2016; Piaggi, Paolo/E-2539-2011; Agnifili,
   Luca/AAC-6345-2022; Figus, Michele/AAA-9808-2019; Scarinci,
   Fabio/AAB-5126-2020
OI Cacciamani, Andrea/0000-0003-1793-9842; Piaggi,
   Paolo/0000-0003-2774-9161; Figus, Michele/0000-0003-2243-9033; Varano,
   Monica/0000-0002-6530-1563; Scarinci, Fabio/0000-0001-5444-4377
FU Ministry of Health; Fondazione Roma
FX The research for this paper was financially supported by the Ministry of
   Health and Fondazione Roma.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hesgaard HB, 2012, ACTA OPHTHALMOL, V90, pe498, DOI 10.1111/j.1755-3768.2011.02352.x
   Hwang JU, 2012, RETINA-J RET VIT DIS, V32, P652, DOI 10.1097/IAE.0b013e318233abb4
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Lazzeri S, 2013, J CLIN EXP OPHTHALMO, V4, P293, DOI [10.4172/2155-9570.1000293, DOI 10.4172/2155-9570.1000293.]
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
NR 36
TC 4
Z9 4
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 2
BP 74
EP 81
DI 10.1159/000371393
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC8AX
UT WOS:000350591400003
PM 25662794
DA 2022-11-30
ER

PT J
AU Maguire, MG
   Ying, GS
   McCannel, CA
   Liu, CC
   Dai, Y
AF Maguire, Maureen G.
   Ying, Gui-shuang
   McCannel, Colin A.
   Liu, Chengcheng
   Dai, Yang
CA Complications Age Related Macular
TI Statin Use and the Incidence of Advanced Age-related Macular
   Degeneration in the Complications of Age-related Macular Degeneration
   Prevention Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; CHOLESTEROL-LOWERING MEDICATIONS; REDUCTASE
   INHIBITORS; 5-YEAR INCIDENCE; GRADING SYSTEM; RISK-FACTORS; MACULOPATHY;
   PROGRESSION; ASSOCIATION; BIOMARKERS
AB Objective: To evaluate the impact of statin use on the incidence of advanced age-related macular degeneration (AMD) and its components, choroidal neovascularization (CNV) and geographic atrophy (GA), among patients with bilateral large drusen.
   Design: Cohort study within a multicenter, randomized, clinical trial.
   Participants: Patients enrolled in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT).
   Methods: Eligibility criteria for the clinical trial required that participants have > 10 large (>125 mu m) drusen and visual acuity >= 20/40 in each eye. Patients scheduled for their final CAPT visit after May 2005 were interviewed on their history of use of cholesterol-lowering medications, including statins. Trained readers identified CNV and end point GA (>1 Macular Photocoagulation Study disc area of GA) based on review of fluorescein angiograms and fundus photographs taken at annual follow-up visits and when patients reported symptoms. The risk ratio for participants developing CNV or developing GA associated with statin use was estimated with time-dependent Cox proportional hazards models.
   Main Outcome Measures: Development of advanced AMD, CNV, and end point GA.
   Results: Among 764 patients eligible for the interview, 744 (97.4%) patients completed the interview on medication use. Statin use was reported by 296 (39.8%) of those interviewed, with the majority, 187 (63.2%) of the 296, beginning use after enrollment in CAPT. Among 744 patients, advanced AMD developed in 332 (22.5%) eyes of 242 (32.5%) patients, CNV in 222 (15%) eyes of 176 (23.7%) patients, and GA in 114 (7.7%) eyes of 80 (10.8%) patients. With adjustment for other risk factors, the estimated risk ratio for eyes (95% confidence interval) associated with statin use was 1.15 (0.87-1.52) for advanced AMD, 1.35 (0.99-1.83) for CNV, and 0.80 (0.46-1.39) for GA.
   Conclusions: The CAPT data are not consistent with a strong protective effect (risk ratio, <= 50.85) of statins on the development of advanced AMD among patients with bilateral large drusen.
C1 [Maguire, Maureen G.] Univ Penn, CAPT Coordinating Ctr, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [McCannel, Colin A.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 University of Pennsylvania; Mayo Clinic
RP Maguire, MG (通讯作者)，Univ Penn, CAPT Coordinating Ctr, Sch Med, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenn.edu
OI McCannel, Colin Archibald/0000-0003-0774-6414
FU National Eye Institute [EY012211, EY012261, EY012279]; National
   Institutes of Health; Department of Health and Human Services; Research
   to Prevent Blindness; Mayo Foundation; NATIONAL EYE INSTITUTE
   [U10EY012261, U10EY012279, U10EY012211] Funding Source: NIH RePORTER
FX Supported by grants EY012211, EY012261, and EY012279, from the National
   Eye Institute, National Institutes of Health, Department of Health and
   Human Services, an unrestricted grant from Research to Prevent Blindness
   and a grant from the Mayo Foundation.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2004, AM J OPHTHALMOL, V138, P688, DOI 10.1016/j.ajo.2004.05.015
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Ridker PM, 2001, CIRCULATION, V103, P1191
   Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
   2008, OPHTHALMOLOGY, V115, P1474
   2006, OPHTHALMOLOGY, V113, P1974
   2004, CLIN TRIALS, V1, P91
   2004, OPHTHALMOLOGY, V111, P1307
NR 31
TC 36
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2009
VL 116
IS 12
BP 2381
EP 2385
DI 10.1016/j.ophtha.2009.06.055
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530HE
UT WOS:000272579200018
PM 19850347
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Kano, M
   Yamamoto, A
   Saito, M
   Maruko, I
   Kawasaki, R
   Sekiryu, T
   Okada, AA
   Iida, T
AF Koizumi, Hideki
   Kano, Mariko
   Yamamoto, Akiko
   Saito, Masaaki
   Maruko, Ichiro
   Kawasaki, Ryo
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
TI Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for
   Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY; VEGF
   TRAP-EYE; INTRAVITREAL AFLIBERCEPT; PHOTODYNAMIC THERAPY; RANIBIZUMAB;
   VASCULOPATHY; VERTEPORFIN; BEVACIZUMAB; HYPERPERMEABILITY
AB PURPOSE: To investigate changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, consecutive, interventional case series.
   METHODS: This study included 102 eyes of 102 patients with treatment-naive neovascular AMD. All 102 eyes underwent 3 consecutive monthly 2.0 mg intravitreal aflibercept injections at baseline, 1 month, and 2 months. Choroidal thickness during 3 months were evaluated using either swept-source optical coherence tomography (OCT) or enhanced-depth imaging OCT.
   RESULTS: Of the 102 eyes, 46 eyes (45.1%) were diagnosed as typical neovascular AMD and 56 eyes (54.9%) as polypoidal choroidal vasculopathy. After intravitreal aflibercept injections, the mean subfoveal choroidal thickness decreased from 252.0 +/- 99.7 mu m at baseline to 217.9 +/- 95.6 mu m at 3 months (P < .0001; percentage change from baseline, 86.5%). Mean choroidal thickness measured at 3 mm from the foveal center in the superior, inferior, temporal, and nasal directions also decreased significantly from 258.7 +/- 85.9 mu m to 236.4 +/- 84.6 mu m, 229.9 +/- 93.0 mu m to 208.6 +/- 86.5 mu m, 237.4 +/- 86.5 mu m to 214.6 +/- 79.5 mu m, and 183.7 +/- 97.0 mu m to 162.3 +/- 90.6 mu m, respectively (P < .0001 for all directions). Both subtypes of neovascular AMD demonstrated a similar trend toward decreasing choroidal thickness during the follow-up period.
   CONCLUSIONS: Choroidal thickness significantly decreased not only at the foveal center but also in the entire macula after 3 monthly intravitreal aflibercept injections for neovascular AMD. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Koizumi, Hideki; Maruko, Ichiro; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, Tokyo 1628666, Japan.
   [Kano, Mariko; Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Kawasaki, Ryo] Yamagata Univ, Fac Med, Dept Publ Hlth, Yamagata 990, Japan.
C3 Tokyo Women's Medical University; Fukushima Medical University; Kyorin
   University; Yamagata University
RP Koizumi, H (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM koizumi.hideki@twmu.ac.jp
RI Kawasaki, Ryo/B-7266-2009; Maruko, Ichiro/AFP-1311-2022; Saito,
   Masaaki/ABI-2783-2020; Kawasaki, Ryo/H-9716-2019
OI Kawasaki, Ryo/0000-0002-7492-6303; Maruko, Ichiro/0000-0001-5647-6372;
   Saito, Masaaki/0000-0003-1494-6350; Koizumi, Hideki/0000-0002-9610-4386;
   Sekiryu, Tetsuju/0000-0001-8042-2729
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [25670739]
FX This study was supported in part by Grant No. 25670739 from the Ministry
   of Education, Culture, Sports, Science and Technology-Japan (H.K.).
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gass JD, 1996, STEREOSCOPIC ATLAS M, P1038
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Ogasawara Masashi, 2012, Nippon Ganka Gakkai Zasshi, V116, P643
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 40
TC 78
Z9 81
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2015
VL 159
IS 4
BP 627
EP 633
DI 10.1016/j.ajo.2014.12.025
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE4FV
UT WOS:000351787400002
PM 25555799
DA 2022-11-30
ER

PT J
AU Contreras, AV
   Zenteno, JC
   Fernandez-Lopez, JC
   Rodriguez-Corona, U
   Falfan-Valencia, R
   Sebastian, L
   Morales, F
   Ochoa-Contreras, D
   Carnevale, A
   Silva-Zolezzi, I
AF Contreras, Alejandra V.
   Carlos Zenteno, Juan
   Carlos Fernandez-Lopez, Juan
   Rodriguez-Corona, Ulises
   Falfan-Valencia, Ramces
   Sebastian, Leticia
   Morales, Fabiola
   Ochoa-Contreras, Daniel
   Carnevale, Alessandra
   Silva-Zolezzi, Irma
TI CFH haplotypes and ARMS2, C2, C3, and CFB alleles show association with
   susceptibility to age-related macular degeneration in Mexicans
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; FACTOR-B; UNITED-STATES;
   EYE DISEASE; COMPONENT 2; 3 GENES; POPULATION; RISK; VARIANT
AB Purpose: To evaluate the contribution of genetic variants of complement factor H (CFH), complement component 2 and 3 (C2 and C3), complement factor B (CFB), and age-related maculopathy susceptibility 2 (ARMS2) to age-related macular degeneration (AMD) risk in the Mexican Mestizo population.
   Methods: Analysis included 282 unrelated Mexican patients with advanced AMD, 205 healthy controls, and 280 population controls. Stereoscopic fundus images were graded on the Clinical Age-Related Maculopathy System (CARMS). We designed a resequencing strategy using primers with M13 adaptor for the 23 exons of the CFH gene in a subgroup of 96 individuals clinically evaluated: 48 AMD cases and 48 age-and sex-matched healthy controls. Single nucleotide polymorphisms (SNPs) in C3 (Arg80Gly and Pro292Leu), C2 (rs547154), CFB (Leu9His), and ARMS2 (Ala69Ser) were genotyped in all patients, healthy and population controls using TaqMan assay.
   Results: All evaluated individuals were Mexican Mestizos, and their genetic ancestry was validated using 224 ancestry informative markers and calculating F-st values. The CFH resequencing revealed 19 SNPs and a common variant in the intron 2 splice acceptor site; three CFH haplotypes inferred from individual genotypes, showed significant differences between cases and controls. The risk alleles in C3 (rs1047286, odds ratio [OR]=2.48, 95% confidence interval [CI]=1.64-3.75, p=1.59E-05; rs2230199, OR=2.15, 95% CI=1.48-3.13, p=6.28E-05) and in ARMS2 (rs10490924, OR=3.09, 95% CI=2.48-3.86, p=5.42E-23) were strongly associated with risk of AMD. The protective effect of alleles in C2 (rs547154) and CFB (rs4151667) showed a trend but was not significantly associated after correction for multiple testing.
   Conclusions: Our results show that ARMS2 and C3 are major contributors to advanced AMD in Mexican patients, while the contributions of CFH, C2, and CFB are minor to those of other populations, reveling significant ethnic differences in minor allele frequencies. We provide evidence that two specific common haplotypes in the CFH gene predispose individuals to AMD, while another may confer reduced risk of disease in this admixed population.
C1 [Contreras, Alejandra V.; Carlos Fernandez-Lopez, Juan; Rodriguez-Corona, Ulises; Sebastian, Leticia; Morales, Fabiola; Carnevale, Alessandra] Inst Nacl Med Genom, Mexico City, DF, Mexico.
   [Ochoa-Contreras, Daniel] Hosp Dr Luis Sanchez Bulnes, Asociac Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Carlos Zenteno, Juan] Inst Ophthalmol Conde Valenciana, Dept Genet, Mexico City, DF, Mexico.
   [Carlos Zenteno, Juan] Inst Ophthalmol Conde Valenciana, Res Unit, Mexico City, DF, Mexico.
   [Carlos Zenteno, Juan] Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Mexico City, DF, Mexico.
   [Falfan-Valencia, Ramces] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab HLA, Mexico City, DF, Mexico.
   [Silva-Zolezzi, Irma] Nestle Res Ctr, Nutr & Hlth Dept, CH-1000 Lausanne, Switzerland.
C3 Instituto Nacional de Medicina Genomica; Universidad Nacional Autonoma
   de Mexico; Nestle SA
RP Contreras, AV (通讯作者)，Perifer Sur 4809, Mexico City 14610, DF, Mexico.
EM acontreras@inmegen.gob.mx
RI Fernandez, Juan Carlos/C-4976-2013; Falfán-Valencia, Ramcés/M-7331-2018;
   Contreras, Alejandra Virginia/E-7815-2013
OI Fernandez, Juan Carlos/0000-0003-3680-4193; Falfán-Valencia,
   Ramcés/0000-0001-6877-8124; , Ulises/0000-0001-9286-0857; Contreras,
   Alejandra Virginia/0000-0003-3653-5958; Leticia,
   Sebastian-Medina/0000-0002-1976-2713
FU Consejo Nacional de Ciencia y Tecnologia [SALUD-2008-C01-87887];
   Instituto Nacional de Medicina Genomica [06/2007]
FX This work was supported by Consejo Nacional de Ciencia y Tecnologia
   grant SALUD-2008-C01-87887, and by Instituto Nacional de Medicina
   Genomica grant 06/2007. The authors declare no conflict of interest.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Arturo Santos JAP, 2001, CEGUERA LEGAL PREVAL
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hampton T, 2010, JAMA-J AM MED ASSOC, V304, P1541, DOI 10.1001/jama.2010.1411
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sans M, 2000, HUM BIOL, V72, P155
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Silva-Zolezzi I, 2009, P NATL ACAD SCI USA, V106, P8611, DOI 10.1073/pnas.0903045106
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 50
TC 15
Z9 15
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 14
PY 2014
VL 20
BP 105
EP 116
PG 12
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AB5JT
UT WOS:000331825400001
PM 24453474
DA 2022-11-30
ER

PT J
AU Schaal, KB
   Freund, KB
   Litts, KM
   Zhang, YH
   Messinger, JD
   Curcio, CA
AF Schaal, Karen B.
   Freund, K. Bailey
   Litts, Katie M.
   Zhang, Yuhua
   Messinger, Jeffrey D.
   Curcio, Christine A.
TI OUTER RETINAL TUBULATION IN ADVANCED AGE-RELATED MACULAR DEGENERATION
   Optical Coherence Tomographic Findings Correspond to Histology
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photoreceptors; Muller cells; age-related macular degeneration; outer
   retinal tubulation; ellipsoid; reflectivity; optical coherence
   tomography; histology; transmission electron microscopy
ID 2ND REFLECTIVE BAND; MITOCHONDRIAL DYNAMICS; PHOTORECEPTOR ROSETTES;
   RETINITIS-PIGMENTOSA; GEOGRAPHIC ATROPHY; CONE FUNCTION;
   NEURODEGENERATION; FISSION; MODEL; ACCUMULATION
AB Purpose:To compare optical coherence tomography (OCT) and histology of outer retinal tubulation (ORT) secondary to advanced age-related macular degeneration in patients and in postmortem specimens, with particular attention to the basis of the hyperreflective border of ORT.Method:A private referral practice (imaging) and an academic research laboratory (histology) collaborated on two retrospective case series. High-resolution OCT raster scans of 43 eyes (34 patients) manifesting ORT secondary to advanced age-related macular degeneration were compared to high-resolution histologic sections through the fovea and superior perifovea of donor eyes (13 atrophic age-related macular degeneration and 40 neovascular age-related macular degeneration) preserved 4 hours after death.Results:Outer retinal tubulation seen on OCT correlated with histologic findings of tubular structures consisted largely of cones lacking outer segments and lacking inner segments. Four phases of cone degeneration were histologically distinguishable in ORT lumenal walls, nascent, mature, degenerate, and end stage (inner segments and outer segments, inner segments only, no inner segments, and no photoreceptors and only Muller cells forming external limiting membrane, respectively). Mitochondria, which are normally long and bundled within inner segment ellipsoids, were small and scattered within shrunken inner segments and cell bodies of surviving cones. A lumenal border was delimited by an external limiting membrane. Outer retinal tubulation observed in closed and open configurations was distinguishable from cysts and photoreceptor islands on both OCT and histology. Hyperreflective lumenal material seen on OCT represents trapped retinal pigment epithelium and nonretinal pigment epithelium cells.Conclusion:The defining OCT features of ORT are location in the outer nuclear layer, a hyperreflective band differentiating it from cysts, and retinal pigment epithelium that is either dysmorphic or absent. Histologic and OCT findings of outer retinal tubulation corresponded in regard to composition, location, shape, and stages of formation. The reflectivity of ORT lumenal walls on OCT apparently does not require an outer segment or an inner/outer segment junction, indicating an independent reflectivity source, possibly mitochondria, in the inner segments.
C1 [Schaal, Karen B.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Litts, Katie M.; Zhang, Yuhua; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Litts, Katie M.] Univ Alabama Birmingham, Vis Sci Grad Program, Birmingham, AL 35294 USA.
C3 Vitreous Retina Macula Consultants of New York; University of Alabama
   System; University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn Alabama Vis Res Labs, Dept Ophthalmol, Room 360,1670 Univ Blvd, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Litts, Katie M/AAK-1564-2021; Freund, K. Bailey/V-7488-2018
OI Litts, Katie M/0000-0001-6707-8273; Freund, K.
   Bailey/0000-0002-7888-9773
FU NIH [EY06109, 5R21EY021903]; International Retina Research Foundation;
   EyeSight Foundation of Alabama; Research to Prevent Blindness, Inc;
   Vision Science Graduate Program at UAB; Macula Foundation; Edward N. and
   Della L. Thome Memorial Foundation; NATIONAL EYE INSTITUTE [R01EY006109,
   P30EY003039, R01EY024378, R21EY021903] Funding Source: NIH RePORTER
FX Supported by NIH grants EY06109 (C.A.C. and J.D.M.), 5R21EY021903
   (Y.Z.), International Retina Research Foundation (Y.Z.), EyeSight
   Foundation of Alabama (Y.Z.), unrestricted funds to the Department of
   Ophthalmology from Research to Prevent Blindness, Inc (C.A.C. and Y.Z.),
   the Vision Science Graduate Program at UAB (K.M.L.), and the Macula
   Foundation (K.B.F.). Acquisition of donor eyes received additional
   support from International Retinal Research Foundation, National Eye
   Institute P30 EY003039, and the Arnold and Mabel Beckman Initiative for
   Macular Research. Creation of Project MACULA received additional support
   from the Edward N. and Della L. Thome Memorial Foundation.
CR ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Ding XQ, 2009, HUM MOL GENET, V18, P4770, DOI 10.1093/hmg/ddp440
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   Eagle RC, 2013, EYE, V27, P128, DOI 10.1038/eye.2012.237
   Ellabban AA, 2012, EYE, V26, P1086, DOI 10.1038/eye.2012.101
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Greenberg JP, 2014, JAMA OPHTHALMOL, V132, P437, DOI 10.1001/jamaophthalmol.2013.7987
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Lu RW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.060504
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   MacAskill AF, 2010, TRENDS CELL BIOL, V20, P102, DOI 10.1016/j.tcb.2009.11.002
   Maresca A, 2013, MOL CELL NEUROSCI, V55, P62, DOI 10.1016/j.mcn.2012.08.004
   McInnes J, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-12
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mrejen S, 2013, OPHTHALMOLOGY, V120, pE32, DOI 10.1016/j.ophtha.2013.01.039
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Papastefanou VP, 2013, BRIT J OPHTHALMOL, V97, P1014, DOI 10.1136/bjophthalmol-2013-303234
   Polyak S., 1957, VERTEBRATE VISUAL SY
   Sergouniotis PI, 2012, OPHTHALMOLOGY, V119, P596, DOI 10.1016/j.ophtha.2011.09.017
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stuck MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032484
   TSO MOM, 1969, ARCH PATHOL, V88, P664
   TSUKAMOTO Y, 1992, VISION RES, V32, P1809, DOI 10.1016/0042-6989(92)90042-H
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Tychinsky V, 2009, J BIOPHOTONICS, V2, P494, DOI 10.1002/jbio.200910042
   van de Pavert SA, 2004, J CELL SCI, V117, P4169, DOI 10.1242/jcs.01301
   WILLIAMS DS, 1990, J COMP NEUROL, V295, P155, DOI 10.1002/cne.902950113
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wong IY, 2012, CURR OPIN OPHTHALMOL, V23, P210, DOI 10.1097/ICU.0b013e3283524162
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Xu JH, 2013, J NEUROSCI, V33, P14939, DOI 10.1523/JNEUROSCI.0909-13.2013
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 58
TC 78
Z9 83
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1339
EP 1350
DI 10.1097/IAE.0000000000000471
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600007
PM 25635579
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Man, REK
   Gan, ATL
   Fenwick, EK
   Teo, KYC
   Tan, ACS
   Cheung, GCM
   Teo, ZL
   Kumari, N
   Wong, TY
   Cheng, CY
   Lamoureux, EL
AF Man, Ryan Eyn Kidd
   Gan, Alfred Tau Liang
   Fenwick, Eva K.
   Teo, Kelvin Yi Chong
   Tan, Anna C. S.
   Cheung, Gemmy Chui Ming
   Teo, Zhen Ling
   Kumari, Neelam
   Wong, Tien Yin
   Cheng, Ching-Yu
   Lamoureux, Ecosse Luc
TI Impact of incident age-related macular degeneration and associated
   vision loss on vision-related quality of life
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE vision
ID DISEASE; RASCH; SEVERITY; BURDEN; EYE
AB Background We examined the associations between the 6-year incidence of age-related macular degeneration (AMD) and vision-related quality of life (VRQoL), and the contribution of presenting visual acuity (VA), in an Asian population. Methods Fundus images from the Singapore Chinese Eye Study, a population-based cohort study (baseline: 2009-2011; follow-up: 2015-2017), were graded using a modified Wisconsin age-related maculopathy grading system. Incident AMD was defined as no baseline AMD in both eyes and early/late AMD in the worse eye at follow-up. Presenting VA was assessed using the logarithm of the minimum angle of resolution chart at 4 m under standard lighting conditions with habitual correction. Multiple linear regression models determined the associations between AMD incidence with changes in the Rasch-transformed scores of the Reading, Mobility and Emotional VRQoL domains of the 32-item Impact of Visual Impairment (IVI-32) questionnaire, adjusted for traditional confounders. The contribution of presenting VA to changes in VRQoL was also estimated. Results Of the 2251 participants without AMD at baseline (mean age (SD): 57.7 (9) years, 51.4% women), 101 (4.5%) and 11 (0.5%) developed incident early and late AMD at follow-up, respectively. Incident late AMD was associated with significant 30.3%, 32.5% and 30.9% decrements in Reading, Mobility and Emotional IVI scores, respectively. The contribution of presenting VA ranged between 1.62% and 4.35% of the observed decrements. No significant associations were noted with incident early AMD. Conclusion Incident late AMD had a substantial impact on all aspects of VRQoL, with presenting VA contributing only minimally to this longitudinal relationship.
C1 [Man, Ryan Eyn Kidd; Gan, Alfred Tau Liang; Fenwick, Eva K.; Teo, Kelvin Yi Chong; Tan, Anna C. S.; Cheung, Gemmy Chui Ming; Teo, Zhen Ling; Kumari, Neelam; Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse Luc] Singapore Eye Res Inst, Singapore, Singapore.
   [Man, Ryan Eyn Kidd; Teo, Kelvin Yi Chong; Tan, Anna C. S.; Cheung, Gemmy Chui Ming; Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse Luc] Duke NUS Med Sch, Singapore 169857, Singapore.
   [Man, Ryan Eyn Kidd; Teo, Kelvin Yi Chong; Tan, Anna C. S.; Cheung, Gemmy Chui Ming; Teo, Zhen Ling; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Kumari, Neelam] Khoo Teck Puat Hosp, Dept Ophthalmol & Visual Sci, Singapore, Singapore.
   [Wong, Tien Yin; Cheng, Ching-Yu; Lamoureux, Ecosse Luc] Natl Univ Singapore, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Lamoureux, EL (通讯作者)，Duke NUS Med Sch, Singapore 169857, Singapore.
EM ecosse@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Man, Ryan/0000-0001-5028-605X; Teo, Kelvin/0000-0002-7458-7081; Fenwick,
   Eva/0000-0003-0417-2048; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Singapore Ministry of Health's National Medical Research Council
   [STaR/0003/2008, NMRC/CIRG/1417/2015, NMRC/CIRG/1488/2018,
   NMRC/OFLCG/004a/2018]; Singapore Bio Imaging Consortium [C-011/2006];
   Biomedical Research Council [08/1/35/19/550]; National Medical Research
   Council (NMRC) Senior-Clinician Scientist Awards [NMRC/CSASI/0009/2016,
   NMRC/CSASI/0012/2017]; NMRC Transition Award [MOH-TA19may-0002]
FX This research is supported by the Singapore Ministry of Health's
   National Medical Research Council (STaR/0003/2008, NMRC/CIRG/1417/2015,
   NMRC/CIRG/1488/2018 and NMRC/OFLCG/004a/2018), the Singapore Bio Imaging
   Consortium (C-011/2006) and the Biomedical Research Council
   (08/1/35/19/550). ELL and C-YC are supported by the National Medical
   Research Council (NMRC) Senior-Clinician Scientist Awards
   (#NMRC/CSASI/0009/2016 for ELL; #NMRC/CSASI/0012/2017 for C-YC), and
   REKM is supported by the NMRC Transition Award (#MOH-TA19may-0002).
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc11-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc10-S062]
   ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Calvert M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5267
   Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS POP A
   Chien TW, 2008, RASCH MEAS T, V22, P1171
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fenwick EK, 2017, INVEST OPHTH VIS SCI, V58, P6379, DOI 10.1167/iovs.16-20950
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Fenwick EK, 2016, JAMA OPHTHALMOL, V134, P1299, DOI 10.1001/jamaophthalmol.2016.3692
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Gershon Richard C, 2005, J Appl Meas, V6, P109
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Linacre, 2014, USERS GUIDE WINSTEPS
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Majithia S, 2020, BRIT J OPHTHALMOL, V104, P610, DOI 10.1136/bjophthalmol-2019-314760
   Man REK, 2020, OPHTHALMOLOGY, V127, P1145, DOI 10.1016/j.ophtha.2020.01.056
   Weber Joseph A, 2010, Home Health Care Serv Q, V29, P105, DOI 10.1080/01621424.2010.511505
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   WHO, 2011, WORLD REPORT ON DISABILITY, P1
   Wolfe E W, 1999, J Outcome Meas, V3, P134
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 34
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2022
VL 106
IS 8
BP 1063
EP 1068
DI 10.1136/bjophthalmol-2020-318269
EA FEB 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3N6ON
UT WOS:000727740900001
PM 33637622
DA 2022-11-30
ER

PT J
AU Zuo, CG
   Wen, F
   Li, M
   Zhang, XZ
   Chen, H
   Wu, KF
   Zeng, RP
AF Zuo, Chengguo
   Wen, Feng
   Li, Meng
   Zhang, Xiongze
   Chen, Hui
   Wu, Kunfang
   Zeng, Renpan
TI COL1A2 polymorphic markers confer an increased risk of neovascular
   age-related macular degeneration in a Han Chinese population
SO MOLECULAR VISION
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRACRANIAL ANEURYSMS; GENE
   POLYMORPHISMS; CLINICOPATHOLOGICAL CORRELATION; JAPANESE POPULATION;
   ASSOCIATION; EXPRESSION; CFH; PERICYTES; MEMBRANES
AB Purpose: We have previously documented that neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) have multiple different clinical and genetic characteristics. In this study, we investigated the association of rs42524 in the alpha-2 type I collagen (COL1A2) gene, which has been identified as a risk variant for intracranial aneurysm, with nAMD and PCV in a Han Chinese population.
   Methods: The study prospectively recruited 195 patients with PCV, 136 patients with nAMD, and 181 control individuals. We genotyped the rs42524 polymorphism of COL1A2 using the Multiplex SNaPshot System and direct DNA sequencing. Genotype and allele frequencies were evaluated with PLINK software.
   Results: The rs42524 polymorphism was modestly significantly associated with nAMD [minor allele: G, p(allelic)=0.04253, odds ratio=0.5285 (95% confidence interval: 0.2832-0.9866)], but not with PCV [minor allele: G, p(allelic)=0.4164, odds ratio=1.2110 (95% confidence interval: 0.7631-1.9210)]. The p values for the additive model were significant for nAMD but not for the dominant or recessive models. None of the models for PCV were statistically significant. The size of our sample cohort resulted in a post hoc power of more than 80% to detect associations of rs42524 with nAMD and PCV.
   Conclusions: The rs42524 polymorphism is a risk allele for nAMD in a Han Chinese population. rs42524 in COL1A2 confers different levels of susceptibility to nAMD and PCV.
C1 [Zuo, Chengguo; Wen, Feng; Li, Meng; Zhang, Xiongze; Chen, Hui; Wu, Kunfang; Zeng, Renpan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@yahoo.com.cn
RI meng, li/GVT-2063-2022
FU National Natural Science Foundation of China [81070745]; Medical
   Scientific Research Foundation of Guangdong Province, China [B2011108];
   Fundamental Research Funds of State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81070745), the Medical Scientific Research
   Foundation of Guangdong Province, China (grant number: B2011108) and the
   Fundamental Research Funds of State Key Laboratory of Ophthalmology.
CR Allt G, 2001, CELLS TISSUES ORGANS, V169, P1, DOI 10.1159/000047855
   Bessho H, 2009, MOL VIS, V15, P1107
   Caballero S, 2011, INVEST OPHTH VIS SCI, V52, P2490, DOI 10.1167/iovs.10-6351
   Chen HY, 2012, MOL VIS, V18, P816
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Iida Tomohiro, 2005, Nippon Ganka Gakkai Zasshi, V109, P383
   Ikonomidis JS, 2006, CIRCULATION, V114, pI365, DOI 10.1161/CIRCULATIONAHA.105.000810
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Joo SP, 2009, SURG NEUROL, V72, P48, DOI 10.1016/j.surneu.2009.02.009
   Kazi M, 2003, J VASC SURG, V38, P1283, DOI 10.1016/S0741-5214(03)00791-2
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2009, MOL VIS, V15, P1819
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2010, MOL VIS, V16, P231
   Lima LH, 2011, OPHTHALMIC GENET, V32, P80, DOI 10.3109/13816810.2010.544362
   Lindahl K, 2009, BIOCHEM BIOPH RES CO, V384, P501, DOI 10.1016/j.bbrc.2009.05.006
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ponticos M, 2004, MATRIX BIOL, V22, P619, DOI 10.1016/j.matbio.2003.12.002
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Roos YBWEM, 2004, STROKE, V35, P2276, DOI 10.1161/01.STR.0000141415.28155.46
   Tanaka K, 2011, MOL VIS, V17, P2751
   van Dijk FS, 2010, GENET MED, V12, P736, DOI 10.1097/GIM.0b013e3181f01617
   von Tell D, 2006, EXP CELL RES, V312, P623, DOI 10.1016/j.yexcr.2005.10.019
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yoneyama T, 2004, STROKE, V35, P443, DOI 10.1161/01.STR.0000110788.45858.DC
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeng R, 2011, OPHTHALMIC GENET
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   Zhu YF, 2008, J NEUROSURG, V109, P1060, DOI 10.3171/JNS.2008.109.12.1060
NR 45
TC 10
Z9 10
U1 0
U2 7
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 30
PY 2012
VL 18
IS 183-84
BP 1787
EP 1793
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 973AJ
UT WOS:000306323100002
PM 22815632
DA 2022-11-30
ER

PT J
AU Park, KH
   Ryu, E
   Tosakulwong, N
   Wu, YH
   Edwards, AO
AF Park, Kyu Hyung
   Ryu, Euijung
   Tosakulwong, Nirubol
   Wu, Yanhong
   Edwards, Albert O.
TI Common variation in the SERPING1 gene is not associated with age-related
   macular degeneration in two independent groups of subjects
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E; C1 INHIBITOR; RISK;
   POLYMORPHISMS; MACULOPATHY; VARIANT; DRUSEN; SUSCEPTIBILITY; LINKAGE
AB Purpose: Common genetic variation in the complement component 1 inhibitor gene (SERPING1) was recently reported to increase the risk of developing age-related macular degeneration (AMD). This study was performed to replicate the association between SERPING1 and AMD.
   Methods: Seven single nucleotide polymorphisms (SNPs) tagging common haplotypes across SERPING1 were genotyped on 786 (The Mayo Clinic) subjects and the association with AMD studied using single SNP and haplotype association analyses. The SNP in intron 6 (rs2511989) previously reported to increase the risk of AMD was studied in an additional 1,541 subjects from the Age-Related Eye Disease Study (AREDS). Association with specific subtypes of AMD and interaction with four other loci: complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2/ LOC387715), High Temperature Requirement Factor A1 (HTRA1), complement factor B/complement component 2 (CFB/C2), and complement component 3 (C3) involved in AMD was explored.
   Results: The seven tag-SNPs were not associated with AMD in the Mayo subjects (p = 0.13-0.70) and rs2511989 was also not associated with AMD in the Mayo or AREDS subjects (p = 0.44-0.45). Evaluation of haplotypes across SERPING1 did not reveal association with AMD (p = 0.14-0.97). SNPs were not associated with AMD subtypes (early, geographic atrophy, or exudation). No interaction with other AMD risk variants was observed.
   Conclusions: We were unable to replicate the reported association between SERPING1 and AMD in two independent groups of subjects.
C1 [Park, Kyu Hyung; Tosakulwong, Nirubol; Edwards, Albert O.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Gyeonggi, South Korea.
   [Ryu, Euijung] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA.
   [Wu, Yanhong] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
C3 Mayo Clinic; Seoul National University (SNU); Mayo Clinic; Mayo Clinic
RP Edwards, AO (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM edwardslab@mayo.edu
RI Park, Kyu Hyung/J-5481-2012
FU Foundation Fighting Blindness, Owing Mills, MD [EY014467]; American
   Health Assistance Foundation, Clarksburg, MD,; Research to Prevent
   Blindness, New York, NY; Mayo Foundation, Rochester, MN; Seoul National
   University Bundang Hospital, Seoul, Korea; NATIONAL EYE INSTITUTE
   [R01EY014467] Funding Source: NIH RePORTER
FX The research was supported by EY014467, the Foundation Fighting
   Blindness, Owing Mills, MD, the American Health Assistance Foundation,
   Clarksburg, MD, unrestricted departmental grants from Research to
   Prevent Blindness, New York, NY, Mayo Foundation, Rochester, MN, and
   Seoul National University Bundang Hospital, Seoul, Korea.
CR Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Blanch Alvaro, 2002, Hum Mutat, V20, P405, DOI 10.1002/humu.9073
   Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cumming SA, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e114
   Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 52
TC 35
Z9 37
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 23
PY 2009
VL 15
IS 17-19
BP 200
EP 207
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 421NA
UT WOS:000264364400003
PM 19169411
DA 2022-11-30
ER

PT J
AU Gupta, SK
   Murthy, GVS
   Morrison, N
   Price, GM
   Dherani, M
   John, N
   Fletcher, AE
   Chakravarthy, U
AF Gupta, Sanjeev K.
   Murthy, Gudlavalleti V. S.
   Morrison, Nicoli
   Price, Gill M.
   Dherani, Mukesh
   John, Neena
   Fletcher, Astrid E.
   Chakravarthy, Usha
TI Prevalence of early and late age-related macular degeneration in a rural
   population in Northern India: The INDEYE feasibility study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID NATIONAL-HEALTH; MACULOPATHY; EYE
AB PURPOSE. To assess the prevalence of age-related macular degeneration (AMD) in a rural population in Northern India.
   METHODS. In a pilot feasibility study, 1443 people (median age, 60 years: 52% women), were identified from enumeration of the 50+ age group in 11 randomly sampled villages from a rural, periurban district of Haryana, Northern India. Of those identified, 87% attended an eye examination that included digital fundus photography. Fundus images were graded at a single reading center using definitions from the Wisconsin Age-Related Maculopathy Grading System.
   RESULTS. Fundus photographs were available for 1101 participants. Overall, 28.8% of participants had ungradable fundus images due to cataract. Including all with ungradable images in the denominator, the prevalence of soft drusen was 34.0% (95% confidence interval [CI] 26.1-42.9); of soft indistinct drusen, 2.2% (95% CI, 1.1 - 4.4); and of pigmentary irregularities, 10.8% (95% CI, 7.1-16.1). There were 15 (1.4%) cases of late-stage AMD (95% CI, 0.8-2.3) with the prevalence rising from 0.4% in the 50- to 59-year age range to 4.6% in those aged 70 years or older.
   CONCLUSIONS. Drusen and pigmentary irregularities are common among the rural northern Indian population. The prevalence of late AMD is similar to that encountered in Western settings and is likely to contribute significantly to the burden of vision loss in older people in the developing world.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Community Ophthalmol, New Delhi 110029, India.
   Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland.
C3 University of London; London School of Hygiene & Tropical Medicine; All
   India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; Queens University Belfast
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
OI Dherani, Mukesh/0000-0002-3055-9636; Chakravarthy,
   Usha/0000-0002-2606-3734; Gupta, Sanjeev/0000-0002-2014-5333
FU Wellcome Trust [066082] Funding Source: Medline
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Rajan S Irudaya, 2003, J Aging Soc Policy, V15, P11, DOI 10.1300/J031v15n02_02
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   *STAT CORP, 2003, STAT STAT SOFTW REL
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   West S, 2001, B WORLD HEALTH ORGAN, V79, P244
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
NR 20
TC 56
Z9 57
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2007
VL 48
IS 3
BP 1007
EP 1011
DI 10.1167/iovs.06-0712
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 142YF
UT WOS:000244686500009
PM 17325139
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Liew, G
   Mitchell, P
   Wong, TY
   Rochtchina, E
   Wang, JJ
AF Liew, Gerald
   Mitchell, Paul
   Wong, Tien Yin
   Rochtchina, Elena
   Wang, Jie Jin
TI The Association of Aspirin Use With Age-Related Macular Degeneration
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID 5-YEAR INCIDENCE; POOLED FINDINGS; MEDICATION USE; RISK-FACTORS;
   MACULOPATHY; PREVALENCE; MORTALITY; SYSTEM
AB Objective: To determine whether regular aspirin use is associated with a higher risk for developing age-related macular degeneration (AMD) by using analyzed data from a 15-year prospective cohort.
   Methods: A prospective analysis was conducted of data from an Australian population-based cohort with 4 examinations during a 15-year period (1992-1994 to 2007-2009). Participants completed a detailed questionnaire at baseline assessing aspirin use, cardiovascular disease status, and AMD risk factors. Age-related macular degeneration was graded side-by-side from retinal photographs taken at each study visit to assess the incidence of neovascular (wet) AMD and geographic atrophy (dry AMD) according to the international AMD classification.
   Results: Of 2389 baseline participants with follow-up data available, 257 individuals (10.8%) were regular aspirin users and 63 of the 2389 developed neovascular AMD. Persons who were regular aspirin users were more likely to have incident neovascular AMD: the 15-year cumulative incidence was 9.3% in users and 3.7% in non-users. After adjustment for age, sex, smoking, history of cardiovascular disease, systolic blood pressure, and body mass index, persons who were regular aspirin users had a higher risk of developing neovascular AMD (odds ratio [OR], 2.46; 95% CI, 1.25-4.83). The association showed a dose-response effect (multivariate-adjusted P=.01 for trend). Aspirin use was not associated with the incidence of geographic atrophy (multivariate-adjusted OR, 0.99; 95% CI, 0.59-1.65).
   Conclusion: Regular aspirin use is associated with increased risk of incident neovascular AMD, independent of a history of cardiovascular disease and smoking.
C1 [Liew, Gerald; Mitchell, Paul; Rochtchina, Elena; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Liew, Gerald; Wong, Tien Yin; Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
C3 University of Sydney; Centre for Eye Research Australia; University of
   Melbourne; National University of Singapore; Singapore National Eye
   Center
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Liew, Gerald/AAB-6870-2022; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Wong, Tien
   Yin/AAC-9724-2020
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264
FU National Health & Medical Research Council Australia [153948, 211069,
   302068]
FX The study was supported by project grants 153948, 211069, and 302068
   from the National Health & Medical Research Council Australia.
CR American Foundation for the Blind, 2011, SEN SIT WELC PAG
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Evans M., 2011, TELEGRAPH
   Fox News.com, 2011, FOX NEWS COM    1003
   HANSCH GM, 1981, CLIN IMMUNOL IMMUNOP, V21, P228, DOI 10.1016/0090-1229(81)90211-7
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Liew G, 2006, J HYPERTENS, V24, P1329, DOI 10.1097/01.hjh.0000234113.33025.33
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nicolucci A, 2008, JAMA-J AM MED ASSOC, V300, P2180, DOI 10.1001/jama.2008.625
   Parker-Pope T., 2008, NY TIMES
   Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0
   Seshasai SRK, 2012, ARCH INTERN MED, V172, P209, DOI 10.1001/archinternmed.2011.628
   Shankar A, 2006, ARCH INTERN MED, V166, P188, DOI 10.1001/archinte.166.2.188
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099
NR 32
TC 39
Z9 40
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 258
EP 264
DI 10.1001/jamainternmed.2013.1583
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400001
PM 23337937
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Lee, DW
   Kim, CG
   Kim, JW
AF Kim, Jae Hui
   Chang, Young Suk
   Lee, Dong Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Incidence and Timing of the First Recurrence in Neovascular Age-Related
   Macular Degeneration: Comparison Between Ranibizumab and Aflibercept
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE recurrence; antivascular endothelial growth factor; ranibizumab;
   aflibercept; age-related macular degeneration; polypoidal choroidal
   vasculopathy; choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; ANTI-VEGF
   THERAPY; INTRAVITREAL AFLIBERCEPT; GEOGRAPHIC ATROPHY; EFFICACY; TRAP;
   BEVACIZUMAB; THICKNESS; INJECTION
AB Purpose: To compare the incidence and timing of first recurrence between patients who were treated with ranibizumab and aflibercept in neovascular age-related macular degeneration (AMD).
   Methods: This retrospective study included 120 patients who received the diagnosis of treatment-naive typical neovascular AMD or polypoidal choroidal vasculopathy (PCV) and were treated using either ranibizumab (n = 73) or aflibercept (n = 47). Recurrence within 10 months of the third injection was compared between the 2 treatment groups.
   Results: In all 120 patients, there was no difference in recurrence between the ranibizumab and the aflibecept groups (P = 0.846). One hundred five patients completed 12 months follow-up. In typical neovascular AMD, disease recurred in 69.6% (16/23) of patients in the ranibizumab group, with a mean period of 4.41.8 months after the third injection. In the aflibercept group, the equivalent values were 68.8% (11/16) and 4.5 +/- 1.4 months. In PCV, disease recurred in 72.5% (29/40) of patients in the ranibizumab group, with a mean period of 3.8 +/- 1.7 months after the third injection. In the aflibercept group, the equivalent values were 69.2% (18/26) and 4.3 +/- 2.0 months.
   Conclusions: Although the incidence of recurrence was slightly higher and the duration between the third injection and the first recurrence was slightly shorter in patients treated using ranibizumab, the differences were not significant. Our results require confirmation in further studies.
C1 [Kim, Jae Hui; Lee, Dong Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Coll Med, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Fauser S, 2016, BR J OPHTHALMOL
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 25
TC 12
Z9 12
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2017
VL 33
IS 6
BP 445
EP 451
DI 10.1089/jop.2016.0098
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EZ8NM
UT WOS:000404983300004
PM 28384009
DA 2022-11-30
ER

PT J
AU Nicolas, CM
   Robman, LD
   Tikellis, G
   Dimitrov, PN
   Dowrick, A
   Guymer, RH
   McCarty, CA
AF Nicolas, CM
   Robman, LD
   Tikellis, G
   Dimitrov, PN
   Dowrick, A
   Guymer, RH
   McCarty, CA
TI Iris colour, ethnic origin and progression of age-related macular
   degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; ethnic origin; iris colour
ID CAUSE-SPECIFIC PREVALENCE; BALTIMORE EYE SURVEY; BLUE-MOUNTAINS EYE;
   RISK-FACTORS; VISUAL IMPAIRMENT; RACIAL-DIFFERENCES; MACULOPATHY;
   DISEASE; PIGMENTATION; CLASSIFICATION
AB Aim: To investigate the relationship between iris colour, ethnic origin and the progression of age-related macular degeneration (AMD).
   Methods: Participants were recruited from the population-based Melbourne Visual Impairment Project or the prospective, randomized, double-masked Vitamin E, Cataract and Age-Related Macular Degeneration study. From these two cohorts, 171 participants aged between 52 and 93 years who were identified as having early AMD features at their baseline examination (1992-1995) were followed for an average of 6.8 years (until 2001) to determine the progression rate of early AMD. The participants' iris colour was categorized as light, intermediate or dark. Ethnic origin was categorized as Anglo-Saxon or non-Anglo-Saxon, according to the participants' grandparents' country of birth.
   Results: In total, 53 (31%) of the 171 participants showed signs of AMD progression. Participants with light iris colour had twofold the risk of AMD progression of those with dark or intermediate iris colours, although the age-adjusted and multivariate-adjusted associations were not significant (both P = 0.13). Age-adjusted and multivariate comparisons of Anglo-Saxon ethnic origin to non-Anglo-Saxon ethnic origin showed a noticeable but non-significant association with progression of AMD (P= 0.22 and P= 0.14, respectively).
   Conclusion: Individuals with light iris colour or of Anglo-Saxon ethnic origin had a strong tendency to greater progression of AMD. A larger sample is required to confirm these clinically important, but statistically non-significant, associations.
C1 Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Marshfield Med Res Fdn, Marshfield, WI 54449 USA.
C3 Centre for Eye Research Australia; University of Melbourne
RP Nicolas, CM (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
OI Guymer, Robyn/0000-0002-9441-4356; McCarty,
   Catherine/0000-0003-1089-0142
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BERGER JW, 2001, AGE RELATED MACULAR
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   GIBSON JM, 1986, T OPHTHAL SOC UK, V105, P463
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOSS SE, 1987, OPHTHALMOLOGY, V94, P1226
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 31
TC 25
Z9 26
U1 0
U2 3
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2003
VL 31
IS 6
BP 465
EP 469
DI 10.1046/j.1442-9071.2003.00711.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 745FM
UT WOS:000186678700003
PM 14641151
DA 2022-11-30
ER

PT J
AU Tufail, A
   Patel, PJ
   Egan, C
   Hykin, P
   da Cruz, L
   Gregor, Z
   Dowler, J
   Majid, MA
   Bailey, C
   Mohamed, Q
   Johnston, R
   Bunce, C
   Xing, W
AF Tufail, Adnan
   Patel, Praveen J.
   Egan, Catherine
   Hykin, Philip
   da Cruz, Lyndon
   Gregor, Zdenek
   Dowler, Jonathan
   Majid, Mohammed A.
   Bailey, Clare
   Mohamed, Quresh
   Johnston, Robert
   Bunce, Catey
   Xing, Wen
CA ABC Trial Investigators
TI Bevacizumab for neovascular age related macular degeneration (ABC
   Trial): multicentre randomised double masked study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN; RANIBIZUMAB; SECONDARY; EFFICACY; SAFETY
AB Objectives To evaluate the efficacy and safety of intravitreous bevacizumab injections for the treatment of neovascular age related macular degeneration.
   Design Prospective, double masked, multicentre, randomised controlled trial.
   Setting Three ophthalmology centres in the United Kingdom.
   Participants 131 patients (mean age 81) with wet age related macular degeneration randomised 1: 1 to intervention or control.
   Interventions Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals followed by further treatment if required at six week intervals) or standard treatment available at the start of the trial (photodynamic treatment with verteporfin for predominantly classic type neovascular age related macular degeneration, or intravitreal pegaptanib or sham treatment for occult or minimally classic type neovascular age related macular degeneration).
   Main outcome measures Primary outcome: proportion of patients gaining >= 15 letters of visual acuity at one year (54 weeks). Secondary outcomes: proportion of patients with stable vision and mean change in visual acuity.
   Results Of the 131 patients enrolled in the trial, five patients did not complete the study because of adverse events, loss to follow-up, or death. In the bevacizumab group, 21 (32%) patients gained 15 or more letters from baseline visual acuity compared with two (3%) in the standard care group (P<0.001); the estimated adjusted odds ratio was 18.1 (95% confidence interval 3.6 to 91.2) and the number needed to treat was 4 (3 to 6). In addition, the proportion of patients who lost fewer than 15 letters of visual acuity from baseline was significantly greater among those receiving bevacizumab treatment (91% (59) v 67% (44) in standard care group; P<0.001). Mean visual acuity increased by 7.0 letters in the bevacizumab group with a median of seven injections compared with a decrease of 9.4 letters in the standard care group (P<0.001), and the initial improvement at week 18 (plus 6.6 letters) was sustained to week 54. Among 65 patients treated with bevacizumab, there were no cases of endophthalmitis or serious uveitis related to the intervention. All end points with respect to visual acuity in the study eye at 54 weeks favoured bevacizumab treatment over standard care.
   Conclusions Bevacizumab 1.25 mg intavitreous injections given as part of a six weekly variable retreatment regimen is superior to standard care (pegaptanib sodium, verteporfin, sham), with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 54 weeks.
C1 [Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Dept, London EC1V 2PD, England.
   [Majid, Mohammed A.; Bailey, Clare] Bristol Eye Hosp, Bristol BSL 2LX, Avon, England.
   [Bunce, Catey; Xing, Wen] Moorfields Eye Hosp NHS Fdn Trust, Dept Res & Dev, London EC1V 2PD, England.
   [Mohamed, Quresh; Johnston, Robert] Cheltenham Gen Hosp, Gloucestershire Eye Dept, Cheltenham GL53 7AN, Glos, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Bristol Eye Hospital; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General
   Hospital
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Med Retina Dept, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
RI , Fred/B-8158-2013; Aslam, Tariq/A-8532-2016
OI , Fred/0000-0003-2809-9930; Bunce, Catey/0000-0002-0935-3713;
   Sivaprasad, Sobha/0000-0001-8952-0659; Tufail,
   Adnan/0000-0001-6131-7640; Aslam, Tariq/0000-0002-9739-7280;
   Fraser-Bell, Samantha/0000-0001-5646-9359; Richardson,
   Matthew/0000-0002-7390-9480
FU Moorfields Eye Hospital; Department of Health through National Institute
   for Health Research; UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology; National Eye Research
   Centre, Bristol
FX This study was funded by the special trustees of Moorfields Eye
   Hospital. We also received financial support from the Department of
   Health through an award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology. The views expressed in this publication are those of
   the authors and not necessarily those of the Department of Health.
   Additional local support was obtained from the National Eye Research
   Centre, Bristol.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   *CTR PREV OPTH BIO, 2009, COMP AG REL MAC DEG
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   *IVAN TRIAL, 2009, CTEU BRIST
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   PEDERSEN KB, 2008, ACTA OPHTHALMOL 1216
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2007, LANCET, V370, P1479, DOI 10.1016/S0140-6736(07)61624-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Taylor HR, 2007, LANCET, V370, P1481, DOI 10.1016/S0140-6736(07)61628-6
   Wagle AM, 2007, LANCET, V370, P1481, DOI 10.1016/S0140-6736(07)61629-8
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 34
TC 152
Z9 154
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUN 10
PY 2010
VL 340
AR c2459
DI 10.1136/bmj.c2459
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 611MF
UT WOS:000278818700002
PM 20538634
OA Green Accepted, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Chang, YC
   Cheng, CK
AF Chang, Yun-Chia
   Cheng, Cheng-Kuo
TI DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL
   VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; choroidal thickness; pachychoroid; intravitreal injection;
   polypoidal choroidal vasculopathy; central serous chorioretinopathy;
   age-related macular degeneration
ID MACULAR DEGENERATION; VASCULAR HYPERPERMEABILITY; PHOTODYNAMIC THERAPY;
   SPECTRUM DISORDERS; THICKNESS; RANIBIZUMAB; ANGIOGRAPHY; EVEREST
AB Purpose: Recent investigations have found a biphasic pattern of choroidal thickness within polypoidal choroidal vasculopathy (PCV) patients. This study aims to investigate the relationship between choroidal thickness and the clinical features of PCV eyes. Method: We investigated the correlation between various clinical features including subfoveal choroidal thickness (SFCT) and the response to 3-monthly anti-vascular endothelial growth factor (VEGF) treatments in 62 consecutive, treatment-naive PCV patients (66 eyes). After finding out SFCT as the only factor that was correlated with anti-VEGF treatment, we then set up to determine a best cutoff line for SFCT that could be used as a parameter to differentiate PCV patients into pachychoroid and nonpachychoroid groups using the Youden index for best combined specificity and sensitivity. We then compared the demographic features, clinical characteristics, and the response to anti-VEGF between both groups, to determine whether there is a difference between these two groups. Results: Subfoveal choroidal thickness was the only significant factor for the treatment effect. The SFCT of 267.5 mu m is the best cutoff line. The pachychoroid group showed significant younger ages (64.1 +/- 9.6 vs. 72.0 +/- 8.2,P= 0.004), fewer age-related macular degeneration-like features (50.0 vs. 81.3%,P= 0.027), more central serous chorioretinopathy-like features (typical retinal pigment epithelial mottling [61.1 vs. 16.7%,P= 0.0014] and choroidal vascular hyperpermeability [88.9 vs. 37.5%,P= 0.0002]), and less response to 3-monthly anti-VEGF treatments (27.8 vs. 83.3%,P< 0.0001) as compared to the nonpachychoroid group. Conclusion: Polypoidal choroidal vasculopathy patients could be subclassified into pachychoroid and nonpachychoroid groups. The pachychoroid subtype of PCV has significantly younger ages, fewer age-related macular degeneration-like features, more central serous chorioretinopathy-like features, and less response to anti-VEGF treatment.
C1 [Chang, Yun-Chia; Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 111, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University
RP Cheng, CK (通讯作者)，Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 111, Taiwan.
EM ckcheng.md@yahoo.com.tw
RI Chang, Yunchia/ABD-2506-2021
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yanagi Y, 2017, RETINA, V38, P1509
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 34
TC 25
Z9 26
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2020
VL 40
IS 7
BP 1403
EP 1411
DI 10.1097/IAE.0000000000002583
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG9VH
UT WOS:000546379800025
PM 31181038
DA 2022-11-30
ER

PT J
AU Palestine, AG
   Wagner, BD
   Patnaik, JL
   Baldermann, R
   Mathias, MT
   Mandava, N
   Lynch, AM
AF Palestine, Alan G.
   Wagner, Brandie D.
   Patnaik, Jennifer L.
   Baldermann, Rebecca
   Mathias, Marc T.
   Mandava, Naresh
   Lynch, Anne M.
TI Plasma C-C Chemokine Concentrations in Intermediate Age-Related Macular
   Degeneration
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age-related macular degeneration; inflammation; chemokines; CCL2; CCL3;
   CCL4; CCL5; RANTES
ID CELLS; EXPRESSION; PROTEINS; GENE; MICE; CCL4
AB Purpose: To determine the relationship between plasma concentrations of the C-C chemokines CCL2, CCL3, CCL4, and CCL5 and intermediate age-related macular degeneration (iAMD) patients compared with control inidividuals to further define the inflammatory pathways associated with age-related macular degeneration.Methods: The concentrations of CCL2, CCL3, CCL4, and CCL5 were measured using multiplex assays in plasma collected from 210 patients with iAMD and 102 control individuals with no macular degeneration as defined by multi-modal imaging. Non-inflammatory data included in the analysis were: age, sex, family history of AMD, history of smoking, body mass index, presence of reticular pseudo-drusen and cardiovascular disease. Median concentrations as well as a cutoff value for each chemokine were compared between the two groups.Results: The median concentrations of CCL2 and CCL4 did not differ between control and iAMD groups, however, CCL2 was elevated in iAMD when a cutoff comparison was used (p < 0.05). Median CCL3 and CCL5 concentrations were significantly decreased in the macular degeneration group compared with controls (p < 0.001) as well as when a cutoff value comparison was used. CCL3 and CCL5 were negatively correlated in cases and positively correlated in controls.Conclusions: Plasma CCL3 and CCL5 concentrations were significantly decreased and CCL2 concentrations were increased in patients with iAMD compared with controls, suggesting a role for C-C chemokines in the systemic inflammatory processes associated with disease development.
C1 [Palestine, Alan G.; Wagner, Brandie D.; Patnaik, Jennifer L.; Mathias, Marc T.; Mandava, Naresh; Lynch, Anne M.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
   [Wagner, Brandie D.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
   [Baldermann, Rebecca] Univ Colorado, Colorado Clin & Translat Sci Inst, Anschutz Med Campus, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Colorado School of Public Health; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus
RP Palestine, AG (通讯作者)，Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
EM alan.palestine@cuanschutz.edu
FU National Eye Institute of the National Institutes of Health
   [R01EY032456]; Research to Prevent Blindness; NIH/NCATS Colorado CTSA
   [UL1 TR002535]; Frederic C. Hamilton Macular Degeneration Center; Sue
   Anschutz-Rogers Eye Center Research Fund
FX This research was supported by the National Eye Institute of the
   National Institutes of Health under award number R01EY032456 (AL), a
   Research to Prevent Blindness grant to the Department of Ophthalmology,
   University of Colorado, the Frederic C. Hamilton Macular Degeneration
   Center, Sue Anschutz-Rogers Eye Center Research Fund, and by NIH/NCATS
   Colorado CTSA Grant Number UL1 TR002535.
CR Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Badacz R, 2019, J PHYSIOL PHARMACOL, V70, P545, DOI 10.26402/jpp.2019.4.06
   Cardona Sandra M, 2013, Methods Mol Biol, V1013, P1, DOI 10.1007/978-1-62703-426-5_1
   Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651
   Chen RC, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.12.7
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   de Jager SCA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045804
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fischer FR, 2001, J IMMUNOL, V167, P1637, DOI 10.4049/jimmunol.167.3.1637
   Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200
   Honey K, 2006, NAT REV IMMUNOL, V6, P427, DOI 10.1038/nri1862
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Silva AS, 2012, MOL VIS, V18, P2288
   Tang P, 2014, OXID MED CELL LONGEV, V2014, P1, DOI 10.1155/2014/208408
   Thorsen SU, 2014, SCAND J IMMUNOL, V80, P452, DOI 10.1111/sji.12240
   Tomioka R, 2014, INTERNAL MED, V53, P361, DOI 10.2169/internalmedicine.53.1246
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 28
TC 1
Z9 2
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 18
PY 2021
VL 8
AR 710595
DI 10.3389/fmed.2021.710595
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XI5RV
UT WOS:000726169400001
PM 34869411
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Morgan, DJ
   DeAngelis, MM
AF Morgan, Denise J.
   DeAngelis, Margaret M.
TI Differential Gene Expression in Age-Related Macular Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MICROARRAY ANALYSIS; DNA METHYLATION; IL17RC
   PROMOTER; NONCODING RNAS; HUMAN RETINA; VARIANT; RISK; SUSCEPTIBILITY;
   TRANSCRIPTOME
AB Gene expression is the first step in ascribing function between an associated gene and disease. Understanding how variation in a gene influences expression, particularly in tissues affected by the disease, may help elucidate what influences the phenotypic outcome of that disease. Previous studies of the genetics of age-related macular degeneration (AMD) have identified several risk factors, but have not yet bridged the gap between gene association and identifying a specific mechanism or function that is involved in the pathogenesis of AMD. Advances in genomic technologies, such as RNA sequencing (RNA-seq), single cell RNA-seq, bilsulfite sequencing, and/or whole genome methylation, will be powerful tools for identifying genes/pathways that are differentially expressed in those with AMD versus those without AMD. These technologies should advance the field of AMD research so that appropriate preventive and therapeutic targets can be developed.
C1 [Morgan, Denise J.; DeAngelis, Margaret M.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP DeAngelis, MM (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
EM margaret.deangelis@utah.edu
RI DeAngelis, e/J-7863-2015
FU National Institutes of Health [EY-014458]; ALSAM Foundation; Edward N. &
   Della L. Thome Memorial Fund; Carl Marshall Reeves & Mildred Almen
   Reeves Foundation; Research to Prevent Blindness Foundation; NATIONAL
   EYE INSTITUTE [R01EY014458] Funding Source: NIH RePORTER
FX This work is supported by National Institutes of Health Grant EY-014458,
   the ALSAM Foundation, the Edward N. & Della L. Thome Memorial Fund, Carl
   Marshall Reeves & Mildred Almen Reeves Foundation, and an unrestricted
   grant from the Research to Prevent Blindness Foundation to the
   University of Utah Department of Ophthalmology and Visual Sciences.
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Brunet A, 2014, J GERONTOL A-BIOL, V69, pS17, DOI 10.1093/gerona/glu042
   Cepko CL, 2012, J NEUROSCI, V32, P6415, DOI 10.1523/JNEUROSCI.0295-12.2012
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gamazon ER, 2012, AM J HUM GENET, V90, P1046, DOI 10.1016/j.ajhg.2012.04.023
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Hrdlickova B, 2014, BBA-MOL BASIS DIS, V1842, P1910, DOI 10.1016/j.bbadis.2014.03.011
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Irvin MR, 2014, CIRCULATION, V130, P565, DOI 10.1161/CIRCULATIONAHA.114.009158
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2010, MOL VIS, V16, P1317
   Karunakaran DKP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075964
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lalonde E, 2011, GENOME RES, V21, P545, DOI 10.1101/gr.111211.110
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Majewski J, 2011, TRENDS GENET, V27, P72, DOI 10.1016/j.tig.2010.10.006
   Mamdani F, 2013, DIS MARKERS, V2013, P11, DOI 10.1155/2013/748095
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Payne Andrew J, 2013, Mo Med, V110, P429
   Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473
   Petronis A, 2010, NATURE, V465, P721, DOI 10.1038/nature09230
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Potok ME, 2013, CELL, V153, P759, DOI 10.1016/j.cell.2013.04.030
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smith RP, 2012, GENOME MED, V4, DOI 10.1186/gm344
   Stevenson KR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-536
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trombetta John J, 2014, Curr Protoc Mol Biol, V107, DOI 10.1002/0471142727.mb0422s107
   Twine NA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016266
   Voisin S, 2015, EUR J HUM GENET, V23, P654, DOI 10.1038/ejhg.2014.139
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yendrek Craig R, 2012, BMC Res Notes, V5, P506, DOI 10.1186/1756-0500-5-506
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang SJ, 2014, GENE, V533, P366, DOI 10.1016/j.gene.2013.09.029
   Zhang ZY, 2012, MOL VIS, V18, P2961
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
NR 76
TC 11
Z9 11
U1 0
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD AUG
PY 2015
VL 5
IS 8
AR a017210
DI 10.1101/cshperspect.a017210
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CS4FU
UT WOS:000362031800001
PM 25342062
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ambreen, F
   Khan, WA
   Qureshi, N
   Qureshi, IZ
AF Ambreen, Fareeha
   Khan, Wajid Ali
   Qureshi, Nadeem
   Qureshi, Irfan Zia
TI Assessment of serum lipids in patients with age related macular
   degeneration from Pakistan
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE AMD; Lipid profile; Pakistan
ID RISK-FACTORS; CARDIOVASCULAR-DISEASE; BRUCHS MEMBRANE; STATIN USE;
   MACULOPATHY; LIPOPROTEIN; ASSOCIATION; CHOLESTEROL; EYE
AB Objective: To determine serum lipids in patients with age related macular degeneration from Pakistani population.
   Methods: The study was a cross sectional, randomized and case-control. Selected subjects ages were >= 50 years and were normotensive, non-diabetic with no family history of any such disease and no complication of posterior ocular chamber other than age related macular degeneration (AMD). Controls were age matched healthy individuals with no symptoms of AMD. Diagnosis of AMD was done through conventional diagnostic techniques by professional ophthalmologists. Serum samples were analyzed for total cholesterol, triglycerides, LDL and HDL using commercially available kits. Data were compared with Student's t-test. Pearson correlation was calculated for relationship between different parameters. P<0.05 was considered significant.
   Results: Compared to controls, AMD patients had significantly greater total cholesterol concentration (p<0.041), and power HDL/LDL ratio (p<0.038), while serum triglycerides, HDL and LDL were non-significantly different from control subjects. Total cholesterol in AMD patients was significantly correlated with TG. LDL and HDL (p<0.0001).
   Conclusion: The study indicates that high cholesterol might be a predictor of AMD and can be a diagnostic parameter.
C1 [Ambreen, Fareeha; Qureshi, Irfan Zia] Quaid I Azam Univ, Lab Anim & Human Physiol, Islamabad, Pakistan.
   [Khan, Wajid Ali; Qureshi, Nadeem] Al Shifa Trust Eye Hosp, Rawalpindi, Pakistan.
C3 Quaid I Azam University
RP Qureshi, IZ (通讯作者)，Quaid I Azam Univ, Lab Anim & Human Physiol, Islamabad, Pakistan.
EM irfanzia@qau.edu.pk
FU university research fund, Quaid-i-Azam University Islamabad, Pakistan
FX The authors thank all the participants of the study, the patients and
   the control subjects. We are grateful to all the residents and staff of
   Al-Shifa Trust Eye hospital for their appreciable cooperation during the
   screening of patients, to the Director NORI for extending laboratory
   facilities to carry out lipid profiles. The research was supported by
   the university research fund, Quaid-i-Azam University Islamabad,
   Pakistan.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Adelman RA., 2011, US OPHTHALMIC REV, V4, P96
   Belda SJI, 2001, ARCH SOC ESP OFTALMO, V76, P13
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despres Jean-Pierre, 2007, Crit Pathw Cardiol, V6, P51, DOI 10.1097/HPC.0b013e318057d4c9
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jiayin G, 2009, MOL CELL PROTEOMICS, V8, P1338
   Kaiserman I, 2006, AM J OPHTHALMOL, V142, P441, DOI 10.1016/j.ajo.2006.04.031
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   vans JR, 2001, PROGRETIN EYE RES, V20, P227
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Zafar SN, 2009, AL SHIFA J OPHTHALMO, V5, P24
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 29
TC 5
Z9 5
U1 0
U2 3
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD JUN
PY 2014
VL 64
IS 6
BP 664
EP 669
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA AI4WX
UT WOS:000336868300012
PM 25252486
DA 2022-11-30
ER

PT J
AU Lee, J
   Suh, HS
   Hwang, IC
AF Lee, Jungmin
   Suh, Heuy Sun
   Hwang, In Cheol
TI The Relationship between Age-Related Macular Degeneration and
   Cardiovascular Disease: A Meta-Analysis
SO IRANIAN JOURNAL OF PUBLIC HEALTH
LA English
DT Review
DE Age-related macular degeneration; Cardiovascular disease; Meta-analysis;
   Stroke
ID RISK-FACTORS; MYOCARDIAL-INFARCTION; HEMORRHAGIC STROKE; BURDEN;
   MACULOPATHY; ATHEROSCLEROSIS; HETEROGENEITY; IMPAIRMENT
AB Background: Age-related macular degeneration (AMD) and cardiovascular disease (CVD) share pathogenic mechanisms, and their lead-lag relationship remains unclear. We performed a meta-analysis of data from longitudinal studies to evaluate the interactive association between age-related macular degeneration (AMD) and cardiovascular disease (CVD).
   Methods: A literature search was performed in PubMed, Embase, and Cochrane Library up to Feb 2019. Estimates were pooled by study quality and type of AMD and CVD. Publication bias was assessed by Begg's test.
   Results: We identified nine studies for the risk of AMD in CVD and ten studies for the risk of CVD in AMD. Overall, evidence for the risk of CVD in AMD patients was most robust. Both early and late AMD preceded CVD, but more solid significance existed in late AMD. Among the types of CVD, stroke was more tightly associated with AMD than coronary heart disease. Publication bias was not significant in either direction.
   Conclusion: AMD is a risk factor for CVD, which is primarily driven by the increased risk of stroke in patients with late AMD. Moreover, these results suggested that AMD treatment and screening for CVD in AMD patients may have unexplored clinical benefits.
C1 [Lee, Jungmin] Univ Calif Berkeley, Dept Cognit Sci, Berkeley, CA 94720 USA.
   [Suh, Heuy Sun; Hwang, In Cheol] Gachon Univ, Gil Med Ctr, Dept Family Med, Coll Med, Incheon, South Korea.
C3 University of California System; University of California Berkeley;
   Gachon University
RP Hwang, IC (通讯作者)，Gachon Univ, Gil Med Ctr, Dept Family Med, Coll Med, Incheon, South Korea.
EM spfe0211@gmail.com
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Di Napoli M, 2001, STROKE, V32, P1444, DOI 10.1161/01.STR.32.6.1443-a
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201000
   Fernandez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142968
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Foo VHX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27202-w
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Glasziou PP, 2002, STAT MED, V21, P1503, DOI 10.1002/sim.1183
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Lee WJA, 2017, PHARMACOEPIDEM DR S, V26, P1277, DOI 10.1002/pds.4299
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rempe RG, 2016, J CEREBR BLOOD F MET, V36, P1481, DOI 10.1177/0271678X16655551
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wang X, 2013, STROKE, V44, P1833, DOI 10.1161/STROKEAHA.113.001326
   Wang XZ, 2014, OPHTHALMOLOGY, V121, P1837, DOI 10.1016/j.ophtha.2014.03.017
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JN, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105567, 10.1371/journal.pone.0103823]
   Yan T, 2015, NEUROSCI BULL, V31, P717, DOI 10.1007/s12264-015-1567-z
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhou FF, 2015, J STROKE CEREBROVASC, V24, P784, DOI 10.1016/j.jstrokecerebrovasdis.2014.11.005
NR 55
TC 0
Z9 0
U1 0
U2 4
PU IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY
PI TEHRAN
PA SCHOOL PUBLIC HEALTH & INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN
SN 2251-6085
EI 2251-6093
J9 IRAN J PUBLIC HEALTH
JI Iran J. Public Health
PD FEB
PY 2021
VL 50
IS 2
BP 219
EP 231
PG 13
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA QJ6FW
UT WOS:000619785300002
PM 33747986
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Varma, R
   Foong, AWP
   Lai, MY
   Choudhury, F
   Klein, R
   Azen, SP
AF Varma, Rohit
   Foong, Athena W. P.
   Lai, Mei-Ying
   Choudhury, Farzana
   Klein, Ronald
   Azen, Stanley P.
CA Los Angeles Latino Eye Study Grp
TI Four-Year Incidence and Progression of Age-Related Macular Degeneration:
   The Los Angeles Latino Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; BLUE MOUNTAINS EYE; BEAVER DAM EYE; 5-YEAR INCIDENCE;
   VISUAL IMPAIRMENT; SEVERITY SCALE; MACULOPATHY; POPULATION; PREVALENCE;
   ROTTERDAM
AB PURPOSE: To estimate 4-year incidence and progression of early and advanced age-related macular degeneration (AMP).
   DESIGN: Population-based cohort study.
   METHODS: A comprehensive ophthalmologic examination including stereoscopic fundus photography was performed on adult Latinos at baseline and follow-up. Photographs were graded using a modified Wisconsin Age-Related Maculopathy Grading System. For estimations of incidence and progression of AMP, the Age Related Eye Disease Study Scale was used. Main outcome measures are incidence and progression of early AMD (drusen type, drusen size, and retinal pigmentary abnormalities) and advanced AMD (exudative AMD and geographic atrophy).
   RESULTS: A total of 4658 of 6100 subjects (76%) completed the follow-up examination. The 4-year incidence of early AMD was 7.5% (95% Cl: 6.7, 8.4) and advanced AMD was 0.2% (95% CI: 0.1, 0.4). Progression of any AMD occurred in 9.2% (95% CI: 8.3, 10.1) of at-risk participants. Incidence and progression increased with age. Incidence of early AMP in the second eye (11.2%) was higher than incidence in the first eye (6.9%). Baseline presence of soft indistinct large drusen >= 250 mu m in diameter was more likely to predict the 4-year incidence of pigmentary abnormalities, geographic atrophy, and exudative AMD than smaller or hard or soft distinct drusen.
   CONCLUSIONS: Age-specific incidence and progression of AMD in Latinos are lower than in non-Hispanic whites. While incident early AMD is more often unilateral, the risk of its development in the second is higher than in the first eye. Older people and those with soft indistinct large drusen had a higher risk of developing advanced AMD compared to those who were younger and did not have soft indistinct large drusen. (Am J Ophthalmol 2010;149:741-751. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Varma, Rohit; Foong, Athena W. P.; Azen, Stanley P.] Univ So Calif, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Varma, Rohit; Foong, Athena W. P.; Azen, Stanley P.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Varma, Rohit; Lai, Mei-Ying; Choudhury, Farzana; Azen, Stanley P.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Klein, Ronald] Univ Wisconsin Madison, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California; University of
   Wisconsin System; University of Wisconsin Madison
RP Varma, R (通讯作者)，Univ So Calif, Doheny Eye Inst, Suite 4900,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND [NEI U10-EY11753,
   EY-03040]; Research to Prevent Blindness, New York, New York; NATIONAL
   EYE INSTITUTE [U10EY011753, P30EY003040] Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY GRANTS FROM NATIONAL INSTITUTES OF HEALTH,
   BETHESDA, MARYLAND (NEI U10-EY11753 and EY-03040) and an unrestricted
   grant from Research to Prevent Blindness, New York, New York. Rohit
   Varma is a Research to Prevent Blindness Sybil B. Harrington Scholar.
   The authors have no proprietary or commercial interest in any materials
   discussed in the manuscript. Involved in design and conduct of the study
   (R.V., SPA.); collection, management, analysis, and interpretation of
   the data (A.W.P.F., ML., F.C., R.K., SPA., R.V.); and preparation,
   review, or approval of the manuscript (A.W.P.F., ML., 12.K., SPA.,
   R.V.). The study protocol was approved by the Institutional Review Board
   (IRB)/Ethics Committee at the University of Southern California and all
   study procedures adhered to the recommendations of the Declaration of
   Helsinki. Written consent was obtained from all participants.
CR Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gudnadottir GS, 2005, ACTA OPHTHALMOL SCAN, V83, P333, DOI 10.1111/j.1600-0420.2005.00451.x
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   McKean-Cowdin R, 2007, AM J OPHTHALMOL, V143, P1013, DOI 10.1016/j.ajo.2007.02.022
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Shtir CJ, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-71
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   *US BUR CENS, 2004, US INT PROJ AG SEX R
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 21
Z9 22
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2010
VL 149
IS 5
BP 741
EP 751
DI 10.1016/j.ajo.2010.01.009
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 593WT
UT WOS:000277493800009
PM 20399926
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Grisanti, S
   Zhu, Q
   Tatar, O
   Lueke, J
   Lueke, M
   Tura, A
   Grisanti, S
AF Grisanti, Swaantje
   Zhu, Qi
   Tatar, Olcay
   Lueke, Julia
   Lueke, Matthias
   Tura, Aysegul
   Grisanti, Salvatore
TI DIFFERENTIAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-A ISOFORMS
   IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE VEGF-A isoforms; age-related macular degeneration; real-time reverse
   transcription PCR; choroidal neovascular membranes
ID VERTEPORFIN-PHOTODYNAMIC THERAPY; VEGF ISOFORMS; CHOROIDAL
   NEOVASCULARIZATION; DIABETIC-RETINOPATHY; OXYGEN DISTRIBUTION; TUMOR
   ANGIOGENESIS; RETINA; MEMBRANES; MOUSE; CELLS
AB Purpose: To investigate the role of vascular endothelial growth factor-A ( VEGF-A) isoforms in neovascular age-related macular degeneration.
   Methods: Choroidal neovascular membranes (CNV) were excised in 24 patients, 8 of them underwent previous photodynamic therapy. All procedures were performed before anti-VEGF therapies were implemented in Germany. Normal human donor eyes served as controls. Messenger RNA expression of total VEGF-A and VEGF-A isoforms was measured.
   Results: Vascular endothelial growth factor-A(121) is the most abundant isoform in CNV and control tissues. In controls, VEGF-A(121) is lowest in neural retina and highest in choroids. For total VEGF-A and VEGF-A(165), this is vice versa. VEGF-A(165) and VEGF-A(189) are significantly higher in CNV than in control choroids, the opposite is found for VEGF-A(121). After photodynamic therapy, total VEGF-A and VEGF-A(121) are increased, VEGF-A(165) and VEGF-A(189) are decreased. Age-dependently, there is an increase in VEGF-A(165) and a decrease in VEGF-A(121).
   Conclusion: Vascular endothelial growth factor-A isoforms are differentially distributed, suggesting that tissue-specific regulation of various isoforms is physiologically important. The disruption of this homeostasis in CNV membranes may be significant in the onset and progression of neovascular age-related macular degeneration. Our findings support the dominant role of VEGF-A(121) in neovascular age-related macular degeneration but hint that VEGF-A(165) may have an equivalent role in other neovascular retinal pathology.
C1 [Grisanti, Swaantje; Zhu, Qi; Lueke, Julia; Lueke, Matthias; Tura, Aysegul; Grisanti, Salvatore] Med Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany.
   [Tatar, Olcay] Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
C3 University of Lubeck; Hacettepe University
RP Grisanti, S (通讯作者)，Med Univ Lubeck, Dept Ophthalmol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM swaantje.peters@gmail.com
FU Jung-Stiftung fuer Wissenschaft und Forschung, Germany
FX Supported by Jung-Stiftung fuer Wissenschaft und Forschung, Germany.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   Cramer T, 2004, OSTEOARTHR CARTILAGE, V12, P433, DOI 10.1016/j.joca.2004.02.003
   D'Amore PA, 2007, AM J PATHOL, V171, P14, DOI 10.2353/ajpath.2007.070385
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Guo P, 2001, CANCER RES, V61, P8569
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kusters B, 2003, CANCER RES, V63, P5408
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752
   MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35
   Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Starita Carla, 2007, Dev Ophthalmol, V39, P122, DOI 10.1159/000098504
   Stewart EA, 2011, EXP EYE RES, V93, P761, DOI 10.1016/j.exer.2011.09.010
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Wang XF, 2005, INVEST OPHTH VIS SCI, V46, P1508, DOI 10.1167/iovs.04-0951
   Yu DY, 2006, INVEST OPHTH VIS SCI, V47, P1109, DOI 10.1167/iovs.05-1118
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zygalaki E, 2005, CLIN CHEM, V51, P1518, DOI 10.1373/clinchem.2004.046987
NR 39
TC 15
Z9 15
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2015
VL 35
IS 4
BP 764
EP 772
DI 10.1097/IAE.0000000000000385
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE5OL
UT WOS:000351884900027
PM 25494018
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Kabiesz, A
   Nowak, M
   Spiewak, D
AF Michalska-Malecka, K.
   Kabiesz, A.
   Nowak, M.
   Spiewak, D.
TI Age related macular degeneration - challenge for future: Pathogenesis
   and new perspectives for the treatment
SO EUROPEAN GERIATRIC MEDICINE
LA English
DT Article
DE Age related macular degeneration; Angiogenesis; Free oxygen radical;
   Genetic polymorphism
ID RETINAL-PIGMENT EPITHELIUM; CHLAMYDIA-PNEUMONIAE INFECTION; HIGH-DOSE
   SUPPLEMENTATION; GROWTH-FACTOR VEGF; OXIDATIVE STRESS; APOLIPOPROTEIN-E;
   BETA-CAROTENE; VISION LOSS; FLUOCINOLONE ACETONIDE; COMPLEMENT
   ACTIVATION
AB The authors presents the review of the literature concerning the pathogenesis, classification, risk factors as well as perspectives for the treatment of age-related macular degeneration (AMD). AMD is a progressive illness, which is the most common cause of blindness in developed countries. The degenerative changes associated with both forms (dry and wet AMD) occur in the central part of retina, the macula, but the exact aetiology is still not unclear. The pathogenesis of AMD includes: lipofuscine genesis, drusogenesis, and local inflammatory state, as well as neoangiogenesis. Multiple studies have assessed the role of genetic variants on AMD development and progression, especially with complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes, the two major susceptibility genes for AMD. The disease has been associated with light-induced oxidative damage, accumulation of cholesterol and other lipids, and has been linked to systemic factors such as smoking, hypertension and atherosclerosis. Also female gender, and a high body-mass index (BMI > 30) have been reported as the important demographic and environmental risk factors in AMD. The neovascular form of AMD is characterized by the formation of subretinal choroidal neovascularization (CNV) and is the cause of most cases of blindness in the elders. Currently, the only approved treatment for dry AMD is the use of AREDS formulation. In the near future, it is likely that the treatment of dry AMD will be a combination of different drugs that will target the different pathways involved in the pathogenesis and progression of dry AMD. Exudative AMD is treated through injections of anti-VEGF A drugs as pegaptanib or ranibizumab and bevacizumab, which are considered the standard drugs. Aflibercept, or VEGF Trap-eye, is a novel compound derived from the native VEGF receptor (VEGFR) that binds to all VEGF and VEGF-B isoforms as well as to PlGF. It may be considered an attractive alternative to other anti-VEGF agents. (C) 2014 The Authors. Published by Elsevier Masson SAS.
C1 [Michalska-Malecka, K.; Kabiesz, A.; Spiewak, D.] Med Univ Silesia, Univ Ctr Ophthalmol & Oncol, Dept Ophthalmol, PL-40952 Katowice, Poland.
   [Nowak, M.] Med Univ Silesia, Dept Pathophysiol & Endocrinol, Div Pathophysiol, PL-41800 Zabrze, Poland.
C3 Medical University Silesia; Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Med Univ Silesia, Univ Ctr Ophthalmol & Oncol, Dept Ophthalmol, Ceglana St 35, PL-40952 Katowice, Poland.
EM k.michalska.malecka@gmail.com
OI MICHALSKA-MALECKA, KATARZYNA/0000-0002-0550-8386; Nowak,
   Mariusz/0000-0003-1754-9959
CR Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bone RA, 2012, ACTA BIOCHIM POL, V59, P91
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   CARDIN AD, 1988, BIOCHEM BIOPH RES CO, V154, P741, DOI 10.1016/0006-291X(88)90202-1
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Danulescu R, 2012, MED-SURG J, V116, P1136
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dzik JM, 2010, ACTA BIOCHIM POL, V57, P443
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P6081, DOI 10.1167/iovs.11-7388
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Glybina IV, 2010, INVEST OPHTH VIS SCI, V51, P4243, DOI 10.1167/iovs.09-4492
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haab O, 1885, AUGENHEILKUNDE, V9, P383
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kajdaniuk D, 2013, ENDOKRYNOL POL, V64, P384, DOI 10.5603/EP.2013.0022
   Kajdaniuk D, 2011, ENDOKRYNOL POL, V62, P444
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim DY, 2012, ACTA OPHTHALMOL, V10, P1111
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lai RK, 2002, VISUAL NEUROSCI, V19, P175, DOI 10.1017/S0952523802191152
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McConnell V, 2005, Ulster Med J, V74, P82
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michalska-Malecka K, 2013, CLIN INTERV AGING, V8, P1041, DOI 10.2147/CIA.S44834
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Qin L, 2014, GRAEF ARCH CLIN EXP, V252, P23, DOI 10.1007/s00417-013-2418-0
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   SHIMANO H, 1989, ATHEROSCLEROSIS, V79, P257, DOI 10.1016/0021-9150(89)90132-9
   SIEST G, 1995, CLIN CHEM, V41, P1068
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Statystyczny Glowny Urzad, 2011, LIF EXP TABL POL CEN
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Vertuani S, 2004, CURR PHARM DESIGN, V10, P1677, DOI 10.2174/1381612043384655
   Wisniewska-Becker A, 2012, ACTA BIOCHIM POL, V59, P119
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 99
TC 27
Z9 27
U1 0
U2 44
PU ELSEVIER MASSON, CORPORATION OFFICE
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 1878-7649
EI 1878-7657
J9 EUR GERIATR MED
JI Eur. Geriatr. Med.
PD FEB
PY 2015
VL 6
IS 1
BP 69
EP 75
DI 10.1016/j.eurger.2014.09.007
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA CA9BE
UT WOS:000349214500016
OA hybrid
DA 2022-11-30
ER

PT J
AU Faber, C
   Singh, A
   Falk, MK
   Juel, HB
   Sorensen, TL
   Nissen, MH
AF Faber, Carsten
   Singh, Amardeep
   Falk, Mads Kruger
   Juel, Helene Baek
   Sorensen, Torben Lykke
   Nissen, Mogens Holst
TI Age-related Macular Degeneration Is Associated with Increased Proportion
   of CD56D(+) T Cells in Peripheral Blood
SO OPHTHALMOLOGY
LA English
DT Article
ID SYSTEMIC COMPLEMENT ACTIVATION; ANTI-RETINAL ANTIBODIES; C-REACTIVE
   PROTEIN; EXPRESSION; GAMMA; IDENTIFICATION; BIOMARKERS; INDUCTION;
   EFFECTORS; DRUSEN
AB Purpose: To examine the association between age-related changes in the T-cell compartment and prevalence of age-related macular degeneration (AMD).
   Design: Case-control study.
   Participants: A total of 117 AMD cases and 106 controls were included prospectively.
   Methods: Fresh-drawn peripheral blood samples were processed for flow cytometric analysis of T-cell populations. Plasma samples were analyzed for anti-cytomegalovirus (CMV) immunoglobulin (Ig) G and complement factor H (CFH) Y402H genotype. The diagnosis of AMD was made according to the Clinical Age-Related Maculopathy Staging System.
   Main Outcome Measures: Association between frequency of aged T cells and prevalence of AMD.
   Results: The prevalence of AMD was associated with distinct age-related changes in the T-cell compartment. Specifically, the patients with AMD had an increased frequency of CD28(-) T cells that expressed the CD56 surface marker (patients, 34.9% vs. aged controls, 25.8%; P=0.002). Participants in the highest tertile of CD56(+)CD28(-) T cells had an odds ratio (OR) for the presence of AMD of 3.2 (95% confidence interval [CI], 1.2-8.8) after adjustment for CFH genotype, anti-CMV IgG positivity, age, sex, and smoking history. The adjusted OR of the presence of AMD for persons having at least 1 CFH H402 risk allele increased from 3.5 (95% CI, 1.5-8.1) to 13.3 (95% CI, 3.3-53.6) for persons with at least 1 CFH H402 risk allele and above the median level of CD56(+)CD28(-) T cells.
   Conclusions: We found increased levels of circulating aged CD56(+)CD28(-) T cells in patients with AMD. Although this supports the notion of AMD as a systemic disease, it also suggests that the adaptive immune system is implicated in its pathogenesis. (C) 2013 by the American Academy of Ophthalmology.
C1 [Faber, Carsten; Juel, Helene Baek; Nissen, Mogens Holst] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Fac Hlth Sci, DK-2200 Copenhagen N, Denmark.
   [Singh, Amardeep; Falk, Mads Kruger; Sorensen, Torben Lykke] Copenhagen Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
   [Singh, Amardeep; Falk, Mads Kruger; Sorensen, Torben Lykke] Univ Copenhagen, DK-2200 Copenhagen N, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Faber, C (通讯作者)，Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Fac Hlth Sci, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.
EM carstenfaber@gmail.com
RI Nissen, Mogens/B-4825-2008; Faber, Carsten/I-4150-2013; Sørensen, Torben
   Lykke L/N-1417-2014; Faber, Carsten/N-3210-2019; Juel,
   Helene/AAD-2843-2020; Singh, Amardeep/ABI-4544-2020
OI Nissen, Mogens/0000-0001-7729-8667; Faber, Carsten/0000-0002-2517-7270;
   Sørensen, Torben Lykke L/0000-0002-6790-0199; Faber,
   Carsten/0000-0002-2517-7270; Juel, Helene B/0000-0002-5763-8545
FU Lundbeckfonden; Danish Eye Research Foundation; Fabrikant Einar
   Willumsens Mindelegat; Grosserer Chr. Andersens Legat; Marie og Borge
   Krogs Fond; Dagmar Marshalls Fond; Fight for Sight Denmark
FX Supported by Lundbeckfonden, The Danish Eye Research Foundation,
   Fabrikant Einar Willumsens Mindelegat, Grosserer Chr. Andersens Legat,
   Marie og Borge Krogs Fond, Dagmar Marshalls Fond, Fight for Sight
   Denmark, and Augustinus Fonden. The sponsor or funding organization had
   no role in the design or conduct of this research.
CR Ahn JK, 2005, J IMMUNOL, V175, P6133, DOI 10.4049/jimmunol.175.9.6133
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Bergstrom I, 2012, ATHEROSCLEROSIS, V224, P515, DOI 10.1016/j.atherosclerosis.2012.07.033
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Chidrawar S, 2009, CLIN EXP IMMUNOL, V155, P423, DOI 10.1111/j.1365-2249.2008.03785.x
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cookson S, 2003, BLOOD, V102, P2195, DOI 10.1182/blood-2003-01-0232
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Kelly-Rogers J, 2006, HUM IMMUNOL, V67, P863, DOI 10.1016/j.humimm.2006.08.292
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koreck A, 2002, CLIN EXP IMMUNOL, V127, P176, DOI 10.1046/j.1365-2249.2002.01721.x
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979
   Li WX, 2010, CLIN RHEUMATOL, V29, P315, DOI 10.1007/s10067-009-1322-9
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu BY, 2010, MOL VIS, V16, P184
   Michel JJ, 2007, ARTHRITIS RHEUM-US, V56, P43, DOI 10.1002/art.22310
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Vallejo AN, 2011, AGEING RES REV, V10, P354, DOI 10.1016/j.arr.2010.09.006
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 42
TC 36
Z9 39
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2013
VL 120
IS 11
BP 2310
EP 2316
DI 10.1016/j.ophtha.2013.04.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FT
UT WOS:000326681700029
PM 23747161
DA 2022-11-30
ER

PT J
AU Dewan, A
   Liu, MG
   Hartman, S
   Zhang, SSM
   Liu, DTL
   Zhao, C
   Tam, POS
   Chan, WM
   Lam, DSC
   Snyder, M
   Barnstable, C
   Pang, CP
   Hoh, J
AF DeWan, Andrew
   Liu, Mugen
   Hartman, Stephen
   Zhang, Samuel Shao-Min
   Liu, David T. L.
   Zhao, Connie
   Tam, Pancy O. S.
   Chan, Wai Man
   Lam, Dennis S. C.
   Snyder, Michael
   Barnstable, Colin
   Pang, Chi Pui
   Hoh, Josephine
TI HTRA1 promoter polymorphism in wet age-related macular degeneration
SO SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK; SUSCEPTIBILITY; GENE; ASSOCIATION; JAPANESE;
   CHINESE; DISEASE; VARIANT; CFH
AB Age-related macular degeneration (AMD), the most common cause of irreversible vision loss in individuals aged older than 50 years, is classified as either wet (neovascular) or dry (nonneovascular). Inherited variation in the complement factor H gene is a major risk factor for drusen in dry AMD. Here we report that a single-nucleotide polymorphism in the promoter region of HTRA1, a serine protease gene on chromosome 10q26, is a major genetic risk factor for wet AMD. A whole-genome association mapping strategy was applied to a Chinese population, yielding a P value of < 10(-11). Individuals with the risk-associated genotype were estimated to have a likelihood of developing wet AMD 10 times that of individuals with the wild-type genotype.
C1 Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.
   Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.
   Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   Rockefeller Univ, Genom Resource Ctr, New York, NY 10021 USA.
C3 Yale University; Yale University; Yale University; Chinese University of
   Hong Kong; Rockefeller University
RP Hoh, J (通讯作者)，Yale Univ, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
RI Barnstable, Colin/GLU-9219-2022; Barnstable, Colin/ABB-4822-2021; Lam,
   Dennis/AAL-1211-2020; Pang, Chi P/I-5388-2014
OI Snyder, Michael/0000-0003-0784-7987; DeWan, Andrew/0000-0002-7679-8704;
   Barnstable, Colin/0000-0002-7011-4068
CR Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Okamoto H, 2006, MOL VIS, V12, P156
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 24
TC 667
Z9 728
U1 3
U2 52
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD NOV 10
PY 2006
VL 314
IS 5801
BP 989
EP 992
DI 10.1126/science.1133807
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 103OG
UT WOS:000241896000052
PM 17053108
DA 2022-11-30
ER

PT J
AU Ly, A
   Yapp, M
   Nivison-Smith, L
   Assaad, N
   Hennessy, M
   Kalloniatis, M
AF Ly, Angelica
   Yapp, Michael
   Nivison-Smith, Lisa
   Assaad, Nagi
   Hennessy, Michael
   Kalloniatis, Michael
TI Developing prognostic biomarkers in intermediate age-related macular
   degeneration: their clinical use in predicting progression
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related macular degeneration; disease staging; prognosis;
   progression
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   RETINAL-PIGMENT EPITHELIUM; LUMINANCE VISUAL-ACUITY; GEOGRAPHIC-ATROPHY;
   FUNDUS AUTOFLUORESCENCE; RETICULAR PSEUDODRUSEN; DARK-ADAPTATION;
   FUNCTION-TESTS; FELLOW-EYES
AB Age-related macular degeneration is a common, complex and blinding eye disease. When early and intermediate levels of severity are detected in one or both eyes, there is a wide-ranging 0.4 to 53 per cent risk of progression to advanced disease in five years. In order to maximise visual outcomes for their patients, practising eye-care professionals must be able to stratify patients according to their risk of progression, intervene (for example by recommending smoking cessation or nutritional supplements and Amsler grid self-monitoring in intermediate disease) and monitor accordingly. With the aid of ocular imaging, a range of under-recognised yet meaningful risk factors have been identified. The purpose of this review is to assist the eye-care practitioner in stratifying the risk of progression in intermediate age-related macular degeneration using the range of established and emerging precursory signs that herald loss of vision.
C1 [Ly, Angelica; Yapp, Michael; Nivison-Smith, Lisa; Assaad, Nagi; Hennessy, Michael; Kalloniatis, Michael] Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Yapp, Michael; Nivison-Smith, Lisa; Kalloniatis, Michael] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Assaad, Nagi; Hennessy, Michael] Prince Wales Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of New South Wales Sydney
RP Kalloniatis, M (通讯作者)，Ctr Eye Hlth, Sydney, NSW, Australia.; Kalloniatis, M (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM m.kalloniatis@unsw.edu.au
RI Ly, Angelica/J-2070-2019; Hennessy, Michael/AAN-8444-2021
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Hennessy, Michael/0000-0003-2750-9344;
   Nivison-Smith, Lisa/0000-0001-6677-1949
FU University of New South Wales [P535430]; National Health and Medical
   Research Council (NHMRC) [1033224]; NHMRC grant
FX The authors thank Tyson Xu for his assistance in the literature search
   and for identifying the case images. This work was supported, in part,
   by grants and awards from the University of New South Wales (Early
   Career Research Grant 2015-2016 #P535430, an Australian Postgraduate
   Award), and a National Health and Medical Research Council (NHMRC) grant
   (#1033224). Guide Dogs NSW/ACT is a partner in the NHMRC grant and also
   provided a supplementary PhD scholarship for AL and support for LN-S.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   American Optometric Association Consensus Panel on Care of the Patient with Age Related Macular Degeneration, 2004, OPT CLIN PRACT GUID
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bell K, 2012, EUR J PREV CARDIOL, V19, P1474, DOI 10.1177/1741826711424494
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Canadian Journal of Optometry, 2015, CANADIAN J OPTOMETRY
   Cassels NK, 2017, SURV OPHTHALMOL
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Choi A, 2016, P ARVO C SEATTL 2016
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Damen JAAG, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2416
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P932, DOI 10.1097/OPX.0000000000000246
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Fragiotta Serena, 2017, Int J Retina Vitreous, V3, P8, DOI 10.1186/s40942-017-0061-3
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KALLONIATIS M, 1993, OPHTHAL PHYSL OPT, V13, P155, DOI 10.1111/j.1475-1313.1993.tb00445.x
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kianoush S, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0565-6
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Liu L, 2014, OPTOMETRY VISION SCI, V91, P956, DOI 10.1097/OPX.0000000000000324
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Lovie-Kitchin JE, 2000, OPHTHAL PHYSL OPT, V20, P360
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P339, DOI 10.1016/j.jcjo.2014.04.018
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P494, DOI 10.1080/08820538.2017.1307423
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   RANZCO, 2016, RANZCO REF PATH AMD
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   The Royal College of Ophthalmologists, 2013, AG REL MAC DEG GUID
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wong EN, 2017, ASIA-PAC J OPHTHALMO, V6, P70, DOI 10.22608/APO.201643
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yehoshua Z, 2012, OPHTHALMIC RES, V48, P6, DOI 10.1159/000339841
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 95
TC 10
Z9 10
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAR
PY 2018
VL 101
IS 2
BP 172
EP 181
DI 10.1111/cxo.12624
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY0JF
UT WOS:000426496400004
PM 29136680
OA Bronze
DA 2022-11-30
ER

PT J
AU Knez, N
   Sisko, K
   Pahor, D
AF Knez, N.
   Sisko, K.
   Pahor, D.
TI Corneal Thickness in Patients with Age-related Macular Degeneration
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE AGE-RELATED MACULAR DEGENERATION (AMD); CORNEAL THICKNESS; GALILEI (TM)
   DUAL SCHEIMPFLUG ANALYSER; RETINAL THICKNESS; OPTICAL COHERENCE
   TOMOGRAPHY; RISK FACTOR
ID OPTICAL COHERENCE TOMOGRAPHY; ORBSCAN-II; ULTRASOUND; ASSOCIATIONS;
   SCHEIMPFLUG
AB This observational study was designed to compare corneal thickness in patients with age-related macular degeneration (AMD) with the thickness in healthy control subjects to determine if there is a correlation between corneal thickness and the development of AMD. A total of 69 patients (119 eyes) with AMD and 31 healthy subjects (56 eyes) were evaluated. Corneal thickness was measured with a Galilei (TM) Dual Scheimpflug Analyser and retinal thickness was measured using optical coherence tomography. There was no significant difference in mean corneal thickness or mean retinal thickness between the AMD and control groups and no correlation between corneal and retinal thickness in either group. The results confirmed that corneal thickness is not associated with the development of AMD and cannot be used during diagnosis.
C1 [Pahor, D.] Univ Clin Ctr Maribor, Dept Ophthalmol, Maribor 2000, Slovenia.
   [Knez, N.; Sisko, K.; Pahor, D.] Univ Maribor, Fac Med, SLO-2000 Maribor, Slovenia.
C3 University of Maribor; University of Maribor
RP Pahor, D (通讯作者)，Univ Clin Ctr Maribor, Dept Ophthalmol, Ljubljanska 5, Maribor 2000, Slovenia.
EM d.pahor@ukc.mb.si
CR *AM AC OPHTH, 2007, BAS CLIN SCI COURS, P54
   *AM AC OPHTH, 2007, BAS CLIN SCI COURS, P15
   Auffarth GU, 2008, OPHTHALMOLOGE, V105, P810, DOI 10.1007/s00347-008-1821-0
   Bialek-Szymanska Anna, 2007, Klin Oczna, V109, P127
   BUSTED N, 1981, BRIT J OPHTHALMOL, V65, P687, DOI 10.1136/bjo.65.10.687
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Ciolino JB, 2008, AM J OPHTHALMOL, V145, P75, DOI 10.1016/j.ajo.2007.08.026
   Ehlers N, 2004, EXP EYE RES, V78, P543, DOI 10.1016/j.exer.2003.09.017
   Evereklioglu C, 2002, J PEDIAT OPHTH STRAB, V39, P274, DOI 10.3928/0191-3913-20020901-07
   Evereklioglu C, 2002, EUR J OPHTHALMOL, V12, P24, DOI 10.1177/112067210201200105
   Fletcher EC, 2008, EYE, V22, P742, DOI 10.1038/sj.eye.6703008
   HANSEN FK, 1971, ACTA OPHTHALMOL, V49, P467
   Hashemi H, 2007, J CATARACT REFR SURG, V33, P1701, DOI 10.1016/j.jcrs.2007.05.040
   Hazin R, 2009, J NATL MED ASSOC, V101, P134, DOI 10.1016/S0027-9684(15)30825-7
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Jonas JB, 2005, INVEST OPHTH VIS SCI, V46, P1269, DOI 10.1167/iovs.04-0265
   Kanski JJ, 2007, CLIN OPHTHALMOLOGY, P627
   Kaushik S, 2006, AM J OPHTHALMOL, V141, P884, DOI 10.1016/j.ajo.2005.12.026
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Kymionis GD, 2007, CORNEA, V26, P182, DOI 10.1097/ICO.0b013e31802c9def
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   MARTIDIS A, 2004, OPHTHALMOLOGY, P925
   Mattes D, 2009, MOL VIS, V15, P343
   McBee Wendy L, 2003, Curr Opin Ophthalmol, V14, P159, DOI 10.1097/00055735-200306000-00009
   Menassa N, 2008, J CATARACT REFR SURG, V34, P1742, DOI 10.1016/j.jcrs.2008.06.024
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Muller M, 2008, KLIN MONATSBL AUGENH, V225, P194, DOI 10.1055/s-2008-1027241
   Pahor D, 2008, KLIN MONATSBL AUGENH, V225, P713, DOI 10.1055/s-2007-963761
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   PEDERSEN U, 1984, ORL J OTO-RHINO-LARY, V46, P38, DOI 10.1159/000275682
   Pelletier AL, 2009, AM FAM PHYSICIAN, V79, P963
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   ROH S, 2004, OPHTHALMOLOGY, P779
   Sanchis-Gimeno JA, 2005, CORNEA, V24, P39, DOI 10.1097/01.ico.0000138836.45070.0f
   SAXENA S, 2006, OPTICAL COHERENCE TO, P2
   SOUBRONE G, 2006, OPTICAL COHERENCE TO, P110
   Unger F, 2008, ACTA MEDICO BIOTECHN, V1, P11
   Wildner K, 2007, KLIN MONATSBL AUGENH, V224, P832, DOI 10.1055/s-2007-963639
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   YOUNGQUIST RC, 1987, OPT LETT, V12, P158, DOI 10.1364/OL.12.000158
NR 42
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD SEP-OCT
PY 2009
VL 37
IS 5
BP 1552
EP 1560
DI 10.1177/147323000903700533
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 537SD
UT WOS:000273133200033
PM 19930863
DA 2022-11-30
ER

PT J
AU Rullo, J
   Far, PM
   Quinn, M
   Sharma, N
   Bae, S
   Irrcher, I
   Sharma, S
AF Rullo, Jacob
   Far, Parsa Mehraban
   Quinn, Matthew
   Sharma, Neel
   Bae, Steven
   Irrcher, Isabella
   Sharma, Sanjay
TI Local oral and nasal microbiome diversity in age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROGRESSION; INFECTION; GENE; CFH; GUT
AB Age-related macular degeneration (AMD) is a chronic degenerative disease of the retina. Recent reports have highlighted the potential role of mucosal surface microbes in the pathogenesis of AMD. In this case-control study, the composition of the nasal and oral microbiota in newly diagnosed neovascular age-related macular degeneration cases (6 male, 7 female) was compared to controls without retinal diseases (2 male, 3 female). PCR amplification of 16S rRNA genes was performed with universal primers amplifying the V4 variable region (515F-806R). Distinct microbial community characterization was achieved using Principal Coordinates Analysis (PCoA) of the Bray-Curtis index with comparative analysis between cases and controls performed within QIIME 2. Sequencing of all cases and controls revealed clear separation with strong beta diversity between oral and nasal microbial communities (p < 0.001). Microbial composition differed between cases and controls in both oral and nasal samples. The top three oral microbes identified as different compared to controls included Burkholderiales (7.41 log2fold change, p = 3.29E-05), Actinomyceataceae (6.22 log2fold change, p = 3.73E-06) and Gemella (5.28 log2fold change, p = 0.0002). The top three nasal microbes identified as different compared to controls included Rothia (13.6 log2fold change, p = 3.63E-18), Actinobacteria (10.29 log2fold change, p = 9.81E-10) and Propionibacteriales (8.73 log2fold change, p = 6.74E-09). These relative shifts in communities of bacteria detected in newly diagnosed neovascular AMD patients may suggest additional mechanistic links in disease pathogenesis.
C1 [Rullo, Jacob; Far, Parsa Mehraban; Quinn, Matthew; Sharma, Neel; Bae, Steven; Irrcher, Isabella; Sharma, Sanjay] Queens Univ, Kingston Hlth Sci Ctr, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
C3 Queens University - Canada
RP Rullo, J (通讯作者)，Queens Univ, Kingston Hlth Sci Ctr, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM jrullo@qmed.ca
OI Bae, Steven/0000-0001-5759-3036; Quinn, Matthew/0000-0003-1987-9265
FU Physicians Services Incorporated
FX We would like to acknowledge Metagenome Bio Inc. for their assistance in
   the methodological interpretation and statistical analysis of the 16S
   rRNA data. We would like to acknowledge uBiome Inc for their involvement
   in the 16S rRNA methodology and sequencing of participant samples. Jacob
   Rullo was funded by a Research Trainee Award by Physicians Services
   Incorporated.
CR Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bonyadi MHJ, 2018, ACTA OPHTHALMOL, V96, pe105, DOI 10.1111/aos.13494
   Cady NC, 2003, BIOSENS BIOELECTRON, V19, P59, DOI 10.1016/S0956-5663(03)00123-4
   Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]
   Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Epstein SE, 2000, ARTERIOSCL THROM VAS, V20, P1417, DOI 10.1161/01.ATV.20.6.1417
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Huang JQ, 2002, LANCET, V359, P14, DOI 10.1016/S0140-6736(02)07273-2
   HUMMEL W, 1989, J MICROBIOL METH, V9, P201, DOI 10.1016/S0167-7012(97)00050-X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145
   Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107
   Mahe F, 2014, PEERJ, V2, DOI 10.7717/peerj.593
   McInnes P., 2010, MANUAL PROCEDURES HU
   Minalla A. R., 2001, INT SOC OPTICS PHOTO, P90
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584
   Timms VJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148731
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 25
TC 10
Z9 11
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 2
PY 2020
VL 10
IS 1
AR 3862
DI 10.1038/s41598-020-60674-3
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE8XC
UT WOS:000562887500007
PM 32123200
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dhoot, DS
   Kaiser, PK
AF Dhoot, Dilsher S.
   Kaiser, Peter K.
TI Ranibizumab for age-related macular degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN THERAPY; INTRAVITREAL
   INJECTION; CHOROIDAL NEOVASCULARIZATION; NATURAL-HISTORY;
   PHARMACOKINETICS; TRIAL; VERTEPORFIN; MULTICENTER; EXPRESSION
AB Introduction: Age-related macular degeneration (AMD) is the leading cause of blindness in patients over 50 years in the developed world. The wet form of AMD is responsible for the majority of severe vision loss. VEGF-A is a key component in the development of wet AMD. Ranibizumab is an anti-VEGF agent that has established itself as the gold standard in the treatment of neovascular AMD. Herein, we review the pharmacology, pharmacokinetics, efficacy and safety of ranibizumab.
   Areas covered: Since its approval in 2006, ranibizumab has revolutionized the treatment of wet AMD. In two pivotal Phase III trials, MARINA and ANCHOR, ranibizumab (0.5 mg) prevented moderate visual loss in 90 and 96% of patients, respectively, and improved vision by 15 letters or more in 33 and 40% of patients, respectively. Fixed monthly dosing regimens were compared with quarterly dosing regimens in PIER and EXCITE studies and support the superiority of fixed monthly dosing. The CATT trial revealed that bevacizumab was not inferior to ranibizumab when dosed monthly. As-needed treatment regimens of ranibizumab were also found to be non-inferior to monthly ranibizumab after 1 year of follow-up.
   Expert opinion: Ranibizumab has positively altered the treatment of wet AMD and offers hope for millions of patients.
C1 [Dhoot, Dilsher S.; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
RI Dhoot, Dilsher/ABD-5417-2021
OI Kaiser, Peter/0000-0001-5126-045X
FU Research to Prevent Blindness
FX This work was supported by grant from the Research to Prevent Blindness.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 2009, QLT ANNOUCES 12 MONT
   [Anonymous], 2010, LUC RAN INJ
   [Anonymous], 2010, BAYER REGENERON REPO
   [Anonymous], 2010, QLT ANNOUNCES FINAL
   [Anonymous], 2010, 12 MONTH RESULTS DEN
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Blick SK, 2007, DRUGS, V67, P1207
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, p[e1, 12]
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   PEER J, 1995, LAB INVEST, V72, P638
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tseng JJ, 2011, J GLAUCOMA
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 72
TC 24
Z9 27
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD MAR
PY 2012
VL 12
IS 3
BP 371
EP 381
DI 10.1517/14712598.2012.660523
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 894RS
UT WOS:000300444900011
PM 22309606
DA 2022-11-30
ER

PT J
AU Sarkar, A
   Dyawanapelly, S
AF Sarkar, Aira
   Dyawanapelly, Sathish
TI Nanodiagnostics and Nanotherapeutics for age-related macular
   degeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Age-related macular degeneration; Choroidal neovascularization;
   Nanoparticles; Drug delivery; Posterior segment of the eye; Intravitreal
   injection
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; SOLID LIPID
   NANOPARTICLES; DRUG-DELIVERY; IN-VITRO; CHOROIDAL NEOVASCULARIZATION;
   PLGA NANOPARTICLES; INORGANIC NANOPARTICLES; DIABETIC-RETINOPATHY; OXIDE
   NANOPARTICLES
AB Age-related macular degeneration (AMD) is the third leading cause worldwide blindness that causes permanent central vision impairment in older people. Over the past few years, there has been significant progress in the diagnosis and therapy of AMD. Currently available diagnostic and therapeutic strategies are clinically limited to manage AMD. The intravitreal (IVT) injection therapy has its shortcomings due to the ocular barriers and frequent administration of drugs into the vitreous humor of the eye. The safe and effective formulations will address the unmet medical needs of AMD. Various engineered nanoformulations, composed of polymers, lipids, proteins, inorganic materials, have been significantly investigated for the management of AMD over the past decade. The purpose of the review was to provide a comprehensive overview of the current state-of-the-art clinical diagnosis and treatment modalities for AMD. This review highlights the progress and future perspectives of nanodiagnostics and nanotherapeutics.
C1 [Sarkar, Aira; Dyawanapelly, Sathish] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
C3 Institute of Chemical Technology - Mumbai
RP Dyawanapelly, S (通讯作者)，Inst Chem Technol, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
EM sa.dyawanapelly@ictmumbai.edu.in
RI DYAWANAPELLY, SATHISH/AHC-3560-2022; Dyawanapelly, Sathish/AAK-1843-2020
OI DYAWANAPELLY, SATHISH/0000-0002-2310-1651; Dyawanapelly,
   Sathish/0000-0002-2310-1651; Sarkar, Aira/0000-0001-7756-3299
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Agrawal R, 2016, EXPERT REV MED DEVIC, V13, P519, DOI 10.1080/17434440.2016.1186540
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ampornpruet Atchara, 2005, Journal of the Medical Association of Thailand, V88, pS51
   Badiee P, 2018, J BIOMED MATER RES A, V106, P2261, DOI 10.1002/jbm.a.36424
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhattacharya R, 2004, NANO LETT, V4, P2479, DOI 10.1021/nl0483789
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Borrelli E, 2019, BRIT J OPHTHALMOL, V103, P610, DOI 10.1136/bjophthalmol-2018-311849
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Chaharband F, 2020, NANOMED-NANOTECHNOL, V26, DOI 10.1016/j.nano.2020.102181
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   Chen J, 2008, ADV EXP MED BIOL, V613, P53, DOI 10.1007/978-0-387-74904-4_5
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Dasari BC, 2017, MOL THER-NUCL ACIDS, V8, P77, DOI 10.1016/j.omtn.2017.06.004
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de la Fuente M, 2010, ADV DRUG DELIVER REV, V62, P100, DOI 10.1016/j.addr.2009.11.026
   del Pozo-Rodriguez A, 2016, EUR J PHARM BIOPHARM, V109, P184, DOI 10.1016/j.ejpb.2016.10.016
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Ding L, 2020, IEEE T IMAGE PROCESS, V29, P6561, DOI 10.1109/TIP.2020.2991530
   Du JD, 2016, DRUG DELIV TRANSL RE, V6, P781, DOI 10.1007/s13346-016-0299-6
   Dyawanapelly S, 2019, BIOORG CHEM, V82, P17, DOI 10.1016/j.bioorg.2018.09.020
   Dyawanapelly S, 2016, DRUG DELIV TRANSL RE, V6, P365, DOI 10.1007/s13346-016-0295-x
   Dyawanapelly S, 2015, CURR DRUG METAB, V16, P522, DOI 10.2174/1389200216666141219122614
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Falavarjani KG, 2016, J CURR OPHTHALMOL, V28, P57, DOI 10.1016/j.joco.2016.04.001
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman WR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1647, DOI 10.1001/archopht.122.11.1647
   Gan L, 2013, BIOMATERIALS, V34, P5978, DOI 10.1016/j.biomaterials.2013.04.035
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Gross N, 2013, MOL VIS, V19, P54
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hamed E, 2001, J CONTROL RELEASE, V73, P329, DOI 10.1016/S0168-3659(01)00356-X
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Hironaka K, 2011, EUR J PHARM BIOPHARM, V79, P119, DOI 10.1016/j.ejpb.2011.01.019
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   Hu Y., 2020, NEW ENGL J MED, V382, P1708, DOI DOI 10.1073/pnas.1618029113
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Ilochonwu BC, 2020, J CONTROL RELEASE, V326, P419, DOI 10.1016/j.jconrel.2020.07.031
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Jalali Subhadra, 2003, Community Eye Health, V16, P25
   Janagam DR, 2017, ADV DRUG DELIVER REV, V122, P31, DOI 10.1016/j.addr.2017.04.001
   Jo DH, 2014, NANO RES, V7, P844, DOI 10.1007/s12274-014-0445-8
   Jo DH, 2012, NANOMED-NANOTECHNOL, V8, P784, DOI 10.1016/j.nano.2011.09.003
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Karumanchi DK, 2018, J DRUG DELIV SCI TEC, V47, P275, DOI 10.1016/j.jddst.2018.07.003
   Keane PA, 2018, EYE AI AUTONOMOUS DI
   Kels BD, 2015, CLIN DERMATOL, V33, P140, DOI 10.1016/j.clindermatol.2014.10.006
   Kim Jin-Seok, 2016, Journal of Pharmaceutical Investigation, V46, P387, DOI 10.1007/s40005-016-0260-1
   Kim SJ, 2010, EXPERT REV OPHTHALMO, V5, P699, DOI 10.1586/EOP.10.48
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kolate A, 2014, J CONTROL RELEASE, V192, P67, DOI 10.1016/j.jconrel.2014.06.046
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Kreuger J, 2016, NAT REV DRUG DISCOV, V15, P125, DOI 10.1038/nrd.2015.2
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Lai TYY, 2012, EYE, V26, P1004, DOI 10.1038/eye.2012.97
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Liew G, 2006, BMJ-BRIT MED J, V332, P3, DOI 10.1136/bmj.332.7532.3
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Llabot JM, 2019, J DRUG DELIV SCI TEC, V52, P379, DOI 10.1016/j.jddst.2019.04.042
   Lohse SE, 2012, J AM CHEM SOC, V134, P15607, DOI 10.1021/ja307589n
   Ludwig A, 2005, ADV DRUG DELIVER REV, V57, P1595, DOI 10.1016/j.addr.2005.07.005
   de Redin IL, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107697
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Madhusudhan Savitha, 2014, ScientificWorldJournal, V2014, P536161, DOI 10.1155/2014/536161
   Mahaling B, 2018, NANOSCALE, V10, DOI 10.1039/c8nr00058a
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Mishra V, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040191
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Mochimaru H, 2009, INVEST OPHTH VIS SCI, V50, P4410, DOI 10.1167/iovs.08-3044
   Mohammadpour Mehrdad, 2015, Adv Biomed Res, V4, P124, DOI 10.4103/2277-9175.158039
   Moiseev RV, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070321
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   Mun EA, 2014, MOL PHARMACEUT, V11, P3556, DOI 10.1021/mp500332m
   Necas J, 2008, VET MED-CZECH, V53, P397, DOI 10.17221/1930-VETMED
   Nii T, 2005, INT J PHARMACEUT, V298, P198, DOI 10.1016/j.ijpharm.2005.04.029
   Nishie H, 2016, ONCOTARGET, V7, P74259, DOI 10.18632/oncotarget.12366
   Nowak M.S, 2020, KLIN OCZNA
   Ojea-Jimenez I, 2013, CURR DRUG METAB, V14, P518, DOI 10.2174/13892002113149990008
   Pandey AN, 2014, SAUDI J OPHTHALMOL, V28, P310, DOI 10.1016/j.sjopt.2013.11.001
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Park JH, 2016, SCI REP-UK, V6, DOI [10.1038/srep37762, 10.1111/j.1755-3768.2016.0333]
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Ribatti D, 2005, BRIT J HAEMATOL, V128, P303, DOI 10.1111/j.1365-2141.2004.05291.x
   Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schuman Joel S, 2008, Trans Am Ophthalmol Soc, V106, P426
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Seyfoddin A, 2010, DRUG DELIV, V17, P467, DOI 10.3109/10717544.2010.483257
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Singh R, 2020, NANOMED-NANOTECHNOL, V28, DOI 10.1016/j.nano.2020.102205
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   SMETANA K, 1987, J BIOMED MATER RES, V21, P1247, DOI 10.1002/jbm.820211007
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Streets J, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88030030
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Suri R, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105489
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tahara K, 2017, ASIAN J PHARM SCI, V12, P394, DOI 10.1016/j.ajps.2017.03.002
   Tamaki Y, 2009, NANOMEDICINE-UK, V4, P341, DOI 10.2217/NNM.09.10
   Thakur N, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0516-9
   Tonnu PA, 2005, BRIT J OPHTHALMOL, V89, P847, DOI 10.1136/bjo.2004.056614
   Torrecilla J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/161794
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Urias EA, 2017, VISION RES, V139, P221, DOI 10.1016/j.visres.2017.06.015
   van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Vismara E, 2017, MOLECULES, V22, DOI 10.3390/molecules22071030
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wilkie D.A, 2013, OCULAR PHARM TOXICOL, P143
   Wolfesberger B, 2007, J COMP PATHOL, V137, P30, DOI 10.1016/j.jcpa.2007.03.003
   Wong LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121977
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 155
TC 11
Z9 11
U1 1
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 10
PY 2021
VL 329
BP 1262
EP 1282
DI 10.1016/j.jconrel.2020.10.054
EA FEB 2021
PG 21
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA QT1EB
UT WOS:000626334700093
PM 33129920
DA 2022-11-30
ER

PT J
AU Klein, ML
   Francis, PJ
   Ferris, FL
   Hamon, SC
   Clemons, TE
AF Klein, Michael L.
   Francis, Peter J.
   Ferris, Frederick L., III
   Hamon, Sara C.
   Clemons, Traci E.
TI Risk Assessment Model for Development of Advanced Age-Related Macular
   Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CORONARY-HEART-DISEASE; BEAVER DAM EYE;
   COLORECTAL-CANCER; SEVERITY SCALE; BLOOD-PRESSURE; PREDICTION;
   MACULOPATHY; SUSCEPTIBILITY; PROGRESSION
AB Objective: To design a risk assessment model for development of advanced age-related macular degeneration (AMD) incorporating phenotypic, demographic, environmental, and genetic risk factors.
   Methods: We evaluated longitudinal data from 2846 participants in the Age-Related Eye Disease Study. At baseline, these individuals had all levels of AMD, ranging from none to unilateral advanced AMD (neovascular or geographic atrophy). Follow-up averaged 9.3 years. We performed a Cox proportional hazards analysis with demographic, environmental, phenotypic, and genetic covariates and constructed a risk assessment model for development of advanced AMD. Performance of the model was evaluated using the C statistic and the Brier score and externally validated in participants in the Complications of Age-Related Macular Degeneration Prevention Trial.
   Results: The final model included the following independent variables: age, smoking history, family history of AMD (first-degree member), phenotype based on a modified Age-Related Eye Disease Study simple scale score, and genetic variants CFH Y402H and ARMS2 A69S. The model did well on performance measures, with very good discrimination (C statistic=0.872) and excellent calibration and overall performance (Brier score at 5 years=0.08). Successful external validation was performed, and a risk assessment tool was designed for use with or without the genetic component.
   Conclusions: We constructed a risk assessment model for development of advanced AMD. The model performed well on measures of discrimination, calibration, and overall performance and was successfully externally validated. This risk assessment tool is available for online use.
C1 [Klein, Michael L.; Francis, Peter J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   [Klein, Michael L.; Francis, Peter J.] Legacy Good Samaritan Hosp & Med Ctr, Devers Eye Inst, Portland, OR USA.
   [Ferris, Frederick L., III] NEI, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Hamon, Sara C.] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
C3 Oregon Health & Science University; Devers Eye Institute; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Emmes Corporation; Rockefeller University
RP Klein, ML (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM kleinm@ohsu.edu
RI Mitchell, Paul/P-1498-2014
OI Ferris, Frederick/0000-0002-4933-0639
FU Casey Eye Institute; Research to Prevent Blindness, New York, New York;
   Bea Arveson Macular Degeneration Fund; Foundation Fighting Blindness,
   Owings Mills, Maryland; NATIONAL EYE INSTITUTE [ZIAEY000485] Funding
   Source: NIH RePORTER
FX This work was supported by the Casey Eye Institute Macular Degeneration
   Fund (Drs Klein and Francis), Research to Prevent Blindness, New York,
   New York (Drs Klein and Francis), the Bea Arveson Macular Degeneration
   Fund (Dr Klein), and the Foundation Fighting Blindness, Owings Mills,
   Maryland (Dr Francis).
CR American Academy of Ophthalmology, 2009, FREQ OC EX
   Antoniou Antonis C, 2006, Future Oncol, V2, P257, DOI 10.2217/14796694.2.2.257
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Coleman AL, 2008, SURV OPHTHALMOL, V53, pS3, DOI 10.1016/j.survophthal.2008.08.006
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Freedman AN, 2009, J CLIN ONCOL, V27, P686, DOI 10.1200/JCO.2008.17.4797
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gerds TA, 2007, BIOMETRICS, V63, P1283, DOI 10.1111/j.1541-0420.2007.00832.x
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   GRAF W, 1994, EUR J CANCER, V30A, P453, DOI 10.1016/0959-8049(94)90417-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Hippisley-Cox J, 2008, BMJ-BRIT MED J, V336, P1475, DOI 10.1136/bmj.39609.449676.25
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   KANNEL WB, 1975, ANGIOLOGY, V26, P1, DOI 10.1177/000331977502600101
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lango H, 2008, DIABETES, V57, P3129, DOI 10.2337/db08-0504
   LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Lin X, 2009, DIABETOLOGIA, V52, P600, DOI 10.1007/s00125-008-1254-y
   Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Mansberger SL, 2008, SURV OPHTHALMOL, V53, pS11, DOI 10.1016/j.survophthal.2008.08.005
   Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742
   Moeller SM, 2009, J NUTR, V139, P1692, DOI 10.3945/jn.109.107748
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rojas J, 2009, INVEST OPHTH VIS SCI, V50, P2384, DOI 10.1167/iovs.08-2670
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wilson PWF, 2007, ARCH INTERN MED, V167, P1068, DOI 10.1001/archinte.167.10.1068
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Witkin AJ, 2006, AM J OPHTHALMOL, V142, P945, DOI 10.1016/j.ajo.2006.07.024
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 76
TC 57
Z9 58
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2011
VL 129
IS 12
BP 1543
EP 1550
DI 10.1001/archophthalmol.2011.216
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 861BX
UT WOS:000297995000004
PM 21825180
OA Bronze
DA 2022-11-30
ER

PT J
AU Baba, T
   Kitahashi, M
   Kubota-Taniai, M
   Oshitari, T
   Yamamoto, S
AF Baba, Takayuki
   Kitahashi, Masayasu
   Kubota-Taniai, Mariko
   Oshitari, Toshiyuki
   Yamamoto, Shuichi
TI Two-Year Course of Subfoveal Pigment Epithelial Detachment in Eyes with
   Age-Related Macular Degeneration and Visual Acuity Better than 20/40
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidopathy; Retinal pigment epithelial detachment
ID INTRAVITREAL BEVACIZUMAB INJECTION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS; NATURAL-HISTORY; TEARS;
   NEOVASCULARIZATION; SECONDARY
AB Purpose: To investigate the course of subfoveal pigment epithelial detachments (PEDs) in eyes with age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) >= 20/40. Methods: Thirty-seven eyes of 35 patients with a subfoveal PED were divided into an avascular PED group (n = 11), a vascularized PED group due to polypoidal choroidal vasculopathy (PCV, n = 14) and an occult choroidal neovascularization (CNV) group (n = 12). Intravitreal bevacizumab or ranibizumab was given as needed. The BCVA, central foveal thickness, PED thickness, and lesion size were measured at baseline and at 2 years after the initial examination. Results: The BCVA did not change significantly in the avascular group, decreased from 0.06 +/- 0.11 to 0.23 +/- 0.15 logMAR units in the PCV group and from 0.12 +/- 0.12 to 0.71 +/- 0.70 logMAR units in the CNV group. At 2 years, the central foveal and PED thicknesses were not significantly different among the 3 groups, and the lesion was significantly larger in the PCV and CNV groups than in the avascular group. Conclusions: The vascularized PED cases had a poorer visual outcome than avascular PEDs with anti-VEGF drugs at the 2-year follow-up. Copyright (C) 2012 S. Karger AG, Basel
C1 [Baba, Takayuki] Chiba Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Chuo Ku, Chiba 2600856, Japan.
C3 Chiba University
RP Baba, T (通讯作者)，Chiba Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.
EM babatakayuki@nifty.com
OI Oshitari, Toshiyuki/0000-0002-8273-845X
FU Japan Society for the Promotion of Science KAKENHI [23791966]
FX The authors thank Professor Duco Hamasaki from the Bascom Palmer Eye
   Institute of the University of Miami for his critical discussion and
   editing of the final manuscript. This work was supported by the Japan
   Society for the Promotion of Science KAKENHI 23791966, Grant-in-Aid for
   Young Scientists (B).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   BIRD AC, 1991, EYE, V5, P1
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   SHIRAKASHI A, 1992, Nippon Ganka Gakkai Zasshi, V96, P677
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
NR 29
TC 23
Z9 24
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 228
IS 2
BP 102
EP 109
DI 10.1159/000337251
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981EP
UT WOS:000306950000005
PM 22508168
DA 2022-11-30
ER

PT J
AU Kijlstra, A
   Berendschot, TTJM
AF Kijlstra, Aize
   Berendschot, Tos T. J. M.
TI Age-Related Macular Degeneration: A Complementopathy?
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Complement system; Immunopathology;
   Factor D
ID QUALITY-OF-LIFE; RETINAL-PIGMENT EPITHELIUM; MEMBRANE ATTACK COMPLEX;
   ALTERNATIVE PATHWAY; ADIPOSE-TISSUE; HIGH-RISK; BRUCHS MEMBRANE; FACTOR
   B; FACTOR-I; ACTIVATION
AB Age-related macular degeneration (AMD) is a progressive eye disease affecting many elderly individuals. It has a multifactorial pathogenesis and is associated with numerous environmental (e.g. smoking, light and nutrition) and genetic risk factors. A breakthrough in the mechanisms causing AMD is emerging; the involvement of the alternative pathway of the complement system appears to play a pivotal role. This has led to the statement that AMD is a disease caused by a hyperactive complement system, allowing the term 'complementopathy' to define it more precisely. Abundant evidence includes: the identification of drusen components as activators of complement, immunohistochemical data showing the presence of many species of the complement system in the retinal pigment epithelium-Bruch's membrane-choroidocapillary region of AMD eyes, a strong association of AMD with certain genetic complement protein variants, raised complement levels in blood from AMD patients and the preliminary successful treatments of geographic atrophy with complement factor D (FD) inhibitors. FD is the rate-limiting enzyme of the alternative complement pathway, and is produced by adipose tissue. Recent findings suggest that nutrition may play a role in controlling the level of FD in the circulation. Addressing modifiable risk factors such as smoking and nutrition may thus offer opportunities for the prevention of AMD. (C) 2015 S. Karger AG, Basel
C1 [Kijlstra, Aize; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
   [Kijlstra, Aize] Wageningen UR Livestock Res, Wageningen, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Wageningen University & Research
RP Kijlstra, A (通讯作者)，Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM aize.kijlstra@wur.nl
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Bone RA, 2012, ACTA BIOCHIM POL, V59, P91
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Chung HY, 2009, AM J CLIN NUTR, V90, P533, DOI 10.3945/ajcn.2009.27712
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Esterbauer H, 1999, EUR J CLIN INVEST, V29, P653
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   HYLKEMA HA, 1983, EXP EYE RES, V37, P257, DOI 10.1016/0014-4835(83)90160-4
   Kaliappan S, 2008, FEBS LETT, V582, P3451, DOI 10.1016/j.febslet.2008.09.009
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klos A, 2013, PHARMACOL REV, V65, P500, DOI 10.1124/pr.111.005223
   Koenderman L, 2014, IMMUNOL LETT, V162, P95, DOI 10.1016/j.imlet.2014.10.010
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Landrier JF, 2012, NUTRIENTS, V4, P1622, DOI 10.3390/nu4111622
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   Ma WX, RETINAL DEGENERATIVE
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Marback RF, 2007, CLINICS, V62, P573, DOI 10.1590/S1807-59322007000500007
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Meyer-Ruesenberg B, 2010, KLIN MONATSBL AUGENH, V227, P646, DOI 10.1055/s-0029-1245118
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   NAPOLITANO A, 1994, INT J OBESITY, V18, P213
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Renner AB, 2004, VISUAL NEUROSCI, V21, P827, DOI 10.1017/S0952523804216030
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 86
TC 24
Z9 25
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 54
IS 2
BP 64
EP 73
DI 10.1159/000432401
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ9KQ
UT WOS:000360933800002
PM 26159686
OA Bronze
DA 2022-11-30
ER

PT J
AU Mackenzie, PJ
   Chang, TS
   Scott, IU
   Linder, M
   Hay, D
   Feuer, WJ
   Chambers, K
AF Mackenzie, PJ
   Chang, TS
   Scott, IU
   Linder, M
   Hay, D
   Feuer, WJ
   Chambers, K
TI Assessment of vision-related function in patients with age-related
   macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; HEALTH SURVEY SF-36; VITREORETINAL SURGERY OUTCOMES;
   VISUAL FUNCTION QUESTIONNAIRE; CATARACT-SURGERY; CLINICAL-TESTS; INDEX
   VF-14; MACULOPATHY; IMPAIRMENT; PREVALENCE
AB Objective: To investigate the validity of the visual function index (VF-14) in assessing visual function in patients with age-related macular degeneration (AMD).
   Design: Prospective noncomparative observational case series.
   Participants: One hundred fifty-nine consecutive patients attending a sole practitioner's academic retina-only clinic from May 1998 through August 1998 and from May 1999 through August 1999.
   Main Outcome Measures: Correlations were calculated between the VF-14 scores and the medical outcomes study 36-item short form (SF-36), weighted comorbidity scale, visual acuity and clinical AMD severity (stage), and vision self-assessment scales. Documentation of the severity of macular degeneration was performed by a sole examiner.
   Results: There was a moderately strong correlation between visual acuity and trouble with vision (r = 0.51), satisfaction with vision (r = -0.50), and overall quality of vision (r = -0.56). A strong correlation was noted between VF-14 score and patients' self-rating of amount of trouble with vision (r = -0.67), satisfaction with vision (r = 0.62), and overall quality of vision (r = 0.67). In comparison, correlations between SF-36 score and patients' self-rating of amount of trouble with vision, satisfaction with vision, and overall quality of vision ranged from r = 0.37 to r = -0.40. Linear regression analysis for the overall study population indicated that AMD severity was not an independently significant predictor of VF-14 score after adjusting for visual acuity. However, among patients with 20/20 vision in the better eye, AMD severity was an independently significant predictor of VF-14 score after adjusting for visual acuity in the worse eye.
   Conclusions: The VF-14 exhibits a considerable degree of validity as a measure of functional impairment in patients with AMD. Age-related macular degeneration severity was an independently significant predictor 01 VF-14 score in the group of patients with 20/20 vision in the better eye, but this did not hold true for the overall study population. Age-related macular degeneration is associated with substantial impairment in reported visual function. (C) 2002 by the American Academy of Ophthalmology.
C1 Univ So Calif, Doheny Eye Inst, Div Vitreo Retinal Surg, Los Angeles, CA 90033 USA.
   Univ British Columbia, Dept Ophthalmol, Div Vitreo Retinal Surg, Vancouver, BC, Canada.
   Miami Univ, Dept Ophthalmol, Bascom Palmer Eye Inst, Div Vitreo Retinal Surg, Miami, FL USA.
   British Columbia Ctr Epidemiol & Int Ophthalmol, Vancouver, BC, Canada.
C3 Doheny Eye Institute; University of Southern California; University of
   British Columbia; Bascom Palmer Eye Institute
RP Chang, TS (通讯作者)，Univ So Calif, Doheny Eye Inst, Div Vitreo Retinal Surg, 1450 San Pablo St, Los Angeles, CA 90033 USA.
OI Scott, Ingrid/0000-0002-3908-7153
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Alonso J, 1997, OPHTHALMOLOGY, V104, P799, DOI 10.1016/S0161-6420(97)30230-9
   *AM MED ASS, 1993, GUID EV PERM IMP, P217
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   CORNONIHUNTLEY JC, 1990, HLTH STAT WELL BEING
   Courtright P, 1998, Ophthalmic Epidemiol, V5, P13, DOI 10.1076/opep.5.1.13.1498
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   DAMIANO AM, 1995, MED CARE, V33, P120
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gresset J, 1997, CAN J OPHTHALMOL, V32, P31
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   HARRIS T, 1989, AM J CLIN NUTR, V50, P1145, DOI 10.1093/ajcn/50.5.1145
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1
   Kurtenbach A, 1999, BRIT J OPHTHALMOL, V83, P43, DOI 10.1136/bjo.83.1.43
   LEE PP, 1995, QUAL LIFE RES, V4, P319, DOI 10.1007/BF01593884
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Musch DC, 1997, AM J OPHTHALMOL, V124, P1
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P369, DOI 10.1007/BF00168267
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 1998, OPHTHALMOLOGY, V105, P795, DOI 10.1016/S0161-6420(98)95017-5
   Scott IU, 1997, OPHTHALMOLOGY, V104, P1041, DOI 10.1016/S0161-6420(97)30189-4
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Streiner DL, 1995, HLTH MEASUREMENT SCA
   Thalji LHC, 1991, NATL SURVEY FUNCTION
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Ware JE, 1993, SF 36 HLTH SURVEY MA, P1
   WETZLER HP, 1992, HLTH STAT QUESTIONNA
   WRIGHT KW, 1992, ARCH OPHTHALMOL-CHIC, V110, P1607, DOI 10.1001/archopht.1992.01080230107032
   [No title captured]
NR 54
TC 71
Z9 75
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2002
VL 109
IS 4
BP 720
EP 729
AR PII S0161-6420(01)01021-1
DI 10.1016/S0161-6420(01)01021-1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 535GC
UT WOS:000174636000031
PM 11927429
DA 2022-11-30
ER

PT J
AU Ruan, Y
   Jiang, SB
   Gericke, A
AF Ruan, Yue
   Jiang, Subao
   Gericke, Adrian
TI Age-Related Macular Degeneration: Role of Oxidative Stress and Blood
   Vessels
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; pathogenesis; oxidative stress;
   dysregulated lipid metabolism; choroidal vascular dysfunction; genetic
   factor
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE
   SYNTHASE; HIGH-DENSITY-LIPOPROTEIN; REGULATORY PROTEINS CFHR1;
   SIMPLIFIED SEVERITY SCALE; MITOCHONDRIAL-DNA DAMAGE; COA REDUCTASE
   INHIBITORS; GENOME-WIDE ASSOCIATION; NF-KAPPA-B
AB Age-related macular degeneration (AMD) is a common irreversible ocular disease characterized by vision impairment among older people. Many risk factors are related to AMD and interact with each other in its pathogenesis. Notably, oxidative stress and choroidal vascular dysfunction were suggested to be critically involved in AMD pathogenesis. In this review, we give an overview on the factors contributing to the pathophysiology of this multifactorial disease and discuss the role of reactive oxygen species and vascular function in more detail. Moreover, we give an overview on therapeutic strategies for patients suffering from AMD.
C1 [Ruan, Yue; Jiang, Subao; Gericke, Adrian] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Langenbeckstr 1, D-55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz
RP Ruan, Y; Gericke, A (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Langenbeckstr 1, D-55131 Mainz, Germany.
EM yruan@uni-mainz.de; sjiang@uni-mainz.de;
   adrian.gericke@unimedizin-mainz.de
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   AnandBabu K, 2016, EXP EYE RES, V152, P100, DOI 10.1016/j.exer.2016.09.009
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   [Anonymous], 2014, WORLD J OPHTHALMOL
   ARCHER DB, 1981, AM J OPHTHALMOL, V91, P433, DOI 10.1016/0002-9394(81)90230-0
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cezario SM, 2015, ARQ BRAS OFTALMOL, V78, P85, DOI 10.5935/0004-2749.20150023
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen CC, 2004, MOL PHARMACOL, V66, P683
   Chen M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.10.31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Cornel Stefan, 2015, Rom J Ophthalmol, V59, P235
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Datla SR, 2007, ARTERIOSCL THROM VAS, V27, P2319, DOI 10.1161/ATVBAHA.107.149450
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Jong PTVM, 2016, OPHTHALMOL EYE DIS, V8, P5, DOI 10.4137/OED.S40523
   de Sotomayor MA, 2001, BIOCHEM BIOPH RES CO, V280, P486
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Dontsov AE, 1999, FREE RADICAL BIO MED, V26, P1436, DOI 10.1016/S0891-5849(99)00003-9
   Duncan JL, 2010, ARCH OPHTHALMOL-CHIC, V128, P244, DOI 10.1001/archophthalmol.2009.399
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleissner F, 2011, ANTIOXID REDOX SIGN, V15, P933, DOI 10.1089/ars.2010.3502
   Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gericke A, 2019, EXP EYE RES, V181, P150, DOI 10.1016/j.exer.2019.01.022
   Glickman RD, 2011, EYE CONTACT LENS, V37, P196, DOI 10.1097/ICL.0b013e31821e45a9
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Gupta S, 2009, J CELL MOL MED, V13, P1004, DOI 10.1111/j.1582-4934.2009.00697.x
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Haider NB, 2014, PATHOBIOLOGY OF HUMAN DISEASE: A DYNAMIC ENCYCLOPEDIA OF DISEASE MECHANISMS, P2084, DOI 10.1016/B978-0-12-386456-7.04706-7
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heiss C, 2015, ANTIOXID REDOX SIGN, V22, P1230, DOI 10.1089/ars.2014.6158
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hong P, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1498-0
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jiang HY, 2017, J NEUROCHEM, V143, P375, DOI 10.1111/jnc.14214
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kashiwagi S, 2002, CIRC RES, V91, pE55, DOI 10.1161/01.RES.0000047529.26278.4D
   Ke KM, 2006, DRUG AGING, V23, P217, DOI 10.2165/00002512-200623030-00004
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim S, 2007, 2007 IEEE NINTH WORKSHOP ON MULTIMEDIA SIGNAL PROCESSING, P48, DOI 10.1109/MMSP.2007.4412815
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Korani S, 2019, DRUG DISCOV TODAY, V24, P567, DOI 10.1016/j.drudis.2018.09.023
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Laspas P, 2014, EXP EYE RES, V127, P1, DOI 10.1016/j.exer.2014.06.018
   Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Li JJ, 2003, CORONARY ARTERY DIS, V14, P329, DOI 10.1097/01.mca.0000078062.22445.60
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liao JK, 2002, INT J CARDIOL, V86, P5, DOI 10.1016/S0167-5273(02)00195-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Liu S, 2020, BIOL OPEN, V9, DOI 10.1242/bio.048736
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Madamanchi NR, 2013, FREE RADICAL BIO MED, V61, P473, DOI 10.1016/j.freeradbiomed.2013.04.001
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marek V, 2018, FREE RADICAL BIO MED, V126, P27, DOI 10.1016/j.freeradbiomed.2018.07.012
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marumo T, 1999, J VASC RES, V36, P510, DOI 10.1159/000025694
   McDougal DH, 2015, COMPR PHYSIOL, V5, P439, DOI 10.1002/cphy.c140014
   Meng D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048393
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Munzel T, 2005, ARTERIOSCL THROM VAS, V25, P1551, DOI 10.1161/01.ATV.0000168896.64927.bb
   Nagata Makoto, 2005, Current Drug Targets - Inflammation and Allergy, V4, P503, DOI 10.2174/1568010054526322
   Nagel A., 1868, CRYST EYE FUNDUS KLI, V4, P417
   Nagiel A, 2015, INVEST OPHTH VIS SCI, V56
   Nakashima Y, 2017, FREE RADICAL BIO MED, V108, P300, DOI 10.1016/j.freeradbiomed.2017.03.010
   Naso F, 2020, EMBO J, V39, DOI 10.15252/embj.2019102468
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pechan P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017335
   Pechanova O, 2007, PHYSIOL RES, V56, pS7, DOI 10.33549/physiolres.931392
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Prea SM, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/201726
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   Rogers LM, 2017, CLIN CANCER RES, V23, P954, DOI 10.1158/1078-0432.CCR-16-1275
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x
   Schulz E, 2011, HYPERTENS RES, V34, P665, DOI 10.1038/hr.2011.39
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spiteller G, 2007, MOL BIOTECHNOL, V37, P5, DOI 10.1007/s12033-007-0057-6
   Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013
   Sreekumar PG, 2006, BIOCHEM BIOPH RES CO, V346, P1200, DOI 10.1016/j.bbrc.2006.06.021
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stieger K, 2011, METHODS MOL BIOL, V807, P179, DOI 10.1007/978-1-61779-370-7_8
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Sun Y, 2018, ANNU REV VIS SCI, V4, P101, DOI 10.1146/annurev-vision-091517-034018
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Testini C, 2019, EMBO REP, V20, DOI 10.15252/embr.201947845
   Tien PT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72600-8
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Tschulakow AV, 2018, PEERJ, V6, DOI 10.7717/peerj.4482
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsujinaka H, 2018, DIABETES, V67, DOI 10.2337/db18-595-P
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Van Bergen T, 2015, INVEST OPHTH VIS SCI, V56, P5280, DOI 10.1167/iovs.14-15513
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   von der Emde L, 2020, OPHTHALMOLOGICA, V243, P120, DOI 10.1159/000503609
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61
   Wang HB, 2020, ANGIOGENESIS, V23, P685, DOI 10.1007/s10456-020-09740-y
   Wang HB, 2014, MOL VIS, V20, P231
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Winkler B S, 1999, Mol Vis, V5, P32
   Wolfensberger T., 1998, RETINAL PIGMENT EPIT, P103
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu CH, 2016, INT IMMUNOPHARMACOL, V33, P119, DOI 10.1016/j.intimp.2016.02.009
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yadav UCS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/690545
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zadeh JK, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5181429
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
NR 221
TC 18
Z9 18
U1 3
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 3
AR 1296
DI 10.3390/ijms22031296
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QD2AJ
UT WOS:000615327700001
PM 33525498
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Midena, E
   Pilotto, E
AF Midena, E.
   Pilotto, E.
TI Microperimetry in age: related macular degeneration
SO EYE
LA English
DT Review
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; PROGRESSING
   GEOGRAPHIC ATROPHY; INDOCYANINE GREEN ANGIOGRAPHY; CENTRAL VISION LOSS;
   FUNDUS AUTOFLUORESCENCE; RETINAL SENSITIVITY; CHOROIDAL
   NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN; FUNCTIONAL-CHANGES
AB Age-related macular degeneration (AMD) is one of the major causes of visual loss and legal blindness in people over 55. Visual function tests are the cornerstone of visual function investigation and any therapeutic approach to AMD implies, as primary endpoint, the maintenance or improvement of visual function. The progression of visual impairment and the quantification of final residual visual function are currently determined by means of visual acuity quantification. The quantification of high-contrast visual acuity though has many drawbacks and cannot be considered a complete functional examination. Microperimetry is a non-invasive method used to analyse fixation and central visual field defects in a topographic related manner. The introduction of mesopic and more recently scotopic microperimetry, in research and clinical practice of macular disorders, now allows us to better investigate macular function as it strictly relates to macular morphology. We therefore can monitor the functional natural history and quantify the beneficial or detrimental effects of different therapies. The application of microperimetry in clinical studies has provided interesting diagnostic and prognostic information on functional macular changes in AMD patients. The present review brings new updates on the correlation between macular changes, mainly described with optical coherence tomography, and microperimetry changes in patients with AMD.
C1 [Midena, E.; Pilotto, E.] Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
   [Midena, E.] IRCCS, GB Bietti Fdn, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI Midena, Edoardo/AAB-6010-2020
CR ACOSTA F, 1991, OPHTHALMOLOGY, V98, P1820
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chieh JJ, 2008, RETINA-J RET VIT DIS, V28, P1522, DOI 10.1097/IAE.0b013e318186c634
   Cohen SY, 2003, GRAEF ARCH CLIN EXP, V241, P785, DOI 10.1007/s00417-003-0744-3
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Giorgi D, 2005, APPL PSYCHOPHYS BIOF, V30, P389, DOI 10.1007/s10484-005-8424-1
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hariri S, 2012, INVEST OPHTH VIS SCI, V53, P1982, DOI 10.1167/iovs.11-8395
   Hartmann KI, 2015, OSLI RETINA, V46, P824, DOI 10.3928/23258160-20150909-06
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   Longhin E, 2013, CAN J OPHTHALMOL, V48, P375, DOI 10.1016/j.jcjo.2013.05.021
   Marc RE, 2008, MOL VIS, V14, P782
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Midena E, 2007, PERIMETRY FUNDUS INT, P15
   Midena E, 2007, EJO, V17, P65
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Mori F, 2001, AM J OPHTHALMOL, V132, P897, DOI 10.1016/S0002-9394(01)01216-8
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Oshima Y, 1998, RETINA-J RET VIT DIS, V18, P109, DOI 10.1097/00006982-199818020-00003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pilotto E, 2007, PERIMETRY FUNDUS INT, P7
   Pilotto E, 2016, JAMA OPHTHALMOL, V134, P873, DOI 10.1001/jamaophthalmol.2016.1535
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Pilotto E, 2015, BRIT J OPHTHALMOL, V99, P1082, DOI 10.1136/bjophthalmol-2014-306338
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Pilotto E, 2010, GRAEF ARCH CLIN EXP, V248, P1331, DOI 10.1007/s00417-010-1405-y
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Sholl HP, 2004, INVEST OPHTH VIS SCI, V45, P574
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 99
TC 28
Z9 28
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2017
VL 31
IS 7
BP 985
EP 994
DI 10.1038/eye.2017.34
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA4YA
UT WOS:000405448600003
PM 28257134
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Petrukhin, K
AF Petrukhin, Konstantin
TI New therapeutic targets in atrophic age-related macular degeneration
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE age-related macular degeneration; atrophic
ID EPITHELIUM-DERIVED FACTOR; CILIARY NEUROTROPHIC FACTOR; RETINAL-PIGMENT
   EPITHELIUM; FIBRILLARY ACIDIC PROTEIN; NITRIC-OXIDE SYNTHASE; D
   MONOCLONAL-ANTIBODY; N-TERT-BUTYLNITRONE; LIPOFUSCIN-LIKE INCLUSIONS;
   INTRAOCULAR GENE-TRANSFER; FACTOR-H POLYMORPHISM
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. There is no effective treatment for the most prevalent atrophic (dry) form of AMD. Atrophic AMD is triggered by abnormalities in the retinal pigment epithelium (RPE) that lies beneath the photoreceptor cells and normally provides critical metabolic support to these light-sensing cells. Secondary to RPE dysfunction, macular rods and cones degenerate leading to the irreversible loss of vision. Oxidative stress, formation of drusen, accumulation of lipofuscin, local inflammation and reactive gliosis represent the pathologic processes implicated in pathogenesis of atrophic AMD. This review discusses potential target areas for small-molecule and biologic intervention, which may lead to development of new therapeutic treatments for atrophic AMD.
C1 Columbia Univ, Dept Ophthalmol, Inst Eye, New York, NY 10032 USA.
C3 Columbia University
RP Petrukhin, K (通讯作者)，Columbia Univ, Dept Ophthalmol, Inst Eye, Annex,Suite 503,630 W 168th St, New York, NY 10032 USA.
EM kep4@columbia.edu
OI Petrukhin, Konstantin/0000-0002-5545-6924
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Aston K, 2001, INORG CHEM, V40, P1779, DOI 10.1021/ic000958v
   Baker K, 1998, J PHARMACOL EXP THER, V284, P215
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berger AS, 2003, OPHTHALMOLOGY, V110, P383, DOI 10.1016/S0161-6420(02)01738-4
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   Bode C, 2003, MOL VIS, V9, P144
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Caballero S, 2004, GRAEF ARCH CLIN EXP, V242, P85, DOI 10.1007/s00417-003-0813-7
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298
   Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delori FC, 1998, DOC OPHTH P, V62, P37
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dentchev T, 2003, MOL VIS, V9, P184
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EKSTROM P, 1988, INVEST OPHTH VIS SCI, V29, P1363
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fintz AC, 2003, INVEST OPHTH VIS SCI, V44, P818, DOI 10.1167/iovs.01-1144
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fong JJ, 2006, ANN PHARMACOTHER, V40, P461, DOI 10.1345/aph.1E636
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Fung M, 2001, J THORAC CARDIOV SUR, V122, P113, DOI 10.1067/mtc.2001.114777
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   Goto R, 2005, JPN J OPHTHALMOL, V49, P363, DOI 10.1007/s10384-004-0213-5
   GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012
   GROSCHE J, 1995, NEUROSCI LETT, V185, P119, DOI 10.1016/0304-3940(94)11239-F
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Harada T, 2000, NEURON, V26, P533, DOI 10.1016/S0896-6273(00)81185-X
   HARTIG W, 1995, J NEUROCYTOL, V24, P507, DOI 10.1007/BF01179976
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hershko C, 1998, BRIT J HAEMATOL, V101, P399, DOI 10.1046/j.1365-2141.1998.00726.x
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Hourcade DE, 1998, J BIOL CHEM, V273, P25996, DOI 10.1074/jbc.273.40.25996
   Hughes EH, 2004, EXP EYE RES, V78, P1077, DOI 10.1016/j.exer.2004.02.002
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   John SK, 2000, MOL VIS, V6, P204
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones KJ, 1999, J NEUROBIOL, V40, P560, DOI 10.1002/(SICI)1097-4695(19990915)40:4<560::AID-NEU11>3.0.CO;2-I
   Kaldi I, 2003, EXP EYE RES, V76, P453, DOI 10.1016/S0014-4835(02)00334-2
   Kapitskaya M, 2006, ASSAY DRUG DEV TECHN, V4, P253, DOI 10.1089/adt.2006.4.253
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 1999, INVEST OPHTH VIS SCI, V40, P175
   Katz ML, 1995, MECH AGEING DEV, V84, P29, DOI 10.1016/0047-6374(95)01633-B
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KATZ ML, 1987, MECH AGEING DEV, V39, P81, DOI 10.1016/0047-6374(87)90088-1
   KENNEDY CJ, 1909, EYE 6, V9, P763
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimaszewski Jan, 2004, Belgian Journal of Entomology, V6, P3
   Lame Mary E, 2004, Drug Metabol Drug Interact, V20, P11
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lefrancois T, 1997, J NEUROSCI, V17, P4121
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   LEWIS GP, 1995, INVEST OPHTH VIS SCI, V36, P2404
   Li Jennifer S, 2006, Expert Rev Cardiovasc Ther, V4, P649, DOI 10.1586/14779072.4.5.649
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Liu CD, 1999, J NEUROSCI, V19, P4778
   LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404
   Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Mahaffey KW, 2006, AM HEART J, V152, P291, DOI 10.1016/j.ahj.2006.03.027
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maples KR, 2004, CNS DRUGS, V18, P1071, DOI 10.2165/00023210-200418150-00003
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Mayer EJ, 2005, BRIT J OPHTHALMOL, V89, P102, DOI 10.1136/bjo.2004.057687
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Mocco J, 2006, J NEUROSURG, V105, P595, DOI 10.3171/jns.2006.105.4.595
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407
   Morgan D, 2006, J ALZHEIMERS DIS, V9, P425
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Naik H R, 1995, Adv Pharmacol, V33, P315, DOI 10.1016/S1054-3589(08)60673-0
   Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474
   Neufeld AH, 2002, EXP EYE RES, V75, P521, DOI 10.1006/exer.2002.2042
   Neufeld EJ, 2006, BLOOD, V107, P3436, DOI 10.1182/blood-2006-02-002394
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Nisbet-Brown E, 2003, LANCET, V361, P1597, DOI 10.1016/S0140-6736(03)13309-0
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Peterson SL, 2005, NEUROTOXICOLOGY, V26, P969, DOI 10.1016/j.neuro.2005.04.002
   Pickering MC, 2006, P NATL ACAD SCI USA, V103, P9649, DOI 10.1073/pnas.0601094103
   Pong K, 2003, EXPERT OPIN BIOL TH, V3, P127
   Quigley HA, 2004, EYE, V18, P1085, DOI 10.1038/sj.eye.6701577
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Ranchon I, 2001, INVEST OPHTH VIS SCI, V42, P1375
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Romero-Borja F, 2005, APPL OPTICS, V44, P4032, DOI 10.1364/AO.44.004032
   Rother RP, 2004, LUPUS, V13, P328, DOI 10.1191/0961203303lu1021oa
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Salvemini D, 2002, NAT REV DRUG DISCOV, V1, P367, DOI 10.1038/nrd796
   Samardzija M, 2006, INVEST OPHTH VIS SCI, V47, P5181, DOI 10.1167/iovs.06-0556
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Steinberg Roy H., 1994, Current Opinion in Neurobiology, V4, P515, DOI 10.1016/0959-4388(94)90052-3
   Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#
   Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Tasman W, 2004, ARCH OPHTHALMOL-CHIC, V122, P648, DOI 10.1001/archopht.122.4.648
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Theroux P, 2006, CAN J CARDIOL, V22, p18B, DOI 10.1016/S0828-282X(06)70982-5
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Trudeau-Lame ME, 2003, DRUG METAB DISPOS, V31, P147, DOI 10.1124/dmd.31.2.147
   Undar A, 2002, ANN THORAC SURG, V74, P355, DOI 10.1016/S0003-4975(02)03656-1
   Undar A, 2002, EUR J CARDIO-THORAC, V22, P330, DOI 10.1016/S1010-7940(02)00298-1
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   VanOrden HE, 2006, ANN PHARMACOTHER, V40, P1110, DOI 10.1345/aph.1G566
   Vasilevko V, 2006, NEUROCHEM INT, V49, P113, DOI 10.1016/j.neuint.2006.03.019
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wahlin KJ, 2001, EXP EYE RES, V73, P693, DOI 10.1006/exer.2001.1078
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wen R, 1996, J NEUROSCI, V16, P5986
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wolkenberg SE, 2006, BIOORG MED CHEM LETT, V16, P5001, DOI 10.1016/j.bmcl.2006.07.056
   Yamazaki H, 2002, INVEST OPHTH VIS SCI, V43, P919
   Yeoh J, 2006, EXPERT OPIN PHARMACO, V7, P2355, DOI 10.1517/14656566.7.17.2355
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yu DY, 2002, COMP BIOCHEM PHYS A, V132, P47, DOI 10.1016/S1095-6433(01)00528-1
   Zack DJ, 2000, NEURON, V26, P285, DOI 10.1016/S0896-6273(00)81160-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 209
TC 44
Z9 76
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD MAY
PY 2007
VL 11
IS 5
BP 625
EP 639
DI 10.1517/14728222.11.5.625
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 161DD
UT WOS:000245993600005
PM 17465722
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Guymer, R
   Mones, JM
   Tufail, A
   Jaffe, GJ
AF Sadda, SriniVas R.
   Guymer, Robyn
   Mones, Jordi M.
   Tufail, Adnan
   Jaffe, Glenn J.
TI Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular
   Age-Related Macular Degeneration Systematic Literature Review and Expert
   Opinion
SO OPHTHALMOLOGY
LA English
DT Review
ID GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB TREATMENT;
   VISUAL-ACUITY; OUTCOMES; VEGF; PROLIFERATION; MANAGEMENT; SECONDARY;
   BURDEN
AB Topic: To summarize the rates of atrophy, risk factors, and atrophy-associated visual outcomes in patients with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (VEGF) treatment for macular neovascularization (MNV).
   Clinical Relevance: Age-related macular degeneration is a leading cause of vision loss worldwide, and VEGF inhibitors are the primary treatment for nAMD. However, atrophy is observed frequently in eyes treated with anti-VEGF therapy, prompting questions regarding a causative role for these therapies in atrophy development.
   Methods: PubMed was searched for articles published in the past 5 years (January 1, 2014, through January 10, 2019). Studies including atrophy outcome(s) in patients with age-related macular degeneration who received anti-VEGF treatment were included. Review articles, retrospective studies, case reports or studies, preclinical studies, prevalence data reports, and non-English studies were excluded. Randomization was not required.
   Results: Overall, 145 studies were identified; 29 publications were included, with cohorts ranging from 8 to 1185 eyes. Imaging methods used to assess atrophy varied across studies. All studies confirmed the occurrence of atrophy, and when available, longitudinal data from the included studies demonstrated an increase in atrophy incidence over time. Key risk factors or phenotypes associated with atrophy were fellow eye atrophy, reticular pseudodrusen, increased injections, and type 3 lesion. In addition, visual acuity loss was noted with foveal atrophy.
   Discussion: All studies demonstrated that atrophy occurs in the context of MNV treated with anti-VEGF therapy; however, it is not clear whether anti-VEGF treatment is causative of atrophy versus being associated with atrophy development. The included studies were not designed or powered to assess atrophy as a primary outcome. In addition, it is difficult to determine whether prognostic factors directly affect atrophy. Furthermore, patient populations in clinical trials do not necessarily represent real-world patients. Although phenotypes and risk factors may help to identify those at greater risk of atrophy developing, it is important to recognize that adequately treating exudative MNV remains the best option to optimize vision outcomes in patients with nAMD, particularly given the risk of vision loss with undertreatment observed in the real world. (C) 2019 by the American Academy of Ophthalmology.
C1 [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Mones, Jordi M.] Inst Macula, Barcelona, Spain.
   [Mones, Jordi M.] Barcelona Macula Fdn, Barcelona, Spain.
   [Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Tufail, Adnan] Moorfields Eye Hosp, NHS Trust, London, England.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Duke University
RP Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Doheny Vis Res Ctr, Suite 211,1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Tufail, Adnan/0000-0001-6131-7640
FU Novartis Pharma AG, Basel, Switzerland - Novartis Pharma AG
FX Supported by Novartis Pharma AG, Basel, Switzerland. The sponsor or
   funding organization participated in the review of the manuscript (for
   accuracy only). Medical writing assistance was funded by Novartis Pharma
   AG under the direction of the authors.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2018, AM J OPHTHALMOL, P19284
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Daniel E, 2017, OPHTHALMOL RETINA, V1, P25, DOI 10.1016/j.oret.2016.09.001
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Rebhun CB, 2020, RETINA-J RET VIT DIS, V40, P266, DOI 10.1097/IAE.0000000000002402
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   SADDA SR, 2018, INVEST OPHTH VIS SCI, V59
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zandi S, 2017, OSLI RETINA, V48, P326, DOI 10.3928/23258160-20170329-07
NR 54
TC 27
Z9 27
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2020
VL 127
IS 5
BP 648
EP 659
DI 10.1016/j.ophtha.2019.11.010
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE7XR
UT WOS:000526937900022
PM 32081493
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sobrin, L
   Reynolds, R
   Yu, Y
   Fagerness, J
   Leveziel, N
   Bernstein, PS
   Souied, EH
   Daly, MJ
   Seddon, JM
AF Sobrin, Lucia
   Reynolds, Robyn
   Yu, Yi
   Fagerness, Jesen
   Leveziel, Nicolas
   Bernstein, Paul S.
   Souied, Eric H.
   Daly, Mark J.
   Seddon, Johanna M.
TI ARMS2/HTRA1 Locus Can Confer Differential Susceptibility to the Advanced
   Subtypes of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VARIANT; RISK; HTRA1; GENES; POLYMORPHISM;
   ASSOCIATION; MACULOPATHY; LOC387715/ARMS2; INCREASES
AB PURPOSE: To determine if genetic variants that have been associated with age-related macular degeneration (AMD) have a differential effect on the risk of choroidal neovascularization (CNV) and geographic atrophy.
   DESIGN: Genetic association study.
   METHODS: SETTING: Multicenter study. STUDY POPULATION: Seven hundred forty-nine participants with geographic atrophy and 3209 participants with CNV were derived from 4 AMD studies with similar procedures from Tufts Medical Center, the Age-Related Eye Disease Study, University of Utah, and Hopital Intercommunal de Creteil. PROCEDURES: AMD grade was assigned based on fundus photography and examination using the clinical age-related maculopathy staging system. All samples were genotyped for single nucleotide polymorphisms (SNPs) previously associated with AMD. Allele frequencies were compared between participants with CNV and geographic atrophy using PLINK within each cohort and Mantel-Haenszel meta-analysis was performed to combine odds ratios (OR). MAIN OUTCOME MEASURES: Differences in allele frequencies between participants with geographic atrophy and CNV.
   RESULTS: The frequency of the T allele of ARMS2/HTRA1 rs10490924 was significantly higher in participants with CNV than in those with geographic atrophy (OR, 1.37; 95% confidence interval, 1.21-1.54; P value = 4.2 x 10(-7)). This result remained statistically significant when excluding individuals who had geographic atrophy in 1 eye and CNV in the contralateral eye (P = 2.2 x 10(-4)). None of the other SNPs showed a significant differential effect for CNV vs geographic atrophy, including CFH, C2/CFB, C3, CFI, LIPC, and TIMP3.
   CONCLUSIONS: Genetic variation at the ARMS2/HTRA1 locus confers a differential risk for CNV vs geographic atrophy in a well-powered sample. (Am J Ophthalmol 2011;151:345-352. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Seddon, Johanna M.] Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Boston, MA 02111 USA.
   [Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Fagerness, Jesen; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Program Med & Populat Genet, Boston, MA 02114 USA.
   [Fagerness, Jesen; Daly, Mark J.] Broad Inst, Cambridge, MA USA.
   [Leveziel, Nicolas; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Hop Intercommunal Creteil, Creteil, France.
   [Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts Medical Center; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts
   General Hospital; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Utah System of
   Higher Education; University of Utah; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752; Sobrin, Lucia/0000-0003-1575-0819;
   Nicolas, Leveziel/0000-0001-8533-9457
FU National Institutes of Health, Bethesda, Maryland [RO1-EY11309,
   RO1-EY13435, R24-EY017404, K12-EY16335, EY-11600]; Massachusetts Lions
   Eye Research Fund, Inc, New Bedford, Massachusetts; Research to Prevent
   Blindness, Inc, New York, New York; Pfizer; Genentech; NATIONAL EYE
   INSTITUTE [R01EY011309, R24EY017404, R29EY011600, R01EY011600,
   R01EY013435, K12EY016335, P30EY014800] Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED IN PART BY GRANTS RO1-EY11309,
   RO1-EY13435, R24-EY017404, K12-EY16335, and EY-11600 from the National
   Institutes of Health, Bethesda, Maryland; Massachusetts Lions Eye
   Research Fund, Inc, New Bedford, Massachusetts; unrestricted grants and
   Career Development Award from Research to Prevent Blindness, Inc, New
   York, New York; National Center for Research Resources, Bethesda,
   Maryland; The Macula Vision Research Foundation, West Conshohocken,
   Pennsylvania; and the Macular Degeneration Research Fund of the
   Ophthalmic Epidemiology and Generics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine, Boston,
   Massachusetts. Dr Sobrin has been a consultant for Alcon Laboratories.
   Dr Souied has been a consultant for Novartis and Bausch & Lomb and
   received lecture fees from Bausch & Lomb. Dr Seddon has a patent
   application with Tufts Medical Center and has received grant funding
   from Pfizer and Genentech. Involved in design of the study (L.S.,
   M.J.D.,.J.M.S.); conduct of the study (L.S., R.R., J.F., J.M.S.);
   collection, management, analysis, and interpretation of the data (L.S.,
   R.R., Y.Y., J.F., N.L., P.S.B., E.H.S., M.J.D., J.M.S.); and
   preparation, review, or approval of the manuscript (L.S., Y.Y., J.F.,
   N.L., P.S.B., El-IS., M.J.D., J.M.S.). This study was approved by the
   Tufts Medical Center Institutional Review Board prospectively. The study
   is HIPAA compliant and proper informed consent for participation in the
   research was obtained.
CR Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2008, MOL VIS, V14, P1395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 58
Z9 61
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2011
VL 151
IS 2
BP 345
EP 352
DI 10.1016/j.ajo.2010.08.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 712ZX
UT WOS:000286705900024
PM 21122828
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hooper, CY
   Guymer, RH
AF Hooper, CY
   Guymer, RH
TI New treatments in age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; new
   treatments
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TISSUE-PLASMINOGEN-ACTIVATOR;
   ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL SUBRETINAL HEMORRHAGE;
   RANDOMIZED CLINICAL-TRIAL; VASCULAR-PERMEABILITY FACTOR; BILATERAL
   VISUAL IMPAIRMENT; RETINAL-PIGMENT EPITHELIUM; EXTERNAL-BEAM RADIATION;
   DOUBLE-MASKED TRIAL
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in individuals 50 years and older in the developed world. Choroidal neovascularization (CNV) in exudative AMD is responsible for the majority of severe vision loss. Until recently, laser photocoagulation was the only well-established and widely accepted treatment for CNV. However, it is beneficial only for a small subset of patients, has a high rate of CNV persistence and recurrence and results in iatrogenic, collateral damage to the overlying retina. These issues make it difficult to recommend in the case of subfoveal lesions. Consequently, numerous experimental therapeutic interventions are under investigation with the common objective of destroying the CNV but leaving the foveal neurosensory retina intact. Treatment modalities can be grouped into five major categories: photodynamic therapy; radiotherapy; transpupillary thermotherapy; anti-angiogenic and angiostatic agents; and surgical intervention. The present review aims to explain the rationale behind these new treatments, analyse the evidence for their safety and efficacy, determine their stage of development and indicate in which patients they are potentially useful.
C1 Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.
OI Guymer, Robyn/0000-0002-9441-4356
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Ahuja RM, 2001, INVEST OPHTH VIS SCI, V42, pS443
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Akmansu M, 1998, INT J RADIAT ONCOL, V40, P923, DOI 10.1016/S0360-3016(97)00859-6
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Benner JD, 2001, INVEST OPHTH VIS SCI, V42, pS444
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   BINDER S, 2002, ASS RES VIS OPHTH M
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P1241, DOI 10.3109/02713688909013903
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2000, EYE, V14, P151, DOI 10.1038/eye.2000.45
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHAN CK, 1994, OPHTHALMOLOGY, V101, P289
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   de Juan E, 2001, EYE, V15, P413, DOI 10.1038/eye.2001.146
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   DELPRIORE LV, 1997, SEMIN OPHTHALMOL, V12, P45
   Desai V., 1998, IOVS, V39, pS385
   Dintelmann TS, 1999, GRAEF ARCH CLIN EXP, V237, P830, DOI 10.1007/s004170050320
   Donati G, 1999, Semin Ophthalmol, V14, P2, DOI 10.3109/08820539909056057
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   ECKARDT C, 2000, RETINA 2000
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   ENGLER CB, 1993, ACTA OPHTHALMOL, V71, P27
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gelisken O, 1999, Semin Ophthalmol, V14, P27, DOI 10.3109/08820539909056060
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GILLIES M, 2002, CLIN EXPT OPHTHALM S, V30, pA64
   GILLIES MC, 1993, BRIT J OPHTHALMOL, V77, P759, DOI 10.1136/bjo.77.12.759
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Godfrey DG, 1999, AM J OPHTHALMOL, V128, P88, DOI 10.1016/S0002-9394(99)00063-X
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GUYER D, 2002, CLIN EXPT OPHTHALM S, V30, pA61
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   GUYER DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P1383, DOI 10.1001/archopht.1992.01080220045019
   Haller J A, 2000, Semin Ophthalmol, V15, P81
   HART PM, 1995, BRIT J OPHTHALMOL, V79, P562, DOI 10.1136/bjo.79.6.562
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Hollick EJ, 1996, EYE, V10, P609, DOI 10.1038/eye.1996.139
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   Husain D, 1997, SEMIN OPHTHALMOL, V12, P14
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Ip M, 1999, Semin Ophthalmol, V14, P11, DOI 10.3109/08820539909056058
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   JAAKKOLA A, 1994, ACTA OPHTHALMOL, V72, P545
   JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kaven C, 2001, OPHTHALMOLOGICA, V215, P284, DOI 10.1159/000050875
   KIRKPATRICK JNP, 1993, BRIT J OPHTHALMOL, V77, P766, DOI 10.1136/bjo.77.12.766
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambert H M, 2000, Semin Ophthalmol, V15, P92
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   LEWIS ML, 1993, GRAEF ARCH CLIN EXP, V231, P615, DOI 10.1007/BF00921954
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   Lip PL, 2000, INVEST OPHTH VIS SCI, V41, P2115
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LOUGHNAN MS, 1992, AUST NZ J OPHTHALMOL, V20, P173, DOI 10.1111/j.1442-9071.1992.tb00936.x
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   McCarty MF, 1997, MED HYPOTHESES, V49, P123, DOI 10.1016/S0306-9877(97)90217-6
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1993, OPHTHALMOLOGY, V100, P9
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   POLINER LS, 1993, OPHTHALMOLOGY, V100, P1417
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   PRZYDRYGA J, 2002, CLIN EXPT OPHTHALM S, V30, pA66
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Robertson DM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1512
   Sanders JB, 2001, INVEST OPHTH VIS SCI, V42, pS513
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 1999, Semin Ophthalmol, V14, P35, DOI 10.3109/08820539909056061
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   SOUBRANE G, 2002, CLIN EXPT OPHTHALM S, V30, pA66
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   STERNBERG P, 1990, ARCH OPHTHALMOL-CHIC, V108, P720, DOI 10.1001/archopht.1990.01070070106045
   Tang J, 2001, INVEST OPHTH VIS SCI, V42, pS442
   Thoelen A, 1995, Ger J Ophthalmol, V4, P137
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   THOMAS MA, 1993, AM J OPHTHALMOL, V115, P563, DOI 10.1016/S0002-9394(14)71451-5
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsujikawa M, 1998, AM J OPHTHALMOL, V126, P348, DOI 10.1016/S0002-9394(98)00089-0
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   *VERT PHOT THER ST, 2001, INT J RADIAT ONCOL, V131, P541
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 177
TC 47
Z9 60
U1 0
U2 8
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD OCT
PY 2003
VL 31
IS 5
BP 376
EP 391
DI 10.1046/j.1442-9071.2003.00683.x
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 724EA
UT WOS:000185473100003
PM 14516424
DA 2022-11-30
ER

PT J
AU Shin, HJ
   Chung, H
   Kim, HC
AF Shin, Hyun Jin
   Chung, Hyewon
   Kim, Hyung Chan
TI ASSOCIATION BETWEEN FOVEAL MICROSTRUCTURE AND VISUAL OUTCOME IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE integrity of photoreceptor layer; prognostic factors; visual outcome;
   age-related macular degeneration
ID VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY;
   CHOROIDAL NEOVASCULARIZATION; PHOTORECEPTOR LAYER; ACUITY; RANIBIZUMAB;
   BEVACIZUMAB; PEGAPTANIB; INTEGRITY; RETINA
AB Purpose: To investigate the correlation between foveal photoreceptor integrity and final visual acuity after treatment of eyes with neovascular age-related macular degeneration, and to determine the visual prognostic factors.
   Methods: We retrospectively studied 40 eyes of 40 patients with neovascular age-related macular degeneration who were treated successfully with intravitreal anti-vascular endothelial growth factor injection. Using spectral-domain optical coherence tomography, the eyes were categorized into three groups at the final visit, the V group with a completely visible photoreceptor inner and outer segment junction (IS/OS), the P group with a partially detected IS/OS, and the I group with an invisible IS/OS. The length of disrupted IS/OS and external limiting membrane, central macular thickness, and choroidal neovascularization size at the initial and final visits were measured. Retinal pigment epithelium regularity and outer nuclear layer thickness at the final visit were also evaluated.
   Results: Final visual acuity was closely associated with IS/OS integrity at the final visit. Final visual acuity (logarithm of minimum angle of resolution) in the V group (0.13 +/- 0.10) was better than that in the P group (0.41 +/- 0.31), and final visual acuity in the P group was better than that in the I group (0.97 +/- 0.51) (P < 0.001). Shorter disrupted IS/OS and external limiting membrane length at the final visit were closely associated with better final visual acuity. Preservation of the IS/OS and external limiting membrane, thinner central macular thickness, and shorter choroidal neovascularization height before treatment were associated with intact photoreceptor integrity after resolution of exudation. However, central macular thickness, outer nuclear layer thickness, and retinal pigment epithelium regularity at the final visit had no significant correlation with photoreceptor integrity.
   Conclusion: Foveal photoreceptor integrity was closely associated with final visual acuity in neovascular age-related macular degeneration after treatment. Initial visual acuity, IS/OS and external limiting membrane integrity, central macular thickness, and choroidal neovascularization height were correlated with final photoreceptor integrity, and they would be visual prognostic factors after resolution of exudation. RETINA 31: 1627-1636, 2011
C1 [Shin, Hyun Jin; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 4-12 Hwayang Dong, Seoul 143729, South Korea.
EM eyekim@kuh.ac.kr
RI Shin, Hyunjin/ABF-6057-2021
FU Konkuk University Medical Center
FX Supported by the Konkuk University Medical Center Research Grant 2010.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chang LK, 2008, RETINA-J RET VIT DIS, V28, P969, DOI 10.1097/IAE.0b013e3181744165
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hangai Masanori, 2007, Nippon Ganka Gakkai Zasshi, V111, P509
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   MARSHALL J, 1975, BRIT J OPHTHALMOL, V59, P610, DOI 10.1136/bjo.59.11.610
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Sakamoto A, 2009, CLIN EXP OPHTHALMOL, V37, P208, DOI 10.1111/j.1442-9071.2009.01914.x
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Valmaggia C, 2009, KLIN MONATSBL AUGENH, V226, P294, DOI 10.1055/s-0028-1109298
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Watchtlin J, 2003, GRAEFES ARCH CLIN EX, V241, P218
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 32
TC 42
Z9 47
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1627
EP 1636
DI 10.1097/IAE.0b013e31820d3d01
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100023
PM 21606888
DA 2022-11-30
ER

PT J
AU Gelfand, BD
   Ambati, J
AF Gelfand, Bradley D.
   Ambati, Jayakrishna
TI A Revised Hemodynamic Theory of Age-Related Macular Degeneration
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL BLOOD-FLOW; RETINAL-PIGMENT
   EPITHELIUM; COHERENCE TOMOGRAPHY ANGIOGRAPHY; NLRP3 INFLAMMASOME
   ACTIVATION; MEMBRANE ATTACK COMPLEX; SHEAR-STRESS; BRUCHS MEMBRANE;
   HUMAN EYES; ALU RNA
AB Age-related macular degeneration (AMD) afflicts one out of every 40 individuals worldwide, causing irreversible central blindness in millions. The transformation of various tissue layers within the macula in the retina has led to competing conceptual models of the molecular pathways, cell types, and tissues responsible for the onset and progression of AMD. A model that has persisted for over 6 decades is the hemodynamic, or vascular theory of AMD progression, which states that vascular dysfunction of the choroid underlies AMD pathogenesis. Here, we re-evaluate this hypothesis in light of recent advances on molecular, anatomic, and hemodynamic changes underlying choroidal dysfunction in AMD. We propose an updated, detailed model of hemodynamic dysfunction as a mechanism of AMD development and progression.
C1 [Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Kentucky, Dept Optometry & Visual Sci, Lexington, KY 40506 USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Biomed Engn, Lexington, KY USA.
   [Gelfand, Bradley D.] Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY USA.
   [Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Optometry & Visual Sci, Lexington, KY 40506 USA.; Ambati, J (通讯作者)，Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
EM ja9qr@virginia.edu
RI Gelfand, Brad/L-3926-2019
FU NIH [DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238,
   R01EY024068]; Doris Duke Distinguished Clinical Scientist Award;
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research; Ellison Medical Foundation Senior Scholar in Aging Award;
   Foundation Fighting Blindness Individual Investigator Research Award;
   Harrington Discovery Institute Scholar-Innovator Award; John Templeton
   Foundation; Dr. E. Vernon Smith and Eloise C. Smith Macular Degeneration
   Endowed Chair; American Heart Association; International Retinal
   Research Foundation; National Center for Research Resources, National
   Institutes of Health [UL1TR000117]; National Center for Advancing
   Translational Sciences, National Institutes of Health [UL1TR000117];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY022238,
   R01EY020672, R01EY024068, R01EY018836, R01EY018350] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP1GM114862]
   Funding Source: NIH RePORTER
FX We thank James McDonough (University of Kentucky), Tingting Tang
   (University of Kentucky), Huidan Yu (IUPUI), and the members of our
   group for scientific discussions. J.A. was supported by NIH grants
   (DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238, and
   R01EY024068), Doris Duke Distinguished Clinical Scientist Award,
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, Ellison Medical Foundation Senior Scholar in Aging Award,
   Foundation Fighting Blindness Individual Investigator Research Award,
   Harrington Discovery Institute Scholar-Innovator Award, John Templeton
   Foundation, and Dr. E. Vernon Smith and Eloise C. Smith Macular
   Degeneration Endowed Chair; B.D.G. by the American Heart Association,
   the International Retinal Research Foundation, and by the National
   Center for Research Resources and the National Center for Advancing
   Translational Sciences, National Institutes of Health, through Grant
   UL1TR000117, The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Boon RA, 2009, HAMOSTASEOLOGIE, V29, P39, DOI 10.1055/s-0037-1616937
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, P128, DOI 10.1136/bjophthalmol-2011-300572
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Coassin M, 2010, BRIT J OPHTHALMOL, V94, P1678, DOI 10.1136/bjo.2009.168864
   Comparison of Age-related Macular Degeneration Treatments Trials Research Group et al, 2016, OPHTHALMOLOGY
   Coon BG, 2015, J CELL BIOL, V208, P975, DOI 10.1083/jcb.201408103
   Cordeiro S, 2010, INVEST OPHTH VIS SCI, V51, P6001, DOI 10.1167/iovs.09-4720
   De Wilde D., 2015, ANN BIOMED ENG
   dela Paz NG, 2013, BIOCHEM BIOPH RES CO, V434, P641, DOI 10.1016/j.bbrc.2013.03.134
   dela Paz NG, 2012, J CELL SCI, V125, P831, DOI 10.1242/jcs.084301
   DeVerse JS, 2012, AM J PHYSIOL-HEART C, V302, pH2498, DOI 10.1152/ajpheart.00869.2011
   Diller KR, ADV HEAT TRANSFER, P341
   Faby H, 2014, GRAEF ARCH CLIN EXP, V252, P1737, DOI 10.1007/s00417-014-2750-z
   Fan WD, 2015, J CELL SCI, V128, P70, DOI 10.1242/jcs.154252
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gewaily DY, 2014, AM J OPHTHALMOL, V158, P525, DOI 10.1016/j.ajo.2014.06.004
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Goettsch W, 2008, J CELL PHYSIOL, V214, P491, DOI 10.1002/jcp.21229
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harry BL, 2008, ARTERIOSCL THROM VAS, V28, P2003, DOI 10.1161/ATVBAHA.108.164707
   Hayreh SS, 2010, AM J OPHTHALMOL, V150, P940, DOI 10.1016/j.ajo.2010.08.011
   Herrmann P, 2015, NEUROBIOL AGING, V36, P2637, DOI 10.1016/j.neurobiolaging.2015.05.019
   Hirata Y, 2004, INVEST OPHTH VIS SCI, V45, P1954, DOI 10.1167/iovs.03-0759
   Hwang J, 2003, J BIOL CHEM, V278, P47291, DOI 10.1074/jbc.M305150200
   Inagaki K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/729792
   Iwami H, 2014, EXP EYE RES, V124, P37, DOI 10.1016/j.exer.2014.04.014
   Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kinderlerer AR, 2008, J BIOL CHEM, V283, P14636, DOI 10.1074/jbc.M800362200
   KIRYU J, 1994, INVEST OPHTH VIS SCI, V35, P3724
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   LEVESQUE MJ, 1990, BIOMATERIALS, V11, P702, DOI 10.1016/0142-9612(90)90031-K
   Lewis DM, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/4/045010
   Li M, 2009, ANN BIOMED ENG, V37, P1082, DOI 10.1007/s10439-009-9684-3
   Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0
   Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597
   LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504
   Obi S, 2012, AM J PHYSIOL-CELL PH, V303, pC595, DOI 10.1152/ajpcell.00133.2012
   Orr AW, 2008, CIRC RES, V103, P671, DOI 10.1161/CIRCRESAHA.108.182097
   Orr AW, 2007, J CELL BIOL, V176, P719, DOI 10.1083/jcb.200609008
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   Phelps JE, 2000, AM J PHYSIOL-HEART C, V278, pH469, DOI 10.1152/ajpheart.2000.278.2.H469
   Pilotto E, 2016, JAMA OPHTHALMOL
   Possek E, 1905, Z AUGENHEILKD, V13, P771
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saker S, 2014, EXP EYE RES, V121, P161, DOI 10.1016/j.exer.2014.02.016
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schlanltz F.G, 2016, BR J OPHTHALMOL
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seebach J, 2000, LAB INVEST, V80, P1819, DOI 10.1038/labinvest.3780193
   Sekiyama E, 2012, FASEB J, V26, P567, DOI 10.1096/fj.11-184127
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith JR, 2007, INVEST OPHTH VIS SCI, V48, P2676, DOI 10.1167/iovs.06-0598
   Song W, 2015, ADV METEOROL, V2015, DOI 10.1155/2015/213534
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Ukropec JA, 2002, EXP CELL RES, V273, P240, DOI 10.1006/excr.2001.5453
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wainwright PR, 2007, PHYS MED BIOL, V52, P3335, DOI 10.1088/0031-9155/52/12/002
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia WH, 2012, HYPERTENSION, V59, P1225, DOI 10.1161/HYPERTENSIONAHA.111.179820
   Xiao H, 2013, CIRCULATION, V128, P632, DOI 10.1161/CIRCULATIONAHA.113.002714
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhu L, 2006, J BIOMECH ENG-T ASME, V128, P203, DOI 10.1115/1.2165692
   Zouache MA, 2015, J FLUID MECH, V774, P37, DOI 10.1017/jfm.2015.243
NR 122
TC 30
Z9 31
U1 1
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD AUG
PY 2016
VL 22
IS 8
BP 656
EP 670
DI 10.1016/j.molmed.2016.06.009
PG 15
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA DT5NR
UT WOS:000381530400008
PM 27423265
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Housset, M
   Sennlaub, F
AF Housset, Michael
   Sennlaub, Florian
TI Thrombospondin-1 and Pathogenesis of Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
ID INDUCED MACROPHAGE APOPTOSIS; RETINAL DEGENERATION; IMMUNE PRIVILEGE;
   BRUCHS MEMBRANE; MOUSE MODEL; T-CELLS; ANGIOGENESIS; INFLAMMATION;
   ACTIVATION; EXPRESSION
AB The cardinal features of age-related macular degeneration (AMD) are the accumulation of subretinal debris, subretinal inflammation, neovascularization, and degeneration of the photoreceptors and retinal pigment epithelium (RPE). Thrombospondin-1 (TSP-1) is a major matricellular protein that is physiologically expressed in the RPE and choroid, but severely diminished in eyes with AMD. TSP-1 plays an important role in phagocytosis, potently inhibits neovascularization, and mediates immune suppression and immune privilege. The lack of TSP-1 could have a central role in the pathogenesis of AMD as it is implicated in the major pathways that seem to be deficient in the disease. We here give an overview of the major functions of TSP-1 and how it could intervene in AMD pathogenesis.
C1 [Housset, Michael; Sennlaub, Florian] Univ Paris 06, Sorbonne Univ, Inst Vis, UMR S 968, Paris, France.
   [Housset, Michael; Sennlaub, Florian] CNRS, UMR 7210, Paris, France.
   [Housset, Michael; Sennlaub, Florian] INSERM, U968, Paris, France.
   [Sennlaub, Florian] DHU ViewMaintain, INSERM DHOS CIC 1423, Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France.
C3 UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); CNRS - National Institute for
   Biology (INSB); UDICE-French Research Universities; Universite Paris
   Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); CHNO des Quinze-Vingts; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite
RP Sennlaub, F (通讯作者)，INSERM, Inst Vis, UMR S 968, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Sennlaub, Florian/F-2756-2017
OI Sennlaub, Florian/0000-0003-4412-1341
FU European Research Council [210345] Funding Source: Medline
CR Adamus J, 1967, Wiad Lek, V20, P1471
   Annis DS, 2006, J THROMB HAEMOST, V4, P459, DOI 10.1111/j.1538-7836.2006.01723.x
   BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240
   Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749
   Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8
   Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Ghazi NG, 2002, RETINA-J RET VIT DIS, V22, P509, DOI 10.1097/00006982-200208000-00023
   GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624
   Grimbert P, 2006, J IMMUNOL, V177, P3534, DOI 10.4049/jimmunol.177.6.3534
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hegner C., 1916, KLIN MONATSBL AUGENH, V57, P27
   Hollborn M, 2004, INVEST OPHTH VIS SCI, V45, P2033, DOI 10.1167/iovs.03-0656
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Isenberg JS, 2008, CELL MOL LIFE SCI, V65, P728, DOI 10.1007/s00018-007-7488-x
   Kazerounian S, 2008, CELL MOL LIFE SCI, V65, P700, DOI 10.1007/s00018-007-7486-z
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635
   Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627
   Levy O, 2013, INVEST OPHTH VIS SCI, V54
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li SS, 2006, BLOOD, V108, P3112, DOI 10.1182/blood-2006-04-016832
   Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez-Dee Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/296069
   Luhmann U. F., 2009, INVEST OPHTHALMOL VI
   Manna PP, 2005, J BIOL CHEM, V280, P29637, DOI 10.1074/jbc.M500922200
   Masli S, 2014, CURR EYE RES, V39, P759, DOI 10.3109/02713683.2013.877936
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Navarro-Alvarez N, 2011, CELL MOL IMMUNOL, V8, P285, DOI 10.1038/cmi.2010.83
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   Oganesian A, 2008, MOL BIOL CELL, V19, P563, DOI 10.1091/mbc.E07-07-0649
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Quesada AJ, 2005, CELL DEATH DIFFER, V12, P649, DOI 10.1038/sj.cdd.4401615
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Savill J, 1997, BRIT MED BULL, V53, P491
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Singhal PC, 1999, J IMMUNOL, V162, P3031
   Singhal PC, 2000, IMMUNOLOGY, V100, P57, DOI 10.1046/j.1365-2567.2000.00007.x
   Stern M, 1996, AM J PATHOL, V149, P911
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Xia CH, 2011, INVEST OPHTH VIS SCI, V52, P6572, DOI 10.1167/iovs.10-7082
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
NR 79
TC 10
Z9 12
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD SEP 1
PY 2015
VL 31
IS 7
SI SI
BP 406
EP 412
DI 10.1089/jop.2015.0023
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA CQ9CI
UT WOS:000360908100008
PM 26062001
DA 2022-11-30
ER

PT J
AU Wong, CW
   Wong, TY
   Cheung, CMG
AF Wong, Chee Wai
   Wong, Tien Y.
   Cheung, Chui Ming Gemmy
TI Polypoidal Choroidal Vasculopathy in Asians
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE polypoidal choroidal vasculopathy; Asians; epidemiology; risk factors;
   genetics; photodynamic therapy; anti vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; CENTRAL SEROUS
   CHORIORETINOPATHY; FLUENCE PHOTODYNAMIC THERAPY; OPTICAL COHERENCE
   TOMOGRAPHY; C-REACTIVE PROTEIN; INTRAVITREAL RANIBIZUMAB INJECTIONS;
   MACULAR EPIRETINAL BRACHYTHERAPY; PIGMENT EPITHELIAL DETACHMENT;
   INDOCYANINE GREEN ANGIOGRAPHY
AB Age related macular degeneration (AMD) in Asians has been suggested to differ from their Western counterparts in terms of epidemiology, pathogenesis, clinical presentation and treatment. In particular, polypoidal choroidal vasculopathy (PCV) appears to be the predominant subtype of exudative AMD in Asian populations, in contrast to choroidal neovascularization secondary to AMD (CNV-AMD) in Western populations. Epidemiological data on PCV has been largely limited to hospital-based studies and there are currently no data on the incidence of PCV. Similarities and differences in risk factor profile between PCV and CNV-AMD point to some shared pathogenic mechanisms but also differential underlying mechanisms leading to the development of each phenotype. Serum biomarkers such as CRP, homocysteine and matrix metalloproteinases suggest underlying inflammation, atherosclerosis and deranged extracellular matrix metabolism as possible pathogenic mechanisms. In addition, recent advances in genome sequencing have revealed differences in genetic determinants of each subtype. While the standard of care for CNV-AMD is anti-vascular endothelial growth factor (VEGF) therapy, photodynamic therapy (PDT) has been the mainstay of treatment for PCV, although long-term visual prognosis remains unsatisfactory. The optimal treatment for PCV requires further clarification, particularly with different types of anti-VEGF agents and possible benefits of reduced fluence PDT.
C1 [Wong, Chee Wai; Wong, Tien Y.; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Wong, Chee Wai; Wong, Tien Y.; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Program, Duke NUS Grad Med Sch, Singapore 169857, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Wong, TY (通讯作者)，Singapore Eye Res Inst, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wongcheewai81@gmail.com; wong.tien.yin@snec.com.sg;
   gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chaikitmongkol V, 2013, JAMA OPHTHALMOL, V131, P260, DOI 10.1001/jamaophthalmol.2013.1733
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen HY, 2012, MOL VIS, V18, P816
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cheung CMG, 2014, EYE, V28, P1148, DOI 10.1038/eye.2014.105
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   ClinicalTrials.gov, VIS OUTC PAT SYMPT M
   ClinicalTrials.gov, AFL POL CHOR VASC PL
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Friedman WA, 2011, NEUROL RES, V33, P803, DOI 10.1179/1743132811Y.0000000043
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hata Masayuki, 2012, Nippon Ganka Gakkai Zasshi, V116, P937
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Introini U, 2015, OPHTHALMOLOGICA, V233, P82, DOI 10.1159/000368561
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame G. T., INTRAVITREAL AFLIBER
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kubisz P, 2010, ACTA DIABETOL, V47, P119, DOI 10.1007/s00592-009-0127-2
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mahdy RA, 2010, EYE, V24, P1576, DOI 10.1038/eye.2010.86
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nagase Satoko, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe5, DOI 10.3928/15428877-20120130-02
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pawlak K, 2008, CYTOKINE, V43, P98, DOI 10.1016/j.cyto.2008.03.011
   Pawlak K, 2007, CLIN BIOCHEM, V40, P81, DOI 10.1016/j.clinbiochem.2006.09.001
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Romano MR, 2011, CURR DRUG TARGETS, V12, P190
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Sayanagi K, 2014, GRAEF ARCH CLIN EXP, V252, P3, DOI 10.1007/s00417-013-2474-5
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Sun HP, 2014, INT J OPHTHALMOL-CHI, V7, P872, DOI 10.3980/j.issn.2222-3959.2014.05.25
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong C. W., 2014, RETINA IN PRESS
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zeng RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075711
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 227
TC 69
Z9 73
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2015
VL 4
IS 5
BP 782
EP 821
DI 10.3390/jcm4050782
PG 40
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT9MV
UT WOS:000363142200001
PM 26239448
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Shima, C
   Gomi, F
   Sawa, M
   Sakaguchi, H
   Tsujikawa, M
   Tano, Y
AF Shima, Chiharu
   Gomi, Fumi
   Sawa, Miki
   Sakaguchi, Hirokazu
   Tsujikawa, Motokazu
   Tano, Yasuo
TI One-year results of combined photodynamic therapy and intravitreal
   bevacizumab injection for retinal pigment epithelial detachment
   secondary to age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Pigment epithelial detachment; Age-related macular degeneration;
   Photodynamic therapy; Intravitreal bevacizumab; Combination therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ANGIOMATOUS PROLIFERATION;
   JAPANESE PATIENTS; VERTEPORFIN THERAPY; AVASTIN; OCCULT; VASCULOPATHY;
   EFFICACY; TRIAL; TEARS
AB To evaluate the efficacy of combined photodynamic therapy (PDT) and intravitreal bevacizumab injection in eyes with a serous pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD).
   Twenty-two eyes with a serous PED exceeding two disc areas associated with AMD with choroidal vascular abnormalities [choroidal neovascularization (n = 10), polypoidal choroidal vasculopathy (n = 9), and retinal angiomatous proliferation (n = 3)] received combined PDT and intravitreal bevacizumab, and were followed about every 6 weeks for more than 1 year. Additional treatments were given for residual or recurrent lesions. The main outcome measures were changes in the PED height measured by optical coherence tomography, and the best-corrected visual acuity.
   After one treatment, the PED resolved in 12 eyes (55%) and the PED decreased in ten eyes (45%). There was no recurrence in eight (36%) eyes; however, PED recurred in 14 eyes. At 1 year, the average PED height decreased to 413 microns from the baseline 751 microns (p < 0.001). Twenty eyes (91%) had improved or stabilized vision; two eyes had decreased vision due to a retinal pigment epithelial tear and subretinal hemorrhage.
   Combined PDT and intravitreal bevacizumab may decrease the PED height and stabilize visual acuity at 1 year.
C1 [Shima, Chiharu; Gomi, Fumi; Sawa, Miki; Sakaguchi, Hirokazu; Tsujikawa, Motokazu; Tano, Yasuo] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   LAZIC R, 2007, CLIN EXP OPHTHALMOL, V245, P68, DOI DOI 10.1007/S00417-006-0466-4
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 26
TC 22
Z9 23
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2009
VL 247
IS 7
BP 899
EP 906
DI 10.1007/s00417-009-1067-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 451DT
UT WOS:000266451600004
PM 19308441
DA 2022-11-30
ER

PT J
AU Song, DL
   Ying, GS
   Dunaief, JL
   Bhuyan, R
   Li, YF
   Maguire, MG
   Grunwald, JE
   Daniel, E
   Hagstrom, S
   Martin, DF
AF Song, Delu
   Ying, Gui-Shuang
   Dunaief, Joshua L.
   Bhuyan, Rupak
   Li, Yafeng
   Maguire, Maureen G.
   Grunwald, Juan E.
   Daniel, Ebenezer
   Hagstrom, Stephanie
   Martin, Daniel F.
CA Comparison Age-Related Macular
TI ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL
   HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION
   TREATMENT TRIALS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; oral iron supplements; retinal/subretinal hemorrhage
ID COMPLEMENT FACTOR-H; NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH;
   FEATURES; POLYMORPHISM; VARIANT
AB Purpose: Because patients often take iron supplements without medical indication, and iron can accumulate in vascular endothelial cells, the authors evaluated the association of oral iron supplementation with retinal/subretinal hemorrhage in patients with neovascular age-related macular degeneration.
   Methods: A post hoc secondary data analysis of comparison of age-related macular degeneration treatments trials was performed. Participants were interviewed for use of oral iron supplements. Trained readers evaluated retinal/subretinal hemorrhage in baseline fundus photographs. Adjusted odds ratios from multivariate logistic regression models assessed the association between iron use and baseline hemorrhage adjusted by age, sex, smoking, hypertension, anemia, and use of antiplatelet/anticoagulant drugs.
   Results: Among 1,165 participants, baseline retinal/subretinal hemorrhage was present in the study eye in 71% of 181 iron users and in 61% of 984 participants without iron use (adjusted odds ratio = 1.47, P = 0.04), and the association was dose dependent (adjusted linear trend P = 0.048). Iron use was associated with hemorrhage in participants with hypertension (adjusted odds ratio = 1.87, P = 0.006) but not without hypertension. The association of iron use with hemorrhage remained significant among hypertensive participants without anemia (adjusted odds ratio = 1.85, P = 0.02).
   Conclusion: Among participants of comparison of age-related macular degeneration treatments trials, the use of oral iron supplements was associated with retinal/subretinal hemorrhage in a dose-response manner. Unindicated iron supplementation may be detrimental in patients with wet age-related macular degeneration.
C1 [Song, Delu; Ying, Gui-Shuang; Dunaief, Joshua L.; Bhuyan, Rupak; Li, Yafeng; Maguire, Maureen G.; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Hagstrom, Stephanie; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic
   Foundation
RP Ying, GS (通讯作者)，Univ Penn, Perelman Sch Med, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@pennmedicine.upenn.edu
FU National Center for Advancing Translational Sciences of the NIH
   [KL2TR001879]; NEI/NIH, Bethesda, Maryland [U10 EY017823, U10 EY017825,
   U10 EY017826, U10 EY017828, R21EY023689]; Research to Prevent Blindness;
   F.M. Kirby Foundation; Paul and Evanina Bell Mackall Foundation Trust;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001879]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001583]
   Funding Source: NIH RePORTER
FX Supported by the National Center for Advancing Translational Sciences of
   the NIH (KL2TR001879), NEI/NIH, Bethesda, Maryland (cooperative
   agreement nos: U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   and R21EY023689), Research to Prevent Blindness, the F.M. Kirby
   Foundation, and the Paul and Evanina Bell Mackall Foundation Trust.
CR Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   CIBIS PA, 1957, AM J OPHTHALMOL, V44, P158, DOI 10.1016/0002-9394(57)90444-0
   Dickinson A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-14
   Dickinson A, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-29
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kennedy ET, 2013, ECOL FOOD NUTR, V52, P76, DOI 10.1080/03670244.2012.706000
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   SYVERSEN K, 1979, ACTA OPHTHALMOL, V57, P358
   Ueda Y, 2017, BLOOD, V129, P1184, DOI 10.1182/blood-2016-07-728253
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 27
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1965
EP 1972
DI 10.1097/IAE.0000000000002295
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300017
PM 30157115
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Heier, JS
AF Heier, Jeffrey S.
TI PATHOLOGY BEYOND NEOVASCULARIZATION New Targets in Age-Related Macular
   Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE atrophy; exudative age-related macular degeneration; fibrosis;
   integrins; vascular disrupting agents
ID RANIBIZUMAB
AB Control of choroid neovascularization may be important but insufficient to preserve long-term vision threatened by age-related macular degeneration. A retrospective analysis of patients who were early participants in anti-vascular endothelial growth factor studies, other pathologic processes, particularly fibrosis and atrophy, have participated in vision loss independent of new vessel growth. The recent interest in combination treatment strategies has been dominated by more effective blockade of angiogenic signaling, but it may also be necessary to incorporate therapies that block fibrosis, inhibit atrophy or other pathophysiologic processes not directly related to neovascularization to achieve the ultimate goal of preserving sight for a long term. RETINA 29:S39-S41, 2009
C1 Ophthalm Consultants Boston, Boston, MA 02114 USA.
C3 Ophthalmic Consultants of Boston
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   KLATT K, 2007 ARVO ANN M, P1233
   Nieder C, 2007, REV RECENT CLIN TRIA, V2, P163, DOI 10.2174/157488707781662733
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 4
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S39
EP S41
DI 10.1097/IAE.0b013e3181ad26c1
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700015
PM 19553799
DA 2022-11-30
ER

PT J
AU Yonekawa, Y
   Kim, IK
AF Yonekawa, Yoshihiro
   Kim, Ivana K.
TI Clinical Characteristics and Current Treatment of Age-Related Macular
   Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; TISSUE-PLASMINOGEN ACTIVATOR; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION; VERTEPORFIN
   PHOTODYNAMIC THERAPY; THICK SUBMACULAR HEMORRHAGE; ENDOTHELIAL
   GROWTH-FACTOR; VEGF TRAP-EYE; GEOGRAPHIC ATROPHY; PNEUMATIC DISPLACEMENT
AB Age-related macular degeneration (AMD) is a multifactorial degeneration of photoreceptors and retinal pigment epithelium. The societal impact is significant, with more than 2 million individuals in the United States alone affected by advanced stages of AMD. Recent progress in our understanding of this complex disease and parallel developments in therapeutics and imaging have translated into new management paradigms in recent years. However, there are many unanswered questions, and diagnostic and prognostic precision and treatment outcomes can still be improved. In this article, we discuss the clinical features of AMD, provide correlations with modern imaging and histopathology, and present an overview of treatment strategies.
C1 [Yonekawa, Yoshihiro; Kim, Ivana K.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Kim, IK (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
EM Ivana_Kim@meei.harvard.edu
OI Kim, Ivana/0000-0003-0310-6129
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer D, 2013, ASS RES VIS OPHTH AN
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   LAATIKAINEN L, 1977, INVEST OPHTH VIS SCI, V16, P1154
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Regillo C, 2013, ANN M AM AC OPHTH NE
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tsai JC, 2013, CAN J OPHTHALMOL, V48, P141, DOI 10.1016/j.jcjo.2013.02.003
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WHO, 2013, PREV BLINDN VIS IMP
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yonekawa Y, 2013, CAN J OPHTHALMOL, V48, pE59, DOI 10.1016/j.jcjo.2012.12.015
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 122
TC 39
Z9 41
U1 0
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JAN
PY 2015
VL 5
IS 1
AR a017178
DI 10.1101/cshperspect.a017178
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CD6YM
UT WOS:000351236900004
PM 25280900
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lin, TC
   Hung, KH
   Peng, CH
   Liu, JH
   Woung, LC
   Tsai, CY
   Chen, SJ
   Chen, YT
   Hsu, CC
AF Lin, Tai-Chi
   Hung, Kuo-Hsuan
   Peng, Chi-Hsien
   Liu, Jorn-Hon
   Woung, Lin-Chung
   Tsai, Ching-Yao
   Chen, Shih-Jen
   Chen, Yan-Ting
   Hsu, Chih-Chien
TI Nanotechnology-based drug delivery treatments and specific targeting
   therapy for age-related macular degeneration
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   nanotechnology; target therapy; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; DEXAMETHASONE
   INTRAVITREAL IMPLANT; OCULAR NEOVASCULARIZATION; SUSTAINED DELIVERY;
   FACTOR VEGF; NANOPARTICLES; CELLS; POLYMORPHISM; RANIBIZUMAB
AB Nanoparticles combined with cells, drugs, and specially designed genes provide improved therapeutic efficacy in studies and clinical setting, demonstrating a new era of treatment strategy, especially in retinal diseases. Nanotechnology-based drugs can provide an essential platform for sustaining, releasing and a specific targeting design to treat retinal diseases. Poly-lactic-co-glycolic acid is the most widely used biocompatible and biodegradable polymer approved by the Food and Drug Administration. Many studies have attempted to develop special devices for delivering small-molecule drugs, proteins, and other macromolecules consistently and slowly. In this article, we first review current progress in the treatment of age-related macular degeneration. Then, we discuss the function of vascular endothelial growth factor (VEGF) and the pharmacological effects of anti-VEGF-A antibodies and soluble or modified VEGF receptors. Lastly, we summarize the combination of anti-angiogenic therapy and nanomedicines, and review current potential targeting therapy in age-related macular degeneration. Copyright (C) 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
C1 [Lin, Tai-Chi; Hung, Kuo-Hsuan; Chen, Shih-Jen; Hsu, Chih-Chien] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Lin, Tai-Chi; Hung, Kuo-Hsuan; Peng, Chi-Hsien; Chen, Yan-Ting; Hsu, Chih-Chien] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Hung, Kuo-Hsuan] Natl Yang Ming Univ Hosp, Dept Ophthalmol, Yilan, Taiwan.
   [Peng, Chi-Hsien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Peng, Chi-Hsien] Fu Jen Catholic Univ, Taipei, Taiwan.
   [Peng, Chi-Hsien; Woung, Lin-Chung; Tsai, Ching-Yao; Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Liu, Jorn-Hon] Cheng Hsin Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Woung, Lin-Chung; Tsai, Ching-Yao] Taipei City Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Yan-Ting] Changhua Christian Hosp, Dept Ophthalmol, Changhua, Taiwan.
   [Chen, Yan-Ting] Cent Taiwan Univ Sci & Technol, Dept Optometry, Taichung, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic
   University; National Yang Ming Chiao Tung University; Cheng Hsin General
   Hospital; Taipei City Hospital; Changhua Christian Hospital; Central
   Taiwan University Science & Technology
RP Hsu, CC (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM chihchienym@gmail.com
OI WOUNG, LIN-CHUNG/0000-0002-0700-7606
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018
   Ambati BK, 2007, BRIT J OPHTHALMOL, V91, P505, DOI 10.1136/bjo.2006.107417
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Amrite AC, 2008, J PHARMACOL EXP THER, V324, P749, DOI 10.1124/jpet.107.128918
   Boddu SHS, 2010, J OCUL PHARMACOL TH, V26, P37, DOI 10.1089/jop.2009.0074
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Daull P, 2013, J OCUL PHARMACOL TH, V29, P258, DOI 10.1089/jop.2012.0044
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   GIORDANO GG, 1995, CURR EYE RES, V14, P761, DOI 10.3109/02713689508995797
   Goldman J, 2007, FASEB J, V21, P1003, DOI 10.1096/fj.06-6656com
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Jani PD, 2007, INVEST OPHTH VIS SCI, V48, P2030, DOI 10.1167/iovs.06-0853
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Joukov V, 1996, EMBO J, V15, P290
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Palamoor M, 2013, COLLOID SURFACE B, V112, P474, DOI 10.1016/j.colsurfb.2013.07.039
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pavlakovic H, 2010, ANN NY ACAD SCI, V1207, pE7, DOI 10.1111/j.1749-6632.2010.05714.x
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shmueli RB, 2013, BIOMATERIALS, V34, P7544, DOI 10.1016/j.biomaterials.2013.06.044
   Singh N, 2013, BLOOD, V121, P4242, DOI 10.1182/blood-2012-08-453043
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Suen WLL, 2013, J CONTROL RELEASE, V167, P21, DOI 10.1016/j.jconrel.2013.01.004
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Ungaro F, 2012, J PHARM PHARMACOL, V64, P1217, DOI 10.1111/j.2042-7158.2012.01486.x
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Veritti D, 2013, OPHTHALMOLOGICA, V230, P131, DOI 10.1159/000351651
   Wittchen ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073070
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Zarbin MA, 2010, CAN J OPHTHALMOL, V45, P457, DOI 10.3129/i10-090
   Zarena AS, 2011, THER DELIV, V2, P259, DOI 10.4155/TDE.10.82
NR 51
TC 16
Z9 17
U1 1
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD NOV
PY 2015
VL 78
IS 11
BP 635
EP 641
DI 10.1016/j.jcma.2015.07.008
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CZ5DJ
UT WOS:000367122400003
PM 26383186
OA Bronze
DA 2022-11-30
ER

PT J
AU Baek, JS
   Cho, HJ
   Cho, SW
   Kim, CG
   Kim, JW
AF Baek, Ji Sun
   Cho, Han Joo
   Cho, Sung Won
   Kim, Chul Gu
   Kim, Jong Woo
TI INTRAVITREAL RANIBIZUMAB INJECTION FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION IN PHAKIC VERSUS PSEUDOPHAKIC EYES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; pseudophakia; ranibizumab
ID EXTRACAPSULAR CATARACT-EXTRACTION; POSTERIOR VITREOUS DETACHMENT;
   GROWTH-FACTORS; SURGERY; MACULOPATHY; DISEASE; HEALTH
AB Purpose: To compare the effect of intravitreal ranibizumab injections for the treatment of neovascular age-related macular degeneration between phakic and pseudophakic eyes.
   Methods: We retrospectively reviewed the medical records of 110 patients with neovascular age-related macular degeneration receiving intravitreal ranibizumab therapy and categorized them into 2 subgroups: phakic group (75 eyes) and pseudophakic group (45 eyes). For all patients, the initial three loading injections were performed by month, and reinjection was performed as needed. Main outcome measures included best-corrected visual acuity and central macular thickness as assessed by optical coherence tomography.
   Results: The mean age of the patients was 72 +/- 4.2 years, and the patients were followed up for an average of 18 +/- 3.6 months. At the last visit, the average number of injections was 3.87 +/- 1.18 in the phakic group and 3.62 +/- 1.17 in the pseudophakic group. After injection, the mean logarithm of the minimum angle of resolution of best-corrected visual acuity improved from 0.88 +/- 0.65 to 0.75 +/- 0.66 in the phakic group and from 0.86 +/- 0.54 to 0.74 +/- 0.09 in the pseudophakic group. Average central macular thickness decreased from 561 +/- 289 mu m to 419 +/- 216 mu m in the phakic group and from 559 +/- 232 mu m to 429 +/- 166 mu m in the pseudophakic group. There was no statistically significant difference in the injection number, best-corrected visual acuity improvement was achieved, and central macular thickness improvement was achieved between the phakic group and pseudophakic group.
   Conclusion: The therapeutic effect of intravitreal ranibizumab injection for neovascular age-related macular degeneration did not show differences between phakic and pseudophakic eyes. RETINA 33:467-473, 2013
C1 [Baek, Ji Sun; Cho, Han Joo; Cho, Sung Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp, 156,4Ga Yeoungdeungpo Dong, Seoul, South Korea.
EM ccnnrr@naver.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Bettelheim FA, 2004, EXP EYE RES, V79, P713, DOI 10.1016/j.exer.2004.07.011
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   CORWIN JM, 1981, SURV OPHTHALMOL, V25, P287, DOI 10.1016/0039-6257(81)90155-7
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Goldenberg D, 2008, EXPERT REV OPHTHALMO, V3, P273, DOI 10.1586/17469899.3.3.273
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Hikichi T, 2012, OPHTHALMOLOGY, V119, P2102, DOI 10.1016/j.ophtha.2012.03.050
   Hilford D, 2009, EYE, V23, P1388, DOI 10.1038/eye.2008.273
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   HYKIN PG, 1993, OPHTHALMOLOGY, V100, P394
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Mirshahi A, 2009, J CATARACT REFR SURG, V35, P987, DOI 10.1016/j.jcrs.2009.02.016
   Neal RE, 2005, EXP EYE RES, V80, P337, DOI 10.1016/j.exer.2004.09.015
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Peters S, 2008, BRIT J OPHTHALMOL, V92, P541, DOI 10.1136/bjo.2007.133496
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Stefansson E, 2005, GRAEFES ARCH CLIN EX, V123, P209
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wilkinson CP, 1997, MICHELS RETINAL DETA, P9
NR 27
TC 7
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 467
EP 473
DI 10.1097/IAE.0b013e3182753b2a
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200002
PM 23400082
DA 2022-11-30
ER

PT J
AU Cascella, R
   Ragazzo, M
   Strafella, C
   Missiroli, F
   Borgiani, P
   Angelucci, F
   Marsella, LT
   Cusumano, A
   Novelli, G
   Ricci, F
   Giardina, E
AF Cascella, Raffaella
   Ragazzo, Michele
   Strafella, Claudia
   Missiroli, Filippo
   Borgiani, Paola
   Angelucci, Francesco
   Marsella, Luigi Tonino
   Cusumano, Andrea
   Novelli, Giuseppe
   Ricci, Federico
   Giardina, Emiliano
TI Age-Related Macular Degeneration: Insights into Inflammatory Genes
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; ENDOTHELIAL DYSFUNCTION;
   CARDIOVASCULAR-DISEASE; NLRP3 INFLAMMASOME; CIGARETTE-SMOKING; OXIDATIVE
   STRESS; BRUCHS MEMBRANE; RISK-FACTORS; MACULOPATHY
AB Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that affects approximately 8.7% of elderly people worldwide (>55 years old). AMD is characterized by a multifactorial aetiology that involves several genetic and environmental risk factors (genes, ageing, smoking, family history, dietary habits, oxidative stress, and hypertension). In particular, ageing and cigarette smoking (including oxidative compounds and reactive oxygen species) have been shown to significantly increase susceptibility to the disease. Furthermore, different genes (CFH, CFI, C2, C3, IL-6, IL-8, and ARMS2) that play a crucial role in the inflammatory pathway have been associated with AMD risk. Several genetic and molecular studies have indicated the participation of inflammatory molecules (cytokines and chemokines), immune cells (macrophages), and complement proteins in the development and progression of the disease. Taking into consideration the genetic and molecular background, this review highlights the genetic role of inflammatory genes involved in AMD pathogenesis and progression.
C1 [Cascella, Raffaella; Ragazzo, Michele; Strafella, Claudia; Borgiani, Paola; Marsella, Luigi Tonino; Novelli, Giuseppe; Giardina, Emiliano] Univ Roma Tor Vergata, Sch Med, Dept Biomed & Prevent, I-00133 Rome, Italy.
   [Missiroli, Filippo; Cusumano, Andrea; Ricci, Federico] PTV Fdn Policlin Tor Vergata, UOSD Retinal Pathol, I-00133 Rome, Italy.
   [Angelucci, Francesco; Giardina, Emiliano] Santa Lucia Fdn, Mol Genet Lab UILDM, I-00142 Rome, Italy.
C3 University of Rome Tor Vergata; IRCCS Santa Lucia
RP Cascella, R (通讯作者)，Univ Roma Tor Vergata, Sch Med, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.
EM raffaellacascella@virgilio.it
RI Giardina, Emiliano/J-1965-2012; Novelli, Giuseppe/GQB-3329-2022;
   Novelli, Giuseppe/A-5195-2013; ricci, federico/AAC-3836-2020; Strafella,
   Claudia/AAA-5929-2019; Novelli, Giuseppe/T-8822-2019
OI Novelli, Giuseppe/0000-0002-7781-602X; Novelli,
   Giuseppe/0000-0002-7781-602X; ricci, federico/0000-0002-4224-9280;
   Strafella, Claudia/0000-0003-1334-0920; giardina,
   emiliano/0000-0002-2741-5009; Marsella, Luigi
   Tonino/0000-0002-7005-7526; BORGIANI, PAOLA/0000-0003-0859-4328
CR Adami S., 2014, BIODRUGS
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ansar W, 2013, IMMUNOL RES, V56, P131, DOI 10.1007/s12026-013-8384-0
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bank S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098815
   Benowitz NL, 2003, PROG CARDIOVASC DIS, V46, P91, DOI 10.1016/S0033-0620(03)00087-2
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bonomi M, 2014, ADV EXP MED BIOL, V816, P107, DOI 10.1007/978-3-0348-0837-8_5
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Colobran R, 2010, CLIN EXP IMMUNOL, V162, P41, DOI 10.1111/j.1365-2249.2010.04224.x
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao LB, 2010, EUR J CANCER, V46, P1333, DOI 10.1016/j.ejca.2010.03.011
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Giardina Emiliano, 2004, Current Drug Targets - Inflammation and Allergy, V3, P129, DOI 10.2174/1568010043343877
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Green RW, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10
   Harman D, 2009, BIOGERONTOLOGY, V10, P783, DOI 10.1007/s10522-009-9253-z
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Libby P, 2006, AM J CLIN NUTR, V83, p456S
   Libby P, 2007, NUTR REV, V65, pS140, DOI [10.1111/j.1753-4887.2007.tb00352.x, 10.1301/nr.2007.dec.S140-S146]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Maru GB, 2014, ADV EXP MED BIOL, V816, P437, DOI 10.1007/978-3-0348-0837-8_17
   Masters SL, 2011, TRENDS MOL MED, V17, P276, DOI 10.1016/j.molmed.2011.01.005
   Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506
   Melik-Parsadaniantz S, 2008, J NEUROIMMUNOL, V198, P62, DOI 10.1016/j.jneuroim.2008.04.022
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   Natl. Eye Inst, 2014, AG REL MAC DEG AMD
   Novelli G, 2003, CURR OPIN CARDIOL, V18, P368, DOI 10.1097/00001573-200309000-00008
   Nuzzo D, 2014, INFLAMMATION, V37, P639, DOI 10.1007/s10753-013-9780-2
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schramm E. C., 2014, MOL IMMUNOL, V5890, P161
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Trouw LA, 2011, IMMUNOL LETT, V138, P35, DOI 10.1016/j.imlet.2011.02.014
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Virdis A, 2014, MATURITAS, V78, P179, DOI 10.1016/j.maturitas.2014.04.012
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   World Health Organization, 2004, VISION 2020 RIGHT SI
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeng FX, 2013, GRAEF ARCH CLIN EXP, V251, P2539, DOI 10.1007/s00417-013-2442-0
NR 115
TC 53
Z9 57
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 582842
DI 10.1155/2014/582842
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU7EL
UT WOS:000345763500001
PM 25478207
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Xu, D
   Kaiser, PK
AF Xu, David
   Kaiser, Peter K.
TI Intravitreal aflibercept for neovascular age-related macular
   degeneration
SO IMMUNOTHERAPY
LA English
DT Article
DE aflibercept; macular degeneration; VEGF; VEGF-Trap
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; BEVACIZUMAB AVASTIN THERAPY;
   VEGF-TRAP; CHOROIDAL NEOVASCULARIZATION; PHASE-II; CLINICAL-TRIALS;
   OVARIAN-CANCER; RANIBIZUMAB; ANGIOGENESIS
AB Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. Intravitreally administered anti-VEGF drugs have been developed to halt neovascular growth in AMD. Randomized trials have demonstrated the excellent safety profile and significant benefit of anti-VEGF therapy in maintaining vision. Aflibercept (Eylea(R); Regeneron, NY, USA) is a soluble decoy receptor against VEGF that offers greater potency and binding affinity than other anti-VEGF drugs. Having received US FDA approval for neovascular AMD in November 2011, aflibercept given every 8 weeks after a loading dose was 'clinically equivalent' and statistically noninferior to the current FDA-approved therapy ranibizumab (Lucentis(R); Genentech, CA, USA), given every 4 weeks. This article discusses the clinical background of AMD, development of aflibercept, results of the clinical trials and the future role of aflibercept in ocular neovascular diseases.
C1 [Xu, David; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Eucid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Regeneron; Bayer
FX PK Kaiser receives consulting fees from Regeneron and Bayer. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benz MS, AMERICAN ACADEMY OF
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Byrne AT, 2003, CLIN CANCER RES, V9, P5721
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Coleman RL, 2012, GYNECOL ONCOL, V127, P538, DOI 10.1016/j.ygyno.2012.08.020
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gotlieb WH, 2012, LANCET ONCOL, V13, P154, DOI 10.1016/S1470-2045(11)70338-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   Jumper JM, 2012, PRESENTED AT AMERICA
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klettner A, 2010, INVEST OPHTH VIS SCI, V49, P4523
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Major J, 2012, PRESENTED AT AMERICA
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Morabito A, 2006, ONCOLOGIST, V11, P753, DOI 10.1634/theoncologist.11-7-753
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2009, OPHTHALMOLOGY, V116
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Sharma A, 2012, PRESENTED AT AMERICA
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Sullivan LA, 2010, MABS-AUSTIN, V2, P165, DOI 10.4161/mabs.2.2.11360
   Tarhini AA, 2011, CLIN CANCER RES, V17, P6574, DOI 10.1158/1078-0432.CCR-11-1463
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Twardowski P, 2010, UROLOGY, V76, P923, DOI 10.1016/j.urology.2010.04.025
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wulff C, 2001, J CLIN ENDOCR METAB, V86, P3377, DOI 10.1210/jc.86.7.3377
   Wulff C, 2001, ENDOCRINOLOGY, V142, P3244, DOI 10.1210/en.142.7.3244
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 76
TC 7
Z9 8
U1 0
U2 18
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD FEB
PY 2013
VL 5
IS 2
BP 121
EP 130
DI 10.2217/IMT.12.158
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 086HN
UT WOS:000314674800009
PM 23413903
DA 2022-11-30
ER

PT J
AU Saito, K
   Yamamoto, T
   Tsuchiya, D
   Kawasaki, R
   Haneda, S
   Yamashita, H
AF Saito, Koko
   Yamamoto, Teiko
   Tsuchiya, Daijiro
   Kawasaki, Ryo
   Haneda, Shion
   Yamashita, Hidetoshi
TI Effect of combined treatment with sub-Tenon injection of triamcinolone
   acetonide and photodynamic therapy in Japanese patients with age-related
   macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; polypoidal
   choroidal vasculopathy; sub-Tenon injection; triamcinolone acetonide
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; DOSE INTRAVITREAL TRIAMCINOLONE;
   VERTEPORFIN; NEOVASCULARIZATION
AB To evaluate the benefit of the combination of a single sub-Tenon injection of triamcinolone acetonide (STTA) with photodynamic therapy (PDT) for the treatment of age-related macular degeneration (AMD) in Japanese patients.
   The medical records of 111 eyes of 111 patients were reviewed retrospectively. Forty-five eyes underwent combined treatment with STTA and PDT, and 66 eyes underwent PDT alone. Time to vision loss, defined as a change of 0.3 or more logarithm of minimum angle of resolution (logMAR) units, and time to retreatment were evaluated using the Kaplan-Meier survival analyses. Cox regression models were used to estimate the hazard ratios for those end points to investigate clinical risk characteristics.
   Patients who underwent combined STTA with PDT had a significantly lower risk of retreatment than did those who underwent PDT alone (hazard ratio, 0.59; 95% confidence interval, 0.36-0.99). This beneficial association was found only in patients without polypoidal choroidal vasculopathy (PCV) lesions. However, combined treatment with STTA and PDT had no beneficial effect in reducing visual loss when compared with treatment with PDT alone.
   Combined treatment with STTA and PDT had a beneficial effect in reducing retreatment of AMD in Japanese patients. Those who had PCV lesions did not benefit from this additional treatment.
C1 [Saito, Koko] Shinoda Gen Hosp, Dept Ophthalmol, Yamagata 9900045, Japan.
   [Saito, Koko; Yamamoto, Teiko; Tsuchiya, Daijiro; Kawasaki, Ryo; Haneda, Shion; Yamashita, Hidetoshi] Yamagata Univ, Fac Med, Dept Ophthalmol & Visual Sci, Yamagata 990, Japan.
   [Kawasaki, Ryo] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Yamagata University; Centre for Eye Research Australia; University of
   Melbourne
RP Saito, K (通讯作者)，Shinoda Gen Hosp, Dept Ophthalmol, 2-68 Sakura Cho, Yamagata 9900045, Japan.
EM kokokiy@shinoda-hp.or.jp
RI Kawasaki, Ryo/B-7266-2009; Kawasaki, Ryo/H-9716-2019
OI Kawasaki, Ryo/0000-0002-7492-6303; 
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 30
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2009
VL 53
IS 5
BP 512
EP 518
DI 10.1007/s10384-009-0703-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 509OF
UT WOS:000271026600014
PM 19847608
DA 2022-11-30
ER

PT J
AU Balasubramanian, S
   Lei, JQ
   Nittala, MG
   Velaga, SB
   Haines, J
   Pericak-Vance, MA
   Stambolian, D
   Sadda, SR
AF Balasubramanian, Siva
   Lei, Jianqin
   Nittala, Muneeswar G.
   Velaga, Swetha B.
   Haines, Jonathan
   Pericak-Vance, Margaret A.
   Stambolian, Dwight
   Sadda, Srinivas R.
TI ASSOCIATION OF DRUSEN VOLUME WITH CHOROIDAL PARAMETERS IN NONNEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; SD-OCT; drusen volume; choroidal
   intensity; choroidal thickness
ID OPTICAL COHERENCE TOMOGRAPHY; BRUCHS MEMBRANE; MORPHOMETRIC-ANALYSIS;
   THICKNESS; EYES; CHORIOCAPILLARIS; REPRODUCIBILITY; SUBANALYSIS;
   DISEASE; RPE
AB Purpose: The choroid is thought to be relevant to the pathogenesis of nonneovascular age-related macular degeneration, but its role has not yet been fully defined. In this study, we evaluate the relationship between the extent of macular drusen and specific choroidal parameters, including thickness and intensity.
   Methods: Spectral domain optical coherence tomography images were collected from two distinct, independent cohorts with nonneovascular age-related macular degeneration: Amish (53 eyes of 34 subjects) and non-Amish (40 eyes from 26 subjects). All spectral domain optical coherence tomography scans were obtained using the Cirrus HD-OCT with a 512 x 128 macular cube (6 x 6 mm) protocol. The Cirrus advanced retinal pigment epithelium analysis tool was used to automatically compute drusen volume within 3 mm (DV3) and 5 mm (DV5) circles centered on the fovea. The inner and outer borders of the choroid were manually segmented, and the mean choroidal thickness and choroidal intensity (i.e., brightness) were calculated. The choroidal intensity was normalized against the vitreous and nerve fiber layer reflectivity. The correlation between DV and these choroidal parameters was assessed using Pearson and linear regression analysis.
   Results: A significant positive correlation was observed between normalized choroidal intensity and DV5 in the Amish (r = 0.42, P = 0.002) and non-Amish (r = 0.33, P = 0.03) cohorts. Also, DV3 showed a significant positive correlation with normalized choroidal intensity in both the groups (Amish: r = 0.30, P = 0.02; non-Amish: r = 0.32, P = 0.04). Choroidal thickness was negatively correlated with normalized choroidal intensity in both Amish (r = 20.71, P = 0.001) and non-Amish (r = 20.43, P = 0.01) groups. Normalized choroidal intensity was the most significant constant predictor of DV in both the Amish and non-Amish groups.
   Conclusion: Choroidal intensity, but not choroidal thickness, seems to be associated with drusen volume in Amish and non-Amish populations. These observations suggest that choroidal parameters beyond thickness warrant further study in the setting of age-related macular degeneration.
C1 [Balasubramanian, Siva; Lei, Jianqin; Nittala, Muneeswar G.; Velaga, Swetha B.; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1450 San Pablo St, Los Angeles, CA 90033 USA.
   [Balasubramanian, Siva; Lei, Jianqin; Nittala, Muneeswar G.; Velaga, Swetha B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.
   [Haines, Jonathan] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University; Case Western Reserve University; University of Miami;
   University of Pennsylvania; Pennsylvania Medicine
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020
FU National Eye Institute, Bethesda, Maryland [RO1 EY023164-03]; Department
   of Ophthalmology at the Perelman School of Medicine, Univ. of
   Pennsylvania, Philadelphia, Pennsylvania; Macular Vision Research
   Foundation; F.M. Kirby Foundation; Carl Zeiss Meditec; Optos; Allergan;
   Genentech; NATIONAL EYE INSTITUTE [R01EY023164] Funding Source: NIH
   RePORTER
FX Supported by the National Eye Institute, Bethesda, Maryland (grant #RO1
   EY023164-03) and the Department of Ophthalmology at the Perelman School
   of Medicine, Univ. of Pennsylvania, Philadelphia, Pennsylvania. Funds
   also were received from the Macular Vision Research Foundation and F.M.
   Kirby Foundation.; S. R. Sadda is a consultant for Carl Zeiss Meditec,
   Optos, Allergan, Genentech, Alcon, Novartis, and Roche. He receives
   research funding from Carl Zeiss Meditec, Optos, Allergan, and
   Genentech. He also receives honoraria from Carl Zeiss Meditec, Optos,
   and Allergan. The remaining authors have no any conflicting interests to
   disclose.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Agrawal R, 2016, RETINA, V36, P1
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hu ZH, 2013, OSLI RETINA, V44, pS5, DOI 10.3928/23258160-20131101-02
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   VANDRIEL D, 1980, MICRON, V11, P451, DOI 10.1016/0047-7206(80)90091-6
   Vujosevic S, 2012, RETINA, V32, P1
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 34
TC 5
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1880
EP 1887
DI 10.1097/IAE.0000000000001428
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GH
UT WOS:000411680300020
PM 28169876
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Rosenfeld, PJ
AF Yehoshua, Zohar
   Rosenfeld, Philip J.
TI Strategies for Following Dry Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Drusen; Geographic atrophy; Choroidal neovascularization; Progression;
   Spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; PREFERENTIAL HYPERACUITY PERIMETER;
   GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; SUBGROUP ANALYSIS;
   SEVERITY SCALE; RANIBIZUMAB; RISK; AUTOFLUORESCENCE; PROGRESSION
AB Spectral domain optical coherence tomography (SDOCT) provides a novel strategy for imaging and monitoring progression in patients with age-related macular degeneration (AMD). The advantage of SDOCT over other imaging modalities or functional tests is that one modality can be used to image both drusen and geographic atrophy while obtaining reproducible, quantitative data on both drusen morphology and the area of geographic atrophy. Moreover, this strategy enables the clinician to follow the disease as it progresses from drusen to both geographic atrophy and choroidal neovascularization. No other imaging modality is able to quantitatively assess all forms of AMD. This unique feature of SDOCT makes it the ideal imaging modality for monitoring patients with AMD, providing routine care, and for following patients in clinical trials designed to assess the efficacy of new drugs for the treatment of dry AMD. Copyright (C) 2012 S. Karger AG, Basel
C1 [Yehoshua, Zohar; Rosenfeld, Philip J.] Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Bascom Palmer Eye Inst, Miller Sch Med, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
FU Carl Zeiss Meditec Inc.
FX Drs. Yehoshua and Rosenfeld received research support from Carl Zeiss
   Meditec Inc. Dr. Rosenfeld has received honoraria for lectures from Carl
   Zeiss Meditec Inc.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Robison CD, 2011, BRIT J OPHTHALMOL, V95, P1419, DOI 10.1136/bjo.2010.194886
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Stur M, 2010, OPHTHAL SURG LAS IM, V41, P598, DOI 10.3928/15428877-20100830-05
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 37
TC 3
Z9 3
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2012
VL 48
SU 1
BP 6
EP 10
DI 10.1159/000339841
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 994FT
UT WOS:000307917000002
PM 22907143
DA 2022-11-30
ER

PT J
AU Xu, LN
   Mrejen, S
   Jung, JJ
   Gallego-Pinazo, R
   Thompson, D
   Marsiglia, M
   Freund, KB
AF Xu, Luna
   Mrejen, Sarah
   Jung, Jesse J.
   Gallego-Pinazo, Roberto
   Thompson, Desmond
   Marsiglia, Marcela
   Freund, K. Bailey
TI GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL
   GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; choroidal
   neovascularization; classification of choroidal neovascularization;
   geographic atrophy; infrared imaging; spectral domain optical coherence
   tomography; treat-and-extend regimen
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; TYPE-3; RANIBIZUMAB; VERTEPORFIN; THERAPY; PROGRESSION;
   TREAT; TAP
AB Purpose: To examine factors associated with the apparent growth of geographic atrophy (GA) in a consecutive series of eyes with treatment-naive neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor therapy on a treat-and-extend regimen.
   Methods: This was a retrospective cohort study. Two independent graders identified areas of GA using near-infrared reflectance imaging and spectral domain optical coherence tomography (SD-OCT). Neovascular lesion subtypes were classified based on fluorescein angiography (FA) as occult choroidal neovascularization, classic choroidal neovascularization, retinal angiomatous proliferation, or mixed choroidal neovascularization, and by the anatomical classification system which utilizes FA and SD-OCT as Types 1 (sub-retinal pigment epithelium), 2 (subretinal), 3 (intraretinal), or mixed neovascularization.
   Results: Ninety-one patients (94 eyes) fit the inclusion criteria, of which 52 eyes (55.3%) experienced apparent GA growth. The odds of developing apparent GA were significantly lower in Type 1 neovascularization compared to the other lesion types (P < 0.001). Using both FA and SD-OCT to classify neovascular age-related macular degeneration significantly improves the goodness of fit in the correlation between apparent GA growth and baseline neovascular lesion type (P < 0.001).
   Conclusion: Treatment-naive neovascular age-related macular degeneration eyes with Type 1 neovascularization at baseline were less likely to develop GA than eyes with other types. The correlation between apparent GA growth and subtype of neovascularization is stronger when lesions are classified with an anatomic grading that utilizes both FA and SD-OCT.
C1 [Xu, Luna; Mrejen, Sarah; Jung, Jesse J.; Gallego-Pinazo, Roberto; Marsiglia, Marcela; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Xu, Luna] New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
   [Xu, Luna] St Vincents Med Ctr, Dept Med, Bridgeport, CT USA.
   [Mrejen, Sarah; Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, Retina Div, Dept Ophthalmol, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Columbia Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
C3 Vitreous Retina Macula Consultants of New York; New York Eye & Ear
   Infirmary of Mount Sinai; St. Vincent's Medical Center; Manhattan Eye
   Ear & Throat Hospital; New York University; Columbia University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital; Macula Foundation Inc.; Bayer; Novartis; Heidelberg
   Engineering; Thea; Sensimed
FX Supported by a research grant from the LuEsther T. Mertz Retinal
   Research Center, Manhattan Eye, Ear, and Throat Hospital, and The Macula
   Foundation Inc.; K. B. Freund is a consultant to Regeneon, Genentech,
   Bayer HealthCare, Thrombogenics, and Heidelberg Engineering (honorarium
   for each). R. Gallego-Pinazo is a consultant to Carl Zeiss Meditec,
   Bayer, and Novartis (honorarium for each) and received research support
   from Bayer, Novartis, Heidelberg Engineering, Thea, and Sensimed. The
   other authors have no conflicting interests to disclose.
CR Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Macular Photocoagulation Study Group, 1996, ARCH OPHTHALMOL-CHIC, V114, P1023
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Querques G, 2013, J FR OPHTALMOL, V36, pE1, DOI 10.1016/j.jfo.2012.04.013
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 35
TC 81
Z9 82
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2015
VL 35
IS 2
BP 176
EP 186
DI 10.1097/IAE.0000000000000374
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA2UU
UT WOS:000348764200004
PM 25387047
DA 2022-11-30
ER

PT J
AU Emsfors, A
   Christensson, L
   Elgan, C
AF Emsfors, Asa
   Christensson, Lennart
   Elgan, Carina
TI Nursing actions that create a sense of good nursing care in patients
   with wet age-related macular degeneration
SO JOURNAL OF CLINICAL NURSING
LA English
DT Article
DE caring; critical incidents; interviews; nurse-patient relations;
   nursing; nursing activity; nursing care; older patients; ophthalmology;
   patients' experience
ID CRITICAL INCIDENT TECHNIQUE; PHOTODYNAMIC THERAPY; PATIENTS EXPERIENCES;
   CENTERED CARE; RANIBIZUMAB; EYE
AB Aims and objectives. To identify and describe nursing actions performed by nurses that create a sense of good nursing care in patients with wet age-related macular degeneration.
   Background. People who suffer from wet age-related macular degeneration risk central vision loss. Treatment with antivascular endothelial growth factor is the only available option at present that preserves vision and no definitive cure currently exists. Patients feel that they are compelled to accept this treatment because they might otherwise become blind.
   Design. An explorative and descriptive design based on the critical incident technique was used.
   Method. Interviews with 16 Swedish patients who all had received intravitreal treatment for wet age-related macular degeneration.
   Results. Two main areas of good nursing care were identified: 'Being perceived as an individual' and 'Being empowered'. The first area was divided into two categories: being respectful and being engaged. Being respectful was observed when nurses had a benevolent attitude towards their patients and answered questions kindly and politely. Patients saw themselves as individuals when nurses were available for conversation and focused on them. The second area was divided into two categories: encouraging participation and creating confidence. Encouraging participation refers to when nurses provided information continuously. Nurses instilled confidence and trust in their patients by keeping promises and by being honest.
   Conclusions. A respectful interaction between patients and caregivers is necessary for patients to obtain beneficial health care.
   Relevance to clinical practice. Patient interviews revealed important information about nursing actions that created a sense of good nursing care in patients with wet age-related macular degeneration. Nurses acknowledged people as individuals and created trust by building partnerships and sharing decision-making. To address each patient's concerns, nurses need to prioritise each patient's narrative and participation by documenting agreements in their medical record.
C1 [Emsfors, Asa] Cent Hosp Kristianstad, Dept Ophthalmol, SE-29185 Kristianstad, Sweden.
   [Christensson, Lennart] Jonkoping Univ, Sch Hlth & Welf, Dept Nursing Sci, Jonkoping, Sweden.
   [Elgan, Carina] Kristianstad Univ, Sch Hlth & Soc, Kristianstad, Sweden.
C3 Jonkoping University; Kristianstad University
RP Emsfors, A (通讯作者)，Cent Hosp Kristianstad, Dept Ophthalmol, SE-29185 Kristianstad, Sweden.
EM Asa.RonnEmsfors@skane.se
FU Bayer HealthCare, Stockholm, Sweden
FX We thank all participants who contributed to the study and shared their
   experiences and thoughts. The study was supported by Bayer HealthCare,
   Stockholm, Sweden.
CR Attree M, 2001, J ADV NURS, V33, P456, DOI 10.1046/j.1365-2648.2001.01689.x
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Edvardsson D, 2010, PERSONCENTRERAD OMVA
   Edvardsson JD, 2005, SCAND J CARING SCI, V19, P344, DOI 10.1111/j.1471-6712.2005.00356.x
   Ekman I, 2011, EUR J CARDIOVASC NUR, V10, P248, DOI 10.1016/j.ejcnurse.2011.06.008
   Eldh AC, 2006, NURS ETHICS, V13, P503, DOI 10.1191/0969733006nej898oa
   Eriksson K, 2016, INT J NURS STUD, V56, P27, DOI 10.1016/j.ijnurstu.2015.12.008
   FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hudon C, 2012, PATIENT EDUC COUNS, V88, P170, DOI 10.1016/j.pec.2012.01.009
   Kemppainen JK, 2000, J ADV NURS, V32, P1264, DOI 10.1046/j.1365-2648.2000.01597.x
   Kim J, 2010, JPN J OPHTHALMOL, V54, P325, DOI 10.1007/s10384-010-0825-x
   Larsson IE, 2011, SCAND J CARING SCI, V25, P575, DOI 10.1111/j.1471-6712.2010.00866.x
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   National Association for Ophthalmic Nurses and The Swedish Society of Nursing, 2009, DESCR QUAL REQ REG N
   Pennbrant S, 2013, RES AGING, V35, P163, DOI 10.1177/0164027512436430
   Ronn Emsfors A, 2013, INT J OPHTHALMIC PRA, V4, P4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schluter J, 2008, J ADV NURS, V61, P107, DOI 10.1111/j.1365-2648.2007.04490.x
   Slater Lynne, 2006, Contemp Nurse, V23, P135
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Suhonen R, 2012, SCAND J CARING SCI, V26, P372, DOI 10.1111/j.1471-6712.2011.00943.x
   Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), 2008, RAN TREAT AG REL MAC
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
NR 29
TC 7
Z9 7
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD SEP
PY 2017
VL 26
IS 17-18
BP 2680
EP 2688
DI 10.1111/jocn.13749
PG 9
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA FF4LJ
UT WOS:000408919200016
PM 28152206
DA 2022-11-30
ER

PT J
AU Song, M
   Chen, BH
AF Song, Mi
   Chen, Baihua
TI The Association Between Consumption of 100% Fruit Juice and Risk of
   Age-Related Macular Degeneration: Data From the National Health and
   Nutrition Examination Survey Database
SO FRONTIERS IN NUTRITION
LA English
DT Article
DE association; 100% fruit juice; pure juice; age-related macular
   degeneration; NHANES
ID BEVERAGE CONSUMPTION; PREVALENCE; CHILDREN; OBESITY
AB Age-related macular degeneration (AMD) is the main irreversible blindness disease worldwide. The current study aimed to investigate whether the consumption of 100% fruit juice increases the risk of age-related macular degeneration and find approaches to prevent and reduce the development of age-related macular degeneration from the aspect of dietary habits. A cross-sectional clinical study design was adopted. We screened participants from the 2005 to 2006 NHANES database. The logistic regression model was used to evaluate the relationship between 100% fruit juice consumption and advanced AMD and to adjust variables such as demographics, general health status, body mass index (BMI), health-related behaviors, systemic complications, and ophthalmic complications. The results show that 100% fruit juice consumption did not affect early AMD and any AMD. High consumers of 100% fruit juice are more likely to develop advanced age-related macular degeneration than those who never drink 100% fruit juice.
C1 [Song, Mi; Chen, Baihua] Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Peoples R China.
   [Song, Mi; Chen, Baihua] Hunan Clin Res Ctr Ophthalm Dis, Changsha, Peoples R China.
C3 Central South University
RP Chen, BH (通讯作者)，Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Peoples R China.; Chen, BH (通讯作者)，Hunan Clin Res Ctr Ophthalm Dis, Changsha, Peoples R China.
EM chenbaihua2017@csu.edu.cn
CR Agarwal S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102513
   Atkinson FS, 2008, DIABETES CARE, V31, P2281, DOI 10.2337/dc08-1239
   Auerbach BJ, 2018, ADV NUTR, V9, P78, DOI 10.1093/advances/nmx006
   Auerbach BJ, 2018, PREV MED, V109, P8, DOI 10.1016/j.ypmed.2018.01.004
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Bortsov AV, 2011, ACTA DIABETOL, V48, P275, DOI 10.1007/s00592-010-0246-9
   Davidson TL, 2004, INT J OBESITY, V28, P933, DOI 10.1038/sj.ijo.0802660
   DellaValle DM, 2005, APPETITE, V44, P187, DOI 10.1016/j.appet.2004.11.003
   Dennison BA, 1997, PEDIATRICS, V99, P15
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gardener H, 2012, J GEN INTERN MED, V27, P1120, DOI 10.1007/s11606-011-1968-2
   Guasch-Ferre M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3109
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hyson DA, 2015, ADV NUTR, V6, P37, DOI 10.3945/an.114.005728
   Imamura F, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3576
   Khan TA, 2019, EUR J CLIN NUTR, V73, P1556, DOI 10.1038/s41430-019-0514-x
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061420
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Miller C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030817
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nunes PM, 2021, NATURE, V597, P180, DOI 10.1038/d41586-021-02195-1
   Qiu M, 2017, OPHTHALMOLOGY, V124, P1229, DOI 10.1016/j.ophtha.2017.03.049
   Ravn-Haren G, 2013, EUR J NUTR, V52, P1875, DOI 10.1007/s00394-012-0489-z
   Shefferly A, 2016, PEDIATR OBES, V11, P221, DOI 10.1111/ijpo.12048
   Swithers SE, 2008, BEHAV NEUROSCI, V122, P161, DOI 10.1037/0735-7044.122.1.161
   U.S. Department of Agriculture Agricultural Research Service, 2016, DOC US GUID COMP FOO
   US Department of Health and Human Services and US Department of Agriculture, 2015, DIET GUID AM 2015 20, V8
   van Grieken A, 2015, PEDIATR OBES, V10, P126, DOI 10.1111/ijpo.235
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Walker RW, 2014, NUTRITION, V30, P928, DOI 10.1016/j.nut.2014.04.003
   Wang YC, 2008, PEDIATRICS, V121, pE1604, DOI 10.1542/peds.2007-2834
   WHO, 2015, WHONMHNHD152
   Wojcicki JM, 2012, AM J PUBLIC HEALTH, V102, P1630, DOI 10.2105/AJPH.2012.300719
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093471
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 40
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD APR 21
PY 2022
VL 9
AR 812476
DI 10.3389/fnut.2022.812476
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 1R2MT
UT WOS:000803210100001
PM 35529466
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sawada, T
   Wang, XY
   Sawada, O
   Saishin, Y
   Ohji, M
AF Sawada, Tomoko
   Wang, Xiying
   Sawada, Osamu
   Saishin, Yoshitsugu
   Ohji, Masahito
TI Aqueous vascular endothelial growth factor and aflibercept
   concentrations after bimonthly intravitreal injections of aflibercept
   for age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; aqueous; bimonthly
   intravitreal injections; vascular endothelial growth factor
ID CHOROIDAL NEOVASCULAR MEMBRANES; EPITHELIUM-DERIVED FACTOR; INTRAOCULAR
   PHARMACOKINETICS; DIABETIC-RETINOPATHY; VITREOUS LEVELS; HUMOR LEVELS;
   VEGF-TRAP; RANIBIZUMAB; BEVACIZUMAB; SUPPRESSION
AB ImportanceClinical evidence supports the efficacy of bimonthly aflibercept injection for age-related macular degeneration.
   BackgroundThe study aimed to evaluate aqueous vascular endothelial growth factor and aflibercept concentrations and the efficacy of bimonthly aflibercept in patients with age-related macular degeneration.
   DesignThis study is a prospective, interventional case series.
   ParticipantsEnrolled were 35 eyes with exudative age-related macular degeneration from 35 patients.
   MethodsPatients received three bimonthly intravitreal aflibercept without loading doses. We collected the aqueous humor just before each injection, measured vascular endothelial growth factor and aflibercept concentrations by enzyme-linked immunosorbent assay and measured best-corrected visual acuity and central retinal subfield thickness before and after the injections.
   Main outcome measuresAqueous vascular endothelial growth factor and aflibercept concentrations were measured.
   ResultsThe vascular endothelial growth factor concentration was 135.460.5pg/mL (mean +/- standard deviation, range 60.6-323.4) at baseline and below the lowest detectable limit in all eyes at month 2 and in 32 eyes at month 4 (P<0.001 [month 2] and P<0.001 [month 4]). The mean aflibercept concentration was 20.3ng/mL at month 2 and 28.0ng/mL at month 4. The mean logarithm of the minimum angle of resolution visual acuity improved from 0.50 +/- 0.36 at baseline to 0.36 +/- 0.40 at month 6 (P<0.001). The mean central retinal subfield thickness decreased from 353 +/- 100m at baseline to 236 +/- 45m at month 6 (P<0.001).
   Conclusions and RelevanceBimonthly aflibercept injections without loading doses may be considered a treatment option for age-related macular degeneration.
C1 [Sawada, Tomoko; Sawada, Osamu; Saishin, Yoshitsugu; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
   [Wang, Xiying] Harbin Med Univ, Hosp Eye, Affiliated Hosp 1, Key Lab,Harbin Med Univ Eye Ctr, Harbin, Heilongjiang, Peoples R China.
C3 Shiga University of Medical Science; Harbin Medical University
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Klaver CC, 1988, ARCH OPHTHALMOL-CHIC, V116, P653
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Sawada T, 2014, GRAEF ARCH CLIN EXP, V252, P1545, DOI 10.1007/s00417-014-2612-8
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   US Food and Drug Administration, 2011, FDA LAB INF EYL
   Wang XY, 2014, GRAEF ARCH CLIN EXP, V252, P1033, DOI 10.1007/s00417-013-2505-2
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 38
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2018
VL 46
IS 1
BP 46
EP 53
DI 10.1111/ceo.13002
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW6WF
UT WOS:000425459600007
PM 28621038
DA 2022-11-30
ER

PT J
AU Markowitz, SN
   Devenyi, RG
   Munk, MR
   Croissant, CL
   Tedford, SE
   Ruckert, R
   Walker, MG
   Patino, BE
   Chen, LN
   Nido, M
   Tedford, CE
AF Markowitz, Samuel N.
   Devenyi, Robert G.
   Munk, Marion R.
   Croissant, Cindy L.
   Tedford, Stephanie E.
   Ruckert, Rene
   Walker, Michael G.
   Patino, Beatriz E.
   Chen, Lina
   Nido, Monica
   Tedford, Clark E.
TI A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH
   PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dry age-related macular degeneration; drusen; light-emitting diode;
   low-level light therapy; photobiomodulation; vision loss; best-corrected
   visual acuity; mitochondria; contrast sensitivity
ID THERAPY IMPROVES VISION; LASER THERAPY; VISUAL-ACUITY; EYE DISEASE;
   GEOGRAPHIC ATROPHY; LEVEL; PROGRESSION; PERSPECTIVES; IRRADIATION;
   DRUSEN
AB Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3x per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments. Results: Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of >= 5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (>= 5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P< 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P< 0.05). No device-related adverse events were reported. Conclusion: Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.
C1 [Markowitz, Samuel N.; Devenyi, Robert G.; Patino, Beatriz E.; Chen, Lina; Nido, Monica] Univ Toronto, Dept Ophthalmol, Toronto, ON, Canada.
   [Devenyi, Robert G.] Univ Hlth Network, Dept Ophthalmol, Toronto, ON, Canada.
   [Munk, Marion R.] Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Croissant, Cindy L.; Tedford, Stephanie E.; Tedford, Clark E.] LumiThera Inc, Poulsho, WA USA.
   [Ruckert, Rene] Eyegnos Consulting, Bern, Switzerland.
   [Walker, Michael G.] Walker Biosci, Carlsbad, CA USA.
C3 University of Toronto; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto; University of Bern;
   University Hospital of Bern
RP Tedford, CE (通讯作者)，19332 Powder Hill Pl, Poulsbo, WA 98370 USA.
EM ctedford@lumithera.com
RI Nido, Monica Daibert/AAP-8842-2021
OI Nido, Monica Daibert/0000-0001-7930-4207
FU National Institutes of Health, National Eye Institute
   [3R43EY025508-01S1]
FX The sponsor supported clinical site costs, data management, data
   analysis, and preparation of the manuscript. The study was partially
   supported by the National Institutes of Health, National Eye Institute
   #3R43EY025508-01S1.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7
   Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023
   Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S
   Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Ivandic BT, 2014, PHOTOMED LASER SURG, V32, P181, DOI 10.1089/pho.2013.3535
   Ivandic BT, 2012, PHOTOMED LASER SURG, V30, P167, DOI 10.1089/pho.2011.3089
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3
   Qin S, 2008, J INFLAMM RES, V1, P49
   Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Tang J, 2013, INVEST OPHTH VIS SCI, V54, P3681, DOI 10.1167/iovs.12-11018
   Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 34
TC 20
Z9 20
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1471
EP 1482
DI 10.1097/IAE.0000000000002632
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400015
PM 31404033
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Kunimoto, D
   Ohji, M
   Maturi, RK
   Sekiryu, T
   Md, YW
   Pan, G
   Li, XY
   Schneider, S
   Iida, T
   Kakinoki, M
   Kawamura, H
   Mori, R
   Musashi, K
   Oshima, Y
   Otake, H
   Sakanishi, Y
   Sawada, T
   Sekiryu, T
   Takeuchi, S
   Terasaki, H
   Callanan, D
   Chu, T
   Gupta, S
   Izad, A
   Kunimoto, D
   Maturi, R
   Patel, S
AF Kunimoto, Derek
   Ohji, Masahito
   Maturi, Raj K.
   Sekiryu, Tetsuju
   Md, Ying Wang
   Pan, Grace
   Li, Xiao-Yan
   Schneider, Susan
   Iida, Tomohiro
   Kakinoki, Masashi
   Kawamura, Hajime
   Mori, Ryusaburou
   Musashi, Kunihiro
   Oshima, Yuji
   Otake, Hiroshi
   Sakanishi, Yoshihito
   Sawada, Tomoko
   Sekiryu, Tetsuju
   Takeuchi, Shinobu
   Terasaki, Hiroko
   Callanan, David
   Chu, Thomas
   Gupta, Sunil
   Izad, Alexander
   Kunimoto, Derek
   Maturi, Raj
   Patel, Sunil
CA BAMBOO Study Grp
   CYPRESS Study Grp
TI Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in
   Patients With Neovascular Age-Related Macular Degeneration: Studies in
   Japan and the United States
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   VISION-RELATED FUNCTION; ANKYRIN REPEAT PROTEIN; RANIBIZUMAB TREATMENT;
   AFLIBERCEPT; TRIAL; TRAP; EYE
AB BACKGROUND AND OBJECTIVE: To evaluate comparability of abicipar petrol (abicipar) effects in patients with treatment-naive neovaseular age-related macular degeneration (nAMD) in Japan and the United States.
   PATIENTS AND METHODS: Phase 2, multicenter, randomized, double-masked, 20-week studies (BAMBOO, Japan; CYPRESS, United States). Patients (n = 25 each study) received three monthly intravitreal injections of abicipar 1 mg or 2 mg or five monthly intravitreal injections of ranibizumab 0.5 mg.
   RESULTS: Mean best-corrected visual acuity change from baseline at week 16 (primary endpoint) for abicipar 1 mg, abicipar 2 mg, and ranibizumab was +7.8 letters, +8.9 letters, and +17.4 letters (BAMBOO); +4.4 letters, +10.1 letters, and +15.2 letters (CYPRESS). Mean central retinal thickness change from baseline was -187.3 mu m, -196.5 pm, and -230.4 mu m (BAMBOO); -106.5 mu m, -112.8 mu m, and -124.4 mu m (CYPRESS). Uveitis or vitritis was reported in three abicipar-treated patients.
   CONCLUSION: Abicipar demonstrated extended duration of effect and safety that were comparable between Japanese and non-Japanese patients with nAMD. Abicipar effectively treated Japanese patients with polypoidal choroidal vasculopathy.
C1 [Kunimoto, Derek] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Shiga, Japan.
   [Maturi, Raj K.] Midwest Eye Inst, Indianapolis, IN USA.
   [Maturi, Raj K.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan.
   [Md, Ying Wang; Pan, Grace; Li, Xiao-Yan; Schneider, Susan] Allergan Plc, Irvine, CA USA.
C3 Shiga University of Medical Science; Indiana University System; Indiana
   University Bloomington; Fukushima Medical University; AbbVie; Allergan
RP Kunimoto, D (通讯作者)，2152 S Vineyard,Suite 139,Bldg 12, Mesa, AZ 85210 USA.
EM derek_kunimoto@yahoo.com
RI Otake, Hiroshi/AAB-1327-2020
OI Otake, Hiroshi/0000-0002-4776-3211; Sekiryu, Tetsuju/0000-0001-8042-2729
CR Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hirakata T, 2016, CLIN OPHTHALMOL, V10, P969, DOI 10.2147/OPTH.S101596
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim JH, 2017, J OCUL PHARMACOL TH, V33, P445, DOI 10.1089/jop.2016.0098
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smithwick Elizabeth, 2017, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V16, P33, DOI 10.2174/1871523016666170502115816
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 28
TC 17
Z9 17
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2019
VL 50
IS 2
BP E10
EP E22
DI 10.3928/23258160-20190129-13
PG 13
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HL6KP
UT WOS:000458843200002
PM 30768224
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Hariprasad, SM
   Shah, GK
AF Hariprasad, SM
   Shah, GK
TI Treatment of juxtafoveal choroidal neovascularization with photodynamic
   therapy using verteporfin in eyes with age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; PHOTOCOAGULATION
AB To report the results of treating juxtafoveal choroidal neovascularization with photodynamic therapy using verteporfin in eyes with age-related macular degeneration. Seven patients with predominantly classic juxtafoveal choroidal neovascularization were treated by photodynamic therapy using verteporfin. Three of the 7 patients had a gain in visual acuity and 2 had a stabilization of vision. The remaining 2 patients had a decrease in visual acuity. Subfoveal extension of the choroidal neovascularization was not observed in any patient and all choroidal neovascularization lesions after treatment were found to be nonperfused on fluorescein angiography. The encouraging results based on this small pilot study suggest that photodynamic therapy should be considered for treatment of select juxtafoveal choroidal neovascularization due to age-related macular degeneration.
C1 Barnes Retina Inst, St Louis, MO 63144 USA.
C3 Washington University (WUSTL)
RP Shah, GK (通讯作者)，Barnes Retina Inst, 1600 S Brentwood Blvd,8th Floor, St Louis, MO 63144 USA.
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRANCATO R, 1990, RETINA-J RET VIT DIS, V10, P239, DOI 10.1097/00006982-199010000-00002
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Jampol LM, 2002, AM J OPHTHALMOL, V134, P99, DOI 10.1016/S0002-9394(02)01463-0
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2005
VL 36
IS 3
BP 258
EP 260
DI 10.3928/1542-8877-20050501-16
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 926KO
UT WOS:000229122300014
PM 15957487
DA 2022-11-30
ER

PT J
AU Blair, MP
   Gupta, M
   Blair, NP
   Shahidi, M
AF Blair, Michael P.
   Gupta, Mayank
   Blair, Norman P.
   Shahidi, Mahnaz
TI Association Between Retinal Thickness and Retinal Pigment Epithelium
   Elevation in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION
AB BACKGROUND AND OBJECTIVE: To determine the association between retinal pigment epithelium elevation and maxmium retinal thickness in patients with age-related macular degeneration.
   PATIENTS AND METHODS: Fifteen patients (mean age = 76 +/- 8 years) with age-related macular degeneration and pigment epithelial detachment under went optical coherence tomography The images were analyzed by two observers to measure maximum retinal thickness and the width and maximum height of the pigment epithelial detachment. Linear regression analysis was performed to determine the association between maximum retinal thickness and retinal pigments epithelium elevation.
   RESULTS: The results indicated high correlations between observers in identifying pigment epithelial detachment edges and measuring retinal pigment epithelium elevation and maximum retinal thickness. Pigment epithelial detachment height ranged from 82 to 599 microns. Mean maximum retoma thickness was 424 +/- 150 microns. Increased maximum retinal thickness was associated with more elevated retinal pigment epithelium (r = 0.7; P = .003).
   CONCLUSION: Retinal thickness was associated with pigment epithelial detachment height, warranting future investigations into pathophysiologic mechanisms leading to and potential treatment for pigment epithelial detachment and associated retinal thickening.
C1 [Blair, Michael P.; Gupta, Mayank; Blair, Norman P.; Shahidi, Mahnaz] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Shahidi, M (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
FU NATIONAL EYE INSTITUTE [R01EY014275, P30EY001792] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY14275, EY01792] Funding Source: Medline
CR Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh Rishi, 2007, International Ophthalmology Clinics, V47, P65, DOI 10.1097/IIO.0b013e31802bd6b3
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 9
TC 3
Z9 3
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2010
VL 41
IS 2
BP 175
EP 181
DI 10.3928/15428877-20100303-04
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 569OG
UT WOS:000275606400004
PM 20307034
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Olson, LM
   Schnetz-Boutaud, N
   Gallins, P
   Agarwal, A
   Iannaccone, A
   Kritchevsky, SB
   Garcia, M
   Nalls, MA
   Newman, AB
   Scott, WK
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Olson, Lana M.
   Schnetz-Boutaud, Nathalie
   Gallins, Paul
   Agarwal, Anita
   Iannaccone, Alessandro
   Kritchevsky, Stephen B.
   Garcia, Melissa
   Nalls, Michael A.
   Newman, Anne B.
   Scott, William K.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Using Genetic Variation and Environmental Risk Factor Data to Identify
   Individuals at High Risk for Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; PIGMENT OPTICAL-DENSITY; BREAST-CANCER;
   UNITED-STATES; FACTOR-B; ASSOCIATION; POLYMORPHISM; DISEASE; VARIANT;
   SUSCEPTIBILITY
AB A major goal of personalized medicine is to pre-symptomatically identify individuals at high risk for disease using knowledge of each individual's particular genetic profile and constellation of environmental risk factors. With the identification of several well-replicated risk factors for age-related macular degeneration (AMD), the leading cause of legal blindness in older adults, this previously unreachable goal is beginning to seem less elusive. However, recently developed algorithms have either been much less accurate than expected, given the strong effects of the identified risk factors, or have not been applied to independent datasets, leaving unknown how well they would perform in the population at large. We sought to increase accuracy by using novel modeling strategies, including multifactor dimensionality reduction (MDR) and grammatical evolution of neural networks (GENN), in addition to the traditional logistic regression approach. Furthermore, we rigorously designed and tested our models in three distinct datasets: a Vanderbilt-Miami (VM) clinic-based case-control dataset, a VM family dataset, and the population-based Age-related Maculopathy Ancillary (ARMA) Study cohort. Using a consensus approach to combine the results from logistic regression and GENN models, our algorithm was successful in differentiating between high- and low-risk groups (sensitivity 77.0%, specificity 74.1%). In the ARMA cohort, the positive and negative predictive values were 63.3% and 70.7%, respectively. We expect that future efforts to refine this algorithm by increasing the sample size available for model building, including novel susceptibility factors as they are discovered, and by calibrating the model for diverse populations will improve accuracy.
C1 [Spencer, Kylee L.; Olson, Lana M.; Schnetz-Boutaud, Nathalie; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA.
   [Gallins, Paul; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA.
   [Iannaccone, Alessandro] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Memphis, TN USA.
   [Kritchevsky, Stephen B.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
   [Garcia, Melissa] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
   [Nalls, Michael A.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA.
   [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
C3 Vanderbilt University; University of Miami; Vanderbilt University;
   University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; Wake Forest University; National Institutes of Health
   (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes
   of Health (NIH) - USA; NIH National Institute on Aging (NIA);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Spencer, KL (通讯作者)，Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA.
EM Kylee.Spencer@vanderbilt.edu
RI Haines, Jonathan/C-3374-2012; Newman, Anne B./C-6408-2013
OI Haines, Jonathan/0000-0002-4351-4728; Newman, Anne
   B./0000-0002-0106-1150; Iannaccone, Alessandro/0000-0001-5737-8424;
   Kritchevsky, Stephen/0000-0003-3336-6781; Scott,
   William/0000-0001-9336-6404
FU National Institutes of Health (NIH)/National Eye Institute [EY12118,
   EY000409]; NIH/National Institute on Aging (NIA) [N01-AG-6-2101,
   N01-AG-6-2103, N01-AG-6-2106]; International Retinal Research
   Foundation, Inc., Birmingham, AL; Research to Prevent Blindness, New
   York, NY; NIH/NIA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY012118, U10EY012118, K23EY000409] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [N01AG062101, N01AG062106, N01AG062103]
   Funding Source: NIH RePORTER
FX This work was supported by grants EY12118 (to M.A.P.-V. and J.L.H.) and
   EY000409 (K23 Award to A.I.) from the National Institutes of Health
   (NIH)/National Eye Institute, contracts N01-AG-6-2101, N01-AG-6-2103,
   N01-AG-6-2106 (to S.B.K.) from the NIH/National Institute on Aging
   (NIA), grants from the International Retinal Research Foundation, Inc.,
   Birmingham, AL (to A.I.), by Research to Prevent Blindness, New York, NY
   (Career Development Award to A.I. and an unrestricted grant to the UTHSC
   Hamilton Eye Institute), and in part by the Intramural Research Program
   of the NIH/NIA. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janssens ACJW, 2007, GENET MED, V9, P528, DOI 10.1097/GIM.0b013e31812eece0
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mistry K, 2003, J AM BOARD FAM PRACT, V16, P95, DOI 10.3122/jabfm.16.2.95
   Motsinger-Reif AA, 2008, GENET EPIDEMIOL, V32, P325, DOI 10.1002/gepi.20307
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pepe MS, 2004, STAT EVALUATION MED
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith RA, 2009, CA-CANCER J CLIN, V59, P27, DOI 10.3322/caac.20008
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VELEZ DR, 2007, GENET EPIDEMIOL
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 38
TC 37
Z9 37
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 24
PY 2011
VL 6
IS 3
AR e17784
DI 10.1371/journal.pone.0017784
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 740RG
UT WOS:000288811500009
PM 21455292
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shin, JY
   Kwon, KY
   Byeon, SH
AF Shin, Joo Youn
   Kwon, Kye Yoon
   Byeon, Suk Ho
TI Association between choroidal thickness and the response to intravitreal
   ranibizumab injection in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; choroidal thickness; optical coherence tomography; polypoidal
   choroidal vasculopathy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; HEALTHY EYES; CHORIOCAPILLARIS;
   VASCULOPATHY; BEVACIZUMAB; COMBINATION; PATTERNS
AB Purpose: To investigate the relationship between the choroidal thicknesses of eyes of patients with age-related macular degeneration (AMD) and the outcomes of intravitreal ranibizumab injection.
   Methods: We reviewed the medical records of 141 consecutive eyes (80 with typical neovascular AMD and 61 with polypoidal choroidal vasculopathy [PCV]) treated by intravitreal ranibizumab and 121 normal control eyes matched in terms of age and spherical equivalent (SE). Eyes of patients were divided into three subgroups with thin, medium and thick choroids. We investigated the relationships between choroidal thickness and treatment outcomes of intravitreal ranibizumab.
   Results: In eyes with typical neovascular AMD, thin choroids were associated with older age (linear regression; p < 0.0001) and larger choroidal neovascularization (CNV) lesions (p = 0.049). Patients with thin choroids had a higher prevalence of intra-/subretinal fluid (generalized estimated equation; thin versus medium p < 0.0001; thin versus thick p = 0.003), and less visual gain from baseline to 12 months after treatment, than did other subgroups (linear mixed model; thin versus medium p < 0.0001; thin versus thick p = 0.023). PCV eyes with thick choroids more often had retinal fluid, and eyes with thin choroids experienced more frequent resolution of retinal fluid, from baseline to 12 months after treatment (thick versus medium p < 0.0001, thick versus thin p < 0.0001, thin versus medium p = 0.001). No intergroup difference in post-treatment functional outcome was noted in eyes with PCV (p = 0.584).
   Conclusions: Subfoveal choroidal thickness was associated with functional and anatomical outcomes after intravitreal ranibizumab injection in eyes with typical neovascular AMD and PCV.
C1 [Shin, Joo Youn; Kwon, Kye Yoon; Byeon, Suk Ho] Yonsei Univ, Coll Med, Dept Ophthalmol, Severance Hosp,Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM shbyeon@yuhs.ac
OI Shin, Joo Youn/0000-0003-4543-477X; Byeon, suk ho/0000-0001-8101-0830
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF) - Ministry of Education [2013R1A1A2007865]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2013R1A1A2007865). The authors want to thank Jung Hwa
   Hong, Mi Kyung Song (Biostatistics Collaboration Unit, Yonsei University
   College of Medicine) for statistical support (generalized estimate
   equation and linear mixed model).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   FRIEDMAN E, 1964, ARCH OPHTHALMOL-CHIC, V71, P842
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 41
TC 23
Z9 23
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2015
VL 93
IS 6
BP 524
EP 532
DI 10.1111/aos.12653
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS1BO
UT WOS:000361797700031
PM 25581639
OA Bronze
DA 2022-11-30
ER

PT J
AU Rauch, R
   Weingessel, B
   Maca, SM
   Vecsei-Marlovits, PV
AF Rauch, Renate
   Weingessel, Birgit
   Maca, Saskia M.
   Vecsei-Marlovits, Pia V.
TI TIME TO FIRST TREATMENT The Significance of Early Treatment of Exudative
   Age-related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; duration
   of symptoms; ranibizumab
ID RANIBIZUMAB; PREVALENCE
AB Purpose: To determine whether the time span between initial symptoms and treatment with ranibizumab in patients with neovascular age-related macular degeneration has an effect on visual outcome.
   Method: In this retrospective study, 45 patients with exudative age-related macular degeneration were split into 3 groups depending on the duration of visual symptoms-Group I: <1 month, Group II: 1 month to 6 months, and Group III: >6 months. Best-corrected visual acuity, clinical ophthalmologic examination, and central retinal thickness as measured by optical coherence tomography were recorded at baseline and 2 months later. Fluorescein angiography was performed at baseline. Treatment consisted of 2 intravitreal injections of 1.25 mg of ranibizumab at baseline and after 4 weeks.
   Results: The mean time span between initial symptoms and treatment was 59 +/- 62 days. In all groups, a reduction of retinal thickness was observed. Shorter disease duration, as estimated by persistence of visual symptoms, was correlated with a better visual outcome after treatment. Patients in Group I demonstrated a significant increase in best-corrected visual acuity (P = 0.007). Patients of Group II (P = 0.095) and Group III (P = 0.271) still achieved a visual improvement in best-corrected visual acuity, albeit not significant. The mean change in best-corrected visual acuity was 0.08 +/- 0.1 in all patients and was not statistically significant between groups (P = 0.87).
   Conclusion: Duration of visual symptoms <1 month before treatment is associated with a better visual outcome. Treatment of new-onset wet age-related macular degeneration should be initiated as soon as possible. RETINA 32:1260-1264, 2012
C1 [Rauch, Renate; Weingessel, Birgit; Maca, Saskia M.; Vecsei-Marlovits, Pia V.] Hietzing Hosp, Dept Ophthalmol, A-1130 Vienna, Austria.
   [Rauch, Renate; Weingessel, Birgit; Maca, Saskia M.; Vecsei-Marlovits, Pia V.] Karl Landsteiner Inst Proc Optimizat & Qual Manag, Vienna, Austria.
C3 Hietzing Hospital
RP Vecsei-Marlovits, PV (通讯作者)，Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.
EM veronika.vecsei-marlovits@wienkav.at
RI Weingessel, Birgit/ABD-5201-2021; Weingessel, Birgit/AAM-6617-2021
OI Weingessel, Birgit/0000-0002-1110-0432; 
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Grover S, 2009, INVEST OPHTHALMOL VI
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 17
TC 38
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2012
VL 32
IS 7
BP 1260
EP 1264
DI 10.1097/IAE.0b013e3182018df6
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 965QK
UT WOS:000305782100005
PM 22186738
DA 2022-11-30
ER

PT J
AU Kankanahalli, S
   Burlina, PM
   Wolfson, Y
   Freund, DE
   Bressler, NM
AF Kankanahalli, Srihari
   Burlina, Philippe M.
   Wolfson, Yulia
   Freund, David E.
   Bressler, Neil M.
TI Automated Classification of Severity of Age-Related Macular Degeneration
   from Fundus Photographs
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISION-RELATED FUNCTION; PHOTODYNAMIC THERAPY; DRUSEN DETECTION; RETINA;
   SEGMENTATION; RANIBIZUMAB; IMAGES; SCALE
AB PURPOSE. To evaluate an automated analysis of retinal fundus photographs to detect and classify severity of age-related macular degeneration compared with grading by the Age-Related Eye Disease Study (AREDS) protocol.
   METHODS. Following approval by the Johns Hopkins University School of Medicine's Institution Review Board, digitized images (downloaded at http://www.ncbi.nlm.nih.gov/gap/) of field 2 (macular) fundus photographs from AREDS obtained over a 12-year longitudinal study were classified automatically using a visual words method to compare with severity by expert graders.
   RESULTS. Sensitivities and specificities, respectively, of automated imaging, when compared with expert fundus grading of 468 patients and 2145 fundus images are: 98.6% and 96.3% when classifying categories 1 and 2 versus categories 3 and 4; 96.1% and 96.1% when classifying categories 1 and 2 versus category 3; 98.6% and 95.7% when classifying category 1 versus category 3; and 96.0% and 94.7% when classifying category 1 versus categories 3 and 4;
   CONCLUSIONS. Development of an automated analysis for classification of age-related macular degeneration from digitized fundus photographs has high sensitivity and specificity when compared with expert graders and may have a role in screening or monitoring. (Invest Ophthalmol Vis Sci. 2013;54:1789-1796) DOI:10.1167/iovs.12-10928
C1 [Kankanahalli, Srihari; Burlina, Philippe M.; Freund, David E.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA.
   [Burlina, Philippe M.] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
   [Burlina, Philippe M.; Wolfson, Yulia; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University Applied Physics
   Laboratory; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine
RP Burlina, PM (通讯作者)，11100 Johns Hopkins Rd, Laurel, MD 20723 USA.
EM philippe.burlina@jhuapl.edu
RI Freund, D.E./AAW-9401-2020
FU Johns Hopkins Applied Physics Laboratory
FX Supported in part by the Johns Hopkins Applied Physics Laboratory under
   internal research and development funds and unrestricted donations to
   the Johns Hopkins University School of Medicine.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study (AREDS) Research Group, DEF FIN AG REL MAC D
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   BREIMAN L, 2001, MACH LEARN, V0045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Checco P, 2006, P IEEE INT S CIRC SY
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duda R. O., 2000, PATTERN CLASSIFICATI, V2nd
   Fei-Fei L, 2005, PROC CVPR IEEE, P524
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Giancardo L, 2008, THESIS U BOURGOGNE B
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Jain A. K., 1989, FUNDAMENTALS DIGITAL
   Karnowski TP, 2008, IEEE ENG MED BIO, P5433, DOI 10.1109/IEMBS.2008.4650443
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee N, 2008, I S BIOMED IMAGING, P1215, DOI 10.1109/ISBI.2008.4541221
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2006, MED IMAGE ANAL, V10, P888, DOI 10.1016/j.media.2006.09.006
   Parvathi SS, 2007, P INT C COMP INT MUL
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Santos-Villalobos H, 2011, IEEE ENG MED BIO, P6236, DOI 10.1109/IEMBS.2011.6091540
   Sbeh B, 1997, P 1997 INT C IM PROC
   Scotland GS, 2010, BRIT J OPHTHALMOL, V94, P712, DOI 10.1136/bjo.2008.151126
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Thaibaoui A, 2000, INT C PATT RECOG, P748, DOI 10.1109/ICPR.2000.903025
   US Department of Commerce US Census Bureau, 2012 STAT ABSTR NAT
NR 31
TC 27
Z9 28
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 1789
EP 1796
DI 10.1167/iovs.12-10928
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400029
PM 23361512
DA 2022-11-30
ER

PT J
AU Shijo, T
   Sakurada, Y
   Yoneyama, S
   Kikushima, W
   Sugiyama, A
   Matsubara, M
   Fukuda, Y
   Mabuchi, F
   Kashiwagi, K
AF Shijo, Taiyo
   Sakurada, Yoichi
   Yoneyama, Seigo
   Kikushima, Wataru
   Sugiyama, Atsushi
   Matsubara, Mio
   Fukuda, Yoshiko
   Mabuchi, Fumihiko
   Kashiwagi, Kenji
TI Association between Polygenic Risk Score and One-Year Outcomes Following
   As-Needed Aflibercept Therapy for Exudative Age-Related Macular
   Degeneration
SO PHARMACEUTICALS
LA English
DT Article
DE age-related macular degeneration; polygenic risk score; aflibercept
   therapy; treatment outcomes; ARMS2; CFH
ID SUBFOVEAL CHOROIDAL THICKNESS; RANIBIZUMAB INJECTIONS; VEGF-TRAP; A69S
AB We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (n = 129) and polypoidal choroidal vasculopathy (n = 132). A total of 261 patients were treated with as-needed intravitreal aflibercept injection (IAI) after three monthly IAIs and the completion of a one-year follow-up. One hundred and seventy-two healthy volunteers served as controls. Genotyping of ARMS2 A69S (rs10490924), CFH I62V (rs800292), SKIV2L-C2-CFB (rs429608), C3 (rs2241394), ADAMTS-9 (rs6795735) and CETP (rs3764261) was performed for all participants. A total of 63 PRSs were quantified. There was a positive association between the PRS involving ARMS2, CFH, C3, and ADAMTS-9 and best-corrected visual acuity at twelve months (p = 0.046, multiple regression analysis). When comparing PRSs of patients requiring retreatment and of patients without retreatment, 35 PRSs were significantly greater in patients requiring retreatment than in patients without requiring retreatment, with the PRS involving ARMS2 and CFH being most significantly associated (p = 1.6 x 10(-4)). The number of additional injections was significantly associated with 40 PRSs and the PRS involving ARMS2 and CFH showed a most significant p-value (p = 2.42 x 10(-6)). Constructing a PRS using a combination with high-risk variants might be informative for predicting the response to IAI for exudative AMD.
C1 [Shijo, Taiyo; Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Sugiyama, Atsushi; Matsubara, Mio; Fukuda, Yoshiko; Mabuchi, Fumihiko; Kashiwagi, Kenji] Univ Yamanashi, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093898, Japan.
EM tshijoh@yamanashi.ac.jp; sakurada@yamanashi.ac.jp;
   syoneyama@yamanashi.ac.jp; wkikushima@yamanashi.ac.jp;
   asugiyama@yamanashi.ac.jp; miom@yamanashi.ac.jp;
   ysugiyama@yamanashi.ac.jp; mabuchif-oph@umin.ac.jp;
   kenjik@yamanashi.ac.jp
OI Kashiwagi, Kenji/0000-0001-8506-8503
CR Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Fan BJ, 2019, JAMA OPHTHALMOL, V137, P1190, DOI 10.1001/jamaophthalmol.2019.3109
   Fukuda Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082459
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mabuchi F, 2020, AM J OPHTHALMOL, V215, P135, DOI 10.1016/j.ajo.2020.03.014
   Mabuchi F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183709
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsubara M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237330
   Nannini DR, 2018, OPHTHALMOLOGY, V125, P815, DOI 10.1016/j.ophtha.2017.12.014
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2018, GRAEF ARCH CLIN EXP, V256, P99, DOI 10.1007/s00417-017-3847-y
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Sugiyama A, 2018, OPHTHALMOLOGICA, V239, P52, DOI 10.1159/000480439
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 31
TC 4
Z9 4
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD SEP
PY 2020
VL 13
IS 9
AR 257
DI 10.3390/ph13090257
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OF9BR
UT WOS:000581493900001
PM 32962278
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Berenberg, TL
   Metelitsina, TI
   Madow, B
   Dai, Y
   Ying, GS
   Dupont, JC
   Grunwald, L
   Brucker, AJ
   Grunwald, JE
AF Berenberg, Thomas L.
   Metelitsina, Tatyana I.
   Madow, Brian
   Dai, Yang
   Ying, Gui-Shuang
   Dupont, Joan C.
   Grunwald, Lili
   Brucker, Alexander J.
   Grunwald, Juan E.
TI THE ASSOCIATION BETWEEN DRUSEN EXTENT AND FOVEOLAR CHOROIDAL BLOOD FLOW
   IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; laser Doppler flowmetry; drusen;
   drusen quantification; choroidal blood flow; computer program
ID FUNDUS; CIRCULATION
AB Purpose: To investigate the relationship between drusen extent and foveolar choroidal blood flow in nonexudative age-related macular degeneration.
   Methods: Total drusen area, average druse area, and total drusen number were determined using a computer program developed to quantify the extent of manually outlined drusen from fundus photographs of 157 patients (239 eyes) with nonexudative age-related macular degeneration. Laser Doppler flowmetry was used to assess relative choroidal blood velocity (ChB(Vel)), volume (ChB(Vol)), and flow (ChB(Flow)) in the center of the fovea.
   Results: We found a significant inverse relationship between total drusen area and ChB(Vol) or ChB(Flow). For every 1-mm(2) increase in total drusen area, ChB(Vol) decreased by 0.0061 arbitrary units (P = 0.03) and ChB(Flow) decreased by 0.23 arbitrary units (P = 0.049). Average druse area was also significantly inversely related to ChB(Vol) and ChB(Flow). For every 0.01-mm(2) increase in average druse area, the ChB(Vol) decreased by 0.0149 arbitrary units (P = 0.001) and the ChB(Flow) decreased by 0.4951 arbitrary units (P = 0.003). Adjustment for age weakened the significance, although it remained strong for average druse area versus ChB(Flow) (P = 0.017) and ChB(Vol) (P = 0.004). The computer-aided quantification of drusen used in this study showed high intra- and intergrader agreement.
   Conclusion: In patients with nonexudative age-related macular degeneration, there is an association between increased drusen extent and decreased ChB(Vol) and ChB(Flow). This suggests the presence of ischemia and possibly the reason why patients with high-risk drusen are prone to advanced disease. RETINA 32:25-31, 2012
C1 [Berenberg, Thomas L.; Metelitsina, Tatyana I.; Madow, Brian; Dai, Yang; Ying, Gui-Shuang; Dupont, Joan C.; Grunwald, Lili; Brucker, Alexander J.; Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juan.grunwald@uphs.upenn.edu
FU National Eye Institute [EY12769]; Vivian Simkins Lasko Research Fund;
   Nina C. Mackall Trust; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [R01EY012769] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Grant EY12769, the Vivian
   Simkins Lasko Research Fund, the Nina C. Mackall Trust, and an
   unrestricted grant from the Research to Prevent Blindness.
CR [Anonymous], 1997, OPHTHALMOLOGY, V105, P11
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Riva CE, 1996, OCULAR BLOOD FLOW, P128
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva Charles E., 2001, International Ophthalmology, V23, P183, DOI 10.1023/A:1014433913240
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
NR 18
TC 66
Z9 66
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2012
VL 32
IS 1
BP 25
EP 31
DI 10.1097/IAE.0b013e3182150483
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 870IE
UT WOS:000298661800005
PM 21878837
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kishan, AU
   Modjtahedi, BS
   Morse, LS
   Lee, P
AF Kishan, Amar U.
   Modjtahedi, Bobeck S.
   Morse, Lawrence S.
   Lee, Percy
TI Radiation Therapy for Neovascular Age-related Macular Degeneration
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PROTON-BEAM IRRADIATION;
   X-RAY-IRRADIATION; ENDOTHELIAL GROWTH-FACTOR; OPHTHALMIC PLAQUE
   RADIOTHERAPY; RANDOMIZED CLINICAL-TRIAL; AMD 6-MONTH SAFETY; LOW-DOSE
   RADIATION; RANIBIZUMAB THERAPY; FOLLOW-UP
AB In the enormity of the public health burden imposed by age-related macular degeneration (ARMD), much effort has been directed toward identifying effective and efficient treatments. Currently, anti-vascular endothelial growth factor (VEGF) injections have demonstrated considerably efficacy in treating neovascular ARMD, but patients require frequent treatment to fully benefit. Here, we review the rationale and evidence for radiation therapy of ARMD. The results of early photon external beam radiation therapy are included to provide a framework for the sequential discussion of evidence for the usage of stereotactic radiation therapy, proton therapy, and brachytherapy. The evidence suggests that these 3 modern modalities can provide a dose-dependent benefit in the treatment of ARMD. Most importantly, preliminary data suggest that all 3 can be used in conjunction with anti-VEGF therapeutics, thereby reducing the frequency of anti-VEGF injections required to maintain visual acuity. (c) 2013 Elsevier Inc.
C1 [Kishan, Amar U.] Harvard Univ, Sch Med, Boston, MA USA.
   [Modjtahedi, Bobeck S.; Morse, Lawrence S.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Lee, Percy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA.
C3 Harvard University; Harvard Medical School; University of California
   System; University of California Davis; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Lee, P (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, 200 UCLA Med Plaza, Los Angeles, CA 90095 USA.
OI Morse, Lawrence/0000-0002-1758-2348
CR Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   AMOAKU WMK, 1992, GRAEF ARCH CLIN EXP, V230, P569, DOI 10.1007/BF00181780
   Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 1996, Arch Ophthalmol, V114, P400
   [Anonymous], 2003, Nippon Ganka Gakkai Zasshi, V107, P326
   Archambeau JO, 1998, INT J RADIAT ONCOL, V40, P1125, DOI 10.1016/S0360-3016(97)00919-X
   Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Barakat MR, 2011, ARCH OPHTHALMOL-CHIC, V129, P628, DOI 10.1001/archophthalmol.2011.99
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   Bert C, 2012, MED PHYS, V39, P1716, DOI 10.1118/1.3691903
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chalam KV, 2011, RETINA-J RET VIT DIS, V31, P169, DOI 10.1097/IAE.0b013e3181dee621
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3
   Cole CJ, 2009, EYE, V23, P1377, DOI 10.1038/eye.2008.255
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183
   ELSAS T, 1988, ACTA OPHTHALMOL, V66, P65
   Eter Nicole, 2001, International Ophthalmology, V24, P13, DOI 10.1023/A:1014445524293
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Finger PT, 2008, INT J RADIAT ONCOL, V70, P974, DOI 10.1016/j.ijrobp.2007.11.045
   Finger PT, 2009, SURV OPHTHALMOL, V54, P545, DOI 10.1016/j.survophthal.2009.06.004
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   FINGER PT, 1993, INT J RADIAT ONCOL, V27, P849, DOI 10.1016/0360-3016(93)90459-9
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1997, SURV OPHTHALMOL, V42, P215, DOI 10.1016/S0039-6257(97)00088-X
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Giuliari GP, 2011, ACTA ONCOL, V50, P6, DOI 10.3109/0284186X.2010.500299
   GORDON KB, 1995, INT J RADIAT ONCOL, V31, P1123, DOI 10.1016/0360-3016(95)00062-4
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GUYTON JS, 1948, ARCH OPHTHALMOL-CHIC, V40, P389, DOI 10.1001/archopht.1948.00900030397002
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   HART PM, 1995, BRIT J OPHTHALMOL, V79, P562, DOI 10.1136/bjo.79.6.562
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hess C, 2001, BRIT J CANCER, V85, P2010, DOI 10.1054/bjoc.2001.2166
   Hoeller U, 2005, EYE, V19, P1151, DOI 10.1038/sj.eye.6701743
   Hokkanen J, 1997, MED PHYS, V24, P211, DOI 10.1118/1.597927
   Hollick EJ, 1996, EYE, V10, P609, DOI 10.1038/eye.1996.139
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Horgan N, 2008, RETINA-J RET VIT DIS, V28, P987, DOI 10.1097/IAE.0b013e31816b3192
   Hori K, 2004, INT J RADIAT ONCOL, V60, P1564, DOI 10.1016/j.ijrobp.2004.06.208
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Lambooij AC, 2001, GRAEF ARCH CLIN EXP, V239, P539, DOI 10.1007/s004170100314
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Levinson DR, 2011, REV MEDICARE B
   Lommatzsch P, 1974, Surv Ophthalmol, V19, P85
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Munshi Anusheel, 2007, J Cancer Res Ther, V3, P12
   Nordal RA, 2004, CLIN CANCER RES, V10, P3342, DOI 10.1158/1078-0432.CCR-03-0426
   Order SE, 2003, RAD THERAPY BENIGN D
   Park SS, 2012, RETINA-J RET VIT DIS, V32, P956, DOI 10.1097/IAE.0b013e31822a8d6a
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Robbins MEC, 2004, INT J RADIAT BIOL, V80, P251, DOI 10.1080/09553000410001692726
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   SCHALING DF, 1989, GRAEF ARCH CLIN EXP, V227, P194, DOI 10.1007/BF02169796
   SEDDON JM, 1987, OPHTHALMOLOGY, V94, P354
   Senan S, 2007, ONCOLOGIST, V12, P465, DOI 10.1634/theoncologist.12-4-465
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Trikha R, 2011, RETINA-J RET VIT DIS, V31, P1303, DOI 10.1097/IAE.0b013e318203ee46
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Valmaggia C, 1997, DOC OPHTHALMOL, V93, P317, DOI 10.1007/BF02569069
   Wachsberger P, 2003, CLIN CANCER RES, V9, P1957
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zur C, 2001, J FR OPHTALMOL, V24, P949
NR 106
TC 16
Z9 16
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2013
VL 85
IS 3
BP 583
EP 597
DI 10.1016/j.ijrobp.2012.07.2352
PG 15
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 086MA
UT WOS:000314687000016
PM 22975610
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Falk, MK
   Singh, A
   Hviid, TVF
   Nissen, MH
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Falk, Mads Kruger
   Singh, Amardeep
   Hviid, Thomas Vauvert Faurschou
   Nissen, Mogens Hoist
   Sorensen, Torben Lykke
TI Association of CD11b(+) Monocytes and Anti-Vascular Endothelial Growth
   Factor Injections in Treatment of Neovascular Age-Related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CIRCULATING MONOCYTES; MACROPHAGES; EXPRESSION; INFLAMMATION;
   ACTIVATION; CCR2(+); CD200; RISK
AB IMPORTANCE CD11b(+) immune cells have been implicated in the formation of choroidal neovascularization in experimental studies on animals and disease-association studies on humans. However, the clinical importance of such observations remains unknown.
   OBJECTIVE To investigate whether the proportion of CD11b(+) circulating monocytes is associated with the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
   DESIGN, SETTING, AND PARTICIPANTS These observational cohort studies collected data from January 1, 2010, through December 31, 2013, and from January 1, 2015, through December 31, 2018. Fresh venous blood samples were acquired for flow cytometric immune studies in patients with neovascular AMD or PCV receiving treatment with aflibercept or ranibizumab as needed for 36 months. Patients (n = 81) without immune diseases were consecutively recruited from a single center in Denmark.
   EXPOSURES Proportion of CD11b(+) circulating monocytes.
   MAIN OUTCOMES AND MEASURES The estimation of the number of intravitreal anti-VEGF injections given at 12, 24, and 36 months by the proportion of CD11b(+) circulating monocytes and the correlation between these values. The angiogenic role of CD11b(+) circulating monocytes was further evaluated by investigating the expression of the known proangiogenic receptor CCR2.
   RESULTS Eighty-one patients were included in the analysis (54% women; mean [SD] age, 76 [7] years). The proportion of CD11b(+) monocytes at baseline positively estimated the future number of anti-VEGF injections at 12 (rho = 0.77; 95% CI, 0.35-0.93; P = .004), 24 (rho = 0.82; 95% CI, 0.44-0.95; P = .002), and 36 (rho = 0.78; 95% CI, 0.34-0.94; P = .005) months. This association was also found retrospectively in a larger sample of patients with neovascular AMD at 12 (rho = 0.46; 95% CI, 0.16-0.68; P = .004), 24 (rho = 0.49; 95% CI, 0.20-0.70; P = .002), and 36 (rho = 0.65; 95% CI, 0.41-0.80; P < .001) months and patients with PCV at 12 (rho = 0.27; 95% CI, -0.28 to 0.68; P = .30), 24 (rho = 0.60; 95% CI, 0.12-0.85; P =.02), and 36 (rho = 0.70; 95% CI, 0.27-0.90; P = .005) months, suggesting that this association is not specific to AMD but rather reflects VEGF activity in neovascularization. CD11b(+) monocytes highly coexpressed CCR2, an important monocytic marker of proangiogenic activity.
   CONCLUSIONS AND RELEVANCE Results of this study demonstrated that the proportion of circulating CD11b(+) monocytes estimated and correlated with the number of anti-VEGF injections in patients with neovascular AMD and PCV. Additional longitudinal studies are needed to determine whether these findings have clinical relevance to influence treatment algorithms or provide novel targets for medical therapy.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Sorensen, Torben Lykke] Zealand Univ Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Hviid, Thomas Vauvert Faurschou; Nissen, Mogens Hoist; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Falk, Mads Kruger] Zealand Univ Hosp Naestved, Dept Ophthalmol, Naestved, Denmark.
   [Singh, Amardeep] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Div Ophthalmol, Lund, Sweden.
   [Hviid, Thomas Vauvert Faurschou] Zealand Univ Hosp, Dept Clin Biochem, CIRRI, Roskilde, Denmark.
   [Nissen, Mogens Hoist] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Lund University; Skane University Hospital;
   University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020; Singh, Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation; Fight for Sight Denmark; Velux
   Foundation; Beckett Foundation; Synoptik Foundation; University of
   Copenhagen
FX This work was supported by the Danish Eye Research Foundation, Fight for
   Sight Denmark, the Velux Foundation, the Beckett Foundation, the
   Synoptik Foundation, and a faculty stipend from the University of
   Copenhagen.
CR Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Brockmann C, 2018, ACTA OPHTHALMOL, V96, pE789, DOI 10.1111/aos.13716
   Bunce C, 2014, BRIT J OPHTHALMOL, V98, P408, DOI 10.1136/bjophthalmol-2013-304587
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chakouri S, 2018, AM J OPHTHALMOL, V186, P174, DOI 10.1016/j.ajo.2017.10.040
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Danish Ophthalmological Society, TREATM REC INCL MED
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rifai N, 2001, CLIN CHEM, V47, P28
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sedeh FB, 2017, DAN MED J, V64
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
NR 38
TC 11
Z9 11
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2019
VL 137
IS 5
BP 515
EP 522
DI 10.1001/jamaophthalmol.2019.0010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HX6HB
UT WOS:000467503600012
PM 30844038
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Notomi, S
   Shiose, S
   Ishikawa, K
   Fukuda, Y
   Kano, K
   Mori, K
   Wada, I
   Kaizu, Y
   Matsumoto, H
   Akiyama, M
   Sonoda, KH
AF Notomi, Shoji
   Shiose, Satomi
   Ishikawa, Keijiro
   Fukuda, Yosuke
   Kano, Kumiko
   Mori, Kenichiro
   Wada, Iori
   Kaizu, Yoshihiro
   Matsumoto, Hidetaka
   Akiyama, Masato
   Sonoda, Koh-Hei
TI Drusen and pigment abnormality predict the development of neovascular
   age-related macular degeneration in Japanese patients
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PROSPECTIVE COHORT; SEVERITY SCALE;
   MULTICENTER; PREVALENCE; DIAGNOSIS; SUBTYPES; 5-YEAR
AB Drusen are known to be the important hallmark to predict the development of age-related macular degeneration (AMD). The prevalence of drusen is lower in Asians compared with Caucasians so that the role of signs constituting early AMD is not well established in Asian populations as in Western countries. In this study, we retrospectively investigated clinical characteristics and 5-year incidence of neovascular AMD (nAMD) in the fellow eye of unilateral nAMD patients. Of 296 consecutive unilateral nAMD patients who had been followed up more than 5 years, 170 typical AMD, 119 polypoidal choroidal vasculopathy, and 7 retinal angiomatous proliferation were included. To examine factors associated with nAMD occurrence in the fellow eye, drusen and pigmentary abnormality in the fellow eye were classified into 4 categories; Category 1: no or small drusen < 63 mu m (37.2%), Category 2: 63-125 mu m medium drusen or pigmentary abnormality (22.2%), Category 3: large drusen > 125 mu m (25.0%), Category P: pachydrusen (15.5%). The mean sub-foveal choroidal thickness (SFCT) was Category 1: 276 mu m, Category 2: 308 mu m, Category 3: 246 mu m, and Category P: 302 mu m, respectively. Of note, SFCT in Category 2 and Category P was significantly larger than those of Category 3. Finally, the 5-year incidence of nAMD in the fellow eye was 32/296 (10.8%); Category 1: 0/110 (0%), Category 2: 12/66 (18.2%), Category 3: 20/74 (27.0%), and Category P: 0/46 (0%). Thus, signs of intermediate AMD (large drusen) as well as those of early AMD, especially the pigmentary abnormality, may contribute to development of bilateral nAMD in Japanese patients.
C1 [Notomi, Shoji; Shiose, Satomi; Ishikawa, Keijiro; Fukuda, Yosuke; Kano, Kumiko; Mori, Kenichiro; Wada, Iori; Kaizu, Yoshihiro; Sonoda, Koh-Hei] Kyushu Univ, Fac Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Matsumoto, Hidetaka] Gunma Univ, Grad Sch Med, Dept Ophthalmol, Maebashi, Gumma, Japan.
   [Akiyama, Masato] Kyushu Univ, Fac Med Sci, Dept Ocular Pathol & Imaging Sci, Fukuoka, Japan.
C3 Kyushu University; Gunma University; Kyushu University
RP Notomi, S (通讯作者)，Kyushu Univ, Fac Med Sci, Dept Ophthalmol, Fukuoka, Japan.
EM noutomi.shouji.926@m.kyushu-u.ac.jp
RI Akiyama, Masato/AHC-2589-2022
OI Matsumoto, Hidetaka/0000-0003-2311-0280; Notomi,
   Shoji/0000-0002-7935-4244
FU Japan Society for the Promotion of Science [JP19K09931]; Grant of The
   Clinical Research Promotion Foundation 2020
FX Japan Society for the Promotion of Science, Grant-in-Aid for Scientific
   Research; JP19K09931. Grant of The Clinical Research Promotion
   Foundation 2020, Dr. Shoji Notomi.
CR Akagi-Kurashige Y, 2018, JPN J OPHTHALMOL, V62, P137, DOI 10.1007/s10384-017-0554-5
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Obata R, 2018, BRIT J OPHTHALMOL, V102, P1047, DOI 10.1136/bjophthalmol-2016-309980
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sasaki M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.23
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sheth J, 2020, EYE, V34, P1501, DOI 10.1038/s41433-020-0886-0
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tsujikawa A, 2018, JPN J OPHTHALMOL, V62, P127, DOI 10.1007/s10384-017-0556-3
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 28
TC 5
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2021
VL 16
IS 7
AR e0255213
DI 10.1371/journal.pone.0255213
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UA5TU
UT WOS:000685225200019
PM 34314466
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nizawa, T
   Kitahashi, M
   Baba, T
   Iwase, T
   Kubota-Taniai, M
   Hattori, Y
   Shiko, Y
   Kawasaki, Y
   Iwase, T
   Sato, T
   Ogawa, S
   Sugawara, T
   Yamamoto, S
AF Nizawa, Tomohiro
   Kitahashi, Masayasu
   Baba, Takayuki
   Iwase, Takehito
   Kubota-Taniai, Mariko
   Hattori, Yoko
   Shiko, Yuki
   Kawasaki, Yohei
   Iwase, Takayuki
   Sato, Takatoshi
   Ogawa, Shoko
   Sugawara, Takeshi
   Yamamoto, Shuichi
TI Improvements of Retinal Sensitivity after Intravitreal Injection of
   Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration
   with or without Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Retinal sensitivity; Microperimetry; Age-related macular degeneration;
   Polypoidal choroidal vasculopathy; Aflibercept
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; VEGF TRAP; MICROPERIMETRY;
   RANIBIZUMAB; OUTCOMES; THERAPY; RESISTANCE; MORPHOLOGY; THICKNESS
AB Purpose: We aim to determine the effects of intravitreal aflibercept (IVA) on the mean sensitivity (MS) of the central retina, best-corrected visual acuity (BCVA), and central foveal thickness (CFT) in eyes with neovascular age-related macular degeneration (nAMD) with or without polypoidal choroidal vasculopathy (PCV). Methods: This was a prospective, interventional study. All eyes were treatment-naive with nAMD with or without PCV. Each eye received 3 monthly IVA injections followed by an IVA injection every 2 months for 12 months. The primary outcome was the change in the MS within the central 2 degrees. The secondary outcomes were the changes in BCVA, CFT, greatest linear dimension (GLD), and percentage of eyes with a dry macula. Results: Thirty-seven eyes of 37 patients were studied. A significant improvement of the MS (dB) was observed +4.9 +/- 4.6 dB (mean +/- standard deviation) at 3 M (p < 0.001), +5.5 +/- 4.9 dB at 6 (p < 0.001), and +7.0 +/- 3.4 dB at 12 M (p < 0.001) compared to the baseline in all eyes. The MS of the eyes with non-PCV was not significantly different from that of eyes with PCV (p = 1.00, 1.00, 1.00, and 0.76 at baseline, 3, 6, and 12 M, respectively). The MS of 11 patients whose BCVA remained unchanged was significantly improved by +6.5 +/- 2.8 dB at 3 M (p < 0.001), +6.1 +/- 4.3 dB at 6 M (p < 0.001), and +6.4 +/- 4.8 dB at 12 M (p = 0.003) compared to the baseline. The mean BCVA was significantly improved from the baseline to 3 M (p < 0.001), 6 M (p = 0.027), and 12 M (p = 0.003) in all eyes. The BCVA was improved or maintained in 97% of the patients at 12 M. The mean CFT and GLD were significantly reduced at 12 M (p < 0.001). Twenty-two eyes (71%) had a dry macula at 12 M. Conclusions: IVA administered by a fixed dosing regimen led to significant improvements of the central MS, BCVA, and macular morphology at 1 year in eyes with nAMD with or without PCV. These results were not significantly different between eyes with non-PCV and with PCV. The improvements of the MS of the retina of the central 2 degrees in a subgroup whose BCVA remained unchanged through the 12-month experimental period was also significant. We conclude that the MS of the central 2 degrees might be a better marker than the BCVA in determining the effectiveness of IVA treatments and might be helpful in determining early effects on the retina before BCVA changes can be detected.
C1 [Nizawa, Tomohiro; Kitahashi, Masayasu; Baba, Takayuki; Iwase, Takehito; Kubota-Taniai, Mariko; Yamamoto, Shuichi] Chiba Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Chiba, Japan.
   [Nizawa, Tomohiro] Johns Hopkins Univ, Wilmer Ophthalmol Inst, Baltimore, MD 21218 USA.
   [Hattori, Yoko; Shiko, Yuki; Kawasaki, Yohei; Iwase, Takayuki; Sato, Takatoshi; Ogawa, Shoko; Sugawara, Takeshi] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan.
C3 Chiba University; Johns Hopkins University; Johns Hopkins Medicine;
   Chiba University
RP Nizawa, T (通讯作者)，Chiba Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Chiba, Japan.; Nizawa, T (通讯作者)，Johns Hopkins Univ, Wilmer Ophthalmol Inst, Baltimore, MD 21218 USA.
EM tomohiro-niizawa@hotmail.co.jp
OI Shiko, Yuki/0000-0002-3959-9343; Hattori, Yoko/0000-0002-5989-9554
FU Bayer Yakuhin, Ltd (Osaka, Japan)
FX The authors received financial support for the study from Bayer Yakuhin,
   Ltd (Osaka, Japan). Bayer Yakuhin had no role in the design of the
   study, data collection, data analysis, interpretation of the data, or
   writing of this report.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Csaky KG, 2019, SURV OPHTHALMOL, V64, P353, DOI 10.1016/j.survophthal.2019.01.014
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study, 2021, LANCET GLOB HEALTH, V9, P144
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Michalska-Malecka K, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017599
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Moshfeghi DM, 2020, BRIT J OPHTHALMOL, V104, P1223, DOI 10.1136/bjophthalmol-2019-315021
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Oeverhaus M, 2017, OPHTHALMOLOGICA, V238, P6, DOI 10.1159/000468949
   Ono A, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011737
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2606, DOI 10.1167/iovs.14-15977
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 50
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP
PY 2021
VL 244
IS 4
BP 347
EP 360
DI 10.1159/000517187
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UL6QG
UT WOS:000692773000011
PM 34015785
DA 2022-11-30
ER

PT J
AU Nussenblatt, RB
   Byrnes, G
   Sen, HN
   Yeh, S
   Faia, L
   Meyerle, C
   Wroblewski, K
   Li, ZQ
   Liu, BY
   Chew, E
   Sherry, PR
   Friedman, P
   Gill, F
   Ferris, F
AF Nussenblatt, Robert B.
   Byrnes, Gordon
   Sen, H. Nida
   Yeh, Steven
   Faia, Lisa
   Meyerle, Catherine
   Wroblewski, Keith
   Li, Zhuqing
   Liu, Baoying
   Chew, Emily
   Sherry, Patti R.
   Friedman, Penelope
   Gill, Fred
   Ferris, Frederick, III
TI A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT
   OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; immunosuppression; T cell; choroidal
   neovascularization
ID RAPAMYCIN; THERAPY; SUSCEPTIBILITY; INFLAMMATION; SIROLIMUS; UVEITIS;
   VARIANT; ALPHA; CELLS; HTRA1
AB Background: Age-related macular degeneration remains the leading cause of irreversible blindness in the United States and the developed world. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications have become standard of care for the treatment of the wet form of the disease. Recent reports have demonstrated an association with various immune factors. We aimed to investigate the effect of immunosuppressive therapy in the clinical course of the wet form of the disease. We compared anti-VEGF therapy plus one of three systemic immunosuppressive therapies versus anti-VEGF therapy alone for recurrent choroidal neovascularization associated with age-related macular degeneration.
   Methods: This was a pilot, Phase I/II, prospective, randomized, unmasked, single-center trial. Patients with subretinal exudation secondary to recurrent choroidal neovascularization associated with age-related macular degeneration were included in the study. Patients were randomized to 1 of 3 systemic arms immunosuppressive agents (daclizumab, rapamycin, or infliximab) for 6 months plus intraocular anti-VEGF therapy if indicated, compared with a group who received only anti-VEGF therapy if indicated.
   Results: The number of anti-VEGF injections per group, visual acuity, retinal thickness, and safety measures were assessed in all groups. Thirteen patients were randomized; comparing anti-VEGF injections before and during the study, a decrease in the number of injections from 0.73 injections per month to 0.42 for daclizumab and from 0.67 to 0.34 for sirolimus was seen, while no apparent decrease was seen for either infliximab or observation. Visual acuities were maintained in all groups.
   Conclusion: These preliminary data suggest that some immunosuppressive agents given systemically can alter the clinical course of the wet form of the disease and support the notion that more definitive clinical trials of immune mediation of age-related macular degeneration are indicated. RETINA 30:1579-1587, 2010
C1 [Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Byrnes, Gordon] Retina Grp Washington, Fairfax, VA USA.
   [Wroblewski, Keith] Walter Reed Army Med Ctr, Dept Ophthalmol, Washington, DC USA.
   [Gill, Fred] NIH, Ctr Clin, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); United States Department of Defense; United States Army; Walter
   Reed National Military Medical Center; National Institutes of Health
   (NIH) - USA; NIH Clinical Center (CC)
RP Nussenblatt, RB (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10,Room 10N112,10 Ctr Dr, Bethesda, MD 20892 USA.
EM drbob@nei.nih.gov
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland; NATIONAL EYE INSTITUTE [ZIAEY000439] Funding Source: NIH
   RePORTER
FX Supported by intramural funds of the National Eye Institute, National
   Institutes of Health, Bethesda, Maryland.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Dejneka NS, 2004, MOL VIS, V10, P964
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   MARTIN DF, 1995, J IMMUNOL, V154, P922
   Mottershead M, 2007, EXPERT OPIN BIOL TH, V7, P1583, DOI 10.1517/14712598.7.10.1583
   Nussenblatt RB, 2003, J AUTOIMMUN, V21, P283, DOI 10.1016/S0896-8411(03)00113-6
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2007, ACTA OPHTHALMOL SCAN, V85, P230, DOI 10.1111/j.1600-0420.2006.00858.x
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029
   Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 29
TC 63
Z9 64
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1579
EP 1587
DI 10.1097/IAE.0b013e3181e7978e
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600004
PM 20847709
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yazdi, MH
   Faramarzi, MA
   Nikfar, S
   Falavarjani, KG
   Abdollahi, M
AF Yazdi, Mohammad Hossein
   Faramarzi, Mohammad All
   Nikfar, Shekoufeh
   Falavarjani, Khalil Ghasemi
   Abdollahi, Mohammad
TI Ranibizumab and aflibercept for the treatment of wet age-related macular
   degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE aflibercept; anti-VEGF; ranibizumab; wet age related macular
   degeneration
ID RETINAL ANGIOMATOUS PROLIFERATION; VEGF TRAP-EYE; ENDOTHELIAL
   GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; CHOROIDAL NEOVASCULARIZATION;
   2.0 MG; BEVACIZUMAB; INJECTION; THERAPY; FLUID
AB Introduction: Wet age-related macular degeneration (AMD) is a potentially blinding eye disease that causes vision loss among individuals > 50 years old. The main goal in the treatment of wet AMD is to inhibit the choroidal neovas-cularization (CNV). Currently, ranibizumab and aflibercept are two available anti-VEGF drug for the treatment of wet AMD. Here, we reviewed the clinical outcome of treatment with ranibizumab or aflibercept in patients with wet AMD from recent studies with a special focus on eyes with unusual presentations or treatment resistant and compared these agents with other available wet AMD therapies.
   Areas covered: For this review, a literature search from 2011 to present was performed using the following terms (or combination of terms): anti-vascular endothelial growth factors, anti-VEGF, age-related macular degeneration, AMD, aflibercept, and ranibizumab. The studies were limited to studies used ranibizumab, and especially those switched from ranibizumab to aflibercept. Also the clinical trial website (www.clinicaltrials.gov) was searched for recently completed trials of aflibercept or ranibizumab for wet AMD treatment.
   Expert opinion: Ranibizumab and aflibercept are effective for the treatment of wet AMD including those with retinal angiomatous proliferation (RAP) and CNV unresponsive to other anti-VEGF agents. Although high-dose ranibizumab has the potential to treat unresponsive CNV, switching to another anti-VEGF agent may be a preferable option in these eyes.
C1 [Yazdi, Mohammad Hossein] Dept Res & Dev, Pasteur Inst Iran, Karaj, Iran.
   [Faramarzi, Mohammad All] Univ Tehran Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tehran, Iran.
   [Faramarzi, Mohammad All] Univ Tehran Med Sci, Dept Pharmaceut Biotechnol, Biotechnol Res Ctr, Tehran, Iran.
   [Nikfar, Shekoufeh] Univ Tehran Med Sci, Dept Pharmacoecon, Tehran, Iran.
   [Nikfar, Shekoufeh] Univ Tehran Med Sci, Fac Pharm, Pharmaceut Adm, Tehran, Iran.
   [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Alcram Hosp, Eye Res Ctr, Dept Ophthalmol, Tehran, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Tehran, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr, Tehran, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran.
   [Abdollahi, Mohammad] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Tehran, Iran.
C3 Le Reseau International des Instituts Pasteur (RIIP); Pasteur Institute
   of Iran; Tehran University of Medical Sciences; Tehran University of
   Medical Sciences; Tehran University of Medical Sciences; Tehran
   University of Medical Sciences; Iran University of Medical Sciences;
   Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Tehran University of Medical Sciences; Tehran University of
   Medical Sciences
RP Abdollahi, M (通讯作者)，Univ Tehran Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tehran, Iran.
EM Mohammad@Sina.TUMS.Ac.Ir
RI Falavarjani, Khalil Ghasemi/I-4029-2019; Yazdi, Mohammad
   Hossein/N-7144-2016; Abdollahi, Mohammad/B-9232-2008
OI Yazdi, Mohammad Hossein/0000-0001-8567-8555; Abdollahi,
   Mohammad/0000-0003-0123-1209; Ghasemi Falavarjani,
   Khalil/0000-0001-5221-1844; Faramarzi, Mohammad Ali/0000-0002-8822-453X
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 2012, FDA DRUG APPR DAT
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho H, 2014, EUR J OPHTHALMOL, V24, P576, DOI 10.5301/ejo.5000421
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Dashti-Khavidaki S, 2015, DARU, V23, DOI 10.1186/s40199-015-0110-0
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hashemi S, 2014, EXPERT OPIN BIOL TH, V14, P1837, DOI 10.1517/14712598.2014.967210
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Inoue M, 2014, BRIT J OPHTHALMOL, V98, P956, DOI 10.1136/bjophthalmol-2013-304251
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Maier M, 2013, OPHTHALMOLOGE, V110, P1171, DOI 10.1007/s00347-012-2732-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mavija M, 2014, MED ARCH, V68, P204, DOI DOI 10.5455/MEDARH.2014.68.204-208
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Nguyen QD, 2012, J OCUL PHARMACOL TH, V28, P581, DOI 10.1089/jop.2011.0261
   Querques G, 2015, OPHTHALMIC RES, V53, P194, DOI 10.1159/000379754
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Sinha R, 2009, INDIAN J OPHTHALMOL, V57, P481
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 51
TC 15
Z9 17
U1 2
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD SEP
PY 2015
VL 15
IS 9
BP 1349
EP 1358
DI 10.1517/14712598.2015.1057565
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CP4UT
UT WOS:000359878800009
PM 26076760
DA 2022-11-30
ER

PT J
AU Yan, Q
   Weeks, DE
   Xin, HY
   Swaroop, A
   Chew, EY
   Huang, H
   Ding, Y
   Chen, W
AF Yan, Qi
   Weeks, Daniel E.
   Xin, Hongyi
   Swaroop, Anand
   Chew, Emily Y.
   Huang, Heng
   Ding, Ying
   Chen, Wei
TI Deep-learning-based prediction of late age-related macular degeneration
   progression
SO NATURE MACHINE INTELLIGENCE
LA English
DT Article
ID GENETIC SUSCEPTIBILITY; EYE DISEASE; IMAGES; CLASSIFICATION; PATTERNS;
   AREDS; AMD
AB Both genetic and environmental factors influence the etiology of age-related macular degeneration (AMD), a leading cause of blindness. AMD severity is primarily measured by images of the fundus of the retina and recently developed machine learning methods can successfully predict AMD progression using image data. However, none of these methods have used both genetic and image data for predicting AMD progression. Here we used both genotypes and fundus images to predict whether an eye had progressed to late AMD with a modified deep convolutional neural network. In total, we used 31,262 fundus images and 52 AMD-associated genetic variants from 1,351 subjects from the Age-Related Eye Disease Study, which provided disease severity phenotypes and fundus images available at baseline and follow-up visits over a period of 12 years. Our results showed that fundus images coupled with genotypes could predict late AMD progression with an averaged area-under-the-curve value of 0.85 (95%confidence interval 0.83-0.86). The results using fundus images alone showed an averaged area under the receiver operating characteristic curve value of 0.81 (95%confidence interval 0.80-0.83). We implemented our model in a cloud-based application for individual risk assessment. Age-related macular degeneration is a serious eye disease which should be detected as early as possible. Using both fundus images and genetic information, a deep neural network is able to detect the severity of the disease and predict its progression seven years into the future.
C1 [Yan, Qi; Xin, Hongyi; Chen, Wei] Univ Pittsburgh, Dept Pediat, UPMC Childrens Hosp Pittsburgh, Div Pulm Med, Pittsburgh, PA 15260 USA.
   [Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.; Ding, Ying; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Huang, Heng] Univ Pittsburgh, Dept Elect & Comp Engn, Swanson Sch Engn, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; National Institutes
   of Health (NIH) - USA; NIH National Eye Institute (NEI); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Yan, Q; Chen, W (通讯作者)，Univ Pittsburgh, Dept Pediat, UPMC Childrens Hosp Pittsburgh, Div Pulm Med, Pittsburgh, PA 15260 USA.; Chen, W (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.; Ding, Y; Chen, W (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
EM qiy17@pitt.edu; yingding@pitt.edu; wec47@pitt.edu
RI Xin, Hongyi/AAH-8947-2021
OI Chen, Wei/0000-0001-7196-8703; Yan, Qi/0000-0002-5236-9673; Weeks,
   Daniel/0000-0001-9410-7228; Swaroop, Anand/0000-0002-1975-1141
FU NSF [IIS 1852606, IIS 1837956]; NEI Intramural Research Program
   [ZIAEY000546]; UK Biobank Resource [43252]
FX H.H. was partially supported by NSF IIS 1852606 and IIS 1837956. A.S.
   was supported by NEI Intramural Research Program grant number
   ZIAEY000546. The independent validation has been conducted using the UK
   Biobank Resource under Application Number 43252.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Angermueller C, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156651
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chollet F., 2015, DEEP LEARNING HUMANS
   Christopher M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35044-9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Devalla SK, 2018, INVEST OPHTH VIS SCI, V59, P63, DOI 10.1167/iovs.17-22617
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Graf E, 1999, STAT MED, V18, P2529
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hao J, 2018, IEEE INT C BIOINFORM, P381, DOI 10.1109/BIBM.2018.8621345
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kotikalapudi R., 2017, NEURAL NETWORK VISUA
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ribeiro MT, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P1135, DOI 10.1145/2939672.2939778
   Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P2112, DOI 10.1109/TBME.2014.2314714
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
NR 43
TC 32
Z9 33
U1 1
U2 23
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2522-5839
J9 NAT MACH INTELL
JI Nat. Mach. Intell.
PD FEB
PY 2020
VL 2
IS 2
BP 141
EP +
DI 10.1038/s42256-020-0154-9
PG 12
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA NR0MM
UT WOS:000571258300012
PM 32285025
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Nghiem-Buffet, S
   Giocanti-Auregan, A
   Jung, C
   Dubois, L
   Dourmad, P
   Galbadon, L
   Fajnkuchen, F
   Quentel, G
   Cohen, SY
AF Nghiem-Buffet, Sylvia
   Giocanti-Auregan, Audrey
   Jung, Camille
   Dubois, Lise
   Dourmad, Pauline
   Galbadon, Lea
   Fajnkuchen, Franck
   Quentel, Gabriel
   Cohen, Salomon Y.
TI RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR
   RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; reticular pseudodrusen; choroidal
   thickness; prognosis; ranibizumab
ID SUBRETINAL DRUSENOID DEPOSITS; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; VISUAL OUTCOMES; BEVACIZUMAB; EYES; PREVALENCE; ASSOCIATION;
   AMD
AB Purpose: To investigate reticular pseudodrusen (RPD) as a potential baseline factor predictive of a poor 1-year response to intravitreal ranibizumab in eyes with neovascular age-related macular degeneration.
   Methods: Retrospective, monocentric case series including 98 consecutive naive neovascular age-related macular degeneration patients. Presence of RPD was assessed by two graders based on color, blue-light, fundus autofluorescence pictures, and spectral-domain optical coherence tomography. A correlation between the presence of RPD and the visual change was investigated. Other baseline characteristics studied in a monovariate and multivariate analysis were the following: age, gender, affected side, loading dose, type of neovascularization, presence of retinal pigment epithelial detachment >250 mu m, subretinal or intraretinal fluid, blood over >50% of the lesion, and subfoveal choroidal thickness.
   Results: The presence of RPD was not associated with a visual change (P = 0.96), but with a thin subfoveal choroidal thickness at baseline (P < 0.0001). The monovariate analysis showed that the presence of blood at baseline was associated with visual gain (P = 0.007).
   Conclusion: The presence of RPD at baseline was not identified as a factor associated with a poor 1-year response to ranibizumab in eyes with neovascular age-related macular degeneration. Studies with a longer follow-up may be needed to assess the impact of RPD on the visual prognosis of eyes with neovascular age-related macular degeneration.
C1 [Nghiem-Buffet, Sylvia; Dubois, Lise; Dourmad, Pauline; Galbadon, Lea; Fajnkuchen, Franck; Quentel, Gabriel; Cohen, Salomon Y.] Ophthalm Ctr Imaging & Laser, Paris, France.
   [Giocanti-Auregan, Audrey] Avicenne Hosp, AP HP, Dept Ophthalmol, Bobigny, France.
   [Giocanti-Auregan, Audrey] Univ Paris 13, Bobigny, France.
   [Jung, Camille] Intercity Hosp, Ctr Clin & Biol Res, Creteil, France.
   [Cohen, Salomon Y.] Intercity Hosp, Dept Ophthalmol, Creteil, France.
   [Cohen, Salomon Y.] Univ Paris Est, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris 13; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
OI JUNG, Camille/0000-0001-8486-8939
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Chhablani J, 2012, RETINA-J RET VIT DIS, V32, P1465, DOI 10.1097/IAE.0b013e3182475aea
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Saito M, 2016, JPN J OPHTHALMOL, V60, P42, DOI 10.1007/s10384-015-0417-x
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 42
TC 6
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2017
VL 37
IS 1
BP 53
EP 59
DI 10.1097/IAE.0000000000001134
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH7JF
UT WOS:000391948300008
PM 27380430
DA 2022-11-30
ER

PT J
AU Rennie, CA
   Hannan, S
   Maycock, N
   Kang, C
AF Rennie, Christina A.
   Hannan, Shabeeba
   Maycock, Nick
   Kang, Chee
TI Age-related macular degeneration: what do patients find on the internet?
SO JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
LA English
DT Article
ID QUALITY; INFORMATION; EDUCATION
AB Objective To assess the quality of information and readability of the top internet sites for age-related macular degeneration (AMD).
   Design An examination of the technical information provision, quality and readability of websites found during an internet search for 'age-related macular degeneration'.
   Setting Six internet search engines were used to find 26 unique sites on AMD.
   Main outcome measures Technical information and quality were assessed using a simple grading system. Readability was assessed using a Simple Measure Of Gobbledygook (SMOG) rating.
   Results Twelve organizational, seven academic and seven commercial sites were identified. The average technical scores were 82.3%, 67.9% and 65.2% for each type of site, respectively (P=0.097, one way ANOVA). The average quality scores were 62.2%, 62.6%, and 49.5% for each type of site, respectively (P=0.356, one-way ANOVA). The average SMOG ratings were 16.3, 16.1, and 16.2 for each type of site, respectively (P=0.983, one-way ANOVA). Fifteen of the sites provided details of new and emerging treatments, with seven providing a detailed discussion.
   Conclusions Many websites are now meeting the challenge of providing comprehensive information about AMD and its new treatments. Quality scores were disappointing, with sites needing to provide more evidence of authorship and attribution of information. The majority of sites had SMOG scores above 10, making them difficult for the average person to understand. As physicians we need to help design and direct patients to sites that provide high quality, current information.
C1 Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   Queen Alexandra Hosp, Portsmouth PO6 3LY, Hants, England.
C3 University of Southampton; Portsmouth Hospitals NHS Trust; Queen
   Alexandra Hospital
RP Rennie, CA (通讯作者)，Southampton Gen Hosp, Southampton Eye Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM chris_rennie@yahoo.com
OI Maycock, Nick/0000-0001-8858-727X
CR Bessell Tracey L, 2002, Health Expect, V5, P28, DOI 10.1046/j.1369-6513.2002.00156.x
   Coulter A., 2006, ASSESSING QUALITY IN
   Croft DR, 2002, CHEST, V121, P1301, DOI 10.1378/chest.121.4.1301
   EATON L, 2002, BMJ-BRIT MED J, V325, P989
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Graber MA, 1999, J FAM PRACTICE, V48, P58
   Kahana A, 2004, ARCH OPHTHALMOL-CHIC, V122, P380, DOI 10.1001/archopht.122.3.380
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Martins EN, 2005, BRIT J OPHTHALMOL, V89, P565, DOI 10.1136/bjo.2004.055111
   MCLAUGHLIN GH, 1969, J READING, V12, P639
   Moult B, 2004, HEALTH EXPECT, V7, P165, DOI 10.1111/j.1369-7625.2004.00273.x
   MURRAY E, 2001, BMJ-BRIT MED J, V325, P490
   Nayak L., 2006, UNIVERSAL ACCESS INF, V5, P170, DOI [10.1007/s10209-006-0029-9, DOI 10.1007/S10209-006-0029-9]
   O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731
   Powell JA, 2003, J ROY SOC MED, V96, P74, DOI 10.1258/jrsm.96.2.74
   RIDEOUT V, 2005, EHLTH ELDERLY SENIOR, V7223
   Risk A, 2001, J MED INTERNET RES, V3, DOI 10.2196/jmir.3.4.e28
   Shepperd S, 1999, BMJ-BRIT MED J, V319, P764, DOI 10.1136/bmj.319.7212.764
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stone TW, 2001, SOUTHERN MED J, V94, P22
   Theodosiou L., 2003, ADV PSYCHIAT TREATME, V9, P387, DOI [DOI 10.1192/APT.9.5.387, 10.1192/apt.9.5.387]
NR 21
TC 8
Z9 9
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0141-0768
EI 1758-1095
J9 J ROY SOC MED
JI J. R. Soc. Med.
PD OCT
PY 2007
VL 100
IS 10
BP 473
EP 477
DI 10.1258/jrsm.100.10.473
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 221SF
UT WOS:000250246900017
PM 17911131
OA Green Published
DA 2022-11-30
ER

PT J
AU Fuse, N
   Mengkegale, M
   Miyazawa, A
   Abe, T
   Nakazawa, T
   Wakusawa, R
   Nishida, K
AF Fuse, Nobuo
   Mengkegale, Mingge
   Miyazawa, Akiko
   Abe, Toshiaki
   Nakazawa, Toru
   Wakusawa, Ryosuke
   Nishida, Kohji
TI Polymorphisms in ARMS2 (LOC387715) and LOXL1 Genes in the Japanese With
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H POLYMORPHISM; BODY-MASS
   INDEX; ENVIRONMENTAL ASSOCIATIONS; EXFOLIATION GLAUCOMA; RISK-FACTORS;
   VARIANT; HTRA1; SUSCEPTIBILITY; POPULATION
AB PURPOSE: To determine whether polymorphisms in the ARMS2 (LOC387715) gene and the lysyl oxidase-like 1 (LOXL1) gene are associated with age-related macular degeneration (AMD) in Japanese patients.
   DESIGN: Clinically relevant laboratory investigation.
   METHODS: Forty-one unrelated Japanese subjects with dry AMD, 50 subjects with exudative (wet) AMD, and 60 subjects with polypoidal choroidal vasculopathy (PCV) were studied. The single nucleotide polymorphisms (SNPs), p.Ala69Ser of the ARMS2 gene and p.Argl41Leu of the LOXL1 gene, were amplified by polymerase chain reaction, directly sequenced, and genotyped.
   RESULTS: For the ARMS2 gene, the genotype frequency of the p.Ala69Ser single nucleotide polymorphism in eyes with dry AMD was not significantly different from that in the controls (P = .04), but the frequency was significantly higher in the exudative AMD group (P = 3.1 x 10(-8)) and PCV group (P = 6.9 x 10(-3)). For the LOXL1 gene, the genotype frequency of the p.Argl41Leu single nucleotide polymorphism was not statistically higher in the dry AMD and PCV groups than in the control group (dry AMD, P = .05; PCV, P = .16), but was statistically higher in the exudative AMD group (P = 6.8 x 10(-3)). Regression analyses showed significant associations between the ARMS2 gene and LOXL1 gene in patients with exudative AMD.
   CONCLUSIONS: The p.Ala69Ser polymorphism of the ARMS2 gene is strongly associated with exudative AMD and PCV and is associated marginally with dry AMD. The polymorphisms in the LOXL1 gene did not predispose the individual to dry AMD and PCV. These findings suggest that there is a significant association between the ARMS2 gene and LOXL1 gene in exudative AMD. (Am J Ophthalmol 2011;151:550-556. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Fuse, Nobuo; Mengkegale, Mingge; Miyazawa, Akiko; Abe, Toshiaki; Nakazawa, Toru; Wakusawa, Ryosuke; Nishida, Kohji] Tohoku Univ, Grad Sch Med, Dept Ophthalmol, Sendai, Miyagi 9808574, Japan.
C3 Tohoku University
RP Fuse, N (通讯作者)，Tohoku Univ, Grad Sch Med, Dept Ophthalmol, Sendai, Miyagi 9808574, Japan.
EM fusen@oph.med.tohoku.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610
CR [Anonymous], 2000, OPHTHALMOLOGY, V107, P2224
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Forsius H, 1988, Acta Ophthalmol Suppl, V184, P71
   Forsman E, 2007, ACTA OPHTHALMOL SCAN, V85, P500, DOI 10.1111/j.1600-0420.2007.00978.x
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2008, MOL VIS, V14, P1338
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   SEDDON J, 2001, EPIDEMIOLOGY AGE REL, P1039
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Tarkkanen A, 2002, ACTA OPHTHALMOL SCAN, V80, P151, DOI 10.1034/j.1600-0420.2002.800206.x
   Thomassin L, 2005, J BIOL CHEM, V280, P42848, DOI 10.1074/jbc.M506832200
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Yamamoto T, 2005, OPHTHALMOLOGY, V112, P1661, DOI 10.1016/j.ophtha.2005.05.012
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
NR 32
TC 30
Z9 32
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2011
VL 151
IS 3
BP 550
EP 556
DI 10.1016/j.ajo.2010.08.048
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725BO
UT WOS:000287620400025
PM 21236409
DA 2022-11-30
ER

PT J
AU Geerlings, MJ
   Kersten, E
   Groenewoud, JMM
   Fritsche, LG
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
AF Geerlings, Maartje J.
   Kersten, Eveline
   Groenewoud, Joannes M. M.
   Fritsche, Lars G.
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Geographic distribution of rare variants associated with age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; HIGH-RISK;
   GENETIC-VARIATION; COMMON VARIANTS; CFH GENE; POPULATIONS; MUTATION;
   CONFERS; R1210C
AB Purpose: A recent genome-wide association study by the International Age-related Macular Degeneration Genomics Consortium (IAMDGC) identified seven rare variants that are individually associated with age-related macular degeneration (AMD), the most common cause of vision loss in the elderly. In literature, several of these rare variants have been reported with different frequencies and odds ratios across populations of Europe and North America. Here, we aim to describe the representation of these seven AMD-associated rare variants in different geographic regions based on 24 AMD studies.
   Methods: We explored the occurrence of seven rare variants independently associated with AMD (CFH rs121913059 (p.Arg1210Cys), CFI rs141853578 (p.Gly119Arg), C3 rs147859257 (p.Lys155Gln), and C9 rs34882957 (p.Pro167Ser)) and three non-coding variants in or near the CFH gene (rs148553336, rs35292876, and rs191281603) in 24 AMD case-control studies. We studied the difference in distribution, interaction, and effect size for each of the rare variants based on the minor allele frequency within the different geographic regions.
   Results: We demonstrate that two rare AMD-associated variants in the CFH gene (rs121913059 [p.Arg1210Cys] and rs35292876) deviate in frequency among different geographic regions (p=0.004 and p=0.001, respectively). The risk estimates of each of the seven rare variants were comparable across the geographic regions.
   Conclusions: The results emphasize the importance of identifying population-specific rare variants, for example, by performing sequencing studies in case-control studies of various populations, because their identification may have implications for diagnostic screening and personalized treatment.
C1 [Geerlings, Maartje J.; Kersten, Eveline; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands.
   [Fritsche, Lars G.] Norwegian Univ Sci & Technol, NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Norwegian
   University of Science & Technology (NTNU); Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Hollander, Anneke den/N-4911-2014; Fritsche, Lars G/AAF-9387-2019;
   Groenewoud, Hans JMM/R-3588-2017; Geerlings, Maartje/P-8309-2015;
   Kersten, Eveline/P-8173-2015; Geerlings, Maartje/P-3338-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Geerlings, Maartje/0000-0003-1164-3573;
   Geerlings, Maartje/0000-0003-1164-3573
FU NIH [R01EY022310]; European Research Council under European Union's
   Seventh Framework Programme / ERC [310644]; European Union's Horizon
   research and innovation program [634479];  [HHSN268201200008I]; NATIONAL
   EYE INSTITUTE [R01EY022310] Funding Source: NIH RePORTER
FX We would like to acknowledge the contribution of the International AMD
   Genomics Consortium (IAMDGC) that is supported by a grant from NIH
   (R01EY022310). Full list of IAMDGC members is provided in S2 Appendix.
   Geno-typing was supported by a contract (HHSN268201200008I) to the
   Center for Inherited Disease Research. The research leading to these
   results has received funding from the European Research Council under
   the European Union's Seventh Framework Programme (FP/2007-2013) / ERC
   Grant Agreement n. 310644 (MACULA). This project has received funding
   from the European Union's Horizon 2020 research and innovation program
   under grant agreement No 634479.
CR Alexander P, 2014, MOL VIS, V20, P1253
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Auer PL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0138-2
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Duvvari MR, 2015, MOL VIS, V21, P285
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   KING G, 2001, POLITICAL ANAL, V0009
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Mathieson I, 2012, NAT GENET, V44, P243, DOI 10.1038/ng.1074
   Miyake M, 2015, JPN J OPHTHALMOL, V59, P273, DOI 10.1007/s10384-015-0394-0
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shen Si-kui, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P570, DOI 10.3760/cma.j.issn.1003-9406.2012.05.015
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wong CW, 2016, PROG RETIN EYE RES S, V53
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 25
TC 4
Z9 4
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 27
PY 2018
VL 24
BP 75
EP 82
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA FU3RH
UT WOS:000423768900001
PM 29410599
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, UM
   Richard, G
   Augustin, A
   Aylward, WG
   Bandello, F
   Corcostegui, B
   Cunha-Vaz, J
   Gaudric, A
   Leys, A
   Schlingemann, RO
AF Schmidt-Erfurth, Ursula M.
   Richard, Gisbert
   Augustin, Albert
   Aylward, William G.
   Bandello, Francesco
   Corcostegui, Borja
   Cunha-Vaz, Jose
   Gaudric, Alain
   Leys, Anita
   Schlingemann, Rainier O.
CA EURETINA
TI Guidance for the treatment of neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   guidelines; photocoagulation; photodynamic therapy; antiangiogenic
   therapy; combination therapy
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; PEGAPTANIB SODIUM; VERTEPORFIN THERAPY; BEVACIZUMAB
   AVASTIN; VISUAL-ACUITY; VEGF; RANIBIZUMAB; SECONDARY
AB Neovascular age-related macular degeneration is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever. This review article will focus on summarizing the actual options in the management of neovascular age-related macular degeneration and provide a short overview about recent therapeutic options in clinical and preclinical evaluation. The recent development of anti-VEGF substances for use in clinical routine has markedly improved the prognosis of patients with neovascular AMD. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF), for the first time in the history of AMD treatments, results in a significant increase in visual acuity in patients with neovascular AMD. Overall, antiangiogenic approaches provide vision maintenance in over 90% and substantial improvement in 25-40% of patients. The combination with occlusive therapies like photodynamic therapy (PDT) potentially offers a reduction of re-treatment frequency and long-term maintenance of the treatment benefit. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. Nevertheless, the growing number of novel therapeutic options will have to provide proof of concept in randomized controlled clinical trials, a major challenge in view of the rapidly evolving field. For those therapies, which are already in clinical use, reasonable diagnostic tools for follow-up need to be developed, as the burden of continuous clinical monitoring of all patients and all indications is significant for patients and doctors. Ultimately, economic issues will be the limiting factor for the clinical availability of different treatment options.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, Hamburg, Germany.
   Moorfields Eye Hosp, London, England.
   Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   Autonom Univ Barcelona, Inst Ocular Microsurg, Barcelona, Spain.
   Univ Hosp Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   Hop Lariboisiere, Ophthalmol Serv, Paris, France.
   Univ Leuven, Dept Ophthalmol, Louvain, Belgium.
C3 Medical University of Vienna; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   Udine; Autonomous University of Barcelona; Universidade de Coimbra;
   Centro Hospitalar e Universitario de Coimbra (CHUC); Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal
   - APHP; UDICE-French Research Universities; Universite Paris Cite; KU
   Leuven
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM Ursula.schmidt-erfurth@meduniwien.ac.at
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682; Cunha-Vaz,
   Jose/0000-0002-0947-9850; Augustin, Prof. Dr. Albert
   J./0000-0003-1591-0536; Gaudric, Alain/0000-0002-2486-4722
CR *AAO, 2006, PREF PRACT PATT AG R
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHAGN TS, 2006, IOVS, V45
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAGOUDAS ES, 2005, AM AC OPHTH SUBSP M
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HEIER J, 2004, IOVS, V45
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MIELER W, 2006, ANN M AM SOC RET SPE
   MILLER JW, 2005, AM SOC RET SPEC PROG
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 2006, ANN M AS PAC ASS OPH
   SCHMIDTERFURTH UM, 2006, IOVS, V47
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
NR 41
TC 80
Z9 89
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2007
VL 85
IS 5
BP 486
EP 494
DI 10.1111/j.1600-0420.2007.00979.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 193OF
UT WOS:000248282700003
PM 17655610
DA 2022-11-30
ER

PT J
AU Bashshur, ZF
   Schakal, A
   Hamam, RN
   El Haibi, CP
   Jaafar, RF
   Noureddin, BN
AF Bashshur, Ziad F.
   Schakal, Alexandre
   Hamam, Rola N.
   El Haibi, Christelle P.
   Jaafar, Rola F.
   Noureddin, Baha' N.
TI Intravitreal bevacizumab vs verteporfin photodynamic therapy for
   Neovascular age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AVASTIN; SAFETY; VEGF; ANTIBODY;
   PHARMACOKINETICS; RANIBIZUMAB; ANGIOGRAPHY; INJECTION; MEMBRANES
AB Objective: To compare verteporfin photodynamic therapy (PDT) with intravitreal bevacizumab for management of choroidal neovascularization (CNV) associated with age- related macular degeneration.
   Methods: Patients with predominantly classic CNV were prospectively randomized to receive standard PDT or intravitreal bevacizumab injections (2.5 mg). Best-corrected visual acuity (BCVA) measured by Snellen charts, central retinal thickness by optical coherence tomography, and greatest linear dimension of the CNV by fluorescein angiography were compared between the groups at baseline and at 3 and 6 months. Main outcome measures were stability or improvement in BCVA, decrease in central retinal thickness, and stability in greatest linear dimension.
   Results: Mean baseline BCVA, central retinal thickness, and greatest linear dimension were not statistically different between the bevacizumab (n= 32) and PDT (n= 30) groups. Mean central retinal thickness was significantly better at 3 and 6 months in the bevacizumab group vs the PDT group (P=. 04 and P=. 002, respectively). At 3 months, mean BCVA and greatest linear dimension were not significantly different between the 2 groups. At 6 months, mean BCVA and greatest linear dimension were significantly better in the bevacizumab group (P <. 001 and P=. 02, respectively).
   Conclusion: During 6 months, intravitreal bevacizumab was superior to PDT in controlling predominantly classic CNV in age- related macular degeneration. Additional randomized clinical trials are necessary to determine if this benefit will remain with longer follow- up.
C1 Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
   St Josephs Univ, Hotel Dieu France, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut; American University of Beirut; Saint
   Joseph University Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
RI Jaafar, Rola/AFB-0063-2022; Jaafar, Rola F/X-9979-2018; Hamam,
   Rola/K-7454-2019
OI Jaafar, Rola F/0000-0001-9477-7678; Hamam, Rola/0000-0001-8044-4215
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREMIGNI E, 2006, BR J OPHTHALMOL, V90, P1034
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   SPALDE RF, 2006, RETINA, V26, P383
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
NR 42
TC 61
Z9 63
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2007
VL 125
IS 10
BP 1357
EP 1361
DI 10.1001/archopht.125.10.1357
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 218EK
UT WOS:000249998600006
PM 17923543
OA Bronze
DA 2022-11-30
ER

PT J
AU Augood, C
   Chakravarthy, U
   Young, I
   Vioque, J
   de Jong, PTVM
   Bentham, G
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vingerling, JR
   Fletcher, AE
AF Augood, Cristina
   Chakravarthy, Usha
   Young, Ian
   Vioque, Jesus
   de Jong, Paulus T. V. M.
   Bentham, Graham
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Vingerling, Johannes R.
   Fletcher, Astrid E.
TI Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic
   acid intakes, and associations with neovascular age-related macular
   degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID 3RD NATIONAL-HEALTH; CIGARETTE-SMOKING; VISUAL IMPAIRMENT; RISK-FACTORS;
   FATTY-ACIDS; MACULOPATHY; PREVALENCE; NUTRITION; EUREYE; RANIBIZUMAB
AB Background: Fish intake, the major source of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may reduce the risk of age-related macular degeneration (AMD).
   Objective: We investigated the association of oily fish and dietary DHA and EPA with neovascular AMD (NV-AMD).
   Design: Participants aged >= 65 y in the cross-sectional population-based EUREYE study underwent fundus photography and were interviewed by using a food-frequency questionnaire. Fundus images were graded by the International Classification System for Age Related Maculopathy. Questionnaire data were converted to nutrient intakes with the use of food-composition tables. Survey logistic regression was used to calculate odds ratios (ORs) and 95% CIs of energy-adjusted quartiles of EPA or DHA with NV-AMD, taking into account potential confounders.
   Results: Dietary intake data and fundus images were available for 105 cases with NV-AMD and for 2170 controls without any features of early or late AMD. Eating oily fish at least once per week compared with less than once per week was associated with a halving of the odds of NV-AMD (OR = 0.47; 95% CI: 0.33, 0.68; P = 0.002). Compared with the lowest quartile, there was a significant trend for decreased odds with increasing quartiles of either DHA or EPA. ORs in the highest quartiles were 0.32 (95% CI: 0.12, 0.87; P = 0.03) for DHA and 0.29 (95% CI: 0.11, 0.73; P = 0.02) for EPA.
   Conclusions: Eating oily fish at least once per week compared with less than once per week was associated with a halving of the OR for NV-AMD.
C1 [Augood, Cristina; Fletcher, Astrid E.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, London WC1E 7HT, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Young, Ian] Queens Univ Belfast, Ctr Clin & Populat Sci, Belfast, Antrim, North Ireland.
   [Bentham, Graham] Univ E Anglia, Ctr Environm Risk, E Anglia, England.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Netherlands Inst Neurosci,KNAW, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.; Vingerling, Johannes R.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Haukeland Sykehus Univ Bergen, Bergen, Norway.
   [Soubrane, Gisele] Univ De Creteil, Clin Ophthalmol, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
   [Vingerling, Johannes R.] Univ Miguel Hernandez, Dept Salud Publ, Alicante & CIBER Epidemiol & Salud Publ CIBERESP, Altea, Spain.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Queens University Belfast; Queens University Belfast; University of East
   Anglia; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic
   Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC;
   National Institute for Health Development - Estonia; University of
   Bergen; Haukeland University Hospital; University of Verona; Aristotle
   University of Thessaloniki; CIBER - Centro de Investigacion Biomedica en
   Red; CIBERESP; Universidad Miguel Hernandez de Elche
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Vioque, Jesus/A-1066-2008; Rahu, Mati/A-9981-2008
OI Vioque, Jesus/0000-0002-2284-148X; Topouzis, Fotis/0000-0002-8966-537X;
   Young, Ian/0000-0003-3890-3152; Chakravarthy, Usha/0000-0002-2606-3734
FU European Commission Vth Framework [QLK6-CT-1999-02094]; Macular Disease
   Society UK; Estonian Ministry of Education and Science [01921112s02];
   Fondo de Investigacion Sanitaria [FIS 01/1692E, RCESP C 03/09]; Oficina
   de Ciencia y Tecnologia Generalitat Valenciana [CTGCA/2002/06]; Thomas
   Pocklington Trust
FX EUREYE was supported by the European Commission Vth Framework
   (QLK6-CT-1999-02094). Additional funding for the cameras was provided by
   the Macular Disease Society UK. MR was supported by the Estonian
   Ministry of Education and Science (target funding 01921112s02).
   Additional funding in Alicante was received from the Fondo de
   Investigacion Sanitaria. (grants FIS 01/1692E and RCESP C 03/09) and the
   Oficina de Ciencia y Tecnologia Generalitat Valenciana (grant
   CTGCA/2002/06). CA was supported by a grant from the Thomas Pocklington
   Trust.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FINCH S, 1998, NAT DIET NUTR SURVEY
   Gebauer SK, 2006, AM J CLIN NUTR, V83, p1526S, DOI 10.1093/ajcn/83.6.1526S
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   NETTLETON JA, 1991, J AM DIET ASSOC, V91, P331
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   U.S. Department of Agriculture A.R.S., 2005, USDA NAT NUTR DAT ST
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Willett W., 1990, NUTR EPIDEMIOLOGY
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
NR 30
TC 116
Z9 121
U1 0
U2 16
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG 1
PY 2008
VL 88
IS 2
BP 398
EP 406
DI 10.1093/ajcn/88.2.398
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 346FY
UT WOS:000259055300020
PM 18689376
OA Bronze
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
AF van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
TI The risk and natural course of age-related maculopathy - Follow-up at
   61/2 years in the Rotterdam study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULAR DEGENERATION; PREVALENCE; PROGRESSION;
   PROGNOSIS; DRUSEN
AB Objectives: To evaluate the natural course of age-related maculopathy (ARM) and to assess the incidence and absolute risk of its final stage, age-related macular degeneration (AMD).
   Methods: In a population-based prospective cohort study of 6418 persons 55 years and older, we studied the incidence and natural course of ARM. Subjects underwent identical examinations, including stereoscopic fundus photography, at baseline and at 2.0 and 6(1/2) years' follow-up. Age-related maculopathy was graded according to the International Classification and Grading System for ARM and AMD, and stratified into 5 exclusive stages. Incidence was expressed in rates and 5-year absolute risks.
   Results: At follow-up, 47 new cases of AMD were identified, with a ratio of neovascular-atrophic AMD of 1.4:1. The 5-year risk of AMD increased with more severe stages to 28.0% for subjects 55 years and older with indistinct drusen and pigmentary irregularities (stage 3). Age, but not sex, independently increased this risk to a maximum of 42.0% for subjects with stage 3 ARM who were 80 years and older. Individual ARM fundus signs that predicted best the development of AMD were 10 or more large drusen (125 mm) and 10% or more of the grid area covered by drusen. Subjects who developed atrophic AMD showed no significant (P=.25) differences in baseline fundus signs and natural course compared with subjects who developed neovascular AMD.
   Conclusions: We provide the absolute risk of AMD as a function of age and early ARM fundus signs, and showed that both are prominent independent risk factors. The progression of ARM stages follows, after the appearance of the first soft drusen, a distinct course at a gradual pace that accelerates with increasing age. Arch Ophthalmol. 2003;121:519-526.
C1 Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 14
TC 265
Z9 267
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2003
VL 121
IS 4
BP 519
EP 526
DI 10.1001/archopht.121.4.519
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664QM
UT WOS:000182071800011
PM 12695249
OA Bronze
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Spanjol, J
AF Vojnikovic, Bozidar
   Spanjol, Josip
TI Prednisolone neuroprotective therapy in age-related macular degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE macular degeneration; glucocorticoid therapy; neuroprotection
AB 134 patients with Age-related Macular Degeneration (AMD) (aging 47-75 years) were treated in therapy procedure with parabulbar injections of Methylprednisolone Acetate and Prednisolone Acetate. In the first group of patients with AMD (n = 71 patients) were treated with Methylprednisolone acetate, and second group (n = 63 patients) with Prednisolone acetate. Each patient was given doses of 60 mg, through two weeks, 10 mg every second day. It's estimated in all patients ameliorate in macular threshold, so that it's in the group with Methylprednisolone treatment, ameliorate effect begins after first week, than in second group, treated with Prednisolone, initial ameliorate effect is after second week. Complete effect in both groups is after 2 months. It can be concluded that the treatment of AMD with glucocorticoids has the ameliorate effect in vision loss and it is decided that earlier effect in the group treated with Methylprednisolone, is probably of higher affinity for glucocorticoid receptors.
C1 Eye Polyclin Dr B Vojnikov, Rijeka, Croatia.
   Rijeka Univ Hosp, Dept Urol, Rijeka, Croatia.
C3 University of Rijeka
RP Vojnikovic, B (通讯作者)，Eye Polyclin Dr B Vojnikov, Antuna Barca 3B, Rijeka, Croatia.
EM decv@decv.com
RI Španjol, Josip/A-1004-2010; Španjol, Josip/O-3756-2018
OI Španjol, Josip/0000-0002-5551-8128; Spanjol, Josip/0000-0001-9686-3393
CR ARTOLA A, 1993, OPHTHALMIC RES, V25, P172, DOI 10.1159/000267286
   GLICKMAN RD, 1992, PHOTOCHEM PHOTOBIOL, V55, P191, DOI 10.1111/j.1751-1097.1992.tb04227.x
   OPHIR A, 1992, OPHTHALMIC SURG LAS, V23, P284
   Rosner M, 1997, EXP EYE RES, V65, P485, DOI 10.1006/exer.1997.0360
   Solberg Y, 1999, SURV OPHTHALMOL, V44, pS85, DOI 10.1016/S0039-6257(99)00093-4
   UEJIMA Y, 1993, MECH AGEING DEV, V67, P129, DOI 10.1016/0047-6374(93)90117-A
   VERIAC S, 1992, CURR EYE RES, V11, P275, DOI 10.3109/02713689209001779
NR 7
TC 2
Z9 2
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 69
EP 70
PG 2
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800017
PM 17469755
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Ozimek, M
   Srisomboon, T
   Patikulsila, D
   Fraser-bell, S
   Chhablani, J
   Choovuthayakorn, J
   Watanachai, N
   Kunavisarut, P
   Rodriguez-Valdes, PJ
   Lozano-Rechy, D
   Lupidi, M
   Al-Sheikh, M
   Fung, AT
   Busch, C
   Mehta, H
   Gabrielle, PH
   Zur, D
   Ramon, D
   Sangkaew, A
   Ingviya, T
   Amphornprut, A
   Cebeci, Z
   Couturier, A
   Mendes, TS
   Giancipoli, E
   Iglicki, M
   Invernizzi, A
   Lains, I
   Rehak, M
   Sala-Puigdollers, A
   Okada, M
   Loewenstein, A
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Ozimek, Malgorzata
   Srisomboon, Titipol
   Patikulsila, Direk
   Fraser-bell, Samantha
   Chhablani, Jay
   Choovuthayakorn, Janejit
   Watanachai, Nawat
   Kunavisarut, Paradee
   Rodriguez-Valdes, Patricio J.
   Lozano-Rechy, David
   Lupidi, Marco
   Al-Sheikh, Mayss
   Fung, Adrian T.
   Busch, Catharian
   Mehta, Hemal
   Gabrielle, Pierre-Henry
   Zur, Dinah
   Ramon, Dan
   Sangkaew, Apisara
   Ingviya, Thammasin
   Amphornprut, Atchara
   Cebeci, Zafer
   Couturier, Aude
   Mendes, Thais Sousa
   Giancipoli, Ermete
   Iglicki, Matias
   Invernizzi, Alessandro
   Lains, Ines
   Rehak, Matus
   Sala-Puigdollers, Anna
   Okada, Mali
   Loewenstein, Anat
   Bressler, Neil M.
TI Polypoidal Choroidal Vasculopathy Based on Non-ICGA Criteria in White
   Patients With Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB; DIAGNOSIS; EFFICACY;
   JAPANESE; SAFETY
AB PURPOSE: To determine prevalence of probable poly-poidal choroidal vasculopathy (PCV) among White patients with neovascular age-related macular degeneration (nAMD) using non-indocyanine green angiography (ICGA) criteria & BULL; DESIGN: Multicenter, multinational, retrospective, cross-sectional study. METHODS: A total of 208 treatmentnaive eyes from Hispanic and non-Hispanic White individuals diagnosed with nAMD were included. All underwent color fundus photography (CFP), optical coherence tomography (OCT), and fluorescein angiography (FFA). De-identified images of study eyes were sent to 2 groups of graders. Group 1 reviewed CFP, OCT, and FFA to confirm nAMD diagnosis. Group 2 reviewed CFP and OCT to determine highly suggestive features for PCV. Probable PCV diagnosis defined as the presence of > 2 of 4 highly suggestive features for PCV: notched or fibrovascular pigment epithelial detachment (PED) on CFP, sharply-peaked PED, notched PED, and hyperreflective ring on OCT. RESULTS: Eleven eyes were excluded because of poor image quality (6) or non-nAMD diagnosis (5). Of 197 eligible eyes (197 patients), the mean age (SD) was 78.8 years (8.9), 44.2% were men, 26.4% were Hispanic, and 73.6% were non-Hispanic White individuals; 41.1%, 23.4%, 9.1%, and 2.5% had > 1, > 2, > 3, and 4 highly suggestive features. Results showed that 23.4% (95% CI, 17.6%-29.9%) had probable PCV diagnosis. Pre-dominantly occult CNV was more frequently found in probable PCV than nAMD subgroup (84.8% vs 64.9%, P = .01). Hispanic White individuals had a lower prevalence of probable PCV than non-Hispanic White individuals (9.6% vs 28.2%, P = .006) CONCLUSIONS: These findings suggest that probable PCV occurs between 17.6% and 29.9% in White individuals with nAMD, and more commonly in non-Hispanic than in Hispanic White individuals. (C) 2022 Elsevier Inc. All rights reserved.)
C1 [Chaikitmongkol, Voraporn; Srisomboon, Titipol; Patikulsila, Direk; Chhablani, Jay; Watanachai, Nawat; Kunavisarut, Paradee; Sangkaew, Apisara] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Ozimek, Malgorzata] Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland.
   [Ozimek, Malgorzata] Eye Surg Ctr Prof Zagorski Nowy Sacz, NowySacz, Poland.
   [Srisomboon, Titipol] Nakornping Hosp, Dept Ophthalmol, Chiang Mai, Thailand.
   [Fraser-bell, Samantha] Univ Sydney, Save Sight Inst, Dept Ophthalmol ogy, Sydney, NSW, Australia.
   [Chhablani, Jay] Univ Pittsburgh, Dept Ophthalmol, Eye Ctr, Pittsburgh, PA USA.
   [Rodriguez-Valdes, Patricio J.] Tecnol Monterrey, Hosp Zambrano Hellion, Inst Oftalmol & Ciencias Visuales, Monterrey, Mexico.
   [Lozano-Rechy, David] Conde Valenciana Eye Inst, Mexico City, Mexico.
   [Lupidi, Marco] Polytech Univ Marche, Dept Expt & Clin Med, Eye Clin, Ancona, Italy.
   [Al-Sheikh, Mayss] Univ Perugia, Fdn Macula Onlus, Di NOG Mi Sect Ophthalmol, Perugia, Italy.
   [Al-Sheikh, Mayss] Univ Hosp Zurich, Univ Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Fung, Adrian T.] Univ Sydney, Westmead & Cent Clin Sch, Specialty Ophthalmol & Eye Hlth, Sydney, NSW, Australia.
   [Fung, Adrian T.] Macquarie Univ Hosp, Fac Med Hlth & Human Sci, Dept Ophthalmol, Sydney, NSW, Australia.
   [Busch, Catharian; Rehak, Matus] Univ Leipzig, Dept Ophthalmol, Leipzig, Germany.
   [Mehta, Hemal] Royal Free London NHS Fdn Trust, Dept Ophthalmol, London, England.
   [Gabrielle, Pierre-Henry] Univ Hosp Dijon, Dept Ophthalmol, Dijon, France.
   [Zur, Dinah; Ramon, Dan; Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Ingviya, Thammasin] Prince Songkla Univ, Fac Med, Dept Family Med & Prevent Med, Hat Yai, Thailand.
   [Amphornprut, Atchara] Rangsit Univ, Rajvithi Hosp, Fac Med, Dept Ophthalmol, Bangkok, Thailand.
   [Cebeci, Zafer] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey.
   [Couturier, Aude] Univ Paris, Hop Lariboisiere, AP HP, Ophthalmol Dept, Paris, France.
   [Mendes, Thais Sousa] Univ Fed Sao Paulo, Dept Oph thalmol, Sao Paulo, Brazil.
   [Giancipoli, Ermete] Osped Vito Fazzi, Dept Ophthalmol, Piazza Filippo Muratore, Lecce, Italy.
   [Iglicki, Matias] Univ Buenos Aires, Buenos Aires, Argentina.
   [Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Invernizzi, Alessandro] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Lains, Ines] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA.
   [Rehak, Matus] Justus Liebig Univ Giessen, Dept Ophthalmol, Giessen, Germany.
   [Sala-Puigdollers, Anna] Hosp Clin Barcelona, Inst Clin Oftalmol ICOF, Barcelona, Spain.
   [Okada, Mali] Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, East Melbourne, Australia.
   [Bressler, Neil M.] Retina Div Wilmer Eye Inst, Johns Hopkins Sch Med, Baltimore, MD USA.
   [Bressler, Neil M.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
C3 Chiang Mai University; Medical University of Lublin; University of
   Sydney; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Tecnologico de Monterrey; Marche Polytechnic
   University; University of Perugia; University of Zurich; University
   Zurich Hospital; University of Sydney; Macquarie University; Leipzig
   University; University of London; University College London; Royal Free
   London NHS Foundation Trust; CHU Dijon Bourgogne; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Prince of
   Songkla University; Rajavithi Hospital; Rangsit University; Istanbul
   University; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; Universidade Federal de Sao Paulo
   (UNIFESP); Azienda Ospedaliera Vito Fazzi; University of Buenos Aires;
   University of Milan; Luigi Sacco Hospital; University of Sydney; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Justus Liebig University Giessen; University of Barcelona; Hospital
   Clinic de Barcelona; Royal Victorian Eye & Ear Hospital; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
CR Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liew G, 2021, EYE, V35, P1011, DOI 10.1038/s41433-020-0834-z
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2022
VL 244
BP 58
EP 67
DI 10.1016/j.ajo.2022.07.024
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5V7ZB
UT WOS:000877443100005
PM 35952753
DA 2022-11-30
ER

PT J
AU Manresa, N
   Mulero, J
   Losada, M
   Zafrilla, P
AF Manresa, Noemi
   Mulero, Juana
   Losada, Manuel
   Zafrilla, Pilar
TI EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE
   IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INDUCED OXIDATIVE STRESS;
   MYOCARDIAL-INFARCTION; RISK-FACTORS; CARDIOVASCULAR RISK;
   HYPERHOMOCYSTEINEMIA; EXPRESSION; BIOMARKERS; INHIBITORS; INCREASES
AB Purpose:
   To investigate homocysteine (Hcy) concentration in the blood plasma and the vitreous in patients with exudative age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor therapy.
   Methods:
   Plasma Hcy and vitreous Hcy levels were analyzed in 73 exudative age-related macular degeneration patients (50.7% received pegaptanib 0.3 mg and 50.3% received ranibizumab 0.5 mg) and compared with 80 controls and 40 patients with idiopathic epiretinal membranes, respectively. Homocysteine concentration was measured by immunonephelometric particle test, and it was determined before and after antiangiogenic therapy.
   Results:
   The mean Hcy concentrations (+/- SD) of blood plasma and vitreous were 13.0 +/- 4.2 mu mol/L and 1.00 +/- 0.3 mu mol/L in patients treated with pegaptanib; in ranibizumab group, they were 12.8 +/- 2.5 mu mol/L and 1.4 +/- 0.6 mu mol/L, respectively. The results of plasma and vitreous Hcy indicated statistically significant differences between exudative age-related macular degeneration patients and control groups (P = 0.03 and P = 0.02). After 6 months with both intravitreal therapies, the plasma and vitreous Hcy concentrations did not change significantly (P = 0.1).
   Conclusion:
   Pegaptanib and ranibizumab did not increase the plasma or vitreous Hcy concentrations.
C1 [Manresa, Noemi; Mulero, Juana; Zafrilla, Pilar] Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
   [Losada, Manuel] Univ Hosp Jose M Morales Meseguer, Dept Ophthalmol, Murcia, Spain.
C3 Universidad Catolica de Murcia
RP Manresa, N (通讯作者)，Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
EM noemi-mr@hotmail.com
RI Zafrilla, Pilar/H-8132-2012
FU laboratory Pzifer
FX Supported by Hospital Jose M. Morales Meseguer for development of this
   work, voluntary participation of patients, and the collaboration of
   analysis (M. Jose Carpes) in the study. Also, the study was partly
   supported by a grant from the laboratory Pzifer.
CR Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brar VS, 2012, OXID STRESS APPL BAS, P585, DOI 10.1007/978-1-61779-606-7_29
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Coral K, 2009, INVEST OPHTH VIS SCI, V50, P3607, DOI 10.1167/iovs.08-2667
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Guba M, 2005, BLOOD, V105, P4463, DOI 10.1182/blood-2004-09-3540
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kerr BA, 2012, NAT MED, V18, P1184, DOI 10.1038/nm.2881
   Kieran MW, 2012, COLD SPRING HARB PER, V2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee I, 2007, BIOSCI BIOTECH BIOCH, V71, P1203, DOI 10.1271/bbb.60657
   Lim CP, 2012, BRIT J OPHTHALMOL, V96, P704, DOI 10.1136/bjophthalmol-2011-301044
   Malinowska J, 2012, ACTA BIOCHIM POL, V59, P185
   Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Lecumberri JJN, 2013, REV CLIN ESP, V213, P229, DOI 10.1016/j.rce.2013.01.012
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Penedones A, 2014, J OCUL PHARMACOL TH, V30, P729, DOI 10.1089/jop.2013.0206
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Tyagi SC, 2005, CELL BIOCHEM BIOPHYS, V43, P37, DOI 10.1385/CBB:43:1:037
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang YX, 2011, AM J PHYSIOL-CELL PH, V301, pC695, DOI 10.1152/ajpcell.00322.2010
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1264, DOI 10.1001/archopht.125.9.1264
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
NR 48
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2015
VL 35
IS 9
BP 1765
EP 1771
DI 10.1097/IAE.0000000000000552
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2YK
UT WOS:000361196600008
PM 25923955
DA 2022-11-30
ER

PT J
AU Vittorio, AF
   Nguyen, V
   Barthelmes, D
   Arnold, JJ
   Cheung, CMG
   Murray, N
   Gillies, MC
AF Vittorio, Alexander F.
   Vuong Nguyen
   Barthelmes, Daniel
   Arnold, Jennifer J.
   Cheung, Chui M. G.
   Murray, Neil
   Gillies, Mark C.
CA Fight Retinal Blindness Study Grp
TI SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH
   FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; AMD; bevacizumab; cigarette; ranibizumab; nicotine
ID INTRAVITREAL RANIBIZUMAB THERAPY; VISUAL-ACUITY OUTCOMES; BASE-LINE
   PREDICTORS; CIGARETTE-SMOKING; RISK-FACTORS; PREVALENCE; VEGF;
   ASSOCIATION; AFLIBERCEPT; MACULOPATHY
AB Purpose: To assess whether smoking status affects 1-year visual outcomes in eyes treated with vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Methods: Retrospective analysis of data from a prospectively designed, multicenter, observational database. Nine hundred and eighty seven treatment-naive eyes of patients with neovascular age-related macular degeneration were tracked by the Fight Retinal Blindness! outcome registry in Australia, New Zealand, Singapore, and Switzerland who had documented smoking status at baseline and commenced vascular endothelial growth factor inhibitor therapy from January 2006 to December 2016. Generalized additive models were used to display visual acuity results. Results: There was a significant difference in mean improvement in visual acuity at 12 months between nonsmokers, ex-smokers, and current smokers (7.7 vs. 6.1 vs. 3.5 letters of change;P= 0.046) among patients who completed 12 months of treatment when adjusted for age, baseline visual acuity, and choroidal neovascular membrane lesion type and nested for practice. There was no significant difference in the median number of injections over 12 months of treatment by smoking status. Current smokers were a mean of 6.2 years younger than nonsmokers when they started treatment (P< 0.001). Conclusion: This study found inferior 12-month visual outcomes in patients who continued to smoke while receiving vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
C1 [Vittorio, Alexander F.] Princess Alexandra Hosp, Dept Ophthalmol, Brisbane, Qld, Australia.
   [Vuong Nguyen; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Cheung, Chui M. G.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Murray, Neil] Rotorua Eye Clin, Rotorua, New Zealand.
C3 University of Sydney; University of Zurich; University Zurich Hospital;
   Singapore National Eye Center
RP Gillies, MC (通讯作者)，Save Sight Inst, South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
FU Bayer; Novartis; Roche; NHMRC; RANZCO Eye Foundation; Royal Australian
   NZ College of Ophthalmologists Eye Foundation; National Health and
   Medical Research Council, Australia (NHMRC); Macular Disease Foundation,
   Australia
FX D. Barthelmes has research grants and travel expenses for Bayer &
   Novartis and acts as consultant for Alcon. J. J. Arnold has received
   honoraria from Novartis, Bayer, and Allergan and is a member of the
   medical advisory boards for Novartis, Bayer, and Allergan. C. M. G.
   Cheung has grants and personal fees from Bayer, grants and personal fees
   from Novartis, personal fees from Allergan, and grants from Roche. M. C.
   Gillies has grants from NHMRC, grants from RANZCO Eye Foundation, grants
   and others from Novartis, and grants and others from Bayer and is an
   inventor of the software used to track real-world outcomes in this
   study. Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012), and a
   grant from the Macular Disease Foundation, Australia. Funding was also
   provided by Novartis and Bayer. These supporting organizations had no
   role in the design or conduct of the research. The remaining authors
   have no conflict of interests to disclose.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   [Anonymous], 2016, GLOBAL HLTH OBSERVAT
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bott D, 2018, J PUBLIC HEALTH-UK, V40, P614, DOI 10.1093/pubmed/fdx115
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chu YK, 2013, INVEST OPHTH VIS SCI, V54, P7329, DOI 10.1167/iovs.13-12149
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Giovino GA, 2012, LANCET, V380, P668, DOI 10.1016/S0140-6736(12)61085-X
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kamao H, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2353428
   Kanoff J, 2013, SEMIN OPHTHALMOL, V28, P355, DOI 10.3109/08820538.2013.825292
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Ng M, 2014, JAMA-J AM MED ASSOC, V311, P183, DOI 10.1001/jama.2013.284692
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Peters SAE, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005663
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   R Core Team, 2017, R: A language and environment for statistical computing
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Williams GS, 2015, SAUDI J OPHTHALMOL, V29, P187, DOI 10.1016/j.sjopt.2015.02.004
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 51
TC 2
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1696
EP 1703
DI 10.1097/IAE.0000000000002679
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800008
PM 31613840
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Souied, EH
   Freund, KB
   Querques, G
   Miere, A
   Gal-Or, O
   Sacconi, R
   Sadda, SR
   Sarraf, D
AF Borrelli, Enrico
   Souied, Eric H.
   Freund, K. Bailey
   Querques, Giuseppe
   Miere, Alexandra
   Gal-Or, Orly
   Sacconi, Riccardo
   Sadda, Srinivas R.
   Sarraf, David
TI REDUCED CHORIOCAPILLARIS FLOW IN EYES WITH TYPE 3 NEOVASCULARIZATION AND
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choriocapillaris; optical coherence tomography angiography; Type 3
   neovascularization; age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL ANGIOMATOUS PROLIFERATION;
   ENDOTHELIAL GROWTH-FACTOR; CLINICOPATHOLOGICAL CORRELATION; CHOROIDAL
   THICKNESS; MOTION CORRECTION; SWEPT-SOURCE; FELLOW EYE; ANGIOGRAPHY;
   CLASSIFICATION
AB Purpose: To study choriocapillaris (CC) flow in eyes with Type 3 neovascularization (NV) and age-related macular degeneration, using optical coherence tomography angiography analysis.
   Methods: In this multicenter, retrospective, observational study, we collected data from 21 patients with unilateral Type 3 NV and age-related macular degeneration, based on clinical examination, structural optical coherence tomography, and fluorescein angiography when available. An additional group of 20 nonneovascular age-related macular degeneration eyes with unilateral Type 1 or Type 2 NV due to age-related macular degeneration was included for comparison. En face optical coherence tomography angiography imaging (3 x 3 mm scans) with quantitative microvascular analysis of the CC was performed. Main outcome measures were: 1) the percent nonperfused choriocapillaris area; and 2) the average CC signal void size.
   Results: We included 21 patients with unilateral Type 3 NV (15 female, 71.5%) and 20 patients with unilateral Type 1 or 2 NV (9 female, 45.0% P = 0.118). Mean +/- SD age was 82.1 +/- 7.4 years in the unilateral Type 3 patients and 78.3 +/- 8.1 in unilateral Type 1/2 NV subjects (P = 0.392). The percent nonperfused choriocapillaris area was 56.3 +/- 8.1% in eyes with Type 3 NV and 51.9 +/- 4.3% in the fellow eyes (P = 0.016). The average signal void size was also increased in those eyes with Type 3 NV (939.9 +/- 680.9 mu m(2)), compared with the fellow eyes (616.3 +/- 304.2 mu m(2), P = 0.039). The number of signal voids was reduced in the Type 3 NV eyes (604.5 +/- 282.9 vs. 747.3 +/- 195.8, P = 0.046). The subfoveal choroidal thickness was 135.9 +/- 54.2 mu m in eyes with Type 3 NV and 167.2 +/- 65.4 mu m in the fellow eyes (P = 0.003). In addition, the fellow eyes of patients with unilateral Type 3 NV displayed more significant CC flow abnormalities versus the fellow eyes with unilateral Type 1/2 NV (percent nonperfused choriocapillaris area = 51.9 +/- 4.3% vs. 46.0 +/- 2.1%, respectively, P < 0.0001; and average signal void size 616.3 +/- 304.2 mu m(2) versus 351.4 +/- 65.5 mu m(2), respectively, P < 0.0001; and number of signal voids 747.3 +/- 195.8 vs. 998.5 +/- 147.3, respectively, P < 0.0001).
   Conclusion: Eyes with unilateral Type 3 NV illustrated increased CC nonperfusion versus fellow nonneovascular eyes. These results suggest that choroidal ischemia may play an important role in the development of Type 3 NV.
C1 [Borrelli, Enrico; Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Ophthalmol Clin, Dept Med & Sci Ageing, Chieti, Italy.
   [Souied, Eric H.; Miere, Alexandra] Univ Paris XII, Dept Ophthalmol, Ctr Intercommunal Creteil, Creteil, France.
   [Freund, K. Bailey; Gal-Or, Orly] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey; Gal-Or, Orly] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Querques, Giuseppe; Sacconi, Riccardo] San Raffaele Univ Hosp, Dept Opthalmol, Milan, Italy.
   [Gal-Or, Orly] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Sacconi, Riccardo] Univ Verona, Eye Clin, Dept Neurol Biomed & Movement Sci, Verona, Italy.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Doheny Eye Institute; G d'Annunzio University of
   Chieti-Pescara; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil; Vitreous Retina Macula Consultants of New York; Manhattan Eye
   Ear & Throat Hospital; New York University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Rabin Medical Center;
   University of Verona; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los
   Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Geffen Sch Med, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Borrelli, Enrico/AAR-3693-2020; Miere, Alexandra/AIC-4074-2022; Freund,
   K. Bailey/V-7488-2018
OI Borrelli, Enrico/0000-0003-2815-5031; Miere,
   Alexandra/0000-0003-4123-8210; Sacconi, Riccardo/0000-0003-2891-2012;
   Freund, K. Bailey/0000-0002-7888-9773; Querques,
   Giuseppe/0000-0002-3292-9581
FU Research to Prevent Blindness, Inc; Macula Foundation Inc, New York, NY
FX Supported by an Unrestricted Grant from Research to Prevent Blindness,
   Inc to the Department of Ophthalmology, Stein Eye Institute, UCLA (D.S.)
   and the Macula Foundation Inc, New York, NY.
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Borrelli E, 2019, RETINA-J RET VIT DIS, V39, P1216, DOI 10.1097/IAE.0000000000002123
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 49
TC 77
Z9 77
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1968
EP 1976
DI 10.1097/IAE.0000000000002198
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600019
PM 29746411
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Fleckenstein, M
   Fiebig, BS
   Schmitz-Valckenberg, S
   Bindewald-Wittich, A
   Keilhauer, CN
   Renner, AB
   Mackensen, F
   Mossner, A
   Pauleikhoff, D
   Adrion, C
   Mansmann, U
   Scholl, HPN
   Holz, FG
   Weber, BHF
AF Fritsche, Lars G.
   Fleckenstein, Monika
   Fiebig, Britta S.
   Schmitz-Valckenberg, Steffen
   Bindewald-Wittich, Almut
   Keilhauer, Claudia N.
   Renner, Agnes B.
   Mackensen, Friederike
   Moessner, Andreas
   Pauleikhoff, Daniel
   Adrion, Christine
   Mansmann, Ulrich
   Scholl, Hendrik P. N.
   Holz, Frank G.
   Weber, Bernhard H. F.
TI A Subgroup of Age-Related Macular Degeneration is Associated With
   Mono-Allelic Sequence Variants in the ABCA4 Gene
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; FUNDUS AUTOFLUORESCENCE PATTERNS;
   STARGARDT-DISEASE; GEOGRAPHIC ATROPHY; MISSENSE MUTATIONS; TRANSPORTER
   GENE; RISK; PROGRESSION; LIPOFUSCIN; DYSTROPHY
AB PURPOSE. Age-related macular degeneration (AMD) is a heterogeneous condition of high prevalence and complex etiology involving genetic as well as environmental factors. By fundus autofluorescence (FAF) imaging, AMD can be classified into several distinct phenotypes, with one subgroup characterized by fine granular pattern with peripheral punctate spots (GPS[+]). Some features of GPS[+] overlap with Stargardt disease (STGD1), a recessive macular dystrophy caused by biallelic sequence variants in the ATP-binding cassette transporter 4 (ABCA4) gene. The aim of this study was to investigate the role of ABCA4 in GPS[+].
   METHODS. The ABCA4 gene was sequenced in 25 patients with the GPS[+] phenotype and 29 with geographic atrophy (GA)-AMD but no signs of GPS (GPS[-]). In addition, frequencies of risk-increasing alleles at three known AMD susceptibility loci, including complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and complement component 3 (C3), were evaluated.
   RESULTS. We demonstrate that GPS[+] is associated significantly with monoallelic ABCA4 sequence variants. Moreover, frequencies of AMD risk-increasing alleles at CFH, ARMS2, and C3 are similar in GPS[+] and STGD1 patients, with risk allele frequencies in both subcategories comparable to population-based control individuals estimated from 3,510 individuals from the NHLBI Exome Sequencing Project.
   CONCLUSIONS. Our data suggest that the GPS[+] phenotype is accounted for by monoallelic variants in ABCA4 and unlikely by the well-established AMD risk-increasing alleles at CFH, ARMS2, and C3. These findings provide support for a complex role of ABCA4 in the etiology of a minor proportion of patients with AMD. (Invest Ophthalmol Vis Sci. 2012;53:2112-2118) DOI:10.1167/iovs.11-8785
C1 [Fritsche, Lars G.; Fiebig, Britta S.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Renner, Agnes B.] Univ Regensburg, Dept Ophthalmol, D-93053 Regensburg, Germany.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Bindewald-Wittich, Almut; Scholl, Hendrik P. N.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Mackensen, Friederike] Univ Heidelberg, Dept Ophthalmol, Heidelberg, Germany.
   [Moessner, Andreas] Univ Leipzig, Dept Ophthalmol, Leipzig, Germany.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Adrion, Christine; Mansmann, Ulrich] Univ Munich, Dept Med Informat Biometry & Epidemiol, Munich, Germany.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Regensburg; University of Regensburg; University of Bonn;
   University of Wurzburg; Ruprecht Karls University Heidelberg; Leipzig
   University; St. Franziskus-Hospital; University of Munich; Johns Hopkins
   University; Johns Hopkins Medicine
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Bindewald-Wittich,
   Almut/0000-0002-8151-3953; Adrion, Christine/0000-0003-2408-2533; Weber,
   Bernhard H.F./0000-0002-8808-7723; Fleckenstein,
   Monika/0000-0001-8321-8037
FU Deutsche Forschungsgemeinschaft [WE1259/18-1, WE1259/19-2]; Research
   Priority Program Age-Related Macular Degeneration [SPP 1088 Ho
   1926/1-3]; Ruth and Milton Steinbach Foundation New York; Alcon Research
   Institute; EU; Integrated Project "EVI-GENORET" [LSHG-CT-2005-512036];
   German Society of Ophthalmology; BONFOR, Faculty of Medicine, University
   of Bonn [O-137-0012]
FX Supported in part by grants from the Deutsche Forschungsgemeinschaft
   WE1259/18-1 (BHFW), WE1259/19-1 (BHFW), WE1259/19-2 (BHFW); Research
   Priority Program Age-Related Macular Degeneration SPP 1088 Ho 1926/1-3
   (FGH); the Ruth and Milton Steinbach Foundation New York (BHFW); the
   Alcon Research Institute (BHFW); EU FP6, Integrated Project
   "EVI-GENORET" LSHG-CT-2005-512036 (FGH, HPNS); German Society of
   Ophthalmology research grant (MF); BONFOR Program, Faculty of Medicine,
   University of Bonn, grant O-137-0012 (MF).
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Aguirre-Lamban J, 2011, INVEST OPHTH VIS SCI, V52, P6206, DOI 10.1167/iovs.10-5743
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   [Anonymous], 2011, R LANG ENV STAT COMP
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421
   Cideciyan AV, 2005, INVEST OPHTH VIS SCI, V46, P4739, DOI 10.1167/iovs.05-0805
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2009, RETINA-J RET VIT DIS, V29, P181, DOI 10.1097/IAE.0b013e31818a2c01
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li B, 2009, BIOINFORMATICS, V25, P2744, DOI 10.1093/bioinformatics/btp528
   Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martinez-Mir A, 1998, NAT GENET, V15, P236
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   Zernant J, 2011, INVEST OPHTH VIS SCI, V52, P8479, DOI 10.1167/iovs.11-8182
NR 45
TC 61
Z9 62
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2012
VL 53
IS 4
BP 2112
EP 2118
DI 10.1167/iovs.11-8785
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 937PC
UT WOS:000303669400048
PM 22427542
DA 2022-11-30
ER

PT J
AU Bailey, JNC
   Hoffman, JD
   Sardell, RJ
   Scott, WK
   Pericak-Vance, MA
   Haines, JL
AF Bailey, Jessica N. Cooke
   Hoffman, Joshua D.
   Sardell, Rebecca J.
   Scott, William K.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI The Application of Genetic Risk Scores in Age-Related Macular
   Degeneration: A Review
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration (AMD); genetics; risk score
ID GENOMEWIDE-SCAN; SUSCEPTIBILITY LOCI; MACULOPATHY; CFH; RARE;
   ASSOCIATION; PROGRESSION; PREDICTION; VARIANT; ARMS2
AB Age-related macular degeneration (AMD), a highly prevalent and impactful disease of aging, is inarguably influenced by complex interactions between genetic and environmental factors. Various risk scores have been tested that assess measurable genetic and environmental contributions to disease. We herein summarize and review the ability and utility of these numerous models for prediction of AMD and suggest additional risk factors to be incorporated into clinically useful predictive models of AMD.
C1 [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Inst Computat Biol, Cleveland, OH 44106 USA.
   [Hoffman, Joshua D.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA.
   [Sardell, Rebecca J.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
C3 Case Western Reserve University; Case Western Reserve University;
   University of California System; University of California San Francisco;
   University of Miami
RP Bailey, JNC; Haines, JL (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.; Bailey, JNC; Haines, JL (通讯作者)，Case Western Reserve Univ, Inst Computat Biol, Cleveland, OH 44106 USA.
EM jnc43@case.edu; joshua.hoffman@ucsf.edu; r.sardell@med.miami.edu;
   bscott@med.miami.edu; mpericak@med.miami.edu; jlh213@case.edu
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Bailey, Jessica
   Cooke/Q-5062-2019; Haines, Jonathan/C-3374-2012; Mitchell,
   Paul/P-1498-2014
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Bailey, Jessica
   Cooke/0000-0002-4001-8702; Haines, Jonathan/0000-0002-4351-4728; 
FU PhRMA Foundation Postdoctoral Informatics Fellowship; NIH [EY022310,
   EY012118, EY023164];  [T32 EY023194]; NATIONAL EYE INSTITUTE
   [R01EY012118, T32EY023194, R01EY023164, R01EY022310, U10EY012118]
   Funding Source: NIH RePORTER
FX Jessica N. Cooke Bailey is partially supported by a PhRMA Foundation
   Postdoctoral Informatics Fellowship. Rebecca J. Sardell is supported by
   T32 EY023194. This work was also supported by NIH grants EY022310,
   EY012118, and EY023164.
CR Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Cooke Bailey J.N., 2014, COLD SPRING HARB PER
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ingelman-Sundberg M, 2015, J INTERN MED, V277, P152, DOI 10.1111/joim.12325
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Janssens ACJW, 2007, GENET MED, V9, P528, DOI 10.1097/GIM.0b013e31812eece0
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Lewis Cathryn M, 2002, Brief Bioinform, V3, P146, DOI 10.1093/bib/3.2.146
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Sahebi L., 2013, ISRN GENET, V2013
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Williamson JF, 2011, GENOMICS, V98, P412, DOI 10.1016/j.ygeno.2011.08.002
   Wu Y, 2015, INT J CLIN EXP PATHO, V8, P7403
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 69
TC 15
Z9 15
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2016
VL 5
IS 3
AR 31
DI 10.3390/jcm5030031
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DI7VW
UT WOS:000373711100004
PM 26959068
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lin, JB
   Halawa, OA
   Husain, D
   Miller, JW
   Vavvas, DG
AF Lin, Jonathan B.
   Halawa, Omar A.
   Husain, Deeba
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Dyslipidemia in age-related macular degeneration
SO EYE
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; DRUSEN;
   CHOLESTEROL; PROGRESSION; METABOLOMICS; MACULOPATHY; POPULATION;
   ETIOLOGY
AB Lipid-rich drusen are the sine qua non of age-related macular degeneration (AMD), the leading cause of blindness in older adults in the developed world. Efforts directed at uncovering effective therapeutic strategies have led to the hypothesis that altered lipid metabolism may play a pathogenic role in AMD. This hypothesis is supported by the fact that: (1) drusen, the hallmark histopathologic feature of AMD, are composed of lipids, (2) polymorphisms of genes involved in lipid homeostasis are associated with increased odds of AMD, (3) metabolomics studies show that patients with AMD have alterations in metabolites from lipid pathways, and (4) alterations in serum lipid profiles as a reflection of systemic dyslipidemia are associated with AMD. There is strong evidence that statins, which are well described for treating dyslipidemia and reducing risk associated with cardiovascular disease, may have a role for treating certain cohorts of AMD patients, but this has yet to be conclusively proven. Of interest, the specific changes in serum lipoprotein profiles associated with decreased cardiovascular risk (i.e., high HDL levels) have been shown in some studies to be associated with increased risk of AMD. In this review, we highlight the evidence that supports a role for altered lipid metabolism in AMD and provide our perspective regarding the remaining questions that need to be addressed before lipid-based therapies can emerge for specific cohorts of AMD patients.
C1 [Lin, Jonathan B.; Halawa, Omar A.; Husain, Deeba; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Mass Eye & Ear, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School
RP Vavvas, DG (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Retina Serv, Mass Eye & Ear, Boston, MA 02115 USA.
EM demetrios_vavvas@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996; Vavvas, Demetrios/0000-0002-8622-6478
FU Monte J. Wallace Chair in Retina; Ines and Fred Yeatts Retina Research
   lab fund; MLS Foundation; American Macular Degeneration Foundation
FX DGV was supported by the Monte J. Wallace Chair in Retina, the Ines and
   Fred Yeatts Retina Research lab fund, the MLS Foundation, and the
   American Macular Degeneration Foundation. The funders played no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the paper.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   ALBRINK MJ, 1963, AM J OPHTHALMOL, V55, P709, DOI 10.1016/0002-9394(63)92428-0
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fernandez-Vega B, 2020, ACTA OPHTHALMOL, V98, pE282, DOI 10.1111/aos.14280
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kosowski M, 2021, MOLECULES, V26, DOI 10.3390/molecules26102838
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   Mao FF, 2019, INVEST OPHTH VIS SCI, V60, P4966, DOI 10.1167/iovs.19-27325
   Mast N, 2018, DRUG METAB DISPOS, V46, P1528, DOI 10.1124/dmd.118.083345
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071
   Sacks FM, 2020, ARTERIOSCL THROM VAS, V40, P2714, DOI 10.1161/ATVBAHA.120.314609
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van der Kant R, 2019, CELL STEM CELL, V24, P363, DOI 10.1016/j.stem.2018.12.013
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   Wang K, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010301
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
NR 63
TC 2
Z9 2
U1 2
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 312
EP 318
DI 10.1038/s41433-021-01780-y
EA JAN 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000741317500003
PM 35017697
DA 2022-11-30
ER

PT J
AU Mathew, R
   Pearce, E
   Sivaprasad, S
AF Mathew, Raeba
   Pearce, Elizabeth
   Sivaprasad, Sobha
TI Determinants of Fixation in Eyes With Neovascular Age-Related Macular
   Degeneration Treated With Intravitreal Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL-NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; VISUAL-ACUITY
AB PURPOSE: To correlate the anatomic features of the macula with functional parameters like location and stability of fixation in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab injections.
   DESIGN: Retrospective analysis.
   METHODS: The location and stability of fixation were determined in 41 eyes of 41 patients treated with ranibizumab for neovascular age-related macular degeneration for at least 12 months. All patients underwent 3 injections of ranibizumab 1 month apart and were retreated according to predefined criteria. The fixation parameters measured with microperimetry were correlated to visual acuity, qualitative measures on optical coherence tomography, and patterns of autofluorescence.
   RESULTS: The location of fixation was predominantly central in 68.29%, poor central in 2.4%, and predominantly eccentric in 29.27%. The fixation was stable in 80.5%, relatively unstable in 7.3%, and unstable in 12.2%. The factors that determined central and stable location of fixation were better visual acuity (P = .004), absence of subretinal thickening (P = .003), intact subfoveal third hyperreflective band (P = .006), and intact external limiting membrane (P = .036). Autofluorescence pattern within the 4-degree circle of fovea did not correlate with fixation characteristics. However, complete absence of autofluorescence in this area was a poor prognostic indicator for central fixation.
   CONCLUSIONS: Anatomic characteristics of the macula determine fixation patterns in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab injections. Further studies focused on eyes with complete absence of autofluorescence in the central 4-degree circle of fovea may help to define the disease characteristics in this group. (Am J Ophthalmol 2012; 153:490-496. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Mathew, Raeba; Pearce, Elizabeth; Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Mathew, R (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM r_mathew@hotmail.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Novartis; Allergan; Pfizer
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL, CONFLICTS OF INTEREST, and indicate no financial support.
   Dr Sivaprasad has received research grants, travel fees, and speaker
   fees from and has participated on the advisory boards of Novartis,
   Allergan, and Pfizer. Involved in Design and conduct of study (R.M.,
   E.P., S.S.); Collection of data (R.M., E.P.); Management, analysis, and
   interpretation of data (R.M., S.S.); and Preparation, review, and
   approval of manuscript (R.M., S.S.). The study was approved
   prospectively by the chair of the Ethics Committee of King's College
   Hospital, NHS Foundation Trust, and adhered to the tenets of the
   Declaration of Helsinki.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Pearce E, 2011, EYE, V25, P149, DOI 10.1038/eye.2010.167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
NR 12
TC 6
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2012
VL 153
IS 3
BP 490
EP 496
DI 10.1016/j.ajo.2011.08.034
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907CB
UT WOS:000301394300014
PM 22071230
DA 2022-11-30
ER

PT J
AU Sin, HPY
   Liu, DTL
   Lam, DSC
AF Sin, Helena P. Y.
   Liu, David T. L.
   Lam, Dennis S. C.
TI Lifestyle modification, nutritional and vitamins supplements for
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; anthocyanins; antioxidants; fatty
   acids; omega-3; lutein; vitamins; zeaxanthin
ID DIETARY GLYCEMIC INDEX; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS; PLASMA
   HOMOCYSTEINE; 5-YEAR INCIDENCE; EYE DISEASE; RISK; MACULOPATHY; LUTEIN;
   ANTHOCYANINS
AB . Purpose: To provide a systematic review of the published studies pertaining to the lifestyle modification, dietary, nutritional and vitamins supplements for preventing occurrence or halting deterioration of age-related macular degeneration (AMD). Methods: The literature searches from 1990 to December 2010 with following keywords, age related macular degeneration, nutrition, antioxidant, diet and vitamins supplements using search engines Pubmed, Google Scholar, Medline and the Cochrane Library. Meta-analyses, population-based cohort studies and case-controlled trials were reviewed, whereas small cases series, case reports, commentaries, abstracts in proceedings or personal observations were excluded. Results: Smoking and obesity are identified risk factors for AMD. High dietary intakes of omega-3 fatty acids, and macular xanthophylls lutein and zeaxanthin have been associated with a lower risk of prevalence and incidence in AMD. Vitamin B and extracts from wolfberry, Gingko biloba and berry anthocyanins were also subjects of intense research interests, but there has been no concluding scientific evidence yet. The Age-Related Eye Disease study (AREDS) is the only large-scale randomized controlled clinical trial to show beneficial effect of AREDS formulation of vitamins C, E, beta-carotene and zinc with copper in reducing the risk progression to advanced AMD in patients with intermediate AMD or with advanced AMD in one eye. Conclusion: Quit smoking is an important advice to patients to prevent or slow the progress of AMD. There is no recommendation for routine nutritional or vitamins supplementation for primary prevention. However, patients with documented intermediate risk of AMD or advanced AMD in one eye are recommended to take AREDS-type vitamin supplements.
C1 [Sin, Helena P. Y.; Liu, David T. L.; Lam, Dennis S. C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Liu, DTL (通讯作者)，Hong Kong Eye Hosp, Univ Eye Ctr, Dept Ophthalmol & Visual Sci, 3-F, Hong Kong, Hong Kong, Peoples R China.
EM david_tlliu@yahoo.com
RI Lam, Dennis/AAL-1211-2020
OI Sin, Pui Yee/0000-0002-3332-7937
CR Ashfield-Watt PAL, 2001, BIOMED PHARMACOTHER, V55, P425, DOI 10.1016/S0753-3322(01)00125-1
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cheng CY, 2005, BRIT J NUTR, V93, P123, DOI 10.1079/BJN20041284
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Durukan AH, 2006, J CATARACT REFR SURG, V32, P1041, DOI 10.1016/j.jcrs.2006.02.041
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans J.R., 2000, COCHRANE DB SYST REV, V2
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Manheimer E, 2009, J ALTERN COMPLEM MED, V15, P1001, DOI 10.1089/acm.2008.0414
   Mares JA, 2010, ARCH OPHTHALMOL-CHIC
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 46
TC 53
Z9 59
U1 0
U2 83
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2013
VL 91
IS 1
BP 6
EP 11
DI 10.1111/j.1755-3768.2011.02357.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078WG
UT WOS:000314130400005
PM 22268800
DA 2022-11-30
ER

PT J
AU Fang, HH
   Li, F
   Fu, HZ
   Sun, X
   Cao, XX
   Lin, FB
   Son, JM
   Kim, SH
   Quellec, G
   Matta, S
   Shankaranarayana, SM
   Chen, YT
   Wang, CH
   Shah, NA
   Lee, CY
   Hsu, CC
   Xie, H
   Lei, BY
   Baid, U
   Innani, S
   Dang, K
   Shi, WX
   Kamble, R
   Singhal, N
   Wang, CW
   Lo, SC
   Orlando, JI
   Bogunovic, H
   Zhang, XL
   Xu, YW
AF Fang, Huihui
   Li, Fei
   Fu, Huazhu
   Sun, Xu
   Cao, Xingxing
   Lin, Fengbin
   Son, Jaemin
   Kim, Sunho
   Quellec, Gwenole
   Matta, Sarah
   Shankaranarayana, Sharath M.
   Chen, Yi-Ting
   Wang, Chuen-Heng
   Shah, Nisarg A.
   Lee, Chia-Yen
   Hsu, Chih-Chung
   Xie, Hai
   Lei, Baiying
   Baid, Ujjwal
   Innani, Shubham
   Dang, Kang
   Shi, Wenxiu
   Kamble, Ravi
   Singhal, Nitin
   Wang, Ching-Wei
   Lo, Shih-Chang
   Orlando, Jose Ignacio
   Bogunovic, Hrvoje
   Zhang, Xiulan
   Xu, Yanwu
CA iChallenge-AMD Study Grp
TI ADAM Challenge: Detecting Age-Related Macular Degeneration From Fundus
   Images
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Lesions; Image segmentation; Biomedical optical imaging; Optical
   imaging; Retina; Diseases; Task analysis; AMD detection; optic disc
   segmentation; fovea localization; lesion segmentation
ID FOVEA LOCALIZATION; OPTIC DISC; SEGMENTATION; NETWORK; CLASSIFICATION;
   RELIABILITY; ENSEMBLE; LESIONS; CUP
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment among elderly in the world. Early detection of AMD is of great importance, as the vision loss caused by this disease is irreversible and permanent. Color fundus photography is the most cost-effective imaging modality to screen for retinal disorders. Cutting edge deep learning based algorithms have been recently developed for automatically detecting AMD from fundus images. However, there are still lack of a comprehensive annotated dataset and standard evaluation benchmarks. To deal with this issue, we set up the Automatic Detection challenge on Age-related Macular degeneration (ADAM), which was held as a satellite event of the ISBI 2020 conference. The ADAM challenge consisted of four tasks which cover the main aspects of detecting and characterizing AMD from fundus images, including detection of AMD, detection and segmentation of optic disc, localization of fovea, and detection and segmentation of lesions. As part of the ADAM challenge, we have released a comprehensive dataset of 1200 fundus images with AMD diagnostic labels, pixel-wise segmentation masks for both optic disc and AMD-related lesions (drusen, exudates, hemorrhages and scars, among others), as well as the coordinates corresponding to the location of the macular fovea. A uniform evaluation framework has been built to make a fair comparison of different models using this dataset. During the ADAM challenge, 610 results were submitted for online evaluation, with 11 teams finally participating in the onsite challenge. This paper introduces the challenge, the dataset and the evaluation methods, as well as summarizes the participating methods and analyzes their results for each task. In particular, we observed that the ensembling strategy and the incorporation of clinical domain knowledge were the key to improve the performance of the deep learning models.
C1 [Fang, Huihui; Sun, Xu; Cao, Xingxing; Xu, Yanwu] Baidu Inc, Intelligent Healthcare Unit, Beijing 100085, Peoples R China.
   [Li, Fei; Lin, Fengbin; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou 510623, Peoples R China.
   [Fu, Huazhu] Agcy Sci Technol & Res, Inst High Performance Comp, Singapore 138632, Singapore.
   [Son, Jaemin; Kim, Sunho] VUNO Inc, Seoul 06536, South Korea.
   [Quellec, Gwenole; Matta, Sarah] INSERM, UMR 1101, F-29200 Brest, France.
   [Matta, Sarah] Univ Bretagne Occidentale, Lab Traitement Informat Med, F-29200 Brest, France.
   [Shankaranarayana, Sharath M.] Zasti India Pvt Ltd, Chennai 600113, Tamil Nadu, India.
   [Chen, Yi-Ting] Graphen Inc, New York, NY 10110 USA.
   [Wang, Chuen-Heng] Muen Biomed & Optoelect Technol Inc, Taipei 115, Taiwan.
   [Shah, Nisarg A.] Indian Inst Technol Jodhpur, Dept Elect Engn, Karwar 342030, Rajasthan, India.
   [Lee, Chia-Yen] Natl United Univ, Dept Elect Engn, Miaoli 36003, Taiwan.
   [Hsu, Chih-Chung] Natl Cheng Kung Univ, Inst Data Sci, Dept Stat, Tainan 701, Taiwan.
   [Xie, Hai; Lei, Baiying] Shenzhen Univ, Sch Biomed Engn, Shenzhen 518060, Peoples R China.
   [Baid, Ujjwal; Innani, Shubham] SGGS Inst Engn & Technol, Nanded 431606, India.
   [Dang, Kang; Shi, Wenxiu] VoxelCloud Ltd, Shanghai 201114, Peoples R China.
   [Kamble, Ravi; Singhal, Nitin] AIRA Matrix, Thana 400604, Maharashtra, India.
   [Wang, Ching-Wei; Lo, Shih-Chang] Natl Taiwan Univ Sci & Technol, Grad Inst Biomed Engn, Taipei 106, Taiwan.
   [Orlando, Jose Ignacio] UNICEN, Yatiris Grp, PLADEMA Inst, CONICET, RA-7000 Tandil, Argentina.
   [Bogunovic, Hrvoje] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Artificial Intelligence Ret, A-1090 Vienna, Austria.
C3 Baidu; Sun Yat Sen University; Agency for Science Technology & Research
   (A*STAR); A*STAR - Institute of High Performance Computing (IHPC);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bretagne Occidentale; Universite de Bretagne Occidentale;
   Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Jodhpur; National United University; National Cheng
   Kung University; Shenzhen University; Shri Guru Gobind Singhji Institute
   of Engineering & Technology; National Taiwan University of Science &
   Technology; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); Medical University of Vienna
RP Xu, YW (通讯作者)，Baidu Inc, Intelligent Healthcare Unit, Beijing 100085, Peoples R China.; Zhang, XL (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangdong Prov Key Lab Ophthalmol & Visual Sci, Guangzhou 510623, Peoples R China.
EM fanghuihuibit@163.com; lifei57@mail.sysu.edu.cn; hzfu@ieee.org;
   pamixsun@foxmail.com; caoxingxing@baidu.com; linfb52@163.com;
   woalsdnd@gmail.com; ksunho0660@vuno.co; gwenole.quellec@inserm.fr;
   sarah.matta@univ-brest.fr; sharathms.iit@gmail.com; timchen@graphen.ai;
   andrew.wang@mail2000.com.tw; shah.2@iitj.ac.in; leecyya@gmail.com;
   cchsu@gs.ncku.edu.tw; shehare@szu.edu.cn; leiby@szu.edu.cn;
   ujjwalbaid0408@gmail.com; 2016bec035@sggs.ac.in;
   kdang@voxelcloud.net.cn; 1553916604@qq.com; ravi.kamble@airamatrix.com;
   nitin.singhal@airamatrix.com; cwwang1979@gmail.com;
   edward70932@gmail.com; jiorlando@pladema.exa.unicen.edu.ar;
   hrvoje.bogunovic@meduniwien.ac.at; zhangxl2@mail.sysu.edu.cn;
   xuyanwu@baidu.com
RI Fu, Huazhu/A-1411-2014; Fang, Huihui/GZG-9742-2022; Wang,
   Ching-Wei/GXV-5212-2022; Quellec, Gwenole/L-9946-2015
OI Fu, Huazhu/0000-0002-9702-5524; Wang, Ching-Wei/0000-0001-9992-6863; Lo,
   Shih-Chang/0000-0003-2461-0498; Fang, Huihui/0000-0003-3380-7970; Sun,
   Xu/0000-0001-9155-0427; Quellec, Gwenole/0000-0003-1669-7140
FU High-Level Hospital Construction Project, Zhongshan Ophthalmic Center,
   Sun Yat-sen University [303020104]; Singapore A*STAR Advanced
   Manufacturing and Engineering (AME) Programmatic Fund [A20H4b0141];
   Young Talent Support Project of Guangzhou Association for Science and
   Technology (2022)
FX This work was supported in part by the High-Level Hospital Construction
   Project, Zhongshan Ophthalmic Center, Sun Yat-sen University, under
   Grant 303020104; in part by the Singapore A*STAR Advanced Manufacturing
   and Engineering (AME) Programmatic Fund, under Grant A20H4b0141; and in
   part by the Young Talent Support Project of Guangzhou Association for
   Science and Technology (2022).
CR Akram MU, 2013, 2013 INTERNATIONAL CONFERENCE ON ELECTRONICS, COMPUTER AND COMPUTATION (ICECCO), P17, DOI 10.1109/ICECCO.2013.6718217
   Almazroa A, 2018, PROC SPIE, V10579, DOI 10.1117/12.2293584
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anitha J., 2014, PROC INT C ELECT COM, P1
   [Anonymous], 2019, PALM CHALLENGE PATHO
   BARTKO JJ, 1991, SCHIZOPHRENIA BULL, V17, P483, DOI 10.1093/schbul/17.3.483
   Brownlee J., 2018, MACHINE LEARNING MAS
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chea N, 2021, CMC-COMPUT MATER CON, V67, P411, DOI 10.32604/cmc.2021.013390
   Chen L., 2017, ARXIV
   Cui Y, 2019, PROC CVPR IEEE, P9260, DOI 10.1109/CVPR.2019.00949
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Engelberts J, 2019, INVEST OPHTH VIS SCI, V60
   Fang H., 2022, ARXIV
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fu H., 2019, IEEE DATAPORT, DOI [10.21227/55pk-8z03, DOI 10.21227/55PK-8Z03]
   Fu HZ, 2020, MED IMAGE ANAL, V66, DOI 10.1016/j.media.2020.101798
   Fu HZ, 2018, IEEE T MED IMAGING, V37, P2493, DOI 10.1109/TMI.2018.2837012
   Garcia M, 2010, MED ENG PHYS, V32, P1085, DOI 10.1016/j.medengphy.2010.07.014
   Geirhos R, 2020, NAT MACH INTELL, V2, P665, DOI 10.1038/s42256-020-00257-z
   Girshick R., 2017, ARXIV, DOI [10.48550/arXiv.1612.03144, DOI 10.48550/ARXIV.1612.03144]
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guo S, 2019, NEUROCOMPUTING, V349, P52, DOI 10.1016/j.neucom.2019.04.019
   Guo XX, 2020, IEEE J BIOMED HEALTH, V24, P2315, DOI 10.1109/JBHI.2020.2971593
   Nguyen HD, 2022, IEEE T AFFECT COMPUT, V13, P226, DOI 10.1109/TAFFC.2019.2946540
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   He AL, 2021, IEEE T MED IMAGING, V40, P143, DOI 10.1109/TMI.2020.3023463
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Howard A. G., ARXIV, DOI DOI 10.48550/ARXIV.1704.04861
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Jiang YM, 2020, IEEE T BIO-MED ENG, V67, P335, DOI 10.1109/TBME.2019.2913211
   Khened M, 2019, MED IMAGE ANAL, V51, P21, DOI 10.1016/j.media.2018.10.004
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kouwenhoven E, 2009, PHYS MED BIOL, V54, P2863, DOI 10.1088/0031-9155/54/9/018
   Li T, 2021, MED IMAGE ANAL, V69, DOI 10.1016/j.media.2021.101971
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu HY, 2019, LECT NOTES COMPUT SC, V11365, P625, DOI 10.1007/978-3-030-20873-8_40
   Maiya SR, 2020, INT CONF ACOUST SPEE, P1125, DOI 10.1109/ICASSP40776.2020.9053177
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Orlando JI, 2020, MED IMAGE ANAL, V59, DOI 10.1016/j.media.2019.101570
   Orlando JI, 2018, COMPUT METH PROG BIO, V153, P115, DOI 10.1016/j.cmpb.2017.10.017
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Playout C, 2019, IEEE T MED IMAGING, V38, P2434, DOI 10.1109/TMI.2019.2906319
   Porwal P, 2020, MED IMAGE ANAL, V59, DOI 10.1016/j.media.2019.101561
   Ramachandran P, 2017, ARXIV, DOI DOI 10.48550/ARXIV.1710.05941
   Ranganathan Priya, 2017, Perspect Clin Res, V8, P187, DOI 10.4103/picr.PICR_123_17
   Rapalli Vamshi Krishna, 2019, Recent Pat Drug Deliv Formul, V13, P283, DOI 10.2174/1872211314666200117095917
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Sekiguchi R, 2020, UBICOMP/ISWC '20 ADJUNCT: PROCEEDINGS OF THE 2020 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING AND PROCEEDINGS OF THE 2020 ACM INTERNATIONAL SYMPOSIUM ON WEARABLE COMPUTERS, P335, DOI 10.1145/3410530.3414346
   Shankaranarayana SM, 2017, LECT NOTES COMPUT SC, V10554, P168, DOI 10.1007/978-3-319-67561-9_19
   Shorten C, 2019, J BIG DATA-GER, V6, DOI 10.1186/s40537-019-0197-0
   Son J, 2020, OPHTHALMOLOGY, V127, P85, DOI 10.1016/j.ophtha.2019.05.029
   Szegedy C, 2017, AAAI CONF ARTIF INTE, P4278
   Tabassum M, 2020, IEEE ACCESS, V8, P102733, DOI 10.1109/ACCESS.2020.2998635
   Tan JH, 2017, INFORM SCIENCES, V420, P66, DOI 10.1016/j.ins.2017.08.050
   Tan MX, 2019, PR MACH LEARN RES, V97
   Thakur N, 2019, EXPERT SYST APPL, V127, P308, DOI 10.1016/j.eswa.2019.03.009
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Visser M, 2019, NEUROIMAGE-CLIN, V22, DOI 10.1016/j.nicl.2019.101727
   Wang SJ, 2019, IEEE T MED IMAGING, V38, P2485, DOI 10.1109/TMI.2019.2899910
   Wu J., 2022, ARXIV
   Xie RT, 2021, IEEE T MED IMAGING, V40, P116, DOI 10.1109/TMI.2020.3023254
   Xie SN, 2017, PROC CVPR IEEE, P5987, DOI 10.1109/CVPR.2017.634
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhou Z., 2018, ARXIV
   Zhou ZH, 2002, ARTIF INTELL, V137, P239, DOI 10.1016/S0004-3702(02)00190-X
   ZIJDENBOS AP, 1994, IEEE T MED IMAGING, V13, P716, DOI 10.1109/42.363096
NR 73
TC 0
Z9 0
U1 1
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD OCT
PY 2022
VL 41
IS 10
BP 2828
EP 2847
DI 10.1109/TMI.2022.3172773
PG 20
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 4Z7RE
UT WOS:000862400100023
PM 35507621
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Bucan, I
   Herman, JS
   Tomic, IJ
   Gornik, O
   Vatavuk, Z
   Bucan, K
   Lauc, G
   Polasek, O
AF Bucan, Ivona
   Herman, Jelena Skunca
   Tomic, Iris Jeroncic
   Gornik, Olga
   Vatavuk, Zoran
   Bucan, Kajo
   Lauc, Gordan
   Polasek, Ozren
TI N-Glycosylation Patterns across the Age-Related Macular Degeneration
   Spectrum
SO MOLECULES
LA English
DT Article
DE age-related macular degeneration; N-glycans; prediction; biomarker;
   discovery
ID RHEUMATOID-ARTHRITIS; INFLAMMATION; CANCER; SERUM; GLYCOME;
   GLYCOPROTEIN; COMPLEMENT; DIAGNOSIS; DISEASES; GLYCANS
AB The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies. Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum. We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korcula. All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls. We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs. There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral. In addition, 45 (0.9%) subjects were recorded as having early-onset retinal drusen. We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD. Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)). We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)). Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases. Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans. As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
C1 [Bucan, Ivona; Bucan, Kajo] Clin Hosp Ctr Split, Split 21000, Croatia.
   [Herman, Jelena Skunca; Vatavuk, Zoran] Clin Hosp Ctr Sisters Mercy, Zagreb 10000, Croatia.
   [Tomic, Iris Jeroncic; Polasek, Ozren] Univ Split, Dept Publ Hlth, Sch Med, Split 21000, Croatia.
   [Gornik, Olga; Bucan, Kajo] Univ Split, Dept Ophthalmol, Sch Med, Split 21000, Croatia.
   [Gornik, Olga; Lauc, Gordan] Genos Ltd, Zagreb 10000, Croatia.
   [Lauc, Gordan] Univ Zagreb, Fac Pharm & Biochem, Zagreb 10000, Croatia.
   [Polasek, Ozren] Algebra Univ Coll, Algebra LAB, Ilica 242, Zagreb 10000, Croatia.
C3 University of Split; University of Split; University of Split;
   University of Zagreb; University of Zagreb, School of Dental Medicine
RP Polasek, O (通讯作者)，Univ Split, Dept Publ Hlth, Sch Med, Split 21000, Croatia.; Polasek, O (通讯作者)，Algebra Univ Coll, Algebra LAB, Ilica 242, Zagreb 10000, Croatia.
EM ivona1993bucan@gmail.com; jskuncaherman@gmail.com;
   iris.jeroncic@mefst.hr; olga.gornik@genos.hr; zvatavuk@hotmail.com;
   kajobucan@gmail.com; glauc@genos.hr; ozren.polasek@mefst.hr
RI Lauc, Gordan/K-5864-2012; Polasek, Ozren/B-6002-2011
OI Lauc, Gordan/0000-0003-1840-9560; Polasek, Ozren/0000-0002-5765-1862;
   Bucan, Ivona/0000-0002-6482-3925
FU Medical Research Council (UK); European Commission Framework 6 project
   EUROSPAN [LSHG-CT-2006-018947]; European Commission Framework 7 project
   BBMRI-LPC [FP7 313010]; Republic of Croatia Ministry of Science,
   Education and Sports research grant [216-1080315-0302]; Croatian
   National Centre of Research Excellence in Personalized Healthcare
   [KK.01.1.1.01.0010]; Centre of Competence in Molecular Diagnostics
   [KK.01.2.2.03.0006]
FX This study was funded by grants from the Medical Research Council (UK),
   the European Commission Framework 6 project EUROSPAN (contract no.
   LSHG-CT-2006-018947), the European Commission Framework 7 project
   BBMRI-LPC (FP7 313010), the Republic of Croatia Ministry of Science,
   Education and Sports research grant (216-1080315-0302), the Croatian
   National Centre of Research Excellence in Personalized Healthcare (grant
   number KK.01.1.1.01.0010), and the Centre of Competence in Molecular
   Diagnostics (KK.01.2.2.03.0006).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ahuja S, 2014, INVEST OPHTH VIS SCI, V55, P654, DOI 10.1167/iovs.13-13783
   Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Arnold JN, 2008, PROTEOMICS, V8, P3284, DOI 10.1002/pmic.200800163
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bucan K, 2022, EUR J OPHTHALMOL, V32, P410, DOI 10.1177/1120672121998900
   Budimir D, 2011, CROAT MED J, V52, P262, DOI 10.3325/cmj.2011.52.262
   Campbell H, 2007, HUM MOL GENET, V16, P233, DOI 10.1093/hmg/ddl473
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Chintalapudi SR, 2019, FEBS J, V286, P4876, DOI 10.1111/febs.15006
   Cindric A, 2021, ADV EXP MED BIOL, V1325, P341, DOI 10.1007/978-3-030-70115-4_17
   Cvetko A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100410
   Dorschmann P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239272
   Doherty M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26805-7
   Gligorijevic N, 2018, THROMB RES, V166, P43, DOI 10.1016/j.thromres.2018.04.005
   Habazin S, 2021, J PROTEOMICS, V245, DOI 10.1016/j.jprot.2021.104293
   Halper J, 2014, ADV EXP MED BIOL, V802, P49, DOI 10.1007/978-94-007-7893-1_4
   Higai K, 2003, CLIN CHIM ACTA, V329, P117, DOI 10.1016/S0009-8981(02)00427-8
   Hou HF, 2019, OMICS, V23, P660, DOI 10.1089/omi.2019.0004
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klaric L, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax0301
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Knezevic A, 2009, J PROTEOME RES, V8, P694, DOI 10.1021/pr800737u
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190
   Lan Y, 2016, AM J CANCER RES, V6, P2390
   Lin CW, 2015, P NATL ACAD SCI USA, V112, P10611, DOI 10.1073/pnas.1513456112
   Liu D, 2019, OMICS, V23, P607, DOI 10.1089/omi.2019.0032
   Liu D, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1616-2
   Liu Q, 2020, SCAND J RHEUMATOL, V49, P146, DOI 10.1080/03009742.2019.1641615
   Low SWY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147293
   Lundstrom SL, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1389-7
   MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Messina A, 2021, ALLERGY, V76, P2500, DOI 10.1111/all.14775
   Miura Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142645
   Miyahara K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074861
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Nakagawa H, 2007, J CHROMATOGR B, V853, P133, DOI 10.1016/j.jchromb.2007.03.003
   Nguyen-Khuong T, 2015, GLYCOBIOLOGY, V25, P269, DOI 10.1093/glycob/cwu108
   Novokmet M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04347
   Pagan JD, 2018, CELL, V172, P564, DOI 10.1016/j.cell.2017.11.041
   Pan YQ, 2021, AM J CANCER RES, V11, P3002
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pavic T, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1695-0
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Plackett TP, 2003, FASEB J, V17, P688, DOI 10.1096/fj.02-0452fje
   ROOK GAW, 1991, J AUTOIMMUN, V4, P779, DOI 10.1016/0896-8411(91)90173-A
   Rudan I, 2009, CROAT MED J, V50, P4, DOI 10.3325/cmj.2009.50.4
   Schaffert A, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03024
   Swaminathan S, 2014, AAPS J, V16, P311, DOI 10.1208/s12248-014-9563-1
   Tomoda T, 2016, PANCREATOLOGY, V16, P44, DOI 10.1016/j.pan.2015.11.002
   Vujasinovic M, 2020, UNITED EUR GASTROENT, V8, P584, DOI 10.1177/2050640620916027
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamaguchi Y, 2020, GLYCOBIOLOGY, V30, P214, DOI 10.1093/glycob/cwz068
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zillikens MC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00031-7
NR 62
TC 1
Z9 1
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2022
VL 27
IS 6
AR 1774
DI 10.3390/molecules27061774
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0D9WG
UT WOS:000776338000001
PM 35335137
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cruess, AF
   Berger, A
   Colleaux, K
   Greve, M
   Harvey, P
   Kertes, PJ
   Sheidow, T
   Tourville, E
   Williams, G
   Wong, D
AF Cruess, Alan F.
   Berger, Alan
   Colleaux, Kevin
   Greve, Mark
   Harvey, Patricia
   Kertes, Peter J.
   Sheidow, Thomas
   Tourville, Eric
   Williams, Geoff
   Wong, David
TI Canadian expert consensus: optimal treatment of neovascular age-related
   macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   INTRAVITREAL INJECTION; INTRAOCULAR INFLAMMATION; FLUORESCEIN
   ANGIOGRAPHY; MYOCARDIAL-INFARCTION; RANIBIZUMAB LUCENTIS;
   CIGARETTE-SMOKING; ANTI-VEGF; BEVACIZUMAB
AB Background: New therapeutic approaches, particularly anti-vascular endothelial growth factor (anti-VEGF) therapies, prevent, and in some cases reverse, vision damage caused by age-related macular degeneration (AMD). Unequal access to care across Canada remains a problem for many retina specialists and their patients.
   Objective: To develop a consensus concerning the management of patients with exudative age-related macular degeneration (AMD).
   Design: Consensus document.
   Participants: Ten Canadian retina specialists.
   Methods: The development of a consensus among Canadian experts concerning optimal treatment of AMD began with a review of the clinical evidence, daily practices, existing guidelines, and current national and international approvals and policies. The experts met on June 29, 2010, in Quebec City to discuss their findings and to propose strategies for consensus.
   Results: The result of this expert panel is a consensus proposal for Canadian ophthalmologists and retina specialists who are treating patients with or at risk for developing neovascular AMD.
   Conclusions: The consensus provides guidelines to aid retina specialists in managing exudative AMD. Currently, ranibizumab is the only agent with sufficient Level I evidence and a Health Canada-approved indication for the treatment of wet AMD. Bevacizumab has been shown to be noninferior in preserving and improving visual acuity when compared to ranibizumab. Potential safety differences between the 2 drugs remain to be elucidated. The positioning of ranibizumab in this therapeutic area will be further defined as additional data for existing and emerging therapies become available. Until then, this agent remains the therapy of choice for individuals with neovascular AMD..
C1 [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 2Y9, Canada.
   [Berger, Alan; Harvey, Patricia; Kertes, Peter J.; Wong, David] Univ Toronto, Toronto, ON, Canada.
   [Colleaux, Kevin] Univ Saskatchewan, Saskatoon, SK, Canada.
   [Greve, Mark] Univ Alberta, Edmonton, AB, Canada.
   [Sheidow, Thomas] Univ Western Ontario, London, ON, Canada.
   [Tourville, Eric] Univ Laval, Quebec City, PQ, Canada.
   [Williams, Geoff] Univ Calgary, Calgary, AB, Canada.
C3 Dalhousie University; University of Toronto; University of Saskatchewan;
   University of Alberta; Western University (University of Western
   Ontario); Laval University; University of Calgary
RP Cruess, AF (通讯作者)，Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 2Y9, Canada.
EM alan.cruess@dal.ca
OI Wong, David/0000-0003-1376-845X; Sheidow, Tom/0000-0001-6370-1857
FU Alcon; Novartis; Pfizer; Novartis Ophthalmics; Novartis Ophthalmics
   Canada; Alcon Canada; Bayer; Bayer/Regeneron; GlaxoSmithKline; QLT;
   Novartis Pharmaceuticals Canada
FX A.C. holds no equity position with any pharmaceutical company. He has
   received consulting fees for advisory board meetings and honoraria for
   speaking engagements from a number of entities, including Alcon,
   Novartis, and Pfizer. A.B. has received honoraria from Novartis
   Ophthalmics Canada, Alcon Canada, Bayer Canada, and Bausch and Lomb. He
   is the National Principal Investigator for the RESPOND clinical trial on
   diabetic macular edema, which is sponsored by Novartis Ophthalmics. St.
   Michael's Hospital receives unrestricted educational grants from
   Novartis Ophthalmics Canada and Alcon Canada. K.C. has received
   consultant funding from Bayer and Novartis and research funding and
   speaker fees from Novartis. M.G. is a consultant for Novartis (ACUITY
   program) and Bausch & Lomb. P.H. has no conflict of interest to disclose
   in relation to the content of this document. P.K. has received research
   funding from Novartis, Bayer/Regeneron, and GlaxoSmithKline. He is a
   consultant for Bausch & Lomb and Arctic Dx and has received honoraria
   from Alcon, Allergan, Novartis, and Bayer. T.S. has been a paid advisory
   panel member for Novartis, QLT, and Pfizer. He has also received
   research funding from Novartis, QLT, and Pfizer and is co-Principal
   Investigator for the RESPOND trial in diabetic macular edema. E.T. is a
   paid consultant for Alcon, Novartis, Allergan, and Bausch & Lomb. He has
   received speaker honoraria from Alcon, Novartis, Allergan, Bausch &
   Lomb, and Pfizer as well as honoraria to conduct clinical research for
   Novartis. G.W. has been a consultant or advisory board participant and
   has been involved in clinical trials for Pfizer, Novartis, Regeneron,
   Allergan, MD Collaborate, Arctic Dx, and Bausch & Lomb. D.W. is a
   consultant For Novartis, Labtician, Diagnos, Bayer, MD Collaborate,
   Alcon, Arctic DX, and Allergan. He has received research funding from
   Novartis, QLT, and Alcon.; The meeting was organized by SNELL Medical
   Communication Montreal, PQ). and funding for the meeting, including a
   single night's accommodation, was provided as an unrestricted grant from
   Novartis Pharmaceuticals Canada. Honoraria were provided to the
   participants to develop and present slides to generate discussion.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2010, RETINA TODAY
   Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bellan L, 2007, CAN J OPHTHALMOL, V42, P34, DOI 10.3129/canjophthalmol.06-115
   Bolz M, 2008, 8 EUR C VIENN AUSTR
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Boyer DS, 2008, SAFETY OVERVIEW RANI
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown Gary C, 2007, Trans Am Ophthalmol Soc, V105, P160
   Brown GC, 2004, RETINA-J RET VIT DIS, V24, P139, DOI 10.1097/00006982-200402000-00019
   CATT: Lucentis-Avastin Trial. Manual of Procedures, LUC AV TRIAL MAN PRO
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess A, 2009, CAN J OPHTHALMOL, V44, P548, DOI 10.3129/i09-140
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Foundations for a Canadian vision health strategy, PREV AV BLINDN PROM
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gower EW, 2011, ASS RES VIS OPHTH AR
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Henschel A, 2009, EUR J OPHTHALMOL, V19, P831, DOI 10.1177/112067210901900523
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Hudson H, 2009, RET C NEW YORK NY
   Jackson KM, 2008, ARCH OPHTHALMOL-CHIC, V126, P493, DOI 10.1001/archopht.126.4.493
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kaiser PK, 2009, AM AC OPHTH ANN M
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lai TY, 2010, INVEST OPHTHALMOL  S, V51, pS2228
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Micieli JA, 2010, CAN J OPHTHALMOL, V45, P231, DOI 10.3129/i10-027
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Winkler BS, 1999, MOL VIS, V5
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 79
TC 19
Z9 20
U1 0
U2 19
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2012
VL 47
IS 3
BP 227
EP 235
DI 10.1016/j.jcjo.2012.03.007
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 978RL
UT WOS:000306763100008
PM 22687297
DA 2022-11-30
ER

PT J
AU Wolff, B
   Quaranta-El Maftouhi, M
   Mateo-Montoya, A
   Sahel, JA
   Mauget-Faysse, M
AF Wolff, Benjamin
   Quaranta-El Maftouhi, Maddalena
   Mateo-Montoya, Aranzazu
   Sahel, Jose-alain
   Mauget-Faysse, Martine
TI Outer retinal cysts in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; inflammation;
   retinal cysts; spectral domain OCT
ID PIGMENT EPITHELIUM; BRUCHS MEMBRANE; INVOLVEMENT; DRUSEN; CELLS
AB Purpose: To describe novel cystic structures ('outer retinal cysts' or ORC) found in the outer retina in age-related macular degeneration (AMD).
   Methods: One hundred and seventy-three consecutive eyes of 88 AMD patients were prospectively examined with spectral domain optical coherence tomography (SD-OCT). The prevalence of ORCs was searched, and their sizes and shapes were determined.
   Results: SD-OCT revealed round or ovoid, intraretinal, hyporeflective cystic structures with a hyperreflective border in 60 eyes (56%) with neovascular AMD and in six eyes (21%) with atrophic AMD. These cystic structures were of different sizes and shapes. They remained stable in all the patients after a follow-up period of 6 months.
   Conclusions: Outer retinal cyst is a new type of cystic structure recently identified in AMD patients. ORCs should not be confused with intraretinal exudates or cystoid cavities and therefore do not require any treatment. The histopathological nature of ORC remains to be determined. Further studies are necessary to determine their true origin.
C1 [Wolff, Benjamin; Quaranta-El Maftouhi, Maddalena; Mauget-Faysse, Martine] Ctr Ophtalmol Rabelais, Lyon, France.
   [Wolff, Benjamin; Mateo-Montoya, Aranzazu; Sahel, Jose-alain] Fdn Ophtalmol Rothschild, Paris, France.
RP Wolff, B (通讯作者)，12-14 Rue Rabelais, F-69006 Lyon, France.
EM bwolff@hotmail.fr
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; wolff,
   benjamin/0000-0003-4709-692X
CR BERNAUDIN JF, 1980, PRECIS HISTOLOGIE HU
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   WOLTER J R, 1955, Klin Monbl Augenheilkd Augenarztl Fortbild, V127, P687
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 11
TC 13
Z9 16
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2011
VL 89
IS 6
BP E496
EP E499
DI 10.1111/j.1755-3768.2011.02144.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812BE
UT WOS:000294261900004
PM 21631905
DA 2022-11-30
ER

PT J
AU Koizumi, H
   Yamamoto, A
   Ogasawara, M
   Maruko, I
   Hasegawa, T
   Itagaki, K
   Sekiryu, T
   Okada, AA
   Iida, T
AF Koizumi, Hideki
   Yamamoto, Akiko
   Ogasawara, Masashi
   Maruko, Ichiro
   Hasegawa, Taiji
   Itagaki, Kanako
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
TI Macular atrophy after aflibercept therapy for neovascular age-related
   macular degeneration: outcomes of Japanese multicenter study
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Aflibercept; Macular atrophy; Vascular endothelial growth factor
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PIGMENT EPITHELIAL ATROPHY; VEGF
   TRAP-EYE; GEOGRAPHIC ATROPHY; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   GROWTH; THICKNESS
AB Purpose To evaluate the development and rate of growth in macular atrophy after intravitreal injections of aflibercept (IVAs) for neovascular age-related macular degeneration (AMD) over a 2-year period. Study design Retrospective, interventional, consecutive case series. Methods This study included 94 eyes of 92 patients with treatment-naive AMD involving the foveal center treated with IVAs at 3 university hospitals in Japan. The patients underwent IVAs bimonthly after 3 initial monthly doses in the first year. The protocol was converted to a treat-and-extend regimen in the second year. The incidence and growth rate of macular atrophy were quantified based on hypoautofluorescence detected by fundus autofluorescence images. Additionally, possible background factors related to the development and rate of growth of macular atrophy were investigated. Results Of 94 eyes, 39 (41.5%) had typical AMD and 55 (58.5%) had polypoidal choroidal vasculopathy. Ten eyes (10.6%) had macular atrophy at the baseline. Of the remaining 84 eyes, 14 (16.7%) had developed new macular atrophy at 2 years, the square root of the growth rate of atrophy was 0.52 mm/year. In multivariate analyses, a poorer best-corrected visual acuity (P = 0.01) and the presence of intraretinal fluid (P = 0.04) at baseline were found to be the independent predictors for the development of macular atrophy. No factors were found that were significantly related to the growth rate of the macular atrophy. Conclusions Our study determined the incidence and rate of growth of macular atrophy after IVAs for neovascular AMD in clinical settings. Eyes with vision reduction and intraretinal fluid at the baseline develop macular atrophy more frequently after IVAs for neovascular AMD.
C1 [Koizumi, Hideki; Maruko, Ichiro; Hasegawa, Taiji; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara,Nishihara Cho, Nishihara, Okinawa 9030125, Japan.
   [Yamamoto, Akiko; Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Ogasawara, Masashi; Itagaki, Kanako; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
C3 Tokyo Women's Medical University; University of Ryukyus; Kyorin
   University; Fukushima Medical University
RP Koizumi, H (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.; Koizumi, H (通讯作者)，Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara,Nishihara Cho, Nishihara, Okinawa 9030125, Japan.
EM hkoizumi@med.u-ryukyu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022; Hasegawa, Taiji/ABG-8260-2021
OI Maruko, Ichiro/0000-0001-5647-6372; Koizumi, Hideki/0000-0002-9610-4386
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [25670739]
FX The authors thank Ryo Kawasaki, Department of Ophthalmology, Osaka
   University, and Yuji Yamamoto, Department of Ophthalmology, Kyoto
   Prefectural University of Medicine, for statistical expertise. This
   study was supported in part by Grant No. 25670739 from the Ministry of
   Education, Culture, Sports, Science and Technology-Japan (H.K.).
CR Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Gass JD, 1996, STEREOSCOPIC ATLAS M, V2, P1038
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 33
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2020
VL 64
IS 4
BP 338
EP 345
DI 10.1007/s10384-020-00745-0
EA MAY 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MC1OL
UT WOS:000534972500001
PM 32447586
DA 2022-11-30
ER

PT J
AU Kolosova, NG
   Muraleva, NA
   Zhdankina, AA
   Stefanova, NA
   Fursova, AZ
   Blagosklonny, MV
AF Kolosova, Nataliya G.
   Muraleva, Natalia A.
   Zhdankina, Anna A.
   Stefanova, Natalia A.
   Fursova, Anzhela Z.
   Blagosklonny, Mikhail V.
TI Prevention of Age-Related Macular Degeneration-Like Retinopathy by
   Rapamycin in Rats
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AMD-LIKE RETINOPATHY; EXTENDS LIFE-SPAN;
   IGFBP-3 SECRETION; MAMMALIAN TARGET; MTOR; INSULIN; SENESCENCE; VEGF;
   CANCER
AB Age-related macular degeneration, a neurodegenerative and vascular retinal disease, is the most common cause of blindness in the Western countries. Evidence accumulates that target of rapamycin is involved in aging and age-related diseases, including neurodegeneration. The target of rapamycin inhibitor, rapamycin, suppresses the senescent cell phenotype and extends life span in diverse species, including mice. Rapamycin decreases senescence-associated phenotypes in retinal pigment epithelial cells in culture. Herein, we investigated the effect of rapamycin on spontaneous retinopathy in senescence-accelerated OXYS rats, an animal model of age-related macular degeneration. Rats were treated with either 0.1 or 0.5 mg/kg rapamycin, which was given orally as a food mixture. In a dose-dependent manner, rapamycin decreased the incidence and severity of retinopathy. Rapamycin improved some (but not all) histological abnormalities associated with retinopathy. Thus, in retinal pigment epithelial cell layers, rapamycin decreased nuclei heterogeneity and normalized intervals between nuclei. In photoreceptor cells, associated neurons, and radial glial cells, rapamycin prevented nuclear and cellular pyknosis. More important, rapamycin prevented destruction of ganglionar neurons in the retina. Rapamycin did not exert any adverse effects on the retina in control disease-free Wistar rats. Taken together, our data suggest the therapeutic potential of rapamycin for treatment and prevention of retinopathy. (Am J Pathol 2012, 181:472-477; http://dx.doi.org/10.1016/j.ajpath.2012.04.018)
C1 [Blagosklonny, Mikhail V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC, Buffalo, NY 14263 USA.
   [Kolosova, Nataliya G.; Muraleva, Natalia A.; Stefanova, Natalia A.; Fursova, Anzhela Z.] Russian Acad Sci, Inst Cytol & Genet, Siberian Div, Novosibirsk 630090, Russia.
   [Zhdankina, Anna A.] Siberian State Med Univ, Tomsk, Russia.
C3 Roswell Park Cancer Institute; Russian Academy of Sciences; Institute of
   Cytology & Genetics ICG SB RAS; Siberian State Medical University
RP Blagosklonny, MV (通讯作者)，Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC, L3-312,Elm & Carlton St, Buffalo, NY 14263 USA.
EM mikhail.blagosklonny@roswellpark.org
RI Muraleva, Natalia/S-2392-2018; Kolosova, Nataliya G/AAR-7409-2020;
   Stefanova, Natalia/V-1530-2018; fursova, anzhella/AAE-1495-2022;
   Kolosova, Nataliya G/P-3178-2015
OI Muraleva, Natalia/0000-0002-0665-1723; Kolosova, Nataliya
   G/0000-0003-2398-8544; fursova, anzhella/0000-0001-6311-5452; Kolosova,
   Nataliya G/0000-0003-2398-8544; Anna, Zhdankina/0000-0002-4954-7416;
   Stefanova, natalia/0000-0001-5127-5993
FU Russian Federal Agency for Science and Innovation [16.513.11.3107];
   Russian Foundation for Basic Research [11-04-00666]; presidium of the
   Russian Academy of Science [21.13]
FX Supported by a state contract from the Russian Federal Agency for
   Science and Innovation (16.513.11.3107) and grants from the Russian
   Foundation for Basic Research (11-04-00666) and the presidium of the
   Russian Academy of Science (21.13). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486
   Anisimov VN, 2010, AM J PATHOL, V176, P2092, DOI 10.2353/ajpath.2010.091050
   Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blagosklonny MV, 2008, CANCER BIOL THER, V7, P1520, DOI 10.4161/cbt.7.10.6663
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288
   Blagosklonny MV, 2011, CELL CYCLE, V10, P4217, DOI 10.4161/cc.10.24.18595
   Blagosklonny MV, 2009, AGING-US, V1, P281, DOI 10.18632/aging.100034
   Blagosklonny MV, 2009, AGING-US, V1, P357, DOI 10.18632/aging.100040
   Campistol JM, 2006, J AM SOC NEPHROL, V17, P581, DOI 10.1681/ASN.2005090993
   Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559
   Dejneka NS, 2004, MOL VIS, V10, P964
   Demidenko ZN, 2011, CELL CYCLE, V10, P1557, DOI 10.4161/cc.10.10.15789
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059
   Katewa SD, 2011, EXP GERONTOL, V46, P382, DOI 10.1016/j.exger.2010.11.036
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Korbolina EE, 2012, AGING-US, V4, P49, DOI 10.18632/aging.100427
   Krebs M, 2007, DIABETES, V56, P1600, DOI 10.2337/db06-1016
   Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265
   Leung LY, 2006, THER DRUG MONIT, V28, P51, DOI 10.1097/01.ftd.0000179838.33020.34
   Major P, 2011, AGING-US, V3, P189, DOI 10.18632/aging.100298
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Markovets AM, 2011, AGING-US, V3, P44
   Miller RA, 2011, J GERONTOL A-BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Nicoletti F, 2011, DRUG DISCOV TODAY, V16, P715, DOI 10.1016/j.drudis.2011.05.008
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saprunova VB, 2010, BIOCHEMISTRY-MOSCOW+, V75, P130, DOI 10.1134/S0006297910020021
   Slomiany MG, 2006, J PHARMACOL EXP THER, V318, P666, DOI 10.1124/jpet.106.104158
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831
   Stefanova NA, 2011, J ETHNOPHARMACOL, V138, P624, DOI 10.1016/j.jep.2011.10.017
   Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200
   Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0
   Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239
   Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200
   Tsang CK, 2007, DRUG DISCOV TODAY, V12, P112, DOI 10.1016/j.drudis.2006.12.008
   Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a
   Veroux M, 2011, TRANSPL INT, V24, pE115, DOI 10.1111/j.1432-2277.2011.01356.x
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 57
TC 61
Z9 69
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2012
VL 181
IS 2
BP 472
EP 477
DI 10.1016/j.ajpath.2012.04.018
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 983TO
UT WOS:000307141800012
PM 22683466
OA Bronze
DA 2022-11-30
ER

PT J
AU Matsumiya, W
   Honda, S
   Bessho, H
   Kusuhara, S
   Tsukahara, Y
   Negi, A
AF Matsumiya, Wataru
   Honda, Shigeru
   Bessho, Hiroaki
   Kusuhara, Sentaro
   Tsukahara, Yasutomo
   Negi, Akira
TI Early Responses to Intravitreal Ranibizumab in Typical Neovascular
   Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; BEVACIZUMAB
AB Purpose. To evaluate the early response to intravitreal ranibizumab (IVR) in two different phenotypes of age-related macular degenerations (AMD): typical neovascular AMD (tAMD) and polypoidal choroidal vasculopathy (PCV). Methods. Sixty eyes from 60 patients (tAMD 28, PCV 32 eyes) were recruited. Three consecutive IVR treatments (0.5mg) were performed every month. Change in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) was then compared between the tAMD and PCV groups. Results. The mean BCVA logMAR was significantly improved at month 1 and month 3 after the initial IVR in the tAMD group, but there was no change in the PCV group. Both phenotypes showed significant improvements in the CRT during the 3 months after the initial IVR. There were no significant differences in the improvements of the CRT in the tAMD versus the PCV group. In the stepwise analysis, a worse pretreatment BCVA and tAMD lesions were significantly beneficial for a greater improvement of BCVA at 3 months after the initial IVR. Conclusions. The phenotype of tAMD showed a significantly better early response to IVR than PCV in terms of BCVA improvement.
C1 [Matsumiya, Wataru; Honda, Shigeru; Bessho, Hiroaki; Kusuhara, Sentaro; Tsukahara, Yasutomo; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kusuhara, Sentaro/0000-0002-6458-539X
FU Ministry of Education, Science and Culture, Tokyo, Japan [20592042]
FX This study was supported by a Grant-in-Aid (C) 20592042 (SH) from the
   Ministry of Education, Science and Culture, Tokyo, Japan. The funding
   organization had no role in the design or conduct of this research.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P81, DOI 10.1159/000317908
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Hikichi T., 2010, AM J OPHTHALMOL, V150, P674
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P311, DOI 10.1007/s00417-008-0995-0
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mekjavic P. J., ACTA OPHTHA IN PRESS
   Mimoun G., 2010, AM J OPHTHALMOL, V150, P692
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 23
Z9 25
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 742020
DI 10.1155/2011/742020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100032
PM 21772985
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Romano, F
   Arrigo, A
   Sacchi, R
   Scanzi, G
   Ferri, C
   Bandello, F
AF Parodi, Maurizio Battaglia
   Romano, Francesco
   Arrigo, Alessandro
   Sacchi, Raffaele
   Scanzi, Gianluca
   Ferri, Camilla
   Bandello, Francesco
TI Real-life anti-vascular endothelial growth factor treatment for
   age-related macular degeneration and diabetic macular edema in an
   Italian tertiary referral hospital
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; diabetic macular edema; diabetic
   retinopathy; retina; retina-medical therapies
ID VISUAL-ACUITY OUTCOMES; NEOVASCULAR AMD; WORLD OUTCOMES; RANIBIZUMAB;
   THERAPY
AB Purpose: To study the real-life outcomes of intravitreal anti-vascular endothelial growth factor treatment in patients affected by age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital over a 2-year follow-up. Methods: Patients with confirmed diagnosis of age-related macular degeneration or diabetic macular edema and 2 years of follow-up were retrospectively analyzed. They underwent a loading dose of three monthly anti-vascular endothelial growth factor injections, with re-treatment performed following a "pro-re-nata" regimen. Best-corrected visual acuity and central retinal thickness were collected and statistically analyzed. Results: In total, 167 diabetic macular edema eyes and 108 age-related macular degeneration eyes were included. Mean age was 63.4 +/- 11.8 years for diabetic macular edema and 75.6 +/- 8.4 years for age-related macular degeneration. For diabetic macular edema patients, mean number of injections was 5.0 +/- 1.7 at 1 year and 2.8 +/- 1.8 at 2 years. Mean best-corrected visual acuity improved from 60 Early Treatment for Diabetic Retinopathy Study letters to 66.7 letters at 1 year, and to 70 letters at 2 years (p < 0.001). Mean central retinal thickness decreased from 459 +/- 148 mu m to 327 +/- 163 mu m and 261 +/- 89 mu m, respectively, at the first and the second year (p < 0.001).With respect to age-related macular degeneration patients, mean number of injections was 5.3 +/- 2.2 at 1 year and 3.3 +/- 1.5 at 2 years. Mean best-corrected visual acuity improved from 63 Early Treatment for Diabetic Retinopathy Study letters to 68 letters at 1 year and to 70 letters at 2 years (p < 0.001). Mean central retinal thickness was 411 +/- 146 mu m, decreasing to 271 +/- 93 mu m at 1 year and 260 +/- 68 mu m at 2 years (p < 0.001). Conclusions: Our study described the 2-year real-life outcome of anti-vascular endothelial growth factor treatment of diabetic macular edema and age-related macular degeneration.
C1 [Parodi, Maurizio Battaglia; Arrigo, Alessandro; Sacchi, Raffaele; Scanzi, Gianluca; Bandello, Francesco] Univ Vita Salute, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
   [Parodi, Maurizio Battaglia; Arrigo, Alessandro; Sacchi, Raffaele; Scanzi, Gianluca; Bandello, Francesco] Univ Vita Salute, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Romano, Francesco] Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci, Eye Clin, Milan, Italy.
   [Ferri, Camilla] IRCCS Osped San Raffaele, Dept Pharm, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; University of Milan; Luigi
   Sacco Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.; Arrigo, A (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
RI bandello, francesco/AAH-2405-2019
OI bandello, francesco/0000-0003-3238-9682; Scanzi,
   Gianluca/0000-0002-2119-3580; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Arrigo, Alessandro/0000-0003-4715-8414
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Maggio E, 2018, AM J OPHTHALMOL, V195, P209, DOI 10.1016/j.ajo.2018.08.004
   Parodi MB, 2017, J OCUL PHARMACOL TH, V33, P123, DOI 10.1089/jop.2016.0091
   Patrao NV, 2016, AM J OPHTHALMOL, V172, P51, DOI 10.1016/j.ajo.2016.09.002
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 15
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2020
VL 30
IS 6
BP 1461
EP 1466
AR 1120672119880386
DI 10.1177/1120672119880386
EA OCT 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PF7SQ
UT WOS:000491448300001
PM 31617403
DA 2022-11-30
ER

PT J
AU Holekamp, NM
AF Holekamp, Nancy M.
TI Review of Neovascular Age-Related Macular Degeneration Treatment Options
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS; BEVACIZUMAB AVASTIN; VISUAL
   OUTCOMES; RANIBIZUMAB; DISEASE; THERAPY; PREVALENCE; INJECTION; REGIMENS
AB Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite unprecedented improvements in vision preservation that patients can achieve with anti-vascular endothelial growth factor (VEGF) agents, innovations are needed to reduce the burden of intravitreal injections and improve outcomes in patients who do not respond adequately to currently available agents. The best present option for vision preservation is a "zero-tolerance for fluid" schedule of monitoring and intravitreal injections that patients may need to follow for many years. This treatment burden has resulted in patients not achieving optimal benefit or even falling through the cracks. This article reviews state-of-the-art management approaches including as-needed and treat-and-extend dosing regimens designed to reduce treatment burden.
C1 [Holekamp, Nancy M.] Pepose Vis Inst, Retinal Serv, Chesterfield, MO 63017 USA.
   [Holekamp, Nancy M.] Washington Univ, Sch Med, Clin Ophthalmol, St Louis, MO 63130 USA.
C3 Washington University (WUSTL)
RP Holekamp, NM (通讯作者)，Pepose Vis Inst, Retinal Serv, Chesterfield, MO 63017 USA.; Holekamp, NM (通讯作者)，Washington Univ, Sch Med, Clin Ophthalmol, St Louis, MO 63130 USA.
EM nholekamp@peposevision.com
FU Regeneron Pharmaceuticals, Inc.
FX This activity is supported by an independent medical education grant
   from Regeneron Pharmaceuticals, Inc.
CR *AM AC OPTH, AG REL MAC DEG PREF
   [Anonymous], 2018, LUC PRESCR INF
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barlas Stephen, 2019, P T, V44, P45
   Blanco-Garavito R, 2018, RETINA-J RET VIT DIS, V38, P2285, DOI 10.1097/IAE.0000000000001928
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2018, OPHTHALMOL RETINA, V2, P667, DOI 10.1016/j.oret.2018.01.010
   *EUR MED AG COMM M, 2012, ASS REP EYL AFL PROC
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Hahn P, 2015, JAMA OPHTHALMOL, V133, P421, DOI 10.1001/jamaophthalmol.2014.5650
   Hahn P, 2013, OPHTHALMOLOGY, V120, P1100, DOI 10.1016/j.ophtha.2012.11.018
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holekamp NM, 2018, AM J OPHTHALMOL, V187, pXXVIII, DOI 10.1016/j.ajo.2017.11.003
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khurana RN, 2017, JAMA OPHTHALMOL, V135, P800, DOI 10.1001/jamaophthalmol.2017.1815
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein C, 2019, METHODS, V154, P21, DOI 10.1016/j.ymeth.2018.11.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kolber MR, 2013, CAN FAM PHYSICIAN, V59, P503
   Kunzmann K., 2018, MD MAGAZINE
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   McLaughlin MD, 2017, OPHTHALMOLOGY, V124, P667, DOI 10.1016/j.ophtha.2017.01.001
   Melo GB, 2020, BRIT J OPHTHALMOL, V104, P291, DOI 10.1136/bjophthalmol-2019-313823
   Melo GB, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-018-0153-8
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   *OFF INSP GEN, 2012, MED PAYM DRUGS US TR
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pershing S, 2017, JAMA OPHTHALMOL, V135, P459, DOI 10.1001/jamaophthalmol.2017.0133
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   SINGH RP, GLOBAL TRENDS RETINA
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spooner K, 2019, ACTA OPHTHALMOL, V97, pE706, DOI 10.1111/aos.14046
   Staes C, 2013, AM J HEALTH-SYST PH, V70, P1301, DOI 10.2146/ajhp130049
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Storey PP, 2019, AM J OPHTHALMOL, V199, P200, DOI 10.1016/j.ajo.2018.11.023
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
   2019, EYL PRESCR INF
   2019, RETINA SPECIALIST
   2019, AV PRESCR INF
   2017, MVAS PRESCR INF
NR 72
TC 32
Z9 32
U1 0
U2 3
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JUL
PY 2019
VL 25
IS 7
SU S
BP S172
EP S181
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA JQ3JO
UT WOS:000498845600001
PM 31419088
DA 2022-11-30
ER

PT J
AU Gower, EW
AF Gower, Emily W.
TI Anti-VEGF therapies for the treatment of age-related macular
   degeneration
SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
LA English
DT Article
DE age-related macular degeneration; bevacizumab; intravitreal injections;
   ranibizumab; vascular endothelial growth factor
AB Age-related macular degeneration is the leading cause of blindness in European-derived populations. Recently, drugs have been developed that not only reduce the risk of vision loss, but can actually improve visual acuity. This article provides a summary of a recent comparative effectiveness trial evaluating two of these drugs. The study found that visual acuity outcomes were similar for the two drugs and that monthly dosing provided a slight advantage over as-needed treatment. The role of long-term differences in retinal thickening, geographic atrophy and potential differences in serious adverse events between the two drugs need further research.
C1 Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27157 USA.
C3 Wake Forest University
RP Gower, EW (通讯作者)，Wake Forest Sch Med, Dept Epidemiol & Prevent, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM egower@wakehealth.edu
FU Genentech LLC
FX A portion of E Gower's salary has been paid through contract research
   funds from Genentech LLC to E Gower's University. The author has no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR [Anonymous], 2011, 2 YEAR RES PHAS 3 ST
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gower E, 2011, ASS RES VIS OPHTH AN
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2010, NEW ENGL J MED, V363, P105, DOI 10.1056/NEJMp1001201
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   United States Senate Special Committee on Aging, 2011, STAT J BLUM DEP ADM
NR 12
TC 1
Z9 1
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 2042-6305
EI 2042-6313
J9 J COMP EFFECT RES
JI J. Comp. Eff. Res.
PD NOV
PY 2012
VL 1
IS 6
BP 485
EP 488
DI 10.2217/CER.12.57
PG 4
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA V32SL
UT WOS:000208970800011
PM 24236467
DA 2022-11-30
ER

PT J
AU Ly, A
   Nivison-Smith, L
   Assaad, N
   Kalloniatis, M
AF Ly, Angelica
   Nivison-Smith, Lisa
   Assaad, Nagi
   Kalloniatis, Michael
TI Infrared reflectance imaging in age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE age-related macular degeneration; chair-side reference; drusen;
   infrared; retina
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL
   DRUSENOID DEPOSITS; GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN; GRADING
   SYSTEM; PIGMENT-EPITHELIUM; IN-VIVO; DISEASE; CLASSIFICATION
AB Purpose: The purpose of this article is to describe the appearance of age-related macular degeneration (AMD) phenotypes using infrared (IR) reflectance imaging. IR reflectance imaging of the retina has the potential to highlight specific sub-retinal features and pathology. However, its role in macular disease, specifically AMD, is often underestimated and requires clarification.
   Recent findings: Recent advances in clinical methods, imaging and scientific knowledge may be integrated to improve the accuracy of disease stratification in AMD. In particular, IR imaging holds an underutilised sensitivity to detect reticular pseudodrusen, which have been repeatedly described as a high-risk sign for late AMD.
   Summary: This article provides clinically relevant descriptions of AMD phenotypes using IR reflectance imaging. The findings are integrated with images from cases seen at the Centre for Eye Health. As primary eye-care providers assume a critical role in the detection, diagnosis and management of AMD, we also provide a chair-side reference to assist clinicians in interpreting IR images in AMD.
C1 [Ly, Angelica; Nivison-Smith, Lisa; Assaad, Nagi; Kalloniatis, Michael] Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Nivison-Smith, Lisa; Kalloniatis, Michael] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW 2031, Australia.
C3 University of New South Wales Sydney
RP Kalloniatis, M (通讯作者)，Ctr Eye Hlth, Sydney, NSW, Australia.; Kalloniatis, M (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM m.kalloniatis@unsw.edu.au
RI Nivison-Smith, Lisa/H-3297-2019; Ly, Angelica/J-2070-2019
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Nivison-Smith, Lisa/0000-0001-6677-1949
FU University of New South Wales [P535430]; University of New South Wales
   (Australian Postgraduate Award); National Health and Medical Research
   Council (NHMRC) [1033224]; NHMRC
FX This work was supported, in part, by grants and awards from the
   University of New South Wales (Early Career Research Grant 2015
   #P535430, an Australian Postgraduate Award), and a National Health and
   Medical Research Council (NHMRC) grant (#1033224). Guide Dogs NSW/ACT is
   a partner in the NHMRC grant and also provided a supplementary PhD
   scholarship for AL and support for LN-S. The authors would also like to
   thank Dr. Michael Hennessy, Paula Katalinic, Michael Yapp, David Pye,
   Dr. Andrew Whatham and Carol Chu for their expert review of the included
   clinical cases.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Bastian N, 2013, KLIN MONATSBL AUGENH, V230, P270, DOI 10.1055/s-0032-1328159
   Beausencourt E, 2000, OPHTHALMOLOGY, V107, P375, DOI 10.1016/S0161-6420(99)00056-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Chong GT, 2012, CURR OPIN OPHTHALMOL, V23, P79, DOI 10.1097/ICU.0b013e32834ff431
   Cukras Catherine, 2007, International Ophthalmology Clinics, V47, P51, DOI 10.1097/IIO.0b013e31802bd785
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Devisetti K, 2011, IEEE ENG MED BIO, P3958, DOI 10.1109/IEMBS.2011.6090983
   Elsner AE, 2000, OPT EXPRESS, V6, P243, DOI 10.1364/OE.6.000243
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Hammer DX, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2335470
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Jamous KF, 2015, CLIN EXP OPHTHALMOL, V43, P308, DOI 10.1111/ceo.12466
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Remky A, 1999, GRAEF ARCH CLIN EXP, V237, P897, DOI 10.1007/s004170050383
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Sharp PF, 1997, PHYS MED BIOL, V42, P951, DOI 10.1088/0031-9155/42/5/014
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 58
TC 27
Z9 27
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAY
PY 2016
VL 36
IS 3
SI SI
BP 303
EP 316
DI 10.1111/opo.12283
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP2RC
UT WOS:000378336600007
PM 27112225
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Lee, JH
   Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Lee, Ji Hyun
   Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Difference in treatment burden of neovascular age-related macular
   degeneration among different types of neovascularization
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Retinal
   angiomatous proliferation; Type 3 neovascularization; Polypoidal
   choroidal vasculopathy; Burden
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GROWTH-FACTOR THERAPY; VISUAL
   PROGNOSIS; DISEASE BURDEN; EXTEND REGIMEN; FELLOW EYE; RANIBIZUMAB;
   AFLIBERCEPT; PREVALENCE; MEMBRANES
AB Purpose To evaluate the difference in the treatment burden among different types of neovascular age-related macular degeneration (AMD). Methods This retrospective, observational study included 431 patients who were diagnosed with neovascular AMD. Patients were divided into three groups: type 1 or 2 neovascularization group (n = 167), type 3 neovascularization group (n = 50), and polypoidal choroidal vasculopathy (PCV) group (n = 214). The number of hospital visits per year and the number of anti-vascular endothelial growth factor (VEGF) injections per year were compared among these groups. Furthermore, the incidence of bilateral involvement during the follow-up period was compared among the groups. Results The mean follow-up period was 50.6 +/- 11.3 months. The number of hospital visits per year was significantly higher in the type 1 or 2 neovascularization group (mean: 6.1 +/- 1.5) and type 3 neovascularization (6.6 +/- 1.6) than in the PCV group (6.0 +/- 1.5) (P < 0.001). The number of anti-VEGF injections per year was significantly higher in type 3 neovascularization group (3.1 +/- 1.7) than in the type 1 or 2 neovascularization group (2.3 +/- 1.5) or the PCV group (2.3 +/- 1.2) (P = 0.042). There was a significant difference in the incidence of bilateral involvement among patients in type 1 or 2 neovascularization group (20.4%), type 3 neovascularization group (46.0%), and the PCV group (15.4%) (P < 0.001). Conclusions The high frequency of hospital visits and that of anti-VEGF injections in patients with type 3 neovascularization suggests high treatment burden in these patients. The high incidence of bilateral involvement could be one of the primary reasons for high treatment burden in patients with type 3 neovascularization.
C1 [Lee, Ji Hyun; Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital Research Center; Kim's Eye Hospital (Seoul, South
   Korea)
FX This study was supported by Kim's Eye Hospital Research Center. Kim's
   Eye Hospital (Seoul, South Korea) provided funding for English editing
   support. The sponsor had no role in the design or conduct of this
   research.
CR Arias L, 2020, RETINA-J RET VIT DIS, V40, P1234, DOI 10.1097/IAE.0000000000002582
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P71, DOI 10.1016/j.jcjo.2015.11.003
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Doguizi S, 2018, EUR J OPHTHALMOL, V28, P63, DOI 10.5301/ejo.5001001
   Elshout M, 2016, OPHTHALMOLOGY, V123, P2408, DOI 10.1016/j.ophtha.2016.07.015
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hong T, 2014, INVEST OPHTH VIS SCI, V55, P7589, DOI 10.1167/iovs.14-14262
   Kim JH, 2019, OPTOMETRY VISION SCI, V96, P686, DOI 10.1097/OPX.0000000000001419
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1661, DOI 10.1007/s00417-019-04373-4
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1183, DOI 10.1007/s00417-019-04306-1
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   Kim JH, 2020, SEMIN OPHTHALMOL, V35, P33, DOI 10.1080/08820538.2019.1701045
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2356, DOI 10.1097/IAE.0000000000001876
   Kim JH, 2019, RETINA-J RET VIT DIS, V39, P1672, DOI 10.1097/IAE.0000000000002239
   Koh GCH, 2013, OSTEOPOROSIS INT, V24, P1981, DOI 10.1007/s00198-012-2183-7
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nguyen NCI, 2018, EYE, V32, P1544, DOI 10.1038/s41433-018-0126-z
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 57
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 259
IS 7
BP 1821
EP 1830
DI 10.1007/s00417-020-05028-5
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TI3LH
UT WOS:000605543600005
PM 33404679
DA 2022-11-30
ER

PT J
AU Malamos, P
   Ahlers, C
   Mylonas, G
   Schutze, C
   Deak, G
   Ritter, M
   Sacu, S
   Schmidt-Erfurth, U
AF Malamos, Panagiotis
   Ahlers, Christian
   Mylonas, Giorgos
   Schuetze, Christopher
   Deak, Gabor
   Ritter, Markus
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI EVALUATION OF SEGMENTATION PROCEDURES USING SPECTRAL DOMAIN OPTICAL
   COHERENCE TOMOGRAPHY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral domain OCT; neovascular age-related macular degeneration
   (nAMD); segmentation procedures
ID CHOROIDAL NEOVASCULARIZATION; HIGH-DEFINITION
AB Purpose: The purpose of this study was to evaluate standardized automated segmentation procedures of spectral domain optical coherence tomography (SD-OCT) in imaging of age-related macular degeneration.
   Methods: Twenty-nine eyes of 29 patients with neovascular age-related macular degeneration were included. Three groups were assigned, according to the predominant localization of extravasated fluid in the intra-, subretinal, and subretinal pigment epithelium (RPE) compartment. Automated segmentation procedures were evaluated in B scans of 512 X 128 X 1024 and 200 X 200 X 1024 scan patterns using SD-OCT (Cirrus). Alignment errors at the internal limiting membrane, actual RPE, and extrapolation of the physiologic RPE (RPE fit) were graded using a standardized classification system.
   Results: The rate of severe alignment failures was 56% and 41% for the 512 X 128 and the 200 X 200 raster pattern, respectively. Internal limiting membrane and actual RPE boundaries were most correctly delineated in the 200 X 200 raster pattern. Retinal pigment epithelium fit alignment was generally poor in 50% of scans. Retinal thickness values defined by internal limiting membrane and actual RPE segmentation were 90% accurate and not compromised by RPE fit misalignment. Subretinal fluid was demarcated most reliably. Alignment errors may occur together with a large spectrum of morphologic alterations.
   Conclusion: Automated algorithms of SD-OCT demonstrate a substantial rate of alignment failures in the assessment of exudative age-related macular degeneration pathologies, which are usually associated with misinterpretation of boundaries at the (sub) RPE level. RETINA 31: 453-463, 2011
C1 [Malamos, Panagiotis; Ahlers, Christian; Mylonas, Giorgos; Schuetze, Christopher; Deak, Gabor; Ritter, Markus; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Deak, Gabor] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
C3 Medical University of Vienna; Semmelweis University
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Ritter, Markus/0000-0003-1406-8340; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Hawkins BS, 1999, MOL VIS, V5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Panozzo Giacomo, 2003, Semin Ophthalmol, V18, P74, DOI 10.1076/soph.18.2.74.15854
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rivellese M, 2000, OPHTHALMIC SURG LAS, V31, P192
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Voo Irene, 2004, Ophthalmol Clin North Am, V17, P21, DOI 10.1016/j.ohc.2003.12.002
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 19
TC 16
Z9 16
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2011
VL 31
IS 3
BP 453
EP 463
DI 10.1097/IAE.0b013e3181eef031
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722YW
UT WOS:000287472400005
PM 21221050
DA 2022-11-30
ER

PT J
AU Ortak, H
   Demir, S
   Ates, O
   Benli, I
   Sogut, E
   Sahin, M
AF Ortak, Huseyin
   Demir, Selim
   Ates, Omer
   Benli, Ismail
   Sogut, Erkan
   Sahin, Mehmet
TI The Role of MMP2 (-1306C > T) and TIMP2 (-418 G > C) Promoter Variants
   in Age-related Macular Degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; gene; matrix metalloproteinase;
   polymorphisms
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; METALLOPROTEINASE ACTIVITY;
   MATRIX METALLOPROTEINASES; EXPRESSION; INHIBITOR; DEPOSITS; RISK; RPE
AB Purpose: To investigate the possible association between the matrix metalloproteinase 2 (-1306C>T) (rs 243865) and tissue inhibitors of matrix metalloproteinase 2 (-418 G>C) (rs 8179090) polymorphisms and the risk of age-related macular degeneration.
   Methods: This case-controlled prospective study included 144 age-related macular degeneration patients and 172 control subjects. All subjects were screened for age, gender, hypertension (HT), diabetes (DM), and body mass index (BMI). Serum levels of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), and smoking were also determined. Genomic DNA was extracted from peripheral leukocytes from ethylenediaminetetraacetic acid anticoagulated blood. Genotyping of the MMP2 (-1306C>T) and TIMP2 (-418 G>C) polymorphisms was performed using real-time polymerase chain reaction.
   Results: Genotype distributions or allelic frequencies of MMP2 (-1306C>T) and TIMP2 (-418 G>C) did not significantly differ between patients with AMD and control subjects. Similarly, no significant differences in either genotype distributions or allelic frequencies of MMP2 (-1306C>T) and TIMP2 (-418 G>C) were found between dry and wet AMD.
   Conclusion: MMP2 (-1306C>T) and TIMP2 (-418 G>C) promoter variants are unlikely to have a major role in age-related macular degeneration risk susceptibility.
C1 [Ortak, Huseyin; Demir, Selim] Gaziosmanpasa Univ, Dept Ophthalmol, Fac Med, Tokat, Turkey.
   [Ates, Omer] Gaziosmanpasa Univ, Dept Med Biol, Fac Med, Tokat, Turkey.
   [Benli, Ismail; Sogut, Erkan; Sahin, Mehmet] Gaziosmanpasa Univ, Dept Biochem, Fac Med, Tokat, Turkey.
C3 Gaziosmanpasa University; Gaziosmanpasa University; Gaziosmanpasa
   University
RP Ortak, H (通讯作者)，Gaziosmanpasa Univ, Dept Ophthalmol, Fac Med, Tokat, Turkey.
EM huseyin.ortak@hotmail.com
RI benli, ismail/A-7441-2016
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 1999, MOL VIS, V5
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Nackman GB, 1997, SURGERY, V122, P39, DOI 10.1016/S0039-6060(97)90262-2
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948
   Zhou YF, 2004, CARCINOGENESIS, V25, P399, DOI 10.1093/carcin/bgh020
NR 29
TC 10
Z9 11
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2013
VL 34
IS 4
BP 217
EP 222
DI 10.3109/13816810.2013.781192
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 251YB
UT WOS:000326969200005
PM 23536957
DA 2022-11-30
ER

PT J
AU Nowak, JZ
AF Nowak, Jerzy Z.
TI Age-related macular degeneration (AMD): pathogenesis and therapy
SO PHARMACOLOGICAL REPORTS
LA English
DT Review
DE age-related macular degeneration; AMD; pathogenesis; lipofuscin; drusen;
   inflammation; therapeutic strategies
ID EPITHELIUM-DERIVED FACTOR; SUPPRESSES CHOROIDAL NEOVASCULARIZATION;
   GROWTH-FACTOR VEGF; PIGMENT EPITHELIUM; INTRAVITREAL TRIAMCINOLONE;
   OCULAR NEOVASCULARIZATION; VERTEPORFIN THERAPY; BEVACIZUMAB AVASTIN;
   DRUSEN; ANGIOGENESIS
AB Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a complex interaction of metabolic, functional, genetic and environmental factors, remains poorly understood. For these reasons currently used therapeutic approaches are insuffiently effective. Although major abnormalities are seen in four functionally interrelated tissues, i.e., photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaries, the impairment of RPE cell functions is an early and crucial event in the molecular pathways leading to clinically relevant AMD changes. RPE progressively degenerate, which results in a progressive irreversible degeneration of photoreceptors. Four processes: lipofuscinogenesis, drusogenesis, inflammation and neovascularization, specifically contribute to the development of two forms of AMD, the dry form (non-exudative; geographic atrophy) and the wet form (exudative, neovascular). This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental, forthcoming therapeutic strategies.
C1 Med Univ, Polish Acad Sci, Dept Pharmacol, Ctr Med Biol, PL-93232 Lodz, Poland.
C3 Polish Academy of Sciences
RP Nowak, JZ (通讯作者)，Med Univ, Polish Acad Sci, Dept Pharmacol, Ctr Med Biol, Zeligowskiego 7-9, PL-93232 Lodz, Poland.
EM jznowak@pharm.am.lodz.pl
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2006, POL J ENV STUD
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Kerr DJ, 2004, NAT CLIN PRACT ONCOL, V1, P39, DOI 10.1038/ncponc0026
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KIM IK, 2006, INVEST OPHTH VIS SCI, P357
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KONDERDING MA, 2004, EXPER OPIN THER TAR, V8, P255
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Lau SC, 2005, CURR OPIN MOL THER, V7, P493
   MATGRAIN TH, 2004, PROG RETIN EYE RES, V23, P523
   McConnell V, 2005, Ulster Med J, V74, P82
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nowak J.Z., 2005, MAG OKUL, V2
   Nowak Jerzy Z, 2004, Klin Oczna, V106, P90
   NOWAK JZ, 2004, OKULISTYKA, V7, P49
   NOWAK JZ, 2006, IN PRESS MAG OKUL
   NOWAK JZ, 2005, MAG OKUL, V2, P103
   Pietras RJ, 2005, EVID-BASED COMPL ALT, V2, P49, DOI 10.1093/ecam/neh066
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Warburton S, 2005, MOL VIS, V11, P1122
   WIKTOROWSKAOWCZ.A, 2004, OKULISTYKA, V7, P39
   WIKTOROWSKAOWCZ.A, 2006, IN PRESS MAG OKUL
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 59
TC 426
Z9 473
U1 3
U2 73
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD MAY-JUN
PY 2006
VL 58
IS 3
BP 353
EP 363
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 073KE
UT WOS:000239740900003
PM 16845209
DA 2022-11-30
ER

PT J
AU Yoneyama, S
   Sakurada, Y
   Kikushima, W
   Sugiyama, A
   Tanabe, N
   Mabuchi, F
   Kubota, T
   Iijima, H
AF Yoneyama, Seigo
   Sakurada, Yoichi
   Kikushima, Wataru
   Sugiyama, Atsushi
   Tanabe, Naohiko
   Mabuchi, Fumihiko
   Kubota, Takeo
   Iijima, Hiroyuki
TI GENETIC FACTORS ASSOCIATED WITH CHOROIDAL VASCULAR HYPERPERMEABILITY AND
   SUBFOVEAL CHOROIDAL THICKNESS IN POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE subfoveal choroidal thickness; choroidal vascular hyperpermeability;
   polypoidal choroidal vasculopathy; ARMS2; CFH
ID COMPLEMENT FACTOR-H; CENTRAL SEROUS CHORIORETINOPATHY; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS; JAPANESE
   POPULATION; LOC387715 A69S; VARIANTS; SUSCEPTIBILITY; RANIBIZUMAB
AB Purpose: To investigate genetic factors associated with choroidal vascular hyperpermeability (CVH) and subfoveal choroidal thickness in eyes with treatment-naive polypoidal choroidal vasculopathy.
   Methods: We studied 149 consecutive patients with polypoidal choroidal vasculopathy. The presence of CVH was evaluated using indocyanine green angiography. Subfoveal choroidal thickness and axial length were measured by spectral domain optical coherence tomography and optical biometry, respectively. Genotyping of three single nubleotide polymorphisms (SNPs), including age-related maculopathy susceptibility 2 (ARMS2) A69S (rs10490924), complement factor H (CFH) I62V (rs800292), and CFH (rs1329428), which are reportedly associated with central serous chorioretinopathy, was conducted using TaqMan technology.
   Results: Thicker subfoveal choroidal thickness was associated with younger age, shorter axial length, G-allele frequency in ARMS2 A69S (rs10490924), and T-allele frequency in CFH (rs1329428) (P = 0.001, P < 0.001, P = 0.004, and P = 0.002, respectively; multiple regression analysis). Among 149 eyes with polypoidal choroidal vasculopathy, 35 eyes (23.5%) exhibited CVH on indocyanine green angiography. Patients with CVH had a significantly higher frequency of the G allele of ARMS2 A69S (rs10490924) and the T allele of CFH (rs1329428), which are reported to be risk alleles for central serous chorioretinopathy (P = 0.006 and P = 0.032, respectively; multivariate regression analysis).
   Conclusion: Subfoveal choroidal thickness and CVH in eyes with treatment-naive polypoidal choroidal vasculopathy were associated with ARMS2 A69S (rs10490924) and CFH (rs1329428).
C1 [Yoneyama, Seigo; Sakurada, Yoichi; Kikushima, Wataru; Sugiyama, Atsushi; Tanabe, Naohiko; Mabuchi, Fumihiko; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
   [Kubota, Takeo] Univ Yamanashi, Fac Med, Dept Epigenet, Kofu, Yamanashi, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
FU JSPS (Japan Society for the Promotion of Science) KAKENHI [23791972]
FX Supported in part by JSPS (Japan Society for the Promotion of Science)
   KAKENHI Grant Number 23791972.
CR Bessho H, 2011, MOL VIS, V17, P977
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   OKABE S, 1982, ACTA MED OKAYAMA, V36, P11
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
NR 32
TC 26
Z9 27
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1535
EP 1541
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200032
PM 26745149
DA 2022-11-30
ER

PT J
AU Chiang, A
   Regillo, CD
AF Chiang, Allen
   Regillo, Carl D.
TI Preferred therapies for neovascular age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; macular degeneration; neovascularization; ranibizumab;
   vascular endothelial growth factor
ID INTRAVITREAL BEVACIZUMAB AVASTIN; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; ANTI-VEGF AGENTS; PHOTODYNAMIC THERAPY; COMBINATION
   THERAPY; RANIBIZUMAB; VERTEPORFIN; SAFETY; EXPRESSION; SECONDARY
AB Purpose of review
   This report reviews the current treatment strategies and ongoing clinical trials in the treatment of neovascular age-related macular degeneration (AMD).
   Recent findings
   The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Combination therapy incorporating photodynamic therapy and antivascular endothelial growth factor (anti-VEGF) therapy may represent an alternative treatment approach and randomized multicenter clinical trials are ongoing. In addition, new pharmacologic agents like VEGF Trap-Eye are being developed and investigated; preliminary 1-year results with VEGF Trap-Eye are encouraging.
   Summary
   Ranibizumab or bevacizumab monotherapy remains the preferred therapy in the management of neovascular AMD at the present time. Ongoing clinical trials will help determine the efficacy of ranibizumab relative to bevacizumab, evaluate the long-term efficacy and safety of combination therapy modalities, and assess the role of new pharmacologic agents.
C1 [Chiang, Allen; Regillo, Carl D.] Thomas Jefferson Univ, Jefferson Med Coll, Retina Serv, Wills Eye Inst, Philadelphia, PA 19107 USA.
   [Regillo, Carl D.] Mid Atlantic Retina, Wyndmoor, PA USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Thomas Jefferson Univ, Jefferson Med Coll, Retina Serv, Wills Eye Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 2010, BAYER REGENERON REPO
   Arias Elizabeth, 2010, Natl Vital Stat Rep, V58, P1
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bolz M, 2008, 8 EURETINA C VIENN M
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Kent D, 2003, MOL VIS, V9, P747
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lim JY., 2010, ACTA OPHTHALMOL
   MEYER CF, 2008, INVEST OPHTHALMOL VI
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SHIENBAUM G, 2010, ARVO FORT LAUD FLOR
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wan MJ, 2010, CAN J OPHTHALMOL, V45, P375, DOI 10.3129/i10-011
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 61
TC 18
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2011
VL 22
IS 3
BP 199
EP 204
DI 10.1097/ICU.0b013e32834597d9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YQ
UT WOS:000289508400011
PM 21427571
DA 2022-11-30
ER

PT J
AU Sohrab, MA
   Smith, RT
   Fawzi, AA
AF Sohrab, Mahsa A.
   Smith, R. Theodore
   Fawzi, Amani A.
TI Imaging Characteristics of Dry Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE hyperspectral; imaging; dry age-related macular degeneration; OCT;
   autofluorescence
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC
   ATROPHY; RETICULAR PSEUDODRUSEN; DRUSEN MEASUREMENT; HIGH-RISK;
   MACULOPATHY; CLASSIFICATION; SEGMENTATION; PHOTOGRAPHS
AB Purpose: To review the current literature regarding the imaging characteristics of dry age-related macular degeneration (AMD) lesions, with a special focus on drusen and geographic atrophy imaging. We also explore the role of novel approach of hyperspectral imaging in AMD.
   Methods: Review of current literature as well as findings in a small group of patients imaged with hyperspectral imaging.
   Results: The use of optical coherence tomography, and especially fourier-domain devices, has enhanced our ability to classify various lesions of dry AMD. The increasing role of autofluorescence in characterization and prognostication in geographic atrophy is reviewed. The advances made in automated detection and multimodal imaging are highlighted, with their potential to revolutionize this area of research.
   Conclusions: Recent advances in retinal imaging have improved our understanding of the characteristics and prognostication of dry AMD, with an increasing role for multimodal imaging and image correlations. The potential future role of hyperspectral imaging in dry AMD is also presented herein.
C1 [Sohrab, Mahsa A.; Fawzi, Amani A.] Univ So Calif, Doheny Eye Inst, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Smith, R. Theodore] Columbia Univ, Dept Ophthalmol, Harkness Eye Inst, New York, NY 10027 USA.
C3 Doheny Eye Institute; University of Southern California; Columbia
   University
RP Fawzi, AA (通讯作者)，Univ So Calif, Doheny Eye Inst, Dept Ophthalmol, Keck Sch Med, 1450 San Pablo St,DEI 3614, Los Angeles, CA 90033 USA.
EM afawzi@doheny.org
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558; smith, theodore/0000-0002-1693-943X
FU NEI
FX The authors would like to acknowlege NEI grant support in this work.
CR APTE RS, 2002, INVEST OPHTHALMOL VI, V43
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1988, RETINA-J RET VIT DIS, V8, P102, DOI 10.1097/00006982-198808020-00004
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   FEENEYBURNS L, 1993, AM J OPHTHALMOL, V100, P1519
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENYON KR, 1985, AM J OPHTHALMOL, V100, P119, DOI 10.1016/S0002-9394(14)74993-1
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEE N, 2010, P 32 C ENG IN PRESS
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sajda P, 2004, IEEE T MED IMAGING, V23, P1453, DOI 10.1109/TMI.2004.834626
   Sajda P., 2003, 4 INT S IND COMP AN
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   SEBAG M, 1991, ACTA OPHTHALMOL, V69, P603
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Smith RT, 2004, J BIOMED OPT, V9, P162, DOI 10.1117/1.1630604
   SMITH RT, 2010, BR J OPHTHALMOL
   SMITH RT, 2004, INVEST OPHTH VIS SCI, V458, P2940
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 61
TC 10
Z9 12
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 156
EP 166
DI 10.3109/08820538.2011.570848
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200012
PM 21609229
DA 2022-11-30
ER

PT J
AU Xu, L
   Li, Y
   Zheng, Y
   Jonas, JB
AF Xu, L.
   Li, Y.
   Zheng, Y.
   Jonas, J. B.
TI Associated factors for age related maculopathy in the adult population
   in China: the Beijing eye study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CAUSE-SPECIFIC PREVALENCE; VISUAL IMPAIRMENT; MACULAR DEGENERATION;
   RISK-FACTORS; BEAVER DAM; CATARACT-SURGERY; POOLED FINDINGS; LENS
   OPACITIES; NORTHERN CHINA; URBAN
AB Background: To evaluate factors associated with the prevalence of age related maculopathy (ARM) in the adult Chinese population.
   Methods: The Beijing Eye Study, a population based prevalence study, included 4439 out of 5324 subjects from a rural area and an urban region of greater Beijing, aged 40+ years and invited to participate (response rate 83.4%). Fundus photographs were graded using the Wisconsin Age-Related Maculopathy Grading system. The following parameters were graded: drusen size, drusen type, and the area covered by drusen; pigmentary abnormalities; geographic atrophy; and exudative ARM.
   Results: Fundus photographs were available for 8655 eyes of 4376 (98.6%) subjects. Early age related macular degeneration (ARD), late ARD, and exudative ARD, respectively, were present in 1.4%, 0.20%, and 0.10% of the subjects. In a binary logistic regression analysis, early ARM was statistically associated with age (p < 0.001; 95% CI: 1.04 to 1.08), hyperopic refractive error (p = 0.008; 95% CI: 1.04 to 1.28), rural region (p < 0.001; 95% CI: 0.17 to 0.49), and lower level of education (p = 0.01; 95% CI: 1.07 to 1.65). Early ARM was not significantly associated with the optic disc size (p = 0.42), and size of beta zone of peripapillary atrophy (p = 0.28), the self reported diagnosis of diabetes mellitus (p = 0.39; OR: 1.37; 95% CI: 0.66 to 2.85), amount of cortical cataract (p = 0.72), subcapsular cataract (p = 0.98), nuclear cataract (p = 0.26), sex (p = 0.23), cataract surgery (p = 1.0; OR: 0.96; 95% CI: 0.13 to 6.95), glaucomatous optic nerve damage (p = 0.77; OR: 0.62; 95% CI: 0.15 to 2.52), and history of smoking (p = 0.66; OR: 1.14; 95% CI: 0.65 to 2.00).
   Conclusions: Hyperopic refractive error besides age was the single most important risk factor for ARM in adult Chinese. Other associated factors were rural region and lower level of education.
C1 Heidelberg Univ, Dept Ophthalmol, Fac Clin Med Mannheim, D-6800 Mannheim, Germany.
   Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   Capital Univ Med Sci, Beijing, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Capital Medical University;
   Capital Medical University
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jonas@augen.ma.uni-heidelberg.de
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cheung SW, 2000, OPHTHAL PHYSL OPT, V20, P119, DOI 10.1046/j.1475-1313.2000.00488.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   HYMAN L, 2003, CURR OPIN OPHTHALMOL, V13, P171
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang Y, 2006, BRIT J OPHTHALMOL, V90, P353, DOI 10.1136/bjo.2005.081521
   WANG Y, 2006, IN PRESS AM J OPHTHA
   Xu L, 2006, OPHTHALMOLOGY, V113, P747, DOI 10.1016/j.ophtha.2006.01.026
   Xu L, 2006, AM J OPHTHALMOL, V141, P591, DOI 10.1016/j.ajo.2005.10.018
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 49
TC 100
Z9 101
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1087
EP 1090
DI 10.1136/bjo.2006.096123
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700010
PM 16774957
OA Green Published
DA 2022-11-30
ER

PT J
AU Synek, S
   Vojnikovic, B
   Pahor, D
AF Synek, Svatopluk
   Vojnikovic, Bozo
   Pahor, Dana
TI Epidemiology and Quality of Life of Patients with Age-Related Macular
   Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE age-related macular degeneration; dry form; wet form; epidemiology;
   quality of life; Croatia
ID BETA-CAROTENE; VITAMIN-A; MACULOPATHY
AB It is well known that age-related macular degeneration (AMD), besides glaucoma and diabetic retinopathy, represents a major cause of low vision and blindness throughout the world. In this study, specific causal factors of AMD are analyzed, emphasizing the causal role and effects of sunlight, no matter which part of its spectrum, in a longer exposition through life. The accent is also put on the influence of lifestyle as well as vitamin and antioxidants supplementation in development or prevention of AMD.
C1 [Synek, Svatopluk] Masaryk Univ, Dept Ophthalmol & Optometry, St Anne Hosp, Fac Med, Brno, Czech Republic.
   [Vojnikovic, Bozo] Daily Eye Clin Dr Bozo Vojnikovic, Rijeka, Croatia.
   [Pahor, Dana] Teaching Inst Publ Hlth Primorsko Goranska Cty, Dept Hlth Ecol, Rijeka, Croatia.
C3 Masaryk University Brno; St Anne's University Hospital Brno
   (FNUSA-ICRC); University of Rijeka
RP Synek, S (通讯作者)，Dept Ophthalmol, Pekarska 53, Brno 65691, Czech Republic.
EM svatopluk.synek@fnusa.cz
RI Synek, Svatopluk/B-9815-2011
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kohl S, 1997, J MED GENET, V34, P620, DOI 10.1136/jmg.34.8.620
   MORSE JH, 1983, UNDERSTANDING LOW VI
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P3
   Vojnikovic B, 2009, COLLEGIUM ANTROPOL, V33, P747
NR 17
TC 4
Z9 4
U1 0
U2 11
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 25
EP 28
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100006
PM 21302701
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Zeng, SM
   Faidley, EA
   Mullins, RF
AF Skeie, Jessica M.
   Zeng, Shemin
   Faidley, Elizabeth A.
   Mullins, Robert F.
TI Angiogenin in age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; RETINAL-PIGMENT EPITHELIUM; POSTMORTEM
   EYES; BRUCHS MEMBRANE; GROWTH-FACTOR; PROTEIN; CELLS; CHORIOCAPILLARIS;
   BINDING; ACTIN
AB Purpose: Age-related macular degeneration (AMD) is a common blinding disease in the elderly population. AMD is frequently complicated by choroidal neovascularization, causing irreversible losses in visual acuity. Proteins that induce pathologic angiogenesis in other systems include angiogenin, a small protein involved in angiogenesis in tumor metastases. Our goal was to determine if angiogenin participates in angiogenesis during choroidal neovascular membrane formation in AMD.
   Methods: The expression of angiogenin in the human retina and retinal pigment epithelium (RPE)-choroid was determined using reverse-transcription (RT)-PCR and immunoblotting. Localization of angiogenin in human control eyes and in eyes with choroidal neovascularization was determined using immunohistochemistry. Potential angiogenin-mediated effects on endothelial cell migration, as well as angiogenin internalization by Rf/6a cells, were determined.
   Results: Angiogenin was synthesized by the human choroid and retina and localized to normal and pathologic vasculature. Angiogenin did not change the migratory behavior of Rf/6a chorioretinal endothelial cells; however, these cells did internalize exogenous angiogenin in culture.
   Conclusions: Chorioretinal endothelial cells bind and internalize angiogenin, a protein localized to the choroid in normal eyes, as well as in some drusen and in neovascular membranes in AMD eyes. Angiogenin has been shown to participate in angiogenesis in other tissues. Although angiogenin does not increase the migratory behavior of these cells, it may play a role in other aspects of endothelial cell activation in neovascular AMD.
C1 [Skeie, Jessica M.; Zeng, Shemin; Faidley, Elizabeth A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA USA.
C3 University of Iowa
RP Mullins, RF (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891
FU NEI [EY017451]; Foundation Fighting Blindness; Macula Vision Research
   Foundation; NATIONAL EYE INSTITUTE [R01EY017451, F32EY022280] Funding
   Source: NIH RePORTER
FX The authors thank Iowa Lions Eye Bank for their partnership in obtaining
   donated human eyes for AMD research. This study was supported in part by
   NEI EY017451 (R.F.M.), the Foundation Fighting Blindness, and the Macula
   Vision Research Foundation (R.F.M.).
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Duranyildiz D, 2009, BREAST, V18, P26, DOI 10.1016/j.breast.2008.09.004
   FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gao XW, 2008, ACTA BIOCH BIOPH SIN, V40, P619, DOI 10.1111/j.1745-7270.2008.00442.x
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hu GF, 2000, J CELL BIOCHEM, V76, P452, DOI 10.1002/(SICI)1097-4644(20000301)76:3<452::AID-JCB12>3.0.CO;2-Z
   HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kim HM, 2007, BIOCHEM BIOPH RES CO, V352, P509, DOI 10.1016/j.bbrc.2006.11.047
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Maier R, 2006, MOL VIS, V12, P1143
   Mullins RF, 2006, MOL VIS, V12, P224
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Ozaki H, 1996, OPHTHALMIC RES, V28, P356, DOI 10.1159/000267929
   Pyatibratov MG, 2010, ARCH BIOCHEM BIOPHYS, V495, P74, DOI 10.1016/j.abb.2009.12.024
   SCHULTZ G S, 1991, Eye (London), V5, P170
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 16
Z9 16
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 23
PY 2011
VL 17
IS 65
BP 576
EP 582
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 732PM
UT WOS:000288200100001
PM 21364907
DA 2022-11-30
ER

PT J
AU Rush, RB
   Simunovic, MP
   Vandiver, L
   Aragon, AV
   Ysasaga, JE
AF Rush, Ryan B.
   Simunovic, Matthew P.
   Vandiver, Lorelei
   Aragon, Antonio V., II
   Ysasaga, Jason E.
TI TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION The Importance of Baseline Characteristics
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; posterior vitreous detachment; treat-and-extend;
   age-related macular degeneration
ID RANIBIZUMAB; PHARMACOKINETICS; DISEASE; HEALTH; IMPACT
AB Purpose: To evaluate the factors affecting visual and anatomical outcomes and the number of intravitreal bevacizumab injections required in the treatment of neovascular age-related macular degeneration using a treat-and-extend regimen.
   Methods: Retrospective consecutive case series. The charts of subjects treated with intravitreal bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen over a 12-month period were reviewed. The key variables explored were patient age, phakic status, posterior vitreous detachment status, baseline best-corrected visual acuity (BCVA), baseline central macular thickness (CMT), and type of chorodial neovascularization. The primary outcome measures were improvement in BCVA of 3 logMAR lines or more, maintenance of BCVA within 3 logMAR lines of baseline, number of intravitreal injections delivered over a 12-month period, and final CMT on optical coherence tomography.
   Results: A total of 230 eyes met the criteria. Mean presenting BCVA was Snellen 20/55 (0.44 logMAR) and mean final BCVA was Snellen 20/44 (0.35 logMAR) (P < 0.001). A total of 23.5% (95% confidence interval [CI], 18.5-29.4%) of the subjects demonstrated an improvement in BCVA of 3 or more logMAR lines, whereas 96.5% (95% CI, 93.3-98.2%) of the subjects lost fewer than 3 logMAR lines. Mean CMT on optical coherence tomography changed from a baseline average of 373.1 mu m (95% CI, 360.3-386.1 mu m) to a final average of 305.5 mu m (95% CI, 290.0-316.0 mu m). The average number of injections during the 12-month period was 9.2 (95% CI, 9.0-9.4). Posterior vitreous detachment was associated with fewer injections on univariate and multivariate analysis (8.7 injections in the posterior vitreous detachment group versus 9.8 in the non-posterior vitreous detachment group, P < 0.001). Patients with poorer presenting BCVA and greater baseline CMTs were more likely to demonstrate a 3 or more logMAR line improvement in BCVA. Thinner final CMTs were independently associated with thinner presenting CMTs and fewer injections.
   Conclusion: Favorable visual and anatomical outcomes may be achieved with intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration using a treat-and-extend regimen. Our study suggests that posterior vitreous detachment may play a role in the efficacy of intravitreal bevacizumab during the treatment of neovascular age-related macular degeneration.
C1 [Rush, Ryan B.; Aragon, Antonio V., II; Ysasaga, Jason E.] Southwest Retina Specialists, Amarillo, TX 79106 USA.
   [Rush, Ryan B.; Vandiver, Lorelei; Aragon, Antonio V., II; Ysasaga, Jason E.] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA.
   [Simunovic, Matthew P.] Sydney Eye Hosp, Sydney, NSW, Australia.
   [Simunovic, Matthew P.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; Texas Tech University Health Sciences
   Center Amarillo; University of Sydney
RP Rush, RB (通讯作者)，Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX 79106 USA.
EM Ryanbradfordrush21@hotmail.com
RI Simunovic, Matthew P/B-4913-2011; Simunovic, Matthew/AAS-8946-2020
OI Simunovic, Matthew/0000-0003-0596-1356; Rush, Ryan/0000-0003-2790-6155
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Goldenberg DT, 2009, DEV OPHTHALMOL, V44, P31, DOI 10.1159/000223943
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Jumper JM, 2012, PREFERENCE TRENDS SU
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 18
TC 20
Z9 20
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2014
VL 34
IS 5
BP 846
EP 852
DI 10.1097/IAE.0000000000000033
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GM
UT WOS:000337148700005
PM 24240560
DA 2022-11-30
ER

PT J
AU Patel, PJ
   Chen, FK
   Rubin, GS
   Tufail, A
AF Patel, Praveen J.
   Chen, Fred K.
   Rubin, Gary S.
   Tufail, Adnan
TI Intersession repeatability of visual acuity scores in age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; RANIBIZUMAB; CHARTS; VERTEPORFIN;
   CONSISTENCY; PROTOCOL; DISEASE; DESIGN
AB PURPOSE. To describe the intersession repeatability of visual acuity measures obtained with Early Treatment of Diabetic Retinopathy Study (ETDRS) charts in patients with age-related macular degeneration.
   METHODS. Visual acuity was measured in four sessions over 12 weeks using a standardized protocol with ETDRS charts in 107 nontreated eyes of 107 patients with age-related macular degeneration enrolled in an ongoing clinical trial.
   RESULTS. Data from 90 patients were included in the analysis. The 95% coefficient of repeatability (CR) was 12 ETDRS letters and ranged from 9 letters for 29 eyes with small to intermediate drusen only to 17 letters for 25 eyes with late AMD (macular scars or geographic atrophy). Ten (11%) eyes had a 5-letter reduction or more in visual acuity at the week 1 visit compared with baseline. Excluding seven eyes with visual acuity measurements potentially affected by measurement-related factors (a change in testing distance between visits) the revised CR was 10 letters for the cohort (n = 83) and 11 letters for the late-AMD subgroup (n = 18).
   CONCLUSIONS. Intersession ETDRS visual acuity measurements are subject to considerable variability in patients with AMD. The variability may be due to both measurement-and disease-related factors. The variable readings have implications for AMD clinical trial design and for the assessment and treatment of patients with neovascular AMD. Further work is needed to determine both the sources of variability in visual acuity measurements and the optimal change criterion for visual acuity measurements in this important group of patients.
C1 [Patel, Praveen J.; Chen, Fred K.; Tufail, Adnan] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Rubin, Gary S.] UCL, Inst Ophthalmol, London, England.
   [Rubin, Gary S.] Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London
RP Tufail, A (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@moorfields.nhs.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Tufail, Adnan/0000-0001-6131-7640
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Bland JM, 1996, BRIT MED J, V313, P744
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Camparini M, 2001, INVEST OPHTH VIS SCI, V42, P1226
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Dong LM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1523, DOI 10.1001/archopht.120.11.1523
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Lovie-Kitchin JE, 2000, OPTOMETRY VISION SCI, V77, P412, DOI 10.1097/00006324-200008000-00008
   Raasch TW, 1998, OPTOMETRY VISION SCI, V75, P342, DOI 10.1097/00006324-199805000-00024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 20
TC 62
Z9 64
U1 2
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2008
VL 49
IS 10
BP 4347
EP 4352
DI 10.1167/iovs.08-1935
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355IZ
UT WOS:000259703900020
PM 18566455
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Salminen, A
   Haapasalo, A
   Soininen, H
   Hiltunen, M
AF Kaarniranta, Kai
   Salminen, Antero
   Haapasalo, Annakaisa
   Soininen, Hilkka
   Hiltunen, Mikko
TI Age-Related Macular Degeneration (AMD): Alzheimer's Disease in the Eye?
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Review
DE Age-related macular degeneration (AMD); aggregation; aging; Alzheimer's
   disease; autophagy; lysosome; oxidative stress; proteasome
ID COMPLEMENT FACTOR-H; MITOCHONDRIAL-DNA DAMAGE; RETINAL-PIGMENT
   EPITHELIUM; MILD COGNITIVE IMPAIRMENT; HTRA1 PROMOTER POLYMORPHISM;
   UBIQUITIN-PROTEASOME SYSTEM; AMYLOID PRECURSOR PROTEIN; GLYCATION
   END-PRODUCTS; VASCULAR RISK-FACTORS; E EPSILON-4 ALLELE
AB Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD), including stress stimuli such as oxidative stress and inflammation. In both diseases, the detrimental intra- and extracellular deposits have many similarities. Aging, hypercholesterolaemia, hypertension, obesity, arteriosclerosis, and smoking are risk factors to develop AMD and AD. Cellular aging processes have similar organelle and signaling association in the retina and brain tissues. However, it seems that these diseases have a different genetic background. In this review, differences and similarities of AMD and AD are thoroughly discussed.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Salminen, Antero; Haapasalo, Annakaisa; Soininen, Hilkka; Hiltunen, Mikko] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Salminen, Antero; Haapasalo, Annakaisa; Soininen, Hilkka; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Haapasalo,
   Annakaisa/0000-0003-0959-2957
FU Kuopio University Hospital [5772708, 5503726]; Finnish Cultural
   Foundation; North Savo Fund; Finnish Eye Foundation; Finnish Funding
   Agency for Technology and Innovation, Health Research Council of the
   Academy of Finland; Nordic Centre of Excellence in Neurodegeneration;
   Paivikki and Sakari Sohlberg Foundation; Sigrid Juselius Foundation
FX This work was supported by the EVO grants 5772708 and 5503726 of Kuopio
   University Hospital, the Finnish Cultural Foundation and its North Savo
   Fund, the Finnish Eye Foundation, the Finnish Funding Agency for
   Technology and Innovation, Health Research Council of the Academy of
   Finland, the Nordic Centre of Excellence in Neurodegeneration, the
   Paivikki and Sakari Sohlberg Foundation and Sigrid Juselius Foundation.
CR Alexeyev MF, 2009, FEBS J, V276, P5768, DOI 10.1111/j.1742-4658.2009.07269.x
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   ALUISE CD, NEUROBIOL DIS, V3, P221
   Amadio M, 2009, J ALZHEIMERS DIS, V16, P409, DOI 10.3233/JAD-2009-0967
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Butterfield DA, 2010, BBA-MOL CELL BIOL L, V1801, P924, DOI 10.1016/j.bbalip.2010.02.005
   Butterfield DA, 2006, NEUROBIOL DIS, V22, P223, DOI 10.1016/j.nbd.2005.11.002
   Butterfield DA, 2006, NEUROSCI LETT, V397, P170, DOI 10.1016/j.neulet.2005.12.017
   Cardoso SM, 2010, EXP NEUROL, V223, P294, DOI 10.1016/j.expneurol.2009.06.008
   Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7
   Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0
   Castellani RJ, 2001, FREE RADICAL BIO MED, V31, P175, DOI 10.1016/S0891-5849(01)00570-6
   CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569
   CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dei R, 2002, ACTA NEUROPATHOL, V104, P113, DOI 10.1007/s00401-002-0523-y
   DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forero DA, 2006, J CELL MOL MED, V10, P796, DOI 10.1111/j.1582-4934.2006.tb00439.x
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009
   Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Griffin WST, 1998, BRAIN PATHOL, V8, P65
   GRIMM S, 2010, AMINO ACIDS, DOI DOI 10.1007/S00726-010-0646-8
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Haapasalo A, 2010, BIOCHEM SOC T, V38, P150, DOI 10.1042/BST0380150
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hiltunen M, 2006, J BIOL CHEM, V281, P32240, DOI 10.1074/jbc.M603106200
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hutt D, 2010, SCIENCE, V329, P766, DOI 10.1126/science.1194160
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jaeger PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011102
   Janse DM, 2004, J BIOL CHEM, V279, P21415, DOI 10.1074/jbc.M402954200
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Kaarniranta K, 2002, MOL BRAIN RES, V101, P136, DOI 10.1016/S0169-328X(02)00179-1
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kalaria RN, 1997, LANCET, V349, P1174, DOI 10.1016/S0140-6736(05)63052-8
   Kang EL, 2010, J BIOL CHEM, V285, P24108, DOI 10.1074/jbc.M109.092742
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x
   Keller JN, 2006, AGEING RES REV, V5, P1, DOI 10.1016/j.arr.2005.06.002
   Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x
   Keller JN, 2005, NEUROLOGY, V64, P1152, DOI 10.1212/01.WNL.0000156156.13641.BA
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447
   Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006
   Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107
   KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034
   Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Madeo F, 2009, GENE DEV, V23, P2253, DOI 10.1101/gad.1858009
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219
   Mishto M, 2006, NEUROBIOL AGING, V27, P54, DOI 10.1016/j.neurobiolaging.2004.12.004
   Moreira PI, 2007, J NEUROPATH EXP NEUR, V66, P674
   Moreira PI, 2010, EXPERT REV NEUROTHER, V10, P1209, DOI 10.1586/ERN.10.84
   Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P2, DOI 10.1016/j.bbadis.2009.10.006
   MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006
   Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nunomura A, 1999, J NEUROSCI, V19, P1959
   Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759
   Oddo S, 2008, J CELL MOL MED, V12, P363, DOI 10.1111/j.1582-4934.2008.00276.x
   Ohta K, 2010, AUTOPHAGY, V6, P345, DOI 10.4161/auto.6.3.11228
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Paine MG, 2005, FEBS LETT, V579, P5029, DOI 10.1016/j.febslet.2005.08.010
   Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pasinetti GM, 2001, J NEUROSCI RES, V65, P471, DOI 10.1002/jnr.1176
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033
   Pivtoraiko VN, 2009, ANTIOXID REDOX SIGN, V11, P481, DOI 10.1089/ARS.2008.2263
   Powell SR, 2005, FREE RADICAL BIO MED, V38, P1093, DOI 10.1016/j.freeradbiomed.2005.01.003
   Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777
   Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972
   Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Sarajarvi T, 2009, J BIOL CHEM, V284, P34433, DOI 10.1074/jbc.M109.036202
   Schipper HM, 2006, NEUROBIOL AGING, V27, P252, DOI 10.1016/j.neurobiolaging.2005.01.016
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Seitsonen S, 2006, MOL VIS, V12, P796
   Shacka JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P718, DOI 10.2741/2714
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Shin TM, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-16
   Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490
   SMITH MA, 1994, AM J PATHOL, V145, P42
   Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Sultana R, 2010, J ALZHEIMERS DIS, V19, P341, DOI 10.3233/JAD-2010-1222
   TABATON M, 1991, P NATL ACAD SCI USA, V88, P2098, DOI 10.1073/pnas.88.6.2098
   Tan Z, 2007, CELL DEATH DIFFER, V14, P1721, DOI 10.1038/sj.cdd.4402180
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tank EMH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000382
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012
   Turunen M, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2009.08.010
   Viiri J, 2010, MOL VIS, V16, P1399
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weger M, 2007, MOL VIS, V13, P1274
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhu X, 2007, CELL MOL LIFE SCI, V64, P2202, DOI 10.1007/s00018-007-7218-4
   Zhu XW, 2007, BBA-MOL BASIS DIS, V1772, P494, DOI 10.1016/j.bbadis.2006.10.014
   Zhu XW, 2004, LANCET NEUROL, V3, P219, DOI 10.1016/S1474-4422(04)00707-0
   Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6
   ZUBENKO GS, 1994, AM J MED GENET, V54, P199, DOI 10.1002/ajmg.1320540306
NR 196
TC 183
Z9 188
U1 1
U2 38
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2011
VL 24
IS 4
BP 615
EP 631
DI 10.3233/JAD-2011-101908
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 788XE
UT WOS:000292476900001
PM 21297256
OA hybrid
DA 2022-11-30
ER

PT J
AU Khandhadia, S
   Cipriani, V
   Yates, JRW
   Lotery, AJ
AF Khandhadia, S.
   Cipriani, V.
   Yates, J. R. W.
   Lotery, A. J.
TI Age-related macular degeneration and the complement system
SO IMMUNOBIOLOGY
LA English
DT Review
DE Complement factor H/genetics; Complement pathway; Alternative/genetics;
   Complement system proteins/genetics; Humans; Immunogenetic phenomena;
   Inflammation/genetics; Inflammation/immunology; Macular
   degeneration/genetics; Macular degeneration/immunology; Polymorphism;
   Single nucleotide; Proteins/genetics
ID FACTOR-H Y402H; PIGMENT EPITHELIAL-CELLS; CHLAMYDIA-PNEUMONIAE
   INFECTION; FACTOR HY402H POLYMORPHISM; C-REACTIVE PROTEIN; MEMBRANE
   ATTACK COMPLEX; GENOME-WIDE ASSOCIATION; SERPING1 GENE; CFH GENE;
   CHOROIDAL NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. It is a complex multifactorial disease, and despite new advances in treatment, many patients still succumb to visual impairment. The complement pathway has been implicated in the pathogenesis of many diseases, and recently variants in several genes encoding complement pathway proteins have been associated with AMD. Complement proteins have been found in histological specimens of eyes with AMD. Altered levels of both intrinsic complement proteins and activated products have been found in the circulation of patients with AMD. Complement activation may be triggered by oxidative stress, resulting from retinal exposure to incoming light; indeed an inter-play between these two pathological processes seems to exist. Finally, complement inhibitors are currently being evaluated in clinical trials. This article reviews the role of the complement system in AMD, and the potential of complement inhibition in preventing the devastating blindness resulting from this disease. (C) 2011 Elsevier GmbH. All rights reserved.
C1 [Lotery, A. J.] Univ Southampton, Clin Neurosci Div, Southampton Eye Unit, Southampton S016 6YD, Hants, England.
   [Cipriani, V.; Yates, J. R. W.] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Cipriani, V.; Yates, J. R. W.] Moorfields Eye Hosp, London, England.
   [Lotery, A. J.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England.
C3 University of Southampton; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of Southampton; University
   Hospital Southampton NHS Foundation Trust
RP Lotery, AJ (通讯作者)，Univ Southampton, Clin Neurosci Div, Southampton Eye Unit, Tremona Rd, Southampton S016 6YD, Hants, England.
EM A.J.Lotery@soton.ac.uk
RI Cipriani, Valentina/A-8549-2012; Mohammed, Imran/J-8271-2012
OI Cipriani, Valentina/0000-0002-0839-9955; Mohammed,
   Imran/0000-0002-8412-0768; Lotery, Andrew/0000-0001-5541-4305
FU TFC Frost Charitable Trust; Frimley Park NHS Trust; Gift of Sight
   Appeal; Guide Dogs for the Blind Association; Department of Health's
   NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital; UCL Institute of Ophthalmology; MRC [G0000067] Funding Source:
   UKRI; Medical Research Council [G0000067] Funding Source: researchfish;
   National Institute for Health Research [NF-SI-0507-10094] Funding
   Source: researchfish
FX SK is funded by grants from the TFC Frost Charitable Trust, Frimley Park
   NHS Trust and the Gift of Sight Appeal. VC is funded by a grant from the
   Guide Dogs for the Blind Association. This research has received a
   proportion of its funding from the Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital
   and UCL Institute of Ophthalmology. The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health. We would like to thank the reviewers for their
   valuable comments.
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   AGOSTONI A, 1980, ANN ALLERGY, V44, P299
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Apte R.S., 2009, ARVO M, V50, P5011
   ARLAUD GJ, 1979, BIOCHIM BIOPHYS ACTA, V576, P151, DOI 10.1016/0005-2795(79)90494-X
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BARTOK I, 1995, J IMMUNOL, V154, P5367
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Carter JG, 2011, ACTA OPHTHALMOL, V89, pE212, DOI 10.1111/j.1755-3768.2009.01788.x
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Cousins S.W., 2010, ARVO M, V51, P1251
   Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dhillon B., 2010, INVEST OPHTHALMOL VI
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FARBER DB, 1995, INVEST OPHTH VIS SCI, V36, P263
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Genentech, 2011, NCT01229215 NLM GEN
   Genentech, 2011, NCT00973011 NLM GEN
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gosswein T, 2008, CYTOGENET GENOME RES, V121, P181, DOI 10.1159/000138883
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kelly U, 2009, INVEST OPHTH VIS SCI, V50, P1540, DOI 10.1167/iovs.08-2782
   Kerr FK, 2008, MOL IMMUNOL, V45, P670, DOI 10.1016/j.molimm.2007.07.008
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim IK, 2008, MOL VIS, V14, P1487
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klaver CCW, 2008, LANCET, V372, P1788, DOI 10.1016/S0140-6736(08)61349-5
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kociok N, 2010, GRAEF ARCH CLIN EXP, V248, P1145, DOI 10.1007/s00417-010-1371-4
   Koehl J, 2006, CURR OPIN MOL THER, V8, P529
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kralovicova J, 2009, LANCET, V373, P461, DOI 10.1016/S0140-6736(09)60168-9
   LAI YL, 1978, INVEST OPHTH VIS SCI, V17, P634
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Liu J, 2009, BRIT J OPHTHALMOL, V93, P379, DOI 10.1136/bjo.2008.143388
   Liu X., 2010, RETINA
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Loyet K.M., 2010, ARVO M, V51, P2980
   Lu F, 2010, MOL VIS, V16, P1
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Mayer G, 2004, BIODRUGS, V18, P351, DOI 10.2165/00063030-200418060-00002
   Mckay GJ, 2010, MOL VIS, V16, P194
   MERI S, 1990, IMMUNOLOGY, V71, P1
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Narendra U, 2009, MOL VIS, V15, P731
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nilsson S.C., 2011, MOL IMMUNOL
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Novartis Pharmaceuticals, 2011, NCT01255462 NLM NOV
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto H, 2006, MOL VIS, V12, P156
   Ophthotech Corporation, 2011, NCT00709527 NLM OPHT
   Ophthotech Corporation, 2011, NCT00950638 NLM OPHT
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park KH, 2009, MOL VIS, V15, P200
   Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Perkins SJ, 2010, ADV EXP MED BIOL, V703, P25, DOI 10.1007/978-1-4419-5635-4_3
   POZNANSKY MC, 1989, J IMMUNOL, V143, P1254
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L., 2010, OPHTHALMOLOGY
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Seland J.H., 2009, ACTA OPHTHALMOLOGICA
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   University of Miami, 2011, NCT00935883 NLM U MI
   van Lookeren Campagne M., 2010, ARVO M, V51, P4511
   van Soest SS, 2007, MOL VIS, V13, P1608
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Weger M, 2007, MOL VIS, V13, P1274
   WELCH TR, 1990, J PEDIATR-US, V116, pS92, DOI 10.1016/S0022-3476(05)82709-X
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zeng JX, 2010, MOL VIS, V16, P2273
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636
   Zhou W., 2011, INTRARENAL SYNTHESIS
   ZICCARDI RJ, 1976, J IMMUNOL, V116, P504
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 239
TC 131
Z9 139
U1 1
U2 36
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD FEB
PY 2012
VL 217
IS 2
SI SI
BP 127
EP 146
DI 10.1016/j.imbio.2011.07.019
PG 20
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 902GI
UT WOS:000301026200002
PM 21868123
DA 2022-11-30
ER

PT J
AU Totan, Y
   Yagci, R
   Bardak, Y
   Ozyurt, H
   Kendir, F
   Yilmaz, G
   Sahin, S
   Tig, US
AF Totan, Yueksel
   Yagci, Ramazan
   Bardak, Yavuz
   Ozyurt, Huseyin
   Kendir, Fadime
   Yilmaz, Guelsen
   Sahin, Semsettin
   Tig, Ufuk Sahin
TI Oxidative Macromolecular Damage in Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; DNA oxidation; Lipid peroxidation;
   Oxidative stress; Protein oxidation
ID MITOCHONDRIAL-DNA DAMAGE; POSSIBLE MECHANISM; STRESS; RETINA; OXYGEN
AB Purpose: To evaluate oxidative damage to the macromolecules, including protein, lipid, and DNA, in association with total oxidation status (TOS), total antioxidant capacity (TAC) in patients with exudative age-related macular degeneration (AMD).
   Materials and Methods: Serum levels of malondialdehyde (MDA) as an index of lipid peroxidation, protein carbonyl (PC) as a marker of protein oxidation, 8-hydroxy-2-deoxyguanosine (8-OHdG) as an indicator of oxidative DNA damage along with TOS, TAC were measured by specific methods in 47 patients with exudative AMD and 25 age- and sex-matched healthy subjects.
   Results: Significantly higher MDA, PC, 8-OHdG, TOS, and lower TAC levels were detected in the serum of patients with exudative AMD compared with their controls (p<0.001).
   Conclusion: The results indicate that an imbalance between TOS and TAC leads to not only increased lipid damage, but also protein and DNA damage. These first reported results suggest that protein and DNA damage might also play a role in the pathogenesis of AMD.
C1 [Totan, Yueksel; Yagci, Ramazan] Fatih Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Bardak, Yavuz; Kendir, Fadime; Tig, Ufuk Sahin] Suleyman Demirel Univ, Sch Med, Dept Ophthalmol, Isparta, Turkey.
   [Ozyurt, Huseyin; Sahin, Semsettin] Gazi Osman Pasa Univ, Sch Med, Dept Biochem, Tokat, Turkey.
   [Yilmaz, Guelsen] Ankara Numune Training & Res Hosp, Dept Biochem, Ankara, Turkey.
C3 Fatih University; Suleyman Demirel University; Gaziosmanpasa University;
   Ankara Numune Training & Research Hospital
RP Yagci, R (通讯作者)，Fakulteler M Keskin S 9-3, TR-06590 Cankaya, Turkey.
EM ramazan-yagci@yahoo.com
RI OZYURT, Huseyin/N-4351-2015; Yilmaz, Gulsen/O-3923-2016
OI OZYURT, Huseyin/0000-0003-2327-4082; Yilmaz, Gulsen/0000-0002-9630-3852
FU Scientific Research Fund of Fatih University [P53010603]
FX The authors thank Aysel Akkaya, Professor at the Department of
   Statistics in Middle East Technical University, Ankara, Turkey, for her
   assistance in all the statistical analyses performed. This project is
   supported by the Scientific Research Fund of Fatih University under the
   project number P53010603.
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Aslan M, 2007, NUTR METAB CARDIOVAS, V17, P734, DOI 10.1016/j.numecd.2006.08.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1
   Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Harman D, 1998, ANN NY ACAD SCI, V854, P1, DOI 10.1111/j.1749-6632.1998.tb09886.x
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Kono Y, 2006, CIRC J, V70, P1001, DOI 10.1253/circj.70.1001
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Pan HZ, 2008, BRIT J OPHTHALMOL, V92, P548, DOI 10.1136/bjo.2007.130542
   Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336
   Tarpey MM, 2004, AM J PHYSIOL-REG I, V286, pR431, DOI 10.1152/ajpregu.00361.2003
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Voss P, 2006, FREE RADICAL RES, V40, P1339, DOI 10.1080/10715760600953859
   Wang AL, 2008, MOL VIS, V14, P644
   Winkler BS, 1999, MOL VIS, V5
   Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010
NR 25
TC 59
Z9 60
U1 0
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2009
VL 34
IS 12
BP 1089
EP 1093
DI 10.3109/02713680903353772
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 531ON
UT WOS:000272677400011
PM 19958129
DA 2022-11-30
ER

PT J
AU Smith, TC
   Lee, L
AF Smith, Timothy C.
   Lee, Lawrence
TI Age related macular degeneration - New developments in treatment
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; INJECTION; SAFETY
AB BACKGROUND
   Age related macular degeneration (AMD) is a common condition seen in general practice. Over the past few years, new understanding of the condition has seen the rapid development of increasingly effective treatments.
   OBJECTIVE
   This article discusses the pathogenesis of AMD and how this relates to the most up to date treatments for the disease. It aims to provide general practitioners with timely information regarding these significant advances, which may assist in the management of patients with AMD.
   DISCUSSION
   Increasingly, AMD sufferers independently source information about the latest treatments. Consequently GPs are likely to hear more questions from their patients regarding treatment options. Antivascular endothelial growth factor drugs show exciting potential for an often debilitating condition. However, early referral and treatment is vital to successful outcomes and GPs can play an essential role in this process. As well, they can serve to provide ongoing information and Counselling to their patients with AMD.
C1 [Smith, Timothy C.] City Eye Ctr, Brisbane, Qld, Australia.
   [Lee, Lawrence] Univ Queensland, Dept Ophthalmol, St Lucia, Qld 4067, Australia.
C3 University of Queensland
RP Smith, TC (通讯作者)，City Eye Ctr, Brisbane, Qld, Australia.
EM tsmith@med.usyd.edu.au
CR *AREDS, 2001, ARCH OPHTHALMOL-CHIC, V119, P383
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   *GEN INC, PREL PHAS 3 DAT SHOW
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   *NAT EY I, NATL I HLTH STIM DEV
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   PACKO KH, 2004, AUDIO DIGEST OIPHTHA, P42
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 16
TC 11
Z9 11
U1 0
U2 2
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD MAY
PY 2007
VL 36
IS 5
BP 359
EP 361
PG 3
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 278LI
UT WOS:000254286800021
PM 17492074
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Bonyadi, M
   Soheilian, M
   Karimi, S
AF Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Bonyadi, Mortaza
   Soheilian, Masoud
   Karimi, Saeed
TI Association of Combined Complement Factor H Y402H and ARMS/LOC387715
   A69S Polymorphisms with Age-related Macular Degeneration: A
   Meta-analysis
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration (AMD); ARMS2; LOC387715 A69S; CFH
   Y402H; meta-analysis; synergistic effect
ID SUSCEPTIBILITY LOCI; GENE POLYMORPHISMS; GENOMEWIDE SCAN; ARMS2; RISK;
   CFH; MACULOPATHY; LOC387715; ALLELES; PREVALENCE
AB Purpose: Complement factor H (CFH) Y402H (rs1061170) and age-related maculopathy susceptibility2 (ARMS2)/LOC387715 A69S (rs10490924) polymorphisms shown to have significant association with age-related macular degeneration (AMD). In this meta-analysis, we pooled the results of the available association studies between combined ARMS2/LOC387715A69S-CFHY402H genotypes and AMD to estimate the possible synergistic or multiplicative effects.Methods: Heterogeneity of studies was evaluated using the Cochran Q-test and the I-square index. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA. To estimate the additive or supra-additive effects, we calculated relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), synergy index (S), and multiplicative index (V).Results: We included eight studies with 2915 AMD patients and 3505 control subjects. Considering the GGTT genotypes as reference lines, the pooled AMD Odds Ratios for stratified combined genotypes were 2.32 (95% CI 1.64-3.28) for GGnon-TT, 2.49 (95% CI 1.72-3.60) for non-GGTT, and 7.82 (95% CI 5.09-12.00) for non-GGnon-TT. Pooled synergy analysis revealed RERI = 4.08 (95% CI 3.15-5.27), AP = 0.50 (95% CI 0.42-0.57), S = 2.31 (95% CI 1.9-2.82), and V = 1.21 (95% CI 0.93-1.49).Conclusion: This analysis revealed the synergistic and positive multiplicative effect of these two genes indicating that there is a common pathway of ARMS2/LOC387715 and CFH in AMD pathogenesis which may be the complement system pathway.
C1 [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud; Karimi, Saeed] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; University of Tabriz
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Karimi, Saeed/AAW-4905-2020; Yaseri, Mehdi/I-1645-2018; Hossein,
   Jabbarpoor Bonyadi Mohammad/A-1886-2014; Soheilian, Masoud/AAW-4743-2020
OI Yaseri, Mehdi/0000-0002-4066-873X; Soheilian, Masoud/0000-0001-7508-426X
FU Ophthalmic Research Center [1321]
FX This research was funded by the Ophthalmic Research Center (Grant no.
   1321).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GICLAS PC, 1979, J IMMUNOL, V122, P146
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang XF, 2010, HUM HERED, V70, P269, DOI 10.1159/000321967
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Xu YL, 2008, MOL VIS, V14, P1373
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zhao JY, 2006, AM J HUM GENET, V79, P831, DOI 10.1086/508571
   Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104
NR 45
TC 10
Z9 10
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC
PY 2016
VL 41
IS 12
BP 1519
EP 1525
DI 10.3109/02713683.2016.1158274
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EF8UD
UT WOS:000390604500001
PM 27269047
DA 2022-11-30
ER

PT J
AU Gambon, R
   Barthelmes, D
   Amstutz, C
   Fleischhauer, J
   Kurz-Levin, M
   Zweifel, S
AF Gambon, R.
   Barthelmes, D.
   Amstutz, C.
   Fleischhauer, J.
   Kurz-Levin, M.
   Zweifel, S.
TI Preliminary Results of Aflibercept in Treatment-Naive Choroidal
   Neovascularization of Wet Age-Related Macular Degeneration
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE age-related macular degeneration; exudative age-related macular
   degeneration; treatment-naive choroidal neovascularization; anti-VEGF
   therapy; aflibercept
ID VEGF-TRAP
AB Background: The aim of this study was to evaluate the early response of aflibercept as first-line therapy in treatment-naive patients with newly diagnosed choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Patients and Methods: An analysis of 35 eyes (35 patients, 28 female, 7 male) with treatment-naive active CNV was undertaken. Lesion activity was determined based on fluorescein angiography, clinical and optical coherence tomography (OCT) findings, including the presence of sub-, intraretinal fluid, retinal pigment epithelial (RPE) detachment and hemorrhage. Logarithm of the minimum angle of resolution (LogMAR) charts were used for testing best corrected or best available visual acuity (BCVA). Treatment response was evaluated based on changes in BCVA and lesion activity.
   Results: Classic or predominantly classic CNV was diagnosed in 7 eyes (20.0%), occult or minimally classic in 21 eyes (60.0%), retinal angiomatous proliferation in 5 eyes (14.3%) and polypoidal choroidal vasculopathy in 2 eyes (5.7%). Lesion activity was evaluated as unchanged in only one eye. In all other eyes, a definite treatment response was observed with complete resolution of fluid in 20 eyes after a single injection. Three eyes did not show improved sub-RPE fluid with smaller pigment epithelial detachments. A rip of the RPE was seen in 3 eyes. All patients maintained vision, 7 patients (7 eyes) gained > 15 letters from baseline to month 2 follow-up, of whom 4 reached this level of visual acuity after one injection. The visual acuity gains in this study were maintained through 6 months.
   Conclusion: There seems to be a rapid treatment response to aflibercept independent of the underlying CNV. Aflibercept may be beneficial even in eyes with large pigment epithelial detachments due to exudative AMD.
C1 [Gambon, R.; Barthelmes, D.; Amstutz, C.; Fleischhauer, J.; Kurz-Levin, M.; Zweifel, S.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital
RP Zweifel, S (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM sandrine.zweifel@gmail.com
RI Zweifel, Sandrine/AAX-5045-2020
CR Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Major J, 2012, LAS VEG NV AM SOC RE
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
NR 7
TC 5
Z9 5
U1 0
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2014
VL 231
IS 4
BP 423
EP 426
DI 10.1055/s-0034-1368292
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI4PX
UT WOS:000336848400042
PM 24771183
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Messinger, JD
   Sloan, KR
   McGwin, G
   Medeiros, NE
   Spaide, RF
AF Curcio, Christine A.
   Messinger, Jeffrey D.
   Sloan, Kenneth R.
   McGwin, Gerald
   Medeiros, Nancy E.
   Spaide, Richard F.
TI SUBRETINAL DRUSENOID DEPOSITS IN NON-NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION Morphology, Prevalence, Topography, and Biogenesis Model
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; basal linear deposit; cholesterol;
   fovea; histopathology; lipoproteins; macula; photoreceptors; reticular
   drusen; subretinal drusenoid deposit
ID RETICULAR PSEUDODRUSEN; APOLIPOPROTEIN-E; BRUCHS MEMBRANE;
   HIGH-RESOLUTION; BASAL DEPOSITS; COMPLEMENT ACTIVATION; GEOGRAPHIC
   ATROPHY; PIGMENT-EPITHELIUM; LIPID-METABOLISM; HUMAN RETINA
AB Purpose: To characterize the morphology, prevalence, and topography of subretinal drusenoid deposits, a candidate histological correlate of reticular pseudodrusen, with reference to basal linear deposit (BlinD), a specific lesion of age-related macular degeneration, and to propose a biogenesis model for both lesion.
   Methods: Donor eyes with median death-to-preservation of 2: 40 hours were postfixed in osmium tannic acid paraphenylenediamine and prepared for macula-wide high-resolution digital sections. Annotated thicknesses of 21 chorioretinal layers were determined at standard locations in sections through the fovea and the superior perifovea.
   Results: In 22 eyes of 20 white donors (83.1 +/- 7.7 years), SDD appeared as isolated or confluent drusenoid dollops punctuated by tufts of retinal pigment epithelium apical processes and associated with photoreceptor perturbation. Subretinal drusenoid deposits and BlinD were detected in 85 and 90% of non-neovascular age-related macular degeneration donors, respectively. Subretinal drusenoid deposit was thick (median, 9.4 mu m) and more abundant in the perifovea than in the fovea (P < 0.0001). BlinD was thin (median, 2.1 mu m) and more abundant in the fovea than in the perifovea (P < 0.0001).
   Conclusion: Subretinal drusenoid deposits and BlinD prevalence in age-related macular degeneration eyes are high. Subretinal drusenoid deposits organized morphology, topography, and impact on surrounding photoreceptors imply specific processes of biogenesis. Contrasting topographies of subretinal drusenoid deposits and BlinD suggest relationships with differentiable aspects of rod and cone physiology, respectively. A 2-lesion 2-compartment biogenesis model incorporating outer retinal lipid homeostasis is presented. RETINA 33:265-276, 2013
C1 [Curcio, Christine A.; Messinger, Jeffrey D.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Comp & Informat Sci, Birmingham, AL 35294 USA.
   [McGwin, Gerald] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Medeiros, Nancy E.] Retina Specialists N Alabama, Huntsville, AL USA.
   [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Vitreous
   Retina Macula Consultants of New York
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, EyeSight Fdn Alabama Vis Res Labs, Sch Med, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Spaide, Richard/ABD-7368-2020; Mitchell, Paul/P-1498-2014
FU NIH [EY06109]; International Retinal Research Foundation; Research to
   Prevent Blindness, Inc; EyeSight Foundation of Alabama; NATIONAL EYE
   INSTITUTE [R01EY006109] Funding Source: NIH RePORTER
FX Supported by NIH grants EY06109, International Retinal Research
   Foundation, Research to Prevent Blindness, Inc, EyeSight Foundation of
   Alabama.
CR Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Asztalos BF, 2011, CURR OPIN LIPIDOL, V22, P176, DOI 10.1097/MOL.0b013e3283468061
   Barter PJ, 2002, ATHEROSCLEROSIS SUPP, V3, P39, DOI 10.1016/S1567-5688(02)00041-7
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Curcio CA, BIOMETRICS IMP UNPUB
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Dowhan W., 2002, NEW COMPR BIOCH, P1, DOI DOI 10.1016/50167-7306(02)36003-4
   DUDLEY PA, 1978, FEBS LETT, V95, P57, DOI 10.1016/0014-5793(78)80051-9
   Ebrahimi KB, INVEST OPHTHALMOL VI, V53
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hageman GS, 1999, MOL VIS, V5
   Hayashi H, 2011, BIOL PHARM BULL, V34, P453, DOI 10.1248/bpb.34.453
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2012, OPHTHALMOLOGY
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schneeberger SA, 1997, RETINA-J RET VIT DIS, V17, P38, DOI 10.1097/00006982-199701000-00008
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong P, 2000, MOL VIS, V6, P184
   Yu CJ, 2010, BBA-MOL CELL BIOL L, V1801, P819, DOI 10.1016/j.bbalip.2010.05.001
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 85
TC 262
Z9 267
U1 0
U2 37
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2013
VL 33
IS 2
BP 265
EP 276
DI 10.1097/IAE.0b013e31827e25e0
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 081TI
UT WOS:000314344800002
PM 23266879
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Lee, H
   Kim, S
   Kim, MA
   Chung, H
   Kim, HC
AF Lee, Hyungwoo
   Kim, SoHyeon
   Kim, Myung Ae
   Chung, Hyewon
   Kim, Hyung Chan
TI Morphology of en face Haller vessel and macular neovascularization at
   baseline and 3 months as predictive factors in age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; TYPE-1
   NEOVASCULARIZATION; ANGIOGRAPHY; HISTORY
AB The clinical implication of en face imaging of Haller vessels and macular neovascularization (MNV) in neovascular age-related macular degeneration (nAMD) is not well established. The purpose of this study is to investigate whether the early-phase morphology of en face Haller vessel and MNV is related to the injection frequency and visual outcome in treatment-naive nAMD. En face images of Haller vessel and MNV were acquired from 52 eyes at baseline, after three loading doses and at 12 months later using optical coherence tomography (OCT) and OCT angiography. Vessel area, diameter, length, intersection number, fractal dimension, and lacunarity were calculated. Patients were classified according to the injection frequency (< 5 as the infrequent group) and visual gain (>= 0.3 logMAR) over 12 months. The infrequent group was associated with a longer Haller vessel length after loading doses (OR 3.05, P = 0.01), while visual gain was associated with a smaller maximal MNV diameter after loading doses (OR 0.22, P = 0.03). A predictive model for frequent injection based on the Haller vessel length demonstrated an AUC of 0.71. In conclusion, the en face Haller vessel and MNV morphology after loading doses can be used as biomarkers for the injection frequency and visual gain during the first year in treatment-naive nAMD patients.
C1 [Lee, Hyungwoo; Kim, SoHyeon; Kim, Myung Ae; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05030, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM eyekim@kuh.ac.kr
FU Konkuk University Medical Center Research Grant
FX This study was supported by the Konkuk University Medical Center
   Research Grant 2020.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Hotaling NA, 2015, BIOMATERIALS, V61, P327, DOI 10.1016/j.biomaterials.2015.05.015
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karperien A., FRACLAC IMAGEJ
   Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee H, 2020, RETINA-J RET VIT DIS, V40, P1704, DOI 10.1097/IAE.0000000000002678
   Nagai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47738-9
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Savastano MC, 2015, OSLI RETINA, V46, P561, DOI 10.3928/23258160-20150521-07
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   SMITH TG, 1989, J NEUROSCI METH, V27, P173, DOI 10.1016/0165-0270(89)90100-3
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   SUTERA SP, 1993, ANNU REV FLUID MECH, V25, P1, DOI 10.1146/annurev.fl.25.010193.000245
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
NR 25
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 25
PY 2022
VL 12
IS 1
AR 10821
DI 10.1038/s41598-022-15139-0
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 2J4PR
UT WOS:000815641500006
PM 35752643
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wood, A
   Margrain, T
   Binns, AM
AF Wood, Ashley
   Margrain, Thomas
   Binns, Alison Mary
TI Detection of Early Age-Related Macular Degeneration Using Novel
   Functional Parameters of the Focal Cone Electroretinogram
SO PLOS ONE
LA English
DT Article
ID FREQUENCY-DOMAIN ANALYSIS; FELLOW EYES; A-WAVE; RETINAL MORPHOLOGY; ROD;
   ERG; RESPONSES; LIGHT; MACULOPATHY; DYSFUNCTION
AB The focal cone electroretinogram is a sensitive marker for macular disease, but have we unlocked its full potential? Typically assessment of waveform parameters is subjective and focuses on a small number of locations (e.g. the a-wave). This study evaluated the discriminatory and diagnostic potential of 4 conventional and 15 novel, objectively determined, parameters in patients with early Age-related Macular Degeneration. Focal cone electroretinograms were recorded in 54 participants with early Age-related Macular Degeneration (72.9 +/- 8.2 years) and 54 healthy controls (69 +/- 7.7 years). Conventional a and b wave amplitudes and implicit times were measured and compared to novel parameters derived from both the 1st and 2nd derivatives and the frequency-domain power spectrum of the electroretinogram. Statistically significant differences between groups were shown for all conventional parameters, the majority of 1st and 2nd derivative parameters and the power spectrum at 25 and 30 Hz. Receiver operating characteristics showed that both conventional and 1st and 2nd derivative implicit times had provided the best diagnostic potential. A regression model showed a small improvement over any individual parameter investigated. The non-conventional parameters enhanced the objective evaluation of the focal electroretinogram, especially when the amplitude was low. Furthermore, the novel parameters described here allow the implicit time of the electroretinogram to be probed at points other than the peaks of the a and b waves. Consequently these novel analysis techniques could prove valuable in future electrophysiological investigation, detection and monitoring of Age-related Macular Degeneration.
C1 [Wood, Ashley; Margrain, Thomas] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3AX, S Glam, Wales.
   [Binns, Alison Mary] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 Cardiff University; City University London
RP Wood, A (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3AX, S Glam, Wales.
EM wooda2@cardiff.ac.uk
OI Binns, Alison/0000-0001-8621-498X; Margrain, Tom/0000-0003-1280-0809
FU institutional funding at Cardiff University
FX This research was carried out and supported by institutional funding at
   Cardiff University, no external funding was received. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ASI H, 1992, CLIN VISION SCI, V7, P9
   Bach M, 2013, CELL TISSUE RES, V353, P287, DOI 10.1007/s00441-013-1598-6
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   BRETON ME, 1992, DOC OPHTHALMOL, V79, P337, DOI 10.1007/BF00160948
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
   Chamie J, 2005, WORLD POPULATION PRO
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Friedburg C, 2001, J PHYSIOL-LONDON, V534, P217, DOI 10.1111/j.1469-7793.2001.t01-1-00217.x
   FULTON AB, 1978, VISION RES, V18, P793, DOI 10.1016/0042-6989(78)90119-0
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Granit R, 1933, J PHYSIOL-LONDON, V77, P207, DOI 10.1113/jphysiol.1933.sp002964
   GUR M, 1980, J OPT SOC AM, V70, P53, DOI 10.1364/JOSA.70.000053
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   HOOD DC, 1990, INVEST OPHTH VIS SCI, V31, P2070
   HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468
   LACHAPELLE P, 1986, DOC OPHTHALMOL, V63, P337
   Lei B, 1999, VISUAL NEUROSCI, V16, P743, DOI 10.1017/S0952523899164137
   Mentzer AE, 2005, DOC OPHTHALMOL, V111, P95, DOI 10.1007/s10633-005-4517-7
   Miyake Y, 1998, Nagoya J Med Sci, V61, P79
   Mortlock KE, 2010, DOC OPHTHALMOL, V121, P123, DOI 10.1007/s10633-010-9239-9
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Paupoo AAV, 2000, J PHYSIOL-LONDON, V529, P469, DOI 10.1111/j.1469-7793.2000.00469.x
   PEACHEY NS, 1987, VISION RES, V27, P859, DOI 10.1016/0042-6989(87)90002-2
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Shiells RA, 1999, VISUAL NEUROSCI, V16, P503, DOI 10.1017/S0952523899163119
   Stroud K.A., 1986, FURTHER ENG MATH
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
   Vincent A, 2013, RETINA-J RET VIT DIS, V33, P5, DOI 10.1097/IAE.0b013e31827e2306
   WALI N, 1992, DOC OPHTHALMOL, V80, P1, DOI 10.1007/BF00161226
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Westall Carol A., 2001, Documenta Ophthalmologica, V102, P115, DOI 10.1023/A:1017535207481
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 46
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 5
PY 2014
VL 9
IS 5
AR e96742
DI 10.1371/journal.pone.0096742
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI1ZV
UT WOS:000336656000122
PM 24796326
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Calippe, B
   Guillonneau, X
   Sennlaub, F
AF Calippe, Bertrand
   Guillonneau, Xavier
   Sennlaub, Florian
TI Complement factor H and related proteins in age-related macular
   degeneration
SO COMPTES RENDUS BIOLOGIES
LA English
DT Review
DE Age-related macular degeneration; Complement Factor H; Protective
   haplotypes
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR-I; ALLOTYPIC VARIANT; COFACTOR
   ACTIVITY; BINDING-AFFINITY; GENE-EXPRESSION; ADVANCED AMD; FACTOR-B;
   RISK; ACTIVATION
AB Age-related macular degeneration (AMD) is the major cause of legal blindness in the industrialized world. Polymorphisms and recently discovered rare mutations of the Complement Factor H gene have been shown to be strongly associated with AMD. The deletion of CFH-related proteins 1 and 3, proteins that share homologous regions with CFH, is found in protective haplotypes. The following is a critical review of the current state of knowledge of the implication of CFH and CFH-related proteins 1 and 3 in AMD. (C) 2014 Published by Elsevier Masson SAS on behalf of Academie des sciences.
C1 [Calippe, Bertrand; Guillonneau, Xavier; Sennlaub, Florian] INSERM, U968, F-75012 Paris, France.
   [Calippe, Bertrand; Guillonneau, Xavier; Sennlaub, Florian] Univ Paris 06, Inst Vis, UMR S 968, F-75012 Paris, France.
   [Calippe, Bertrand; Guillonneau, Xavier; Sennlaub, Florian] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM DHOS CIC 503, F-75012 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite
RP Sennlaub, F (通讯作者)，INSERM, U968, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021;
   Sennlaub, Florian/F-2756-2017
OI Guillonneau, xavier/0000-0001-7379-3935; guillonneau,
   xavier/0000-0001-7379-3935; Sennlaub, Florian/0000-0003-4412-1341
FU INSERM; ANR Maladies neurologiques et psychiatriques [ANR-08-MNPS-003];
   ANR Geno [R09099DS]; ERC [ERC-2007 St.G. 210345]
FX The authors wish to thank Christopher Brent Murray for critical review
   of the manuscript. This work was supported by grants from INSERM, ANR
   Maladies neurologiques et psychiatriques (ANR-08-MNPS-003), ANR Geno
   2009 (R09099DS), and ERC starting Grant (ERC-2007 St.G. 210345). FS is a
   recipient of a contract Interface from AP-HP.
CR ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   AVERY VM, 1993, J IMMUNOL, V151, P5545
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Flierman R, 2007, IMMUNOBIOLOGY, V212, P363, DOI 10.1016/j.imbio.2006.11.005
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Griffiths MR, 2009, J IMMUNOL, V182, P4368, DOI 10.4049/jimmunol.0800205
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khandhadia S., 2013, OPHTHALMOLOGY
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Losse J, 2010, J IMMUNOL, V184, P912, DOI 10.4049/jimmunol.0901702
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Luo C, 2011, MOL VIS, V17, P1588
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Ma W, 2013, SCI REP-UK, V3, DOI 10.1038/srep01537
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Ufret-Vincenty R.L., 2012, YNVEST OPHTHALMOL VI, V51, P5878
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 70
TC 11
Z9 11
U1 0
U2 17
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 1631-0691
EI 1768-3238
J9 CR BIOL
JI C. R. Biol.
PD MAR
PY 2014
VL 337
IS 3
BP 178
EP 184
DI 10.1016/j.crvi.2013.12.003
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AF8TC
UT WOS:000334987500005
PM 24702844
DA 2022-11-30
ER

PT J
AU Fraser-Bell, S
   Wu, J
   Klein, R
   Azen, SP
   Varma, R
AF Fraser-Bell, S
   Wu, J
   Klein, R
   Azen, SP
   Varma, R
CA Los Angeles Latino Eye Study Grp
TI Smoking, alcohol intake, estrogen use, and age-related macular
   degeneration in latinos: The Los Angeles Latino eye stud
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; CIGARETTE-SMOKING; RISK-FACTORS;
   5-YEAR INCIDENCE; VISUAL-ACUITY; UNITED-STATES; MACULOPATHY;
   CONSUMPTION; PREVALENCE
AB PURPOSE: To assess the association between smoking, alcohol intake, estrogen use, and both early age,related macular degeneration (AMD) (soft indistinct drusen, retinal pigment abnormalities) and advanced AMD (exudative AMD, geographic atrophy) in the Latino community.
   DESIGN: Population-based, cross-sectional study.
   METHODS: Complete ophthalmic examination included stereoscopic macular photographs graded with a modified Wisconsin Age,related Maculopathy Grading System. A history of smoking, alcohol intake, and exogenous estrogen use was obtained by interview. Logistic regression was performed, and odds ratios (OR) were calculated with each AMD lesion as a dependent variable.
   RESULTS: There were 5875 participants (92.4%) with gradable photographs. Having ever smoked was associated with a higher risk of having advanced AMD (OR, 2.4). Heavy consumption of alcohol (> 5 drinks per session) was significantly associated with a greater risk of having exudative AMD (OR, 5.8) and geographic atrophy (OR, 12.7) Beer drinking was associated with a higher risk of having advanced AMD (OR, 2.9), whereas wine drinking appeared to be protective for increased retinal pigment (OR, 0.7). Exogenous estrogen use also appeared to be protective from soft indistinct drusen (OR, 0.5) and increased retinal pigment (OR, 0.6), but power was limited in the assessment of its association with advanced AMD.
   CONCLUSION: Smoking and heavy alcohol consumption, particularly beer, was associated with a greater risk of having advanced AMD; exogenous estrogen use appeared to have a weak protective effect in Latino participants. Similar modifiable risk factors have been identified previously in non-Hispanic white patients, which suggests that common pathogenic mechanisms may be associated with AMD in persons of different ethnicities.
C1 Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   Univ So Calif, Sch Pharm, Dept Pharmaceut Econ & Policy, Los Angeles, CA USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
C3 University of Southern California; University of Southern California;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Southern California
RP Varma, R (通讯作者)，Doheny Eye Inst, Suite 4900,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Wu,
   Joanne/0000-0003-0932-4979
FU NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI
   NIH HHS [P30 EY003040, U10 EY011753, EY 03040, EY 11753] Funding Source:
   Medline
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   CHAN CWC, 1991, AUST NZ J OPHTHALMOL, V19, P321, DOI 10.1111/j.1442-9071.1991.tb00680.x
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   EVANS J, 1995, CAUSES BLINDNESS PAR
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KLAVER CC, 1998, ARCH OPHTALMOL, V116, P638
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   *US DEP AGR, 1990, HUM NUTR INF SERV PU
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 42
TC 83
Z9 86
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2006
VL 141
IS 1
BP 79
EP 87
DI 10.1016/j.ajo.2005.08.024
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000FQ
UT WOS:000234446700012
PM 16386980
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Akagi-Kurashige, Y
   Yuzawa, M
   Ishibashi, T
   Nakanishi, H
   Nakatani, E
   Teramukai, S
   Fukushima, M
   Yoshimura, N
AF Tsujikawa, Akitaka
   Akagi-Kurashige, Yumiko
   Yuzawa, Mitsuko
   Ishibashi, Tatsuro
   Nakanishi, Hideo
   Nakatani, Eiji
   Teramukai, Satoshi
   Fukushima, Masanori
   Yoshimura, Nagahisa
CA AMD2000 Study Grp
TI Baseline data from a multicenter, 5-year, prospective cohort study of
   Japanese age-related macular degeneration: an AMD2000 report
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Drusen; Multimodal imaging;
   International classification; Polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   CLINICAL CHARACTERISTICS; PHOTODYNAMIC THERAPY; RISK-FACTORS;
   MACULOPATHY; PREVALENCE; POPULATION; NEOVASCULARIZATION; CLASSIFICATION
AB To report research participants' baseline characteristics in the AMD2000 study, a prospective, multicenter, 5-year, observational cohort study of Japanese age-related macular degeneration (AMD). The characteristics were determined using multimodal imaging.
   Patients with AMD were recruited at 18 clinical sites in Japan between April 2006 and March 2009. Each patient underwent a complete ophthalmic examination, including measurement of best-corrected visual acuity (Landolt chart), indirect ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, optical coherence tomography imaging, fundus photography, and fluorescein and indocyanine green angiography.
   Four hundred sixty participants (326 men [70.9%]) were included in the study. At enrollment, 131 eyes (28.5%) had hard drusen and 125 eyes (27.2%) had soft drusen in the macular area. A total of 455 eyes (98.9%) were diagnosed as having wet AMD, and 5 eyes (1.1%), as having dry AMD. Of the 455 eyes with wet AMD, 209 eyes (45.4%) had typical AMD, 228 eyes (49.6%) had polypoidal choroidal vasculopathy (PCV), and 18 eyes (3.9%) had retinal angiomatous proliferation. The size of choroidal neovascularization (CNV) was significantly smaller with indocyanine green angiography than with fluorescein angiography (P < 0.001). Poor baseline visual acuity was associated with cystoid macular edema, older age, scar, extrafoveal macular edema, subfoveal CNV, large branching vascular network, and hard exudates.
   Japanese patients with AMD are predominantly male, lack drusen, and have a high rate of PCV.
C1 [Tsujikawa, Akitaka; Akagi-Kurashige, Yumiko; Nakanishi, Hideo; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.
   [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Nakatani, Eiji; Teramukai, Satoshi; Fukushima, Masanori] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan.
   [Teramukai, Satoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan.
C3 Kyoto University; Nihon University; Kyushu University; Institute for
   Biomedical Research & Innovation (IBRI); Kyoto Prefectural University of
   Medicine
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Nakatani, Eiji/O-2782-2013; Teramukai,
   Satoshi/I-2249-2019
OI TAMURA, Hiroshi/0000-0002-7740-2732; Nakatani, Eiji/0000-0002-4876-446X;
   Teramukai, Satoshi/0000-0003-2184-0597; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zhang J, 2015, OPTOMETRY VISION SCI, V92, pE21, DOI 10.1097/OPX.0000000000000440
NR 38
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2018
VL 62
IS 2
BP 127
EP 136
DI 10.1007/s10384-017-0556-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY6AZ
UT WOS:000426923200003
PM 29270814
DA 2022-11-30
ER

PT J
AU Lin, H
   Mares, JA
   LaMonte, MJ
   Brady, WE
   Sahli, MW
   Klein, R
   Klein, BEK
   Nie, J
   Millen, AE
AF Lin, Henry
   Mares, Julie A.
   LaMonte, Michael J.
   Brady, William E.
   Sahli, Michelle W.
   Klein, Ronald
   Klein, Barbara E. K.
   Nie, Jing
   Millen, Amy E.
TI Association between Dietary Xanthophyll (Lutein and Zeaxanthin) Intake
   and Early Age-Related Macular Degeneration: The Atherosclerosis Risk in
   Communities Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; ARMS2; CFH; HDL; lutein and
   zeaxanthin; xanthophyll
ID CORONARY-HEART-DISEASE; LONG-TERM INCIDENCE; 5-YEAR INCIDENCE;
   ANTIOXIDANTS; CAROTENOIDS; MACULOPATHY; LUTEIN/ZEAXANTHIN; INFLAMMATION;
   PROGRESSION; PREVALENCE
AB Purpose: To examine the association between xanthophyll intake and prevalent early age-related macular degeneration (AMD) using data from the Atherosclerosis Risk in Communities Study (n = 10,295). Potential effect modification by genetic polymorphisms and biomarkers of high-density lipoprotein (HDL) metabolism was explored.
   Methods: Xanthophyll intake was assessed at visit 1 (1987-1989) using food frequency questionnaires. Prevalent early AMD was assessed at visit 3 (1993-1995) via retinal photographs. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for AMD by quintiles of xanthophyll intake, adjusted for age, sex, race, field center, and pack-years of smoking. To evaluate effect modification, the association between tertiles (T) of xanthophyll intake and AMD was stratified by complement factor H (CFH) rs1061170 and age-related maculopathy susceptibility 2 (ARMS2) rs10490924 genotypes, as well as by median cutpoints of HDL biomarkers.
   Results: Xanthophyll intake was not associated with AMD in the overall sample, Caucasians (n = 8257), or African-Americans (n = 2038). Exploratory analyses observed that the association between xanthophyll intake and AMD varied statistically significantly by CFH rs1061170 genotype among Caucasians (p for interaction = 0.045) but not African Americans. No interactions were observed between xanthophyll intake and ARMS2 rs10490924. Moreover, higher xanthophyll intake was associated with decreased odds of AMD among participants with lower HDL (OR = 0.79, 95% CI 0.57-1.09) but not higher HDL (p for interaction = 0.048).
   Conclusion: Xanthophyll intake was not associated with early AMD. Further studies to investigate this association by genetic susceptibility or variations in HDL metabolism are needed.
C1 [Lin, Henry; LaMonte, Michael J.; Brady, William E.; Nie, Jing; Millen, Amy E.] Univ Buffalo State Univ New York, Dept Epidemiol & Environm Hlth, 270F Farber Hall,3435 Main St, Buffalo, NY 14214 USA.
   [Mares, Julie A.; Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Sahli, Michelle W.] Univ Michigan, Dept Publ Hlth & Hlth Sci, Flint, MI 48503 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; University of Wisconsin System; University of Wisconsin
   Madison; University of Michigan System; University of Michigan;
   University of Michigan Flint
RP Millen, AE (通讯作者)，Univ Buffalo State Univ New York, Dept Epidemiol & Environm Hlth, 270F Farber Hall,3435 Main St, Buffalo, NY 14214 USA.
EM aemillen@buffalo.edu
RI LaMonte, Mike/AAC-9953-2021
FU NIH National Institute on Aging [R01 AG041776]; NIH National Heart,
   Lung, and Blood Institute [R01 HL103706]; NIH Office of Dietary
   Supplements [R01 HL103706-S1]; Research to Prevent Blindness; National
   Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
   R01HL59367, R01HL086694]; National Human Genome Research Institute
   [U01HG004402]; National Institutes of Health [HHSN268200625226C,
   UL1RR025005]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR001412] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL086694, R01HL103706, R01HL059367, R01HL087641] Funding Source: NIH
   RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG004402] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG041776] Funding
   Source: NIH RePORTER
FX This research is supported by the NIH National Institute on Aging grant
   number R01 AG041776, NIH National Heart, Lung, and Blood Institute grant
   number R01 HL103706, and the NIH Office of Dietary Supplements grant
   number R01 HL103706-S1 and an unrestricted grant from Research to
   Prevent Blindness.; The Atherosclerosis Risk in Communities Study is
   carried out as a collaborative study supported by National Heart, Lung,
   and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C),
   R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research
   Institute contract U01HG004402; and National Institutes of Health
   contract HHSN268200625226C. Infrastructure was partly supported by Grant
   Number UL1RR025005, a component of the National Institutes of Health and
   NIH Roadmap for Medical Research.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Atherosclerosis Risk in Communities Study Manual, ATH RISK COMM STUD M
   Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holzer M, 2013, BBA-MOL CELL BIOL L, V1831, P1442, DOI 10.1016/j.bbalip.2013.06.004
   Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   SHAHAR E, 1993, ARTERIOSCLER THROMB, V13, P1205, DOI 10.1161/01.ATV.13.8.1205
   SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stevens J, 1996, NUTR RES, V16, P735, DOI 10.1016/0271-5317(96)00064-4
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang J, 2015, PROCEEDINGS 3RD IAPR ASIAN CONFERENCE ON PATTERN RECOGNITION ACPR 2015, P21, DOI 10.1109/ACPR.2015.7486458
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 41
TC 7
Z9 7
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2017
VL 24
IS 5
BP 311
EP 322
DI 10.1080/09286586.2017.1290259
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL0MB
UT WOS:000413904400005
PM 28332910
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Iacono, P
   Parodi, MB
   Introini, U
   La Spina, C
   Varano, M
   Bandello, F
AF Iacono, Pierluigi
   Parodi, Maurizio B.
   Introini, Ugo
   La Spina, Carlo
   Varano, Monica
   Bandello, Francesco
TI INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION WITH LARGE
   SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; subfoveal choroidal
   neovascularization; anti-VEGF; intravitreal ranibizumab
ID TISSUE-PLASMINOGEN ACTIVATOR; GROWTH-FACTOR PRODUCTION; PNEUMATIC
   DISPLACEMENT; SUBRETINAL HEMORRHAGE; NATURAL-HISTORY; INJECTION;
   MANAGEMENT; SECONDARY; FIBROBLASTS; THROMBIN
AB Purpose: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration.
   Methods: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage > 50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features.
   Results: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 +/- 0.22 (logarithm of the minimum angle of resolution +/- standard deviation) and 342 +/- 56 mm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 +/- 0.41 (P = 0.04), and mean central macular thickness decreased to 236 +/- 26 mm (P, 0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered.
   Conclusion: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.
C1 [Iacono, Pierluigi; Varano, Monica] GB Bietti Fdn Ophthalmol, Sci Inst Admiss & Care, I-00198 Rome, Italy.
   [Parodi, Maurizio B.; Introini, Ugo; La Spina, Carlo; Bandello, Francesco] Univ Vita Salute San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Vita-Salute San Raffaele University
RP Iacono, P (通讯作者)，GB Bietti Fdn Ophthalmol, Sci Inst Admiss & Care, Via Livenza 3, I-00198 Rome, Italy.
EM pierluigi.iacono@libero.it
RI bandello, francesco/AAH-2405-2019; Parodi, Maurizio
   Battaglia/K-7876-2016; Iacono, Pierluigi/AAD-3158-2020; Varano,
   Monica/K-8573-2016
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; La Spina, Carlo/0000-0002-0733-9846;
   Varano, Monica/0000-0002-6530-1563
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heriot W, 1996, VAIL VITR M VAIL CO
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hollborn M, 2012, INVEST OPHTH VIS SCI, V53, P5930, DOI 10.1167/iovs.11-9214
   Hollborn M, 2009, INVEST OPHTH VIS SCI, V50, P4452, DOI 10.1167/iovs.08-3194
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Ollivier V, 2000, ARTERIOSCL THROM VAS, V20, P1374, DOI 10.1161/01.ATV.20.5.1374
   Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHA IN PRESS, VS0002-S9394, P00068
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
NR 27
TC 24
Z9 24
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2014
VL 34
IS 2
BP 281
EP 287
DI 10.1097/IAE.0b013e3182979e33
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DF
UT WOS:000336959400011
PM 23851632
DA 2022-11-30
ER

PT J
AU Yoshida, I
   Shiba, T
   Taniguchi, H
   Takahashi, M
   Murano, T
   Hiruta, N
   Hori, Y
   Bujo, H
   Maeno, T
AF Yoshida, Izumi
   Shiba, Tomoaki
   Taniguchi, Hikari
   Takahashi, Mao
   Murano, Takeyoshi
   Hiruta, Nobuyuki
   Hori, Yuichi
   Bujo, Hdieaki
   Maeno, Takatoshi
TI Evaluation of plasma vascular endothelial growth factor levels after
   intravitreal injection of ranibizumab and aflibercept for exudative
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Plasma vascular endothelial growth
   factor; Aflibercept; Ranibizumab; Intravitreal injection
ID METASTATIC COLORECTAL-CANCER; VEGF TRAP; PHASE-II; BEVACIZUMAB;
   FLUOROURACIL; LEUCOVORIN; MACULOPATHY; BLINDNESS; EYE
AB To evaluate the plasma vascular endothelial growth factor (VEGF) levels after one intravitreal injection of aflibercept or ranibizumab in patients with exudative age-related macular degeneration (AMD).
   Twenty-four Japanese with exudative AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation were included. Fourteen patients received an intravitreal injection of aflibercept, and ten patients received an intravitreal injection of ranibizumab. Plasma VEGF levels were evaluated within 7 days before the intravitreal injections and 1 day, 1 week, and 1 month after the intravitreal injection.
   In the ranibizumab group, the mean plasma VEGF levels were 245.7 +/- 233.4 pg/ml before the injection, 246.6 +/- 304.8 pg/ml after 1 day, 217.8 +/- 212.9 pg/ml after 1 week, and 260.0 +/- 290.1 pg/ml after 1 month. The plasma VEGF levels did not decrease significantly in patients in the ranibizumab group at any time point. In the aflibercept group, the mean plasma VEGF levels were 280.0 +/- 170.3 pg/ml before the intravitreal injection and 8.2 +/- 12.9 pg/ml after 1 day, 9.1 +/- 9.1 pg/ml after 1 week, and 41.9 +/- 41.4 pg/ml after 1 month (p < 0.0001, vs before injection).
   Intravitreally injected aflibercept reduced plasma VEGF over at least 1 month. In contrast, intravitreal injection of ranibizumab did not cause a significant reduction in the plasma VEGF levels.
C1 [Yoshida, Izumi; Shiba, Tomoaki; Taniguchi, Hikari; Hori, Yuichi; Maeno, Takatoshi] Toho Univ, Dept Ophthalmol, Sakura Med Ctr, Sakura, Chiba 2858741, Japan.
   [Takahashi, Mao] Toho Univ, Cardiovasc Ctr, Sakura Med Ctr, Sakura, Chiba 2858741, Japan.
   [Murano, Takeyoshi; Bujo, Hdieaki] Toho Univ, Dept Clin Lab & Expt Res Med, Sakura Med Ctr, Chiba, Japan.
   [Hiruta, Nobuyuki] Toho Univ, Dept Pathol, Sakura Med Ctr, Chiba, Japan.
C3 Toho University; Toho University; Toho University; Toho University
RP Shiba, T (通讯作者)，Toho Univ, Dept Ophthalmol, Sakura Med Ctr, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.
EM tomoaki-s@sakura.med.toho-u.ac.jp
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 29
TC 33
Z9 34
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2014
VL 252
IS 9
BP 1483
EP 1489
DI 10.1007/s00417-014-2717-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO9WA
UT WOS:000341709000017
PM 25030237
DA 2022-11-30
ER

PT J
AU Itakura, K
   Takahashi, I
   Nakashima, E
   Yanagi, M
   Kawasaki, R
   Neriishi, K
   Wang, JJ
   Wong, TY
   Hida, A
   Ohishi, W
   Kiuchi, Y
AF Itakura, Katsumasa
   Takahashi, Ikuno
   Nakashima, Eiji
   Yanagi, Masahide
   Kawasaki, Ryo
   Neriishi, Kazuo
   Wang, Jie Jin
   Wong, Tien Yin
   Hida, Ayumi
   Ohishi, Waka
   Kiuchi, Yoshiaki
TI Exposure to Atomic Bomb Radiation and Age-Related Macular Degeneration
   in Later Life: The Hiroshima-Nagasaki Atomic Bomb Survivor Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; epidemiology; radiation damage; atomic
   bomb; retina
ID BEAVER DAM EYE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; JAPANESE
   POPULATION; IONIZING-RADIATION; PREVALENCE; MACULOPATHY; ASSOCIATION;
   STROKE
AB PURPOSE. To investigate the association between radiation exposure from the atomic bombings and the prevalence of age-related macular degeneration (AMD) among older residents of Hiroshima and Nagasaki.
   METHODS. The Adult Health Study is a cohort study of atomic bomb survivors living in Hiroshima and Nagasaki, comprising 2153 participants who underwent examinations with retinal fundus photographs in 2006-2008. The radiation dose to the eye for the analysis was estimated with the revised dosimetry system (DS02). The retinal photographs were graded according to the Wisconsin Age-Related Maculopathy Grading System modified for nonstereoscopic retinal images. Early and late AMD were defined according to the type of lesion detected in the worse eye of the participants. Person-specific data were analyzed by using a logistic regression model to assess the association between radiation dose and AMD.
   RESULTS. Among the 1824 subjects with gradable retinal images (84.7% of the overall participants), the estimated eye dose was widely distributed, with a mean of 0.45 Gy and standard deviation of 0.74 Gy. The prevalence of early and late AMD was 10.5% and 0.3%, respectively. There were no significant associations between radiation dose and AMD, with each 1-Gy increase in exposure, adjusted odds ratio was 0.93 (95% confidence interval [CI], 0.75-1.15) for early AMD and 0.79 (95% CI, 0.21-2.94) for late AMD.
   CONCLUSIONS. No significant associations were found between atomic bomb irradiation early in life and the prevalence of early or late AMD later in life among Japanese atomic bomb survivors.
C1 [Itakura, Katsumasa; Yanagi, Masahide; Kawasaki, Ryo; Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Itakura, Katsumasa; Yanagi, Masahide; Kiuchi, Yoshiaki] Hiroshima Univ, Dept Ophthalmol & Visual Sci, Hiroshima 7348551, Japan.
   [Takahashi, Ikuno; Neriishi, Kazuo; Ohishi, Waka] Radiat Effects Res Fdn, Dept Clin Studies, Hiroshima, Japan.
   [Nakashima, Eiji] Radiat Effects Res Fdn, Dept Stat, Hiroshima, Japan.
   [Kawasaki, Ryo] Yamagata Univ, Fac Med, Dept Publ Hlth, Yamagata 990, Japan.
   [Neriishi, Kazuo] Yachiyo Hosp, Hiroshima, Japan.
   [Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Hida, Ayumi] Radiat Effects Res Fdn, Dept Clin Studies, Nagasaki, Japan.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Hiroshima University; Radiation Effects
   Research Foundation - Japan; Radiation Effects Research Foundation -
   Japan; Yamagata University; University of Sydney; Westmead Institute for
   Medical Research; National University of Singapore; Singapore National
   Eye Center; Radiation Effects Research Foundation - Japan
RP Kiuchi, Y (通讯作者)，Hiroshima Univ, Dept Ophthalmol & Visual Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM ykiuchi@hiroshima-u.ac.jp
RI wang, jie/GRS-0942-2022; Wong, Tien Yin/AAC-9724-2020; Wang, Jie
   Jin/P-1499-2014; Kawasaki, Ryo/B-7266-2009; Kawasaki, Ryo/H-9716-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898;
   Kawasaki, Ryo/0000-0002-7492-6303; 
CR ARCHER D B, 1991, Eye (London), V5, P239
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961
   Baker ML, 2008, STROKE, V39, P1371, DOI 10.1161/STROKEAHA.107.496091
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Cullings HM, 2006, RADIAT RES, V166, P219, DOI 10.1667/RR3546.1
   Denham JW, 2002, RADIOTHER ONCOL, V63, P129, DOI 10.1016/S0167-8140(02)00060-9
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Gabir MM, 2000, DIABETES CARE, V23, P1108, DOI 10.2337/diacare.23.8.1108
   Hayashi T, 2012, FASEB J, V26, P4765, DOI 10.1096/fj.12-215228
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kar S, 2010, RESP PHYSIOL NEUROBI, V174, P299, DOI 10.1016/j.resp.2010.08.019
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Little MP, 2008, RADIAT RES, V169, P99, DOI 10.1667/RR1070.1
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Minamoto A, 2004, INT J RADIAT BIOL, V80, P339, DOI 10.1080/09553000410001680332
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Peiretti E, 2006, EUR J OPHTHALMOL, V16, P637, DOI 10.1177/112067210601600426
   Preston DL, 2004, RADIAT RES, V162, P377, DOI 10.1667/RR3232
   Takahashi I, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000654
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 39
TC 6
Z9 6
U1 0
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2015
VL 56
IS 9
BP 5401
EP 5406
DI 10.1167/iovs.15-16680
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WW
UT WOS:000362882800047
PM 26275137
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, CG
   Yoo, SJ
   Cho, SW
   Lee, DW
   Kim, JW
   Lee, JH
AF Cho, Han Joo
   Kim, Chul Gu
   Yoo, Su Jin
   Cho, Sung Won
   Lee, Dong Won
   Kim, Jong Woo
   Lee, Joon H.
TI Retinal Functional Changes Measured by Microperimetry in Neovascular
   Age-Related Macular Degeneration Treated With Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; EYE DISEASE; THERAPY; EDEMA
AB PURPOSE: To evaluate the retinal functional changes measured by scanning laser ophthalmoscope microperimetry in neovascular age-related macular degeneration treated with ranibizumab injections.
   DESIGN: Prospective, interventional case series.
   METHODS: A total of 42 eyes of 39 patients with neovascular age-related macular degeneration were included. After an initial 3 loading injections of ranibizumab, 0.5 mg per injection per month, injection was performed as needed. Evaluation of best-corrected visual acuity, microperimetry, and optical coherence tomography were performed before treatment and 3 months, 6 months, and 12 months after treatment. According to the appearance of the subfoveal choroidal neovascular membrane on fluorescein angiography, the study group was divided into patients with a predominantly or purely classic choroidal neovascular membrane, those with a minimally classic choroidal neovascular membrane, and patients with occult choroidal neovascular membrane.
   RESULTS: In all the subjects, mean retinal sensitivity of the central 12-degree area had increased significantly from 4.89 +/- 3.1 dB to 9.82 +/- 2.1 dB at month 12 (P = .01). The number of absolute scotoma points decreased significantly from 11.3 +/- 3.2 to 5.9 +/- 2.4 at month 12 (P = .01). However, in the subgroup analysis, the mean retinal sensitivity improvement, decreased absolute scotoma size, best-corrected visual acuity improvement, and central macular thickness improvement did not differ significantly among the groups.
   CONCLUSIONS: Intravitreal 0.5 mg ranibizumab therapy improves retinal function, quantified not only by visual acuity, but also by mean retinal sensitivity and fixation stability, as assessed by scanning laser ophthalmoscope microperimetry. Measurement of retinal sensitivity may facilitate evaluation of the effectiveness of intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration. (Am J Ophthalmol 2013;155:118-126. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Cho, Han Joo; Kim, Chul Gu; Yoo, Su Jin; Cho, Sung Won; Lee, Dong Won; Kim, Jong Woo; Lee, Joon H.] Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Dept Ophthalmol,Kims Eye Hosp, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, CG (通讯作者)，Konyang Univ, Coll Med, Myung Gok Eye Res Inst, Dept Ophthalmol,Kims Eye Hosp, 156,4Ga, Seoul, South Korea.
EM ccnnrr@naver.com
OI Cho, Han Joo/0000-0001-7336-5762
FU Novartis Korea, Seoul, Korea
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following was reported.
   Publication of this article was supported by a grant of Novartis Korea,
   Seoul, Korea. The funding organization had no role in the design or
   conduct of this research. Involved in Design of study (H.J.C., C.G.K.,
   S.J.Y., J.W.K.); Acquisition of data (H.J.C., S.J.Y., D.W.L., S.W.C.);
   Analysis of data (H.J.C., C.G.K., J.W.K., J.H.L.); Interpretation of
   data (H.J.C., C.G.K., J.W.K., J.H.L.); Preparation of manuscript
   (H.J.C., C.G.K.); Review of manuscript (H.J.C., C.G.K., S.W.C., D.W.L.,
   J.W.K., J.H.L.); and Approval of manuscript (C.G.K., J.W.K.). This
   prospective study was approved by the Institutional Review Board of
   Kim's Eye Hospital, Konyang University College of Medicine. Clinical
   research in this study followed the tenets of the Declaration of
   Helsinki. Written informed consent was obtained from all subjects before
   enrollment.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Grossniklaus HE, 2006, OPHTHALMOLOGY, V113, P267, DOI 10.1016/j.ophthzi.2005.10.031
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL, V24, pS335
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Midena E, 2007, EUR J OPHTHALMOL, V17, P63, DOI 10.1177/112067210701700109
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabates FN, 2011, RETINA-J RET VIT DIS, V31, P1294, DOI 10.1097/IAE.0b013e3182019be2
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Tao Y, 2010, RETINA-J RET VIT DIS, V30, P1426, DOI 10.1097/IAE.0b013e3181d5e964
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
NR 29
TC 18
Z9 18
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2013
VL 155
IS 1
BP 118
EP 126
DI 10.1016/j.ajo.2012.07.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 066ML
UT WOS:000313224800012
PM 23022163
DA 2022-11-30
ER

PT J
AU Tran, THC
   Despretz, P
   Boucart, M
AF Thi Ha Chau Tran
   Despretz, Pascal
   Boucart, Muriel
TI Space Representation in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision; macular degeneration; visual memory; space representation
ID QUALITY-OF-LIFE; FUNDUS AUTOFLUORESCENCE; MOBILITY PERFORMANCE;
   GEOGRAPHIC ATROPHY; WATERLOO VISION; VISUAL FUNCTION; OLDER-ADULTS;
   FIELD LOSS; SCENE; RECOGNITION
AB Purpose. To investigate the effect of age-related macular degeneration (AMD) on memory for spatial representations in realistic environments.
   Methods. Participants were 19 patients with AMD and 13 age-matched observers. In a short-term spatial memory task, observers were first presented with one view of a scene (the prime view), and their task was to change the viewpoint forward or backward to match the prime view. Memory performance was measured as the number of snapshots between the selected view and the prime view.
   Results. When selecting a match to the prime view, both people with AMD and those in the control group showed systematic biases toward the middle view of the range of snapshots. People with AMD exhibited a stronger middle bias after presentation of close and far prime views while navigating accurately after a middle prime view. No relation was found between visual acuity, visual field defect, or lesion size and the memory performance.
   Conclusions. Memory tasks using indoor scenes can be accomplished when central vision is impoverished, as with AMD. Stronger center bias for a scene location suggests that people with AMD rely more on their memory of a canonical view.
C1 [Thi Ha Chau Tran; Despretz, Pascal; Boucart, Muriel] Univ Lille Nord France, CNRS, Lab Neurosci & Pathol Fonct, Lille, France.
   [Thi Ha Chau Tran] Hop St Vincent de Paul, Serv Ophtalmol, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille
RP Boucart, M (通讯作者)，CHRU Lille, Hop Roger Salengro, Lab Neurosci & Pathol Fonct, F-59037 Lille, France.
EM m-boucart@chru-lille.fr
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
CR Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Fortenbaugh FC, 2008, INVEST OPHTH VIS SCI, V49, P2765, DOI 10.1167/iovs.07-1021
   Fortenbaugh FC, 2007, VISION RES, V47, P2506, DOI 10.1016/j.visres.2007.06.012
   Greene MR, 2009, PSYCHOL SCI, V20, P464, DOI 10.1111/j.1467-9280.2009.02316.x
   Greene MR, 2009, COGNITIVE PSYCHOL, V58, P137, DOI 10.1016/j.cogpsych.2008.06.001
   Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hemmer P., 2009, P 31 ANN C COGN SCI, P1557
   Hemmer P, 2009, TOP COGN SCI, V1, P189, DOI 10.1111/j.1756-8765.2008.01010.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Huttenlocher J, 2000, J EXP PSYCHOL GEN, V129, P220, DOI 10.1037//0096-3445.129.2.220
   INTRAUB H, 1993, J EXP PSYCHOL LEARN, V19, P1387, DOI 10.1037/0278-7393.19.6.1387
   Intraub H, 1998, J EXP PSYCHOL LEARN, V24, P186, DOI 10.1037/0278-7393.24.1.186
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Konkle T., 2007, J VISION, V7, P1049, DOI [10.1167/7.9.1049, DOI 10.1167/7.9.1049]
   Konkle T., 2007, P 29 ANN COGN SCI SO, P407
   Konkle T, 2011, J EXP PSYCHOL HUMAN, V37, P23, DOI 10.1037/a0020413
   Kuyk T, 1996, J Am Optom Assoc, V67, P403
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   OLIVA A, 2010, VISION 3D ENV, P308
   Oliva A, 2006, PROG BRAIN RES, V155, P23, DOI 10.1016/S0079-6123(06)55002-2
   Palmer S. E., 1981, ATTENTION PERFORM, V9, P135
   Patel I, 2006, INVEST OPHTH VIS SCI, V47, P65, DOI 10.1167/iovs.05-0582
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Shelton AL, 2001, COGNITIVE PSYCHOL, V43, P274, DOI 10.1006/cogp.2001.0758
   Shelton AL, 2001, PSYCHOL SCI, V12, P343, DOI 10.1111/1467-9280.00363
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soong GP, 2001, OPTOMETRY VISION SCI, V78, P657, DOI 10.1097/00006324-200109000-00011
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   Swaine W., 1925, Transactions of the Optical Society, V27, P9, DOI 10.1088/1475-4878/27/1/303
   Tarita-Nistor L, 2012, INVEST OPHTHALMOL VI, V53
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   TURANO K, 1991, CLIN VISION SCI, V6, P289
   Waller D, 2006, MEM COGNITION, V34, P491, DOI 10.3758/BF03193573
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
NR 45
TC 3
Z9 3
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 1012
EP 1020
DI 10.1097/OPX.0000000000000313
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500025
PM 24978865
DA 2022-11-30
ER

PT J
AU Klein, R
   Peto, T
   Bird, A
   Vannewkirk, MR
AF Klein, R
   Peto, T
   Bird, A
   Vannewkirk, MR
TI The epidemiology of age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; SKIN SUN SENSITIVITY; LONG-TERM INCIDENCE;
   RISK-FACTORS; CIGARETTE-SMOKING; 5-YEAR INCIDENCE; FUNDUS
   AUTOFLUORESCENCE; 10-YEAR INCIDENCE; CARDIOVASCULAR-DISEASE; JAPANESE
   POPULATION
AB PURPOSE: To review the epidemiology of age,related macular degeneration (AMD).
   DESIGN: Evidence from epidemiologic data regarding the natural history of AMD and its risk factors are presented.
   RESULTS: Large, soft drusen associated with pigmentary abnormalities increase the risk of progression to advanced AMD. Large soft drusen may fade over time. Advanced AMD is more likely to be present in whites than blacks, despite the similar prevalence of soft drusen in both groups. Neovascular AMD is more frequent than geographic atrophy in most population-based studies in whites in America, Australia, and the Netherlands than in similar population,based studies in Iceland and Norway. After age and family history, there are few consistent relationships of risk factors to AMD. Of these, the relationship of smoking, hypertension, and cataract surgery to advanced AMD have been most consistent.
   CONCLUSIONS: Long-term epidemiologic studies have provided information on the distribution and the natural history of AMD and its associated risk factors. It is not known what effect reduction of blood pressure and the cessation of smoking might have on the incidence and progression of AMD. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
   Univ London, Univ Coll London, Dept Clin Ophthalmol, Inst Ophthalmol, London, England.
   So Hlth Southland, Invercargill, New Zealand.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of London; University College London
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Bjornsson OM, 2003, INVEST OPHTH VIS SCI, V44, pU109
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER SB, 1998, MAC SOC M BOC RAT FL, P86
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   CHUMBLEY LC, 1977, S AFR MED J, V52, P316
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Gillies MC, 2001, INVEST OPHTH VIS SCI, V42, pS522
   Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAKKINEN L, 1984, SCAND J SOC MED, P1
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOLTZ FG, 1994, AM J OPHTHALMOL, V117, P19
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jain I S, 1984, Indian J Ophthalmol, V32, P343
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   JOHNSON GJ, 1984, CAN J OPHTHALMOL, V19, P224
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2003, INVEST OPHTH VIS SCI, V44, pU110
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Munoz BE, 2003, INVEST OPHTH VIS SCI, V44, pU129
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Rosenberg T, 1987, Arctic Med Res, V46, P13
   Rosenberg T, 1987, Arctic Med Res, V46, P64
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SHATZ H, 1975, INT OPHTHALMOL CLIN, V15, P169
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   TOMANY SC, IN PRESS OPHTHALMOLO
   Tong L, 2003, INVEST OPHTH VIS SCI, V44, pU353
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   vanLeeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P955
   VANLEEUWEN R, 2003, BRIT MED J, V226, P255
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINORES SA, 1988, EXP EYE RES, V46, P545, DOI 10.1016/S0014-4835(88)80011-3
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WANG JJ, IN PRESS OPHTHALMOLO
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WU L, 1987, EYE SCI, V3, P175
   WU L, 1987, EYE SCI, V3, P179
   WU ZQ, 1992, CHINESE J OPHTHALMOL, V28, P246
   WYATT HT, 1973, CAN J OPHTHALMOL, V8, P291
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 129
TC 702
Z9 739
U1 1
U2 73
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2004
VL 137
IS 3
BP 486
EP 495
DI 10.1016/j.ajo.2003.11.069
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804VF
UT WOS:000220325500015
PM 15013873
DA 2022-11-30
ER

PT J
AU Kanoff, J
   Miller, J
AF Kanoff, Justin
   Miller, Joan
TI Pharmacogenetics of the Treatment Response of Age-Related Macular
   Degeneration with Ranibizumab and Bevacizumab
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; complement factor H; macular degeneration;
   pharmacogenetics; ranibizumab
ID COMPLEMENT FACTOR-H; ASSOCIATION; SUSCEPTIBILITY; POLYMORPHISMS;
   LOC387715; RISK; GENE; VEGF; MACULOPATHY; INCREASES
AB Introduction: Age-related macular degeneration is a major cause of blindness among people aged 50 and older in industrialized countries. Anti-VEGF therapy has been tremendously successful in the treatment of neovascular macular degeneration. Examining the pharmacogenetics of patients' response to the anti-VEGF molecules could allow for a tailored treatment strategy based on patients' underlying genetics rather than the "one-size fits all" approach currently used. Methods: Review of the English literature for papers examining the pharmacogenetics of treatment response of neovascular macular degeneration to either ranibizumab or bevacizumab. Polymorphisms in CFH, ARMS2, HTRA1 and VEGF A were examined and reviewed. Results: Patients with the high-risk CC genotype in complement factor H (CFH) had a worse response to therapy with ranibizumab and bevacizumab. No clear trends were found with ARMS2, HTRA1 and VEGF A. Conclusions: The goal of personalized medicine is to craft a treatment program that is ideally suited to an individual patient's disease and genetic make-up rather than simply what works for a large population who share similar disease characteristics. Continued research is needed to achieve this goal for the treatment of age-related macular degeneration.
C1 [Kanoff, Justin; Miller, Joan] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Kanoff, J (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM Justin_Kanoff@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kloeckener-Gruissem B, 2001, IOVS, V52, P4694
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
NR 41
TC 11
Z9 11
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2013
VL 28
IS 5-6
BP 355
EP 360
DI 10.3109/08820538.2013.825292
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239QP
UT WOS:000326040800014
PM 24010796
DA 2022-11-30
ER

PT J
AU Klein, R
   Cruickshanks, KJ
   Myers, CE
   Sivakumaran, TA
   Iyengar, SK
   Meuer, SM
   Schubert, CR
   Gangnon, RE
   Klein, BEK
AF Klein, Ronald
   Cruickshanks, Karen J.
   Myers, Chelsea E.
   Sivakumaran, Theru A.
   Iyengar, Sudha K.
   Meuer, Stacy M.
   Schubert, Carla R.
   Gangnon, Ronald E.
   Klein, Barbara E. K.
TI The Relationship of Atherosclerosis to the 10-Year Cumulative Incidence
   of Age-related Macular Degeneration: The Beaver Dam Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; RISK-FACTORS; CARDIOVASCULAR-DISEASE; 5-YEAR
   INCIDENCE; VISUAL-ACUITY; MACULOPATHY; EYE; PREVALENCE; PROGRESSION;
   POPULATION
AB Objective: To describe the relationships of intima-media thickness (IMT), plaque in the carotid artery, angina, myocardial infarction (MI), and stroke to the 10-year cumulative incidence of early and late age-related macular degeneration (AMD) and progression of AMD.
   Design: Cohort study.
   Participants: A total of 1700 persons aged 53 to 96 years who participated in both the Epidemiology of Hearing Loss Study and the Beaver Dam Eye Study in 1998-2000, with photographs gradable for AMD at 5-year (2003-2005) and 10-year (2008-2010) follow-up examinations.
   Methods: The IMT and presence of plaque were assessed using B-mode ultrasonography of the carotid artery. Presence of angina, MI, and stroke were defined on the basis of a self-reported history of physician diagnosis. The presence and severity of AMD were determined by systematic grading of stereoscopic color fundus photographs.
   Main Outcome Measures: Age-related macular degeneration.
   Results: The 10-year cumulative incidence of early AMD was 15.7%, and the 10-year cumulative incidence of late AMD was 4.0%. After adjusting for age, sex, body mass index, smoking status, age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) genotypes, and other factors, mean IMT was associated with the 10-year incidence of early AMD (odds ratio [OR] per 0.1 mm IMT, 1.11; 95% confidence interval [CI], 1.00-1.21; P = 0.03) and late AMD (OR per 0.1 mm IMT, 1.27; CI, 1.10-1.47; P = 0.001). Mean IMT was associated with the 10-year incidence of pure geographic atrophy (OR per 0.1 mm IMT, 1.31; CI, 1.05-1.64; P = 0.02) but not exudative AMD (OR per 0.1 mm IMT, 1.14; CI, 0.97-1.34; P = 0.11). Similar associations were found for maximum IMT. The number of sites with plaque was related to the incidence of late AMD (OR per 0.1 mm IMT, 2.79 for 4-6 sites vs. none; CI, 1.06-7.37; P = 0.04) but not to early AMD. A history of angina, MI, or stroke was not related to any incident AMD outcome.
   Conclusions: In these population-based data, carotid artery IMT and carotid plaques had a weak relationship to the incidence of late AMD that was independent of systemic and genetic risk factors. Angina, MI, and stroke were not related to AMD. It is unclear whether the carotid IMT is a risk indicator of processes affecting Bruch's membrane and the retinal pigment epithelium, or a measure of atherosclerosis affecting susceptibility to AMD.
C1 [Klein, Ronald; Cruickshanks, Karen J.; Myers, Chelsea E.; Meuer, Stacy M.; Schubert, Carla R.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Cruickshanks, Karen J.; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   Cincinnati Children's Hospital Medical Center; Case Western Reserve
   University; University of Wisconsin System; University of Wisconsin
   Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714; Klein,
   Ronald/0000-0002-4428-6237
FU National Institutes of Health Grants [EY06594, EY013279, AG11099];
   Research to Prevent Blindness, New York, New York; National Eye
   Institute; National Institute on Aging; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [R01EY013279, U10EY006594] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R37AG011099, R01AG011099] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY06594 (B.E.K.K. and
   R.K.), EY013279 (K.J.C.), and AG11099 (K.J.C.), and Research to Prevent
   Blindness (R.K. and B.E.K.K., Senior Scientific Investigator Awards;
   K.J.C., Lew R. Wasserman Award), New York, New York. The National Eye
   Institute and National Institute on Aging provided funding for the
   entire study, including collection and analyses of data; Research to
   Prevent Blindness provided additional support for data analyses. Neither
   funding organization had a role in the design or conduct of this
   research. The content is solely the responsibility of the authors and
   does not necessarily reflect the official views of the National Eye
   Institute, the National Institute on Aging, or the National Institutes
   of Health.
CR *ARIC STUD GROUP, 1991, J NEUROIMAGING, V1, P68
   Atherosclerosis Risk in Communities Study Protocol, 1999, ATH RISK COMM STUD P, V6B, P4
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Cruickshanks KJ, 2003, ARCH OTOLARYNGOL, V129, P1041, DOI 10.1001/archotol.129.10.1041
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klein BE, 2009, NTIS PUBLICATION, V179-202, P223
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 1999, NTIS PUBLICATION, V170-90, P208
   Klein R, 1991, NTIS PUBLICATION, p[146, 182]
   Klein R, 1995, NTIS PUBLICATION, p[133, 184]
   Klein R, 1991, NTIS PUBLICATION
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   LI RL, 1994, STROKE, V25, P2377, DOI 10.1161/01.STR.25.12.2377
   McCarty CA, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-25
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zaliuniene D, 2008, EUR J OPHTHALMOL, V18, P384, DOI 10.1177/112067210801800312
   Zhong WJ, 2012, ATHEROSCLEROSIS, V224, P506, DOI 10.1016/j.atherosclerosis.2012.07.024
   1976, PREV MED, V5, P207
NR 49
TC 32
Z9 32
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
BP 1012
EP 1019
DI 10.1016/j.ophtha.2012.11.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140VE
UT WOS:000318683400020
PM 23399375
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Oszajca, K
   Szemraj, M
   Szemraj, J
   Jurowski, P
AF Oszajca, Katarzyna
   Szemraj, Maciej
   Szemraj, Janusz
   Jurowski, Piotr
TI Association analysis of genetic polymorphisms and expression levels of
   selected genes involved in extracellular matrix turnover and
   angiogenesis with the risk of age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related macular degeneration; single nucleotide polymorphism;
   metalloproteinase; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; SERUM-LEVELS;
   FACTOR VEGF; OXIDATIVE STRESS; PROMOTER; AMD; METALLOPROTEINASE-7;
   NEOVASCULARIZATION; SUSCEPTIBILITY
AB Background: Age-related macular degeneration is a progressive eye disease affecting the macula and causing acute visual loss particularly in elder people. The aim of the study was an attempt to discern an influence of expression levels and functional genetic polymorphisms of selected genes related to the extracellular matrix turnover or neovascularization on age-related macular degeneration occurrence and progression. Methods: We conducted a case-control study of 200 polish patients with recognized age-related macular degeneration (dry and wet) and compared the results with those obtained from matched 100 healthy control subjects. TaqMan Genotyping Assays were employed to examine the following single nucleotide polymorphisms: matrix metalloproteinase (MMP)-2 -735C/T, MMP-7 -181A/G, MMP-9 -1702T/A, and -1562C/T; tissue inhibitors of metalloproteinase (TIMP)-2 -418G/C; vascular endothelial growth factor (VEGF) +405 G/C and +936 C/T, VEGFR-2 +1719 T/A and -271 G/A. Real-time polymerase chain reaction was assessed to determine the mRNA quantity. Serum levels of proteins were measured using enzyme-linked immunosorbent assay. Results: The single nucleotide polymorphism genotyping showed that TT genotype for MMP-9 -1702T/A and CC genotype for VEGF +936C/T increase markedly the risk of age-related macular degeneration but do not influence on its progression. Additionally, the possible protective effect of CC genetic variant in MMP-9 -1562C/T polymorphism against progression of age-related macular degeneration was observed. We also found significant differences in systemic expression levels of MMP-2, -7, -9, TIMP-2, vascular endothelial growth factor, VEGFR-2, and pigment epithelium-derived factor between studied group. The research demonstrated evident differences in serum levels of MMP-2, -7, -9, TIMP-2, vascular endothelial growth factor, and pigment epithelium-derived factor between wet and dry age-related macular degeneration patients. Conclusions: We can conclude that disturbances in angiogenic homeostasis and processes of extracellular matrix turnover occurring in age-related macular degeneration-affected ocular tissues may be reflected in changes in systemic expression levels of the investigated genes.
C1 [Oszajca, Katarzyna; Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
   [Szemraj, Maciej; Jurowski, Piotr] Cent Vet Hosp, Dept Ophthalmol & Visual Rehabil, Lodz, Poland.
C3 Medical University Lodz
RP Oszajca, K (通讯作者)，Med Univ Lodz, Dept Med Biochem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
EM katarzyna.oszajca@umed.lodz.pl
RI ; Oszajca, Katarzyna/S-9288-2016
OI Jurowski, Piotr/0000-0003-1471-8577; Oszajca,
   Katarzyna/0000-0002-7070-8720
FU Polish National Science Centre [NN 402 591340]
FX This work was supported by grant NN 402 591340 from the Polish National
   Science Centre.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambreen F, 2015, MOL VIS, V21, P985
   An SJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-144
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/928315, 10.1155/2013/434010]
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Duellman T, 2014, J VASC SURG, V60, P613, DOI 10.1016/j.jvs.2014.03.274
   Fang AM, 2009, MOL VIS, V15, P2710
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hussain AA, 2017, J NEURODEGENER DIS, V2017
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jormsjo S, 2001, ARTERIOSCL THROM VAS, V21, P1834, DOI 10.1161/hq1101.098229
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Li L, 2016, MED SCI MONITOR, V22, P31, DOI 10.12659/MSM.895163
   Liutkeviciene R, 2016, OPHTHALMIC GENET, V37, P170, DOI 10.3109/13816810.2015.1020556
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogata N, 2005, AM J OPHTHALMOL, V140, P937, DOI 10.1016/j.ajo.2005.05.037
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Ornek N, 2016, INT J OPHTHALMOL-CHI, V9, P556, DOI 10.18240/ijo.2016.04.13
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stefanini FR, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/632307
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yu CY, 2004, CANCER RES, V64, P7622, DOI 10.1158/0008-5472.CAN-04-1521
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788
   Zhou YF, 2004, CARCINOGENESIS, V25, P399, DOI 10.1093/carcin/bgh020
NR 58
TC 4
Z9 4
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV 2
PY 2018
VL 39
IS 6
BP 684
EP 698
DI 10.1080/13816810.2018.1525752
PG 15
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA HC3DP
UT WOS:000451681700003
PM 30289322
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Pokroy, R
   Mimouni, M
   Barayev, E
   Segev, F
   Geffen, N
   Nemet, AY
   Segal, O
AF Pokroy, Russell
   Mimouni, Michael
   Barayev, Edward
   Segev, Fani
   Geffen, Noa
   Nemet, Arie Y.
   Segal, Ori
TI PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE subretinal hyperreflective material; SHRM; HRM; SD-OCT; AMD; choroidal
   neovascularization; bevacizumab; well-defined SHRM; visual outcomes
ID VISUAL OUTCOMES; RANIBIZUMAB; PREDICTORS; EYES
AB Purpose: To study the correlation between subretinal hyperreflective material (SHRM) seen on spectral domain optical coherence tomography at baseline and visual outcomes after intravitreal bevacizumab injection in neovascular age-related macular degeneration.
   Methods: Consecutive patient charts with treatment-naive center-involved neovascular age-related macular degeneration treated with 3 monthly intravitreal bevacizumab's, continued as needed, from 2011 to 2014 were reviewed. Baseline spectral domain optical coherence tomography SHRM parameters (height, width, area, reflectivity, border definition, and homogeneity) and established optical coherence tomography biomarkers of neovascular activity (intraretinal fluid, subretinal fluid, retinal volume, central retinal thickness, and pigment epithelial detachment presence) were collected. These baseline parameters were correlated with visual acuity at baseline, 3 and 12 months.
   Results: Seventy-three eyes of 73 patients, 47 (64.4%) having central SHRM at baseline, were studied. Mean age was 79.2 +/- 8.9 years. Mean best-corrected visual acuity was 0.70 +/- 0.57 logarithm of the minimum angle of resolution (20/100), 0.73 +/- 0.55 (20/107), and 0.76 +/- 0.63 (20/115) at baseline, 3 and 12 months, respectively. Baseline parameters with a significant predictive value of 12-month visual acuity by univariate analysis were presence of intraretinal fluid, presence of SHRM, highly reflective SHRM, well-defined SHRM borders, and thick SHRM. These parameters, with the exception of high reflectivity, were significant on multivariate regression analysis. The most predictive baseline parameter was well-defined SHRM borders.
   Conclusion: This study supports the use of SHRM as a prognostic biomarker when interpreting optical coherence tomography in neovascular age-related macular degeneration. Baseline parameters predicting poorer vision 1 year after intravitreal bevacizumab treatment were as follows: presence of central SHRM, well-defined SHRM borders, intraretinal fluid, and thicker SHRM.
C1 [Pokroy, Russell] Tel Aviv Univ, Sackler Fac Med, Assaf Harofeh Med Ctr, Dept Ophthalmol, Zerifin, Israel.
   [Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
   [Barayev, Edward; Segev, Fani; Geffen, Noa; Nemet, Arie Y.; Segal, Ori] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Dept Ophthalmol, Kefar Sava, Israel.
C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler
   Faculty of Medicine; Rambam Health Care Campus; Tel Aviv University;
   Sackler Faculty of Medicine
RP Segal, O (通讯作者)，Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
EM orisegal@gmail.com
RI Mimouni, Michael/S-2916-2018; Pokroy, Russell/AAM-9861-2020
OI Mimouni, Michael/0000-0002-4661-0993; Pokroy,
   Russell/0000-0002-6489-8353
CR Abazov VM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.161803
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 19
TC 29
Z9 29
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1485
EP 1491
DI 10.1097/IAE.0000000000001748
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400016
PM 28654630
DA 2022-11-30
ER

PT J
AU Pennesi, ME
   Neuringer, M
   Courtney, RJ
AF Pennesi, Mark E.
   Neuringer, Martha
   Courtney, Robert J.
TI Animal models of age related macular degeneration
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT
   FACTOR-H; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; EXPERIMENTAL
   SUBRETINAL NEOVASCULARIZATION; DENSITY LIPOPROTEIN RECEPTOR; HIGH-FAT
   DIET; BRUCHS MEMBRANE; APOLIPOPROTEIN-E; TRANSGENIC MICE
AB Age related macular degeneration (AMD) is the leading cause of vision loss of those over the age of 65 in the industrialized world. The prevalence and need to develop effective treatments for AMD has lead to the development of multiple animal models. AMD is a complex and heterogeneous disease that involves the interaction of both genetic and environmental factors with the unique anatomy of the human macula. Models in mice, rats, rabbits, pigs and non-human primates have recreated many of the histological features of AMD and provided much insight into the underlying pathological mechanisms of this disease. In spite of the large number of models developed, no one model yet recapitulates all of the features of human AMD. However, these models have helped reveal the roles of chronic oxidative damage, inflammation and immune dysregulation, and lipid metabolism in the development of AMD. Models for induced choroidal neovascularization have served as the backbone for testing new therapies. This article will review the diversity of animal models that exist for AMD as well as their strengths and limitations. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Pennesi, Mark E.; Neuringer, Martha; Courtney, Robert J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Pennesi, ME (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM pennesim@ohsu.edu
FU Foundation Fighting Blindness; Research to Prevent Blindness; K08 Career
   Development Award [1 K08 EY021186-01]; NIH [RR-00163]; NATIONAL CENTER
   FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [K08EY021186] Funding Source: NIH RePORTER
FX We would like to thank Laura Erker for critical reading of this
   manuscript. Funding: Foundation Fighting Blindness (CDA to M.E.P. and
   grant to M.N.), Research to Prevent Blindness (Unrestricted, CEI), K08
   Career Development Award: 1 K08 EY021186-01 and NIH grant RR-00163
   (M.N.).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   BELLHORN RW, 1981, INVEST OPHTH VIS SCI, V21, P771
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, NUTR REV, V69, P231, DOI 10.1111/j.1753-4887.2011.00382.x
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELMOFTY AAM, 1980, EXP EYE RES, V31, P147, DOI 10.1016/0014-4835(80)90075-5
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Fu YL, 2007, INVEST OPHTH VIS SCI, V48, P5184, DOI 10.1167/iovs.07-0469
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBAUM MH, 1983, RETINA-J RET VIT DIS, V3, P114, DOI 10.1097/00006982-198300320-00008
   GOLDBERG MF, 1976, INVEST OPHTH VISUAL, V15, P443
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1403, DOI 10.1007/s00417-008-0911-7
   Gouras P, 2010, GRAEF ARCH CLIN EXP, V248, P973, DOI 10.1007/s00417-010-1325-x
   GRAVES DT, 1995, CRIT REV ORAL BIOL M, V6, P109, DOI 10.1177/10454411950060020101
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P125, DOI 10.1007/s00417-002-0615-3
   Julien S, 2008, MOL VIS, V14, P1358
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiilgaard JF, 2005, ACTA OPHTHALMOL SCAN, V83, P697, DOI 10.1111/j.1600-0420.2005.00566.x
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Koh HJ, 2006, RETINA-J RET VIT DIS, V26, P202, DOI 10.1097/00006982-200602000-00014
   Kolosova NG, 2003, B EXP BIOL MED+, V136, P415, DOI 10.1023/B:BEBM.0000010967.24302.78
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Lassota N, 2007, GRAEF ARCH CLIN EXP, V245, P1189, DOI 10.1007/s00417-006-0518-9
   Lassota N, 2010, ACTA OPHTHALMOL, V88, P300, DOI 10.1111/j.1755-3768.2008.01439.x
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek G, 2006, ADV EXP MED BIOL, V572, P109
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malinovi M.R., 1980, INVEST OPHTH VIS SCI, V19, P357
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Markovets AM, 2011, AGING-US, V3, P44
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Marsili S, 2004, EXP EYE RES, V79, P595, DOI 10.1016/j.exer.2004.06.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Neuringer M., 2010, ATROPHIC MACULAR DEG
   Ni M, 2005, EXP EYE RES, V81, P286, DOI 10.1016/j.exer.2005.01.027
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   OGATA N, 1992, Nippon Ganka Gakkai Zasshi, V96, P180
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Patel BN, 2002, J NEUROSCI, V22, P6578
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Peden MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017140
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Reich S, 2003, MOL VIS, V9, P210
   Rennel ES, 2011, MICROCIRCULATION, V18, P598, DOI 10.1111/j.1549-8719.2011.00120.x
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SALGANIK RI, 1994, BIOCHEM BIOPH RES CO, V199, P726, DOI 10.1006/bbrc.1994.1289
   SALGANIK RI, 1994, BIOCHEM BIOPH RES CO, V205, P180, DOI 10.1006/bbrc.1994.2647
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmack I, 2009, MOL VIS, V15, P146
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shen WY, 2004, ARCH OPHTHALMOL-CHIC, V122, P353, DOI 10.1001/archopht.122.3.353
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Silva RLE, 2005, INVEST OPHTH VIS SCI, V46, P3323, DOI 10.1167/iovs.04-1210
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P100, DOI 10.1016/S0002-9394(99)80243-8
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6
   Takada Yuriko, 1993, Nippon Ganka Gakkai Zasshi, V97, P595
   Takada Yuriko, 1994, Nippon Ganka Gakkai Zasshi, V98, P955
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takeda T, 1997, EXP GERONTOL, V32, P105, DOI 10.1016/S0531-5565(96)00036-8
   TAKEDA T, 1994, ARCH GERONTOL GERIAT, V19, P185, DOI 10.1016/0167-4943(94)90039-6
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P661, DOI 10.1097/00006982-200408000-00040
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P660, DOI 10.1097/00006982-200408000-00039
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Uchiki T., 2011, AGING CELL
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Weikel C.A., 2011, INVESTIGATIVE OPHTHA
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   WILSON DJ, 1987, AM J OPHTHALMOL, V103, P167, DOI 10.1016/S0002-9394(14)74222-9
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang D, 2005, INVEST OPHTH VIS SCI, V46, P3031, DOI 10.1167/iovs.04-1510
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
   ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543
   Zhang ZX, 2011, CURR EYE RES, V36, P838, DOI 10.3109/02713683.2011.593107
   Zhao L, 2007, MOL VIS, V13, P873
   Zhu J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 292
TC 227
Z9 244
U1 0
U2 66
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 487
EP 509
DI 10.1016/j.mam.2012.06.003
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900010
PM 22705444
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Huang, EJC
   Wu, SH
   Lai, CH
   Kuo, CN
   Wu, PL
   Chen, CL
   Chen, CY
   King, YC
   Wu, PC
AF Huang, E. J-C
   Wu, S-H
   Lai, C-H
   Kuo, C-N
   Wu, P-L
   Chen, C-L
   Chen, C-Y
   King, Y-C
   Wu, P-C
TI Prevalence and risk factors for age-related macular degeneration in the
   elderly Chinese population in south-western Taiwan: the Puzih eye study
SO EYE
LA English
DT Article
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   SINGAPORE MALAY EYE; JAPANESE POPULATION; ADULT-POPULATION; TERM
   INCIDENCE; BEIJING EYE; MACULOPATHY; ANTIOXIDANTS
AB Aim This study aimed to ascertain the prevalence of and the risk factors associated with early and late age-related macular degeneration (AMD) among Chinese individuals aged >= 65 years residing in Puzih, Taiwan.
   Methods This population-based cross-sectional study graded digital colour photographs of the ocular fundus of 673 individuals using the Wisconsin Age-Related Maculopathy Grading System. We compared the characteristics of individuals with early and late AMD using chi(2)-analyses and described risk factors for early and late AMD using odds ratios and 95% confidence intervals.
   Results Individuals with late AMD were significantly older and more likely to have hypertension. Further, their sunlight exposure time was longer than that of those with early AMD, only drusen, or no AMD lesions (P<0.01). A history of hyperlipidaemia for >10 years was a significant risk factor for early AMD, while old age, hypertension for >10 years, and exposure to sunlight for >8 h per day were associated with late AMD.
   Conclusions The prevalence rate of early AMD in the present study was 15.0%, which is similar to that reported for Caucasians and Japanese included in the European Eye Study and the Hisayama Study, respectively. The late AMD prevalence rate of 7.3% found among our study participants was comparable to that reported by the Greenland Inuit Eye Study and Reykjavik Study, but considerably lower than that reported for Caucasians, indicating that late AMD might be less prevalent among Asians than Caucasians.
C1 [Huang, E. J-C; Wu, S-H; Lai, C-H; Kuo, C-N; Wu, P-L; Chen, C-L; Chen, C-Y; King, Y-C; Wu, P-C] Chang Gung Mem Hospital Chiayi, Dept Ophthalmol, Chiayi, Taiwan.
   [Huang, E. J-C; Wu, S-H; Lai, C-H; Kuo, C-N; Wu, P-L; Chen, C-L; Chen, C-Y; Wu, P-C] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Lai, C-H] Chang Gung Univ Sci & Technol, Dept Nursing, Chiayi, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University of Science & Technology
RP Lai, CH (通讯作者)，Chang Gung Mem Hosp Chiayi, Dept Ophthalmol, 6 West Sec,Chiapu Rd, Putzu City 613, Chiayi County, Taiwan.
EM oph4557@gmail.com
FU Chang Gung Memorial Hospital, ROC [CMRP680341, CMRP680342]
FX This study was supported by a grant from the Chang Gung Memorial
   Hospital, ROC: CMRP680341, CMRP680342.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], 2009, DUKE MED HLTH NEWS, V15, P6
   [Anonymous], 2000, OPHTHALMOLOGY, V107, P2224
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, OPHTHALMOLOGY, V117, P921
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vela C, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-5
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wu Z Q, 1992, Zhonghua Yan Ke Za Zhi, V28, P246
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 48
TC 30
Z9 31
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2014
VL 28
IS 6
BP 705
EP 714
DI 10.1038/eye.2014.55
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK3QQ
UT WOS:000338340200010
PM 24625378
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ramshekar, A
   Wang, HB
   Hartnett, ME
AF Ramshekar, Aniket
   Wang, Haibo
   Hartnett, M. Elizabeth
TI Regulation of Rac1 Activation in Choroidal Endothelial Cells: Insights
   into Mechanisms in Age-Related Macular Degeneration
SO CELLS
LA English
DT Review
DE age-related macular degeneration; macular neovascularization; choroidal
   endothelial cells; rho gtpases
ID NADPH OXIDASE; CRYSTAL-STRUCTURE; BINDING PROTEIN; IQGAP1; MIGRATION;
   RAP1; NEOVASCULARIZATION; CALMODULIN; CDC42; TRANSMIGRATION
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide. Vision loss from the neovascular form is associated with the invasion of choroidal endothelial cells into the neural retina to form vision-threatening macular neovascularization (MNV). Anti-angiogenic agents are the current standard of care but are effective in only similar to 50% of AMD cases. The molecular mechanisms involved in invasive MNV point to the importance of regulating signaling pathways that lead to pathologic biologic outcomes. In studies testing the effects of AMD-related stresses, activation of the Rho GTPase, Rac1, was found to be important for the choroidal endothelial cell invasion into the neural retina. However, current approaches to prevent Rac1 activation are inefficient and less effective. We summarize active Rac1-mediated mechanisms that regulate choroidal endothelial cell migration. Specifically, we discuss our work regarding the role of a multidomain protein, IQ motif containing GTPase activating protein 1 (IQGAP1), in sustaining pathologic Rac1 activation and a mechanism by which active Rap1, a Ras-like GTPase, may prevent active Rac1-mediated choroidal endothelial cell migration.
C1 [Ramshekar, Aniket; Wang, Haibo; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Hartnett, ME (通讯作者)，Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM me.hartnett@hsc.utah.edu
FU National Institutes of Health/National Eye Institute [F30EY032311,
   R01EY015130, R01EY017011]; National Institutes of Health Core Grant
   [P30EY014800]; Research to Prevent Blindness, New York, NY
FX The work was supported by the National Institutes of Health/National Eye
   Institute R01EY015130 and R01EY017011 to M.E.H., the National Institutes
   of Health/National Eye Institute F30EY032311 to A.R., the National
   Institutes of Health Core Grant (P30EY014800), and an Unrestricted Grant
   from Research to Prevent Blindness, New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah.
CR Abel AM, 2015, MOL IMMUNOL, V65, P336, DOI 10.1016/j.molimm.2015.02.012
   Aitsebaomo J, 2004, J BIOL CHEM, V279, P17963, DOI 10.1074/jbc.M311721200
   Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5
   Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976
   Barbera S, 2021, MATRIX BIOL, V99, P1, DOI 10.1016/j.matbio.2021.05.006
   Benson CE, 2021, ANGIOGENESIS, V24, P417, DOI 10.1007/s10456-021-09768-8
   Berdyshev EV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016571
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164
   Borland G, 2009, BRIT J PHARMACOL, V158, P70, DOI 10.1111/j.1476-5381.2008.00087.x
   Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Carmona G, 2009, BLOOD, V113, P488, DOI 10.1182/blood-2008-02-138438
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Chrzanowska-Wodnicka M, 2008, BLOOD, V111, P2647, DOI 10.1182/blood-2007-08-109710
   Chrzanowska-Wodnicka M, 2017, CURR OPIN HEMATOL, V24, P248, DOI 10.1097/MOH.0000000000000332
   Colijn JM, 2021, JAMA OPHTHALMOL, V139, P743, DOI 10.1001/jamaophthalmol.2021.1407
   DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001
   Dong FY, 2016, KIDNEY INT, V89, P1160, DOI 10.1016/j.kint.2015.09.006
   Epting D, 2010, CIRC RES, V107, P45, DOI 10.1161/CIRCRESAHA.109.213983
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hedman AC, 2015, EMBO REP, V16, P427, DOI 10.15252/embr.201439834
   Hernandez-Garcia R, 2015, VASC PHARMACOL, V74, P60, DOI 10.1016/j.vph.2015.10.003
   Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464
   Ikeda S, 2005, ARTERIOSCL THROM VAS, V25, P2295, DOI 10.1161/01.ATV.0000187472.55437.af
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   JALKH AE, 1990, OPHTHALMOLOGY, V97, P1614
   Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165
   Jeong HW, 2007, J BIOL CHEM, V282, P20752, DOI 10.1074/jbc.M700487200
   Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183
   Khan KA, 2019, FEBS J, V286, P3299, DOI 10.1111/febs.14985
   Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D
   Kurella VB, 2009, J BIOL CHEM, V284, P14857, DOI 10.1074/jbc.M808974200
   Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363
   Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X
   Li JJ, 2018, CURR EYE RES, V43, P934, DOI 10.1080/02713683.2018.1454477
   Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004
   Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200
   Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2
   Majolee J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254386
   Malarkannan S, 2012, J IMMUNOL, V188, P2057, DOI 10.4049/jimmunol.1102439
   MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0
   Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9
   Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200
   Mittra RA, 2002, OPTOMETRY VISION SCI, V79, P218, DOI 10.1097/00006324-200204000-00008
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Pannekoek WJ, 2014, CELL ADHES MIGR, V8, P100, DOI 10.4161/cam.27352
   Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010
   Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Ramos CJ, 2018, J BIOL CHEM, V293, P717, DOI 10.1074/jbc.M117.815381
   Ramshekar A, 2021, FASEB J, V35, DOI 10.1096/fj.202100112R
   Sanematsu F, 2010, CIRC RES, V107, P1102, DOI 10.1161/CIRCRESAHA.110.223388
   Sassmannshausen M, 2021, OPHTHALMOL RETINA, V5, P241, DOI 10.1016/j.oret.2020.07.019
   Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200
   Su ZJ, 2004, P NATL ACAD SCI USA, V101, P12212, DOI 10.1073/pnas.0404631101
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tojo T, 2005, CIRCULATION, V111, P2347, DOI 10.1161/01.CIR.0000164261.62586.14
   Tosi GM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.30
   Tosi GM, 2017, J CELL PHYSIOL, V232, P1767, DOI 10.1002/jcp.25689
   Urao N, 2008, CIRC RES, V103, P212, DOI 10.1161/CIRCRESAHA.108.176230
   van Buul JD, 2014, CELL ADHES MIGR, V8, P108, DOI 10.4161/cam.27599
   Wang HB, 2021, ANGIOGENESIS, V24, P583, DOI 10.1007/s10456-021-09770-0
   Wang HB, 2020, ANGIOGENESIS, V23, P685, DOI 10.1007/s10456-020-09740-y
   Wang HB, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020040
   Wang HB, 2016, INVEST OPHTH VIS SCI, V57, P5525, DOI 10.1167/iovs.16-19691
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24111
   WEISSBACH L, 1994, J BIOL CHEM, V269, P20517
   White CD, 2012, CELL SIGNAL, V24, P826, DOI 10.1016/j.cellsig.2011.12.005
   Wittchen ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073070
   Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
NR 96
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD SEP
PY 2021
VL 10
IS 9
AR 2414
DI 10.3390/cells10092414
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UU8NO
UT WOS:000699051900001
PM 34572063
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Weinstein, O
   Abu Tailakh, M
   Lifshitz, T
   Novack, V
   Levy, J
AF Weinstein, Orly
   Abu Tailakh, Muhammad
   Lifshitz, Tova
   Novack, Victor
   Levy, Jaime
TI Intravitreal bevacizumab treatment for neovascular age-related macular
   degeneration and thromboembolic events
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Thromboembolic events; neovascular age-related macular degeneration;
   intravitreal bevacizumab
ID SYSTEMIC SAFETY; RANIBIZUMAB; THERAPY; RISK; AVASTIN; CANCER
AB Background: Systemic complications of intravitreal anti-vascular endothelial growth factor agents are relatively uncommon but highly significant. Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. Secondary objective: To analyze the association between injection frequency and the risk for thromboembolic events, the time interval between the injection and the thromboembolic events, and the influence of chronic diseases on complications rate. Design: A retrospective cohort study. Methods: Consecutive neovascular age-related macular degeneration patients receiving intravitreal bevacizumab at Soroka University Medical Center from December 2005 to December 2013 were included. Thromboembolic events analyzed included acute coronary syndrome, acute myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. The thromboembolic event rate was compared 2 years prior and 2 years after the initial intravitreal bevacizumab injection. Results: A total of 2102 patients were included. Acute coronary syndrome and stroke rate were higher 2 years after intravitreal bevacizumab (p = 0.03 and p = 0.01, respectively). No statistical significant difference was found for the rest of thromboembolic events. Patients older than 80 years and patients receiving less than six intravitreal bevacizumab injections were more likely to experience stroke. Patients with known cardiovascular risk factors before starting injections did not develop significant more thromboembolic events. Conclusion: In our study population, patients treated with intravitreal bevacizumab were significantly more likely to experience stroke during 2 years after first injection.
C1 [Weinstein, Orly; Lifshitz, Tova] Soroka Univ, Med Ctr, Dept Ophthalmol, Beer Sheva, Israel.
   [Weinstein, Orly] Minist Hlth, Jerusalem, Israel.
   [Weinstein, Orly; Abu Tailakh, Muhammad; Lifshitz, Tova; Novack, Victor] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   [Abu Tailakh, Muhammad] Soroka Univ, Med Ctr, Clin Res Ctr & Nursing Res Unit, Beer Sheva, Israel.
   [Novack, Victor] Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel.
   [Levy, Jaime] Hadassah Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
C3 Ben Gurion University; Soroka Medical Center; Ben Gurion University; Ben
   Gurion University; Soroka Medical Center; Ben Gurion University; Soroka
   Medical Center; Hebrew University of Jerusalem; Hadassah University
   Medical Center
RP Levy, J (通讯作者)，Hadassah Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM levjaime@gmail.com
RI Abu Tailakh, Muhammad/ABC-9475-2021; Abu Tailakh, Muhammad/Z-4608-2019
OI Abu Tailakh, Muhammad/0000-0003-3770-0927; Abu Tailakh,
   Muhammad/0000-0003-3770-0927
CR Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Dedania VS, 2016, CURR OPIN OPHTHALMOL, V27, P224, DOI 10.1097/ICU.0000000000000257
   Etminan M, 2016, AM J OPHTHALMOL, V166, P205, DOI 10.1016/j.ajo.2016.03.026
   Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gault N, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-016-0278-0
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Johnson D, 2013, CURR OPIN OPHTHALMOL, V24, P205, DOI 10.1097/ICU.0b013e32835f8ec0
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
NR 23
TC 5
Z9 5
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2020
VL 30
IS 1
BP 66
EP 71
DI 10.1177/1120672118823128
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JW5HV
UT WOS:000503083900018
PM 30618282
DA 2022-11-30
ER

PT J
AU Chen, L
   Messinger, JD
   Zhang, YH
   Spaide, RF
   Freund, KB
   Curcio, CA
AF Chen, Ling
   Messinger, Jeffrey D.
   Zhang, Yuhua
   Spaide, Richard F.
   Freund, K. Bailey
   Curcio, Christine A.
TI SUBRETINAL DRUSENOID DEPOSIT IN AGE-RELATED MACULAR DEGENERATION
   Histologic Insights Into Initiation, Progression to Atrophy, and Imaging
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; autofluorescence; clinicopathologic
   correlation; color fundus photography; histology; optical coherence
   tomography; photoreceptors; retinal pigment epithelium; subretinal
   drusenoid deposits
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; RETICULAR
   PSEUDODRUSEN; GEOGRAPHIC ATROPHY; CLINICOPATHOLOGICAL CORRELATION;
   TYPE-3 NEOVASCULARIZATION; MICROGLIAL CELLS; NATURAL-HISTORY; GRADING
   SYSTEM; FELLOW EYES
AB Purpose: To clarify the role of subretinal drusenoid deposits (SDD; pseudodrusen) in the progression of age-related macular degeneration through high-resolution histology. Methods: In 33 eyes of 32 donors (early age-related macular degeneration, n = 15; geographic atrophy, n = 9; neovascular age-related macular degeneration, n = 7; unremarkable, n = 2), and 2 eyes of 2 donors with in vivo multimodal imaging including optical coherence tomography, examples of SDD contacting photoreceptors were assessed. Results: Subretinal drusenoid deposits were granular extracellular deposits at the apical retinal pigment epithelium (RPE); the smallest were 4-mu m wide. Outer segment (OS) fragments and RPE organelles appeared in some larger deposits. A continuum of photoreceptor degeneration included OS disruption, intrusion into inner segments, and disturbance of neurosensory retina. In a transition to outer retinal atrophy, SDD appeared to shrink, OS disappeared, inner segment shortened, and the outer nuclear layer thinned and became gliotic. Stage 1 SDD on optical coherence tomography correlated with displaced OS. Confluent and disintegrating Stage 2 to 3 SDD on optical coherence tomography and dot pseudodrusen by color fundus photography correlated with confluent deposits and ectopic RPE. Conclusion: Subretinal drusenoid deposits may start at the RPE as granular, extracellular deposits. Photoreceptor OS, RPE organelles, and cell bodies may appear in some advanced deposits. A progression to atrophy associated with deposit diminution was confirmed. Findings support a biogenesis hypothesis of outer retinal lipid cycling.
C1 [Chen, Ling; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Chen, Ling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Zhang, Yuhua] Univ Calif Los Angeles, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA USA.
   [Spaide, Richard F.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Doheny Eye Institute; University of California System;
   University of California Los Angeles; Vitreous Retina Macula Consultants
   of New York; Manhattan Eye Ear & Throat Hospital; New York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn Alabama, Dept Ophthalmol & Visual Sci,Vis Res Labs, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Spaide, Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Chen, Ling/0000-0002-5552-4667; Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, New York; John P. and Shirley H. Sarks Fund at UAB;
   Heidelberg Engineering; NIH [R01EY024378, R01EY06019]; EyeSight
   Foundation of Alabama; International Retinal Research Foundation; Edward
   N. and Della L. Thome Foundation; Arnold and Mabel Beckman Initiative
   for Macular Research; Research to Prevent Blindness
FX Supported by The Macula Foundation, New York, the John P. and Shirley H.
   Sarks Fund at UAB, and Heidelberg Engineering. The Project MACULA
   website and the recovery of human donor eyes for research has been
   supported by NIH grant R01EY06019, EyeSight Foundation of Alabama,
   International Retinal Research Foundation, Edward N. and Della L. Thome
   Foundation, the Arnold and Mabel Beckman Initiative for Macular
   Research, and Research to Prevent Blindness. Purchase of the slide
   scanner was made possible by the Carl G. and Pauline Buck Trust. Y.
   Zhang was supported by the NIH grant R01EY024378.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Di Pierdomenico J, 2019, NEURAL REGEN RES, V14, P1186, DOI 10.4103/1673-5374.251204
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krebs W., 1991, PRIMATE RETINA CHORO
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   MCMENAMIN PG, 1990, ANAT REC, V227, P245, DOI 10.1002/ar.1092270213
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rashid K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00176
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Scoles D, 2017, RETINA-J RET VIT DIS, V37, P741, DOI 10.1097/IAE.0000000000001203
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P12, DOI 10.1097/IAE.0000000000002362
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 90
TC 34
Z9 34
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 618
EP 631
DI 10.1097/IAE.0000000000002657
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800004
PM 31599795
OA Green Accepted
DA 2022-11-30
ER

PT J
AU McCarter, RV
   Neville, CE
   Silvestri, G
   Montgomery, S
   Moore, E
   Silvestri, V
   Cardwell, CR
   Hogg, RE
   Woodside, JV
   McKay, GJ
AF McCarter, Rachel V.
   Neville, Charlotte E.
   Silvestri, Giuliana
   Montgomery, Shannon
   Moore, Evelyn
   Silvestri, Vittorio
   Cardwell, Christopher R.
   Hogg, Ruth E.
   Woodside, Jayne V.
   McKay, Gareth J.
TI Dietary patterns were not associated with age-related macular
   degeneration: a cross-sectional analysis in the Irish Nun Eye Study
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE Age-related macular degeneration; Diet; Dietary patterns; Nutrition
ID FISH CONSUMPTION; VITAMIN-C; RISK; FAT; CLASSIFICATION; CARBOHYDRATE;
   MACULOPATHY; PROGRESSION; DISEASE; INDEX
AB Background Analysing dietary patterns (DP) evaluates overall dietary intake, taking account of its complexity, quality, variance and the interaction between different foods, providing an alternative approach for the evaluation of nutritional influences on age-related macular degeneration (AMD) risk.
   Aims To evaluate the relationship between DP and AMD in an older female population.
   Methods Data was analysed from the cross-sectional Irish Nun Eye Study involving 1233 older women with a restricted lifestyle (mean age 76.3 years [range, 56-100 years). The Wisconsin Age-related Maculopathy Grading System was used to classify digital colour macular fundus images and dietary intake was assessed using a food frequency questionnaire (n=1033). A posteriori DP were derived using principal component analysis. Logistic regression models examined associations between DP and AMD risk with adjustment for confounders.
   Results Two DP were identified: a 'healthy' pattern characterised by a high intake of oily fish, wholegrains, vegetables and fruit; and an 'unhealthy' pattern characterised by high-fat dairy products, sugar, sweets and chips. Of the participants included within the analysis, AMD status were categorised as controls (n=818, 86.9%), early AMD (n=83, 8.8%) and late AMD (n=21, 2.2%). Regression analysis failed to identify any significant associations between healthy or unhealthy DP and AMD risk, in unadjusted and adjusted models.
   Conclusion No evidence of an association between the DP identified and AMD risk was detected in this well-characterised population. Further research is required to determine the overall dietary influences on AMD risk in general population cohorts.
C1 [McCarter, Rachel V.; Neville, Charlotte E.; Montgomery, Shannon; Cardwell, Christopher R.; Hogg, Ruth E.; Woodside, Jayne V.; McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Silvestri, Giuliana; Moore, Evelyn; Silvestri, Vittorio] Belfast Hlth & Social Care Trust, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Woodside, Jayne V.] Queens Univ Belfast, Sch Med Dent & Biomed Sci, UKCRC Ctr Excellence Publ Hlth, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP McKay, GJ (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; McKay, Gareth/AAZ-2601-2020
OI Hogg, Ruth E./0000-0001-9413-2669; McKay, Gareth/0000-0001-8197-6280;
   McCarter, Rachel/0000-0002-6270-026X; Silvestri,
   Giuliana/0000-0001-5662-5374; Cardwell, Chris/0000-0002-2689-4335;
   Woodside, Jayne/0000-0002-5691-4659
FU Northern Ireland Health; Personal Social Services Research and
   Development Office
FX G. Silvestri reports grants from Northern Ireland Health and Personal
   Social Services Research and Development Office during this study,
   personal fees from Bayer and non-financial support from Allergan outside
   the submitted work. G. McKay reports personal fees from Boehringer
   Ingelheim.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   [Anonymous], 2006, FOOD PORTION SIZES
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Braakhuis Andrea, 2017, Diseases, V5, DOI 10.3390/diseases5010003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2017, INVEST OPHTH VIS SCI, V58, P1404, DOI 10.1167/iovs.16-20454
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Guenther PM, 2008, J AM DIET ASSOC, V108, P1896, DOI 10.1016/j.jada.2008.08.016
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kastorini CM, 2013, ARTIF INTELL MED, V59, P175, DOI 10.1016/j.artmed.2013.08.005
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McGowan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136434
   McGowan A, 2015, INVEST OPHTH VIS SCI, V56, P382, DOI 10.1167/iovs.14-15523
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moghaddam E, 2006, J NUTR, V136, P2506, DOI 10.1093/jn/136.10.2506
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Neville CE, 2018, J NUTR HEALTH AGING, V22, P751, DOI 10.1007/s12603-017-0992-2
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Stevens R, 2015, CLIN NUTR ESPEN, V10, pE112, DOI 10.1016/j.clnesp.2015.03.080
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
NR 37
TC 4
Z9 4
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD AUG
PY 2019
VL 188
IS 3
BP 1005
EP 1012
DI 10.1007/s11845-018-1932-9
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IJ2OD
UT WOS:000475743900039
PM 30467806
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nam, KT
   Chung, HW
   Jang, S
   Kim, SW
   Oh, J
   Yun, C
AF Nam, Ki Tae
   Chung, Hyun Woo
   Jang, Sungmin
   Kim, Seong-Woo
   Oh, Jaeryung
   Yun, Cheolmin
TI FEATURES OF THE MACULAR AND PERIPAPILLARY CHOROID AND CHORIOCAPILLARIS
   IN EYES WITH NONEXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choriocapillaris; choroid; flow voids;
   optical coherence tomography angiography
AB Purpose: We investigated macular and peripapillary choroidal thickness (CT) and flow voids in the choriocapillaris in eyes with nonexudative age-related macular degeneration.
   Methods: We retrospectively reviewed the medical records of patients with nonexudative age-related macular degeneration and classified their eyes into three categories: pachydrusen, drusen, and subretinal drusenoid deposit. Mean macular and peripapillary CT and choriocapillaris flow void area were compared among the three groups.
   Results: The three groups included 29, 33, and 33 patients, respectively. The mean macular and peripapillary CT findings were 260.64 +/- 75.85 mm and 134.47 +/- 46.28 mm for the pachydrusen group; 163.63 +/- 64.08 mm and 93.47 +/- 39.07 mm for the drusen group; and 95.33 +/- 28.87 mm and 56.06 +/- 11.64 mm for the subretinal drusenoid deposit group (all, P, 0.001). Mean macular and peripapillary flow void area varied among the subretinal drusenoid deposit group (57.07 +/- 6.16% and 55.38 +/- 6.65%), drusen group (58.30 +/- 6.98% and 49.11 +/- 9.11%) and pachydrusen group (50.09 +/- 5.77% and 45.47 +/- 8.06%) (all P, 0.001).
   Conclusion: The peripapillary CT and flow voids in the choriocapillaris varied according to the features of drusen in nonexudative age-related macular degeneration eyes. Greater flow voids and thinner CT in eyes with subretinal drusenoid deposits may suggest that these eyes have diffuse choroidal abnormalities both in and outside the macula.
C1 [Nam, Ki Tae; Chung, Hyun Woo; Jang, Sungmin; Kim, Seong-Woo; Oh, Jaeryung; Yun, Cheolmin] Korea Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Yun, C (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 123,Jeokgeum Ro, Ansan, Gyeonggi Do, South Korea.
EM yuncheolmin@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU National Research Foundation of Korea - Korean government (Ministry of
   Science, ICT & Future Planning) [NRF-2017R1C1B5076520]
FX Supported by a National Research Foundation of Korea grant funded by the
   Korean government (Ministry of Science, ICT & Future Planning)
   (NRF-2017R1C1B5076520).
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yun C, 2020, INT OPHTHALMOL, V40, P325, DOI 10.1007/s10792-019-01182-w
   Yun C, 2017, GRAEF ARCH CLIN EXP, V255, P1923, DOI 10.1007/s00417-017-3742-6
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 30
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2270
EP 2276
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100003
PM 31934923
DA 2022-11-30
ER

PT J
AU Danis, R
   McLaughlin, MM
   Tolentino, M
   Staurenghi, G
   Ye, L
   Xu, CF
   Kinn, RY
   Johnson, MW
AF Danis, Ronald
   McLaughlin, Megan M.
   Tolentino, Michael
   Staurenghi, Giovanni
   Ye, Li
   Xu, Chun-Fang
   Kinn, Robert Y.
   Johnson, Mark W.
CA Pazopanib Eye Drops Study Grp
TI Pazopanib eye drops: a randomised trial in neovascular age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   RANIBIZUMAB; KINASE INHIBITOR; ASSOCIATION; POLYMORPHISM; RISK; CFH;
   THERAPY; DISEASE
AB Aims To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration.
   Methods 70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29.
   Results No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89 gm) in patients with the CFH TT genotype who received 5 mg/mL TID (p=0.01, n=5). Mean increases in BCVA were observed in the 5 mg/mL TID overall (4.32 letters (p=0.002, n=26)) and in those that with CFH Y402H TT (6.96 letters (p=0.02, n=5)) and CT (4.09 letters (p=0.05, n=9)) genotypes. No safety signals that precluded continued investigation were detected.
   Conclusions 5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.
C1 [Danis, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53717 USA.
   [McLaughlin, Megan M.; Kinn, Robert Y.] GlaxoSmithKline, King Of Prussia, PA USA.
   [Tolentino, Michael] Ctr Retina & Macular Dis, Winter Haven, FL USA.
   [Staurenghi, Giovanni] Univ Milan, Eye Clin, Dept Clin Sci, Novara, Italy.
   [Ye, Li] GlaxoSmithKline, Upper Providence, PA USA.
   [Xu, Chun-Fang] GlaxoSmithKline, Stevenage, Herts, England.
   [Johnson, Mark W.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   GlaxoSmithKline; University of Milan; GlaxoSmithKline; GlaxoSmithKline;
   University of Michigan System; University of Michigan
RP Danis, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 8010 Excelsior Dr, Madison, WI 53717 USA.
EM rpdanis@wisc.edu
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251; Ciulla,
   Thomas/0000-0001-5557-6777; Johnson, Mark W/0000-0001-9720-8761; Xu,
   Chun-Fang/0000-0002-8747-0683
FU GlaxoSmithKline
FX These studies were sponsored and funded by GlaxoSmithKline.
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Food and Drug Administration, FDA LAB INF
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
NR 25
TC 20
Z9 22
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2014
VL 98
IS 2
BP 172
EP 178
DI 10.1136/bjophthalmol-2013-303117
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 294TF
UT WOS:000330069300008
PM 24227801
DA 2022-11-30
ER

PT J
AU Senabouth, A
   Daniszewski, M
   Lidgerwood, GE
   Liang, HH
   Hernandez, D
   Mirzaei, M
   Keenan, SN
   Zhang, R
   Han, XK
   Neavin, D
   Rooney, L
   Sanchez, MIGL
   Gulluyan, L
   Paulo, JA
   Clarke, L
   Kearns, LS
   Gnanasambandapillai, V
   Chan, CL
   Nguyen, U
   Steinmann, AM
   McCloy, RA
   Farbehi, N
   Gupta, VK
   Mackey, DA
   Bylsma, G
   Verma, N
   MacGregor, S
   Watt, MJ
   Guymer, RH
   Powell, JE
   Hewitt, AW
   Pebay, A
AF Senabouth, Anne
   Daniszewski, Maciej
   Lidgerwood, Grace E.
   Liang, Helena H.
   Hernandez, Damian
   Mirzaei, Mehdi
   Keenan, Stacey N.
   Zhang, Ran
   Han, Xikun
   Neavin, Drew
   Rooney, Louise
   Sanchez, Maria Isabel G. Lopez
   Gulluyan, Lerna
   Paulo, Joao A.
   Clarke, Linda
   Kearns, Lisa S.
   Gnanasambandapillai, Vikkitharan
   Chan, Chia-Ling
   Nguyen, Uyen
   Steinmann, Angela M.
   McCloy, Rachael A.
   Farbehi, Nona
   Gupta, Vivek K.
   Mackey, David A.
   Bylsma, Guy
   Verma, Nitin
   MacGregor, Stuart
   Watt, Matthew J.
   Guymer, Robyn H.
   Powell, Joseph E.
   Hewitt, Alex W.
   Pebay, Alice
TI Transcriptomic and proteomic retinal pigment epithelium signatures of
   age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PLURIPOTENT STEM-CELLS; GEOGRAPHIC ATROPHY;
   LIPID-PEROXIDATION; RETINITIS-PIGMENTOSA; DISEASE MECHANISMS;
   SUSCEPTIBILITY; EXPRESSION; RANIBIZUMAB; GENOTYPE
AB Age-related macular degeneration (AMD) is a leading cause of vision loss, and there is no approved treatment for AMD with geographic atrophy. Here, the authors used transcriptomic and proteomic analyses of patient induced pluripotent stem cell-derived retinal pigment epithelium to better understand disease mechanisms.
   There are currently no treatments for geographic atrophy, the advanced form of age-related macular degeneration. Hence, innovative studies are needed to model this condition and prevent or delay its progression. Induced pluripotent stem cells generated from patients with geographic atrophy and healthy individuals were differentiated to retinal pigment epithelium. Integrating transcriptional profiles of 127,659 retinal pigment epithelium cells generated from 43 individuals with geographic atrophy and 36 controls with genotype data, we identify 445 expression quantitative trait loci in cis that are asssociated with disease status and specific to retinal pigment epithelium subpopulations. Transcriptomics and proteomics approaches identify molecular pathways significantly upregulated in geographic atrophy, including in mitochondrial functions, metabolic pathways and extracellular cellular matrix reorganization. Five significant protein quantitative trait loci that regulate protein expression in the retinal pigment epithelium and in geographic atrophy are identified - two of which share variants with cis- expression quantitative trait loci, including proteins involved in mitochondrial biology and neurodegeneration. Investigation of mitochondrial metabolism confirms mitochondrial dysfunction as a core constitutive difference of the retinal pigment epithelium from patients with geographic atrophy. This study uncovers important differences in retinal pigment epithelium homeostasis associated with geographic atrophy.
C1 [Senabouth, Anne; Zhang, Ran; Neavin, Drew; Gnanasambandapillai, Vikkitharan; Chan, Chia-Ling; Nguyen, Uyen; Steinmann, Angela M.; McCloy, Rachael A.; Farbehi, Nona; Powell, Joseph E.] Garvan Weizmann Ctr Cellular Genom, Garvan Inst Med Res, Sydney, NSW 2010, Australia.
   [Daniszewski, Maciej; Lidgerwood, Grace E.; Hernandez, Damian; Keenan, Stacey N.; Rooney, Louise; Gulluyan, Lerna; Watt, Matthew J.; Pebay, Alice] Univ Melbourne, Dept Anat & Physiol, Parkville, Vic 3010, Australia.
   [Daniszewski, Maciej; Lidgerwood, Grace E.; Liang, Helena H.; Hernandez, Damian; Sanchez, Maria Isabel G. Lopez; Clarke, Linda; Kearns, Lisa S.; Guymer, Robyn H.; Hewitt, Alex W.; Pebay, Alice] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Mirzaei, Mehdi; Gupta, Vivek K.] Macquarie Univ, Macquarie Med Sch, Fac Med Hlth & Human Sci, Sydney, NSW 2109, Australia.
   [Han, Xikun; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Brisbane, Qld 4006, Australia.
   [Paulo, Joao A.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.
   [Mackey, David A.; Bylsma, Guy] Univ Western Australia, Ctr Vis Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Mackey, David A.; Verma, Nitin; Hewitt, Alex W.] Univ Tasmania, Sch Med, Hobart, Tas 7005, Australia.
   [Guymer, Robyn H.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg, Ophthalmol, East Melbourne, Vic 3002, Australia.
   [Powell, Joseph E.] Univ New South Wales, UNSW Cellular Genom Futures Inst, Sydney, NSW 2052, Australia.
   [Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7000, Australia.
   [Pebay, Alice] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3010, Australia.
C3 Garvan Institute of Medical Research; University of Melbourne; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   Macquarie University; QIMR Berghofer Medical Research Institute; Harvard
   University; Harvard Medical School; Lions Eye Institute; University of
   Western Australia; University of Tasmania; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of New South Wales Sydney;
   University of Tasmania; Menzies Institute for Medical Research; Royal
   Melbourne Hospital; University of Melbourne
RP Powell, JE (通讯作者)，Garvan Weizmann Ctr Cellular Genom, Garvan Inst Med Res, Sydney, NSW 2010, Australia.; Pebay, A (通讯作者)，Univ Melbourne, Dept Anat & Physiol, Parkville, Vic 3010, Australia.; Hewitt, AW; Pebay, A (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.; Hewitt, AW (通讯作者)，Univ Tasmania, Sch Med, Hobart, Tas 7005, Australia.; Hewitt, AW (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg, Ophthalmol, East Melbourne, Vic 3002, Australia.; Powell, JE (通讯作者)，Univ New South Wales, UNSW Cellular Genom Futures Inst, Sydney, NSW 2052, Australia.; Hewitt, AW (通讯作者)，Univ Tasmania, Menzies Inst Med Res, Hobart, Tas 7000, Australia.; Pebay, A (通讯作者)，Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3010, Australia.
EM j.powell@garvan.org.au; hewitt.alex@gmail.com; apebay@unimelb.edu.au
RI Farbehi, Nona/HCH-9718-2022; Hernandez, Damian/GSI-5679-2022;
   Lidgerwood, Grace/AAS-7439-2020; Gupta, Vivek Kumar/AAB-8940-2022;
   Mackey AO, David/H-5340-2014
OI Lidgerwood, Grace/0000-0002-1774-5944; Senabouth,
   Anne/0000-0002-8798-9821; Neavin, Drew/0000-0002-1783-6491; Hernandez de
   Santiago, Hector Damian/0000-0001-8990-6607; Liang,
   Helena/0000-0002-4270-8707; Mirzaei, Mehdi/0000-0001-8727-4984; Gupta,
   Vivek/0000-0002-0202-7843; Mackey AO, David/0000-0001-7914-4709
FU National Health and Medical Research Council (NHMRC) [1154389, 1154543,
   1175781]; Macular Disease Foundation Australia; NHMRC [1059369,
   1181010]; DHB Foundation; Australian Vision Research; Medical Research
   Future Fund-Stem Cell Therapies Mission [MRF1200678]; NIH/NIGMS
   [GM132129]; University of Melbourne; retina Australia
FX We thank all participants who donated skin biopsies. This research was
   supported by National Health and Medical Research Council (NHMRC)
   Practitioner Fellowship (A.W.H.), Senior Research Fellowship (A.P.,
   1154389; S.M., 1154543), and Investigator grant (J.E.P., 1175781), by
   research grants from the Macular Disease Foundation Australia (R.H.G.,
   A.W.H., J.E.P., and A.P.), the NHMRC (research grant 1059369, R.H.G.,
   A.P., synergy grant 1181010, R.H.G. and A.P.), the DHB Foundation
   (G.E.L. and A.P.), retina Australia (A.W.H. and A.P.), Australian Vision
   Research (G.E.L., A.W.H., and A.P.), the Medical Research Future
   Fund-Stem Cell Therapies Mission (G.E.L., A.W.H., and A.P., MRF1200678),
   NIH/NIGMS grant R01 (J.A.P., GM132129), the University of Melbourne and
   Operational Infrastructure Support from the Victorian Government.
CR Alquicira-Hernandez J, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1862-5
   Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Battle A, 2015, SCIENCE, V347, P664, DOI 10.1126/science.1260793
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chekuri A, 2019, AGING CELL, V18, DOI 10.1111/acel.13011
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crombie DE, 2017, SLAS DISCOV, V22, P1016, DOI 10.1177/2472555217696797
   Cui WT, 2021, ANN HUM GENET, V85, P235, DOI 10.1111/ahg.12441
   Cunha SR, 2009, J CELL MOL MED, V13, P4364, DOI 10.1111/j.1582-4934.2009.00943.x
   Dalvi S, 2019, ADV EXP MED BIOL, V1186, P1, DOI 10.1007/978-3-030-28471-8_1
   Daniszewski M., 2022, CELL GENOMICS, V2, DOI [10.1016/j.xgen.2022.100142, DOI 10.1016/J.XGEN.2022.100142]
   Daniszewski M, 2018, ISCIENCE, V7, P30, DOI 10.1016/j.isci.2018.08.016
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   Delaneau O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15452
   Dhirachaikulpanich D, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00808
   Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Edwards SL, 2013, AM J HUM GENET, V93, P779, DOI 10.1016/j.ajhg.2013.10.012
   Fernandez MR, 2007, CELL MOL LIFE SCI, V64, P1419, DOI 10.1007/s00018-007-7091-1
   Ferreira MAR, 2008, NAT GENET, V40, P1056, DOI 10.1038/ng.209
   Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   de Jorge EG, 2018, MOL IMMUNOL, V102, P42, DOI 10.1016/j.molimm.2018.06.011
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   He B, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00830-3
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Heaton H, 2020, NAT METHODS, V17, P615, DOI 10.1038/s41592-020-0820-1
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Henry A, 2018, INVEST OPHTH VIS SCI, V59, P2679, DOI 10.1167/iovs.18-24021
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38
   Hunter AA, 2016, CURR EYE RES, V41, P410, DOI 10.3109/02713683.2015.1016179
   Jiang LH, 2020, CELL, V183, P269, DOI 10.1016/j.cell.2020.08.036
   Jiang SB, 2020, J BUON, V25, P2078
   Jorgenson E, 2016, EUR J HUM GENET, V24, P1049, DOI 10.1038/ejhg.2015.247
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kang HM, 2018, NAT BIOTECHNOL, V36, P89, DOI 10.1038/nbt.4042
   Kellner U, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042089
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolodziejczyk AA, 2015, CELL STEM CELL, V17, P471, DOI 10.1016/j.stem.2015.09.011
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Lidgerwood GE, 2021, GENOM PROTEOM BIOINF, V19, P223, DOI 10.1016/j.gpb.2020.08.002
   Lidgerwood GE, 2018, BBA-MOL CELL BIOL L, V1863, P750, DOI 10.1016/j.bbalip.2018.04.007
   Lidgerwood GE, 2016, STEM CELL REV REP, V12, P179, DOI 10.1007/s12015-015-9636-2
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Maiti P, 2020, NUCLEIC ACIDS RES, V48, P7924, DOI 10.1093/nar/gkaa592
   Manian KV, 2021, CELL STEM CELL, V28, P846, DOI 10.1016/j.stem.2021.02.006
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   Minton K, 2018, NAT REV IMMUNOL, V18, DOI 10.1038/nri.2017.154
   Mirauta BA, 2020, ELIFE, V9, DOI 10.7554/eLife.57390
   Nagano H, 2018, P NATL ACAD SCI USA, V115, P8370, DOI 10.1073/pnas.1804243115
   Navarrete-Perea J, 2018, J PROTEOME RES, V17, P2226, DOI 10.1021/acs.jproteome.8b00217
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Petrus-Reurer S, 2022, STEM CELL REP, V17, P1458, DOI 10.1016/j.stemcr.2022.05.005
   Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039
   Porte S, 2011, CELL MOL LIFE SCI, V68, P1065, DOI 10.1007/s00018-010-0508-2
   Qi QB, 2012, HUM MOL GENET, V21, P4774, DOI 10.1093/hmg/dds300
   Rathkey JK, 2020, J BIOL CHEM, V295, P3228, DOI 10.1074/jbc.RA119.010604
   Ratnapriya R, 2019, NAT GENET, V51, P1067, DOI 10.1038/s41588-019-0430-y
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Raviv S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004360
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Savitski MM, 2015, MOL CELL PROTEOMICS, V14, P2394, DOI 10.1074/mcp.M114.046995
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schondorf DC, 2018, CELL REP, V23, P2979, DOI 10.1016/j.celrep.2018.05.009
   Schriml LM, 2019, NUCLEIC ACIDS RES, V47, pD955, DOI 10.1093/nar/gky1032
   Schriml LM, 2012, NUCLEIC ACIDS RES, V40, pD940, DOI 10.1093/nar/gkr972
   Shaibani A, 2015, INT J NEUROSCI, V125, P43, DOI 10.3109/00207454.2014.904858
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Smedley D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-22
   Stanton CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11898-3
   Stevelink R, 2019, MOL GENET METAB REP, V21, DOI 10.1016/j.ymgmr.2019.100518
   Strunz T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008934
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Sun L, 2015, INT J CLIN EXP MED, V8, P1677
   Sun W, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0065-4
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tiwari A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28755
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Volpato V, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.042317
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang T, 2019, MITOCHONDRION, V47, P114, DOI 10.1016/j.mito.2019.05.007
   Wei L, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000375
   Wills QF, 2013, NAT BIOTECHNOL, V31, P748, DOI 10.1038/nbt.2642
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Wolock SL, 2019, CELL SYST, V8, P281, DOI 10.1016/j.cels.2018.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054037
   Yusuf IH, 2018, OPHTHALMIC GENET, V39, P263, DOI 10.1080/13816810.2017.1408848
   Zhao TT, 2021, AGING DIS, V12, P529, DOI 10.14336/AD.2020.0912
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 142
TC 0
Z9 0
U1 9
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 26
PY 2022
VL 13
IS 1
AR 4233
DI 10.1038/s41467-022-31707-4
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 3I3LS
UT WOS:000832623400009
PM 35882847
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, Peter K.
TI OVERVIEW OF RADIATION TRIALS FOR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macula;
   radiation
AB Radiotherapy is a promising adjunctive tool to antiangiogenesis therapies for control of the choroidal neovascularization that characterizes exudative (wet) age-related macular degeneration. Historically, radiation monotherapy sufficient to effectively eradicate choroidal neovascularization has been associated with mixed results; however, newer techniques and delivery platforms have been developed to improve efficacy. The most significant improvements are technical advances that improve the precision of energy delivery, so that tissue destruction remains confined to the target. In addition, several combination therapies are showing promise for enhanced effect. Other strategies, such as pretreating neovascular tissue to increase its sensitivity to radiation, thereby reducing the energy dose, may also be viable. However, even though the modern delivery systems permit relatively low dosages, there are risks of radiotherapy to ocular tissue, and its role remains speculative, pending results of ongoing trials. RETINA 29:S34-S35, 2009
C1 Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Sivagnanavel V, 2004, COCHRANE DB SYST REV, V4
   2007, HAW EYE M JAN
NR 2
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S34
EP S35
DI 10.1097/IAE.0b013e3181ad242f
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700013
PM 19553797
DA 2022-11-30
ER

PT J
AU Klein, RJ
   Zeiss, C
   Chew, EY
   Tsai, JY
   Sackler, RS
   Haynes, C
   Henning, AK
   SanGiovanni, JP
   Mane, SM
   Mayne, ST
   Bracken, MB
   Ferris, FL
   Ott, J
   Barnstable, C
   Hoh, J
AF Klein, RJ
   Zeiss, C
   Chew, EY
   Tsai, JY
   Sackler, RS
   Haynes, C
   Henning, AK
   SanGiovanni, JP
   Mane, SM
   Mayne, ST
   Bracken, MB
   Ferris, FL
   Ott, J
   Barnstable, C
   Hoh, J
TI Complement factor H polymorphism in age-related macular degeneration
SO SCIENCE
LA English
DT Article
ID GENOMEWIDE-SCAN; SUSCEPTIBILITY LOCI; EXTENDED FAMILIES; DISEASE;
   DRUSEN; ASSOCIATIONS; ACTIVATION; REGIONS; PROJECT; PROTEIN
AB Age-related macular degeneration (AMD) is a major cause of blindness in the elderly. We report a genome-wide screen of 96 cases and 50 controls for polymorphisms associated with AMD. Among 116,204 single-nucleotide polymorphisms genotyped, an intronic and common variant in the complement factor H gene (CFH) is strongly associated with AMD (nominal P value <10(-7)). in individuals homozygous for the risk allele, the likelihood of AMD is increased by a factor of 7.4 (95% confidence interval 2.9 to 19). Resequencing revealed a polymorphism in linkage disequilibrium with the Ask allele representing a tyrosine-histidine change at amino acid 402. This polymorphism is in a region of CFH that binds heparin and C-reactive protein. The CFH gene is located on chromosome 1 in a region repeatedly linked to AMD in family-based studies.
C1 Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.
   NEI, Bethesda, MD 20892 USA.
   EMMES Corp, Rockville, MD 20850 USA.
   Yale Univ, WM Keck Facil, New Haven, CT 06511 USA.
C3 Yale University; Rockefeller University; Yale University; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Emmes Corporation; Yale University
RP Hoh, J (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
RI Barnstable, Colin/GLU-9219-2022; SanGiovanni, John Paul/AAU-3895-2020;
   SanGiovanni, John Paul/A-7605-2008; Barnstable, Colin/ABB-4822-2021;
   Klein, Robert/K-1888-2013; Mohammed, Imran/J-8271-2012
OI Klein, Robert/0000-0003-3539-5391; Mohammed, Imran/0000-0002-8412-0768;
   Barnstable, Colin/0000-0002-7011-4068; SanGiovanni, John
   Paul/0000-0001-7199-7053; Ferris, Frederick/0000-0002-4933-0639
FU NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR016090] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [Z01EY000394, R01EY015771] Funding
   Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE
   [K25HG000060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTH [R01MH044292] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Devlin B, 2004, NAT GENET, V36, P1129, DOI 10.1038/ng1104-1129
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   McIntyre LM, 2000, GENET EPIDEMIOL, V19, P18, DOI 10.1002/1098-2272(200007)19:1<18::AID-GEPI2>3.0.CO;2-Y
   McKay GJ, 2004, MOL VIS, V10, P682
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   TEMPLETON AR, 1987, GENETICS, V117, P343
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wistow G, 2002, MOL VIS, V8, P205
NR 30
TC 3151
Z9 3463
U1 5
U2 341
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 15
PY 2005
VL 308
IS 5720
BP 385
EP 389
DI 10.1126/science.1109557
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 917TL
UT WOS:000228492000044
PM 15761122
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chuang, JZ
   Yang, N
   Nakajima, N
   Otsu, W
   Fu, C
   Yang, HH
   Lee, MP
   Akbar, AF
   Badea, TC
   Guo, ZQ
   Nuruzzaman, A
   Hsu, KS
   Dunaief, JL
   Sung, CH
AF Chuang, Jen-Zen
   Yang, Nan
   Nakajima, Nobuyuki
   Otsu, Wataru
   Fu, Cheng
   Yang, Howard Hua
   Lee, Maxwell Ping
   Akbar, Armaan Fazal
   Badea, Tudor Constantin
   Guo, Ziqi
   Nuruzzaman, Afnan
   Hsu, Kuo-Shun
   Dunaief, Joshua L.
   Sung, Ching-Hwa
TI Retinal pigment epithelium-specific CLIC4 mutant is a mouse model of dry
   age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INTRACELLULAR CHANNEL 4; NUCLEAR TRANSLOCATION; MOLECULAR-MECHANISMS;
   DARK-ADAPTATION; KNOCKOUT MICE; MEMBRANE; CELLS; ACCUMULATION;
   INFLAMMATION; CHOLESTEROL
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. Dry AMD has unclear etiology and no treatment. Lipid-rich drusen are the hallmark of dry AMD. An AMD mouse model and insights into drusenogenesis are keys to better understanding of this disease. Chloride intracellular channel 4 (CLIC4) is a pleomorphic protein regulating diverse biological functions. Here we show that retinal pigment epithelium (RPE)-specific Clic4 knockout mice exhibit a full spectrum of functional and pathological hallmarks of dry AMD. Multidisciplinary longitudinal studies of disease progression in these mice support a mechanistic model that links RPE cell-autonomous aberrant lipid metabolism and transport to drusen formation.
   Age-related macular degeneration (AMD) is a leading cause of blindness and is characterised by the accumulation of lipid deposits, called drusen. Here, the authors show that mice lacking chloride intracellular channel 4 in retinal pigment epithelium have defective lipid processing in the eye and pathological features mirroring human AMD, including drusen formation.
C1 [Chuang, Jen-Zen; Yang, Nan; Nakajima, Nobuyuki; Otsu, Wataru; Fu, Cheng; Guo, Ziqi; Nuruzzaman, Afnan; Hsu, Kuo-Shun; Sung, Ching-Hwa] Weill Cornell Med, Dept Ophthalmol, Margaret M Dyson Vis Res Inst, 1300 York Ave, New York, NY 10065 USA.
   [Yang, Howard Hua; Lee, Maxwell Ping] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Akbar, Armaan Fazal; Badea, Tudor Constantin] NEI, NIH, Bethesda, MD 20892 USA.
   [Badea, Tudor Constantin] Transilvania Univ Brasov, Sch Med, Res & Dev Inst, Brasov, Romania.
   [Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Dept Ophthalmol,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Sung, Ching-Hwa] Weill Cornell Med, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10065 USA.
   [Nakajima, Nobuyuki] Tokai Univ, Dept Urol, Hiratsuka, Kanagawa, Japan.
   [Otsu, Wataru] Gifu Pharmaceut Univ, Dept Biomed Res Lab, Gifu, Japan.
   [Hsu, Kuo-Shun] Sloan Kettering Canc Inst, New York, NY USA.
C3 Cornell University; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Transylvania University of
   Brasov; University of Pennsylvania; Pennsylvania Medicine; Cornell
   University; Tokai University; Gifu Pharmaceutical University; Memorial
   Sloan Kettering Cancer Center
RP Chuang, JZ; Sung, CH (通讯作者)，Weill Cornell Med, Dept Ophthalmol, Margaret M Dyson Vis Res Inst, 1300 York Ave, New York, NY 10065 USA.; Sung, CH (通讯作者)，Weill Cornell Med, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10065 USA.
EM jzchuang@med.cornell.edu; chsung@med.cornell.edu
RI Yang, Nan/AAQ-4510-2021; Badea, Tudor Constantin/B-1654-2018
OI Yang, Nan/0000-0002-6052-5728; Badea, Tudor
   Constantin/0000-0003-3086-6713; Akbar, Armaan/0000-0002-4255-9019;
   Nakajima, Nobuyuki/0000-0001-6307-032X; Otsu,
   Wataru/0000-0002-5930-1954; Chuang, Jen-Zen/0000-0001-7056-8871
FU NIH [RO1 EY 032966, EY 029428, RR0293T00]; RPB; Stein Innovation Award
   from Research To Prevent Blindness (RPB); Alcon Research Award; Research
   to Prevent Blindness [EY015240, EY028916]; Paul and Evanina Bell Mackall
   Foundation Trust; Intramural Research Program of the NIH; National
   Cancer Institute; Intramural Research Funds from the N.E.I; Simons
   Foundation [SF349247]; NYSTAR; NIH National Institute of General Medical
   Sciences [GM103310]
FX We thank Drs. Nancy J Philp providing MCT3 antibody, Ashleigh Raczkowski
   performing FIB-SEM imaging, Christine Curcio for advice on lipid
   histological staining, as well as Kiyoharu Miyagishima, Wei Li, and
   Haohua Qian for advice on DC-ERG assays. We apologized for citing review
   articles in some places instead of original research papers due to the
   limits of referencing by the journal. Grants from NIH RO1 EY 032966, EY
   029428, and RPB support this work. C.-H.S. is a recipient of the Stein
   Innovation Award from Research To Prevent Blindness (RPB), and an Alcon
   Research Award. J.L.D. is supported by EY015240, EY028916, an
   unrestricted Research to Prevent Blindness grant and the Paul and
   Evanina Bell Mackall Foundation Trust. M.P.L. and H.H.Y. are supported
   by the Intramural Research Program of the NIH and the National Cancer
   Institute. A.F.A. and T.C.B. are supported through Intramural Research
   Funds from the N.E.I. to T.C.B. FIB-SEM was performed at the Simons
   Electron Microscopy Center and National Resource for Automated Molecular
   Microscopy located at the New York Structural Biology Center, supported
   by grants from the Simons Foundation (SF349247), NYSTAR, and the NIH
   National Institute of General Medical Sciences (GM103310) with
   additional support from the NIH (RR0293T00).
CR Argenzio E, 2014, J CELL SCI, V127, P5189, DOI 10.1242/jcs.150623
   Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chou SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10412
   Chuang Jen-Zen, 2015, Cilia, V4, P4, DOI 10.1186/s13630-015-0013-1
   Chuang JZ, 2010, MOL BIOL CELL, V21, P3017, DOI 10.1091/mbc.E09-10-0907
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   FOWLER SD, 1985, J HISTOCHEM CYTOCHEM, V33, P833, DOI 10.1177/33.8.4020099
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   He GA, 2011, EUR J IMMUNOL, V41, P1221, DOI 10.1002/eji.201041266
   Hsu KS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48438-0
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Kagiali ZCU, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900558
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kolesnikov AV, 2017, P NATL ACAD SCI USA, V114, pE9675, DOI 10.1073/pnas.1712405114
   Kolesnikov AV, 2010, J NEUROSCI, V30, P11222, DOI 10.1523/JNEUROSCI.4239-09.2010
   Kretschmer F, 2017, J NEUROPHYSIOL, V118, P300, DOI 10.1152/jn.00055.2017
   Kretschmer F, 2015, J NEUROSCI METH, V256, P91, DOI 10.1016/j.jneumeth.2015.08.007
   Kretschmer F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078058
   Li CB, 2001, OPTOMETRY VISION SCI, V78, P425, DOI 10.1097/00006324-200106000-00015
   Li MZ, 2019, PSYCHIAT RES, V276, P79, DOI 10.1016/j.psychres.2019.04.017
   Littler DR, 2005, FEBS J, V272, P4996, DOI 10.1111/j.1742-4658.2005.04909.x
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mahamid J, 2019, P NATL ACAD SCI USA, V116, P16866, DOI 10.1073/pnas.1903642116
   Malik M, 2012, P NATL ACAD SCI USA, V109, P6130, DOI 10.1073/pnas.1201351109
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200
   Miyagishima KJ, 2020, JOVE-J VIS EXP, DOI 10.3791/61491
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Oorni K, 2000, J LIPID RES, V41, P1703
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Ponsioen B, 2009, MOL BIOL CELL, V20, P4664, DOI 10.1091/mbc.E09-06-0529
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Ruivo R, 2009, BBA-MOL CELL RES, V1793, P636, DOI 10.1016/j.bbamcr.2008.12.008
   Saddala MS, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0199-1
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Shukla A, 2010, NUCLEUS-PHILA, V1, P144
   Shukla A, 2009, NAT CELL BIOL, V11, P777, DOI 10.1038/ncb1885
   Singh H, 2007, MOL MEMBR BIOL, V24, P41, DOI 10.1080/09687860600927907
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thelen AM, 2017, TRENDS CELL BIOL, V27, P843, DOI 10.1016/j.tcb.2017.07.006
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   Tsuiki E, 2007, INVEST OPHTH VIS SCI, V48, P2858, DOI 10.1167/iovs.06-0768
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff ML, 2004, J PHYSIOL-LONDON, V557, P821, DOI 10.1113/jphysiol.2004.064014
   Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), 2017, Ophthalmology, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Yamauchi Y, 2016, J LIPID RES, V57, P77, DOI 10.1194/jlr.M063784
NR 81
TC 1
Z9 1
U1 4
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 18
PY 2022
VL 13
IS 1
AR 374
DI 10.1038/s41467-021-27935-9
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YI8WE
UT WOS:000744122300018
PM 35042858
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lains, I
   Miller, JB
   Mukai, R
   Mach, S
   Vavvas, D
   Kim, IK
   Miller, JW
   Husain, D
AF Lains, Ines
   Miller, John B.
   Mukai, Ryo
   Mach, Steven
   Vavvas, Demetrios
   Kim, Ivana K.
   Miller, Joan W.
   Husain, Deeba
TI HEALTH CONDITIONS LINKED TO AGE-RELATED MACULAR DEGENERATION ASSOCIATED
   WITH DARK ADAPTATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE related macular degeneration; dark adaptation; medical history
ID VITAMIN-A; VISUAL FUNCTION; RETINOID CYCLE; OLDER-ADULTS; EYE DISEASE;
   MACULOPATHY; OBESITY; REPRODUCIBILITY; QUESTIONNAIRE; SENSITIVITY
AB Purpose: To determine the association between dark adaption (DA) and different health conditions linked with age-related macular degeneration (AMD).
   Methods: Cross-sectional study, including patients with AMD and a control group. Age-related macular degeneration was graded according to the Age-Related Eye Disease Study (AREDS) classification. We obtained data on medical history, medications, and lifestyle. Dark adaption was assessed with the extended protocol (20 minutes) of AdaptDx (MacuLogix). For analyses, the right eye or the eye with more advanced AMD was selected. Multivariate linear and logistic regressions were performed, accounting for age and AMD stage.
   Results: Seventy-eight subjects (75.6% AMD; 24.4% controls) were included. Multivariate assessments revealed that body mass index (BMI; beta = 0.30, P = 0.045), taking AREDS vitamins (beta = 5.51, P < 0.001), and family history of AMD (beta = 2.68, P = 0.039) were significantly associated with worse rod intercept times. Abnormal DA (rod intercept time >= 6.5 minutes) was significantly associated with family history of AMD (beta = 1.84, P = 0.006), taking AREDS supplements (beta = 1.67, P = 0.021) and alcohol intake (beta = 0.07, P = 0.017).
   Conclusion: Besides age and AMD stage, a higher body mass index, higher alcohol intake, and a family history of AMD seem to impair DA. In this cohort, the use of AREDS vitamins was also statistically linked with impaired DA, most likely because of an increased severity of disease in subjects taking them.
C1 [Lains, Ines; Miller, John B.; Mukai, Ryo; Mach, Steven; Vavvas, Demetrios; Kim, Ivana K.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Lains, Ines] Univ Coimbra, Dept Ophthalmol, Fac Med, Coimbra, Portugal.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra
RP Husain, D (通讯作者)，Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Vavvas, Demetrios/0000-0002-8622-6478; Kim, Ivana/0000-0003-0310-6129;
   Husain, Deeba/0000-0002-8494-0950
FU Portuguese Foundation for Science and Technology/Harvard Medical School
   Portugal Program [HMSP-ICJ/006/2013]; Miller Retina Research Found
   (Mass. Eye and Ear); Miller Champalimaud Award (Mass. Eye and Ear);
   Research to Prevent Blindness, Inc, New York; NATIONAL EYE INSTITUTE
   [R01EY030088, T32EY007145] Funding Source: NIH RePORTER
FX Supported by Miller Retina Research Found (Mass. Eye and Ear), Miller
   Champalimaud Award (Mass. Eye and Ear), unrestricted departmental Grant
   from Research to Prevent Blindness, Inc, New York, and Portuguese
   Foundation for Science and Technology/Harvard Medical School Portugal
   Program (HMSP-ICJ/006/2013).
CR ADAMS AJ, 1975, NATURE, V257, P481, DOI 10.1038/257481a0
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207
   Bavinger JC, 2016, INVEST OPHTH VIS SCI, V57, P208, DOI 10.1167/iovs.15-17281
   BLOMBERG LARS-H., 1959, ACTA OPHTHALMOL, V37, P274
   CAMPBELL TD, 1981, ALCOHOL CLIN EXP RES, V5, P34
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jeyakumar SM, 2015, INDIAN J MED RES, V141, P275, DOI 10.4103/0971-5916.156554
   Khan SA, 2007, J STUD ALCOHOL DRUGS, V68, P493, DOI 10.15288/jsad.2007.68.493
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pereira SE, 2012, OBES SURG, V22, P602, DOI 10.1007/s11695-011-0522-y
   Rothman KJ, 2008, INT J OBESITY, V32, pS56, DOI 10.1038/ijo.2008.87
   RUSSELL RM, 1978, ANN INTERN MED, V88, P622, DOI 10.7326/0003-4819-88-5-622
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Thompson DA, 2005, HUM MOL GENET, V14, P3865, DOI 10.1093/hmg/ddi411
   Topolski T. D., 2006, Preventing Chronic Disease, V3, pA118
   Trasino SE, 2015, SCI REP-UK, V5, DOI 10.1038/srep15893
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Vuksanovic M, 2014, J PUBLIC HEALTH-HEID, V22, P257, DOI 10.1007/s10389-014-0619-6
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 43
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2018
VL 38
IS 6
BP 1145
EP 1155
DI 10.1097/IAE.0000000000001659
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CC
UT WOS:000440627100013
PM 28452839
DA 2022-11-30
ER

PT J
AU Mukai, R
   Sato, T
   Kishi, S
AF Mukai, Ryo
   Sato, Taku
   Kishi, Shoji
TI REPAIR MECHANISM OF RETINAL PIGMENT EPITHELIAL TEARS IN AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; Bruch membrane; retinal pigment
   epithelial tears; spectral domain optical coherence tomography;
   subretinal fluid; swept-source optical coherence tomography
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   GROWTH-FACTOR THERAPY; GOOD VISUAL-ACUITY; CLINICOPATHOLOGICAL
   CORRELATION; PHOTODYNAMIC THERAPY; PRESERVATION; VERTEPORFIN; FOVEA
AB Purpose: To investigate repair mechanisms of retinal pigment epithelial (RPE) tears in age-related macular degeneration.
   Methods: The authors retrospectively studied 10 eyes with age-related macular degeneration that developed RPE tears during follow-up or after treatment with an antivascular endothelial growth factor drug or photodynamic therapy combined with ranibizumab. After development of the RPE tears, all follow-ups exceeded 13 months. Spectral domain or swept-source optical coherence tomography have been used to examine consecutive retinal changes where the RPE tears developed and attempted to determine the repair mechanisms.
   Results: Retinal pigment epithelial tears developed during the natural course (n = 4) after ranibizumab treatment (n = 2) and after photodynamic therapy and ranibizumab (n = 4). Subretinal fluid persisted for more than 6 months after the RPE tears developed (n = 4), with the area where the RPE was lost found to be covered with thickened proliferative tissue. In 6 eyes where the subretinal fluid was absorbed within 2 months, optical coherence tomography showed the outer retina appeared to be directly attached to Bruch membrane, and there was attenuation of the normal hyperreflective band attributable to normal RPE during follow-up.
   Conclusion: Results suggest that two repair processes may be present in the area where RPE tears developed. Persistent subretinal fluid may lead to repair with thick proliferative tissue, while the outer retina appears to attach to Bruch membrane when there is early subretinal fluid resolution after RPE tear development.
C1 [Mukai, Ryo; Sato, Taku; Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Mukai, R (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM ryohmukai@gmail.com
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Coscas G, 1990, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V67, P13
   Coscas G, 1990, REV INT TRACH PATHOL, V67, P17
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lee MY, 2011, RETINA-J RET VIT DIS, V31, P65, DOI 10.1097/IAE.0b013e3181e586e3
   MACHEMER R, 1991, ARCH OPHTHALMOL-CHIC, V109, P1492
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   NEGI A, 1984, OPHTHALMOLOGY, V91, P1678
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   West S, 2001, B WORLD HEALTH ORGAN, V79, P244
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 26
TC 23
Z9 23
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2015
VL 35
IS 3
BP 473
EP 480
DI 10.1097/IAE.0000000000000337
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4AO
UT WOS:000350293100026
PM 25207945
DA 2022-11-30
ER

PT J
AU Aberami, S
   Nikhalashree, S
   Bharathselvi, M
   Biswas, J
   Sulochana, KN
   Coral, K
AF Aberami, Seeneevasan
   Nikhalashree, Sampath
   Bharathselvi, Muthuvel
   Biswas, Jyotirmay
   Sulochana, Konerirajapuram Natarajan
   Coral, Karunakaran
TI Elemental concentrations in Choroid-RPE and retina of human eyes with
   age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Heavy metals; Elements; ICP-MS;
   Retina; Choroid-RPE
ID OXIDATIVE STRESS; HEALTH; CADMIUM; NICKEL; SYSTEM; LEAD
AB Heavy metals, metallic and toxic elements are reported to play an essential role in the complex multifactorial pathogenesis of age-related macular degeneration (AMD). This study was aimed to measure the concentrations of these elements in choroid-RPE and retina of human donor eyes with and without age-related macular degeneration associated changes. Human cadaver donor eyeballs were obtained from the CU Shah eye bank, Sankara Nethralaya Eye Hospital, India, after removal of the cornea. 39 control and 51 AMD donor eyes were used in this study. Alabama grading was done on the histopathological sections to identify early and late age related macular degeneration changes. Concentrations of lead, cadmium, chromium, cobalt, nickel, arsenic and selenium were determined in choroid-RPE and retina using Inductively Coupled Plasma Mass Spectrometer (ICP-MS). Further, gene expression of oxidative stress-related genes, Nrf-2, HO-1, GCLC, GCLM, and detoxification related gene GSTpi was performed. The data were analyzed for statistical significance using Graph Pad (R) Prism 5 software. Donor eyes with early and late AMD had significantly higher levels of lead, cadmium, chromium, arsenic, and nickel in choroid-RPE and retina compared to the control eyes. Selenium was significantly increased in late AMD compared to control. No significant difference was observed in the levels of cobalt between eyes with and without AMD. Decreased transcript levels of oxidative stress-related genes were observed in the choroid-RPE and retinal tissues. Nrf-2 (p < 0.05), HO-1 and GCLC expressions were lowered in the retina of AMD, whereas GCLM and GSTpi expressions were decreased (p < 0.05) with an increase in HO-1 in choroid-RPE of AMD. This study provides evidence that alterations of the heavy metals and toxic elements along with oxidative stress may play a role in the pathogenesis of AMD.
C1 [Aberami, Seeneevasan; Nikhalashree, Sampath; Bharathselvi, Muthuvel; Sulochana, Konerirajapuram Natarajan; Coral, Karunakaran] Vis Res Fdn, RS Mehta Jain Dept Biochem & Cell Biol, Sankara Nethralaya, KBIRVO Block, Chennai, Tamil Nadu, India.
   [Biswas, Jyotirmay] Med Res Fdn, Sankara Nethralaya, Dept Ocular Pathol, Chennai, Tamil Nadu, India.
   [Nikhalashree, Sampath] SASTRA Deemed Be Univ, Sch Chem & Biotechnol, Thanjavur, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Coral, K (通讯作者)，Vis Res Fdn, RS Mehta Jain Dept Biochem & Cell Biol, Sankara Nethralaya, KBIRVO Block, Chennai, Tamil Nadu, India.
EM ceeyem08@gmail.com
RI Coral, Karunakaran/AAK-2880-2021
OI Biswas, Jyotirmay/0000-0003-1214-5429
FU Council of Scientific and Industrial Research, India
   [27(0264)/12/EMR-II]
FX Council of Scientific and Industrial Research, India -
   27(0264)/12/EMR-II.
CR Afridi H, 2011, BIOL TRACE ELEM RES, V142, P350, DOI 10.1007/s12011-010-8796-9
   [Anonymous], 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000254pub4, DOI 10.1002/14651858.CD000254PUB4]
   Apel W, 2013, DOC OPHTHALMOL, V126, P69, DOI 10.1007/s10633-012-9356-8
   Bhuvana N, 2014, IOSR J APPL CHEM, V7, P47
   Biswas Jyotirmay, 2002, Indian Journal of Ophthalmology, V50, P201
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   BUSH VJ, 1995, CLIN CHEM, V41, P284
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Copple IM, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8165458
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Das KK, 2008, INDIAN J MED RES, V128, P412
   Deshpande S., 2012, J MED NUTR NUTRACEUT, V1, p83 86, DOI [10.4103/2278-019X.101292, DOI 10.4103/2278-019X.101292]
   Dias IHK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066407
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Ghosh P, 2007, J EXPO SCI ENV EPID, V17, P215, DOI 10.1038/sj.jes.7500510
   Gungor ED, 2018, J TRACE ELEM MED BIO, V48, P16, DOI 10.1016/j.jtemb.2018.02.019
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kim MH, 2016, J EXPO SCI ENV EPID, V26, P214, DOI 10.1038/jes.2014.75
   Kleiman NJ, 2016, J TOXICOL ENV HEAL A, V79, P339, DOI 10.1080/15287394.2016.1151392
   Krishnakumar S., 2016, FRONT CUR TRENDS ENG, V1, P42
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mehra R, 2003, INDIAN J BIOCHEM BIO, V40, P131
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Rai NK, 2013, TOXICOL APPL PHARM, V273, P242, DOI 10.1016/j.taap.2013.05.003
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Siji Thomas, 2015, International Journal of Chemical Sciences, V13, P53
   Sridhar SGD, 2017, APPL WATER SCI, V7, P4651, DOI 10.1007/s13201-017-0628-z
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Takayama K, 2016, OXID MED CELL LONGEV, P1
   Velmurugan GV, 2013, CARDIOVASC RES, V100, P143, DOI 10.1093/cvr/cvt125
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Xie XB, 2017, MOL VIS, V23, P520
NR 38
TC 13
Z9 13
U1 0
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2019
VL 186
AR 107718
DI 10.1016/j.exer.2019.107718
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU6FY
UT WOS:000483683100014
PM 31271759
DA 2022-11-30
ER

PT J
AU Montesel, A
   Gigon, A
   Giacuzzo, C
   Mantel, I
   Eandi, CM
AF Montesel, Andrea
   Gigon, Anthony
   Giacuzzo, Clarice
   Mantel, Irmela
   Eandi, Chiara M.
TI TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN Functional and Anatomical
   Impact on Patients With Neovascular Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19; lockdown; retina; intravitreal injections;
   anti-VEGF; neovascular age-related macular degeneration
ID RANIBIZUMAB; THERAPY; REGIMEN
AB Purpose: To investigate the visual and anatomical impact of intravitreal injection treatment deferral because of the COVID-19 lockdown on patients affected by neovascular age-related macular degeneration. Methods: We retrospectively reviewed 314 patients (394 eyes) who were scheduled to receive the impact of intravitreal injections during the Swiss lockdown. We compared patients who continued to receive scheduled impact of intravitreal treatment without clinical consultation (Group Continue C"; n = 215) and patients for whom the impact of intravitreal treatment was completely deferred (Group Stop, S"; n = 179). Functional and anatomical parameters were collected at four time points before and after the lockdown. Results: In Group C, the visual acuity at baseline and after the lockdown did not differ significantly. In Group S, the visual acuity deteriorated significantly compared with baseline and then improved slightly after the resumption of treatment, but it did not recover to baseline values. The mean central subfield thickness remained stable in Group C, whereas it increased in Group S and then returned to prelockdown values after the resumption of treatment. Conclusion: An "injection-only" approach was effective in managing patients with neovascular age-related macular degeneration during the pandemic lockdown, whereas patients who deferred their scheduled treatment showed partially irreversible deterioration of visual function. We recommend treatment continuation in patients with neovascular age-related macular degeneration during a lockdown.
C1 [Montesel, Andrea; Gigon, Anthony; Giacuzzo, Clarice; Mantel, Irmela; Eandi, Chiara M.] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
   [Eandi, Chiara M.] Univ Torino, Dept Surg Sci, Turin, Italy.
C3 University of Lausanne; University of Turin
RP Eandi, CM (通讯作者)，Jules Gonin Eye Hosp, Ave France 15, CH-1002 Lausanne, Switzerland.
EM ceandi@gmail.com
CR Ashkenazy N, 2021, CLIN OPHTHALMOL, V15, P413, DOI 10.2147/OPTH.S296345
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Hoeferlin Cory, 2021, SN Compr Clin Med, V3, P3, DOI 10.1007/s42399-020-00633-1
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Laurent K, 2020, J FR OPHTALMOL, V43, P539
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Parke DW, 2020, JAMA OPHTHALMOL, V138, P599, DOI 10.1001/jamaophthalmol.2020.2004
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Romano F, 2020, OPHTHALMOL RETINA, V4, P1209, DOI 10.1016/j.oret.2020.06.027
   Safadi K, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000487
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Swiss Federal Council, ORD MEAS COMB COR CO
   Trivizki O, 2020, AM J OPHTHALMOL, V219, P222, DOI 10.1016/j.ajo.2020.06.028
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Xu D, 2020, CURR OPIN OPHTHALMOL, V31, P427, DOI 10.1097/ICU.0000000000000692
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
NR 29
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 634
EP 642
DI 10.1097/IAE.0000000000003369
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200007
PM 34907122
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, J
   Jiang, M
   Yuan, F
   Feng, KY
   Cai, YD
   Xu, X
   Chen, L
AF Zhang, Jian
   Jiang, Min
   Yuan, Fei
   Feng, Kai-Yan
   Cai, Yu-Dong
   Xu, Xun
   Chen, Lei
TI Identification of Age-Related Macular Degeneration Related Genes by
   Applying Shortest Path Algorithm in Protein-Protein Interaction Network
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID INFLAMMASOME ACTIVATION; RETINAL DEGENERATION; WNT/BETA-CATENIN; RISK;
   PREDICTION; HYPOTHESIS; INHIBITION; DRUSEN; CELLS; MODEL
AB This study attempted to find novel age-related macular degeneration (AMD) related genes based on 36 known AMD genes. The well-known shortest path algorithm, Dijkstra's algorithm, was applied to find the shortest path connecting each pair of known AMD related genes in protein-protein interaction (PPI) network. The genes occurring in any shortest path were considered as candidate AMD related genes. As a result, 125 novel AMD genes were predicted. The further analysis based on betweenness and permutation test indicates that there are 10 genes involved in the formation or development of AMD and may be the actual AMD related genes with high probability. We hope that this contribution would promote the study of age-related macular degeneration and discovery of novel effective treatments.
C1 [Zhang, Jian; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Jiang, Min; Yuan, Fei] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, State Key Lab Med Genom, Shanghai 200025, Peoples R China.
   [Jiang, Min; Yuan, Fei] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China.
   [Feng, Kai-Yan] Shenzhen Beishan Ind Zone, Beijing Genom Inst, Shenzhen 518083, Peoples R China.
   [Cai, Yu-Dong] Shanghai Univ, Inst Syst Biol, Shanghai 200444, Peoples R China.
   [Chen, Lei] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes
   for Biological Sciences, CAS; Beijing Genomics Institute (BGI); Shanghai
   University; Shanghai Maritime University
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Ophthalmol, Shanghai 200080, Peoples R China.
EM drxuxun@tom.com; chen_lei1@163.com
RI Chen, Lei/A-2275-2011
OI Chen, Lei/0000-0003-3068-1583; cai, yudong/0000-0001-5664-7979
FU National Science and Technology Major Projects of the Twelfth Five-Year
   Plan [2011ZX09302-007-02]; National Basic Research Program of China
   [2011CB510102, 2011CB510101]; National Natural Science Foundation of
   China [81273424, 81170862, 31371335, 61202021, 61373028]; Innovation
   Program of Shanghai Municipal Education Commission [12ZZ087, 12YZ120];
   Shanghai Educational Development Foundation [12CG55]; grant of "The
   First-class Discipline of Universities in Shanghai"
FX This paper is supported by the National Science and Technology Major
   Projects of the Twelfth Five-Year Plan (no. 2011ZX09302-007-02),
   National Basic Research Program of China (no. 2011CB510102 and no.
   2011CB510101), National Natural Science Foundation of China (no.
   81273424, no. 81170862, no. 31371335, no. 61202021, and no. 61373028),
   Innovation Program of Shanghai Municipal Education Commission (no.
   12ZZ087 and no. 12YZ120), Shanghai Educational Development Foundation
   (no. 12CG55), and grant of "The First-class Discipline of Universities
   in Shanghai".
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Antoniak Katarzyna, 2008, Klin Oczna, V110, P211
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Benjamini Y, 2001, ANN STAT, V29, P1165
   Braunger BM, 2013, NEUROBIOL DIS, V50, P1, DOI 10.1016/j.nbd.2012.09.008
   Bunescu R, 2005, ARTIF INTELL MED, V33, P139, DOI 10.1016/j.artmed.2004.07.016
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen L, 2014, BBA-PROTEINS PROTEOM, V1844, P207, DOI 10.1016/j.bbapap.2013.05.021
   Chen L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/485034
   Chen L, 2013, CURR BIOINFORM, V8, P200, DOI 10.2174/1574893611308020008
   Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035254
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Cheng JL, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-65
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Craven J. B. M., 2005, MARKOV NETWORKS DETE
   Davis J., 2006, P 23 INT C MACH LEAR, P233, DOI [10.1145/1143844.1143874, DOI 10.1145/1143844.1143874]
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong ZZ, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-34
   Dryja T. P., 1998, SCIENCE, V279
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gao P, 2012, PROTEIN PEPTIDE LETT, V19, P910, DOI 10.2174/092986612802084528
   Gao YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045944
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gormen T. H., 1990, INTRO ALGORITHMS
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017668
   Hu LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014556
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Jiang M, 2013, MOL BIOSYST, V9, P2720, DOI 10.1039/c3mb70089e
   Johnson DE, 2000, DRUG DISCOV TODAY, V5, P445, DOI 10.1016/S1359-6446(00)01559-2
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lambiase A, 2009, ANN I SUPER SANITA, V45, P439
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li BQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065207
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217
   Murakami Y., 2013, CELL DEATH DIFFERENT
   Niu B, 2006, PROTEIN PEPTIDE LETT, V13, P489, DOI 10.2174/092986606776819619
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Sanges D, 2013, CELL REP, V4, P271, DOI 10.1016/j.celrep.2013.06.015
   Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085
   Sarangarajan R, 2005, OPHTHALMIC RES, V37, P136, DOI 10.1159/000085533
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tong X., 2013, MACULAR DEGENERATION
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vuong L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067381
   Wan J, 2012, DEV CELL, V22, P334, DOI 10.1016/j.devcel.2011.11.020
   Wang A.L., 2009, PLOS ONE, V4
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162
   Yamanishi Y, 2010, BIOINFORMATICS, V26, pi246, DOI 10.1093/bioinformatics/btq176
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 69
TC 21
Z9 21
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 523415
DI 10.1155/2013/523415
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 280KG
UT WOS:000329027600001
PM 24455700
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Tateiwa, H
   Kuroiwa, S
   Gaun, S
   Arai, J
   Yoshimura, N
AF Tateiwa, H
   Kuroiwa, S
   Gaun, S
   Arai, J
   Yoshimura, N
TI Polypoidal choroidal vasculopathy with large vascular network
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; INDOCYANINE GREEN ANGIOGRAPHY; MACULAR
   DEGENERATION; BLACK-WOMEN
AB Purpose: To report characteristics of polypoidal choroidal vasculopathy (PCV) of large vascular networks that expand across the retinal vascular arcade. Methods: Among 60 consecutive eves diagnosed as having PCV by fluorescein and indocyanine green (ICG) angiography, 12 eyes (9 patients) showed large lesions. The clinical and angiographic features of these 12 eyes were studied retrospectively. Results: Cases of large PCV typically showed dilated network vessels, which spread radially, and multiple polypoidal dilations at the end of the network vessels. Most of the polypoidal dilations formed clusters resembling bunches of grapes and caused large serous and/or hemorrhagic pigment epithelial detachments (PEDs). Among the 12 eyes, 5 showed rapid expansion of the lesions and became large PCVs within 3-24 months. In these eyes, ICG angiography revealed mesh-like choroidal vessels beneath the retinal pigment epithelium. Conclusion: PCV with a large vascular network that expands across the vascular arcade is not uncommon. Some of these cases seems to have characteristics of choroidal neovascularization rather than choroidal vasculopathy. It is not easy to distinguish such cases from exudative age-related macular degeneration even though they showed typical findings of PCV on ICG angiography.
C1 Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
C3 Shinshu University
RP Yoshimura, N (通讯作者)，Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 14
TC 27
Z9 30
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2002
VL 240
IS 5
BP 354
EP 361
DI 10.1007/s00417-002-0459-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 564TQ
UT WOS:000176330000005
PM 12073058
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Johnson, M
   Huang, JD
   Rudolf, M
AF Curcio, Christine A.
   Johnson, Mark
   Huang, Jiahn-Dar
   Rudolf, Martin
TI Apolipoprotein B-containing lipoproteins in retinal aging and
   age-related macular degeneration
SO JOURNAL OF LIPID RESEARCH
LA English
DT Review
DE retinal pigment epithelium; Bruch's membrane; drusen; basal deposits;
   cholesterol; retinyl ester
ID TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; BASAL LINEAR
   DEPOSIT; HUMAN ATHEROSCLEROTIC LESIONS; ENDOTHELIAL GROWTH-FACTOR;
   PIGMENT EPITHELIAL-CELLS; BRUCHS MEMBRANE; UNESTERIFIED CHOLESTEROL;
   COMPLEMENT ACTIVATION; LIPID-ACCUMULATION
AB The largest risk factor for age-related macular degeneration (ARMD) is advanced age. With aging, there is a striking accumulation of neutral lipids in Bruch's membrane (BrM) of normal eye that continues through adulthood. This accumulation has the potential to significantly impact the physiology of the retinal pigment epithelium (RPE). It also ultimately leads to the creation of a lipid wall at the same locations where drusen and basal linear deposit, the pathognomonic extracellular, lipid-containing lesions of ARMD, subsequently form. Here, we summarize evidence obtained from light microscopy, ultrastructural studies, lipid histochemistry, assay of isolated lipoproteins, and gene expression analysis. These studies suggest that lipid deposition in BrM is at least partially due to accumulation of esterified cholesterol-rich, apolipoprotein B-containing lipoprotein particles produced by the RPE. Furthermore, we suggest that the formation of ARMD lesions and their aftermath may be a pathological response to the retention of a subendothelial apolipoprotein B lipoprotein, similar to a widely accepted model of atherosclerotic coronary artery disease (Tabas, I., K.J. Williams, and J. Boren. 2007. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116: 1832-1844). This view provides a conceptual basis for the development of novel treatments that may benefit ARMD patients in the future.-Curcio, C. A., M. Johnson, J-D. Huang, and M. Rudolf. Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J. Lipid Res. 2010. 51: 451-467.
C1 [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Johnson, Mark] Northwestern Univ, Dept Biomed Engn, Evanston, IL USA.
   [Huang, Jiahn-Dar] NEI, NIH, Bethesda, MD 20892 USA.
   [Rudolf, Martin] Lubeck Univ Klinikum Schleswig Holstein, Lubeck, Germany.
C3 University of Alabama System; University of Alabama Birmingham;
   Northwestern University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
EM curcio@uab.edu
RI Johnson, Mark/B-6921-2009
FU National Institutes of Health [EY06109, EY014662]; International Retinal
   Research Foundation; American Health Assistance Foundation; EyeSight
   Foundation of Alabama; Research to Prevent Blindness, Inc.; Macula
   Vision Research Foundation; Roger Johnson Prize in Macular Degeneration
   Research; Deutsche Forschungsgemeinschaft; NATIONAL EYE INSTITUTE
   [R01EY006109, R01EY014662] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health grants
   EY06109 and EY014662, the International Retinal Research Foundation, the
   American Health Assistance Foundation, the EyeSight Foundation of
   Alabama, Research to Prevent Blindness, Inc., the Macula Vision Research
   Foundation, the Roger Johnson Prize in Macular Degeneration Research,
   and Deutsche Forschungsgemeinschaft. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health.
CR Adiels M, 2008, ARTERIOSCL THROM VAS, V28, P1225, DOI 10.1161/ATVBAHA.107.160192
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   BOCAN TMA, 1986, AM J PATHOL, V123, P413
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   BROEKHUYSE RM, 1972, BIOCHIM BIOPHYS ACTA, V280, P637, DOI 10.1016/0005-2760(72)90143-9
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   Burtis C. A., 1999, TIETZ TXB CLIN CHEM
   Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   CHAO FF, 1990, AM J PATHOL, V136, P169
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FIJALKOWSKI N, 2009, INVEST OPHTH VIS SCI, V50, pE774
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FRANK JS, 1989, J LIPID RES, V30, P967
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gaynor PM, 1996, J LIPID RES, V37, P1849
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez-Fernandez F, 2008, EXP EYE RES, V86, P169, DOI 10.1016/j.exer.2006.09.003
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GORIN MB, 1994, OPHTHALMIC GENET, V15, P151, DOI 10.3109/13816819409057843
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   GUYTON JR, 1993, AM J PATHOL, V143, P1444
   GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hacquebard M, 2005, CURR OPIN CLIN NUTR, V8, P133, DOI 10.1097/00075197-200503000-00005
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Handa James T., 2007, International Ophthalmology Clinics, V47, P15, DOI 10.1097/IIO.0b013e31802bd546
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HAVEL RJ, 2001, METABOLIC MOL BASIS, P2707
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HUANG JD, 2008, INVEST OPHTH VIS SCI, V49, pE1752
   HUANG JD, 2007, INVEST OPHTHALMOL VI
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Iglesias A, 1996, CLIN CHIM ACTA, V248, P157, DOI 10.1016/0009-8981(95)06251-3
   Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jonas A., 2002, BIOCH LIPIDS LIPOPRO, P483
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C
   KRUTH HS, 1984, AM J PATHOL, V114, P201
   KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8
   Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lusis AJ, 2004, CIRCULATION, V110, P1868, DOI 10.1161/01.CIR.0000143041.58692.CC
   Madsen EM, 2004, J BIOL CHEM, V279, P55271, DOI 10.1074/jbc.M411404200
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   MESSINGER JD, 2009, INVEST OPHTHALMOL VI
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oksjoki R, 2007, FRONT BIOSCI-LANDMRK, V12, P4696, DOI 10.2741/2419
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520
   Pentikainen MO, 2000, J INTERN MED, V247, P359, DOI 10.1046/j.1365-2796.2000.00655.x
   Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679
   Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Schonfeld G, 2003, J LIPID RES, V44, P878, DOI 10.1194/jlr.R300002-JLR200
   SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895
   Segrest JP, 2001, J LIPID RES, V42, P1346
   SEIFERT PS, 1989, LAB INVEST, V60, P747
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHOTTON DM, 1995, RAPID FREEZING FREEZ, P1
   Shoulders CC, 2005, CURR TOP MED CHEM, V5, P283, DOI 10.2174/1568026053544560
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Smith E B, 1974, Adv Lipid Res, V12, P1
   SMITH EB, 1967, J ATHEROSCLER RES, V7, P171, DOI 10.1016/S0368-1319(67)80079-6
   Smith JD, 2002, AGEING RES REV, V1, P345, DOI 10.1016/S1568-1637(02)00005-3
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARY HC, 1994, CIRCULATION, V89, P2462, DOI 10.1161/01.CIR.89.5.2462
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   Suzuki M, 2007, MOL VIS, V13, P772
   Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   TALMUD PJ, 1992, CLIN GENET, V42, P62
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Torzewski M, 1998, ARTERIOSCL THROM VAS, V18, P369, DOI 10.1161/01.ATV.18.3.369
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WAUGH DA, 1984, LAB INVEST, V51, P702
   WETTERAU JR, 1992, SCIENCE, V258, P999
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YEE RD, 1976, AM J OPHTHALMOL, V82, P64, DOI 10.1016/0002-9394(76)90666-8
   Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 200
TC 134
Z9 135
U1 2
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD MAR
PY 2010
VL 51
IS 3
BP 451
EP 467
DI 10.1194/jlr.R002238
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 555LW
UT WOS:000274513300002
PM 19797256
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ertan, E
   Dogan, M
   Polat, O
   Efe, N
   Akdogan, M
   Inan, S
   Duman, R
   Duman, R
AF Ertan, Elif
   Dogan, Mustafa
   Polat, Onur
   Efe, Neriman
   Akdogan, Muberra
   Inan, Sibel
   Duman, Resat
   Duman, Rahmi
TI Switch to aflibercept in the treatment of neovascular age-related
   macular degeneration: 30-month results
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Ranibizumab/therapeutic use; Angiogenesis
   inhibitors/therapeutic use; Intravitreal injections; Retina/pathology;
   Visual acuity
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; VEGF TRAP;
   BEVACIZUMAB; MACROPHAGE; RESPONDERS; FLUID; AMD; EYE
AB Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis (R)) to aflibercept (Eylea (R)) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after >= 6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 +/- 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 +/- 8.8 ranibizumab injections (range 6-38). After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 +/- 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Conclusion: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.
C1 [Ertan, Elif] Gaziosmanpasa Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Dogan, Mustafa; Efe, Neriman; Akdogan, Muberra; Inan, Sibel] Afyonkarahisar Univ Hlth Sci, Sch Med, Dept Ophthalmol, Afyon, Turkey.
   [Polat, Onur] Bursa Dunya Goz Hosp, Dept Ophthalmol, Bursa, Turkey.
   [Duman, Resat] Bursa City Hosp, Dept Ophthalmol, Bursa, Turkey.
   [Duman, Rahmi] Liv Hosp, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara Liv Hospital
RP Ertan, E (通讯作者)，Gaziosmanpasa Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
EM elif-ertan@hotmail.com
RI Duman, Reşat/ABD-6350-2021; POLAT, ONUR/U-3193-2019; Akdogan,
   Muberra/X-9977-2018; akdogan, muberra/AAK-1435-2021; DOGAN,
   Mustafa/C-2642-2014
OI POLAT, ONUR/0000-0002-3105-8139; akdogan, muberra/0000-0003-4846-312X;
   ERTAN, ELIF/0000-0001-5147-9814; DOGAN, Mustafa/0000-0001-7237-9847
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ertan E, EUR RES J, DOI [10.18621/eurj.446300, DOI 10.18621/EURJ.446300]
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 28
TC 0
Z9 0
U1 1
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2021
VL 84
IS 3
BP 225
EP 229
DI 10.5935/0004-2749.20210036
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL8II
UT WOS:000657156800006
PM 33567025
OA gold
DA 2022-11-30
ER

PT J
AU Johnson, EJ
AF Johnson, Elizabeth J.
TI Age-related macular degeneration and antioxidant vitamins: recent
   findings
SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
LA English
DT Article
DE age-related macular degeneration; antioxidants; nutrition; omega-3 fatty
   acids
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; BLUE MOUNTAINS EYE;
   FOLIC-ACID; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; PLASMA
   HOMOCYSTEINE; CAROTENOIDS; MACULOPATHY; METAANALYSIS
AB Purpose of review
   The purpose of the present review is to evaluate the most recent evidence for a role of antioxidant nutrients in the prevention or delay in progression of age-related macular degeneration (AMD), a major cause of visual impairment and blindness in the aging population.
   Recent findings
   Recent human studies (>2008) report a decreased AMD risk with increased intakes of lutein/zeaxanthin, B vitamins, zinc and docosahexaenoic acid but an increased risk with increased intakes of beta-carotene and vitamin E. These latter findings are inconsistent with previous reports (<2008).
   Summary
   Findings on the association of certain antioxidants and docosahexaenoic acid support a role for nutrition in a decreased risk of AMD. The inconsistent findings of an increased risk with increased intake of beta-carotene and vitamin E warrants continued investigation into these relationships.
C1 Tufts Univ, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
C3 Tufts University
RP Johnson, EJ (通讯作者)，Tufts Univ, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM elizabeth.johnson@tufts.edu
FU Agricultural Research Service [58-1950-7-707]
FX The present study was supported in part by Agricultural Research
   Service, agreement 58-1950-7-707. Any opinions, findings, conclusions or
   recommendations expressed in this publication are those of the author
   and do not necessarily reflect the view of the US Department of
   Agriculture.
CR [Anonymous], 2009, AGE RELATED EYE DIS
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Briefel RR, 2000, J NUTR, V130, p1367S, DOI 10.1093/jn/130.5.1367S
   Cho E, 1998, AGE RELATED MACULAR, P57
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   CLANDININ MT, 1994, J PEDIATR-US, V125, pS25, DOI 10.1016/S0022-3476(06)80733-X
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   ENGER SM, 1995, CANCER EPIDEM BIOMAR, V4, P201
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   JUMPSEN J, 1997, BRAIN DEV RELATIONSH
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   MUTKUTMONINORRI.M, 2000, CANC LETT, V150, P101
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarks SH, 1994, RETINA, P149
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119
   Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Woo KS, 1999, J AM COLL CARDIOL, V34, P2002, DOI 10.1016/S0735-1097(99)00469-6
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
NR 44
TC 36
Z9 40
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1363-1950
J9 CURR OPIN CLIN NUTR
JI Curr. Opin. Clin. Nutr. Metab. Care
PD JAN
PY 2010
VL 13
IS 1
BP 28
EP 33
DI 10.1097/MCO.0b013e32833308ff
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 537LG
UT WOS:000273113800006
PM 19841580
DA 2022-11-30
ER

PT J
AU Scotti, F
   Milani, P
   Setaccioli, M
   Maestroni, S
   Sidenius, N
   De Lorenzi, V
   Massacesi, A
   Bergamini, F
   Zerbini, G
AF Scotti, Fabrizio
   Milani, Paolo
   Setaccioli, Marco
   Maestroni, Silvia
   Sidenius, Nicolai
   De Lorenzi, Valentina
   Massacesi, Amedeo
   Bergamini, Fulvio
   Zerbini, Gianpaolo
TI Increased soluble urokinase plasminogen activator receptor (suPAR)
   levels in neovascular age-related macular degeneration: a role for
   inflammation in the pathogenesis of the disease?
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Soluble urokinase
   plasminogen activator receptor; Inflammation; Prevention
ID C-REACTIVE PROTEIN; ASSOCIATION; METAANALYSIS; INVOLVEMENT; BIOMARKERS;
   MORTALITY; MATRIX; CANCER; RISK
AB Purpose To evaluate the plasma concentration of the soluble form of the urokinase-type plasminogen activator receptor ((s)uPAR), an established biomarker of chronic inflammation, in patients affected by neovascular age-related macular degeneration.
   Methods Forty consecutive patients affected by age-related macular degeneration and 52 subjects with no history of the disease were included in this case-control study. The two groups of individuals considered for the study were matched for age, sex, and class of medications taken. Plasma concentration of suPAR was measured using a specific ELISA assay (suPARnostic, Birkeroed, Denmark).
   Results The case and control groups were similar for age, gender distribution, weight, height, and systolic and diastolic blood pressure, as well as for dyslipidemia and high blood pressure medication (P>0.28). The plasma concentrations of suPAR were significantly increased in patients with neovascular age-related macular degeneration when compared to controls (6.19 +/- 2.2ng/ml, vs 5.21 +/- 1.5, respectively, mean +/- SD P=0.01).
   Conclusions Patients with neovascular age-related macular degeneration display increased plasma levels of suPAR, suggesting that chronic inflammation may be involved in the pathogenesis of the disease.
C1 [Scotti, Fabrizio; Milani, Paolo; Setaccioli, Marco; Massacesi, Amedeo; Bergamini, Fulvio] IRCCS Ist Auxol Italiano, Dept Ophthalmol, Milan, Italy.
   [Maestroni, Silvia; Zerbini, Gianpaolo] IRCCS San Raffaele Sci Inst, Diabet Res Inst, Complicat Diabet Unit, Milan, Italy.
   [Sidenius, Nicolai; De Lorenzi, Valentina] IFOM FIRC Inst Mol Oncol, Unit Cell Matrix Signalling, Milan, Italy.
C3 IRCCS Istituto Auxologico Italiano; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; IFOM - FIRC Institute of Molecular Oncology
RP Zerbini, G (通讯作者)，IRCCS San Raffaele Sci Inst, Diabet Res Inst, Complicat Diabet Unit, Milan, Italy.
EM zerbini.gianpaolo@hsr.it
RI Zerbini, Gianpaolo/K-6723-2016
OI Milani, Paolo/0000-0002-0409-6201; De Lorenzi,
   Valentina/0000-0002-7429-6524
FU International Agency for the Prevention of Blindness (IAPB), Italian
   section
FX This study was supported by a Grant from the International Agency for
   the Prevention of Blindness (IAPB), Italian section (Dr Scotti).
CR ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Avan A, 2018, J CELL PHYSIOL, V233, P8508, DOI 10.1002/jcp.26791
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Cascella R, 2017, ONCOTARGET, V9, P7812, DOI [10.18632/oncotarget.23241, DOI 10.18632/ONCOTARGET.23241]
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Dande RR, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/3232848
   De Lorenzi V, 2016, EMBO REP, V17, P982, DOI 10.15252/embr.201541681
   Del Rosso M, 1999, CLIN EXP RHEUMATOL, V17, P485
   Desmedt S, 2017, CRIT REV CL LAB SCI, V54, P117, DOI 10.1080/10408363.2016.1269310
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Eugen-Olsen J, 2010, J INTERN MED, V268, P296, DOI 10.1111/j.1365-2796.2010.02252.x
   Hodges GW, 2015, CAN J CARDIOL, V31, P1293, DOI 10.1016/j.cjca.2015.03.023
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Ichihara N, 2017, J ARRYTHM, V33, P469, DOI 10.1016/j.joa.2017.05.003
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kronbichler A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2068691
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Small KW, 2017, RETINA-J RET VIT DIS, V37, P1630, DOI 10.1097/IAE.0000000000001475
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stephens RW, 1997, CLIN CHEM, V43, P1868
   Toldi G, 2013, CLIN CHEM LAB MED, V51, P327, DOI 10.1515/cclm-2012-0221
   Xin XL, 2018, RETINA-J RET VIT DIS, V38, P497, DOI 10.1097/IAE.0000000000001741
   Xue W, 1998, J CUTAN PATHOL, V25, P469, DOI 10.1111/j.1600-0560.1998.tb01777.x
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 34
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2019
VL 257
IS 5
BP 899
EP 903
DI 10.1007/s00417-018-04230-w
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT9JS
UT WOS:000464886200006
PM 30617582
DA 2022-11-30
ER

PT J
AU Williams, BL
   Seager, NA
   Gardiner, JD
   Pappas, CM
   Cronin, MC
   Filippo, CAD
   Anstadt, RA
   Liu, J
   Toso, MA
   Nichols, L
   Parnell, TJ
   Eve, JR
   Bartel, PL
   Zouache, MA
   Richards, BT
   Hageman, GS
AF Williams, Brandi L.
   Seager, Nathan A.
   Gardiner, Jamie D.
   Pappas, Chris M.
   Cronin, Monica C.
   Filippo, Cristina Amat di San
   Anstadt, Robert A.
   Liu, Jin
   Toso, Marc A.
   Nichols, Lisa
   Parnell, Timothy J.
   Eve, Jacqueline R.
   Bartel, Paul L.
   Zouache, Moussa A.
   Richards, Burt T.
   Hageman, Gregory S.
TI Chromosome 10q26-driven age-related macular degeneration is associated
   with reduced levels of HTRA1 in human retinal pigment epithelium
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; Bruch's
   membrane; HTRA1; cis-regulatory element
ID SERINE-PROTEASE; EXTRACELLULAR-MATRIX; SUBCORTICAL INFARCTS; STEM-CELLS;
   FACTOR-H; ARMS2; EXPRESSION; GENE; SUSCEPTIBILITY; 10Q26
AB Genome-wide association studies have identified the chromosome 10q26 (Chr10) locus, which contains the age-related maculopathy susceptibility 2 (ARMS2) and high temperature requirement A serine peptidase 1 (HTRA1) genes, as the strongest genetic risk factor for age-related macular degeneration (AMD) [L.G. Fritsche et al., Annu. Rev. Genomics Hum. Genet. 15, 151-171, (2014)]. To date, it has been difficult to assign causality to any specific single nucleotide polymorphism (SNP), haplotype, or gene within this region because of high linkage disequilibrium among the disease-associated variants [J. Jakobsdottir et al. Am. J. Hum. Genet. 77, 389-407 (2005); A. Rivera et al. Hum. Mol. Genet. 14, 3227-3236 (2005)]. Here, we show that HTRA1 messenger RNA (mRNA) is reduced in retinal pigment epithelium (RPE) but not in neural retina or choroid tissues derived from human donors with homozygous risk at the 10q26 locus. This tissue-specific decrease is mediated by the presence of a noncoding, cis-regulatory element overlapping the ARMS2 intron, which contains a potential Lhx2 transcription factor binding site that is disrupted by risk variant rs36212733. HtrA1 protein increases with age in the RPE-Bruch's membrane (BM) interface in Chr10 nonrisk donors but fails to increase in donors with homozygous risk at the 10q26 locus. We propose that HtrA1, an extracellular chaperone and serine protease, functions to maintain the optimal integrity of the RPE-BM interface during the aging process and that reduced expression of HTRA1 mRNA and protein in Chr10 risk donors impairs this protective function, leading to increased risk of AMD pathogenesis. HtrA1 augmentation, not inhibition, in high-risk patients should be considered as a potential therapy for AMD.
C1 [Williams, Brandi L.; Seager, Nathan A.; Gardiner, Jamie D.; Pappas, Chris M.; Cronin, Monica C.; Filippo, Cristina Amat di San; Anstadt, Robert A.; Liu, Jin; Toso, Marc A.; Nichols, Lisa; Eve, Jacqueline R.; Bartel, Paul L.; Zouache, Moussa A.; Richards, Burt T.; Hageman, Gregory S.] Univ Utah, Steele Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Parnell, Timothy J.] Univ Utah, Huntsman Canc Inst, Bioinformat Anal, Salt Lake City, UT 84132 USA.
   [Cronin, Monica C.] BioFire Diagnost, Mol Syst, Biochem R&D, Salt Lake City, UT 84112 USA.
   [Filippo, Cristina Amat di San] Utah Publ Hlth Lab, Infect Dis, Taylorsville, UT 84129 USA.
   [Eve, Jacqueline R.] Intermt Healthcare, Dept Pulmonol, Murray, UT 84107 USA.
   [Bartel, Paul L.] ARUP Labs, PharmaDX, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; Utah System of Higher Education; University of Utah;
   Intermountain Healthcare; Intermountain Medical Center; Utah System of
   Higher Education; University of Utah; ARUP Laboratories
RP Williams, BL; Hageman, GS (通讯作者)，Univ Utah, Steele Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
EM brandi.williams@hsc.utah.edu; gregory.hageman@hsc.utah.edu
OI Eve, Jacqueline/0000-0002-3159-5620; Cronin, Monica/0000-0001-9696-7512;
   Parnell, Timothy/0000-0002-3632-3691
FU NIH [R01 EY014800, R24 EY017404]; Research to Prevent Blindness, New
   York, NY; National Cancer Institute of the NIH [P30CA042014]; Voyant
   Biotherapeutics LLC
FX This work was supported in part by grants from the NIH (R01 EY014800,
   R24 EY017404), charitable donations made to the Sharon Eccles Steele
   Center for Translational Medicine, Voyant Biotherapeutics LLC, and an
   unrestricted grant from Research to Prevent Blindness, New York, NY, to
   the Department of Ophthalmology and Visual Sciences, University of Utah.
   Research reported in this publication utilized the Bioinformatics Shared
   Resource and High-Throughput Genomics at Huntsman Cancer Institute at
   the University of Utah, which is supported by the National Cancer
   Institute of the NIH under Award No. P30CA042014. We are grateful to the
   families of all the eye donors for their generous gifts, without which
   this work would not have been possible.
CR Alten F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112311
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen PH, 2019, AM J PATHOL, V189, P1423, DOI 10.1016/j.ajpath.2019.03.013
   Cherry TJ, 2020, P NATL ACAD SCI USA, V117, P9001, DOI 10.1073/pnas.1922501117
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hansen G, 2013, CELL MOL LIFE SCI, V70, P761, DOI 10.1007/s00018-012-1076-4
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Liao SM, 2017, MOL VIS, V23, P318
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Muralidharan B, 2017, J NEUROSCI, V37, P194, DOI 10.1523/JNEUROSCI.2836-16.2016
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Oide T, 2008, NEUROPATHOLOGY, V28, P132, DOI 10.1111/j.1440-1789.2007.00864.x
   Owen ME, 2013, GRAEF ARCH CLIN EXP, V251, P367, DOI 10.1007/s00417-012-2168-4
   Peng SM, 2013, STEM CELL TRANSL MED, V2, P534, DOI 10.5966/sctm.2012-0134
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Samuel W, 2017, MOL VIS, V23, P60
   SCHRODER JM, 1995, ACTA NEUROPATHOL, V89, P116, DOI 10.1007/BF00296354
   Tennstaedt A, 2012, J BIOL CHEM, V287, P20931, DOI 10.1074/jbc.M111.316232
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Uemura M, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00545
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zellner A, 2018, ACTA NEUROPATHOL, V136, P111, DOI 10.1007/s00401-018-1853-8
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
   Zurawa-Janicka D, 2017, ARCH BIOCHEM BIOPHYS, V621, P6, DOI 10.1016/j.abb.2017.04.004
NR 48
TC 14
Z9 14
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 27
PY 2021
VL 118
IS 30
AR e2103617118
DI 10.1073/pnas.2103617118
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UA3CJ
UT WOS:000685039600002
PM 34301870
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ni, Z
   Hui, P
AF Ni, Zhang
   Hui, Peng
TI Emerging Pharmacologic Therapies for Wet Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Vascular epithelial growth factor;
   Choroidal neovascularization; Antiangiogenesis; Anti-inflammatory;
   Target therapy
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE;
   KINASE INHIBITOR; VEGF FAMILY; RANIBIZUMAB; VERTEPORFIN; BEVACIZUMAB
AB As researchers and clinicians are beginning to understand that wet age-related macular degeneration (AMD) is more than simply a vascular disease that includes angiogenic, vascular and inflammatory components, they are exploring new agents with different mechanisms of action addressing multiple targets in this complex pathophysiology. Some of them are already available in human trials or even approved vascular epithelial growth factor (VEGF) blockers such as Macugen, Lucentis, Avastin, VEGF Trap-Eye and Cand5; VEGF receptor blockers such as TG100801, vatalanib, pazopanib, Sirna-027 and a vaccine approach; inflammation inhibitors and immunosuppressants such as Retaane, Kenalog, ARC1905, POT-4, OT-551. The last group is mixed, containing agents such as Zybrestat, AdPEGF, Sirolimus, JSM6427, ATG003, E10030. This article reviews these currently emerging agents and briefly discusses the next step for the treatment of wet AMD. Copyright (c) 2009 S. Karger AG, Basel
C1 [Ni, Zhang; Hui, Peng] Chongqing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Chongqing 400016, Peoples R China.
   [Ni, Zhang; Hui, Peng] Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
   [Ni, Zhang; Hui, Peng] Chongqing Eye Inst, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Hui, P (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Chongqing 400016, Peoples R China.
EM pengh9@yahoo.com.cn
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735
   Dejneka NS, 2004, MOL VIS, V10, P964
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   *FDA, FDA APPR NEW BIOL TR
   *FDA, FDA APPR FIRST ANG I
   FDA, FDA APPR NEW DRUG TR
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   *MAAM STUD, AV MAC VERS AV VER M
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Mochimaru H, 2007, INVEST OPHTH VIS SCI, V48, P4795, DOI 10.1167/iovs.07-0425
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROBERTS D, 2008, LOS ANG B PALM EYE I
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SINGH RP, 26 ANN M AM SOC RET
   Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253
   Tozer GM, 2001, CANCER RES, V61, P6413
   Uckermann O, 2005, J PHARMACOL EXP THER, V315, P1036, DOI 10.1124/jpet.105.092353
   Wigginton JM, 2001, J CLIN INVEST, V108, P51
   Wolf A, 2008, BRIT J OPHTHALMOL, V92, P1298, DOI 10.1136/bjo.2008.138396
   Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797
   ZENG H, 2000, J BIOL CHEM, V159, P993
NR 53
TC 54
Z9 72
U1 0
U2 32
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 6
BP 401
EP 410
DI 10.1159/000228926
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513WE
UT WOS:000271354000010
PM 19622904
DA 2022-11-30
ER

PT J
AU Campagne, MV
   LeCouter, J
   Yaspan, BL
   Ye, WL
AF Campagne, Menno van Lookeren
   LeCouter, Jennifer
   Yaspan, Brian L.
   Ye, Weilan
TI \Mechanisms of age-related macular degeneration and therapeutic
   opportunities
SO JOURNAL OF PATHOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); dry AMD; wet AMD; neovascular
   AMD (NVAMD); best corrected visual acuity (BCVA); geographic atrophy
   (GA); choroidal neovascularization (CNV); retinal pigmented epithelial
   (RPE) cells
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; OCCULT CHOROIDAL
   NEOVASCULARIZATION; VEGF-TRAP; FACTOR-B; PDGF-B; SUBRETINAL
   NEOVASCULARIZATION; INTRAVITREAL RANIBIZUMAB; STRONG ASSOCIATION;
   SUBGROUP ANALYSIS
AB As the age of the population increases in many nations, age-related degenerative diseases pose significant socioeconomic challenges. One of the key degenerative diseases that compromise quality of life is age-related macular degeneration (AMD). AMD is a multi-faceted condition that affects the central retina, which ultimately leads to blindness in millions of people worldwide. The pathophysiology and risk factors for AMD are complex, and the symptoms manifest in multiple related but distinct forms. The ability to develop effective treatments for AMD will depend on a thorough understanding of the underlying pathophysiology, risk factors, and driver molecular pathways, as well as the ability to develop useful animal models. This review provides an overview of the aforementioned aspects in AMD. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [LeCouter, Jennifer; Ye, Weilan] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
   [Yaspan, Brian L.] Genentech Inc, ITGR Human Genet Dept, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Ye, WL (通讯作者)，Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
EM ye.weilan@gene.com
OI Ye, Weilan/0000-0002-6219-3982; Yaspan, Brian/0000-0002-3787-2510
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chan-Ling T, 2011, INVEST OPHTH VIS SCI, V52, P399, DOI 10.1167/iovs.10-5403
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Condren AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053386
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawson WW, 2008, VISION RES, V48, P360, DOI 10.1016/j.visres.2007.08.006
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Garron L K, 1963, Trans Am Ophthalmol Soc, V61, P545
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jayson GC, 2005, J CLIN ONCOL, V23, P973, DOI 10.1200/JCO.2005.01.032
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KOHLER T, 1983, ACTA ANAT, V116, P55, DOI 10.1159/000145725
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kuroki AM, 2002, OPHTHALMIC RES, V34, P200, DOI 10.1159/000063886
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lanzetta P, 2013, BR J OPHTHA IN PRESS, DOI 10.1136/bjophthalmol-2013-303394
   Lassota N, 2007, GRAEF ARCH CLIN EXP, V245, P1189, DOI 10.1007/s00417-006-0518-9
   Lassota N, 2010, ACTA OPHTHALMOL, V88, P300, DOI 10.1111/j.1755-3768.2008.01439.x
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li XR, 2012, TRENDS MOL MED, V18, P119, DOI 10.1016/j.molmed.2011.11.006
   Lien S., 2008, V181, P131
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Mitchell TS, 2008, ANGIOGENESIS, V11, P141, DOI 10.1007/s10456-007-9085-x
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   Muller H., 1856, GRAEFES ARCH CLIN EX, V2, P1, DOI DOI 10.1007/BF02720657
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   OHKUMA H, 1983, INVEST OPHTH VIS SCI, V24, P481
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ribatti D, 2011, CANCER LETT, V307, P1, DOI 10.1016/j.canlet.2011.02.043
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Serruys Patrick W, 2003, Int J Cardiovasc Intervent, V5, P214
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang GF, 2013, JAMA OPHTHALMOL, V131, P804, DOI 10.1001/jamaophthalmol.2013.589
   Wang X, 2013, ARVO ASS RES VIS OPH, P10
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 140
TC 223
Z9 235
U1 9
U2 115
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JAN
PY 2014
VL 232
IS 2
BP 151
EP 164
DI 10.1002/path.4266
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 269DI
UT WOS:000328220600007
PM 24105633
OA Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Gangnon, RE
   Lee, KE
   Klein, BEK
   Iyengar, SK
   Sivakumaran, TA
   Klein, R
AF Gangnon, Ronald E.
   Lee, Kristine E.
   Klein, Barbara E. K.
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Klein, Ronald
TI Severity of Age-Related Macular Degeneration in 1 Eye and the Incidence
   and Progression of Age-Related Macular Degeneration in the Fellow Eye
   The Beaver Dam Eye Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; MULTISTATE-MODELS; MACULOPATHY; POPULATION; PERIOD
AB IMPORTANCE Previous studies regarding the severity of age-related macular degeneration (AMD) in 1 eye and its prognostic implications for the fellow eye have focused on the incidence of neovascular AMD in the fellow eye of participants with neovascular AMD in the other eye. It is unclear to what extent the severity of AMD in 1 eye affects the incidence, progression, and regression of AMD in its fellow eye across the entire range of AMD severity.
   OBJECTIVE To investigate the effect of the severity of AMD in 1 eye on the incidence, progression, and regression of AMD in the fellow eye.
   DESIGN, SETTING AND PARTICIPANTS The Beaver Dam Eye Study is a longitudinal population-based study of age-related eye diseases conducted in the city and township of Beaver Dam, Wisconsin. Examinations were performed every 5 years over a 20-year period (from the baseline examination in 1988-1990 to 2008-2010). Study participants (n = 4379) were 43 to 86 years of age at the baseline examination. At baseline and in up to 4 subsequent examinations, retinal photographs were taken.
   MAIN OUTCOMES AND MEASURES Incidence, progression, and regression of AMD (assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photographs and adjusted for age, sex, and the Y402H polymorphism in the complement factor H gene on chromosome 1q) and mortality.
   RESULTS More severe AMD in 1 eye was associated with increased incidence of AMD and accelerated progression in its fellow eye (levels 1-2: hazard ratio [HR], 4.90 [95% CI, 4.26-5.63]; levels 2-3: HR, 2.09 [95% CI, 1.42-3.06]; levels 3-4: HR, 2.38 [95% CI, 1.74-3.25]; levels 4-5: HR, 2.46 [95% CI, 1.65-3.66]). Less severe AMD in 1 eye was associated with less progression of AMD in its fellow eye (levels 2-3: HR, 0.42 [95% CI, 0.33-0.55]; levels 3-4: HR, 0.50 [95% CI, 0.34-0.83]). We estimate that 51% of participants who develop any AMD always maintain AMD severity states within 1 step of each other between eyes; 90% of participants stay within 2 steps.
   CONCLUSIONS AND RELEVANCE Using multistate models, we show that AMD severity in 1 eye tracks AMD severity in its fellow eye.
C1 [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Lee, Kristine E.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Genet & Ophthalmol, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Cincinnati
   Children's Hospital Medical Center
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Wisconsin Alumni Res Fdn, Room 417,610 N Walnut St, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714
FU National Institutes of Health [EY06594]; Research to Prevent Blindness,
   New York, New York; NATIONAL EYE INSTITUTE [U10EY006594] Funding Source:
   NIH RePORTER
FX The National Institutes of Health (grant EY06594 to R. Klein and B. E.
   K. Klein) provided funding for the entire study, including collection
   and analyses of data; further support for data analyses was provided by
   an unrestricted grant from Research to Prevent Blindness, New York, New
   York.
CR Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gangnon RE, 2014, INVEST OPHTH VIS SCI, V55, P1780, DOI 10.1167/iovs.13-12375
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Keilhauer CN, 2011, OPHTHALMIC GENET, V32, P237, DOI 10.3109/13816810.2011.592177
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, PB95273827
   Klein R, 1991, PB91149823
   Klein R, 1991, PB91184267
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   R Foundation for Statistical Computing V. Austria. . R Development Core Team, 2008, R LANG ENV STAT COMP
   Tibshirani R.J., 1993, MONOGRAPHS STAT APPL, V57, P1
NR 25
TC 21
Z9 21
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2015
VL 133
IS 2
BP 125
EP 132
DI 10.1001/jamaophthalmol.2014.4252
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB5NB
UT WOS:000349673100001
PM 25340497
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Sikorav, A
   Semoun, O
   Zweifel, S
   Jung, C
   Srour, M
   Querques, G
   Souied, EH
AF Sikorav, Anne
   Semoun, Oudy
   Zweifel, Sandrine
   Jung, Camille
   Srour, Mayer
   Querques, Giuseppe
   Souied, Eric H.
TI Prevalence and quantification of geographic atrophy associated with
   newly diagnosed and treatment-naive exudative age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE PATTERNS;
   CHOROIDAL-NEOVASCULARIZATION; TREATMENTS TRIALS; PROGRESSION;
   MACULOPATHY; THERAPY; GROWTH; FORM; EYE
AB Objective To identify and quantify geographic atrophy (GA) associated with neovascular age-related macular degeneration (AMD) at initial presentation using a fundus autofluorescence (FAF) semi-automated software and to correlate the results with demographic and clinical data.
   Design Retrospective, observational study.
   Methods The study population consisted of treatmentnaive patients with newly diagnosed neovascular AMD. Best-corrected visual acuity, fundus photographs, infrared reflectance, FAF and spectral-domain optical coherence tomography were performed, associated with fluorescein and indocyanine green angiographies. Identification of GA was independently performed by three readers. Quantification of atrophy areas was done using RegionFinder Software (RFA), a semi-automated software embedded in Spectralis device (Heidelberg Engineering, Germany).
   Results We included 206 eyes of 173 consecutive patients (72% female, mean age: 79.7 +/- 9.1 years). Type I choroidal neovascularisation (CNV) was observed in 44.2% of eyes, type II CNV was observed in 20.9% and mixed CNV lesion was observed in 11.7%. Polypoidal choroidal vasculopathy was diagnosed in 7.7% and type III CNV was diagnosed in 15.5%. Analysis of FAF frames showed that GA was associated with nAMD in 46/206 eyes (22.3%). Taking into account data both from Region Finder and multimodal imaging, our results suggest that GA was present in 24.3% of eyes newly diagnosed with exudative AMD. Mean size of GA was 1.23 +/- 1.76 mm(2) (range 0.03-7.39).
   Conclusion GA is associated with nAMD in 1/4 of cases at initial presentation. Combined imaging, including RFA is an effective tool to identify and quantify GA at diagnosis.
C1 [Sikorav, Anne; Semoun, Oudy; Srour, Mayer; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Zweifel, Sandrine] Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Jung, Camille] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Clin Res Ctr, Creteil, France.
   [Querques, Giuseppe] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Zurich; University Zurich Hospital; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Semoun, O (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.; Semoun, O (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94010 Creteil, France.
EM oudysemoun@hotmail.com
RI Zweifel, Sandrine/AAX-5045-2020
OI JUNG, Camille/0000-0001-8486-8939; Querques,
   Giuseppe/0000-0002-3292-9581
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Investigators IS, 2012, OPHTHALMOLOGY, V119, P1399
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   McCarthy LC, 2012, AM J OPHTHALMOL, V154, P568, DOI 10.1016/j.ajo.2012.03.021
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Panthier C, 2013, RETINA, V34, P576
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schachar IH, 2013, JAMA OPHTHALMOL, V131, P1009, DOI 10.1001/jamaophthalmol.2013.4014
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 44
TC 6
Z9 8
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2017
VL 101
IS 4
BP 438
EP 444
DI 10.1136/bjophthalmol-2015-308065
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP5HT
UT WOS:000397410300012
PM 27503391
DA 2022-11-30
ER

PT J
AU Couch, SM
   Bakri, SJ
AF Couch, Steven M.
   Bakri, Sophie J.
TI Review of Combination Therapies for Neovascular Age-Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE eye; macular degeneration; photodynamic therapy; anti-vegf; lucentis;
   avastin; ranibizumab; bevacizumab; retina; combination therapy
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; VERTEPORFIN PHOTODYNAMIC THERAPY;
   SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   RETINAL ANGIOMATOUS PROLIFERATION; RANDOMIZED CLINICAL-TRIAL;
   NONINFECTIOUS ENDOPHTHALMITIS; REDUCED-FLUENCE; TRIPLE THERAPY;
   BEVACIZUMAB
AB While angiogenesis is one of the factors associated with the development of CNV due to age-related macular degeneration (AMD), inflammation and oxidative stress also appear to play a role. Treatment of CNV with intravitreal anti-vascular endothelial growth factor monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and combination therapy may target the CNV through multiple mechanisms, thus reducing treatment frequency or improving visual outcome. Photodynamic therapy ( with regular or reduced fluence), as well as intravitreal steroids are used in combination with anti-VEGF therapy. This paper reviews the many clinical trials that have been performed utilizing several combinations of double and triple therapy. While combination therapy is biologically justifiable, further study is required to determine correct combinations and dosage.
C1 [Couch, Steven M.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Couch, SM (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM sbakri@hotmail.com
FU Research to Prevent Blindness, New York, NY
FX This manuscript was supported by Research to Prevent Blindness, New
   York, NY.
CR Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   Ahmadieh H, 2008, EUR J OPHTHALMOL, V18, P297, DOI 10.1177/112067210801800222
   Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Argenti D, 2000, J CLIN PHARMACOL, V40, P770, DOI 10.1177/00912700022009413
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Blaha GR, 2008, OPHTHAL SURG LAS IM, V39, P6, DOI 10.3928/15428877-20080101-02
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Busch T, 2009, RETINA-J RET VIT DIS, V29, pS36, DOI 10.1097/IAE.0b013e3181ad25e8
   Calvo-Gonzalez C, 2008, BRIT J OPHTHALMOL, V92, P74, DOI 10.1136/bjo.2007.128942
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Duguid IG, 2000, CURR EYE RES S, V11, P153
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Fackler TK, 2006, ANN ACAD MED SINGAP, V35, P701
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Galor A, 2007, OPHTHALMOLOGY, V114, P1912, DOI 10.1016/j.ophtha.2007.05.037
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Iwama D, 2008, BRIT J OPHTHALMOL, V92, P1352, DOI 10.1136/bjo.2008.141754
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1296, DOI 10.1097/IAE.0b013e3181814482
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maberley D, 2009, OPHTHALMOLOGY, V116, P2149, DOI 10.1016/j.ophtha.2009.04.032
   Mantel I, 2006, EUR J OPHTHALMOL, V16, P705, DOI 10.1177/112067210601600507
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   Roth DB, 2009, OPHTHAL SURG LAS IM, V40, P467, DOI 10.3928/15428877-20090901-05
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schadlu R, 2007, GRAEF ARCH CLIN EXP, V245, P1667, DOI 10.1007/s00417-007-0619-0
   SHAH C, 2006, EVIDENCE BASED OPHTH, V7, P132
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Sommer A, 1998, ACTA DERM-VENEREOL, V78, P15
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274
NR 71
TC 21
Z9 23
U1 0
U2 5
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 114
EP 120
DI 10.3109/08820538.2011.577130
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200006
PM 21609223
DA 2022-11-30
ER

PT J
AU Yeung, L
   Kuo, CN
   Chao, AN
   Chen, KJ
   Wu, WC
   Lai, CH
   Wang, NK
   Hwang, YS
   Chen, CL
   Lai, CC
AF Yeung, Ling
   Kuo, Chien-Neng
   Chao, An-Ning
   Chen, Kuan-Jen
   Wu, Wei-Chi
   Lai, Chien-Hsiung
   Wang, Nan-Kai
   Hwang, Yih-Shiou
   Chen, Ching-Lung
   Lai, Chi-Chun
TI ANGIOGRAPHIC SUBTYPES OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN TAIWAN A
   Prospective Multicenter Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   polypoidal choroidal neovascularization; polypoidal choroidal
   vasculopathy; retinal angiomatous proliferation
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; CLASSIFICATION; JAPANESE;
   DISEASE
AB Purpose: To determine the incidence and clinical characteristics of angiographic subtypes of polypoidal choroidal vasculopathy (PCV).
   Methods: It is a prospective, multicenter, cross-sectional study. Patients with newly diagnosed exudative macular degeneration are classified into PCV, age-related macular degeneration (AMD), and retinal angiomatous proliferation. Polypoidal choroidal vasculopathy is further classified into two subtypes depending on the presence (Type 1: polypoidal choroidal neovascularization) or absence (Type 2: typical PCV) of feeder vessels on indocyanine green angiography.
   Results: We enrolled 169 patients: 76 (45%) with PCV, 75 (44.4%) with AMD, and 14 (8.3%) with retinal angiomatous proliferation. Of the patients with PCV, 20 (26%) were classified as Type 1 PCV and 56 (74%) were classified as Type 2 PCV. The Type 1 PCV had a similar mean age compared to the AMD group (73.1 +/- 9.6 vs. 75.6 +/- 8.8 years, P = 0.281) and the Type 2 PCV (68.8 +/- 9.6 years) was younger than the AMD group (P, 0.001). Type 1 PCV presented with worse visual acuity compared with the AMD. Both PCV subtypes had a higher incidence of hemorrhagic complications (85% and 75% respectively).
   Conclusion: Type 2 PCV is more common than Type 1 PCV in Taiwan. Our results support the hypothesis that polypoidal choroidal neovascularization and typical PCV may be distinct entities.
C1 [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Yeung, Ling; Kuo, Chien-Neng; Chao, An-Ning; Chen, Kuan-Jen; Wu, Wei-Chi; Lai, Chien-Hsiung; Wang, Nan-Kai; Hwang, Yih-Shiou; Chen, Ching-Lung; Lai, Chi-Chun] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Kuo, Chien-Neng; Lai, Chien-Hsiung; Chen, Ching-Lung; Lai, Chi-Chun] Chang Gung Mem Hosp, Dept Ophthalmol, Chiayi, Taiwan.
   [Chao, An-Ning; Chen, Kuan-Jen; Wu, Wei-Chi; Wang, Nan-Kai; Hwang, Yih-Shiou] Chang Gung Mem Hosp, Dept Ophthalmol, 5 Fu Shin St, Taoyuan 333, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung Memorial Hospital
RP Lai, CC (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, 5 Fu Shin St, Taoyuan 333, Taiwan.
EM chichun.lai@gmail.com
RI Wang, Nan-Kai/AAO-6559-2020; Wang, Nan-Kai/D-6608-2011
OI Wang, Nan-Kai/0000-0002-6277-9879; Wang, Nan-Kai/0000-0002-6277-9879;
   Chen, Kuan-Jen/0000-0002-4994-8391; Lai, Chi-Chun/0000-0001-9547-7212;
   Chao, An-Ning/0000-0002-4761-9244
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jeong S, 2016, BR J OPHTHA IN PRESS
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2018
VL 38
IS 2
BP 263
EP 271
DI 10.1097/IAE.0000000000001556
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KQ
UT WOS:000428735400012
PM 28196060
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Machalinska, A
   Vereb, Z
   Salminen, A
   Petrovski, G
   Kauppinen, A
AF Kaarniranta, Kai
   Machalinska, Anna
   Vereb, Zoltan
   Salminen, Antero
   Petrovski, Goran
   Kauppinen, Anu
TI Estrogen Signalling in the Pathogenesis of Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Degeneration; estrogen; inflammation; macula; oxidative stress; retina
ID NF-KAPPA-B; DNA-BINDING ACTIVITY; OXIDATIVE STRESS; RECEPTOR-ALPHA;
   DIETARY-FAT; REPRODUCTIVE FACTORS; HORMONE REPLACEMENT; 17-BETA
   ESTRADIOL; CATARACT-SURGERY; GENE-EXPRESSION
AB Age-related macular degeneration (AMD) is a multifactorial eye disease that is associated with aging, family history, smoking, obesity, cataract surgery, arteriosclerosis, hypertension, hypercholesterolemia and unhealthy diet. Gender has commonly been classified as a weak or inconsistent risk factor for AMD. This disease is characterized by degeneration of retinal pigment epithelial (RPE) cells, Bruch's membrane, and choriocapillaris, which secondarily lead to damage and death of photoreceptor cells and central visual loss. Pathogenesis of AMD involves constant oxidative stress, chronic inflammation, and increased accumulation of lipofuscin and drusen. Estrogen has both anti-oxidative and anti-inflammatory capacity and it regulates signaling pathways that are involved in the pathogenesis of AMD. In this review, we discuss potential cellular signaling targets of estrogen in retinal cells and AMD pathology.
C1 [Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai; Kauppinen, Anu] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Machalinska, Anna] Pomeranian Med Univ, Dept Gen Pathol, Szczecin, Poland.
   [Vereb, Zoltan; Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, Stem Cells & Eye Res Lab, H-4012 Debrecen, Hungary.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Petrovski, Goran] Univ Debrecen, Hungarian Acad Sci, Apoptosis & Genom Res Grp, H-4012 Debrecen, Hungary.
   [Petrovski, Goran] Univ Szeged, Dept Ophthalmol, Szeged, Hungary.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Pomeranian Medical University; University of Debrecen;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Hungarian Academy of Sciences; University of Debrecen;
   Szeged University
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uef.fi
RI Vereb, Zoltan/I-6356-2019; Vereb, Zoltan/AAR-4092-2020
OI Vereb, Zoltan/0000-0002-9518-2155; Petrovski, Goran/0000-0003-2905-9252;
   /0000-0002-0035-1471; Kaarniranta, Kai/0000-0003-2600-8679
FU Kuopio University Hospital; Finnish Eye Foundation; Finnish Funding
   Agency for Technology and Innovation; Health Research Council of the
   Academy of Finland; Orion-Farmos Research Foundation; Paivikki and
   Sakari Sohlberg Foundation
FX This work was supported by the VTR grants of Kuopio University Hospital
   (KK), the Finnish Eye Foundation (KK), the Finnish Funding Agency for
   Technology and Innovation (KK), Health Research Council of the Academy
   of Finland (AK, KK), the Orion-Farmos Research Foundation (AK) and the
   Paivikki and Sakari Sohlberg Foundation (AK, KK). No conflict of
   interest.
CR Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x
   Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4
   Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646
   Cascio C, 2007, EXP EYE RES, V85, P166, DOI 10.1016/j.exer.2007.02.008
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007
   Cuzzocrea S, 2000, ENDOCRINOLOGY, V141, P1455, DOI 10.1210/en.141.4.1455
   Dasari B, 2013, CURR EYE RES, V38, P1159, DOI 10.3109/02713683.2013.811257
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Eisner A, 2011, CURR EYE RES, V36, P867, DOI 10.3109/02713683.2011.594202
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2
   Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403
   Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Koka S, 1998, J INTERF CYTOK RES, V18, P479, DOI 10.1089/jir.1998.18.479
   Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4
   Lei L, 2013, EXP EYE RES, V112, P57, DOI 10.1016/j.exer.2013.04.006
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moeinpour F, 2007, MOL IMMUNOL, V44, P3317, DOI 10.1016/j.molimm.2007.02.023
   Moor AN, 2004, EXP EYE RES, V78, P933, DOI 10.1016/j.exer.2004.01.001
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nishihara E, 2000, ENDOCRINOLOGY, V141, P615, DOI 10.1210/en.141.2.615
   Nixon E, 2012, INVEST OPHTH VIS SCI, V53, P4739, DOI 10.1167/iovs.12-9517
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Petrea RE, 2009, STROKE, V40, P1032, DOI 10.1161/STROKEAHA.108.542894
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0
   Reed JL, 2004, NEUROSCI LETT, V367, P60, DOI 10.1016/j.neulet.2004.05.077
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Singer CA, 1999, J NEUROSCI, V19, P2455
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   STEIN B, 1995, MOL CELL BIOL, V15, P4971
   Sun WH, 1998, BIOCHEM BIOPH RES CO, V244, P691, DOI 10.1006/bbrc.1998.8324
   Tamer C, 2007, AM J OPHTHALMOL, V143, P212, DOI 10.1016/j.ajo.2006.09.054
   Tani A, 2013, CYTOKINE, V62, P86, DOI 10.1016/j.cyto.2013.02.011
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064
   Tretter L, 2005, PHILOS T R SOC B, V360, P2335, DOI 10.1098/rstb.2005.1764
   Vegeto E, 2002, MOL PSYCHIATR, V7, P236, DOI 10.1038/sj.mp.4001007
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Vina J, 2006, FREE RADICAL RES, V40, P1359, DOI 10.1080/10715760600952851
   VINDING T, 1983, ACTA OPHTHALMOL, V61, P45
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   Zhao RQ, 2012, INT J MED SCI, V9, P825, DOI 10.7150/ijms.5180
NR 94
TC 29
Z9 31
U1 0
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB
PY 2015
VL 40
IS 2
BP 226
EP 233
DI 10.3109/02713683.2014.925933
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ4TB
UT WOS:000348214800012
PM 24911983
DA 2022-11-30
ER

PT J
AU Ambati, J
AF Ambati, Jayakrishna
TI Age-Related Macular Degeneration and the Other Double Helix The Cogan
   Lecture
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TOLL-LIKE RECEPTOR-3; SMALL INTERFERING RNAS; DOUBLE-STRANDED-RNA;
   EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; IN-VIVO DELIVERY; NF-KAPPA-B;
   OCULAR NEOVASCULARIZATION; BINDING-SITE; MOUSE MODEL; SIRNA
AB The study and therapy of age-related macular degeneration (AMD), a leading cause of blindness worldwide, have taken great strides over the past decade. During the same time, a central role for RNA in many human diseases has been discovered. We have identified anti-angiogenic functions for synthetic double stranded RNAs (dsRNAs) in neovascular AMD and cytotoxic functions for endogenous dsRNAs in atrophic AMD. These findings provide new insights into the pathogenesis and therapy of both forms of AMD. (Invest Ophthalmol Vis Sci. 2011;52:2166-2169) DOI:10.1167/iovs.11-7328
C1 [Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Vis Sci, Lexington, KY USA.
C3 University of Kentucky
RP Ambati, J (通讯作者)，740 S Limestone St, Lexington, KY 40536 USA.
EM jamba2@email.uky.edu
FU National Institutes of Health Office of the Director; National Eye
   Institute; Research to Prevent Blindness (RPB); Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research; Dr. E. Vernon Smith
   and Eloise C. Smith Macular Degeneration Endowed Chair; American Health
   Assistance Foundation; International Retinal Research Foundation; Macula
   Vision Research Foundation; E. Matilda Ziegler Foundation for the Blind;
   Jahnigen Career Development Award; University of Kentucky
FX Supported by the National Institutes of Health Office of the Director,
   the National Eye Institute, an unrestricted departmental grant from
   Research to Prevent Blindness (RPB), an RPB Senior Scientific
   Investigator Award, an RPB Lew R. Wasserman Merit Award, an RPB
   Physician Scientist Award, the Doris Duke Distinguished Clinical
   Scientist Award, the Burroughs Wellcome Fund Clinical Scientist Award in
   Translational Research, the Dr. E. Vernon Smith and Eloise C. Smith
   Macular Degeneration Endowed Chair, the American Health Assistance
   Foundation, the International Retinal Research Foundation, the Macula
   Vision Research Foundation, the E. Matilda Ziegler Foundation for the
   Blind, the the Jahnigen Career Development Award, and a University of
   Kentucky Physician Scientist Award.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103
   Berge M, 2010, AM J PATHOL, V177, P3192, DOI 10.2353/ajpath.2010.100157
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253
   Cubillos-Ruiz JR, 2009, J CLIN INVEST, V119, P2231, DOI 10.1172/JCI37716
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   ELIAS H, 1971, SCIENCE, V174, P993, DOI 10.1126/science.174.4013.993
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kariko K, 2004, CELLS TISSUES ORGANS, V177, P132, DOI 10.1159/000079987
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kortylewski M, 2009, NAT BIOTECHNOL, V27, P925, DOI 10.1038/nbt.1564
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Mouton PR, 2002, PRINCIPLES PRACTICE
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Pirher N, 2008, NAT STRUCT MOL BIOL, V15, P761, DOI 10.1038/nsmb.1453
   Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200
   Reich S, 2003, MOL VIS, V9, P210
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosner B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2110
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Smith C, 2006, NAT METHODS, V3, P475, DOI 10.1038/nmeth0606-475
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   WHITHER RNA, 2003, NAT CELL BIOL, V5, P489
   Wilmo AP, 2010, WORLD ALZHEIMER REPO
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 54
TC 22
Z9 23
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2011
VL 52
IS 5
BP 2166
EP 2169
DI 10.1167/iovs.11-7328
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 746XK
UT WOS:000289282600011
PM 21471430
OA Green Published
DA 2022-11-30
ER

PT J
AU Lin, TZ
   Dans, K
   Meshi, A
   Muftuoglu, IK
   Amador-Patarroyo, MJ
   Chen, KC
   Cheng, LY
   Freeman, WR
AF Lin, Tiezhu
   Dans, Kunny
   Meshi, Amit
   Muftuoglu, Ilkay Kilic
   Amador-Patarroyo, Manuel J.
   Chen, Kevin C.
   Cheng, Lingyun
   Freeman, William R.
TI AGE-RELATED MACULAR DEGENERATION-ASSOCIATED PERIPAPILLARY CHOROIDAL
   NEOVASCULARIZATION IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE peripapillary CNV; neovascular AMD; anti-VEGF; bevacizumab; aflibercept;
   optical coherence tomography
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; SUBRETINAL
   NEOVASCULARIZATION; RANIBIZUMAB; VASCULOPATHY; AFLIBERCEPT;
   NONRESPONDERS; MEMBRANES; EFFICACY
AB Purpose: To characterize the natural history and response of age-related macular degeneration-associated peripapillary choroidal neovascularization to anti-vascular endothelial growth factor therapy.
   Methods: This was a retrospective case series of patients with peripapillary choroidal neovascularization secondary to neovascular age-related macular degeneration. All patients underwent complete ophthalmologic examination and retinal imaging including fluorescein angiography and spectral domain optical coherence tomography at each visit. Eyes with subretinal or intraretinal macular fluid were treated with anti-vascular endothelial growth factor monotherapy using a modified as-needed treatment algorithm.
   Results: Thirty-three eyes of 27 patients were included. The median age was 82 years (range, 62-94), and the median duration of follow-up was 65 months (range, 6-165). Fourteen eyes (58%) without fovea-involving fluid at baseline subsequently developed exudation after a median observation period of 16 months (range, 4-107). Ten of 24 eyes (42%) without initial macular fluid remained dry during the entire follow-up. The median number of injections required until complete fluid reabsorption was 3 (range, 1-21) during the first treatment cycle. The median time to fluid recurrence was 6 months (range, 3-74).
   Conclusion: Peripapillary choroidal neovascularization secondary to wet age-related macular degeneration has a slow progression, may not require treatment for a prolonged period, and responds rapidly to anti-vascular endothelial growth factor treatment with good visual outcomes.
C1 [Lin, Tiezhu; Dans, Kunny; Meshi, Amit; Muftuoglu, Ilkay Kilic; Amador-Patarroyo, Manuel J.; Chen, Kevin C.; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
   [Lin, Tiezhu] He Univ, He Eye Hosp, Dept Ophthalmol, Shenyang, Peoples R China.
   [Dans, Kunny] DOH Eye Ctr, East Ave Med Ctr, Dept Ophthalmol, Quezon City, Philippines.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Amador-Patarroyo, Manuel J.] Barraquer Inst Amer, Ophthalmol Super Sch, Dept Ophthalmol, Bogota, Colombia.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI Chen, Kevin/GYU-8963-2022; lin, Tiezhu/AAY-1971-2020
OI Amador-Patarroyo, Manuel J./0000-0001-6058-5678
FU UCSD Vision Research Center Core Grant [P30EY022589]; Research to
   Prevent Blindness, NY
FX Supported in part by an UCSD Vision Research Center Core Grant
   P30EY022589, an unrestricted fund from Research to Prevent Blindness, NY
   (W.R.F.). The funding organization had no role in the design or conduct
   of this research. The institution has received funding to conduct trials
   of anti-VEGF drugs, and the conflicts are managed through UCSD policy.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Davis AS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1073, DOI 10.1001/archophthalmol.2012.465
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Hamoudi H, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/602729
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   Martin D, 2011, NEW ENGL J MED, V364, P1
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Nochez Y, 2009, J FR OPHTALMOL, V32, P25, DOI 10.1016/j.jfo.2008.10.002
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah SP, 2010, ACTA OPHTHALMOL, V88, pe243, DOI 10.1111/j.1755-3768.2009.01590.x
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spandau UHM, 2007, ACTA OPHTHALMOL SCAN, V85, P340, DOI 10.1111/j.1600-0420.2006.00832.x
   Wang HY, 2013, INT J OPHTHALMOL-CHI, V6, P600, DOI 10.3980/j.issn.2222-3959.2013.05.09
NR 31
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1936
EP 1944
DI 10.1097/IAE.0000000000002272
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300013
PM 30028411
DA 2022-11-30
ER

PT J
AU Agrawal, R
   Balne, PK
   Wei, X
   Bijin, VA
   Lee, B
   Ghosh, A
   Narayanan, R
   Agrawal, M
   Connolly, J
AF Agrawal, Rupesh
   Balne, Praveen Kumar
   Wei, Xin
   Bijin, Veonice Au
   Lee, Bernett
   Ghosh, Arkasubhra
   Narayanan, Raja
   Agrawal, Mukesh
   Connolly, John
TI Cytokine Profiling in Patients With Exudative Age-Related Macular
   Degeneration and Polypoidal Choroidal Vasculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE exudative age-related macular degeneration; choroidal
   neovascularization; polypoidal choroidal vasculopathy; aqueous humor
   cytokine profiles; plasma cytokine profiles; inflammation
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY;
   AQUEOUS-HUMOR; TRIAMCINOLONE ACETONIDE; RANIBIZUMAB TREATMENT; INCREASED
   EXPRESSION; CELLS; PATHOGENESIS; INFLAMMATION; BIOMARKERS
AB PURPOSE. The purpose of this study was to investigate the cytokine profiles in plasma and aqueous humor of patients with choroidal neovascularization (CNV) due to exudative AMD and polypoidal choroidal vasculopathy (PCV).
   METHODS. In this cross-sectional study, 16 patients clinically diagnosed with AMD, 18 patients with PCV, and 50 age-and sex-matched cataract patients without AMD/PCV (controls) were enrolled. Study subjects were treatment naive, and 200 lL undiluted aqueous humor and 5 mL peripheral venous blood were collected from the study subjects. Clinical samples were analyzed for 41 different cytokines by Luminex bead-based multiplex assay. Cytokines concentrations with detection rates of 50% or more were included for the analysis, and the differences in plasma and aqueous humor cytokines levels between each group were analyzed.
   RESULTS. The age of the patients with AMD and PCV was 70.62 +/- 10.15 (mean +/- SD) and 71.48 +/- 9.08 years, respectively, and that in the control group was 62.8 +/- 10.67 years. Aqueous humor cytokines growth-regulated oncogene (GRO), macrophage-derived chemokine (MDC), and macrophage inflammatory protein (MIP)-1 alpha were significantly higher in AMD patients than controls (all P < 0.04), and GRO, MDC, MIP-1 alpha, IL-8, IFN-gamma-inducible protein 10, and monocyte chemotactic protein levels were significantly higher in PCV patients than controls (all P < 0.03). Soluble CD40 ligand and platelet-derived growth factor-AA levels were higher in plasma of healthy controls compared with AMD subjects. No significant differences in cytokine levels were observed between AMD and PCV patients for both plasma and aqueous humor.
   CONCLUSIONS. In AMD and PCV patients, our data suggest that the pathologic changes are primarily driven by dysregulation of local immune factors in the eye, whereas the plasma cytokine levels are not elevated.
C1 [Agrawal, Rupesh; Balne, Praveen Kumar] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan, Singapore 308433, Singapore.
   [Agrawal, Rupesh; Balne, Praveen Kumar] Singapore Eye Res Inst, Singapore, Singapore.
   [Wei, Xin] Khoo Teck Puat Hosp, Dept Ophthalmol & Visual Sci, Singapore, Singapore.
   [Bijin, Veonice Au; Connolly, John] Inst Mol & Cell Biol, Singapore, Singapore.
   [Lee, Bernett] Singapore Immunol Network, Singapore, Singapore.
   [Ghosh, Arkasubhra] Narayana Nethralaya Fdn, GROW Res Lab, Bangalore, Karnataka, India.
   [Narayanan, Raja] LV Prasad Eye Inst, Hyderabad, Telangana, India.
   [Agrawal, Mukesh] Vimta Labs Ltd, Hyderabad, Telangana, India.
C3 Tan Tock Seng Hospital; National University of Singapore; Singapore
   National Eye Center; Agency for Science Technology & Research (A*STAR);
   A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for
   Science Technology & Research (A*STAR); A*STAR - Singapore Immunology
   Network (SIgN); L. V. Prasad Eye Institute
RP Agrawal, R (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan, Singapore 308433, Singapore.
EM rupesh_agrawal@ttsh.com.sg
RI Balne, Praveen Kumar/X-7075-2019; Narayanan, Raja/AAT-3098-2021
OI Balne, Praveen Kumar/0000-0001-8365-9991; Narayanan,
   Raja/0000-0001-9688-5859; Wei, Xin/0000-0001-8865-1956; Ghosh,
   Arkasubhra/0000-0002-6570-5891
FU National Healthcare Group Thematic Grant [NTG/13008]
FX Supported by National Healthcare Group Thematic Grant NTG/13008.
CR Abu El-Asrar AM, 2006, EUR CYTOKINE NETW, V17, P155, DOI 10.1684/ecn.2006.0033
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Alfaro V, 2006, AGE RELATED MACULAR
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barczyk A, 2014, INT J IMMUNOPATH PH, V27, P185, DOI 10.1177/039463201402700205
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Grierson R, 2013, J OCUL PHARMACOL TH, V29, P530, DOI 10.1089/jop.2012.0013
   Hasegawa M, 2011, CLIN RHEUMATOL, V30, P231, DOI 10.1007/s10067-010-1610-4
   Hu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147346
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kamppeter BA, 2008, OPHTHALMOLOGY, V115, P1372, DOI 10.1016/j.ophtha.2008.01.019
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kothur K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149411
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Kunikata H, 2012, ACTA OPHTHALMOL, V90, P162, DOI 10.1111/j.1755-3768.2010.01892.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Liao YY, 2016, ONCOTARGET, V7, P4310, DOI 10.18632/oncotarget.6708
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu F, 2016, MOL VIS, V22, P352
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   McConnell V, 2005, Ulster Med J, V74, P82
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Mo JS, 2000, EXP EYE RES, V70, P221, DOI 10.1006/exer.1999.0778
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Peter Delves J, 2011, ROITTS ESSENTIAL IMM
   Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18
   Ribeiro S, 2005, PHARMACOL THERAPEUT, V107, P44, DOI 10.1016/j.pharmthera.2005.01.004
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Schoenberger SD, 2012, INVEST OPHTH VIS SCI, V53, P5906, DOI 10.1167/iovs.12-10410
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   SHURE D, 1992, BIOCHEM BIOPH RES CO, V186, P1510, DOI 10.1016/S0006-291X(05)81577-3
   Sugai K, 2016, J ALLERGY CLIN IMMUN, V137, P774, DOI 10.1016/j.jaci.2015.08.032
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yogo Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-80
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhang BK, 2013, IMMUNOL LETT, V153, P58, DOI 10.1016/j.imlet.2013.07.005
NR 59
TC 29
Z9 29
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2019
VL 60
IS 1
BP 376
EP 382
DI 10.1167/iovs.18-24387
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ4BV
UT WOS:000457119800008
PM 30682207
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Li, ML
   Dolz-Marco, R
   Huisingh, C
   Messinger, JD
   Feist, RM
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Li, Miaoling
   Dolz-Marco, Rosa
   Huisingh, Carrie
   Messinger, Jeffrey D.
   Feist, Richard M.
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI CLINICOPATHOLOGIC CORRELATION OF GEOGRAPHIC ATROPHY SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; basallaminar deposits; basal linear
   deposits; drusen; subretinal drusenoid deposits; external limiting
   membrane; outer retina; photoreceptors; retinal pigment epithelium;
   Muller cells; optical coherence tomography; fundus autofluorescence;
   histology; complete retinal pigment epithelium and outer retinal
   atrophy; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   RETINAL-PIGMENT EPITHELIUM; RETICULAR PSEUDODRUSEN; NATURAL-HISTORY;
   EYES; NEOVASCULARIZATION; AUTOFLUORESCENCE; PHENOTYPES; EVOLUTION
AB Purpose: In an eye with geographic atrophy (GA) secondary to age-related macular degeneration, we correlated ex vivo histologic features with findings recorded in vivo using optical coherence tomography (OCT), near-infrared reflectance imaging, and fundus autofluorescence.
   Methods: In the left eye of an 86-year-old white woman, in vivo near-infrared reflectance and eye-tracked OCT B-scans at each of 6 clinic visits and a baseline fundus autofluorescence image were correlated with high-resolution histologic images of the preserved donor eye.
   Results: Clinical imaging showed a small parafoveal multilobular area of GA, subfoveal soft drusen, refractile drusen, hyperreflective lines near the Bruch membrane, subretinal drusenoid deposit (reticular pseudodrusen), and absence of hyperautofluorescent foci at the GA margin. By histology, soft drusen end-stages included avascular fibrosis with highly reflective cholesterol crystals. These accounted for hyperreflective lines near the Bruch membrane in OCT and plaques in near-infrared reflectance imaging. Subretinal drusenoid deposit was thick, continuous, extracellular, extensive outside the fovea, and associated with distinctive retinal pigment epithelium dysmorphia and photoreceptor degeneration. A hyporeflective wedge corresponded to ordered Henle fibers without cellular infiltration. The external limiting membrane descent, which delimits GA, was best visualized in high-quality OCT B-scans. Retinal pigment epithelium and photoreceptor changes at the external limiting membrane descent were consistent with our recent histologic survey of donor eyes.
   Conclusion: This case informs on the extent, topography, and lifecycle of extracellular deposits. High-quality OCT scans are required to reveal all tissue features relevant to age-related macular degeneration progression to GA, especially the external limiting membrane descent. Histologically validated signatures of structural OCT B-scans can serve as references for other imaging modalities.
C1 [Li, Miaoling; Huisingh, Carrie; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Li, Miaoling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Dolz-Marco, Rosa] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dolz-Marco, Rosa; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
   [Feist, Richard M.] Retina Consultants Alabama, Birmingham, AL USA.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Roche Holding; Genentech; New York
   University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn, Dept Ophthalmol & Visual Sci,Alabama Vis Res Lab, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Dolz-Marco R, 2016, INVEST OPHTH VIS SCI, V57, P6440, DOI 10.1167/iovs.16-20265
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Polyak S., 1957, VERTEBRATE VISUAL SY
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tan AC, 2018, SCI TRANSL MED, V10, P466
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 70
TC 30
Z9 30
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 802
EP 816
DI 10.1097/IAE.0000000000002461
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900025
PM 30839495
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Apte, RS
AF Apte, Rajendra S.
TI Pegaptanib sodium for the treatment of age-related macular degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE age-related macular degeneration; aptamer; choroidal neovascularization;
   pegaptanib; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM;
   VASCULAR-PERMEABILITY FACTOR; HEPARIN-BINDING DOMAIN; CHOROIDAL
   NEOVASCULARIZATION; FACTOR VEGF; IRIS NEOVASCULARIZATION;
   RECEPTOR-BINDING; CLINICAL-TRIALS; APTAMER NX1838
AB Background: Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeability. Objective: To briefly present the pharmacology, clinical efficacy and safety, and role of pegaptanib in treating ocular neovascular diseases. Methods: A systematic literature review and synopsis. Results/conclusion: After more than 10 years in development, clinical trials have shown pegaptanib efficacy in treating choroidal neovascularization of age-related macular degeneration. Its excellent ocular and systemic safety profiles have been confirmed in up to 3 years of experience. Early phase, well-controlled studies also suggest therapeutic benefit in diabetic retinopathy and retinal vein occlusion.
C1 Washington Univ, St Louis Med, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, St Louis, MO 63110 USA.
C3 Saint Louis University; Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, St Louis Med, Dept Ophthalmol & Visual Sci, Barnes Retina Inst, 660 S Euclid Ave,PO Box 8096, St Louis, MO 63110 USA.
EM Apte@lvision.wusd.edu
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   ALTAWEEL MM, 2007, INVEST OPHTHALMOL VI, V48
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   BASHSHUR ZF, 2007, AM J OPHTHALMOL 1205
   Baumwell S, 2007, NEPHRON CLIN PRACT, V106, pC72, DOI 10.1159/000101801
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brownbill P, 2007, ENDOCRINOLOGY, V148, P4734, DOI 10.1210/en.2007-0180
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Demir R, 2007, ACTA HISTOCHEM, V109, P257, DOI 10.1016/j.acthis.2007.02.008
   DRENSER KA, 2006, INVEST OPHTHALMOL VI, V47
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FILIPPOPOULOS T, 2006, INVEST OPHTHALMOL VI, V47
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FRIBERG TR, 2007, INVEST OPHTHAMOL VIS, V48
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   GONZALEZ VH, 2007, INVEST OPHTHALMOL VI, V48
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   SUNER IJ, 2006, ANN M AM AC OPHTH LA
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   TRESE MT, 2006, INVEST OPHTHALMOL VI, V47
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   WELLS JA, 2007, INVEST OPHTHALMOL VI, V48
NR 80
TC 43
Z9 48
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD FEB
PY 2008
VL 9
IS 3
BP 499
EP 508
DI 10.1517/14656566.9.3.499
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 266BK
UT WOS:000253406000015
PM 18220500
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Kifley, A
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Kifley, Annette
   Mitchell, Paul
TI Thyroid Dysfunction and Ten-Year Incidence of Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Blue Mountains Eye Study; thyroid dysfunction; age-related macular
   degeneration; older adults; incidence
ID BLUE-MOUNTAINS-EYE; OXIDATIVE STRESS; OLDER POPULATION; 5-YEAR
   INCIDENCE; RISK-FACTORS; MACULOPATHY; ASSOCIATION; ANTIOXIDANT;
   PROGRESSION; PREVALENCE
AB PURPOSE. Epidemiologic evidence of a relationship between thyroid dysfunction and age-related macular degeneration (AMD) is inconsistent and unclear. We aimed to assess the prospective associations between serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) measurements, as well as thyroid dysfunction (hyperthyroidism and hypothyroidism) and incidence of AMD.
   METHODS. Categories of thyroid dysfunction were defined according to a serum TSH screen followed by serum FT4 assessment, and were available in 906 participants (aged 55+ years) at risk of AMD incidence (from 1997-1999 to 2007-2009). Continuous serum FT4 measures were available regardless of TSH screening results in 583 participants at risk of AMD incidence. Age-related macular degeneration was assessed from retinal photographs.
   RESULTS. Participants with overt hyperthyroidism compared to those with normal thyroid function at baseline had increased risk of developing any incident AMD, after adjusting for age, sex, smoking, fish consumption, and variants in AMD susceptibility genes (CFH and ARMS2): odds ratio (OR) 3.51 (95% confidence interval [CI] 1.16-10.65). Participants who reported current use of thyroxine (n = 67; 7.3%) versus those who were not current users (n = 839) had a 68% increased risk of incident AMD, multivariable-adjusted OR 1.68 (95% CI 1.01-2.82). Similarly, participants who had ever been on thyroxine medication (n = 77; 8.4%) compared to those who had never been on thyroxine (n = 829) also had a higher risk of any AMD, multivariable-adjusted OR 1.91 (95% CI 1.18-3.09).
   CONCLUSIONS. Overt hyperthyroidism was independently associated with an increased risk of incident AMD. Thyroxine usage in older adults was also positively associated with incidence of AMD.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
   Univ Sydney, Westmead Inst, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Gopinath, B (通讯作者)，Westmead Hosp, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Gopinath, Bamini/K-4286-2019; Liew,
   Gerald/AAB-6870-2022
OI Gopinath, Bamini/0000-0003-3573-359X; 
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Millennium Institute; Macular Disease
   Foundation Australia; Blackmores Dr Paul Beaumont Fellowship
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (Grant Nos. 974159, 991407, 211069,
   262120) and Westmead Millennium Institute. BG is supported by a Macular
   Disease Foundation Australia and Blackmores Dr Paul Beaumont Fellowship.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   COX DR, 1972, J R STAT SOC B, V34, P187
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Goodrich M E, 1999, Ophthalmic Epidemiol, V6, P279, DOI 10.1076/opep.6.4.279.4188
   Gopinath B, 2010, INTERN MED J, V40, P642, DOI 10.1111/j.1445-5994.2009.02156.x
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gopinath B, 2013, MATURITAS, V75, P159, DOI 10.1016/j.maturitas.2013.03.009
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Ittermann T, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0343-2
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   MANO T, 1995, J ENDOCRINOL, V145, P131, DOI 10.1677/joe.0.1450131
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsai CC, 2007, ARCH OPHTHALMOL-CHIC, V125, P1652, DOI 10.1001/archopht.125.12.1652
   Venditti P, 1997, J ENDOCRINOL, V155, P151, DOI 10.1677/joe.0.1550151
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 33
TC 22
Z9 21
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5273
EP 5277
DI 10.1167/iovs.16-19735
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600023
PM 27716857
OA gold
DA 2022-11-30
ER

PT J
AU Barkmeier, AJ
   Carvounis, PE
AF Barkmeier, Andrew J.
   Carvounis, Petros E.
TI Retinal Pigment Epithelial Tears and the Management of Exudative
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelial (RPE) tear;
   retinal pigment epithelial (RPE) rip; pigment epithelial detachment;
   bevacizumab; ranibizumab; vascular endothelial growth factor
ID INTRAVITREAL BEVACIZUMAB INJECTION; OPTICAL COHERENCE TOMOGRAPHY;
   CHOROIDAL NEOVASCULARIZATION SECONDARY; PHOTODYNAMIC THERAPY;
   CLINICOPATHOLOGICAL CORRELATION; LASER PHOTOCOAGULATION; RANIBIZUMAB;
   VEGF; DETACHMENT; PATHOGENESIS
AB Tears of the retinal pigment epithelium (RPE) are a known and potentially catastrophic complication of exudative age-related macular degeneration (AMD). Eyes with vascularized retinal pigment epithelial detachments (PED) are especially at risk for the development of RPE tears. This long-recognized complication faces increased scrutiny in an era of improved anti-angiogenic treatments for AMD, particularly given that these newly developed therapeutics have been implicated as a potential factor in the formation of some RPE tears.
C1 [Barkmeier, Andrew J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Carvounis, Petros E.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
C3 Mayo Clinic; Baylor College of Medicine
RP Barkmeier, AJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM barkmeier.andrew@mayo.edu
RI Barkmeier, Andrew/AAV-1021-2020
OI Carvounis, Petros/0000-0002-3879-3486
FU Research to Prevent Blindness, New York, New York, USA; Regeneron - VIEW
   1 trial; NEI - CATT trial; NEI - AREDS 2 trial
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. Publication of
   this article was supported by funding received from Research to Prevent
   Blindness, New York, New York, USA. Andrew J Barkmeier receives grant
   support from Regeneron - VIEW 1 trial, NEI - CATT trial, and NEI - AREDS
   2 trial.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arroyo JG, 1997, AM J OPHTHALMOL, V123, P377, DOI 10.1016/S0002-9394(14)70134-5
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Emerson GG, 2005, AM J OPHTHALMOL, V140, P316, DOI 10.1016/j.ajo.2005.01.028
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Ghassemifar R, 2006, CELL TISSUE RES, V323, P117, DOI 10.1007/s00441-005-0046-7
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Iijima H, 1999, RETINA-J RET VIT DIS, V19, P198, DOI 10.1097/00006982-199905000-00004
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
   Kroyer K, 2008, ACTA OPHTHALMOL, V86, P338, DOI 10.1111/j.1600-0420.2007.00993.x
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   LEVIN LA, 1991, AM J OPHTHALMOL, V112, P396, DOI 10.1016/S0002-9394(14)76246-4
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   MAGUIRE JI, 1990, BRIT J OPHTHALMOL, V74, P556, DOI 10.1136/bjo.74.9.556
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   MEYER CH, 2001, GRAEFES ARCH CLIN EX, V239, P235
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Peng SM, 2010, INVEST OPHTH VIS SCI, V51, P3216, DOI 10.1167/iovs.09-4162
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 70
TC 10
Z9 10
U1 0
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 94
EP 103
DI 10.3109/08820538.2011.571055
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200004
PM 21609221
DA 2022-11-30
ER

PT J
AU Zhu, DH
   Wu, J
   Spee, C
   Ryan, SJ
   Hinton, DR
AF Zhu, DanHong
   Wu, Jian
   Spee, Christine
   Ryan, Stephen J.
   Hinton, David R.
TI BMP4 Mediates Oxidative Stress-induced Retinal Pigment Epithelial Cell
   Senescence and Is Overexpressed in Age-related Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NORMAL HUMAN FIBROBLASTS; PROTEIN-KINASE PATHWAY; MAP KINASE; IN-VITRO;
   SIGNALING PATHWAYS; ARPE-19 CELLS; GROWTH ARREST; UV-RADIATION;
   EXPRESSION; P53
AB The retinal pigment epithelium is a primary site of pathology in age-related macular degeneration. Oxidative stress and senescence are both thought to be important mediators of macular degeneration pathogenesis. We demonstrate here that bone morphogenetic protein-4 is highly expressed in the retinal pigment epithelium and adjacent extracellular matrix of patients with dry age-related macular degeneration. In vitro studies revealed that sublethal oxidative stress increased bone morphogenetic protein-4 expression in retinal pigment epithelial cells, and both bone morphogenetic protein-4 and persistent mild oxidative stress can induce retinal pigment epithelial cell senescence through p53-p21(Cip1/WAF1)-Rb pathway. We further demonstrate that bone morphogenetic protein-4 acts as a mediator in oxidative stress-induced senescence and that this mediator function is via Smad and the p38 signaling pathway to increase and activate p53 and p21(Cip1/WAF1) and decrease phospho-Rb. Oxidative stress-induced senescence can be blocked by Chordin-like, an antagonist of bone morphogenetic protein-4, or SB203580, a phospho-p38 inhibitor. Our results suggest that oxidative stress and bone morphogenetic protein-4 may interact to promote retinal pigment epithelial cell senescence and that bone morphogenetic protein-4 may represent a novel therapeutic target to inhibit the progressive effects of oxidative stress and senescence in dry age-related macular degeneration.
C1 [Zhu, DanHong; Wu, Jian; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Zhu, DanHong; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Univ So Calif, Keck Sch Med, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Zhu, DanHong; Spee, Christine; Ryan, Stephen J.; Hinton, David R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Ryan, Stephen J.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave,HMR209, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
FU National Institutes of Health [EY01545]; Core [EY03040]; NATIONAL EYE
   INSTITUTE [P30EY003040, R01EY001545] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part by National Institutes of
   Health Grants EY01545 (to S. J. R.) and Core grant EY03040.
CR Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779
   Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200
   Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278
   Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043
   Chretien A, 2008, FREE RADICAL BIO MED, V44, P1732, DOI 10.1016/j.freeradbiomed.2008.01.026
   Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   EL DW, 1993, CELL, V75, P817
   Furuta Y, 1997, DEVELOPMENT, V124, P2203
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Goswami M, 2001, DEV BIOL, V236, P259, DOI 10.1006/dbio.2001.0338
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kendall SE, 2005, MOL CELL BIOL, V25, P7711, DOI 10.1128/MCB.25.17.7711-7724.2005
   Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Nagata Y, 2007, MACROMOLECULES, V40, P6, DOI 10.1021/ma062007s
   Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304
   Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379
   Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1975, International Ophthalmology Clinics, V15, P169, DOI 10.1097/00004397-197501510-00014
   Sengle G, 2008, J BIOL CHEM, V283, P13874, DOI 10.1074/jbc.M707820200
   Seomun Y, 2005, MOL VIS, V11, P764
   Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875
   She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sorescu GP, 2004, CIRC RES, V95, P773, DOI 10.1161/01.RES.0000145728.22878.45
   Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517
   Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06
   Wachi H, 2005, CLIN BIOCHEM, V38, P643, DOI 10.1016/j.clinbiochem.2005.04.006
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   WHEATLEY HM, 1995, ARCH OPHTHALMOL-CHIC, V113, P103, DOI 10.1001/archopht.1995.01100010105028
   Yu JD, 2004, J BIOL CHEM, V279, P42211, DOI 10.1074/jbc.M408223200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng YX, 1996, ONCOGENE, V12, P1557
   Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391
NR 70
TC 66
Z9 70
U1 1
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 3
PY 2009
VL 284
IS 14
BP 9529
EP 9539
DI 10.1074/jbc.M809393200
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 425WS
UT WOS:000264669100059
PM 19158083
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Meyers, KJ
   Liu, Z
   Millen, AE
   Iyengar, SK
   Blodi, BA
   Johnson, E
   Snodderly, DM
   Klein, ML
   Gehrs, KM
   Tinker, L
   Sarto, GE
   Robinson, J
   Wallace, RB
   Mares, JA
AF Meyers, Kristin J.
   Liu, Zhe
   Millen, Amy E.
   Iyengar, Sudha K.
   Blodi, Barbara A.
   Johnson, Elizabeth
   Snodderly, D. Max
   Klein, Michael L.
   Gehrs, Karen M.
   Tinker, Lesley
   Sarto, Gloria E.
   Robinson, Jennifer
   Wallace, Robert B.
   Mares, Julie A.
TI Joint Associations of Diet, Lifestyle, and Genes with Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID METABOLIC SYNDROME; EYE DISEASE; ANTIOXIDANTS; LUTEIN; RISK; ZINC; CFH;
   CAROTENOIDS; SUSCEPTIBILITY; INFLAMMATION
AB Purpose: Unhealthy lifestyles have been associated with increased odds for age-related macular degeneration (AMD). Whether this association is modified by genetic risk for AMD is unknown and was investigated.
   Design: Interactions between healthy lifestyles AMD risk genotypes were studied in relation to the prevalence of AMD, assessed 6 years later.
   Participants: Women 50 to 79 years of age in the Carotenoids in Age-Related Eye Disease Study with exposure and AMD data (n - 1663).
   Methods: Healthy lifestyle scores (0-6 points) were assigned based on Healthy Eating Index scores, physical activity (metabolic equivalent of task hours/week), and smoking pack years assessed in 1994 and 1998. Genetic risk was based on Y402H in complement factor H (CFH) and A69S in age-related maculopathy susceptibility locus 2 (ARMS2). Additive and multiplicative interactions in odds ratios were assessed using the synergy index and a multiplicative interaction term, respectively.
   Main Outcome Measures: AMD presence and severity were assessed from grading of stereoscopic fundus photographs taken in 2001-2004. AMD was present in 337 women, 91% of whom had early AMD.
   Results: The odds of AMD were 3.3 times greater (95% confidence interval [CI], 1.8-6.1) in women with both low healthy lifestyle score (0-2) and high-risk CFH genotype (CC), relative to those who had low genetic risk (TT) and high healthy lifestyle scores (4-6). There were no significant additive (synergy index [SI], 1.08; 95% CI, 0.70-1.67) or multiplicative (P-interaction = 0.94) interactions in the full sample. However, when limiting the sample to women with stable diets before AMD assessment (n = 728) the odds for AMD associated with low healthy lifestyle scores and high-risk CFH genotype were strengthened (odds ratio, 4.6; 95% CI, 1.8-11.6) and the synergy index was significant (SI, 1.34; 95% CI, 1.05-1.70). Adjusting for dietary lutein and zeaxanthin attenuated, and therefore partially explained, the joint association. There were no significant additive or multiplicative interactions for ARMS2 and lifestyle score.
   Conclusions: Having unhealthy lifestyles and 2 CFH risk alleles increased AMD risk (primarily in the early stages), in an or additive or greater (synergistic) manner. However, unhealthy lifestyles increased AMD risk regardless of AMD risk genotype. (C) 2015 by the American Academy of Ophthalmology.
C1 [Meyers, Kristin J.; Liu, Zhe; Blodi, Barbara A.; Mares, Julie A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, McPherson Eye Res Inst, Madison, WI 53726 USA.
   [Millen, Amy E.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Johnson, Elizabeth] Tufts Univ, Res Ctr Aging, Jean Mayer USDA Human Nutr, Boston, MA 02111 USA.
   [Snodderly, D. Max] Univ Texas Austin, Dept Neurosci, Austin, TX 78712 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
   [Gehrs, Karen M.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Dept Canc Prevent Res Program, Seattle, WA 98104 USA.
   [Sarto, Gloria E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Obstet & Gynecol, Madison, WI 53726 USA.
   [Robinson, Jennifer; Wallace, Robert B.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA.
C3 University of Wisconsin System; University of Wisconsin Madison; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Case Western Reserve University; Tufts University;
   United States Department of Agriculture (USDA); University of Texas
   System; University of Texas Austin; Oregon Health & Science University;
   University of Iowa; Fred Hutchinson Cancer Center; University of
   Wisconsin System; University of Wisconsin Madison; University of Iowa
RP Mares, JA (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 North Walnut St,1063 WARF, Madison, WI 53726 USA.
EM jmarespe@wisc.edu
RI /S-1190-2019; , Jennifer/AAD-8336-2019
OI /0000-0001-7488-250X; Snodderly, Donald/0000-0002-3428-609X; Li,
   Xiaoying/0000-0002-9383-5757; Gehrs, Karen/0000-0003-4510-9678
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [EY013018, EY016886]; Research to Prevent Blindness, Inc, New
   York, New York; Retina Research Foundation (Houston, TX); Carl and
   Mildred Reeves Foundation (Columbus, IN); National Heart, Lung, and
   Blood Institute, National Institutes of Health, Bethesda, Maryland
   [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
   HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; NATIONAL
   CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [U10EY013018, R01EY016886] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant nos.: EY013018, EY016886); Research to Prevent
   Blindness, Inc, New York, New York; the Retina Research Foundation
   (Houston, TX); and the Carl and Mildred Reeves Foundation (Columbus,
   IN). The Women's Health Initiative is funded by the National Heart,
   Lung, and Blood Institute, National Institutes of Health, Bethesda,
   Maryland (grant nos.: HHSN268201100046C, HHSN268201100001C,
   HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and
   HHSN271201100004C).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bekkouche L, 2014, HORM METAB RES, V46, P274, DOI 10.1055/s-0033-1363657
   Berendschot T, 2013, IOVS, V54, P4214
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Duncan A, 2012, AM J CLIN NUTR, V95, P64, DOI 10.3945/ajcn.111.023812
   Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Galor A, 2011, CURR OPIN OPHTHALMOL, V22, P477, DOI 10.1097/ICU.0b013e32834bbe7a
   Hallqvist T, 1996, J INTERN MED, V239, P377, DOI 10.1046/j.1365-2796.1996.431782000.x
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Knol MJ, 2011, EUR J EPIDEMIOL, V26, P433, DOI 10.1007/s10654-011-9554-9
   Laurie CC, 2010, GENET EPIDEMIOL, V34, P591, DOI 10.1002/gepi.20516
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Moreto F, 2015, DIABETES METAB SYNDR
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Poole KES, 2006, STROKE, V37, P243, DOI 10.1161/01.STR.0000195184.24297.c1
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Reid D, 2011, AM J CLIN NUTR, V93, P1006, DOI 10.3945/ajcn.110.008490
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2010, MOL VIS, V16, P2412
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Tomaszewski M, 2003, ARTERIOSCL THROM VAS, V23, P1640, DOI 10.1161/01.ATV.0000087036.75849.0B
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang MX, 2013, ATHEROSCLEROSIS, V227, P380, DOI 10.1016/j.atherosclerosis.2013.01.021
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 50
TC 38
Z9 39
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2286
EP 2294
DI 10.1016/j.ophtha.2015.07.029
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800031
PM 26354764
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pieramici, DJ
   Avery, RL
AF Pieramici, Dante J.
   Avery, Robert L.
TI Ranibizumab: treatment in patients with neovascular age-related macular
   degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE AMD; LUCENTIS; neovascular age-related macular degeneration;
   ranibizumab; vascular endothelial growth factor A; VEGF-A
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHY FINDINGS; FACTOR
   ANTIBODY FRAGMENT; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB AVASTIN(R);
   INTRAVITREAL INJECTION; CRYSTAL-STRUCTURE; NONHUMAN PRIMATE;
   TUMOR-CELLS; VEGF
AB Vascular endothelial growth factor (VEGF)-A is a major regulator of angiogenesis and vascular permeability implicated in the development of diseases involving pathological angiogenesis and increased vascular permeability, such as neovascular age-related macular degeneration (AMD). LUCENTISTM (ranibizumab), a humanised antigen-binding fragment (Fab) that neutralises all VEGF-A isoforms and their biologically active degradation products, was recently approved by the FDA. Ranibizumab is the first FDA-approved treatment for neovascular AMD that maintains or improves vision in >= 90% patients and provides a >= 15-letter improvement in visual acuity for a quarter to a third of patients with all choroidal neovascularisation subtypes. Ranibizumab was associated with a <= 1.7% rate of key serious ocular adverse events, such as endophthalmitis and uveitis, in two pivotal Phase III trials.
C1 Calif Retina Consultants & Res Fdn, Santa Barbara, CA 93103 USA.
RP Pieramici, DJ (通讯作者)，Calif Retina Consultants & Res Fdn, 515 E Micheltorena St,Suite C, Santa Barbara, CA 93103 USA.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Akiyama H, 2005, MOL PHARMACOL, V68, P1543, DOI 10.1124/mol.105.015628
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baca M, 1997, J BIOL CHEM, V272, P10678
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Presta LG, 1997, CANCER RES, V57, P4593
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROSENFELD PJ, 2005, OPHTHALMOLOGY, V113, P632
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
NR 40
TC 33
Z9 35
U1 1
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD NOV
PY 2006
VL 6
IS 11
BP 1237
EP 1245
DI 10.1517/14712598.6.11.1237
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 099UL
UT WOS:000241621600015
PM 17049020
DA 2022-11-30
ER

PT J
AU Do, DV
AF Do, Diana V.
TI Antiangiogenic Approaches to Age-Related Macular Degeneration in the
   Future
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RANIBIZUMAB
AB Neovascular age-related macular degeneration (AMD) is a complex disease that likely involves multiple angiogenic agents that contribute to the development of choroidal neovascularization (CNV). Although inhibition of vascular endothelial growth factor with ranibizumab has demonstrated efficacy and safety in the treatment of neovascular AMD, novel treatments targeting different mechanisms that play a role in CNV development currently are being investigated. Data from these clinical trials will increase our knowledge of the pathogenesis of AMD and likely provide additions to the treatment armamentarium for improving vision and quality of life in patients with AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found in the CME frontmatter. Ophthalmology 2009;116:S24-S26 (C) 2009 by the American Academy of Ophthalmology.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Do, DV (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Maumenee 740,600 N Wolfe St, Baltimore, MD 21287 USA.
EM ddo@jhmi.edu
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CLINICALTRIALS, 2009, PHAS 1 SAF TOL PHARM
   *CLINICALTRIALS, EFF SAF VERT PHOT TH
   *CLINICALTRIALS, RED FLUENC VIS ANT D
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2007, MOL VIS, V13, P196
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
NR 14
TC 24
Z9 24
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
SU S
BP S24
EP S26
DI 10.1016/j.ophtha.2009.06.049
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RY
UT WOS:000270794700004
PM 19800536
DA 2022-11-30
ER

PT J
AU El-Mollayess, GM
   Mahfoud, Z
   Schakal, AR
   Salti, HI
   Jaafar, D
   Bashshur, ZF
AF El-Mollayess, Georges M.
   Mahfoud, Ziyad
   Schakal, Alexandre R.
   Salti, Haytham I.
   Jaafar, Dalida
   Bashshur, Ziad F.
TI INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION Effect of Baseline Visual Acuity
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; baseline visual acuity;
   bevacizumab; choroidal neovascularization
ID RANIBIZUMAB TREATMENT; NATURAL-HISTORY; DETACHMENT; OUTCOMES
AB Purpose: To study prospectively the safety and efficacy of intravitreal bevacizumab for eyes with neovascular age-related macular degeneration with baseline visual acuity better than 70 letters (Snellen equivalent better than 20/40).
   Methods: Patients with treatment-naive neovascular age-related macular degeneration were categorized prospectively into three groups according to baseline visual acuity: Group 1 (better than 70 letters), Group 2 (70 to 61 letters), and Group 3 (60 to 51 letters). Best-corrected visual acuity and central retinal thickness using optical coherence tomography were measured at baseline and at each follow-up visit. Intravitreal bevacizumab was administered according to an as-needed optical coherence tomography-guided regimen. Main outcome measure was mean best-corrected visual acuity for each group at 12 months.
   Results: Each group included 30 patients (30 eyes). Improvement in central retinal thickness was similar among the 3 groups (P = 0.964). Mean letter gain in visual acuity at 12 months was +0.4, +3.8, and +4.2 for Groups 1, 2, and 3, respectively (P = 0.42). Mean best-corrected visual acuity at 12 months was 78.4 letters for Group 1, 70.0 letters for Group 2, and 61.1 letters for Group 3 (P < 0.001). All eyes in Group 1 (100%) avoided losing 15 letters of best-corrected visual acuity versus 83.3% in Group 2 and 80.0% in Group 3. This difference was significant only between Group 1 and Group 3 (P = 0.02).
   Conclusion: Intravitreal bevacizumab for eyes with neovascular age-related macular degeneration and baseline visual acuity better than 70 letters was safe and able to maintain this vision over 12 months.
C1 [El-Mollayess, Georges M.; Salti, Haytham I.; Jaafar, Dalida; Bashshur, Ziad F.] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Mahfoud, Ziyad] Weill Cornell Med Coll, Dept Publ Hlth, Doha, Qatar.
   [Schakal, Alexandre R.] St Josephs Univ, Hotel Dieu France, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut; Weill Cornell Medical College Qatar;
   American University of Beirut; Saint Joseph University Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
OI Mahfoud, Ziyad/0000-0003-4098-6401
FU University Research Board at the American University of Beirut
FX Supported by the University Research Board at the American University of
   Beirut.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2010, COMP AGE RELATED MAC, P41
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Axer-Siegel R, 2012, RETINA-J RET VIT DIS, V32, P1811, DOI 10.1097/IAE.0b013e31825db771
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 7
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1828
EP 1835
DI 10.1097/IAE.0b013e3182877a0d
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500010
PM 23615342
DA 2022-11-30
ER

PT J
AU Mouallem, A
   Sarraf, D
   Chen, XJ
   Capuano, V
   Souied, EH
   Querques, G
AF Mouallem, Alexandra
   Sarraf, David
   Chen, Xuejing
   Capuano, Vittorio
   Souied, Eric H.
   Querques, Giuseppe
TI DOUBLE RETINAL PIGMENT EPITHELIUM TEARS IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; fluorescein angiography; fundus autofluorescence; neovascular
   age-related macular degeneration; retinal pigment epithelium tear;
   spectral-domain optical coherence tomography; vascularized pigment
   epithelium detachment
ID ANTI-VEGF THERAPY; PHOTODYNAMIC THERAPY; RANIBIZUMAB; MECHANISM
AB Purpose: To describe the occurrence and treatment outcomes of double retinal pigment epithelium (RPE) tears in neovascular age-related macular degeneration and to elucidate the mechanism of tear development by means of multimodal imaging analysis.
   Methods: Fundus autofluorescence, spectral-domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography were retrospectively studied before and after the occurrence of first and second RPE tears and at the final visit.
   Results: Twelve eyes of 10 patients that developed double RPE tears, either simultaneously (6 eyes) or at variable intervals after repeated intravitreal anti-vascular endothelial growth factor administration (6 eyes), were included. First RPE tears developed after a mean of 4.5 +/- 2.7 anti-vascular endothelial growth factor injections; second RPE tears developed after a mean of 7.1 +/- 5.2 anti-vascular endothelial growth factor injections. Mean best-corrected visual acuity was 20/63 at baseline evaluation, 20/76 after occurrence of first tear, 20/90 after occurrence of second tear, and 20/95 at final visit (P > 0.05 for all). Multimodal imaging revealed in all cases a Type 1 neovascular lesion adherent to the posterior surface of the RPE and spanning a significant portion of the pigment epithelium detachment with variable orientation; after development of double tears, the RPE seemed retracted on both borders of the neovascular network.
   Conclusion: Double RPE tears may occur on opposite sides of a vascularized pigment epithelium detachment, in eyes with neovascular age-related macular degeneration after anti-vascular endothelial growth factor therapy, because of neovascular contraction of a Type 1 neovascular complex, adherent to the posterior surface of the RPE and spanning a significant portion of the pigment epithelium detachment area.
C1 [Mouallem, Alexandra; Capuano, Vittorio; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Sarraf, David; Chen, Xuejing] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
   [Sarraf, David] Kaiser Permanente Med Ctr, Woodland Hills, CA USA.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System; Kaiser
   Permanente
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581; chen,
   xuejing/0000-0001-6827-0152
CR Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   KOENIG F, 1989, J FR OPHTALMOL, V12, P775
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
NR 16
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2016
VL 36
IS 11
BP 2197
EP 2204
DI 10.1097/IAE.0000000000001062
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1AY
UT WOS:000387079800028
PM 27145251
DA 2022-11-30
ER

PT J
AU Casten, RJ
   Rovner, BW
   Edmonds, SE
AF Casten, RJ
   Rovner, BW
   Edmonds, SE
TI The impact of depression in older adults with age-related macular
   degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID SYMPTOMS
AB This study examined how depression impacts age-related macular degeneration (AMD) disability among 114 elderly AMD patients. Results indicated that 49 patients met DSM-IV criteria for syndromal depression, and that visual acuity was the only variable significantly associated with vision-specific function. For general function, health was significant, and the relationship between visual acuity and function was only significant for depressed patients. Given that AMD results in high rates of depression and that depression exacerbates physical disability in AMD, devising optimal ways to identify and treat depressed patients in ophthalmology clinics is clearly important.
C1 Wills Eye Hosp & Res Inst, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA.
   Wills Eye Hosp & Res Inst, Low Vis Clin, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University
RP Casten, RJ (通讯作者)，Wills Eye Hosp & Res Inst, 900 Walnut St,8th Floor, Philadelphia, PA 19107 USA.
CR APA, 1994, DIAGNOSTIC STAT MANU
   Beckmann A, 1999, ELECTROCHEM COMMUN, V1, P46, DOI 10.1016/S1388-2481(98)00013-7
   DATH P, 1994, FAM PRACT, V11, P260, DOI 10.1093/fampra/11.3.260
   FOLSTEIN MF, 1985, PSYCHOL MED, V15, P809, DOI 10.1017/S0033291700005031
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   *LIGHTH INT, 2000, STAT VIS IMP RES MAN
   MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   RADLOFF L S, 1986, Clinical Gerontologist, V5, P119
   Steffens DC, 2000, ARCH GEN PSYCHIAT, V57, P601, DOI 10.1001/archpsyc.57.6.601
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
NR 12
TC 19
Z9 19
U1 0
U2 1
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 11 PENN PLAZA SUITE 300, NEW YORK, NY
   10001 USA
SN 0145-482X
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JUN
PY 2002
VL 96
IS 6
BP 399
EP 406
DI 10.1177/0145482X0209600603
PG 8
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 569TD
UT WOS:000176617600003
DA 2022-11-30
ER

PT J
AU Park, YG
   Rhu, HW
   Kang, S
   Roh, YJ
AF Park, Young Gun
   Rhu, Hyun Wook
   Kang, Seungbum
   Roh, Young Jung
TI New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB TREATMENT;
   GROWTH-FACTORS; SAFETY; TRIAL; EFFICACY; OCCULT
AB Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.
C1 [Park, Young Gun; Rhu, Hyun Wook; Kang, Seungbum; Roh, Young Jung] Catholic Univ Korea, Dept Ophthalmol, Yeouido St Marys Hosp, Coll Med, Seoul 150713, South Korea.
C3 Catholic University of Korea
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Yeouido St Marys Hosp, Coll Med, 62 Yeouido Dong, Seoul 150713, South Korea.
EM youngjungroh@hanmail.net
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   [Anonymous], 2008, DRUGS R&D, V9, P261
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chiang A, 2011, CURR OPIN OPHTHALMOL, V22, P199, DOI 10.1097/ICU.0b013e32834597d9
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kang S, 2011, JPN J OPHTHALMOL, V55, P123, DOI 10.1007/s10384-010-0910-1
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 43
TC 10
Z9 12
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 637316
DI 10.1155/2012/637316
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979DM
UT WOS:000306795100001
PM 22496964
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Hayashi, M
   Chernov, M
   Usukura, M
   Abe, K
   Ono, Y
   Izawa, M
   Hori, S
   Hori, T
   Takakura, K
AF Hayashi, M
   Chernov, M
   Usukura, M
   Abe, K
   Ono, Y
   Izawa, M
   Hori, S
   Hori, T
   Takakura, K
TI Gamma knife surgery for choroidal neovascularization in age-related
   macular degeneration - Technical note
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE gamma knife surgery; age-related macular degeneration; treatment
   planning
ID RADIOTHERAPY; SUBFOVEAL; TRIAL
AB The authors conducted a study to determine a way of overcoming the poor-quality demonstration of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) on conventional magnetic resonance (MR) imaging studies.
   The poor MR imaging demonstration of CNV in patients with AMD makes the use of gamma knife surgery more difficult. This difficulty, however, can be overcome by use of a modified time-of-flight MR imaging sequence with Gd enhancement and coronal reconstruction.
C1 Tokyo Womens Med Univ, Dept Neurosurg, Inst Neurol, Shinjuku Ku, Tokyo 1628666, Japan.
   Tokyo Womens Med Univ, Dept Neuroradiol, Tokyo 1628666, Japan.
   Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo 1628666, Japan.
C3 Tokyo Women's Medical University; Tokyo Women's Medical University;
   Tokyo Women's Medical University
RP Hayashi, M (通讯作者)，Tokyo Womens Med Univ, Dept Neurosurg, Inst Neurol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM GKRmoto@aol.com
RI Chernov, Mikhail F./H-5659-2012
OI Hori, Tomokatsu/0000-0001-7611-896X
CR Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Haas A, 2000, J NEUROSURG, V93, P172, DOI 10.3171/jns.2000.93.supplement_3.0172
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HAYASHI M, 2003, STEREOTAC RADIOTHER, V7, P1
   HORI S, 2002, CURRENT FUTURE RADIO, P91
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
NR 9
TC 3
Z9 3
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD JAN
PY 2005
VL 102
SU S
BP 200
EP 203
DI 10.3171/jns.2005.102.s_supplement.0200
PG 4
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 888PG
UT WOS:000226386100041
PM 15662810
DA 2022-11-30
ER

PT J
AU Rai, BB
   Morley, MG
   Bernstein, PS
   Maddess, T
AF Rai, Bhim B.
   Morley, Michael G.
   Bernstein, Paul S.
   Maddess, Ted
TI Severity of age-related macular degeneration at first presentation in
   Bhutan: a 3-year national study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE AMD presentation; AMD profile; AMD registry; AMD screening program;
   Severity of AMD
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PREVALENCE; PREDICTORS; THERAPY
AB Background Medical services are still developing in Bhutan. There is no published national report on age-related macular degeneration (AMD). We therefore aim to determine the demographic characteristics and severity of AMD at first presentation among Bhutanese patients attending their recently inaugurated vitreoretinal (VR) clinics over a 3-year national survey, and to inform national health policy to develop suitable health program to prevent AMD-related blindness and visual impairment. Methods A retrospective cross-sectional consecutive case series study was conducted on all new AMD cases in Bhutan. If a patient presented with asymmetrical AMD, the eye with more severe AMD was considered. If both the eyes had the same severity one eye was chosen randomly. Collection of demographic data and clinical details including diagnostic testing (fundus photography, OCT and fluorescent angiography) and clinical staging were performed. Results Of 521 new AMD patients aged 71.9 +/- 11.3 years, 306/521 (58.7%) were males (p = 0.005). At their first presentation, 234/521 patients (44.9%) already had late-stage AMD. Importantly, 69/234 patients (29.5%), that is half of total neovascular AMD (nAMD) patients, had disciform scars (DS) which were beyond treatment, and 7/234 patients (3.0%) had geographic atrophy (GA). Seven patients had retinal pigment epithelium tear at presentation. Fourteen of nineteen polypoidal choroidal vasculopathy (PCV) patients were younger than 50 years. Conclusions Half of nAMD cases presented as DS not amenable to the treatment. Many potentially treatable nAMD patients had already lost central vision and were legally blind. Young people with PCV losing vision early in life with longer morbidity-affected life and socio-economic burden was concerning. GA and DS cases need visual rehabilitation to improve their QoL. Incorporating a screening program for AMD with effective health education, and maintaining a national AMD Registry, would potentially lower AMD-related blindness and visual impairment.
C1 [Rai, Bhim B.; Maddess, Ted] Australian Natl Univ, John Curtin Sch Med Res, 131 Garran Rd Acton, Canberra, ACT 2601, Australia.
   [Rai, Bhim B.] Royal Govt Bhutan, Minist Hlth, JDW Natl Referral Hosp, Thimphu, Bhutan.
   [Morley, Michael G.] Harvard Med Sch, Boston, MA 02115 USA.
   [Bernstein, Paul S.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
C3 Australian National University; John Curtin School of Medical Research;
   Harvard University; Harvard Medical School; Utah System of Higher
   Education; University of Utah
RP Rai, BB (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, 131 Garran Rd Acton, Canberra, ACT 2601, Australia.; Rai, BB (通讯作者)，Royal Govt Bhutan, Minist Hlth, JDW Natl Referral Hosp, Thimphu, Bhutan.
EM bhim.rai@anu.edu.au
RI Bahadur, Bhim/C-2972-2017; Maddess, Ted/A-3200-2008
OI Bahadur, Bhim/0000-0003-0748-4581; Maddess, Ted/0000-0003-4591-3658;
   Bernstein, Paul/0000-0002-4228-7666
FU John Curtin School of Medical Research at the Australian National
   University
FX The study was supported by the John Curtin School of Medical Research at
   the Australian National University.
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Behera UC, 2021, INDIAN J OPHTHALMOL, V69, P2939, DOI 10.4103/ijo.IJO_1508_21
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Camelo S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4984927
   Cecchini M, 2012, ISR J HEALTH POLICY, V1, DOI 10.1186/2045-4015-1-18
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   deloitte, SOCIOECONOMIC COST M
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Dorji Tandin, 2016, WHO South East Asia J Public Health, V5, P44, DOI 10.4103/2224-3151.206552
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim JH, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163580
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lepcha NT, 2013, OPHTHAL EPIDEMIOL, V20, P212, DOI 10.3109/09286586.2013.794902
   Lhamo N, 2011, J ETHNOBIOL ETHNOMED, V7, DOI 10.1186/1746-4269-7-3
   Maddess T, 2020, NEW FRONT OPHTHALMOL, V6, P1, DOI 10.15761/NFO.1000251
   Ministry of Information and Communication, 2017, BHUT INF MED IMP STU
   mowhs, THROMDE RULES
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Rachitskaya Aleksandra V, 2015, Curr Ophthalmol Rep, V3, P26, DOI 10.1007/s40135-014-0057-1
   Rai BB, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01675-8
   Rai BB, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01335-x
   Rai BB, 2019, ASIA-PAC J OPHTHALMO, V8, P481, DOI 10.1097/01.APO.0000604400.50700.2d
   Rai BB, 2021, GRAEF ARCH CLIN EXP, V259, P613, DOI 10.1007/s00417-020-04891-6
   researchers, EYES FUTURE CLEAR OU
   Rinchen S, 2018, J HEALTH RES, V32, P288, DOI 10.1108/JHR-05-2018-031
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Sharma Jayendra, 2014, WHO South East Asia J Public Health, V3, P226, DOI 10.4103/2224-3151.206745
   tobaccocontrollaws, BIG BAN BHUTANSJOURN
   UNESCO, 2021, ED DISR REC
   van Dijk EHC, 2021, GRAEF ARCH CLIN EXP, V259, P351, DOI 10.1007/s00417-020-04844-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
NR 41
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 9
PY 2022
VL 22
IS 1
AR 298
DI 10.1186/s12886-022-02520-w
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2T4ZF
UT WOS:000822484100001
PM 35810276
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Barikian, A
   Mahfoud, Z
   Abdulaal, M
   Safar, A
   Bashshur, ZF
AF Barikian, Anita
   Mahfoud, Ziyad
   Abdulaal, Marwan
   Safar, Ammar
   Bashshur, Ziad F.
TI Induction With Intravitreal Bevacizumab Every Two Weeks in the
   Management of Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULARIZATION; TRAP-EYE; RANIBIZUMAB; TRIAL; VEGF; THERAPY; SWITCH
AB center dot PURPOSE: To explore the benefit of rapid induction with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD).
   center dot DESIGN: Single-institution prospective randomized pilot study.
   center dot METHODS: Patients with treatment-naive neovascular AMD were randomized 1:1:1 into 1 of 3 groups based on the induction sequence: (1) every 2 weeks for 3 consecutive injections; (2) every 4 weeks for 3 consecutive injections; and (3) immediate pro re nata (prn) after the first injection. Retinal angiomatous proliferation and polypoidal choroidal vasculopathy were excluded. Best-corrected visual acuity (BCVA) and central retinal thickness using optical coherence tomography (OCT) were measured at baseline and at each follow-up. After induction, bevacizumab was administered as needed based mainly on OCT. Main outcome measure was mean initial fluid-free interval after induction. Secondary outcomes were mean improvement in BCVA and central retinal thickness.
   center dot RESULTS: Each group included 30 patients (30 eyes). Mean initial fluid-free interval was 2.4, 3.4, and 3.5 months for biweekly induction, monthly induction, and immediate pm groups, respectively (P = .03). Significance was lost when corrected for age and sex (P = .073). Mean improvement in BCVA, central retinal thickness, and total number of injections were similar among the groups at 12 months. Six eyes in the biweekly induction group developed subretinal fibrosis vs no eyes in the other 2 groups (P = .003).
   center dot CONCLUSION: Biweekly induction with intravitreal bevacizumab for treatment-naive neovascular AMD does not increase initial fluid-free interval or cause significant anatomic and functional benefit compared to monthly induction or immediate pm. There is also the potential development of subretinal fibrosis with biweekly induction. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Barikian, Anita; Abdulaal, Marwan; Bashshur, Ziad F.] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Mahfoud, Ziyad] Weill Cornell Med Coll, Dept Global & Publ Hlth, Doha, Qatar.
   [Safar, Ammar] Amer Hosp Dubai, Dept Ophthalmol, Dubai, U Arab Emirates.
C3 American University of Beirut; Weill Cornell Medical College Qatar
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
OI Mahfoud, Ziyad/0000-0003-4098-6401
FU Novartis; Allergan (Center Valley, Pennsylvania, USA); American
   University of Beirut Medical Center, Beirut, Lebanon
FX The authors indicate no financial interest in any product discussed in
   this study. Z.F.B. has participated on advisory boards for Novartis and
   Bayer; has received honoraria from Bayer (Leverkusen, Germany) and
   Novartis (Basel, Switzerland) as invited speaker; and has received
   research grants from Novartis and Allergan (Center Valley, Pennsylvania,
   USA). This study was supported by American University of Beirut Medical
   Center, Beirut, Lebanon.
CR Beoyon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   El-Sabagh HA, 2011, OPHTHALMOLOGY, V118, P636, DOI 10.1016/j.ophtha.2010.08.038
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Olajumoke S, 2011, CLIN EXP OPHTHALMOL, V39, P3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 29
TC 19
Z9 20
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2015
VL 159
IS 1
BP 131
EP 137
DI 10.1016/j.ajo.2014.10.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY7NU
UT WOS:000347747500018
PM 25308787
DA 2022-11-30
ER

PT J
AU Kim, J
   Lee, YJ
   Won, JY
AF Kim, Jongmin
   Lee, Yeo Jin
   Won, Jae Yon
TI Molecular Mechanisms of Retinal Pigment Epithelium Dysfunction in
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; retinal pigment epithelium
ID ALPHA-B-CRYSTALLIN; MITOCHONDRIAL-DNA DAMAGE; 670 NM LIGHT; OXIDATIVE
   STRESS; COMPLEMENT-SYSTEM; GROWTH-FACTOR; VASCULAR-PERMEABILITY;
   VISUAL-ACUITY; LASER THERAPY; CELL-DENSITY
AB The retinal pigment epithelium (RPE), situated upon Bruch's membrane, plays multiple roles in the ocular system by interacting with photoreceptors and. Therefore, dysfunction of the RPE causes diseases related to vision loss, such as age-related macular degeneration (AMD). Despite AMD being a global cause of blindness, the pathogenesis remains unclear. Understanding the pathogenesis of AMD is the first step for its prevention and treatment. This review summarizes the common pathways of RPE dysfunction and their effect in AMD. Potential treatment strategies for AMD based on targeting the RPE have also been discussed.
C1 [Kim, Jongmin] Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Pohang 37673, South Korea.
   [Lee, Yeo Jin; Won, Jae Yon] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.
   [Lee, Yeo Jin; Won, Jae Yon] Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, Seoul 14662, South Korea.
C3 Pohang University of Science & Technology (POSTECH); Catholic University
   of Korea; Catholic University of Korea
RP Won, JY (通讯作者)，Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.; Won, JY (通讯作者)，Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, Seoul 14662, South Korea.
EM mandarinbear@postech.ac.kr; yeojin@nate.com; jaywon24@catholic.ac.kr
FU National Research Foundation of Korea - Korea government (MSIP)
   [NRF-2021R1C1C1008042]; Catholic University of Korea, Eunpyeong St.
   Mary's Hospital
FX This work has been supported by the National Research Foundation of
   Korea grant funded by the Korea government (MSIP) (NRF-2021R1C1C1008042)
   and The Catholic University of Korea, Eunpyeong St. Mary's Hospital.
   Research Institute of Medical Science.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Caceres PS, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a027847
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Candas D, 2014, ANTIOXID REDOX SIGN, V20, P1599, DOI 10.1089/ars.2013.5305
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Desjardins DM, 2016, INVEST OPHTH VIS SCI, V57, P2706, DOI 10.1167/iovs.15-18397
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Farjood F, 2017, MOL VIS, V23, P431
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Fuma S, 2015, MOL VIS, V21, P883
   Gangalum RK, 2004, J BIOL CHEM, V279, P43374, DOI 10.1074/jbc.C400371200
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3
   Ho DT, 2006, J BIOL CHEM, V281, P13169, DOI 10.1074/jbc.M601010200
   Hogan M., 1971, PHILA SAUNDERS
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KHATAMI M, 1986, EXP EYE RES, V43, P607, DOI 10.1016/S0014-4835(86)80027-6
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kivinen N., 2018, THESIS U MICHIGAN AN
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kurtz JC, 1998, DOC OPHTH P, V62, P47
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Lavey B.J., 2013, P MECH LOW LIGHT THE, P85690
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   MARMOR MF, 1990, EYE, V4, P340, DOI 10.1038/eye.1990.46
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   MILLER SS, 1990, J PHYSIOL-LONDON, V424, P283, DOI 10.1113/jphysiol.1990.sp018067
   MILLER SS, 1977, J MEMBRANE BIOL, V36, P337, DOI 10.1007/BF01868158
   MILLER SS, 1977, EXP EYE RES, V25, P235, DOI 10.1016/0014-4835(77)90090-2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Newsholme P, 2007, J PHYSIOL-LONDON, V583, P9, DOI 10.1113/jphysiol.2007.135871
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136851
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Senanayake PD, 2006, EXP EYE RES, V83, P235, DOI 10.1016/j.exer.2005.10.034
   Shadrach KG, 2003, INVEST OPHTH VIS SCI, V44, pU77
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shrestha R, 2020, CURR EYE RES, V45, P1155, DOI 10.1080/02713683.2020.1722180
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Surendran H, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02134-x
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Toms M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40507-8
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Ved N, 2017, CLIN SCI, V131, P1225, DOI 10.1042/CS20170102
   Verkman AS, 2008, PROG RETIN EYE RES, V27, P420, DOI 10.1016/j.preteyeres.2008.04.001
   Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Watanabe G, 2009, CANCER SCI, V100, P2368, DOI 10.1111/j.1349-7006.2009.01316.x
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119570
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   ZAVAZAVA N, 1991, CLIN EXP IMMUNOL, V84, P163
NR 141
TC 5
Z9 5
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 22
AR 12298
DI 10.3390/ijms222212298
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XF5LZ
UT WOS:000724112900001
PM 34830181
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Apte, RS
   Bressler, NM
AF Apte, RS
   Bressler, NM
TI Foveal congenital hypertrophy of the retinal pigment epithelium in the
   setting of geographic atrophy from age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report a case of presumed congenital hypertrophy of the retinal pigment epithelium in the fovea of an 88-year-old woman in the setting of geographic atrophy from age-related macular degeneration.
   DESIGN: Observational case report.
   METHODS: An 88-year-old woman was examined.
   RESULTS: Best-corrected visual acuity was 20/63 in the right eye and 20/50 in the left eye. Multifocal areas of geographic atrophy and large,sized drusen were seen in the maculae of both eyes. Biomicroscopic examination of the right eye showed hyperpigmentation consistent with congenital hypertrophy of the retinal pigment epithelium through the center of the macula. No prior photographic documentation of the retina was available.
   CONCLUSION: This case suggests that foveal congenital hypertrophy of the retinal pigment epithelium may be seen in the setting of macular geographic atrophy. Although it is theoretically possible that the hyperpigmentation is reactive rather than congenital, the pigmentation is typical for congenital hypertrophy and is unlike any reactive pigmentation in our experience or described in a MEDLINE search of features of age-related macular degeneration. The case suggests that a hypertrophic process of the retinal pigment epithelium may coexist within or immediately adjacent to the anatomic boundaries of an atrophic process such as geographic atrophy from age-related macular degeneration.
C1 Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Retinal Vasc Ctr, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，550 N Broadway,Suite 115, Baltimore, MD 21205 USA.
CR BEUTTNER H, 1975, AM J OPHTHALMOL, V79, P177
   BEUTTNER H, 2001, RETINA, P634
   Nishikatsu H, 1996, OPHTHALMOLOGICA, V210, P126, DOI 10.1159/000310689
NR 3
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2003
VL 135
IS 1
BP 120
EP 121
DI 10.1016/S0002-9394(02)01845-7
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 632QG
UT WOS:000180233900032
PM 12504720
DA 2022-11-30
ER

PT J
AU Do, DV
   Rhoades, W
   Nguyen, QD
AF Do, Diana V.
   Rhoades, William
   Nguyen, Quan Dong
TI PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; pharmacokinetics; half-life;
   aflibercept; intravitreal VEGF inhibitors; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR PHARMACOKINETICS; SYSTEMIC
   SAFETY; INJECTION; EYE
AB Purpose: To investigate the half-life of aflibercept in aqueous humor after a single intravitreal injection in patients with neovascular age-related macular degeneration. Methods: Prospective, noncomparative, interventional case series of five eyes with neovascular age-related macular degeneration naive to anti-vascular endothelial growth factor therapy were enrolled and treated with intravitreal aflibercept. At baseline, best-corrected visual acuity, optical coherence tomography imaging, and aqueous humor (treatment eye) and blood/plasma samples were taken. Patients underwent best-corrected visual acuity, optical coherence tomography imaging, and sampling of aqueous humor from the eye and blood/plasma at six additional post-treatment time points of 4 hours and Days 1, 3, 7, 14, and 28. Concentrations of aflibercept were quantified using an enzyme-linked immunosorbent assay. Results: Median peak concentration (Cmax) of free aflibercept in the aqueous was 122 mg/L. The median half-life of free aflibercept was 11 days in the eye. In plasma, the concentrations of free aflibercept were low and transient, reaching undetectable levels during the first week after injection, and undetectable in all patients at time points beyond 7 days. Conclusion: The pharmacokinetic profile in the aqueous humor described here together with the previously reported affinity of aflibercept for vascular endothelial growth factor is consistent with and adds to our understanding for the duration of its clinical efficacy.
C1 [Do, Diana V.; Nguyen, Quan Dong] Stanford Univ, Sch Med, Byers Eye Inst, 2370 Watson Court,Suite 228, Palo Alto, CA 94303 USA.
   [Rhoades, William] Associated Retinal Consultants, Grand Rapids, MI USA.
C3 Stanford University
RP Do, DV (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst, 2370 Watson Court,Suite 228, Palo Alto, CA 94303 USA.
EM dianado@stanford.edu
FU Regeneron Pharmaceuticals
FX Supported by Regeneron Pharmaceuticals through an investigator initiated
   study designed and conducted by D. V. Do.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Epstein P, 2007, ANN INTERN MED, V146, P532, DOI 10.7326/0003-4819-146-7-200704030-00011
   Jampol LM, 2018, OPHTHALMOLOGY, V125, P1054, DOI 10.1016/j.ophtha.2018.01.019
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 13
TC 19
Z9 21
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 643
EP 647
DI 10.1097/IAE.0000000000002566
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800006
PM 31145389
DA 2022-11-30
ER

PT J
AU Baird, PN
   Chakrabarti, S
AF Baird, Paul N.
   Chakrabarti, Subhabrata
TI How genetic studies have advanced our understanding of age-related
   macular degeneration and their impact on patient care: a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age related macular degeneration; epigenetics; genetic variants;
   gene-environment; next generation sequencing
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; COPY NUMBER POLYMORPHISM;
   ENVIRONMENT INTERACTION; RISK; SUSCEPTIBILITY; VARIANT; CFH;
   MACULOPATHY; EXOME
AB The last 10 years have seen an unprecedented explosion in our knowledge regarding the genomic basis of age-related macular degeneration. This has come about through major advances in computing power, microfabrication of large numbers of molecular markers on chips and improved statistical algorithms for analysis. In tandem, it has become clear that age-related macular degeneration appears to be a multifactorial disease with influences from genetic and structural variants, as well as epigenetic involvement. The combination of these factors with known environmental determinants indicates the highly complex nature of this disease, but at the same time also offers insights into risk prediction and disease stratification through genotype profiling.
C1 [Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Chakrabarti, Subhabrata] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
C3 Centre for Eye Research Australia; University of Melbourne; L. V. Prasad
   Eye Institute
RP Baird, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Ocular Genet Unit, Level 1,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
RI Chakrabarti, Subhabrata/F-2468-2015
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; Baird,
   Paul/0000-0002-1305-3502
FU Australia-India Strategic Research Fund (AISRF); Department of
   Biotechnology (DBT), Government of India; Department of Innovation,
   Industry, Science and Research (DIISR), Government of Australia;
   Australian Academy of Science; National Health and Medical Research
   Council (NHMRC) Centre for Clinical Research Excellence [529923]; NHMRC
   [1028444]
FX We acknowledge support from the Australia-India Strategic Research Fund
   (AISRF) jointly funded through the Department of Biotechnology (DBT),
   Government of India and the Department of Innovation, Industry, Science
   and Research (DIISR), Government of Australia, an Australia-India Senior
   Visiting Fellowship from the Australian Academy of Science (PNB), the
   National Health and Medical Research Council (NHMRC) Centre for Clinical
   Research Excellence #529923 - Translational Clinical Research in Major
   Eye Diseases and NHMRC Senior Research Fellowship #1028444 to PNB. CERA
   receives operational infrastructure support from the Victorian
   Government, Australia.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bick D, 2011, CURR OPIN PEDIATR, V23, P594, DOI 10.1097/MOP.0b013e32834b20ec
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Coonrod EM, 2013, ARCH PATHOL LAB MED, V137, P415, DOI 10.5858/arpa.2012-0107-RA
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gilissen C, 2012, EUR J HUM GENET, V20, P490, DOI 10.1038/ejhg.2011.258
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gullapalli RR, 2012, CLIN LAB MED, V32, P585, DOI 10.1016/j.cll.2012.07.005
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harrison RJ, 2012, SEMIN CELL DEV BIOL, V23, P230, DOI 10.1016/j.semcdb.2012.01.006
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Kubista KE, 2011, MOL VIS, V17, P2080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Majewski J, 2011, J MED GENET, V48, P580, DOI 10.1136/jmedgenet-2011-100223
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mutz KO, 2013, CURR OPIN BIOTECH, V24, P22, DOI 10.1016/j.copbio.2012.09.004
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Ozsolak F, 2011, WIRES RNA, V2, P565, DOI 10.1002/wrna.84
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thomas D, 2010, ANNU REV PUBL HEALTH, V31, P21, DOI 10.1146/annurev.publhealth.012809.103619
   Thomas D, 2010, NAT REV GENET, V11, P259, DOI 10.1038/nrg2764
   Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 83
TC 5
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2014
VL 42
IS 1
BP 53
EP 64
DI 10.1111/ceo.12235
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA1OC
UT WOS:000330864600007
PM 24112216
DA 2022-11-30
ER

PT J
AU Wong, CW
   Liao, JM
   Cheung, GC
   Khor, CC
   Vithana, EN
   Wang, JJ
   Mitchell, P
   Aung, T
   Wong, TY
   Cheng, CY
AF Wong, Chee Wai
   Liao, Jiemin
   Cheung, Gemmy C.
   Khor, Chiea Chuen
   Vithana, Eranga N.
   Wang, Jie Jin
   Mitchell, Paul
   Aung, Tin
   Wong, Tien Y.
   Cheng, Ching-Yu
TI Lens Status Influences the Association between CFH Polymorphisms and
   Age-Related Macular Degeneration: Findings from Two Population-Based
   Studies in Singapore
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BLUE MOUNTAINS EYE; BEAVER DAM EYE; INTRAOCULAR
   LENSES; CATARACT-SURGERY; RISK-FACTORS; POOLED FINDINGS; MALAY EYE;
   MACULOPATHY; SUSCEPTIBILITY
AB Aims
   To determine the differential effects of genetic polymorphism in CFH and ARMS2 on risk of age-related macular degeneration (AMD) between phakic vs. pseudophakic/aphakic eyes.
   Methods
   9,529 eyes of 4,918 participants from the Singapore Malay Eye Study and Singapore Indian Eye Study were analyzed. Participants had detailed eye examinations, including slit-lamp examinations and dilated fundus photography. AMD grading was performed according to the Wisconsin age-related maculopathy grading system. Lens status was defined. Single nucleotide polymorphisms (SNPs) rs10801555 (Y402H) within CFH and rs3750847 in ARMS2 were assessed. The main outcome measure was early AMD or any AMD.
   Results
   No significant associations between the CFH Y402H genotypes and early AMD were found in phakic individuals. In contrast, among pseudophakic/aphakic individuals, the CFH Y402H risk genotypes were significantly associated with higher odds of early AMD, with an OR of 1.57 (95% CI: 1.07-2.29) for GA genotype and 2.40 (95% CI: 1.25-4.61) for AA genotype, compared to those with GG genotype. There was significant interaction between pseudophakic/aphakic status and CFH Y402H variant on risk of early AMD (p = 0.037), adjusting for age, gender, and the first 5 genetic principal components. No significant interaction was found between lens status and ARMS2 rs3750847.
   Conclusions
   CFH genetic polymorphism and pseudophakic/aphakic status may have a potential synergistic effect on early AMD, suggesting roles for the complement system and related pathways in the pathogenesis of AMD in eyes after cataract surgery.
C1 [Wong, Chee Wai; Liao, Jiemin; Cheung, Gemmy C.; Vithana, Eranga N.; Aung, Tin; Wong, Tien Y.; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Liao, Jiemin; Aung, Tin; Wong, Tien Y.; Cheng, Ching-Yu] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
   [Liao, Jiemin; Aung, Tin; Wong, Tien Y.; Cheng, Ching-Yu] Natl Univ Hlth Syst, Singapore, Singapore.
   [Cheung, Gemmy C.; Vithana, Eranga N.; Wong, Tien Y.; Cheng, Ching-Yu] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Khor, Chiea Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   University of Sydney; Westmead Institute for Medical Research
RP Cheng, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
EM chingyu.cheng@duke-nus.edu.sg
RI Cheng, Ching-Yu/Y-2229-2019; Mitchell, Paul/P-1498-2014; Wong, Tien
   Yin/AAC-9724-2020; Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Wang, Jie Jin/0000-0001-9491-4898; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Khor, Chiea Chuen/0000-0002-1128-4729
FU American Health Assistance Foundation [M2011068]; National Medical
   Research Council, Singapore [NMRC 0976/2003, STaR/0003/2008,
   CSA/033/2012, CG/SERI/2010]; Biomedical Research Council, Singapore
   [BMRC 09/1/35/19/616, 08/1/35/19/550]; NMRC [CSA/033/2012]
FX Supported by funding from the American Health Assistance Foundation
   (M2011068), and grants from the National Medical Research Council,
   Singapore (NMRC 0976/2003, STaR/0003/2008, CSA/033/2012, CG/SERI/2010),
   and the Biomedical Research Council, Singapore (BMRC 09/1/35/19/616 and
   08/1/35/19/550). Ching-Yu Cheng is supported by an award from NMRC
   (CSA/033/2012). The Singapore Tissue Network and the Genome Institute of
   Singapore, Agency for Science, Technology and Research, Singapore
   provided services for tissue archival and genotyping, respectively. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abela-Formanek C, 2002, J CATARACT REFR SURG, V28, P50, DOI 10.1016/S0886-3350(01)01122-1
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Barbour W, 2005, OPHTHAL RES, V37, P255, DOI 10.1159/000087100
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards KH, 2010, CLIN EXP OPTOM, V93, P390, DOI 10.1111/j.1444-0938.2010.00538.x
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fritsche LG, 2013, NAT GENET
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gemmy Cheung CM, 2012, AM J OPHTHALMOL
   Gold G, 2003, AM J MED GENET B, V119B, P44, DOI 10.1002/ajmg.b.10010
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hollick EJ, 1998, J CATARACT REFR SURG, V24, P361, DOI 10.1016/S0886-3350(98)80324-6
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x
   Pokidysheva EN, 2001, ARTIF ORGANS, V25, P453, DOI 10.1046/j.1525-1594.2001.025006453.x
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WENZEL M, 1988, GRAEF ARCH CLIN EXP, V226, P449, DOI 10.1007/BF02170007
   Werner L, 2008, CURR OPIN OPHTHALMOL, V19, P41, DOI 10.1097/ICU.0b013e3282f20132
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
NR 49
TC 3
Z9 3
U1 4
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2015
VL 10
IS 3
AR e0119570
DI 10.1371/journal.pone.0119570
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE9BN
UT WOS:000352138500113
PM 25786237
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Finger, RP
   Puth, MT
   Schmid, M
   Barthelmes, D
   Guymer, RH
   Gillies, M
AF Finger, Robert P.
   Puth, Marie-Therese
   Schmid, Matthias
   Barthelmes, Daniel
   Guymer, Robyn H.
   Gillies, Mark
TI Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment
   for Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DISEASE PROGRESSION; MARKOV-MODELS; BLINDNESS; RANIBIZUMAB; IMPACT;
   TIMES
AB Importance Neovascular age-related macular degeneration (nAMD), the largest single cause of irreversible severe vision loss in high-income countries, can now be treated with vascular endothelial growth factor (VEGF) inhibitors, but to our knowledge, no data on lifetime outcomes are available. Objective To determine visual acuity (VA) outcomes of anti-VEGF treatment for nAMD in both eyes for patients' remaining lifetime. Design, Setting, and Participants Multistate modeling using real-world cohort data of 3192 patients with nAMD (>67 000 visits) treated in routine eye clinics in Australia, New Zealand, and Switzerland. Data were analyzed between 2007 and 2015. Exposures Intravitreal anti-VEGF treatment at the treating physician's discretion and prospective data collection in standardized registry. Main Outcomes and Measures Visual acuity in both eyes over the remaining lifetime. Results For the mean remaining lifetime of 11 years, an estimated 12% (n = 371; 95% CI, 345-400) of the sample retained driving VA and an estimated 15% (n = 463; 95% CI, 434-495) reading VA in at least 1 eye. At that time, an estimated 82% of the sample (n = 2629; 95% CI, 2590-2660) had dropped out. Younger age at baseline and more injections during the first year of treatment were associated with better long-term outcomes. Conclusions and Relevance Anti-VEGF treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. More than 80% of patients will cease treatment over that time, having likely experienced a deterioration of vision beforehand. This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-VEGF treatment to persons in need.
   Question What are lifetime outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration? Findings In this multistate model using real-world data, an estimated 12% of the sample retained driving visual acuity and 15% reading visual acuity in at least 1 eye over their mean remaining lifetime of 11 years. More injections and younger age at baseline were associated with better outcomes. Meaning Good lifetime vision outcomes can be achieved with anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration with more injections and an earlier start, increasing the chances of good outcomes and highlighting the need to provide easy access to this treatment.
   This study evaluates visual acuity outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in both eyes for patients' remaining life span.
C1 [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Puth, Marie-Therese; Schmid, Matthias] Univ Bonn, IMBIE, Fac Med, Bonn, Germany.
   [Barthelmes, Daniel; Gillies, Mark] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol & Eye Hlth, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 University of Bonn; University of Bonn; University of Sydney; University
   of Zurich; University Zurich Hospital; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robert.finger@ukbonn.de
OI Schmitz, Marie-Therese/0000-0003-1351-9381; Schmid,
   Matthias/0000-0002-0788-0317
FU German Scholars Organization/Else Kroner Fresenius Stiftung
   [GSO/EKFS-16]; Royal Australian and New Zealand College of
   Ophthalmologists Eye Foundation (2007-2009); National Health and Medical
   Research Council, Australia (NHMRC 2010-2012); Macular Disease
   Foundation, Australia; Walter Gertrud Siegenthaler Foundation, Zurich,
   Switzerland; Swiss National Foundation; National Health and Medical
   Research Council, Australia practitioner fellowship; National Health and
   Medical Research Council of Australia [GNT1103013]
FX This work was in part supported by the German Scholars Organization/Else
   Kroner Fresenius Stiftung (GSO/EKFS-16). The Fight Retinal Blindness
   Project was supported by a grant from the Royal Australian and New
   Zealand College of Ophthalmologists Eye Foundation (2007-2009); a grant
   from the National Health and Medical Research Council, Australia (NHMRC
   2010-2012); and a grant from the Macular Disease Foundation, Australia.
   Dr Gillies is a Sydney Medical Foundation Fellow and is supported by an
   National Health and Medical Research Council, Australia practitioner
   fellowship. Dr Barthelmes was supported byWalter Gertrud Siegenthaler
   Foundation, Zurich, Switzerland, and the Swiss National Foundation. Dr
   Guymer was supported by National Health and Medical Research Council of
   Australia fellowship grant GNT1103013. Centre for Eye Research receives
   operational infrastructure support from the Victorian government.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   COLENBRANDER A, 1995, AM J OCCUP THER, V49, P865, DOI 10.5014/ajot.49.9.865
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Finger RP, 2012, BRIT J OPHTHALMOL, V96, P1276, DOI 10.1136/bjophthalmol-2011-301201corr1
   Gil J, 2007, AMYOTROPH LATERAL SC, V8, P224, DOI 10.1080/17482960701278562
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grand MK, 2019, STAT MED, V38, P1802, DOI 10.1002/sim.8069
   Jackson CH, 2002, STAT MED, V21, P113, DOI 10.1002/sim.886
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P1118, DOI 10.1136/bjo.86.10.1118
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Minicuci N, 2005, EXP GERONTOL, V40, P997, DOI 10.1016/j.exger.2005.08.011
   Petiot V, 2007, NEUROEPIDEMIOLOGY, V28, P56, DOI 10.1159/000098518
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sweeting MJ, 2010, STAT MED, V29, P1161, DOI 10.1002/sim.3812
   Westborg I, 2018, OPHTHAL EPIDEMIOL, V25, P176, DOI 10.1080/09286586.2017.1397701
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 2
Z9 2
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2020
VL 138
IS 12
BP 1234
EP 1240
DI 10.1001/jamaophthalmol.2020.3989
EA OCT 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PS6GH
UT WOS:000581905400001
PM 33057589
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yoon, JM
   Shin, DH
   Kong, M
   Ham, DI
AF Yoon, Je Moon
   Shin, Dong Hoon
   Kong, Mingui
   Ham, Don-Il
TI Age-related macular degeneration eyes presenting with cuticular drusen
   and reticular pseudodrusen
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CLINICAL CHARACTERISTICS; CHOROIDAL THICKNESS; DEPOSITS; PREVALENCE;
   FEATURES; ASSOCIATION; DETACHMENT
AB This study aimed to describe the clinical characteristics of age-related macular degeneration (AMD) eyes with both cuticular drusen (CD) and reticular pseudodrusen (RPD). Clinical records of patients diagnosed with CD or RPD with multimodal imaging was reviewed for patients diagnosed with both CD and RPD. The distribution patterns of CD (macular and diffuse type) and RPD (localized, intermediate, and diffuse type), presence of soft drusen, large drusen (> 200 mu m), variant subretinal drusenoid deposits, and macular complications were investigated. Of the 220 eyes of 110 patients diagnosed with CD and 926 eyes of 463 patients diagnosed with RPD, 13 eyes of seven patients met the diagnostic criteria for both CD and RPD. The mean age at initial presentation was 71.4 +/- 8.8 years and six patients were female. The mean subfoveal choroidal thickness was 143.8 +/- 25.1 mu m. The distribution of CD was of the macular type in all eyes. Distribution of RPD was localized in 11 eyes (84.6%) and intermediate in two eyes (15.4%). Soft drusen, large drusen, and variant subretinal drusenoid deposits were present in 13 (100%), 12 (92.3%) and, seven (53.8%) eyes, respectively. Macular neovascularization was observed in two eyes (15.4%). CD and RPD can coexist in eyes with AMD. Multimodal imaging should be used for AMD eyes with features suggestive of CD and RPD, considering the high likelihood of developing late AMD.
C1 [Yoon, Je Moon; Ham, Don-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
   [Shin, Dong Hoon; Kong, Mingui] Hangil Eye Hosp, Retina Ctr, Incheon, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
EM oculus@naver.com
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kong M, 2019, RETINA-J RET VIT DIS, V39, P1945, DOI 10.1097/IAE.0000000000002263
   Kumawat D, 2021, J OPHTHAL VIS RES, V16, P187, DOI 10.18502/jovr.v16i2.9082
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen-Uretsky S, 2016, RETINA-J RET VIT DIS, V36, P1111, DOI 10.1097/IAE.0000000000000831
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P448, DOI 10.1007/s10384-019-00692-5
   Sakurada Y, 2018, OPHTHALMOL RETINA, V2, P815, DOI 10.1016/j.oret.2018.03.009
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Shin DH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68493-2
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 32
TC 1
Z9 1
U1 1
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 5
PY 2022
VL 12
IS 1
AR 5681
DI 10.1038/s41598-022-09608-9
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0L5OM
UT WOS:000781522600013
PM 35383241
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Farah, ME
   Cardillo, JA
   Luzardo, AC
   Calucci, D
   Williams, GA
   Costa, RA
AF Farah, ME
   Cardillo, JA
   Luzardo, AC
   Calucci, D
   Williams, GA
   Costa, RA
TI Indocyanine green mediated photothrombosis for the management of
   predominantly classic choroidal neovascularisation caused by age related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; VERTEPORFIN; OCCULT
AB Aims: To study the effectiveness of indocyanine green mediated photothrombosis in the management of predominantly classic subfoveal choroidal neovascularisation associated with age related macular degeneration.
   Methods: Prospective, non-comparative, interventional case series of nine patients with predominantly classic subfoveal choroidal neovascularisation secondary to age related macular degeneration who declined photocoagulation or verteporfin photodynamic therapy. Patients were submitted to one or more treatments with an intravenous injection of a small volume of high concentration indocyanine green solution followed by low irradiance, large spot 810 nm continuous laser application via a transpupillary approach. Main outcome measures were change in best corrected visual acuity and macular exudative manifestations.
   Results: After 12 months of follow up, the final best corrected visual acuity was the same ( plus or minus two ETDRS lines) in five eyes (55%), improved more than two ETDRS lines in three eyes (33%), and worsened by more than two lines in the remaining eye. The improved vision was probably related to partial or complete restoration of the macular architecture as a result of fluid resolution, whereas the worsened vision was primarily the result of treatment failure in achieving substantial choroidal neovascular occlusion. There were no complications related to the procedure.
   Conclusion: Indocyanine green mediated photothrombosis may be an effective alternative treatment for predominantly classic subfoveal choroidal neovascularisation caused by age related macular degeneration.
C1 Univ Fed Sao Paulo, Paulista Sch Med, Inst Visao IPEPO, Dept Ophthalmol, Sao Paulo, Brazil.
   Associated Retinal Consultants, Beaumont Eye Inst, Royal Oak, MI USA.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Farah, ME (通讯作者)，Av Ibijau,331,4 Andar, BR-04524020 Sao Paulo, Brazil.
EM mefarah@uol.com.br
RI Farah, Michel Eid E/F-3285-2012; Costa, Rogerio A/E-6930-2013
OI Farah, Michel Eid E/0000-0001-5951-0193; Costa, Rogerio
   A/0000-0002-0800-2233; Cardillo, Jose Augusto/0000-0002-5791-3201
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Costa RA, 2002, CURR EYE RES, V25, P287, DOI 10.1076/ceyr.25.5.287.13496
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   FOX IJ, 1956, AM J PHYSIOL, V187, P599
   GROSSWEINER LI, 1994, SCI PHOTOTHERAPY, P27
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Navajas EV, 2003, EYE, V17, P563, DOI 10.1038/sj.eye.6700457
   PAUMGARTNER P, 1970, ANN NY ACAD SCI, V170, P134
   Roizenblatt R, 2003, LASER MED SCI, V18, P43, DOI 10.1007/s10103-002-0249-z
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
NR 14
TC 8
Z9 10
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2004
VL 88
IS 8
BP 1055
EP 1059
DI 10.1136/bjo.2003.035808
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838QD
UT WOS:000222727100018
PM 15258024
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Paez-Escamilla, M
   Jhingan, M
   Gallagher, DS
   Singh, SR
   Fraser-Bell, S
   Chhablani, J
AF Paez-Escamilla, Manuel
   Jhingan, Mahima
   Gallagher, Denise S.
   Singh, Sumit Randhir
   Fraser-Bell, Samantha
   Chhablani, Jay
TI Age-related macular degeneration masqueraders: From the obvious to the
   obscure
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; mimickers; drusen; geographic atrophy;
   neovascularization; pigment epithelial detachment; subretinal
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide with increasing prevalence owing to increased life expectancy. Intravitreal injections of antivascular endothelial growth factor agents are commonly used in exudative AMD and oral antioxidant medication for nonexudative AMD; however, many disorders mimic exudative and nonexudative AMD, and misdiagnosis can seriously affect the management of these patients. We summarize the demographics and clinical and imaging characteristics of each of the conditions that masquerade as AMD. As some of the conditions have features of AMD, a short update on the classical features of AMD is also included. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Paez-Escamilla, Manuel; Gallagher, Denise S.; Chhablani, Jay] Univ Pittsburgh, Dept Ophthalmol, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
   [Jhingan, Mahima; Singh, Sumit Randhir] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Fraser-Bell, Samantha] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of California System; University of California
   San Diego; University of Sydney
RP Chhablani, J (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Med Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Chhablani,
   Jay/0000-0003-1772-3558; Paez-Escamilla, Manuel/0000-0003-3488-9680
CR Abujamra S, 2008, ARQ BRAS OFTALMOL, V71, P819, DOI 10.1590/S0004-27492008000600010
   Adhi M, 2014, OSLI RETINA, V45, P614, DOI 10.3928/23258160-20141118-20
   Ahnood D, 2017, SURV OPHTHALMOL, V62, P113, DOI 10.1016/j.survophthal.2016.10.003
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Atmaca LS, 1997, ACTA OPHTHALMOL SCAN, V75, P657
   Audere M, 2016, MEDICINA-LITHUANIA, V52, P180, DOI 10.1016/j.medici.2016.04.001
   Awan MA, 2008, CLIN EXP OPTOM, V91, P476, DOI 10.1111/j.1444-0938.2008.00268.x
   Bansal R, 2018, INT OPHTHALMOL, V38, P2149, DOI 10.1007/s10792-017-0664-6
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Bennett N, 2018, ADV THER, V35, P591, DOI 10.1007/s12325-018-0698-9
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Bouchenaki N, 2001, OPHTHALMOLOGY, V108, P54, DOI 10.1016/S0161-6420(00)00428-0
   Braimah IZ, 2017, BRIT J OPHTHALMOL, V101, P1201, DOI 10.1136/bjophthalmol-2016-309994
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Ceklic L, 2017, RETINA-J RET VIT DIS, V37, P687, DOI 10.1097/IAE.0000000000001236
   Chang MY, 2016, SURV OPHTHALMOL, V61, P745, DOI 10.1016/j.survophthal.2016.03.007
   Chapron T, 2019, EYE, V33, P385, DOI 10.1038/s41433-018-0213-1
   Chatziralli I, 2019, RETINA-J RET VIT DIS, V39, P1, DOI 10.1097/IAE.0000000000002327
   Chatziralli Irini, 2018, Int J Retina Vitreous, V4, P33, DOI 10.1186/s40942-018-0137-8
   Chen SN, 2020, OCUL IMMUNOL INFLAMM, V28, P33, DOI 10.1080/09273948.2019.1588335
   Choi EY, 2020, OPHTHALMOLOGICA, V243, P136, DOI 10.1159/000501724
   Clemons TE, 2008, INVEST OPHTH VIS SCI, V49, P4340, DOI 10.1167/iovs.08-1749
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dalvin LA, 2016, OPHTHALMOLOGY, V123, P1588, DOI 10.1016/j.ophtha.2016.02.018
   Dalvin Lauren A, 2016, Retin Cases Brief Rep, V10, P72, DOI 10.1097/ICB.0000000000000164
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Daruich A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-77
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Diaz RI, 2015, SURV OPHTHALMOL, V60, P279, DOI 10.1016/j.survophthal.2015.02.005
   DOUGLAS AA, 1968, BRIT J OPHTHALMOL, V52, P742, DOI 10.1136/bjo.52.10.742
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Fernandes SRM, 2000, SEMIN ARTHRITIS RHEU, V30, P33, DOI 10.1053/sarh.2000.8364
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P1496, DOI 10.1097/IAE.0b013e3181aade47
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Furino C, 2008, OPHTHALMOLOGICA, V222, P240, DOI 10.1159/000130427
   Gahn GM, 2018, VISION BASEL, V2, P31
   Gardner TW, 2006, CURR EYE RES, V31, P535, DOI 10.1080/02713680600746112
   GASS JDM, 1978, ARCH OPHTHALMOL-CHIC, V96, P428
   Gilbert RM, 2020, AM J OPHTHALMOL, V213, P244, DOI 10.1016/j.ajo.2020.01.031
   Giuffre C, 2017, EUR J OPHTHALMOL, V27, pE39, DOI 10.5301/ejo.5000875
   Godley BF, 1996, OPHTHALMOLOGY, V103, P893, DOI 10.1016/S0161-6420(96)30590-3
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Gunduz K, 2009, EYE, V23, P497, DOI 10.1038/eye.2008.244
   Haimovici R, 2002, EYE, V16, P7, DOI 10.1038/sj.eye.6700018
   Hamada S, 2006, EYE, V20, P199, DOI 10.1038/sj.eye.6701852
   Harbour JW, 2019, AM J OPHTHALMOL, V197, P168, DOI 10.1016/j.ajo.2018.08.045
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   HILBORN MD, 1993, AM J ROENTGENOL, V161, P1253, DOI 10.2214/ajr.161.6.8249737
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hulleman JD, 2016, ADV EXP MED BIOL, V854, P153, DOI 10.1007/978-3-319-17121-0_21
   Jun I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09629-9
   Karagiannis D, 2019, SEMIN OPHTHALMOL, V34, P436, DOI 10.1080/08820538.2019.1642920
   Khairallah Moncef, 2007, International Ophthalmology, V27, P125, DOI 10.1007/s10792-006-9013-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krause L, 2005, GRAEF ARCH CLIN EXP, V243, P545, DOI 10.1007/s00417-004-1029-1
   Laovirojjanakul W, 2017, CASE REP OPHTHALM, V8, P429, DOI 10.1159/000479308
   LEFLER WH, 1971, AM J OPHTHALMOL, V71, P224, DOI 10.1016/0002-9394(71)90394-1
   Li HK, 2010, OPHTHALMOLOGY, V117, P324, DOI 10.1016/j.ophtha.2009.07.006
   Li JL, 2017, MOL VIS, V23, P1048
   Li JJ, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1045-x
   Lin DS, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-87
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20980
   Logan S, 2013, P NATL ACAD SCI USA, V110, P5446, DOI 10.1073/pnas.1217251110
   Machida S, 2004, JPN J OPHTHALMOL, V48, P392, DOI 10.1007/s10384-004-0087-6
   Mansour Ahmad M, 2017, Am J Ophthalmol Case Rep, V7, P83, DOI 10.1016/j.ajoc.2017.06.011
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   Matsuo T, 2000, RETINA-J RET VIT DIS, V20, P16, DOI 10.1097/00006982-200001000-00003
   Miere A, 2018, RETINA-J RET VIT DIS, V38, P1301, DOI 10.1097/IAE.0000000000001733
   Mohabati D, 2018, CLIN OPHTHALMOL, V12, P2167, DOI 10.2147/OPTH.S174573
   Molday RS, 2010, PROG LIPID RES, V49, P476, DOI 10.1016/j.plipres.2010.07.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Munk MR, 2015, RETINA-J RET VIT DIS, V35, P334, DOI 10.1097/IAE.0000000000000370
   Murata T, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/3853794
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Noh Sung Rae, 2019, Korean J Ophthalmol, V33, P506, DOI 10.3341/kjo.2019.0065
   Obana A, 1999, BRIT J OPHTHALMOL, V83, P429, DOI 10.1136/bjo.83.4.429
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Olguin-Manriquez Francisco, 2018, Int J Retina Vitreous, V4, P30, DOI 10.1186/s40942-018-0132-0
   Oliveira J, 2017, BIOMED OPT EXPRESS, V8, P281, DOI 10.1364/BOE.8.000281
   Palejwala NV, 2016, RETINA-J RET VIT DIS, V36, P119, DOI 10.1097/IAE.0000000000000659
   Pece A, 1997, ACTA OPHTHALMOL SCAN, V75, P261
   Pellegrini M, 2018, RETINA-J RET VIT DIS, V38, P1338, DOI 10.1097/IAE.0000000000001730
   PETTIT TH, 1970, ARCH OPHTHALMOL-CHIC, V83, P27
   Peyman M, 2019, J CURR OPHTHALMOL, V31, P55, DOI 10.1016/j.joco.2018.09.007
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Quaranta M, 1996, AM J OPHTHALMOL, V122, P663, DOI 10.1016/S0002-9394(14)70484-2
   Querques G, 2013, GRAEF ARCH CLIN EXP, V251, P705, DOI 10.1007/s00417-012-2106-5
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Romano F, 2019, EYE, V33, P1916, DOI 10.1038/s41433-019-0483-2
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2019, AM J OPHTHALMOL, V204, P26, DOI 10.1016/j.ajo.2019.02.036
   Sahoo NK, 2019, SURV OPHTHALMOL, V64, P30, DOI 10.1016/j.survophthal.2018.09.001
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P448, DOI 10.1007/s10384-019-00692-5
   SALLET G, 1995, GRAEF ARCH CLIN EXP, V233, P677, DOI 10.1007/BF00164669
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   Sawa M, 2006, OPHTHALMOLOGY, V113, P814, DOI 10.1016/j.ophtha.2006.01.037
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Schatz Howard, 2012, Retina, V32 Suppl 1, pOP893
   Schellevis RL, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.576
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Semeraro F, 2019, CLIN OPHTHALMOL, V13, P2341, DOI 10.2147/OPTH.S220845
   Shields CL, 2012, ARCH OPHTHALMOL-CHIC, V130, P850, DOI 10.1001/archophthalmol.2012.1135
   SHIELDS CL, 1988, SURV OPHTHALMOL, V33, P17, DOI 10.1016/0039-6257(88)90069-0
   Shimada H, 2008, JPN J OPHTHALMOL, V52, P282, DOI 10.1007/s10384-008-0566-2
   Shiraki Kunihiko, 2001, International Ophthalmology, V24, P243, DOI 10.1023/A:1025433431654
   Singh AD, 2005, EYE, V19, P482, DOI 10.1038/sj.eye.6701475
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Small KW, 2019, OPHTHALMOL RETINA, V3, P607, DOI 10.1016/j.oret.2019.03.002
   Small KW, 2016, OPHTHALMOLOGY, V123, P9, DOI 10.1016/j.ophtha.2015.10.006
   SMALL KW, 1991, BRIT J OPHTHALMOL, V75, P401, DOI 10.1136/bjo.75.7.401
   Sorensen S, 2015, CONTEMP CLIN TRIALS, V42, P68, DOI 10.1016/j.cct.2015.03.007
   Sousa K, 2020, CLIN OPHTHALMOL, V14, P525, DOI 10.2147/OPTH.S232202
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P392, DOI 10.1097/IAE.0000000000000420
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1315, DOI 10.1097/IAE.0b013e318286cc77
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Tavallali Ali, 2016, J Ophthalmic Vis Res, V11, P429
   Thuruthumaly C, 2014, CURR OPIN OPHTHALMOL, V25, P508, DOI 10.1097/ICU.0000000000000100
   Toledo JJ, 2018, OPHTHALMOL RETINA, V2, P613, DOI 10.1016/j.oret.2017.10.006
   Van Rijssen TJ, 2019, AM J OPHTHALMOL, V205, P1, DOI 10.1016/j.ajo.2019.03.025
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   Vazquez-Alfageme C, 2019, OPHTHALMOL RETINA, V3, P429, DOI 10.1016/j.oret.2019.01.001
   Venkatesh R, 2020, CLIN EXP OPTOM, V103, P324, DOI 10.1111/cxo.12965
   Venkatesh R, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419852011
   von der Burchard C, 2018, GRAEF ARCH CLIN EXP, V256, P1623, DOI 10.1007/s00417-018-4040-7
   Walter SD, 2016, JAMA OPHTHALMOL, V134, P734, DOI 10.1001/jamaophthalmol.2016.0913
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wolfensberger TJ, 1999, OPHTHALMOLOGY, V106, P285, DOI 10.1016/S0161-6420(99)90067-2
   Wu KF, 2016, OCUL IMMUNOL INFLAMM, V24, P261, DOI 10.3109/09273948.2015.1015741
   Wu ML, 2019, COMPUT METH PROG BIO, V182, DOI 10.1016/j.cmpb.2019.105101
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yang PZ, 2019, OCUL IMMUNOL INFLAMM, V27, P1195, DOI 10.1080/09273948.2019.1624781
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yokoi T, 2016, OPHTHALMOLOGY, V123, P1783, DOI 10.1016/j.ophtha.2016.04.029
   Zhang KY, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0988-7
   Zhang T, 2014, RETINA-J RET VIT DIS, V34, P2462, DOI 10.1097/IAE.0000000000000259
   Zhang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095528
   Zhang XZ, 2013, OPHTHALMOLOGY, V120, P2678, DOI 10.1016/j.ophtha.2013.05.012
   Zhao XY, 2018, GRAEF ARCH CLIN EXP, V256, P1101, DOI 10.1007/s00417-018-3980-2
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 162
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2021
VL 66
IS 2
BP 153
EP 182
DI 10.1016/j.survophthal.2020.08.005
EA FEB 2021
PG 30
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ1VV
UT WOS:000624315700001
PM 32971140
DA 2022-11-30
ER

PT J
AU Coscas, F
   Coscas, G
   Souied, E
AF Coscas, Florence
   Coscas, Gabriel
   Souied, Eric
TI Polypoidal choroidal vasculopathy and macroaneurysm: respective roles of
   scanning laser ophthalmoscopy-indocyanine green angiography and optical
   coherence tomography
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal polypoidal vasculopathy;
   Intravitreal injection; Macroaneurysm; SD-OCT; SLO-ICG
ID MACULAR DEGENERATION; NEOVASCULARIZATION
AB Purpose. To report on a patient with exudative age-related macular degeneration, polypoidal choroidal vasculopathy, and macroaneurysm.
   Methods. Scanning laser ophthalmoscopy (SLO)-indocyanine green angiography (ICGA) demonstrated the coexistence of several lesions in the same patient. Optical coherence tomography (OCT) combined with ICGA defined the nature of the lesions and the severity of the exudative phenomena.
   Results. The eye tracking system ensured precise follow-up of the course of the lesions on both ICGA and spectral domain (SD) OCT. Image correlation provided a precise diagnosis, defining the indications for local and systemic therapy.
   Conclusions. In this patient with multiple lesions, only correlation of clinical examinations and SLO-ICG and SD-OCT imaging allowed a complete assessment with the proposal of a coherent and effective treatment plan.
C1 [Coscas, Florence; Coscas, Gabriel; Souied, Eric] Ctr Hosp Intercommunal, F-94010 Creteil, France.
   [Coscas, Florence; Coscas, Gabriel] Ctr Odeon, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Coscas, F (通讯作者)，Ctr Hosp Intercommunal, 40 Ave Verdun, F-94010 Creteil, France.
EM coscas.f@wanadoo.fr
CR Chen Yanli, 2008, International Ophthalmology, V28, P119, DOI 10.1007/s10792-007-9113-2
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   COSCAS G, 2004, ATLAS INDOCYANINE GR, P383
   COSCAS G, 2008, OPTICAL COHERENCE TO, P411
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Savar A, 2009, OPHTHAL SURG LAS IM, V40, P403, DOI 10.3928/15428877-20096030-09
NR 6
TC 8
Z9 8
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2011
VL 21
IS 3
BP 331
EP 335
DI 10.5301/EJO.2010.2803
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760UL
UT WOS:000290349300019
PM 20853255
DA 2022-11-30
ER

PT J
AU Lee, H
   Jin, YZ
   Roh, M
   Tsacogianis, TN
   Park, S
   Choi, NK
   Kim, SC
AF Lee, Hemin
   Jin, Yinzhu
   Roh, Miin
   Tsacogianis, Theodore N.
   Park, Sangshin
   Choi, Nam-Kyong
   Kim, Seoyoung C.
TI Risk of Cataract Surgery and Age-Related Macular Degeneration After
   Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A
   Multi-Database Cohort Study
SO DRUGS & AGING
LA English
DT Article
ID ACUTE-PHASE RESPONSE; BISPHOSPHONATES; CALCIUM
AB Background and Objective There is a relative lack of head-to-head comparisons of denosumab against other osteoporosis drugs on safety. We aimed to explore ocular outcomes in patients with osteoporosis initiating denosumab vs zoledronic acid. Methods We conducted a cohort study using claims data (2010-15) from two large US commercial insurance databases including patients with osteoporosis who were aged 50 years or older and initiators of denosumab or zoledronic acid. The primary outcomes were (1) receipt of cataract surgery and development of (2) wet age-related macular degeneration and (3) dry age-related macular degeneration within 365 days after initiation of denosumab vs zoledronic acid. Propensity score fine stratification and weighting were used to control for potential confounding, and we calculated the incidence rate and hazard ratio for each outcome in the cohorts. The estimates from the two databases were combined with a fixed-effects model meta-analysis. Results The study cohort included 50,821 denosumab and 67,471 zoledronic acid initiators. In the propensity score-weighted analysis, compared to zoledronic acid use, denosumab was associated with a modestly decreased risk of undergoing cataract surgery (hazard ratio 0.91; 95% confidence interval 0.85-0.98) but not with the risk of wet age-related macular degeneration (hazard ratio 1.29; 95% confidence interval 0.99-1.70) or dry age-related macular degeneration (hazard ratio 1.03; 95% confidence interval 0.98-1.09). Conclusions In this large population-based cohort study of 118,292 patients with osteoporosis, initiation of denosumab was associated with a modestly decreased risk of cataract surgery vs zoledronic acid. The risk of age-related macular degeneration was similar between the two drugs.
C1 [Lee, Hemin; Jin, Yinzhu; Tsacogianis, Theodore N.; Kim, Seoyoung C.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremt St,Suite 3-030, Boston, MA 02120 USA.
   [Lee, Hemin; Jin, Yinzhu; Tsacogianis, Theodore N.; Kim, Seoyoung C.] Harvard Med Sch, 1620 Tremt St,Suite 3-030, Boston, MA 02120 USA.
   [Roh, Miin] Harvard Med Sch, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02120 USA.
   [Park, Sangshin] Univ Seoul, Grad Sch Urban Publ Hlth, Seoul, South Korea.
   [Choi, Nam-Kyong] Ewha Womans Univ, Dept Hlth Convergence, Seoul, South Korea.
   [Kim, Seoyoung C.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02120 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard Medical School;
   Joslin Diabetes Center, Inc.; University of Seoul; Ewha Womans
   University; Harvard University; Brigham & Women's Hospital
RP Kim, SC (通讯作者)，Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremt St,Suite 3-030, Boston, MA 02120 USA.; Kim, SC (通讯作者)，Harvard Med Sch, 1620 Tremt St,Suite 3-030, Boston, MA 02120 USA.; Kim, SC (通讯作者)，Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02120 USA.
EM SYKIM@bwh.harvard.edu
RI Jin, Yinzhu/AAA-9359-2021; Jin, Yinzhu/AAC-2591-2020
OI Jin, Yinzhu/0000-0002-1397-3106; Kim, Seoyoung/0000-0002-2517-3579
FU Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and
   Women's Hospital
FX This study was supported by the Division of Pharmacoepide-miology and
   Pharmacoeconomics at Brigham and Women's Hospital.
CR Augoulea A, 2017, J MUSCULOSKEL NEURON, V17, P444
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Breen TL, 2004, J CLIN ONCOL, V22, P1531, DOI 10.1200/JCO.2004.99.013
   Chehade LK, 2019, OSTEOPOROSIS INT, V30, P1117, DOI 10.1007/s00198-019-04850-w
   Choi NK, 2017, J BONE MINER RES, V32, P611, DOI 10.1002/jbmr.3019
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
   Deeks ED, 2008, DRUG AGING, V25, P963, DOI 10.2165/0002512-200825110-00007
   Desai RJ, 2017, EPIDEMIOLOGY, V28, P249, DOI 10.1097/EDE.0000000000000595
   Fraunfelder FW, 2004, OPHTHALMOLOGY, V111, P1275, DOI 10.1016/j.ophtha.2003.12.052
   Fraunfelder FW, 2003, AM J OPHTHALMOL, V135, P219, DOI 10.1016/S0002-9394(02)01840-8
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470-2045(18)30862-3
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365-2249.2005.02665.x
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Kaur Harpreet, 2011, Endocr Pract, V17, pe101, DOI 10.4158/EP11081.CR
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213-8587(17)30188-2
   Makras P, 2013, CLIN ENDOCRINOL, V79, P499, DOI 10.1111/cen.12188
   Mammo Z, 2016, AM J OPHTHALMOL, V168, P62, DOI 10.1016/j.ajo.2016.04.022
   Melton LJ, 2000, J BONE MINER RES, V15, P2309, DOI 10.1359/jbmr.2000.15.12.2309
   Or C, 2013, BRIT J OPHTHALMOL, V97, P1074, DOI 10.1136/bjophthalmol-2013-303355
   Papapetrou PD, 2009, HORM-INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Patel DV, 2015, OSTEOPOROSIS INT, V26, P499, DOI 10.1007/s00198-014-2872-5
   Patel DV, 2013, OPHTHALMOLOGY, V120, P773, DOI 10.1016/j.ophtha.2012.10.028
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010-0597
   Saito T, 2017, OSTEOPOROSIS INT, V28, P3289, DOI 10.1007/s00198-017-4175-0
   Tang DX, 2003, INVEST OPHTH VIS SCI, V44, P2059, DOI 10.1167/iovs.02-0345
   Umunakwe OC, 2017, DIGIT J OPHTHALMOL, V23, P109
   Woo TCS, 2006, CLIN ONCOL-UK, V18, P545, DOI 10.1016/j.clon.2006.04.013
   Wu JQ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0865-3
   Yoshida K, 2015, NAT REV RHEUMATOL, V11, P437, DOI 10.1038/nrrheum.2015.30
NR 30
TC 2
Z9 2
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD APR
PY 2020
VL 37
IS 4
BP 311
EP 320
DI 10.1007/s40266-020-00745-2
EA FEB 2020
PG 10
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA KX0EA
UT WOS:000515878800001
PM 32026309
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
AF Campochiaro, Peter A.
TI Gene Transfer for Neovascular Age-Related Macular Degeneration
SO HUMAN GENE THERAPY
LA English
DT Review
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION;
   OCULAR NEOVASCULARIZATION; PROLIFERATIVE RETINOPATHY; PROLONGED
   BLOCKADE; MEDIATED DELIVERY; TISSUE INHIBITOR
AB Age-related macular degeneration (AMD) is a complex disease that has two phases: a degenerative phase often referred to as nonneovascular AMD (non-NVAMD) or dry AMD and a phase dominated by growth of new blood vessels in the subretinal space, referred to as NVAMD or wet AMD. Advances in the understanding of the molecular pathogenesis of NVAMD have led to new drug therapies that have provided major benefits to patients. However, those treatments require frequent intraocular injections that in many patients must be continued indefinitely to maintain visual benefits. Gene transfer to augment expression of endogenous anti-angiogenic proteins is an alternative approach that has the potential to provide long-term stability in patients with NVAMD. Studies in animal models that mimic aspects of NVAMD have identified several possible transgenes, and a clinical trial in patients with advanced NVAMD has suggested that the approach may be feasible. Many important questions remain, but the rationale and preliminary data are compelling. The results of two ongoing clinical trials may answer several of the questions and help direct future research.
C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU National Eye Institute [EY05951, EY12609, EY10017]; Genzyme and Oxford
   BioMedica; NATIONAL EYE INSTITUTE [R01EY010017, R01EY012609] Funding
   Source: NIH RePORTER
FX This work was supported by grants EY05951, EY12609, and EY10017 from the
   National Eye Institute. P.A.C. is the George S. and Dolores Dore Eccles
   Professor of Ophthalmology.; The author receives funding from Genzyme
   and Oxford BioMedica for conduct of clinical trials.
CR APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313
   Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.0.CO;2-F
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Li QH, 2008, MOL VIS, V14, P1760
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shen JK, 2006, FASEB J, V20, P723, DOI 10.1096/fj.05-5046fje
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Takahashi K, 2002, HUM GENE THER, V13, P1305, DOI 10.1089/104303402760128531
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
NR 54
TC 23
Z9 28
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD MAY
PY 2011
VL 22
IS 5
BP 523
EP 529
DI 10.1089/hum.2011.050
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 754VY
UT WOS:000289887000002
PM 21443427
OA Green Published
DA 2022-11-30
ER

PT J
AU Palkovits, S
   Seidel, G
   Pertl, L
   Malle, EM
   Hausberger, S
   Makk, J
   Singer, C
   Osterholt, J
   Herzog, SA
   Haas, A
   Weger, M
AF Palkovits, Stefan
   Seidel, Gerald
   Pertl, Laura
   Malle, Eva M.
   Hausberger, Silke
   Makk, Johanna
   Singer, Christoph
   Osterholt, Julia
   Herzog, Sereina A.
   Haas, Anton
   Weger, Martin
TI MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR
   EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal thickness;
   choroidal volume
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; THICKNESS CHANGES;
   RANIBIZUMAB INJECTIONS; NEOVASCULARIZATION; PENETRATION; EDEMA; EYES
AB Purpose: To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naive eyes with exudative age-related macular degeneration.
   Methods: The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment.
   Results: Forty-seven patients with a mean age of 80 +/- 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm(3) (interquartile range 3.4-5.9) to median 3.9 mm(3) (interquartile range 3.1-5.6) between the baseline and final examination (difference -0.46 mm(3), 95% confidence interval: -0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 mu m (interquartile range 116.0-244.5) at baseline to 139.0 mu m (interquartile range 102.5-212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment.
   Conclusion: The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.
C1 [Palkovits, Stefan; Seidel, Gerald; Pertl, Laura; Malle, Eva M.; Hausberger, Silke; Makk, Johanna; Singer, Christoph; Osterholt, Julia; Haas, Anton; Weger, Martin] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8010 Graz, Austria.
   [Herzog, Sereina A.] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Palkovits, S (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8010 Graz, Austria.
EM stefan.palkovits@hotmail.com
RI Herzog, Sereina A/K-8865-2017
OI Herzog, Sereina A/0000-0002-5373-5866
CR Ahn SJ, 2015, INVEST OPHTH VIS SCI, V56, P5794, DOI 10.1167/iovs.14-16006
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], 1991, Ophthalmology, V98, P786
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Chhablani J, 2012, INVEST OPHTH VIS SCI, V53, P2274, DOI 10.1167/iovs.12-9435
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Ghassemifar R, 2006, CELL TISSUE RES, V323, P117, DOI 10.1007/s00441-005-0046-7
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim H, 2009, MOL VIS, V15
   Kim KH, 2015, OPHTHALMOLOGICA, V234, P109, DOI 10.1159/000437276
   Lains I, 2014, RETINA-J RET VIT DIS, V34, P1199, DOI 10.1097/IAE.0000000000000053
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Park SY, 2013, AM J OPHTHALMOL, V156, P557, DOI 10.1016/j.ajo.2013.04.027
   Razavi S, 2015, AM J OPHTHALMOL
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seidel G, 2015, AM J OPHTHALMOL, V159, P365, DOI 10.1016/j.ajo.2014.11.002
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Terasaki H, 2015, RETINA-J RET VIT DIS, V35, P1007, DOI 10.1097/IAE.0000000000000428
   Unlu C, 2015, INT J OPHTHALMOL-CHI, V8, P849, DOI 10.3980/j.issn.2222-3959.2015.04.38
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
NR 32
TC 4
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2017
VL 37
IS 12
BP 2262
EP 2268
DI 10.1097/IAE.0000000000001480
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3NL
UT WOS:000425214400007
PM 28129216
DA 2022-11-30
ER

PT J
AU Nashine, S
AF Nashine, Sonali
TI Potential Therapeutic Candidates for Age-Related Macular Degeneration
   (AMD)
SO CELLS
LA English
DT Review
DE age-related macular degeneration (AMD); retina; AMD therapeutics
ID CILIARY NEUROTROPHIC FACTOR; RETINAL GANGLION-CELLS; SMALL GTPASE RAP1;
   OXIDATIVE STRESS; AMYLOID-BETA; CHOROIDAL NEOVASCULARIZATION;
   ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CELECOXIB
AB Aging contributes to the risk of development of ocular diseases including, but not limited to, Age-related Macular Degeneration (AMD) that is a leading cause of blindness in the United States as well as worldwide. Retinal aging, that contributes to AMD pathogenesis, is characterized by accumulation of drusen deposits, alteration in the composition of Bruch's membrane and extracellular matrix, vascular inflammation and dysregulation, mitochondrial dysfunction, and accumulation of reactive oxygen species (ROS), and subsequent retinal pigment epithelium (RPE) cell senescence. Since there are limited options available for the prophylaxis and treatment of AMD, new therapeutic interventions are constantly being looked into to identify new therapeutic targets for AMD. This review article discusses the potential candidates for AMD therapy and their known mechanisms of cytoprotection in AMD. These target therapeutic candidates include APE/REF-1, MRZ-99030, Ciliary NeuroTrophic Factor (CNTF), RAP1 GTPase, Celecoxib, and SS-31/Elamipretide.
C1 [Nashine, Sonali] Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Nashine, S (通讯作者)，Univ Calif Irvine, Dept Ophthalmol, Irvine, CA 92697 USA.
EM snashine@uci.edu
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576
   Allingham MJ, 2019, INVEST OPHTH VIS SCI, V60
   Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531
   Amrite AC, 2008, J PHARMACOL EXP THER, V324, P749, DOI 10.1124/jpet.107.128918
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Birukova AA, 2009, J APPL PHYSIOL, V107, P1900, DOI 10.1152/japplphysiol.00462.2009
   BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017
   Bosch-Morell F, 2020, NEURAL REGEN RES, V15, P2207, DOI 10.4103/1673-5374.284978
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Carmona G, 2009, BLOOD, V113, P488, DOI 10.1182/blood-2008-02-138438
   Chen M, 2011, INVEST OPHTH VIS SCI, V52, P7027, DOI 10.1167/iovs.11-7524
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Chrzanowska-Wodnicka M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145689
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206
   Duchniewicz M, 2006, MOL CELL BIOL, V26, P643, DOI 10.1128/MCB.26.2.643-653.2006
   Dudek J, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00090
   Flatt T, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0562-z
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Frydman-Marom A, 2009, ANGEW CHEM INT EDIT, V48, P1981, DOI 10.1002/anie.200802123
   Fukuhra S, 2006, J BIOCHEM MOL BIOL, V39, P132
   Gravius A, 2013, INVEST OPHTH VIS SCI, V54
   Guan ZJ, 2005, ARTERIOSCL THROM VAS, V25, P96, DOI 10.1161/01.ATV.0000150418.14698.75
   Hill BG, 2012, BIOL CHEM, V393, P1485, DOI 10.1515/hsz-2012-0198
   Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633
   Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004
   Ikon N, 2017, BBA-BIOMEMBRANES, V1859, P1156, DOI 10.1016/j.bbamem.2017.03.013
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275
   Khan SS, 2017, AGING CELL, V16, P624, DOI 10.1111/acel.12601
   Kim SJ, 2014, INVEST OPHTH VIS SCI, V55, P1409, DOI 10.1167/iovs.13-13667
   Koh SWM, 2002, INVEST OPHTH VIS SCI, V43, P2887
   Kolb H., 1995, WEBVISION ORG RETINA
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lafosse E, 2020, CONTACT LENS ANTERIO, V43, P103, DOI 10.1016/j.clae.2019.08.005
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Li JJ, 2018, CURR EYE RES, V43, P934, DOI 10.1080/02713683.2018.1454477
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Li Y, 2007, J IMMUNOL, V179, P8322, DOI 10.4049/jimmunol.179.12.8322
   Li Y, 2014, INVEST OPHTH VIS SCI, V55, P4461, DOI 10.1167/iovs.14-14451
   Lotz B, 1996, NEUROLOGY, V46, P1244
   Luheshi LM, 2007, PLOS BIOL, V5, P2493, DOI 10.1371/journal.pbio.0050290
   Maysinger D, 1996, EXP NEUROL, V138, P177, DOI 10.1006/exnr.1996.0056
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Pasha SPBS, 2018, J PHARMACOL EXP THER, V367, P108, DOI 10.1124/jpet.118.248088
   PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Rammes G, 2020, NEUROPHARMACOLOGY, V179, DOI 10.1016/j.neuropharm.2020.108267
   Ramos CJ, 2018, J BIOL CHEM, V293, P717, DOI 10.1074/jbc.M117.815381
   Sabate R, 2005, J PHYS CHEM B, V109, P11027, DOI 10.1021/jp050716m
   SANDGREN O, 1995, SURV OPHTHALMOL, V40, P173, DOI 10.1016/S0039-6257(95)80025-5
   Schoenberger SD, 2012, INVEST OPHTH VIS SCI, V53, P5906, DOI 10.1167/iovs.12-10410
   Seedher N, 2003, AAPS PharmSciTech, V4, pE33
   Sendtner M, 1997, J NEUROSCI, V17, P6999
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Silvestri G, 2012, EYE, V26, P1357, DOI 10.1038/eye.2012.165
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Sun YZ, 2017, CELL PHYSIOL BIOCHEM, V44, P1640, DOI 10.1159/000485764
   Szeto HH, 2006, AAPS J, V8, pE277, DOI 10.1007/BF02854898
   Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Wang HB, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.56
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
   Wittchen ES, 2011, INVEST OPHTH VIS SCI, V52, P7455, DOI 10.1167/iovs.11-7295
   Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200
   Wu XQ, 2019, ACTA BIOCH BIOPH SIN, V51, P411, DOI 10.1093/abbs/gmz020
   Yan JL, 2008, MOL CELL BIOL, V28, P5803, DOI 10.1128/MCB.00393-08
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695
NR 94
TC 9
Z9 9
U1 3
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD SEP
PY 2021
VL 10
IS 9
AR 2483
DI 10.3390/cells10092483
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UV3LP
UT WOS:000699384800001
PM 34572131
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Han, L
   Ma, ZZ
   Wang, CG
   Hu, YT
   Jin, Y
AF Han, Liang
   Ma, Zhizhong
   Wang, Changguan
   Hu, Yuntao
   Jin, Ying
TI Morphologic Features and Viability Analysis of Human Detached Retinal
   Pigment Epithelium in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BRUCHS MEMBRANE; CLINICOPATHOLOGICAL CORRELATION; TEARS;
   TRANSPLANTATION; TRANSLOCATION; COMPLEX; RABBIT
AB PURPOSE: To evaluate the morphologic features and viability of human retinal pigment epithelium (RPE) cells captured from the pigment epithelium detachment (PED) region outside the choroidal neovascular membrane lesion in eyes with hemorrhagic age-related macular degeneration.
   DESIGN: Prospective, observational case series.
   METHODS: Five specimens of the RPE sheet were obtained from the PED region after choroidal neovascular membrane excision in 5 eyes of 5 patients during RPE transplantation for hemorrhagic age-related macular degeneration. The specimens were stained with hematoxylin and eosin and with periodic acid-Schiff. Immunohistochemistry analysis for RPE-65 and zonula occludens-1 also was performed. RPE cells from the PED region were cultured and passaged 5 times. Scanning and transmission electron microscopy were performed to analyze the specimens.
   RESULTS: The RPE cells of the specimens contained brownish pigment and were autofluorescent in vitro. Periodic acid-Schiff staining revealed that the Bruch membrane below the RPE monolayer was not intact. The specimens demonstrated positive results for both zonula occludens-1 and RPE-65 staining. The RPE basement membrane in the specimen was observed by both scanning and transmission electron microscopy. Intercellular tight junctions among RPE cells of the specimen also were observed. RPE cells captured from the PED region were cultured successfully and were passaged 5 times.
   CONCLUSIONS: The RPE sheet developed from the PED region outside the choroidal neovascular membrane lesion had tight intercellular junctions, a simple RPE basement membrane, and active cellular viability. This monolayer RPE sheet may be considered as a substitution for subfoveal RPE loss in eyes with hemorrhagic age-related macular degeneration. (Am J Ophthalmol 2013;155:474-483. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Han, Liang; Ma, Zhizhong; Wang, Changguan; Hu, Yuntao; Jin, Ying] Peking Univ, Dept Ophthalmol, Hosp 3, Key Lab Vis Loss & Restorat,Minist Educ, Beijing 100191, Peoples R China.
C3 Peking University
RP Jin, Y (通讯作者)，Peking Univ, Dept Ophthalmol, Hosp 3, 49 N Garden Rd, Beijing 100191, Peoples R China.
EM jinyingcmu@yahoo.com.cn
FU National Basic Research Program of China (973 program) [2011CB510200];
   Peking University Third Hospital, Beijing, People's Republic of China
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Sponsored by
   Grant 2011CB510200 from the National Basic Research Program of China
   (973 program) and a research grant from Peking University Third
   Hospital, Beijing, People's Republic of China. The funding organizations
   had no role in the design or conduct of this research. Involved in
   Design of study (M.Z.Z, H.L., J.Y.); Conduct of study (M.Z.Z, H.L.,
   J.Y.); Data collection (M.Z.Z, H.L., J.Y., W.C.G., H.Y.T.); Data
   analysis and interpretation (H.L., J.Y., W.C.G., H.Y.T.); and
   Preparation, review, and approval of the manuscript (M.Z.Z, H.L., J.Y.).
CR Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   ELDIRINI AA, 1992, GRAEF ARCH CLIN EXP, V230, P292, DOI 10.1007/BF00176307
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   GOURAS P, 1992, GRAEF ARCH CLIN EXP, V230, P468, DOI 10.1007/BF00175936
   GREEN SN, 1983, RETINA-J RET VIT DIS, V3, P16, DOI 10.1097/00006982-198300310-00004
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Guyer DR, 2006, RETINA, P39
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lee DBN, 2006, AM J PHYSIOL-RENAL, V290, pF20, DOI 10.1152/ajprenal.00052.2005
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 31
TC 2
Z9 4
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2013
VL 155
IS 3
BP 474
EP 483
DI 10.1016/j.ajo.2012.09.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 096TA
UT WOS:000315426000009
PM 23218698
DA 2022-11-30
ER

PT J
AU Wen, F
   Chen, CZ
   Wu, DZ
   Li, HT
AF Wen, F
   Chen, CZ
   Wu, DZ
   Li, HT
TI Polypoidal choroidal vasculopathy in elderly Chinese patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; PIGMENT EPITHELIAL DETACHMENTS
AB Purpose: To investigate the frequency and clinical features of polypoidal choroidal vasculopathy (PCV) in a consecutive series of elderly Chinese patients. Methods: A restrospective analysis of 166 consecutive patients 50 years or older with diagnosis of exudative age-related macular degeneration (AMD) was conducted. Color fundus photographs were taken and fluorescein and indocyanine green (ICG) angiography were performed in all patients. Results: Of the 166 patients, 37 patients (22.3%) initially suspected of having exudative AMD were ultimately diagnosed as having PCV. Twenty-seven men (73.0%) were affected, 32 patients (86.5%) were unilaterally involved. Of 42 eyes with PCV, 27 eyes (64.3%) demonstrated polypoidal dilations with branching vascular network, and the other 15 eyes (35.7%) showed scattered polypoidal dilations without identifiable continuous branching vascular network on ICG angiography. The predominant location for these lesions was at the macular region in 26 eyes (61.9%), the temporal vascular arcade in 9 eyes (21.4%), the peripapillary area in 6 eyes (14.3%), and the midperiphery in 1 eye (2.4%). Conclusions: PCV is a common disease in elderly Chinese patients. In our study group PCV mainly affected men and was mostly unilateral. Most of the lesions were located in the macular region and temporal vascular arcade.
C1 Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, 54 Xianlie Rd, Guangzhou 510060, Peoples R China.
EM wfwzt@163.net
OI Chen, Changzheng/0000-0002-7281-552X
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   KELINER RC, 1990, RETINA, V10, P7
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1982, MAC SOC M 5 FEB 1982
NR 15
TC 106
Z9 126
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2004
VL 242
IS 8
BP 625
EP 629
DI 10.1007/s00417-003-0667-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 855EP
UT WOS:000223956300002
PM 15257461
DA 2022-11-30
ER

PT J
AU van de Ven, JPH
   Smailhodzic, D
   Boon, CJF
   Fauser, S
   Groenewoud, JMM
   Chong, NV
   Hoyng, CB
   Klevering, BJ
   den Hollander, AI
AF van de Ven, Johannes P. H.
   Smailhodzic, Dzenita
   Boon, Camiel J. F.
   Fauser, Sascha
   Groenewoud, Joannes M. M.
   Chong, N. Victor
   Hoyng, Carel B.
   Klevering, B. Jeroen
   den Hollander, Anneke I.
TI Association analysis of genetic and environmental risk factors in the
   cuticular drusen subtype of age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   GLOMERULONEPHRITIS TYPE-II; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   CFH GENE; FACTOR-B; POLYMORPHISM; VARIANTS; HTRA1; MACULOPATHY
AB Purpose: To assess the association of gender, cigarette smoking, body-mass index, and nine genetic risk variants with cuticular drusen (CD), a well recognized subtype of age-related macular degeneration (AMD).
   Methods: A total of 757 patients with AMD, including 217 patients with CD, and 553 control individuals were interviewed with a questionnaire and underwent an ophthalmic examination. Venous blood samples were obtained for genomic DNA extraction, and genotyping was performed of single nucleotide polymorphisms previously associated with AMD. Odds ratios were calculated for patients with CD, using unaffected control individuals as a reference. Furthermore, odds ratios in patients with CD were compared to those in patients with "non-CD" AMD.
   Results: The CD subtype of AMD was significantly associated with current smoking as well as variants in the complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), complement factor B/complement component 2 (CFB/C2), complement component 3 (C3), and apolipoprotein E (APOE) genes. In patients with CD, the association with the CFH Y402H risk allele was significantly higher (p=0.022), whereas the association with current smoking was significantly lower (p<0.001) than in the heterogeneous group of patients with "non-CD" AMD.
   Conclusions: The AMD subtype of CD was associated with previously identified genetic AMD risk factors. However, the association with the CFH Y402H risk allele appeared to be stronger, whereas the association with smoking was less pronounced when compared to AMD as a whole. This study suggests a more important role for genetic factors than environmental factors in the development of this well defined subtype of AMD. These findings stress the importance of detailed phenotyping in AMD to identify homogeneous AMD subtypes, which may be associated with different risk factors and disease mechanisms. Such studies will improve the accuracy of predictive models and the effectiveness of preventive and therapeutic options in AMD.
C1 [van de Ven, Johannes P. H.; Smailhodzic, Dzenita; Boon, Camiel J. F.; Hoyng, Carel B.; Klevering, B. Jeroen; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6526 EX Nijmegen, Netherlands.
   [Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol, NL-6525 ED Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, HTA, NL-6525 ED Nijmegen, Netherlands.
   [Chong, N. Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; University of Cologne; Radboud University
   Nijmegen; Radboud University Nijmegen; University of Oxford; Radboud
   University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6526 EX Nijmegen, Netherlands.
EM a.denhollander@ohk.umcn.nl
RI Groenewoud, Hans JMM/R-3588-2017; Klevering, B.J./L-4434-2015;
   Hollander, Anneke den/N-4911-2014; Hoyng, C.B./H-8050-2014; Boon,
   CJF/P-7534-2014
OI Groenewoud, Hans JMM/0000-0002-4974-150X; Boon, CJF/0000-0002-6737-7932
FU Netherlands Organization for Scientific Research (Vidi Innovational
   Research Award) [016.096.309]; Foundation Fighting Blindness USA
   [C-GE-0811-0548-RAD04]
FX We thank F. Schoenmaker-Koller, B. Bakker, B. Janssen, A. Brucker, and
   T. Janssen - van Kempen for excellent technical assistance. This study
   was supported by the Netherlands Organization for Scientific Research
   (Vidi Innovational Research Award 016.096.309 to A.I.d.H.), and the
   Foundation Fighting Blindness USA (C-GE-0811-0548-RAD04 to A.I.d.H.).
   The authors do not have any financial interests to disclose.
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farah SE, 2009, OPHTHAL SURG LAS IM, V40, P416, DOI 10.3928/15428877-20096030-13
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hassenstein A, 2003, KLIN MONATSBL AUGENH, V220, P492
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van de Ven JPH, 2012, ARCH OPHTHALMOL
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 47
TC 34
Z9 35
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 18
PY 2012
VL 18
IS 241
BP 2271
EP 2278
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 994TF
UT WOS:000307954200001
PM 22933840
DA 2022-11-30
ER

PT J
AU Avitabile, T
   Boscia, F
   Dell'Erba, A
   Introini, U
   Lanzetta, P
   Locatelli, P
   Ricci, F
   Staurenghi, G
   Varano, M
   Zotti, F
AF Avitabile, Teresio
   Boscia, Francesco
   Dell'Erba, Alessandro
   Introini, Ugo
   Lanzetta, Paolo
   Locatelli, Paolo
   Ricci, Federico
   Staurenghi, Giovanni
   Varano, Monica
   Zotti, Fiorenza
TI Definition of indicators of appropriateness in the management of
   neovascular age-related macular degeneration: An expert opinion
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Appropriateness; clinical practice; indicator; wet age-related macular
   degeneration; diagnostic-therapeutic pathway; vascular endothelial
   growth factor inhibitors
ID TREAT-AND-EXTEND; DAILY CLINICAL-PRACTICE; GROWTH-FACTOR THERAPY;
   INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; TREATMENT OUTCOMES; TREATMENT
   REGIMEN; 2-YEAR OUTCOMES; FOLLOW-UP; AFLIBERCEPT
AB Wet age-related macular degeneration is a chronic condition culminating, in most cases, in blindness. The introduction of anti-angiogenic agents in 2006 has represented a major breakthrough in the treatment of the disease, but timely and effective treatment with regular follow-up and monitoring is mandatory to stabilize and preserve visual acuity. In clinical practice, however, appropriate therapy provision is frequently challenged by economic and organizational issues that result in suboptimal visual outcomes and increased incidence of legal blindness. International Guidelines have defined a diagnostic and therapeutic pathway to ensure the best practice in wet age-related macular degeneration management, but reference parameters to evaluate and compare the performance of Retina Centers are lacking. To address the appropriateness of wet age-related macular degeneration management in Italy, a multidisciplinary panel of ten experts gathered in three meetings. They defined three sets of indicators and relative benchmark values that each Center should comply with to ensure patients optimal care already from the first access: (a) clinical intervention indicators, to determine the possible Center's deviation from the diagnostic and therapeutic pathway; (b) outcome indicator, to evaluate the socioeconomic impact of the healthcare systems' performance; (c) management indicators, to test the size of the gap between the Center's supply and demand. Once the indicators have been analyzed, healthcare systems can plan actions to improve appropriateness and monitor their effects. However, to put this in practice, a concerted effort by all parts involved in healthcare provision is required, together with adequate systems to analyze clinical and administrative documentation.
C1 [Avitabile, Teresio] Univ Catania, G Rodolico Eye Clin, Catania, Italy.
   [Boscia, Francesco] Univ Sassari, Dept Surg Microsurg & Med Sci, Sassari, Italy.
   [Dell'Erba, Alessandro; Zotti, Fiorenza] Univ Bari, Interdisciplinary Dept Med, Sect Legal Med, Bari, Italy.
   [Introini, Ugo] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Udine, Italy.
   [Locatelli, Paolo] Politecn Milan, Dept Management Econ & Ind Engn, Milan, Italy.
   [Ricci, Federico] Univ Tor Vergata, Unit Retinal Dis, Policlin Tor Vergata, Rome, Italy.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Ophthalmol Clin, Milan, Italy.
   [Varano, Monica] IRCCS GB Bietti Fdn, Via Livenza 3, I-00198 Rome, Italy.
C3 University of Catania; University of Sassari; Universita degli Studi di
   Bari Aldo Moro; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; University of Udine; Polytechnic University of Milan;
   University of Rome Tor Vergata; Policlin Tor Vergata; University of
   Milan; Luigi Sacco Hospital; IRCCS - Fondazione "G.B. Bietti" per lo
   Studio e la Ricerca in Oftalmologia
RP Varano, M (通讯作者)，IRCCS GB Bietti Fdn, Via Livenza 3, I-00198 Rome, Italy.
EM monica.varano@fondazionebietti.it
RI Avitabile, Teresio/AAC-6076-2022; Boscia, Francesco/AAC-7729-2022
OI Varano, Monica/0000-0002-6530-1563; Lanzetta, Paolo/0000-0003-3746-141X
FU Novartis Farma SpA Italy
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Financial
   support for this study was provided entirely by a contract with Novartis
   Farma SpA Italy. The funding agreement ensured the authors' independence
   in designing the study, interpreting the data, writing, and publishing
   the report.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cazet-Supervielle A, 2015, OPHTHALMOLOGICA, V234, P26, DOI 10.1159/000430470
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Chong V, 2016, EYE, V30, P1526, DOI 10.1038/eye.2016.202
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Ghazala Fadi, 2013, BMJ Qual Improv Rep, V2, DOI 10.1136/bmjquality.u201733.w993
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Khanani AM, 2019, CLIN OPHTHALMOL, V13, P347, DOI 10.2147/OPTH.S191170
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Li J.Q., 2017, RETINAL DIS EUROPE P
   Li JQ, 2019, BR J OPHTHALMOL, DOI 10.1136/bjophthalmol-2019-314422
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mainz J, 2003, INT J QUAL HEALTH C, V15, P523, DOI 10.1093/intqhc/mzg081
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Manuale di formazione per il governo clinico: monitoraggio delle performance cliniche, 2012, MAN FORM GOV CLIN MO
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mennini FS, 2019, PHARMACOECONOMICS, V4, P6
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagiv O, 2017, OPHTHALMOLOGICA, V238, P217, DOI 10.1159/000479437
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Talks JS, 2017, EYE, V31, P1613, DOI 10.1038/eye.2017.86
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   WHO Priority eye diseases, WHO PRIOR EYE DIS
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 69
TC 1
Z9 2
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2020
VL 30
IS 4
BP 795
EP 804
AR 1120672120915685
DI 10.1177/1120672120915685
EA MAY 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MF1JK
UT WOS:000533969100001
PM 32389030
OA Green Published
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Kim, KM
   Kim, HS
   Lee, DW
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Kim, Kyoung Min
   Kim, Hyoung Seok
   Lee, Dong Won
   Kim, Chul Gu
   Kim, Jong Woo
TI Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial
   Growth Factor Treatment in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VEGF TRAP-EYE; INTRAVITREAL AFLIBERCEPT;
   CHOROIDAL THICKNESS; FACTOR THERAPY; RANIBIZUMAB; NEOVASCULARIZATION;
   BEVACIZUMAB; INJECTION; TEARS
AB OBJECTIVE: To evaluate the therapeutic response of pigment epithelial detachment (PED) to anti vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD), and identify predictive factors for PED resolution after treatment.
   DESIGN: Retrospective, interventional case series.
   METHODS: A total of 202 treatment-naive nAMD eyes presenting PED at baseline were retrospectively included and analyzed. All patients were treated with an initial series of 3 monthly loading injections of ranibizumab or aflibercept, followed by additional injections as required.
   RESULTS: After 12 months of treatment, the mean PED height decreased from 453 +/- 261 mu m at baseline to.230 +/- 142 mu m (P =.002), and the mean best corrected visual acuity improved from 0.71 +/- 0.41 logarithm of the minimal angle of resolution (Snellen equivalent, 20/102) to 0.60 +/- 0.36 (20/79) (P = .024). The proportion of complete PED resolution after treatment was 19.3% (39 eyes). Multivariate logistic regression analysis was used to find baseline characteristics associated with a higher chance of PED resolution, including lower PED height at baseline (P =.018), polypoidal choroidal vasculopathy (P = .015), or retinal angiomatous proliferation (P = .010) compared to typical nAMD; serous PED (P = .022) compared to fibrovascular PED; and aflibercept (P = .039) compared to ranibizumab.
   CONCLUSIONS: PEDs secondary to nAMD showed significant functional and anatomic improvement after intravitreal anti-VEGF injections over 12 months. However, the anti-VEGF treatment showed limited efficacy for the complete resolution of PED. The PED type, nAMD subtype, baseline PED height, and anti-VEGF drug type was associated with a higher probability of PED resolution after treatment. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Cho, Han Joo; Kim, Kyoung Min; Kim, Hyoung Seok; Lee, Dong Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp,Myung Gok Eye Res Inst, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4ga Yeoungdeungpo Dong, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 32
TC 37
Z9 39
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2016
VL 166
BP 112
EP 119
DI 10.1016/j.ajo.2016.03.039
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO2QD
UT WOS:000377624000017
PM 27048998
DA 2022-11-30
ER

PT J
AU Oishi, A
   Tsujikawa, A
   Yamashiro, K
   Ooto, S
   Tamura, H
   Nakanishi, H
   Ueda-Arakawa, N
   Miyake, M
   Akagi-Kurashige, Y
   Hata, M
   Yoshikawa, M
   Kuroda, Y
   Takahashi, A
   Yoshimura, N
AF Oishi, Akio
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Ooto, Sotaro
   Tamura, Hiroshi
   Nakanishi, Hideo
   Ueda-Arakawa, Naoko
   Miyake, Masahiro
   Akagi-Kurashige, Yumiko
   Hata, Masayuki
   Yoshikawa, Munemitsu
   Kuroda, Yoshimasa
   Takahashi, Ayako
   Yoshimura, Nagahisa
TI One-Year Result of Aflibercept Treatment on Age-Related Macular
   Degeneration and Predictive Factors for Visual Outcome
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL RANIBIZUMAB INJECTIONS;
   OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; VERTEPORFIN;
   THICKNESS; ACUITY; LAPTOP
AB PURPOSE: To investigate the efficacy of periodic injection of aflibercept in each subtype of age-related macular degeneration (AMD) and to explore the predictive factors for visual outcome in clinical settings.
   DESIGN: Prospective nonrandomized interventional case series.
   METHODS: Patients with AMD were recruited and were administered aflibercept injections once a month for 3 months followed by once every 2 months for 8 months. The logarithm of the minimal angle of resolution (logMAR) at 12 months and improvement of vision from baseline were compared among polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and typical AMD. Regression rate of polypoidal lesions was assessed. We also performed regression analysis with logMAR at 12. months as the dependent variable.
   RESULTS: The study sample consisted of 98 patients: 46 had typical AMD, 42 had PCV, and 10 had RAP. Mean logMAR improved from 0.36 to 0.21 in 12 months. While there was no difference in visual improvement between typical AMD and PCV, final logMAR was better in PCV (0.32 +/- 0.09 vs 0.08 +/- 0.04, P = .016). Thirty-nine PCV patients underwent follow-up angiography, and regression of polyps was observed in 27 cases (69.2%). Multiple regression analysis showed that the presence of external limiting membrane (ELM), smaller greatest linear dimension, and the presence of polypoidal lesion were associated with better visual outcome (R-2 = 0.53, P = 2.73 x 10(-14))
   CONCLUSIONS: Periodic injection of aflibercept is effective for PCV as well as for typical AMD. The statuses of ELM, greatest linear dimension, and polypoidal lesion are predictive for visual outcome. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Oishi, Akio; Tsujikawa, Akitaka; Yamashiro, Kenji; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Ueda-Arakawa, Naoko; Miyake, Masahiro; Akagi-Kurashige, Yumiko; Hata, Masayuki; Yoshikawa, Munemitsu; Kuroda, Yoshimasa; Takahashi, Ayako; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
C3 Kyoto University
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; Oishi, Akio/AAE-9996-2020; TAMURA,
   Hiroshi/H-1855-2011
OI Miyake, Masahiro/0000-0001-7410-3764; Oishi, Akio/0000-0002-0977-9458;
   TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science, Tokyo, Japan [24791847];
   Ministry of Education, Culture, Sports, Science, and Technology (MEXT),
   Tokyo, Japan
FX This research was supported in part by a grant-in-aid for scientific
   research (No. 24791847) from the Japan Society for the Promotion of
   Science, Tokyo, Japan and the Innovative Techno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems,
   from the Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT), Tokyo, Japan.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 28
TC 81
Z9 84
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2015
VL 159
IS 5
BP 853
EP 860
DI 10.1016/j.ajo.2015.01.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5VW
UT WOS:000353365000005
PM 25634529
DA 2022-11-30
ER

PT J
AU Cunningham, ET
   Feiner, L
   Chung, C
   Tuomi, L
   Ehrlich, JS
AF Cunningham, Emmett T., Jr.
   Feiner, Leonard
   Chung, Carol
   Tuomi, Lisa
   Ehrlich, Jason S.
TI Incidence of Retinal Pigment Epithelial Tears after Intravitreal
   Ranibizumab Injection for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; BEVACIZUMAB INJECTION; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; DETACHMENT; AVASTIN;
   VERTEPORFIN; SECONDARY
AB Objective: To explore the association between treatment for neovascular age-related macular degeneration (AMD) and incidence and timing of retinal pigment epithelium (RPE) tears in ranibizumab-treated patients versus control treatment.
   Design: Results from 3 phase III clinical trials (ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in age-related macular degeneration [ANCHOR], Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related macular degeneration [MARINA], and A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization [CNV] with or without Classic CNV Secondary to Age-Related Macular Degeneration [PIER]) were retrospectively reviewed to identify patients who developed RPE tears during the study period, detected on fluorescein angiography performed at prespecified intervals.
   Participants: Patients with baseline and post-baseline angiographic assessments.
   Methods: Patients received intravitreal ranibizumab (0.3 or 0.5 mg) or control treatment (verteporfin photodynamic therapy [PDT] in ANCHOR and sham intravitreal injections in ANCHOR, MARINA, and PIER).
   Main Outcome Measures: Incidence and timing of RPE tears during the treatment period.
   Results: Data from 1298 patients were analyzed. No statistically significant differences in RPE tear incidence were observed. The pooled rate of RPE tears was 1.8% with 0.5 mg ranibizumab, 3.0% with 0.3 mg ranibizumab, and 1.6% in the control group. Most (76%; 16/21) RPE tears in ranibizumab-treated patients were identified within 3 months of initiating treatment, whereas the majority (80%; 4/5) of late-onset RPE tears occurred in control patients. In patients who developed RPE tears, better visual acuity (VA) outcomes were observed in those treated with ranibizumab versus control treatment.
   Conclusions: As studied in these trials, no statistically significant differences in the incidence of RPE tears within a 2-year treatment period were observed in patients who received ranibizumab (0.5 or 0.3 mg) versus control treatment, although most RPE tears with ranibizumab occurred within 3 months of initiating treatment. Mean VA was better in patients who developed RPE tears while receiving ranibizumab than in those who received control treatment, suggesting a potential benefit of continued ranibizumab therapy in patients with neovascular AMD who developed RPE tears.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 2447-2452 (C) 2011 by the American Academy of Ophthalmology.
C1 [Cunningham, Emmett T., Jr.] Stanford Univ, Dept Ophthalmol, Sch Med, Stanford, CA 94305 USA.
   [Cunningham, Emmett T., Jr.] Stanford Univ, Sch Med, Calif Pacific Med Ctr, Stanford, CA 94305 USA.
   [Feiner, Leonard] Retina Associates New Jersey, Teaneck, NJ USA.
   [Chung, Carol; Tuomi, Lisa; Ehrlich, Jason S.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Stanford University; California Pacific Medical Center; Stanford
   University; Roche Holding; Genentech
RP Cunningham, ET (通讯作者)，W Coast Retina Med Grp Inc, 185 Berry St,Lobby 2,Suite 130, San Francisco, CA 94107 USA.
EM emmett_cunningham@yahoo.com
FU Genentech, Inc.
FX Drs. Cunningham and Feiner have received no financial support. The
   design and conduct of the study and the data collection, management, and
   analysis and interpretation of the data were supported by Genentech,
   Inc. Medical writing and editorial support were provided by Christina
   McManus, PhD, Envision Scientific Solutions, funded by Genentech, Inc.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salz D, 2010, REV OPHTHALMOL, V18, P66
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
NR 35
TC 58
Z9 62
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2011
VL 118
IS 12
BP 2447
EP 2452
DI 10.1016/j.ophtha.2011.05.026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863BO
UT WOS:000298138000021
PM 21872935
DA 2022-11-30
ER

PT J
AU Mantel, I
   Gianniou, C
   Dirani, A
AF Mantel, Irmela
   Gianniou, Christina
   Dirani, Ali
TI CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB
   THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON
   MONTHLY RANIBIZUMAB TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF therapy; ranibizumab; aflibercept; neovascular age-related
   macular degeneration; observe and plan regimen
ID GROWTH-FACTOR VEGF; INTRAVITREAL AFLIBERCEPT; ANATOMICAL OUTCOMES;
   BEVACIZUMAB; FLUID; EYES; TACHYPHYLAXIS; VERTEPORFIN; RESISTANT; TRAP
AB Purpose:To compare the effects of converting to aflibercept therapy with continuing ranibizumab therapy in eyes with neovascular age-related macular degeneration requiring monthly ranibizumab treatment.Methods:Patients were selected from the 104 patients (115 eyes) already enrolled in an Observe and Plan prospective case series that included treating neovascular age-related macular degeneration with ranibizumab for 24 months. Patients who still needed monthly retreatment at the end of a 2-year study were randomized to either continue ranibizumab therapy or to convert to aflibercept therapy. Outcome measures included average interval between treatments, resolution of exudative signs, number of retreatments, and change in visual acuity over 12 months (the third treatment year).Results:Nineteen patients (21 eyes) met the inclusion criteria. Ten eyes were randomized to receive aflibercept, and 11 eyes remained on ranibizumab. Groups were balanced for baseline characteristics. Outcomes were similar in the 2 groups over a 12-month study duration, with no statistical difference.Conclusion:This comparative pilot study suggests that neovascular age-related macular degeneration requiring monthly retreatment with ranibizumab may respond in similar ways to both ranibizumab and aflibercept treatment. Larger sample sizes would be needed to confirm this observation.
C1 [Mantel, Irmela; Gianniou, Christina; Dirani, Ali] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Mantel, Irmela; Gianniou, Christina; Dirani, Ali] Fdn Asile Aveugles, Jules Gonin Eye Hosp, Med Retina Clin, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, Fdn Asile Aveugles, Ave France 15,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gianniou C, 2015, RETINA
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Jang L, 2014, GRAEFES ARCH CLIN EX
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 33
TC 20
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2016
VL 36
IS 1
BP 53
EP 58
DI 10.1097/IAE.0000000000000664
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2BN
UT WOS:000367600400007
PM 26166797
DA 2022-11-30
ER

PT J
AU Ghosh, S
   Stepicheva, N
   Yazdankhah, M
   Shang, P
   Watson, AM
   Hose, S
   Liu, HT
   Weiss, J
   Zigler, JS
   Valapala, M
   Watkins, SC
   Sinha, D
AF Ghosh, Sayan
   Stepicheva, Nadezda
   Yazdankhah, Meysam
   Shang, Peng
   Watson, Alan M.
   Hose, Stacey
   Liu, Haitao
   Weiss, Joseph
   Zigler, J. Samuel, Jr.
   Valapala, Mallika
   Watkins, Simon C.
   Sinha, Debasish
TI The role of lipocalin-2 in age-related macular degeneration (AMD)
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Lipocalin-2 (LCN-2); Age-related macular degeneration (AMD);
   Inflammation; AKT2 signaling; Retinal degeneration
ID GELATINASE-ASSOCIATED LIPOCALIN; INFLAMMATORY RESPONSE; PROTEIN FAMILY;
   NEUTROPHIL LIPOCALIN; ENDOCYTIC RECEPTORS; PROTEOMIC ANALYSIS; IRON
   HOMEOSTASIS; EPITHELIAL-CELLS; MEGALIN; MICE
AB Lipocalins are a family of secreted adipokines which play important roles in various biological processes. Lipocalin-2 (LCN-2) has been shown to be involved in acute and chronic inflammation. This particular protein is critical in the pathogenesis of several diseases including cancer, diabetes, obesity, and multiple sclerosis. Herein, we discuss the general molecular basis for the involvement of LCN-2 in acute infections and chronic disease progression and also ascertain the probable role of LCN-2 in ocular diseases, particularly in age-related macular degeneration (AMD). We elaborate on the signaling cascades which trigger LCN-2 upregulation in AMD and suggest therapeutic strategies for targeting such pathways.
C1 [Ghosh, Sayan; Stepicheva, Nadezda; Yazdankhah, Meysam; Shang, Peng; Hose, Stacey; Liu, Haitao; Weiss, Joseph; Sinha, Debasish] Univ Pittsburgh, Sch Med, Childrens Hosp, Dept Ophthalmol, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
   [Watson, Alan M.; Watkins, Simon C.] Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA USA.
   [Watson, Alan M.; Watkins, Simon C.] Univ Pittsburgh, Sch Med, Dept Cellular Biol, Pittsburgh, PA USA.
   [Zigler, J. Samuel, Jr.; Sinha, Debasish] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Valapala, Mallika] Indiana Univ, Sch Optometry, Bloomington, IN USA.
   [Sinha, Debasish] Univ Pittsburgh, Sch Med, Childrens Hosp, Dept Ophthalmol Cell Biol & Dev Biol, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins
   University; Indiana University System; Indiana University Bloomington;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Ghosh, S; Sinha, D (通讯作者)，Univ Pittsburgh, Sch Med, Childrens Hosp, Dept Ophthalmol, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.; Sinha, D (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.; Sinha, D (通讯作者)，Univ Pittsburgh, Sch Med, Childrens Hosp, Dept Ophthalmol Cell Biol & Dev Biol, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM sayang@pitt.edu; Debasish@pitt.edu
RI Liu, Haitao/AAY-3944-2021; Watkins, Simon/ABG-2590-2021; Ghosh,
   Sayan/ABB-8587-2021
OI Liu, Haitao/0000-0002-3757-779X; Watkins, Simon/0000-0003-4092-1552;
   /0000-0002-3780-5641
FU National Eye Institute [EY019037-S]; RPB/IRRF Catalyst Award for
   Innovative Research Approaches for AMD; BrightFocus Foundation; Jennifer
   Salvitti Davis Chair in Ophthalmology; Research to Prevent Blindness
   (Ophthalmology, UPMC), NY
FX This study was funded by National Eye Institute: EY019037-S (DS),
   RPB/IRRF Catalyst Award for Innovative Research Approaches for AMD (DS),
   BrightFocus Foundation, Jennifer Salvitti Davis Chair in Ophthalmology
   (DS), Research to Prevent Blindness (Ophthalmology, UPMC), NY
CR Ahnstrom J, 2007, J LIPID RES, V48, P1754, DOI 10.1194/jlr.M700103-JLR200
   Aigner F, 2007, AM J TRANSPLANT, V7, P779, DOI 10.1111/j.1600-6143.2006.01723.x
   Asimakopoulou A, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00430
   Assemat E, 2005, GENE EXPR PATTERNS, V6, P69, DOI 10.1016/j.modgep.2005.04.014
   AXELSSON L, 1995, SCAND J CLIN LAB INV, V55, P577, DOI 10.3109/00365519509110257
   Bachman MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000622
   Berard JL, 2012, GLIA, V60, P1145, DOI 10.1002/glia.22342
   Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103
   Bi FF, 2013, P NATL ACAD SCI USA, V110, P4069, DOI 10.1073/pnas.1218497110
   BLASER J, 1995, CLIN CHIM ACTA, V235, P137, DOI 10.1016/0009-8981(95)06020-7
   Bolignano D, 2008, AM J KIDNEY DIS, V52, P595, DOI 10.1053/j.ajkd.2008.01.020
   Borkham-Kamphorst E, 2011, LIVER INT, V31, P656, DOI 10.1111/j.1478-3231.2011.02495.x
   BUNDGAARD JR, 1994, BIOCHEM BIOPH RES CO, V202, P1468, DOI 10.1006/bbrc.1994.2096
   Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54
   Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562, DOI 10.1152/ajprenal.2001.280.4.F562
   Chun BY, 2015, INVEST OPHTH VIS SCI, V56, P3691, DOI 10.1167/iovs.15-16851
   Coorens M, 2019, J BIOL CHEM, V294, P6027, DOI 10.1074/jbc.RA118.007290
   Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896
   Ortega MC, 2012, GLIA, V60, P851, DOI 10.1002/glia.22316
   Dahl SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02717
   Dartt DA, 2011, OCUL SURF, V9, P126, DOI 10.1016/S1542-0124(11)70022-2
   Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027
   Dussurget O, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00050
   Elkhidir Areej E, 2017, BMC Res Notes, V10, P285, DOI 10.1186/s13104-017-2604-y
   Eller K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067693
   Fisher CE, 2006, DEV BIOL, V296, P279, DOI 10.1016/j.ydbio.2006.06.007
   Fitzgerald M, 2007, EXP BRAIN RES, V183, P171, DOI 10.1007/s00221-007-1032-y
   FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2
   FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507
   FLOWER DR, 1994, FEBS LETT, V354, P7, DOI 10.1016/0014-5793(94)01078-1
   Flower DR, 1996, BIOCHEM J, V318, P1
   Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5
   Fu Y, 2016, CYTOKINE, V86, P10, DOI 10.1016/j.cyto.2016.07.003
   Ganfornina MD, 2000, MOL BIOL EVOL, V17, P114, DOI 10.1093/oxfordjournals.molbev.a026224
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6
   HAMILTON RT, 1985, J CELL PHYSIOL, V123, P201, DOI 10.1002/jcp.1041230208
   Hofmaier F, 2011, INVEST OPHTH VIS SCI, V52, P2314, DOI 10.1167/iovs.10-6475
   Holden VI, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00125-18
   Howe CL, 2014, GLIA, V62, P692, DOI 10.1002/glia.22635
   Hu CX, 2018, ONCOTARGETS THER, V11, P8099, DOI 10.2147/OTT.S181223
   Jeon S, 2013, J BIOL CHEM, V288, P24116, DOI 10.1074/jbc.M113.454140
   Jha MK, 2014, EXP NEUROL, V254, P41, DOI 10.1016/j.expneurol.2014.01.009
   Jiang J, 2018, INVEST OPHTH VIS SCI, V59, P4986, DOI 10.1167/iovs.18-25067
   John-Aryankalayil M, 2006, MOL VIS, V12, P55
   Karadag Z, 2018, BRATISL MED J, V119, P302, DOI 10.4149/BLL_2018_057
   Kehrer JP, 2010, CELL BIOL TOXICOL, V26, P83, DOI 10.1007/s10565-009-9119-9
   KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557
   Kim JW, 2016, CLIN CHIM ACTA, V462, P140, DOI 10.1016/j.cca.2016.09.011
   Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7
   Kjeldsen L, 1996, J IMMUNOL METHODS, V198, P155, DOI 10.1016/S0022-1759(96)00153-6
   KJELDSEN L, 1993, BLOOD, V82, P3183
   Konig O, 2008, FASEB J, V22, P410, DOI 10.1096/fj.07-9171com
   Korol A, 2014, AM J PATHOL, V184, P2001, DOI 10.1016/j.ajpath.2014.03.013
   Kundu P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003887
   Lee S, 2007, J IMMUNOL, V179, P3231, DOI 10.4049/jimmunol.179.5.3231
   Lee S, 2009, J NEUROSCI, V29, P234, DOI 10.1523/JNEUROSCI.5273-08.2009
   Li XC, 2014, AM J PHYSIOL-RENAL, V307, pF222, DOI 10.1152/ajprenal.00693.2013
   Lin CW, 2016, CARCINOGENESIS, V37, P712, DOI 10.1093/carcin/bgw050
   Lundgren S, 1997, J HISTOCHEM CYTOCHEM, V45, P383, DOI 10.1177/002215549704500306
   Makhezer N, 2019, MUCOSAL IMMUNOL, V12, P117, DOI 10.1038/s41385-018-0086-4
   Mallbris L, 2002, EXP DERMATOL, V11, P584, DOI 10.1034/j.1600-0625.2002.110611.x
   Mannelqvist M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-169
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Marino M, 2001, THYROID, V11, P47, DOI 10.1089/10507250150500667
   Marzolo MP, 2011, BIOL RES, V44, P89, DOI 10.4067/S0716-97602011000100012
   Mizuta K, 1999, HEARING RES, V129, P83, DOI 10.1016/S0378-5955(98)00221-4
   Morieri ML, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2925-4
   Nairz M, 2015, EUR J IMMUNOL, V45, P3073, DOI 10.1002/eji.201545569
   Nairz M, 2015, CELL HOST MICROBE, V18, P254, DOI 10.1016/j.chom.2015.06.017
   Nam Y, 2014, J BIOL CHEM, V289, P16773, DOI 10.1074/jbc.M113.542282
   Nasioudis D, 2015, MED MICROBIOL IMMUN, V204, P471, DOI 10.1007/s00430-015-0394-1
   Naude PJW, 2012, FASEB J, V26, P2811, DOI 10.1096/fj.11-202457
   Parmar T, 2018, J IMMUNOL, V200, P3128, DOI 10.4049/jimmunol.1701573
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   Peruchetti DB, 2014, J BIOL CHEM, V289, P16790, DOI 10.1074/jbc.M114.549717
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Richardson DR, 2005, CELL, V123, P1175, DOI 10.1016/j.cell.2005.12.008
   Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e
   Schmidt-Ott KM, 2007, J AM SOC NEPHROL, V18, P407, DOI 10.1681/ASN.2006080882
   Schroll A, 2012, EUR J IMMUNOL, V42, P3346, DOI 10.1002/eji.201142351
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Shashidharamurthy R, 2013, ARTHRITIS RHEUM-US, V65, P1064, DOI 10.1002/art.37840
   Shen MQ, 2016, BBA-PROTEINS PROTEOM, V1864, P787, DOI 10.1016/j.bbapap.2016.04.001
   Srinivasan G, 2012, J IMMUNOL, V189, P1911, DOI 10.4049/jimmunol.1200892
   Steigedal M, 2014, J IMMUNOL, V193, P6081, DOI 10.4049/jimmunol.1401528
   Suk K, 2012, CURR NEUROPHARMACOL, V10, P72, DOI 10.2174/157015912799362733
   Suzuki T, 2013, ANTIMICROB AGENTS CH, V57, P6319, DOI 10.1128/AAC.00254-13
   Tang WY, 2018, INVEST OPHTH VIS SCI, V59, P6014, DOI 10.1167/iovs.18-25213
   Tang WY, 2018, CELL PHYSIOL BIOCHEM, V46, P375, DOI 10.1159/000488472
   Ueno S, 2018, INVEST OPHTH VIS SCI, V59, P370, DOI 10.1167/iovs.17-22438
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Venge P, 2018, UPSALA J MED SCI, V123, P1, DOI 10.1080/03009734.2017.1420112
   Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004
   Wang Y, 2007, CLIN CHEM, V53, P34, DOI 10.1373/clinchem.2006.075614
   Warszawska JM, 2013, J CLIN INVEST, V123, P3363, DOI 10.1172/JCI67911
   Xu B, 2013, WORLD J SURG, V37, P1892, DOI 10.1007/s00268-013-2009-6
   Xu SY, 2000, BBA-PROTEIN STRUCT M, V1482, P298, DOI 10.1016/S0167-4838(00)00163-1
   Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224
   Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106
   Yoshikawa K, 2017, HEPATOL COMMUN, V1, P946, DOI 10.1002/hep4.1109
   Yun BA, 2018, ANN LAB MED, V38, P425, DOI 10.3343/alm.2018.38.5.425
   Zhao P, 2014, J BIOL CHEM, V289, P5960, DOI 10.1074/jbc.M113.532234
   Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462
   Zheng LT, 2009, J NEUROCHEM, V111, P1238, DOI 10.1111/j.1471-4159.2009.06410.x
NR 106
TC 14
Z9 14
U1 4
U2 12
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 835
EP 851
DI 10.1007/s00018-019-03423-8
EA JAN 2020
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000505415200001
PM 31901947
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ferreira, A
   Silva, N
   Furtado, MJ
   Carneiro, A
   Lume, M
   Andrade, JP
AF Ferreira, Andre
   Silva, Nisa
   Furtado, Maria Joao
   Carneiro, Angela
   Lume, Miguel
   Andrade, Jose P.
TI Serum vitamin D and age-related macular degeneration: Systematic review
   and meta-analysis
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE vitamin D; 25-hydroxy vitamin D; age-related macular degeneration;
   retina; retinal degeneration
ID D DEFICIENCY; ATHEROSCLEROSIS RISK; 25-HYDROXYVITAMIN D; ASSOCIATION;
   CLASSIFICATION; MACULOPATHY; PREVALENCE; NUTRITION; DISEASE; HEALTH
AB Vitamin D may be implicated in the pathophysiology of several ocular diseases, but its role in age-related macular degeneration (AMD) remains uncertain. We sought to review systematically the existing evidence to evaluate the association between serum 25hydroxyvitamin D 25(OH)D levels and AMD. A four-database search (PubMed, ISI Web of Science, Cochrane, and Scopus) was performed from inception to May 2020 using the MeSH terms: ("Macular Degeneration" OR "Age-related macular degeneration" OR "Retinal degeneration" OR "Macula lutea") AND ("Vitamin D" OR "Ergocalciferols" OR "Cholecalciferol" OR "25-Hydroxyvitamin D"). Random-effects meta-analyses were performed to compute 1) the standard mean difference in 25(OH)D concentration between AMD and non-AMD patients and 2) the AMD risk according to serum 25(OH)D levels. Eighteen observational studies enrolling 75,294 patients after a selection process among 375 original abstracts were selected. No significant differences were found, but there appears to exist a trend for late AMD among subjects with a serum 25(OH)D level below 50 nmol/L (odds ratio, 1.8; 95% confidence interval: 1.00-3.24, P = 0.05). There is no clear evidence of a definitive association between serum 25(OH)D and AMD risk, mainly due to heterogeneity in study procedures and lack of longitudinal designs. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Ferreira, Andre; Silva, Nisa; Furtado, Maria Joao; Lume, Miguel] Ctr Hosp Univ Porto, Serv Ophthalmol, Porto, Portugal.
   [Ferreira, Andre; Andrade, Jose P.] Univ Porto, Dept Biomed, Unit Anat, Fac Med, Porto, Portugal.
   [Carneiro, Angela] Hosp Sao Joao, Serv Ophthalmol, Porto, Portugal.
   [Carneiro, Angela] Univ Porto, Dept Surg & Physiol, Ophthalmol Unit, Fac Med, Porto, Portugal.
   [Andrade, Jose P.] Univ Porto, Ctr Hlth Technol & Serv Res CINTESIS, Fac Med, Porto, Portugal.
C3 Universidade do Porto; Sao Joao Hospital; Universidade do Porto;
   Universidade do Porto
RP Ferreira, A (通讯作者)，Ctr Hosp Univ Porto, Serv Ophthalmol, Porto, Portugal.; Ferreira, A (通讯作者)，Univ Porto, Dept Biomed, Unit Anat, Fac Med, Porto, Portugal.
EM andre.ferreira@live.com.pt
RI Ferreira, André/GQB-3891-2022; Andrade, José Paulo/L-8036-2013
OI Ferreira, André/0000-0001-8577-5128; Andrade, José
   Paulo/0000-0003-2585-200X
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Bernstein M, 2012, J ACAD NUTR DIET, V112, P1255, DOI 10.1016/j.jand.2012.06.015
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bouillon R, 2013, J CLIN ENDOCR METAB, V98, pE1283, DOI 10.1210/jc.2013-1195
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Layana AG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101120
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2014, INVEST OPHTH VIS SCI, V55, P5298, DOI 10.1167/iovs.14-13918
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Hara K, 2018, J PEDIATR ENDOCR MET, V31, P1105, DOI 10.1515/jpem-2018-0275
   Hashemi R, 2018, INTERV MED APPL SCI, V10, P127, DOI 10.1556/1646.10.2018.22
   Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood-2005-03-1029
   Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hollis BW, 2007, J STEROID BIOCHEM, V103, P473, DOI 10.1016/j.jsbmb.2006.11.004
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kan Emrah, 2020, Oman Med J, V35, pe83, DOI 10.5001/omj.2020.01
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim KL, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011908, 10.1097/md.0000000000011908]
   Lai JKC, 2012, INTERN MED J, V42, P43, DOI 10.1111/j.1445-5994.2011.02471.x
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Nikolakopoulou A, 2014, EVID-BASED MENT HEAL, V17, P53, DOI 10.1136/eb-2014-101795
   OrganizationWH, 2020, BLINDNESS VISIONIMPA
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parva NR, 2018, CUREUS, V10, DOI 10.7759/cureus.2741
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Tomada I, 2015, ANTIAGEING NUTRIENTS, P335
   van den Ouweland JMW, 2010, J CHROMATOGR B, V878, P1163, DOI 10.1016/j.jchromb.2010.03.035
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu W, 2016, INVEST OPHTH VIS SCI, V57, P2168, DOI 10.1167/iovs.15-18218
NR 57
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2021
VL 66
IS 2
BP 183
EP 197
DI 10.1016/j.survophthal.2020.07.003
EA FEB 2021
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ1VV
UT WOS:000624315700002
PM 32768420
DA 2022-11-30
ER

PT J
AU Huang, LL
   Zhang, HB
   Cheng, CY
   Wen, F
   Tam, POS
   Zhao, PQ
   Chen, HY
   Li, Z
   Chen, LJ
   Tai, ZF
   Yamashiro, K
   Deng, SP
   Zhu, XJ
   Chen, WQ
   Cai, L
   Lu, F
   Li, YF
   Cheung, CMG
   Shi, Y
   Miyake, M
   Lin, Y
   Gong, B
   Liu, XQ
   Sim, KS
   Yang, JY
   Mori, K
   Zhang, XZ
   Cackett, PD
   Tsujikawa, M
   Nishida, K
   Hao, F
   Ma, S
   Lin, H
   Cheng, J
   Fei, P
   Lai, TYY
   Tang, SB
   Laude, A
   Inoue, S
   Yeo, IY
   Sakurada, Y
   Zhou, Y
   Iijima, H
   Honda, S
   Lei, CT
   Zhang, L
   Zheng, H
   Jiang, D
   Zhu, X
   Wong, TY
   Khor, CC
   Pang, CP
   Yoshimura, N
   Yang, ZL
AF Huang, Lulin
   Zhang, Houbin
   Cheng, Ching-Yu
   Wen, Feng
   Tam, Pancy O. S.
   Zhao, Peiquan
   Chen, Haoyu
   Li, Zheng
   Chen, Lijia
   Tai, Zhengfu
   Yamashiro, Kenji
   Deng, Shaoping
   Zhu, Xianjun
   Chen, Weiqi
   Cai, Li
   Lu, Fang
   Li, Yuanfeng
   Cheung, Chui-Ming G.
   Shi, Yi
   Miyake, Masahiro
   Lin, Yin
   Gong, Bo
   Liu, Xiaoqi
   Sim, Kar-Seng
   Yang, Jiyun
   Mori, Keisuke
   Zhang, Xiongzhe
   Cackett, Peter D.
   Tsujikawa, Motokazu
   Nishida, Kohji
   Hao, Fang
   Ma, Shi
   Lin, He
   Cheng, Jing
   Fei, Ping
   Lai, Timothy Y. Y.
   Tang, Sibo
   Laude, Augustinus
   Inoue, Satoshi
   Yeo, Ian Y.
   Sakurada, Yoichi
   Zhou, Yu
   Iijima, Hiroyuki
   Honda, Shigeru
   Lei, Chuntao
   Zhang, Lin
   Zheng, Hong
   Jiang, Dan
   Zhu, Xiong
   Wong, Tien-Ying
   Khor, Chiea-Chuen
   Pang, Chi-Pui
   Yoshimura, Nagahisa
   Yang, Zhenglin
TI A missense variant in FGD6 confers increased risk of polypoidal
   choroidal vasculopathy
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FACTOR-H GENE; NUCLEOTIDE EXCHANGE FACTOR;
   COMPLEMENT COMPONENT 2; MACULAR DEGENERATION; OXIDIZED PHOSPHOLIPIDS;
   DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; POLYMORPHISM; SUSCEPTIBILITY
AB Polypoidal choroidal vasculopathy (PCV), a subtype of 'wet' age-related macular degeneration (AMD), constitutes up to 55% of cases of wet AMD in Asian patients. In contrast to the choroidal neovascularization (CNV) subtype, the genetic risk factors for PCV are relatively unknown. Exome sequencing analysis of a Han Chinese cohort followed by replication in four independent cohorts identified a rare c.986A>G (p.Lys329Arg) variant in the FGD6 gene as significantly associated with PCV (P = 2.19 x 10(-16), odds ratio (OR) = 2.12) but not with CNV (P = 0.26, OR = 1.13). The intracellular localization of FGD6-Arg329 is distinct from that of FGD6-Lys329. In vitro, FGD6 could regulate proangiogenic activity, and oxidized phospholipids increased expression of FGD6. FGD6-Arg329 promoted more abnormal vessel development in the mouse retina than FGD6-Lys329. Collectively, our data suggest that oxidized phospholipids and FGD6-Arg329 might act synergistically to increase susceptibility to PCV.
C1 [Huang, Lulin; Zhang, Houbin; Tai, Zhengfu; Zhu, Xianjun; Cai, Li; Lu, Fang; Li, Yuanfeng; Shi, Yi; Lin, Yin; Gong, Bo; Liu, Xiaoqi; Yang, Jiyun; Hao, Fang; Ma, Shi; Lin, He; Cheng, Jing; Zhou, Yu; Zhang, Lin; Zheng, Hong; Jiang, Dan; Zhu, Xiong; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Sichuan Acad Med Sci, Key Lab Human Dis Gene Study, Chengdu 610054, Peoples R China.
   [Huang, Lulin; Zhang, Houbin; Tai, Zhengfu; Zhu, Xianjun; Cai, Li; Lu, Fang; Li, Yuanfeng; Shi, Yi; Lin, Yin; Gong, Bo; Liu, Xiaoqi; Yang, Jiyun; Hao, Fang; Ma, Shi; Lin, He; Cheng, Jing; Zhou, Yu; Zhang, Lin; Zheng, Hong; Jiang, Dan; Zhu, Xiong; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu 610054, Peoples R China.
   [Huang, Lulin; Tai, Zhengfu; Yang, Zhenglin] Chinese Acad Sci, Inst Chengdu Biol, Chengdu, Peoples R China.
   [Huang, Lulin; Tai, Zhengfu; Yang, Zhenglin] Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Peoples R China.
   [Huang, Lulin; Zhang, Houbin; Tai, Zhengfu; Zhu, Xianjun; Shi, Yi; Lin, Yin; Zhang, Lin; Yang, Zhenglin] Univ Elect Sci & Technol China, Ctr Informat Biomed, Chengdu 610054, Peoples R China.
   [Cheng, Ching-Yu; Li, Zheng; Cheung, Chui-Ming G.; Cackett, Peter D.; Yeo, Ian Y.; Wong, Tien-Ying; Khor, Chiea-Chuen] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Li, Zheng; Cheung, Chui-Ming G.; Wong, Tien-Ying; Khor, Chiea-Chuen] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Cheng, Ching-Yu; Yeo, Ian Y.; Wong, Tien-Ying] Duke Natl Univ Singapore Grad Med Sch, Singapore, Singapore.
   [Wen, Feng; Tam, Pancy O. S.; Zhang, Xiongzhe; Tang, Sibo] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Zhao, Peiquan; Fei, Ping] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Chen, Haoyu; Chen, Weiqi] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Haoyu; Chen, Weiqi] Chinese Univ Hong Kong, Shantou, Peoples R China.
   [Li, Zheng; Sim, Kar-Seng; Khor, Chiea-Chuen] Genome Inst Singapore, Dept Human Genet, Singapore, Singapore.
   [Chen, Lijia; Lai, Timothy Y. Y.; Pang, Chi-Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Yamashiro, Kenji; Miyake, Masahiro; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Deng, Shaoping; Mori, Keisuke] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama, Japan.
   [Cackett, Peter D.] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Hlth Care Grp Eye Inst, Singapore, Singapore.
   [Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.
   [Sakurada, Yoichi; Honda, Shigeru] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 657, Japan.
   [Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi, Japan.
   [Lei, Chuntao] Sichuan Acad Med Sci, Dept Ophthalmol, Chengdu, Peoples R China.
   [Lei, Chuntao] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Chinese Academy of Sciences;
   Chinese Academy of Sciences; University of Electronic Science &
   Technology of China; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; Sun Yat Sen
   University; Shanghai Jiao Tong University; Shantou University; Agency
   for Science Technology & Research (A*STAR); A*STAR - Genome Institute of
   Singapore (GIS); Chinese University of Hong Kong; Kyoto University;
   Saitama Medical University; Osaka University; Tan Tock Seng Hospital;
   Saitama Medical University; Kobe University; University of Yamanashi;
   Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital
RP Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Sichuan Acad Med Sci, Key Lab Human Dis Gene Study, Chengdu 610054, Peoples R China.; Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu 610054, Peoples R China.; Yang, ZL (通讯作者)，Chinese Acad Sci, Inst Chengdu Biol, Chengdu, Peoples R China.; Yang, ZL (通讯作者)，Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Peoples R China.; Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Ctr Informat Biomed, Chengdu 610054, Peoples R China.
EM zliny@yahoo.com
RI Chen, Li Jia/I-5078-2014; Chen, Haoyu/A-7432-2013; Miyake,
   Masahiro/V-1261-2019; KOSUGI, Shinji/GYR-2946-2022; Hao,
   Fang/GRJ-3165-2022; Zhang, Houbin/A-8887-2012; Lai, Timothy Y
   Y/AAC-2120-2020; Honda, Shigeru/W-4761-2019; Yang, Jiyun/AAS-3937-2020;
   Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019
OI Chen, Li Jia/0000-0003-3500-5840; Chen, Haoyu/0000-0003-0676-4610;
   Miyake, Masahiro/0000-0001-7410-3764; Lai, Timothy Y
   Y/0000-0002-7832-6428; Wong, Tien Yin/0000-0002-8448-1264; Cheng,
   Ching-Yu/0000-0003-0655-885X; Li, Zheng/0000-0002-7060-2213; Nishida,
   Kohji/0000-0001-9069-3610; Khor, Chiea Chuen/0000-0002-1128-4729;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Yamashiro,
   Kenji/0000-0001-9354-8558; Zhang, Houbin/0000-0002-2968-7454; Zhu,
   Xianjun/0000-0002-2531-7552; Sim, Kar Seng/0000-0002-3822-7759
FU National Natural Science Foundation of China [81170883, 81430008,
   81200723, 81300802, 81170882, 81371030, 81271005]; Department of Science
   and Technology of Sichuan Province, China [2014SZ0169, 2015SZ0052,
   2015SZ0060, 2016HH00X, 2015JQO057, 2014HH0009, 2014JZ0004]; General
   Research Fund, Hong Kong [467708, 468810]; National Medical Research
   Council, Singapore [NMRC/TCR/002-SERI/2008, R626/47/2008TCR, CSA
   R613/34/2008, NMRC 0796/2003, STaR/0003/2008]; National Research
   Foundation of Singapore, Biomedical Research Council, Singapore [BMRC
   09/1/35/19/616, 08/1/35/19/550, 10/1/35/19/675]; Genome Institute of
   Singapore [GIS/12-AR2105]; National Medical Research Council (NMRC)
   [0796/2003, IRG07nov013, IRG09nov014, NMRC 1176/2008, NIG/1003/2009,
   CG/SERI/2010, CSA/033/2012]; Biomedical Research Council in Singapore
   [BMRC 08/1/35/19/550, 09/1/35/19/616, 10/1/35/19/671]; Bright Focus
   Foundation, USA [M2011068]
FX We thank all the patients with AMD and their families for participating
   in this study. This work was carried out on behalf of the Genetics of
   AMD in Asians (GAMA) Consortium. This research project was supported by
   the National Natural Science Foundation of China (81170883, 81430008
   (Z.Y.), 81200723 and 81300802 (L.H.), 81170882 (Y. Shi), 81371030 (H.
   Zhang), and 81271005 (Xianjun Zhu)); grants from the Department of
   Science and Technology of Sichuan Province, China (2014SZ0169,
   2015SZ0052 (Z.Y.), 2015SZ0060 (Y.L.), 2016HH00X, 2015JQO057 (L.H.),
   2014HH0009 (H. Zhang), and 2014JZ0004 (Y. Shi)); research grants 467708
   and 468810 from the General Research Fund, Hong Kong; the National
   Medical Research Council, Singapore (NMRC/TCR/002-SERI/2008
   (R626/47/2008TCR), CSA R613/34/2008, NMRC 0796/2003, and
   STaR/0003/2008); the National Research Foundation of Singapore,
   Biomedical Research Council, Singapore (BMRC 09/1/35/19/616,
   08/1/35/19/550, and 10/1/35/19/675); and the Genome Institute of
   Singapore (GIS/12-AR2105). This research was also supported by the
   National Medical Research Council (NMRC grants 0796/2003, IRG07nov013,
   IRG09nov014, NMRC 1176/2008, NIG/1003/2009, CG/SERI/2010, and
   CSA/033/2012) and the Biomedical Research Council (BMRC 08/1/35/19/550,
   09/1/35/19/616, and 10/1/35/19/671) in Singapore; the Bright Focus
   Foundation, USA (M2011068); and the National Medical Research Council,
   Singapore (CSA/033/2012).
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Berliner JA, 2005, NEW ENGL J MED, V353, P9, DOI 10.1056/NEJMp058118
   Berliner JA, 2009, J LIPID RES, V50, pS207, DOI 10.1194/jlr.R800074-JLR200
   Bochkov VN, 2006, CIRC RES, V99, P900, DOI 10.1161/01.RES.0000245485.04489.ee
   Bonne C, 2000, J FR OPHTALMOL, V23, P835
   Chen YH, 2014, NAT GENET, V46, P1115, DOI 10.1038/ng.3078
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fu WQ, 2013, NATURE, V493, P216, DOI 10.1038/nature11690
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Johnson RC, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-724
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kurogane Y, 2012, ARTERIOSCL THROM VAS, V32, P988, DOI 10.1161/ATVBAHA.111.244004
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee S, 2012, CIRC RES, V111, P778, DOI 10.1161/CIRCRESAHA.111.256859
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200
   Moltke I, 2014, NATURE, V512, P190, DOI 10.1038/nature13425
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Oskolkova OV, 2008, BLOOD, V112, P330, DOI 10.1182/blood-2007-09-112870
   Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Purcell SM, 2014, NATURE, V506, P185, DOI 10.1038/nature12975
   Romanoski CE, 2010, AM J HUM GENET, V86, P399, DOI 10.1016/j.ajhg.2010.02.002
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Steenblock C, 2014, J BIOL CHEM, V289, P18347, DOI 10.1074/jbc.M113.504894
   Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tang HY, 2014, NAT GENET, V46, P45, DOI 10.1038/ng.2827
   Tiwari HK, 1997, GENET EPIDEMIOL, V14, P1131, DOI 10.1002/(SICI)1098-2272(1997)14:6<1131::AID-GEPI95>3.3.CO;2-7
   Tual-Chalot S, 2013, JOVE-J VIS EXP, DOI 10.3791/50546
   Wang CL, 2014, NAT GENET, V46, P409, DOI 10.1038/ng.2924
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong R, 2004, EYE, V18, P262, DOI 10.1038/sj.eye.6700637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Zhao JY, 2006, AM J HUM GENET, V79, P831, DOI 10.1086/508571
   [No title captured]
NR 75
TC 47
Z9 56
U1 1
U2 38
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2016
VL 48
IS 6
BP 640
EP +
DI 10.1038/ng.3546
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DN0HE
UT WOS:000376744200011
PM 27089177
DA 2022-11-30
ER

PT J
AU Kaufman, SR
AF Kaufman, Steven R.
TI Developments in age-related macular degeneration: Diagnosis and
   treatment
SO GERIATRICS
LA English
DT Article
DE age-related macular degeneration; exudative; macula; non-exudative;
   retina
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL INJECTION; PHOTODYNAMIC
   THERAPY; SUPPLEMENTATION; ASSOCIATIONS; VERTEPORFIN; EYE
AB Age-related macular degeneration (ARMD) is the leading cause of legal blindness of Americans over age 65 years. Severe loss of vision is usually due to exudative ARMD, of which there are about 200,000 new cases in the United States annually. Until recently, only a small fraction of patients benefited from treatment, but advances in the early diagnosis of the disease and major developments in therapy have substantially improved the prognosis of patients with ARMD. Because visual loss substantially reduces quality of life, effective management of ARMD will have increasing public health importance as the population ages. The American Academy of Ophthalmology recommends that people over age 65 years should have a comprehensive eye examination every 1 to 2 years to check for cataracts, macular degeneration, glaucoma, and other conditions. Those who complain of difficulty reading, driving at night, or adapting from sunlight to indoor lighting might have macular degeneration.
C1 Case Sch Med, Dept Ophthalmol, Cleveland, OH USA.
C3 Case Western Reserve University
RP Kaufman, SR (通讯作者)，Case Sch Med, Dept Ophthalmol, Cleveland, OH USA.
CR ALLIKMETS R, 2008, RETINA TODAY, V3, P39
   *AM SOC RET SPEC, 2006, REP PAT MINS WET AMD
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   CORN AL, 1996, FDN LOW VISION CLIN, P446
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   *THOMPS HEALTHC IN, 2008, BEV PHYS DESK REF, P1199
   Trevino Richard, 2008, Optometry, V79, P397, DOI 10.1016/j.optm.2007.09.017
   2009, RETINAL PHYS     JAN, P57
NR 18
TC 13
Z9 13
U1 0
U2 4
PU ADVANSTAR COMMUNICATIONS INC
PI WOODLAND HILLS
PA 6200 CANOGA AVE, 2ND FLR, WOODLAND HILLS, CA 91367 USA
SN 0016-867X
J9 GERIATRICS
JI Geriatrics
PD MAR
PY 2009
VL 64
IS 3
BP 16
EP 19
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 420CK
UT WOS:000264265800004
PM 19351219
DA 2022-11-30
ER

PT J
AU Sayanagi, K
   Gomi, F
   Sawa, M
   Ohji, M
   Tano, Y
AF Sayanagi, Kaori
   Gomi, Fumi
   Sawa, Miki
   Ohji, Masahito
   Tano, Yasuo
TI Long-term follow-up of polypoidal choroidal vasculopathy after
   photodynamic therapy with verteporfin
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; photodynamic therapy; Japanese
   Age-Related Macular Degeneration Trial; long-term follow-up; recurrence
ID MACULAR DEGENERATION; JAPANESE PATIENTS
AB Purpose To report on the clinical features of three cases of polypoidal choroidal vasculopathy (PCV) during long-term follow-up after photodynamic therapy (PDT).
   Design Interventional case reports.
   Methods Among the participants in the Japanese Age-Related Macular Degeneration Trial (JAT) at our hospital, a PCV was seen in three eyes at baseline on retrospective analysis of indocyanine green angiography (ICGA) using fundus camera. We report the clinical features of these cases during more than 4 years follow-up.
   Results The mean number of PDT treatments was 5.7. Improved visual acuity (VA) and cessation of fluorescein leakage was achieved within 18 months in all eyes; however, subretinal hemorrhage and subfoveal fluid recurred due to new or recurrent PCV. The final VA decreased markedly in two eyes.
   Conclusions The eyes with PCV, which had been treated successfully with PDT, may have developed new or recurrent PCV during long-term follow-up. Periodical ICGA would be needed to detect abnormal choroidal vascular changes.
C1 Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, Rm E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   GOMI F, IN PRESS GRAEFES ARC
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 10
TC 35
Z9 37
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2007
VL 245
IS 10
BP 1569
EP 1571
DI 10.1007/s00417-007-0582-9
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209RJ
UT WOS:000249405400020
PM 17437122
DA 2022-11-30
ER

PT J
AU Seider, N
   Beiran, I
   Miller-Lotan, R
   Dori, D
   Karp, J
   Miller, B
   Levy, AP
AF Seider, N
   Beiran, I
   Miller-Lotan, R
   Dori, D
   Karp, J
   Miller, B
   Levy, AP
TI Haptoglobin phenotype in age-related macular degeneration patients
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR COMPLICATIONS
AB Purpose: To investigate a possible role of the haptoglobin phenotype in the development of exudative age, related macular degeneration (AMD) in human subjects.
   Design: Prospective, observational, comparative population study.
   Methods: The study was carried out in an institutional setting. All patients referred because of exudative AMD in one eye during an 18-month period were included in the study group. A group of patients treated for other ocular diseases and not having AMD in either eye served as control. Haptoglobin phenotype was determined from a blood sample drawn from each patient in both the study and control groups. The main outcome measure was the distribution of the haptoglobin phenotype in the study and control group.
   Results: One hundred eighty-five participants were included in the study. Ninety-eight had exudative AMD, and 87 were AMD-free. The difference between the study and control groups in distribution of the haptoglobin phenotype was found to be statistically insignificant.
   Conclusions: Our results suggest that the haptoglobin phenotype has no effect on the prevalence of exudative AMD.
C1 Rambam Med Ctr, Alberto Moscona Dept Ophthalmol, IL-31096 Haifa, Israel.
   Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.
   Efrat Med Clin, Dept Ophthalmol, Kiryat Bialik, Israel.
C3 Rambam Health Care Campus; Technion Israel Institute of Technology;
   Technion Israel Institute of Technology; Rappaport Faculty of Medicine
RP Beiran, I (通讯作者)，Rambam Med Ctr, Alberto Moscona Dept Ophthalmol, POB 9602, IL-31096 Haifa, Israel.
OI Miller, Benjamin/0000-0003-1647-0122
CR Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   Levy AP, 2000, NEW ENGL J MED, V343, P969, DOI 10.1056/NEJM200009283431313
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Nakhoul FM, 2000, JAMA-J AM MED ASSOC, V284, P1244, DOI 10.1001/jama.284.10.1244-a
   Nakhoul FM, 2001, DIABETOLOGIA, V44, P602, DOI 10.1007/s001250051666
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Roguin A, 2001, AM J CARDIOL, V87, P330, DOI 10.1016/S0002-9149(00)01368-0
   Wassell J, 1999, ANN CLIN BIOCHEM, V36, P609, DOI 10.1177/000456329903600507
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2003
VL 136
IS 5
BP 911
EP 914
DI 10.1016/S0002-9394(03)00575-0
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735ZW
UT WOS:000186146000018
PM 14597045
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Chen, W
   Schu, M
   Yaspan, BL
   Yu, Y
   Thorleifsson, G
   Zack, DJ
   Arakawa, S
   Cipriani, V
   Ripke, S
   Igo, RP
   Buitendijk, GHS
   Sim, XL
   Weeks, DE
   Guymer, RH
   Merriam, JE
   Francis, PJ
   Hannum, G
   Agarwal, A
   Armbrecht, AM
   Audo, I
   Aung, T
   Barile, GR
   Benchaboune, M
   Bird, AC
   Bishop, PN
   Branham, KE
   Brooks, M
   Brucker, AJ
   Cade, WH
   Cain, MS
   Campochiaroll, PA
   Chan, CC
   Cheng, CY
   Chew, EY
   Chin, KA
   Chowers, I
   Clayton, DG
   Cojocaru, R
   Conley, YP
   Cornes, BK
   Daly, MJ
   Dhillon, B
   Edwards, A
   Evangelou, E
   Fagemess, J
   Ferreyra, HA
   Friedman, JS
   Geirsdottir, A
   George, RJ
   Gieger, C
   Gupta, N
   Hagstrom, SA
   Harding, SP
   Haritoglou, C
   Heckenlively, JR
   Hoz, FG
   Hughes, G
   Ioannidis, JPA
   Ishibashi, T
   Joseph, P
   Jun, G
   Kamatani, Y
   Katsanis, N
   Keilhauer, CN
   Khan, JC
   Kim, IK
   Kiyohara, Y
   Klein, BEK
   Klein, R
   Kovach, JL
   Kozak, I
   Lee, CJ
   Lee, KE
   Lichtner, P
   Lotery, AJ
   Meitinger, T
   Mitchell, P
   Mohand-Said, S
   Moore, AT
   Morgan, DJ
   Margaux, AM
   Myers, CE
   Naj, AC
   Nakamura, Y
   Okada, Y
   Orlin, A
   Ortube, MC
   Othman, MI
   Pappas, C
   Park, KH
   Pauer, GJT
   Peachey, NS
   Poch, O
   Priya, RR
   Reynolds, R
   Richardson, AJ
   Ripp, R
   Rudolph, G
   Ryu, E
   Sahel, JA
   Schaumberg, DA
   Scholl, HPN
   Schwartz, SG
   Scott, WK
   Shahid, H
   Sigurdsson, H
   Silvestri, G
   Sivakumaran, TA
   Smith, RT
   Sobrin, L
   Souied, EH
   Stambolian, DE
   Stefansson, H
   Sturgill-Short, GM
   Takahashi, A
   Tosakulwong, N
   Truitt, BJ
   Tsironi, EE
   Uitterlinden, AG
   van Duijn, CM
   Vijaya, L
   Vingerling, JR
   Vithana, EN
   Webster, AR
   Wichmann, HE
   Winkler, TW
   Wong, TY
   Wright, AF
   Zelenika, D
   Zhang, M
   Zhao, L
   Zhang, K
   Klein, ML
   Hageman, GS
   Lathrop, GM
   Stefansson, K
   Allikmets, R
   Baird, PN
   Gorin, MB
   Wang, JJ
   Klaver, CCW
   Seddon, JM
   Pericak-Vance, MA
   Iyengar, SK
   Yates, JRW
   Swaroop, A
   Weber, BHF
   Kubo, M
   DeAngelis, MM
   Leveillard, T
   Thorsteinsdottir, U
   Haines, JL
   Farrer, LA
   Heid, IM
   Abecasis, GR
AF Fritsche, Lars G.
   Chen, Wei
   Schu, Matthew
   Yaspan, Brian L.
   Yu, Yi
   Thorleifsson, Gudmar
   Zack, Donald J.
   Arakawa, Satoshi
   Cipriani, Valentina
   Ripke, Stephan
   Igo, Robert P., Jr.
   Buitendijk, Gabrielle H. S.
   Sim, Xueling
   Weeks, Daniel E.
   Guymer, Robyn H.
   Merriam, Joanna E.
   Francis, Peter J.
   Hannum, Gregory
   Agarwal, Anita
   Armbrecht, Ana Maria
   Audo, Isabelle
   Aung, Tin
   Barile, Gaetano R.
   Benchaboune, Mustapha
   Bird, Alan C.
   Bishop, Paul N.
   Branham, Kari E.
   Brooks, Matthew
   Brucker, Alexander J.
   Cade, William H.
   Cain, Melinda S.
   Campochiaroll, Peter A.
   Chan, Chi-Chao
   Cheng, Ching-Yu
   Chew, Emily Y.
   Chin, Kimberly A.
   Chowers, Itay
   Clayton, David G.
   Cojocaru, Radu
   Conley, Yvette P.
   Cornes, Belinda K.
   Daly, Mark J.
   Dhillon, Baljean
   Edwards, Albert
   Evangelou, Evangelos
   Fagemess, Jesen
   Ferreyra, Henry A.
   Friedman, James S.
   Geirsdottir, Asbjorg
   George, Ronnie J.
   Gieger, Christian
   Gupta, Neel
   Hagstrom, Stephanie A.
   Harding, Simon P.
   Haritoglou, Christos
   Heckenlively, John R.
   Hoz, Frank G.
   Hughes, Guy
   Ioannidis, John P. A.
   Ishibashi, Tatsuro
   Joseph, Peronne
   Jun, Gyungah
   Kamatani, Yoichiro
   Katsanis, Nicholas
   Keilhauer, Claudia N.
   Khan, Jane C.
   Kim, Ivana K.
   Kiyohara, Yutaka
   Klein, Barbara E. K.
   Klein, Ronald
   Kovach, Jaclyn L.
   Kozak, Igor
   Lee, Clara J.
   Lee, Kristine E.
   Lichtner, Peter
   Lotery, Andrew J.
   Meitinger, Thomas
   Mitchell, Paul
   Mohand-Saied, Saddek
   Moore, Anthony T.
   Morgan, Denise J.
   Morrison, Margaux A.
   Myers, Chelsea E.
   Naj, Adam C.
   Nakamura, Yusuke
   Okada, Yukinori
   Orlin, Anton
   Ortube, M. Carolina
   Othman, Mohammad I.
   Pappas, Chris
   Park, Kyu Hyung
   Pauer, Gayle J. T.
   Peachey, Neal S.
   Poch, Olivier
   Priya, Rinki Ratna
   Reynolds, Robyn
   Richardson, Andrea J.
   Ripp, Raymond
   Rudolph, Guenther
   Ryu, Euijung
   Sahel, Jose-Alain
   Schaumberg, Debra A.
   Scholl, Hendrik P. N.
   Schwartz, Stephen G.
   Scott, William K.
   Shahid, Humma
   Sigurdsson, Haraldur
   Silvestri, Giuliana
   Sivakumaran, Theru A.
   Smith, R. Theodore
   Sobrin, Lucia
   Souied, Eric H.
   Stambolian, Dwight E.
   Stefansson, Hreinn
   Sturgill-Short, Gwen M.
   Takahashi, Atsushi
   Tosakulwong, Nirubol
   Truitt, Barbara J.
   Tsironi, Evangelia E.
   Uitterlinden, Andre G.
   van Duijn, Cornelia M.
   Vijaya, Lingam
   Vingerling, Johannes R.
   Vithana, Eranga N.
   Webster, Andrew R.
   Wichmann, H-Erich
   Winkler, Thomas W.
   Wong, Tien Y.
   Wright, Alan F.
   Zelenika, Diana
   Zhang, Ming
   Zhao, Ling
   Zhang, Kang
   Klein, Michael L.
   Hageman, Gregory S.
   Lathrop, G. Mark
   Stefansson, Kari
   Allikmets, Rando
   Baird, Paul N.
   Gorin, Michael B.
   Wang, Jie Jin
   Klaver, Caroline C. W.
   Seddon, Johanna M.
   Pericak-Vance, Margaret A.
   Iyengar, Sudha K.
   Yates, John R. W.
   Swaroop, Anand
   Weber, Bernhard H. F.
   Kubo, Michiaki
   DeAngelis, Margaret M.
   Leveillard, Thierry
   Thorsteinsdottir, Unnur
   Haines, Jonathan L.
   Farrer, Lindsay A.
   Heid, Iris M.
   Abecasis, Goncalo R.
CA AMD Gene Consortium
TI Seven new loci associated with age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E;
   INFLUENCES RISK; SUSCEPTIBILITY; GENE; VARIANTS; CFH; POLYMORPHISM;
   HAPLOTYPE
AB Age-related macular degeneration (AMD) is a common cause of blindness in older individuals. To accelerate the understanding of AMD biology and help design new therapies, we executed a collaborative genome-wide association study, including >17,100 advanced AMD cases and >60,000 controls of European and Asian ancestry. We identified 19 loci associated at P < 5 x 10(-8) These loci show enrichment for genes involved in the regulation of complement activity, lipid metabolism, extracellular matrix remodeling and angiogenesis. Our results include seven loci with associations reaching P < 5 x 10-8 for the first time, near the genes COL8A1-FILIP1L, IER3-DDR1, SLC16A8, TGFBR1, RAD51B, ADAMTS9 and B3GALTL. A genetic risk score combining SNP genotypes from all loci showed similar ability to distinguish cases and controls in all samples examined. Our findings provide new directions for biological, genetic and therapeutic studies of AMD.
C1 [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Fritsche, Lars G.; Chen, Wei; Sim, Xueling; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Chen, Wei] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med,Med Ctr, Div Pediat Pulm Med Allergy & Immunol,Dept Pediat, Pittsburgh, PA USA.
   [Schu, Matthew; Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Sect Biomed Genet, Boston, MA 02118 USA.
   [Schu, Matthew; Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med, Sect Biomed Genet, Boston, MA USA.
   [Yaspan, Brian L.; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Yaspan, Brian L.; Haines, Jonathan L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA.
   [Yu, Yi; Chin, Kimberly A.; Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Thorleifsson, Gudmar; Stefansson, Hreinn] deCODE Genet, Reykjavik, Iceland.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   [Zack, Donald J.; Sahel, Jose-Alain; Leveillard, Thierry] Univ Paris 06, Dept Genet, Inst Vis, UMRS 968, Paris, France.
   [Zack, Donald J.; Campochiaroll, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Neurosci, Baltimore, MD 21205 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Inst Genet Med, Baltimore, MD 21205 USA.
   [Arakawa, Satoshi; Kubo, Michiaki] RIKEN, CGM, Res Grp Genotyping, Lab Genotyping Dev, Yokohama, Kanagawa, Japan.
   [Cipriani, Valentina; Bird, Alan C.; Moore, Anthony T.; Webster, Andrew R.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Cipriani, Valentina; Bird, Alan C.; Moore, Anthony T.; Sahel, Jose-Alain; Webster, Andrew R.; Yates, John R. W.] UCL, Inst Ophthalmol, London, England.
   [Ripke, Stephan; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Ripke, Stephan] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA USA.
   [Igo, Robert P., Jr.; Joseph, Peronne; Truitt, Barbara J.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Buitendijk, Gabrielle H. S.; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Sim, Xueling] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Guymer, Robyn H.; Cain, Melinda S.; Richardson, Andrea J.; Wong, Tien Y.; Baird, Paul N.; Wang, Jie Jin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Merriam, Joanna E.; Barile, Gaetano R.; Smith, R. Theodore; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Francis, Peter J.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
   [Hannum, Gregory] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
   [Agarwal, Anita] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN USA.
   [Agarwal, Anita] Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37212 USA.
   [Armbrecht, Ana Maria; Dhillon, Baljean; Mohand-Saied, Saddek] Univ Edinburgh, Dept Ophthalmol, Edinburgh, Midlothian, Scotland.
   [Armbrecht, Ana Maria; Dhillon, Baljean; Mohand-Saied, Saddek] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Sahel, Jose-Alain; Leveillard, Thierry] INSERM, U968, Paris, France.
   [Mohand-Saied, Saddek; Sahel, Jose-Alain; Leveillard, Thierry] CNRS, UMR 7210, Paris, France.
   [Aung, Tin; Cheng, Ching-Yu; Cornes, Belinda K.; Vithana, Eranga N.; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Aung, Tin; Cheng, Ching-Yu; Vithana, Eranga N.; Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Benchaboune, Mustapha; Mohand-Saied, Saddek; Sahel, Jose-Alain] Ctr Invest Clin 503, Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM Direct Hosp & Org Soins, Paris, France.
   [Bishop, Paul N.] Univ Manchester, Fac Med & Human Sci, Inst Human Dev, Manchester, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp Natl Hlth Serv NHS Fdn, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Branham, Kari E.; Heckenlively, John R.; Othman, Mohammad I.; Swaroop, Anand] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Brooks, Matthew; Cojocaru, Radu; Friedman, James S.; Gupta, Neel; Priya, Rinki Ratna; Swaroop, Anand] NEI, Neurobiol Neurodegenerabon & Repair Lab N NNRL, US Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Brucker, Alexander J.] Penn Presbyterian Med Ctr, Scheie Eye Inst, Philadelphia, PA USA.
   [Cade, William H.; Naj, Adam C.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Cade, William H.; Naj, Adam C.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn Dept Human Genet, Miami, FL 33136 USA.
   [Campochiaroll, Peter A.; Scholl, Hendrik P. N.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, US Natl Inst Hlth, Bethesda, MD USA.
   [Cheng, Ching-Yu] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching-Yu] Duke Natl Univ Singapore Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, US Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Clayton, David G.; Khan, Jane C.; Shahid, Humma; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA.
   [Edwards, Albert] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
   [Evangelou, Evangelos] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
   [Fagemess, Jesen] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Fagemess, Jesen; Lee, Clara J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
   [Ferreyra, Henry A.; Hughes, Guy; Kozak, Igor; Lee, Clara J.; Zhang, Ming; Zhao, Ling; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Ferreyra, Henry A.; Hughes, Guy; Kozak, Igor; Lee, Clara J.; Zhang, Ming; Zhao, Ling; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Geirsdottir, Asbjorg; Sigurdsson, Haraldur] Natl Univ Hosp Reykjavik, Dept Ophthalmol, Reykjavik, Iceland.
   [George, Ronnie J.; Vijaya, Lingam] Vis Res Fdn, Glaucoma Project, Madras, Tamil Nadu, India.
   [Gieger, Christian; Heid, Iris M.] Deutsch Forschungszentrum Gesundheit & Umwelt, Helmholtz Zentrum Manchen, Inst Genet Epidemiol, Neuherberg, Germany.
   [Hagstrom, Stephanie A.; Pauer, Gayle J. T.; Peachey, Neal S.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Harding, Simon P.] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3BX, Merseyside, England.
   [Haritoglou, Christos; Rudolph, Guenther] Univ Munich, Augenklin, D-80539 Munich, Germany.
   [Hoz, Frank G.; Scholl, Hendrik P. N.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Hughes, Guy; Zhang, Ming; Zhao, Ling; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA.
   [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02118 USA.
   [Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
   [Jun, Gyungah; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Kamatani, Yoichiro; Lathrop, G. Mark] Ctr Etud Polymorphisme Humain CEPH, Fdn Jean Dausset, Paris, France.
   [Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, D-97070 Wurzburg, Germany.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Khan, Jane C.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia.
   [Kim, Ivana K.; Schaumberg, Debra A.; Sobrin, Lucia] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Kim, Ivana K.; Sobrin, Lucia] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Kiyohara, Yutaka; Thorsteinsdottir, Unnur] Kyushu Univ, Grad Sch Med Sci, Dept Environm Med, Fukuoka, Japan.
   [Klein, Barbara E. K.; Klein, Ronald; Lee, Kristine E.; Myers, Chelsea E.] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Klein, Barbara E. K.; Klein, Ronald; Lee, Kristine E.; Myers, Chelsea E.] Univ Wisconsin, Sch Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Lichtner, Peter; Meitinger, Thomas] Deutsch Forschungszentrum Gesundheit & Umwelt, Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany.
   [Lotery, Andrew J.] Univ Southampton, Fac Med Clin & Expt Sci, Southampton, Hants, England.
   [Meitinger, Thomas] Tech Univ Munich, Inst Human Genet, D-80290 Munich, Germany.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Mohand-Saied, Saddek] Univ Paris 06, Dept Therapeut, Inst Vis, UMRS 968, Paris, France.
   [Morgan, Denise J.; Morrison, Margaux A.; Stefansson, Kari; DeAngelis, Margaret M.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med, Tokyo, Japan.
   [Okada, Yukinori; Takahashi, Atsushi] RIKEN, Lab Stat Anal, Yokohama, Kanagawa, Japan.
   [Orlin, Anton] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Ortube, M. Carolina; Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Ortube, M. Carolina; Gorin, Michael B.] Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Pappas, Chris; Hageman, Gregory S.] Univ Utah, Moran Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Kyeounggi, South Korea.
   [Peachey, Neal S.; Sturgill-Short, Gwen M.] Louis Stokes Vet Affairs Med Ctr, Res Serv, Cleveland, OH USA.
   [Poch, Olivier; Ripp, Raymond] IGBMC, Lab Integrat Bioinformat & Genom, Illkirch Graffenstaden, France.
   [Ryu, Euijung; Tosakulwong, Nirubol] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA.
   [Sahel, Jose-Alain] Fdn Ophtalmol Adolphe Rothschild, Paris, France.
   [Sahel, Jose-Alain] Acad Sci Inst France, Paris, France.
   [Schaumberg, Debra A.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
   [Shahid, Humma] Addenbrookes Hosp, Dept Ophthalmol, Cambridge, England.
   [Sigurdsson, Haraldur; Stefansson, Kari; Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Silvestri, Giuliana] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA.
   [Smith, R. Theodore] Columbia Univ, Dept Biomed Engn, New York, NY USA.
   [Souied, Eric H.] Univ Paris Est, Hop Henri Mondor, Ctr Rech Clin Ophthalmol, Hop Intercommunal Creteil, Creteil, France.
   [Stambolian, Dwight E.] Univ Penn, Dept Ophthalmol & Genet, Philadelphia, PA 19104 USA.
   [Tsironi, Evangelia E.] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Wichmann, H-Erich] Deutsch Forschungszentrum Gesundheit & Umwelt, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany.
   [Gorin, Michael B.] Univ Munich, Inst Med Informat, Munich, Germany.
   [Wichmann, H-Erich; Gorin, Michael B.] Univ Munich, Klinikum Grosshadern, D-80539 Munich, Germany.
   [Kubo, Michiaki] Univ Munich, Inst Biometry, Munich, Germany.
   [Wichmann, H-Erich] Univ Munich, Inst Epidemiol, Munich, Germany.
   [Winkler, Thomas W.; Heid, Iris M.] Univ Regensburg, Dept Epidemiol & Prevent Med, D-93053 Regensburg, Germany.
   [Wright, Alan F.] Inst Genet & Mol Med, Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Zelenika, Diana; Lathrop, G. Mark] Ctr Energie Atom, Inst Genom, Ctr Natl Genotypage, Evry, France.
   [Zhang, Ming; Zhang, Kang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, Chengdu 610064, Peoples R China.
   [Zhang, Ming; Zhang, Kang] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610064, Peoples R China.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Ctr Clin Invest, Cleveland, OH 44106 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
C3 University of Regensburg; University of Michigan System; University of
   Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Boston University; Boston University;
   Vanderbilt University; Vanderbilt University; Tufts Medical Center;
   Johns Hopkins University; Johns Hopkins Medicine; UDICE-French Research
   Universities; Sorbonne Universite; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   RIKEN; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London; Harvard University; Massachusetts General Hospital; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Case Western Reserve University; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC;
   National University of Singapore; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; Columbia University; Oregon Health &
   Science University; University of California System; University of
   California San Diego; Vanderbilt University; Vanderbilt University;
   University of Edinburgh; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   UDICE-French Research Universities; Universite Paris Cite; National
   University of Singapore; Singapore National Eye Center; National
   University of Singapore; CHNO des Quinze-Vingts; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; University of Manchester; University
   of Manchester; University of Michigan System; University of Michigan;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Pennsylvania; Pennsylvania Medicine; Pennsylvania
   Presbyterian Medical Center; University of Miami; University of Miami;
   Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); National
   University of Singapore; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Hebrew University of Jerusalem; University
   of Cambridge; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Oregon; University of
   Ioannina; Harvard University; Massachusetts General Hospital; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; University of California System; University of California San
   Diego; University of California System; University of California San
   Diego; Landspitali National University Hospital; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health; Cleveland Clinic Foundation; University of Liverpool; University
   of Hamburg; University Medical Center Hamburg-Eppendorf; University of
   Munich; University of Bonn; University of California System; University
   of California San Diego; Stanford University; Stanford University;
   Stanford University; Kyushu University; Boston University; Boston
   University; Boston University; Boston University; Foundation Jean
   Dausset-CEPH; Duke University; Duke University; Duke University;
   University of Wurzburg; Royal Perth Hospital; University of Western
   Australia; University of Western Australia; Harvard University; Harvard
   Medical School; Harvard University; Massachusetts Eye & Ear Infirmary;
   Kyushu University; University of Wisconsin System; University of
   Wisconsin Madison; University of Wisconsin System; University of
   Wisconsin Madison; Bascom Palmer Eye Institute; University of Miami;
   Helmholtz Association; Helmholtz-Center Munich - German Research Center
   for Environmental Health; University of Southampton; Technical
   University of Munich; University of Sydney; University of Sydney;
   Westmead Institute for Medical Research; UDICE-French Research
   Universities; Sorbonne Universite; Utah System of Higher Education;
   University of Utah; University of Tokyo; RIKEN; Cornell University;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Utah System of Higher Education; University of
   Utah; Seoul National University (SNU); US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Case Western Reserve
   University; Louis Stokes Cleveland Veterans Affairs Medical Center;
   Institut National de la Sante et de la Recherche Medicale (Inserm); Mayo
   Clinic; Fondation Adolphe de Rothschild; Harvard University; Brigham &
   Women's Hospital; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; University of Iceland;
   Queens University Belfast; Cincinnati Children's Hospital Medical
   Center; Columbia University; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; University of Pennsylvania; University
   of Thessaly; Erasmus University Rotterdam; Erasmus MC; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health; University of Munich; University of Munich;
   University of Munich; University of Munich; University of Regensburg;
   University of Edinburgh; CEA; UDICE-French Research Universities;
   Universite Paris Saclay; Sichuan University; Sichuan University;
   Columbia University; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Tufts University; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; Boston University; Boston University; Boston
   University; Boston University
RP Abecasis, GR (通讯作者)，Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
EM jonathan@chgr.mc.vanderbilt.edu; farrer@bu.edu;
   iris.heid@klinik.uni-regensburg.de; goncalo@umich.edu
RI Meitinger, Thomas/O-1318-2015; Haines, Jonathan/C-3374-2012; wang,
   jie/GRS-0942-2022; Wichmann, Heinz Erich/AAA-5695-2022; Peachey,
   Neal/G-5533-2010; Kamatani, Yoichiro/N-5513-2015; Farrer,
   Lindsay/AAS-1035-2020; Branham, Kari/AAA-8336-2022; Kubo,
   Michiaki/N-7947-2015; Wong, Tien Yin/AAC-9724-2020; Weeks, Daniel
   E/B-2995-2012; Léveillard, Thierry/AAR-1804-2020; Evangelou,
   Evangelos/C-3033-2013; Allikmets, Rando/ABD-4533-2021; Zhang,
   Kang/Y-2740-2019; Chen, Wei/AAX-5994-2020; Cheng, Ching-Yu/Y-2229-2019;
   Ripke, Stephan/AAK-5486-2021; DeAngelis, e/J-7863-2015; Sahel,
   Jose-Alain/F-3172-2017; Daly, Mark J/B-2453-2017; Kozak,
   Igor/AAC-4645-2019; Ioannidis, John P. A./G-9836-2011; Klaver, Caroline
   C.W./A-2013-2016; Mitchell, Paul/P-1498-2014; Abecasis, Goncalo
   R/B-7840-2010; Stefansson, Kari/AAE-7187-2019; Sim,
   Xueling/AAZ-6652-2020; Wang, Jie Jin/P-1499-2014; Cipriani,
   Valentina/A-8549-2012; Zhao, Ling/D-9005-2015; Cheng,
   Ching-Yu/K-7017-2013; /S-1190-2019; Fritsche, Lars G/AAF-9387-2019
OI Haines, Jonathan/0000-0002-4351-4728; Peachey, Neal/0000-0002-4419-7226;
   Wong, Tien Yin/0000-0002-8448-1264; Weeks, Daniel E/0000-0001-9410-7228;
   Léveillard, Thierry/0000-0001-5692-8770; Evangelou,
   Evangelos/0000-0002-5488-2999; Zhang, Kang/0000-0002-4549-1697; Chen,
   Wei/0000-0001-7196-8703; Cheng, Ching-Yu/0000-0003-0655-885X; Sahel,
   Jose-Alain/0000-0002-4831-1153; Daly, Mark J/0000-0002-0949-8752; Sim,
   Xueling/0000-0002-1233-7642; Wang, Jie Jin/0000-0001-9491-4898;
   Cipriani, Valentina/0000-0002-0839-9955; Cheng,
   Ching-Yu/0000-0003-0655-885X; /0000-0001-7488-250X; Fritsche, Lars
   G/0000-0002-2110-1690; Conley, Yvette/0000-0002-1784-6067; Zhao,
   Ling/0000-0002-6644-2886; Bishop, Paul/0000-0001-7937-7932; Van Duijn,
   Cornelia/0000-0002-2374-9204; Weber, Bernhard H.F./0000-0002-8808-7723;
   smith, theodore/0000-0002-1693-943X; ripke, stephan/0000-0003-3622-835X;
   george, ronnie/0000-0001-7368-0252; Farrer, Lindsay/0000-0001-5533-4225;
   Branham, Kari/0000-0002-2492-254X; Klaver, Caroline/0000-0002-2355-5258;
   Swaroop, Anand/0000-0002-1975-1141; Harding, Simon/0000-0003-4676-1158;
   Zack, Don/0000-0002-7966-1973; Schu, Matthew/0000-0003-0630-1026; Scott,
   William/0000-0001-9336-6404; Silvestri, Giuliana/0000-0001-5662-5374;
   Klein, Ronald/0000-0002-4428-6237; Audo, Isabelle/0000-0003-0698-5309;
   Abecasis, Goncalo/0000-0003-1509-1825; Ratnapriya,
   Rinki/0000-0002-0469-4631; Guymer, Robyn/0000-0002-9441-4356; Yaspan,
   Brian/0000-0002-3787-2510; Meitinger, Thomas/0000-0002-8838-8403; Kim,
   Ivana/0000-0003-0310-6129; Baird, Paul/0000-0002-1305-3502; Gieger,
   Christian/0000-0001-6986-9554; Jun, Gyungah/0000-0002-3230-8697;
   Stefansson, Hreinn/0000-0002-9331-6666; Igo, Robert/0000-0002-0024-1993;
   Katsanis, Nicholas/0000-0002-2480-0171; Lotery,
   Andrew/0000-0001-5541-4305
FU Medical Research Council [MC_U127584475, G0000067, MR/K006584/1] Funding
   Source: Medline; NEI NIH HHS [R01 EY022005, R01 EY021163, P30 EY019007,
   R01 EY013435, P30 EY014800, R01 EY022310, R24 EY019861, R01 EY011309]
   Funding Source: Medline; NHGRI NIH HHS [R01 HG007022] Funding Source:
   Medline; Medical Research Council [MC_PC_U127584475] Funding Source:
   researchfish; National Institute for Health Research [NF-SI-0507-10094,
   NF-SI-0507-10204] Funding Source: researchfish; MRC [MC_U127584475]
   Funding Source: UKRI; NATIONAL EYE INSTITUTE [R01EY022005, P30EY014800,
   R01EY022310, ZIAEY000475, ZIAEY000222, ZICEY000461, R01EY013435,
   ZIAEY000418] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [R01HG007022] Funding Source: NIH RePORTER
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Brooks MJ, 2011, MOL VIS, V17, P3034
   Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Craddock N, 2010, NATURE, V464, P713, DOI 10.1038/nature08979
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   So HC, 2011, GENET EPIDEMIOL, V35, P310, DOI 10.1002/gepi.20579
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 51
TC 566
Z9 579
U1 1
U2 150
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD APR
PY 2013
VL 45
IS 4
BP 433
EP 439
DI 10.1038/ng.2578
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 115VS
UT WOS:000316840600015
PM 23455636
OA Green Accepted, Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Choi, JK
   Lym, YL
   Moon, JW
   Shin, HJ
   Cho, B
AF Choi, Jae Kyung
   Lym, Youl Lee
   Moon, Jun Woong
   Shin, Hyun Jin
   Cho, Belong
TI Diabetes Mellitus and Early Age-related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; MACULOPATHY;
   PATHOGENESIS; ASSOCIATION; SMOKING; BURDEN
AB Objective: To examine the association of diabetes mellitus and early age-related macular degeneration (AMD) in Korean adults 50 years and older.
   Methods: This study included 3008 participants aged 50 to 87 years. Early AMD was assessed from retinal photographs based on a modified Wisconsin AMD grading system. Diabetes mellitus was defined as a fasting glucose level of 126 mg/dL or greater or the use of antidiabetic medications. Logistic regression was used to examine the association between diabetes mellitus and early AMD.
   Results: There were 88 subjects with early AMD and 315 subjects with diabetes mellitus. After adjusting for age, sex, current smoking, obesity, and hypertension, significant association was found between diabetes mellitus and early AMD. Subjects with diabetes mellitus were more likely to have early AMD (odds ratio, 1.87; 95% confidence interval, 1.07-3.28) than were those without diabetes mellitus.
   Conclusion: There is a relationship between diabetes mellitus and early AMD in Korean adults 50 years and older. The underlying biological processes remain to be determined.
C1 [Cho, Belong] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Family Med, Sch Med, Seoul 110744, South Korea.
   [Choi, Jae Kyung; Lym, Youl Lee] Konkuk Univ, Sch Med, Med Ctr, Dept Family Med,Ctr Hlth Promot, Seoul, South Korea.
   [Moon, Jun Woong; Shin, Hyun Jin] Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Konkuk University; Konkuk University Medical Center; Konkuk University;
   Konkuk University Medical Center
RP Cho, B (通讯作者)，Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Family Med, Sch Med, 101 Daehangno, Seoul 110744, South Korea.
EM belong@snu.ac.kr
RI Cho, Belong/GLU-3443-2022; Shin, Hyunjin/ABF-6057-2021
OI Cho, Belong/0000-0001-9558-689X; 
FU Konkuk University
FX This article was supported by Konkuk University in 2008.
CR Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
NR 28
TC 35
Z9 36
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2011
VL 129
IS 2
BP 196
EP 199
DI 10.1001/archophthalmol.2010.355
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 721CQ
UT WOS:000287329500013
PM 21320966
DA 2022-11-30
ER

PT J
AU Falcao, MS
   Freitas-Costa, P
   Beato, JN
   Pinheiro-Costa, J
   Rocha-Sousa, A
   Carneiro, A
   Brandao, EM
   Falcao-Reis, F
AF Falcao, Manuel Sousa
   Freitas-Costa, Paulo
   Beato, Joao Nuno
   Pinheiro-Costa, Joao
   Rocha-Sousa, Amandio
   Carneiro, Angela
   Brandao, Elisete Maria
   Falcao-Reis, Fernando
TI Safety and Effectiveness of Cataract Surgery with Simultaneous
   Intravitreal Anti-VEGF in Patients with Previously Treated Exudative
   Age-Related Macular Degeneration
SO ACTA MEDICA PORTUGUESA
LA English
DT Article
DE Cataract Extraction; Macular Degeneration; Neovascularization;
   Phacoemulsification; Treatment Outcome; Vascular Endothelial Growth
   Factors
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR; EYE DISEASE; RANIBIZUMAB;
   BEVACIZUMAB; PROGRESSION; THICKNESS; PHACOEMULSIFICATION; MACULOPATHY;
   OUTCOMES
AB Introduction: To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration.
   Material and Methods: Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simultaneous phacoemulsification and intravitreal ranibizumab or bevacizumab. The patients were followed for 12 months after surgery using a pro re nata strategy. Visual acuity, foveal and choroidal thickness changes were evaluated 1, 6 and 12 months post-operatively.
   Results: There was a statistically significant increase in mean visual acuity at one (13.4 letters, p < 0.05), six (11.5 letters, p < 0.05) and twelve months (11.3 letters, p < 0.05) without significant changes in retinal or choroidal morphology. At 12 months, 86% of eyes were able to maintain visual acuity improvement. There were no significant differences between the two anti-vascular endothelial growth factor drugs and no complications developed during follow-up.
   Discussion: Simultaneous phacoemulsification and intravitreal anti-vascular endothelial growth factor is safe and allows improvement in visual acuity in patients with visually significant cataracts and exudative age-related macular degeneration. Visual acuity gains were maintained with a pro re nata strategy showing that in this subset of patients, phacoemulsification may be beneficial.
   Conclusion: Cataract surgery and simultaneous anti-vascular endothelial growth factor therapy improves visual acuity in patients with exudative age-related macular degeneration.
C1 [Falcao, Manuel Sousa; Freitas-Costa, Paulo; Beato, Joao Nuno; Pinheiro-Costa, Joao; Rocha-Sousa, Amandio; Carneiro, Angela; Falcao-Reis, Fernando] Ctr Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.
   [Falcao, Manuel Sousa; Beato, Joao Nuno; Rocha-Sousa, Amandio; Carneiro, Angela; Brandao, Elisete Maria; Falcao-Reis, Fernando] Univ Porto, Fac Med, Dept Sense Organs, Oporto, Portugal.
   [Freitas-Costa, Paulo; Pinheiro-Costa, Joao] Univ Porto, Fac Med, Dept Anat, Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto
RP Falcao, MS (通讯作者)，Ctr Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.; Falcao, MS (通讯作者)，Univ Porto, Fac Med, Dept Sense Organs, Oporto, Portugal.
EM falcao@med.up.pt
RI Falcao/AAQ-8509-2020; Rocha-Sousa, Amandio/AAG-4500-2020; Carneiro,
   Angela/N-9680-2013
OI Falcao/0000-0003-4718-0910; Freitas-da-Costa, Paulo/0000-0002-9567-4467;
   Falcao-Reis, Fernando/0000-0002-5995-9430; Carneiro,
   Angela/0000-0002-3370-7243; Rocha-Sousa, Amandio/0000-0001-8374-0298
FU FCT Portuguese grants from FCT, Lisbon, Portugal through Unidade I&D
   Cardiovascular, Porto, Portugal [PTDC/SAU-ORG/110683/2009, 51/94-FCT]
FX This paper received grants from: FCT Portuguese grants from FCT, Lisbon,
   Portugal (PTDC/SAU-ORG/110683/2009), through Unidade I&D Cardiovascular,
   Porto, Portugal (51/94-FCT).
CR Biro Z, 2008, EYE, V22, P8, DOI 10.1038/sj.eye.6702460
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Casparis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub2
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Falcao MS, 2014, CLIN OPHTHALMOL, V8, P55, DOI 10.2147/OPTH.S53989
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Henriques J, 2015, ACTA MEDICA PORT, V28, P107, DOI 10.20344/amp.5361
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Lobo CL, 2004, J CATARACT REFR SURG, V30, P752, DOI 10.1016/S0886-3350(03)00582-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mittra RA, 2000, ARCH OPHTHALMOL-CHIC, V118, P912
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Ohsugi H, 2014, J CATARACT REFR SURG, V40, P184, DOI 10.1016/j.jcrs.2013.07.036
   Patel JI, 2006, BRIT J OPHTHALMOL, V90, P697, DOI 10.1136/bjo.2005.087403
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   von Jagow B, 2007, GRAEF ARCH CLIN EXP, V245, P1765, DOI 10.1007/s00417-007-0605-6
NR 29
TC 5
Z9 5
U1 0
U2 7
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD FEB
PY 2017
VL 30
IS 2
BP 127
EP 133
DI 10.20344/amp.7850
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2FW
UT WOS:000397199600007
PM 28527480
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ammar, MJ
   Hsu, J
   Chiang, AL
   Ho, AC
   Regillo, CD
AF Ammar, Michael J.
   Hsu, Jason
   Chiang, Allen
   Ho, Allen C.
   Regillo, Carl D.
TI Age-related macular degeneration therapy: a review
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; clinical trials; exudative age-related
   macular degeneration; nonexudative age-related macular degeneration;
   review
ID PROTECTION
AB Purpose of review The purpose of this review is to describe the current clinical landscape of potential future therapies for both nonexudative (dry) and exudative (wet) age-related macular degeneration (AMD). We highlight some of the more promising treatments that are furthest along in development. Recent findings Patients with dry AMD have long been hoping for a highly efficacious treatment that may slow disease progression or even help regain vision. Patients with wet AMD have many effective treatment options but still there are those who have suboptimal responses or are burdened by the high frequency of treatment. We detail exciting new concepts and targets for novel medications. Specifically, for dry AMD we discuss research looking at complement inhibition, neuroprotection, visual cycle modulators, cell-based therapies, and anti-inflammatory agents. For wet AMD we summarize new, potentially more durable anti-vascular endothelial growth factor agents, extended release options, and gene therapy. There are promising new strategies for AMD. Many of the potential new treatments are in or have recently completed phase 2 or phase 3 clinical trials with promising results thus far, including some that have received US Food and Drug Administration approval. Additional therapeutic breakthroughs will likely continue to occur thanks to the number of clinical trials that are nearing the finish line.
C1 [Ammar, Michael J.; Hsu, Jason; Chiang, Allen; Ho, Allen C.; Regillo, Carl D.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina Serv, 800Walnut St, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Ammar, MJ (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina Serv, 800Walnut St, Philadelphia, PA 19107 USA.
EM ammar.mike@gmail.com
OI Ho, Allen/0000-0003-3921-608X
CR (ADVM), ADVM ADV BIOT SHAR M
   Alikhan A, 2010, AM J CLIN DERMATOL, V11, P79, DOI 10.2165/11530200-000000000-00000
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], STUD EFF SAF RAN POR
   [Anonymous], PHAS 3 STUD EV PORT
   [Anonymous], SAF EFF STUD OPREGEN
   [Anonymous], STUD SUBR IMPL HUM E
   [Anonymous], SAF EFF STUD AB PEG
   [Anonymous], STUD ENC CELL TECHN
   [Anonymous], ADVM 022 INTR GEN TH
   [Anonymous], STUD COMP EFF SAF IN
   [Anonymous], OP LAB PHAS 1 CLIN S
   [Anonymous], STUD EV EFF SAF KSI
   [Anonymous], STUD ASS SAF TOL EFF
   [Anonymous], RECLAIM 2 STUD EV SA
   [Anonymous], RET PIGM EP SAF STUD
   [Anonymous], CLIN STUD EV TREATM
   [Anonymous], ALL MOL PARTN PRES L
   [Anonymous], 2019, BEOVU BROL INJ
   [Anonymous], AAVCAGSCD59 TREATM W
   [Anonymous], RGX 314 GEN THER NEO
   [Anonymous], ZIM SUBJ GEOGR ATR S
   [Anonymous], SAF EFF AB PEG PAT N
   [Anonymous], SAF EFF STUD BRIM IN
   [Anonymous], STUD EV FAR RO686746
   [Anonymous], PHAS 3 STUD ALK 001
   Brown EE, 2018, RETINAL DEGENERATIVE, V1074
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   ClinicalTrials.gov, STUD EV EFF SAF FAR
   ClinicalTrials.gov, EFF SAF TRIAL CONB I
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Escher D, 2015, EURETINA C
   EYLEA (aflibercept), 2014, INJ PACK INS
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kashani AH, 2019, OPHTHALMOL RETINA
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Khanani AM, RET SUBSP DAY AM AC
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Mettu P, RETINAL PHYS
   National Institutes of Health (NIH), 2019, NIH RES RESC PHOT PR
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sena DF, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006539.pub4
   Singh RP, 2018, MAC SOC ANN M 21 24
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
NR 53
TC 48
Z9 52
U1 9
U2 39
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2020
VL 31
IS 3
BP 215
EP 221
DI 10.1097/ICU.0000000000000657
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB3SS
UT WOS:000524557700010
PM 32205470
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Maloberti, B
   Fajnkuchen, F
   Nghiem-Buffet, S
   Delahaye-Mazza, C
   Grenet, T
   Quentel, G
AF Cohen, Salomon Yves
   Maloberti, Bertrand
   Fajnkuchen, Franck
   Nghiem-Buffet, Sylvia
   Delahaye-Mazza, Corinne
   Grenet, Typhaine
   Quentel, Gabriel
TI Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Ranibizumab; Bimonthly
   fixed regimen
ID INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; BEVACIZUMAB; PREDICTORS;
   OUTCOMES; TREAT
AB Background/Purpose: Recently, aflibercept was proposed with a protocol of a bimonthly fixed regimen. Our purpose was to evaluate the results of this regimen in patients treated with ranibizumab. Method: We conducted a retrospective analysis of consecutive patients with naive neovascular age-related macular degeneration treated with a bimonthly fixed regimen of intravitreal injections of ranibizumab after 3 monthly injections. Examination was performed every 4 weeks for 52 weeks, with the possibility of unscheduled rescue injections of ranibizumab. Results: A total of 27 patients, 24 women and 3 men, aged from 68 to 90 years (mean: 81.2) were analyzed; 25 eyes (92.5%) lost <15 letters. Mean BCVA rose from 58.3 (range +/- 12.9) to 66.7 (range +/- 14.3) letters. The mean visual gain was 8.40 (range +/- 13.2) letters; 11 patients (40.7%) gained >= 15 letters. The mean number of injections of ranibizumab was 8.77. Conclusion: Bimonthly intravitreal ranibizumab achieved satisfactory visual results. However, patients who required additional injections did not experience significant visual gain. (C) 2013 S. Karger AG, Basel
C1 [Cohen, Salomon Yves; Maloberti, Bertrand; Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Delahaye-Mazza, Corinne; Grenet, Typhaine; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, FR-75015 Paris, France.
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, FR-75015 Paris, France.
EM sycsyc75@gmail.com
FU CIL-ASSOC, the Association for Education and Research, Centre
   Ophtalmologique d'Imagerie et de Laser, Paris, France
FX This study was supported by CIL-ASSOC, the Association for Education and
   Research, Centre Ophtalmologique d'Imagerie et de Laser, Paris, France.
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 25
TC 9
Z9 10
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 2
BP 80
EP 85
DI 10.1159/000356401
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296AE
UT WOS:000330156700003
PM 24356074
DA 2022-11-30
ER

PT J
AU Yang, JY
   Yuan, MZ
   Wang, EQ
   Xia, S
   Chen, YX
AF Yang, Jingyuan
   Yuan, Mingzhen
   Wang, Erqian
   Xia, Song
   Chen, Youxin
TI Noninvasive multimodal imaging in diagnosing polypoidal choroidal
   vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diagnosis; Imaging; Polypoidal
   choroidal vasculopathy
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; FUNDUS
   AUTOFLUORESCENCE; ADULT CHINESE; SPECIFICITY; FEATURES
AB Purpose To investigate the diagnostic accuracy of noninvasive multimodal imaging methods in diagnosing polypoidal choroidal vasculopathy (PCV) and distinguishing PCV from typical neovascular age-related macular degeneration (nvAMD). Methods Retrospective study. Imaging features of noninvasive multimodal imaging methods, including fundus photography (FP), B-scan optical coherence tomography (OCT), en face OCT, OCT angiography, and autofluorescence, of 103 eyes with PCV or typical nvAMD were reviewed. Diagnostic strategy was established based on imaging features and was validated in other 105 eyes with PCV or typical nvAMD. Results Features of subretinal orange nodule on FP, thumb-like PED on OCT, notched PED on OCT, bubble sign on OCT, and Bruch's membrane depression under serosanguinous PED on OCT were more common. When the diagnostic strategy of using at least 2 of 5 features was performed, there is 0.88 sensitivity and 0.92 specificity for diagnosing PCV. The results of the validation test further confirmed the diagnostic strategy with 0.94 sensitivity and 0.93 specificity. Conclusions Noninvasive multimodal imaging, especially FP and B-scan OCT, provide high sensitivity and specificity for diagnosing PCV and distinguishing PCV from typical nvAMD, when at least 2 of 5 suggestive imaging features are present.
C1 [Yang, Jingyuan; Yuan, Mingzhen; Wang, Erqian; Chen, Youxin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
   [Yang, Jingyuan; Yuan, Mingzhen; Wang, Erqian; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Xia, Song] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
EM chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
FU National Natural Science Foundation of China (NSFC) [81670879]
FX National Natural Science Foundation of China (NSFC) (81670879).
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Hajian-Tilaki K, 2014, J BIOMED INFORM, V48, P193, DOI 10.1016/j.jbi.2014.02.013
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Suzuki M, 2013, GRAEF ARCH CLIN EXP, V251, P2331, DOI 10.1007/s00417-013-2336-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   WOLF S, 1992, AM J OPHTHALMOL, V114, P638, DOI 10.1016/S0002-9394(14)74501-5
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 33
TC 4
Z9 6
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 16
PY 2019
VL 19
IS 1
AR 229
DI 10.1186/s12886-019-1244-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JO3MY
UT WOS:000497486200001
PM 31733642
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Fleckenstein, M
   Scholl, HPN
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Scholl, Hendrik P. N.
   Holz, Frank G.
TI Fundus Autofluorescence and Progression of Age-related Macular
   Degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; fundus autofluorescence; lipofuscin;
   retinal autofluorescence; retinal pigment epithelium; scanning laser
   ophthalmoscopy
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE; HUMAN RPE
   CELLS; GEOGRAPHIC ATROPHY; IN-VIVO; CHOROIDAL-NEOVASCULARIZATION;
   JUNCTIONAL ZONE; LIPOFUSCIN ACCUMULATION; BRUCHS MEMBRANE; AGING RETINA
AB Fundus autofluorescence imaging is air imaging method that provides additional information compared to conventional imaging techniques. It permits to topographically map lipofuscin distribution of tire retinal pigment epithelial cell monolayer. Excessive accumulation of lipofuscin granules in the lysosomal compartment of retinal pigment epithelium cells represents a common downstream pathogenetic pathway in various hereditary and complex retinal diseases including age-related macular degeneration (AMD). This comprehensive review contains air introduction in fundus autofluorescence imaging, including basic considerations, the origin of the signal, different imaging methods, and a brief overview of fundus autofluorescence findings in normal subjects. Furthermore, it summarizes cross-sectional and longitudinal fundus autofluorescence findings in patients with AMD, addresses the pathophysiological significance of increased fundus autofluorescence, and characterizes different fundus autofluorescence phenotypes as well as fundus autofluorescence alterations with disease progression. (Surv Ophthalmol 54:96-117, 2009. (C) 2009 Elsevier Inc. All rights reserved.)
C1 [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Scholl, Hendrik P. N.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Cerviño, Alejandro/L-5853-2014
OI Cerviño, Alejandro/0000-0001-8014-3279; Fleckenstein,
   Monika/0000-0001-8321-8037
FU German Research Council (DFG) [SPP 1088, Ho 1926/1-3]; Heisenberg
   fellowship [SCHO 734/2-1]; EU FP6; "EVI-GENORET" [LSHG-CT-2005-512036]
FX The authors reported no proprietary or commercial interest in any
   product mentioned or concept discussed in this article. The preparation
   of this review was supported by the German Research Council (DFG) SPP
   1088; Ho 1926/1-3; Heisenberg fellowship SCHO 734/2-1; and EU FP6,
   Integrated Project "EVI-GENORET" (LSHG-CT-2005-512036).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Bird A.C., 2004, AGE RELATED MACULAR
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DELORI FC, 1994, APPL OPTICS, V33, P7429
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1987, ADV BIOSCI, V64, P23
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Framme C, 2006, OPHTHAL SURG LAS IM, V37, P406, DOI 10.3928/15428877-20060901-08
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hammer M, 2006, MOL VIS, V12, P1348
   Hashimoto T, 1999, JPN J OPHTHALMOL, V43, P375, DOI 10.1016/S0021-5155(99)00094-5
   Hogan MJ, 1972, AM ACAD OPHTH OTOL, V76, P64
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hopkins J, 2006, INVEST OPHTH VIS SCI, V47, P2269, DOI 10.1167/iovs.05-1482
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   *I ANS, 2000, Z1361 ANSI
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 1999, BRIT J OPHTHALMOL, V83, P276, DOI 10.1136/bjo.83.3.276
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   MACHEMER R, 1970, AM J OPHTHALMOL, V70, P1
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Maguire MG, 1996, RETINA-J RET VIT DIS, V16, P167, DOI 10.1097/00006982-199616020-00019
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2007, ATLAS FUNDUS IMAGING, P331
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF., 2007, ATLAS FUNDUS AUTOFLU, P49
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spital G, 1998, KLIN MONATSBL AUGENH, V213, P23, DOI 10.1055/s-2008-1034939
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   von Ruckmann A, 1998, OPHTHALMOLOGE, V95, P699, DOI 10.1007/s003470050338
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P81, DOI 10.1055/s-2008-1034951
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wabbels B, 2006, GRAEF ARCH CLIN EXP, V244, P36, DOI 10.1007/s00417-005-0043-2
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 105
TC 130
Z9 138
U1 3
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2009
VL 54
IS 1
BP 96
EP 117
DI 10.1016/j.survophthal.2008.10.004
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 406HD
UT WOS:000263284700005
PM 19171212
DA 2022-11-30
ER

PT J
AU Coleman, DJ
   Silverman, RH
   Rondeau, MJ
   Lloyd, HO
   Khanifar, AA
   Chan, RVP
AF Coleman, D. Jackson
   Silverman, Ronald H.
   Rondeau, Mark J.
   Lloyd, Harriet O.
   Khanifar, Aziz A.
   Chan, R. V. Paul
TI Age-related macular degeneration: choroidal ischaemia?
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroid; Macula; Degeneration; Treatment Medical; Imaging
ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW; BRUCHS MEMBRANE;
   MORPHOMETRIC-ANALYSIS; SILDENAFIL CITRATE; ROC ANALYSIS; DRUSEN;
   NEOVASCULARIZATION; CHORIOCAPILLARIS; THICKNESS
AB Aim
   Our aim is to use ultrasound to non-invasively detect differences in choroidal microarchitecture possibly related to ischaemia among normal eyes and those with wet and dry age-related macular degeneration (AMD).
   Design
   Prospective case series of subjects with dry AMD, wet AMD and age-matched controls.
   Methods
   Digitised 20MHz B-scan radiofrequency ultrasound data of the region of the macula were segmented to extract the signal from the retina and choroid. This signal was processed by a wavelet transform, and statistical modelling was applied to the wavelet coefficients to examine differences among dry, wet and non-AMD eyes. Receiver operating characteristic (ROC) analysis was used to evaluate a multivariate classifier.
   Results
   In the 69 eyes of 52 patients, 18 did not have AMD, 23 had dry AMD and 28 had wet AMD. Multivariate models showed statistically significant differences between groups. Multiclass ROC analysis of the best model showed an excellent volume-under-curve of 0.892 +/- 0.17. The classifier is consistent with ischaemia in dry AMD.
   Conclusions
   Wavelet augmented ultrasound is sensitive to the organisational elements of choroidal microarchitecture relating to scatter and fluid tissue boundaries such as seen in ischaemia and inflammation, allowing statistically significant differentiation of dry, wet and non-AMD eyes. This study further supports the association of ischaemia with dry AMD and provides a rationale for treating dry AMD with pharmacological agents to increase choroidal perfusion.
   ClinicalTrials.gov registration
   NCT00277784.
C1 [Coleman, D. Jackson; Silverman, Ronald H.; Lloyd, Harriet O.] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
   [Silverman, Ronald H.] FL Lizzi Ctr Biomed Engn, New York, NY USA.
   [Rondeau, Mark J.] Self Similar Grp LLC, New York, NY USA.
   [Khanifar, Aziz A.] Retina Grp Washington, Silver Spring, MD USA.
   [Chan, R. V. Paul] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
C3 Columbia University; Cornell University
RP Coleman, DJ (通讯作者)，Columbia Univ, Med Ctr, Dept Ophthalmol, Edward S Harkness Eye Inst, 635 West 165th St, New York, NY 10032 USA.
EM djceye@gmail.com
RI Silverman, Ronald H/A-5155-2018
OI Silverman, Ronald H/0000-0003-1509-3011; Rondeau,
   Mark/0000-0002-1896-1200
FU NIH [1R01EB000238]; Dyson Foundation; St. Giles Foundation; Research to
   Prevent Blindness; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND
   BIOENGINEERING [R01EB000238] Funding Source: NIH RePORTER
FX This study was supported in part by NIH grant 1R01EB000238, the Dyson
   Foundation, the St. Giles Foundation and Research to Prevent Blindness.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bayram I, 2006, 2006 IEEE 12TH DIGITAL SIGNAL PROCESSING WORKSHOP & 4TH IEEE SIGNAL PROCESSING EDUCATION WORKSHOP, VOLS 1 AND 2, P596, DOI 10.1109/DSPWS.2006.265493
   Ben Salah M, 2010, IEEE T IMAGE PROCESS, V19, P220, DOI 10.1109/TIP.2009.2032940
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Chaux C, 2007, IEEE T INFORM THEORY, V53, P4680, DOI 10.1109/TIT.2007.909104
   Chaux C, 2006, IEEE T IMAGE PROCESS, V15, P2397, DOI 10.1109/TIP.2006.875178
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Coleman D. J., 2005, ULTRASONOGRAPHY EYE
   Coleman DJ, 2004, OPHTHALMOLOGY, V111, P1344, DOI 10.1016/j.ophtha.2003.10.029
   COLEMAN DJ, 1979, AM J OPHTHALMOL, V88, P369
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Everson RM, 2006, PATTERN RECOGN LETT, V27, P918, DOI 10.1016/j.patrec.2005.10.016
   Fitzgerald MEC, 2005, EXP EYE RES, V81, P478, DOI 10.1016/j.exer.2005.03.008
   Fitzgerald MEC, 2001, VISUAL NEUROSCI, V18, P299, DOI 10.1017/S0952523801182143
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   FRIEDMAN E., 1965, BIBLANAT, V7, P129
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hodos W, 1998, VISUAL NEUROSCI, V15, P273, DOI 10.1017/S0952523898152070
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kim DY, 2012, ACTA OPHTHALMOL, V10, P1111
   Kingsbury N, 2001, APPL COMPUT HARMON A, V10, P234, DOI 10.1006/acha.2000.0343
   Lai D, 2007, P ANN INT IEEE EMBS, P6524
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Nakas CT, 2004, STAT MED, V23, P3437, DOI 10.1002/sim.1917
   Pan JC, 2008, 2008 INTERNATIONAL CONFERENCE ON AUDIO, LANGUAGE AND IMAGE PROCESSING, VOLS 1 AND 2, PROCEEDINGS, P1121, DOI 10.1109/ICALIP.2008.4590017
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Povazay B, 2009, INVEST OPHTH VIS SCI, V50, P1856, DOI 10.1167/iovs.08-2869
   Rakvongthai Y, 2010, IEEE T SIGNAL PROCES, V58, P3545, DOI 10.1109/TSP.2010.2046698
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reiner A, 2010, EXP EYE RES, V90, P734, DOI 10.1016/j.exer.2010.03.006
   Rindskopf D., 2010, ADV SOCIAL SCI RES U, P167
   Selesnick IW, 2005, IEEE SIGNAL PROC MAG, V22, P123, DOI 10.1109/MSP.2005.1550194
   Serbes G, 2010, IEEE ENG MED BIO, P1840, DOI 10.1109/IEMBS.2010.5626445
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang GM, 2010, J ACOUST SOC AM, V128, pEL323, DOI 10.1121/1.3505760
NR 45
TC 55
Z9 57
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2013
VL 97
IS 8
BP 1020
EP 1023
DI 10.1136/bjophthalmol-2013-303143
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186JI
UT WOS:000322039400017
PM 23740965
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Keilhauer, CN
   Fritsche, LG
   Guthoff, R
   Haubitz, I
   Weber, BH
AF Keilhauer, Claudia N.
   Fritsche, Lars G.
   Guthoff, Rainer
   Haubitz, Imme
   Weber, Bernhard H.
TI Age-related macular degeneration and coronary heart disease: Evaluation
   of genetic and environmental associations
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE Age-related macular degeneration; Coronary heart disease; Genetic risk
   factors; Case-control study; CFH Y402H; CFH I62V; Delta CFHR3/CFHR1;
   ARMS2 A69S
ID COMPLEMENT FACTOR-H; INCIDENT MYOCARDIAL-INFARCTION; CARDIOVASCULAR
   RISK-FACTORS; FACTOR-B; POLYMORPHISM; MORTALITY; INFLAMMATION;
   POPULATION; VARIANT; C3
AB An association between coronary heart disease (CHD) and age-related macular degeneration (AMD) has long been postulated but results from epidemiological case-control studies, and genetic analyses have been ambiguous. In this study we illuminate the association between AMD and CHD with respect to genetic and environmental risk factors, age of disease onset and AMD subgroups. AMD patients (n = 1036) and age-matched control subjects (n = 412) between 68 and 95 years of age were included in the case-control study. A medical history of CHD, cerebral stroke and arterial hypertension was determined for each individual. The assessment of interacting factors included the current use of systemic medications and smoking habits. Analysis of AMD associated genetic variants included frequent polymorphisms at the complement factor H (CFH, MIM 134370) gene (rs1061170 [p. Y402H], rs800292 [p. I62V]), the complement factor H-related 3 (CFHR3, MIM 605336)/complement factor H-related 1 (CFHR1, MIM 134371) locus (rs6677604; proxy for Delta CFHR3/CFHR1; r(2) = 0.97) as well as the age-related maculopathy susceptibility 2 (ARMS2, MIM 611313) gene (rs10490924 [p. A69S]).
   Logistic regression identified a significant positive association of AMD with AMD-risk variants in CFH, ARMS2, and smoking >= 20 packs/year. A history of CHD and the current use of antihyperuricemic agents were inversely associated with the disease. Significantly fewer patients with rs6677604 nonrisk genotype A/A regularly used statins. ARMS2: p. A69S risk variant was significantly associated with exsudative AMD. AMD patients with risk variants at rs1061170 (CFH: p. Y402H) and ARMS2 and smokers (>= 20 packs/year) were significantly earlier affected by AMD than those carrying the non-risk variants at each locus.
   Our data support three major conclusions. First, the age of AMD onset is significantly influenced by genetic and environmental risk factors. Second, in support of previous reports we also show that the ARMS2 rs10490924: T allele is significantly linked to exsudative AMD. And finally, a self-reported history of CHD was inversely associated with AMD in this study. Novel therapeutic strategies aiming at preventing the development of AMD may considerably differ from those that have been developed to treat cardiovascular disorders as both common disorders likely underlie different pathomechanisms. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   [Fritsche, Lars G.; Weber, Bernhard H.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Guthoff, Rainer] Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany.
   [Haubitz, Imme] Univ Wurzburg, Inst Biometry & Stat, D-97080 Wurzburg, Germany.
C3 University of Wurzburg; University of Regensburg; Heinrich Heine
   University Dusseldorf; University of Wurzburg
RP Keilhauer, CN (通讯作者)，Univ Wurzburg, Dept Ophthalmol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
EM ckeilhauer@yahoo.com; bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Weber, Bernhard
   H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft [WE 1259/19-2]; Alcon Research
   Institute; Ruth and Milton Steinbach Foundation New York
FX This study was in part supported by a grant from the Deutsche
   Forschungsgemeinschaft (WE 1259/19-2), the Alcon Research Institute and
   the Ruth and Milton Steinbach Foundation New York (to BHFW).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   [Anonymous], 2008, OPHTHALMOLOGY, V115, P1474
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Grimes DA, 2005, LANCET, V365, P1429, DOI 10.1016/S0140-6736(05)66379-9
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haskard DO, 2008, CURR OPIN LIPIDOL, V19, P478, DOI 10.1097/MOL.0b013e32830f4a06
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hogg RE, 2012, RETINA-J RET VIT DIS, V32, P1950, DOI 10.1097/IAE.0b013e31824dadf1
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iltumur K, 2005, APMIS, V113, P167, DOI 10.1111/j.1600-0463.2005.apm1130303.x
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koeijvoets KCMC, 2009, EUR HEART J, V30, P618, DOI 10.1093/eurheartj/ehn568
   Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Muscari A, 1998, ACTA CARDIOL, V53, P345
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Pai JK, 2007, EUR HEART J, V28, P1297, DOI 10.1093/eurheartj/ehm090
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   SEIFERT PS, 1989, ARTERIOSCLEROSIS, V9, P802, DOI 10.1161/01.ATV.9.6.802
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Speidl WS, 2005, EUR HEART J, V26, P2294, DOI 10.1093/eurheartj/ehi339
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   YASUDA M, 1990, CIRCULATION, V81, P156, DOI 10.1161/01.CIR.81.1.156
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 63
TC 17
Z9 18
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 1878-0849
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD FEB
PY 2013
VL 56
IS 2
BP 72
EP 79
DI 10.1016/j.ejmg.2012.10.005
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 085PY
UT WOS:000314627900002
PM 23103884
DA 2022-11-30
ER

PT J
AU Weber, BHF
   Issa, PC
   Pauly, D
   Herrmann, P
   Grassmann, F
   Holz, FG
AF Weber, Bernhard H. F.
   Issa, Peter Charbel
   Pauly, Diana
   Herrmann, Philipp
   Grassmann, Felix
   Holz, Frank G.
TI The Role of the Complement System in Age-Related Macular Degeneration
SO DEUTSCHES ARZTEBLATT INTERNATIONAL
LA English
DT Article
ID FACTOR-H POLYMORPHISM; VISUAL IMPAIRMENT; RISK-FACTORS; PROGRESSION;
   CFH; SUSCEPTIBILITY; GENES; BLINDNESS; GERMANY; VITAMIN
AB Background: Age-related macular degeneration (AMD) is a common retinal disease in older people. In Europe, about 1.6% of persons over age 65 and more than 13% of persons over age 85 have late-stage AMD, which can severely impair vision. The development of AMD is influenced both by environmental factors and by a strong hereditary component.
   Methods: We selectively searched the PubMed database for articles published between April 2001 and November 2013 with the key words "age-related macular degeneration," "risk factor," "complement," and "therapy." The website www.clinicaltrials.gov was also used to search for relevant clinical trials.
   Results: Old age and smoking are confirmed risk factors for AMD. Moreover, genetic association studies have pointed to signaling pathways in which the complement system, a part of the individual's innate immune system, takes on a central role in the pathogenesis of the disease. Several clinical trials designed to interfere specifically with these pathomechanisms have yielded rather disappointing results, although a phase II study of the monoclonal antibody lampalizumab showed that blocking complement factor D lessened the progression of geographic atrophy. A risk model based on 13 genetic markers was found to have positive predictive values in predisposed individuals that ranged from 5.1% (in persons aged 65 to 69) to 91.7% (in persons aged 85 or older). It should be borne in mind that 50% of patients with AMD are not carriers of risk-associated markers.
   Conclusion: There is no rationale at present for genetic testing to estimate the individual risk of developing AMD. Several recent clinical trials have incorporated current pathophysiological knowledge, but nearly all of these trials have yielded negative findings, with only one exception.
C1 [Weber, Bernhard H. F.; Pauly, Diana; Grassmann, Felix] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Issa, Peter Charbel; Herrmann, Philipp; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Herrmann, Philipp] UCL Inst Ophthalmol, London, England.
C3 University of Regensburg; University of Bonn; University of London;
   University College London
RP Holz, FG (通讯作者)，Univ Eye Clin, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM bweb@klinik.uni-regensburg.de; Frank.Holz@ukb.uni-bonn.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/E-8935-2018
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Weber, Bernhard H.F./0000-0002-8808-7723;
   Grassmann, Felix/0000-0003-1390-7528
FU Heidelberg Engineering; Novartis; Bayer; ProRetina Deutschland; Acucela;
   Alcon; Allergan; Genentech; Roche; Merz; Pfizer
FX Prof. Charbel Issa has received trial funding from Heidelberg
   Engineering and Novartis. He has received lecture fees and reimbursement
   of travel expenses from Novartis and Bayer.; Dr. Pauly has received
   trial funding (third-party funds) from ProRetina Deutschland.; Prof.
   Holz has received consultancy and lecture fees from Acucela, Alcon,
   Allergan, Genentech, Novartis, Roche, Merz, Heidelberg Engineering, and
   Bayer. He has received reimbursement of travel expenses and conference
   fees from Roche, Novartis, Genentech, and Bayer. He has also received
   trial funding from Bayer, Novartis, Genentech, Acuela, and Pfizer.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Burton H, 2012, CLIN MED, V12, P416, DOI 10.7861/clinmedicine.12-5-416
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Finger RP, 2012, DTSCH ARZTEBL INT, V109, P484, DOI 10.3238/arztebl.2012.0484
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guttmacher AE, 2010, NAT REV GENET, V11, P161, DOI 10.1038/nrg2735
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   Ho L, 2011, EPIDEMIOLOGIE AMD AL, P3
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Holz FG, 2011, ALTERSABHANGIGE MAKU, P347
   Holz FG, 2014, OPHTHLAMOLOGY
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Offit K, 2011, HUM GENET, V130, P3, DOI 10.1007/s00439-011-1028-3
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGE, V107, P1016, DOI 10.1007/s00347-010-2160-5
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Yehoshua Z, 2013, OPHTHALMOLOGY
NR 42
TC 39
Z9 47
U1 0
U2 13
PU DEUTSCHER AERZTE-VERLAG GMBH
PI COLOGNE
PA DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY
SN 1866-0452
J9 DTSCH ARZTEBL INT
JI Dtsch. Arztebl. Int.
PD FEB 21
PY 2014
VL 111
IS 8
DI 10.3238/arztebl.2014.0133
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AD3YI
UT WOS:000333182000003
PM 24622760
OA Green Published
DA 2022-11-30
ER

PT J
AU Dhodapkar, RM
   Martell, D
   Hafler, BP
AF Dhodapkar, Rahul M.
   Martell, Diego
   Hafler, Brian P.
TI Glial-mediated neuroinflammatory mechanisms in age-related macular
   degeneration
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE Age-related macular degeneration; Neuroinflammation; Glia-glia
   interactions; Glia-neuron interactions; Neurodegeneration
ID OPTICAL COHERENCE TOMOGRAPHY; COMPLEMENT FACTOR-H; HYPERREFLECTIVE FOCI;
   RETINAL MICROGLIA; ANTI-VEGF; ACTIVATION; TSPO; THERAPY; CELLS; CD200
AB Age-related macular degeneration (AMD) is a neurodegenerative disorder characterized by photoreceptor and retinal pigment epithelium loss often complicated by neovascularization and is one of the leading causes of irreversible vision loss worldwide. However, the precise pathophysiology of AMD remains to date unclear, and there is a dearth of effective therapies for the early stages of the disease. A growing body of evidence has identified microglia-mediated neuroinflammation as a key driver of neuronal damage in AMD, presenting a novel avenue for the development of pharmacological agents targeting this cell population. The local microglial response interacts with other glia as well as engages in crosstalk with peripheral immunological niches. This article presents a review of the current evidence regarding the involvement of glia in the pathophysiology of AMD, an overview of the key immune circuits and effector mechanisms shown to be active in AMD, and potential therapeutic avenues targeting glial involvement.
C1 [Dhodapkar, Rahul M.] Yale Univ, Yale Sch Med, New Haven, CT USA.
   [Martell, Diego; Hafler, Brian P.] Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.
   [Hafler, Brian P.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA.
C3 Yale University; Yale University; Yale University
RP Hafler, BP (通讯作者)，Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.; Hafler, BP (通讯作者)，Yale Univ, Dept Pathol, New Haven, CT 06520 USA.
EM brian.hafler@yale.edu
OI Dhodapkar, Rahul/0000-0002-2014-7515; Martell, Diego/0000-0002-8839-1864
FU Doris Duke Clinical Scientist Development Award; Thome Memorial
   Foundation Award for Age-Related Macular Degeneration Research; Reynold
   and Michiko Spector Award in Neuroscience; Hoffmann-La Roche
   Pharmaceuticals; Nayan Therapeutics
FX B.P.H. receives research funding from the Doris Duke Clinical Scientist
   Development Award, the Thome Memorial Foundation Award for Age-Related
   Macular Degeneration Research, Nayan Therapeutics, the Reynold and
   Michiko Spector Award in Neuroscience, and Hoffmann-La Roche
   Pharmaceuticals.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Axtell RC, 2008, IMMUNITY, V28, P600, DOI 10.1016/j.immuni.2008.04.006
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Sauvage MAD, 2013, CELL DEATH DIFFER, V20, P1546, DOI 10.1038/cdd.2013.108
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Fernandez-Arjona MD, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00472
   Duan ST, 2020, ANNU REV IMMUNOL, V38, P365, DOI 10.1146/annurev-immunol-102419-035900
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Franco-Bocanegra DK, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060639
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Karlstetter M, 2017, EMBO MOL MED, V9, P154, DOI 10.15252/emmm.201606627
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent D, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110392
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Klee K, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107816
   Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54
   Koning N, 2009, J NEUROPATH EXP NEUR, V68, P159, DOI 10.1097/NEN.0b013e3181964113
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee CYD, 2010, J NEURAL TRANSM, V117, P949, DOI 10.1007/s00702-010-0433-4
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mages K, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1424-5
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Papadopoulos Z, 2019, EUR J OPHTHALMOL, V29, P368, DOI 10.1177/1120672119832432
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pilotto E, 2020, OPHTHALMOLOGY, V127, P1774, DOI 10.1016/j.ophtha.2020.03.024
   Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Selvaraj V, 2015, TRENDS ENDOCRIN MET, V26, P341, DOI 10.1016/j.tem.2015.02.007
   Sharma A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay8514
   Sheridan GK, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130181
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   van Olst L, 2018, AGING CELL, V17, DOI 10.1111/acel.12790
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang SK, 2019, P NATL ACAD SCI USA, V116, P10140, DOI 10.1073/pnas.1901787116
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   WEBB M, 1984, J NEUROCHEM, V43, P1061, DOI 10.1111/j.1471-4159.1984.tb12844.x
   Werry EL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133161
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034
   Wu J, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6648191
   Yao HL, 2014, NEURAL REGEN RES, V9, P1047, DOI 10.4103/1673-5374.133169
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
NR 94
TC 2
Z9 2
U1 2
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2297
EI 1863-2300
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD SEP
PY 2022
VL 44
IS 5
SI SI
BP 673
EP 683
DI 10.1007/s00281-022-00939-3
EA MAY 2022
PG 11
WC Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology
GA 4Y4CP
UT WOS:000791058600002
PM 35513496
DA 2022-11-30
ER

PT J
AU Olivier, S
   Chow, DR
   Packo, KH
   MacCumber, MW
   Awh, CC
AF Olivier, S
   Chow, DR
   Packo, KH
   MacCumber, MW
   Awh, CC
TI Subretinal recombinant tissue plasminogen activator injection and
   pneumatic displacement of thick submacular hemorrhage in age-related
   macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; NATURAL-HISTORY; GAS; MANAGEMENT; REMOVAL;
   RABBITS; SPACE
AB Objective: To evaluate the anatomic and visual outcomes after a surgical procedure for displacement of thick submacular hemorrhage in patients with age-related macular degeneration.
   Design: Retrospective, noncomparative, interventional case series.
   Participants: Twenty-nine consecutive eyes of 28 patients with thick submacular hemorrhage secondary to age-related macular degeneration.
   Intervention: The procedure consisted of a pars plana vitrectomy with subretinal recombinant tissue plasminogen activator injection (125 mg/ml) through a translocation microcannula, followed by fluid-air exchange and postoperative prone positioning.
   Main Outcome Measures: Intraoperative and postoperative surgical complications, preoperative and postoperative best-corrected visual acuities, postoperative fluorescein angiography results, and additional postoperative treatments.
   Results: Total subfoveal blood displacement was achieved in 25 eyes, with subtotal displacement in the others. Based on fluorescein angiography results, 8 eyes were eligible for additional postoperative treatments. At 3 months, 17 eyes had gained more than 2 lines of visual acuity, whereas 3 had lost more than 2 lines. The difference between preoperative and 3-month postoperative visual acuity was statistically significant (P = 0.0167). Complications consisted of 2 cases of vitreous hemorrhage that cleared within 4 weeks.
   Conclusions: This surgical technique seems useful in displacing thick submacular hemorrhage secondary to age-related macular degeneration, allowing postoperative fluorescein angiography testing and, potentially, subsequent treatments. No significant complication from the procedure was identified. However, further controlled studies will be required to assess its efficacy in the management of this difficult clinical problem. (C) 2004 by the American Academy of Ophthalmology.
C1 Rush Univ, Rush Med Coll, Dept Ophthalmol, Chicago, IL 60612 USA.
   Illinois Retina Associates, Chicago, IL USA.
   Retina Vitreous Associates, Nashville, TN USA.
C3 Rush University
RP Olivier, S (通讯作者)，71 W 156th,Suite 400, Harvey, IL 60426 USA.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNER JD, 1991, ARCH OPHTHALMOL-CHIC, V109, P1731, DOI 10.1001/archopht.1991.01080120115039
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Boone DE, 1996, RETINA-J RET VIT DIS, V16, P518, DOI 10.1097/00006982-199616060-00009
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 2002, ARCH OPHTHALMOL-CHIC, V120, P102
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   *SUBM SURG TRIALS, 2000, AM J OPHTHALMOL, V130, pP387
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 26
TC 107
Z9 117
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2004
VL 111
IS 6
BP 1201
EP 1208
DI 10.1016/j.ophtha.2003.10.020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824SY
UT WOS:000221708100019
PM 15177972
OA Bronze
DA 2022-11-30
ER

PT J
AU Moore, NA
   Bracha, P
   Hussain, RM
   Morral, N
   Ciulla, TA
AF Moore, Nicholas A.
   Bracha, Peter
   Hussain, Rehan M.
   Morral, Nuria
   Ciulla, Thomas A.
TI Gene therapy for age-related macular degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Adeno-associated virus; age-related macular degeneration; gene therapy;
   retina; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; DEPENDENT
   ADENOVIRAL VECTORS; RETINAL-PIGMENT EPITHELIUM; RANDOMIZED
   CLINICAL-TRIAL; AAV VECTORS; CHOROIDAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; OPEN-LABEL; CORNEAL NEOVASCULARIZATION
AB Introduction: In neovascular age related macular degeneration (nAMD), gene therapy to chronically express anti-vascular endothelial growth factor (VEGF) proteins could ameliorate the treatment burden of chronic intravitreal therapy and improve limited visual outcomes associated with real world' undertreatment.Areas covered: In this review, the authors assess the evolution of gene therapy for AMD. Adeno-associated virus (AAV) vectors can transduce retinal pigment epithelium; one such early application was a phase I trial of AAV2-delivered pigment epithelium derived factor gene in advanced nAMD. Subsequently, gene therapy for AMD shifted to the investigation of soluble fms-like tyrosine kinase-1 (sFLT-1), an endogenously expressed VEGF inhibitor, binding and neutralizing VEGF-A. After some disappointing results, research has centered on novel vectors, including optimized AAV2, AAV8 and lentivirus, as well as genes encoding other anti-angiogenic proteins, including ranibizumab, aflibercept, angiostatin and endostatin. Also, gene therapy targeting the complement system is being investigated for geographic atrophy due to non-neovascular AMD.Expert opinion: The success of gene therapy for AMD will depend on the selection of the most appropriate therapeutic protein and its level of chronic expression. Future investigations will center on optimizing vector, promoter and delivery methods, and evaluating the risks of the chronic expression of anti-angiogenic or anti-complement proteins.
C1 [Moore, Nicholas A.; Bracha, Peter; Hussain, Rehan M.; Ciulla, Thomas A.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46290 USA.
   [Ciulla, Thomas A.] Midwest Eye Inst, Retina Serv, Indianapolis, IN USA.
   [Morral, Nuria] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46290 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington
RP Ciulla, TA (通讯作者)，Indiana Univ Sch Med, Retina Serv, Midwest Eye Inst, 10300 North Illinois St, Indianapolis, IN 46290 USA.
EM thomasciulla@gmail.com
RI Morral, Nuria/AAC-7149-2020; Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   [Anonymous], 2017, RST001
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Avalanche biotechnologies inc., ANN POS TOP LIN PHAS
   Avalanche biotechnologies inc, 2017, CORP PRES
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Booth C, 2016, TRENDS MOL MED, V22, P317, DOI 10.1016/j.molmed.2016.02.002
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheng LY, 2005, RETINA-J RET VIT DIS, V25, P193, DOI 10.1097/00006982-200502000-00013
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   Everson EM, 2016, CURR OPIN VIROL, V21, P41, DOI 10.1016/j.coviro.2016.07.010
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996
   Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hareendran S, 2013, REV MED VIROL, V23, P399, DOI 10.1002/rmv.1762
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Kay MA, 2003, NATURE, V424, P251, DOI 10.1038/424251b
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar M, 2001, HUM GENE THER, V12, P1893, DOI 10.1089/104303401753153947
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai LJ, 2007, J BIOMED SCI, V14, P313, DOI 10.1007/s11373-007-9153-7
   Lai YKY, 2003, ADV EXP MED BIOL, V533, P447
   Le Guiner C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102538
   Lisowski L, 2015, CURR OPIN PHARMACOL, V24, P59, DOI 10.1016/j.coph.2015.07.006
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitchell AM, 2010, CURR GENE THER, V10, P319
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Morral N, 1997, HUM GENE THER, V8, P1275, DOI 10.1089/hum.1997.8.10-1275
   Morral N, 1998, HUM GENE THER, V9, P2709, DOI 10.1089/hum.1998.9.18-2709
   Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   O'Callaghan J, 2017, HUM MOL GENET, V26, P1230, DOI 10.1093/hmg/ddx028
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Regenxbio, 2017, CORP PRES
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz R, 2009, HUM GENE THER, V20, P87, DOI 10.1089/hum.2008.081
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Scaria A, 2016, MOL THER, V24, pS98, DOI 10.1016/S1525-0016(16)33058-1
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Shaw A, 2014, BIOMEDICINES, V2, P14, DOI 10.3390/biomedicines2010014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sochor MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep17105
   Stieger K, 2006, MOL THER, V13, P967, DOI 10.1016/j.ymthe.2005.12.001
   Stieger K, 2011, METHODS MOL BIOL, V807, P179, DOI 10.1007/978-1-61779-370-7_8
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yu-Wai-Man P, 2016, BRIT J OPHTHALMOL, V100, P1322, DOI 10.1136/bjophthalmol-2015-308329
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998
NR 84
TC 40
Z9 43
U1 0
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2017
VL 17
IS 10
BP 1235
EP 1244
DI 10.1080/14712598.2017.1356817
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FF7OM
UT WOS:000409205800005
PM 28726562
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lin, JM
   Wan, L
   Tsai, YY
   Lin, HJ
   Tsai, Y
   Lee, CC
   Tsai, CH
   Tseng, SH
   Tsai, FJ
AF Lin, Jane-Ming
   Wan, Lei
   Tsai, Yi-Yu
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tseng, Sung-Huei
   Tsai, Fuu-Jen
TI Pigment epithelium-derived factor gene Met72Thr polymorphism is
   associated with increased risk of wet age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITS CHOROIDAL NEOVASCULARIZATION; HTRA1
   PROMOTER POLYMORPHISM; FACTOR-H POLYMORPHISM; NEUROTROPHIC ACTIVITY;
   OCULAR NEOVASCULARIZATION; NONINHIBITORY SERPIN; INCREASED EXPRESSION;
   GEOGRAPHIC ATROPHY; UNITED-STATES
AB PURPOSE: To investigate the Met72Thr (T/C) polymorphism (rs1136287) of pigment epithelium,derived factor (PEDF) gene exon 3 in unrelated Taiwan Chinese patients with late age related macular degeneration (AMD) and control subjects without AMD.
   DESIGN: Retrospective case-control study.
   METHODS: We enrolled 190 unrelated Taiwan Chinese patients with late AMD and 90 age, and gender-matched control subjects. Grading of late AMD was classified based on a standardized set of diagnostic criteria established by the International Age-Related Maculopathy Epidemiologic Study. Late AMD was classified as either atrophic (dry, grade 4) or neovascular (wet, grade 5). Atrophic AMD refers to dry late-stage AMD without neovascularization, and wet AMD refers to neovascular AMD. Genomic deoxyribonucleic acid was prepared from peripheral blood obtained from all AMD patients and control subjects. Polymerase chain reaction analysis was used to analyze this polymorphism.
   RESULTS: Of the 190 participants with late AMD, atrophic AMD was diagnosed in 104 patients and wet AMD was diagnosed in 86 patients. The genotype distribution of the Met72Thr (T/C) variant of PEDF was TT (homozygous T), TC (heterozygous), and CC (homozygous C). The T allele was found significantly more frequently in wet AMD patients than in controls (50% vs 31%; P = .0005). The allele frequencies in atrophic AMD (30%) and controls (31%) did not differ significantly (all P = .87). The homozygous T genotype was more prevalent in wet AMD than in controls (26/86 [30%] vs nine/90 [10%]; odds ratio, 3.9; all P = .0015). The homozygous T genotype in atrophic AMD patients (8%) and controls (10%) did not differ significantly (all P = .75).
   CONCLUSIONS: Our data suggest that the PEDF Met72Thr T allele may be a risk factor for wet AMD in the Taiwan Chinese population. PEDF may play a role in the pathogenesis of wet AMD.
C1 [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan.
   [Lin, Jane-Ming; Tsai, Yi-Yu; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan.
   [Wan, Lei; Lee, Cheng-Chun; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.
   [Tsai, Yushin; Tsai, Fuu-Jen] Grad Inst Chinese Med Sci, Beijing, Peoples R China.
   [Tsai, Yushin; Tsai, Fuu-Jen] Med Univ, Taichung, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
   [Tseng, Sung-Huei] Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 70428, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; Asia University Taiwan; National Cheng
   Kung University; National Cheng Kung University Hospital
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Rd, Taichung 404, Taiwan.
EM d0704@mail.cmuh.org.tw
RI Tsai, Fuu-Jen/J-4140-2015; Wan, Lei/F-4719-2010
OI Wan, Lei/0000-0002-9525-3232
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.0.CO;2-F
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koenekoop R, 1999, MOL VIS, V5
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   TATAR O, 1962, ARCH OPHTHALMOL-CHIC, V124, P815
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
NR 51
TC 28
Z9 31
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2008
VL 145
IS 4
BP 716
EP 721
DI 10.1016/j.ajo.2007.11.006
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282EN
UT WOS:000254550500021
PM 18226801
DA 2022-11-30
ER

PT J
AU Mogk, M
AF Mogk, Marja
TI The Difference That Age Makes: Cultural Factors That Shape Older Adults'
   Responses to Age-Related Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID VISUAL IMPAIRMENT; ADAPTATION
AB This article suggests that approaching vision loss from age-related macular degeneration from a sociocultural perspective, specifically considering perceptions of aging, blindness, disability, and generational viewpoints and norms, may be critical to understanding older adults' responses to vision loss and visual rehabilitation.
C1 Calif Lutheran Univ, Dept English, Thousand Oaks, CA 91360 USA.
C3 California Lutheran University
RP Mogk, M (通讯作者)，Calif Lutheran Univ, Dept English, 60 W Olsen Rd,3900M, Thousand Oaks, CA 91360 USA.
EM mmogk@callutheran.edu
CR Blauner B., 1987, QUAL SOCIOL, V10, P46, DOI [10.1007/BF00988268, DOI 10.1007/BF00988268]
   Bolt D, 2005, J VISUAL IMPAIR BLIN, V99, P141, DOI 10.1177/0145482X0509900303
   Booth W., 1992, ART GROWING OLDER
   Brennan M., 2004, INT J PSYCHOL RELIG, V14, P193, DOI [DOI 10.1207/S15327582IJPR1403_4, 10.1207/s15327582ijpr1403_4]
   CHARLTON JI, 2000, NOTHING US OUT US DI
   Cholden L, 1954, B MENNINGER CLIN, V18, P107
   DAHLBERG A, 2004, BEING YOUNG VISUALLY
   Davis L., 1995, ENFORCING NORMALCY D
   Goffman Erving., 1963, BEHAV PUBLIC PLACES
   Horowitz A, 1997, GERONTOLOGIST, V37, P620, DOI 10.1093/geront/37.5.620
   Kleege Georgina, 1999, SIGHT UNSEEN
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Linton S., 1998, CLAIMING DISABILITY
   Longmore Paul K., 2001, NEW DISABILITY HIST
   MANNHEIM K, 1952, ESSAYS SOCIOLOGY KNO, P98
   Mattingly C., 1998, HEALING DRAMAS CLIN, V7
   Michalko Rod., 1998, MYSTERY EYE SHADOW B
   Milian M., 2001, DIVERSITY VISUAL IMP
   Mitchell D., 1997, BODY PHYS DIFFERENCE
   Neugarten B. L., 1996, MEANINGS AGE
   Priestly M., 2003, DISABILITY LIFE COUR
   Scott J, 2000, BRIT J SOCIOL, V51, P355, DOI 10.1111/j.1468-4446.2000.00355.x
   Shapiro J., 1994, NO PITY PEOPLE DISAB
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
NR 25
TC 7
Z9 7
U1 0
U2 2
PU AMER FOUNDATION BLIND
PI NEW YORK
PA J VISUAL IMPAIRMENT BLINDNESS 11 PENN PLAZA SUITE 300, NEW YORK, NY
   10001 USA
SN 0145-482X
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2008
VL 102
IS 10
SI SI
BP 581
EP 590
DI 10.1177/0145482X0810201002
PG 10
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 365YI
UT WOS:000260445400002
DA 2022-11-30
ER

PT J
AU Ozkiris, A
AF Ozkiris, Abdullah
TI Anti-VEGF agents for age-related macular degeneration
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE age-related macular degeneration; anti-VEGF agents
ID INTRAVITREAL BEVACIZUMAB AVASTIN; TISSUE-PLASMINOGEN ACTIVATOR;
   PHOTODYNAMIC THERAPY; TRIAMCINOLONE ACETONIDE; RANIBIZUMAB; VERTEPORFIN;
   SMOKING; NEOVASCULARIZATION; EPIDEMIOLOGY; MACULOPATHY
AB Age-related macular degeneration (AMD) is a leading cause of legal blindness in the elderly in the industrialized world and the third major cause of blindness around the globe. Although neovascular AMD is less prevalent than atrophic AMD, it accounts for most cases with severe visual loss from AMD. VEGF seems to be a key contributary factor in the pathophysiology underlying neovascular AMD. Until recently, treatment options for neovascular AMD were limited. With the recent development of anti-VEGF therapies that have demonstrated efficacy in studies with broad eligibility criteria, the repertoire of treatments for neovascular AMD has been significantly expanded to now include the various recognized angiographic lesion subtypes. To discuss recent anti-VEGF agents in the management of AMD. Although therapy with anti-VEGF agents is the gold standard with promising results, many intravitreal injections are often required, and they do not cure all cases of wet AMD. With the recent advances in the medical therapy of exudative AMD, there is reason to be optimistic about future management of AMD as well.
C1 [Ozkiris, Abdullah] Acibadem Univ, Fac Med, Istanbul, Turkey.
C3 Acibadem University
RP Ozkiris, A (通讯作者)，Acibadem Univ, Fac Med, Cad Ariburnu Apt 132-8, TR-38030 Kayseri, Turkey.
EM aozkiris@erciyes.edu.tr
CR Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   ASTRAZENECA AB, 2007, Patent No. 20040566841
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BAYER SCHERING PHARM, 2007, Patent No. 20058038187
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown MM, 2007, CURR OPIN OPHTHALMOL, V18, P194, DOI 10.1097/ICU.0b013e3281377209
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHILDRENS MED CTR, 2006, Patent No. 535670
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Ciulla TA, 2001, BRIT J OPHTHALMOL, V85, P510, DOI 10.1136/bjo.85.5.510
   CLEMONS TE, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417
   COLL GE, 1995, RETINA-J RET VIT DIS, V15, P319, DOI 10.1097/00006982-199515040-00009
   CSL LTD, 2007, Patent No. 200700799
   CTI EUROP SRL, 2006, Patent No. 20050517805
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Eter N, 2003, OPHTHALMOLOGE, V100, P314, DOI 10.1007/s00347-002-0693-y
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN INC, 2006, LUCENTIS
   GENENTECH INC, 2008, Patent No. 2008226629
   Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   KYOWA HAKKO KOGYO KK, 2008, Patent No. 20060277121
   LILLY CO, 2008, Patent No. 20060735794
   METHYLGENE INC, 2008, Patent No. 20060851548
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2001, Semin Ophthalmol, V16, P201, DOI 10.1076/soph.16.4.201.10298
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   NOVARTIS AG, 2007, Patent No. 20020351909
   NOVARTIS AG, 2007, Patent No. 20020121645
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Radimer KL, 2000, J AM DIET ASSOC, V100, P447, DOI 10.1016/S0002-8223(00)00137-1
   Raju TNK, 1999, LANCET, V354, P1567, DOI 10.1016/S0140-6736(05)76606-X
   REGENERON PHARM, 2006, Patent No. 20067000521
   REGENERON PHARM, 2007, Patent No. 2006086544
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHERING AG, 2006, Patent No. 200602342
   Schmidt-Erfurth U, 2006, ARCH OPHTHALMOL-CHIC, V124, P561, DOI 10.1001/archopht.124.4.561
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 70
TC 24
Z9 26
U1 2
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD JAN
PY 2010
VL 20
IS 1
BP 103
EP 118
DI 10.1517/13543770902762885
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 548EO
UT WOS:000273942600006
PM 20021287
DA 2022-11-30
ER

PT J
AU Miyake, M
   Ooto, S
   Yamashiro, K
   Takahashi, A
   Yoshikawa, M
   Akagi-Kurashige, Y
   Ueda-Arakawa, N
   Oishi, A
   Nakanishi, H
   Tamura, H
   Tsujikawa, A
   Yoshimura, N
AF Miyake, Masahiro
   Ooto, Sotaro
   Yamashiro, Kenji
   Takahashi, Ayako
   Yoshikawa, Munemitsu
   Akagi-Kurashige, Yumiko
   Ueda-Arakawa, Naoko
   Oishi, Akio
   Nakanishi, Hideo
   Tamura, Hiroshi
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Pachychoroid neovasculopathy and age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COMPLEMENT FACTOR-H; CENTRAL SEROUS
   CHORIORETINOPATHY; GENOME-WIDE ASSOCIATION; RETICULAR PSEUDODRUSEN;
   JAPANESE; THICKNESS; RISK; NEOVASCULARIZATION; POLYMORPHISM
AB Pachychoroid neovasculopathy is a recently proposed clinical entity of choroidal neovascularization (CNV). As it often masquerades as neovascular age-related macular degeneration (AMD), it is currently controversial whether pachychoroid neovasculopathy should be distinguished from neovascular AMD. This is because its characteristics have yet to be well described. To estimate the relative prevalence of pachychoroid neovasculopathy in comparison with neovascular AMD and to investigate the phenotypic/genetic differences of the two diseases, we evaluated 200 consecutive Japanese patients who agreed to participate in the genetic study and diagnosed with pachychoroid neovasculopathy or neovascular AMD. Pachychoroid neovasculopathy was observed in 39 individuals (19.5%), which corresponds to one fourth of neovascular AMD. Patients with pachychoroid neovasculopathy were significantly younger (p = 5.1 x 10(-5)) and showed a greater subfoveal choroidal thickness (p = 3.4 x 10(-14)). Their genetic susceptibility to AMD was significantly lower than that of neovascular AMD; ARMS2 rs10490924 (p = 0.029), CFH rs800292 (p = 0.013) and genetic risk score calculated from 11 AMD susceptibility genes (p = 3.8 x 10(-3)). Current results implicate that the etiologies of the two conditions must be different. Thus, it will be necessary to distinguish these two conditions in future studies.
C1 [Miyake, Masahiro; Ooto, Sotaro; Yamashiro, Kenji; Takahashi, Ayako; Yoshikawa, Munemitsu; Akagi-Kurashige, Yumiko; Ueda-Arakawa, Naoko; Oishi, Akio; Nakanishi, Hideo; Tamura, Hiroshi; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Miyake, Masahiro] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Inserm U852, Kyoto, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Dept Ophthalmol, Takamatsu, Kagawa 760, Japan.
C3 Kyoto University; Kyoto University; Kagawa University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; TAMURA, Hiroshi/H-1855-2011; Oishi,
   Akio/AAE-9996-2020
OI Miyake, Masahiro/0000-0001-7410-3764; TAMURA,
   Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan
FX This work is partly supported by the Innovative Tchno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems,
   from the Ministry of Education, Culture, Sports, Science and Technology
   (MEXT), Japan.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yoshimura K, 2012, NEUROUROL URODYNAM, V31, P1266, DOI 10.1002/nau.22250
   Yuan DQ, 2013, MOL VIS, V19, P374
NR 45
TC 106
Z9 112
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 6
PY 2015
VL 5
AR 16204
DI 10.1038/srep16204
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV4KQ
UT WOS:000364236100001
PM 26542071
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Siddiqui, MAA
   Keating, GM
AF Siddiqui, MAA
   Keating, GM
TI Pegaptanib - In exudative age-related macular degeneration
SO DRUGS
LA English
DT Article
ID GROWTH-FACTOR VEGF
AB Pegaptanib, an aptamer, is an antagonist of vascular endothelial growth factor that has shown efficacy in the treatment of patients with exudative age-related macular degeneration (AMD).
   In two randomised, double-masked trials in patients with exudative AMD (n = 1208), the proportion of responders (those losing < 15 letters of visual acuity) at 54 weeks was significantly higher in intravitreous pegaptanib 0.3mg recipients than in those receiving sham injections (70% vs 55%; p < 0.001). These trials were conducted concurrently and analysed as a single study; the treatments were given every 6 weeks for 48 weeks. The improvement in visual acuity with pegaptanib was maintained in a I-year extension of these trials.
   Similar favourable results with pegaptanib 0.3mg were seen in terms of the secondary efficacy endpoints (e.g. proportion of patients experiencing severe loss of visual acuity or legal blindness in the study eye). These vision-improving effects of pegaptanib were associated with beneficial angiographic effects.
   Intravitreous pegaptanib 0.3-3mg was well tolerated with most ocular adverse events being mild-to-moderate and transient. Serious injection-related adverse events occurred in <= 1.3% of patients treated with pegaptanib. There were no systemic adverse events that could be definitely attributed to pegaptanib.
C1 Adis Int Ltd, Auckland 1311, New Zealand.
C3 Adis International
RP Siddiqui, MAA (通讯作者)，Adis Int Ltd, 41 Centorian Dr,Mairangi Bay,Private Bag 65901, Auckland 1311, New Zealand.
EM demail@adis.co.nz
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CAPONE A, 2005, 28 ANN MAC SOC M 200
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   DAMICO DJ, 28 ANN MAC SOC M 200
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   *EY PHARM INC PFIZ, PROD INF MAC PEG SOD
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Kim Rubin W., 2004, International Ophthalmology Clinics, V44, P41, DOI 10.1097/00004397-200404440-00005
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   MIELER WF, 28 ANN MAC SOC M 200
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SINGERMAN LJ, 28 ANN MAC SOC M 200
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
NR 21
TC 58
Z9 69
U1 1
U2 10
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PY 2005
VL 65
IS 11
BP 1571
EP 1577
DI 10.2165/00003495-200565110-00010
PG 7
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 951ND
UT WOS:000230936500010
PM 16033295
DA 2022-11-30
ER

PT J
AU Beatty, S
   Chakravarthy, U
   Nolan, JM
   Muldrew, KA
   Woodside, JV
   Denny, F
   Stevenson, MR
AF Beatty, Stephen
   Chakravarthy, Usha
   Nolan, John M.
   Muldrew, Katherine A.
   Woodside, Jayne V.
   Denny, Frances
   Stevenson, Michael R.
TI Secondary Outcomes in a Clinical Trial of Carotenoids with
   Coantioxidants versus Placebo in Early Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL PERFORMANCE; HUMAN RETINA; VITAMIN-C; LUTEIN; PIGMENT;
   MACULOPATHY; ZEAXANTHIN; SUPPLEMENTATION; ANTIOXIDANTS; PROGRESSION
AB Purpose: To report the secondary outcomes in the Carotenoids with Coantioxidants in Age-Related Maculopathy trial.
   Design: Randomized double-masked placebo-controlled clinical trial (registered as ISRCTN 94557601).
   Participants: Participants included 433 adults 55 years of age or older with early age-related macular degeneration (AMD) in 1 eye and late-stage disease in the fellow eye (group 1) or early AMD in both eyes (group 2).
   Intervention: An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc or placebo. Best-corrected visual acuity (BCVA), contrast sensitivity (CS), Raman spectroscopy, stereoscopic colour fundus photography, and serum sampling were performed every 6 months with a minimum follow-up time of 12 months.
   Main Outcome Measures: Secondary outcomes included differences in BCVA (at 24 and 36 months), CS, Raman counts, serum antioxidant levels, and progression along the AMD severity scale (at 12, 24, and 36 months).
   Results: The differential between active and placebo groups increased steadily, with average BCVA in the former being approximately 4.8 letters better than the latter for those who had 36 months of follow-up, and this difference was statistically significant (P = 0.04). In the longitudinal analysis, for a 1-log-unit increase in serum L, visual acuity was better by 1.4 letters (95% confidence interval, 0.3-2.5; P = 0.01), and a slower progression along a morphologic severity scale (P = 0.014) was observed.
   Conclusions: Functional and morphologic benefits were observed in key secondary outcomes after supplementation with L, Z, and coantioxidants in persons with early AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:600-606 (C) 2013 by the American Academy of Ophthalmology.
C1 [Beatty, Stephen; Nolan, John M.] Waterford Inst Technol, Macular Pigment Res Grp, Waterford City, Waterford, Ireland.
   [Chakravarthy, Usha] Royal Victoria Hosp, Inst Clin Sci, Ctr Vasc & Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Muldrew, Katherine A.; Woodside, Jayne V.; Stevenson, Michael R.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT7 1NN, Antrim, North Ireland.
   [Denny, Frances] Exploristics, Belfast, Antrim, North Ireland.
C3 South East Technological University (SETU); Queens University Belfast
RP Chakravarthy, U (通讯作者)，Royal Victoria Hosp, Inst Clin Sci, Ctr Vasc & Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Woodside, Jayne/0000-0002-5691-4659;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Bausch and Lomb, Dr. Mann Pharma, Berlin, Germany; Economic and Social
   Research Council [ES/G007438/1] Funding Source: researchfish; ESRC
   [ES/G007438/1] Funding Source: UKRI
FX Supported by a grant from Bausch and Lomb, Dr. Mann Pharma, Berlin,
   Germany. The data set was managed and analyzed by the independent
   statistician (MRS) and his team. The senior corresponding author (UC)
   had full access to the data outputs. The funders had no access to the
   data, were not involved in the data analysis, and had no role in the
   construction of the manuscript, except in the approval of the final
   draft.
CR Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   CRAFT NE, 1992, METHOD ENZYMOL, V213, P185
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gibson RS, 2008, BRIT J NUTR, V99, pS14, DOI 10.1017/S0007114508006818
   Glynn RJ, 2000, AM J EPIDEMIOL, V151, P965, DOI 10.1093/oxfordjournals.aje.a010140
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stringham JM, 2004, INVEST OPHTH VIS SCI, V45, P3838, DOI 10.1167/iovs.04-0038
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   VandenBosch ME, 1997, EYE, V11, P411, DOI 10.1038/eye.1997.87
   Walls G L, 1933, Br J Ophthalmol, V17, P705, DOI 10.1136/bjo.17.12.705
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
NR 28
TC 55
Z9 59
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2013
VL 120
IS 3
BP 600
EP 606
DI 10.1016/j.ophtha.2012.08.040
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100XJ
UT WOS:000315738200026
PM 23218821
DA 2022-11-30
ER

PT J
AU Polley, S
   Cipriani, V
   Khan, JC
   Shahid, H
   Moore, AT
   Yates, JRW
   Hollox, EJ
AF Polley, Shamik
   Cipriani, Valentina
   Khan, Jane C.
   Shahid, Humma
   Moore, Anthony T.
   Yates, John R. W.
   Hollox, Edward J.
TI Analysis of copy number variation at DMBT1 and age-related macular
   degeneration
SO BMC MEDICAL GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; STRONG ASSOCIATION; BACTERIA BINDING; LECTIN
   PATHWAY; RISK-FACTORS; SUSCEPTIBILITY; VARIANT; DISEASE; CFH;
   POLYMORPHISMS
AB Background: DMBT1 is a gene that shows extensive copy number variation (CNV) that alters the number of bacteria-binding domains in the protein and has been shown to activate the complement pathway. It lies next to the ARMS2/HTRA1 genes in a region of chromosome 10q26, where single nucleotide variants have been strongly associated with age-related macular degeneration (AMD), the commonest cause of blindness in Western populations. Complement activation is thought to be a key factor in the pathogenesis of this condition. We sought to investigate whether DMBT1 CNV plays any role in the susceptibility to AMD.
   Methods: We analysed long-range linkage disequilibrium of DMBT1 CNV1 and CNV2 with flanking single nucleotide polymorphisms (SNPs) using our previously published CNV and HapMap Phase 3 SNP data in the CEPH Europeans from Utah (CEU). We then typed a large cohort of 860 AMD patients and 419 examined age-matched controls for copy number at DMBT1 CNV1 and CNV2 and combined these data with copy numbers from a further 480 unexamined controls.
   Results: We found weak linkage disequilibrium between DMBT1 CNV1 and CNV2 with the SNPs rs1474526 and rs714816 in the HTRA1/ARMS2 region. By directly analysing copy number variation, we found no evidence of association of CNV1 or CNV2 with AMD.
   Conclusions: We have shown that copy number variation at DMBT1 does not affect risk of developing age-related macular degeneration and can therefore be ruled out from future studies investigating the association of structural variation at 10q26 with AMD.
C1 [Polley, Shamik; Hollox, Edward J.] Univ Leicester, Dept Genet, Leicester, Leics, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] UCL, UCL Inst Ophthalmol, London, England.
   [Cipriani, Valentina] UCL, UCL Genet Inst, London, England.
   [Cipriani, Valentina; Moore, Anthony T.] Moorfields Eye Hosp, London, England.
   [Khan, Jane C.; Shahid, Humma; Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge, England.
   [Moore, Anthony T.] UCSF Med Sch, Dept Ophthalmol, San Francisco, CA USA.
   [Khan, Jane C.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA, Australia.
   [Shahid, Humma] Cambridge Univ Hosp NHS Fdn Trust, Dept Ophthamol, Cambridge, England.
C3 University of Leicester; University of London; University College
   London; University of London; University College London; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of Cambridge; University of California
   System; University of California San Francisco; Lions Eye Institute;
   University of Western Australia; Royal Perth Hospital; University of
   Western Australia; University of Cambridge
RP Hollox, EJ (通讯作者)，Univ Leicester, Dept Genet, Leicester, Leics, England.
EM ejh33@le.ac.uk
RI Cipriani, Valentina/A-8549-2012; POLLEY, SHAMIK/O-5236-2018
OI Cipriani, Valentina/0000-0002-0839-9955; POLLEY,
   SHAMIK/0000-0002-3965-7013; Hollox, Edward/0000-0002-0115-2298
FU Government of India Ministry of Social Justice and Empowerment PhD
   studentship; MRC New Investigator Grant [GO801123]; Medical Research
   Council; National Institute for Health Research (NIHR) Biomedical
   Research Centre (BRC) at Moorfields Eye Hospital NHS Foundation Trust;
   UCL Institute of Ophthalmology; MRC [G0000067] Funding Source: UKRI;
   Medical Research Council [G0000067] Funding Source: researchfish
FX This work was funded by a Government of India Ministry of Social Justice
   and Empowerment PhD studentship to SP and EJH. EJH was supported in part
   by an MRC New Investigator Grant (GO801123). The collection of patient
   and control samples was funded by a grant from the Medical Research
   Council to JRWY and ATM. VC is funded by the National Institute for
   Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
   The views expressed in this article are those of the authors and not
   necessarily those of the Government of India, NHS, the NIHR or the
   Department of Health. We thank the clinicians who helped with
   recruitment, the Reading Centre at Moorfields Eye Hospital, London for
   grading fundus photographs and the subjects who participated in the
   research. We would like to thank Mark Jobling and Jenny Bowdrey for
   access and support in using an ABI 3130xl capillary electrophoresis
   machine.
CR Barnes C, 2008, NAT GENET, V40, P1245, DOI 10.1038/ng.206
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bikker FJ, 2004, J BIOL CHEM, V279, P47699, DOI 10.1074/jbc.M406095200
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOACKLE RJ, 1993, MOL IMMUNOL, V30, P309, DOI 10.1016/0161-5890(93)90059-K
   Cantsilieris S, 2013, HUM MUTAT, V34, P1, DOI 10.1002/humu.22172
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   DeGiorgio M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004561
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handsaker RE, 2015, NAT GENET, V47, P296, DOI 10.1038/ng.3200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jumblatt MM, 2006, INFECT IMMUN, V74, P4058, DOI 10.1128/IAI.01951-05
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leito JTD, 2011, MOL IMMUNOL, V49, P185, DOI 10.1016/j.molimm.2011.08.010
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Muller H, 2012, ARTERIOSCL THROM VAS, V32, P442, DOI 10.1161/ATVBAHA.111.239830
   Polley S, 2015, P NATL ACAD SCI USA, V112, P5105, DOI 10.1073/pnas.1416531112
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reichhardt MP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00205
   Renner M, 2007, GASTROENTEROLOGY, V133, P1499, DOI 10.1053/j.gastro.2007.08.007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sasaki H, 2002, CANCER RES, V62, P1790
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
NR 44
TC 3
Z9 3
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JUL 15
PY 2016
VL 17
AR 44
DI 10.1186/s12881-016-0311-5
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DS0KV
UT WOS:000380285400001
PM 27416785
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Coco, RM
   Sala-Puigdollers, A
AF Coco, Rosa M.
   Sala-Puigdollers, Anna
TI Management of significant reactivation of old disciform scars in wet
   Age-Related Macular Degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Disciform scar; Indocyanine green
   angiography; Laser photocoagulation
ID LASER PHOTOCOAGULATION; HEMORRHAGIC COMPLICATIONS; RANIBIZUMAB;
   BEVACIZUMAB
AB Background: Fibrotic disciform scars represent the end-stage of wet age-related macular degeneration (AMD) and ophthalmologists tend not to treat them. However, reactivation can occur resulting in further worsening of patients. The aim of this study is to describe the clinical outcomes of 10 patients with disciform scars from age-related macular degeneration (AMD) that have subsequently reactivated.
   Methods: Indocyanine green angiography (ICG) was used to identify the active areas and these "hot spots" (HS) that were subsequently treated with focal laser photocoagulation.
   Results: In 10 out of 11 patients with potential reactivation of an AMD scar, a treatable HS was found on the ICG at the border of the disciform scar. The identified HS was treated with focal laser photocoagulation. Post treatment these areas became inactive. However in 2 cases, reactivation occurred requiring retreatment a few months later.
   Conclusions: AMD patients who are noted to have disciform scars that are increasing in size and signs of activation such as lipid exudation and subretinal haemorrhage should undergo ICG imaging to look for HS. These patients could benefit from focal laser to stabilize the disease and avoid complications and further peripheral visual loss. It is suspected that these patients may have the polypoidal subtype of AMD.
C1 [Coco, Rosa M.; Sala-Puigdollers, Anna] Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, E-47011 Valladolid, Spain.
C3 Universidad de Valladolid
RP Coco, RM (通讯作者)，Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Campus Miguel Delibes,P Belen 17, E-47011 Valladolid, Spain.
EM rosa@ioba.med.uva.es
RI Martin, Rosa Maria Coco/H-4511-2015
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Sala-Puigdollers,
   Anna/0000-0001-5792-6937
CR American Academy of Ophthalmology Retina Panel, 2011, PREF PRACT PATT GUID
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cho HJ, 2012, CAN J OPHTHALMOL, V47, P170, DOI 10.1016/j.jcjo.2012.01.005
   Cousins S, 2008, GRAEF ARCH CLIN EXP, V246, P1677, DOI 10.1007/s00417-008-0905-5
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P315
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Parodi MB, 2012, ARCH OPHTHALMOL-CHIC, V130, P934, DOI 10.1001/archophthalmol.2011.2617
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHATZ H, 1991, ARCH OPHTHALMOL-CHIC, V109, P1549, DOI 10.1001/archopht.1991.01080110085041
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Virgili B, 2007, COCHRANE DB SYST REV, V18
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 22
TC 2
Z9 3
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 25
PY 2014
VL 14
AR 82
DI 10.1186/1471-2415-14-82
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK4EH
UT WOS:000338376300001
PM 24965122
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhou, B
   Wang, B
AF Zhou, Bo
   Wang, Bin
TI Pegaptanib for the treatment of age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE pegaptanib; neovascular age-related macular degeneration; vascular
   endothelial growth factor; VEGF(165); aptamer
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; FACTOR APTAMER;
   ANGIOGENESIS; EXPRESSION; VEGF; INJECTION; MEMBRANES
AB Although neovascular (wet) age-related macular degeneration (AMD) only accounts for 10-20% of all AMD, the majority (about 90%) of severe vision loss associated with AMD is due to this form. Results from recent studies have implied that vascular endothelial growth factor (VEGF), particularly VEGF(165), plays a predominant role in the development of ocular neovascularization and vascular leakage secondary to AMD. Thus VEGF is an important therapeutic target in neovascular AMD. Pegaptanib; an anti-VEGF aptamer, can selectively bind with VEGF165 and inhibit both the growth of blood vessels and vascular leakage, and was approved by the Food and Drug Administration in the United States as the therapy for the treatment of all subtypes of neovascular AMD in December 2004. This review summaries the mechanism, preclinical and clinical studies, and adverse events of pegaptanib treatment. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Nanjing Med Univ, Dept Pharmacol, Nanjing 210029, Jiangsu Prov, Peoples R China.
C3 Nanjing Medical University
RP Wang, B (通讯作者)，Nanjing Med Univ, Dept Pharmacol, 140 Hanzhong Rd, Nanjing 210029, Jiangsu Prov, Peoples R China.
EM binwang@njmu.edu.cn
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bellandi E, 1999, SOLID STATE PHENOM, V65-6, P35, DOI 10.4028/www.scientific.net/SSP.65-66.35
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rowe-Rendleman C, 2004, BRAIN RES BULL, V62, P549, DOI 10.1016/S0361-9230(03)00072-8
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Schwartz S, 2005, DRUGS, V65, P1578, DOI 10.2165/00003495-200565110-00011
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Wang B, 2005, CLIN CHEM, V51, P1541, DOI 10.1373/clinchem.2005.050955
   Wang B, 2003, J OCUL PHARMACOL TH, V19, P457, DOI 10.1089/108076803322473015
   WIJNGAARDEN P, 2005, JAMA-J AM MED ASSOC, V290, P1509
   WINFRIED M, 2005, DRUGS, V65, P1578
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 37
TC 50
Z9 51
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2006
VL 83
IS 3
BP 615
EP 619
DI 10.1016/j.exer.2006.02.010
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 073OD
UT WOS:000239751600019
PM 16678158
DA 2022-11-30
ER

PT J
AU Miura, M
   Yamanari, M
   Iwasaki, T
   Elsner, AE
   Makita, S
   Yatagai, T
   Yasuno, Y
AF Miura, Masahiro
   Yamanari, Masahiro
   Iwasaki, Takuya
   Elsner, Ann E.
   Makita, Shuichi
   Yatagai, Toyohiko
   Yasuno, Yoshiaki
TI Imaging polarimetry in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER POLARIMETRY; NERVE-FIBER
   LAYER; BLOOD-VESSEL QUANTIFICATION; HIGH-SPEED; IN-VIVO;
   ULTRAHIGH-RESOLUTION; POLARIZATION ANALYSIS; SUBRETINAL STRUCTURES;
   IMPROVED CONTRAST
AB PURPOSE. To evaluate the birefringence properties of eyes with age-related macular degeneration (AMD). To compare the information from two techniques-scanning laser polarimetry (GDx) and polarization-sensitive spectral-domain optical coherence tomography (OCT)- and investigate how they complement each other.
   METHODS. The authors prospectively examined the eyes of two healthy subjects and 13 patients with exudative AMD. Using scanning laser polarimetry, they computed phase-retardation maps, average reflectance images, and depolarized light images. To obtain polarimetry information with improved axial resolution, they developed a fiber-based, polarization-sensitive, spectral-domain OCT system and measured the phase retardation associated with birefringence in the same eyes.
   RESULTS. Both GDx and polarization-sensitive spectral-domain optical coherence tomography detected abnormal birefringence at the locus of exudative lesions. Polarization-sensitive, spectral-domain OCT showed that in the old lesions with fibrosis, phase-retardation values were significantly larger than in the new lesions (P = 0.020). Increased scattered light and altered polarization scramble were associated with portions of the lesions.
   CONCLUSIONS. GDx and polarization-sensitive spectral-domain OCT are complementary in probing birefringence properties in exudative AMD. Polarimetry findings in exudative AMD emphasized different features and were related to the progression of the disease, potentially providing a noninvasive tool for microstructure in exudative AMD.
C1 [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Miura, Masahiro; Yamanari, Masahiro; Iwasaki, Takuya; Makita, Shuichi; Yasuno, Yoshiaki] Tokyo Med Univ, Computat Opt & Ophthalmol Grp, Tokyo, Japan.
   [Yatagai, Toyohiko] Univ Tsukuba, Inst Appl Phys, Tsukuba, Ibaraki, Japan.
   [Miura, Masahiro; Yamanari, Masahiro; Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki, Japan.
   [Elsner, Ann E.] Indiana Univ, Sch Optometry, Bloomington, IN USA.
C3 Tokyo Medical University; Tokyo Medical University; University of
   Tsukuba; University of Tsukuba; Indiana University System; Indiana
   University Bloomington
RP Miura, M (通讯作者)，Tokyo Med Univ, Dept Ophthalmol, Kasumigaura Hosp, 3-20-1 Chuo, Inashiki, Ibaraki 3000395, Japan.
EM m-miura@tokyo-med.ac.jp
RI Makita, Shuichi/G-3806-2011; Yasuno, Yoshiaki/F-2586-2011; Yamanari,
   Masahiro/B-3147-2010
OI Makita, Shuichi/0000-0002-6614-3640; Yasuno,
   Yoshiaki/0000-0003-1645-7948; Yamanari, Masahiro/0000-0001-9873-2151
FU NEI NIH HHS [R01 EY007624-19, EY007624, R01 EY007624] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R29EY007624, R01EY007624, P30EY019008]
   Funding Source: NIH RePORTER
CR Bagga H, 2003, INVEST OPHTH VIS SCI, V44, P1969, DOI 10.1167/iovs.02-0923
   BARTSCH DU, 1993, NEUROSCI BIOBEHAV R, V17, P459
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Cense B, 2004, J BIOMED OPT, V9, P121, DOI 10.1117/1.1627774
   CENSE B, 2005, OPTICAL COHERENCE TO
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   HEE MR, 1992, J OPT SOC AM B, V9, P903, DOI 10.1364/JOSAB.9.000903
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2007, J OPT SOC AM A, V24, P1431, DOI 10.1364/JOSAA.24.001431
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Park BH, 2004, OPT LETT, V29, P2512, DOI 10.1364/OL.29.002512
   Pierce MC, 2004, J INVEST DERMATOL, V123, P458, DOI 10.1111/j.0022-202X.2004.23404.x
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   SPENCER WH, 1985, OPHTHALMIC PATHOLOGY, P926
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
   WEINREB RN, 1995, AM J OPHTHALMOL, V119, P627, DOI 10.1016/S0002-9394(14)70221-1
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2003, OPT LETT, V28, P1745, DOI 10.1364/OL.28.001745
   Yamanari M, 2006, OPT EXPRESS, V14, P6502, DOI 10.1364/OE.14.006502
   Yasuno Y, 2002, OPT LETT, V27, P1803, DOI 10.1364/OL.27.001803
   Zhou QY, 2002, INVEST OPHTH VIS SCI, V43, P2221
NR 31
TC 79
Z9 80
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2008
VL 49
IS 6
BP 2661
EP 2667
DI 10.1167/iovs.07-0501
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307GG
UT WOS:000256306800049
PM 18515594
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Singh, R
   Wurzelmann, JI
   Ye, L
   Henderson, L
   Hossain, M
   Trivedi, T
   Kelly, DS
AF Singh, Rishi
   Wurzelmann, John I.
   Ye, Li
   Henderson, Linda
   Hossain, Mohammad
   Trivedi, Trupti
   Kelly, Deborah S.
TI CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN
   SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE multitarget tyrosine kinase inhibitor; safety; pharmacokinetics; central
   retinal thickness; neovascularization; pazopanib; topical; ocular;
   age-related macular degeneration; AMD
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; CHOROIDAL
   NEOVASCULARIZATION; KINASE INHIBITOR; RANIBIZUMAB; THERAPY;
   PHARMACOGENETICS
AB Purpose: To evaluate pazopanib 10 mg/mL eye drops (pazopanib) in healthy subjects and in subjects with previously untreated subfoveal choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Study 1 (single center, randomized, placebo-controlled, double-masked) included 3 cohorts of 12 to 13 healthy subjects each who instilled pazopanib or placebo 4 times daily for 2 weeks. Study 2 (multicenter open-label) included 19 subjects with neovascular age-related macular degeneration who instilled pazopanib 4 times daily for 12 weeks. Both studies evaluated pharmacokinetics and safety. Study 2 also evaluated efficacy.
   Results: Steady-state concentrations of pazopanib in plasma seemed to be reached by Week 2. At Week 4 (Study 2), there were no meaningful changes from baseline in the mean central retinal thickness (37.9 mu m) or best-corrected visual acuity (0.1 letters) (primary endpoint), retinal morphology, choroidal neovascularization size, or total lesion size. Complement Factor H genotype had no effect on changes from baseline in the best-corrected visual acuity or central retinal thickness. The most common pazopanib-related ocular adverse events included eye irritation (Study 1, n = 7) and instillation site pain (Study 2, n = 3). No serious adverse events were reported.
   Conclusion: Pazopanib was well tolerated. In subjects with previously untreated neovascular age-related macular degeneration, pazopanib instilled 4 times daily as monothereapy did not seem to improve the best-corrected visual acuity or decrease the central retinal thickness.
C1 [Singh, Rishi] Cleveland Clin, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Wurzelmann, John I.] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA.
   [Ye, Li; Henderson, Linda; Hossain, Mohammad; Trivedi, Trupti] GlaxoSmithKline, Res & Dev, King Of Prussia, PA USA.
   [Kelly, Deborah S.] GlaxoSmithKline, Res & Dev, Collegeville, PA USA.
C3 Cleveland Clinic Foundation; GlaxoSmithKline; GlaxoSmithKline;
   GlaxoSmithKline
RP Wurzelmann, JI (通讯作者)，GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
EM john.i.wurzelmann@gsk.com
FU GlaxoSmithKline
FX Supported by GlaxoSmithKline. Medical writing support was sponsored by
   GlaxoSmithKline and was provided by Cullen T. Vogelson, PhD, and Usha
   Sivaprasad, PhD, of Illuminated Research, LLC, Fort Worth, TX.
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Danis R, 2012, BR J OPHTHALMOL, V98, P172
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 15
Z9 15
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2014
VL 34
IS 9
BP 1787
EP 1795
DI 10.1097/IAE.0000000000000179
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO8UL
UT WOS:000341630400014
PM 24896137
DA 2022-11-30
ER

PT J
AU Essex, RW
   Nguyen, V
   Daien, V
   Steinmann, S
   Walton, R
   Gillies, MC
   Barthelmes, D
AF Essex, Rohan W.
   Vuong Nguyen
   Daien, Vincent
   Steinmann, Sarah
   Walton, Richard
   Gillies, Mark C.
   Barthelmes, Daniel
TI Trainee-led versus specialist-led management of neovascular age-related
   macular degeneration: a registry-based study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macula; Degeneration; Choroid; Neovascularisation
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; NATIONAL OPHTHALMOLOGY DATABASE;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB; OUTCOMES; VERTEPORFIN; MULTICENTER;
   AFLIBERCEPT; ANCHOR; MARINA
AB Objective To compare the outcomes of trainee-led and specialist-led management of neovascular age-related macular degeneration. Design Prospective multicentre registry-based observational study. Setting Ophthalmology training centres in Australia and Europe where both trainee-led and specialist-led models of care coexist. Participants Treatment-naive eyes with neovascular age-related macular degeneration and at least 12 months follow-up. 726 eyes were included in the study from two centres, 534 receiving trainee-led treatment and 192 specialist-led treatment. Interventions The management and outcomes of patients receiving trainee-led care were compared with those receiving specialist-led care. Main outcomes measures The primary outcome was the mean change in visual acuity at 12 months from first injection. Outcomes were also presented at 36 months where available. Results The mean age of participants was 79 years and 65% were female. The adjusted change in acuity at 12 months in trainee-led vs specialist-led eyes was +3.2 letters vs +4.1 letters (difference -0.9 letters, 95% CI -3.4 to 1.5, p=0.473). The mean adjusted change in acuity at 36 months was -0.9 letters in trainees vs +0.2 letters for specialists (difference -1.1 letters, 95% CI -5.1 to 2.9, p=0.596). Eyes treated by trainees received fewer injections on average to 36 months (15.0 vs 19.0, p=0.004), although this trend was observed at one centre only. Conclusions No significant differences in outcome between eyes managed by trainees and eyes managed by specialists were observed. Appropriately structured trainee-led management of neovascular age-related macular degeneration is a reasonable approach where regulatory and practical considerations allow it.
C1 [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Essex, Rohan W.] Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
   [Vuong Nguyen; Daien, Vincent; Walton, Richard; Gillies, Mark C.; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] INSERM, U1061, Montpellier, France.
   [Steinmann, Sarah; Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 Australian National University; Royal Victorian Eye & Ear Hospital;
   University of Sydney; Universite de Montpellier; CHU de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; University of Zurich; University Zurich
   Hospital
RP Essex, RW (通讯作者)，Australian Natl Univ, Acad Unit Ophthalmol, Garran, ACT 2605, Australia.
EM Rohan.Essex@act.gov.au
RI DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Essex, Rohan/0000-0001-5323-0334;
   Nguyen, Vuong/0000-0001-9070-9803
FU Macular Disease Foundation, Australia; NHMRC practitioner fellowship;
   Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland; Holcim
   Foundation; Swiss National Foundation
FX Supported by a grant from the Macular Disease Foundation, Australia. MG
   is a Sydney Medical Foundation Fellow and is supported by an NHMRC
   practitioner fellowship. DB was supported by the Walter and Gertrud
   Siegenthaler Foundation Zurich, Switzerland, the Holcim Foundation and
   the Swiss National Foundation.
CR [Anonymous], 2016, R LANG ENV STAT COMP
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan NSW, 2017, J CATARACT REFR SURG, V43, P358, DOI 10.1016/j.jcrs.2016.12.026
   DaCosta J, 2014, EYE, V28, P734, DOI 10.1038/eye.2014.69
   Day AC, 2015, EYE, V29, P552, DOI 10.1038/eye.2015.3
   Day AC, 2016, OPHTHALMOLOGY, V123, P1711, DOI 10.1016/j.ophtha.2016.04.002
   Falavarjani KG, 2015, CAN J OPHTHALMOL, V50, P33, DOI 10.1016/j.jcjo.2014.09.005
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   Narendran N, 2009, EYE, V23, P31, DOI 10.1038/sj.eye.6703049
   National Eye Institute, 2010, AGE RELATED MACULAR
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Samalia P, 2016, NEW ZEAL MED J, V129, P32
   Therneau, 2012, COXME MIXED EFFECTS
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 27
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2019
VL 103
IS 8
BP 1158
EP 1162
DI 10.1136/bjophthalmol-2018-311852
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN8FF
UT WOS:000478915300025
PM 30385435
DA 2022-11-30
ER

PT J
AU Scuteri, D
   Vero, A
   Zito, M
   Naturale, MD
   Bagetta, G
   Nucci, C
   Tonin, P
   Corasaniti, MT
AF Scuteri, Damiana
   Vero, Ada
   Zito, Mariacristina
   Naturale, Maria Diana
   Bagetta, Giacinto
   Nucci, Carlo
   Tonin, Paolo
   Corasaniti, Maria Tiziana
TI Diabetic retinopathy and age-related macular degeneration: a survey of
   pharmacoutilization and cost in Calabria, Italy
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy;
   pharmacovigilance; ranibizumab; anti-VEGFs; retrospective study
ID ENDOTHELIAL DYSFUNCTION; PREVALENCE; EPIDEMIOLOGY; INFLAMMATION
AB The aged population is constantly growing, thus fostering an increase in age-dependent diseases. Among these, diabetic retinopathy (DR) along with age-related macular degeneration entails progressive vision loss. Since such conditions are associated with the proliferation of novel vessels, their pharmacotherapeutic management consists of the intravitreal injection of anti-vascular endothelial growth factor drugs, able to hinder the driving of vascular proliferation prompted by vascular endothelial growth factor. The humanized anti-vascular endothelial growth factor monoclonal antibody ranibizumab provided evidence for efficacy in several trials, hence earning approval by the US Food and Drug Administration for therapeutic use in all the stages of DR. Due to the lack of epidemiologic and pharmacoeconomic evaluation in the local Calabria Region context, the present retrospective observational study focused on prevalence of DR and age-related macular degeneration, treatment and cost of therapy with ranibizumab in 870 patients arriving to clinical observation at the "Mater Domini" University Hospital in Calabria, Italy from January 2014 to June 2017. Data were extracted from the database of ophthalmology ward and subjected to statistical analysis. The results suggest that the most frequent retinal diseases are age-related macular degeneration and DR and that the use of ranibizumab has been decreasing over the 4-year study period together with the associated cost per patient which was similar for both disorders. Therefore, appropriateness of treatment with drugs other than ranibizumab needs to be assessed in this setting and deep monitoring of pharmacologic treatment for retinal diseases is necessary to prevent or delay visual acuity decrease and complete vision loss. Study procedures were performed in accordance with the "Mater Domini" University Hospital ethical standards of the responsible committee on human experimentation
C1 [Scuteri, Damiana; Bagetta, Giacinto] Univ Calabria, Preclin & Translat Pharmacol, Dept Pharm Hlth Sci & Nutr, Arcavacata Di Rende, Cosenza, Italy.
   [Vero, Ada; Zito, Mariacristina] Mater Domini Univ Hosp, Pharm Unit, Catanzaro, Italy.
   [Naturale, Maria Diana; Corasaniti, Maria Tiziana] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Nucci, Carlo] Univ Roma Tor Vergata, Dept Expt Med, Ophtalmol Unit, Rome, Italy.
   [Tonin, Paolo] S Anna Inst, Reg Ctr Serious Brain Injuries, Crotone, Italy.
C3 University of Calabria; Magna Graecia University of Catanzaro;
   University of Rome Tor Vergata
RP Bagetta, G (通讯作者)，Univ Calabria, Preclin & Translat Pharmacol, Dept Pharm Hlth Sci & Nutr, Arcavacata Di Rende, Cosenza, Italy.
EM giacinto.bagetta@unical.it
RI Corasaniti, Maria Tiziana/N-1332-2015; Tonin, Paolo/K-7483-2016;
   Bagetta, Giacinto/N-9716-2018; SCUTERI, DAMIANA/AAX-5571-2020
OI Corasaniti, Maria Tiziana/0000-0001-6472-0697; Tonin,
   Paolo/0000-0002-4867-1378; Bagetta, Giacinto/0000-0001-8540-6218;
   SCUTERI, DAMIANA/0000-0001-5846-7058
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Atlanta GCfDCaP US Department of Health and Human Services, 2017, NAT DIAB STAT REP
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Comitato R, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040093
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Herat LY, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/9254126
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Keane PA, 2011, CLIN OPHTHALMOL, V5, P771, DOI 10.2147/OPTH.S13774
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petrella RJ, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/723169
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Sasso FC, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3113
   Spijkerman AMW, 2007, DIABETIC MED, V24, P969, DOI 10.1111/j.1464-5491.2007.02217.x
   van Hecke MV, 2005, DIABETOLOGIA, V48, P1300, DOI 10.1007/s00125-005-1799-y
   Vottonen P, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13706
   Vujosevic S, 2017, J DIABETES COMPLICAT, V31, P1348, DOI 10.1016/j.jdiacomp.2017.04.010
   Vujosevic S, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3627465
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhao Yue, 2018, Drugs Context, V7, P212532, DOI 10.7573/dic.212532
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
NR 25
TC 3
Z9 3
U1 0
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD AUG
PY 2019
VL 14
IS 8
BP 1445
EP 1448
AR PMID 30964071
DI 10.4103/1673-5374.253528
PG 4
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA IC5WL
UT WOS:000471039600027
PM 30964071
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, MH
   Zhao, D
   Cho, J
   Guallar, E
AF Kim, Myung Hun
   Zhao, Di
   Cho, Juhee
   Guallar, Eliseo
TI Cadmium exposure and age-related macular degeneration
SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; cadmium; Korean National Health and
   Nutrition Examination Survey (KNHANES)
ID HUMAN RETINA; POPULATION; TOXICITY; LEAD; ACCUMULATION; ASSOCIATION;
   PROGRESSION; PROTECTION; HEALTH; URINE
AB Cadmium (Cd) has been proposed as a risk factor for age-related macular degeneration (AMD), but the association between Cd exposure and AMD risk in large population studies is unknown. This study evaluated the association of Cd exposure with AMD in a large representative sample of Korean men and women. This was a cross-sectional study of 3865 Korean adults >= 40 years of age who participated in the Korean National Health and Nutrition Examination Survey (KNHANES) during 2008-2011. Cd concentrations in whole blood were measured by graphite-furnace atomic absorption spectrometry. The presence of AMD was determined in digital non-mydriatic fundus photographs. Cd levels were higher in participants with AMD compared with those without AMD (1.3 vs 1.1 mu g/l, respectively, P < 0.001). In fully adjusted models, the odds ratio for AMD comparing the highest with the lowest Cd quartiles was 1.92 (95% CI = 1.08-3.39; P for trend 0.029). In restricted cubic spline models, the association between Cd and AMD was approximately linear, with no evidence of threshold effects. Blood Cd concentrations were independently associated with the prevalence of AMD. If the association is proven causal, population-based preventive strategies to decrease Cd exposure could reduce the population burden of AMD.
C1 [Kim, Myung Hun] Saevit Eye Hosp, 1065 Jungang Ro, Goyang 410817, Gyeonggi Do, South Korea.
   [Kim, Myung Hun] Seoul Natl Univ, Grad Sch Publ Hlth, Dept Epidemiol, Seoul, South Korea.
   [Zhao, Di; Cho, Juhee; Guallar, Eliseo] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
   [Zhao, Di; Cho, Juhee; Guallar, Eliseo] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
   [Cho, Juhee] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea.
   [Cho, Juhee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Biostat & Clin Epidemiol Ctr, Seoul, South Korea.
C3 Seoul National University (SNU); Johns Hopkins University; Johns Hopkins
   Bloomberg School of Public Health; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health; Sungkyunkwan University
   (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kim, MH (通讯作者)，Saevit Eye Hosp, 1065 Jungang Ro, Goyang 410817, Gyeonggi Do, South Korea.
EM philip.mhkim@gmail.com
RI Cho, Juhee/ABD-2280-2021
CR [Anonymous], 1993, IARC Monogr Eval Carcinog Risks Hum, V58, P1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker K, 2003, INT J HYG ENVIR HEAL, V206, P15, DOI 10.1078/1438-4639-00188
   Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cave M, 2010, ENVIRON HEALTH PERSP, V118, P1735, DOI 10.1289/ehp.1002720
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Faroon O., 2012, TOXICOLOGICAL PROFIL
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1
   Jin TY, 1998, NEUROTOXICOLOGY, V19, P529
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Moon CS, 1995, ENVIRON RES, V71, P46, DOI 10.1006/enrs.1995.1066
   Moon CS, 2003, INT ARCH OCC ENV HEA, V76, P282, DOI 10.1007/s00420-002-0415-4
   Nawrot TS, 2010, BIOMETALS, V23, P769, DOI 10.1007/s10534-010-9343-z
   Nordberg GF, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P445, DOI 10.1016/B978-012369413-3/50078-1
   Satarug S, 2003, TOXICOL LETT, V137, P65, DOI 10.1016/S0378-4274(02)00381-8
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Small RG, 1999, OPHTHALMOLOGY, V106, P2043, DOI 10.1016/S0161-6420(99)90519-5
   STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   U.S. Geological Survey, 2010, MIN COMM SUMM 2010
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Winkler BS, 1999, MOL VIS, V5
   Yiin SJ, 1999, J TOXICOL ENV HEAL A, V57, P403, DOI 10.1080/009841099157601
NR 36
TC 11
Z9 11
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1559-0631
EI 1559-064X
J9 J EXPO SCI ENV EPID
JI J. Expo. Sci. Environ. Epidemiol.
PD MAR-APR
PY 2016
VL 26
IS 2
BP 214
EP 218
DI 10.1038/jes.2014.75
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA DF6EO
UT WOS:000371448900012
PM 25388812
DA 2022-11-30
ER

PT J
AU Or, C
   Chui, L
   Fallah, N
   Forooghian, F
AF Or, Chris
   Chui, Lica
   Fallah, Nader
   Forooghian, Farzin
TI VOLUMETRIC ASSESSMENT OF THE RESPONSIVENESS OF PIGMENT EPITHELIAL
   DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO
   INTRAVITREAL BEVACIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular; age-related macular degeneration; pigment epithelial
   detachment; intravitreal bevacizumab; optical coherence tomography;
   volumetric analysis
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY; VISUAL-ACUITY;
   PREDICTIVE FACTORS; RANIBIZUMAB; AFLIBERCEPT; EYES; SENSITIVITY;
   RETREATMENT
AB Purpose:To determine baseline factors that can predict the response of pigment epithelial detachments (PEDs) in neovascular age-related macular degeneration to treatment with intravitreal bevacizumab (IVB).Methods:Patients with newly diagnosed neovascular age-related macular degeneration and PED who were treated exclusively with IVB were included. Response to treatment was defined by change in PED volume (determined using spectral-domain optical coherence tomography). PEDs were classified as either predominantly serous or fibrovascular. Multivariable regression and receiver operating characteristic analyses were performed.Results:A total of 48 eyes were identified (mean follow-up time 73 weeks). Overall, the response to the first IVB treatment was predictive of the response to treatment at the final visit (P = 0.015). Serous PEDs had a greater decrease in volume at the final visit (P = 0.008). With respect to both PED types, a decrease in PED volume of 21% after the first IVB treatment was predictive of an overall decrease in volume of 30% at the final visit (sensitivity 83%, specificity 76%).Conclusion:In neovascular age-related macular degeneration, serous PEDs respond more favorably to IVB than fibrovascular PEDs. Overall, for both types of PED, the response to the first treatment is predictive of the final response to treatment. Taken together, the results would suggest that if there is less than 21% reduction in PED volume after the first IVB treatment, and/or the PED is predominantly fibrovascular, then switching to another antivascular endothelial growth factor agent should be considered.
C1 [Or, Chris; Chui, Lica; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
   [Fallah, Nader] Univ British Columbia, Dept Med, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia
RP Forooghian, F (通讯作者)，St Pauls Hosp, Dept Ophthalmol, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
RI Fallah, Nader/D-4145-2012
OI Fallah, Nader/0000-0002-7746-4773
FU Retina Foundation of Canada
FX This study was funded by a grant from the Retina Foundation of Canada.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Ozkaya A, 2014, J FR OPHTALMOL, V37, P280, DOI 10.1016/j.jfo.2013.08.006
   Patel KH, 2013, EYE, V27, P668
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Tolentino MJ, 2014, EXPERT OPIN INV DRUG, V22, P1
NR 34
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 264
EP 271
DI 10.1097/IAE.0000000000000795
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500005
PM 26418445
DA 2022-11-30
ER

PT J
AU Tranos, P
   Vacalis, A
   Asteriadis, S
   Koukoula, S
   Vachtsevanos, A
   Perganta, G
   Georgalas, I
AF Tranos, Paris
   Vacalis, Athanasios
   Asteriadis, Solon
   Koukoula, Stavrenia
   Vachtsevanos, Athanasios
   Perganta, Georgia
   Georgalas, Ilias
TI Resistance to antivascular endothelial growth factor treatment in
   age-related macular degeneration
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE antiVEGF; age related macular degeneration; treatment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; NEOVASCULARIZATION;
   RANIBIZUMAB; TACHYPHYLAXIS; ANASTOMOSIS; PREVALENCE; ASSOCIATION
AB Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in people aged over 65 years in developed countries. Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis and its proven role in the pathological neovascularization in wet AMD has provided evidence for the use of anti-VEGF agents as potential therapies. In this study, we review the literature for the possible causes of failure after treatment with anti-VEGF agents and attempt to propose an algorithm of suggestive actions to increase the chances of successful management of such difficult cases.
C1 [Tranos, Paris; Vacalis, Athanasios; Asteriadis, Solon; Koukoula, Stavrenia; Vachtsevanos, Athanasios; Perganta, Georgia] Retina Ctr, Thessaloniki, Greece.
   [Georgalas, Ilias] Univ Athens, Dept Ophthalmol, G Gennimatas Hosp Athens, Athens 15452, Greece.
C3 National & Kapodistrian University of Athens
RP Georgalas, I (通讯作者)，Univ Athens, Dept Ophthalmol, 59 Chrysanthemon St, Athens 15452, Greece.
EM igeorgalas@yahoo.com
RI Georgalas, Ilias/AAD-5946-2019
OI Georgalas, Ilias/0000-0002-6171-5865
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brantley MA, 2007, OPHTHALMOLOGY, V93, P610
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Manoj SM, 2011, KERALA J OPHTHALMOLO
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shiragami C, 2007, RETINA-J RET VIT DIS, V27, P198, DOI 10.1097/01.iae.0000224938.61915.f0
   Shirakata Y, 2012, JPN J OPHTHALMOL, V56, P599, DOI 10.1007/s10384-012-0183-y
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Stewart MW, 2011, RETINA, V32, P434
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Teper SJ, 2010, MOL VIS, V16, P2598
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 51
TC 47
Z9 49
U1 2
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 485
EP 490
DI 10.2147/DDDT.S43470
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 163VW
UT WOS:000320366400002
PM 23818759
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Cheong, KX
   Teo, KYC
   Cheung, CMG
AF Cheong, Kai Xiong
   Teo, Kelvin Yi Chong
   Cheung, Chui Ming Gemmy
TI Influence of pigment epithelial detachment on visual acuity in
   neovascular age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE pigment epithelial detachment(s); age-related macular degeneration;
   neovascular age-related macular degeneration; choroidal
   neovascularisation; anti-VEGF; bevacizumab; ranibizumab; aflibercept;
   visual acuity; vision
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; OCCULT
   CHOROIDAL NEOVASCULARIZATION; ANTI-VEGF THERAPY; RETINAL ANGIOMATOUS
   PROLIFERATION; INTRAVITREAL RANIBIZUMAB; TYPE-3 NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; ANATOMICAL OUTCOMES; GEOGRAPHIC ATROPHY
AB Pigment epithelial detachment (PED), the anatomical separation of the retinal pigment epithelium from the Bruch membrane, is common in many chorioretinal diseases, including neovascular age-related macular degeneration. PED is present in about 30% to 80% of neovascular age-related macular degeneration patients based on the CATT, EXCITE, and VIEW studies. The influence of PED on visual acuity is controversial as a result of inconsistent results reported by various studies. With advances in imaging technologies, it is possible to evaluate not only the presence or absence of PED, but also detailed quantitative parameters, such as height, width, greatest linear diameter, area, volume, and reflectivity within the PED. We performed a comprehensive literature review to evaluate the relationship of PED with visual acuity. In summary, the presence or persistence of a PED may still be compatible with relatively good visual acuity. There is no strong evidence that the presence of a PED or aspects of its morphology has a significant impact on visual acuity. The presence of a PED may be predictive of the need for more regular treatment. More well-designed studies with standardized PED definitions and classifications are needed to evaluate the relationship between PED and visual acuity. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Cheong, Kai Xiong; Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Teo, Kelvin Yi Chong; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
OI Teo, Kelvin/0000-0002-7458-7081
FU Duke/Duke-NUS Research Collaborations grant
   [Duke/Duke-NUS/RECA(Pilot)2016/0020]; Biomedical Research Council
   Singapore [SPF2014/002]; National Medical Research Council Open Fund
   Large Collaborative Grant [NMRC/LCG/004/2018]
FX Supported by: Duke/Duke-NUS Research Collaborations grant:
   Duke/Duke-NUS/RECA(Pilot)2016/0020, Biomedical Research Council
   Singapore grant: SPF2014/002, National Medical Research Council Open
   Fund Large Collaborative Grant:NMRC/LCG/004/2018.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Alshahrani ST, CLIN OPHTHALMOL
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Ashraf M, ACTA OPHTHALMOL
   Azar G, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7438083
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Blanco-Garavito R, 2018, RETINA-J RET VIT DIS, V38, P2285, DOI 10.1097/IAE.0000000000001928
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2018, EUR J OPHTHALMOL, V28, P677, DOI 10.1177/1120672117747034
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Cheong KX, 2020, EYE, V34, P2257, DOI 10.1038/s41433-020-0803-6
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CM, 2018, ANN EYE SCI, V3, P56, DOI [10.21037/aes.2018.11.02, DOI 10.21037/AES.2018.11.02]
   Cheung CMG, OPHTHALMOL RETINA
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Cho HJ, AM J OPHTHALMOL
   Choi CS, 2016, OSLI RETINA, V47, P245, DOI 10.3928/23258160-20160229-07
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2015, ACTA OPHTHALMOL, V93, pE600, DOI 10.1111/aos.12683
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Daien V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1208-9
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   de Massougnes S, RETINA
   de Massougnes S, 2018, RETINA-J RET VIT DIS, V38, P717, DOI 10.1097/IAE.0000000000001613
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Inan Sibel, 2019, Rom J Ophthalmol, V63, P238
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Jaffe GJ, OPHTHALMOLOGY
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalouda P, SEMIN OPHTHALMOL
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kim K, 2019, RETINA-J RET VIT DIS, V39, P303, DOI 10.1097/IAE.0000000000001947
   Kocak I., INT OPHTHALMOL
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen PP, RETINA
   Lee Dong Kyu, 2016, Korean J Ophthalmol, V30, P265, DOI 10.3341/kjo.2016.30.4.265
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Lee JY, OPHTHALMOLOGY
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2018, AM J OPHTHALMOL, V191, pXLI, DOI 10.1016/j.ajo.2017.12.019
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Mokwa NF, J OPHTHALMOL
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Or C, 2016, RETINA-J RET VIT DIS, V36, P264, DOI 10.1097/IAE.0000000000000795
   Ozkaya A, 2014, J FR OPHTALMOL, V37, P280, DOI 10.1016/j.jfo.2013.08.006
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Patel KH, EYE
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Ristau T, 2013, J CLIN EXP OPHTHALMO, V4, P1
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1114, DOI 10.4103/ijo.IJO_638_18
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2181, DOI 10.1097/IAE.0000000000000764
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Suzuki M, BR J OPHTHALMOL
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tarakcioglu HN, 2019, J FR OPHTALMOL, V42, P22, DOI 10.1016/j.jfo.2018.06.005
   Teo KYC, 2019, ASIA-PAC J OPHTHALMO, V8, P165, DOI 10.22608/APO.201909
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Tyagi P, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0824-0
   Varshney N, 2013, CAN J OPHTHALMOL, V48, P210, DOI 10.1016/j.jcjo.2013.01.023
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Yu JJ, OPHTHALMOLOGY
   Yuksel H, 2013, ARQ BRAS OFTALMOL, V76, P209, DOI 10.1590/S0004-27492013000400002
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zhao C, 2016, MED SCI MONITOR, V22, P833, DOI 10.12659/MSM.895528
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 160
TC 5
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2021
VL 66
IS 1
BP 68
EP 97
DI 10.1016/j.survophthal.2020.05.003
PG 30
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN8XA
UT WOS:000604754300006
PM 32428539
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Chakravarthy, U
   Birch, DG
   Staurenghi, G
   Henry, EC
   Brittain, C
AF Sadda, Srinivas R.
   Chakravarthy, Usha
   Birch, David G.
   Staurenghi, Giovanni
   Henry, Erin C.
   Brittain, Christopher
TI CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; COLOR
   FUNDUS PHOTOGRAPHS; VISUAL-ACUITY LOSS; RETICULAR PSEUDODRUSEN;
   MULTIFOCAL ELECTRORETINOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   AUTOFLUORESCENCE PATTERNS; FLUORESCEIN ANGIOGRAPHY; COMPLEMENT
   ACTIVATION
AB Purpose:To summarize the recent literature describing the application of modern technologies in the study of patients with geographic atrophy (GA) secondary to age-related macular degeneration.Methods:Review of the literature describing the terms and definitions used to describe GA, imaging modalities used to capture and measure GA, and the tests of visual function and functional deficits that occur in patients with GA.Results:In this paper, we describe the evolution of the definitions used to describe GA. We compare imaging modalities used in the characterization of GA, report on the sensitivity and specificity of the techniques where data exist, and describe the correlations between these various modes of capturing the presence of GA. We review the functional tests that have been used in patients with GA, and critically examine their ability to detect and quantify visual deficits.Conclusion:Ophthalmologists and retina specialists now have a wide range of assessments available for the functional and anatomic characterization of GA in patients with age-related macular degeneration. To date, studies have been limited by their unimodal approach, and we recommend that future studies of GA use multimodal imaging. We also suggest strategies for the optimal functional testing of patients with GA.
C1 [Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Sadda, Srinivas R.] Univ Calif Angeles, David Geffen Sch Med, Los Angeles, CA USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Birch, David G.] Retina Fdn Southwest, Dallas, TX USA.
   [Birch, David G.] Texas Southwestern State Univ, Dept Ophthalmol, Dallas, TX USA.
   [Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Henry, Erin C.] Genentech Inc South, San Francisco, CA USA.
   [Brittain, Christopher] Hoffmann La Roche Ltd, Basel, Switzerland.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Queens University
   Belfast; Retina Foundation of the Southwest; University of Milan; Luigi
   Sacco Hospital; Roche Holding; Genentech; Roche Holding
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
EM ssadda@doheny.org
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251; Chakravarthy,
   Usha/0000-0002-2606-3734
FU Hoffmann-La Roche; Roche; Optos; Optovue; Centervue; Heidelberg
   Engineering; Quantel Medical; Novartis; Carl Zeiss Meditec; Alcon;
   Allergan; NATIONAL EYE INSTITUTE [R01EY009076] Funding Source: NIH
   RePORTER
FX S. R. Sadda has served as a consultant to Genentech, Roche, Allergan,
   Novartis, Stem Cell Inc, Iconic, Avalanche, Optos, and Carl Zeiss
   Meditec. U. Chakravarthy has attended advisory boards for Hoffmann-La
   Roche and Genentech. Her institution has received grants from
   Hoffmann-La Roche and she is principal investigator in trials sponsored
   by Roche. D. G. Birch has been a consultant for AGTC, Acucela, Inc.,
   Shire Pharmaceuticals, ISIS/GSK, QLT, and Thrombogenics. G. Staurenghi
   is principal investigator in trials sponsored by Roche. He is also
   consultant for Heidelberg Engineering, Quantel Medical, Carl Zeiss
   Meditec, Alcon, Allergan, Bayer, Boehringer Ingelheim, Genentech, GSK,
   Novartis, Roche. His institution received grants from Optos, Optovue,
   Centervue, Heidelberg Engineering, Quantel Medical, Novartis, Carl Zeiss
   Meditec, Alcon, Allergan. He has a patent with Ocular Instruments. E. C.
   Henry is an employee of Genentech, Inc. C. Brittain is an employee of F.
   Hoffmann-La Roche, Ltd.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   BOTTONI FG, 1994, GRAEF ARCH CLIN EXP, V232, P458, DOI 10.1007/BF00195354
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   Chen Q, 2014, RETINA-J RET VIT DIS, V34, P2346, DOI 10.1097/IAE.0000000000000249
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   FISH GE, 1989, OPHTHALMOLOGY, V96, P109
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kapre A, 2015, SENSITIVITY FUNCTION
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kleinman ME, 2016, DEV OPHTHALMOL, V55, P46, DOI 10.1159/000431141
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   Kuehn MH, 2008, EXP EYE RES, V87, P89, DOI 10.1016/j.exer.2008.04.012
   Landa G, 2007, EUR J OPHTHALMOL, V17, P615, DOI 10.1177/112067210701700421
   Leat SJ, 1997, EYE, V11, P893, DOI 10.1038/eye.1997.228
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Morgan JIW, 2008, INVEST OPHTH VIS SCI, V49, P3715, DOI 10.1167/iovs.07-1430
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P6015, DOI 10.1167/iovs.09-3643
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3854, DOI 10.1167/iovs.10-6601
   Pece A, 2005, EUR J OPHTHALMOL, V15, P759, DOI 10.1177/112067210501500616
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Piermarocchi S, 2006, EUR J OPHTHALMOL, V16, P851, DOI 10.1177/112067210601600611
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Radner W, 2014, GRAEF ARCH CLIN EXP, V252, P1297, DOI 10.1007/s00417-014-2646-y
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Ratnam K, 2013, INVEST OPHTH VIS SCI, V54, P5836, DOI 10.1167/iovs.13-12557
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schneider U, 1998, GRAEF ARCH CLIN EXP, V236, P193, DOI 10.1007/s004170050063
   Schneider U, 1997, ACTA OPHTHALMOL SCAN, V75, P653
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Sull A. C., 2008, RETINA TODAY, P39
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Tschosik E, 2015, QUANTIFYING FUNCTION
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
NR 116
TC 53
Z9 54
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2016
VL 36
IS 10
BP 1806
EP 1822
DI 10.1097/IAE.0000000000001283
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ6US
UT WOS:000385998600015
PM 27652913
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Kumar, A
   Sahni, JN
   Stangos, AN
   Campa, C
   Harding, SP
AF Kumar, A.
   Sahni, J. N.
   Stangos, A. N.
   Campa, C.
   Harding, S. P.
TI Effectiveness of ranibizumab for neovascular age-related macular
   degeneration using clinician-determined retreatment strategy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; THICKNESS MEASUREMENTS; MACULOPATHY;
   PREVALENCE; THERAPY
AB Aims To report the effectiveness of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in a tertiary centre.
   Methods 1 year prospective cohort study of patients with a diagnosis of neovascular age-related macular degeneration on fundus fluorescein angiography treated with ranibizumab. Patients received three consecutive monthly treatments, followed by a clinician-determined re-treatment strategy. Data collected included demographic details, baseline and subsequent follow-up visit measurements, refraction protocol best corrected visual acuity (BCVA), contrast sensitivity (CS) and central foveal thickness (CFT) on optical coherence tomography.
   Results 81 patients were included in the study. The mean age was 79.5 years with a male: female ratio 32:49. The mean number of treatments was 5.6 +/- 2.3. Visual outcomes at 12 months showed 17.1% gained >= 15 letters BCVA, 97.4% lost <15 letters and 2.5% lost >= 15 letters. Mean changes at 12 months were: BCVA +3.7 +/- 11.1 (p<0.01); CS + 2.3 +/- 5.1 letters (p<0.001); CFT -100.1 +/- 111.9 mu m (p<0.001).
   Conclusions Clinician-determined re-treatment after a three-dose initiation phase appears to be less effective in improving BCVA than in randomised controlled trials.
C1 [Kumar, A.; Sahni, J. N.; Stangos, A. N.; Campa, C.; Harding, S. P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   [Harding, S. P.] Univ Liverpool, Ophthalmol Res Unit, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool
RP Sahni, JN (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM jayashreesahni@yahoo.co.uk
OI Harding, Simon/0000-0003-4676-1158
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   *EPAR, LUC SUMM PUBL EMEA H
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   *NAT I CLIN EXC, 2008, MAC DEG AG REL RAN P
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 18
TC 31
Z9 31
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2011
VL 95
IS 4
BP 530
EP 533
DI 10.1136/bjo.2009.171868
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 736NZ
UT WOS:000288502700021
PM 20937739
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Chang, Young Suk
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Age-related differences in the prevalence of subtypes of Neovascular
   age-related macular degeneration in the first diagnosed eye
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Polypoidal choroidal vasculopathy; Type 3 neovascularization; Retinal
   angiomatous proliferation
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   RISK-FACTORS; TYPE-3 NEOVASCULARIZATION; VISUAL IMPAIRMENT; FELLOW-EYE;
   ASSOCIATION; JAPANESE; RANIBIZUMAB; OUTCOMES
AB Purpose To evaluate age-related differences in the prevalence of subtypes of neovascular age-related macular degeneration (AMD) in the first diagnosed eye.
   Methods This retrospective, observational study included 1099 eyes of 1099 patients diagnosed with neovascular AMD. The neovascular AMD cases were classified into three subtypes: typical neovascular AMD, polypoidal choroidal vasculopathy (PCV), and type 3 neovascularization. The patients were divided into four groups, according to age: >50 and <60 years, 60 and <70 years, 70 and <80 years, and 80 years. Difference in the prevalence of three AMD subtypes was evaluated among the four age groups.
   Results In the age group >50 and <60years, 34 (25.0%) and 102 patients (75.0%) were diagnosed with typical neovascular AMD and PCV, respectively. In the age group 60 and <70years, 90 (28.1%), 206 (64.4%), and 24 patients (7.5%) were diagnosed with typical neovascular AMD, PCV, and type 3 neovascularization, respectively. In the age group 70 and <80years, the corresponding numbers were 200 (41.9%), 197 (41.3%), and 80 (16.8%), respectively; in the age group 80years, the corresponding values were 83 (50.0%), 39 (23.5%), and 44 (26.5%), respectively. A significant difference was observed in the prevalence of the subtypes of neovascular AMD among the four age groups (chi-square test, P<0.001).
   Conclusion Subtype prevalence in newly diagnosed neovascular AMD differs significantly according to age. This result suggests that different pathophysiology may be involved in the development of different subtypes of neovascular AMD.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital (Seoul, South Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided financial support in
   the form of funding for English editing support. The sponsor had no role
   in the design or conduct of this research.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chang YS, 2016, GRAEF ARCH CLIN EXP, V254, P1083, DOI 10.1007/s00417-015-3173-1
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Lee JE, 2016, BRIT J OPHTHALMOL, V100, P652, DOI 10.1136/bjophthalmol-2015-306678
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 44
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2019
VL 257
IS 5
BP 891
EP 898
DI 10.1007/s00417-018-04228-4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT9JS
UT WOS:000464886200005
PM 30617580
DA 2022-11-30
ER

PT J
AU Mahmoudzadeh, R
   Hinkle, JW
   Hsu, JS
   Garg, SJ
AF Mahmoudzadeh, Raziyeh
   Hinkle, John W.
   Hsu, Jason
   Garg, Sunir J.
TI Emerging treatments for geographic atrophy in age-related macular
   degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; clinical trials; complement;
   geographic atrophy
ID RETINAL PIGMENTED EPITHELIUM; SECONDARY; GROWTH; CELLS; AMD
AB Purpose of review This review describes therapeutic research programs for geographic atrophy (GA) due to age-related macular degeneration (AMD). We highlight clinical trial data from phase I, II, and III studies. Recent findings There are currently no treatments for GA, a form of advanced AMD that causes significant visual morbidity. Currently, therapeutic candidates are being developed to delay further progression of GA or even attempt to reverse some of the damage. The approaches to therapy range from molecular targets to cell transplantation. Studies of these novel treatment approaches have demonstrated varying degrees of success. The progress in understanding the disease pathophysiology as well as clinical trial data is reviewed. There are promising new treatments to prevent GA progression as well as some that may reverse the disease course.
C1 [Mahmoudzadeh, Raziyeh; Hinkle, John W.; Hsu, Jason; Garg, Sunir J.] Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Garg, SJ (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 800 Walnut St, Philadelphia, PA 19107 USA.
EM sgarg@midatlanticretina.com
RI Mahmoudzadeh, Raziyeh/AAD-3047-2019
OI Mahmoudzadeh, Raziyeh/0000-0002-5818-9083
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Annexon Inc, 2020, PHAS 2 MULT RAND PAR
   [Anonymous], 2020, RPE CELL TRANSPL DRY
   [Anonymous], Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
   [Anonymous], 2020, UPD AV PEG GEOGR ATR
   Banin E, 2019, INVEST OPHTH VIS SCI, V60
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chiang TTK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.59
   Cousins SW, 2019, INVEST OPHTH VIS SCI, V60
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Gemini Therapeutics Inc, 2020, NTR
   Gemini Therapeutics Inc, 2020, NTR
   Genentech Inc, 2020, NTR
   Genentech Inc, 2020, NTR
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gyroscope Therapeutics, 2020, NTR
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P384, DOI 10.1016/j.oret.2019.11.011
   Hemera Biosciences, 2020, NTR
   Hemera Biosciences, NTR
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Inc AP, 2020, NTR
   Ionis Pharmaceuticals Inc, NTR
   IVERIC, BIOANN 1 PAT DOS 2 Z
   JAFFE G, 2020, OPHTHALMOLOGY
   Kamao H, 2014, INVEST OPHTH VIS SCI, V55, P8309, DOI 10.1167/iovs.14-14694
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kim BJ, 2020, OPHTHALMOL RETINA, V4, P889, DOI 10.1016/j.oret.2020.03.019
   Kimura A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091584
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Eye Institute (NEI), 2020, NTR
   NGM Biopharmaceuticals Inc, NTR
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Sivaprasad S, 2019, OPHTHALMOL THER, V8, P115, DOI 10.1007/s40123-019-0160-3
   Stealth BioTherapeutics Inc, 2020, NTR
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Vitale S, 2020, JAMA OPHTHALMOL, V138, P610, DOI 10.1001/jamaophthalmol.2020.0824
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
NR 47
TC 5
Z9 5
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2021
VL 32
IS 3
BP 294
EP 300
DI 10.1097/ICU.0000000000000746
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS7CW
UT WOS:000661913000019
PM 33630787
DA 2022-11-30
ER

PT J
AU Cornish, EE
   Teo, KY
   Nguyen, V
   Squirrel, D
   Young, S
   Gillies, MC
   Barthelmes, D
AF Cornish, Elisa E.
   Teo, Kelvin Y.
   Vuong Nguyen
   Squirrel, David
   Young, Stephanie
   Gillies, Mark C.
   Barthelmes, Daniel
TI FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY
   IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Fight Retinal
   Blindness! Project
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bilateral age-related macular degeneration; real-world outcomes;
   registry; neovascular; vascular endothelial growth factor inhibitor; 5
   years incidence of bilateral age-related macular degeneration
ID RANIBIZUMAB
AB Purpose: To compare treatment intensity and mean visual acuity gains for first- and second-affected eyes with age-related macular degeneration nAMD over 5 years of treatment. The cumulative incidence of second-eye involvement was assessed. Method: We analyzed data from the Fight Retinal Blindness! project database, a prospectively designed registry of "real-world" outcomes from Australia, New Zealand, Switzerland, and Singapore. Patients with bilateral age-related macular degeneration with >= 5 years of follow-up on treatment were included. Results: Six thousand five hundred and forty-two eyes being treated for age-related macular degeneration were tracked from 2005 to 2017. Thousand two hundred and sixty-one patients had bilateral age-related macular degeneration; of whom, 302 had 5 years of follow-up. Of these, 170 patients started treatment for each eye at least 2 months apart. The mean baseline visual acuity of second-affected eyes was significantly higher than that of first-eyes (20/50 + 2 vs. 20/80; P < 0.01). Second-affected eyes lost a mean of 5.8 (-9.1 to -2.6) logarithm of the minimum angle of resolution letters after 5 years of treatment, whereas the vision of the first-affected eyes remained stable (P = 0.01). Second-affected eyes received fewer injections than the first-affected eyes after the first year of treatment (6.2/year vs. 7.8/year; P < 0.01) and reactivated earlier (376 vs. 507 days; P = 0.04). The cumulative incidence of second eye involvement was 54% over 5 years. Conclusion: Second-affected eyes received fewer treatments and reactivated earlier. Care should be taken to avoid undertreating second-affected eyes.
C1 [Cornish, Elisa E.; Teo, Kelvin Y.; Vuong Nguyen; Gillies, Mark C.; Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Discipline Clin Ophthalmol & Eye Hlth, 8 Macquarie St, Sydney, NSW 2000, Australia.
   [Teo, Kelvin Y.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Teo, Kelvin Y.] Singapore Eye Res Inst, Singapore, Singapore.
   [Squirrel, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Young, Stephanie] Gladesville Retina, Gladesville, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Singapore National Eye Center; National University
   of Singapore; Singapore National Eye Center; University of Auckland;
   University of Zurich; University Zurich Hospital
RP Cornish, EE (通讯作者)，Univ Sydney, Save Sight Inst, Discipline Clin Ophthalmol & Eye Hlth, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM elisa.cornish@sydney.edu.au
OI Teo, Kelvin/0000-0002-7458-7081
FU Royal Australian NZ College of Ophthalmologists Eye Foundation
   (2007-2009); National Health and Medical Research Council, Australia
   (NHMRC 2010-2012); Macular Disease Foundation, Australia; NHMRC
   practitioner fellowship; Walter and Gertrud Siegenthaler Foundation
   Zurich, Switzerland; Swiss National Foundation; Novartis; Bayer
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012), and a
   grant from the Macular Disease Foundation, Australia. Mark Gillies is a
   Sydney Medical Foundation Fellow and is supported by an NHMRC
   practitioner fellowship. Daniel Barthelmes was supported by the Walter
   and Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss
   National Foundation. Funding was also provided by Novartis and Bayer.
   These supporting organizations had no role in the design or conduct of
   the research.
CR Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Gillies M., 2019, AM J OPHTHALMOL, V10, P10
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   R Core Team, 2017, R LANG ENV STAT COMP
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 10
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 118
EP 124
DI 10.1097/IAE.0000000000002798
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100017
PM 32310628
DA 2022-11-30
ER

PT J
AU Kim, D
   Nam, WH
   Kim, HK
   Yi, K
AF Kim, Dongwook
   Nam, Woo Ho
   Kim, Ha Kyoung
   Yi, Kayoung
TI Does Intravitreal Injections of Bevacizumab for Age-related Macular
   Degeneration Affect Long-term Intraocular Pressure?
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE bevacizumab; age-related macular degeneration (AMD); intraocular
   pressure (IOP)
ID ELEVATION; PERSISTENT
AB Purpose: To evaluate the long-term intraocular pressure (IOP) changes after intravitreal injection of bevacizumab for age-related macular degeneration.
   Patients and Methods: A total of 83 eyes that received intravitreal injections of bevacizumab for age-related macular degeneration were enrolled. IOP measurements at baseline, 6, 12, 18, and 24 months, and at the last follow-up after injection were analyzed. On the basis of the median number of injections, the changes in IOP were compared.
   Results: The mean number of injections was 3.71 + 1.62. There was no significantly higher elevation than baseline IOP (14.11 +/- 2.76 mm Hg) after multiple intravitreal injections of bevacizumab (P > 0.05). In the group which had >= 4 injections, mean IOP measurements were not higher compared with the group which had <4 injections during the follow-up period (P > 0.05). In the patients with preexisting glaucoma (3 eyes), there were no significant increases of IOP during the follow-up period.
   Conclusions: IOP elevation was not observed during the long-term follow-up period. In addition, the numbers of injection and preexisting glaucoma did not affect IOP changes.
C1 [Kim, Dongwook; Nam, Woo Ho; Kim, Ha Kyoung; Yi, Kayoung] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Coll Med, Seoul 150950, South Korea.
C3 Hallym University
RP Yi, K (通讯作者)，Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Coll Med, 948-1 Daerim1 Dong, Seoul 150950, South Korea.
EM kayoungyi@yahoo.co.kr
CR Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kocabora MS, 2008, CLIN OPHTHALMOL, V2, P167
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Park Hye Young, 2005, Korean J Ophthalmol, V19, P122
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Shukla D, 2007, AM J OPHTHALMOL, V144, P453, DOI 10.1016/j.ajo.2007.04.021
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 19
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD SEP
PY 2014
VL 23
IS 7
BP 446
EP 448
DI 10.1097/IJG.0b013e3182946505
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO7WQ
UT WOS:000341563700007
PM 23632401
DA 2022-11-30
ER

PT J
AU Klein, R
   Li, XH
   Kuo, JZ
   Klein, BEK
   Cotch, MF
   Wong, TY
   Taylor, KD
   Rotter, JI
AF Klein, Ronald
   Li, Xiaohui
   Kuo, Jane Z.
   Klein, Barbara E. K.
   Cotch, Mary Frances
   Wong, Tien Y.
   Taylor, Kent D.
   Rotter, Jerome I.
TI Associations of Candidate Genes to Age-Related Macular Degeneration
   Among Racial/Ethnic Groups in the Multi-Ethnic Study of Atherosclerosis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; CARDIOVASCULAR-DISEASE; CHINESE POPULATION;
   RACIAL-DIFFERENCES; UNITED-STATES; PREVALENCE; MACULOPATHY;
   POLYMORPHISMS; EYE; LOC387715
AB PURPOSE: To describe the relationships of selected candidate genes to the prevalence of early age-related macular degeneration (AMD) in a cohort of whites, blacks, Hispanics, and Chinese Americans.
   DESIGN: Cross-sectional study.
   METHODS: SETTING: Multicenter study. STUDY POPULATION: A total of 2456 persons aged 45-84 years with genotype information and fundus photographs. PROCEDURES: Twelve of 2862 single nucleotide polymorphisms (SNPs) from 11 of 233 candidate genes for cardiovascular disease were selected for analysis based on screening with marginal unadjusted P value <.001 within 1 or more racial/ethnic groups. Logistic regression models tested for association in case-control samples. MAIN OUTCOME MEASURE: Prevalence of early AlVID.
   RESULTS: Early AMD was present in 4.0% of the cohort and varied from 2.4% in blacks to 6.0% in whites. The odds ratio increased from 2.3 for 1 to 10.0 for 4 risk alleles in a joint effect analysis of Age-Related Maculopathy Susceptibility 2 rs10490924 and Complement Factor H Y402H (P for trend = 4.2x 10(-7)). Frequencies of each SNP varied among the racial/ethnic groups. Adjusting for age and other factors, few statistically significant associations of the 12 SNPs with AMD were consistent "across all groups. In a multivariate model, most candidate genes did not attenuate the comparatively higher odds of AMD in whites. The higher frequency of risk alleles for several SNPs in Chinese Americans may partially explain their AMD frequency's approaching that of whites.
   CONCLUSIONS: The relationships of 11 candidate genes to early AMD varied among 4 racial/ethnic groups, and partially explained the observed variations in early AMD prevalence among them. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Li, Xiaohui; Kuo, Jane Z.; Taylor, Kent D.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 University of Wisconsin System; University of Wisconsin Madison; Cedars
   Sinai Medical Center; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National University of Singapore;
   Singapore National Eye Center; Centre for Eye Research Australia;
   University of Melbourne
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Rotter, Jerome/AAY-6598-2021; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cotch, Mary
   Frances/0000-0002-2046-4350; Klein, Ronald/0000-0002-4428-6237
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95165,
   N01-HC-95169]; MESA [R01-HL071051, R01-HL071205, R01-HL071250,
   R01-HL071251, R01-HL071252, R01-HL071258, R01-HL071259]; NIH Intramural
   Research Award [ZIAEY000403]; NIH [HL69979]; DIVISION OF EPIDEMIOLOGY
   AND CLINICAL APPLICATIONS [N01HC095163, N01HC095165, N01HC095160,
   N01HC095164, N01HC095159, N01HC095162, N01HC095169, N01HC095161] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [ZIAEY000403] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL069979, R01HL071259, R44HL095169,
   R01HL071205, R01HL071051, R43HL095169, R01HL071252, R21HL095165,
   R01HL071250, R01HL071251, R01HL071258] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [P30DK063491] Funding Source: NIH RePORTER
FX The authors have no proprietary or commercial interest in any materials
   discussed in this article. The Multi-Ethnic Study of Atherosclerosis
   (MESA) was supported by contracts N01-HC-95159 through N01-HC-95165 and
   N01-HC-95169 from the National Heart, Lung, and Blood Institute, MESA
   Family was conducted and supported in collaboration with MESA
   investigators by grants and contracts R01-HL071051, R01-HL071205,
   R01-HL071250, R01-HL071251, R01-HL071252, R01-HL071258, R01-HL071259,
   and NIH Intramural Research Award ZIAEY000403. Additional support was
   provided by NIH grant HL69979 (R.K. and.T.Y.W.) and in part by the
   Cedars-Sinai Board of Governors' Chair in Medical Genetics (J.I.R.).
   None of the above named sponsors or funding organizations had any role
   in the design or conduct of this research. The content is solely the
   responsibility of the authors and does not necessarily reflect the
   official views of the National Heart, Lung, and Blood Institute; the
   National Eye Institute; or the National Institutes of Health.
   Contributions of authors: design of the study (R.K.); conduct of the
   study (R.K.); collection of data (R.K., M.F.C., PR.); analysis of data
   (X.L., J.Z.K., K.D.T.); interpretation of the data (J.I.R., X.L.,
   J.Z.K., B.E.K.K., R.K.); manuscript preparation (R.K., B.E.K.K.,
   J:I.R.); manuscript review (XL., J.Z.K., B.E.K.K., M.F.C., T.Y.W.,
   K.D.T., J.I.R.); and manuscript approval (XL., J.Z.K., B.E.K.K., M.F.C.,
   T.Y.W., K.D.T., J.I.R.).
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bielinski SJ, 2008, ATHEROSCLEROSIS, V201, P339, DOI 10.1016/j.atherosclerosis.2008.02.031
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   de Bakker Paul I W, 2004, Pharmacogenomics, V5, P157, DOI 10.1517/phgs.5.2.157.27480
   Fan JB, 2006, METHOD ENZYMOL, V410, P57, DOI 10.1016/S0076-6879(06)10003-8
   Fan JB, 2006, NAT REV GENET, V7, P632, DOI 10.1038/nrg1901
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Gunderson KL, 2004, GENOME RES, V14, P870, DOI 10.1101/gr.2255804
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haritunians T, 2010, INFLAMM BOWEL DIS, V16, P1830, DOI 10.1002/ibd.21293
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P472, DOI 10.1001/archophthalmol.2010.25
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   MESA Coordinating Center, 2001, MULT STUD ATH FIELD
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tokunaga K, 2001, HUM IMMUNOL, V62, P1001, DOI 10.1016/S0198-8859(01)00301-9
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wassel CL, 2011, OBESITY, V19, P840, DOI 10.1038/oby.2010.229
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
NR 49
TC 15
Z9 15
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2013
VL 156
IS 5
BP 1010
EP 1020
DI 10.1016/j.ajo.2013.06.004
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250NJ
UT WOS:000326859200021
PM 23938121
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Patnaik, JL
   Lynch, AM
   Wagner, BD
   Echalier, EL
   Kohrt, WM
   Mathias, MT
   Siringo, FS
   Palestine, AG
   Mandava, N
AF Patnaik, Jennifer L.
   Lynch, Anne M.
   Wagner, Brandie D.
   Echalier, E. Lacey
   Kohrt, Wendy M.
   Mathias, Marc T.
   Siringo, Frank S.
   Palestine, Alan G.
   Mandava, Naresh
TI Hormone Therapy as a Protective Factor for Age-Related Macular
   Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); menopausal hormone therapy (HT);
   hormone replacement therapy (HRt); ophthalmic epidemiology
ID REPRODUCTIVE FACTORS; REPLACEMENT THERAPY; ESTROGEN-RECEPTOR; POOLED
   FINDINGS; RISK-FACTORS; WOMEN; EYE; MACULOPATHY; ASSOCIATION; GENDER
AB Purpose: The purpose of this study was to determine if the use of menopausal hormone therapy (HT) is related to the development of neovascular (NV) age-related macular degeneration (AMD), geographic atrophy (GA) and/or early/intermediate AMD. Methods: A case-control study was conducted from patients prospectively recruited from July 2014 to June 2019. Cases were females with AMD recruited into a registry and controls were females with age-related cataract and no AMD. Age-related macular degeneration was categorized into NV-AMD, GA, and early/intermediate. Hormone therapy (historic and current) was self-reported by the patient and categorized as ever/never use. Adjusted odds ratios (ORs) from multinomial logistic regressions are presented for each AMD group. Results: Female AMD case patients (n = 409) and controls (n = 132) were included in the analytic database. Almost half (45.5%) of the female AMD patients had NV-AMD, 14.9% had GA, and 39.6% had early/intermediate AMD. Among all study participants, 285 (52.7%) reported historic and/or current use of HT. Controls were significantly more likely to have any HT use (71.2%), compared to 43.0% (p <= 0.001) of NV-AMD patients, 47.5% (p = .002) of GA patients, and 50.6% (p <= 0.001) of early/intermediate AMD patients. Adjusted for potential confounders of age and Caucasian race, cases were significantly more likely to have lower HT use compared to controls: NV-AMD, OR = 0.31 (95%CI: 0.18-0.54), GA, OR = 0.40 (95%CI: 0.20-0.80), and early/intermediate AMD, OR = 0.36 (95%CI: 0.22-0.61). Conclusion: Our case-control study found that the use of HT was associated with a lower odds of all AMD stages studied: NV-AMD, GA and early/intermediate.
C1 [Patnaik, Jennifer L.; Lynch, Anne M.; Wagner, Brandie D.; Echalier, E. Lacey; Mathias, Marc T.; Siringo, Frank S.; Palestine, Alan G.; Mandava, Naresh] Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
   [Wagner, Brandie D.] Univ Colorado, Dept Biostat & Informat, Sch Publ Hlth, Aurora, CO 80045 USA.
   [Kohrt, Wendy M.] Univ Colorado, Div Geriatr Med, Sch Med, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Colorado School of Public Health; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus
RP Patnaik, JL (通讯作者)，Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM Jennifer.Patnaik@cuanschutz.edu
FU Research to Prevent Blindness, Inc.; Colorado Clinical & Translational
   Sciences Institute [CCSTI-UL1 TR002535]; Development and Informatics
   Service Center (DISC) from NIH/NCRR; Frederic C. Hamilton Macular
   Degeneration Center
FX Support from a Challenge Grant to the Department of Ophthalmology from
   Research to Prevent Blindness, Inc. and the Frederic C. Hamilton Macular
   Degeneration Center and the Colorado Clinical & Translational Sciences
   Institute (CCSTI-UL1 TR002535) with the Development and Informatics
   Service Center (DISC) from NIH/NCRR.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Au A, 2016, FRONT NEUROENDOCRIN, V40, P87, DOI 10.1016/j.yfrne.2016.01.002
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Cho BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102816
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Evans J. R., 2017, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000254.PUB4
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Greendale GA, 1997, AM J EPIDEMIOL, V146, P763
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hutchinson CV, 2014, J ENDOCRINOL, V223, pR9, DOI 10.1530/JOE-14-0349
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Lam JSH, 2014, OPHTHAL EPIDEMIOL, V21, P92, DOI 10.3109/09286586.2014.884602
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lynch AM, 2018, RETINA, P1
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Mehta JM, 2019, J WOMENS HEALTH, V28, P705, DOI 10.1089/jwh.2018.7201
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Ouyang P, 2006, J AM COLL CARDIOL, V47, P1741, DOI 10.1016/j.jacc.2005.10.076
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rokicki W, 2014, ANN AGR ENV MED, V21, P70
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Temkin SM, 2019, CANCER-AM CANCER SOC, V125, P499, DOI 10.1002/cncr.31911
   The North American Menopause Society, 2017, HORM THER MENONOTE
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trenti A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030859
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Yang XP, 2011, CURR OPIN NEPHROL HY, V20, P133, DOI 10.1097/MNH.0b013e3283431921
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 41
TC 6
Z9 6
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 3
PY 2020
VL 27
IS 2
BP 148
EP 154
DI 10.1080/09286586.2019.1701041
EA DEC 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KO4TY
UT WOS:000501387400001
PM 31813321
DA 2022-11-30
ER

PT J
AU Ishikawa, K
   Kannan, R
   Hinton, DR
AF Ishikawa, Keijiro
   Kannan, Ram
   Hinton, David R.
TI Molecular mechanisms of subretinal fibrosis in age-related macular
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Extracellular matrix; Epithelial-mesenchymal transition; Growth factor;
   Laser-induced choroidal neovascularization; Macrophage; Matricellular
   protein; Myofibroblasts; Subretinal scar
ID PIGMENT EPITHELIAL-CELLS; CHOROIDAL NEOVASCULAR MEMBRANES; PROLIFERATIVE
   DIABETIC-RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; NLRP3 INFLAMMASOME
   ACTIVATION; MESENCHYMAL TRANSITION; EXTRACELLULAR-MATRIX;
   RETINAL-DETACHMENT; MOUSE MODEL; TNF-ALPHA
AB Subretinal fibrosis is a result of a wound healing response that follows choroidal neovascularization in neovascular age-related macular degeneration (nAMD). Although anti-vascular endothelial growth factor therapy has become a standard treatment that improves visual acuity in many nAMD patients, unsuccessful treatment outcomes have often been attributed to the progression of subretinal fibrosis. In this review, we summarize the cellular and extracellular components of subretinal fibrous membranes and also discuss the possible molecular mechanisms including the functional involvement of growth factors and the inflammatory response in the process. Moreover, we present an murine animal model of sub retinal fibrosis that might facilitate greater understanding of the pathophysiology and the development of novel therapeutic strategies for the inhibition of subretinal fibrosis in nAMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ishikawa, Keijiro; Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Ishikawa, Keijiro; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Ophthalmol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.; Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414
FU National Institutes of Health [EY03040, EY01545]; Arnold and Mabel
   Beckman Foundation; Research to Prevent Blindness, New York, NY; Japan
   Society for Promotion of Science Postdoctoral Fellowships for Research
   Abroad; NATIONAL EYE INSTITUTE [R01EY001545, P30EY003040] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants EY03040,
   EY01545 and the Arnold and Mabel Beckman Foundation and an unrestricted
   grant from Research to Prevent Blindness, New York, NY, 10022. K.
   Ishikawa is supported by a fellowship from the Japan Society for the
   Promotion of Science Postdoctoral Fellowships for Research Abroad. We
   thank Ernesto Barron and Christine Spee for technical assistance. The
   authors declare no conflicts of interest.
CR Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   Bastiaans J, 2013, INVEST OPHTH VIS SCI, V54, P8306, DOI 10.1167/iovs.13-12383
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen HC, 2012, LAB INVEST, V92, P676, DOI 10.1038/labinvest.2011.201
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chen X, 2014, CURR MOL MED, V14, P523, DOI 10.2174/1566524014666140331230411
   Chen YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044937
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cui W, 2014, INT J OPHTHALMOL-CHI, V7, P194, DOI 10.3980/j.issn.2222-3959.2014.02.02
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   Gratchev A, 2001, SCAND J IMMUNOL, V53, P386, DOI 10.1046/j.1365-3083.2001.00885.x
   Greaves NS, 2013, J DERMATOL SCI, V72, P206, DOI 10.1016/j.jdermsci.2013.07.008
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   He SK, 2008, INVEST OPHTH VIS SCI, V49, P4078, DOI 10.1167/iovs.07-1302
   He SK, 2013, MOL VIS, V19, P665
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Hesse M, 2000, AM J PATHOL, V157, P945, DOI 10.1016/S0002-9440(10)64607-X
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kent D, 2003, MOL VIS, V9, P747
   Kimoto K, 2004, INVEST OPHTH VIS SCI, V45, P2431, DOI 10.1167/iovs.03-1276
   Kudelka MR, 2013, EXPERT REV OPHTHALMO, V8, P475, DOI 10.1586/17469899.2013.840095
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Saika S, 2005, LAB INVEST, V85, P838, DOI 10.1038/labinvest.3700294
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schultz GS, 2009, WOUND REPAIR REGEN, V17, P153, DOI 10.1111/j.1524-475X.2009.00466.x
   Sheridan CM, 2002, CURR EYE RES, V25, P279, DOI 10.1076/ceyr.25.5.279.13492
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sohn EH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1127, DOI 10.1001/archophthalmol.2012.1611
   Spraul CW, 2004, OPHTHAL RES, V36, P166, DOI 10.1159/000077330
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Uchida H, 2008, CURR EYE RES, V33, P199, DOI 10.1080/02713680701852090
   VAAGE J, 1990, J LEUKOCYTE BIOL, V48, P274, DOI 10.1002/jlb.48.3.274
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Wree A, 2014, J MOL MED, V92, P1069, DOI 10.1007/s00109-014-1170-1
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
NR 82
TC 108
Z9 114
U1 0
U2 19
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2016
VL 142
SI SI
BP 19
EP 25
DI 10.1016/j.exer.2015.03.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC1JT
UT WOS:000368973300004
PM 25773985
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Orlin, A
   Hadley, D
   Chang, W
   Ho, AC
   Brown, G
   Kaiser, RS
   Regillo, CD
   Godshalk, AN
   Lier, A
   Kaderli, B
   Stambolian, D
AF Orlin, Anton
   Hadley, Dexter
   Chang, Woohyok
   Ho, Allen C.
   Brown, Gary
   Kaiser, Richard S.
   Regillo, Carl D.
   Godshalk, Ashlee N.
   Lier, Audun
   Kaderli, Brian
   Stambolian, Dwight
TI ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI-VASCULAR
   ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; genetics; pharmacogenetic response
ID COMPLEMENT FACTOR-H; LOC387715 GENOTYPES; VISUAL IMPAIRMENT;
   SUSCEPTIBILITY; POLYMORPHISM; VARIANT; Y402H; HTRA1; GENE; MACULOPATHY
AB Purpose: To investigate whether there is an association between known age-related macular degeneration genetic risk variants in the CFH, ARMS2, and HTRA1 genes and response to anti-vascular endothelial growth factor (VEGF) (ranibizumab or bevacizumab) treatment for wet age-related macular degeneration.
   Methods: A retrospective review of 150 patients with documented wet age-related macular degeneration based on clinical examination and fluorescein angiogram was performed. Patients received anti-VEGF therapy with ranibizumab and/or bevacizumab. Patients were genotyped for the single-nucleotide polymorphism rs1061170, rs10490924, rs3750848, rs3793917, rs11200638, and rs932275 and for the indel del443ins54 spanning the CFH, ARMS2, and HTRA1 genes.
   Results: There were 57 patients who were characterized as negative responders to anti-VEGF therapy, and 93 patients who were characterized as positive responders. There was no significant difference in mean baseline visual acuity between the groups. Negative responders were followed for a mean duration of 24.0 months, while positive responders were followed for a mean duration of 22.0 months. Although the frequency of the at-risk alleles was higher in the positive responders when compared with the negative responder, this did not reach statistical significance. Additionally, there was no significant association between genotype and the number of injections or absolute change in visual acuity in both groups of responders.
   Conclusion: In our patient cohort, there was no statistically significant association between response to anti-VEGF therapy and the genotype in both positive-responder and negative-responder groups. Larger studies with more power are necessary to further determine whether a pharmacogenetic association exists between wet age-related macular degeneration and anti-VEGF therapy. RETINA 32:4-9, 2012
C1 [Orlin, Anton; Hadley, Dexter; Stambolian, Dwight] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Hadley, Dexter; Lier, Audun; Kaderli, Brian; Stambolian, Dwight] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Chang, Woohyok] Yeungnam Univ, Coll Med, Dept Ophthalmol, Taegu, South Korea.
   [Ho, Allen C.; Brown, Gary; Kaiser, Richard S.; Regillo, Carl D.] Mid Atlantic Retina, Cherry Hill, NJ USA.
   [Ho, Allen C.; Brown, Gary; Kaiser, Richard S.; Regillo, Carl D.; Godshalk, Ashlee N.] Thomas Jefferson Univ, Dept Ophthalmol, Wills Eye Inst, Philadelphia, PA 19107 USA.
C3 University of Pennsylvania; University of Pennsylvania; Yeungnam
   University; Jefferson University
RP Orlin, A (通讯作者)，1305 York Ave 11th Floor, New York, NY 10021 USA.
EM aorlin@gmail.com
RI Hadley, Dexter/ABB-7568-2021
OI Hadley, Dexter/0000-0003-0990-4674; Ho, Allen/0000-0003-3921-608X
FU Yeungnam University
FX Dr. Chang was supported by a Yeungnam University research grant in 2008.
   A. Orlin, D. Hadley, and W. Chang have contributed equally to the work
   and writing of this manuscript.
CR [Anonymous], 2010, R LANG ENV STAT COMP
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, pe5, DOI DOI 10.1016/J.OPHTHA.2005.11.019
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng X, 2009, OPHTHALMOLOGY, V116, pe1
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Souied EH, 2005, MOL VIS, V11, P1135
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 30
TC 52
Z9 55
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2012
VL 32
IS 1
BP 4
EP 9
DI 10.1097/IAE.0b013e31822a2c7c
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 870IE
UT WOS:000298661800002
PM 21878851
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Haines, JL
   Hauser, MA
   Schmidt, S
   Scott, WK
   Olson, LM
   Gallins, P
   Spencer, KL
   Kwan, SY
   Noureddine, M
   Gilbert, JR
   Schnetz-Boutaud, N
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
AF Haines, JL
   Hauser, MA
   Schmidt, S
   Scott, WK
   Olson, LM
   Gallins, P
   Spencer, KL
   Kwan, SY
   Noureddine, M
   Gilbert, JR
   Schnetz-Boutaud, N
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
TI Complement factor H variant increases the risk of age-related macular
   degeneration
SO SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; MACULOPATHY;
   DISEASE; ASSOCIATION; ACTIVATION; MEMBRANE; PATHWAY; COMMON
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD. We used single-nucleotide polymorphisms to interrogate this region and identified a strongly associated haplotype in two independent data sets. DNA resequencing of the complement factor H gene within this haplotype revealed a common coding variant, Y402H, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This common variant likely explains similar to 43% of AMD in older adults.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   Duke Univ, Med Ctr, Duke Univ Eye Ctr, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Vanderbilt University; Vanderbilt
   University; Duke University; Duke University
RP Pericak-Vance, MA (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, DUMC Box 3445,595 LaSalle St, Durham, NC 27710 USA.
EM mpv@chg.duhs.duke.edu
RI Haines, Jonathan/C-3374-2012; Mohammed, Imran/J-8271-2012; Scott,
   William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Mohammed,
   Imran/0000-0002-8412-0768; Scott, William/0000-0001-9336-6404
FU NCRR NIH HHS [M01 RR-00095] Funding Source: Medline; NEI NIH HHS
   [EY12118, EY015216] Funding Source: Medline; NIA NIH HHS [AG11268]
   Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES
   [M01RR000095] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R03EY015216, R01EY012118, U10EY012118] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [P60AG011268] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   CDC (Cent. Dis. Control Prev.), 2004, MMWR-MORBID MORTAL W, V53, P1069
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
NR 22
TC 1861
Z9 2015
U1 1
U2 80
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD APR 15
PY 2005
VL 308
IS 5720
BP 419
EP 421
DI 10.1126/science.1110359
PG 3
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 917TL
UT WOS:000228492000055
PM 15761120
DA 2022-11-30
ER

PT J
AU Mance, TC
   Kovacevic, D
   Alpeza-Dunato, Z
   Stroligo, MN
   Brumini, G
AF Mance, Tea Caljkusic
   Kovacevic, Damir
   Alpeza-Dunato, Zvjezdana
   Stroligo, Maja Novak
   Brumini, Gordana
TI The Role of Omega6 to Omega3 Ratio in Development and Progression of
   Age-Related Macular Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Review
DE age-related macular degenerations; omega-6 fatty acids; omega-3 fatty
   acids
ID FISH CONSUMPTION; ACID; ASSOCIATIONS
AB The aim of this study is to investigate possible connection between omega-6/omega-3 fatty acid ratio and development and progression of Age-Related Macular Degeneration (ARMD). We examined 125 patients diagnosed with ARMD and divided into 5 groups of 25 patients according to CARMS (Clinical Age-Related Maculopathy Staging System). Control group consists of 51 patients with similar ages, without ARMD. All of them underwent stereobiomicroscopy, fundus photography and fluorescein angiography. Dietary fatty acids intake was measured using food frequency questionairre (FFQ). The FFQ was based on previously validated questionairre (DIETQ, Tinuviel Software, Warington, Ches, UK) and FFQ2 from Blue MountainEye Study. The data were analysed using food nutritient dana from McCance and Widdowson 's Food Composition Tables, supplemented with a food fatty acid content database (Foodbase, London, UK). We noticed statistically significant difference between omega-6/omega-3 ratio in neovascular ARMD (stage 5) and all other groups including control group (p=0.000020).The ratio in Stage 5 was about 11:1 like in Western diet. Stage 4-geographic atrophy (GA) has statistically significant difference in o-mega-6/omega-3 ratio compared with stage I (p=0.000571), stage 2 (p=0.000112) and stage 3 (p=0.000430). The ratio in first three groups is about 7-7.5:1 (greater then Mediteran-4-5:1, but lower then Western Diet-10-20:1). There is no statistically significant difference between first three stages (p>0.05) and stage 4 and control group (p=0.172388). Omega-6/omega-3 ratio is connected with development of neovascular ARMD. Decreased ratio protects against neovascular ARMD. On the contrary, GA seems to be connected with prolonged sunlight exposure (the ratio is about 6:1). It is good to know that changing nutrition habits someone can prevent development of severe neovascular form of ARMD because intravitreal anti-VEGF therapy limitations.
C1 [Mance, Tea Caljkusic; Kovacevic, Damir; Alpeza-Dunato, Zvjezdana; Stroligo, Maja Novak] Rijeka Univ Hosp Ctr, Dept Ophthalmol, Rijeka 51000, Croatia.
   [Brumini, Gordana] Univ Rijeka, Sch Med, Dept Med Informat, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka
RP Mance, TC (通讯作者)，Rijeka Univ Hosp Ctr, Dept Ophthalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM teamance@hotmail.com
RI Brumini, Gordana/O-4925-2018
OI Brumini, Gordana/0000-0003-2401-3212
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Broadfield E, 2003, BRIT J NUTR, V90, P215, DOI 10.1079/BJN2003884
   Caljkusic-Mance T, 2010, COLLEGIUM ANTROPOL, V34, P109
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Orton HD, 2008, EUR J CLIN NUTR, V62, P733, DOI 10.1038/sj.ejcn.1602763
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311
   Synek S, 2010, COLLEGIUM ANTROPOL, V34, P25
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vojnikovic B, 2010, COLLEGIUM ANTROPOL, V34, P5
NR 16
TC 8
Z9 8
U1 1
U2 13
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD SEP
PY 2011
VL 35
SU 2
BP 307
EP 310
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 828MG
UT WOS:000295504500068
PM 22220460
DA 2022-11-30
ER

PT J
AU Lima-Fontes, M
   Meira, L
   Barata, P
   Falcao, M
   Carneiro, A
AF Lima-Fontes, Mario
   Meira, Luis
   Barata, Pedro
   Falcao, Manuel
   Carneiro, Angela
TI Gut microbiota and age-related macular degeneration: A growing
   partnership
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Gut microbiota; Nutrition; Gut
   dysbiosis; Gut-retina axis
ID LONG-TERM INCIDENCE; GEOGRAPHIC ATROPHY; PATHOLOGICAL ANGIOGENESIS;
   CHRONIC INFLAMMATION; CIGARETTE-SMOKING; OBESITY; PATHOGENESIS;
   ASSOCIATION; PREVALENCE; GENETICS
AB Age-related macular degeneration (AMD) is a leading cause of severe, irreversible vision impairment in developed countries, and its prevalence is rising all over the world, increasing sharply with age. AMD represents an acquired degeneration of the retina that causes significant central visual impairment through a combination of noneovascular and neovascular derangement. The main risk factors for the development of advanced AMD are increasing age, genetic factors, and cigarette smoking; however, the exact pathophysiology of AMD is yet relatively poorly understood. In recent years, the gut microbiota has been intensively studied and linked to several pathologic processes, including ocular diseases. In this sense, the aim of this review is to gather published evidence about the relationship between gut microbiota and AMD. (c) 2021 Elsevier Inc. All rights reserved.
C1 [Lima-Fontes, Mario; Falcao, Manuel; Carneiro, Angela] Ctr Hospitalar Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
   [Lima-Fontes, Mario] Univ Porto, Fac Med, Dept Biomed, Porto, Portugal.
   [Meira, Luis] Univ Porto, Fac Med, Porto, Portugal.
   [Barata, Pedro] Univ Porto, I3S: Inst Res & Innovat Hlth, Porto, Portugal.
   [Barata, Pedro] Fernando Pessoa Univ, Fac Hlth Sci, Porto, Portugal.
   [Falcao, Manuel; Carneiro, Angela] Univ Porto, Fac Med, Dept Surg & Physiol, Porto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Universidade do Porto; i3S
   - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto;
   Universidade Fernando Pessoa; Universidade do Porto
RP Lima-Fontes, M (通讯作者)，Ctr Hospitalar Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.; Lima-Fontes, M (通讯作者)，Univ Porto, Fac Med, Dept Biomed, Porto, Portugal.
EM marioruifontes@gmail.com
OI Falcao, Manuel/0000-0003-4718-0910
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Alvarez CA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.556813
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Aragona P, 2021, SURV OPHTHALMOL, V66, P907, DOI 10.1016/j.survophthal.2021.03.010
   Biagi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010667
   Bui BV, 2009, J NEUROCHEM, V111, P589, DOI 10.1111/j.1471-4159.2009.06354.x
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Kanamoto T, 2020, CURR EYE RES, V45, P490, DOI 10.1080/02713683.2019.1666995
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Krajmalnik-Brown R, 2012, NUTR CLIN PRACT, V27, P201, DOI 10.1177/0884533611436116
   Kugadas A, 2016, OCUL SURF, V14, P342, DOI 10.1016/j.jtos.2016.04.004
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Magne F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051474
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morita Y, 2018, AGING-US, V10, P2723, DOI 10.18632/aging.101583
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oresic M, 2009, EXP EYE RES, V89, P604, DOI 10.1016/j.exer.2009.06.018
   Parolini C, 2019, MAR DRUGS, V17, DOI 10.3390/md17060374
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rinninella E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7010014
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Scholz R, 2016, EMBO MOL MED, V8, P1361, DOI 10.15252/emmm.201607165
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011
   Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139
   SIMELL O, 1973, LANCET, V1, P1031
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 55
TC 3
Z9 3
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2022
VL 67
IS 4
BP 883
EP 891
DI 10.1016/j.survophthal.2021.11.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2A8GP
UT WOS:000809734300001
PM 34843745
DA 2022-11-30
ER

PT J
AU Thomas, AS
   Redd, T
   Hwang, T
AF Thomas, Akshay S.
   Redd, Travis
   Hwang, Thomas
TI EFFECT OF SYSTEMIC BETA-BLOCKERS, ACE INHIBITORS, AND ANGIOTENSIN
   RECEPTOR BLOCKERS ON DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION IN
   PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ACE inhibitor; age-related macular degeneration; angiotensin receptor
   blocker; beta-blocker; choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; II TYPE-1
   RECEPTOR; CONVERTING ENZYME; MESSENGER-RNA; RANIBIZUMAB; MODEL; MICE;
   OVEREXPRESSION; ANGIOGENESIS
AB Purpose:Recent studies have suggested that the use of systemic beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models. The purpose of this study is to evaluate if these agents have a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration.Methods:In this single-center retrospective case-control study, the charts of 250 patients with neovascular age-related macular degeneration were compared with those of 250 controls with dry age-related macular degeneration. Charts were reviewed for current and past use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Frequency tables were generated, and associations were examined using chi-square tests, t-tests, and multivariate logistic regression.Results:There was no statistically significant difference between rates of beta-blocker use (P = 0.57), angiotensin-converting enzyme inhibitors use (P = 0.20), or angiotensin receptor blockers use (P = 0.61) between the 2 groups. Additionally, there was no statistically significant difference between rates of use of combinations of the above drugs between the two groups.Conclusion:Although there is growing evidence that beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers can induce regression of choroidal neovascularization in rodent models, these medications do not seem to confer a protective effect against the development of choroidal neovascularization in patients with age-related macular degeneration.
C1 [Thomas, Akshay S.; Hwang, Thomas] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Redd, Travis] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA.
   [Redd, Travis] Oregon Hlth & Sci Univ, Sch Publ Hlth & Preventat Med, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University
RP Hwang, T (通讯作者)，Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM hwangt@ohsu.edu
RI Hwang, Thomas/AAV-5146-2020; Hwang, Thomas S./AAW-6618-2020
OI Hwang, Thomas S./0000-0002-0535-4823
FU Research to Prevent Blindness, New York, NY
FX Supported by an unrestricted grant from Research to Prevent Blindness,
   New York, NY.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2010, MEDIAT INFLAMM, V2010, pxx
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ikeda Y, 2004, CANCER RES, V64, P5178, DOI 10.1158/0008-5472.CAN-03-3589
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
NR 28
TC 15
Z9 15
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1964
EP 1968
DI 10.1097/IAE.0000000000000603
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000006
PM 25996426
DA 2022-11-30
ER

PT J
AU Shin, HJ
   Chung, H
   Kim, HC
AF Shin, Hyun Jin
   Chung, Hyewon
   Kim, Hyung Chan
TI CORRELATION OF FOVEAL MICROSTRUCTURAL CHANGES WITH VISION AFTER
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography; photoreceptor integrity; vision
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; PHOTORECEPTOR LAYER;
   VISUAL-ACUITY; RANIBIZUMAB; INTEGRITY; HOLES; VEGF
AB To investigate the correlation of foveal microstructural changes with vision after intravitreal ranibizumab injection in eye with choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: We retrospectively studied 40 eyes of 40 patients with neovascular age-related macular degeneration who had no previous treatment history of age-related macular degeneration. All patients were treated with 3 monthly intravitreal ranibizumab (0.5 mg/0.05 mL) injections. One month after the third consecutive injection, best-corrected visual acuity (BCVA) was evaluated and the eyes were categorized into 2 groups according to the change in BCVA (good function group: BCVA improvement >= logarithm of minimum angle of resolution 0.3; poor function group: BCVA improvement < logarithm of minimum angle of resolution 0.3). Changes of foveal photoreceptor layer integrity, CNV size (diameter and thickness), central macular thickness, center point thickness, outer nuclear layer thickness, and subretinal fluid in each group were also evaluated using spectral-domain optical coherence tomography.
   Results: The good function group is 20 eyes, and the poor function group is 20 eyes. No significant differences in baseline characteristics of variables including CNV type, initial BCVA, photoreceptor integrity, and CNV size were observed between the two groups. Best-corrected visual acuity in the good function group was 0.30 +/- 0.17 (logarithm of minimum angle of resolution) and that in the poor function group was 0.48 +/- 0.40 (logarithm of minimum angle of resolution). Decreased disrupted length of photoreceptor layer (1,020.80 +/- 974.60) and decreased CNV thickness (78.86 +/- 50.78) were found in the good function group at the end of follow-up. However, no significant differences in changes of CNV diameter, central macular thickness, center point thickness, outer nuclear layer thickness, and resolution of subretinal fluid were observed between the two groups.
   Conclusion: Restoration of foveal photoreceptor integrity and decreased CNV thickness are closely associated with visual improvement in neovascular age-related macular degeneration after treatment. RETINA 33: 964-970, 2013
C1 [Shin, Hyun Jin; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Sch Med, Med Ctr, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 143729, South Korea.
EM eyekim@kuh.ac.kr
RI Shin, Hyunjin/ABF-6057-2021
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hangai Masanori, 2007, Nippon Ganka Gakkai Zasshi, V111, P509
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
NR 23
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 964
EP 970
DI 10.1097/IAE.0b013e3182835f70
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100011
PM 23348865
DA 2022-11-30
ER

PT J
AU de Almeida, LNF
   Carolino, RM
   Sperandio, DC
   Nehemy, MB
   De Marco, LA
AF Frota de Almeida, Luciana Negrao
   Carolino, Rachel Melilo
   Sperandio, Diogo Cazelli
   Nehemy, Marcio Bittar
   De Marco, L. A.
TI The role of molecular genetic factors in age-related macular
   degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/etiology; Age effect; Complement factor H/genetics;
   Base sequence; Polymorphism, single nucleotide; Inflammation
ID COMPLEMENT FACTOR-H; CIGARETTE-SMOKING; STRONG ASSOCIATION;
   APOLIPOPROTEIN-E; FACTOR-B; RISK; SUSCEPTIBILITY; CFH; LOC387715;
   VARIANT
AB Age-related macular degeneration (AMD) is the most frequent cause of irreversible blindness in the elderly in developed countries. Although the etiology of AMD remains largely unknown, numerous studies have suggested that both genes and environmental risk factors significantly influence the risk of developing AMD. Recently, single nucleotide polymorphisms, DNA sequence variations found within the complement factor H (CFH) gene, have been found to be strongly associated with the development of AMD. Several other genes have had at least one positive association finding and deserve further exploration. The purpose of this review is to provide an extensive report of the current data of AMD genetics and the contribution of this knowledge helps to the better understanding of its pathophysiology.
C1 [Carolino, Rachel Melilo] Univ Fed Minas Gerais, Lab Farmacol Bioquim & Mol, Belo Horizonte, MG, Brazil.
   [Nehemy, Marcio Bittar] Univ Fed Minas Gerais, Hosp Sao Geraldo, Serv Retina & Vitreo, Belo Horizonte, MG, Brazil.
   [De Marco, L. A.] Univ Fed Minas Gerais, Programa Posgrad Farmacol Bioquim & Mol, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP de Almeida, LNF (通讯作者)，Av Conselheiro Furtado 2-818, BR-66063060 Belem, Para, Brazil.
EM luciananfalmeida@gmail.com
RI DE MARCO, LUIZ/H-6275-2012; Nehemy, Marcio/ABD-5089-2021
OI DE MARCO, LUIZ/0000-0003-2535-7439; Nehemy, Marcio/0000-0002-4104-0346
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   ALLIKMETS R, 1998, SCIENCE, V279, P1107
   Ambati J, 2004, NAT MED, V10, P663, DOI 10.1038/nm0704-663b
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Csaky K, 2003, OPHTHALMOLOGY, V110, P879
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P532, DOI 10.1016/j.survophthal.2006.06.004
   DUNNEN JT, 2001, HUM GENET, V109, P121
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farah ME, 2001, ARQ BRAS OFTALMOL, V64, P583
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SCHAUMBERG DA, 2007, JAMA-J AM MED ASSOC, V297, P401
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2006, RETINA, P1017
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   WIGGS JL, 2007, ARCH OPHTHALMOL-CHIC, V125, pE1
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 45
TC 5
Z9 6
U1 0
U2 1
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2009
VL 72
IS 4
BP 567
EP 572
DI 10.1590/S0004-27492009000400027
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558OQ
UT WOS:000274754200027
PM 19820804
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lambert, NG
   ElShelmani, H
   Singh, MK
   Mansergh, FC
   Wride, MA
   Padilla, M
   Keegan, D
   Hogg, RE
   Ambati, BK
AF Lambert, Nathan G.
   ElShelmani, Hanan
   Singh, Malkit K.
   Mansergh, Fiona C.
   Wride, Michael A.
   Padilla, Maximilian
   Keegan, David
   Hogg, Ruth E.
   Ambati, Balamurali K.
TI Risk factors and biomarkers of age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Biomarkers; Proteomics; microRNA; sFlt
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN;
   GENOME-WIDE ASSOCIATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   STARGARDT-DISEASE GENE; BODY-MASS INDEX; MICRORNA EXPRESSION PROFILES;
   PLASMA HOMOCYSTEINE LEVEL; MESSENGER-RNA EXPRESSION
AB A biomarker can be a substance or structure measured in body parts, fluids or products that can affect or predict disease incidence. As age-related macular degeneration (AMD) is the leading cause of blindness in the developed world, much research and effort has been invested in the identification of different biomarkers to predict disease incidence, identify at risk individuals, elucidate causative pathophysiological etiologies, guide screening, monitoring and treatment parameters, and predict disease outcomes. To date, a host of genetic, environmental, proteomic, and cellular targets have been identified as both risk factors and potential biomarkers for AMD. Despite this, their use has been confined to research settings and has not yet crossed into the clinical arena. A greater understanding of these factors and their use as potential biomarkers for AMD can guide future research and clinical practice. This article will discuss known risk factors and novel, potential biomarkers of AMD in addition to their application in both academic and clinical settings. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Lambert, Nathan G.; Singh, Malkit K.; Padilla, Maximilian; Ambati, Balamurali K.] John A Moran Eye Ctr, Ambati Lab, 65 Mario Capecchi Dr, Salt Lake City, UT USA.
   [Lambert, Nathan G.; Singh, Malkit K.; Padilla, Maximilian; Ambati, Balamurali K.] Univ Utah, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT USA.
   [ElShelmani, Hanan; Wride, Michael A.] Univ Dublin, Trinity Coll, Sch Nat Sci, Ocular Dev & Neurobiol Res Grp,Zool Dept, Dublin 2, Ireland.
   [Mansergh, Fiona C.] Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland.
   [Keegan, David] Mater Misericordia Hosp, Eccles St, Dublin 7, Ireland.
   [Hogg, Ruth E.] Inst Clin Sci, Ctr Med Expt, Block A,Grosvenor Rd, Belfast, Antrim, North Ireland.
C3 Utah System of Higher Education; University of Utah; Trinity College
   Dublin; Trinity College Dublin; Mater Misericordiae University Hospital
RP Ambati, BK (通讯作者)，Univ Utah, John A Moran Eye Ctr, Ambati Lab, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM Nathan.lambert@hsc.utah.edu; elshelh@tcd.ie; mona.singh@hsc.utah.edu;
   mansergf@tcd.ie; wridem@tcd.ie; maximilianrpadilla413@gmail.com;
   djkeegan71@hotmail.com; r.e.hogg@qub.ac.uk; bala.ambati@utah.edu
RI Mitchell, Paul/P-1498-2014; Hogg, Ruth E./ABC-9602-2020; Wride,
   Michael/D-9143-2013
OI Hogg, Ruth E./0000-0001-9413-2669; Wride, Michael/0000-0002-5728-998X
FU National Institutes of Health [EY014800]; Research to Prevent Blindness,
   Inc., New York, NY; Diabetes Metabolism Consortium Training Grant;
   National Institutes of Health Diabetes T32 Training Grant; Health
   Research Board (HRB) [FB/FAR/2011]; Fighting Blindness Ireland
   [FB/FAR/2011]; Irish Research Council for Science, Engineering &
   Technology/EMBARK Initiative; Mater Vision Institute; Libyan Ministry of
   Higher Education and Scientific Research; Science Foundation Ireland
   (SFI); Macular Society; Irish Research Council (IRD); NATIONAL EYE
   INSTITUTE [R01EY017182, R01EY026029, R01EY017950] Funding Source: NIH
   RePORTER
FX This work was supported by National Institutes of Health (EY014800), an
   Unrestricted Grant from Research to Prevent Blindness, Inc., New York,
   NY, to the Department of Ophthalmology & Visual Sciences, University of
   Utah, a Diabetes Metabolism Consortium Training Grant, and a National
   Institutes of Health Diabetes T32 Training Grant. A Medical Charities
   Research Group (MRCG) grant (FB/FAR/2011), joint funded by the Health
   Research Board (HRB) and Fighting Blindness Ireland, also supported this
   work. Financial support was also provided by the Irish Research Council
   for Science, Engineering & Technology/EMBARK Initiative, Mater Vision
   Institute, Libyan Ministry of Higher Education and Scientific Research,
   Science Foundation Ireland (SFI), the Macular Society, and an Irish
   Research Council (IRD) studentship. An additional generous thanks to Dr.
   Ann Milam, Scheie Eye Institute, University of Pennsylvania for
   contribution of clinical images (Fig. 1).
CR Abdel-Magid AF, 2012, ACS MED CHEM LETT, V3, P781, DOI 10.1021/ml300233n
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Abu-Safieh L, 2011, AM J HUM GENET, V89, P313, DOI 10.1016/j.ajhg.2011.07.010
   Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Akilov OE, 2009, J IMMUNOL, V183, P7994, DOI 10.4049/jimmunol.0900866
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alonso A, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00023
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amorini AM, 2012, MOL CELL BIOCHEM, V359, P205, DOI 10.1007/s11010-011-1015-y
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arora A, 2007, INVEST OPHTH VIS SCI, V48, P3962, DOI 10.1167/iovs.06-1221
   Arora A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-1
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Babanejad M., 2015, OPHTHALMIC GENET, V21, P1
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barba I, 2010, INVEST OPHTH VIS SCI, V51, P4416, DOI 10.1167/iovs.10-5348
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baudet ML, 2012, NAT NEUROSCI, V15, P29, DOI 10.1038/nn.2979
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bessho H, 2012, MOL VIS, V18, P121
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Bush WS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002822
   Cammann H, 2011, CLIN CHEM, V57, P1490, DOI 10.1373/clinchem.2011.166959
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Carugati A, 2001, MOL IMMUNOL, V38, P161, DOI 10.1016/S0161-5890(01)00040-2
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Christen WG, 2015, OPHTHAL EPIDEMIOL, V22, P85, DOI 10.3109/09286586.2015.1012272
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conte I, 2010, P NATL ACAD SCI USA, V107, P15491, DOI 10.1073/pnas.0914785107
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Decembrini S, 2009, P NATL ACAD SCI USA, V106, P21179, DOI 10.1073/pnas.0909167106
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dong Y, 2015, INT J OPHTHALMOL-CHI, V8, P385, DOI 10.3980/j.issn.2222-3959.2015.02.31
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Duffy MJ, 2015, CLIN CHEM, V61, P809, DOI 10.1373/clinchem.2015.239863
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fang AM, 2009, MOL VIS, V15, P2710
   Farrar GJ, 2013, TRENDS GENET, V29, P488, DOI 10.1016/j.tig.2013.05.005
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Goehring AS, 2007, J BIOL CHEM, V282, P33155, DOI 10.1074/jbc.M705167200
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Graham SF, 2013, ANAL CHEM, V85, P1803, DOI 10.1021/ac303163f
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Gress CJ, 2000, J CELL BIOL, V149, P983, DOI 10.1083/jcb.149.4.983
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Hagbi-Levi S, 2016, OPHTHALMIC RES, V55, P126, DOI 10.1159/000441794
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Heckenlively J R, 1996, Trans Am Ophthalmol Soc, V94, P179
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Ishida W, 2011, INVEST OPHTH VIS SCI, V52, P611, DOI 10.1167/iovs.10-6115
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janik-Papis Katarzyna, 2009, Klin Oczna, V111, P178
   Jha A, 2011, J BIOSCIENCES, V36, P621, DOI 10.1007/s12038-011-9109-y
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Keller A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007440
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kovacs B, 2011, INVEST OPHTH VIS SCI, V52, P4402, DOI 10.1167/iovs.10-6879
   Kovacs Katalin A, 2007, Ideggyogy Sz, V60, P169
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Krutzfeldt J, 2006, CELL METAB, V4, P9, DOI 10.1016/j.cmet.2006.05.009
   Kucukevcilioglu M., 2015, INT OPHTHALMOL
   Kuroda TS, 2005, J BIOL CHEM, V280, P28015, DOI 10.1074/jbc.M501465200
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Kutty RK, 2010, MOL VIS, V16, P1475
   Kwon M, 2008, CANCER RES, V68, P7332, DOI 10.1158/0008-5472.CAN-08-1087
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Li FL, 2012, CURR EYE RES, V37, P540, DOI 10.3109/02713683.2012.665561
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lista S, 2014, J NEUROL, V261, P1234, DOI 10.1007/s00415-014-7366-z
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Lutty G, 1999, MOL VIS, V5
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maher AD, 2009, FUTURE MED CHEM, V1, P737, DOI 10.4155/FMC.09.54
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Maiorano NA, 2012, INT J MOL SCI, V13, P558, DOI 10.3390/ijms13010558
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mamas M, 2011, ARCH TOXICOL, V85, P5, DOI 10.1007/s00204-010-0609-6
   Mantel I, 2014, OPHTHALMIC GENET, V35, P12, DOI 10.3109/13816810.2013.766217
   Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Mayeux Richard, 2004, NeuroRx, V1, P182, DOI 10.1602/neurorx.1.2.182
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5
   Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moons KGM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b375
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Moussallieh FM, 2014, MULT SCLER J, V20, P558, DOI 10.1177/1352458513504638
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Orr N, 2012, NAT GENET, V44, P1182, DOI 10.1038/ng.2417
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Park UC, 2014, MOL VIS, V20, P1680
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pavlou MP, 2013, CLIN CHEM, V59, P147, DOI 10.1373/clinchem.2012.184614
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101
   Perera FP, 2000, CARCINOGENESIS, V21, P517, DOI 10.1093/carcin/21.3.517
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pinna A, 2016, CURR EYE RES, V41, P88, DOI 10.3109/02713683.2014.1002044
   Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Ryan D, 2006, MOL VIS, V12, P1175
   Sall JW, 2004, EXP EYE RES, V79, P465, DOI 10.1016/j.exer.2004.06.007
   SanGiovanni JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125548
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schneider R, 2010, J MOL BIOL, V401, P605, DOI 10.1016/j.jmb.2010.06.039
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Singh HP, 2006, AM J OPHTHALMOL, V141, P906, DOI 10.1016/j.ajo.2005.12.009
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smolinska A, 2012, ANAL CHIM ACTA, V750, P82, DOI 10.1016/j.aca.2012.05.049
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2011, INVEST OPHTH VIS SCI, V52, P1748, DOI 10.1167/iovs.09-5112
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Sundermeier TR, 2012, CELL MOL LIFE SCI, V69, P2739, DOI 10.1007/s00018-012-0976-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Sutcliffe P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13050
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Taylor JMG, 2008, CLIN CANCER RES, V14, P5977, DOI 10.1158/1078-0432.CCR-07-4534
   Templeton JP, 2013, INVEST OPHTH VIS SCI, V54, P2599, DOI 10.1167/iovs.12-11175
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Vecino E, 2004, INT J DEV BIOL, V48, P965, DOI 10.1387/ijdb.041891ev
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wada Y, 2003, ARCH OPHTHALMOL-CHIC, V121, P1613, DOI 10.1001/archopht.121.11.1613
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   Wang DB, 2015, MICROSYST TECHNOL, V21, P21, DOI 10.1007/s00542-014-2363-9
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wang VM, 2012, MOL VIS, V18, P2578
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wickremasinghe SS, 2014, RETINA-J RET VIT DIS, V34, P2367, DOI 10.1097/IAE.0000000000000258
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wong CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119570
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wu JH, 2012, OPHTHALMIC RES, V47, P195, DOI 10.1159/000331992
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Xie LQ, 2005, J CARDIOVASC PHARM, V46, P690, DOI 10.1097/01.fjc.0000183568.48389.a1
   Yan NH, 2010, ADV EXP MED BIOL, V664, P203, DOI 10.1007/978-1-4419-1399-9_23
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ye ZM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20914
   Yokokura S, 2005, INVEST OPHTH VIS SCI, V46, P2905, DOI 10.1167/iovs.04-0856
   Yoshina S, 2012, MOL BIOL CELL, V23, P1728, DOI 10.1091/mbc.E11-10-0857
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Yuan DQ, 2013, MOL VIS, V19, P374
   Zeng JX, 2010, MOL VIS, V16, P2273
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhang QJ, 2007, INVEST OPHTH VIS SCI, V48, P530, DOI 10.1167/iovs.06-0669
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
   Zhao H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013735
   Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751
   Zhou J, 2013, CLIN BIOCHEM, V46, P1689, DOI 10.1016/j.clinbiochem.2013.07.002
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhu QB, 2011, J BIOL CHEM, V286, P31749, DOI 10.1074/jbc.M111.259028
NR 426
TC 174
Z9 183
U1 4
U2 47
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2016
VL 54
BP 64
EP 102
DI 10.1016/j.preteyeres.2016.04.003
PG 39
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DU7TK
UT WOS:000382417300004
PM 27156982
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Kirchhof, J
AF Augustin, Albert J.
   Kirchhof, Janna
TI Inflammation and the pathogenesis of age-related macular degeneration
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE Bruch's membrane; drusen; polymorphism; RPE dysfunction; Y402H
ID COMPLEMENT FACTOR-H; BRUCHS MEMBRANE; MORPHOMETRIC-ANALYSIS; PREVALENCE;
   MICROGLIA; SMOKING; DRUSEN; RISK; POLYMORPHISM; MACULOPATHY
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. Many changes occur in various areas of the eye as it ages. These include choroidal thinning, thickening of Bruch's membrane and drusen formation. Each of these is associated with the onset of AMD. Methods: Recent findings on how those changes contribute to the pathogenesis of AMD with a focus on inflammation are examined. Results: There is evidence suggesting that all changes identified so far as being involved in the pathogenesis of AMD are not able to cause AMD alone. Instead, susceptibility genes, and in particular a coding variant of a gene on chromosome 1 result in dysfunction of the immune system. This leads to an inappropriate inflammatory response, which then sets the stage for AMD onset. Conclusions: It is now well-known that AMD is a multi-factorial disease, with environmental causes and genetics all playing a role.
C1 [Augustin, Albert J.; Kirchhof, Janna] Staedt Klinikum Karlsruhe, Dept Ophthalmol, D-76133 Karlsruhe, Germany.
   [Augustin, Albert J.] Johannes Gutenberg Univ Mainz, Dept Ophthalmol, D-55131 Mainz, Germany.
C3 Municipal Hospital Karlsruhe; Johannes Gutenberg University of Mainz
RP Augustin, AJ (通讯作者)，Staedt Klinikum Karlsruhe, Dept Ophthalmol, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM albertjaugustin@googlemail.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   AUGUSTIN AJ, 1991, LIFE SCI, V49, P961, DOI 10.1016/0024-3205(91)90079-Q
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   COATS G, 1905, ROY LONDON OPHTHAL H, V16, P164
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   HING S, 1988, ANN HUM GENET, V52, P117, DOI 10.1111/j.1469-1809.1988.tb01086.x
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Matyszak MK, 1997, ADV EXP MED BIOL, V417, P295
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   NETTLESHIP E, 1884, EYE, V4, P165
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Pagenstecher H. a. G., 1875, ATLAS PATHOLOGISCHEN
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VANDEWOUDE MFJ, 1987, J AM COLL NUTR, V6, P307, DOI 10.1080/07315724.1987.10720192
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Winkler BS, 1999, MOL VIS, V5
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zhang C, 2005, MOL VIS, V11, P887
   Zhou JH, 2005, MOL VIS, V11, P414
   1999, ARTH OPHTHALMOL, V117, P1329
NR 60
TC 59
Z9 61
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD JUN
PY 2009
VL 13
IS 6
BP 641
EP 651
DI 10.1517/14728220902942322
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 460HM
UT WOS:000267178800002
PM 19456269
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Bird, A
   Nitiahpapand, R
   Nicholson, L
   Hykin, P
   Chatziralli, I
AF Sivaprasad, Sobha
   Bird, Alan
   Nitiahpapand, Rynda
   Nicholson, Luke
   Hykin, Phil
   Chatziralli, Irini
CA Moorfields UCL AMD Consortium
TI Perspectives on reticular pseudodrusen in age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE reticular pseudodrusen; subretinal drusenoid deposits; retinal pigment
   epithelium; photoreceptors; choroid; scotopic microperimetry; OCT;
   age-related macular degeneration
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPY; MEDIATED
   DARK-ADAPTATION; GEOGRAPHIC-ATROPHY; CHOROIDAL THICKNESS; ADAPTIVE
   OPTICS; FELLOW-EYES; HIGH-RISK
AB Drusen have been considered the clinical hallmark of age-related macular degeneration (AMD). Reticular pseudodrusen (RPD), although first described about 25 years ago, have only been recently recognized as an additional clinical phenotype of AMD with distinct characteristics on multimodal imaging and significant impact on visual function. Eyes with RPD are at greater risk of progression to advanced AMD when compared with eyes with drusen only. RPD can also occur in the absence of drusen. Unlike features external to the retinal pigment epithelium that have received most attention in AMD, evidence suggests that RPD are associated with changes internal to the RPE. Therefore, new avenues regarding the pathogenesis of AMD are highlighted by these recent observations. We summarize the current knowledge regarding the histology, imaging, and functional changes in eyes with RPD in AMD and offer concepts of future research for the AMD community to discuss. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sivaprasad, Sobha; Bird, Alan; Nicholson, Luke; Hykin, Phil; Chatziralli, Irini] NIHR Moorfields Biomed Res Ctr, Med Retina Dept, 162 City Rd, London EC1V 2PD, England.
   [Sivaprasad, Sobha; Bird, Alan; Nicholson, Luke] UCL, Inst Ophthalmol, Dept Ocular Biol, London, England.
   [Sivaprasad, Sobha; Nitiahpapand, Rynda] Kings Coll London, Laser & Retinal Res Ctr, London, England.
C3 University of London; University College London; University of London;
   King's College London
RP Sivaprasad, S (通讯作者)，NIHR Moorfields Biomed Res Ctr, Med Retina Dept, 162 City Rd, London EC1V 2PD, England.
EM senswathi@aol.com
RI Chatziralli, Irini/AAG-4779-2020; Sivaprasad, S./D-6876-2015
OI Chatziralli, Irini/0000-0001-8523-1024; Sivaprasad,
   S./0000-0001-8952-0659; Nicholson, Luke/0000-0001-6685-4402
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Alten F, RETINA
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Arnold JJ, AM J OPHTHALMOL
   Auge J, OPHTHALMOLOGE
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Capuano V, 2015, BR J OPHTHALMOL
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   CHEN HM, 1993, J LIPID RES, V34, P1943
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cho HJ, AM J OPHTHALMOL
   Coffey PJ, P NATL ACAD SCI US
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gliem M, OPHTHALMOLOGY
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Gliem Martin, 2013, Frontiers in Genetics, V4, P14, DOI 10.3389/fgene.2013.00014
   Goto M, 2008, BIOSCI TRENDS, V2, P218
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heiferman MJ, 2015, RETINA-J RET VIT DIS, V35, P2593, DOI 10.1097/IAE.0000000000000666
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Jackson GR, 2006, OPHTHAL PHYSL OPT, V26, P431, DOI 10.1111/j.1475-1313.2006.00390.x
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim JH, RETINA
   Klein R, OPHTHALMOLOGY
   Klein R, AM J OPHTHALMOL
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindsay KJ, 2014, P NATL ACAD SCI USA, V111, P15579, DOI 10.1073/pnas.1412441111
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Maguire MG, 1996, RETINA-J RET VIT DIS, V16, P167, DOI 10.1097/00006982-199616020-00019
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Midena E, BR J OPHTHALMOL
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nunes RP, 2015, OSLI RETINA, V46, P814, DOI 10.3928/23258160-20150909-05
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, RETINA
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Saade C, 2014, BRIT J OPHTHALMOL, V98, P1729, DOI 10.1136/bjophthalmol-2014-305005
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schick T, 2015, INVEST OPHTH VIS SCI, V56, P7269, DOI 10.1167/iovs.15-16989
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, RETINA
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Stohr H, 2012, ADV EXP MED BIOL, V723, P261, DOI 10.1007/978-1-4614-0631-0_34
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2011, EYE, V25, P1379, DOI 10.1038/eye.2011.162
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Tsai Y, 2014, INVEST OPHTH VIS SCI, V55, P523
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Xu H, GLIA
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu L, RETINA
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Zarbin MA, 2006, BRIT J OPHTHALMOL, V90, P396, DOI 10.1136/bjo.2005.086041
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zweifel SA, OPHTHALMOLOGY
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 151
TC 59
Z9 60
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2016
VL 61
IS 5
BP 521
EP 537
DI 10.1016/j.survophthal.2016.02.005
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DV8WI
UT WOS:000383217000001
PM 26994868
DA 2022-11-30
ER

PT J
AU Gupta, OP
   Brown, GC
   Brown, MM
AF Gupta, Omesh P.
   Brown, Gary C.
   Brown, Melissa M.
TI Age-related macular degeneration: the costs to society and the patient
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cost analysis; cost-effectiveness;
   direct costs; indirect costs; low vision
ID VISUAL IMPAIRMENT; PHOTODYNAMIC THERAPY; ECONOMIC BURDEN; UTILITY; EYE;
   SUPPLEMENTATION; ZINC; AMD
AB Purpose of review
   The current literature was reviewed to assess the patient and societal costs associated with age-related macular degeneration (ARMD).
   Recent findings
   An increasing number of studies discuss the growing direct ophthalmologic, direct nonophthalmologic, and indirect costs associated with ARMD. Most reports, however, focus on only one of these aspects. The prevalence of this debilitating disease will increase as life expectancy increases.
   Summary
   ARMD continues to be a major public health problem in developed countries. The treatment and management of exudative ARMD are changing dramatically. These therapies will likely become a more significant portion of the overall healthcare burden of ARMD. To date, no comprehensive study exists that attempts to calculate the total cost of ARMD.
C1 Thomas Jefferson Univ, Wills Eye, Retina Serv, Philadelphia, PA 19107 USA.
   Ctr Value Based Med, Flourtown, PA USA.
   Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 Jefferson University; University of Pennsylvania; University of
   Pennsylvania
RP Gupta, OP (通讯作者)，Wills Eye Inst, 840 walnut St,10th Floor, Philadelphia, PA 19107 USA.
EM ogupta@hotmail.com
CR Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Eklund K, 2005, DISABIL REHABIL, V27, P1203, DOI 10.1080/09638280500052716
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 21
TC 16
Z9 18
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2007
VL 18
IS 3
BP 201
EP 205
DI 10.1097/ICU.0b013e32810c8df4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 162BL
UT WOS:000246061200004
PM 17435426
DA 2022-11-30
ER

PT J
AU Kimura, M
   Yasukawa, T
   Shibata, Y
   Kato, A
   Hirano, Y
   Uemura, A
   Yoshida, M
   Ogura, Y
AF Kimura, Masayo
   Yasukawa, Tsutomu
   Shibata, Yu
   Kato, Aki
   Hirano, Yoshio
   Uemura, Akiyoshi
   Yoshida, Munenori
   Ogura, Yuichiro
TI Flattening of retinal pigment epithelial detachments after pneumatic
   displacement of submacular hemorrhages secondary to age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Pneumatic displacement; Polypoidal
   choroidal vasculopathy; Submacular hemorrhage; Sulfur hexafluoride;
   Tissue plasminogen activator (tPA)
ID TISSUE-PLASMINOGEN-ACTIVATOR; EXPERIMENTAL SUBRETINAL HEMORRHAGE;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL BEVACIZUMAB; EXPANSILE
   GAS; ANTI-VEGF; VITRECTOMY; MANAGEMENT; TOXICITY; INJECTION
AB Pneumatic displacement of submacular hemorrhages (SMHs) with intravitreal injection of sulfur hexafluoride (SF6) gas with or without tissue plasminogen activator (tPA) and prone posturing is an effective minimally invasive treatment. We observed some cases in which simultaneous flattening of hemorrhagic pigment epithelial detachments (PEDs) occurred after prone posturing. This study evaluated the impact of pneumatic displacement using tPA to treat PEDs and visual outcomes in eyes with SMHs secondary to neovascular age-related macular degeneration (AMD).
   This retrospective analysis reviewed the medical records of 32 patients (33 eyes) who underwent pneumatic displacement for AMD-associated SMHs. The SMHs were related to polypoidal choroidal vasculopathy (PCV) in 24 eyes and typical AMD in nine eyes and treated with intravitreal injection of SF6 gas with tPA. We assessed the postoperative best-corrected visual acuities (BCVAs), prevalence and flattening rates of the PEDs, and the number of additional treatments.
   The mean follow-up period was 35.4 +/- 19.8 months. The BCVAs improved significantly in eyes with PCV compared with eyes with typical AMD. Thirty-one (93.9%) of 33 eyes had an accompanying PED. The PEDs flattened in 14 (58.3%) of 24 eyes with PCV but in only one (14.3%) of seven eyes with typical AMD (p = 0.04). A mean of one additional treatment was administered during the first year in 15 eyes with flattened PEDs, which was significantly (p < 0.05) fewer than the 3.6 additional treatments in 16 eyes with persistent PEDs.
   PEDs often accompany SMHs secondary to neovascular AMD. Pneumatic displacement of the SMHs using tPA unexpectedly flattened the PEDs, especially in eyes with PCV, and was associated with fewer additional treatments.
C1 [Kimura, Masayo; Yasukawa, Tsutomu; Shibata, Yu; Kato, Aki; Hirano, Yoshio; Uemura, Akiyoshi; Yoshida, Munenori; Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.
EM yasukawa@med.nagoya-cu.ac.jp
RI Uemura, Akiyoshi/I-7510-2017
OI Uemura, Akiyoshi/0000-0001-5574-5470; Hirano,
   Yoshio/0000-0002-9173-0839; Yasukawa, Tsutomu/0000-0001-9913-1905
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Heriot WJ, 1997, P UPD MAC SURG AM AC, P82
   Heriot WJ, 1996, INTRAVITREAL GAS TPA
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Kunavisarut P, 2018, ASIA-PAC J OPHTHALMO, V7, P109, DOI 10.22608/APO.2017389
   Matt G, 2010, KLIN MONATSBL AUGENH, V227, P221, DOI 10.1055/s-0028-1109750
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
NR 28
TC 1
Z9 1
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2018
VL 256
IS 10
BP 1823
EP 1829
DI 10.1007/s00417-018-4059-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT7XF
UT WOS:000444744500005
PM 29961921
DA 2022-11-30
ER

PT J
AU Biarnes, M
   Mones, J
   Alonso, J
   Arias, L
AF Biarnes, Marc
   Mones, Jordi
   Alonso, Jordi
   Arias, Luis
TI Update on Geographic Atrophy in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE age-related macular degeneration; geographic atrophy; epidemiology;
   imaging techniques; treatment
ID COMPLEMENT FACTOR-H; FUNDUS AUTOFLUORESCENCE PATTERNS; DISEASE
   PROGRESSION; VISUAL IMPAIRMENT; 10-YEAR INCIDENCE; NATURAL-HISTORY;
   JUNCTIONAL ZONE; RISK-FACTORS; DIETARY-FAT; GLOBAL DATA
AB Age-related macular degeneration (AMD) is the main cause of legal blindness in older patients in developed countries, and geographic atrophy (GA) represents the advanced form of dry AMD. Although it accounts for one third of the cases of late AMD and is responsible for 20% of the cases of severe visual loss due to the disorder. GA currently lacks effective treatment, whereas antiangiogenic therapies have been shown to be successful in managing choroidal neovascularization, the other form of late AMD. Recent advances in GA epidemiology, etiology, genetics, and imaging techniques have renewed the interest in this entity, which is a cause of progressive visual loss even in treated patients with neovascular AMD. This knowledge has triggered many clinical trials targeting different molecules shown to be associated with the disease, and it is hoped that this research will translate into effective drugs for GA in the near future. (Optom Vis Sci 2011; 88: 881-889)
C1 [Biarnes, Marc; Mones, Jordi] Ctr Med Teknon, Inst Macula & Retina, Barcelona 08022, Spain.
   [Alonso, Jordi] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain.
   [Arias, Luis] Bellvitge Hosp, Barcelona, Spain.
C3 Pompeu Fabra University; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona
RP Biarnes, M (通讯作者)，Ctr Med Teknon, Inst Macula & Retina, C Vilana 12,Off 116-117, Barcelona 08022, Spain.
EM biarnes@oo.upc.edu
RI Alonso, Jordi/A-5514-2010; mones, jordi/CAJ-2963-2022
OI Alonso, Jordi/0000-0001-8627-9636; mones, jordi/0000-0003-3685-2160;
   ARIAS, LUIS/0000-0001-7041-5576; Biarnes, Marc/0000-0003-2584-4894
FU Novartis; Allergan; Ophthotech; Notalvision
FX Marc Biarnes participated in the ARC1905 trial by Ophthotech; Jordi
   Mones received consulting fees from Novartis, Allergan, Ophthotech, and
   Notalvision.
CR *AG REL EYE DIS ST, LUT ZEAX OM 3 SUPPL
   ALLIKMETS R, 2008, AM AC OPHTH M ATL GE
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN ML, 2009, AM AC OPHTH M ATL GE
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   PULIAFITO CA, 2008, AM AC OPHTH M ATL GE
   QUILLEN D, 1996, INVEST OPHTH VIS SCI, V47, pS111
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROSENFELD PJ, 2009, RETINAL PHYS
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scorolli L, 2002, CAN J OPHTHALMOL, V37, P399, DOI 10.1016/S0008-4182(02)80042-4
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 80
TC 24
Z9 26
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUL
PY 2011
VL 88
IS 7
BP 881
EP 889
DI 10.1097/OPX.0b013e31821988c1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784DP
UT WOS:000292134800015
PM 21532519
DA 2022-11-30
ER

PT J
AU Nivison-Smith, L
   Milston, R
   Madigan, M
   Kalloniatis, M
AF Nivison-Smith, Lisa
   Milston, Rebecca
   Madigan, Michele
   Kalloniatis, Michael
TI Age-Related Macular Degeneration: Linking Clinical Presentation to
   Pathology
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE macula; AMD; retinal degeneration; imaging
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   SUBRETINAL DRUSENOID DEPOSITS; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; SCANNING LASER OPHTHALMOSCOPY; GEOGRAPHIC
   ATROPHY; BRUCHS MEMBRANE; RETICULAR PSEUDODRUSEN; HIGH-RESOLUTION
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide in the elderly population. Optometrists, as primary eye health care providers, require the skills and knowledge to accurately diagnose and manage AMD patients. There is an overwhelming body of research related to the clinical presentation, etiology, epidemiology, and pathology of this disease. Additionally, the evolution of new imaging modalities creates new opportunities to clinically detect and analyze previously uncharacterized and earlier changes in the retina. The challenge for optometrists is to combine all this information into an applicable knowledge base for use in everyday clinical assessment of AMD so that timely and accurate referrals can be made to retinal specialists. This review attempts to address this issue by linking the clinical presentation of AMD with the underlying disease biology. We emphasize the contribution of recent noninvasive imaging technologies to the clinical assessment of early and more advanced AMD including optical coherence tomography, fundus autofluorescence, and infrared reflectance.
C1 [Nivison-Smith, Lisa; Milston, Rebecca; Madigan, Michele; Kalloniatis, Michael] Univ New S Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Milston, Rebecca; Kalloniatis, Michael] Univ New S Wales, Ctr Eye Hlth, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of New South Wales
   Sydney
RP Kalloniatis, M (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2052, Australia.
EM M.Kalloniatis@unsw.edu.au
OI Nivison-Smith, Lisa/0000-0001-6677-1949; Kalloniatis,
   Michael/0000-0002-5264-4639
FU National Health and Medical Research Council of Australia (NHMRC)
   [1033224]; University of New South Wales Faculty Research Grant;
   University of New South Wales Early Career Researcher Grant; Guide Dogs
   (NSW/ACT); NHMRC grant
FX We thank Mr. Michael Yapp and Dr. Andrew Whatham for their help in
   obtaining some of the clinical images. This work was supported in part
   by National Health and Medical Research Council of Australia (NHMRC)
   grant number 1033224, University of New South Wales Faculty Research
   Grant 2013, and University of New South Wales Early Career Researcher
   Grant 2014. Guide Dogs (NSW/ACT) fully fund the Centre for Eye Health
   and are also partners in the NHMRC grant.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P300, DOI 10.1046/j.1442-9071.2003.00664.x
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Diniz B, 2013, BRIT J OPHTHALMOL, V97, P285, DOI 10.1136/bjophthalmol-2012-302575
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kolb H., WEBVISION ORG RETINA
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Rossberger S, 2013, BRIT J OPHTHALMOL, V97, P518, DOI 10.1136/bjophthalmol-2012-302350
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 95
TC 24
Z9 25
U1 1
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 832
EP 848
DI 10.1097/OPX.0000000000000281
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500005
PM 24879089
DA 2022-11-30
ER

EF